PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	FLING, JA; FISCHER, JR; BOSWELL, RN; REID, MJ				FLING, JA; FISCHER, JR; BOSWELL, RN; REID, MJ			THE RELATIONSHIP OF SERUM IGA CONCENTRATION TO HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION - A CROSS-SECTIONAL STUDY OF HIV-SEROPOSITIVE INDIVIDUALS DETECTED BY SCREENING IN THE UNITED-STATES-AIR-FORCE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									WILFORD HALL USAF MED CTR,DEPT MED,ALLERGY IMMUNOL SERV,LACKLAND AFB,TX 78236	United States Department of Defense; United States Air Force								AMMANN AJ, 1980, IMMUNOLOGIC DISORDER, P260; BERRY CD, 1987, NEW ENGL J MED, V316, P1587, DOI 10.1056/NEJM198706183162507; BIRX DL, 1986, NEW ENGL J MED, V314, P874, DOI 10.1056/NEJM198604033141403; BOYKO WJ, 1985, CAN MED ASSOC J, V133, P28; CONLEY ME, 1987, ANN INTERN MED, V106, P892, DOI 10.7326/0003-4819-106-6-892; FAUCI AS, 1984, ANN INTERN MED, V100, P92, DOI 10.7326/0003-4819-100-1-92; FRIEDMANKIEN AE, 1982, ANN INTERN MED, V96, P693, DOI 10.7326/0003-4819-96-6-693; HOFMANN B, 1985, J INFECT DIS, V152, P838, DOI 10.1093/infdis/152.4.838; KALISH SB, 1984, J INFECT DIS, V149, P148, DOI 10.1093/infdis/149.2.148; LANE HC, 1983, NEW ENGL J MED, V309, P453, DOI 10.1056/NEJM198308253090803; NEEL HB, 1984, ANN OTO RHINOL LARYN, V93, P477, DOI 10.1177/000348948409300513; PAHWA SG, 1984, ANN INTERN MED, V101, P757, DOI 10.7326/0003-4819-101-6-757; POLK BF, 1987, NEW ENGL J MED, V316, P61, DOI 10.1056/NEJM198701083160201; REDFIELD RR, 1986, NEW ENGL J MED, V314, P131, DOI 10.1056/NEJM198601093140232; SELIGMANN M, 1984, NEW ENGL J MED, V311, P1286, DOI 10.1056/NEJM198411153112005; STAHL RE, 1982, AM J MED, V73, P171, DOI 10.1016/0002-9343(82)90174-7; [No title captured]	17	39	41	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1988	82	6					965	970		10.1016/0091-6749(88)90132-7	http://dx.doi.org/10.1016/0091-6749(88)90132-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R6311	3264560				2022-12-18	WOS:A1988R631100003
J	GUTKOWSKI, A; BEDARD, P; DELCARPIO, J; HEBERT, J; PREVOST, M; SCHULZ, J; TURENNE, Y; YEADON, C				GUTKOWSKI, A; BEDARD, P; DELCARPIO, J; HEBERT, J; PREVOST, M; SCHULZ, J; TURENNE, Y; YEADON, C			COMPARISON OF THE EFFICACY AND SAFETY OF LORATADINE, TERFENADINE, AND PLACEBO IN THE TREATMENT OF SEASONAL ALLERGIC RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CHU LAVAL,DEPT IMMUNOL & ALLERGY,ST FOY,QUEBEC,CANADA; ROYAL VICTORIA HOSP,DIV ALLERGY & IMMUNOL,MONTREAL H3A 1A1,QUEBEC,CANADA; CTR MED ST HUBERT,ST HUBERT,QUEBEC,CANADA; CLIN DOMUS MEDICA,MONTREAL,QUEBEC,CANADA	Laval University; McGill University; Royal Victoria Hospital	GUTKOWSKI, A (corresponding author), ST MARYS HOSP,DIV IMMUNOL & RHEUMATOL,3830 LACOMBE AVE,MONTREAL H3T 1M5,QUEBEC,CANADA.							BARLOW JLR, 1982, DRUG RES, V32, pA9; BARNETT A, 1984, AGENTS ACTIONS, V14, P590, DOI 10.1007/BF01978891; BRANDON ML, 1980, ANN ALLERGY, V44, P71; BRUTTMANN G, 1985, ANN ALLERGY, V55, P2; DROUIN MA, 1985, ANN ALLERGY, V55, P747; NICHOLSON AN, 1982, BRIT J CLIN PHARMACO, V13, P199, DOI 10.1111/j.1365-2125.1982.tb01356.x; NORMAN PS, 1985, J ALLERGY CLIN IMMUN, V76, P366, DOI 10.1016/0091-6749(85)90655-4; RICHARDS DM, 1984, DRUGS, V28, P38, DOI 10.2165/00003495-198428010-00003; ROMAN IJ, 1985, ANN ALLERGY, V55, P233; Sutherland D, 1985, Aust Fam Physician, V14, P501	10	39	39	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1988	81	5	1				902	907		10.1016/0091-6749(88)90948-7	http://dx.doi.org/10.1016/0091-6749(88)90948-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N7036	2897388				2022-12-18	WOS:A1988N703600020
J	PERSSON, CGA; DRACO, AB				PERSSON, CGA; DRACO, AB			XANTHINES AS AIRWAY ANTI-INFLAMMATORY DRUGS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									PHARMACOL LAB, S-22100 LUND, SWEDEN		PERSSON, CGA (corresponding author), UNIV LUND HOSP, DEPT CLIN PHARMACOL, S-22185 LUND, SWEDEN.							BAUMGARTEN CR, 1986, J IMMUNOL, V137, P977; BAUMGARTEN CR, 1985, J CLIN INVEST, V76, P191, DOI 10.1172/JCI111945; ERJEFALT I, 1986, ACTA PHYSIOL SCAND, V128, P653, DOI 10.1111/j.1748-1716.1986.tb08027.x; HOGG JC, 1979, FED PROC, V38, P197; HOLTER JF, 1986, J CLIN INVEST, V78, P1513, DOI 10.1172/JCI112743; LICHTENS.LM, 1968, SCIENCE, V161, P902, DOI 10.1126/science.161.3844.902; MAJNO G, 1961, J BIOPHYS BIOCHEM CY, V11, P571, DOI 10.1083/jcb.11.3.571; NACLERIO RM, 1985, AM J MED, V79, P43, DOI 10.1016/0002-9343(85)90087-7; NACLERIO RM, 1986, J ALLERGY CLIN IMMUN, V78, P874, DOI 10.1016/0091-6749(86)90233-2; PAUWELS R, 1985, J ALLERGY CLIN IMMUN, V76, P583, DOI 10.1016/0091-6749(85)90779-1; PERSSON CGA, 1986, ACTA PHYSIOL SCAND, V126, P615, DOI 10.1111/j.1748-1716.1986.tb07863.x; PERSSON CGA, 1986, J ALLERGY CLIN IMMUN, V78, P817, DOI 10.1016/0091-6749(86)90067-9; PERSSON CGA, 1986, J ALLERGY CLIN IMMUN, V78, P780, DOI 10.1016/0091-6749(86)90061-8; PERSSON CGA, 1986, ACTA PHYSIOL SCAND, V127, P95, DOI 10.1111/j.1748-1716.1986.tb07880.x; PERSSON CGA, 1986, LANCET, V2, P1126; Persson CGA, 1985, HDB INFLAMMATION, V5, P61; SHAPIRO P, 1982, LANCET, V1, P793; SVENSJO E, 1984, MICROCIRC ENDOTH LYM, V1, P381; ZWEIFACH BW, 1973, INFLAMMATORY PROCESS, P3	19	39	39	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1988	81	3					605	610		10.1016/0091-6749(88)90203-5	http://dx.doi.org/10.1016/0091-6749(88)90203-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M6181					2022-12-18	WOS:A1988M618100019
J	RACHELEFSKY, GS				RACHELEFSKY, GS			REVIEW OF ASTHMA SELF-MANAGEMENT PROGRAMS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF LOS ANGELES, SCH MED, DEPT PEDIAT, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								Averill B.A., 1980, CIENC BIOL COIMBRA, V5, P167; CLARK NM, 1986, J ALLERGY CLIN IMMUN, V78, P108, DOI 10.1016/0091-6749(86)90122-3; CLARK NM, 1984, J SCHOOL HEALTH, V54, P143, DOI 10.1111/j.1746-1561.1984.tb08796.x; CREER TL, 1985, NIH842364 NAT HEART; ESQUIBEL KP, 1985, J PROF NURS, V8, P55; FIREMAN P, 1981, PEDIATRICS, V68, P341; HILTON S, 1986, LANCET, V1, P26; HINDIALEXANDER MC, 1984, J ALLERGY CLIN IMMUN, V74, P505, DOI 10.1016/0091-6749(84)90386-5; Kubly L S, 1984, Issues Compr Pediatr Nurs, V7, P121, DOI 10.3109/01460868409009050; LEWIS CE, 1984, PEDIATRICS, V74, P478; MAIMAN LA, 1979, JAMA-J AM MED ASSOC, V241, P1919; MCNABB WL, 1985, AM J PUBLIC HEALTH, V75, P1219, DOI 10.2105/AJPH.75.10.1219; Parcel G S, 1980, J Dev Behav Pediatr, V1, P128; RUBIN DH, 1986, PEDIATRICS, V77, P1; WEISS JH, 1981, SUPERSTUFF SELF MANA, V2, P273; WHITMAN N, 1985, HEALTH EDUC QUART, V12, P333, DOI 10.1177/109019818501200312	16	39	40	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1987	80	3	2	S			506	511		10.1016/0091-6749(87)90087-X	http://dx.doi.org/10.1016/0091-6749(87)90087-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K1037	3305670	Bronze			2022-12-18	WOS:A1987K103700034
J	LINDBERG, RE; ARROYAVE, C				LINDBERG, RE; ARROYAVE, C			LEVELS OF IGE IN SERUM FROM NORMAL-CHILDREN AND ALLERGIC CHILDREN AS MEASURED BY AN ENZYME-IMMUNOASSAY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CHILDRENS MEM HOSP, CHICAGO, IL 60614 USA	Ann & Robert H. Lurie Children's Hospital of Chicago	LINDBERG, RE (corresponding author), ABBOTT LABS, CLIN IMMUNOL GRP, DEPT 908, AP 9, ABBOTT PK, IL 60064 USA.							Arroyave C M, 1985, Bol Med Hosp Infant Mex, V42, P605; BERG T, 1969, INT ARCH ALLER A IMM, V36, P219, DOI 10.1159/000230745; BERG T, 1969, ACTA PAEDIATR SCAND, V58, P513, DOI 10.1111/j.1651-2227.1969.tb04753.x; BOUCARD T, 1973, ACTA PAEDIATR SCAND, V62, P633; BROWN WG, 1979, J ALLERGY CLIN IMMUN, V63, P328, DOI 10.1016/0091-6749(79)90127-1; BUSINCO L, 1983, CLIN ALLERGY, V13, P503, DOI 10.1111/j.1365-2222.1983.tb02631.x; CSORBA S, 1976, ACTA PAEDIATR HUNG, V17, P207; DANNAEUS A, 1978, ACTA PAEDIATR SCAND, V67, P497, DOI 10.1111/j.1651-2227.1978.tb16360.x; DONABEDIAN H, 1982, NEW ENGL J MED, V307, P290, DOI 10.1056/NEJM198207293070506; FAIRBANKS TR, 1985, 85TH ANN M AM SOC MI; FURNER KJ, 1974, INT ARCH ALLER A IMM, V47, P650; GAMO T, 1974, ACTA PAEDIATR JPN, V16, P32; GERRARD JW, 1974, J PEDIATR-US, V85, P660, DOI 10.1016/S0022-3476(74)80510-X; GERRARD JW, 1976, ANN ALLERGY, V37, P91; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; GRUNDBACHER FJ, 1975, J ALLERGY CLIN IMMUN, V56, P104, DOI 10.1016/0091-6749(75)90114-1; HAMBURGE.RN, 1974, J ALLERGY CLIN IMMUN, V53, P94; JOHANSSO.SG, 1967, LANCET, V2, P951; JOHANSSON SG, 1968, INT ARCH ALLER A IMM, V34, P1; JOHANSSON SGO, 1978, ALLERGY, V33, P292, DOI 10.1111/j.1398-9995.1978.tb01554.x; JUHLIN L, 1969, ARCH DERMATOL, V100, P12, DOI 10.1001/archderm.100.1.12; KIKKAWA Y, 1973, PEDIATRICS, V51, P690; KJELLMAN NIM, 1976, CLIN ALLERGY, V6, P51, DOI 10.1111/j.1365-2222.1976.tb01411.x; KJELLMAN NIM, 1976, ACTA PAEDIATR SCAND, V65, P465, DOI 10.1111/j.1651-2227.1976.tb04915.x; LEVINE BB, 1972, SCIENCE, V178, P1201, DOI 10.1126/science.178.4066.1201; Nye L, 1975, Clin Allergy, V5, P13; ORGEL HA, 1975, J ALLERGY CLIN IMMUN, V56, P296, DOI 10.1016/0091-6749(75)90104-9; PATTERSON R, 1972, J ALLERGY CLIN IMMUN, V49, P98; PONCE DP, 1983, CLIN ALLERGY, V13, P521, DOI 10.1111/j.1365-2222.1983.tb02633.x; SAVANAT T, 1977, Southeast Asian Journal of Tropical Medicine and Public Health, V8, P149; SOKAL RR, 1969, BIOMETRY, P145; WALDMANN TA, 1972, J IMMUNOL, V109, P304; WITTIG HJ, 1980, J ALLERGY CLIN IMMUN, V66, P305, DOI 10.1016/0091-6749(80)90026-3	33	39	39	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1986	78	4	1				614	618		10.1016/0091-6749(86)90078-3	http://dx.doi.org/10.1016/0091-6749(86)90078-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E5682	3534049				2022-12-18	WOS:A1986E568200009
J	JOHANSSON, SGO				JOHANSSON, SGO			ANTI-IGE ANTIBODIES IN HUMAN-SERUM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material											JOHANSSON, SGO (corresponding author), KAROLINSKA INST,DEPT CLIN IMMUNOL,S-10401 STOCKHOLM 60,SWEDEN.							AALBERSE RC, 1974, J LAB CLIN MED, V83, P831; AALBERSE RC, 1983, J IMMUNOL, V130, P722; BENNICH H, 1970, VOX SANG, V19, P1, DOI 10.1111/j.1423-0410.1970.tb01490.x; CARINI C, 1983, ANN ALLERGY, V51, P251; GOODWIN JS, 1980, CLIN IMMUNOL IMMUNOP, V15, P106, DOI 10.1016/0090-1229(80)90024-0; HASSNER A, 1984, J IMMUNOL, V132, P2844; INGANAS M, 1981, INT ARCH ALLER A IMM, V65, P51, DOI 10.1159/000232737; ITO S, 1983, CLIN EXP IMMUNOL, V51, P407; JEFFERIS R, 1980, RECENT ADV CLIN IMMU, P65; JOHANSSON S G O, 1970, British Journal of Dermatology, V82, P10, DOI 10.1111/j.1365-2133.1970.tb02185.x; JOHANSSON SG, 1967, IMMUNOLOGY, V13, P381; JOHANSSON SGO, 1972, BIOL ROLE IMMUNOGLOB, P211; JOHANSSON SGO, 1985, 12 P INT C ALL CLIN; JOSEPH M, 1980, CLIN EXP IMMUNOL, V40, P416; KENTEN J, 1984, P NATL ACAD SCI-BIOL, V81, P2955, DOI 10.1073/pnas.81.10.2955; LEUNG DYM, 1985, CLIN RES, V33, P161; MAGNUSSON CGM, 1986, INT ARCH ALLER A IMM, V79, P157, DOI 10.1159/000233964; MAGNUSSON CGM, 1986, INT ARCH ALLER A IMM, V79, P149, DOI 10.1159/000233963; MAGNUSSON CGM, 1985, P EUROPEAN ACADEMY A, P144; MAGNUSSON CGM, INT ARCH ALLERGY APP; MELLBYE OJ, 1973, SCAND J IMMUNOL, V2, P17, DOI 10.1111/j.1365-3083.1973.tb02011.x; MERETEY K, 1982, ANN RHEUM DIS, V41, P405, DOI 10.1136/ard.41.4.405; NAWATA Y, 1984, CLIN EXP IMMUNOL, V58, P348; NAWATA Y, 1985, J IMMUNOL, V135, P478; PAYAN DG, 1984, P NATL ACAD SCI-BIOL, V81, P3501, DOI 10.1073/pnas.81.11.3501; QUINTI I, 1986, J ALLERGY CLIN IMMUN, V77, P586, DOI 10.1016/0091-6749(86)90350-7; RANKIN JA, 1982, NATURE, V297, P329, DOI 10.1038/297329a0; ROUZER CA, 1982, P NATL ACAD SCI-BIOL, V79, P5656, DOI 10.1073/pnas.79.18.5656; SAINTREMY JMR, 1983, J IMMUNOL, V130, P1341; SPIEGELBERG HL, 1984, ADV IMMUNOL, V35, P61, DOI 10.1016/S0065-2776(08)60574-X; VANLOGHEM E, 1984, VOX SANG, V46, P195; Waaler E, 1940, ACTA PATHOL MIC SC, V17, P172, DOI DOI 10.1111/J.1699-0463.1940.TB01475.X; WILLIAMS RC, 1972, J CLIN INVEST, V51, P955, DOI 10.1172/JCI106890	33	39	40	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1986	77	4					555	557		10.1016/0091-6749(86)90344-1	http://dx.doi.org/10.1016/0091-6749(86)90344-1			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	A9381	2420851				2022-12-18	WOS:A1986A938100004
J	LOWENSTEIN, H; GRAFFLONNEVIG, V; HEDLIN, G; HEILBORN, H; LILJA, G; NORRLIND, K; PEGELOW, KO; SUNDIN, B				LOWENSTEIN, H; GRAFFLONNEVIG, V; HEDLIN, G; HEILBORN, H; LILJA, G; NORRLIND, K; PEGELOW, KO; SUNDIN, B			IMMUNOTHERAPY WITH CAT-DANDER AND DOG-DANDER EXTRACTS .3. ALLERGEN-SPECIFIC IMMUNOGLOBULIN RESPONSES IN A 1-YEAR DOUBLE-BLIND PLACEBO STUDY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									DANDERYD HOSP,S-18288 DANDERYD,SWEDEN; HUDDINGE UNIV HOSP,S-14186 HUDDINGE,SWEDEN; SASCHKA HOSP,STOCKHOLM,SWEDEN	Danderyds Hospital; Karolinska Institutet	LOWENSTEIN, H (corresponding author), UNIV COPENHAGEN,PROT LAB,SIGURDSGADE 34,DK-2200 COPENHAGEN N,DENMARK.							AXELSEN NH, 1973, SCAND J IMMUNOL, V2, P71, DOI 10.1111/j.1365-3083.1973.tb03782.x; BLANDS J, 1977, ACTA ALLERGOL, V32, P147, DOI 10.1111/j.1398-9995.1977.tb01346.x; HARBOE N, 1973, SCAND J IMMUNOL S, V2, P71; LOWENSTEIN H, 1977, INT ARCH ALLER A IMM, V55, P514, DOI 10.1159/000231965; LOWENSTEIN H, 1985, ALLERGY, V40, P430, DOI 10.1111/j.1398-9995.1985.tb02682.x; Lowenstein H, 1978, Prog Allergy, V25, P1, DOI 10.1159/000314432; LOWENSTEIN H, J ALLERGY CLIN IMMUN; LOWENSTEIN H, 1981, ALLERGOLOGIE, V4, P265; OHMAN JL, 1982, J ALLERGY CLIN IMMUN, V69, P320; OSTERBALLE O, 1983, J ALLERGY CLIN IMMUN, V71, P40, DOI 10.1016/0091-6749(83)90545-6; Schwartz B, 1979, Ugeskr Laeger, V141, P882; SONDERGAARD I, 1984, ALLERGY, V39, P135, DOI 10.1111/j.1398-9995.1984.tb01945.x	12	39	39	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1986	77	3					497	505		10.1016/0091-6749(86)90185-5	http://dx.doi.org/10.1016/0091-6749(86)90185-5			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	A5367	2419384				2022-12-18	WOS:A1986A536700014
J	MOLLER, DR; BROOKS, SM; BERNSTEIN, DI; CASSEDY, K; ENRIONE, M; BERNSTEIN, IL				MOLLER, DR; BROOKS, SM; BERNSTEIN, DI; CASSEDY, K; ENRIONE, M; BERNSTEIN, IL			DELAYED ANAPHYLACTOID REACTION IN A WORKER EXPOSED TO CHROMIUM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CINCINNATI,MED CTR,DEPT MED,DIV IMMUNOL,ML 563,231 BETHESDA AVE,CINCINNATI,OH 45267; UNIV CINCINNATI,MED CTR,DEPT ENVIRONM HLTH,DIV CLIN STUDIES,CINCINNATI,OH 45267	University of Cincinnati; University of Cincinnati					NCRR NIH HHS [RR-0068-18] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000068] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AARONSON DW, 1980, ALLERGIC DISEASE DIA, P231; BERNSTEIN IL, 1976, J ALLERGY CLIN IMMUN, V57, P141, DOI 10.1016/0091-6749(76)90033-6; DVORAK AM, 1979, ARCH PATHOL LAB MED, V103, P113; DVORAK HF, 1974, LAB INVEST, V31, P111; DVORAK HF, 1977, J IMMUNOL, V118, P1549; GECZY CL, 1984, SEMIN IMMUNOPATHOL, V7, P32; HERNANDEZASENSIO M, 1979, J IMMUNOL, V122, P1601; ISHIZAKA K, 1981, J IMMUNOL, V126, P1692; Joulfs H, 1932, LANCET, V2, P182; KAPLAN I, 1963, ARCH DERMATOL, V88, P188, DOI 10.1001/archderm.1963.01590200076015; KESKINEN H, 1980, CLIN ALLERGY, V10, P151, DOI 10.1111/j.1365-2222.1980.tb02092.x; LETTBROWN MA, 1976, J IMMUNOL, V117, P246; MALI JWH, 1963, J INVEST DERMATOL, V41, P111, DOI 10.1038/jid.1963.83; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; MIRZA AM, 1975, INT ARCH ALLER A IMM, V49, P782, DOI 10.1159/000231462; PARKER D, 1984, INT ARCH ALLER A IMM, V73, P123, DOI 10.1159/000233451; PELTONEN L, 1983, CONTACT DERMATITIS, V9, P190, DOI 10.1111/j.1600-0536.1983.tb04356.x; ROCKLIN RE, 1971, J ALLERGY CLIN IMMUN, V48, P276, DOI 10.1016/0091-6749(71)90028-5; ROCKLIN RE, 1981, LYMPHOKINES, V2, P163; SHAFF RE, 1979, ANAL BIOCHEM, V94, P425, DOI 10.1016/0003-2697(79)90385-3; SHELLEY WB, 1964, JAMA-J AM MED ASSOC, V189, P772; TENCATI JR, 1983, ANN INTERN MED, V98, P320, DOI 10.7326/0003-4819-98-3-320; THUESON DO, 1979, J IMMUNOL, V123, P626; THUESON DO, 1982, HUMAN LYMPHOKINES BI, P231; WARD PA, 1977, J IMMUNOL, V119, P416; Williams C D Jr, 1969, N C Med J, V30, P482; 1982 AM C GOVT IND H	27	39	39	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1986	77	3					451	456		10.1016/0091-6749(86)90179-X	http://dx.doi.org/10.1016/0091-6749(86)90179-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	A5367	2936792				2022-12-18	WOS:A1986A536700008
J	HALLWORTH, GW; PADFIELD, JM				HALLWORTH, GW; PADFIELD, JM			A COMPARISON OF THE REGIONAL DEPOSITION IN A MODEL NOSE OF A DRUG DISCHARGED FROM METERED AEROSOL AND METERED-PUMP NASAL DELIVERY SYSTEMS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											HALLWORTH, GW (corresponding author), GLAXO GRP RES LTD,PARK RD,WARE SG12 0DJ,HERTS,ENGLAND.							BENJAMIN EJ, 1983, J PHARM SCI, V72, P380, DOI 10.1002/jps.2600720415; DAVIES PJ, 1980, DRUG DEV IND PHARM, V6, P645, DOI 10.3109/03639048009065320; Fry F.A., 1973, J AEROSOL SCI, V4, P113; HALLWORTH GW, 1976, J PHARM PHARMACOL, V28, P890, DOI 10.1111/j.2042-7158.1976.tb04087.x; HALLWORTH GW, 1976, J PHARM PHARMACOL, V28, P898, DOI 10.1111/j.2042-7158.1976.tb04088.x; HALLWORTH GW, UNPUB J PHARM PHARM; HATHAWAY D, 1973, AEROSOL AGE, V18, P28; HEYDER J, 1975, INHALED PARTICLES, V4, P107; HOUNAM RF, 1971, INHALED PARTICLES, V3, P71; MISZUK S, 1980, J PHARM SCI, V69, P713, DOI 10.1002/jps.2600690628; MYGIND N, 1978, RHINOLOGY, V16, P1; PROCTOR F, 1971, INHALED PARTICLES, V1, P59; RANCE RW, 1974, J SOC COSMET CHEM, V25, P545; SATO Y, 1982, OTORHINOLARYNGOLOG S, V2, P137; TURNER KJ, 1980, AEROSOL AGE, V25, P24; UNNO T, 1982, JPN J OTOL TOKYO, V85, P277; YU CD, 1984, J PHARM SCI, V73, P344	17	39	40	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1986	77	2					348	353		10.1016/S0091-6749(86)80116-6	http://dx.doi.org/10.1016/S0091-6749(86)80116-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	A0899	3944385				2022-12-18	WOS:A1986A089900014
J	NICKELSEN, JA; GEORGITIS, JW; REISMAN, RE				NICKELSEN, JA; GEORGITIS, JW; REISMAN, RE			LACK OF CORRELATION BETWEEN TITERS OF SERUM ALLERGEN-SPECIFIC IGE AND SYMPTOMS IN UNTREATED PATIENTS WITH SEASONAL ALLERGIC RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SUNY BUFFALO,BUFFALO GEN HOSP,ALLERGY RES LAB,BUFFALO,NY 14260	Buffalo General Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NCCIH NIH HHS [5R01 AT 0130326] Funding Source: Medline	NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		FREIDHOFF LR, 1983, J ALLERGY CLIN IMMUN, V72, P274, DOI 10.1016/0091-6749(83)90032-5; GEORGITIS J W, 1982, Journal of Allergy and Clinical Immunology, V69, P100; GEORGITIS JW, 1983, J ALLERGY CLIN IMMUN, V71, P92, DOI 10.1016/0091-6749(83)90139-2; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; MATHEWS KP, 1981, INT ARCH ALLER A IMM, V66, P218, DOI 10.1159/000232821; NICKELSEN J, 1982, Journal of Allergy and Clinical Immunology, V69, P100; NICKELSEN JA, 1981, J ALLERGY CLIN IMMUN, V68, P41, DOI 10.1016/0091-6749(81)90121-4; NICKELSEN JA, 1981, J ALLERGY CLIN IMMUN, V68, P33, DOI 10.1016/0091-6749(81)90120-2; NICKELSEN JA, 1983, CLIN ALLERGY, V13, P509, DOI 10.1111/j.1365-2222.1983.tb02632.x; NICKELSEN JA, 1983, J ALLERGY CLIN IMMUN, V71, P118, DOI 10.1016/0091-6749(83)90244-0; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; NORMAN PS, 1965, J ALLERGY, V36, P284, DOI 10.1016/0021-8707(65)90087-0; OKUDA M, 1977, ARCH OTO-RHINO-LARYN, V214, P241, DOI 10.1007/BF00458318; PLATTSMILLS TAE, 1976, J CLIN INVEST, V57, P1041, DOI 10.1172/JCI108346; SIEGEL S, 1956, NONPARAMETRIC STAT, P202; WYPYCH J I, 1984, Journal of Allergy and Clinical Immunology, V73, P140	16	39	41	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1986	77	1	1				43	48		10.1016/0091-6749(86)90320-9	http://dx.doi.org/10.1016/0091-6749(86)90320-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AZD36	2418088				2022-12-18	WOS:A1986AZD3600008
J	ROBINSON, C; HARDY, CC; HOLGATE, ST				ROBINSON, C; HARDY, CC; HOLGATE, ST			PULMONARY SYNTHESIS, RELEASE, AND METABOLISM OF PROSTAGLANDINS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											ROBINSON, C (corresponding author), SOUTHAMPTON GEN HOSP,CTR BLOCK,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND.			Robinson, Clive/0000-0001-6253-7864				ALLY AI, 1982, PROSTAGLANDINS, V24, P575, DOI 10.1016/0090-6980(82)90015-6; ANDERSON MW, 1976, PROSTAGLANDINS, V11, P645, DOI 10.1016/0090-6980(76)90067-8; ARMSTRONG JM, 1978, BRIT J PHARMACOL, V62, P125, DOI 10.1111/j.1476-5381.1978.tb07014.x; BIANCO S, 1978, PHARMACOL RES COMMUN, V10, P657, DOI 10.1016/S0031-6989(78)80009-5; BLACKWELL GJ, 1978, BRIT J PHARMACOL, V62, P79, DOI 10.1111/j.1476-5381.1978.tb07009.x; DAWSON W, 1976, NATURE, V262, P699, DOI 10.1038/262699a0; ELING TE, 1981, CLIN RES PROC, V17, P611; ELING TE, 1977, PROSTAGLANDINS, V14, P51, DOI 10.1016/0090-6980(77)90156-3; GREEN K, 1974, LANCET, V2, P1419; GRIFFIN M, 1983, NEW ENGL J MED, V308, P436, DOI 10.1056/NEJM198302243080807; HAMBERG M, 1971, J BIOL CHEM, V246, P6713; HANSEN HS, 1976, PROSTAGLANDINS, V12, P647, DOI 10.1016/0090-6980(76)90044-7; HARDY C, 1984, THORAX, V39, P696; HARDY C, 1985, AM REV RESPIR DIS, V131, P18; HARDY CC, 1984, NEW ENGL J MED, V311, P209, DOI 10.1056/NEJM198407263110401; HOLGATE ST, 1984, J IMMUNOL, V133, P2138; LEWIS RA, 1982, J IMMUNOL, V129, P1627; LEWIS RA, 1982, CLIN SCI, V63, pP7; MATHE AA, 1975, AM REV RESPIR DIS, V111, P313; MATHE AA, 1973, BRIT MED J, V1, P193, DOI 10.1136/bmj.1.5847.193; MCGUIRE JC, 1978, ARCH BIOCHEM BIOPHYS, V189, P92, DOI 10.1016/0003-9861(78)90118-2; MORLEY J, 1979, PROSTAGLANDINS, V29, P2004; OATES JA, 1984, ASTHMA PHYSL IMMUNOP, P55; PIPER P, 1971, ANN NY ACAD SCI, V180, P363, DOI 10.1111/j.1749-6632.1971.tb53205.x; PIPER PJ, 1982, BRIT J PHARMACOL, V77, P267, DOI 10.1111/j.1476-5381.1982.tb09295.x; ROBERTS LJ, 1981, J BIOL CHEM, V256, P8384; ROBINSON C, 1982, BIOCHEM PHARMACOL, V31, P633, DOI 10.1016/0006-2952(82)90442-7; ROBINSON C, 1982, BIOCHIM BIOPHYS ACTA, V712, P315, DOI 10.1016/0005-2760(82)90349-6; ROBINSON C, 1984, BIOCHEM PHARMACOL, V33, P395, DOI 10.1016/0006-2952(84)90231-4; ROBINSON C, 1983, BIOCHIM BIOPHYS ACTA, V754, P190, DOI 10.1016/0005-2760(83)90161-3; ROBINSON C, 1983, BR J PHARM, V78, P85; SAMUELSSON B, 1974, BIOCHEM MED METAB B, V11, P298, DOI 10.1016/0006-2944(74)90127-6; SCHLEIMER RP, 1983, J CLIN INVEST, V71, P1830, DOI 10.1172/JCI110938; SCHULMAN ES, 1981, AM REV RESPIR DIS, V124, P402; SCHULMAN ES, 1982, J APPL PHYSIOL, V53, P589, DOI 10.1152/jappl.1982.53.3.589; SETH RV, 1981, BRIT J CLIN PHARMACO, V12, P731, DOI 10.1111/j.1365-2125.1981.tb01297.x; SMITH AP, 1975, CLIN SCI MOL MED, V48, P421, DOI 10.1042/cs0480421; STEEL LK, 1982, J IMMUNOL, V129, P1233; THOMSON NC, 1981, J ALLERGY CLIN IMMUN, V68, P392, DOI 10.1016/0091-6749(81)90138-X; WASSERMAN MA, 1981, CLIN RES PROC, V17, P675	40	39	39	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	2					265	271		10.1016/0091-6749(85)90640-2	http://dx.doi.org/10.1016/0091-6749(85)90640-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	APE89	2410475				2022-12-18	WOS:A1985APE8900004
J	GRAMMER, LC; ROBERTS, M; NICHOLLS, AJ; PLATTS, MM; PATTERSON, R				GRAMMER, LC; ROBERTS, M; NICHOLLS, AJ; PLATTS, MM; PATTERSON, R			IGE AGAINST ETHYLENE-OXIDE ALTERED HUMAN-SERUM ALBUMIN IN PATIENTS WHO HAVE HAD ACUTE DIALYSIS REACTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ROYAL HALLAMSHIRE HOSP,DEPT MED,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND	University of Sheffield	GRAMMER, LC (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611, USA.			Grammer, Leslie/0000-0001-6860-2014	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 11403] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BRUCH CW, 1972, IND STERILIZATION, P49; CRADDOCK PR, 1977, J CLIN INVEST, V59, P879, DOI 10.1172/JCI108710; DOLOVICH J, 1978, J ALLERGY CLIN IMMUN, V62, P30, DOI 10.1016/0091-6749(78)90069-6; LIDD D, 1962, J ALLERGY, V33, P45, DOI 10.1016/0021-8707(62)90062-X; LINDOP CR, 1980, J THORAC CARDIOV SUR, V79, P845; NICHOLLS AJ, 1982, BRIT MED J, V285, P1607, DOI 10.1136/bmj.285.6355.1607; POPLI S, 1982, ARTIF ORGANS, V6, P312; ROBINSON PJ, 1971, BRIT MED J, V1, P528, DOI 10.1136/bmj.1.5748.528; ZEISS CR, 1977, CLIN EXP IMMUNOL, V28, P250; ZEISS CR, 1980, J ALLERGY CLIN IMMUN, V65, P346, DOI 10.1016/0091-6749(80)90211-0; ZEISS CR, 1973, J IMMUNOL, V110, P414	11	39	39	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	4					544	546		10.1016/0091-6749(84)90392-0	http://dx.doi.org/10.1016/0091-6749(84)90392-0			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TN620	6491100				2022-12-18	WOS:A1984TN62000014
J	HINOJOSA, M; MONEO, I; DOMINGUEZ, J; DELGADO, E; LOSADA, E; ALCOVER, R				HINOJOSA, M; MONEO, I; DOMINGUEZ, J; DELGADO, E; LOSADA, E; ALCOVER, R			ASTHMA CAUSED BY AFRICAN MAPLE (TRIPLOCHITON-SCLEROXYLON) WOOD DUST	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CTR ESPECIAL RAMON & CAJAL,SERV IMMUNOL,MADRID 34,SPAIN		HINOJOSA, M (corresponding author), CTR ESPECIAL RAMON & CAJAL,SERV ALERGIA,CARRETERA COLMENAR,KM 9-1,MADRID 34,SPAIN.		Dominguez, Javier/I-1210-2015	Dominguez, Javier/0000-0001-7256-388X				BOOTH BH, 1976, J ALLERGY CLIN IMMUN, V57, P352, DOI 10.1016/0091-6749(76)90092-0; BUSH RK, 1978, AM REV RESPIR DIS, V117, P601; CHANYEUNG M, 1976, AM REV RESPIR DIS, V114, P1027; CHANYEUNG M, 1982, J ALLERGY CLIN IMMUN, V70, P32, DOI 10.1016/0091-6749(82)90198-1; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; CUEVAS M, 1983, INT ARCH ALLER A IMM, V72, P184, DOI 10.1159/000234864; EATON KK, 1973, CLIN ALLERGY, V2, P307; FISHER AA, 1973, CONTACT DERMATITIS, P253; HARTMANN A, 1980, SCHWEIZ MED WSCHR, V110, P278; HOWIE AD, 1976, THORAX, V31, P585, DOI 10.1136/thx.31.5.585; INNOCENTI A, 1980, MED LAVORO, V3, P251; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; MARKIN EL, 1930, J ALLERG, V1, P346; MILLE J, 1969, MED J AUST, V2, P741; MONEO I, 1983, INT ARCH ALLER A IMM, V71, P285, DOI 10.1159/000233406; Nakane P.K., 1979, IMMUNOASSAYS CLIN LA, P81; ORDMAN D, 1949, S Afr Med J, V23, P973; OUCHTERLONY O, 1953, ACTA PATHOL MIC SC, V32, P231; PAGGIARO R, 1981, CLIN ALLERGY, V111, P605; PICKERING C, 1973, CLIN ALLERGY, V2, P307; RAGHUPRASAD PK, 1980, J ALLERGY CLIN IMMUN, V65, P285, DOI 10.1016/0091-6749(80)90157-8; SOSMAN AJ, 1969, NEW ENGL J MED, V281, P977, DOI 10.1056/NEJM196910302811802	22	39	39	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	6					782	786		10.1016/0091-6749(84)90179-9	http://dx.doi.org/10.1016/0091-6749(84)90179-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TW418	6389651	Bronze			2022-12-18	WOS:A1984TW41800004
J	LEWIS, RA				LEWIS, RA			MASTOCYTOSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT RHEUMATOL & IMMUNOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital								BEALL GN, 1960, J CLIN INVEST, V39, P676, DOI 10.1172/JCI104083; BENVENISTE J, 1983, ETHER LIPIDS BIOCH B, P355; BREDFELDT JE, 1980, AM J GASTROENTEROL, V74, P133; BRUNNING RD, 1983, AM J SURG PATHOL, V7, P425, DOI 10.1097/00000478-198307000-00005; CAINELLI T, 1983, ARCH DERMATOL, V119, P1021, DOI 10.1001/archderm.119.12.1021; CAMPBELL EW, 1979, ANN INTERN MED, V90, P940, DOI 10.7326/0003-4819-90-6-940; CAPRON JP, 1978, GASTROENTEROLOGY, V74, P595; CHRISTOPHERS E, 1978, BRIT J DERMATOL, V98, P701, DOI 10.1111/j.1365-2133.1978.tb03592.x; CZARNETZKI BM, 1981, BRIT J DERMATOL, V105, P563, DOI 10.1111/j.1365-2133.1981.tb00800.x; DEMIS DJ, 1963, ANN INTERN MED, V59, P194, DOI 10.7326/0003-4819-59-2-194; ELLIS CK, 1979, J BIOL CHEM, V254, P4152; ENERBACK L, 1966, ACTA PATHOL MIC SC, V66, P289, DOI 10.1111/apm.1966.66.3.289; FINE JD, 1980, INT J DERMATOL, V19, P117, DOI 10.1111/j.1365-4362.1980.tb00272.x; FISHMAN RS, 1979, MAYO CLIN PROC, V54, P51; FITZPATRICK FA, 1983, J BIOL CHEM, V258, P1713; FRIERI M, 1982, ANN INTERN MED, V97, P220, DOI 10.7326/0003-4819-97-2-220; GAGNON JH, 1975, CAN MED ASSOC J, V112, P1329; GRANERUS G, 1983, J INVEST DERMATOL, V80, P410, DOI 10.1111/1523-1747.ep12555351; GUILLET GY, 1982, ARCH DERMATOL, V118, P532, DOI 10.1001/archderm.118.7.532; HARDY CC, 1984, NEW ENGL J MED, V311, P209, DOI 10.1056/NEJM198407263110401; HIRSCHOWITZ BI, 1979, ANN INTERN MED, V90, P769, DOI 10.7326/0003-4819-90-5-769; KAPLAN AP, 1976, J INVEST DERMATOL, V67, P327, DOI 10.1111/1523-1747.ep12514352; KESSLER DA, 1976, INT J CANCER, V18, P703, DOI 10.1002/ijc.2910180520; KEYZER JJ, 1983, NEW ENGL J MED, V309, P1603, DOI 10.1056/NEJM198312293092603; KLATT EC, 1983, CANCER, V51, P1119, DOI 10.1002/1097-0142(19830315)51:6<1119::AID-CNCR2820510624>3.0.CO;2-M; LAGUNOFF D, 1976, ARCH BIOCHEM BIOPHYS, V173, P554, DOI 10.1016/0003-9861(76)90292-7; LEE TH, 1982, J ALLERGY CLIN IMMUN, V70, P73, DOI 10.1016/0091-6749(82)90232-9; LENNERT K, 1979, HISTOPATHOLOGY, V3, P349, DOI 10.1111/j.1365-2559.1979.tb03017.x; LEWIS RA, 1982, J IMMUNOL, V129, P1627; LEWIS RA, 1981, NATURE, V293, P103, DOI 10.1038/293103a0; MACGLASHAN D, 1983, 12 P C EUR AC ALL CL, P267; MACGLASHAN DW, 1982, J CLIN INVEST, V70, P747, DOI 10.1172/JCI110670; MAHOOD JM, 1982, ACTA DERM-VENEREOL, V62, P264; MENCIAHUERTA JM, 1983, J IMMUNOL, V130, P1885; METCALFE DD, 1980, J INVEST DERMATOL, V74, P210, DOI 10.1111/1523-1747.ep12541737; METCALFE DD, 1979, J CLIN INVEST, V64, P1537, DOI 10.1172/JCI109613; MULLER UR, 1983, J ALLERGY CLIN IMMUN, V72, P685, DOI 10.1016/0091-6749(83)90630-9; NENCI G G, 1982, Folia Haematologica (Leipzig), V109, P453; NEWBALL HH, 1976, LUNG CELLS DISEASE, P261; OATES JA, 1962, AM J MED, V32, P333, DOI 10.1016/0002-9343(62)90124-9; PINCKARD RN, 1983, IMMUNOPHARMACOLOGY L, P73; RAZIN E, 1983, J EXP MED, V157, P189, DOI 10.1084/jem.157.1.189; Roberts L J 2nd, 1982, Adv Shock Res, V8, P145; ROBERTS LJ, 1980, NEW ENGL J MED, V303, P1400, DOI 10.1056/NEJM198012113032405; ROBERTS LJ, J CHROMATOGR; RUITENBERG EJ, 1982, INT ARCH ALLER A IMM, V67, P233, DOI 10.1159/000233024; SAGHER F, 1967, MASTOCYTOSIS MAST CE, P94; SCHWARTZ LB, 1983, J IMMUNOL, V130, P1891; SCHWARTZ LB, 1981, J IMMUNOL, V126, P1290; SCOTT HW, 1983, ANN SURG, V197, P507, DOI 10.1097/00000658-198305000-00002; SOSTRE S, 1977, ARCH DERMATOL, V113, P1245, DOI 10.1001/archderm.113.9.1245; SOTER NA, 1979, NEW ENGL J MED, V301, P465, DOI 10.1056/NEJM197908303010903; SOTER NA, 1976, NEW ENGL J MED, V294, P687, DOI 10.1056/NEJM197603252941302; STEVENS RL, 1983, J BIOL CHEM, V258, P5977; TURK J, 1983, J ALLERGY CLIN IMMUN, V71, P189, DOI 10.1016/0091-6749(83)90098-2; WEBB TA, 1982, CANCER, V49, P927, DOI 10.1002/1097-0142(19820301)49:5<927::AID-CNCR2820490517>3.0.CO;2-B; WESTIN J, 1975, SCAND J HAEMATOL, V15, P45	58	39	39	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	6					755	763		10.1016/0091-6749(84)90172-6	http://dx.doi.org/10.1016/0091-6749(84)90172-6			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TW418	6389650				2022-12-18	WOS:A1984TW41800001
J	SCHELLENBERG, RR; WALKER, B; SNYDER, F				SCHELLENBERG, RR; WALKER, B; SNYDER, F			PLATELET-DEPENDENT CONTRACTION OF HUMAN BRONCHUS BY PLATELET-ACTIVATING FACTOR	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract									UNIV BRITISH COLUMBIA,PULM RES LAB,VANCOUVER V6T 1W5,BC,CANADA; OAKLAND UNIV,ROCHESTER,MI 48063	University of British Columbia; Oakland University									0	39	39	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	1					145	145		10.1016/0091-6749(83)90351-2	http://dx.doi.org/10.1016/0091-6749(83)90351-2			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PZ462					2022-12-18	WOS:A1983PZ46200228
J	THORESEN, CE; KIRMILGRAY, K				THORESEN, CE; KIRMILGRAY, K			SELF-MANAGEMENT PSYCHOLOGY AND THE TREATMENT OF CHILDHOOD ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											THORESEN, CE (corresponding author), STANFORD UNIV,SCH EDUC,STANFORD,CA 94305, USA.							ALEXANDER AB, 1981, COMPREHENSIVE HDB BE, V2; ALEXANDER AB, 1981, MED PSYCHOL CONTRIBU; BANDURA A, 1978, AM PSYCHOL, V33, P344, DOI 10.1037/0003-066X.33.4.344; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; BANDURA A, 1982, AM PSYCHOL, V37, P122, DOI 10.1037/0003-066X.37.2.122; BANDURA A, 1969, PRINCIPLES BEHAVIOR; BROADBENT DE, 1977, AM PSYCHOL, V32, P109, DOI 10.1037/0003-066X.32.2.109; JONES RT, 1977, BEHAV MODIF, V1, P147, DOI 10.1177/014544557712001; Kahneman D., 1973, ATTENTION EFFORT; KANFER FH, 1972, BEHAV THER, V3, P398, DOI 10.1016/S0005-7894(72)80140-0; KAROLY P, 1982, SELF MANAGEMENT BEHA; KAUSNER S, 1965, QUEST SELF CONTROL C; Knowles JH., 1977, DOING BETTER FEELING; MISCHEL W, 1973, PSYCHOL REV, V80, P252, DOI 10.1037/h0035002; PRIBRAM KH, 1975, PSYCHOL REV, V82, P116, DOI 10.1037/h0076780; RENNE CM, 1976, J APPL BEHAV ANAL, V9, P1, DOI 10.1901/jaba.1976.9-1; SCHWARTZ GE, 1982, J CONSULT CLIN PSYCH, V50, P1040; SKINNER BF, 1953, SCI HUMAN BEHAVIOR; THORESEN CE, 1974, BEHAVIORAL SELF CONT; THORESEN CE, 1980, BEHAVIOR THERAPIST; WILLEMS EP, 1974, J APPL BEHAV ANAL, V7, P151, DOI 10.1901/jaba.1974.7-151	21	39	39	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	5					596	606		10.1016/0091-6749(83)90487-6	http://dx.doi.org/10.1016/0091-6749(83)90487-6			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	RS163	6643867				2022-12-18	WOS:A1983RS16300013
J	TING, S; ZWEIMAN, B; LAVKER, RM				TING, S; ZWEIMAN, B; LAVKER, RM			CROMOLYN DOES NOT MODULATE HUMAN ALLERGIC SKIN REACTIONS INVIVO	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV PENN,DEPT MED,ALLERGY IMMUNOL SECT,PHILADELPHIA,PA 19104; UNIV PENN,DEPT DERMATOL,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania	TING, S (corresponding author), WILLIAM BEAUMONT ARMY MED CTR,DEPT MED,ALLERGY & IMMUNOL SERV,EL PASO,TX 79920, USA.							ALTOUNYA.RE, 1969, RESPIRATION, VS 26, P131, DOI 10.1159/000192647; ALTOUNYAN RE, 1967, ACTA ALLERGOL, V22, P487; ANAND SC, 1972, ANN ALLERGY, V30, P64; ANKIER SI, 1971, INT ARCH ALLER A IMM, V41, P163, DOI 10.1159/000230512; ATKINS PC, 1978, J ALLERGY CLIN IMMUN, V62, P149, DOI 10.1016/0091-6749(78)90099-4; BIERENSTOCK J, 1980, IMMUNOLOGY, V41, P249; GOOSE J, 1969, IMMUNOLOGY, V16, P749; HAIDER SA, 1977, BRIT MED J, V1, P1570, DOI 10.1136/bmj.1.6076.1570; KALINER MA, 1980, J ALLERGY CLIN IMMUN, V66, P1, DOI 10.1016/0091-6749(80)90131-1; LEVY DA, 1973, J LAB CLIN MED, V81, P291; PEARCE CA, 1974, CLIN EXP IMMUNOL, V17, P437; PEPYS J, 1968, LANCET, V2, P134; PEPYS J, 1979, MAST CELL ITS ROLE H, P199; TING S, 1980, J ALLERGY CLIN IMMUN, V66, P417, DOI 10.1016/0091-6749(80)90122-0	14	39	40	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	1					12	17		10.1016/0091-6749(83)90540-7	http://dx.doi.org/10.1016/0091-6749(83)90540-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PZ461	6185553				2022-12-18	WOS:A1983PZ46100002
J	BACON, JR; MCLEAN, JA; MATHEWS, KP; BANAS, JM				BACON, JR; MCLEAN, JA; MATHEWS, KP; BANAS, JM			PRIMING OF THE NASAL-MUCOSA BY RAGWEED EXTRACT OR BY AN IRRITANT (AMMONIA)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,DIV ALLERGY,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NIAID NIH HHS [AI10391-07] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSEN I, 1974, ARCH ENVIRON HEALTH, V28, P31, DOI 10.1080/00039896.1974.10666429; ANDERSEN IB, 1979, AM REV RESPIR DIS, V119, P619; CONNELL JT, 1968, J ALLERGY, V41, P101; CONNELL JT, 1970, NEW YORK STATE J MED, V70, P1751; CONNELL JT, 1968, J ALLERGY, V41, P123, DOI 10.1016/0021-8707(68)90053-1; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; HASTIE R, 1979, LAB INVEST, V40, P554; MATHEWS KP, 1980, J ALLERGY CLIN IMMUN, V65, P191; MCLEAN JA, 1976, J ALLERGY CLIN IMMUN, V57, P153, DOI 10.1016/0091-6749(76)90034-8; MCLEAN JA, 1979, ANN OTO RHINOL LARYN, V88, P228, DOI 10.1177/000348947908800214; MCLEAN JA, 1977, J ALLERGY CLIN IMMUN, V59, P165, DOI 10.1016/0091-6749(77)90220-2; SCHUMACHER MJ, 1979, J ALLERGY CLIN IMMUN, V64, P202, DOI 10.1016/0091-6749(79)90096-4; SOLOMON WR, 1965, J ALLERGY, V36, P62, DOI 10.1016/0021-8707(65)90033-X; SPEIZER FE, 1966, BRIT J IND MED, V23, P75; TAYLOR G, 1971, Clinical Allergy, V1, P63, DOI 10.1111/j.1365-2222.1971.tb02448.x	15	39	39	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	2					111	116		10.1016/0091-6749(81)90005-1	http://dx.doi.org/10.1016/0091-6749(81)90005-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LB947	7451777				2022-12-18	WOS:A1981LB94700005
J	FREEDMAN, PM; AULT, B				FREEDMAN, PM; AULT, B			BRONCHIAL HYPER-REACTIVITY TO METHACHOLINE IN FARMERS LUNG-DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MARSHFIELD CLIN,DEPT ALLERGY,MARSHFIELD,WI 54449	Marshfield Clinic								BARBEE RA, 1965, P SOC EXP BIOL MED, V118, P546, DOI 10.3181/00379727-118-29901; BOLIN JF, 1980, J ALLERGY CLIN IMMUN, V65, P207; BRAUN SR, 1979, AM REV RESPIR DIS, V119, P185; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; EMANUEL DA, 1964, AM J MED, V37, P392, DOI 10.1016/0002-9343(64)90195-0; FISH JE, 1976, AM REV RESPIR DIS, V113, P579; FREEDMAN PM, 1980, J ALLERGY CLIN IMMUN, V65, P228; GERRARD WJ, 1979, J OCCUP MED, V21, P342; HAPKE EJ, 1968, THORAX, V23, P45; KARR RM, 1978, CHEST, V74, P98, DOI 10.1378/chest.74.1.98; KILBURN KH, 1975, SCIENCE, V189, P634, DOI 10.1126/science.1162344; LAM S, 1979, J ALLERGY CLIN IMMUN, V63, P28, DOI 10.1016/0091-6749(79)90158-1; MAKINO S, 1966, J ALLERGY, V38, P127, DOI 10.1016/0021-8707(66)90036-0; MARX JJ, 1978, J ALLERGY CLIN IMMUN, V62, P185, DOI 10.1016/0091-6749(78)90105-7; MARX JJ, 1979, FED PROC, V38, P941; MELLIS CM, 1978, PEDIATRICS, V61, P446; MOIRA C, 1973, AM REV RESPIR DIS, V108, P1103; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; MUITTARI A, 1968, Annales Medicinae Internae Fenniae, V57, P197; OUELLETTE JJ, 1965, J ALLERGY, V36, P558, DOI 10.1016/0021-8707(65)90193-0; PARKER CD, 1965, ARCH INTERN MED, V115, P452, DOI 10.1001/archinte.1965.03860160078013; PEPYS J, 1965, THORAX, V20, P21, DOI 10.1136/thx.20.1.21; RANKIN J, 1962, ANN INTERN MED, V57, P606, DOI 10.7326/0003-4819-57-4-606; ROBERTS RC, 1976, J ALLERGY CLIN IMMUN, V57, P518, DOI 10.1016/0091-6749(76)90002-6; SCHLUETER D, 1979, ADV ASTHMA ALLERGY P, V5, P14; SCHLUETER DP, 1974, AM J MED, V57, P476, DOI 10.1016/0002-9343(74)90141-7; SEAL RME, 1968, THORAX, V23, P469, DOI 10.1136/thx.23.5.469; SIMONSSO BG, 1965, ACTA ALLERGOL, V20, P325, DOI 10.1111/j.1398-9995.1965.tb03068.x; TOWNLEY RG, 1965, J ALLERGY, V36, P121, DOI 10.1016/0021-8707(65)90161-9; WALKER H, 1969, ELEMENTARY STATISTIC, P149; WILLIAMS J. V., 1963, THORAX, V18, P182, DOI 10.1136/thx.18.2.182	31	39	39	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	1					59	63		10.1016/0091-6749(81)90046-4	http://dx.doi.org/10.1016/0091-6749(81)90046-4			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KZ173	7451772				2022-12-18	WOS:A1981KZ17300011
J	CHANYEUNG, M; GICLAS, PC; HENSON, PM				CHANYEUNG, M; GICLAS, PC; HENSON, PM			ACTIVATION OF COMPLEMENT BY PLICATIC ACID, THE CHEMICAL-COMPOUND RESPONSIBLE FOR ASTHMA DUE TO WESTERN RED CEDAR (THUJA-PLICATA)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NATL JEWISH HOSP & RES CTR,DEPT PEDIAT,DENVER,CO 80206	National Jewish Health	CHANYEUNG, M (corresponding author), UNIV BRITISH COLUMBIA,VANCOUVER GEN HOSP,DEPT MED,RESP CLIN,VANCOUVER V5Z 1L6,BC,CANADA.							BARTON GM, 1971, 1023 CAN FOR SERV DE; BERRENS L, 1974, ANN NY ACAD SCI, V221, P153, DOI 10.1111/j.1749-6632.1974.tb28213.x; BERRENS L, 1972, INT ARCH ALLER A IMM, V43, P347, DOI 10.1159/000230850; CHANYEUNG M, 1971, CAN MED ASSOC J, V105, P56; CHANYEUNG M, 1978, J OCCUP ENVIRON MED, V20, P323; CHANYEUNG M, 1973, AM REV RESPIR DIS, V108, P1094; COOPERS H, 1976, BASIC CLIN IMMUNOLOG, P56; EDWARDS J H, 1974, Clinical Allergy, V4, P379, DOI 10.1111/j.1365-2222.1974.tb01399.x; EDWARDS JH, 1976, CLIN ALLERGY, V6, P19, DOI 10.1111/j.1365-2222.1976.tb01408.x; GARDNER JAF, 1966, CAN J CHEMISTRY, V44, P52, DOI 10.1139/v66-009; Hugli T E, 1978, Adv Immunol, V26, P1, DOI 10.1016/S0065-2776(08)60228-X; KELLER HU, 1976, AGENTS ACTIONS, V6, P326, DOI 10.1007/BF01972250; LAM S, 1979, J ALLERGY CLIN IMMUN, V63, P28, DOI 10.1016/0091-6749(79)90158-1; MARX JJ, 1976, J ALLERGY CLIN IMMUN, V57, P328, DOI 10.1016/0091-6749(76)90089-0; MILNE J, 1969, MED J AUSTRALIA, V2, P741, DOI 10.5694/j.1326-5377.1969.tb107378.x; RAPP HJ, 1970, MOL BASIS COMPLEMENT; WILSON MR, 1977, J ALLERGY CLIN IMMUN, V60, P218, DOI 10.1016/0091-6749(77)90133-6	17	39	39	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	65	5					333	337		10.1016/0091-6749(80)90209-2	http://dx.doi.org/10.1016/0091-6749(80)90209-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JV955	6768786				2022-12-18	WOS:A1980JV95500003
J	MINOR, JD; TOLBER, SG; FRICK, OL				MINOR, JD; TOLBER, SG; FRICK, OL			LEUKOCYTE INHIBITION-FACTOR IN DELAYED-ONSET FOOD ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF SAN FRANCISCO, SCH MED, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco					NIAID NIH HHS [AI 00011, AI 11010] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOCK SA, 1978, CLIN ALLERGY, V8, P559, DOI 10.1111/j.1365-2222.1978.tb01509.x; BROSTOFF J, 1974, P ROY SOC MED, V67, P514, DOI 10.1177/00359157740676P136; BUCKLEY RH, 1969, NEW ENGL J MED, V281, P465, DOI 10.1056/NEJM196908282810903; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; CLAUSEN JE, 1971, ACTA ALLERGOL, V26, P56, DOI 10.1111/j.1398-9995.1971.tb01399.x; DAVID JR, 1972, PROG ALLERGY, V16, P300, DOI 10.1159/000313176; GALANT SP, 1973, CLIN ALLERGY, V3, P363, DOI 10.1111/j.1365-2222.1973.tb01343.x; Gell PGH, 1968, CLIN ASPECTS IMMUNOL, VSecond, P580; GOLBERT TM, 1969, J ALLERGY, V44, P96, DOI 10.1016/0021-8707(69)90005-7; HILL AB, 1977, SHORT TXB MED STAT, P127; HIPPOCRATES, 1957, ENCYCL BRITANNICA, V11, P584; HOFFMAN DR, 1975, IMMUNOCHEMISTRY, V12, P535, DOI 10.1016/0019-2791(75)90080-4; HOFFMAN DR, 1974, J ALLERGY CLIN IMMUN, V54, P165, DOI 10.1016/0091-6749(74)90053-0; ISHIZAKA K, 1967, J IMMUNOL, V99, P1187; LUCRETIUS, RERUM NATURA, V4, P637; May C D, 1972, Clin Allergy, V2, P335, DOI 10.1111/j.1365-2222.1972.tb01298.x; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P432, DOI 10.1016/0091-6749(76)90124-X; MAY CD, 1978, ALLERGY, V33, P166, DOI 10.1111/j.1398-9995.1978.tb01532.x; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P500, DOI 10.1016/0091-6749(76)90194-9; OPPENHEIM JJ, 1969, IMMUNOLOGY, V16, P123; PRAUSNITZ C, 1921, ZBL BAKT           1, V86, P160; ROWE AH, 1931, FOOD ALLERGY; SPEER F, 1975, ANN ALLERGY, V34, P71; TALMAGE DW, 1957, ANNU REV MED, V8, P239, DOI 10.1146/annurev.me.08.020157.001323; WIDE L, 1967, LANCET, V2, P1105; WRAITH DG, 1979, CLIN ALLERGY, V9, P25, DOI 10.1111/j.1365-2222.1979.tb01519.x	27	39	39	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	4					314	321		10.1016/0091-6749(80)90027-5	http://dx.doi.org/10.1016/0091-6749(80)90027-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KM254	6999066				2022-12-18	WOS:A1980KM25400009
J	ATKINS, PC; NORMAN, M; ZWEIMAN, B; ROSENBLUM, F				ATKINS, PC; NORMAN, M; ZWEIMAN, B; ROSENBLUM, F			FURTHER CHARACTERIZATION AND BIOLOGIC ACTIVITY OF RAGWEED ANTIGEN-INDUCED NEUTROPHIL CHEMOTACTIC ACTIVITY IN MAN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV PENN,SCH MED,DEPT PEDIAT,PHILADELPHIA,PA 19104	University of Pennsylvania	ATKINS, PC (corresponding author), UNIV PENN,SCH MED,DEPT MED,ALLERGY & IMMUNOL SECT,PHILADELPHIA,PA 19104, USA.								0	39	39	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	4					251	258		10.1016/0091-6749(79)90140-4	http://dx.doi.org/10.1016/0091-6749(79)90140-4			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HQ469	479476	Bronze			2022-12-18	WOS:A1979HQ46900004
J	KAPLAN, MS; SOLLI, NJ				KAPLAN, MS; SOLLI, NJ			IMMUNOGLOBULIN-E TO COWS-MILK PROTEIN IN BREAST-FED ATOPIC CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											KAPLAN, MS (corresponding author), KAISER PERMANENTE MED CTR,DEPT ALLERGY & CLIN IMMUNOL,OAKLAND,CA 94611, USA.							BJORKSTEN F, 1978, LANCET, V2, P264; Donnally HH, 1930, J IMMUNOL, V19, P15; FOUCARD T, 1973, ACTA PAEDIATR SCAND, V62, P633, DOI 10.1111/j.1651-2227.1973.tb17078.x; FRIER S, 1973, CLIN ALLERGY, V3, P597; GLASER J, 1954, J ALLERGY, V25, P447, DOI 10.1016/0021-8707(54)90009-X; Glaser J, 1966, J Asthma Res, V3, P199, DOI 10.3109/02770906609106920; GOLDSTEIN GB, 1970, J ALLERGY, V46, P270, DOI 10.1016/0021-8707(70)90068-7; HADDAD ZH, 1972, J ALLERGY CLIN IMMUN, V49, P210, DOI 10.1016/0091-6749(72)90084-X; HEMMINGS WA, 1978, LANCET, V2, P575; HOFFMAN DR, 1974, J ALLERGY CLIN IMMUN, V54, P165, DOI 10.1016/0091-6749(74)90053-0; JAKOBSSON, 1978, LANCET, V2, P437; JARRETT, 1977, LANCET, V2, P223; JOHNSTONE DE, 1966, NEW ENGL J MED, V274, P715, DOI 10.1056/NEJM196603312741305; JUTO P, 1979, LANCET, V1, P102; KAPLAN MS, 1977, ANN ALLERGY, V39, P75; LARSEN SA, 1978, J PEDIATR-US, V92, P417, DOI 10.1016/S0022-3476(78)80430-2; Lyon GT, 1928, AM J DIS CHILD, V36, P1012, DOI 10.1001/archpedi.1928.01920290140009; MELAM H, 1972, ALLERGIC DISEASES DI, P571; MUELLER JL, 1963, NEW ENGL J MED, V268, P1220; SOOTHILL JF, 1974, CLIN ALLERG, V3, P511	20	39	39	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	2					122	126		10.1016/0091-6749(79)90045-9	http://dx.doi.org/10.1016/0091-6749(79)90045-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HG426	458055	Bronze			2022-12-18	WOS:A1979HG42600005
J	KALISKER, A; NELSON, HE; MIDDLETON, E				KALISKER, A; NELSON, HE; MIDDLETON, E			DRUG-INDUCED CHANGES OF ADENYLATE-CYCLASE ACTIVITY IN CELLS FROM ASTHMATIC AND NON-ASTHMATIC SUBJECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NATL ASTHMA CTR,DEPT BIOCHEM PHARMACOL,DENVER,CO 80204; FITZSIMONS ARMY MED CTR,ALLERGY CLIN,DENVER,CO 80240									ALSTON WC, 1974, BRIT MED J, V1, P90, DOI 10.1136/bmj.1.5898.90; BOURNE HR, 1971, J PHARMACOL EXP THER, V178, P1; BUSSE WW, 1976, J ALLERGY CLIN IMMUN, V58, P586, DOI 10.1016/0091-6749(76)90205-0; CONOLLY ME, 1976, J CLIN INVEST, V58, P1307, DOI 10.1172/JCI108586; DAVIES KE, 1974, NUCLEIC ACIDS RES, V1, P129, DOI 10.1093/nar/1.1.129; FRANKLIN TJ, 1973, NATURE-NEW BIOL, V246, P146, DOI 10.1038/newbio246146a0; GILLESPIE E, 1974, J ALLERGY CLIN IMMUN, V53, P27, DOI 10.1016/0091-6749(74)90096-7; IGNARRO LJ, 1974, P NATL ACAD SCI USA, V71, P2027, DOI 10.1073/pnas.71.5.2027; KALISKER A, 1973, MOL PHARMACOL, V9, P619; KEIGHLEY JF, 1966, ANN INTERN MED, V65, P985, DOI 10.7326/0003-4819-65-5-985; KIRKPATRICK CH, 1967, AM REV RESPIR DIS, V96, P692; KOLLER CA, 1973, J IMMUNOL, V111, P1610; KRISHNA G, 1968, J PHARMACOL EXP THER, V163, P379; KUO JF, 1969, J BIOL CHEM, V244, P2252; LOCKEY SD, 1967, J ALLERGY, V40, P349, DOI 10.1016/0021-8707(67)90024-X; LOGSDON PJ, 1972, J ALLERGY CLIN IMMUN, V50, P45, DOI 10.1016/0091-6749(72)90078-4; MENDELSOHN J, 1971, J CLIN INVEST, V50, P818, DOI 10.1172/JCI106553; MIDDLETON E, 1968, J ALLERGY, V42, P288, DOI 10.1016/0021-8707(68)90022-1; MILLER JFAP, 1972, NATURE-NEW BIOL, V237, P18, DOI 10.1038/newbio237018a0; MOSIER DE, 1967, SCIENCE, V158, P1573, DOI 10.1126/science.158.3808.1573; NELSON HS, 1975, J ALLERGY CLIN IMMUN, V55, P299, DOI 10.1016/0091-6749(75)90002-0; NEWCOMBE DS, 1975, P NATL ACAD SCI USA, V72, P3124, DOI 10.1073/pnas.72.8.3124; PARKER CW, 1973, J CLIN INVEST, V52, P48, DOI 10.1172/JCI107173; PERKINS JP, 1973, J PHARMACOL EXP THER, V185, P371; REISMAN RE, 1968, J ALLERGY, V41, P37, DOI 10.1016/0021-8707(68)90006-3; REMOLDOD.E, 1974, J BIOL CHEM, V249, P3615; ROMERO JA, 1975, P NATL ACAD SCI USA, V72, P1661, DOI 10.1073/pnas.72.5.1661; SANDLER JA, 1975, J CLIN INVEST, V55, P431, DOI 10.1172/JCI107948; SU YF, 1974, FED PROC, V33, P493; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; WHITE AA, 1971, ANAL BIOCHEM, V41, P372, DOI 10.1016/0003-2697(71)90156-4; ZUCKERFR.D, 1974, J IMMUNOL, V112, P234; ZURIER RB, 1974, J CLIN INVEST, V53, P279	33	39	39	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	60	4					259	265		10.1016/0091-6749(77)90141-5	http://dx.doi.org/10.1016/0091-6749(77)90141-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DX458	198452				2022-12-18	WOS:A1977DX45800011
J	ZELEZNICK, LD; HUNT, KJ; SOBOTKA, AK; VALENTINE, MD; TIPPETT, LO; LICHTENSTEIN, LM				ZELEZNICK, LD; HUNT, KJ; SOBOTKA, AK; VALENTINE, MD; TIPPETT, LO; LICHTENSTEIN, LM			DIAGNOSIS OF HYMENOPTERA HYPERSENSITIVITY BY SKIN TESTING WITH HYMENOPTERA VENOMS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ALCON LABS INC,CTR LABS,DEPT RES,FT WORTH,TX 76101; JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21218	Novartis; Alcon; Johns Hopkins University								ARBESMAN CE, 1966, J ALLERGY, V38, P1, DOI 10.1016/0021-8707(66)90067-0; BARR SE, 1972, ANN ALLERGY, V30, P282; BERNTON HS, 1965, J ALLERGY, V36, P315, DOI 10.1016/0021-8707(65)90038-9; Jeffreys Harold, 1961, THEORY PROBABILITY, V3rd; LICHTENSTEIN LM, 1974, NEW ENGL J MED, V290, P1223, DOI 10.1056/NEJM197405302902204; OCONNOR R, 1964, SCIENCE, V145, P1320, DOI 10.1126/science.145.3638.1320; REISMAN RE, 1975, J ALLERGY CLIN IMMUN, V55, P79; SETTIPANE GA, 1970, ACTA ALLERGOL, V25, P286, DOI 10.1111/j.1398-9995.1970.tb01264.x; SOBOTKA AK, 1974, J ALLERGY CLIN IMMUN, V53, P170, DOI 10.1016/0091-6749(74)90005-0; SWARTZ HJ, 1965, JAMA, V194, P113; VALENTINE MD, 1975, J ALLERGY CLIN IMMUN, V55, P79; YOCUM MW, 1973, J ALLERGY CLIN IMMUN, V52, P265, DOI 10.1016/0091-6749(73)90045-6	12	39	39	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	1					2	9		10.1016/0091-6749(77)90169-5	http://dx.doi.org/10.1016/0091-6749(77)90169-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CS828	64482	Bronze			2022-12-18	WOS:A1977CS82800001
J	BENSON, TE; ARKINS, JA				BENSON, TE; ARKINS, JA			CYTOTOXIC TESTING FOR FOOD ALLERGY - EVALUATION OF REPRODUCIBILITY AND CORRELATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MED COLL WISCONSIN,DEPT MED,ALLERGY & IMMUNOL SECT,MILWAUKEE,WI 53226	Medical College of Wisconsin								[Anonymous], COMMUNICATION; BLACK AP, 1956, PEDIATRICS, V17, P716; BRYAN W. T. K., 1960, LARYNGOSCOPE, V70, P810; BRYAN WTK, 1969, LARYNGOSCOPE, V79, P1453, DOI 10.1288/00005537-196908000-00010; CHAMBERS VV, 1958, J ALLERGY, V29, P93; DICKEY LD, 1971, J AMER MED ASSOC, V217, P214, DOI 10.1001/jama.1971.03190020072026; DRAPER WL, 1972, ARCH OTOLARYNGOL, V95, P168; GOLDMAN AS, 1963, PEDIATRICS, V32, P425; HEINER DC, 1972, J AMER MED ASSOC, V220, P1624; HOSEN H, 1972, Journal of Asthma Research, V10, P131, DOI 10.3109/02770907209108773; LIEBERMAN P, 1975, JAMA-J AM MED ASSOC, V231, P728; LOWELL FC, 1972, J AMER MED ASSOC, V220, P1624; Miller JB, 1972, FOOD ALLERGY PROVOCA; RINKEL HJ, 1951, FOOD ALLERGY, P129; ROWE AH, 1972, FOOD ALLERGY ITS MAN, P40; SHELDON JM, 1967, MANUAL CLINICAL ALLE; SQUIER TL, 1947, J ALLERGY, V18, P156, DOI 10.1016/0021-8707(47)90101-9; ULETT GA, 1974, ANN ALLERGY, V33, P23; ULETT GA, 1974, ANN ALLERGY, V34, P150; WILLOUGHBY JW, 1965, ANN ALLERGY, V23, P543; WIXOM RR, COMMUNICATION	21	39	39	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	4					471	476		10.1016/0091-6749(76)90190-1	http://dx.doi.org/10.1016/0091-6749(76)90190-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CH210	787048				2022-12-18	WOS:A1976CH21000003
J	CENTER, JG; SHULLER, N; ZELEZNICK, LD				CENTER, JG; SHULLER, N; ZELEZNICK, LD			STABILITY OF ANTIGEN E IN COMMERCIALLY PREPARED RAGWEED POLLEN EXTRACTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CTR LABS, RES DEPT, 35 CHANNEL DR, PORT WASHINGTON, NY 11050 USA									BAER H, 1970, J ALLERGY, V45, P347, DOI 10.1016/0021-8707(70)90043-2; FOUCARD T, 1973, Clinical Allergy, V3, P91, DOI 10.1111/j.1365-2222.1973.tb01313.x; HJORTH NIELS, 1958, ACTA ALLERGOL, V12, P316, DOI 10.1111/j.1398-9995.1958.tb03088.x; LAZAR H, 1970, ANN ALLERGY, V28, P214; NORMAN PS, 1972, J ALLERGY CLIN IMMUN, V50, P31, DOI 10.1016/0091-6749(72)90077-2; RANCOUR JM, 1973, J ALLERGY CLIN IMMUN, V51, P114, DOI 10.1016/S0091-6749(73)80078-8; YUNGINGER JW, 1972, J ALLERGY CLIN IMMUN, V50, P326, DOI 10.1016/0091-6749(72)90036-X	7	39	39	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	54	5					305	310		10.1016/0091-6749(74)90016-5	http://dx.doi.org/10.1016/0091-6749(74)90016-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U6412					2022-12-18	WOS:A1974U641200006
J	LOGSDON, PJ; CARNRIGHT, DV; MIDDLETON, E; COFFEY, RG				LOGSDON, PJ; CARNRIGHT, DV; MIDDLETON, E; COFFEY, RG			EFFECT OF PHENTOLAMINE ON ADENYLATE CYCLASE AND ON ISOPROTERENOL STIMULATION IN LEUKOCYTES FROM ASTHMATIC AND NONASTHMATIC SUBJECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CHILDRENS ASTHMA RES INST & HOSP, DEPT BIOCHEM, 3401 W 19TH AVE, DENVER, CO 80204 USA									CASTRODELAMATA R, 1962, J PHARMACOL EXP THER, V135, P197; EVERITT BJ, 1969, J PHARM PHARMACOL, V21, P97, DOI 10.1111/j.2042-7158.1969.tb08204.x; FISHEL CW, 1962, J IMMUNOL, V89, P8; FLEISCH H, 1970, CIRC RES, V26, P151; FLEISCH JH, 1972, J PHARMACOL EXP THER, V181, P425; FLEISCH JH, 1971, BRIT J PHARMACOL, V42, P311, DOI 10.1111/j.1476-5381.1971.tb07115.x; FLEISCH JH, 1970, AM J PHYSIOL, V218, P596, DOI 10.1152/ajplegacy.1970.218.2.596; GOULD L, 1968, AM J CARDIOL, V22, P523, DOI 10.1016/0002-9149(68)90157-4; GOULD L, 1969, AM J CARDIOL, V21, P100; GRIFFIN JP, 1972, LANCET, V1, P1288; HUMES JL, 1969, ANAL BIOCHEM, V32, P210, DOI 10.1016/0003-2697(69)90077-3; KLOTZ S D, 1950, Ann Allergy, V8, P767; KUO JF, 1969, J BIOL CHEM, V244, P2252; LEWIS CM, 1969, J AMER MED ASSOC, V208, P1391, DOI 10.1001/jama.208.8.1391; LOGSDON PJ, 1972, J ALLERGY CLIN IMMUN, V50, P45, DOI 10.1016/0091-6749(72)90078-4; MARCELLE R, 1968, ACTA ALLERGOL, V23, P11, DOI 10.1111/j.1398-9995.1968.tb04043.x; MATHE AA, 1971, J PHARM PHARMACOL, V23, P905, DOI 10.1111/j.2042-7158.1971.tb09891.x; MURAD F, 1962, J BIOL CHEM, V237, P1233; PARKER CW, 1973, J CLIN INVEST, V52, P48, DOI 10.1172/JCI107173; PERSSON H, 1970, ACTA PHARMACOL TOX, V28, P49; PRIME FJ, 1972, B PHYSIO-PATHOL RESP, V8, P99; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; TAKAGI K, 1967, INT PHARMACODYN, V168, P212; TAYLOR SH, 1965, CIRCULATION, V31, P741, DOI 10.1161/01.CIR.31.5.741; TOWNLEY RG, 1967, J ALLERGY, V39, P177, DOI 10.1016/0021-8707(67)90036-6; ZAHIR M, 1971, J CLIN PHARMACOL N D, V11, P197	26	39	39	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	52	3					148	157		10.1016/0091-6749(73)90031-6	http://dx.doi.org/10.1016/0091-6749(73)90031-6			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q7045	4353452				2022-12-18	WOS:A1973Q704500003
J	BERNSTEIN, IL				BERNSTEIN, IL			ENZYME ALLERGY IN POPULATIONS EXPOSED TO LONG-TERM, LOW-LEVEL CONCENTRATIONS OF HOUSEHOLD LAUNDRY PRODUCTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		AUDRAN R, 1960, CR HEBD ACAD SCI, V250, P3909; BELIN L, 1970, LANCET, V2, P1153; BERNSTEIN IL, 1970, ISRAEL J MED SCI, V6, P746; BERSON SA, 1971, NEW ENGL J MED, V284, P688, DOI 10.1056/NEJM197104012841302; BLOCH KJ, 1967, PROG ALLERGY, V10, P84; BRODEUR P, 1971, ENIGMATIC ENZYM 0116, P42; CARTER RO, 1970, J AMER MED ASSOC, V211, P2017, DOI 10.1001/jama.211.12.2017; CRANE R, 1970, 23 ANN M ACEMB WASH; CRIEP LH, 1964, J ALLERGY, V35, P425, DOI 10.1016/0021-8707(64)90068-1; DOLOVICH J, 1971, J ALLERGY, V47, P98; DUBOS R, 1971, SCIENCE, V173, P259, DOI 10.1126/science.173.3993.259; FALLERONI AE, 1971, LANCET, V1, P548; FERRARA A, 1963, J ALLERGY, V34, P460, DOI 10.1016/0021-8707(63)90011-X; FLINDT MLH, 1969, LANCET, V1, P1177; FRANZ T, 1971, J ALLERGY, V47, P170, DOI 10.1016/S0091-6749(71)80295-6; GHERINI AJ, 1961, CALIF MED, V94, P379; GOLDRING IP, 1970, SCIENCE, V170, P73, DOI 10.1126/science.170.3953.73; GREENBERG M, 1970, BMJ-BRIT MED J, V2, P629, DOI 10.1136/bmj.2.5710.629; HAMMOND AL, 1971, SCIENCE, V172, P361, DOI 10.1126/science.172.3981.361; HENDRICKS MH, 1970, J AM OIL CHEM SOC, V47, P207, DOI 10.1007/BF02638872; HENNINGSEN SJ, 1969, P SOC EXP BIOL MED, V132, P459; HOWE C, 1961, NEW ENGL J MED, V265, P332, DOI 10.1056/NEJM196108172650708; HOWELL IL, 1961, JAMA-J AM MED ASSOC, V175, P322, DOI 10.1001/jama.1961.63040040015016; IMANISHI A, 1965, J BIOCHEM-TOKYO, V57, P417, DOI 10.1093/oxfordjournals.jbchem.a128096; KORY RC, 1961, AM J MED, V30, P243, DOI 10.1016/0002-9343(61)90096-1; KUO JF, 1968, J BIOL CHEM, V243, P211; LEVY DA, 1967, J IMMUNOL, V99, P1068; LICHTENSTEIN LM, 1967, J ALLERGY, V40, P160, DOI 10.1016/0021-8707(67)90005-6; LIEBOWITZ D, 1960, JAMA-J AM MED ASSOC, V172, P159, DOI 10.1001/jama.1960.63020020006008c; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUFT S, 1960, J Am Podiatry Assoc, V50, P209; MACLAREN WR, 1957, J ALLERGY, V28, P89, DOI 10.1016/0021-8707(57)90074-6; MCKABA DG, 1971, 27 ANN M ACAD ALL CH; MCMURRAIN KD, 1970, JOM-J OCCUP MED, V12, P416; MITCHELL CA, 1971, AM REV RESPIR DIS, V104, P1; MORIHARA K, 1969, ARCH BIOCHEM BIOPHYS, V129, P620, DOI 10.1016/0003-9861(69)90223-9; NAGY SM, 1971, 27 ANN M AM ACAD ALL; NEWHOUSE ML, 1970, LANCET, V1, P689; NISHIMURA S, 1962, BIOCHIM BIOPHYS ACTA, V55, P421; OGILVIE CM, 1957, J CLIN INVEST, V36, P1, DOI 10.1172/JCI103402; Orange R P, 1969, Adv Immunol, V10, P105, DOI 10.1016/S0065-2776(08)60416-2; PARISH WE, 1970, LANCET, V2, P591; PEPYS J, 1969, LANCET, V1, P1181; ROSE KD, 1960, JAMA-J AM MED ASSOC, V173, P196; SALVAGGIO JE, 1964, J ALLERGY, V35, P62, DOI 10.1016/0021-8707(64)90050-4; SHAPIRO RS, 1971, J ALLERGY, V47, P76, DOI 10.1016/S0091-6749(71)80373-1; SHERLINE DM, 1962, JAMA-J AM MED ASSOC, V181, P1079, DOI 10.1001/jama.1962.03050380057017c; SHORE PA, 1959, J PHARMACOL EXP THER, V127, P182; SIMON A, 1969, DIS CHEST, V56, P98, DOI 10.1378/chest.56.2.98; SLAVIN RG, 1971, J ALLERGY, V47, P97; WICHER V, 1971, INT ARCH ALLER A IMM, V40, P779, DOI 10.1159/000230462; WUTHRICH B, 1969, SCHWEIZ MED WSCHR, V99, P1584; 1969, LANCET, V1, P1195; 1971, N ENGL J MED, V284, P723; 1971, J ALLERGY, V47, P53	55	39	39	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	49	4					219	+						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M1477	4622164				2022-12-18	WOS:A1972M147700003
J	EVANS, R; ARBESMAN, CE; WYPYCH, JI; REISMAN, RE				EVANS, R; ARBESMAN, CE; WYPYCH, JI; REISMAN, RE			IMMUNOLOGICAL EVALUATION OF RAGWEED-SENSITIVE PATIENTS BY NEWER TECHNIQUES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		ARBESMAN CE, 1960, J ALLERGY, V31, P317, DOI 10.1016/0021-8707(60)90068-X; ARBESMAN CE, 1971, J ALLERGY, V47, P85; AVRAMEAS S, 1967, J BIOL CHEM, V242, P1651; BERG T, 1969, INT ARCH ALLER A IMM, V36, P219, DOI 10.1159/000230745; GELL PGH, 1968, CLINICAL ASPECTS IMM, P639; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; ISHIZAKA K, 1966, J IMMUNOL, V97, P75; ISHIZAKA K, 1970, J IMMUNOL, V105, P1459; ISHIZAKA T, 1969, J IMMUNOL, V102, P884; ITO K, 1969, J IMMUNOL, V103, P622; JOHANSSON SGO, 1971, PERSONAL COMMUNICATI; LEVY DA, 1966, J IMMUNOL, V97, P203; LEVY DA, 1971, J CLIN INVEST, V50, P360, DOI 10.1172/JCI106503; LICHTENSTEIN LM, 1970, IMMUNOLOGY, V19, P831; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LICHTENSTEIN LM, 1967, J ALLERGY, V40, P160, DOI 10.1016/0021-8707(67)90005-6; LICHTENSTEIN LM, 1966, J CLIN INVEST, V45, P1126, DOI 10.1172/JCI105419; SHORE PA, 1959, J PHARMACOL EXP THER, V127, P182; Snedecor G.W., 1980, STAT METHODS, V7; STENIUS B, 1969, LANCET, V2, P455; WIDE L, 1967, LANCET, V2, P1105; WIDE L, 1967, IMMUNOCHEMISTRY, V4, P381, DOI 10.1016/0019-2791(67)90097-3	22	39	39	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	49	5					285	&		10.1016/0091-6749(72)90096-6	http://dx.doi.org/10.1016/0091-6749(72)90096-6			0	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M4215	4111966				2022-12-18	WOS:A1972M421500004
J	OHMAN, JL; LAWRENCE, M; LOWELL, FC				OHMAN, JL; LAWRENCE, M; LOWELL, FC			EFFECT OF PROPRANOLOL ON ISOPROTERENOL, RESPONSES OF CORTISOL, ISOPROTERENOL, AND AMINOPHYLLINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		FELARCA AB, 1967, J ALLERGY, V40, P16, DOI 10.1016/0021-8707(67)90055-X; HENRY WL, 1953, AM J PHYSIOL, V174, P455, DOI 10.1152/ajplegacy.1953.174.3.455; HERION JC, 1970, BLOOD-J HEMATOL, V36, P361, DOI 10.1182/blood.V36.3.361.361; HUDSON G, 1968, Seminars in Hematology, V5, P166; KOCHWESE.J, 1968, ARCH INTERN MED, V121, P255, DOI 10.1001/archinte.121.3.255; RECANT L, 1950, J CLIN ENDOCRINOL, V10, P187, DOI 10.1210/jcem-10-2-187; REED CE, 1970, J ALLERGY, V46, P90, DOI 10.1016/0021-8707(70)90076-6; SCHWARTZ HJ, 1968, ANN INTERN MED, V69, P493, DOI 10.7326/0003-4819-69-3-493	8	39	39	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	50	3					151	&		10.1016/0091-6749(72)90046-2	http://dx.doi.org/10.1016/0091-6749(72)90046-2			0	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N4708	5050326				2022-12-18	WOS:A1972N470800004
J	TOURVILLE, DR; WERTLAKE, PT; WEISS, WI; LEUDEMANN, GM				TOURVILLE, DR; WERTLAKE, PT; WEISS, WI; LEUDEMANN, GM			HYPERSENSITIVITY PNEUMONITIS DUE TO CONTAMINATION OF HOME HUMIDIFIER	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note																		BANASZAK EF, 1970, NEW ENGL J MED, V283, P271, DOI 10.1056/NEJM197008062830601; BUECHNER HA, 1958, AM J MED, V25, P234, DOI 10.1016/0002-9343(58)90030-5; CHEW WH, 1967, J IMMUNOL, V98, P220; COHEN HI, 1967, AM J MED, V43, P785, DOI 10.1016/0002-9343(67)90121-0; DICKIE HA, 1958, JAMA-J AM MED ASSOC, V167, P1069, DOI 10.1001/jama.1958.02990260011004; EMANUEL DA, 1964, AM J MED, V37, P392, DOI 10.1016/0002-9343(64)90195-0; EMANUEL DA, 1966, NEW ENGL J MED, V274, P1413, DOI 10.1056/NEJM196606232742504; FINK JN, 1968, ANN INTERN MED, V68, P1205, DOI 10.7326/0003-4819-68-6-1205; FINK JN, 1971, ANN INTERN MED, V74, P80, DOI 10.7326/0003-4819-74-1-80; HARGREAV.FE, 1966, LANCET, V1, P445; HUGHES WF, 1969, AM J DIS CHILD, V118, P777, DOI 10.1001/archpedi.1969.02100040779018; OUCHTERLONY O, 1962, PROG ALLERGY, V6, P30, DOI 10.1159/000313795; PEPYS J, 1966, ANN INTERN MED, V64, P943, DOI 10.7326/0003-4819-64-4-943; PEPYS J, 1963, LANCET, V2, P607; PEPYS J, 1969, MONOGR ALLERGY, V4, P59; PIERCE AK, 1968, AM REV RESPIR DIS, V97, P561; REED CE, 1965, J AMER MED ASSOC, V193, P261, DOI 10.1001/jama.1965.03090040005001; SAKULA A, 1967, BRIT MED J, V3, P708, DOI 10.1136/bmj.3.5567.708; SALVAGGIO JE, 1966, ANN INTERN MED, V64, P748, DOI 10.7326/0003-4819-64-4-748; SCHLUETER DP, 1969, ANN INTERN MED, V70, P457, DOI 10.7326/0003-4819-70-3-457; SWEET LC, 1971, J ALLERGY CLIN IMMUN, V48, P171, DOI 10.1016/0091-6749(71)90013-3; 1969, LANCET, V1, P1195; 1967, BRIT MED J, V3, P691	23	39	39	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	49	4					245	+		10.1016/0091-6749(72)90087-5	http://dx.doi.org/10.1016/0091-6749(72)90087-5			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M1477	4622165				2022-12-18	WOS:A1972M147700005
J	FELARCA, AB; LOWELL, FC				FELARCA, AB; LOWELL, FC			ACCUMULATION OF EOSINOPHILS AND BASOPHILS AT SKIN SITES AS RELATED TO INTENSITY OF SKIN REACTIVITY AND SYMPTOMS IN ATOPIC DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		DVORAK HF, 1970, J EXP MED, V132, P558, DOI 10.1084/jem.132.3.558; EIDINGER D, 1962, NATURE, V196, P683, DOI 10.1038/196683a0; FELARCA AB, 1968, J ALLERGY, V41, P82, DOI 10.1016/0021-8707(68)90016-6; FELARCA AB, 1969, J ALLERGY, V43, P114, DOI 10.1016/0021-8707(69)90131-2; FOWLER JW, 1966, J ALLERGY, V37, P19, DOI 10.1016/0021-8707(66)90106-7; HALLE CI, 1967, J ALLERGY, V39, P33, DOI 10.1016/0021-8707(67)90124-4; LEVY DA, 1971, J CLIN INVEST, V50, P360, DOI 10.1172/JCI106503; RICHERSON HB, 1969, J IMMUNOL, V103, P1431; WOLFJURGENSEN P, 1966, BASOPHILIC LEUKOCYTE, P123	10	39	39	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1971	48	3					125	&		10.1016/0091-6749(71)90007-8	http://dx.doi.org/10.1016/0091-6749(71)90007-8			0	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K3234	4936278	Bronze			2022-12-18	WOS:A1971K323400001
J	Zuraw, B; Lumry, WR; Johnston, DT; Aygoren-Pursun, E; Banerji, A; Bernstein, JA; Christiansen, SC; Jacobs, JS; Sitz, KV; Gower, RG; Gagnon, R; Wedner, HJ; Kinaciyan, T; Hakl, R; Hanzlikova, J; Anderson, JT; McNeil, DL; Fritz, SB; Yang, WH; Tachdjian, R; Busse, PJ; Craig, TJ; Li, HH; Farkas, H; Best, JM; Clemons, D; Cornpropst, M; Dobo, SM; Iocca, HA; Kargl, D; Nagy, E; Murray, SC; Collis, P; Sheridan, WP; Maurer, M; Riedl, MA				Zuraw, Bruce; Lumry, William R.; Johnston, Douglas T.; Aygoren-Pursun, Emel; Banerji, Aleena; Bernstein, Jonathan A.; Christiansen, Sandra C.; Jacobs, Joshua S.; Sitz, Karl V.; Gower, Richard G.; Gagnon, Remi; Wedner, H. James; Kinaciyan, Tamar; Hakl, Roman; Hanzlikova, Jana; Anderson, John T.; McNeil, Donald L.; Fritz, Stephen B.; Yang, William H.; Tachdjian, Raffi; Busse, Paula J.; Craig, Timothy J.; Li, H. Henry; Farkas, Henriette; Best, Jessica M.; Clemons, Desiree; Cornpropst, Melanie; Dobo, Sylvia M.; Iocca, Heather A.; Kargl, Deborah; Nagy, Eniko; Murray, Sharon C.; Collis, Phil; Sheridan, William P.; Maurer, Marcus; Riedl, Marc A.			Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						BCX7353; berotralstat; C1 inhibitor; efficacy; HAE; hereditary angioedema; kallikrein inhibitor; long-term prophylaxis; prophylaxis; safety	QUALITY-OF-LIFE; PATHOPHYSIOLOGY; INHIBITOR; THERAPIES; BURDEN	Background: Berotralstat (BCX7353) is an oral, once-daily inhibitor of plasma kallikrein in development for the prophylaxis of hereditary angioedema (HAE) attacks. Objective: Our aim was to determine the efficacy, safety, and tolerability of berotralstat in patients with HAE over a 24-week treatment period (the phase 3 APeX-2 trial). Methods: APeX-2 was a double-blind, parallel-group study that randomized patients at 40 sites in 11 countries 1:1:1 to receive once-daily berotralstat in a dose of 110 mg or 150 mg or placebo (Clinicaltrials.gov identifier NCT03485911). Patients aged 12 years or older with HAE due to C1 inhibitor deficiency and at least 2 investigator-confirmed HAE attacks in the first 56 days of a prospective run-in period were eligible. The primary efficacy end point was the rate of investigator-confirmed HAE attacks during the 24-week treatment period. Results: A total of 121 patients were randomized; 120 of them received at least 1 dose of the study drug (n = 41, 40, and 39 in the 110-mg dose of berotralstat, 150-mg of dose berotralstat, and placebo groups, respectively). Berotralstat demonstrated a significant reduction in attack rate at both 110 mg (1.65 attacks per month; P = .024) and 150 mg (1.31 attacks per month; P<.001) relative to placebo (2.35 attacks per month). The most frequent treatment-emergent adverse events that occurred more with berotralstat than with placebo were abdominal pain, vomiting, diarrhea, and back pain. No drug-related serious treatment-emergent adverse events occurred. Conclusion: Both the 110-mg and 150-mg doses of berotralstat reduced HAE attack rates compared with placebo and were safe and generally well tolerated. The most favorable benefit-to-risk profile was observed at a dose of 150 mg per day.	[Zuraw, Bruce; Christiansen, Sandra C.; Riedl, Marc A.] Univ Calif San Diego, San Diego, CA 92103 USA; [Lumry, William R.] Allergy & Asthma Specialists Dallas, Dallas, TX USA; [Johnston, Douglas T.] Asthma & Allergy Specialists, Charlotte, NC USA; [Aygoren-Pursun, Emel] Goethe Univ Frankfurt, Univ Hosp Frankfurt, Frankfurt, Germany; [Banerji, Aleena] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA 02115 USA; [Bernstein, Jonathan A.] Univ Cincinnati, Cincinnati, OH USA; [Jacobs, Joshua S.] Allergy & Asthma Clin Res, Walnut Creek, CA USA; [Sitz, Karl V.] Little Rock Allergy & Asthma Clin Res Ctr, Little Rock, AR USA; [Gower, Richard G.] Univ Washington Sch Med, Marycliff Clin Res, Spokane, WA USA; [Gagnon, Remi] Clin Specialisee Allergie Capitale, Quebec City, PQ, Canada; [Wedner, H. James] Washington Univ Sch Med, St Louis, MO USA; [Kinaciyan, Tamar] Med Univ Vienna, Dept Dermatol, Vienna, Austria; [Hakl, Roman] Masaryk Univ, Dept Clin Immunol & Allergol, St Annes Univ Hosp Brno, Brno, Czech Republic; [Hakl, Roman] Masaryk Univ, Fac Med, Brno, Czech Republic; [Hanzlikova, Jana] Fac Hosp, Dept Allergol & Immunol, Plzen, Czech Republic; [Anderson, John T.] Clin Res Ctr Alabama, Birmingham, AL USA; [McNeil, Donald L.] Optimed Res Ltd, Columbus, OH USA; [Fritz, Stephen B.] Portland Clin Res, Portland, OR USA; [Yang, William H.] Univ Ottawa, Ottawa Allergy Res Corp, Dept Med, Ottawa, ON, Canada; [Tachdjian, Raffi] Univ Calif Los Angeles, Dept Pediat, Los Angeles, CA 90024 USA; [Busse, Paula J.] Icahn Sch Med Mt Sinai, Dept Med, Div Clin Immunol & Allergy, New York, NY 10029 USA; [Craig, Timothy J.] Penn State Univ, Dept Med & Pediat, Hershey, PA USA; [Li, H. Henry] Inst Asthma & Allergy, Chevy Chase, MD USA; [Farkas, Henriette] Semmelweis Univ, Dept Internal Med 3, Hungarian Angioedema Reference Ctr, Budapest, Hungary; [Best, Jessica M.; Clemons, Desiree; Cornpropst, Melanie; Dobo, Sylvia M.; Iocca, Heather A.; Kargl, Deborah; Nagy, Eniko; Murray, Sharon C.; Collis, Phil; Sheridan, William P.] BioCryst Pharmaceut, Durham, NC USA; [Maurer, Marcus] Charit Univ Med Berlin, Dept Dermatol & Allergy, Dermatol Allergol, Berlin, Germany	University of California System; University of California San Diego; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; University System of Ohio; University of Cincinnati; Washington University (WUSTL); Medical University of Vienna; Masaryk University Brno; St Anne's University Hospital Brno (FNUSA-ICRC); Masaryk University Brno; University of Ottawa; University of California System; University of California Los Angeles; Icahn School of Medicine at Mount Sinai; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Semmelweis University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Sheridan, WP (corresponding author), 4505 Emperor Blvd,Suite 200, Durham, NC 27703 USA.	bsheridan@biocryst.com	Maurer, Marcus/ABG-2174-2020; Banerji, Aleena/ABG-1245-2021	Maurer, Marcus/0000-0002-4121-481X; Bernstein, Jonathan/0000-0002-3476-1196	BioCryst Pharmaceuticals, Inc.; Harvard Catalyst/The Harvard Clinical and Translational Science Center (National Center for Research Resources, National Institutes of Health ) [UL1 TR001102]; Harvard Catalyst/The Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, National Institutes of Health) [UL1 TR001102]	BioCryst Pharmaceuticals, Inc.(Takeda Pharmaceutical Company Ltd); Harvard Catalyst/The Harvard Clinical and Translational Science Center (National Center for Research Resources, National Institutes of Health ); Harvard Catalyst/The Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, National Institutes of Health)	This study was funded by BioCryst Pharmaceuticals, Inc. At Harvard Medical School, the study was conducted with support from Harvard Catalyst/The Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health award UL1 TR001102).	[Anonymous], 2018, VOICE PATIENT HEREDI; Atkinson Mark J, 2004, Health Qual Life Outcomes, V2, P12, DOI 10.1186/1477-7525-2-12; Aygoren-Pursun E, 2018, NEW ENGL J MED, V379, P352, DOI 10.1056/NEJMoa1716995; Barmettler S, 2019, ALLERGY ASTHMA PROC, V40, P7, DOI 10.2500/aap.2019.40.4195; Bork K, 2006, AM J MED, V119, P267, DOI 10.1016/j.amjmed.2005.09.064; Bork K, 2012, J ALLERGY CLIN IMMUN, V130, P692, DOI 10.1016/j.jaci.2012.05.055; Bygum A, 2015, ACTA DERM-VENEREOL, V95, P706, DOI 10.2340/00015555-2014; Christiansen SC, 2017, IMMUNOL ALLERGY CLIN, V37, P527, DOI 10.1016/j.iac.2017.04.008; GELFAND JA, 1976, NEW ENGL J MED, V295, P1444, DOI 10.1056/NEJM197612232952602; Hincapie AL, 2017, J MANAG CARE SPEC PH, V23, P822, DOI 10.18553/jmcp.2017.23.8.822; Kaplan AP, 2010, J ALLERGY CLIN IMMUN, V126, P918, DOI 10.1016/j.jaci.2010.08.012; Lumry WR, 2010, ALLERGY ASTHMA PROC, V31, P407, DOI 10.2500/aap.2010.31.3394; Maurer M, 2018, WORLD ALLERGY ORGAN, V11, DOI 10.1186/s40413-017-0180-1; Nicola Stefania, 2019, Drugs Context, V8, P212605, DOI 10.7573/dic.212605; Weller K, 2016, ALLERGY, V71, P1203, DOI 10.1111/all.12900; Weller K, 2012, ALLERGY, V67, P1289, DOI 10.1111/all.12007; Zuraw BL, 2008, NEW ENGL J MED, V359, P1027, DOI 10.1056/NEJMcp0803977; Zuraw BL, 2016, CLIN REV ALLERG IMMU, V51, P216, DOI 10.1007/s12016-016-8561-8; Zuraw BL, 2016, J ALLER CL IMM-PRACT, V4, P948, DOI 10.1016/j.jaip.2016.03.024; Zuraw BL, 2011, AM J RHINOL ALLERGY, V25, P373, DOI 10.2500/ajra.2011.25.3661	20	38	38	2	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2021	148	1					164	+		10.1016/j.jaci.2020.10.015	http://dx.doi.org/10.1016/j.jaci.2020.10.015		JUL 2021	18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TE3IE	33098856	hybrid			2022-12-18	WOS:000669906700024
J	Nigrovic, PA; Lee, PY; Hoffman, HM				Nigrovic, Peter A.; Lee, Pui Y.; Hoffman, Hal M.			Monogenic autoinflammatory disorders: Conceptual overview, phenotype, and clinical approach	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Autoinflammation; innate immunity; inflammasome; IFN; NF-kappa B	NF-KAPPA-B; INTERLEUKIN-36-RECEPTOR ANTAGONIST DEFICIENCY; FAMILIAL MEDITERRANEAN FEVER; AICARDI-GOUTIERES-SYNDROME; ADENOSINE-DEAMINASE 2; PERIODIC FEVER; I INTERFERON; PHOSPHOLIPASE C-GAMMA-2; NEUTROPHILIC DERMATOSIS; PYODERMA-GANGRENOSUM	Autoinflammatory diseases are conditions in which pathogenic inflammation arises primarily through antigen-independent hyperactivation of immune pathways. First recognized just over 2 decades ago, the autoinflammatory disease spectrum has expanded rapidly to include more than 40 distinct monogenic conditions. Related mechanisms contribute to common conditions such as gout and cardiovascular disease. Here, we review the basic concepts underlying the "autoinflammatory revolution'' in the understanding of immune-mediated disease and introduce major categories of monogenic autoinflammatory disorders recognized to date, including inflammasomopathies and other IL-1-related conditions, interferonopathies, and disorders of nuclear factor kappa B and/or aberrant TNF activity. We highlight phenotypic presentation as a reflection of pathogenesis and outline a practical approach to the evaluation of patients with suspected autoinflammation.	[Nigrovic, Peter A.; Lee, Pui Y.] Boston Childrens Hosp, Dept Pediat, Div Immunol, Boston, MA USA; [Nigrovic, Peter A.; Lee, Pui Y.] Harvard Med Sch, Div Rheumatol Inflammat & Immun, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; [Hoffman, Hal M.] Rady Childrens Hosp, Div Pediat Allergy Immunol & Rheumatol, San Diego, CA USA; [Hoffman, Hal M.] Univ Calif San Diego, San Diego, CA 92103 USA	Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Rady Childrens Hospital San Diego; University of California System; University of California San Diego	Nigrovic, PA (corresponding author), 60 Fenwood Rd,Hale Bldg Transformat Med,Rm 6002L, Boston, MA 02115 USA.	pnigrovic@bwh.harvard.edu			National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) [2R01AR065538, R01AR075906, R01AR073201, P30AR070253, R21AR076630]; National Heart, Lung, and Blood Institute [R21HL150575]; Fundacion Bechara; Arbuckle Family Fund for Arthritis Research; NIAMS [K08-AR074562]; Rheumatology Research Foundation; Boston Children's Hospital; National Institutes of Health [R01 DK113592, R01 HL140898, R01 R01AI134030]	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Fundacion Bechara; Arbuckle Family Fund for Arthritis Research; NIAMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Rheumatology Research Foundation; Boston Children's Hospital; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	P.A.N. is funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (award nos. 2R01AR065538, R01AR075906, R01AR073201, P30AR070253, and R21AR076630) and the National Heart, Lung, and Blood Institute (award no. R21HL150575), the Fundacion Bechara, and the Arbuckle Family Fund for Arthritis Research. P.Y.L. is supported by the NIAMS (grant no. K08-AR074562), a Rheumatology Research Foundation Investigator Award, and a Boston Children's Hospital Faculty Career Development Award. H.M.H. is funded by the National Institutes of Health (award nos. R01 DK113592, R01 HL140898, and R01 R01AI134030) and a UC collaborative grant.	Adang LA, 2018, MOL GENET METAB, V125, P351, DOI 10.1016/j.ymgme.2018.09.004; Akkoc N, 2010, ARTHRITIS RHEUM-US, V62, P3059, DOI 10.1002/art.27598; Aksentijevich I, 1997, CELL, V90, P797; Aksentijevich I, 2009, NEW ENGL J MED, V360, P2426, DOI 10.1056/NEJMoa0807865; Akula MK, 2016, NAT IMMUNOL, V17, P922, DOI 10.1038/ni.3487; Alperin JM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02496; Alsohime F, 2020, NEW ENGL J MED, V382, P256, DOI 10.1056/NEJMoa1905633; Badran YR, 2017, J EXP MED, V214, P1937, DOI 10.1084/jem.20160724; Bernot A, 1997, NAT GENET, V17, P25; Boisson B, 2015, J EXP MED, V212, P939, DOI 10.1084/jem.20141130; Boisson B, 2012, NAT IMMUNOL, V13, P1178, DOI 10.1038/ni.2457; Booshehri LM, 2019, J CLIN IMMUNOL, V39, P277, DOI 10.1007/s10875-019-00638-z; Booty MG, 2009, ARTHRITIS RHEUM-US, V60, P1851, DOI 10.1002/art.24569; Bracaglia C, 2017, ANN RHEUM DIS, V76, P166, DOI 10.1136/annrheumdis-2015-209020; Brau-Javier CN, 2012, ARCH DERMATOL, V148, P301, DOI 10.1001/archdermatol.2011.2857; Brehm A, 2015, J CLIN INVEST, V125, P4196, DOI 10.1172/JCI81260; Brenner M, 2009, BRIT J DERMATOL, V161, P1199, DOI 10.1111/j.1365-2133.2009.09404.x; Briand C, 2019, ANN RHEUM DIS, V78, P431, DOI 10.1136/annrheumdis-2018-214037; Briggs TA, 2011, NAT GENET, V43, P127, DOI 10.1038/ng.748; Broderick L, 2014, PRIMARY IMMUNODEFICI; Bulua AC, 2011, J EXP MED, V208, P519, DOI 10.1084/jem.20102049; Canna SW, 2017, J ALLERGY CLIN IMMUN, V139, P1698, DOI 10.1016/j.jaci.2016.10.022; Canna SW, 2014, NAT GENET, V46, P1140, DOI 10.1038/ng.3089; Chae JJ, 2011, IMMUNITY, V34, P755, DOI 10.1016/j.immuni.2011.02.020; Chakraborty PK, 2014, BLOOD, V124, P2867, DOI 10.1182/blood-2014-08-591370; Chung LK, 2016, CELL HOST MICROBE, V20, P296, DOI 10.1016/j.chom.2016.07.018; Cooper GS, 2003, AUTOIMMUN REV, V2, P119, DOI 10.1016/S1568-9972(03)00006-5; Crow Y.J., 1993, GENEREVIEWS R; Crow YJ, 2015, NAT REV IMMUNOL, V15, P429, DOI 10.1038/nri3850; De Benedetti F, 2018, NEW ENGL J MED, V378, P1908, DOI 10.1056/NEJMoa1706314; de Carvalho LM, 2017, ARTHRITIS RHEUMATOL, V69, P2081, DOI 10.1002/art.40179; de Jesus AA, 2020, J CLIN INVEST, V130, P1669, DOI 10.1172/JCI129301; de Jesus AA, 2019, J ALLERGY CLIN IMMUN, V143, P1939, DOI 10.1016/j.jaci.2018.12.1012; Deng ZM, 2020, J IMMUNOL, V204, P2360, DOI 10.4049/jimmunol.2000028; Duewell P, 2010, NATURE, V464, P1357, DOI 10.1038/nature08938; Duncan CJA, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aav7501; Ehrlich P, 1910, COLLECTED STUDIES IM, P71; Elkan PN, 2014, NEW ENGL J MED, V370, P921, DOI 10.1056/NEJMoa1307362; Ferreira CR, 2019, J CLIN IMMUNOL, V39, P75, DOI 10.1007/s10875-018-0572-1; FISHER CJ, 1994, JAMA-J AM MED ASSOC, V271, P1836, DOI 10.1001/jama.271.23.1836; Flajnik MF, 2018, NAT REV IMMUNOL, V18, P438, DOI 10.1038/s41577-018-0003-9; Gao WQ, 2016, P NATL ACAD SCI USA, V113, pE4857, DOI 10.1073/pnas.1601700113; Gattorno M, 2019, ANN RHEUM DIS, V78, P1025, DOI 10.1136/annrheumdis-2019-215048; Gernez Y, 2019, J ALLERGY CLIN IMMUN, V144, P1122, DOI 10.1016/j.jaci.2019.06.017; Glocker EO, 2009, NEW ENGL J MED, V361, P2033, DOI 10.1056/NEJMoa0907206; Grandemange S, 2017, ANN RHEUM DIS, V76, P1191, DOI 10.1136/annrheumdis-2016-210021; Gruber C, 2020, J EXP MED, V217, DOI 10.1084/jem.20192319; Hayden MS, 2014, SEMIN IMMUNOL, V26, P253, DOI 10.1016/j.smim.2014.05.004; Henderson LA, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.132508; Hoffman HM, 2017, ARTHRITIS RHEUMATOL, V69, P253, DOI 10.1002/art.39961; Hoffman HM, 2016, J ALLERGY CLIN IMMUN, V138, P3, DOI 10.1016/j.jaci.2016.05.001; Holzinger D, 2015, J ALLERGY CLIN IMMUN, V136, P1337, DOI 10.1016/j.jaci.2015.04.016; Hospach T, 2019, PEDIATR RHEUMATOL, V17, DOI 10.1186/s12969-019-0338-1; Huang C, 2019, CELL REP, V29, P4525, DOI 10.1016/j.celrep.2019.11.105; Jang MA, 2015, AM J HUM GENET, V96, P266, DOI 10.1016/j.ajhg.2014.11.019; Jeru I, 2008, P NATL ACAD SCI USA, V105, P1614, DOI 10.1073/pnas.0708616105; Jeru I, 2011, ARTHRITIS RHEUM-US, V63, P2142, DOI 10.1002/art.30378; Jesus AA, 2014, ANNU REV MED, V65, P223, DOI 10.1146/annurev-med-061512-150641; Kahr WHA, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14816; Kolivras A, 2008, J CUTAN PATHOL, V35, P774, DOI 10.1111/j.1600-0560.2007.00900.x; Kothur K, 2018, NEUROLOGY, V90, P289, DOI 10.1212/WNL.0000000000004921; Krutzke S, 2020, EUR J RHEUMATOL, V7, pS78, DOI 10.5152/eurjrheum.2019.18177; Lalaoui N, 2020, NATURE, V577, P103, DOI 10.1038/s41586-019-1828-5; Lam MT, 2019, J EXP MED, V216, P2778, DOI 10.1084/jem.20190147; Lee PY, 2020, J ALLERGY CLIN IMMUN, V145, P1664, DOI [10.1016/j.jaci.2019.12908, 10.1016/j.jaci.2019.12.908]; Lee PY, 2020, ANN RHEUM DIS, V79, P225, DOI 10.1136/annrheumdis-2019-216030; Lee PY, 2018, FRONT PEDIATR, V6, DOI 10.3389/fped.2018.00282; Lepelley A, 2020, J EXP MED, V217, DOI 10.1084/jem.20200600; Liu Y, 2014, NEW ENGL J MED, V371, P507, DOI 10.1056/NEJMoa1312625; Liu Y, 2012, ARTHRITIS RHEUM-US, V64, P895, DOI 10.1002/art.33368; Loo YM, 2011, IMMUNITY, V34, P680, DOI 10.1016/j.immuni.2011.05.003; Lorden G, 2017, J EXP MED, V214, P511, DOI 10.1084/jem.20161452; Manthiram K, 2020, P NATL ACAD SCI USA, V117, P14405, DOI 10.1073/pnas.2002051117; Mao LM, 2018, J CLIN INVEST, V128, P1793, DOI 10.1172/JCI98642; Marrakchi S, 2011, NEW ENGL J MED, V365, P620, DOI 10.1056/NEJMoa1013068; Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516; Marzano AV, 2016, BRIT J DERMATOL, V175, P882, DOI 10.1111/bjd.14691; Masters SL, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf1471; McDermott MF, 1999, CELL, V97, P133, DOI 10.1016/S0092-8674(00)80721-7; Meuwissen MEC, 2016, J EXP MED, V213, P1163, DOI 10.1084/jem.20151529; Milner JD, 2015, J CLIN IMMUNOL, V35, P527, DOI 10.1007/s10875-015-0177-x; Moghaddas F, 2017, ANN RHEUM DIS, V76, P2085, DOI 10.1136/annrheumdis-2017-211473; Nagakura T, 2017, J RHEUMATOL, V44, P536, DOI 10.3899/jrheum.160672; Navid F, 2017, NAT REV RHEUMATOL, V13, P25, DOI 10.1038/nrrheum.2016.192; Neves JF, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02863; Nigrovic PA, 2015, P NATL ACAD SCI USA, V112, P15785, DOI 10.1073/pnas.1521837113; Ombrello AK, 2019, NEW ENGL J MED, V380, P1582, DOI 10.1056/NEJMc1801927; Ombrello MJ, 2015, P NATL ACAD SCI USA, V112, P15970, DOI 10.1073/pnas.1520779112; Ombrello MJ, 2012, NEW ENGL J MED, V366, P330, DOI 10.1056/NEJMoa1102140; Papa R, 2020, RHEUMATOLOGY, V59, P344, DOI 10.1093/rheumatology/kez270; Park YH, 2020, NAT IMMUNOL, V21, P857, DOI 10.1038/s41590-020-0705-6; Park YH, 2016, NAT IMMUNOL, V17, P914, DOI 10.1038/ni.3457; Poli MC, 2018, AM J HUM GENET, V102, P1126, DOI 10.1016/j.ajhg.2018.04.010; Porcelli SA, 2017, KELLEY FIRESTEINS TX; Rabinovich E, 2005, ANN RHEUM DIS, V64, P1009, DOI 10.1136/ard.2004.029447; Reddy S, 2009, NEW ENGL J MED, V360, P2438, DOI 10.1056/NEJMoa0809568; Reis ES, 2019, NAT REV IMMUNOL, V19, P503, DOI 10.1038/s41577-019-0168-x; Rice GI, 2018, NEW ENGL J MED, V379, P2275, DOI 10.1056/NEJMc1810983; Ridker PM, 2017, NEW ENGL J MED, V377, P1119, DOI 10.1056/NEJMoa1707914; Rose CD, 2015, RHEUMATOLOGY, V54, P1008, DOI 10.1093/rheumatology/keu437; ROSE NR, 1956, J IMMUNOL, V76, P417; Rossi-Semerano L, 2013, PEDIATRICS, V132, pE1043, DOI 10.1542/peds.2012-3935; Saitoh T, 2005, J IMMUNOL, V174, P1507, DOI 10.4049/jimmunol.174.3.1507; Sanchez GAM, 2018, J CLIN INVEST, V128, P3041, DOI 10.1172/JCI98814; Scheffel J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13984-8; Schnappauf O, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01745; Schwartz DM, 2020, ANN RHEUM DIS, V79, P429, DOI 10.1136/annrheumdis-2019-215918; Shinar Y, 2020, CLIN CHEM, V66, P525, DOI 10.1093/clinchem/hvaa024; Shouval DS, 2016, GASTROENTEROLOGY, V151, P1100, DOI 10.1053/j.gastro.2016.08.055; Silverstein AM, 2001, NAT IMMUNOL, V2, P279, DOI 10.1038/86280; Simon A, 2010, P NATL ACAD SCI USA, V107, P9801, DOI 10.1073/pnas.0914118107; Song N, 2017, MOL CELL, V68, P185, DOI 10.1016/j.molcel.2017.08.017; Standing ASI, 2017, J EXP MED, V214, P59, DOI 10.1084/jem.20161228; Steiner A, 2018, CURR RHEUMATOL REP, V20, DOI 10.1007/s11926-018-0749-x; Strober W, 2014, IMMUNOL REV, V260, P249, DOI 10.1111/imr.12193; Sun SC, 2017, NAT REV IMMUNOL, V17, P545, DOI 10.1038/nri.2017.52; Takagi M, 2017, J ALLERGY CLIN IMMUN, V139, P1914, DOI 10.1016/j.jaci.2016.09.038; Tao PF, 2020, NATURE, V577, P109, DOI 10.1038/s41586-019-1830-y; Tardif JC, 2019, NEW ENGL J MED, V381, P2497, DOI 10.1056/NEJMoa1912388; Tassi S, 2010, P NATL ACAD SCI USA, V107, P9789, DOI 10.1073/pnas.1000779107; Tauber M, 2016, J INVEST DERMATOL, V136, P1811, DOI 10.1016/j.jid.2016.04.038; ter Haar N, 2013, ANN RHEUM DIS, V72, P678, DOI 10.1136/annrheumdis-2011-201268; Ter Haar NM, 2019, ANN RHEUM DIS, V78, P1405, DOI 10.1136/annrheumdis-2018-214472; Tong EB, 2020, J LUMIN, V217, DOI 10.1016/j.jlumin.2019.116787; Torrelo A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00927; Torrelo A, 2010, J AM ACAD DERMATOL, V62, P489, DOI 10.1016/j.jaad.2009.04.046; Tsui JL, 2018, ERJ OPEN RES, V4, DOI 10.1183/23120541.00017-2018; Tunca M, 2005, MEDICINE, V84, P1, DOI 10.1097/01.md.0000152370.84628.0c; Uggenti C, 2019, ANNU REV IMMUNOL, V37, P247, DOI 10.1146/annurev-immunol-042718-041257; Van Gijn ME, 2018, J MED GENET, V55, P530, DOI 10.1136/jmedgenet-2017-105216; Vladimer GI, 2012, IMMUNITY, V37, P96, DOI 10.1016/j.immuni.2012.07.006; Volpi S, 2019, J CLIN IMMUNOL, V39, P476, DOI 10.1007/s10875-019-00645-0; Volpi S, 2019, J ALLERGY CLIN IMMUN, V143, P2296, DOI 10.1016/j.jaci.2019.02.003; Volpi S, 2018, CLIN IMMUNOL, V187, P33, DOI 10.1016/j.clim.2017.10.001; Wakil SM, 2015, ARTHRITIS RHEUMATOL, V67, P288, DOI 10.1002/art.38877; Wang DM, 2000, IMMUNITY, V13, P25, DOI 10.1016/S1074-7613(00)00005-4; Watkin LB, 2015, NAT GENET, V47, P654, DOI 10.1038/ng.3279; WITEBSKY E, 1956, J IMMUNOL, V76, P408; Wouters CH, 2014, PEDIATR RHEUMATOL, V12, DOI 10.1186/1546-0096-12-33; Yarilina A, 2010, CURR DIR AUTOIMMUN, V11, P94, DOI 10.1159/000289199; Zhang Q, 2017, CELL, V168, P37, DOI 10.1016/j.cell.2016.12.012; Zhang XQ, 2015, NATURE, V517, P89, DOI 10.1038/nature13801; Zhong FL, 2016, CELL, V167, P187, DOI 10.1016/j.cell.2016.09.001; Zhou Q, 2016, NAT GENET, V48, P67, DOI 10.1038/ng.3459; Zhou Q, 2014, NEW ENGL J MED, V370, P911, DOI 10.1056/NEJMoa1307361; Zhou Q, 2012, AM J HUM GENET, V91, P713, DOI 10.1016/j.ajhg.2012.08.006	146	38	39	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2020	146	5					925	937		10.1016/j.jaci.2020.08.017	http://dx.doi.org/10.1016/j.jaci.2020.08.017			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	OP5VH	33160483	Green Accepted			2022-12-18	WOS:000588153700029
J	Delemarre, T; Holtappels, G; De Ruyck, N; Zhang, N; Nauwynck, H; Bachert, C; Gevaert, E				Delemarre, Tim; Holtappels, Gabriele; De Ruyck, Natalie; Zhang, Nan; Nauwynck, Hans; Bachert, Claus; Gevaert, Elien			Type 2 inflammation in chronic rhinosinusitis without nasal polyps: Another relevant endotype	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CRSsNP; type 2 inflammation; eosinophils; recurrence; asthma	IGE	Background: Chronic rhinosinusitis without nasal polyps (CRSsNP) is mainly considered a type 1 mediated disease. The role and clinical significance of type 2 immune responses in CRSsNP have not been addressed sufficiently; a recent cluster analysis for CRS described the existence of a subgroup of patients with CRSsNP with a type 2 inflammation. Objective: We aimed to characterize the underlying type 2 immune response and its clinical significance in patients with CRSsNP. Methods: A total of 240 patients with CRSsNP were endotyped and subdivided on the basis of expression of marker cytokines. Clinical data such as recurrence, comorbid asthma and allergy, and numbers of blood eosinophils and neutrophils were collected from all patients. A selection of 15 patients was further characterized for the presence of eosinophils, neutrophils, Charcot-Leyden crystals, and eosinophil extracellular traps in the mucosae. Results: A type 2 immune response with increased levels of IL-4, IL-5, eosinophil cationic protein, IgE, and Staphylococcus aureus enterotoxin specific IgE was observed in 49% of patients with CRSsNP. Those patients showed increased numbers of blood and tissue eosinophils, and they displayed a considerable eosinophilic inflammation associated with eosinophil extracellular trap cell death and Charcot-Leyden crystals. A significantly increased prevalence of recurrence and asthma was observed in patients with type 2 CRSsNP compared with in patients with non type 2 CRSsNP. However, only 4 of 117 patients with type 2 CRSsNP developed nasal polyps within 12 years. Conclusion: This study shows that type 2 immune responses in CRSsNP follow similar patterns but are less pronounced than in chronic rhinosinusitis with nasal polyps. Also CRSsNP with a moderate type 2 immune response showed a considerable eosinophilic inflammation with clinical impact.	[Delemarre, Tim; Holtappels, Gabriele; De Ruyck, Natalie; Zhang, Nan; Bachert, Claus; Gevaert, Elien] Univ Ghent, Upper Airways Res Lab, Fac Med, Ghent, Belgium; [Nauwynck, Hans] Univ Ghent, Fac Vet Med, Lab Virol, Ghent, Belgium; [Bachert, Claus] Sun Yat Sen Univ, Int Airway Res Ctr, Affiliated Hosp 1, Guangzhou, Peoples R China; [Bachert, Claus] Karolinska Inst, CLINTEC, Div ENT Dis, Stockholm, Sweden	Ghent University; Ghent University; Sun Yat Sen University; Karolinska Institutet	Bachert, C (corresponding author), Univ Ghent, Upper Airways Res Lab, Dept Head & Skin, C Heymanslaan 10, B-9000 Ghent, Belgium.	Claus.Bachert@ugent.be	Bachert, Claus/J-8825-2012	Nauwynck, Hans/0000-0001-5470-0713; Delemarre, Tim/0000-0001-5901-1618	Fonds Wetenschappelijk Onderzoek [FWO/DPO/108]; FWO Flanders [1515516N]; FWO Flanders (EOS) [GOG2318N]; Interuniversity Attraction Poles Grant [P7/30]	Fonds Wetenschappelijk Onderzoek(FWO); FWO Flanders(FWO); FWO Flanders (EOS); Interuniversity Attraction Poles Grant	E.G. was supported by a postdoctoral research fellowship from the Fonds Wetenschappelijk Onderzoek (FWO/DPO/108). C.B. and E.G. were supported by grants from FWO Flanders (1515516N, EOS project nr. GOG2318N) and the Interuniversity Attraction Poles Grant P7/30.	Ahern S, 2019, MEDICINA-LITHUANIA, V55, DOI 10.3390/medicina55040095; Alsharif S, 2019, LARYNGOSCOPE, V129, P1286, DOI 10.1002/lary.27815; Bachert C, 2001, J ALLERGY CLIN IMMUN, V107, P607, DOI 10.1067/mai.2001.112374; Bachert C, 2019, LANCET, V394, P1638, DOI 10.1016/S0140-6736(19)31881-1; Bachert C, 2018, J ALLERGY CLIN IMMUN, V141, P1543, DOI 10.1016/j.jaci.2018.03.004; Benjamin MR, 2019, J ALLER CL IMM-PRACT, V7, P1010, DOI 10.1016/j.jaip.2018.10.014; Calus L, 2019, CLIN TRANSL ALLERGY, V9, DOI 10.1186/s13601-019-0269-4; Cho SH, 2016, J ALLER CL IMM-PRACT, V4, P575, DOI 10.1016/j.jaip.2016.04.015; De Greve G, 2017, CLIN TRANSL ALLERGY, V7, DOI 10.1186/s13601-017-0157-8; DeConde AS, 2017, LARYNGOSCOPE, V127, P550, DOI 10.1002/lary.26391; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Gevaert E, 2020, J ALLERGY CLIN IMMUN, V145, P427, DOI 10.1016/j.jaci.2019.08.027; Gevaert E, 2017, J ALLERGY CLIN IMMUN, V139, P1849, DOI 10.1016/j.jaci.2017.01.019; Hwang CS, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-44627-z; Pauwels B, 2015, EXPERT REV CLIN IMMU, V11, P349, DOI 10.1586/1744666X.2015.1010517; Persson EK, 2019, SCIENCE, V364, P751, DOI 10.1126/science.aaw4295; Soler ZM, 2010, OTOLARYNG HEAD NECK, V142, P64, DOI 10.1016/j.otohns.2009.10.005; Soler ZM, 2009, OTOLARYNG HEAD NECK, V141, P454, DOI 10.1016/j.otohns.2009.06.085; Stevens WW, 2019, J ALLER CL IMM-PRACT, V7, P2812, DOI 10.1016/j.jaip.2019.05.009; Tan BK, 2017, J ALLERGY CLIN IMMUN, V139, P699, DOI 10.1016/j.jaci.2016.06.063; Tomassen P, 2016, J ALLERGY CLIN IMMUN, V137, P1449, DOI 10.1016/j.jaci.2015.12.1324; Turner JH, 2018, J ALLERGY CLIN IMMUN, V141, P1895, DOI 10.1016/j.jaci.2018.02.002; Ueki S, 2018, BLOOD, V132, P2183, DOI 10.1182/blood-2018-04-842260; Van Zele T, 2006, ALLERGY, V61, P1280, DOI 10.1111/j.1398-9995.2006.01225.x; Van Zele T, 2009, LARYNGOSCOPE, V119, P1753, DOI 10.1002/lary.20484; Verbruggen K, 2009, INT ARCH ALLERGY IMM, V148, P87, DOI 10.1159/000155739; Vlaminck S, 2014, AM J RHINOL ALLERGY, V28, P260, DOI 10.2500/ajra.2014.28.4024; Zhang NW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114241	28	38	44	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2020	146	2					337	+		10.1016/j.jaci.2020.04.040	http://dx.doi.org/10.1016/j.jaci.2020.04.040			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MZ0TA	32417132	Bronze			2022-12-18	WOS:000558835000024
J	Lougaris, V; Soresina, A; Baronio, M; Montin, D; Martino, S; Signa, S; Volpi, S; Zecca, M; Marinoni, M; Baselli, LA; Dellepiane, RM; Carrabba, M; Fabio, G; Putti, MC; Cinetto, F; Lunardi, C; Gazzurelli, L; Benvenuto, A; Bertolini, P; Conti, F; Consolini, R; Ricci, S; Azzari, C; Leonardi, L; Duse, M; Pulvirenti, F; Milito, C; Quinti, I; Cancrini, C; Finocchi, A; Moschese, V; Cirillo, E; Crescenzi, L; Spadaro, G; Marasco, C; Vacca, A; Cardinale, F; Martire, B; Trizzino, A; Licciardello, M; Cossu, F; Di Matteo, G; Badolato, R; Ferrari, S; Giliani, S; Pession, A; Ugazio, A; Pignata, C; Plebani, A				Lougaris, Vassilios; Soresina, Annarosa; Baronio, Manuela; Montin, Davide; Martino, Silvana; Signa, Sara; Volpi, Stefano; Zecca, Marco; Marinoni, Maddalena; Baselli, Lucia Augusta; Dellepiane, Rosa Maria; Carrabba, Maria; Fabio, Giovanna; Putti, Maria Caterina; Cinetto, Francesco; Lunardi, Claudio; Gazzurelli, Luisa; Benvenuto, Alessio; Bertolini, Patrizia; Conti, Francesca; Consolini, Rita; Ricci, Silvia; Azzari, Chiara; Leonardi, Lucia; Duse, Marzia; Pulvirenti, Federica; Milito, Cinzia; Quinti, Isabella; Cancrini, Caterina; Finocchi, Andrea; Moschese, Viviana; Cirillo, Emilia; Crescenzi, Ludovica; Spadaro, Giuseppe; Marasco, Carolina; Vacca, Angelo; Cardinale, Fabio; Martire, Baldassare; Trizzino, Antonino; Licciardello, Maria; Cossu, Fausto; Di Matteo, Gigliola; Badolato, Raffaele; Ferrari, Simona; Giliani, Silvia; Pession, Andrea; Ugazio, Alberto; Pignata, Claudio; Plebani, Alessandro			Long-term follow-up of 168 patients with X-linked agammaglobulinemia reveals increased morbidity and mortality	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						X-linked agammaglobulinemia; Bruton tyrosine kinase; chronic lung disease	MULTIPLE COLORECTAL NEOPLASMS; CONGENITAL AGAMMAGLOBULINEMIA; NATIONAL-REGISTRY; CANCER; EXPERIENCE; MUTATION; CHILDREN; GENE; HYPOGAMMAGLOBULINEMIA; ADENOCARCINOMA	Background: X-linked agammaglobulinemia (XLA) is the prototype of primary humoral immunodeficiencies. Long-term follow-up studies regarding disease-related complications and outcome are scarce. Objective: Our aim was to describe the natural history of XLA. Methods: A nationwide multicenter study based on the Italian Primary Immunodeficiency Network registry was established in 2000 in Italy. Affected patients were enrolled by documenting centers, and the patients' laboratory, clinical, and imaging data were recorded on an annual base. Results: Data on the patients (N = 168) were derived from a cumulative follow-up of 1370 patient-years, with a mean follow-up of 8.35 years per patient. The mean age at diagnosis decreased after establishment of the Italian Primary Immunodeficiency Network registry (84 months before vs 23 months after). Respiratory, skin, and gastrointestinal manifestations were the most frequent clinical symptoms at diagnosis and during long-term follow-up. Regular immunoglobulin replacement treatment reduced the incidence of invasive infections. Affected patients developed chronic lung disease over time (47% after 40 years of follow-up) in the presence of chronic sinusitis (84%). Malignancies were documented in a minority of cases (3.7%). Overall survival for affected patients was significantly reduced when compared with that for the healthy male Italian population, and it further deteriorated in the presence of chronic lung disease. Conclusions: This is the first detailed long-term follow-up study for patients with XLA, revealing that although immunoglobulin replacement treatment reduces the incidence of invasive infections, it does not appear to influence the development of chronic lung disease. The overall survival of affected patients is reduced. Further studies are warranted to improve patients' clinical management and increase awareness among physicians.	[Lougaris, Vassilios; Baronio, Manuela; Gazzurelli, Luisa; Benvenuto, Alessio; Badolato, Raffaele; Plebani, Alessandro] Univ Brescia, Dept Clin & Expt Sci, Pediat Clin, Brescia, Italy; [Lougaris, Vassilios; Baronio, Manuela; Gazzurelli, Luisa; Benvenuto, Alessio; Badolato, Raffaele; Plebani, Alessandro] Univ Brescia, Dept Clin & Expt Sci, Inst Mol Med A Nocivelli, Brescia, Italy; [Lougaris, Vassilios; Baronio, Manuela; Gazzurelli, Luisa; Benvenuto, Alessio; Badolato, Raffaele; Plebani, Alessandro] ASST Spedali Civili Brescia, Piazzale Spedali Civili 1, I-25123 Brescia, Italy; [Soresina, Annarosa] ASST Spedali Civili Brescia, Pediat Clin, Brescia, Italy; [Montin, Davide; Martino, Silvana] Univ Turin, Regina Margherita Children Hosp, Dept Publ Hlth & Pediat, Div Pediat Immunol & Rheumatol, Turin, Italy; [Signa, Sara; Volpi, Stefano] IRCCS Giannina Gaslini, Ctr Malattie Autoinfiammatorie Immunodeficien, Genoa, Italy; [Signa, Sara; Volpi, Stefano] Univ Genoa, Dipartimento Neurosci Riabiltaz Oftalmol Genet &, Genoa, Italy; [Zecca, Marco] Fdn IRCCS Policlini San Matteo, Dept Pediat Hematol Oncol, Pavia, Italy; [Marinoni, Maddalena] F Del Ponte Hosp, ASST Sette Laghi, Dept Paediat, Varese, Italy; [Baselli, Lucia Augusta; Dellepiane, Rosa Maria] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Pediat, Milan, Italy; [Carrabba, Maria; Fabio, Giovanna] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Internal Med, Milan, Italy; [Putti, Maria Caterina] Univ Padua, Pediat Hematol Oncol Unit, Dept Womens & Childrens Hlth, Padua, Italy; [Cinetto, Francesco] Univ Padua, Dept Med DIMED Internal Med 1, Padua, Italy; [Cinetto, Francesco] Ca Foncello Hosp, Rare Dis Ctr Immunol Rheumatol & Resp Dis, Treviso, Italy; [Lunardi, Claudio] Univ Verona, Dept Med, Verona, Italy; [Bertolini, Patrizia] Azienda Osped Univ Parma, Paediat Hematol Oncol Unit, Parma, Italy; [Conti, Francesca; Pession, Andrea] Univ Bologna, St Orsola Univ Hosp, Pediat Unit, Bologna, Italy; [Consolini, Rita] Univ Pisa, Dept Pediat, Sect Pediat Immunol & Rheumatol, Pisa, Italy; [Ricci, Silvia; Azzari, Chiara] Univ Florence, Anna Meyers Hosp, Jeffrey Modell Ctr Primary Immunodeficiency, Dept Pediat Immunol, Florence, Italy; [Leonardi, Lucia; Duse, Marzia] Sapienza Univ, Umberto Hosp 1, Dept Pediat, Rome, Italy; [Pulvirenti, Federica; Milito, Cinzia; Quinti, Isabella] Sapienza Univ Roma, Dept Mol Med, Rome, Italy; [Pulvirenti, Federica; Milito, Cinzia; Quinti, Isabella] Policlin Umberto 1, Dept Infect Dis & Internal Med, Unit Primary Immunodeficiencies Adults, Rome, Italy; [Cancrini, Caterina; Finocchi, Andrea; Di Matteo, Gigliola] Univ Roma Tor Vergata, Bambino Gesu Childrens Hosp, Unit Immune & Infect Dis, Univ Dept Pediat, Rome, Italy; [Cancrini, Caterina; Finocchi, Andrea; Di Matteo, Gigliola] Univ Roma Tor Vergata, Dept Syst Med, Rome, Italy; [Moschese, Viviana; Pignata, Claudio] Tor Vergata Univ, Policlin Tor Vergata, Dept Pediat, Rome, Italy; [Crescenzi, Ludovica] Univ Naples Federico II, Dept Translat Med Sci, Pediat Sect, Naples, Italy; [Crescenzi, Ludovica; Spadaro, Giuseppe] Univ Naples Federico II, Dept Translat Med Sci, Naples, Italy; [Crescenzi, Ludovica; Spadaro, Giuseppe] Univ Naples Federico II, Allergy & Clin Immunol Ctr Basic & Clin Immunol R, Naples, Italy; [Marasco, Carolina; Vacca, Angelo] Univ Ban, Sch Med, Dept Biomed Sci & Human Oncol, Sect Internal Med & Clin Oncol, Bari, Italy; [Cardinale, Fabio] Osped Pediat Giovanni XXIII, Azienda Osped Univ Consorziale Policlin, Pediat Allergy & Pulmunol Unit, Dept Pediat & Emergency, Bari, Italy; [Martire, Baldassare] Monsignor Dimiccoli Hosp, Pediat Unit, Barletta, Italy; [Trizzino, Antonino] ARNAS Civ Cristina & Benfratelli Hosp, Dept Pediat Hematol & Oncol, Palermo, Italy; [Licciardello, Maria] Univ Catania, Dept Pediat, Haematol Oncol Unit, Catania, Italy; [Cossu, Fausto] Univ Cagliari, Antonio Cao Hosp, Pediat Clin 2, Cagliari, Italy; [Ferrari, Simona] Univ Bologna, St Orsola Univ Hosp, Unit Med Genet, Bologna, Italy; [Giliani, Silvia] Univ Brescia, A Nocivelli Inst Mol Med, Dept Mol & Translat Med, Brescia, Italy; [Ugazio, Alberto] IRCCS, Bambino Gesu Childrens Hosp, Inst Child & Adolescent Hlth, Rome, Italy	University of Brescia; University of Brescia; Hospital Spedali Civili Brescia; Hospital Spedali Civili Brescia; A.O.U. Citta della Salute e della Scienza di Torino; University of Turin; University of Genoa; IRCCS Istituto Giannina Gaslini; University of Genoa; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Padua; University of Padua; ULSS 2 Marca TV; Ospedale Ca' Foncello Treviso; University of Verona; University of Parma; University Hospital of Parma; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Bologna; University of Pisa; University of Florence; Sapienza University Rome; University Hospital Sapienza Rome; Sapienza University Rome; Sapienza University Rome; University Hospital Sapienza Rome; IRCCS Bambino Gesu; University of Rome Tor Vergata; University of Rome Tor Vergata; University of Rome Tor Vergata; Policlin Tor Vergata; University of Naples Federico II; University of Naples Federico II; University of Naples Federico II; Universita degli Studi di Bari Aldo Moro; A.R.N.A.S. Ospedali Civico Di Cristina Benfratelli; University of Catania; University of Cagliari; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Bologna; University of Brescia; IRCCS Bambino Gesu	Lougaris, V; Plebani, A (corresponding author), ASST Spedali Civili Brescia, Piazzale Spedali Civili 1, I-25123 Brescia, Italy.; Lougaris, V; Plebani, A (corresponding author), Univ Brescia, Pediat Clin, Piazzale Spedali Civili 1, I-25123 Brescia, Italy.; Lougaris, V; Plebani, A (corresponding author), Univ Brescia, Inst Mol Med Nocivelli, Dept Clin & Expt Sci, Piazzale Spedali Civili 1, I-25123 Brescia, Italy.	vlougarisbs@yahoo.com; alessandro.plebani@unibs.it	Ricci, silvia/AAY-6957-2021; Vacca, Angelo/AAC-9558-2022; Badolato, Raffaele/A-8081-2010; Conti, Francesca/Q-1845-2019; Volpi, Stefano/O-3717-2014; leonardi, lucia/CAI-9838-2022; Cinetto, Francesco/AAE-5328-2019; MOSCHESE, VIVIANA/AHE-8931-2022; Bertolini, Patrizia/AAD-2056-2022; Cinetto, Francesco/J-7386-2018; Baselli, Lucia Augusta/HCH-8750-2022; Finocchi, Andrea/K-5926-2016; Signa, Sara/K-2741-2018; Carrabba, Maria/AAM-5651-2020; /K-2737-2018	Vacca, Angelo/0000-0002-4567-8216; Badolato, Raffaele/0000-0001-7375-5410; Conti, Francesca/0000-0002-3665-8926; Volpi, Stefano/0000-0002-7129-868X; leonardi, lucia/0000-0002-2554-1263; Cinetto, Francesco/0000-0001-8486-5850; MOSCHESE, VIVIANA/0000-0001-7650-0632; Cinetto, Francesco/0000-0001-8486-5850; Baselli, Lucia Augusta/0000-0003-1171-1185; Finocchi, Andrea/0000-0003-0958-8536; Ziyadullaev, Shukhrat/0000-0002-9309-3933; Signa, Sara/0000-0002-9083-1726; Carrabba, Maria/0000-0002-0717-9096; CARDINALE, FABIO/0000-0002-6774-6152; /0000-0001-7140-1694; DI MATTEO, GIGLIOLA/0000-0001-8344-5635	European Reference Network for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases [739543]	European Reference Network for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases	We would like to thank all patients and their families, the nurses, the Associazione Immunodeficienze Primitive [www.aip-it.org]), the Italian Primary Immunodeficiency Network, and the Associazione Italiana Ematologia e Oncologia Pediatrica [www.aieop.org]) for their continuous support. Several of us are members of the European Reference Network for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases (project identification No. 739543). We would also like to thank Fondazione Camillo Golgi, Brescia, Italy, Istituto per le Immunodeficienze Primitive Mario di Martino, Brescia, Italy, and the Jeffrey Modell Foundation (JMF).	Aadam Z, 2016, J CLIN IMMUNOL, V36, P187, DOI 10.1007/s10875-016-0251-z; Abolhassani H, 2016, EXPERT REV CLIN IMMU, V12, P479, DOI 10.1586/1744666X.2016.1139451; ADACHI Y, 1992, DIS COLON RECTUM, V35, P197, DOI 10.1007/BF02050679; Al Sasi O, 2005, PEDIATR RADIOL, V35, P339, DOI 10.1007/s00247-004-1319-0; Bachmeyer C, 2000, EUR J GASTROEN HEPAT, V12, P1033, DOI 10.1097/00042737-200012090-00013; Barmettler S, 2017, J CLIN IMMUNOL, V37, P287, DOI 10.1007/s10875-017-0374-x; Brosens LAA, 2008, CLIN GASTROENTEROL H, V6, P115, DOI 10.1016/j.cgh.2007.08.019; BRUTON OC, 1952, PEDIATRICS, V9, P722; Bryan BA, 2016, J CLIN IMMUNOL, V36, P472, DOI 10.1007/s10875-016-0284-3; Chen XF, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004544; Chisuwa H, 1999, Nihon Shokakibyo Gakkai Zasshi, V96, P1392; El-Sayed ZA, 2019, WORLD ALLERGY ORGAN, V12, DOI 10.1016/j.waojou.2019.100018; Esenboga S, 2018, SCAND J IMMUNOL, V87, DOI 10.1111/sji.12647; Flori NM, 1997, J CLIN IMMUNOL, V17, P333, DOI 10.1023/A:1027382916924; Garcia-Garcia E, 2016, CLIN IMMUNOL, V165, P38, DOI 10.1016/j.clim.2016.02.010; KINLEN LJ, 1985, LANCET, V1, P263; Lackmann GM, 2007, MONATSSCHR KINDERH, V155, pS6, DOI 10.1007/s00112-005-1122-5; Lackmann GM, 2005, J PEDIATR GASTR NUTR, V41, P360, DOI 10.1097/01.MPG.0000153003.59448.36; LAVILLA P, 1993, CANCER, V72, P1528, DOI 10.1002/1097-0142(19930901)72:5<1528::AID-CNCR2820720506>3.0.CO;2-V; LEDERMAN HM, 1995, J PEDIATR-US, V127, P335, DOI 10.1016/S0022-3476(95)70334-9; Milito C, 2019, J ALLERGY CLIN IMMUN, V144, P584, DOI 10.1016/j.jaci.2019.01.051; Moin M, 2004, IMMUNOL INVEST, V33, P81, DOI 10.1081/IMM-120027687; Orange JS, 2010, CLIN IMMUNOL, V137, P21, DOI 10.1016/j.clim.2010.06.012; Pac M, 2017, ARCH MED SCI, V13, P412, DOI 10.5114/aoms.2016.60338; Picard C, 2018, J CLIN IMMUNOL, V38, P96, DOI 10.1007/s10875-017-0464-9; Plebani A, 2002, CLIN IMMUNOL, V104, P221, DOI 10.1006/clim.2002.5241; RYSER O, 1988, J CLIN IMMUNOL, V8, P479, DOI 10.1007/BF00916954; Singh S, 2016, ANN ALLERG ASTHMA IM, V117, P405, DOI 10.1016/j.anai.2016.07.044; Stray-Pedersen A, 2000, J CLIN IMMUNOL, V20, P477, DOI 10.1023/A:1026416017763; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; Vajdic CM, 2010, BLOOD, V116, P1228, DOI 10.1182/blood-2010-03-272351; Valiaho J, 2006, HUM MUTAT, V27, P1209, DOI 10.1002/humu.20410; Van Der Hilst JCH, 2002, NETH J MED, V60, P140; VANDERMEER JWM, 1993, LANCET, V341, P1439, DOI 10.1016/0140-6736(93)90883-I; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; Wang Y, 2009, J CLIN IMMUNOL, V29, P352, DOI 10.1007/s10875-008-9262-8; Winkelstein JA, 2006, MEDICINE, V85, P193, DOI 10.1097/01.md.0000229482.27398.ad; Zenone T, 1997, B CANCER, V84, P813	38	38	39	2	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2020	146	2					429	437		10.1016/j.jaci.2020.03.001	http://dx.doi.org/10.1016/j.jaci.2020.03.001			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MZ0TA	32169379	Bronze, Green Submitted, Green Published			2022-12-18	WOS:000558835000032
J	Blanco, E; Perez-Andres, M; Arriba-Mendez, S; Serrano, C; Criado, I; Del Pino-Molina, L; Silva, S; Madruga, I; Bakardjieva, M; Martins, C; Serra-Caetano, A; Romero, A; Contreras-Sanfeliciano, T; Bonroy, C; Sala, F; Martin, A; Bastida, JM; Lorente, F; Prieto, C; Davila, I; Marcos, M; Kalina, T; Vlkova, M; Chovancova, Z; Cordeiro, AI; Philippe, J; Haerynck, F; Lopez-Granados, E; Sousa, AE; van der Burg, M; van Dongen, JJM; Orfao, A				Blanco, Elena; Perez-Andres, Martin; Arriba-Mendez, Sonia; Serrano, Cristina; Criado, Ignacio; Del Pino-Molina, Lucia; Silva, Susana; Madruga, Ignacio; Bakardjieva, Marina; Martins, Catarina; Serra-Caetano, Ana; Romero, Alfonso; Contreras-Sanfeliciano, Teresa; Bonroy, Carolien; Sala, Francisco; Martin, Alejandro; Maria Bastida, Jose; Lorente, Felix; Prieto, Carlos; Davila, Ignacio; Marcos, Miguel; Kalina, Tomas; Vlkova, Marcela; Chovancova, Zita; Cordeiro, Ana Isabel; Philippe, Jan; Haerynck, Filomeen; Lopez-Granados, Eduardo; Sousa, Ana E.; van der Burg, Mirjam; van Dongen, Jacques J. M.; Orfao, Alberto		EuroFlow PID Grp	Defects in memory B-cell and plasma cell subsets expressing different immunoglobulin-subclasses in patients with CVID and immunoglobulin subclass deficiencies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Immunodeficiency; primary antibody deficiency; selective IgA deficiency; common variable immunodeficiency; immunophenotyping; immunoglobulins; immunoglobulin subclasses; memory B cells; plasma cells; flow cytometry; diagnosis; classification	COMMON VARIABLE IMMUNODEFICIENCY; SELECTIVE IGA DEFICIENCY; PERIPHERAL-BLOOD; FLOW-CYTOMETRY; REFERENCE VALUES; DISORDERS; DIAGNOSIS; HEALTHY; DISEASE; SUBPOPULATIONS	Background: Predominantly antibody deficiencies (PADs) are the most prevalent primary immunodeficiencies, but their B-cell defects and underlying genetic alterations remain largely unknown. Objective: We investigated patients with PADs for the distribution of 41 blood B-cell and plasma cell (PC) subsets, including subsets defined by expression of distinct immunoglobulin heavy chain subclasses. Methods: Blood samples from 139 patients with PADs, 61 patients with common variable immunodeficiency (CVID), 68 patients with selective IgA deficiency (IgAdef), 10 patients with IgG subclass deficiency with IgA deficiency, and 223 age matched control subjects were studied by using flow cytometry with EuroFlow immunoglobulin isotype staining. Patients were classified according to their B-cell and PC immune profile, and the obtained patient clusters were correlated with clinical manifestations of PADs. Results: Decreased counts of blood PCs, memory B cells (MB Cs), or both expressing distinct IgA and IgG subclasses were identified in all patients with PADs. In patients with IgAdef, B-cell defects were mainly restricted to surface membrane (sm)IgA(+) PCs and MBCs, with 2 clear subgroups showing strongly decreased numbers of smIgA(+) PCs with mild versus severe smIgA(+) MBC defects and higher frequencies of nonrespiratory tract infections, autoimmunity, and affected family members. Patients with IgG subclass deficiency with IgA deficiency and those with CVID showed defects in both smIgA(+) and smIgG(+) MBCs and PCs. Reduced numbers of switched PCs were systematically found in patients with CVID (absent in 98%), with 6 different defective MBC (and clinical) profiles: (1) profound decrease in MBC numbers; (2) defective CD27(+) MBCs with almost normal IgG(3)(+) MBCs; (3) absence of switched MBCs; and (4) presence of both unswitched and switched MBCs without and; (5) with IgG(2)(+) MBCs; and (6) with IgA(1)(+) MBCs. Conclusion: Distinct PAD defective B-cell patterns were identified that are associated with unique clinical profiles.	[Blanco, Elena; Perez-Andres, Martin; Criado, Ignacio; Orfao, Alberto] Univ Salamanca USAL, Inst Biomed Res Salamanca IBSAL, Cytometry Serv NUCLEUS, Dept Med Canc Res Ctr,IBMCC,USAL,CSIC, Salamanca, Spain; [Blanco, Elena; Perez-Andres, Martin; Criado, Ignacio; Orfao, Alberto] Inst Salud Carlos III, Biomed Res Networking Ctr Consortium Oncol CIBERO, CB16-12-00400, Madrid, Spain; [Arriba-Mendez, Sonia; Lorente, Felix] Hosp Univ Salamanca, Serv Pediat, Salamanca, Spain; [Contreras-Sanfeliciano, Teresa] Hosp Univ Salamanca, Serv Bioquim Clin, Salamanca, Spain; [Serrano, Cristina] Fdn Jimenez Diaz, Serv Inmunol, Madrid, Spain; [Del Pino-Molina, Lucia; Lopez-Granados, Eduardo] Univ Hosp La Paz, Clin Immunol Dept, Madrid, Spain; [Del Pino-Molina, Lucia; Lopez-Granados, Eduardo] IdiPAZ Inst Hlth Res, Physiopathol Lymphocytes Immunodeficiencies Grp, Madrid, Spain; [Silva, Susana; Serra-Caetano, Ana; Sousa, Ana E.] Univ Lisbon, Fac Med, Inst Med Mol, Lisbon, Portugal; [Madruga, Ignacio; Marcos, Miguel] Univ Salamanca, Hosp Univ Salamanca, Inst Biomed Res Salamanca, Serv Med Intema,Dept Med, Salamanca, Spain; [Bakardjieva, Marina; Kalina, Tomas] Charles Univ Prague, Fac Med 2, Dept Haematol Oncol, CLIP, Prague, Czech Republic; [Martins, Catarina] Univ Nova Lisboa, Fac Ciencias Med, NOVA Med Sch, Lisbon, Portugal; [Romero, Alfonso] Ctr Salud Miguel Armijo, Salamanca, Spain; [Bonroy, Carolien; Philippe, Jan] Univ Hosp Ghent, Dept Lab Med, Ghent, Belgium; [Haerynck, Filomeen] Univ Hosp Ghent, Dept Resp Dis, Ghent, Belgium; [Haerynck, Filomeen] Univ Hosp Ghent, Dept Pediat & Genet, Ghent, Belgium; [Sala, Francisco] Hosp Navarra, Serv Hematol, Pamplona, Spain; [Martin, Alejandro; Maria Bastida, Jose] Hosp Univ Salamanca, Inst Biomed Res Salamanca, Serv Hematol, Salamanca, Spain; [Martin, Alejandro; Maria Bastida, Jose] Inst Salud Carlos III, Biomed Res Networking Ctr Consortium Oncol CIBERO, CB-16-12-00233, Madrid, Spain; [Prieto, Carlos] Univ Salamanca, Bioinformat Serv NUCLEUS, Salamanca, Spain; [Davila, Ignacio] Univ Salamanca USAL, Biomed & Diag Sci Dept, Inst Biomed Res Salamanca, Serv Alergia,Hosp Univ Salamanca, Salamanca, Spain; [Vlkova, Marcela; Chovancova, Zita] Masaryk Univ, St Annes Univ Hosp, Dept Clin Immunol & Allergol, Brno, Czech Republic; [Vlkova, Marcela; Chovancova, Zita] Masaryk Univ, Fac Med, Brno, Czech Republic; [Cordeiro, Ana Isabel] CHLC, Hosp D Estefania, Lisbon, Portugal; [van der Burg, Mirjam] Erasmus MC, Dept Immunol, Rotterdam, Netherlands; [van der Burg, Mirjam] Leiden Univ, Med Ctr, Lab Immunol, Dept Pediat, Leiden, Netherlands; [van Dongen, Jacques J. M.] Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, Leiden, Netherlands	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Instituto de Salud Carlos III; Hospital Universitario La Paz; Universidade de Lisboa; University of Salamanca; Charles University Prague; Universidade Nova de Lisboa; Ghent University; Ghent University Hospital; Ghent University; Ghent University Hospital; Ghent University; Ghent University Hospital; Servicio Navarro de Salud - Osasunbidea; Instituto de Salud Carlos III; University of Salamanca; University of Salamanca; Masaryk University Brno; St Anne's University Hospital Brno (FNUSA-ICRC); Masaryk University Brno; Centro Hospitalar de Lisboa Central, EPE; Erasmus University Rotterdam; Erasmus MC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Orfao, A (corresponding author), Univ Salamanca, Canc Res Ctr, Dept Med, Paseo Univ Coimbra S-N, Salamanca 37007, Spain.	orfao@usal.es	De Arriba Méndez, Sonia/AAC-1234-2020; Criado, Ignacio/ABF-7031-2020; Marcos, Miguel/B-3550-2008; De Arriba Méndez, Sonia/B-4856-2019; Kalina, Tomas/C-1078-2009; Kalina, Tomas/AAC-6655-2019; Kalina, Tomas/AAE-5036-2019; Dávila, Ignacio/K-4453-2012; Haerynck, Filomeen/AAD-6761-2020; philippé, jan/AAG-8964-2019; Martín, Alejandro/B-8611-2018; Prieto, Carlos/G-2382-2016; Perez-Andres, Martin/B-3692-2019; Bastida, Jose Maria/F-5726-2016; Sousa, Ana E./L-2642-2014	Marcos, Miguel/0000-0003-1269-4487; De Arriba Méndez, Sonia/0000-0003-1990-4125; Kalina, Tomas/0000-0003-4475-2872; Kalina, Tomas/0000-0003-4475-2872; Dávila, Ignacio/0000-0001-8485-5513; philippé, jan/0000-0003-4857-5746; Martín, Alejandro/0000-0001-6330-1028; Prieto, Carlos/0000-0001-8178-9768; Perez-Andres, Martin/0000-0003-4599-0776; Martins, Catarina/0000-0003-0353-0421; DEL PINO MOLINA, LUCIA/0000-0003-2392-097X; Contreras, Teresa/0000-0002-2264-7791; Bastida, Jose Maria/0000-0002-8007-3909; Vlkova, Marcela/0000-0003-2122-7784; Caetano, Ana/0000-0002-1626-4364; Bakardjieva, Marina/0000-0002-5919-6306; Bonroy, Carolien/0000-0002-9170-4200; Sousa, Ana E./0000-0002-4618-9799; Blanco Alvarez, Elena/0000-0002-8150-5646; Criado, Ignacio/0000-0003-4120-343X; Haerynck, Filomeen/0000-0001-9161-7361	Junta de Castilla y Leon (Fondo Social Europeo, Valladolid, Spain) [ORDEN EDU/346/2013]; Fondo de Investigacion Sanitaria of Instituto de Salud Carlos III, Madrid, Spain [FIS PI12/00905-FEDER]; Fundacion Mutua Madrilena (Madrid, Spain); CIBERONC, Instituto de Salud Carlos III, Ministerio de Economia y Competitividad, Madrid, Spain [CB16/12/00400, CB/16/12/00233]; FONDOS FEDER [CB16/12/00400, CB/16/12/00233]; Euro-Flow Consortium	Junta de Castilla y Leon (Fondo Social Europeo, Valladolid, Spain); Fondo de Investigacion Sanitaria of Instituto de Salud Carlos III, Madrid, Spain; Fundacion Mutua Madrilena (Madrid, Spain); CIBERONC, Instituto de Salud Carlos III, Ministerio de Economia y Competitividad, Madrid, Spain; FONDOS FEDER(European Commission); Euro-Flow Consortium	E.B. was supported by a grant from the Junta de Castilla y Leon (Fondo Social Europeo, ORDEN EDU/346/2013, Valladolid, Spain). This work was supported by the CB16/12/00400 and CB/16/12/00233 grants (CIBERONC, Instituto de Salud Carlos III, Ministerio de Economia y Competitividad, Madrid, Spain, and FONDOS FEDER), the FIS PI12/00905-FEDER grant (Fondo de Investigacion Sanitaria of Instituto de Salud Carlos III, Madrid, Spain) and a grant from Fundacion Mutua Madrilena (Madrid, Spain). The coordination and innovation processes of this study were supported by the Euro-Flow Consortium.	Abinun M, ESID REGISTRY WORKIN; Abolhassani H, 2015, J INVEST ALLERG CLIN, V25, P218; Abolhassani H, 2014, J ALLERGY CLIN IMMUN, V134, P1375, DOI 10.1016/j.jaci.2014.04.042; Aghamohammadi A, 2008, INT ARCH ALLERGY IMM, V147, P87, DOI 10.1159/000135694; Aghamohammadi A, 2011, INT ARCH ALLERGY IMM, V156, P462, DOI 10.1159/000323903; Al Kindi M, 2012, CLIN EXP IMMUNOL, V167, P275, DOI 10.1111/j.1365-2249.2011.04507.x; Ballow M, 2002, J ALLERGY CLIN IMMUN, V109, P581, DOI 10.1067/mai.2002.122466; Berkowska MA, 2011, BLOOD, V118, P2150, DOI 10.1182/blood-2011-04-345579; Bertinchamp R, 2016, J ALLER CL IMM-PRACT, V4, P1147, DOI 10.1016/j.jaip.2016.07.002; Blanco E, 2018, J ALLERGY CLIN IMMUN, V141, P2208, DOI 10.1016/j.jaci.2018.02.017; Bogaert DJA, 2017, HAEMATOLOGICA, V102, P192, DOI 10.3324/haematol.2016.149112; Bogaert DJA, 2016, J MED GENET, V53, P575, DOI 10.1136/jmedgenet-2015-103690; Bonilla FA, 2016, J ALLER CL IMM-PRACT, V4, P38, DOI 10.1016/j.jaip.2015.07.025; Chapel H, 2008, BLOOD, V112, P277, DOI 10.1182/blood-2007-11-124545; Chapel H, 2016, J ALLER CL IMM-PRACT, V4, P1158, DOI 10.1016/j.jaip.2016.09.006; Chapel H, 2012, J ALLERGY CLIN IMMUN, V130, P1197, DOI 10.1016/j.jaci.2012.05.046; Collins AM, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00235; Cunningham-Rundles C, 2012, HEMATOL-AM SOC HEMAT, P301, DOI 10.1182/asheducation-2012.1.301; de Jong BG, 2017, IMMUNOL CELL BIOL, V95, P744, DOI 10.1038/icb.2017.43; de la Morena MT, 2016, J ALLER CL IMM-PRACT, V4, P1023, DOI 10.1016/j.jaip.2016.09.013; Derksen VFAM, 2017, SEMIN IMMUNOPATHOL, V39, P437, DOI 10.1007/s00281-017-0627-z; Driessen GJ, 2013, HAEMATOLOGICA, V98, P1617, DOI 10.3324/haematol.2013.085076; Driessen GJ, 2011, BLOOD, V118, P6814, DOI 10.1182/blood-2011-06-361881; Durandy A, 2013, NAT REV IMMUNOL, V13, P519, DOI 10.1038/nri3466; Fecteau JF, 2006, J IMMUNOL, V177, P3728, DOI 10.4049/jimmunol.177.6.3728; Fliegauf M, 2015, AM J HUM GENET, V97, P389, DOI 10.1016/j.ajhg.2015.07.008; Flores-Montero J, 2017, LEUKEMIA, V31, P2094, DOI 10.1038/leu.2017.29; Huck K, 2009, CLIN IMMUNOL, V131, P50, DOI 10.1016/j.clim.2008.11.008; Isnardi I, 2010, BLOOD, V115, P5026, DOI 10.1182/blood-2009-09-243071; Jackson KJL, 2014, IMMUNOL CELL BIOL, V92, P729, DOI 10.1038/icb.2014.44; Jolles S, 2013, J ALLER CL IMM-PRACT, V1, P545, DOI 10.1016/j.jaip.2013.09.015; Kalina T, 2012, LEUKEMIA, V26, P1986, DOI 10.1038/leu.2012.122; Kienzler AK, 2017, CLIN EXP IMMUNOL, V188, P326, DOI 10.1111/cei.12947; Kuehn HS, 2016, NEW ENGL J MED, V374, P1032, DOI 10.1056/NEJMoa1512234; Laino J, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/7983217; Leven EA, 2016, J CLIN IMMUNOL, V36, P490, DOI 10.1007/s10875-016-0291-4; Lhermitte L, 2018, LEUKEMIA, V32, P874, DOI 10.1038/leu.2017.313; MacQueen J., 1967, 5 BERK S MATH STAT P, V1, P281; Marasco E, 2017, EUR J IMMUNOL, V47, P131, DOI 10.1002/eji.201646574; Rudolf-Oliveira RCM, 2015, IMMUNOL LETT, V163, P96, DOI 10.1016/j.imlet.2014.11.003; Morbach H, 2010, CLIN EXP IMMUNOL, V162, P271, DOI 10.1111/j.1365-2249.2010.04206.x; Nechvatalova J, 2012, J CLIN IMMUNOL, V32, P441, DOI 10.1007/s10875-012-9655-6; Ochtrop MLG, 2011, BLOOD, V118, P309, DOI 10.1182/blood-2010-11-321695; OGorman MRG, 1997, CLIN IMMUNOL IMMUNOP, V85, P172, DOI 10.1006/clin.1997.4422; Perez-Andres M, 2010, CYTOM PART B-CLIN CY, V78B, pS47, DOI 10.1002/cyto.b.20547; Piatosa B, 2013, J CLIN IMMUNOL, V33, P731, DOI 10.1007/s10875-013-9875-4; Piatosa B, 2010, CYTOM PART B-CLIN CY, V78B, P372, DOI 10.1002/cyto.b.20536; Picard C, 2018, J CLIN IMMUNOL, V38, P96, DOI 10.1007/s10875-017-0464-9; Piqueras B, 2003, J CLIN IMMUNOL, V23, P385, DOI 10.1023/A:1025373601374; Qamar N, 2014, CLIN REV ALLERG IMMU, V46, P120, DOI 10.1007/s12016-013-8378-7; Rodriguez-Cortez VC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8335; Rosel AL, 2015, J ALLERGY CLIN IMMUN, V135, P198, DOI 10.1016/j.jaci.2014.06.022; Schatorje EJH, 2011, SCAND J IMMUNOL, V74, P502, DOI 10.1111/j.1365-3083.2011.02609.x; Schubert D, 2014, NAT MED, V20, P1410, DOI 10.1038/nm.3746; Team R.C, 2015, R LANG ENV STAT COMP; Theunissen P, 2017, BLOOD, V129, P347, DOI 10.1182/blood-2016-07-726307; Tuijnenburg P, 2018, J ALLERGY CLIN IMMUN, V142, P1285, DOI 10.1016/j.jaci.2018.01.039; Unger S, 2014, J CLIN IMMUNOL, V34, P615, DOI 10.1007/s10875-014-0052-1; van den Heuvel D, 2017, J ALLERGY CLIN IMMUN, V139, P1923, DOI 10.1016/j.jaci.2016.10.023; van der Burg M, 2019, FRONT IMMUNOL; van Gent R, 2009, CLIN IMMUNOL, V133, P95, DOI 10.1016/j.clim.2009.05.020; Volk T, 2015, HUM MOL GENET, V24, P7361, DOI 10.1093/hmg/ddv437; Wang N, 2012, CURR OPIN ALLERGY CL, V12, P602, DOI 10.1097/ACI.0b013e3283594219; Wang ZG, 1999, CLIN IMMUNOL, V91, P263, DOI 10.1006/clim.1999.4702; Warnatz K, 2002, BLOOD, V99, P1544, DOI 10.1182/blood.V99.5.1544; Warnes G.R., 2015, GPLOTS VARIOUS R PRO; Wehr C, 2008, BLOOD, V111, P77, DOI 10.1182/blood-2007-06-091744; Wood PM, 2010, CURR OPIN HEMATOL, V17, P356, DOI 10.1097/MOH.0b013e328338f69e; Yazdani R, 2017, SCAND J IMMUNOL, V85, P3, DOI 10.1111/sji.12499	69	38	39	1	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2019	144	3					809	824		10.1016/j.jaci.2019.02.017	http://dx.doi.org/10.1016/j.jaci.2019.02.017			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IW8CV	30826363	Green Published, hybrid			2022-12-18	WOS:000485222300025
J	Fricker, M; Gibson, PG; Powell, H; Simpson, JL; Yang, IA; Upham, JW; Reynolds, PN; Hodge, S; James, AL; Jenkins, C; Peters, MJ; Marks, GB; Baraket, M; Baines, KJ				Fricker, Michael; Gibson, Peter G.; Powell, Heather; Simpson, Jodie L.; Yang, Ian A.; Upham, John W.; Reynolds, Paul N.; Hodge, Sandra; James, Alan L.; Jenkins, Christine; Peters, Matthew J.; Marks, Guy B.; Baraket, Melissa; Baines, Katherine J.			A sputum 6-gene signature predicts future exacerbations of poorly controlled asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; sputum; biomarker; inflammation; exacerbation; macrolide; azithromycin; eosinophil; gene signature; clinical trial	QUALITY-OF-LIFE; GENE-EXPRESSION; AIRWAY HYPERRESPONSIVENESS; DOUBLE-BLIND; PHENOTYPES; INFLAMMATION; SUBTYPES; COUNTS; AZITHROMYCIN; VALIDATION	Background: Improved diagnostic tools for predicting future exacerbation frequency in asthmatic patients are required. A sputum gene expression signature of 6 biomarkers (6-gene signature [6GS], including Charcot-Leyden crystal galectin [CLC]; carboxypeptidase 3 [CPA3]; deoxyribonuclease 1-like 3 [DNASE1L3]; alkaline phosphatase, liver/bone/kidney [ALPL]; CXCR2; and IL1B) predicts inflammatory and treatment response phenotypes in patients with stable asthma. Recently, we demonstrated that azithromycin (AZM) add-on treatment in patients with uncontrolled moderate-to-severe asthma significantly reduced asthma exacerbations (AMAZES clinical trial). Objectives: We sought to test whether the 6GS predicts future exacerbation and inflammatory phenotypes in a subpopulation of AMAZES and to test the effect of AZM therapy on 6GS expression and prognostic capacity. Methods: One hundred forty-two patients (73 placebo-treated and 69 AZM-treated patients) had sputum stored for quantitative PCR of 6GS markers at baseline and after 48 weeks of treatment. Logistic regression and receiver operating characteristic and area under the curve (AUC) determination were performed on baseline measures, and in an exploratory analysis the predictive value of the 6GS was compared with conventional biomarkers for exacerbation and inflammatory phenotypes. Results: The 6GS significantly predicted all future exacerbation phenotypes tested. Calculated AUCs for the 6GS were significantly greater than AUCs for peripheral blood eosinophil counts, sputum neutrophil counts, and combined sputum eosinophil and neutrophil counts. 6GS AUCs were also numerically but not significantly greater than those for fractional exhaled nitric oxide values and sputum eosinophil counts. AZM treatment altered neither 6GS expression nor the predictive capacity of the 6GS for future exacerbation phenotypes. The 6GS was a significant predictor of airway inflammatory phenotype in this population. Conclusion: We demonstrate that a sputum gene signature can predict future exacerbation phenotypes of asthma, with the greatest biomarker performance in identifying those who would experience frequent severe exacerbations. AZM therapy did not modify 6GS expression or biomarker performance, suggesting the therapeutic action of AZM is independent of 6GS-related inflammatory pathways.	[Fricker, Michael; Gibson, Peter G.; Powell, Heather; Simpson, Jodie L.; Baines, Katherine J.] Univ Newcastle, Prior Res Ctr Hlth Lungs, Newcastle, NSW, Australia; [Gibson, Peter G.; Powell, Heather] John Hunter Hosp, Dept Resp & Sleep Med, Newcastle, NSW, Australia; [Yang, Ian A.; Upham, John W.] Univ Queensland, Diamantina Inst, Brisbane, Qld, Australia; [Yang, Ian A.] Prince Charles Hosp, Dept Thorac Med, Brisbane, Qld, Australia; [Upham, John W.] Princess Alexandra Hosp, Dept Resp Med, Brisbane, Qld, Australia; [Reynolds, Paul N.; Hodge, Sandra] Royal Adelaide Hosp, Dept Thorac Med, Adelaide, SA, Australia; [Reynolds, Paul N.; Hodge, Sandra] Hanson Inst, Lung Res Lab, Adelaide, SA, Australia; [Reynolds, Paul N.; Hodge, Sandra] Univ Adelaide, Sch Med, Adelaide, SA, Australia; [James, Alan L.] Sir Charles Gairdner Hosp, Dept Pulm Physiol & Sleep Med, Perth, WA, Australia; [James, Alan L.] Univ Western Australia, Sch Med & Pharmacol, Perth, WA, Australia; [Jenkins, Christine] George Inst Global Hlth, Resp Trials, Sydney, NSW, Australia; [Jenkins, Christine; Peters, Matthew J.] Concord Gen Hosp, Dept Thorac Med, Sydney, NSW, Australia; [Peters, Matthew J.] Macquarie Univ, Fac Med & Hlth Sci, Sydney, NSW, Australia; [Marks, Guy B.] Woolcock Inst Med Res, Sydney, NSW, Australia; [Marks, Guy B.] Univ New South Wales, South Western Sydney Clin Sch, Sydney, NSW, Australia; [Baraket, Melissa] Univ New South Wales, Fac Med, Dept Resp Med, Sydney, NSW, Australia; [Baraket, Melissa] Univ New South Wales, Fac Med, Ingham Inst Liverpool Hosp, Sydney, NSW, Australia	University of Newcastle; John Hunter Hospital; University of Queensland; Prince Charles Hospital; Royal Adelaide Hospital; Hanson Institute; University of Adelaide; University of Western Australia; George Institute for Global Health; University of Sydney; Concord Repatriation General Hospital; Macquarie University; University of Sydney; Woolcock Institute of Medical Research; University of New South Wales Sydney; University of New South Wales Sydney; Ingham Institute for Applied Medical Research; Liverpool Hospital; University of New South Wales Sydney	Fricker, M (corresponding author), Hunter Med Res Inst, Prior Res Ctr Hlth Lungs, Lot 1 Kookaburra Circuit, New Lambton Hts, NSW 2305, Australia.	michael.fricker@newcastle.edu.au	Yang, Ian A/B-9609-2008; FRICKER, MICHAEL/ABE-2316-2021; Marks, Guy B./F-5058-2013; BAINES, KATHERINE JOANNE/G-7654-2013; SIMPSON, JODIE LOUISE/G-7639-2013	Yang, Ian A/0000-0001-8338-1993; Marks, Guy B./0000-0002-8976-8053; BAINES, KATHERINE JOANNE/0000-0002-4240-6581; SIMPSON, JODIE LOUISE/0000-0002-3626-680X; Fricker, Michael/0000-0002-8587-1774; Peters, Matthew/0000-0002-9649-8741	National Health and Medical Research Council of Australia [569246, 1058552, 1078579]; John Hunter Hospital Charitable Trust	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); John Hunter Hospital Charitable Trust	Supported by the National Health and Medical Research Council of Australia (NHMRC project identifiers 569246, 1058552, and 1078579) and the John Hunter Hospital Charitable Trust.	Al-ani S, 2013, FAM PRACT, V30, P621, DOI 10.1093/fampra/cmt055; Anderson SD, 2010, CHEST, V138, p25S, DOI 10.1378/chest.10-0116; Baines KJ, 2017, INT J CHRONIC OBSTR, V12, P541, DOI 10.2147/COPD.S119443; Baines KJ, 2014, J ALLERGY CLIN IMMUN, V133, P997, DOI 10.1016/j.jaci.2013.12.1091; Baines KJ, 2011, J ALLERGY CLIN IMMUN, V127, P153, DOI 10.1016/j.jaci.2010.10.024; Berthon BS, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.00180-2017; Brooks CR, 2017, ALLERGY, V72, P1583, DOI 10.1111/all.13185; Brusselle GG, 2013, THORAX, V68, P322, DOI 10.1136/thoraxjnl-2012-202698; Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013; Denlinger LC, 2017, AM J RESP CRIT CARE, V195, P302, DOI 10.1164/rccm.201602-0419OC; Dweik RA, 2010, AM J RESP CRIT CARE, V181, P1033, DOI 10.1164/rccm.200905-0695OC; Dwyer DF, 2016, NAT IMMUNOL, V17, P878, DOI 10.1038/ni.3445; Fricker M, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.00196-2017; Fricker M, 2017, RESPIROLOGY, V22, P430, DOI 10.1111/resp.13014; Fu JJ, 2015, CHEST, V148, P618, DOI 10.1378/chest.14-2337; Gibson PG, 2017, LANCET, V390, P659, DOI 10.1016/S0140-6736(17)31281-3; Gibson PG, 1998, AM J RESP CRIT CARE, V158, P36, DOI 10.1164/ajrccm.158.1.9705031; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Heaney LG, 2016, THORAX, V71, P187, DOI 10.1136/thoraxjnl-2015-207326; Jayaram L, 2006, EUR RESPIR J, V27, P483, DOI 10.1183/09031936.06.00137704; Joos GF, 2003, EUR RESPIR J, V21, P1050, DOI 10.1183/09031936.03.00008403; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Juniper EF, 1999, CHEST, V115, P1265, DOI 10.1378/chest.115.5.1265; Kuo CHS, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.02135-2016; Lemiere C, 2006, J ALLERGY CLIN IMMUN, V118, P1033, DOI 10.1016/j.jaci.2006.08.003; McGrath KW, 2012, AM J RESP CRIT CARE, V185, P612, DOI 10.1164/rccm.201109-1640OC; Miller MK, 2007, RESP MED, V101, P481, DOI 10.1016/j.rmed.2006.07.005; Moore WC, 2014, J ALLERGY CLIN IMMUN, V133, P1557, DOI 10.1016/j.jaci.2013.10.011; Pavord ID, 1999, LANCET, V353, P2213, DOI 10.1016/S0140-6736(99)01813-9; Peters MC, 2014, J ALLERGY CLIN IMMUN, V133, P388, DOI 10.1016/j.jaci.2013.07.036; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Russell RJ, 2017, CLIN SCI, V131, P1723, DOI 10.1042/CS20160253; Simpson JL, 2006, RESPIROLOGY, V11, P54, DOI 10.1111/j.1440-1843.2006.00784.x; Suzuki Y, 2017, ALLERGY, V72, P1532, DOI 10.1111/all.13197; Wang G, 2016, EUR RESPIR J, V47, P1123, DOI 10.1183/13993003.01098-2015; Wenzel S, 2016, EUR RESP J S60, V48, P1798; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Wong EHC, 2014, LANCET RESP MED, V2, P657, DOI 10.1016/S2213-2600(14)70107-9; Yan XT, 2015, AM J RESP CRIT CARE, V191, P1116, DOI 10.1164/rccm.201408-1440OC	39	38	38	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2019	144	1					51	+		10.1016/j.jaci.2018.12.1020	http://dx.doi.org/10.1016/j.jaci.2018.12.1020			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IF9SM	30682452	Bronze			2022-12-18	WOS:000473432800009
J	Archer, NK; Jo, JH; Lee, SK; Kim, D; Smith, B; Ortines, RV; Wang, Y; Marchitto, MC; Ravipati, A; Cai, STS; Dillen, CA; Liu, HY; Miller, RJ; Ashbaugh, AG; Uppal, AS; Oyoshi, MK; Malhotra, N; Hoff, S; Garza, LA; Kong, HH; Segre, JA; Geha, RS; Miller, LS				Archer, Nathan K.; Jo, Jay-Hyun; Lee, Steven K.; Kim, Dongwon; Smith, Barbara; Ortines, Roger V.; Wang, Yu; Marchitto, Mark C.; Ravipati, Advaitaa; Cai, Shuting S.; Dillen, Carly A.; Liu, Haiyun; Miller, Robert J.; Ashbaugh, Alyssa G.; Uppal, Angad S.; Oyoshi, Michiko K.; Malhotra, Nidhi; Hoff, Sabine; Garza, Luis A.; Kong, Heidi H.; Segre, Julia A.; Geha, Raif S.; Miller, Lloyd S.			Injury, dysbiosis, and filaggrin deficiency drive skin inflammation through keratinocyte IL-1 alpha release	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Skin; atopic dermatitis; keratinocytes; filaggrin; IL-1 alpha; inflammation	OF-FUNCTION-MUTATIONS; ATOPIC-DERMATITIS; ACTIVATING FACTOR; IMMUNE-RESPONSES; STRATUM-CORNEUM; IL-1 FAMILY; T-CELLS; INTERLEUKIN-1-ALPHA; MECHANISMS; MICROBIOME	Background: Atopic dermatitis (AD) is associated with epidermal barrier defects, dysbiosis, and skin injury caused by scratching. In particular, the barrier-defective epidermis in patients with AD with loss-of-function filaggrin mutations has increased IL-1 alpha and IL-1 beta levels, but the mechanisms by which IL-1 alpha, IL-1 beta, or both are induced and whether they contribute to the aberrant skin inflammation in patients with AD is unknown. Objective: We sought to determine the mechanisms through which skin injury, dysbiosis, and increased epidermal IL-1 alpha and IL-1 beta levels contribute to development of skin inflammation in a mouse model of injury-induced skin inflammation in filaggrin-deficient mice without the matted mutation (ft/ft mice). Methods: Skin injury of wild-type, ft/ft, and myeloid differentiation primary response gene-88-deficient ft/ft mice was performed, and ensuing skin inflammation was evaluated by using digital photography, histologic analysis, and flow cytometry. IL-1 alpha and IL-1 beta protein expression was measured by means of ELISA and visualized by using immunofluorescence and immunoelectron microscopy. Composition of the skin microbiome was determined by using 16S rDNA sequencing. Results: Skin injury of ft/ft mice induced chronic skin inflammation involving dysbiosis-driven intracellular IL-1 alpha release from keratinocytes. IL-1 alpha was necessary and sufficient for skin inflammation in vivo and secreted from keratinocytes by various stimuli in vitro. Topical antibiotics or cohousing of ft/ft mice with unaffected wild-type mice to alter or intermix skin microbiota, respectively, resolved the skin inflammation and restored keratinocyte intracellular IL-1 alpha localization. Conclusions: Taken together, skin injury, dysbiosis, and filaggrin deficiency triggered keratinocyte intracellular IL-1 alpha release that was sufficient to drive chronic skin inflammation, which has implications for AD pathogenesis and potential therapeutic targets.	[Archer, Nathan K.; Lee, Steven K.; Kim, Dongwon; Ortines, Roger V.; Wang, Yu; Marchitto, Mark C.; Ravipati, Advaitaa; Cai, Shuting S.; Dillen, Carly A.; Liu, Haiyun; Miller, Robert J.; Ashbaugh, Alyssa G.; Uppal, Angad S.; Garza, Luis A.; Miller, Lloyd S.] Johns Hopkins Univ, Sch Med, Dept Dermatol, Baltimore, MD 21205 USA; [Smith, Barbara] Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD USA; [Miller, Lloyd S.] Johns Hopkins Univ, Sch Med, Dept Med, Div Infect Dis, Baltimore, MD 21205 USA; [Miller, Lloyd S.] Johns Hopkins Univ, Sch Med, Dept Orthopaed Surg, Baltimore, MD USA; [Jo, Jay-Hyun; Kong, Heidi H.] NCI, Dermatol Branch, Ctr Canc Res, Bethesda, MD 20892 USA; [Segre, Julia A.] NHGRI, Microbial Genom Sect, Translat & Funct Genom Branch, NIH, Bethesda, MD 20892 USA; [Oyoshi, Michiko K.; Malhotra, Nidhi; Hoff, Sabine; Geha, Raif S.] Harvard Med Sch, Childrens Hosp, Div Immunol, Boston, MA 02115 USA; [Oyoshi, Michiko K.; Malhotra, Nidhi; Hoff, Sabine; Geha, Raif S.] Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA; [Hoff, Sabine] Bayer AG, TRG Oncol 3, Berlin, Germany; [Miller, Lloyd S.] Johns Hopkins Univ, Dept Mat Sci & Engn, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Bayer AG; Johns Hopkins University	Miller, LS (corresponding author), Johns Hopkins Dept Dermatol, Canc Res Bldg 2,Suite 205,1550 Orleans St, Baltimore, MD 21231 USA.	lloydmiller@jhmi.edu	Kong, Heidi H/L-4856-2018	Kong, Heidi H/0000-0003-4424-064X; garza, luis/0000-0002-6547-9695; Cai, Shuting/0000-0003-3616-0391; Archer, Nathan/0000-0002-8212-8985	National Institutes of Arthritis and Musculoskeletal and Skin Diseases [R01AR069502, R01AR073665, K01AR073924]; National Institute of Allergy and Infectious Diseases [R21AI126896]; Atopic Dermatitis Research Network [U19AI117673-01]; Division of Intramural Research from the US National Institutes of Health, Department of Health and Human Services [ZIAHG000180-17, ZIABC011558-04]; Food Allergy Research & Education (FARE), Inc; HOPE APFED/ARTrust TM Pilot Grant; Harvard Catalyst Clinical and Translational Research Center (NCATS) [8UL 1TR000170]; Boston Children's Hospital Pediatric Associates Award; William F. Milton Fund; NATIONAL CANCER INSTITUTE [ZIABC011558] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZIAHG000180] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI117673, R21AI126896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR064297, K01AR073924, R01AR068280, R01AR073665, R01AR069502] Funding Source: NIH RePORTER	National Institutes of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Atopic Dermatitis Research Network; Division of Intramural Research from the US National Institutes of Health, Department of Health and Human Services; Food Allergy Research & Education (FARE), Inc; HOPE APFED/ARTrust TM Pilot Grant; Harvard Catalyst Clinical and Translational Research Center (NCATS); Boston Children's Hospital Pediatric Associates Award; William F. Milton Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported by the National Institutes of Arthritis and Musculoskeletal and Skin Diseases (grant no. R01AR069502; to L.S.M., grant no. R01AR073665; to L.S.M., and grant no. K01AR073924; to N.K.A.), the National Institute of Allergy and Infectious Diseases (grant no. R21AI126896; to L.S.M.), and a contract/grant from the Atopic Dermatitis Research Network (U19AI117673-01; to R.S.G. and L.S.M.), and the Division of Intramural Research (ZIAHG000180-17 and ZIABC011558-04; to H.H.K. and J.A.S.) from the US National Institutes of Health, Department of Health and Human Services. Supported also by the Food Allergy Research & Education (FARE), Inc (to M.K.O.), the HOPE APFED/ARTrust TM Pilot Grant (to M.K.O.), theWilliam F. Milton Fund, the Harvard Catalyst Clinical and Translational Research Center (NCATS grant no. 8UL 1TR000170; to M.K.O.), and the Boston Children's Hospital Pediatric Associates Award (to M.K.O.).	Brown SJ, 2012, J INVEST DERMATOL, V132, P751, DOI 10.1038/jid.2011.393; Byrd AL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal4651; CARRUTH LM, 1991, J BIOL CHEM, V266, P12162; Chng KR, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2016.106, 10.1038/nmicrobiol.2016.106]; Cho JS, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1003047; Cho JS, 2011, J INVEST DERMATOL, V131, P907, DOI 10.1038/jid.2010.417; Clausen ML, 2017, BRIT J DERMATOL, V177, P1394, DOI 10.1111/bjd.15470; Clausen ML, 2018, JAMA DERMATOL, V154, P293, DOI 10.1001/jamadermatol.2017.5440; Daniels MJ, 2017, INT J MOL SCI, P18; Di Paolo NC, 2016, NAT IMMUNOL, V17, P906, DOI 10.1038/ni.3503; Dillen CA, 2018, J CLIN INVEST, V128, P1026, DOI 10.1172/JCI96481; Dinarello CA, 2009, ANNU REV IMMUNOL, V27, P519, DOI 10.1146/annurev.immunol.021908.132612; Drucker AM, 2017, J INVEST DERMATOL, V137, P26, DOI 10.1016/j.jid.2016.07.012; Dunn KW, 2011, AM J PHYSIOL-CELL PH, V300, pC723, DOI 10.1152/ajpcell.00462.2010; Dupont N, 2011, EMBO J, V30, P4701, DOI 10.1038/emboj.2011.398; Edgar RC, 2011, BIOINFORMATICS, V27, P2194, DOI 10.1093/bioinformatics/btr381; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; Gao PS, 2009, J ALLERGY CLIN IMMUN, V124, P507, DOI 10.1016/j.jaci.2009.07.034; GRANSTEIN RD, 1986, J CLIN INVEST, V77, P1020, DOI 10.1172/JCI112354; Grice EA, 2011, NAT REV MICROBIOL, V9, P244, DOI 10.1038/nrmicro2537; Gross Olaf, 2012, Immunity, V36, P388, DOI 10.1016/j.immuni.2012.01.018; Guerra ES, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006175; Heath WR, 2013, NAT IMMUNOL, V14, P978, DOI 10.1038/ni.2680; Holland DB, 2009, FEMS MICROBIOL LETT, V290, P149, DOI 10.1111/j.1574-6968.2008.01402.x; Idan C, 2015, SCI REP-UK, V5, DOI 10.1038/srep14756; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Jiang XD, 2012, NATURE, V483, P227, DOI 10.1038/nature10851; Kawasaki H, 2012, J ALLERGY CLIN IMMUN, V129, P1538, DOI 10.1016/j.jaci.2012.01.068; Kezic S, 2012, J ALLERGY CLIN IMMUN, V129, P1031, DOI 10.1016/j.jaci.2011.12.989; Kim B, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00391; KOBAYASHI Y, 1990, P NATL ACAD SCI USA, V87, P5548, DOI 10.1073/pnas.87.14.5548; Kong HDH, 2012, GENOME RES, V22, P850, DOI 10.1101/gr.131029.111; Kupper TS, 2004, NAT REV IMMUNOL, V4, P211, DOI 10.1038/nri1310; KUPPER TS, 1986, J EXP MED, V164, P2095, DOI 10.1084/jem.164.6.2095; Leisten S, 2013, J ALLERGY CLIN IMMUN, V131, P1247, DOI 10.1016/j.jaci.2012.12.1576; Lim J, 2012, J BIOL CHEM, V287, P23271, DOI 10.1074/jbc.M112.364281; Magoc T, 2011, BIOINFORMATICS, V27, P2957, DOI 10.1093/bioinformatics/btr507; Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515; McAleer MA, 2013, J ALLERGY CLIN IMMUN, V131, P280, DOI 10.1016/j.jaci.2012.12.668; Miller LS, 2006, IMMUNITY, V24, P79, DOI 10.1016/j.immuni.2005.11.011; Muller S, 2009, PEDIAT ALLERG IMM-UK, V20, P358, DOI 10.1111/j.1399-3038.2008.00808.x; Munoz-Planillo R, 2009, J IMMUNOL, V183, P3942, DOI 10.4049/jimmunol.0900729; Naik S, 2012, SCIENCE, V337, P1115, DOI 10.1126/science.1225152; Nakatsuji T, 2016, J INVEST DERMATOL, V136, P2192, DOI 10.1016/j.jid.2016.05.127; Nemoto-Hasebe I, 2009, J INVEST DERMATOL, V129, P682, DOI 10.1038/jid.2008.280; Nestle FO, 2009, NAT REV IMMUNOL, V9, P679, DOI 10.1038/nri2622; Olaru F, 2010, J INVEST DERMATOL, V130, P1866, DOI 10.1038/jid.2010.37; Ong PY, 2016, CLIN REV ALLERG IMMU, V51, P329, DOI 10.1007/s12016-016-8548-5; Oyoshi MK, 2015, J ALLERGY CLIN IMMUN, V135, P1511, DOI 10.1016/j.jaci.2014.12.1923; Oyoshi MK, 2009, J ALLERGY CLIN IMMUN, V124, P485, DOI 10.1016/j.jaci.2009.05.042; Oyoshi MK, 2009, ADV IMMUNOL, V102, P135, DOI 10.1016/S0065-2776(09)01203-6; Pasparakis M, 2014, NAT REV IMMUNOL, V14, P289, DOI 10.1038/nri3646; Plaut RD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059232; Scharschmidt TC, 2015, IMMUNITY, V43, P1011, DOI 10.1016/j.immuni.2015.10.016; Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09; Sims JE, 2010, NAT REV IMMUNOL, V10, P89, DOI 10.1038/nri2691; Spaulding AR, 2013, CLIN MICROBIOL REV, V26, P422, DOI 10.1128/CMR.00104-12; Venkataraman D, 2014, J ALLERGY CLIN IMMUN, V134, P876, DOI 10.1016/j.jaci.2014.07.033; Weidinger S, 2016, LANCET, V387, P1109, DOI 10.1016/S0140-6736(15)00149-X; Werman A, 2004, P NATL ACAD SCI USA, V101, P2434, DOI 10.1073/pnas.0308705101; WESSENDORF JHM, 1993, J BIOL CHEM, V268, P22100; WOOD LC, 1992, J CLIN INVEST, V90, P482, DOI 10.1172/JCI115884; Zanvit P, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9424; Zeeuwen PLJM, 2017, J ALLERGY CLIN IMMUN, V139, P1368, DOI 10.1016/j.jaci.2016.09.017	64	38	39	6	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2019	143	4					1426	+		10.1016/j.jaci.2018.08.042	http://dx.doi.org/10.1016/j.jaci.2018.08.042			24	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HR7QE	30240702	Green Accepted, Bronze			2022-12-18	WOS:000463348900019
J	Oteros, J; Bartusel, E; Alessandrini, F; Nunez, A; Moreno, DA; Behrendt, H; Schmidt-Weber, C; Traidl-Hoffmann, C; Buters, J				Oteros, Jose; Bartusel, Elke; Alessandrini, Francesca; Nunez, Andres; Moreno, Diego A.; Behrendt, Heidrun; Schmidt-Weber, Carsten; Traidl-Hoffmann, Claudia; Buters, Jeroen			Artemisia pollen is the main vector for airborne endotoxin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Endotoxin; ambient; bacteria; pollen; gram-negative; recombinant Factor c; Davos; Munich; Artemisia species; microbiome; mouse model; allergy; LPS; source; PM10; PM2.5	HOUSE-DUST ENDOTOXIN; EXPOSURE; BACTERIA; DIVERSITY; CHILDREN; INDOOR	Background: Endotoxin (LPS) released from gram-negative bacteria causes strong immunologic and inflammatory effects and, when airborne, can contribute to respiratory conditions, such as allergic asthma. Objectives: We sought to identify the source of airborne endotoxin and the effect of this endotoxin on allergic sensitization. Methods: We determinedLPS levels in outdoor air on a daily basis for 4 consecutive years in Munich (Germany) and Davos (Switzerland). Airwas sampled as particulate matter (PM) greater than 10 mm(PM > 10) and PMbetween 2.5 and 10 mm. LPS levels were determined by using the recombinant Factor C assay. Results: More than 60% of the annual endotoxin exposure was detected in the PM > 10 fraction, showing that bacteria do not aerosolize as independent units or aggregates but adhered to large particles. In Munich 70% of annual exposure was detected between June 12th and August 28th. Multivariate modeling showed that endotoxin levels could be explained by phenological parameters (ie, plant growth). Indeed, days with high airborne endotoxin levels correlated well with the amount of Artemisia pollen in the air. Pollen collected from plants across Europe (100 locations) showed that the highest levels of endotoxin were detected on Artemisia vulgaris (mugwort) pollen, with little on other pollen. Microbiome analysis showed that LPS concentrations on mugwort pollen were related to the presence of Pseudomonas species and Pantoea species communities. In a mouse model of allergic disease, the presence of LPS on mugwort pollen was needed for allergic sensitization. Conclusions: The majority of airborne endotoxin stems from bacteria dispersed with pollen of only one plant: mugwort. This LPS was essential for inducing inflammation of the lung and allergic sensitization.	[Oteros, Jose; Bartusel, Elke; Alessandrini, Francesca; Behrendt, Heidrun; Schmidt-Weber, Carsten; Buters, Jeroen] Tech Univ, Ctr Allergy & Environm ZAUM, Munich, Germany; [Oteros, Jose; Bartusel, Elke; Alessandrini, Francesca; Behrendt, Heidrun; Schmidt-Weber, Carsten; Buters, Jeroen] Tech Univ, German Ctr Lung Res DZL, Munich, Germany; [Oteros, Jose; Bartusel, Elke; Alessandrini, Francesca; Behrendt, Heidrun; Schmidt-Weber, Carsten; Buters, Jeroen] Helmholtz Ctr Munich, Munich, Germany; [Bartusel, Elke; Behrendt, Heidrun; Traidl-Hoffmann, Claudia; Buters, Jeroen] Christine Kuhne Ctr Allergy Res & Educ CK CARE, Davos, Switzerland; [Nunez, Andres; Moreno, Diego A.] Univ Politecn Madrid ETSII UPM, Escuela Tecn Super Ingenieros Ind, Madrid, Spain; [Traidl-Hoffmann, Claudia] Tech Univ Munich, Inst Environm Med UNIKA T, Munich, Germany	Technical University of Munich; Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Universidad Politecnica de Madrid; Technical University of Munich	Buters, J (corresponding author), ZAUM Tech Univ Munich, Biedersteinerstr 29, D-80802 Munich, Germany.	Buters@tum.de	Moreno, Diego A./F-4340-2012; Nunez-Hernandez, Andres/AAZ-3900-2020; Schmidt-Weber, Carsten B./AAU-1621-2021; Oteros, Jose/AAN-5515-2020; BUTERS, JEROEN/AAF-6949-2020	Moreno, Diego A./0000-0003-2271-7013; Nunez-Hernandez, Andres/0000-0002-0781-0001; Schmidt-Weber, Carsten B./0000-0002-3203-8084; Oteros, Jose/0000-0002-9369-8633; Buters, Jeroen/0000-0003-3581-5472	Kuhne foundation/Christine Kuhne-Center for Allergy Research & Education (CK-CARE), Davos, Switzerland; Helmholtz Zentrum Munchen	Kuhne foundation/Christine Kuhne-Center for Allergy Research & Education (CK-CARE), Davos, Switzerland; Helmholtz Zentrum Munchen(Helmholtz Association)	We thank the Kuhne foundation/Christine Kuhne-Center for Allergy Research & Education (CK-CARE), Davos, Switzerland, for financial support and to Deutscher Wetterdienst (DWD), Landesamt fur Umwelt (LfU), and Grisons Agency for Nature and Environment for the weather and air pollution data. For the provision of pollen samples, we thank Lukasz Grewling (Adam Mickiewicz University, Poznan, Poland) and to the company Pharmallerga (http://www.pharmallerga.com/). The pollen data from Davos were provided by MeteoSwiss, and we thank Drs Regula Gehrig and Bernard Clot. We thank Dr Martin Koberle and Katja Krocker for their help in the microbiological analysis. We thank Britta Stolpe, Johanna Grosch, Joana Candeias, Christine Weil, and Gudrun Pusch for their support with the animal model, LPS monitoring, and pollen analysis. We thank Matt Smith (University of Worcester, Worcester, United Kingdom) for reviewing the manuscript. Finally, we acknowledge the Postdoctoral Fellowship Program of the Helmholtz Zentrum Munchen.	Aleklett K, 2014, BOTANY, V92, DOI 10.1139/cjb-2013-0166; Allen J, 2011, J ENVIRON MONITOR, V13, P631, DOI 10.1039/c0em00235f; Alwis KU, 2006, AM J IND MED, V49, P296, DOI 10.1002/ajim.20264; Barberan A, 2015, P NATL ACAD SCI USA, V112, P5756, DOI 10.1073/pnas.1420815112; Barraza F, 2016, ENVIRON INT, V92-93, P97, DOI 10.1016/j.envint.2016.03.039; Bowers RM, 2011, APPL ENVIRON MICROB, V77, P6350, DOI 10.1128/AEM.05498-11; Brodie EL, 2007, P NATL ACAD SCI USA, V104, P299, DOI 10.1073/pnas.0608255104; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Carty CL, 2003, J ENVIRON MONITOR, V5, P953, DOI 10.1039/b308488d; de Man H, 2014, WATER RES, V51, P198, DOI 10.1016/j.watres.2013.10.057; Demokritou P, 2002, J AEROSOL SCI, V33, P1111, DOI 10.1016/S0021-8502(02)00064-2; DeSantis TZ, 2003, BIOINFORMATICS, V19, P1461, DOI 10.1093/bioinformatics/btg200; Erridge C, 2002, MICROBES INFECT, V4, P837, DOI 10.1016/S1286-4579(02)01604-0; Fahlgren C, 2010, APPL ENVIRON MICROB, V76, P3015, DOI 10.1128/AEM.02092-09; FRIEDMAN JH, 1991, ANN STAT, V19, P1, DOI 10.1214/aos/1176347963; Galan C, 2014, AEROBIOLOGIA, V30, P385, DOI 10.1007/s10453-014-9335-5; Garcia J, 2012, J OCCUP ENVIRON HYG, V9, P580, DOI 10.1080/15459624.2012.713301; Gehring U, 2002, AM J RESP CRIT CARE, V166, P939, DOI 10.1164/rccm.200203-256OC; Harrell F. E., 2001, REGRESSION MODELING; Heydenreich B, 2012, CLIN EXP ALLERGY, V42, P76, DOI 10.1111/j.1365-2222.2011.03888.x; HIRST JM, 1952, ANN APPL BIOL, V39, P257, DOI 10.1111/j.1744-7348.1952.tb00904.x; Kallawicha K, 2015, AEROSOL AIR QUAL RES, V15, P1448, DOI 10.4209/aaqr.2015.01.0036; Kulp A, 2010, ANNU REV MICROBIOL, V64, P163, DOI 10.1146/annurev.micro.091208.073413; Lang-Yona N, 2014, SCI TOTAL ENVIRON, V499, P311, DOI 10.1016/j.scitotenv.2014.08.054; Litonjua AA, 2002, J ALLERGY CLIN IMMUN, V110, P736, DOI 10.1067/mai.2002.128948; Liu Andrew H, 2004, Paediatr Respir Rev, V5 Suppl A, pS65, DOI 10.1016/S1526-0542(04)90013-9; Loverock B., 2009, PHARMACOPEIAL FORUM, V35, P1613; Manirajan BA, 2016, ENVIRON MICROBIOL, V18, P5161, DOI 10.1111/1462-2920.13524; Masella AP, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-31; Morgenstern V, 2005, ATMOS ENVIRON, V39, P6931, DOI 10.1016/j.atmosenv.2005.08.022; Oeder S, 2012, AM J RESP CELL MOL, V47, P575, DOI 10.1165/rcmb.2012-0139OC; Ortiz-Martinez MG, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/784212; Salonen H, 2016, ATMOS ENVIRON, V142, P360, DOI 10.1016/j.atmosenv.2016.08.018; Spiewak R., 1996, ANN AGR ENV MED, V3, P57; Spiewak R, 2008, ANN AGR ENV MED, V15, P153; Starkhammar M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104114; Tang R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/179426; Thorne PS, 2009, ENVIRON HEALTH PERSP, V117, P763, DOI 10.1289/ehp.11759; Thorne PS, 2005, AM J RESP CRIT CARE, V172, P1371, DOI 10.1164/rccm.200505-758OC; vanVelzen E, 1996, THORAX, V51, P582, DOI 10.1136/thx.51.6.582; Vatanen T, 2016, CELL, V165, P842, DOI 10.1016/j.cell.2016.04.007; Weikl F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154131; Wimmer M, 2015, ALLERGY, V70, P944, DOI 10.1111/all.12642	43	38	39	5	37	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2019	143	1					369	+		10.1016/j.jaci.2018.05.040	http://dx.doi.org/10.1016/j.jaci.2018.05.040			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HG4BD	30012513	Green Submitted, Bronze, Green Accepted			2022-12-18	WOS:000454918300040
J	Verma, M; Liu, SC; Michalec, L; Sripada, A; Gorska, MM; Alam, R				Verma, Mukesh; Liu, Sucai; Michalec, Lidia; Sripada, Anand; Gorska, Magdalena M.; Alam, Rafeul			Experimental asthma persists in IL-33 receptor knockout mice because of the emergence of thymic stromal lymphopoietin-driven IL-9(+) and IL-13(+) type 2 innate lymphoid cell subpopulations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; type 2 innate lymphoid cells; IL-33 receptor; thymic stromal lymphopoietin; IL-9; mast cells	ALLERGIC AIRWAY INFLAMMATION; EPITHELIAL-CELLS; DENDRITIC CELLS; DUST-MITE; HYPERRESPONSIVENESS; ABSENCE; ST2; INTERLEUKIN-33; HYPERPLASIA; EXPRESSION	Background: IL-33 plays an important role in the development of experimental asthma. Objective: We sought to study the role of the IL-33 receptor suppressor of tumorigenicity 2 (ST2) in the persistence of asthma in a mouse model. Methods: We studied allergen-induced experimental asthma in ST2 knockout (KO) and wild-type control mice. We measured airway hyperresponsiveness by using flexiVent; inflammatory indices by using ELISA, histology, and real-time PCR; and type 2 innate lymphoid cells (ILC2s) in lung single-cell preparations by using flow cytometry. Results: Airway hyperresponsiveness was increased in allergen-treated ST2 KO mice and comparable with that in allergen-treated wild-type control mice. Peribronchial and perivascular inflammation and mucus production were largely similar in both groups. Persistence of experimental asthma in ST2 KO mice was associated with an increase in levels of thymic stromal lymphopoietin (TSLP), IL-9, and IL-13, but not IL-5, in bronchoalveolar lavage fluid. Expectedly, ST2 deletion caused a reduction in IL-13(+) CD4 T cells, forkhead box P3-positive regulatory T cells, and IL-5(+) ILC2s. Unexpectedly, ST2 deletion led to an overall increase in innate lymphoid cells (CD45(+)1in-CD25(+) cells) and IL-13(+) ILC2s, emergence of a TSLP receptor-positive IL-9(+) ILC2 population, and an increase in intraepithelial mast cell numbers in the lung. An anti-TSLP antibody abrogated airway hyperresponsiveness, inflammation, and mucus production in allergen-treated ST2 KO mice. It also caused a reduction in innate lymphoid cell, ILC2, and IL-9(+) and IL-13(+) ILC2 numbers in the lung. Conclusions: Genetic deletion of the IL-33 receptor paradoxically increases TSLP production, which stimulates the emergence of IL-9(+) and IL-13(+) ILC2s and mast cells and leads to development of chronic experimental asthma. An anti-TSLP antibody abrogates all pathologic features of asthma in this model.	[Verma, Mukesh; Liu, Sucai; Michalec, Lidia; Sripada, Anand; Gorska, Magdalena M.; Alam, Rafeul] Natl Jewish Hlth, Dept Med, Div Allergy & Immunol, Denver, CO USA; [Gorska, Magdalena M.; Alam, Rafeul] Univ Colorado Denver, Sch Med, Denver, CO USA; [Michalec, Lidia] Med Univ Lodz, Dept Cytobiol & Prote, Lodz, Poland	National Jewish Health; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Medical University Lodz	Alam, R (corresponding author), Natl Jewish Hlth, Dept Med, 1400 Jackson St, Denver, CO 80206 USA.	alamr@njhealth.org	verma, mukesh/AAB-9330-2020		National Institutes of Health [RO1 AI091614, AI102943, HL126895]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL126895, R01HL122995] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI091614, R01AI102943] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants RO1 AI091614, AI102943, and HL126895.	Allakhverdi Z, 2007, J IMMUNOL, V179, P2051, DOI 10.4049/jimmunol.179.4.2051; Blease K, 2002, AM J PATHOL, V160, P481, DOI 10.1016/S0002-9440(10)64867-5; Blease K, 2001, J IMMUNOL, V166, P5219, DOI 10.4049/jimmunol.166.8.5219; Chackerian AA, 2007, J IMMUNOL, V179, P2551, DOI 10.4049/jimmunol.179.4.2551; Cherry WB, 2008, J ALLERGY CLIN IMMUN, V121, P1484, DOI 10.1016/j.jaci.2008.04.005; Christianson CA, 2015, J ALLERGY CLIN IMMUN, V136, P59, DOI 10.1016/j.jaci.2014.11.037; Endo Y, 2015, IMMUNITY, V42, P294, DOI 10.1016/j.immuni.2015.01.016; Erpenbeck VJ, 2003, J ALLERGY CLIN IMMUN, V111, P1319, DOI 10.1067/mai.2003.1485; Froidure A, 2014, ALLERGY, V69, P1068, DOI 10.1111/all.12435; Godfraind C, 1998, J IMMUNOL, V160, P3989; Goplen N, 2009, J ALLERGY CLIN IMMUN, V123, P925, DOI 10.1016/j.jaci.2009.02.009; Hammad H, 2015, IMMUNITY, V43, P29, DOI 10.1016/j.immuni.2015.07.007; Hoshino K, 1999, J EXP MED, V190, P1541, DOI 10.1084/jem.190.10.1541; Huang YF, 2015, NAT IMMUNOL, V16, P161, DOI 10.1038/ni.3078; Iijima K, 2014, J IMMUNOL, V193, P1549, DOI 10.4049/jimmunol.1302984; Kabata H, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3675; Kearley J, 2011, AM J RESP CRIT CARE, V183, P865, DOI 10.1164/rccm.200909-1462OC; Kim BS, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005374; Klose CSN, 2016, NAT IMMUNOL, V17, P765, DOI 10.1038/ni.3489; Kondo Y, 2008, INT IMMUNOL, V20, P791, DOI 10.1093/intimm/dxn037; Kurowska-Stolarska M, 2008, J IMMUNOL, V181, P4780, DOI 10.4049/jimmunol.181.7.4780; Kurowska-Stolarska M, 2009, J IMMUNOL, V183, P6469, DOI 10.4049/jimmunol.0901575; Liao B, 2015, ALLERGY, V70, P1169, DOI 10.1111/all.12667; Liew FY, 2016, NAT REV IMMUNOL, V16, P676, DOI 10.1038/nri.2016.95; Matta BM, 2014, J IMMUNOL, V193, P4010, DOI 10.4049/jimmunol.1400481; McKinley L, 2008, J IMMUNOL, V181, P4089, DOI 10.4049/jimmunol.181.6.4089; McMillan S, 2002, J EXP MED, V195, P51, DOI 10.1084/jem.20011732; Mohapatra A, 2016, MUCOSAL IMMUNOL, V9, P275, DOI 10.1038/mi.2015.59; Morita H, 2016, J ALLERGY CLIN IMMUN, V138, P1253, DOI 10.1016/j.jaci.2016.09.011; Parker JC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061023; Saglani S, 2013, J ALLERGY CLIN IMMUN, V132, P676, DOI 10.1016/j.jaci.2013.04.012; Schiering C, 2014, NATURE, V513, P564, DOI 10.1038/nature13577; Siracusa MC, 2013, IMMUNITY, V39, P1158, DOI 10.1016/j.immuni.2013.09.016; Stier MT, 2016, J ALLERGY CLIN IMMUN, V138, P814, DOI 10.1016/j.jaci.2016.01.050; Temann UA, 2007, INT IMMUNOL, V19, P1, DOI 10.1093/intimm/dxl117; Townsend MJ, 2000, IMMUNITY, V13, P573, DOI 10.1016/S1074-7613(00)00056-X; Townsend MJ, 2000, J EXP MED, V191, P1069, DOI 10.1084/jem.191.6.1069; Vannella KM, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf1938; Yadava K, 2014, ALLERGY, V69, P1333, DOI 10.1111/all.12469; Yao WG, 2013, IMMUNITY, V38, P360, DOI 10.1016/j.immuni.2013.01.007; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247; Zoltowska AM, 2016, CLIN EXP ALLERGY, V46, P479, DOI 10.1111/cea.12683	42	38	39	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2018	142	3					793	+		10.1016/j.jaci.2017.10.020	http://dx.doi.org/10.1016/j.jaci.2017.10.020			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GS5RJ	29132961	Bronze, Green Accepted			2022-12-18	WOS:000443726500012
J	Liu, XQ; Agerbo, E; Schlunssen, V; Wright, RJ; Li, J; Munk-Olsen, T				Liu, Xiaoqin; Agerbo, Esben; Schlunssen, Vivi; Wright, Rosalind J.; Li, Jiong; Munk-Olsen, Trine			Maternal asthma severity and control during pregnancy and risk of offspring asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; cohort study; control; early onset; late onset; phenotype; pregnancy; severity	FAMILY-HISTORY; EXACERBATIONS; PREVALENCE; ONSET; PERSISTENT; REGISTER; OUTCOMES; STRESS; WOMEN	Background: Severe and uncontrolled asthma during pregnancy has been linked to several unfavorable perinatal outcomes. However, current knowledge on the association between the severity and control of maternal asthma and offspring asthma is sparse. Objective: We sought to investigate the extent to which offspring asthma is influenced by maternal asthma severity and control during pregnancy. Methods: We performed a prospective population-based cohort study. Using linkage of Danish national registers, we constructed a cohort of 675,379 singletons, of which 15,014 children were born to asthmatic mothers. Among them, 7,188 children were born to mothers with active asthma during pregnancy. We categorized mothers with active asthma into 4 groups based on dispensed antiasthma prescriptions and on use of medical services: mild controlled, mild uncontrolled, moderate-to-severe controlled, and moderate-to-severe uncontrolled asthma. The outcomes were offspring early-onset transient, early-onset persistent, and late-onset asthma. We estimated prevalence ratios (PRs) of each phenotype of asthma using a log-binomial model with 95% CIs. Results: Higher prevalence of early-onset persistent asthma was observed among children of asthmatic mothers with mild uncontrolled (PR, 1.19; 95% CI, 1.05-1.35), moderate-to-severe controlled (PR, 1.33; 95% CI, 1.09-1.63), and moderate-to-severe uncontrolled asthma (PR, 1.37; 95% CI, 1.17-1.61) compared with those of mothers with mild controlled asthma. A borderline increased prevalence of early-onset transient asthma was observed among children of mothers with uncontrolled asthma. Conclusion: Maternal uncontrolled asthma increases the risk of early-onset persistent and transient asthma. If replicated, this could suggest that maintaining asthma control in pregnancy is an area for possible prevention of specific phenotypes of offspring asthma.	[Liu, Xiaoqin; Agerbo, Esben; Munk-Olsen, Trine] Aarhus Univ, Natl Ctr Register Based Res, Fuglesangs Alle 26, DK-8210 Aarhus V, Denmark; [Agerbo, Esben] Aarhus Univ, CIRRAU Ctr Integrated Register Based Res, Aarhus, Denmark; [Schlunssen, Vivi] Aarhus Univ, Sect Environm & Occupat Med, Dept Publ Hlth, Aarhus, Denmark; [Agerbo, Esben] IPSYCH, Lundbeck Fdn Initiat Integrat Psychiat Res, Aarhus, Denmark; [Schlunssen, Vivi] Natl Res Ctr Working Environm, Copenhagen, Denmark; [Wright, Rosalind J.] Icahn Sch Med Mt Sinai, Dept Pediat, Kravis Childrens Hosp, New York, NY 10029 USA; [Li, Jiong] Aarhus Univ Hosp, Dept Clin Epidemiol, Aarhus, Denmark	Aarhus University; Aarhus University; Aarhus University; Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH); National Research Centre for the Working Environment; Icahn School of Medicine at Mount Sinai; Aarhus University	Liu, XQ (corresponding author), Aarhus Univ, Natl Ctr Register Based Res, Fuglesangs Alle 26, DK-8210 Aarhus V, Denmark.	lxq@econ.au.dk	li, jiong/L-6534-2014; Liu, Xiaoqin/AAB-7509-2019; Munk-olsen, Trine/AAS-3546-2021; Agerbo, Esben/A-2645-2012	li, jiong/0000-0002-1716-8067; Liu, Xiaoqin/0000-0003-4519-1536; Munk-olsen, Trine/0000-0002-0786-7147; Schlunssen, Vivi/0000-0003-4915-1734; Agerbo, Esben/0000-0002-2849-524X; li, jiong/0000-0003-1125-026X	Danish Council for Independent Research [DFF-5053-00156B, DFF-6110-00019]; iPSYCH; Lundbeck Foundation Initiative for Integrative Psychiatric Research [R155-2014-1724]; Niels Bohr Professorship Grant from the Danish National Research Foundation; Stanley Medical Research Institute; Nordic Cancer Union [176673, 186200]; Karen Elise Jensens Fond; PROCRIN project; Lundbeck Foundation [R248-2017-2003, R155-2014-1724, R155-2014-2647] Funding Source: researchfish; Novo Nordisk Fonden [NNF14SA0015794] Funding Source: researchfish	Danish Council for Independent Research(Det Frie Forskningsrad (DFF)); iPSYCH; Lundbeck Foundation Initiative for Integrative Psychiatric Research; Niels Bohr Professorship Grant from the Danish National Research Foundation; Stanley Medical Research Institute; Nordic Cancer Union; Karen Elise Jensens Fond; PROCRIN project; Lundbeck Foundation(Lundbeckfonden); Novo Nordisk Fonden(Novo Nordisk Foundation)	Supported by the Danish Council for Independent Research (project no. DFF-5053-00156B). E.A. and T.M.-O. are supported by iPSYCH, the Lundbeck Foundation Initiative for Integrative Psychiatric Research (R155-2014-1724). E.A. is also supported by the Niels Bohr Professorship Grant from the Danish National Research Foundation and the Stanley Medical Research Institute. J.L. is supported by the Nordic Cancer Union (176673 and 186200), Danish Council for Independent Research (DFF-6110-00019), Karen Elise Jensens Fond (2016), and PROCRIN project.	Adcock IM, 2007, CURR OPIN IMMUNOL, V19, P694, DOI 10.1016/j.coi.2007.07.016; Andersen TF, 1999, DAN MED BULL, V46, P263; [Anonymous], 2005, J ALLERGY CLIN IMMUN, V115, P34, DOI 10.1016/j.jaci.2004.10.023; Bakhireva LN, 2008, ANN ALLERG ASTHMA IM, V101, P137, DOI 10.1016/S1081-1206(10)60201-3; Blais L, 2014, J ASTHMA, V51, P391, DOI 10.3109/02770903.2013.879880; Bouffard R, 2003, CAN J PSYCHIAT, V48, P546, DOI 10.1177/070674370304800806; Boulet LP, 1999, CAN MED ASSOC J, V161, pS1; Bousquet J, 2010, J ALLERGY CLIN IMMUN, V126, P926, DOI 10.1016/j.jaci.2010.07.019; Bracken MB, 2002, EPIDEMIOL REV, V24, P176, DOI 10.1093/epirev/mxf012; Burke W, 2003, AM J PREV MED, V24, P160, DOI 10.1016/S0749-3797(02)00589-5; Chambers Karen, 2003, Case Manager, V14, P58, DOI 10.1016/j.casemgr.2003.09.003; Chen E, 2007, BRAIN BEHAV IMMUN, V21, P993, DOI 10.1016/j.bbi.2007.03.009; Clifton VL, 2004, PLACENTA, V25, pS45, DOI 10.1016/j.placenta.2004.01.004; Deddens JA, 2008, OCCUP ENVIRON MED, V65, P501, DOI 10.1136/oem.2007.034777; DUFFY DL, 1990, AM REV RESPIR DIS, V142, P1351, DOI 10.1164/ajrccm/142.6_Pt_1.1351; Firoozi F, 2007, THORAX, V62, P581, DOI 10.1136/thx.2006.061572; Giraud V, 2002, EUR RESPIR J, V19, P246, DOI 10.1183/09031936.02.00218402; Haughney J, 2008, RESP MED, V102, P1681, DOI 10.1016/j.rmed.2008.08.003; Helweg-Larsen K, 2011, SCAND J PUBLIC HEALT, V39, P26, DOI 10.1177/1403494811399958; Kildemoes HW, 2011, SCAND J PUBLIC HEALT, V39, P38, DOI 10.1177/1403494810394717; Knudsen LB, 1998, DAN MED BULL, V45, P320; Kwon HL, 2006, IMMUNOL ALLERGY CLIN, V26, P29, DOI 10.1016/j.iac.2005.11.002; Kwon HL, 2003, ANN EPIDEMIOL, V13, P317, DOI 10.1016/S1047-2797(03)00008-5; Lim RH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010134; Litonjua AA, 1998, AM J RESP CRIT CARE, V158, P176, DOI 10.1164/ajrccm.158.1.9710014; Liu XQ, 2014, ALLERGY ASTHMA CL IM, V10, DOI 10.1186/1710-1492-10-13; London SJ, 2001, EPIDEMIOLOGY, V12, P577, DOI 10.1097/00001648-200109000-00019; Maritz GS, 2005, EARLY HUM DEV, V81, P763, DOI 10.1016/j.earlhumdev.2005.07.002; Martel MJ, 2009, EUR RESPIR J, V34, P579, DOI 10.1183/09031936.00074608; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Mikhaylova L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070387; Murphy VE, 2007, PLACENTA, V28, P39, DOI 10.1016/j.placenta.2005.12.010; Murphy VE, 2006, THORAX, V61, P169, DOI 10.1136/thx.2005.049718; Namazy JA, 2013, EUR RESPIR J, V41, P1082, DOI 10.1183/09031936.00195111; Niedzwiecki M, 2012, ALLERGY, V67, P904, DOI 10.1111/j.1398-9995.2012.02841.x; Olesen C, 2001, EPIDEMIOLOGY, V12, P497, DOI 10.1097/00001648-200109000-00006; Pedersen CB, 2011, SCAND J PUBLIC HEALT, V39, P22, DOI 10.1177/1403494810387965; Petersson F, 2011, SCAND J PUBLIC HEALT, V39, P95, DOI 10.1177/1403494811408483; Rothman KJ., 2008, MODERN EPIDEMIOLOGY; Rusconi F, 1999, AM J RESP CRIT CARE, V160, P1617, DOI 10.1164/ajrccm.160.5.9811002; Smith GD, 2008, BASIC CLIN PHARMACOL, V102, P245, DOI 10.1111/j.1742-7843.2007.00191.x; Tegethoff M, 2013, PEDIATRICS, V132, P483, DOI 10.1542/peds.2012-3686; Wright RJ, 2010, AM J RESP CRIT CARE, V182, P25, DOI 10.1164/rccm.200904-0637OC	43	38	41	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2018	141	3					886	+		10.1016/j.jaci.2017.05.016	http://dx.doi.org/10.1016/j.jaci.2017.05.016			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FY6PR	28712803	Bronze, Green Accepted			2022-12-18	WOS:000426974800009
J	Kulis, MD; Patil, SU; Wambre, E; Vickery, BP				Kulis, Michael D.; Patil, Sarita U.; Wambre, Erik; Vickery, Brian P.			Immune mechanisms of oral immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Oral immunotherapy; immune mechanisms; desensitization; sustained unresponsiveness; basophils; T cells; B cells; mast cells; antibodies	REGULATORY B-CELLS; SUSTAINED UNRESPONSIVENESS; PEANUT ALLERGEN; FOOD ALLERGY; TH2 CELLS; IGE; DESENSITIZATION; RESPONSES; CHILDREN; ACTIVATION	Oral immunotherapy (OIT) has demonstrated reproducibly successful desensitization in patients with food allergy completing clinical trials and, in some studies, sustained unresponsiveness. These clinical outcomes have been associated with characteristic modifications in the allergen-specific immune response, but a detailed synthesis of OIT's mechanisms of action is lacking. In this rostrum we review the current evidence regarding the human immune response to OIT, explore possible mechanisms, and identify knowledge gaps for future research.	[Kulis, Michael D.; Vickery, Brian P.] Univ N Carolina, Dept Pediat, Chapel Hill, NC USA; [Patil, Sarita U.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA; [Wambre, Erik] Benaroya Res Inst, Dept Immunol, Seattle, WA USA	University of North Carolina; University of North Carolina Chapel Hill; Harvard University; Massachusetts General Hospital; Benaroya Research Institute	Vickery, BP (corresponding author), 030 MacNider Hall,CB 7231,333 S Columbia St, Chapel Hill, NC 27599 USA.	bvickery@email.unc.edu		Vickery, Brian/0000-0002-7243-5543	National Institutes of Health (NIH); Sanofi; American Academy of Allergy, Asthma & Immunology Foundation; Food Allergy Research & Education (FARE); National Institute of Allergy and Infectious Diseases (NIAID); Astellas; Aimmune; Anaptys Bio; Immune Tolerance Network; Aimmune Therapeutics; NIH/NIAID; FARE; American College of Allergy, Asthma Immunology; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI121491] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Sanofi; American Academy of Allergy, Asthma & Immunology Foundation; Food Allergy Research & Education (FARE); National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Astellas(Astellas Pharmaceuticals); Aimmune; Anaptys Bio; Immune Tolerance Network; Aimmune Therapeutics; NIH/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FARE; American College of Allergy, Asthma Immunology; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	S. U. Patil has received grants from the National Institutes of Health (NIH); Sanofi; the American Academy of Allergy, Asthma & Immunology Foundation; and Food Allergy Research & Education (FARE). E. Wambre has received grants from the National Institute of Allergy and Infectious Diseases (NIAID), Astellas, Aimmune, Anaptys Bio, and the Immune Tolerance Network and has a patent (US 9733247B2 Detection of TH2A Immune response) pending. B. P. Vickery has received personal fees and stock options from Aimmune Therapeutics and has received grants from the NIH/NIAID, FARE, and the American College of Allergy, Asthma & Immunology. M. D. Kulis declares that he has no relevant conflicts of interest.	Altin JA, 2012, J IMMUNOL, V188, P5478, DOI 10.4049/jimmunol.1102994; Ang WXG, 2016, J CLIN INVEST, V126, P4103, DOI 10.1172/JCI87492; Ballmer-Weber BK, 2015, ALLERGY, V70, P391, DOI 10.1111/all.12574; Blumchen K, 2010, J ALLERGY CLIN IMMUN, V126, P83, DOI 10.1016/j.jaci.2010.04.030; Burks AW, 2012, NEW ENGL J MED, V367, P233, DOI 10.1056/NEJMoa1200435; Burton OT, 2014, J ALLERGY CLIN IMMUN, V134, P1310, DOI 10.1016/j.jaci.2014.05.042; Burton OT, 2017, J ALLERGY CLIN IMMUN; Chen X, 2016, CLIN EXP ALLERGY, V46, P1120, DOI 10.1111/cea.12764; Christensen LH, 2008, J ALLERGY CLIN IMMUN, V122, P298, DOI 10.1016/j.jaci.2008.05.026; Dodev TS, 2015, ALLERGY, V70, P720, DOI 10.1111/all.12607; Flinterman AE, 2008, J ALLERGY CLIN IMMUN, V121, P737, DOI 10.1016/j.jaci.2007.11.039; Frischmeyer-Guerrerio PA, 2014, CLIN IMMUNOL, V155, P47, DOI 10.1016/j.clim.2014.08.006; Gorelik M, 2015, J ALLERGY CLIN IMMUN, V135, P1283, DOI 10.1016/j.jaci.2014.11.010; Hadjur S, 2009, IMMUNOL LETT, V122, P37, DOI 10.1016/j.imlet.2008.11.001; Han HW, 2017, IMMUNOL REV, V278, P116, DOI 10.1111/imr.12546; Hoh RA, 2016, J ALLERGY CLIN IMMUN, V137, P157, DOI 10.1016/j.jaci.2015.05.029; Jones SM, 2016, J ALLERGY CLIN IMMUN, V137, P1117, DOI 10.1016/j.jaci.2015.12.1316; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Jones Stacie M, 2009, J Allergy Clin Immunol, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Keet CA, 2013, J ALLERGY CLIN IMMUN, V132, P737, DOI 10.1016/j.jaci.2013.05.006; Keet CA, 2012, J ALLERGY CLIN IMMUN, V129, P448, DOI 10.1016/j.jaci.2011.10.023; Kosoy R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163831; Kwong PD, 2013, NAT REV IMMUNOL, V13, P693, DOI 10.1038/nri3516; Lemke A, 2016, MUCOSAL IMMUNOL, V9, P83, DOI 10.1038/mi.2015.38; Leonard SA, 2012, J ALLERGY CLIN IMMUN, V129, P1579, DOI 10.1016/j.jaci.2012.04.009; MacGinnitie AJ, 2017, J ALLERGY CLIN IMMUN, V139, P873, DOI 10.1016/j.jaci.2016.08.010; Mantel PY, 2007, PLOS BIOL, V5, P2847, DOI 10.1371/journal.pbio.0050329; Mobs C, 2012, J ALLERGY CLIN IMMUN, V130, P1108, DOI 10.1016/j.jaci.2012.07.056; Moher D., 2009, ANN INTERN MED, V6, DOI [10.1371/journal.pmed.100009, DOI 10.18632/aging.103000]; Nadeau KC, 2011, J ALLERGY CLIN IMMUN, V127, P1622, DOI 10.1016/j.jaci.2011.04.009; Nakayama T, 2017, ANNU REV IMMUNOL, V35, P53, DOI 10.1146/annurev-immunol-051116-052350; Narisety SD, 2015, J ALLERGY CLIN IMMUN, V135, pe1; Oka T, 2013, J ALLERGY CLIN IMMUN, V132, P922, DOI 10.1016/j.jaci.2013.05.004; Orgel KA, 2017, J ALLERGY CLIN IMMUN, V139, P366, DOI 10.1016/j.jaci.2016.06.053; Patil SU, 2015, J ALLERGY CLIN IMMUN, V136, P125, DOI 10.1016/j.jaci.2015.03.026; Piconi S, 2010, J IMMUNOL, V185, P7723, DOI 10.4049/jimmunol.1002465; Rivas MN, 2016, J ALLERGY CLIN IMMUN, V138, P801, DOI 10.1016/j.jaci.2016.02.030; Rust B, 2017, CURR ALLERGY ASTHM R, V17, DOI 10.1007/s11882-017-0689-y; Ryan JF, 2016, P NATL ACAD SCI USA, V113, pE1286, DOI 10.1073/pnas.1520180113; Santos AF, 2015, J ALLERGY CLIN IMMUN, V135, P1249, DOI 10.1016/j.jaci.2015.01.012; Santos AF, 2014, J ALLERGY CLIN IMMUN, V134, P645, DOI 10.1016/j.jaci.2014.04.039; Shamji MH, 2012, ALLERGY, V67, P217, DOI 10.1111/j.1398-9995.2011.02745.x; Shreffler WG, 2005, J ALLERGY CLIN IMMUN, V116, P893, DOI 10.1016/j.jaci.2005.06.033; Syed A, 2014, J ALLERGY CLIN IMMUN, V133, P500, DOI 10.1016/j.jaci.2013.12.1037; Thyagarajan A, 2012, CLIN EXP ALLERGY, V42, P1197, DOI 10.1111/j.1365-2222.2012.04028.x; Tordesillas L, 2016, J ALLERGY CLIN IMMUN, V138, P1741, DOI 10.1016/j.jaci.2016.06.048; van de Veen W, 2016, J ALLERGY CLIN IMMUN, V138, P654, DOI 10.1016/j.jaci.2016.07.006; van de Veen W, 2013, J ALLERGY CLIN IMMUN, V131, P1204, DOI 10.1016/j.jaci.2013.01.014; Varshney P, 2011, J ALLERGY CLIN IMMUN, V127, P654, DOI 10.1016/j.jaci.2010.12.1111; Vazquez-Ortiz M, 2016, PEDIAT ALLERG IMM-UK, V27, P117, DOI 10.1111/pai.12510; Vickery BP, 2013, J ALLERGY CLIN IMMUN, V131, pe1; Vickery BP, 2017, J ALLERGY CLIN IMMUN, V139, P173, DOI 10.1016/j.jaci.2016.05.027; Vickery BP, 2014, J ALLERGY CLIN IMMUN, V133, P468, DOI 10.1016/j.jaci.2013.11.007; Vickery BP, 2013, J ALLERGY CLIN IMMUN, V131, P128, DOI 10.1016/j.jaci.2012.10.048; Virkud YV, 2017, J ALLERGY CLIN IMMUN, V139, P882, DOI 10.1016/j.jaci.2016.07.030; Wambre E, 2012, J ALLERGY CLIN IMMUN, V129, pe1; Wambre E, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aam9171; Wambre E, 2012, J ALLERGY CLIN IMMUN, V129, P544, DOI 10.1016/j.jaci.2011.08.034; Wood RA, 2016, J ALLERGY CLIN IMMUN, V137, P973, DOI 10.1016/j.jaci.2016.01.001; Wright BL, 2016, ALLERGY, V71, P1552, DOI 10.1111/all.12895; Yu W, 2016, NAT REV IMMUNOL, V16, P751, DOI 10.1038/nri.2016.111	61	38	39	2	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2018	141	2					491	498		10.1016/j.jaci.2017.12.979	http://dx.doi.org/10.1016/j.jaci.2017.12.979			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FV2PQ	29288078	Green Accepted, Bronze			2022-12-18	WOS:000424410800004
J	Dhondalay, GK; Rael, E; Acharya, S; Zhang, WM; Sampath, V; Galli, SJ; Tibshirani, R; Boyd, SD; Maecker, H; Nadeau, KC; Andorf, S				Dhondalay, Gopal Krishna; Rael, Efren; Acharya, Swati; Zhang, Wenming; Sampath, Vanitha; Galli, Stephen J.; Tibshirani, Robert; Boyd, Scott D.; Maecker, Holden; Nadeau, Kari Christine; Andorf, Sandra			Food allergy and omics	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; bioinformatics; epigenomics; exposomics; genomics; transcriptomics; proteomics; metabolomics; microbiomics; integrative biology; systems biology	GENOME-WIDE ASSOCIATION; B-CELLS; EMERGING APPLICATIONS; ATOPIC-DERMATITIS; GUT MICROBIOTA; MASS CYTOMETRY; PEANUT ALLERGY; MILK ALLERGY; BIG DATA; IMMUNE	Food allergy (FA) prevalence has been increasing over the last few decades and is now a global health concern. Current diagnostic methods for FA result in a high number of false-positive results, and the standard of care is either allergen avoidance or use of epinephrine on accidental exposure, although currently with no other approved treatments. The increasing prevalence of FA, lack of robust biomarkers, and inadequate treatments warrants further research into the mechanism underlying food allergies. Recent technological advances have made it possible to move beyond traditional biological techniques to more sophisticated high-throughput approaches. These technologies have created the burgeoning field of omics sciences, which permit a more systematic investigation of biological problems. Omics sciences, such as genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiomics, and exposomics, have enabled the construction of regulatory networks and biological pathway models. Parallel advances in bioinformatics and computational techniques have enabled the integration, analysis, and interpretation of these exponentially growing data sets and opens the possibility of personalized or precision medicine for FA.	[Dhondalay, Gopal Krishna; Rael, Efren; Acharya, Swati; Zhang, Wenming; Sampath, Vanitha; Galli, Stephen J.; Tibshirani, Robert; Boyd, Scott D.; Maecker, Holden; Nadeau, Kari Christine; Andorf, Sandra] Stanford Univ, Sch Med, Sean N Parker Ctr Allergy & Asthma Res, Stanford, CA 94305 USA; [Galli, Stephen J.; Boyd, Scott D.] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; [Galli, Stephen J.; Maecker, Holden] Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA; [Dhondalay, Gopal Krishna; Rael, Efren; Acharya, Swati; Zhang, Wenming; Sampath, Vanitha; Boyd, Scott D.; Maecker, Holden; Nadeau, Kari Christine; Andorf, Sandra] Stanford Univ, Sch Med, Inst Immun Transplantat & Infect, Stanford, CA 94305 USA; [Tibshirani, Robert] Stanford Univ, Sch Med, Dept Biomed Data Sci, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University; Stanford University; Stanford University	Nadeau, KC (corresponding author), Stanford Univ, Sean N Parker Ctr Allergy & Asthma Res, 269 Campus Dr,CCSR 3215,MC 5366, Stanford, CA 94305 USA.	knadeau@stanford.edu	Zhang, Wenming/AAU-7795-2021; Dhondalay, Gopal Krishna Ramadas/A-3369-2014	Dhondalay, Gopal Krishna Ramadas/0000-0002-1020-0175; Zhang, Wenming/0000-0002-9298-8460; Andorf, Sandra/0000-0002-3093-2568	AADCRC NIAID U19 grant; SNP Center for Allergy and Asthma Research at Stanford University	AADCRC NIAID U19 grant; SNP Center for Allergy and Asthma Research at Stanford University	Authors are funded by AADCRC NIAID U19 grant and SNP Center for Allergy and Asthma Research at Stanford University.	Allen KJ, 2016, CLIN EXP ALLERGY, V46, P42, DOI 10.1111/cea.12685; Alyass A, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0108-y; Andorf S, 2017, J ALLER CL IMM-PRACT, V5, P1325, DOI 10.1016/j.jaip.2017.01.016; [Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; [Anonymous], 2016, FINDING PATH SAFETY; Azad MB, 2015, CLIN EXP ALLERGY, V45, P632, DOI 10.1111/cea.12487; Baar A, 2014, ALLERGY, V69, P1316, DOI 10.1111/all.12464; Bandura DR, 2009, ANAL CHEM, V81, P6813, DOI 10.1021/ac901049w; Bandyopadhyay S, 2017, METHODS MOL BIOL, V1636, P371, DOI 10.1007/978-1-4939-7154-1_24; Bellman R. E., 2003, DYNAMIC PROGRAMMING; Bellman RE, 1957, DYNAMIC PROGRAMMING; Bendall SC, 2011, SCIENCE, V332, P687, DOI 10.1126/science.1198704; Benson M, 2016, J INTERN MED, V279, P229, DOI 10.1111/joim.12412; Binder H, 2013, STAT MED, V32, P1778, DOI 10.1002/sim.5490; Blum HE, 2017, ADV MED SCI-POLAND, V62, P414, DOI 10.1016/j.advms.2017.04.005; Bouakkadia H, 2015, ANN BIOL CLIN-PARIS, V73, P690, DOI 10.1684/abc.2015.1089; Boyd SD, 2017, CURR OPIN IMMUNOL, V48, P82, DOI 10.1016/j.coi.2017.08.007; Bunning BJ, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0665-y; Bunyavanich S, 2016, J ALLERGY CLIN IMMUN, V138, P1122, DOI 10.1016/j.jaci.2016.03.041; Bunyavanich S, 2015, J ALLERGY CLIN IMMUN, V135, P31, DOI 10.1016/j.jaci.2014.10.015; Chen CC, 2016, PEDIAT ALLERG IMM-UK, V27, P254, DOI 10.1111/pai.12522; Davies JM, 2013, J ALLERGY CLIN IMMUN, V131, P972, DOI 10.1016/j.jaci.2012.12.1569; Deaton AM, 2011, GENE DEV, V25, P1010, DOI 10.1101/gad.2037511; Ebrahim A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13091; Feldweg AM, 2017, J ALLER CL IMM-PRACT, V5, P283, DOI 10.1016/j.jaip.2016.11.022; Fiocchi A, 2015, CURR OPIN ALLERGY CL, V15, P234, DOI 10.1097/ACI.0000000000000168; Frazier A, 2014, WORLD ALLERGY ORGAN, V7, DOI 10.1186/1939-4551-7-26; Gaublomme JT, 2015, CELL, V163, DOI 10.1016/j.cell.2015.11.009; Glanville J, 2017, NATURE, V547, P94, DOI 10.1038/nature22976; Goswami R, 2017, J ALLERGY CLIN IMMUN, V139, P1885, DOI 10.1016/j.jaci.2016.12.971; Greenhawt M, 2017, ALLERGY, V72, P1254, DOI 10.1111/all.13100; Greenhawt M, 2015, PEDIATR CLIN N AM, V62, P1509, DOI 10.1016/j.pcl.2015.07.010; Hasin Y, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1215-1; Hesselmar B, 2015, PEDIATRICS, V135, pE590, DOI 10.1542/peds.2014-2968; Hill DA, 2016, BMC PEDIATR, V16, DOI 10.1186/s12887-016-0673-z; Hiragun M, 2016, ALLERGOL INT, V65, P109, DOI 10.1016/j.alit.2015.07.004; Hirano K, 2016, BIOSCI BIOTECH BIOCH, V80, P564, DOI 10.1080/09168451.2015.1116927; Hirota T, 2017, J ALLERGY CLIN IMMUN, V140, P1713, DOI 10.1016/j.jaci.2017.05.034; Hoh RA, 2016, J ALLERGY CLIN IMMUN, V137, P157, DOI 10.1016/j.jaci.2015.05.029; Hong SW, 2017, IMMUNE NETW, V17, P48, DOI 10.4110/in.2017.17.1.48; Hong XM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7304; Hua X, 2016, EBIOMEDICINE, V3, P172, DOI 10.1016/j.ebiom.2015.11.038; Huang J, 2016, FRONT GENET, V7, DOI [10.3389/fgene.2016.00084, 10.3389/fgene.2017.00084]; Jones AL, 2016, J ALLERGY CLIN IMMUN, V137, P1247, DOI 10.1016/j.jaci.2016.01.010; Khodadoust MS, 2017, NATURE, V543, P723, DOI 10.1038/nature21433; Kim DH, 2017, IET SYST BIOL, V11, P87, DOI 10.1049/iet-syb.2016.0016; Kong J, 2015, ALLERGY, V70, P495, DOI 10.1111/all.12579; Kosoy R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163831; Levin M, 2017, J ALLERGY CLIN IMMUN, V139, P1026, DOI 10.1016/j.jaci.2016.06.040; Levin M, 2016, J ALLERGY CLIN IMMUN, V137, P1535, DOI 10.1016/j.jaci.2015.09.027; Li J, 2016, CURR OPIN ALLERGY CL, V16, P257, DOI 10.1097/ACI.0000000000000268; Li J, 2015, J IMMUNOL, V195, P1599, DOI 10.4049/jimmunol.1402310; Li W, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0554-4; Ling ZX, 2014, APPL ENVIRON MICROB, V80, P2546, DOI 10.1128/AEM.00003-14; Looney TJ, 2016, J ALLERGY CLIN IMMUN, V137, P579, DOI 10.1016/j.jaci.2015.07.014; Lowe A, 2017, J INVEST DERMATOL, V137, pS72, DOI 10.1016/j.jid.2017.02.436; Madore AM, 2013, EUR J HUM GENET, V21, P1181, DOI 10.1038/ejhg.2013.13; Candreva AM, 2017, PROTEOMICS, V17, DOI 10.1002/pmic.201700069; Markopoulos C, 2017, EJSO-EUR J SURG ONC, V43, P909, DOI 10.1016/j.ejso.2016.08.012; Martino DJ, 2017, CLIN EXP ALLERGY, V47, P217, DOI 10.1111/cea.12863; Martino D, 2015, J IMMUNOL METHODS, V424, P1, DOI 10.1016/j.jim.2015.04.016; Martino D, 2014, EPIGENETICS-US, V9, P998, DOI 10.4161/epi.28945; Marx V, 2013, NATURE, V496, P253, DOI [10.1038/496253a, 10.1038/498255a]; Mattison CP, 2017, J AGR FOOD CHEM, V65, P1443, DOI 10.1021/acs.jafc.6b04199; McDonald D, 2015, MICROBIOME, V3, DOI 10.1186/s40168-015-0117-2; Nony E, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0642-5; Oettgen HC, 2015, CURR OPIN IMMUNOL, V36, P109, DOI 10.1016/j.coi.2015.07.007; Olson MV, 2011, SCIENCE, V331, P872, DOI 10.1126/science.1203236; Orru S, 2013, INT J IMMUNOPATH PH, V26, P435, DOI 10.1177/039463201302600216; Paparo L, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0252-z; Patel CJ, 2013, HUM GENET, V132, P495, DOI 10.1007/s00439-012-1258-z; Patel CJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010746; Patil SU, 2015, J ALLERGY CLIN IMMUN, V136, P125, DOI 10.1016/j.jaci.2015.03.026; Peeters KABM, 2011, INT ARCH ALLERGY IMM, V155, P23, DOI 10.1159/000318654; Perkin MR, 2016, NEW ENGL J MED, V374, P1733, DOI 10.1056/NEJMoa1514210; Pescatore AM, 2015, J ALLERGY CLIN IMMUN, V135, P1395, DOI 10.1016/j.jaci.2014.10.053; Petrus NCM, 2016, CLIN TRANSL ALLERGY, V6, DOI 10.1186/s13601-016-0105-z; Potaczek DP, 2017, EPIGENOMICS-UK, V9, P539, DOI 10.2217/epi-2016-0162; Rachid R, 2016, CURR OPIN PEDIATR, V28, P748, DOI 10.1097/MOP.0000000000000427; Ramadani F, 2017, ALLERGY, V72, P66, DOI 10.1111/all.12911; Ramadani F, 2015, ALLERGY, V70, P1269, DOI 10.1111/all.12679; Reisacher WR, 2017, CURR OPIN OTOLARYNGO, V25, P235, DOI 10.1097/MOO.0000000000000353; Renz H, 2017, J ALLERGY CLIN IMMUN, V140, P24, DOI 10.1016/j.jaci.2017.05.015; Ryan JF, 2016, P NATL ACAD SCI USA, V113, pE1286, DOI 10.1073/pnas.1520180113; Schadt EE, 2011, NAT REV GENET, V12, DOI 10.1038/nrg2857-c2; Scrivo R, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882-014-0445-5; Sicherer SH, 2014, J ALLERGY CLIN IMMUN, V133, P291, DOI 10.1016/j.jaci.2013.11.020; Spasova DS, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00318; Stelmaszczyk-Emmel A, 2013, ADV EXP MED BIOL, V788, P321, DOI 10.1007/978-94-007-6627-3_43; Stubbington MJT, 2017, SCIENCE, V358, P58, DOI 10.1126/science.aan6828; Sung J, 2016, APPL TRANSL GENOM, V10, P10, DOI 10.1016/j.atg.2016.02.001; Syed A, 2014, J ALLERGY CLIN IMMUN, V133, P500, DOI 10.1016/j.jaci.2013.12.1037; Tebani A, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091555; Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x; Turcanu V, 2017, CURR OPIN IMMUNOL, V48, P92, DOI 10.1016/j.coi.2017.08.009; Turner PJ, 2016, CURR OPIN ALLERGY CL, V16, P441, DOI 10.1097/ACI.0000000000000305; Visscher PM, 2017, AM J HUM GENET, V101, P5, DOI 10.1016/j.ajhg.2017.06.005; Walkner M, 2015, PEDIATR CLIN N AM, V62, P1453, DOI 10.1016/j.pcl.2015.07.003; Webb-Robertson BJM, 2015, J PROTEOME RES, V14, P1993, DOI 10.1021/pr501138h; Wild CP, 2012, INT J EPIDEMIOL, V41, P24, DOI 10.1093/ije/dyr236; Wild CP, 2005, CANCER EPIDEM BIOMAR, V14, P1847, DOI 10.1158/1055-9965.EPI-05-0456; Wishart DS, 2016, NAT REV DRUG DISCOV, V15, P473, DOI 10.1038/nrd.2016.32; Xu C, 2017, G3-GENES GENOM GENET, V7, P2271, DOI 10.1534/g3.117.042408; Yagami T, 2004, INT ARCH ALLERGY IMM, V135, P3, DOI 10.1159/000080036; Yao TC, 2014, J ALLERGY CLIN IMMUN, V133, P248, DOI 10.1016/j.jaci.2013.06.018	105	38	39	4	45	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2018	141	1					20	29		10.1016/j.jaci.2017.11.007	http://dx.doi.org/10.1016/j.jaci.2017.11.007			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR8GH	29307411	Bronze			2022-12-18	WOS:000419312200003
J	Ertas, R; Ozyurt, K; Ozlu, E; Ulas, Y; Avci, A; Atasoy, M; Hawro, T; Maurer, M				Ertas, Ragip; Ozyurt, Kemal; Ozlu, Emin; Ulas, Yilmaz; Avci, Atil; Atasoy, Mustafa; Hawro, Tomasz; Maurer, Marcus			Increased IgE levels are linked to faster relapse in patients with omalizumab-discontinued chronic spontaneous urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							PHARMACODYNAMICS; PHARMACOKINETICS; THERAPY; ASTHMA		[Ertas, Ragip; Ozyurt, Kemal; Ozlu, Emin; Ulas, Yilmaz; Avci, Atil; Atasoy, Mustafa] Saglik Bilimleri Univ, Kayseri Educ & Res Hosp, Dermatol Clin, Kayseri, Turkey; [Hawro, Tomasz; Maurer, Marcus] Charite, Dept Dermatol & Allergy, Berlin, Germany	Kayseri Training & Research Hospital; University of Health Sciences Turkey; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Maurer, M (corresponding author), Charite, Dept Dermatol & Allergy, Berlin, Germany.	marcus.maurer@charite.de	Ertas, Ragip/M-3340-2017; Maurer, Marcus/ABG-2174-2020; Özyurt, Kemal/AAL-4535-2021; Avcı, Atıl/B-4326-2019; Atasoy, Mustafa/D-2679-2014	Ertas, Ragip/0000-0002-9269-2619; Maurer, Marcus/0000-0002-4121-481X; Atasoy, Mustafa/0000-0003-1904-9878; Hawro, Tomasz/0000-0001-9990-1332	Novartis; FAES; Moxie; Genentech; Uriach	Novartis(Novartis); FAES; Moxie; Genentech(Roche HoldingGenentech); Uriach	M. Maurer's institution received grant funding from Novartis, aswell as grants from FAES and Moxie for other work, and he has received financial support from Novartis, Genentech, Uriach, FAES, and Moxie; speaker's fees from Novartis, Genentech, Uriach, and FAES; and a grant from Uriach for other work. The rest of the authors declare that they have no relevant conflicts of interest.	Asero R, 2003, J ALLERGY CLIN IMMUN, V111, P425, DOI 10.1067/mai.2003.15; Corren J, 2008, J ALLERGY CLIN IMMUN, V121, P506, DOI 10.1016/j.jaci.2007.11.026; Fick RB, 2000, IMMUNOPHARMACOLOGY, V48, P307, DOI 10.1016/S0162-3109(00)00229-0; Gericke J, 2017, J ALLERGY CLIN IMMUN, V139, P1059, DOI 10.1016/j.jaci.2016.07.047; Hayashi N, 2007, BRIT J CLIN PHARMACO, V63, P548, DOI 10.1111/j.1365-2125.2006.02803.x; Kolkhir P, 2017, J ALLERGY CLIN IMMUN, V139, P1772, DOI 10.1016/j.jaci.2016.08.050; Lowe PJ, 2009, BRIT J CLIN PHARMACO, V68, P61, DOI 10.1111/j.1365-2125.2009.03401.x; Palacios T, 2016, J ALLER CL IMM-PRACT, V4, P529, DOI 10.1016/j.jaip.2015.11.025; Slavin RG, 2009, J ALLERGY CLIN IMMUN, V123, P107, DOI 10.1016/j.jaci.2008.09.050; Zhao ZT, 2016, J ALLERGY CLIN IMMUN, V137, P1742, DOI 10.1016/j.jaci.2015.12.1342	10	38	43	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2017	140	6					1749	+		10.1016/j.jaci.2017.08.007	http://dx.doi.org/10.1016/j.jaci.2017.08.007			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FO9KI	28870460	Bronze			2022-12-18	WOS:000417206000043
J	Paroni, M; Maltese, V; De Simone, M; Ranzani, V; Larghi, P; Fenoglio, C; Pietroboni, AM; De Riz, MA; Crosti, MC; Maglie, S; Moro, M; Caprioli, F; Rossi, R; Rossetti, G; Galimberti, D; Pagani, M; Scarpini, E; Abrignani, S; Geginat, J				Paroni, Moira; Maltese, Virginia; De Simone, Marco; Ranzani, Valeria; Larghi, Paola; Fenoglio, Chiara; Pietroboni, Anna M.; De Riz, Milena A.; Crosti, Maria C.; Maglie, Stefano; Moro, Monica; Caprioli, Flavio; Rossi, Riccardo; Rossetti, Grazisa; Galimberti, Daniela; Pagani, Massimiliano; Scarpini, Elio; Abrignani, Sergio; Geginat, Jens			Recognition of viral and self-antigens by T(H)1 and T(H)1/T(H)17 central memory cells in patients with multiple sclerosis reveals distinct roles in immune surveillance and relapses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T(H)1/T(H)17 central memory T cells; autoreactivity; multiple sclerosis; John Cunningham Virus; natalizumab; fingolimod	PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; CENTRAL-NERVOUS-SYSTEM; REACTIVE T-CELLS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MYELIN BASIC-PROTEIN; HUMAN TH17 CELLS; JC VIRUS; T-H-17 CELLS; IFN-GAMMA; EXPRESSION	Background: Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS) that is caused by autoreactive T cells and associated with viral infections. However, the phenotype of pathogenic T cells in peripheral blood remains to be defined, and how viruses promote MS is debated. Objective: We aimed to identify and characterize potentially pathogenic autoreactive T cells, as well as protective antiviral T cells, in patients with MS. Methods: We analyzed CD4(+) helper T-cell subsets from peripheral blood or cerebrospinal fluid for cytokine production, gene expression, plasticity, homing potentials, and their reactivity to self-antigens and viral antigens in healthy subjects and patients with MS. Moreover, we monitored their frequencies in untreated and fingolimod- or natalizumab-treated patients with MS. Results: T(H)1/T(H)17 central memory (T(H)1/T(H)17(CM)) cells were selectively increased in peripheral blood of patients with relapsing-remitting MS with a high disease score. T(H)1/T(H)17(CM) cells were closely related to conventional T(H)17 cells but had more pathogenic features. In particular, they could shuttle between lymph nodes and the CNS and produced encephalitogenic cytokines. The cerebrospinal fluid of patients with active MS was enriched for CXCL10 and contained mainly CXCR3-expressing TH1 and T(H)1/T(H)17 subsets. However, while T(H)1 cells responded consistently to viruses, T(H)1/T(H)17(CM) cells reacted strongly with John Cunningham virus in healthy subjects but responded instead to myelin-derived self-antigens in patients with MS. Fingolimod and natalizumab therapies efficiently targeted autoreactive T(H)1/T(H)17(CM) cells but also blocked virus-specific T(H)1 cells. Conclusions: We propose that autoreactive T(H)1/T(H)17(CM) cells expand in patients with MS and promote relapses after bystander recruitment to the CNS, whereas T(H)1 cells perform immune surveillance. Thus the selective targeting of T(H)1/T(H)17 cells could inhibit relapses without causing John Cunningham virus-dependent progressive multifocal encephalomyelitis.	[Paroni, Moira; De Simone, Marco; Ranzani, Valeria; Larghi, Paola; Crosti, Maria C.; Maglie, Stefano; Moro, Monica; Rossi, Riccardo; Rossetti, Grazisa; Pagani, Massimiliano; Abrignani, Sergio; Geginat, Jens] Ist Nazl Genet Mol Romeo & Enrica Invernizzi, INGM, Milan, Italy; [Maltese, Virginia; Fenoglio, Chiara; Pietroboni, Anna M.; De Riz, Milena A.; Galimberti, Daniela; Scarpini, Elio] Univ Milan, Dept Pathophysiol & Transplantat, Neurol Unit, Milan, Italy; [Maltese, Virginia; Fenoglio, Chiara; Pietroboni, Anna M.; De Riz, Milena A.; Galimberti, Daniela; Scarpini, Elio] IRCCS Osped Policlin, Fdn Ca Granda, Milan, Italy; [Caprioli, Flavio] Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy; [Pagani, Massimiliano] Univ Milan, Dept Med Biotechnol & Translat Med, Milan, Italy; [Abrignani, Sergio] Univ Milan, DISCCO, Dept Clin Sci & Community Hlth, Milan, Italy; [Caprioli, Flavio] IRCCS Osped Policlin, Fdn Ca Granda, Gastroenterol & Endoscopy Unit, Milan, Italy	University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; University of Milan; University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico	Geginat, J (corresponding author), INGM, Via Sforza 35, I-20122 Milan, Italy.	geginat@ingm.org	Caprioli, Flavio/AAB-5176-2019; Geginat, Jens/AAA-5818-2019; Galimberti, Daniela/N-7209-2019; Ranzani, Valeria/AAB-8258-2019; rossetti, grazisa/C-3722-2015; Rossi, Riccardo/M-8999-2019; Pietroboni, Anna Margherita/L-2970-2015; Galimberti, Daniela/K-6542-2016; Paroni, Moira/K-6470-2016; Scarpini, Elio/K-6547-2016	Caprioli, Flavio/0000-0002-8077-8175; Geginat, Jens/0000-0003-4813-0384; Galimberti, Daniela/0000-0002-9284-5953; rossetti, grazisa/0000-0001-6361-311X; Rossi, Riccardo/0000-0002-4964-3264; Pietroboni, Anna Margherita/0000-0003-1538-1830; Galimberti, Daniela/0000-0002-9284-5953; Pagani, Massimiliano/0000-0002-7017-9304; Paroni, Moira/0000-0001-8199-3128; Scarpini, Elio/0000-0002-6395-2119; Abrignani, Sergio/0000-0002-0794-3285	Romeo ed Enrica Invernizzi foundation; Ministry of Health [GR-2011-02352001]	Romeo ed Enrica Invernizzi foundation; Ministry of Health	Supported by the Romeo ed Enrica Invernizzi foundation. M.P. and F.C. are supported by the Ministry of Health (Project Code: GR-2011-02352001).	Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P639, DOI 10.1038/ni1467; Aly L, 2011, BRAIN, V134, P2687, DOI 10.1093/brain/awr206; Annunziato F, 2007, J EXP MED, V204, P1849, DOI 10.1084/jem.20070663; Balashov KE, 1999, P NATL ACAD SCI USA, V96, P6873, DOI 10.1073/pnas.96.12.6873; Becattini S, 2015, SCIENCE, V347, P400, DOI 10.1126/science.1260668; Becher B, 2011, CURR OPIN IMMUNOL, V23, P707, DOI 10.1016/j.coi.2011.08.005; Berger JR, 2006, NEUROL RES, V28, P299, DOI 10.1179/016164106X98198; BHARDWAJ V, 1993, J IMMUNOL, V151, P5000; Brettschneider J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007638; Brinkmann V, 2010, NAT REV DRUG DISCOV, V9, P883, DOI 10.1038/nrd3248; Cao YH, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa8038; Cui GW, 2014, P NATL ACAD SCI USA, V111, P1915, DOI 10.1073/pnas.1318281111; Dardalhon V, 2008, J AUTOIMMUN, V31, P252, DOI 10.1016/j.jaut.2008.04.017; De Jager PL, 2009, P NATL ACAD SCI USA, V106, P5264, DOI 10.1073/pnas.0813310106; Delbue S, 2015, J NEUROVIROL, V21, P645, DOI 10.1007/s13365-014-0268-0; Duhen T, 2014, J IMMUNOL, V193, P120, DOI 10.4049/jimmunol.1302734; Fife BT, 2001, J IMMUNOL, V166, P7617, DOI 10.4049/jimmunol.166.12.7617; Fletcher JM, 2010, CLIN EXP IMMUNOL, V162, P1, DOI 10.1111/j.1365-2249.2010.04143.x; Frentsch M, 2005, NAT MED, V11, P1118, DOI 10.1038/nm1292; Galimberti D, 2007, EUR J NEUROL, V14, P162, DOI 10.1111/j.1468-1331.2006.01629.x; Gasnault J, 2003, AIDS, V17, P1443, DOI 10.1097/00002030-200307040-00004; Geginat J, 2013, SEMIN IMMUNOL, V25, P252, DOI 10.1016/j.smim.2013.10.012; Geginat J, 2016, EUR J IMMUNOL, V46, P2306, DOI 10.1002/eji.201646618; Geginat J, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00630; Haghikia A, 2013, TRENDS MOL MED, V19, P309, DOI 10.1016/j.molmed.2013.03.004; Intlekofer AM, 2005, NAT IMMUNOL, V6, P1236, DOI 10.1038/ni1268; Jager A, 2009, J IMMUNOL, V183, P7169, DOI 10.4049/jimmunol.0901906; Jung YW, 2016, P NATL ACAD SCI USA, V113, P8278, DOI 10.1073/pnas.1602899113; Kang ZH, 2013, NAT NEUROSCI, V16, P1401, DOI 10.1038/nn.3505; Kastirr I, 2015, J IMMUNOL, V195, P3617, DOI 10.4049/jimmunol.1501016; Kastirr I, 2014, J IMMUNOL, V193, P3322, DOI 10.4049/jimmunol.1400775; Kebir H, 2007, NAT MED, V13, P1173, DOI 10.1038/nm1651; Kebir H, 2009, ANN NEUROL, V66, P390, DOI 10.1002/ana.21748; Kivisakk P, 2009, NEUROLOGY, V72, P1922, DOI 10.1212/WNL.0b013e3181a8266f; Knier B, 2014, EXPERT OPIN BIOL TH, V14, P503, DOI 10.1517/14712598.2014.887676; Louyeau A, 2015, TRENDS IMMUNOL, V36, P569, DOI 10.1016/j.it.2015.08.006; Lunemann JD, 2008, J EXP MED, V205, P1763, DOI 10.1084/jem.20072397; Magliozzi R, 2013, J NEUROPATH EXP NEUR, V72, P29, DOI 10.1097/NEN.0b013e31827bfc62; Manel N, 2008, NAT IMMUNOL, V9, P641, DOI 10.1038/ni.1610; McDonald WI, 2001, ANN NEUROL, V50, P121, DOI 10.1002/ana.1032; McGill J, 2010, J EXP MED, V207, P521, DOI 10.1084/jem.20091711; Mehling M, 2010, NEUROLOGY, V75, P403, DOI 10.1212/WNL.0b013e3181ebdd64; Ngono AE, 2012, CLIN IMMUNOL, V144, P117, DOI 10.1016/j.clim.2012.05.009; Nizzoli G, 2016, EUR J IMMUNOL, V46, P1622, DOI 10.1002/eji.201546136; Nizzoli G, 2013, BLOOD, V122, P932, DOI 10.1182/blood-2013-04-495424; Noster R, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008706; Okada S, 2015, SCIENCE, V349, P606, DOI 10.1126/science.aaa4282; Ontaneda D, 2015, LANCET NEUROL, V14, P208, DOI 10.1016/S1474-4422(14)70264-9; Peters A, 2011, CURR OPIN IMMUNOL, V23, P702, DOI 10.1016/j.coi.2011.08.007; Purton JF, 2007, J EXP MED, V204, P951, DOI 10.1084/jem.20061805; Ramesh R, 2014, J EXP MED, V211, P89, DOI 10.1084/jem.20130301; Reboldi A, 2009, NAT IMMUNOL, V10, P514, DOI 10.1038/ni.1716; Rivino L, 2004, J EXP MED, V200, P725, DOI 10.1084/jem.20040774; Rivino L, 2010, J EXP MED, V207, P565, DOI 10.1084/jem.20091021; Rothhammer V, 2011, J EXP MED, V208, P2465, DOI 10.1084/jem.20110434; Russo MV, 2015, TRENDS IMMUNOL, V36, P637, DOI 10.1016/j.it.2015.08.002; Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702; Schlager C, 2016, NATURE, V530, P349, DOI 10.1038/nature16939; Serafini B, 2010, J NEUROPATH EXP NEUR, V69, P677, DOI 10.1097/NEN.0b013e3181e332ec; Steinfelder S, 2011, BLOOD, V117, P2839, DOI 10.1182/blood-2010-06-293027; Stinissen P, 2008, EUR J IMMUNOL, V38, P1190, DOI 10.1002/eji.200838371; STONER GL, 1991, ACTA NEUROL SCAND, V83, P20; Tselis A, 2011, SEMIN NEUROL, V31, P307, DOI 10.1055/s-0031-1287656; Vavassori M, 1996, J IMMUNOL, V157, P5739; Wang HK, 2014, NAT IMMUNOL, V15, P667, DOI 10.1038/ni.2890; Wollebo HS, 2015, ANN NEUROL, V77, P560, DOI 10.1002/ana.24371; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8; Zuvich RL, 2009, SEMIN IMMUNOL, V21, P328, DOI 10.1016/j.smim.2009.08.003	68	38	38	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2017	140	3					797	808		10.1016/j.jaci.2016.11.045	http://dx.doi.org/10.1016/j.jaci.2016.11.045			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FF8CA	28237728	Bronze			2022-12-18	WOS:000409241500018
J	House, JS; Wyss, AB; Hoppin, JA; Richards, M; Long, S; Umbach, DM; Henneberger, PK; Freeman, LEB; Sandler, DP; O'Connell, EL; Barker-Cummings, C; London, SJ				House, John S.; Wyss, Annah B.; Hoppin, Jane A.; Richards, Marie; Long, Stuart; Umbach, David M.; Henneberger, Paul K.; Freeman, Laura E. Beane; Sandler, Dale P.; O'Connell, Elizabeth Long; Barker-Cummings, Christie; London, Stephanie J.			Early-life farm exposures and adult asthma and atopy in the Agricultural Lung Health Study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Agriculture; agricultural workers' diseases; allergy and immunology; asthma; hygiene hypothesis; IgE; prenatal exposure delayed effects	ALLERGIC DISEASES; FEEDING OPERATIONS; UNITED-STATES; RISK-FACTORS; CHILDHOOD; SENSITIZATION; CHILDREN; PREVALENCE; PROTECT; ASSOCIATION	Background: Previous studies, mostly from Europe, suggest that early-life farming exposures protect against childhood asthma and allergy; few data exist on asthma and allergy in adults. Objective: We sought to examine associations between early-life farming exposures and current asthma and atopy in an older adult US farming population. Methods: We analyzed data from 1746 farmers and 1555 spouses (mean age, 63) from a case-control study nested within the Agricultural Health Study. Current asthma and early-life farming exposures were assessed via questionnaires. We defined atopy based on specific IgE > 0.70 IU/mL to at least 1 of 10 allergens measured in blood. We used logistic regression, adjusted for age, sex, race, state (Iowa or North Carolina), and smoking (pack years), to estimate associations between early-life exposures and asthma (1198 cases and 2031 noncases) or atopy (578 cases and 2526 noncases). Results: Exposure to the farming environment in utero and in early childhood had little or no association with asthma but was associated with reduced odds of atopy. The strongest association was seen for having a mother who performed farm activities while pregnant (odds ratio, 0.60; 95% CI, 0.48-0.74) and remained significant in models with correlated early-life exposures including early childhood farm animal contact and raw milk consumption. Conclusions: In a large US farming population, early-life farm exposures, particularly maternal farming activities while pregnant, were strongly associated with reduced risk of atopy in adults. These results extend previous work done primarily on childhood outcomes and suggest that protective associations of early-life farming exposures on atopy endure across the life course.	[House, John S.; Wyss, Annah B.; Hoppin, Jane A.; Umbach, David M.; Sandler, Dale P.; London, Stephanie J.] NIEHS, Div Intramural Res, NIH, US Dept HHS, POB 12233, Res Triangle Pk, NC 27709 USA; [Hoppin, Jane A.] North Carolina State Univ, Ctr Human Hlth & Environm, Dept Biol Sci, Raleigh, NC USA; [Richards, Marie; Long, Stuart] Westat Corp, Durham, NC USA; [Henneberger, Paul K.] NIOSH, Div Resp Dis Studies, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA; [Freeman, Laura E. Beane] NCI, Occupat & Environm Epidemiol Branch, Bethesda, MD 20892 USA; [O'Connell, Elizabeth Long; Barker-Cummings, Christie] Social & Sci Syst Inc, Publ Hlth Sci, Epidemiol Ctr, Durham, NC USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of North Carolina; North Carolina State University; Westat; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Social & Scientific Systems	London, SJ (corresponding author), NIEHS, Epidemiol Branch, NIH, POB 12233,MD A3-05, Res Triangle Pk, NC 27709 USA.	london2@niehs.nih.gov	Freeman, Laura E. Beane/C-4468-2015; London, Stephanie/C-3734-2019; House, John S/A-1933-2013	Freeman, Laura E. Beane/0000-0003-1294-4124; London, Stephanie/0000-0003-4911-5290; House, John S/0000-0002-8447-7871; Sandler, Dale/0000-0002-6776-0018	Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences [Z01-E5049030, Z01-E5102385]; National Cancer Institute [Z01-CP010119]; American Recovery and Reinvestment Act (ARRA) funds through NIEHS contract [N01-ES-55546]; NATIONAL CANCER INSTITUTE [Z01CP010119, ZIACP010119] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES049030, ZIAES103126, Z01ES049030, ZIAES102385] Funding Source: NIH RePORTER	Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Recovery and Reinvestment Act (ARRA) funds through NIEHS contract; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by the Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences (Z01-E5049030 and Z01-E5102385) and the National Cancer Institute (Z01-CP010119). Supported in part by American Recovery and Reinvestment Act (ARRA) funds through NIEHS contract number N01-ES-55546. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the National Institute for Occupational Safety and Health. Mention of any company or product does not constitute endorsement by National Institute for Occupational Safety and Health.	Alavanja MCR, 1996, ENVIRON HEALTH PERSP, V104, P362, DOI 10.2307/3432672; Beasley R, 2015, LANCET, V386, P1075, DOI 10.1016/S0140-6736(15)00156-7; Blackwell DL, 2014, VITAL HLTH STAT, V10; Braun-Fahrlander C, 2011, CLIN EXP ALLERGY, V41, P29, DOI 10.1111/j.1365-2222.2010.03665.x; Brooks C, 2013, CURR OPIN ALLERGY CL, V13, P70, DOI 10.1097/ACI.0b013e32835ad0d2; Campbell BE, 2015, CLIN EXP ALLERGY, V45, P744, DOI 10.1111/cea.12429; Chinn S, 1999, EUR RESPIR J, V14, P876, DOI 10.1034/j.1399-3003.1999.14d25.x; Chrischilles E, 2004, J ALLERGY CLIN IMMUN, V113, P66, DOI 10.1016/j.jaci.2003.09.037; Douwes J, 2007, ALLERGY, V62, P1158, DOI 10.1111/j.1398-9995.2007.01490.x; Ege MJ, 2006, J ALLERGY CLIN IMMUN, V117, P817, DOI 10.1016/j.jaci.2005.12.1307; Elholm G, 2016, CLIN EXP ALLERGY, V46, P103, DOI 10.1111/cea.12583; Elholm G, 2013, J ALLERGY CLIN IMMUN, V132, P1239, DOI 10.1016/j.jaci.2013.07.003; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; Fuchs O, 2012, J ALLERGY CLIN IMMUN, V130, P382, DOI 10.1016/j.jaci.2012.04.049; Genuneit J, 2013, PEDIAT ALLERG IMM-UK, V24, P293, DOI 10.1111/pai.12053; Hofmann JN, 2015, CANCER EPIDEM BIOMAR, V24, P587, DOI 10.1158/1055-9965.EPI-14-1246; Hoppin JA, 2009, EUR RESPIR J, V34, P1296, DOI 10.1183/09031936.00005509; Hoppin JA, 2002, AM J RESP CRIT CARE, V165, P683, DOI 10.1164/ajrccm.165.5.2106074; Hoppin JA, 2014, OCCUP ENVIRON MED, V71, P484, DOI 10.1136/oemed-2013-101983; Hoppin JA, 2008, AM J RESP CRIT CARE, V177, P11, DOI 10.1164/rccm.200706-821OC; Jaramillo R, 2013, J ALLERGY CLIN IMMUN, V131, pe1; Jaramillo R, 2013, J ALLERGY CLIN IMMUN, V131, P405, DOI 10.1016/j.jaci.2012.06.033; Kilpelainen M, 2002, ALLERGY, V57, P1130, DOI 10.1034/j.1398-9995.2002.23341.x; Lampi J, 2011, CLIN EXP ALLERGY, V41, P987, DOI 10.1111/j.1365-2222.2011.03777.x; Lash TL., 2009, APPL QUANTITATIVE BI; Lauener RP, 2002, LANCET, V360, P465, DOI 10.1016/S0140-6736(02)09641-1; Leynaert B, 2001, AM J RESP CRIT CARE, V164, P1829, DOI 10.1164/ajrccm.164.10.2103137; Leynaert B, 2006, J ALLERGY CLIN IMMUN, V118, P658, DOI 10.1016/j.jaci.2006.06.015; Merchant JA, 2005, ENVIRON HEALTH PERSP, V113, P350, DOI 10.1289/ehp.7240; Mirabelli MC, 2006, PEDIATRICS, V118, pE66, DOI 10.1542/peds.2005-2812; Muldoon J., 2009, ASTHMA IOWA SURVEILL; Mullane K, 2014, BIOCHEM PHARMACOL, V87, P131, DOI 10.1016/j.bcp.2013.06.026; NC Department of Health and Human Services Department of Public Health, 2013, ASTH EP UPD; Pearce N, 1999, THORAX, V54, P268, DOI 10.1136/thx.54.3.268; Pinart M, 2015, INT ARCH ALLERGY IMM, V168, P110, DOI 10.1159/000442414; Platts-Mills TAE, 2015, J ALLERGY CLIN IMMUN, V136, P3, DOI 10.1016/j.jaci.2015.03.048; Portengen L, 2002, CLIN EXP ALLERGY, V32, P247, DOI 10.1046/j.1365-2222.2002.01310.x; Radon K, 2006, ALLERGY, V61, P443, DOI 10.1111/j.1398-9995.2006.00995.x; Radon K, 2004, CLIN EXP ALLERGY, V34, P1178, DOI 10.1111/j.1365-2222.2004.02005.x; Rennie DC, 2015, J AGROMEDICINE, V20, P302, DOI 10.1080/1059924X.2015.1042612; Rutkowski K, 2014, POSTEP DERM ALERGOL, V31, P77, DOI 10.5114/pdia.2014.40936; Salam MT, 2004, ENVIRON HEALTH PERSP, V112, P760, DOI 10.1289/ehp.6662; Schoos AMM, 2016, J ALLERGY CLIN IMMUN, V137, P844, DOI 10.1016/j.jaci.2015.10.004; Schuijs MJ, 2015, SCIENCE, V349, P1106, DOI 10.1126/science.aac6623; Schulze A, 2007, EUR RESPIR J, V29, P1169, DOI 10.1183/09031936.00127906; Sigurdarson ST, 2006, CHEST, V129, P1486, DOI 10.1378/chest.129.6.1486; Sozanska B, 2013, ALLERGY, V68, P644, DOI 10.1111/all.12147; Van Hoeyveld E, 2015, CLIN CHIM ACTA, V450, P46, DOI 10.1016/j.cca.2015.07.023; von Hertzen L, 2011, EMBO REP, V12, P1089, DOI 10.1038/embor.2011.195; von Mutius E, 2010, NAT REV IMMUNOL, V10, P861, DOI 10.1038/nri2871	50	38	39	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2017	140	1					249	+		10.1016/j.jaci.2016.09.036	http://dx.doi.org/10.1016/j.jaci.2016.09.036			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EZ2LY	27845237	Green Accepted, Bronze			2022-12-18	WOS:000404542000025
J	D'Amato, G; Maesano, IA; Molino, A; Vitale, C; D'Amato, M				D'Amato, Gennaro; Maesano, Isabella Annesi; Molino, Antonio; Vitale, Carolina; D'Amato, Maria			Thunderstorm-related asthma attacks	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Bronchial asthma; severe asthma; near-fatal asthma; thunderstorm-related asthma; meteorological factors and asthma; prevention of thunderstorm; related asthma; asthma-related deaths	CLIMATE-CHANGE; GRASS-POLLEN; EPIDEMICS		[D'Amato, Gennaro] High Special A Cardarelli Hosp, Dept Chest Dis, Div Resp & Allerg Dis, Naples, Italy; [Maesano, Isabella Annesi] Sorbonne Univ, Epidemiol Allerg & Resp Dis Dept EPAR, Pierre Louis Inst Epidemiol & Publ Hlth, IPLESP,UMRS1136,UPMC Univ Paris 06,INSERM,St Anto, Paris, France; [Molino, Antonio; D'Amato, Maria] High Special Hosp V Monaldi, Div Pneumol 1, Naples, Italy; [Molino, Antonio; D'Amato, Maria] Univ Federico II, Sch Med, Naples, Italy; [Vitale, Carolina] Univ Salerno, Dept Med & Surg, Salerno, Italy	Antonio Cardarelli Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; University of Naples Federico II; University of Salerno	D'Amato, G (corresponding author), Univ Naples Federico II, Sch Med, High Special Hosp A Cardarelli Naples, Div Resp & Allerg Dis, Rione Sirignano 810, I-80121 Naples, Italy.; D'Amato, G (corresponding author), Univ Naples Federico II, Sch Specializat Resp Dis, Rione Sirignano 810, I-80121 Naples, Italy.	gdamatomail@gmail.com	molino, antonio/N-8133-2016; Annesi-Maesano, Isabella/D-9173-2016; D'AMATO, Maria/H-3074-2012	molino, antonio/0000-0001-6966-9640; Annesi-Maesano, Isabella/0000-0002-6340-9300; D'AMATO, Maria/0000-0002-5906-5701; D'Amato, Gennaro/0000-0002-0503-9428				BELLOMO R, 1992, MED J AUSTRALIA, V156, P834, DOI 10.5694/j.1326-5377.1992.tb136994.x; D'Amato G, 2016, CLIN EXP ALLERGY, V46, P390, DOI 10.1111/cea.12709; D'Amato G, 2008, J ALLERGY CLIN IMMUN, V121, P537, DOI 10.1016/j.jaci.2007.10.046; D'Amato G, 2016, CURR OPIN ALLERGY CL, V16, P434, DOI 10.1097/ACI.0000000000000301; D'Amato G, 2015, WORLD ALLERGY ORGAN, V8, DOI 10.1186/s40413-015-0073-0; D'Amato G, 2012, EUR RESPIR REV, V21, P82, DOI 10.1183/09059180.00001712; Marks GB, 2001, THORAX, V56, P468, DOI 10.1136/thorax.56.6.468; PACKE GE, 1985, LANCET, V2, P199; Pulimood TB, 2007, J ALLERGY CLIN IMMUN, V120, P610, DOI 10.1016/j.jaci.2007.04.045; Taylor PE, 2002, J ALLERGY CLIN IMMUN, V109, P51, DOI 10.1067/mai.2002.120759	10	38	38	24	100	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2017	139	6					1786	1787		10.1016/j.jaci.2017.03.003	http://dx.doi.org/10.1016/j.jaci.2017.03.003			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EW7VG	28342913				2022-12-18	WOS:000402724600006
J	Riani, M; Le Jan, S; Plee, J; Durlach, A; Le Naour, R; Haegeman, G; Bernard, P; Antonicelli, F				Riani, Meriem; Le Jan, Sebastien; Plee, Julie; Durlach, Anne; Le Naour, Richard; Haegeman, Guy; Bernard, Philippe; Antonicelli, Frank			Bullous pemphigoid outcome is associated with CXCL10-induced matrix metalloproteinase 9 secretion from monocytes and neutrophils but not lymphocytes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Bullous pemphigoid; autoimmunity; inflammation; CXCL10; selective glucocorticoid receptor activator; compound A	AUTOIMMUNE BLISTERING DISEASES; RHEUMATOID-ARTHRITIS; XVII COLLAGEN; GELATINASE-B; IN-VIVO; AUTOANTIBODIES; INFLAMMATION; ELASTASE; RECEPTOR; CELLS	Background: The outcome of bullous pemphigoid (BP), the most frequent autoimmune skin-blistering disease, involves matrix metalloproteinase 9 (MMP-9), IL-17, and IL-23 release from infiltrated inflammatory cells. The chemokine CXCL10 has been associated with several autoimmune diseases, but its participation in BP pathophysiology still needs to be clarified. Objective: We sought to assess whether BP outcome was associated with different CXCL10 levels and to evaluate the contribution of CXCL10 to the described cytokine/protease inflammatory loop associated with disease outcome. Methods: Skin biopsy specimens (n = 16), serum (n 5 114), blister fluid (n 5 23), and primary inflammatory cells from patients with BP were used to investigate CXCL10 expression and function. Results: At baseline, both resident cells, such as keratinocytes and fibroblasts, and infiltrating immune cells expressed CXCL10 at lesional sites in skin of patients with BP. CXCL10 levels were higher in blister fluid (P <.0001) and serum (P <.005) from patients with BP than in serum from age- and sex-matched control subjects (n 5 34). Furthermore, CXCL10 serum levels increased at day 60 only in patients who relapsed within the first year of treatment (n 5 33, P <.005). Interestingly, CXCL10 expression could be upregulated by itself and IL-17 in inflammatory cells. Notably, neutrophils and monocytes from patients with BP, but not lymphocytes, responded to CXCL10 by increasing MMP-9 secretion through the activation of extracellular signal-regulated kinase 1/2, p38, phosphoinositide-3 kinase signaling pathways. Finally, CXCL10-increased MMP-9 secretion was inhibited by methylprednisolone and also by compound A, a novel nonsteroidal glucocorticoid receptor ligand. Conclusion: We showed that increased levels of inflammatory biomarkers in patients with BP, such as CXCL10, favor neutrophil- and monocyte-associated MMP-9 release and disease relapse and opened new therapeutic horizons in patients with this autoimmune disease.	[Riani, Meriem; Le Jan, Sebastien; Plee, Julie; Bernard, Philippe; Antonicelli, Frank] Univ Hosp, Derm I C EA7319, Dermatol Lab, Reims, France; [Plee, Julie; Bernard, Philippe; Antonicelli, Frank] Univ Hosp, Dept Dermatol, Reims, France; [Le Naour, Richard] Univ Reims, Lab IMAB, EA4683, Reims, France; [Durlach, Anne] Univ Hosp, Hosp Maison Blanche, Lab Pol Bouin, Reims, France; [Haegeman, Guy] Univ Ghent, LEGEST, Ghent, Belgium	CHU de Reims; CHU de Reims; Universite de Reims Champagne-Ardenne; Universite de Reims Champagne-Ardenne; CHU de Reims; Universite de Reims Champagne-Ardenne; Ghent University	Antonicelli, F (corresponding author), Univ Reims, Dermatol Lab, Derm I C EA 7319, 51 Rue Cognacq Jay, F-51095 Reims, France.	frank.antonicelli@univ-reims.fr	LE JAN, Sébastien/AAH-3952-2019	LE JAN, Sébastien/0000-0003-4027-2855; LE NAOUR, Richard/0000-0003-1925-6041	Contrat Plan Etat Region (CPER); regional council; French Department of Health's "Projet Hospitalier de Recherche Clinique (PHRC) Interregional''; Centre de Ref erence Maladies Rares "Maladies bulleuses auto-immunes'' at the University Hospital of Reims	Contrat Plan Etat Region (CPER); regional council; French Department of Health's "Projet Hospitalier de Recherche Clinique (PHRC) Interregional''; Centre de Ref erence Maladies Rares "Maladies bulleuses auto-immunes'' at the University Hospital of Reims	Supported by research grants from the Contrat Plan Etat Region (CPER) 2008, the MAISAGE-PB project supported by the regional council, and the French Department of Health's "Projet Hospitalier de Recherche Clinique (PHRC) Interregional'' 2009. S.L.J. was supported by grants from the Centre de Ref erence Maladies Rares "Maladies bulleuses auto-immunes'' at the University Hospital of Reims.	Antonelli A, 2014, AUTOIMMUN REV, V13, P272, DOI 10.1016/j.autrev.2013.10.010; Antonicelli F, 2004, AM J PHYSIOL-LUNG C, V286, pL1319, DOI 10.1152/ajplung.00329.2003; Bondar C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089068; D'Auria L, 1999, EUR CYTOKINE NETW, V10, P123; Di Zenzo G, 2008, CLIN IMMUNOL, V128, P415, DOI 10.1016/j.clim.2008.04.012; Emonard H, 1997, BIOL CHEM, V378, P265, DOI 10.1515/bchm.1997.378.3-4.265; Fichel F, 2014, JAMA DERMATOL, V150, P25, DOI 10.1001/jamadermatol.2013.5757; Grip O, 2007, INFLAMM BOWEL DIS, V13, P566, DOI 10.1002/ibd.20025; Hart D, 2008, J IMMUNOL, V181, P8053, DOI 10.4049/jimmunol.181.11.8053; Hirose M, 2011, J IMMUNOL, V187, P1176, DOI 10.4049/jimmunol.1100596; Huen AC, 2012, ADV WOUND CARE, V1, P244, DOI 10.1089/wound.2011.0355; Koga C, 2008, J INVEST DERMATOL, V128, P2625, DOI 10.1038/jid.2008.111; Krasselt M, 2014, EXPERT REV CLIN IMMU, V10, P557, DOI 10.1586/1744666X.2014.904746; Krasselt M, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4321; Lacotte S, 2009, ANN NY ACAD SCI, V1173, P310, DOI 10.1111/j.1749-6632.2009.04813.x; Le Jan S, 2014, J INVEST DERMATOL, V134, P2908, DOI 10.1038/jid.2014.263; Lee EY, 2009, AUTOIMMUN REV, V8, P379, DOI 10.1016/j.autrev.2008.12.002; Lesovaya E, 2015, ONCOTARGET, V6, P30730, DOI 10.18632/oncotarget.5078; Lin L, 2011, J BIOL CHEM, V286, P37358, DOI 10.1074/jbc.M111.272401; Liu Z, 1997, J CLIN INVEST, V100, P1256, DOI 10.1172/JCI119639; LIU Z, 1993, J CLIN INVEST, V92, P2480, DOI 10.1172/JCI116856; Liu Z, 1998, J EXP MED, V188, P475, DOI 10.1084/jem.188.3.475; Liu Z, 2000, J CLIN INVEST, V105, P113, DOI 10.1172/JCI3693; Liu Z, 2000, CELL, V102, P647, DOI 10.1016/S0092-8674(00)00087-8; Murrell DF, 2012, J AM ACAD DERMATOL, V66, P479, DOI 10.1016/j.jaad.2011.06.032; Nakashima H, 2007, BRIT J DERMATOL, V156, P454, DOI 10.1111/j.1365-2133.2006.07601.x; Niimi Y, 2006, INT ARCH ALLERGY IMM, V139, P104, DOI 10.1159/000090385; Oswald E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031066; Plee J, 2015, SCI REP-UK, V5, DOI 10.1038/srep18001; Sato A, 2015, LEUKEMIA, V29, P145, DOI 10.1038/leu.2014.151; Schmidt E, 2000, ARCH DERMATOL, V136, P174, DOI 10.1001/archderm.136.2.174; Schulze FS, 2014, AM J PATHOL, V184, P2185, DOI 10.1016/j.ajpath.2014.05.007; Shimanovich I, 2004, J PATHOL, V204, P519, DOI 10.1002/path.1674; Sitaru C, 2005, EXP DERMATOL, V14, P861, DOI 10.1111/j.1600-0625.2005.00367.x; Sitaru C, 2009, J INVEST DERMATOL, V129, P822, DOI 10.1038/jid.2009.12; TAKEMATSU H, 1991, ARCH DERMATOL RES, V283, P131, DOI 10.1007/BF00371622; Tan JQ, 2000, J IMMUNOL, V165, P1548, DOI 10.4049/jimmunol.165.3.1548; TAUB DD, 1993, J EXP MED, V177, P1809, DOI 10.1084/jem.177.6.1809; Vaillant L, 1998, ARCH DERMATOL, V134, P1075, DOI 10.1001/archderm.134.9.1075; Verraes S, 2001, J INVEST DERMATOL, V117, P1091, DOI 10.1046/j.0022-202x.2001.01521.x; Yancey KB, 2005, J CLIN INVEST, V115, P825, DOI 10.1172/JCI200524855; Yemelyanov A, 2008, CANCER RES, V68, P4763, DOI 10.1158/0008-5472.CAN-07-6104; Zhao CY, 2015, J DERMATOL, V42, P31, DOI 10.1111/1346-8138.12711	43	38	39	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2017	139	3					863	+		10.1016/j.jaci.2016.08.012	http://dx.doi.org/10.1016/j.jaci.2016.08.012			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EP3QC	27637385	Bronze			2022-12-18	WOS:000397295800019
J	Soones, TN; Lin, JL; Wolf, MS; O'Conor, R; Martynenko, M; Wisnivesky, JP; Federman, AD				Soones, Tacara N.; Lin, Jenny L.; Wolf, Michael S.; O'Conor, Rachel; Martynenko, Melissa; Wisnivesky, Juan P.; Federman, Alex D.			Pathways linking health literacy, health beliefs, and cognition to medication adherence in older adults with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; elderly; health literacy; adherence; medication beliefs; illness beliefs; cognition	INHALED CORTICOSTEROIDS; SELF-MANAGEMENT; OUTCOMES; POOR; CARE; ASSOCIATION; BEHAVIOR; DECLINE; ILLNESS; IMPACT	Background: Limited health literacy is associated with low adherence to asthma controller medications among older adults. Objective: We sought to describe the causal pathway linking health literacy to medication adherence by modeling asthma illness and medication beliefs as mediators. Methods: We recruited adults aged 60 years and older with asthma from hospital and community practices in New York, New York, and Chicago, Illinois. We measured health literacy and medication adherence using the Short Test of Functional Health Literacy in Adults and the Medication Adherence Rating Scale, respectively. We used validated instruments to assess asthma illness and medication beliefs. We assessed cognition using a cognitive battery. Using structural equation modeling, we modeled illness and medication beliefs as mediators of the relationship between health literacy and adherence while controlling for cognition. Results: Our study included 433 patients with a mean age of 67 +/- 6.8 years. The sample had 84% women, 31% non-Hispanic blacks, and 39% Hispanics. The 36% of patients with limited health literacy were more likely to have misconceptions about asthma (P <.001) and asthma medications (P <.001). Health literacy had a direct effect (b 5 0.089; P <.001) as well as an indirect effect on adherence mediated by medications concerns (b 5 0.033; P 5.002). Neither medication necessity (b 5 0.044; P = .138) nor illness beliefs (beta = 0.007; P = .143) demonstrated a mediational role between health literacy and adherence. Conclusions: Interventions designed to improve asthma controller medication adherence in older adults may be enhanced by addressing concerns about medications in addition to using communication strategies appropriate for populations with limited health literacy and cognitive impairments.	[Soones, Tacara N.] Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Med, One Gustave Levy Pl,Box 1070, New York, NY 10029 USA; [Lin, Jenny L.; Martynenko, Melissa; Wisnivesky, Juan P.; Federman, Alex D.] Mt Sinai Sch Med, Div Gen Internal Med, New York, NY USA; [Wolf, Michael S.; O'Conor, Rachel] Northwestern Univ, Feinberg Sch Med, Div Gen Internal Med, Chicago, IL 60611 USA; [Wisnivesky, Juan P.] Mt Sinai Sch Med, Div Pulm Crit Care & Sleep Med, New York, NY USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Northwestern University; Feinberg School of Medicine; Icahn School of Medicine at Mount Sinai	Soones, TN (corresponding author), Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Med, One Gustave Levy Pl,Box 1070, New York, NY 10029 USA.	tacara.soones@mssm.edu	Wolf, Michael/V-3351-2018	Wolf, Michael/0000-0002-4342-6517; Lin, Jenny/0000-0001-7104-8480	National Heart, Lung, and Blood Institute [5R01HL096612-04]; NATIONAL CANCER INSTITUTE [K07CA166462] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by a grant from the National Heart, Lung, and Blood Institute (grant no. 5R01HL096612-04), which played no role in the design or conduct of the study or the interpretation of its findings.	Akinbami Lara J, 2012, NCHS Data Brief, P1; American Lung Association, 2012, TRENDS ASTHM MORB MO; Apter AJ, 2013, J ALLERGY CLIN IMMUN, V132, P321, DOI 10.1016/j.jaci.2013.02.014; Baker DW, 1999, PATIENT EDUC COUNS, V38, P33, DOI 10.1016/S0738-3991(98)00116-5; Barr RG, 2002, ARCH INTERN MED, V162, P1761, DOI 10.1001/archinte.162.15.1761; Bohlman-Nielsen L, 2004, HLTH LITERACY PRESCR; Boyd CM, 2005, JAMA-J AM MED ASSOC, V294, P716, DOI 10.1001/jama.294.6.716; Broadbent E, 2006, J PSYCHOSOM RES, V60, P631, DOI 10.1016/j.jpsychores.2005.10.020; Broers S, 2005, PATIENT EDUC COUNS, V58, P279, DOI 10.1016/j.pec.2005.06.001; Centers for Disease Control and Prevention US Department of Health and Human Services, 2014, 2013 NAT HLTH INT SU; Chambers CV, 1999, RESP MED, V93, P88, DOI 10.1016/S0954-6111(99)90296-2; Cohen JL, 2009, ANN ALLERG ASTHMA IM, V103, P325, DOI 10.1016/S1081-1206(10)60532-7; Dima AL, 2015, EUR RESPIR J, V45, P994, DOI 10.1183/09031936.00172114; Federman AD, 2014, J AM GERIATR SOC, V62, P872, DOI 10.1111/jgs.12797; Federman AD, 2014, J ASTHMA, V51, P162, DOI 10.3109/02770903.2013.852202; Federman AD, 2013, PATIENT EDUC COUNS, V92, P273, DOI 10.1016/j.pec.2013.02.013; Federman AD, 2009, J AM GERIATR SOC, V57, P1475, DOI 10.1111/j.1532-5415.2009.02347.x; Foster JM, 2016, J ASTHMA, V53, P311, DOI 10.3109/02770903.2015.1091473; Gazmararian JA, 1999, JAMA-J AM MED ASSOC, V281, P545, DOI 10.1001/jama.281.6.545; Halm EA, 2006, CHEST, V129, P573, DOI 10.1378/chest.129.3.573; Hanania NA, 2011, J ALLERGY CLIN IMMUN, V128, pS4, DOI 10.1016/j.jaci.2011.06.048; Hilmer SN, 2007, FUND CLIN PHARMACOL, V21, P217, DOI 10.1111/j.1472-8206.2007.00473.x; Horne R, 1999, J PSYCHOSOM RES, V47, P491, DOI 10.1016/S0022-3999(99)00058-6; Horne R, 1999, PSYCHOL HEALTH, V14, P1, DOI 10.1080/08870449908407311; LEVENTHAL H, 1983, HEALTH EDUC QUART, V10, P3, DOI 10.1177/109019818301000101; Leventhal H, 1998, PSYCHOL HEALTH, V13, P717, DOI 10.1080/08870449808407425; Levinthal BR, 2008, J GEN INTERN MED, V23, P1172, DOI 10.1007/s11606-008-0612-2; Manly JJ, 2005, J GERIATR PSYCH NEUR, V18, P213, DOI 10.1177/0891988705281868; Manly JJ, 2003, J CLIN EXP NEUROPSYC, V25, P680, DOI 10.1076/jcen.25.5.680.14579; National Heart Lung and Blood Institute. National Asthma Education and Prevention Program, 2007, 3 NAT HEART LUNG BLO; O'Conor R, 2015, CHEST, V147, P1307, DOI 10.1378/chest.14-0914; O'Mahony D, 2015, AGE AGEING, V44, P213, DOI 10.1093/ageing/afu145; Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100; Pelaez S, 2015, BMC PULM MED, V15, DOI 10.1186/s12890-015-0044-9; Ponieman D, 2009, ANN ALLERG ASTHMA IM, V103, P38, DOI 10.1016/S1081-1206(10)60141-X; Quadrelli SA, 2001, J ASTHMA, V38, P377, DOI 10.1081/JAS-100000259; Rosas-Salazar C, 2012, J ALLERGY CLIN IMMUN, V129, P935, DOI 10.1016/j.jaci.2012.01.040; Sofianou A, 2013, J GEN INTERN MED, V28, P67, DOI 10.1007/s11606-012-2160-z; SPREEN ESO, 1998, COMPENDIUM NEUROPSYC; Steinman MA, 2010, JAMA-J AM MED ASSOC, V304, P1592, DOI 10.1001/jama.2010.1482; Thai A, 2010, J ASTHMA ALLERGY ED, V01, P50, DOI DOI 10.1177/2150129710368850; Villaire M., 2007, HLTH LITERACY PRIMAR; Wang J., 2019, STRUCTURAL EQUATION, DOI [DOI 10.1002/9781118356258, DOI 10.1002/]; Wechsler D, 1997, WMS 3 WECHSLER MEMOR; Weintraub S, 2009, ALZ DIS ASSOC DIS, V23, P91, DOI 10.1097/WAD.0b013e318191c7dd; Williams LK, 2011, J ALLERGY CLIN IMMUN, V128, P1185, DOI 10.1016/j.jaci.2011.09.011; Williams LK, 2004, J ALLERGY CLIN IMMUN, V114, P1288, DOI 10.1016/j.jaci.2004.09.028; Wisnivesky JP, 2009, MED CARE, V47, P243, DOI 10.1097/MLR.0b013e3181847606	48	38	38	3	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2017	139	3					804	809		10.1016/j.jaci.2016.05.043	http://dx.doi.org/10.1016/j.jaci.2016.05.043			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	EP3QC	27555454	Green Accepted, Bronze			2022-12-18	WOS:000397295800012
J	Chen, HH; Handel, N; Ngeow, J; Muller, J; Huhn, M; Yang, HT; Heindl, M; Berbers, RM; Hegazy, AN; Kionke, J; Yehia, L; Sack, U; Blaeser, F; Rensing-Ehl, A; Reifenberger, J; Keith, J; Travis, S; Merkenschlager, A; Kiess, W; Wittekind, C; Walker, L; Ehl, S; Aretz, S; Dustin, ML; Eng, C; Powrie, F; Uhlig, HH				Chen, Hannah H.; Haendel, Norman; Ngeow, Joanne; Muller, James; Huehn, Michael; Yang, Huei-Ting; Heindl, Mario; Berbers, Roos-Marijn; Hegazy, Ahmed N.; Kionke, Janina; Yehia, Lamis; Sack, Ulrich; Blaeser, Frank; Rensing-Ehl, Anne; Reifenberger, Julia; Keith, Julia; Travis, Simon; Merkenschlager, Andreas; Kiess, Wieland; Wittekind, Christian; Walker, Lisa; Ehl, Stephan; Aretz, Stefan; Dustin, Michael L.; Eng, Charis; Powrie, Fiona; Uhlig, Holm H.			Immune dysregulation in patients with PTEN hamartoma tumor syndrome: Analysis of FOXP3 regulatory T cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Regulatory T cells; phosphatases; phosphoinositide 3-kinase; PTEN; PH domain leucine-rich repeat protein phosphatase; PHTS; immunologic synapse; autoimmunity	RESOLUTION MELTING ANALYSIS; RILEY-RUVALCABA-SYNDROME; LYMPHOID HYPERPLASIA; PROMOTER MUTATIONS; AKT-MTOR; KINASE; HOMEOSTASIS; EXPRESSION; PROTEIN; AUTOIMMUNITY	Background: Patients with heterozygous germline mutations in phosphatase and tensin homolog deleted on chromosome 10 (PTEN) experience autoimmunity and lymphoid hyperplasia. Objectives: Because regulation of the phosphoinositide 3-kinase (PI3K) pathway is critical for maintaining regulatory T (Treg) cell functions, we investigate Treg cells in patients with heterozygous germline PTEN mutations (PTEN hamartoma tumor syndrome [PHTS]). Methods: Patients with PHTS were assessed for immunologic conditions, lymphocyte subsets, forkhead box P3 (FOXP3) 1 Treg cell levels, and phenotype. To determine the functional importance of phosphatases that control the PI3K pathway, we assessed Treg cell induction in vitro, mitochondrial depolarization, and recruitment of PTEN to the immunologic synapse. Results: Autoimmunity and peripheral lymphoid hyperplasia were found in 43% of 79 patients with PHTS. Immune dysregulation in patients with PHTS included lymphopenia, CD4(+) T-cell reduction, and changes in T-and B-cell subsets. Although total CD4(+) FOXP3(+) Treg cell numbers are reduced, frequencies are maintained in the blood and intestine. Despite pathogenic PTEN mutations, the FOXP3(+) T cells are phenotypically normal. We show that the phosphatase PH domain leucine-rich repeat protein phosphatase (PHLPP) downstream of PTEN is highly expressed in normal human Treg cells and provides complementary phosphatase activity. PHLPP is indispensable for the differentiation of induced Treg cells in vitro and Treg cell mitochondrial fitness. PTEN and PHLPP form a phosphatase network that is polarized at the immunologic synapse. Conclusion: Heterozygous loss of function of PTEN in human subjects has a significant effect on T-and B-cell immunity. Assembly of the PTEN-PHLPP phosphatase network allows coordinated phosphatase activities at the site of T-cell receptor activation, which is important for limiting PI3K hyperactivation in Treg cells despite PTEN haploinsufficiency.	[Chen, Hannah H.; Huehn, Michael; Yang, Huei-Ting; Berbers, Roos-Marijn; Hegazy, Ahmed N.; Keith, Julia; Travis, Simon; Uhlig, Holm H.] Univ Oxford, Translat Gastroenterol Unit, Oxford OX1 2JD, England; [Dustin, Michael L.; Powrie, Fiona] Univ Oxford, Kennedy Inst Rheumatol, Oxford OX1 2JD, England; [Uhlig, Holm H.] Univ Oxford, Dept Pediat, Oxford OX1 2JD, England; [Haendel, Norman; Merkenschlager, Andreas; Kiess, Wieland] Univ Leipzig, Hosp Children & Adolescents, D-04109 Leipzig, Germany; [Heindl, Mario] Univ Leipzig, Dept Internal Med, D-04109 Leipzig, Germany; [Sack, Ulrich] Univ Leipzig, Inst Immunol & Transfus Med, D-04109 Leipzig, Germany; [Wittekind, Christian] Univ Leipzig, Inst Pathol, D-04109 Leipzig, Germany; [Ngeow, Joanne; Yehia, Lamis; Eng, Charis] Cleveland Clin, Lerner Res Inst, Genom Med Inst, Cleveland, OH 44106 USA; [Yehia, Lamis] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA; [Kionke, Janina] Univ Bonn, Biomed Ctr, Inst Human Genet, Bonn, Germany; [Muller, James; Dustin, Michael L.] NYU, Sch Med, Skirball Inst Biomol Med, New York, NY 10003 USA; [Rensing-Ehl, Anne; Ehl, Stephan] Univ Med Ctr, Ctr Chron Immunodeficiency, Freiburg, Germany; [Reifenberger, Julia] Heinrich Heine Univ, Dept Dermatol, Dusseldorf, Germany; [Walker, Lisa] Churchill Hosp, Dept Clin Genet, Oxford, England; [Eng, Charis] Case Western Reserve Univ, Sch Med, Dept Genet & Genome Sci, Cleveland, OH 44106 USA; [Eng, Charis] Case Western Reserve Univ, CASE Comprehens Canc Ctr, Sch Med, Cleveland, OH 44106 USA; [Ngeow, Joanne] Natl Canc Ctr, Div Med Oncoloy, Canc Genet Serv, Singapore, Singapore	University of Oxford; University of Oxford; University of Oxford; Leipzig University; Leipzig University; Leipzig University; Leipzig University; Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of Bonn; New York University; University of Freiburg; Heinrich Heine University Dusseldorf; University of Oxford; Case Western Reserve University; Case Western Reserve University; National Cancer Centre Singapore (NCCS)	Uhlig, HH (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med Expt Med, Translat Gastroenterol Unit, Oxford OX3 9DU, England.	holm.uhlig@ndm.ox.ac.uk	Dustin, Michael/AAM-4611-2020; Sack, Ulrich/J-6301-2015; Aretz, Stefan/C-1241-2008; Yehia, Lamis/AAI-4996-2020; Reifenberger, Guido/AAE-3599-2019; Joanne, Ngeow/G-9610-2019; Ehl, Stephan/AAM-6006-2020; Ngeow, Joanne/O-1250-2013	Sack, Ulrich/0000-0002-7813-0492; Aretz, Stefan/0000-0002-5228-1890; Yehia, Lamis/0000-0002-6389-3059; Joanne, Ngeow/0000-0003-1558-3627; Ngeow, Joanne/0000-0003-1558-3627; Ehl, Stephan/0000-0002-9265-2721; Hegazy, Ahmed N./0000-0002-2946-8251; Dustin, Michael/0000-0003-4983-6389; Travis, Simon/0000-0002-2690-4361; Uhlig, Holm/0000-0002-6111-7355	Cancer Research UK through the Oxford Cancer Research Centre Development Fund [C38302/A12278, OCRC0612-HU]; University of Leipzig; ECCO grant; UCB through the Oxford Targets Program; Crohn's & Colitis Foundation of America (CCFA); Leona M. and Harry B. Helmsley Charitable Trust; National Medical Research Council, Singapore; Ambrose Monell Foundation; National Cancer Institute [P01CA124570]; F.M. Kirby Foundation; Wellcome Trust; EMBO long-term fellowship; Marie Curie fellowship; MRC [MR/L022699/1] Funding Source: UKRI; NATIONAL CANCER INSTITUTE [P01CA124570] Funding Source: NIH RePORTER; Medical Research Council [MR/L022699/1] Funding Source: researchfish	Cancer Research UK through the Oxford Cancer Research Centre Development Fund; University of Leipzig; ECCO grant; UCB through the Oxford Targets Program; Crohn's & Colitis Foundation of America (CCFA); Leona M. and Harry B. Helmsley Charitable Trust; National Medical Research Council, Singapore(National Medical Research Council, SingaporeUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Ambrose Monell Foundation; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); F.M. Kirby Foundation; Wellcome Trust(Wellcome Trust); EMBO long-term fellowship(European Molecular Biology Organization (EMBO)); Marie Curie fellowship(European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Supported by Cancer Research UK grant no. C38302/A12278 through the Oxford Cancer Research Centre Development Fund (OCRC0612-HU), the University of Leipzig, and partially by an ECCO grant (to H.H.U.). H.H.U. and H.H.C. are supported by UCB through the Oxford Targets Program. H.H.U. and F.P. are supported by the Crohn's & Colitis Foundation of America (CCFA) and the Leona M. and Harry B. Helmsley Charitable Trust. J.N. is a clinical cancer genetics fellow at the Cleveland Clinic Genomic Medicine Institute partially funded by National Medical Research Council, Singapore, and the Ambrose Monell Foundation. L.Y. is a Fulbright International Science and Technology Scholar. C.E. is funded in part by P01CA124570 from the National Cancer Institute, is the Sondra J. and Stephen R. Hardis Endowed Chair in Cancer Genomic Medicine at the Cleveland Clinic, and is an American Cancer Society Clinical Research Professor, partially funded by the F.M. Kirby Foundation. F.P. is supported by the Wellcome Trust. A. N. H. was supported by an EMBO long-term fellowship and a Marie Curie fellowship.	Boccone L, 2006, AM J MED GENET A, V140A, P1965, DOI 10.1002/ajmg.a.31396; Brognard J, 2009, J BIOL CHEM, V284, P15215, DOI 10.1074/jbc.M901468200; Browning MJ, 2015, J MED GENET, V52, P856, DOI 10.1136/jmedgenet-2015-103266; Bunnell SC, 2002, J CELL BIOL, V158, P1263, DOI 10.1083/jcb.200203043; Campi G, 2005, J EXP MED, V202, P1031, DOI 10.1084/jem.20051182; Choudhuri K, 2014, NATURE, V507, P118, DOI 10.1038/nature12951; Deau MC, 2014, J CLIN INVEST, V124, P3923, DOI 10.1172/JCI75746; Delgoffe GM, 2013, NATURE, V501, P252, DOI 10.1038/nature12428; Delgoffe GM, 2009, IMMUNITY, V30, P832, DOI 10.1016/j.immuni.2009.04.014; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; Dustin Michael L, 2007, Curr Protoc Immunol, VChapter 18, DOI 10.1002/0471142735.im1813s76; Erali M, 2010, METHODS, V50, P250, DOI 10.1016/j.ymeth.2010.01.013; Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008; Garritano S, 2009, BMC GENET, V10, DOI 10.1186/1471-2156-10-5; Harada Y, 2010, J EXP MED, V207, P1381, DOI 10.1084/jem.20100004; Haxhinasto S, 2008, J EXP MED, V205, P565, DOI 10.1084/jem.20071477; Heald B, 2010, GASTROENTEROLOGY, V139, P1927, DOI 10.1053/j.gastro.2010.06.061; Heindl M, 2012, GASTROENTEROLOGY, V142, P1093, DOI 10.1053/j.gastro.2012.01.011; Huynh A, 2015, NAT IMMUNOL, V16, P188, DOI 10.1038/ni.3077; Krupica T, 2006, CLIN IMMUNOL, V120, P121, DOI 10.1016/j.clim.2006.04.569; Liang H, 2014, CELL METAB, V19, P836, DOI 10.1016/j.cmet.2014.03.023; Liu GW, 2009, NAT IMMUNOL, V10, P769, DOI 10.1038/ni.1743; Lucas CL, 2014, NAT IMMUNOL, V15, P88, DOI 10.1038/ni.2771; Merkenschlager M, 2010, J EXP MED, V207, P1347, DOI 10.1084/jem.20101156; Mester J, 2013, AM J MED GENET C, V163C, P114, DOI 10.1002/ajmg.c.31364; Miyamoto S, 2010, CIRC RES, V107, P476, DOI 10.1161/CIRCRESAHA.109.215020; Molina JR, 2012, ONCOGENE, V31, P1264, DOI 10.1038/onc.2011.324; Montgomery J, 2007, NAT PROTOC, V2, P59, DOI 10.1038/nprot.2007.10; Mutter GL, 2000, J CLIN ENDOCR METAB, V85, P2334, DOI 10.1210/jc.85.6.2334; Newton RH, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00151; Okkenhaug K, 2013, ANNU REV IMMUNOL, V31, P675, DOI 10.1146/annurev-immunol-032712-095946; Ouyang WM, 2012, NATURE, V491, P554, DOI 10.1038/nature11581; Ouyang W, 2010, NAT IMMUNOL, V11, P618, DOI 10.1038/ni.1884; Patterson SJ, 2011, J IMMUNOL, V186, P5533, DOI 10.4049/jimmunol.1002126; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Procaccini C, 2010, IMMUNITY, V33, P929, DOI 10.1016/j.immuni.2010.11.024; Reifenberger J, 2003, BRIT J DERMATOL, V148, P1040, DOI 10.1046/j.1365-2133.2003.05322.x; Rolf J, 2010, J IMMUNOL, V185, P4042, DOI 10.4049/jimmunol.1001730; Sauer S, 2008, P NATL ACAD SCI USA, V105, P7797, DOI 10.1073/pnas.0800928105; Shrestha S, 2015, NAT IMMUNOL, V16, P178, DOI 10.1038/ni.3076; Soond DR, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00244; Suzuki A, 2003, J EXP MED, V197, P657, DOI 10.1084/jem.20021101; Suzuki A, 2001, IMMUNITY, V14, P523, DOI 10.1016/S1074-7613(01)00134-0; Takahashi Y, 2006, EMBO J, V25, P910, DOI 10.1038/sj.emboj.7600979; Tan MH, 2011, AM J HUM GENET, V88, P42, DOI 10.1016/j.ajhg.2010.11.013; Teresi RE, 2007, AM J HUM GENET, V81, P756, DOI 10.1086/521051; Varma R, 2006, IMMUNITY, V25, P117, DOI 10.1016/j.immuni.2006.04.010; Walsh PT, 2006, J CLIN INVEST, V116, P2521, DOI 10.1172/JCI28057; Zanin-Zhorov A, 2012, P NATL ACAD SCI USA, V109, P1625, DOI 10.1073/pnas.1110120109; Zeiser R, 2008, BLOOD, V111, P453, DOI 10.1182/blood-2007-06-094482; Zeng H, 2013, NATURE, V499, P485, DOI 10.1038/nature12297; Zhou XP, 2003, AM J HUM GENET, V73, P404, DOI 10.1086/377109	52	38	40	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2017	139	2					607	+		10.1016/j.jaci.2016.03.059	http://dx.doi.org/10.1016/j.jaci.2016.03.059			29	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EO9IM	27477328	Green Published, hybrid			2022-12-18	WOS:000397002400026
J	Jackson, DJ; Gern, JE; Lemanske, RF				Jackson, Daniel J.; Gern, James E.; Lemanske, Robert F., Jr.			Lessons learned from birth cohort studies conducted in diverse environments	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Asthma; microbes; rhinovirus; RSV; wheezing; microbiome	RESPIRATORY SYNCYTIAL VIRUS; 1ST 6 YEARS; EARLY-LIFE; ALLERGIC SENSITIZATION; CHILDHOOD ASTHMA; LUNG-FUNCTION; AIRWAY RESPONSIVENESS; RHINOVIRUS INFECTION; PATHOGENIC BACTERIA; PRESCHOOL-CHILDREN	Childhood asthma develops from a complex interaction among host and environmental factors in early life. Birth cohort studies have provided valuable insight into asthma risk factors and the natural history of wheezing and asthma through childhood and beyond. Early life aeroallergen sensitization and wheezing illnesses associated with virus and bacterial infections have been identified as pivotal risk factors for asthma inception. Recently, focus has turned toward protective factors that promote lung health in children. Studies in a variety of environments, including farms and urban communities, suggest that diverse exposures microbes in early life lead to a lower risk of allergy and asthma in childhood. The mechanisms underlying how these exposures and the gut and airway microbiomes alter the host response to allergens and viruses are of interest and an area of ongoing study. Longitudinal follow up of birth cohorts in diverse environments worldwide will continue to provide critical knowledge about the factors that impact the natural history of asthma.	[Jackson, Daniel J.; Gern, James E.; Lemanske, Robert F., Jr.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat, Madison, WI 53706 USA; [Gern, James E.; Lemanske, Robert F., Jr.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Jackson, DJ (corresponding author), 600 Highland Ave,CSC K4-936, Madison, WI 53792 USA.	djj@medicine.wisc.edu			National Institutes Health [P01 HL070831, UM1 AI114271]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL070831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [UM1AI114271, U19AI104317] Funding Source: NIH RePORTER	National Institutes Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the National Institutes Health (grants P01 HL070831 and UM1 AI114271).	Anderson HM, 2016, J ALLERGY CLIN IMMUN; Arrieta MC, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab2271; Bisgaard H, 2012, AM J RESP CRIT CARE, V185, P1183, DOI 10.1164/rccm.201110-1922OC; Bisgaard H, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c4978; Bochkov YA, 2015, P NATL ACAD SCI USA, V112, P5485, DOI 10.1073/pnas.1421178112; Bochkov YA, 2014, J CLIN MICROBIOL, V52, P2461, DOI 10.1128/JCM.00075-14; Bonnelykke K, 2014, NAT GENET, V46, P51, DOI 10.1038/ng.2830; Bousquet J, 2014, J ALLERGY CLIN IMMUN, V133, P1535, DOI 10.1016/j.jaci.2014.01.018; Bousquet J, 2013, INT ARCH ALLERGY IMM, V161, P1, DOI 10.1159/000343018; Brand PLP, 2008, EUR RESPIR J, V32, P1096, DOI 10.1183/09031936.00002108; Bufford JD, 2008, CLIN EXP ALLERGY, V38, P1635, DOI 10.1111/j.1365-2222.2008.03018.x; Caliskan M, 2013, NEW ENGL J MED, V368, P1398, DOI 10.1056/NEJMoa1211592; Camargo CA, 2011, PEDIATRICS, V127, pE180, DOI 10.1542/peds.2010-0442; Carroll KN, 2009, J ALLERGY CLIN IMMUN, V123, P964, DOI 10.1016/j.jaci.2008.12.011; Carroll KN, 2009, J ALLERGY CLIN IMMUN, V123, P1055, DOI 10.1016/j.jaci.2009.02.021; Copenhaver CC, 2004, AM J RESP CRIT CARE, V170, P175, DOI 10.1164/rccm.200312-1647OC; Cox DW, 2015, EUR RESPIR J, V46, P1654, DOI 10.1183/13993003.00397-2015; Devereux G, 2007, AM J CLIN NUTR, V85, P853, DOI 10.1093/ajcn/85.3.853; Dillie KTS, 2008, CLIN EXP ALLERGY, V38, P298, DOI 10.1111/j.1365-2222.2007.02891.x; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Folsgaard NV, 2013, AM J RESP CRIT CARE, V187, P589, DOI 10.1164/rccm.201207-1297OC; Fujimura KE, 2016, NAT MED, V22, P1187, DOI 10.1038/nm.4176; Fujimura KE, 2014, P NATL ACAD SCI USA, V111, P805, DOI 10.1073/pnas.1310750111; Gern JE, 2012, J INFECT DIS, V206, P1342, DOI 10.1093/infdis/jis504; Gern JE, 2010, J ALLERGY CLIN IMMUN, V125, P545, DOI 10.1016/j.jaci.2010.01.037; Gern JE, 2006, J ALLERGY CLIN IMMUN, V117, P72, DOI 10.1016/j.jaci.2005.10.002; Gern JE, 2016, J ALLERGY C IN PRESS; Guilbert TW, 2011, J ALLERGY CLIN IMMUN, V128, P532, DOI 10.1016/j.jaci.2011.06.037; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356, DOI 10.1164/ajrccm.155.4.9105079; Harvey NC, 2014, HEALTH TECHNOL ASSES, V18, P1, DOI 10.3310/hta18450; Havstad S, 2014, J ALLERGY CLIN IMMUN, V134, P722, DOI 10.1016/j.jaci.2014.01.022; Holt PG, 2015, J ALLERGY CLIN IMMUN, V136, P15, DOI 10.1016/j.jaci.2015.05.011; Hong JY, 2014, J ALLERGY CLIN IMMUN, V134, P429, DOI 10.1016/j.jaci.2014.04.020; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Jackson DJ, 2016, J ALLERGY CLIN IMMUN, V137, P659, DOI 10.1016/j.jaci.2016.01.002; Jackson DJ, 2012, AM J RESP CRIT CARE, V185, P281, DOI 10.1164/rccm.201104-0660OC; Kloepfer KM, 2014, J ALLERGY CLIN IMMUN, V133, P1301, DOI 10.1016/j.jaci.2014.02.030; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Leigh R, 2008, J ALLERGY CLIN IMMUN, V121, P1238, DOI 10.1016/j.jaci.2008.01.067; Lezmi G, 2015, AM J RESP CRIT CARE, V192, P164, DOI 10.1164/rccm.201411-1958OC; Litonjua AA, 2007, J ALLERGY CLIN IMMUN, V120, P1031, DOI 10.1016/j.jaci.2007.08.028; Loss GJ, 2016, AM J RESP CRIT CARE, V193, P889, DOI 10.1164/rccm.201507-1493OC; Lynch SV, 2014, J ALLERGY CLIN IMMUN, V134, P593, DOI 10.1016/j.jaci.2014.04.018; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Martinez FD, 2016, NEW ENGL J MED, V375, P871, DOI 10.1056/NEJMra1603287; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; O'Brian AL, 2012, J ALLERGY CLIN IMMUN, V129, P1162, DOI 10.1016/j.jaci.2011.11.046; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Palmer LJ, 2001, AM J RESP CRIT CARE, V163, P37, DOI 10.1164/ajrccm.163.1.2005013; Ramratnam SK, 2016, AM J RESP CRIT CARE; Rautava S, 2012, NAT REV GASTRO HEPAT, V9, P565, DOI 10.1038/nrgastro.2012.144; Regamey N, 2008, AM J RESP CRIT CARE, V177, P837, DOI 10.1164/rccm.200707-977OC; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; Rothers J, 2011, J ALLERGY CLIN IMMUN, V128, P1093, DOI 10.1016/j.jaci.2011.07.015; Rubner FJ, 2016, J ALLERGY CLIN IMMUN; Saglani S, 2005, AM J RESP CRIT CARE, V171, P722, DOI 10.1164/rccm.200410-1404OC; Saglani S, 2015, AM J RESP CRIT CARE, V192, P121, DOI 10.1164/rccm.201505-0989ED; Scholtens S, 2014, J ALLERGY CLIN IMMUN, V133, P885, DOI 10.1016/j.jaci.2013.08.049; Schultz ES, 2016, J ALLERGY CLIN IMMUN, V138, P930, DOI 10.1016/j.jaci.2016.04.014; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Simoes EAF, 2010, J ALLERGY CLIN IMMUN, V126, P256, DOI 10.1016/j.jaci.2010.05.026; Simpson A, 2010, AM J RESP CRIT CARE, V181, P1200, DOI 10.1164/rccm.200907-1101OC; Sly PD, 2008, LANCET, V372, P1100, DOI 10.1016/S0140-6736(08)61451-8; Soler Artigas M, 2011, NAT GENET, V43, P1082, DOI 10.1038/ng.941; Stein MM, 2016, NEW ENGL J MED, V375, P411, DOI 10.1056/NEJMoa1508749; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Stern DA, 2007, J ALLERGY CLIN IMMUN, V120, P835, DOI 10.1016/j.jaci.2007.05.050; Stoltz DJ, 2013, CLIN EXP ALLERGY, V43, P233, DOI 10.1111/cea.12050; Sumino K, 2012, J ALLERGY CLIN IMMUN, V129, P1267, DOI 10.1016/j.jaci.2012.02.033; Tai A, 2014, THORAX, V69, P805, DOI 10.1136/thoraxjnl-2013-204815; Teo SM, 2015, CELL HOST MICROBE, V17, P704, DOI 10.1016/j.chom.2015.03.008; Thomsen SF, 2009, AM J RESP CRIT CARE, V179, P1091, DOI 10.1164/rccm.200809-1471OC; Thysen AH, 2016, J ALLERGY CLIN IMMUN, V137, P1238, DOI 10.1016/j.jaci.2015.08.041; Turato G, 2008, AM J RESP CRIT CARE, V178, P476, DOI 10.1164/rccm.200712-1818OC; Uekert SJ, 2006, J ALLERGY CLIN IMMUN, V118, P1375, DOI 10.1016/j.jaci.2006.09.008; van der Gugten AC, 2013, PEDIATR INFECT DIS J, V32, P827, DOI 10.1097/INF.0b013e318290620e; van der Zalm MM, 2011, AM J RESP CRIT CARE, V183, P262, DOI 10.1164/rccm.200905-0716OC; Visness CM, 2015, J ALLERGY CLIN IMMUN, V136, P1108, DOI 10.1016/j.jaci.2015.03.046; Vissing NH, 2016, PEDIATR INFECT DIS J, V35, P561, DOI 10.1097/INF.0000000000001092; von Mutius E, 2016, J ALLERGY CLIN IMMUN, V137, P680, DOI 10.1016/j.jaci.2015.12.1301; West CE, 2015, J ALLERGY CLIN IMMUN, V135, P3, DOI 10.1016/j.jaci.2014.11.012	82	38	39	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2017	139	2					379	387		10.1016/j.jaci.2016.12.941	http://dx.doi.org/10.1016/j.jaci.2016.12.941			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EO9IM	28183432	Bronze, Green Accepted			2022-12-18	WOS:000397002400001
J	Takeda, T; Unno, H; Morita, H; Futamura, K; Emi-Sugie, M; Arae, K; Shoda, T; Okada, N; Igarashi, A; Inoue, E; Kitazawa, H; Nakae, S; Saito, H; Matsumoto, K; Matsuda, A				Takeda, Tomohiro; Unno, Hirotoshi; Morita, Hideaki; Futamura, Kyoko; Emi-Sugie, Maiko; Arae, Ken; Shoda, Tetsuo; Okada, Naoko; Igarashi, Arisa; Inoue, Eisuke; Kitazawa, Hiroshi; Nakae, Susumu; Saito, Hirohisa; Matsumoto, Kenji; Matsuda, Akio			Platelets constitutively express IL-33 protein and modulate eosinophilic airway inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Airway inflammation; asthma; eosinophil; IL-33; papain; platelet	INNATE LYMPHOID-CELLS; IL-1-LIKE CYTOKINE IL-33; NATURAL HELPER-CELLS; ALLERGIC INFLAMMATION; IN-VIVO; LUNG INFLAMMATION; TYPE-2 IMMUNITY; ST2 RECEPTOR; MAST-CELLS; ASTHMA	Background: Although platelets play a key role in allergic inflammation in addition to their well-established role in hemostasis, the precise mechanisms of how platelets modulate allergic inflammation are not fully understood. IL-33 is an essential regulator of innate immune responses and allergic inflammation. Objective: We sought to determine the expression of IL-33 protein by platelets and its functional significance in airway inflammation. Methods: IL-33 protein in human platelets, the human megakaryocyte cell line MEG-01, and bone marrow-derived mouse megakaryocytes was detected by using Western blot analysis and fluorescent immunostaining. We examined the functional relevance of IL-33 protein in platelets by comparing platelet-intact and platelet-depleted groups in a murine model of IL-33-dependent airway eosinophilia elicited by intranasal administration of papain. We further compared the additive effect of administration of platelets derived from wild-type versus IL-33-deficient mice on the papain-induced eosinophilia. Results: Platelets and their progenitor cells, megakaryocytes, constitutively expressed IL-33 protein (31 kDa). Papain-induced IL-33-dependent airway eosinophilia in mice was significantly attenuated by platelet depletion. Conversely, concomitant administration of platelets derived from wild-type mice but not IL33- deficientmice enhanced the papain-induced airway eosinophilia. Conclusions: Our novel findings suggest that platelets might be important cellular sources of IL-33 protein in vivo and that platelet-derived IL-33 might play a role in airway inflammation. Therefore platelets might become an attractive novel therapeutic target for asthma and probably allergic inflammation.	[Takeda, Tomohiro] Kansai Univ Hlth Sci, Dept Hlth Sci, 2-11-1 Wakaba, Kumatori, Osaka 5900482, Japan; [Takeda, Tomohiro; Unno, Hirotoshi; Morita, Hideaki; Futamura, Kyoko; Emi-Sugie, Maiko; Arae, Ken; Shoda, Tetsuo; Okada, Naoko; Igarashi, Arisa; Nakae, Susumu; Saito, Hirohisa; Matsumoto, Kenji; Matsuda, Akio] Natl Res Inst Child Hlth & Dev, Dept Allergy & Clin Immunol, Tokyo, Japan; [Arae, Ken] Kyorin Univ, Fac Hlth Sci, Dept Immunol, Tokyo, Japan; [Inoue, Eisuke] Natl Ctr Child Hlth & Dev, Clin Res Ctr, Tokyo, Japan; [Kitazawa, Hiroshi] Natl Ctr Child Hlth & Dev, Dept Med Subspecialties, Div Allergy, Tokyo, Japan; [Nakae, Susumu] Univ Tokyo, Inst Med Sci, Ctr Expt Med & Syst Biol, Lab Syst Biol, Tokyo, Japan; [Nakae, Susumu] Japan Sci & Technol Agcy, Precursory Res Embryon Sci & Technol PRESTO, Saitama, Japan	National Center for Child Health & Development - Japan; Kyorin University; National Center for Child Health & Development - Japan; National Center for Child Health & Development - Japan; University of Tokyo; Japan Science & Technology Agency (JST)	Takeda, T (corresponding author), Kansai Univ Hlth Sci, Dept Hlth Sci, 2-11-1 Wakaba, Kumatori, Osaka 5900482, Japan.; Matsumoto, K; Matsuda, A (corresponding author), Natl Res Inst Child Hlth & Dev, Dept Allergy & Clin Immunol, Setagaya Ku, 2-10-1 Okura, Tokyo 1578535, Japan.	jeni@mbk.ocn.ne.jp; matsumoto-k@ncchd.go.jp; matsuda-a@ncchd.go.jp	Kitazawa, Hiroshi/GLV-1422-2022; 岡田, 直子/GRI-9555-2022; Morita, Hideaki/ADL-2008-2022; Morita, Hideaki/S-2214-2016	岡田, 直子/0000-0002-3378-5778; Morita, Hideaki/0000-0003-0928-8322; Saito, Hirohisa/0000-0002-6630-8337; Igarashi, Arisa/0000-0001-7206-3105; Shoda, Tetsuo/0000-0001-8337-5438	National Institute of Biomedical Innovation grant [10-43]; National Center for Child Health and Development [26-9, 26-46]; JSPS KAKENHI grant [23591666]; Grants-in-Aid for Scientific Research [15H04866] Funding Source: KAKEN	National Institute of Biomedical Innovation grant; National Center for Child Health and Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); JSPS KAKENHI grant(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	Supported in part by National Institute of Biomedical Innovation grant ID10-43 (to K.M.), grants from the National Center for Child Health and Development #26-9 (to K.M.) and #26-46 (to M.E.-S.), and JSPS KAKENHI grant no. 23591666 (to A.M.).	Abi-Younes S, 2001, THROMB RES, V101, P279, DOI 10.1016/S0049-3848(00)00402-3; Allakhverdi Z, 2007, J IMMUNOL, V179, P2051, DOI 10.4049/jimmunol.179.4.2051; AVERILL FJ, 1992, AM REV RESPIR DIS, V145, P571, DOI 10.1164/ajrccm/145.3.571; Baekkevold ES, 2003, AM J PATHOL, V163, P69, DOI 10.1016/S0002-9440(10)63631-0; Barr RG, 2007, AM J RESP CRIT CARE, V175, P120, DOI 10.1164/rccm.200603-411OC; Carriere V, 2007, P NATL ACAD SCI USA, V104, P282, DOI 10.1073/pnas.0606854104; CASPARY EA, 1967, NATURE, V214, P286, DOI 10.1038/214286a0; Cayrol C, 2009, P NATL ACAD SCI USA, V106, P9021, DOI 10.1073/pnas.0812690106; Chang YJ, 2011, NAT IMMUNOL, V12, P631, DOI 10.1038/ni.2045; Cherry WB, 2008, J ALLERGY CLIN IMMUN, V121, P1484, DOI 10.1016/j.jaci.2008.04.005; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; de Boer JD, 2012, BLOOD, V119, P3236, DOI 10.1182/blood-2011-11-391532; Duarte D, 2013, ALLERGY, V68, P1073, DOI 10.1111/all.12190; Fujisaka S, 2009, DIABETES, V58, P2574, DOI 10.2337/db08-1475; Fujisawa T, 2002, J ALLERGY CLIN IMMUN, V110, P139, DOI 10.1067/mai.2002.126079; Gudbjartsson DF, 2009, NAT GENET, V41, P342, DOI 10.1038/ng.323; Halim TYF, 2014, IMMUNITY, V40, P425, DOI 10.1016/j.immuni.2014.01.011; Halim TYF, 2012, IMMUNITY, V36, P451, DOI 10.1016/j.immuni.2011.12.020; Hamzeh-Cognasse H, 2013, CRIT CARE, V17, DOI 10.1186/cc11925; Ho LH, 2007, J LEUKOCYTE BIOL, V82, P1481, DOI 10.1189/jlb.0407200; KNAUER KA, 1981, NEW ENGL J MED, V304, P1404, DOI 10.1056/NEJM198106043042307; Kornerup KN, 2007, PLATELETS, V18, P319, DOI 10.1080/09537100701230436; Kowal K, 2006, CLIN EXP ALLERGY, V36, P426, DOI 10.1111/j.1365-2222.2006.02446.x; Kuchler AM, 2008, AM J PATHOL, V173, P1229, DOI 10.2353/ajpath.2008.080014; Licona-Limon P, 2013, NAT IMMUNOL, V14, P536, DOI 10.1038/ni.2617; Lussana F, 2015, J THROMB HAEMOST, V13, P136, DOI 10.1111/jth.12779; Melen E, 2010, J ALLERGY CLIN IMMUN, V126, P631, DOI 10.1016/j.jaci.2010.06.030; MILNE J, 1975, BRIT J IND MED, V32, P302; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Motomura Y, 2014, IMMUNITY, V40, P758, DOI 10.1016/j.immuni.2014.04.013; Moussion C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003331; Nakae S, 2013, ALLERGOL INT, V62, P13, DOI 10.2332/allergolint.13-RAI-0538; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Nile CJ, 2010, IMMUNOLOGY, V130, P172, DOI 10.1111/j.1365-2567.2009.03221.x; Oboki K, 2011, ALLERGY ASTHMA IMMUN, V3, P81, DOI 10.4168/aair.2011.3.2.81; Oboki K, 2010, P NATL ACAD SCI USA, V107, P18581, DOI 10.1073/pnas.1003059107; Ohno T, 2009, J IMMUNOL, V183, P7890, DOI 10.4049/jimmunol.0802449; Page C, 2014, CLIN EXP ALLERGY, V44, P901, DOI 10.1111/cea.12322; Pecaric-Petkovic T, 2009, BLOOD, V113, P1526, DOI 10.1182/blood-2008-05-157818; Pitchford SC, 2004, BLOOD, V103, P639, DOI 10.1182/blood-2003-05-1707; Pitchford SC, 2003, J ALLERGY CLIN IMMUN, V112, P109, DOI 10.1067/mai.2003.1514; Price AE, 2010, P NATL ACAD SCI USA, V107, P11489, DOI 10.1073/pnas.1003988107; Raghavachari N, 2007, CIRCULATION, V115, P1551, DOI 10.1161/CIRCULATIONAHA.106.658641; Rank MA, 2009, J ALLERGY CLIN IMMUN, V123, P1047, DOI 10.1016/j.jaci.2009.02.026; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Spits H, 2013, NAT REV IMMUNOL, V13, P145, DOI 10.1038/nri3365; Sullivan PJ, 2000, RESPIRATION, V67, P514, DOI 10.1159/000067466; Suzukawa M, 2008, J IMMUNOL, V181, P5981, DOI 10.4049/jimmunol.181.9.5981; Talabot-Ayer D, 2009, J BIOL CHEM, V284, P19420, DOI 10.1074/jbc.M901744200; Ulfman LH, 2003, AM J RESP CELL MOL, V28, P512, DOI 10.1165/rcmb.4806; Unno H, 2014, AM J RESP CELL MOL, V51, P344, DOI 10.1165/rcmb.2013-0281OC; von Hundelshausen P, 2007, CIRC RES, V100, P27, DOI 10.1161/01.RES.0000252802.25497.b7; Yagami A, 2010, J IMMUNOL, V185, P5743, DOI 10.4049/jimmunol.0903818; YAMAMOTO H, 1993, J ALLERGY CLIN IMMUN, V91, P79, DOI 10.1016/0091-6749(93)90299-U; Yang H, 2006, J THROMB HAEMOST, V4, P2230, DOI 10.1111/j.1538-7836.2006.02116.x	56	38	39	1	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2016	138	5					1395	+		10.1016/j.jaci.2016.01.032	http://dx.doi.org/10.1016/j.jaci.2016.01.032			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EE4AA	27056266	Bronze			2022-12-18	WOS:000389542700019
J	Auyeung, P; Mittag, D; Hodgkin, PD; Harrison, LC				Auyeung, Priscilla; Mittag, Diana; Hodgkin, Philip D.; Harrison, Leonard C.			Autoreactive T cells in chronic spontaneous urticaria target the IgE Fc receptor I alpha subunit	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic spontaneous urticaria; Fc epsilon RI alpha; IgE; autoantibody; autoreactive T cell; cytokine; immune deviation	CHRONIC IDIOPATHIC URTICARIA; ANTIGEN CLASS-II; QUALITY-OF-LIFE; DOUBLE-BLIND; EPSILON-RI; AUTOANTIBODIES; HISTAMINE; SKIN; ASSOCIATIONS; CYCLOSPORINE	Background: Chronic spontaneous urticaria (CSU) is the recurrence of urticaria without an apparent trigger. Half of the patients with CSU have IgG autoantibodies to Fc epsilon RI alpha on dermal mast cells and basophils, which on activation release mediators responsible for urticaria. IgG autoantibodies infer the presence of antigen/disease-specific T cells and CSU lesions are characterized by T-cell infiltration, but antigen/disease-specific T cells have not been documented in patients with CSU. Objective: We aimed to identify autoreactive T cells to Fc epsilon RI alpha in patients with CSU and determine their relationship with autoantibodies to Fc epsilon RI alpha and their diagnostic value. Methods: T-cell responses to Fc epsilon RI alpha were measured as proliferation by carboxy-fluorescein diacetate succinimidyl ester dye dilution and cytokine secretion by ELISpot. Serum autoantibodies to Fc epsilon RI alpha were detected by radioimmunoprecipitation. Results: Blood CD4 1 T-cell proliferation to FceRIa was detected in 27% of the subjects with CSU and 0% of controls; IFN-gamma responses to Fc epsilon RI alpha were detected in 53%, and IL-5 or IL-13 responses in a minority of subjects with CSU. Serum FceRIa autoantibodies were detected in 43% of subjects with CSU and 0% of controls. IFN-gamma and autoantibody responses to Fc epsilon RI alpha were inversely related, with IFN-gamma responses being detected earlier than autoantibodies in disease. Combined with autoantibody, T-cell responses to Fc epsilon RI alpha conferred high diagnostic sensitivity and specificity. Conclusions: Autoreactive CD4 1 T cells that target Fc epsilon RI alpha were detected in most subjects with CSU, with a cytokine secretion profile more typical of a TH1-cell response. The inverse relationship between IFN-gamma and autoantibody responses to Fc epsilon RI alpha may signify different stages in the disease course. Our findings suggest that measurement of T-cell as well as autoantibody responses to Fc epsilon RI alpha could improve diagnostic accuracy in subjects with CSU.	[Auyeung, Priscilla; Mittag, Diana; Hodgkin, Philip D.; Harrison, Leonard C.] Univ Melbourne, Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3010, Australia; [Auyeung, Priscilla; Mittag, Diana; Hodgkin, Philip D.; Harrison, Leonard C.] Univ Melbourne, Dept Med Biol, Melbourne, Vic 3010, Australia; [Mittag, Diana] Acerta Pharma, Oss, Netherlands	University of Melbourne; Walter & Eliza Hall Institute; University of Melbourne	Harrison, LC (corresponding author), Walter & Eliza Hall Inst Med Res, 1G Royal Parade, Parkville, Vic 3052, Australia.	harrison@wehi.edu.au		Hodgkin, Philip/0000-0002-8604-1940	Australian National Health and Medical Research Council (NHMRC); Royal College of Pathologists of Australasia; CSL Limited	Australian National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Royal College of Pathologists of Australasia; CSL Limited	This work was supported by funding from the Australian National Health and Medical Research Council (NHMRC) (Postgraduate Scholarship to P.A.), the Royal College of Pathologists of Australasia (Research Award to P.A.), and CSL Limited. P.D.H. and L.C.H. were Senior Principal Research Fellows of the NHMRC.	BARLOW RJ, 1995, CLIN EXP ALLERGY, V25, P317, DOI 10.1111/j.1365-2222.1995.tb01049.x; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Bozek A, 2010, INT ARCH ALLERGY IMM, V153, P419, DOI 10.1159/000316354; Chen Jing, 2005, J Huazhong Univ Sci Technolog Med Sci, V25, P354; COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2; Ferrer M, 1998, J ALLERGY CLIN IMMUN, V101, P672, DOI 10.1016/S0091-6749(98)70176-9; Ferrer M, 2002, INT ARCH ALLERGY IMM, V129, P254, DOI 10.1159/000066772; Fiebiger E, 1998, J CLIN INVEST, V101, P243, DOI 10.1172/JCI511; GRATTAN CEH, 1986, BRIT J DERMATOL, V114, P583, DOI 10.1111/j.1365-2133.1986.tb04065.x; Grattan CEH, 2000, BRIT J DERMATOL, V143, P365, DOI 10.1046/j.1365-2133.2000.03664.x; GRATTAN CEH, 1991, CLIN EXP ALLERGY, V21, P695, DOI 10.1111/j.1365-2222.1991.tb03198.x; Grattan CEH, 2002, J AM ACAD DERMATOL, V46, P645, DOI 10.1067/mjd.2002.122759; Grob JJ, 2006, CLIN REV ALLERG IMMU, V30, P47, DOI 10.1385/CRIAI:30:1:047; HARRISON LC, 1993, LANCET, V341, P1365, DOI 10.1016/0140-6736(93)90940-I; Harrison LC, 2013, CURR DIABETES REP, V13, P616, DOI 10.1007/s11892-013-0415-7; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; Honeyman MC, 1997, ANN MED, V29, P401, DOI 10.3109/07853899708999369; JONES RR, 1983, BRIT J DERMATOL, V108, P695, DOI 10.1111/j.1365-2133.1983.tb01082.x; Kanai K, 2006, INT ARCH ALLERGY IMM, V140, P43, DOI 10.1159/000092001; Mannering SI, 2003, J IMMUNOL METHODS, V283, P173, DOI 10.1016/j.jim.2003.09.004; MEKORI YA, 1983, J ALLERGY CLIN IMMUN, V72, P681, DOI 10.1016/0091-6749(83)90629-2; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; NATBONY SF, 1983, J ALLERGY CLIN IMMUN, V71, P177, DOI 10.1016/0091-6749(83)90096-9; Niimi N, 1996, J INVEST DERMATOL, V106, P1001, DOI 10.1111/1523-1747.ep12338544; O'Donnell BF, 1999, BRIT J DERMATOL, V140, P853, DOI 10.1046/j.1365-2133.1999.02815.x; ODonnell BF, 1997, BRIT J DERMATOL, V136, P197; Okada T, 2005, PLOS BIOL, V3, P1047, DOI 10.1371/journal.pbio.0030150; Oztas P, 2004, YONSEI MED J, V45, P392; PARISH CR, 1972, J EXP MED, V135, P298, DOI 10.1084/jem.135.2.298; Rojana-Udomsart A, 2012, J NEUROIMMUNOL, V250, P77, DOI 10.1016/j.jneuroim.2012.05.003; Sabroe RA, 1999, J ALLERGY CLIN IMMUN, V103, P484, DOI 10.1016/S0091-6749(99)70475-6; Stankovich J, 2009, TISSUE ANTIGENS, V74, P17, DOI 10.1111/j.1399-0039.2009.01262.x; Taskapan O, 2008, CLIN EXP DERMATOL, V33, P754, DOI 10.1111/j.1365-2230.2008.02819.x; Tong LJ, 1997, J ALLERGY CLIN IMMUN, V99, P461, DOI 10.1016/S0091-6749(97)70071-X; Ujiie H, 2012, EXP DERMATOL, V21, P901, DOI 10.1111/exd.12011; Unglik G, 2014, URTICARIA PREVALENCE, P185; Vasagar K, 2006, CLIN EXP ALLERGY, V36, P770, DOI 10.1111/j.1365-2222.2006.02494.x; Vena GA, 2006, J AM ACAD DERMATOL, V55, P705, DOI 10.1016/j.jaad.2006.04.078; Ying S, 2002, J ALLERGY CLIN IMMUN, V109, P694, DOI 10.1067/mai.2002.123236; Zuberbier T, 2009, ALLERGY, V64, P1417, DOI 10.1111/j.1398-9995.2009.02179.x	40	38	42	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2016	138	3					761	+		10.1016/j.jaci.2016.04.036	http://dx.doi.org/10.1016/j.jaci.2016.04.036			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DY9ZM	27417022	Bronze			2022-12-18	WOS:000385496000012
J	Xian, M; Wawrzyniak, P; Ruckert, B; Duan, S; Meng, YF; Sokolowska, M; Globinska, A; Zhang, L; Akdis, M; Akdis, CA				Xian, Mu; Wawrzyniak, Paulina; Ruckert, Beate; Duan, Su; Meng, Yifan; Sokolowska, Milena; Globinska, Anna; Zhang, Luo; Akdis, Mubeccel; Akdis, Cezmi A.			Anionic surfactants and commercial detergents decrease tight junction barrier integrity in human keratinocytes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ATOPIC-DERMATITIS; IMMUNE; DISEASE		[Xian, Mu; Wawrzyniak, Paulina; Ruckert, Beate; Meng, Yifan; Sokolowska, Milena; Globinska, Anna; Akdis, Mubeccel; Akdis, Cezmi A.] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland; [Xian, Mu; Wawrzyniak, Paulina; Ruckert, Beate; Meng, Yifan; Sokolowska, Milena; Globinska, Anna; Akdis, Mubeccel; Akdis, Cezmi A.] Christine Kuhne Ctr Allergy Res & Educ, Davos, Switzerland; [Duan, Su] Capital Med Univ, Beijing Tongren Hosp, Dept Allergy, Beijing, Peoples R China; [Zhang, Luo] Capital Med Univ, Beijing Tongren Hosp, Dept Otolaryngol Head & Neck Surg, Beijing, Peoples R China; [Duan, Su; Zhang, Luo] Beijing Inst Otolaryngol, Beijing Key Lab Nasal Dis, Beijing, Peoples R China; [Globinska, Anna] Med Univ Lodz, Dept Immunol Rheumatol & Allergy, Lodz, Poland	Swiss Institute of Allergy & Asthma Research; University of Zurich; Capital Medical University; Capital Medical University; Medical University Lodz	Akdis, CA (corresponding author), Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland.	akdisac@siaf.uzh.ch	Wawrzyniak, Paulina/AAD-7265-2020; Akdis, Cezmi/AAV-4844-2020; Wawrzyniak, Paulina/HCG-8924-2022; Wawrzyniak, Paulina/AAG-3548-2019	Wawrzyniak, Paulina/0000-0001-9641-2103; Akdis, Cezmi/0000-0001-8020-019X; Zhang, Luo/0000-0002-0910-9884; Sokolowska, Milena/0000-0001-9710-6685				Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Esaki H, 2015, J ALLERGY CLIN IMMUN, V135, P153, DOI 10.1016/j.jaci.2014.10.037; Horimukai K, 2014, J ALLERGY CLIN IMMUN, V134, P824, DOI 10.1016/j.jaci.2014.07.060; Kelleher M, 2015, J ALLERGY CLIN IMMUN, V135, P930, DOI 10.1016/j.jaci.2014.12.013; Kuo IH, 2013, J ALLERGY CLIN IMMUN, V131, P266, DOI 10.1016/j.jaci.2012.12.1563; Miller RL, 2014, J ALLERGY CLIN IMMUN, V134, P1001, DOI 10.1016/j.jaci.2014.07.064; Otzen D, 2011, BBA-PROTEINS PROTEOM, V1814, P562, DOI 10.1016/j.bbapap.2011.03.003; Riethmuller C, 2015, J ALLERGY CLIN IMMUN, V136, P1573, DOI 10.1016/j.jaci.2015.04.042; Sicherer SH, 2015, J ALLERGY CLIN IMMUN, V135, P357, DOI 10.1016/j.jaci.2014.12.1906	9	38	41	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2016	138	3					890	893		10.1016/j.jaci.2016.07.003	http://dx.doi.org/10.1016/j.jaci.2016.07.003			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DY9ZM	27596709	Bronze			2022-12-18	WOS:000385496000025
J	Hox, V; O'Connell, MP; Lyons, JJ; Sackstein, P; Dimaggio, T; Jones, N; Nelson, C; Boehm, M; Holland, SM; Freeman, AF; Tweardy, DJ; Olivera, A; Metcalfe, DD; Milner, JD				Hox, Valerie; O'Connell, Michael P.; Lyons, Jonathan J.; Sackstein, Paul; Dimaggio, Thomas; Jones, Nina; Nelson, Celeste; Boehm, Manfred; Holland, Steven M.; Freeman, Alexandra F.; Tweardy, David J.; Olivera, Ana; Metcalfe, Dean D.; Milner, Joshua D.			Diminution of signal transducer and activator of transcription 3 signaling inhibits vascular permeability and anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; immunology; innate immunity; signal transducer and activator of transcription 3; autosomal dominant hyper-IgE syndrome	ENDOTHELIAL GROWTH-FACTOR; CELL-CELL CONTACT; STEM-CELLS; CALCIUM-RELEASE; BETA-CATENIN; NITRIC-OXIDE; VE-CADHERIN; STAT3; EXPRESSION; DISEASE	Background: During IgE-mediated immediate hypersensitivity reactions, vascular endothelial cells permeabilize in response to mast cell mediators. We have demonstrated previously that patients and mice with signal transducer and activator of transcription 3 (STAT3) mutations (autosomal dominant hyper-IgE syndrome [AD-HIES]) are partially protected from anaphylaxis. Objectives: We sought to study the mechanism by which STAT3 contributes to anaphylaxis and determine whether small-molecule inhibition of STAT3 can prevent anaphylaxis. Methods: Using unaffected and STAT3-inhibited or genetic loss-of-function samples, we performed histamine skin prick tests, investigated the contribution of STAT3 to animal models of anaphylaxis, and measured endothelial cell permeability, gene and protein expression, and histamine receptor-mediated signaling. Results: Although mouse mast cell degranulation was minimally affected by STAT3 blockade, mast cell mediator-induced anaphylaxis was blunted in Stat3 mutant mice with AD-HIES and in wild-type mice subjected to small-molecule STAT3 inhibition. Histamine skin prick test responses were diminished in patients with AD-HIES. Human umbilical vein endothelial cells derived from patients with AD-HIES or treated with a STAT3 inhibitor did not signal properly through Src or cause appropriate dissolution of the adherens junctions made up of the proteins vascular endothelial-cadherin and beta-catenin. Furthermore, we found that diminished STAT3 target microRNA17-92 expression in human umbilical vein endothelial cells from patients with AD-HIES is associated with increased phosphatase and tensin homolog (PTEN) expression, which inhibits Src, and increased E2F transcription factor 1 expression, which regulates beta-catenin cellular dynamics. Conclusions: These data demonstrate that STAT3-dependent transcriptional activity regulates critical components for the architecture and functional dynamics of endothelial junctions, thus permitting vascular permeability.	[Hox, Valerie; O'Connell, Michael P.; Lyons, Jonathan J.; Sackstein, Paul; Dimaggio, Thomas; Nelson, Celeste; Olivera, Ana; Metcalfe, Dean D.; Milner, Joshua D.] NIAID, Lab Allerg Dis, NIH, Bethesda, MD USA; [Holland, Steven M.; Freeman, Alexandra F.] NIAID, Lab Clin Infect Dis, NIH, Bethesda, MD USA; [Boehm, Manfred] NHLBI, Ctr Mol Med, NIH, Bethesda, MD USA; [Jones, Nina] Frederick Natl Lab Canc Res, Leidos Biomed Res, Clin Res Directorate CMRP, Frederick, MD USA; [Tweardy, David J.] Baylor Coll Med, Dept Med, Infect Dis Sect, Houston, TX USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Baylor College of Medicine	Milner, JD (corresponding author), NIAID, Genet & Pathogenesis Allergy Sect, Lab Allerg Dis, NIH, NIH Bldg 10-CRC,Rm 5-3950,10 Ctr Dr, Bethesda, MD 20892 USA.	jdmilner@niaid.nih.gov	Hox, Valérie/AAA-5660-2020; Tweardy, David/L-3929-2019; O'Connell, Michael/F-9236-2017; Hox, Valerie/AAS-6504-2020	Hox, Valérie/0000-0003-2390-294X; Lyons, Jonathan/0000-0002-2346-8189; O'Connell, Michael/0000-0002-8615-7660	Intramural Research Program of the National Institute of Allergy and Infectious Diseases; federal funds from the National Cancer Institute, National Institutes of Health [HHSN261200800001E]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL006077, ZIAHL006079, ZIAHL006078] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001206, ZIAAI000647, ZIAAI001092, ZIAAI001098, ZIAAI001183] Funding Source: NIH RePORTER	Intramural Research Program of the National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); federal funds from the National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This research was supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases. This project has been funded in part by federal funds from the National Cancer Institute, National Institutes of Health, under contract no. HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government.	Andriopoulou P, 1999, ARTERIOSCL THROM VAS, V19, P2286, DOI 10.1161/01.ATV.19.10.2286; Armanious H, 2010, INT J CLIN EXP PATHO, V3, P654; BUCKLEY RH, 1972, PEDIATRICS, V49, P59; Casanova JL, 2012, IMMUNITY, V36, P515, DOI 10.1016/j.immuni.2012.03.016; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Dai BB, 2011, CANCER RES, V71, P3658, DOI 10.1158/0008-5472.CAN-10-3647; DAVIS SD, 1966, LANCET, V1, P1013; Deo DD, 2004, J BIOL CHEM, V279, P3497, DOI 10.1074/jbc.M304497200; Dey N, 2008, CANCER RES, V68, P1862, DOI 10.1158/0008-5472.CAN-07-1182; Erlich TH, 2014, J ALLERGY CLIN IMMUN, V134, P460, DOI 10.1016/j.jaci.2013.12.1075; Flanagan SE, 2014, NAT GENET, V46, P812, DOI 10.1038/ng.3040; Freeman AF, 2010, DIS MARKERS, V29, P123, DOI [10.1155/2010/580197, 10.3233/DMA-2010-0734]; Fukuhara S, 2005, MOL CELL BIOL, V25, P136, DOI 10.1128/MCB.25.1.136-146.2005; Furumoto Y, 2011, BLOOD, V118, P5466, DOI 10.1182/blood-2010-09-309955; Gavard J, 2006, NAT CELL BIOL, V8, P1223, DOI 10.1038/ncb1486; Geletu Mulu, 2013, JAKSTAT, V2, pe27363, DOI 10.4161/jkst.27363; Guy S, 2014, CANCERS, V6, P646, DOI 10.3390/cancers6020646; Haapaniemi EM, 2015, BLOOD, V125, P639, DOI 10.1182/blood-2014-04-570101; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; KALINER M, 1981, J ALLERGY CLIN IMMUN, V68, P365, DOI 10.1016/0091-6749(81)90134-2; Kang NI, 2011, J IMMUNOL, V186, P6625, DOI 10.4049/jimmunol.1100007; Kawada M, 2006, CANCER RES, V66, P2913, DOI 10.1158/0008-5472.CAN-05-3460; KIRSCH CM, 1992, EXP LUNG RES, V18, P447, DOI 10.3109/01902149209064339; KOTLIKOFF MI, 1987, AM J PHYSIOL, V253, pC561, DOI 10.1152/ajpcell.1987.253.4.C561; Kuehn HS, 2008, CELL SIGNAL, V20, P625, DOI 10.1016/j.cellsig.2007.11.016; Lee KS, 2006, MOL PHARMACOL, V69, P1829, DOI 10.1124/mol.106.022228; Lien WH, 2014, GENE DEV, V28, P1517, DOI 10.1101/gad.244772.114; Matsumiya T, 2001, EXP CELL RES, V269, P35, DOI 10.1006/excr.2001.5300; MCKINLEY D, 1992, GENOMICS, V13, P814, DOI 10.1016/0888-7543(92)90158-O; Menge T, 2013, STEM CELLS DEV, V22, P148, DOI 10.1089/scd.2012.0165; Milner JD, 2015, BLOOD, V125, P591, DOI 10.1182/blood-2014-09-602763; MITSUHATA H, 1995, J CLIN IMMUNOL, V15, P277, DOI 10.1007/BF01541317; Nemeth MJ, 2007, P NATL ACAD SCI USA, V104, P15436, DOI 10.1073/pnas.0704747104; Olivera A, 2010, J CLIN INVEST, V120, P1429, DOI 10.1172/JCI40659; Pal S, 2001, CANCER RES, V61, P6952; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Qin GJ, 2006, P NATL ACAD SCI USA, V103, P11015, DOI 10.1073/pnas.0509533103; Redell MS, 2011, BLOOD, V117, P5701, DOI 10.1182/blood-2010-04-280123; Rosenbluh J, 2014, TRENDS PHARMACOL SCI, V35, P103, DOI 10.1016/j.tips.2013.11.007; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; Sidibe A, 2014, NAT IMMUNOL, V15, P215, DOI 10.1038/ni.2825; Siegel AM, 2013, J ALLERGY CLIN IMMUN, V132, P1388, DOI 10.1016/j.jaci.2013.08.045; Snyder-Talkington BN, 2013, PART FIBRE TOXICOL, V10, DOI 10.1186/1743-8977-10-35; Steward-Tharp SM, 2014, BLOOD, V123, P2978, DOI 10.1182/blood-2013-09-523167; Takeda K, 1998, J IMMUNOL, V161, P4652; VALONE FH, 1987, BIOCHEM J, V247, P669, DOI 10.1042/bj2470669; van Amerongen R, 2012, DEV BIOL, V369, P101, DOI 10.1016/j.ydbio.2012.06.020; van Haaften G, 2010, GENE DEV, V24, P1, DOI 10.1101/gad.1887110; Wallez Y, 2007, ONCOGENE, V26, P1067, DOI 10.1038/sj.onc.1209855; Wei LH, 2013, J CLIN ENDOCR METAB, V98, pE472, DOI 10.1210/jc.2012-3462; Weis S, 2004, J CELL BIOL, V167, P223, DOI 10.1083/jcb.200408130; Xie W, 2009, J CELL MOL MED, V13, P1719, DOI 10.1111/j.1582-4934.2008.00423.x	52	38	39	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2016	138	1					187	199		10.1016/j.jaci.2015.11.024	http://dx.doi.org/10.1016/j.jaci.2015.11.024			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DR1IL	26948077	Green Accepted, Bronze			2022-12-18	WOS:000379659100021
J	Siroux, V; Boudier, A; Dolgopoloff, M; Chanoine, S; Bousquet, J; Gormand, F; Just, J; Le Moual, N; Nadif, R; Pison, C; Varraso, R; Matran, R; Pin, I				Siroux, Valerie; Boudier, Anne; Dolgopoloff, Maia; Chanoine, Sebastien; Bousquet, Jean; Gormand, Frederic; Just, Jocelyne; Le Moual, Nicole; Nadif, Rachel; Pison, Christophe; Varraso, Raphaelle; Matran, Regis; Pin, Isabelle			Forced midexpiratory flow between 25% and 75% of forced vital capacity is associated with long-term persistence of asthma and poor asthma outcomes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; small airways; FEF25-75; epidemiology; longitudinal	SMALL-AIRWAYS DYSFUNCTION; EXPIRATORY FLOW; LUNG-FUNCTION; CLINICAL EXPRESSION; OSCILLOMETRY; SEVERITY; SYMPTOMS; EXPOSURE; DECLINE	Background: Whether small-airway obstruction contributes to the long-term evolution of asthma remains unknown. Objectives: Our aim was to assess whether the level of forced midexpiratory flow between 25% and 75% of forced vital capacity (FEF25-75) was associated with the persistence of current asthma over 20 years and the subsequent risk for uncontrolled asthma independently of FEV1. Methods: We studied 337 participants (142 children and 225 adults) with current asthma (asthma attacks or treatment in the past 12 months) recruited to the Epidemiological Study on the Genetics and Environment of Asthma (EGEA1) and followed up at the 12- and 20-year surveys. Persistent current asthma was defined by current asthma reported at each survey. A lung function test and a methacholine challenge test were performed at EGEA1 and EGEA2. Adjusted odds ratios (ORs) were estimated for FEF25-75 decreased by 10% of predicted value. Results: A reduced level of FEF25-75 at EGEA1 increased the risk of long-term asthma persistence (adjusted OR, 1.14; 95% CI, 1.00-1.29). In children the association remained significant after further adjustment for FEV1 and in participants with FEV1 of greater than 80% of predicted value. A reduced FEF25-75 level at EGEA1 was significantly associated with more severe bronchial hyperresponsiveness (P <.0001) and with current asthma a decade later, with an association that tended to be stronger in those with (adjusted OR, 1.44; 95% CI, 1.14-1.81) compared with those without (adjusted OR, 1.21; 95% CI, 1.05-1.41) asthma exacerbation. Conclusion: Our analysis is the first to suggest that small-airway obstruction, as assessed based on FEF25-75, might contribute to the long-term persistence of asthma and the subsequent risk for poor asthma outcomes independently from effects of the large airways.	[Siroux, Valerie; Boudier, Anne; Dolgopoloff, Maia; Chanoine, Sebastien; Pin, Isabelle] Univ Grenoble Alpes, Team Environm Epidemiol Appl Reprod & Resp Hlth, IAB, Grenoble, France; [Siroux, Valerie; Boudier, Anne; Dolgopoloff, Maia; Chanoine, Sebastien; Pin, Isabelle] INSERM, IAB, Team Environm Epidemiol Appl Reprod & Resp Hlth, Grenoble, France; [Siroux, Valerie; Boudier, Anne; Dolgopoloff, Maia; Chanoine, Sebastien; Pin, Isabelle] CHU Grenoble, IAB, Team Environm Epidemiol Appl Reprod & Resp Hlth, F-38043 Grenoble, France; [Bousquet, Jean; Le Moual, Nicole; Nadif, Rachel; Varraso, Raphaelle] INSERM, U1168, VIMA Aging & Chron Dis, Epidemiol & Publ Hlth Approaches, Villejuif, France; [Bousquet, Jean; Le Moual, Nicole; Nadif, Rachel; Varraso, Raphaelle] Univ Versailles St Quentin En Yvelines, UMR S 1168, Montigny Le Bretonneux, France; [Bousquet, Jean] Univ Hosp, Montpellier, France; [Bousquet, Jean] MeDALL Mech Dev Allergy, FP7, Montpellier, France; [Gormand, Frederic] CHU Lyon, Dept Pneumol, Lyon, France; [Just, Jocelyne] Hop Armand Trousseau, AP HP, Dept Allergol, Paris, France; [Just, Jocelyne] Univ Paris 06, Paris, France; [Pison, Christophe] CHU Grenoble, Clin Univ Pneumol, Pole Cancerol Med Aigue & Communautaire, F-38043 Grenoble, France; [Pison, Christophe] Inserm 1055, Grenoble, France; [Pison, Christophe] Univ Joseph Fourier, Grenoble, France; [Matran, Regis] Univ Lille Nord France, Lille, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CHU Grenoble Alpes; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; Universite de Montpellier; CHU de Montpellier; CHU Lyon; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Universite de Lille - ISITE; Universite de Lille	Siroux, V (corresponding author), Univ Joseph Fourrier, Inst Albert Boniot, INSERM,U823, Equipe Epidemiol Environm Appl Reprod & Sante Res, F-38706 La Tronche, France.	Valerie.siroux@ujf-grenoble.fr	Varraso, Raphaelle/R-8740-2016; Le Moual, Nicole/R-8976-2016; siroux, valerie/N-1865-2013; PIN, Isabelle/N-3020-2013; Le Moual, Nicole/GNP-5114-2022; GORMAND, FREDERIC/I-1414-2017; Nadif, Rachel/R-2876-2016; Bousquet, Jean/O-4221-2019	Varraso, Raphaelle/0000-0002-3338-7825; Le Moual, Nicole/0000-0002-2723-5569; siroux, valerie/0000-0001-7329-7237; Le Moual, Nicole/0000-0002-2723-5569; Nadif, Rachel/0000-0003-4938-9339; 				Bourdin A, 2006, ALLERGY, V61, P85, DOI 10.1111/j.1398-9995.2006.00970.x; Chinn S, 1997, EUR RESPIR J, V10, P2495, DOI 10.1183/09031936.97.10112495; De Backer W, 2010, J AEROSOL MED PULM D, V23, P137, DOI 10.1089/jamp.2009.0772; de Jong K, 2014, AM J RESP CRIT CARE, V189, P487, DOI 10.1164/rccm.201310-1919LE; Downs SH, 2007, NEW ENGL J MED, V357, P2338, DOI 10.1056/NEJMoa073625; Farah CS, 2012, J ALLERGY CLIN IMMUN, V129, P381, DOI 10.1016/j.jaci.2011.11.017; Hamid Q, 1997, J ALLERGY CLIN IMMUN, V100, P44, DOI 10.1016/S0091-6749(97)70193-3; Jenkins M A, 1993, Paediatr Perinat Epidemiol, V7, P67, DOI 10.1111/j.1365-3016.1993.tb00602.x; KAUFFMANN F, 1995, CLIN EXP ALLERGY, V25, P19, DOI 10.1111/j.1365-2222.1995.tb00413.x; Le Moual N, 2005, AM J RESP CRIT CARE, V172, P440, DOI 10.1164/rccm.200501-111OC; Lipworth B, 2014, LANCET RESP MED, V2, P497, DOI 10.1016/S2213-2600(14)70103-1; Lipworth B, 2013, ANN ALLERG ASTHMA IM, V110, P233, DOI 10.1016/j.anai.2013.02.009; Manoharan A, 2014, EUR RESPIR J, V44, P1353, DOI 10.1183/09031936.00082314; McFadden ER, 2010, J ALLERGY CLIN IMMUN, V126, P535, DOI 10.1016/j.jaci.2010.06.035; MCFADDEN ER, 1972, AM J MED, V52, P725, DOI 10.1016/0002-9343(72)90078-2; MEAD J, 1970, NEW ENGL J MED, V282, P1318, DOI 10.1056/NEJM197006042822311; Moshammer H, 2006, AM J RESP CRIT CARE, V173, P1255, DOI 10.1164/rccm.200510-1552OC; Postma DS, 2015, EUR RESPIR J, V45, P1534, DOI 10.1183/09031936.00214314; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; Quanjer PH, 2012, EUR RESPIR J, V40, P1324, DOI 10.1183/09031936.00080312; Rao DR, 2012, J ASTHMA, V49, P586, DOI 10.3109/02770903.2012.690481; Robinson PD, 2015, J HEART LUNG TRANSPL, V34, P1082, DOI 10.1016/j.healun.2015.03.010; Rosen JB, 2012, J HEART LUNG TRANSPL, V31, P1288, DOI 10.1016/j.healun.2012.09.010; Sanchez M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065090; Scichilone N, 2010, ALLERGY, V65, P897, DOI 10.1111/j.1398-9995.2009.02306.x; Shi YX, 2013, J ALLERGY CLIN IMMUN, V131, P718, DOI 10.1016/j.jaci.2012.09.022; Shi YX, 2012, J ALLERGY CLIN IMMUN, V129, P671, DOI 10.1016/j.jaci.2011.11.002; Simon MR, 2010, J ALLERGY CLIN IMMUN, V126, P527, DOI 10.1016/j.jaci.2010.05.016; Simon MR, 2010, J ALLERGY CLIN IMMUN, V126, pe1; Siroux V, 2009, J ALLERGY CLIN IMMUN, V124, P681, DOI 10.1016/j.jaci.2009.06.010; Takeda T, 2010, RESPIRATION, V80, P120, DOI 10.1159/000242113; Telenga ED, 2013, EUR RESPIR J, V41, P752, DOI 10.1183/09031936.00170912; van der Wiel E, 2014, ALLERGY, V69, P1681, DOI 10.1111/all.12510; van der Wiel E, 2013, J ALLERGY CLIN IMMUN, V131, P646, DOI 10.1016/j.jaci.2012.12.1567; Varraso R, 2013, EUR RESPIR J, V42, P983; Verbanck S, 2012, RESPIRATION, V84, P177, DOI 10.1159/000341742; Xiao YSR, 2012, J DATA SCI, V10, P465	37	38	41	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2016	137	6					1709	+	e6	10.1016/j.jaci.2015.10.029	http://dx.doi.org/10.1016/j.jaci.2015.10.029			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DO1GT	26688518	Bronze			2022-12-18	WOS:000377527200010
J	Jones, AL; Curran-Everett, D; Leung, DYM				Jones, Andrea L.; Curran-Everett, Douglas; Leung, Donald Y. M.			Food allergy is associated with Staphylococcus aureus colonization in children with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							PEANUT ALLERGY; EXPOSURE; SKIN		[Jones, Andrea L.; Curran-Everett, Douglas; Leung, Donald Y. M.] Natl Jewish Hlth, Dept Pediat, Denver, CO USA; [Curran-Everett, Douglas; Leung, Donald Y. M.] Natl Jewish Hlth, Div Biostat & Bioinformat, Denver, CO USA; [Leung, Donald Y. M.] Univ Colorado Denver, Dept Pediat, Aurora, CO USA; [Leung, Donald Y. M.] Hlth Sci Ctr, Aurora, CO USA	National Jewish Health; National Jewish Health; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Leung, DYM (corresponding author), Natl Jewish Hlth, Dept Pediat, Denver, CO USA.; Leung, DYM (corresponding author), Natl Jewish Hlth, Div Biostat & Bioinformat, Denver, CO USA.; Leung, DYM (corresponding author), Univ Colorado Denver, Dept Pediat, Aurora, CO USA.; Leung, DYM (corresponding author), Hlth Sci Ctr, Aurora, CO USA.	leungd@njhealth.org		Curran-Everett, Douglas/0000-0001-5992-4839				Brough HA, 2015, J ALLERGY CLIN IMMUN, V135, P164, DOI 10.1016/j.jaci.2014.10.007; Brough HA, 2014, J ALLERGY CLIN IMMUN, V134, P867, DOI 10.1016/j.jaci.2014.08.011; Forbes-Blom E, 2012, CLIN EXP ALLERGY, V42, P305, DOI 10.1111/j.1365-2222.2011.03861.x; Ganeshan K, 2009, J ALLERGY CLIN IMMUN, V123, P231, DOI 10.1016/j.jaci.2008.10.011; Jones SM, 2014, J ALLERGY CLIN IMMUN, V133, P318, DOI 10.1016/j.jaci.2013.12.1040; Leung DYM, 2014, J ALLERGY CLIN IMMUN, V134, P769, DOI 10.1016/j.jaci.2014.08.008; Merkel PA, 2015, J ALLER CL IMM-PRACT, V3, P973, DOI 10.1016/j.jaip.2015.06.004; Roberts G, 2005, J ALLERGY CLIN IMMUN, V115, P1291, DOI 10.1016/j.jaci.2005.02.038; Schlievert PM, 2010, J ALLERGY CLIN IMMUN, V125, P39, DOI 10.1016/j.jaci.2009.10.039; Sicherer SH, 2014, J ALLERGY CLIN IMMUN, V133, P291, DOI 10.1016/j.jaci.2013.11.020	10	38	41	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2016	137	4					1247	1248		10.1016/j.jaci.2016.01.010	http://dx.doi.org/10.1016/j.jaci.2016.01.010			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DI2TG	26960580	Bronze			2022-12-18	WOS:000373351200033
J	Mirkovic, B; Lavelle, GM; Azim, AA; Helma, K; Gargoum, FS; Molloy, K; Gernez, Y; Dunne, K; Renwick, J; Murphy, P; Moss, RB; Greene, CM; Gunaratnam, C; Chotirmall, SH; McElvaney, NG				Mirkovic, Bojana; Lavelle, Gillian M.; Azim, Ahmed Abdul; Helma, Kristine; Gargoum, Fatma S.; Molloy, Kevin; Gernez, Yael; Dunne, Katie; Renwick, Julie; Murphy, Philip; Moss, Richard B.; Greene, Catherine M.; Gunaratnam, Cedric; Chotirmall, Sanjay H.; McElvaney, Noel G.			The basophil surface marker CD203c identifies Aspergillus species sensitization in patients with cystic fibrosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic bronchopulmonary aspergillosis; Aspergillus fumigatus; basophil activation test; body mass index; CD203c; cystic fibrosis; flow cytometry; FEV1; itraconazole; sensitization	ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ACTIVATION TEST; LUNG-FUNCTION; FUMIGATUS; IGE; STATE; IMPAIRMENT; INFECTION; CONSENSUS; AIRWAY	Background: Colonization by Aspergillus fumigatus in patients with cystic fibrosis (CF) can cause A fumigatus sensitization and/or allergic bronchopulmonary aspergillosis (ABPA), which affects pulmonary function and clinical outcomes. Recent studies show that specific allergens upregulate the surface-expressed basophil marker CD203c in sensitized subjects, a response that can be readily measured by using flow cytometry. Objective: We sought to identify A fumigatus sensitization in patients with CF by using the basophil activation test (BAT). Methods: Patients with CF attending Beaumont Hospital were screened for study inclusion. BAT was used to identify A fumigatus sensitization. Serologic (total and A fumigatus-specific IgE), pulmonary function, and body mass index measurements were performed. Results: The BAT discriminates A fumigatus-sensitized from nonsensitized patients with CF. Persistent isolation of A fumigatus in sputum is a significant risk factor for A fumigatus sensitization. Levels of the A fumigatus-stimulated basophil activation marker CD203c inversely correlated with pulmonary function and body mass index in A fumigatus-sensitized but not nonsensitized patients with CF. Total and A fumigatus-specific IgE, but not IgG, levels are increased in A fumigatus-sensitized patients with CF and ABPA when compared with those in A fumigatus-sensitized and nonsensitized patients with CF without ABPA. Itraconazole treatment did not affect A fumigatus sensitization. Conclusion: Combining the BAT with routine serologic testing allows classification of patients with CF into 3 groups: nonsensitized, A fumigatus-sensitized, and ABPA. Accurate and prompt identification of A fumigatus-associated clinical status might allow early and targeted therapeutic intervention, potentially improving clinical outcomes.	[Mirkovic, Bojana; Lavelle, Gillian M.; Azim, Ahmed Abdul; Helma, Kristine; Gargoum, Fatma S.; Molloy, Kevin; Greene, Catherine M.; Gunaratnam, Cedric; McElvaney, Noel G.] Beaumont Hosp, Royal Coll Surg Ireland, Dept Med, Resp Res Div, Dublin 9, Ireland; [Gernez, Yael] Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; [Moss, Richard B.] Stanford Univ, Sch Med, Dept Paediat, Ctr Excellence Pulm Biol, Stanford, CA 94305 USA; [Dunne, Katie; Renwick, Julie; Murphy, Philip] Trinity Coll Dublin, Dept Clin Microbiol, Dublin, Ireland; [Chotirmall, Sanjay H.] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore 639798, Singapore	Royal College of Surgeons - Ireland; Stanford University; Stanford University; Trinity College Dublin; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University	Chotirmall, SH (corresponding author), Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore 639798, Singapore.	schotirmall@ntu.edu.sg	Abdul Azim, Ahmed/GRS-0120-2022; McElvaney, Noel/A-6809-2010; Moss, Richard B./S-9218-2019; Greene, Catherine M/D-3513-2012; Chotirmall, Sanjay Haresh/K-4127-2015	Moss, Richard B./0000-0003-3611-4221; Greene, Catherine M/0000-0003-2549-2569; Chotirmall, Sanjay Haresh/0000-0003-0417-7607; mcelvaney, Noel/0000-0002-0152-4370; Dunne, Katie/0000-0002-5426-7419; Abdul Azim, Ahmed/0000-0001-7940-4320	Science Foundation Ireland via a United States-Ireland partnership [SFI/08/US/B1676]; US Cystic Fibrosis Foundation	Science Foundation Ireland via a United States-Ireland partnership(Science Foundation Ireland); US Cystic Fibrosis Foundation	Supported by Science Foundation Ireland via a United States-Ireland partnership (grant no. SFI/08/US/B1676) and by the US Cystic Fibrosis Foundation.	Alesina R, 2014, ALLERGOL IMMUNOPATH, V42, P171, DOI 10.1016/j.aller.2012.09.002; Amin R, 2010, CHEST, V137, P171, DOI 10.1378/chest.09-1103; Bafadhel M, 2014, EUR RESPIR J, V43, P64, DOI 10.1183/09031936.00162912; Balzer L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108619; Baxter CG, 2013, J ALLERGY CLIN IMMUN, V132, P560, DOI 10.1016/j.jaci.2013.04.007; Baxter CG, 2013, CHEST, V143, P1351, DOI 10.1378/chest.12-1363; Bergin DA, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007116; Boonsarngsuk V, 2010, SCAND J INFECT DIS, V42, P461, DOI 10.3109/00365541003602064; BOUSQUET J, 1987, CLIN ALLERGY, V17, P529, DOI 10.1111/j.1365-2222.1987.tb02049.x; Brusasco V, 2005, EUR RESPIR J, V26, P1, DOI 10.1183/09031936.05.00034205; Chauhan B, 1997, J IMMUNOL, V159, P4072; Chauhan B, 1996, J CLIN INVEST, V97, P2324, DOI 10.1172/JCI118675; Chirumbolo S, 2012, INT ARCH ALLERGY IMM, V158, P99, DOI 10.1159/000331312; Chmiel James F, 2014, Ann Am Thorac Soc, V11, P1298, DOI 10.1513/AnnalsATS.201405-203AS; Chotirmall SH, 2014, MYCOPATHOLOGIA, V178, P363, DOI 10.1007/s11046-014-9768-y; Chotirmall SH, 2014, INT J BIOCHEM CELL B, V52, P161, DOI 10.1016/j.biocel.2014.03.001; Chotirmall SH, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/723129; Chotirmall SH, 2008, RESP CARE, V53, P1035; Cohen-Cymberknoh M, 2009, J CYST FIBROS, V8, P253, DOI 10.1016/j.jcf.2009.04.008; Coughlan CA, 2012, AM J RESP CRIT CARE, V186, P999, DOI 10.1164/rccm.201203-0478OC; Delhaes L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036313; Denning DW, 2014, CLIN TRANSL ALLERGY, V4, DOI 10.1186/2045-7022-4-14; Fillaux J, 2012, SCAND J INFECT DIS, V44, P842, DOI 10.3109/00365548.2012.695454; Gernez Y, 2012, J CYST FIBROS, V11, P502, DOI 10.1016/j.jcf.2012.04.008; Gernez Y, 2012, J CLIN IMMUNOL, V32, P565, DOI 10.1007/s10875-012-9651-x; Gernez Y, 2011, INT ARCH ALLERGY IMM, V154, P318, DOI 10.1159/000321824; Knutsen Alan P, 2006, Clin Mol Allergy, V4, P3, DOI 10.1186/1476-7961-4-3; Knutsen AP, 2012, J ALLERGY CLIN IMMUN, V129, P280, DOI 10.1016/j.jaci.2011.12.970; Kousha M, 2011, EUR RESPIR REV, V20, P156, DOI 10.1183/09059180.00001011; McMahon MA, 2012, EUR J RADIOL, V81, pE197, DOI 10.1016/j.ejrad.2011.01.114; Menzies D, 2011, ALLERGY, V66, P679, DOI 10.1111/j.1398-9995.2010.02542.x; Mortensen KL, 2011, J CLIN MICROBIOL, V49, P2243, DOI 10.1128/JCM.00213-11; Nepomuceno IB, 1999, CHEST, V115, P364, DOI 10.1378/chest.115.2.364; Niederberger V, 2001, J INVEST DERMATOL, V117, P848, DOI 10.1046/j.0022-202x.2001.01470.x; Peetermans M, 2014, CHEST, V146, pE99, DOI 10.1378/chest.14-0635; Pohl K, 2014, BLOOD, V124, P999, DOI 10.1182/blood-2014-02-555268; Rodriguez-Trabado A, 2008, ALLERGY ASTHMA PROC, V29, P241, DOI 10.2500/aap.2008.29.3114; Sabino R, 2015, J CYST FIBROS, V14, P474, DOI 10.1016/j.jcf.2014.10.005; Santos AF, 2014, J ALLERGY CLIN IMMUN, V134, P645, DOI 10.1016/j.jaci.2014.04.039; Schoos AMM, 2015, ALLERGY, V70, P41, DOI 10.1111/all.12523; Sharma R, 2001, THORAX, V56, P746, DOI 10.1136/thorax.56.10.746; Sokol CL, 2010, MUCOSAL IMMUNOL, V3, P129, DOI 10.1038/mi.2009.137; Stevens DA, 2003, CLIN INFECT DIS, V37, pS225, DOI 10.1086/376525; Tunnicliffe G, 2013, RESP MED, V107, P1113, DOI 10.1016/j.rmed.2013.03.016; Valent P, 2004, METHODS, V32, P265, DOI 10.1016/j.ymeth.2003.08.006; Zandijk E, 2008, CLIN VACCINE IMMUNOL, V15, P1132, DOI 10.1128/CVI.00022-08	46	38	40	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2016	137	2					436	+		10.1016/j.jaci.2015.07.045	http://dx.doi.org/10.1016/j.jaci.2015.07.045			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DC5BN	26388311	Green Submitted, Green Accepted			2022-12-18	WOS:000369235500012
J	Schmid, JM; Wurtzen, PA; Dahl, R; Hoffmann, HJ				Schmid, Johannes Martin; Wurtzen, Peter Adler; Dahl, Ronald; Hoffmann, Hans Jurgen			Pretreatment IgE sensitization patterns determine the molecular profile of the IgG(4) response during updosing of subcutaneous immunotherapy with timothy grass pollen extract	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Grass pollen allergy; subcutaneous immunotherapy; component-resolved diagnosis; allergen component-specific IgE; allergen component-specific IgG(4); molecular allergy; allergen immunotherapy biomarker	FACILITATED ANTIGEN PRESENTATION; ALLERGEN-SPECIFIC IMMUNOTHERAPY; PHLEUM-PRATENSE; SKIN-TEST; THRESHOLD-SENSITIVITY; DOUBLE-BLIND; VACCINATION; SERUM; INHIBITION; RHINITIS	Background: Allergen immunotherapy is an effective treatment of allergic rhinoconjunctivitis. Clinical efficacy is associated with improvement of basophil sensitivity and an increase in allergen-specific immunoglobulin concentration. Objective: We sought to determine whether changes in allergen component-specific serum IgE and IgG(4) levels during the updosing phase of subcutaneous immunotherapy (SCIT) are biomarkers of the immunologic changes that can lead to treatment efficacy. Methods: Twenty-four subjects with grass pollen-induced allergic rhinoconjunctivitis were randomized 3: 1 to receive SCIT (Alutard SQ) or to an open control group. IgE and IgG(4) concentrations were determined for the major allergens Phl p 1 or Phl p 5 by using ImmunoCAP and for 8 grass pollen molecules by using Immuno Solid-phase Allergy Chip (ISAC) before treatment and after updosing. Results: Levels of specific IgE against the dominant major allergens Phl p 1 and Phl p 5 increased from a mean of 23.0 to 48.8 kU/L (P = .01, n = 18) during the updosing phase in ImmunoCAP measurements but decreased from a median of 4.6 ISAC specific units (ISU) to 2.14 ISU (P < .0001, n = 102) when measured by using ISAC against 8 grass allergen components. The updosing phase induced a specific IgG(4) level increase from a median of 0 ISU before treatment to 0.83 ISU after 12 weeks (P < .0001, n = 102) but only for allergen molecules to which pretreatment-specific IgE antibodies were detected (Spearman sigma = 0.72, P < .0001, n = 102). Conclusion: Pretreatment allergen component-specific IgE appears to determine the induction of IgG(4) in the updosing phase. Induced IgG(4) seems to suppress IgE levels on ISAC, resulting in a marked decrease in ISAC-measured specific IgE levels after updosing of SCIT. Thus this decrease in ISAC IgE levels can be used to monitor the blocking effect of allergen-specific immunotherapy-induced non-IgE antibodies.	[Schmid, Johannes Martin; Hoffmann, Hans Jurgen] Aarhus Univ Hosp, Dept Resp Med & Allergy, Norrebrogade 44, DK-8000 Aarhus C, Denmark; [Dahl, Ronald] Aarhus Univ, Dept Clin Med, DK-8000 Aarhus C, Denmark; [Wurtzen, Peter Adler] ALK Abello, Global Res, Horsholm, Denmark; [Dahl, Ronald] Odense Univ Hosp, Allergy Ctr, DK-5000 Odense, Denmark	Aarhus University; Aarhus University; ALK-Abello AS; University of Southern Denmark; Odense University Hospital	Hoffmann, HJ (corresponding author), Aarhus Univ Hosp, Dept Resp Med & Allergy, Norrebrogade 44, DK-8000 Aarhus C, Denmark.	hjh@clin.au.dk	Hoffman, Hans Jurgen/I-6969-2018	Hoffman, Hans Jurgen/0000-0002-6743-7931; Schmid, Johannes/0000-0002-4558-2943	Lundbeck Foundation	Lundbeck Foundation(Lundbeckfonden)	The Lundbeck Foundation funded the study but had no influence on the study design.	Aasbjerg K, 2014, CLIN EXP ALLERGY, V44, P417, DOI 10.1111/cea.12241; Akdis M, 2014, J ALLERGY CLIN IMMUN, V133, P621, DOI 10.1016/j.jaci.2013.12.1088; Asero R, 2005, INT ARCH ALLERGY IMM, V137, P62, DOI 10.1159/000085105; Ball T, 1999, EUR J IMMUNOL, V29, P2026, DOI 10.1002/(SICI)1521-4141(199906)29:06<2026::AID-IMMU2026>3.0.CO;2-2; Baron-Bodo V, 2012, CLIN EXP ALLERGY, V42, P1510, DOI 10.1111/j.1365-2222.2012.04044.x; Bauchau V, 2004, EUR RESPIR J, V24, P758, DOI 10.1183/09031936.04.00013904; Beitia JM, 2014, INT ARCH ALLERGY IMM, V165, P9, DOI 10.1159/000365866; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Bousquet J, 1998, ANN ALLERG ASTHMA IM, V81, P401, DOI 10.1016/S1081-1206(10)63136-5; Burbach GJ, 2009, ALLERGY, V64, P1507, DOI 10.1111/j.1398-9995.2009.02089.x; Calderon MA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001936.pub2; Calderon Moises A, 2012, Clin Transl Allergy, V2, P20, DOI 10.1186/2045-7022-2-20; Canonica GW, 2013, WORLD ALLERGY ORGAN, V6, DOI 10.1186/1939-4551-6-17; Darsow U, 2014, CLIN EXP ALLERGY, V44, P778, DOI 10.1111/cea.12303; Flicker S, 2003, INT ARCH ALLERGY IMM, V132, P13, DOI 10.1159/000073260; Focke M, 2008, CLIN EXP ALLERGY, V38, P1400, DOI 10.1111/j.1365-2222.2008.03031.x; Francis JN, 2008, J ALLERGY CLIN IMMUN, V121, P1120, DOI 10.1016/j.jaci.2008.01.072; Graf N, 2014, RHINOLOGY, V52, P137, DOI [10.4193/Rhin13.145, 10.4193/Rhino13.145]; Hatzler L, 2012, J ALLERGY CLIN IMMUN, V130, P894, DOI 10.1016/j.jaci.2012.05.053; Jahn-Schmid B, 2003, CLIN EXP ALLERGY, V33, P1443, DOI 10.1046/j.1365-2222.2003.01784.x; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; Jutel M, 2014, CURR OPIN ALLERGY CL, V14, P557, DOI 10.1097/ACI.0000000000000121; Klunker S, 2007, J ALLERGY CLIN IMMUN, V120, P688, DOI 10.1016/j.jaci.2007.05.034; Lalek N, 2010, CLIN EXP ALLERGY, V40, P1186, DOI 10.1111/j.1365-2222.2010.03524.x; Linhart B, 2012, VACCINE, V30, P4328, DOI 10.1016/j.vaccine.2011.11.011; Lupinek C, 2014, METHODS, V66, P106, DOI 10.1016/j.ymeth.2013.10.008; Lupinek C, 2012, J ALLERGY CLIN IMMUN, V130, P1418, DOI 10.1016/j.jaci.2012.06.028; Makatsori M, 2013, CURR ALLERGY ASTHM R, V13, P371, DOI 10.1007/s11882-013-0359-7; Mari A, 2003, CLIN EXP ALLERGY, V33, P43, DOI 10.1046/j.1365-2222.2003.01569.x; Martinez-Aranguren R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088394; Matsuoka T, 2013, ALLERGOL INT, V62, P403, DOI 10.2332/allergolint.13-RAI-0650; Nathan RA, 2007, ALLERGY ASTHMA PROC, V28, P3, DOI 10.2500/aap.2007.28.2934; Nopp A, 2006, ALLERGY, V61, P298, DOI 10.1111/j.1398-9995.2006.00987.x; Schmid JM, 2014, J ALLERGY CLIN IMMUN, V134, P741, DOI 10.1016/j.jaci.2014.04.029; Shamji MH, 2011, CLIN EXP ALLERGY, V41, P1235, DOI 10.1111/j.1365-2222.2011.03804.x; Tripodi S, 2009, CLIN EXP ALLERGY, V39, P1225, DOI 10.1111/j.1365-2222.2009.03250.x; Turcanu V, 2010, ALLERGY, V65, P1274, DOI 10.1111/j.1398-9995.2010.02367.x; Valenta R, 2010, ANNU REV IMMUNOL, V28, P211, DOI 10.1146/annurev-immunol-030409-101218; van Neerven RJJ, 1999, J IMMUNOL, V163, P2944; van Neerven RJJ, 2004, CLIN EXP ALLERGY, V34, P420, DOI 10.1111/j.1365-2222.2004.01899.x; VANDERHEIJDEN FL, 1995, CLIN EXP IMMUNOL, V99, P289; vanRee R, 1996, ALLERGY, V51, P108, DOI 10.1111/j.1398-9995.1996.tb00043.x; Wachholz PA, 2003, J ALLERGY CLIN IMMUN, V112, P915, DOI 10.1016/S0091-6749(03)02022-0; Wachholz PA, 2004, CURR OPIN ALLERGY CL, V4, P313, DOI 10.1097/01.all.0000136753.35948.c0; Walker S, 2007, J ALLERGY CLIN IMMUN, V120, P381, DOI 10.1016/j.jaci.2007.03.034; Wilcock LK, 2006, IMMUNOL ALLERGY CLIN, V26, P333, DOI 10.1016/j.iac.2006.02.004; Wurtzen PA, 2008, CLIN EXP ALLERGY, V38, P1290, DOI 10.1111/j.1365-2222.2008.03020.x	47	38	40	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2016	137	2					562	570		10.1016/j.jaci.2015.05.023	http://dx.doi.org/10.1016/j.jaci.2015.05.023			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DC5BN	26141262	Bronze			2022-12-18	WOS:000369235500026
J	Sodikoff, J; Hirano, I				Sodikoff, Jamie; Hirano, Ikuo			Proton pump inhibitor-responsive esophageal eosinophilia does not preclude food-responsive eosinophilic esophagitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SWALLOWED FLUTICASONE; ESOMEPRAZOLE; ADULTS		[Sodikoff, Jamie; Hirano, Ikuo] Northwestern Univ, Feinberg Sch Med, Div Gastroenterol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Hirano, I (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Gastroenterol, Chicago, IL 60611 USA.	i-hirano@northwestern.edu						Dellon ES, 2013, AM J GASTROENTEROL, V108, P1854, DOI 10.1038/ajg.2013.363; Gonsalves N, 2006, GASTROINTEST ENDOSC, V64, P313, DOI 10.1016/j.gie.2006.04.037; Gonsalves N, 2012, GASTROENTEROLOGY, V142, P1451, DOI 10.1053/j.gastro.2012.03.001; Hirano I, 2013, GUT, V62, P489, DOI 10.1136/gutjnl-2011-301817; Kedika RR, 2009, DIGEST DIS SCI, V54, P2312, DOI 10.1007/s10620-009-0951-9; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Moawad FJ, 2013, AM J GASTROENTEROL, V108, P366, DOI 10.1038/ajg.2012.443; Molina-Infante J, 2014, ALIMENT PHARM THER, V40, P955, DOI 10.1111/apt.12914; Molina-Infante J, 2013, ALIMENT PHARM THER, V37, P1157, DOI 10.1111/apt.12332; Molina-Infante J, 2011, CLIN GASTROENTEROL H, V9, P110, DOI 10.1016/j.cgh.2010.09.019; Peterson KA, 2010, DIGEST DIS SCI, V55, P1313, DOI 10.1007/s10620-009-0859-4; Spechler SJ, 2007, AM J GASTROENTEROL, V102, P1301, DOI 10.1111/j.1572-0241.2007.01179.x; van Rhijn BD, 2014, CLIN GASTROENTEROL H, V2	13	38	39	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2016	137	2					631	+		10.1016/j.jaci.2015.07.008	http://dx.doi.org/10.1016/j.jaci.2015.07.008			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DC5BN	26318073	Bronze			2022-12-18	WOS:000369235500040
J	Vinding, RK; Stokholm, J; Chawes, BLK; Bisgaard, H				Vinding, Rebecca K.; Stokholm, Jakob; Chawes, Bo L. K.; Bisgaard, Hans			Blood lipid levels associate with childhood asthma, airway obstruction, bronchial hyperresponsiveness, and aeroallergen sensitization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Blood lipids; asthma; child; respiratory function tests; inflammation	YOUNG-CHILDREN; NONALLERGIC RHINITIS; PULMONARY INFLAMMATION; MYOCARDIAL-INFARCTION; HEART-DISEASE; NITRIC-OXIDE; RISK-FACTORS; CHOLESTEROL; HYPERCHOLESTEROLEMIA; SIMVASTATIN	Background: Studies of children's blood lipid profiles in relation to asthma are few, and the results are ambiguous. Objective: We sought to examine whether the lipid profile is associated with concurrent asthma, altered lung function, and allergic sensitization in children. Methods: High-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and triglyceride levels were measured at ages 5 to 7 years in the Copenhagen Prospective Studies on Asthma in Childhood(2000) at-risk birth cohort. Asthma and allergic rhinitis were diagnosed based on predefined algorithms at age 7 years along with assessments of lung function, bronchial responsiveness, fraction of exhaled nitric oxide (FENO), and allergic sensitization. Associations between lipid levels and clinical outcomes were adjusted for sex, passive smoking, and body mass index. Results: High levels of low-density lipoprotein cholesterol were associated with concurrent asthma (adjusted odds ratio [aOR], 1.93; 95% CI, 1.06-3.55; P=.03) and airway obstruction: 50% of forced expiratory flow (a beta coefficient, -0.13 L/s; 95% CI, -0.24 to -0.03 L/s; P = .01) and specific airway resistance (a beta coefficient, 0.06 kPa/s; 95% CI, 0.00-0.11 kPa/s; P = .05). High levels of high-density lipoprotein cholesterol were associated with improved specific airway resistance (a beta coefficient, -0.11 kPa/s; 95% CI, -0.21 to -0.02; P = .02), decreased bronchial responsiveness (a beta coefficient, 0.53 log-mu mol; 95% CI, 0.00-1.60 log-mmol; P = .05), decreased risk of aeroallergen sensitization aOR, 0.27; 95% CI, 0.01-0.70; P = .01), and a trend of reduced FENO levels (a beta coefficient, -0.22 log-ppb; 95% CI, -0.50 to 0.01 log-ppb; P = .06). High triglyceride levels were associated with aeroallergen sensitization (aOR, 2.01; 95% CI, 1.14-3.56; P=.02) and a trend of increased FENO levels (a beta coefficient, 0.14 log-ppb; 95% CI, -0.02 to 0.30 log-ppb; P = .08). Conclusion: The blood lipid profile is associated with asthma, airway obstruction, bronchial responsiveness, and aeroallergen sensitization in 7-year-old children. These findings suggest that asthma and allergy are systemic disorders with commonalities with other chronic inflammatory disorders.	[Vinding, Rebecca K.; Stokholm, Jakob; Chawes, Bo L. K.; Bisgaard, Hans] Univ Copenhagen, Herlev & Gentofte Hosp, Copenhagen Prospect Studies Asthma Childhood, COPSAC, Copenhagen, Denmark; [Vinding, Rebecca K.; Stokholm, Jakob] Naestved Hosp, Dept Pediat, Naestved, Denmark	University of Copenhagen; Naestved Hospital	Bisgaard, H (corresponding author), Univ Copenhagen, Herlev & Gentofte Hosp, Copenhagen Prospect Studies Asthma Childhood, COPSAC, Ledreborg Alle 34, DK-2820 Gentofte, Denmark.	bisgaard@copsac.com	Bisgaard, Hans/N-4761-2016	Bisgaard, Hans/0000-0003-4131-7592; Chawes, Bo/0000-0001-6846-6243; Vinding, Rebecca Kofod/0000-0002-7680-3040; Stokholm, Jakob/0000-0003-4989-9769	COPSAC; Lundbeck Foundation [R16-A1694]; Ministry of Health [903516]; Danish Council for Strategic Research; Capital Region Research Foundation; Thrasher Research Award	COPSAC; Lundbeck Foundation(Lundbeckfonden); Ministry of Health; Danish Council for Strategic Research(Danske Strategiske Forskningsrad (DSF)); Capital Region Research Foundation; Thrasher Research Award	COPSAC is funded by private and public research funds all listed on www.copsac.com.; The Lundbeck Foundation (R16-A1694), The Ministry of Health (903516), Danish Council for Strategic Research, and Capital Region Research Foundation have provided core support for COPSAC. B.L.K.C. was supported by the Thrasher Research Award. The funding agencies did not have any influence on study design, data collection and analysis, decision to publish or preparation of the manuscript. Thermo Fisher Scientific Inc sponsored the IgE analyses. No pharmaceutical company was involved in the study. The funding agencies did not have any role in design and conduct of the study; collection, management, and interpretation of the data; or preparation, review, or approval of the manuscript.	Agouridis AP, 2011, ANN GASTROENTEROL, V24, P181; Al-Shawwa B, 2006, J ASTHMA, V43, P231, DOI 10.1080/02770900600567056; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Baldan A, 2008, J IMMUNOL, V180, P3560, DOI 10.4049/jimmunol.180.5.3560; Baumruker T, 2003, INT IMMUNOL, V15, P1207, DOI 10.1093/intimm/dxg120; Bisgaard H, 2005, CHEST, V128, P355, DOI 10.1378/chest.128.1.355; Bisgaard H, 2004, ANN ALLERG ASTHMA IM, V93, P381, DOI 10.1016/S1081-1206(10)61398-1; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; Bisgaard H, 1995, EUR RESPIR J, V8, P2067, DOI 10.1183/09031936.95.08122067; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Bisgaard H, 2011, J ALLERGY CLIN IMMUN, V127, P1155, DOI 10.1016/j.jaci.2011.02.007; Borba EF, 2006, CLIN DEV IMMUNOL, V13, P203, DOI 10.1080/17402520600876945; Brown CD, 2000, OBES RES, V8, P605, DOI 10.1038/oby.2000.79; Buchvald F, 2005, J ALLERGY CLIN IMMUN, V115, P1130, DOI 10.1016/j.jaci.2005.03.020; Buchvald F, 2001, AM J RESP CRIT CARE, V163, P699, DOI 10.1164/ajrccm.163.3.2004233; Canto JG, 2012, AM J CARDIOL, V110, P1256, DOI 10.1016/j.amjcard.2012.06.025; Catapano AL, 2011, ATHEROSCLEROSIS, V217, P3, DOI 10.1016/j.atherosclerosis.2011.06.028; Chawes BLK, 2009, ALLERGY, V64, P1547, DOI 10.1111/j.1398-9995.2009.02085.x; Chawes BLK, 2011, DAN MED BULL, V58; Chawes BLK, 2010, J ALLERGY CLIN IMMUN, V126, P567, DOI 10.1016/j.jaci.2010.06.026; Chen YC, 2013, DIABETES METAB SYND, V7, P20, DOI 10.1016/j.dsx.2013.02.026; Cottrell L, 2011, AM J RESP CRIT CARE, V183, P441, DOI 10.1164/rccm.201004-0603OC; Cowan DC, 2010, THORAX, V65, P891, DOI 10.1136/thx.2010.138990; de Onis Mercedes, 2004, Food Nutr Bull, V25, pS15; Engstrom G, 2002, CIRCULATION, V105, P2632, DOI 10.1161/01.CIR.0000017327.69909.FF; Fessler MB, 2009, J ALLERGY CLIN IMMUN, V124, P967, DOI 10.1016/j.jaci.2009.08.005; Iribarren C, 2012, AM J EPIDEMIOL, V176, P1014, DOI 10.1093/aje/kws181; Jeppesen J, 1997, ARTERIOSCL THROM VAS, V17, P1114, DOI 10.1161/01.ATV.17.6.1114; Kim Shin-Hee, 2014, Ann Pediatr Endocrinol Metab, V19, P191, DOI 10.6065/apem.2014.19.4.191; Litonjua AA, 2008, J ALLERGY CLIN IMMUN, V121, P1075, DOI 10.1016/j.jaci.2008.03.005; Loland L, 2008, CHEST, V133, P115, DOI 10.1378/chest.07-1328; McKay A, 2004, J IMMUNOL, V172, P2903, DOI 10.4049/jimmunol.172.5.2903; Mora S, 2008, CIRCULATION, V118, P993, DOI 10.1161/CIRCULATIONAHA.108.777334; Nielsen KG, 2001, AM J RESP CRIT CARE, V164, P554, DOI 10.1164/ajrccm.164.4.2006119; Patel RV, 2011, J GEN INTERN MED, V26, P1036, DOI 10.1007/s11606-011-1698-5; Robertson AKL, 2004, SCAND J IMMUNOL, V59, P285, DOI 10.1111/j.0300-9475.2004.01403.x; Sevelsted A, 2015, PEDIATRICS, V135, pE92, DOI 10.1542/peds.2014-0596; Shore SA, 2008, J ALLERGY CLIN IMMUN, V121, P1087, DOI 10.1016/j.jaci.2008.03.004; Stokes KY, 2002, FREE RADICAL BIO MED, V33, P1026, DOI 10.1016/S0891-5849(02)01015-8; Tse SM, 2013, AM J RESP CRIT CARE, V188, P1076, DOI 10.1164/rccm.201306-1017OC; Vijayakumar J, 2013, J NUCL CARDIOL, V20, P385, DOI 10.1007/s12350-013-9697-z; Yeh YF, 2004, J BIOMED SCI, V11, P599, DOI 10.1007/BF02256124; Yiallouros PK, 2014, INT ARCH ALLERGY IMM, V165, P91, DOI 10.1159/000368405	43	38	40	2	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2016	137	1					68	+		10.1016/j.jaci.2015.05.033	http://dx.doi.org/10.1016/j.jaci.2015.05.033			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DA3UK	26148797	Bronze			2022-12-18	WOS:000367724300045
J	Odio, CD; Milligan, KL; McGowan, K; Spergel, AKR; Bishop, R; Boris, L; Urban, A; Welch, P; Heller, T; Kleiner, D; Jackson, MA; Holland, SM; Freeman, AF				Odio, Camila D.; Milligan, Ki Lee; McGowan, Katherine; Spergel, Amanda K. Rudman; Bishop, Rachel; Boris, Lisa; Urban, Amanda; Welch, Pamela; Heller, Theo; Kleiner, David; Jackson, Mary Anne; Holland, Steven M.; Freeman, Alexandra F.			Endemic mycoses in patients with STAT3-mutated hyper-IgE (Job) syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INHALED CORTICOSTEROIDS; ASTHMA; ADHERENCE		[Odio, Camila D.; Milligan, Ki Lee; McGowan, Katherine; Spergel, Amanda K. Rudman; Holland, Steven M.; Freeman, Alexandra F.] NIAID, NIH, Bethesda, MD 20892 USA; [Bishop, Rachel] NEI, NIH, Bethesda, MD 20892 USA; [Boris, Lisa; Urban, Amanda; Welch, Pamela] Leidos Biomed Res Inc, Clin Monitoring Res Program, Clin Res Directorate, Bethesda, MD USA; [Heller, Theo] NIDDK, NIH, Bethesda, MD 20892 USA; [Kleiner, David] NCI, NIH, Bethesda, MD 20892 USA; [Jackson, Mary Anne] Childrens Mercy Hosp, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Odio, CD (corresponding author), NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	freemaal@mail.nih.gov	Odio, Camila/CAF-7842-2022; Kleiner, David E/N-2770-2013	Odio, Camila/0000-0002-1730-4380; Kleiner, David E/0000-0003-3442-4453; McGowan, Katherine/0000-0002-4128-5722; Heller, Theo/0000-0002-2643-6289	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000647, ZIAAI000646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK075008] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; Intramural NIH HHS [Z99 AI999999] Funding Source: Medline; PHS HHS [HHSN261200800001E] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALBERTIFLOR JJ, 1986, DIGESTION, V33, P176, DOI 10.1159/000199290; Antachopoulos C, 2007, EUR J PEDIATR, V166, P1099, DOI 10.1007/s00431-007-0527-7; Barnes CB, 2015, RESP CARE, V60, P455, DOI 10.4187/respcare.03200; Galgiani JN, 2005, CLIN INFECT DIS, V41, P1217, DOI 10.1086/496991; Holland SM, 2007, NEW ENGL J MED, V357, P1608, DOI 10.1056/NEJMoa073687; Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008; Milner JD, 2008, NATURE, V452, P773, DOI 10.1038/nature06764; Mistro S, 2012, CLIN INFECT DIS, V54, P1774, DOI 10.1093/cid/cis290; Sowerwine KJ, 2012, ANN NY ACAD SCI, V1250, P25, DOI 10.1111/j.1749-6632.2011.06387.x; Sumino K, 2013, CURR OPIN PULM MED, V19, P49, DOI 10.1097/MCP.0b013e32835b117a; Valdez PA, 2012, IMMUNITY, V36, P668, DOI 10.1016/j.immuni.2012.02.013; Van Steenis MNA, 2014, PATIENT PREFER ADHER, V8, P83, DOI 10.2147/PPA.S44185; Wozniak KL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017204	13	38	41	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2015	136	5					1411	1413		10.1016/j.jaci.2015.07.003	http://dx.doi.org/10.1016/j.jaci.2015.07.003			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CW1YE	26292779	Green Accepted			2022-12-18	WOS:000364787200036
J	Calhoun, WJ; Haselkorn, T; Miller, DP; Omachi, TA				Calhoun, William J.; Haselkorn, Tmirah; Miller, Dave P.; Omachi, Theodore A.			Asthma exacerbations and lung function in patients with severe or difficult-to-treat asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							FUNCTION DECLINE; COHORT		[Calhoun, William J.] Univ Texas Med Branch, Galveston, TX 77555 USA; [Haselkorn, Tmirah; Omachi, Theodore A.] Genentech Inc, San Francisco, CA 94080 USA; [Miller, Dave P.] ICON Clin Res, San Francisco, CA USA	University of Texas System; University of Texas Medical Branch Galveston; Roche Holding; Genentech; ICON plc	Calhoun, WJ (corresponding author), Univ Texas Med Branch, Galveston, TX 77555 USA.	wjcalhou@utmb.edu		Calhoun, William/0000-0001-7075-712X; Omachi, Theodore/0000-0001-9167-768X; Miller, Dave/0000-0003-2947-152X				[Anonymous], 2007, 3 US DEP HLTH HUM SE; Bai TR, 2007, EUR RESPIR J, V30, P452, DOI 10.1183/09031936.00165106; Barker M, 2003, J CHEMOMETR, V17, P166, DOI 10.1002/cem.785; Bisgaard H, 2013, CLIN EXP ALLERGY, V43, P1384, DOI 10.1111/cea.12213; Davies D E, 2001, Curr Allergy Asthma Rep, V1, P127, DOI 10.1007/s11882-001-0080-9; Dolan CM, 2004, ANN ALLERG ASTHMA IM, V92, P32, DOI 10.1016/S1081-1206(10)61707-3; Donaldson GC, 2002, THORAX, V57, P847, DOI 10.1136/thorax.57.10.847; O'Byrne PM, 2009, AM J RESP CRIT CARE, V179, P19, DOI 10.1164/rccm.200807-1126OC; Rennard Stephen I, 2004, Proc Am Thorac Soc, V1, P88, DOI 10.1513/pats.2306026; SAETTA M, 1994, EUR RESPIR J, V7, P1505, DOI 10.1183/09031936.94.07081505; Ulrik CS, 1999, EUR RESPIR J, V14, P892, DOI 10.1034/j.1399-3003.1999.14d27.x	11	38	38	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2015	136	4					1125	1127		10.1016/j.jaci.2015.05.014	http://dx.doi.org/10.1016/j.jaci.2015.05.014			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CT7EJ	26104221				2022-12-18	WOS:000362976300043
J	Grabenhenrich, LB; Keil, T; Reich, A; Gough, H; Beschorner, J; Hoffmann, U; Bauer, CP; Forster, J; Schuster, A; Schramm, D; Nitsche, O; Zepp, F; Lee, YA; Bergmann, R; Bergmann, K; Wahn, U; Lau, S				Grabenhenrich, Linus B.; Keil, Thomas; Reich, Andreas; Gough, Hannah; Beschorner, John; Hoffmann, Ute; Bauer, Carl-Peter; Forster, Johannes; Schuster, Antje; Schramm, Dirk; Nitsche, Oliver; Zepp, Fred; Lee, Young-Ae; Bergmann, Renate; Bergmann, Karl; Wahn, Ulrich; Lau, Susanne			Prediction and prevention of allergic rhinitis: A birth cohort study of 20 years	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Infant; preschool child; adolescent; heredity; risk factors; epidemiologic factors; survival analysis; primary prevention	MATERNAL SMOKING; NATURAL COURSE; ASTHMA; CHILDREN; IMPACT; SENSITIZATION; ADOLESCENCE; POPULATION; CHILDHOOD; PREGNANCY	Background: Allergic rhinitis (AR) is one of the most common chronic diseases, usually starting in the first 2 decades of life. Information on predictors, risk, and protective factors is missing because of a lack of long-term prospective studies. Objective: Our aim was to examine early-life environmental and lifestyle determinants for AR up to age 20 years. Methods: In 1990, the Multicenter Allergy Study included 1314 newborns in 5 German cities. Children were evaluated at 19 time points. A Cox regression model examined the associations between 41 independent early-life factors and onset of AR (as the primary outcome), including sensitization against aeroallergens and the secondary outcomes of nonallergic rhinitis and AR plus asthma. Results: Two hundred ninety subjects had AR within 13,179 person years observed. The risk of AR was higher with a parental history of AR (adjusted hazard ratio [aHR], 2.49; 95% CI, 1.93-3.21), urticaria (aHR, 1.32; 95% CI, 1.00-1.74), or asthma (aHR, 1.29; 95% CI, 0.95-1.75). Early allergic sensitization (aHR, 4.53; 95% CI, 3.25-6.32), eczema within the first 3 years of life (aHR, 1.83; 95% CI, 1.38-2.42), male sex (aHR, 1.28; 95% CI, 1.02-1.61), and birthday in summer or autumn (aHR, 1.26; 95% CI, 1.00-1.58) were independent predictors of AR up to age 20 years. None of the other socioeconomic, environmental, lifestyle, pregnancy, and birth-related factors were associated with AR. Conclusion: Only nonmodifiable factors, particularly early allergic sensitization or eczema and parental AR, predicted ARup to age 20 years. No modifiable aspects of early-life environment or lifestyle were identified as targets for primary prevention.	[Grabenhenrich, Linus B.; Keil, Thomas; Reich, Andreas; Gough, Hannah] Charite, Inst Social Med Epidemiol & Hlth Econ, D-10117 Berlin, Germany; [Bergmann, Renate; Bergmann, Karl] Charite, Dept Obstet, D-10117 Berlin, Germany; [Wahn, Ulrich; Lau, Susanne] Charite, Dept Pediat Pneumol & Immunol, D-10117 Berlin, Germany; [Keil, Thomas] Univ Wurzburg, Inst Clin Epidemiol & Biometry, Wurzburg, Germany; [Beschorner, John] Westmecklenburg Hosp, Dept Pediat, Hagenow, Germany; [Hoffmann, Ute; Bauer, Carl-Peter] Tech Univ Munich, Dept Pediat, D-80290 Munich, Germany; [Forster, Johannes] St Josefs Hosp, Dept Pediat, Freiburg, Germany; [Schuster, Antje; Schramm, Dirk] Univ Dusseldorf, Dept Pediat, Dusseldorf, Germany; [Nitsche, Oliver; Zepp, Fred] Univ Med Ctr Mainz, Ctr Pediat & Adolescent Med, Mainz, Germany; [Lee, Young-Ae] Max Delbruck Ctr, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Wurzburg; Technical University of Munich; Heinrich Heine University Dusseldorf; Johannes Gutenberg University of Mainz; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Grabenhenrich, LB (corresponding author), Charite, Inst Social Med Epidemiol & Hlth Econ, Luisenstr 57, D-10117 Berlin, Germany.	linus.grabenhenrich@charite.de	Reich, Andreas/B-1204-2016	Reich, Andreas/0000-0002-3729-0772; Grabenhenrich, Linus/0000-0002-9300-6625; Lau, Susanne/0000-0002-5189-4265				ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bergmann R L, 1994, Pediatr Allergy Immunol, V5, P19, DOI 10.1111/j.1399-3038.1994.tb00343.x; Bergmann R L, 1993, Pediatr Allergy Immunol, V4, P130, DOI 10.1111/j.1399-3038.1993.tb00081.x; Bernaards CA, 2007, STAT MED, V26, P1368, DOI 10.1002/sim.2619; Bousquet J, 2006, J ALLERGY CLIN IMMUN, V117, P158, DOI 10.1016/j.jaci.2005.09.047; Bousquet J, 2012, J ALLERGY CLIN IMMUN, V130, P1049, DOI 10.1016/j.jaci.2012.07.053; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; BraunFahrlander C, 1997, PEDIATR ALLERGY IMMU, V8, P75, DOI 10.1111/j.1399-3038.1997.tb00147.x; Carlsen KCL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043214; Codispoti CD, 2010, J ALLERGY CLIN IMMUN, V125, P1054, DOI 10.1016/j.jaci.2010.02.004; COLE TJ, 1990, EUR J CLIN NUTR, V44, P45; COX DR, 1972, J R STAT SOC B, V34, P187; Davila I, 2009, J INVEST ALLERG CLIN, V19, P25; Dretzke J, 2013, J ALLERGY CLIN IMMUN, V131, P1361, DOI 10.1016/j.jaci.2013.02.013; Gilliland FD, 2001, AM J RESP CRIT CARE, V163, P429, DOI 10.1164/ajrccm.163.2.2006009; Grabenhenrich LB, 2014, J ALLERGY CLIN IMMUN, V133, P979, DOI 10.1016/j.jaci.2013.11.035; Graf N, 2007, INT ARCH ALLERGY IMM, V143, P269, DOI 10.1159/000100572; Greenland S, 1999, EPIDEMIOLOGY, V10, P37, DOI 10.1097/00001648-199901000-00008; Greiner AN, 2011, LANCET, V378, P2112, DOI 10.1016/S0140-6736(11)60130-X; Hatzler L, 2012, J ALLERGY CLIN IMMUN, V130, P894, DOI 10.1016/j.jaci.2012.05.053; Higgins TS, 2012, CURR OPIN OTOLARYNGO, V20, P209, DOI 10.1097/MOO.0b013e3283534821; Keil T, 2010, PEDIAT ALLERG IMM-UK, V21, P962, DOI 10.1111/j.1399-3038.2010.01046.x; Kellberger J, 2012, J ALLERGY CLIN IMMUN, V129, P397, DOI 10.1016/j.jaci.2011.08.016; Kramer MS, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003517.pub2; Kulig M, 1998, PEDIAT ALLERG IMM-UK, V9, P61, DOI 10.1111/j.1399-3038.1998.tb00305.x; Kulig M, 2000, J ALLERGY CLIN IMMUN, V106, P832, DOI 10.1067/mai.2000.110098; Neuman A, 2012, AM J RESP CRIT CARE, V186, P1037, DOI 10.1164/rccm.201203-0501OC; Nieto A, 2014, PEDIAT ALLERG IMM-UK, V25, P516, DOI 10.1111/pai.12272; Nissen SP, 2013, PEDIAT ALLERG IMM-UK, V24, P549, DOI 10.1111/pai.12108; Pinart M, 2012, ALLERGY, V67, P656; Pinart M, 2014, LANCET RESP MED, V2, P131, DOI 10.1016/S2213-2600(13)70277-7; Skoner DR, 2001, J ALLERGY CLIN IMMUN, V108, pS2, DOI 10.1067/mai.2001.115569; Tariq SM, 2000, PEDIATR ALLERGY IMMU, V11, P162, DOI 10.1034/j.1399-3038.2000.00077.x; Thacher JD, 2014, PEDIATRICS, V134, P428, DOI 10.1542/peds.2014-0427; Valero A, 2007, J ALLERGY CLIN IMMUN, V120, P359, DOI 10.1016/j.jaci.2007.04.006; van Beijsterveldt CEM, 2007, EUR RESPIR J, V29, P516, DOI 10.1183/09031936.00065706; Westman M, 2013, ALLERGY, V68, P1571, DOI 10.1111/all.12267; Westman M, 2012, J ALLERGY CLIN IMMUN, V129, P403, DOI 10.1016/j.jaci.2011.09.036; White IR, 2009, STAT MED, V28, P1982, DOI 10.1002/sim.3618	40	38	41	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2015	136	4					932	+		10.1016/j.jaci.2015.03.040	http://dx.doi.org/10.1016/j.jaci.2015.03.040			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CT7EJ	25976706				2022-12-18	WOS:000362976300012
J	Mitsui-Sekinaka, K; Imai, K; Sato, H; Tomizawa, D; Kajiwara, M; Nagasawa, M; Morio, T; Nonoyama, S				Mitsui-Sekinaka, Kanako; Imai, Kohsuke; Sato, Hiroki; Tomizawa, Daisuke; Kajiwara, Michiko; Nagasawa, Masayuki; Morio, Tomohiro; Nonoyama, Shigeaki			Clinical features and hematopoietic stem cell transplantations for CD40 ligand deficiency in Japan	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CD40 ligand; hematopoietic stem cell transplantation; Pneumocystis jirovecii; Cryptosporidium parvum; Cryptococcus neoformans; primary immunodeficiency; hyper-IgM syndrome; combined immunodeficiency; class-switch recombination	HYPER-IGM SYNDROME; X-LINKED IMMUNODEFICIENCY; DENDRITIC CELLS; MUTATIONS; GENE; EXPERIENCE; EXPRESSION	Background: The long-term outcome of X-linked hyper-IgM syndrome (XHIM) caused by mutations in CD40LG is poor, and the only curative treatment is hematopoietic stem cell transplantation (HSCT). Objective: We sought to determine the clinical features and factors affecting outcomes in patients with XHIM. Methods: We enrolled and retrospectively analyzed data from 56 Japanese patients with XHIM, including 29 patients who received HSCT. Results: The long-term survival rate was poor in those not undergoing HSCT (overall survival rate at 40 years of age, 28.2%). The overall survival rate of patients undergoing HSCT (n = 29) was significantly higher than that of those not undergoing HSCT (n = 27, P = .0231). Moreover, event-free and disease-free survival rates were significantly greater in patients 5 years old or younger at the time of transplantation (n = 14) than in older patients (n = 15). Conclusion: On the basis of these results, we concluded that HSCT improved the outcomes of patients with XHIM and that an age of 5 years or younger was optimal for the timing of HSCT because persistent infections and severe organ damage were frequently observed in patients older than 6 years.	[Mitsui-Sekinaka, Kanako; Imai, Kohsuke; Nonoyama, Shigeaki] Natl Def Med Coll, Dept Pediat, Saitama, Japan; [Sato, Hiroki] Natl Def Med Coll, Dept Publ Hlth, Saitama, Japan; [Imai, Kohsuke; Tomizawa, Daisuke; Nagasawa, Masayuki; Morio, Tomohiro] Tokyo Med & Dent Univ, Dept Pediat, Tokyo, Japan; [Kajiwara, Michiko] Tokyo Med & Dent Univ, Hosp Med, Dept Transfus Med, Tokyo, Japan	National Defense Medical College - Japan; National Defense Medical College - Japan; Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Imai, K (corresponding author), Tokyo Med & Dent Univ, Dept Pediat, Bunkyo Ku, 1-5-45 Yushima, Tokyo, Japan.	kimai.ped@tmd.ac.jp	Imai, Kohsuke/Q-2602-2015; Nagasawa, Masayuki/AAX-1734-2020; Nagasawa, Masayuki/CAI-8101-2022; Tomizawa, Daisuke/H-7794-2019	Imai, Kohsuke/0000-0003-2132-8403; Nagasawa, Masayuki/0000-0002-8085-4940; Tomizawa, Daisuke/0000-0003-1520-7007; Morio, Tomohiro/0000-0002-9259-1025; Sekinaka, Kanako/0000-0001-5926-5597; Sato, Hiroki/0000-0002-6061-1511	Grants-in-Aid for Scientific Research [24591541] Funding Source: KAKEN	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))		ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; Bhushan A, 2001, IMMUNOL RES, V24, P311, DOI 10.1385/IR:24:3:311; CAUX C, 1994, J EXP MED, V180, P1263, DOI 10.1084/jem.180.4.1263; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; Elgueta R, 2009, IMMUNOL REV, V229, P152, DOI 10.1111/j.1600-065X.2009.00782.x; Fan XY, 2012, CLIN IMMUNOL, V143, P152, DOI 10.1016/j.clim.2012.01.014; Gennery AR, 2004, BLOOD, V103, P1152, DOI 10.1182/blood-2003-06-2014; Hayward AR, 1997, J IMMUNOL, V158, P977; Hoshino A, 2014, PEDIATR INT, V56, P510, DOI 10.1111/ped.12325; Jain A, 2011, BLOOD, V118, P3811, DOI 10.1182/blood-2011-04-351254; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; Levy J, 1997, J PEDIATR-US, V131, P47, DOI 10.1016/S0022-3476(97)70123-9; Nonoyama S, 1997, HUM GENET, V99, P624, DOI 10.1007/s004390050417; Notarangelo LD, 1996, IMMUNOL TODAY, V17, P511, DOI 10.1016/0167-5699(96)30059-5; Seyama K, 1998, BLOOD, V92, P2421, DOI 10.1182/blood.V92.7.2421.2421_2421_2434; Tomizawa D, 2004, AM J HEMATOL, V76, P33, DOI 10.1002/ajh.20044; Tsuji Y, 2007, HAEMATOLOGICA, V92, P1727, DOI 10.3324/haematol.11531; vanKooten C, 1997, CURR OPIN IMMUNOL, V9, P330, DOI 10.1016/S0952-7915(97)80078-7; Winkelstein JA, 2003, MEDICINE, V82, P373, DOI 10.1097/01.md.0000100046.06009.b0	19	38	41	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2015	136	4					1018	1024		10.1016/j.jaci.2015.02.020	http://dx.doi.org/10.1016/j.jaci.2015.02.020			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CT7EJ	25840720	Bronze			2022-12-18	WOS:000362976300020
J	Schaballie, H; Rodriguez, R; Martin, E; Moens, L; Frans, G; Lenoir, C; Dutre, J; Canioni, D; Bossuyt, X; Fischer, A; Latour, S; Meyts, I; Picard, C				Schaballie, Heidi; Rodriguez, Remy; Martin, Emmanuel; Moens, Leen; Frans, Glynis; Lenoir, Christelle; Dutre, Joris; Canioni, Danielle; Bossuyt, Xavier; Fischer, Alain; Latour, Sylvain; Meyts, Isabelle; Picard, Capucine			A novel hypomorphic mutation in STIM1 results in a late-onset immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							AUTOIMMUNITY; DEFICIENCY		[Schaballie, Heidi; Meyts, Isabelle] Univ Hosp Leuven, Dept Pediat, Leuven, Belgium; [Schaballie, Heidi; Moens, Leen; Frans, Glynis; Bossuyt, Xavier; Meyts, Isabelle] Univ Leuven, KU Leuven, Dept Microbiol & Immunol, Leuven, Belgium; [Rodriguez, Remy; Martin, Emmanuel; Lenoir, Christelle; Latour, Sylvain] Hop Necker Enfants Malad, Inst IMAGINE, INSERM, UMR 1163,Lab Lymphocyte Activat & Susceptibil EBV, Paris, France; [Rodriguez, Remy; Latour, Sylvain; Picard, Capucine] Paris Descartes Univ, Sorbonne Paris Cite, Paris, France; [Frans, Glynis; Bossuyt, Xavier] Univ Hosp Leuven, Dept Lab Med, Leuven, Belgium; [Dutre, Joris] ZNA Hosp, Dept Gastroenterol, Antwerp, Belgium; [Canioni, Danielle] Hop Necker Enfants Malad, Dept Pathol, Paris, France; [Fischer, Alain; Picard, Capucine] Hop Necker Enfants Malad, AP HP, Study Ctr Immunodeficiency, Paris, France; [Fischer, Alain; Picard, Capucine] Inst IMAGINE, INSERM, UMR 1163, Lab Human Genet Infect Dis,Necker Branch, Paris, France	KU Leuven; University Hospital Leuven; KU Leuven; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; KU Leuven; University Hospital Leuven; ZNA Middelheim Hospital; ZNA Stuivenberg; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Schaballie, H (corresponding author), Univ Hosp Leuven, Dept Pediat, Leuven, Belgium.	capucine.picard@inserm.fr	Meyts, Isabelle/Z-3295-2019; Martin, Emmanuel/F-9743-2016; Bossuyt, Xavier/B-2085-2019; Latour, Sylvain/H-3652-2017	Martin, Emmanuel/0000-0003-4211-7373; Bossuyt, Xavier/0000-0001-6856-8485; Rodriguez, Remy/0000-0003-3392-6371; Latour, Sylvain/0000-0001-8238-4391				Byun M, 2010, J EXP MED, V207, P2307, DOI 10.1084/jem.20101597; Fuchs S, 2012, J IMMUNOL, V188, P1523, DOI 10.4049/jimmunol.1102507; Hauck F, 2012, J ALLERGY CLIN IMMUN, V130, P1144, DOI 10.1016/j.jaci.2012.07.029; Oh-Hora M, 2008, NAT IMMUNOL, V9, P432, DOI 10.1038/ni1574; Picard C, 2009, EUR J IMMUNOL, V39, P1966, DOI 10.1002/eji.200939385; Picard C, 2009, NEW ENGL J MED, V360, P1971, DOI 10.1056/NEJMoa0900082; Serriari NE, 2014, CLIN EXP IMMUNOL, V176, P266, DOI 10.1111/cei.12277; Shaw PJ, 2012, J PHYSIOL-LONDON, V590, P4157, DOI 10.1113/jphysiol.2012.233221	8	38	38	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2015	136	3					816	+		10.1016/j.jaci.2015.03.009	http://dx.doi.org/10.1016/j.jaci.2015.03.009			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CQ9EA	25935105	Bronze			2022-12-18	WOS:000360913300041
J	Touzot, F; Neven, B; Dal-Cortivo, L; Gabrion, A; Moshous, D; Cros, G; Chomton, M; Luby, JM; Terniaux, B; Magalon, J; Picard, C; Blanche, S; Fischer, A; Cavazzana, M				Touzot, Fabien; Neven, Benedicte; Dal-Cortivo, Liliane; Gabrion, Aurelie; Moshous, Despina; Cros, Guilhem; Chomton, Maryline; Luby, Jean-Marc; Terniaux, Brigitte; Magalon, Jeremy; Picard, Capucine; Blanche, Stephane; Fischer, Alain; Cavazzana, Marina			CD45RA depletion in HLA-mismatched allogeneic hematopoietic stem cell transplantation for primary combined immunodeficiency: A preliminary study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Combined primary immunodeficiency; hematopoietic stem cell transplantation; graft-versus-host disease; viral infection; immunomagnetic CD45RA depletion; naive T cell	NAIVE T-CELLS; CD4(+); CONSENSUS	Background: Combined immunodeficiencies (CIDs) form a heterogeneous group of inherited conditions that affect the development, function, or both of T cells. The treatment of CIDs with allogeneic hematopoietic stem cell transplantation (HSCT) is complicated by a high incidence of life-threatening infections and an increased risk of graft-versus-host disease (GVHD). Objective: In view of the growing evidence that alloreactivity is mainly derived from human naive T cells, the selective depletion of naive T cells from allografts might constitute a way of reducing alloreactivity while maintaining memory T-cell responsiveness to pathogens. Methods: Five consecutive patients with CIDs and chronic viral infections underwent an allogeneic, HLA-mismatchedHSCT. Given the patients' infection status and the potential risk of severe GVHD in the mismatched setting, the CD34 2 fraction of the allograft was depleted of naive T cells by using magnetic CD45RA beads. Results: Engraftment occurred in 4 of the 5 patients. No severe GVHD occurred. In the 4 engrafted patients viral infections were cleared within 2 months of the HSCT, and both cellular and humoral immunity were re-established within a year of the HSCT. An early T-cell response against viral pathogens was documented in 2 patients. Conclusion: The present pilot study shows that clinical-grade depletion of naive T cells from an allograft through the use of magnetic CD45RA beads seems to be a feasible and efficacious option for the treatment of patients with CIDs at high risk of GVHD, infection, or both in an HLA-mismatched setting.	[Touzot, Fabien; Dal-Cortivo, Liliane; Gabrion, Aurelie; Luby, Jean-Marc; Terniaux, Brigitte; Magalon, Jeremy; Cavazzana, Marina] Hop Necker Enfants Malad, AP HP, Ctr Invest Clin Integre Biotherapies, Dept Biotherapie, F-75015 Paris, France; [Touzot, Fabien; Neven, Benedicte; Moshous, Despina; Cros, Guilhem; Chomton, Maryline; Magalon, Jeremy; Picard, Capucine; Blanche, Stephane; Fischer, Alain; Cavazzana, Marina] Univ Paris 05, Sorbonne Paris Cite, Inst Imagine, Paris, France; [Neven, Benedicte; Moshous, Despina; Cros, Guilhem; Chomton, Maryline; Blanche, Stephane; Fischer, Alain] Hop Necker Enfants Malad, AP HP, Unite Immunol Hematol & Rhumatol Pediat, F-75015 Paris, France; [Picard, Capucine] Hop Necker Enfants Malad, AP HP, Ctr Etude Deficits Immunitaires, F-75015 Paris, France; [Touzot, Fabien; Neven, Benedicte; Moshous, Despina; Picard, Capucine; Fischer, Alain; Cavazzana, Marina] INSERM, UMR1163, Paris, France; [Fischer, Alain] Coll France, F-75231 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; College de France	Touzot, F (corresponding author), Hop Necker Enfants Malad, Dept Biotherapie, 149 Rue Sevres, F-75015 Paris, France.	fabien.touzot@nck.aphp.fr	Moshous, Despina/B-7507-2017; GABRION, AURELIE/K-1812-2017; Touzot, Fabien/T-7797-2018; Picard, Capucine/H-3914-2017	Moshous, Despina/0000-0001-6719-3693; GABRION, AURELIE/0000-0002-1885-2071; Touzot, Fabien/0000-0002-0889-4905; Picard, Capucine/0000-0001-8788-5056; Cavazzana, Marina/0000-0002-0264-0891	Assistance Publique Hopitaux de Paris	Assistance Publique Hopitaux de Paris	Supported by Assistance Publique Hopitaux de Paris.	Al-Herz W, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00162; Anderson BE, 2003, J CLIN INVEST, V112, P101, DOI 10.1172/JCI200317601; Andre-Schmutz I, 2002, TRANSPLANT P, V34, P2927, DOI 10.1016/S0041-1345(02)03491-7; Appay V, 2008, CYTOM PART A, V73A, P975, DOI 10.1002/cyto.a.20643; Bastien JP, 2012, SEMIN ONCOL, V39, P674, DOI 10.1053/j.seminoncol.2012.09.004; Bertaina A, 2014, BLOOD, V124, P822, DOI 10.1182/blood-2014-03-563817; Bleakley M, 2014, BIOL BLOOD MARROW TR, V20, P705, DOI 10.1016/j.bbmt.2014.01.032; Blennow O, 2013, BONE MARROW TRANSPL, V48, P1583, DOI 10.1038/bmt.2013.103; Chen BJ, 2007, BLOOD, V109, P3115, DOI 10.1182/blood-2006-04-016410; Chen BJ, 2008, BIOL BLOOD MARROW TR, V14, P20; Cherel M, 2014, EUR J HAEMATOL, V92, P491, DOI 10.1111/ejh.12283; Cossarizza A, 1996, MECH AGEING DEV, V86, P173, DOI 10.1016/0047-6374(95)01691-0; Distler E, 2011, HAEMATOL-HEMATOL J, V96, P1024, DOI 10.3324/haematol.2010.037481; Gennery AR, 2010, J ALLERGY CLIN IMMUN, V126, P602, DOI 10.1016/j.jaci.2010.06.015; Hacein-Bey-Abina S, 2002, NEW ENGL J MED, V346, P1185, DOI 10.1056/NEJMoa012616; Heimfeld S, 2003, BONE MARROW TRANSPL, V31, P839, DOI 10.1038/sj.bmt.1704019; Jol-van der Zijde CM, 2012, BONE MARROW TRANSPL, V47, P1256, DOI 10.1038/bmt.2011.259; KLEIN C, 1995, BLOOD, V85, P580; Mielke S, 2005, CYTOTHERAPY, V7, P109, DOI 10.1080/14653240510018172; Notarangelo LD, 2010, J ALLERGY CLIN IMMUN, V125, pS182, DOI 10.1016/j.jaci.2009.07.053; Notta F, 2011, SCIENCE, V333, P218, DOI 10.1126/science.1201219; PRZEPIORKA D, 1995, BONE MARROW TRANSPL, V15, P825; Seidel MG, 2005, HAEMATOLOGICA, V90, P1405; Slatter MA, 2013, EXPERT REV CLIN IMMU, V9, P991, DOI 10.1586/1744666X.2013.836061; Teschner D, 2014, BONE MARROW TRANSPL, V49, P138, DOI 10.1038/bmt.2013.114; Warren EH, 2012, BLOOD, V120, P2796, DOI 10.1182/blood-2012-04-347286	26	38	39	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2015	135	5					1303	U728		10.1016/j.jaci.2014.08.019	http://dx.doi.org/10.1016/j.jaci.2014.08.019			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CH4DA	25282016				2022-12-18	WOS:000353980700024
J	Pfeffer, PE; Chen, YH; Woszczek, G; Matthews, NC; Chevretton, E; Gupta, A; Saglani, S; Bush, A; Corrigan, C; Cousins, DJ; Hawrylowicz, CM				Pfeffer, Paul E.; Chen, Yin-Huai; Woszczek, Grzegorz; Matthews, Nick C.; Chevretton, Elfy; Gupta, Atul; Saglani, Sejal; Bush, Andrew; Corrigan, Chris; Cousins, David J.; Hawrylowicz, Catherine M.			Vitamin D enhances production of soluble ST2, inhibiting the action of IL-33	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							HOST-DEFENSE; CELLS; ASTHMA; FAMILY		[Pfeffer, Paul E.; Chen, Yin-Huai; Woszczek, Grzegorz; Matthews, Nick C.; Gupta, Atul; Corrigan, Chris; Cousins, David J.; Hawrylowicz, Catherine M.] Kings Coll London, MRC & Asthma UK Ctr Allerg Mech Asthma, Guys Hosp, London WC2R 2LS, England; [Chevretton, Elfy] Guys Hosp, Dept ENT, Great Maze Pond, London SE1 9RT, England; [Gupta, Atul; Saglani, Sejal; Bush, Andrew] Univ London Imperial Coll Sci Technol & Med, MRC & Asthma UK Ctr Allerg Mech Asthma, Dept Paediat Resp Med, Royal Brompton Hosp, London, England; [Cousins, David J.] Univ Leicester, Glenfield Hosp, Dept Infect Immun & Inflammat, Leicester, Leics, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; Imperial College London; Royal Brompton Hospital; University of London; King's College London; University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital	Pfeffer, PE (corresponding author), Kings Coll London, MRC & Asthma UK Ctr Allerg Mech Asthma, Guys Hosp, London WC2R 2LS, England.	catherine.hawrylowicz@kcl.ac.uk	Saglani, Sejal/AAE-5072-2019; Chen, Hebe/ABH-4764-2020; Hawrylowicz, Catherine/Q-8483-2017	Chen, Hebe/0000-0002-8890-691X; Hawrylowicz, Catherine/0000-0002-2337-7463; Corrigan, Chris/0000-0002-0706-6534; Pfeffer, Paul/0000-0003-0369-2885; Cousins, David/0000-0003-3821-9596	Medical Research Council [G1000758B] Funding Source: researchfish; National Institute for Health Research [NF-SI-0510-10192] Funding Source: researchfish; Asthma UK [09/020, AUK-IG-2014-296, 10/058] Funding Source: researchfish; Medical Research Council [G1000758] Funding Source: Medline; Wellcome Trust [098882/Z/12/Z] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); Asthma UK; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Babina M, 2000, BIOCHEM BIOPH RES CO, V273, P1104, DOI 10.1006/bbrc.2000.3083; Boonstra A, 2001, J IMMUNOL, V167, P4974, DOI 10.4049/jimmunol.167.9.4974; Garlanda C, 2013, IMMUNITY, V39, P1003, DOI 10.1016/j.immuni.2013.11.010; Grotenboer NS, 2013, J ALLERGY CLIN IMMUN, V131, P856, DOI 10.1016/j.jaci.2012.11.028; Hansdottir S, 2008, J IMMUNOL, V181, P7090, DOI 10.4049/jimmunol.181.10.7090; Liew FY, 2010, NAT REV IMMUNOL, V10, P103, DOI 10.1038/nri2692; Mann EH, 2014, ANN NY ACAD SCI, V1317, P57, DOI 10.1111/nyas.12410; Oboki Keisuke, 2010, Allergology International, V59, P143, DOI 10.2332/allergolint.10-RAI-0186; Sharief S, 2011, J ALLERGY CLIN IMMUN, V127, P1195, DOI 10.1016/j.jaci.2011.01.017	9	38	41	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2015	135	3					824	827		10.1016/j.jaci.2014.09.044	http://dx.doi.org/10.1016/j.jaci.2014.09.044			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CD4PF	25457999	Green Published, hybrid			2022-12-18	WOS:000351065000035
J	Tuano, KS; Orange, JS; Sullivan, K; Cunningham-Rundles, C; Bonilla, FA; Davis, CM				Tuano, Karen S.; Orange, Jordan S.; Sullivan, Kathleen; Cunningham-Rundles, Charlotte; Bonilla, Francisco A.; Davis, Carla M.			Food allergy in patients with primary immuno-deficiency diseases: Prevalence within the US Immunodeficiency Network (USIDNET)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							IGA DEFICIENCY; MANIFESTATIONS		[Tuano, Karen S.; Orange, Jordan S.; Davis, Carla M.] Texas Childrens Hosp, Baylor Coll Med, Sect Immunol Allergy & Rheumatol, Houston, TX 77030 USA; [Sullivan, Kathleen] Childrens Hosp Philadelphia, Div Allergy & Immunol, Philadelphia, PA 19104 USA; [Cunningham-Rundles, Charlotte] Mt Sinai Sch Med, Inst Immunol, Dept Med, New York, NY USA; [Cunningham-Rundles, Charlotte] Mt Sinai Sch Med, Inst Immunol, Dept Pediat, New York, NY USA; [Bonilla, Francisco A.] Boston Childrens Hosp, Div Allergy & Immunol, Boston, MA USA	Baylor College of Medicine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Harvard University; Boston Children's Hospital	Tuano, KS (corresponding author), Texas Childrens Hosp, Baylor Coll Med, Sect Immunol Allergy & Rheumatol, Houston, TX 77030 USA.	CMDavis@texaschildrens.org		orange, jordan/0000-0001-7117-7725	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R18AI048693, U24AI086037] Funding Source: NIH RePORTER; NIAID NIH HHS [R18 AI048693, P01 AI061093, U24 AI086037] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aghamohammadi A, 2009, J CLIN IMMUNOL, V29, P130, DOI 10.1007/s10875-008-9229-9; Al-Herz W, 2011, PEDIATR DERMATOL, V28, P494, DOI 10.1111/j.1525-1470.2011.01409.x; Hanifin IM, 2007, DERMATITIS, V18, P82, DOI 10.2310/6620.2007.06034; Jacob CMA, 2008, J CLIN IMMUNOL, V28, pS56, DOI 10.1007/s10875-007-9163-2; Janzi M, 2009, CLIN IMMUNOL, V133, P78, DOI 10.1016/j.clim.2009.05.014; Liu AH, 2010, J ALLERGY CLIN IMMUN, V126, P798, DOI 10.1016/j.jaci.2010.07.026; Notarangelo LD, 2010, J ALLERGY CLIN IMMUN, V125, pS182, DOI 10.1016/j.jaci.2009.07.053; Smitt JHS, 2013, CURR OPIN PEDIATR, V25, P492, DOI 10.1097/MOP.0b013e3283623b9f	8	38	40	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2015	135	1					273	275		10.1016/j.jaci.2014.09.024	http://dx.doi.org/10.1016/j.jaci.2014.09.024			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AY0PG	25441296	Green Accepted			2022-12-18	WOS:000347298200037
J	Tjota, MY; Hrusch, CL; Blaine, KM; Williams, JW; Barrett, NA; Sperling, AI				Tjota, Melissa Y.; Hrusch, Cara L.; Blaine, Kelly M.; Williams, Jesse W.; Barrett, Nora A.; Sperling, Anne I.			Signaling through FcR gamma-associated receptors on dendritic cells drives IL-33-dependent T(H)2-type responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Dendritic cells; immune complexes; house dust mite; FcR gamma; T(H)2; allergic airway inflammation; lungs	PATTERN-RECOGNITION RECEPTOR; C-TYPE LECTIN; IMMUNE-COMPLEXES; DECTIN-2 RECOGNITION; ASTHMA; IL-33; ALLERGEN; INNATE; INFLAMMATION; EXPRESSION	Background: Although allergic sensitization can be generated against various allergens, it is unknown how such a diversity of antigens is able to promote T(H)2-mediated inflammation leading to atopy. Our previous studies demonstrated that allergen-specific IgG immune complexes (ICs) and house dust mite (HDM) extract both induced dendritic cells (DCs) to drive T(H)2-mediated inflammation, but the mechanism by which these diverse stimuli produce similar responses is unknown. Objective: We sought to identify the DC signaling pathways used by T(H)2 stimuli to promote T(H)2-mediated inflammation. Methods: C57BL/6, Fc gamma RIII-/-, FcR gamma(-/-), and ST2(-/-) mice were sensitized and challenged with HDM, and inflammation was assessed based on results of flow cytometry and histology and cytokine production. Bone marrow-derived DCs from these strains were used in signaling and adoptive transfer experiments. Results: Our findings indicate that 2 distinct T(H)2 stimuli, ICs and HDM, use the FcR gamma-associated receptors Fc gamma RIII and Dectin-2, respectively, to promote T(H)2-mediated lung inflammation. In this study we demonstrate that both ICs and HDM induce expression of IL-33, a critical mediator in asthma pathogenesis and the differentiation of T(H)2 cells, in DCs. Upregulation of IL-33 in DCs is dependent on FcR gamma, Toll-like receptor 4, and phosphoinositide 3-kinase. Exogenous IL-33 is sufficient to restore the development of T(H)2 responses in FcR gamma-deficient mice. Finally, adoptive transfer of allergen-pulsed FcR gamma(+/-) bone-marrow derived DCs restores the development of T(H)2-type inflammation in FcR gamma-deficient mice, demonstrating the necessity of this signaling pathway in DCs for allergen-induced inflammation. Conclusion: These data identify a mechanism whereby T(H)2 stimuli signal through FcR gamma-associated receptors on DCs to upregulate IL-33 production and induce T(H)2-mediated allergic airway inflammation.	[Tjota, Melissa Y.; Sperling, Anne I.] Univ Chicago, Comm Immunol, Chicago, IL 60637 USA; [Tjota, Melissa Y.] Univ Chicago, Med Scientist Training Program, Chicago, IL 60637 USA; [Hrusch, Cara L.; Blaine, Kelly M.; Sperling, Anne I.] Univ Chicago, Dept Med, Sect Pulm & Crit Care Med, Chicago, IL 60637 USA; [Williams, Jesse W.] Univ Chicago, Comm Mol Pathogenesis & Mol Med, Chicago, IL 60637 USA; [Barrett, Nora A.] Harvard Univ, Sch Med, Dept Med, Div Rheumatol Immunol & Allergy, Boston, MA USA	University of Chicago; University of Chicago; University of Chicago; University of Chicago; Harvard University; Harvard Medical School	Sperling, AI (corresponding author), Univ Chicago, Dept Med, Sect Pulm & Crit Care, 924 E 57th St,JFK R316, Chicago, IL 60637 USA.	asperlin@uchicago.edu	Sperling, Anne/ACZ-2351-2022	Sperling, Anne I./0000-0002-4265-9212; Tjota, Melissa/0000-0002-5869-3175; Williams, Jesse/0000-0003-3815-0891	National Institutes of Health (NIH) [R21AI094408, K08AI080948, R01HL120952, 5T32HL007605, 5T32HL007237]; Naomi Ragins-Goldsmith Fellowship from the University of Chicago; National Institutes of Health [P30CA14599]; NATIONAL CANCER INSTITUTE [P30CA014599] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000430] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007237, R01HL120952, T32HL007605] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI095230, R21AI094408, K08AI080948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007281] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Naomi Ragins-Goldsmith Fellowship from the University of Chicago; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by National Institutes of Health (NIH) grants R21AI094408 (to A.I.S.), K08AI080948 (to N.A.B.), R01HL120952 (to N.A.B.), 5T32HL007605 (to C.L.H.), and 5T32HL007237 (to J.W.W.) and a Naomi Ragins-Goldsmith Fellowship from the University of Chicago (to M.Y.T.). The University of Chicago Cancer Center Core Facilities used are supported by National Institutes of Health grant P30CA14599.	Bandukwala HS, 2007, J EXP MED, V204, P1875, DOI 10.1084/jem.20061134; Barnes PJ, 2002, ANNU REV PHARMACOL, V42, P81, DOI 10.1146/annurev.pharmtox.42.111901.111143; Barrett NA, 2011, J EXP MED, V208, P593, DOI 10.1084/jem.20100793; Barrett NA, 2009, J IMMUNOL, V182, P1119, DOI 10.4049/jimmunol.182.2.1119; Casas R, 1998, CLIN EXP ALLERGY, V28, P1258; Currie AJ, 2000, J IMMUNOL, V164, P3878, DOI 10.4049/jimmunol.164.7.3878; Desai D, 2009, CLIN EXP IMMUNOL, V158, P10, DOI 10.1111/j.1365-2249.2009.03998.x; Erwin EA, 2005, IMMUNOL ALLERGY CLIN, V25, P1, DOI 10.1016/j.iac.2004.09.008; Gluck J, 2012, INFLAMM RES, V61, P547, DOI 10.1007/s00011-012-0443-9; Grotenboer NS, 2013, J ALLERGY CLIN IMMUN, V131, P856, DOI 10.1016/j.jaci.2012.11.028; Hamerman JA, 2009, IMMUNOL REV, V232, P42, DOI 10.1111/j.1600-065X.2009.00841.x; Hamzaoui A, 2013, J ASTHMA, V50, P803, DOI 10.3109/02770903.2013.816317; Hinds D TC, 2013, AM SOC HUMAN GEN ANN; Holgate ST, 2012, NAT MED, V18, P673, DOI 10.1038/nm.2731; Hsu CL, 2012, J IMMUNOL, V189, P3421, DOI 10.4049/jimmunol.1201224; Hulse KE, 2010, J ALLERGY CLIN IMMUN, V125, P247, DOI 10.1016/j.jaci.2009.10.027; Jacquet A, 2011, TRENDS MOL MED, V17, P604, DOI 10.1016/j.molmed.2011.05.014; Jarzab J, 2000, J INVEST ALLERG CLIN, V10, P24; Kanazawa N, 2007, J DERMATOL SCI, V45, P77, DOI 10.1016/j.jdermsci.2006.09.001; Kitamura K, 2007, J IMMUNOL, V178, P480, DOI 10.4049/jimmunol.178.1.480; Laird MHW, 2009, J LEUKOCYTE BIOL, V85, P966, DOI 10.1189/jlb.1208763; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; MacDonald AS, 2008, J EXP MED, V205, P13, DOI 10.1084/jem.20072665; Parsons MW, 2014, J IMMUNOL, V192, P1361, DOI 10.4049/jimmunol.1301809; Platts-Mills TAE, 2011, IMMUNOL REV, V242, P51, DOI 10.1111/j.1600-065X.2011.01021.x; Prefontaine D, 2009, J IMMUNOL, V183, P5094, DOI 10.4049/jimmunol.0802387; Pulendran B, 2010, NAT IMMUNOL, V11, P647, DOI 10.1038/ni.1894; Ritter M, 2010, P NATL ACAD SCI USA, V107, P20459, DOI 10.1073/pnas.1010337107; Rittirsch D, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000464; Robinson MJ, 2009, J EXP MED, V206, P2037, DOI 10.1084/jem.20082818; Saglani S, 2013, J ALLERGY CLIN IMMUN, V132, P676, DOI 10.1016/j.jaci.2013.04.012; Saijo S, 2010, IMMUNITY, V32, P681, DOI 10.1016/j.immuni.2010.05.001; Sallmann E, 2011, J IMMUNOL, V187, P164, DOI 10.4049/jimmunol.1003392; Sato K, 2006, J BIOL CHEM, V281, P38854, DOI 10.1074/jbc.M606542200; STEVENS WJ, 1984, J ALLERGY CLIN IMMUN, V73, P276, DOI 10.1016/S0091-6749(84)80020-2; Tjota MY, 2013, J CLIN INVEST, V123, P2287, DOI 10.1172/JCI63802; Townsend MJ, 2000, J EXP MED, V191, P1069, DOI 10.1084/jem.191.6.1069; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Williams JW, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3990; Williams Jesse W, 2012, J Allergy (Cairo), V2012, P236075, DOI 10.1155/2012/236075	40	38	38	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2014	134	3					706	+		10.1016/j.jaci.2014.06.013	http://dx.doi.org/10.1016/j.jaci.2014.06.013			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GR	25088053	Green Accepted, Bronze			2022-12-18	WOS:000341372400025
J	Kumar, N; Hanks, ME; Chandrasekaran, P; Davis, BC; Hsu, AP; Van Wagoner, NJ; Merlin, JS; Spalding, C; La Hoz, RM; Holland, SM; Zerbe, CS; Sampaio, EP				Kumar, Nilay; Hanks, Mary E.; Chandrasekaran, Prabha; Davis, Brian C.; Hsu, Amy P.; Van Wagoner, Nicholas J.; Merlin, Jessica S.; Spalding, Christine; La Hoz, Ricardo M.; Holland, Steven M.; Zerbe, Christa S.; Sampaio, Elizabeth P.			Gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation-related primary immunodeficiency is associated with disseminated mucormycosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CHRONIC MUCOCUTANEOUS CANDIDIASIS; CHILDREN		[Kumar, Nilay; Davis, Brian C.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; [Van Wagoner, Nicholas J.; Merlin, Jessica S.] Univ Alabama Birmingham, Dept Med, Div Infect Dis, Birmingham, AL 35294 USA; [Hanks, Mary E.; Chandrasekaran, Prabha; Hsu, Amy P.; Spalding, Christine; Holland, Steven M.; Zerbe, Christa S.; Sampaio, Elizabeth P.] NIAID, Lab Clin Infect Dis, NIH, Bethesda, MD 20892 USA; [La Hoz, Ricardo M.] Wake Forest Univ, Bowman Gray Sch Med, Dept Med, Infect Dis Sect, Winston Salem, NC 27103 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Wake Forest University; Wake Forest Baptist Medical Center	Kumar, N (corresponding author), Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.	sampaioe@niaid.nih.gov		La Hoz, Ricardo/0000-0002-1560-3192	Intramural NIH HHS [Z99 AI999999] Funding Source: Medline; NIAID NIH HHS [K23 AI097267] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000647, ZIAAI000646, K23AI097267] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alvarez E, 2010, REV IBEROAM MICOL, V27, P80, DOI 10.1016/j.riam.2010.01.006; Atra A, 2000, BRIT J CANCER, V82, P1396, DOI 10.1054/bjoc.1999.1083; Casanova JL, 2012, IMMUNITY, V36, P515, DOI 10.1016/j.immuni.2012.03.016; Fanfair RN, 2012, NEW ENGL J MED, V367, P2214, DOI 10.1056/NEJMoa1204781; Hori T, 2012, J CLIN IMMUNOL, V32, P1213, DOI 10.1007/s10875-012-9744-6; Liang KP, 2006, J CLIN MICROBIOL, V44, P892, DOI 10.1128/JCM.44.3.892-898.2006; Liu LY, 2011, J EXP MED, V208, P1635, DOI 10.1084/jem.20110958; Sampaio EP, 2013, J ALLERGY CLIN IMMUN, V131, P1624, DOI 10.1016/j.jaci.2013.01.052; Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003; Uzel G, 2013, J ALLERGY CLIN IMMUN, V131, P1611, DOI 10.1016/j.jaci.2012.11.054; Walsh TJ, 2012, CLIN INFECT DIS, V54, pS55, DOI 10.1093/cid/cir868	11	38	40	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2014	134	1					236	239		10.1016/j.jaci.2014.02.037	http://dx.doi.org/10.1016/j.jaci.2014.02.037			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AL2BH	24709374	Green Accepted			2022-12-18	WOS:000338930300035
J	Sharma, S; Litonjua, A				Sharma, Sunita; Litonjua, Augusto			Asthma, allergy, and responses to methyl donor supplements and nutrients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; asthma; betaine; choline; vitamin B2; vitamin B6; vitamin B12; folate; methyl donor; microbiome	FOLIC-ACID SUPPLEMENTS; CHILDHOOD ASTHMA; GUT MICROBIOTA; WHEEZING ILLNESS; OXIDATIVE STRESS; DNA METHYLATION; FOLATE STATUS; LUNG-FUNCTION; CHOLINE; PREGNANCY	After a brief period of stabilization, recent data have shown that the prevalence of asthma and allergic diseases continues to increase. Atopic diseases are major public health problems resulting in significant disability and resource use globally. Although environmental factors influence the development of atopic disease, dietary changes might partially explain the high burden of atopic disease. Potential mechanisms through which diet is suspected to effect asthma and allergy susceptibility are through epigenetic changes, including DNA methylation. Dietary methyl donors are important in the one-carbon metabolic pathway that is essential for DNA methylation. Findings from both observational studies and interventional trials of dietary methyl donor supplementation on the development and treatment of asthma and allergy have produced mixed results. Although issues related to the differences in study design partially explain the heterogeneous results, 2 other issues have been largely overlooked in these studies. First, these nutrients affect one of many pathways and occur in many of the same foods. Second, it is now becoming clear that the human intestinal microbiome is involved in the metabolism and production of the B vitamins and other methyl donor nutrients. Future studies will need to account for both the interrelationships between these nutrients and the effects of the microbiome.	[Sharma, Sunita; Litonjua, Augusto] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA; [Sharma, Sunita; Litonjua, Augusto] Harvard Univ, Sch Med, Boston, MA USA; [Sharma, Sunita; Litonjua, Augusto] Brigham & Womens Hosp, Dept Med, Div Pulm & Crit Care Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Sharma, S (corresponding author), Brigham & Womens Hosp, Channing Div Network Med, 181 Longwood Ave, Boston, MA 02115 USA.	sunita.sharma@channing.harvard.edu			 [R01 HL111108];  [K08 HL096833];  [U01 HL091528]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL096833, R01HL111108, R01HL091528] Funding Source: NIH RePORTER	; ; ; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by R01 HL111108. S.S. is funded by K08 HL096833. A. L. is funded by U01 HL091528 and R01 HL111108.	Abrams P, 2002, AM J OBSTET GYNECOL, V187, P126, DOI 10.1067/mob.2002.125704; Allan K, 2011, J AM DIET ASSOC, V111, P258, DOI 10.1016/j.jada.2010.10.048; ALWAIZ M, 1992, METABOLISM, V41, P135, DOI 10.1016/0026-0495(92)90140-6; Anderson OS, 2012, J NUTR BIOCHEM, V23, P853, DOI 10.1016/j.jnutbio.2012.03.003; Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190; Aufreiter S, 2009, AM J CLIN NUTR, V90, P116, DOI 10.3945/ajcn.2008.27345; Bailey L, 2006, FOLATE; Bekkers MBM, 2012, EUR RESPIR J, V39, P1468, DOI 10.1183/09031936.00094511; Bjorksten B, 2008, PEDIAT ALLERG IMM-UK, V19, P110, DOI 10.1111/j.1399-3038.2007.00601.x; Blatter J, 2013, AM J RESP CRIT CARE, V188, P12, DOI 10.1164/rccm.201302-0317PP; Blusztajn JK, 1998, SCIENCE, V281, P794, DOI 10.1126/science.281.5378.794; Boeke CE, 2012, EPIGENETICS-US, V7, P253, DOI 10.4161/epi.7.3.19082; Bueso AK, 2011, PEDIAT ALLERG IMM-UK, V22, P19, DOI 10.1111/j.1399-3038.2010.01013.x; Centers for Disease Control and Prevention, 2011, MMWR-MORBID MORTAL W, V60, P547; Centers for Disease Control Prevention (CDC), 1992, MMWR-MORBID MORTAL W, V41, P1; Claus SP, 2013, ANNU REV FOOD SCI T, V4, P381, DOI 10.1146/annurev-food-030212-182612; COLLIPP PJ, 1975, ANN ALLERGY, V35, P93; Combs G, 1992, VITAMIN B12 VITAMINS; Craig SAS, 2004, AM J CLIN NUTR, V80, P539; D'Aimmo MR, 2012, J APPL MICROBIOL, V112, P975, DOI 10.1111/j.1365-2672.2012.05261.x; DeVries A, 2013, ASIAN PAC J ALLERGY, V31, P183; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Edwards TM, 2007, ENVIRON HEALTH PERSP, V115, P1264, DOI 10.1289/ehp.9951; Farres MN, 2011, INTERNAL MED, V50, P205, DOI 10.2169/internalmedicine.50.4424; Francavilla R, 2012, PEDIAT ALLERG IMM-UK, V23, P420, DOI 10.1111/j.1399-3038.2012.01286.x; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; Fryer Anthony A, 2009, Epigenetics, V4, P394; GANLEY OH, 1958, J LAB CLIN MED, V51, P709; Garcia-Marcos L, 2013, PEDIAT ALLERG IMM-UK, V24, P330, DOI 10.1111/pai.12071; Gaur S N, 1997, Indian J Chest Dis Allied Sci, V39, P107; Gehring U, 2010, AM J RESP CRIT CARE, V181, P596, DOI 10.1164/rccm.200906-0858OC; Granell R, 2008, CLIN EXP ALLERGY, V38, P320, DOI 10.1111/j.1365-2222.2007.02902.x; Gruzieva O, 2013, EPIDEMIOLOGY, V24, P54, DOI 10.1097/EDE.0b013e318276c1ea; Gupta S K, 1997, Indian J Chest Dis Allied Sci, V39, P149; LeBlanc JG, 2013, CURR OPIN BIOTECH, V24, P160, DOI 10.1016/j.copbio.2012.08.005; Haberg SE, 2009, ARCH DIS CHILD, V94, P180, DOI 10.1136/adc.2008.142448; Haberg SE, 2011, J ALLERGY CLIN IMMUN, V127, P262, DOI 10.1016/j.jaci.2010.10.004; Heinrich J, 2001, EUR RESPIR J, V17, P395, DOI 10.1183/09031936.01.17303950; Hollingsworth JW, 2008, J CLIN INVEST, V118, P3462, DOI 10.1172/JCI34378; Hure A, 2009, PUBLIC HEALTH NUTR, V12, P853, DOI 10.1017/S1368980008003212; Husemoen LLN, 2006, INT J EPIDEMIOL, V35, P954, DOI 10.1093/ije/dyl094; JAMA, JAMA; Jung J, 2013, CLIN EXP ALLERGY, V43, P425, DOI 10.1111/cea.12089; Karmaus W, 2013, CURR OPIN ALLERGY CL, V13, P63, DOI 10.1097/ACI.0b013e32835ad0e7; Kerkhof M, 2013, J ALLERGY CLIN IMMUN; Khan Mohammad Beigi P., 2007, J ALLERGY CLIN IMMUN, V120, P13, DOI [10.1007/978-3-319-47907-1_4, DOI 10.1007/978-3-319-47907-1_4]; Kiefte-de Jong JC, 2012, J NUTR, V142, P731, DOI 10.3945/jn.111.154948; Kim HP, 2013, EPIGENOMICS-UK, V5, P195, DOI [10.2217/epi.13.14, 10.2217/EPI.13.14]; Klee GG, 2000, CLIN CHEM, V46, P1277; Konstantinova SV, 2008, AM J CLIN NUTR, V88, P1663, DOI 10.3945/ajcn.2008.26531; Lewis S, 1996, THORAX, V51, P670, DOI 10.1136/thx.51.7.670; Li ZY, 2008, J LIPID RES, V49, P1187, DOI 10.1194/jlr.R700019-JLR200; Lin JH, 2013, J ALLERGY CLIN IMMUN, V131, P918, DOI 10.1016/j.jaci.2012.10.046; Lin SY, 2011, AM J RHINOL ALLERGY, V25, pE66, DOI 10.2500/ajra.2011.25.3580; Litonjua AA, 2008, IMMUNOL ALLERGY CLIN, V28, P603, DOI 10.1016/j.iac.2008.03.005; Litonjua AA, 2006, AM J CLIN NUTR, V84, P903, DOI 10.1093/ajcn/84.4.903; Ly NP, 2011, J ALLERGY CLIN IMMUN, V127, P1087, DOI 10.1016/j.jaci.2011.02.015; Magdelijns FJH, 2011, PEDIATRICS, V128, pE135, DOI 10.1542/peds.2010-1690; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; Matsui EC, 2009, J ALLERGY CLIN IMMUN, V123, P1253, DOI 10.1016/j.jaci.2009.03.007; McKeever TM, 2004, AM J RESP CRIT CARE, V170, P725, DOI 10.1164/rccm.200405-611PP; McLoughlin RM, 2011, J ALLERGY CLIN IMMUN, V127, P1097, DOI 10.1016/j.jaci.2011.02.012; McNeil SD, 2001, P NATL ACAD SCI USA, V98, P10001, DOI 10.1073/pnas.171228998; Mehta AK, 2009, EUR J CLIN INVEST, V39, P934, DOI 10.1111/j.1365-2362.2009.02190.x; Mehta AK, 2010, IMMUNOBIOLOGY, V215, P527, DOI 10.1016/j.imbio.2009.09.004; Mitchell EA, 2012, THORAX, V67, P941, DOI 10.1136/thoraxjnl-2011-200901; Miyake Y, 2011, PEDIAT ALLERG IMM-UK, V22, P69, DOI 10.1111/j.1399-3038.2010.01081.x; Moens AL, 2008, CIRCULATION, V117, P1810, DOI 10.1161/CIRCULATIONAHA.107.725481; Moore JB, 2011, ADV NUTR, V2, P355, DOI 10.3945/an.111.000554; Nicolai T, 2003, EUR RESPIR J, V21, P956, DOI 10.1183/09031936.03.00041103a; Nurmatov U, 2011, J ALLERGY CLIN IMMUN, V127, P724, DOI 10.1016/j.jaci.2010.11.001; Nwaru BI, 2011, EUR J CLIN NUTR, V65, P937, DOI 10.1038/ejcn.2011.67; O'Keefe SJD, 2009, J NUTR, V139, P2044, DOI 10.3945/jn.109.104380; Okun JG, 2002, J BIOL CHEM, V277, P14674, DOI 10.1074/jbc.M200997200; Ozdoganoglu T, 2012, THER ADV RESPIR DIS, V6, P11, DOI 10.1177/1753465811431975; Park Bo-hyun, 2005, J Prev Med Public Health, V38, P437; Patel BD, 2006, THORAX, V61, P388, DOI 10.1136/thx.2004.024935; Pearce N, 2007, THORAX, V62, P758, DOI 10.1136/thx.2006.070169; Powers HJ, 2007, BRIT J NUTR, V98, P665, DOI 10.1017/S0007114507795326; Ptashne M, 2007, CURR BIOL, V17, pR233, DOI 10.1016/j.cub.2007.02.030; Quyen Dao To, 2004, J Med Invest, V51, P171; REYNOLDS RD, 1985, AM J CLIN NUTR, V41, P684, DOI 10.1093/ajcn/41.4.684; Richard-Tremblay AA, 2013, CURR DRUG SAF, V8, P153, DOI 10.2174/15748863113089990034; Rossi M, 2011, NUTRIENTS, V3, P118, DOI 10.3390/nu3010118; Shaheen Maha A, 2011, Indian J Dermatol, V56, P673, DOI 10.4103/0019-5154.91827; Sordillo JE, 2013, INT ARCH ALLERGY IMM, V161, P37, DOI 10.1159/000343004; Steegers-Theunissen RP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007845; Strachan DP, 1996, BRIT MED J, V312, P1195; Strozzi GP, 2008, J CLIN GASTROENTEROL, V42, pS179, DOI 10.1097/MCG.0b013e31818087d8; SUR S, 1993, ANN ALLERGY, V70, P147; SZCZEKLIK A, 1990, EUR RESPIR J, V3, P535; Tang WHW, 2013, NEW ENGL J MED, V368, P1575, DOI 10.1056/NEJMoa1109400; Thuesen BH, 2010, ALLERGY, V65, P1446, DOI 10.1111/j.1398-9995.2010.02378.x; Thuesen BH, 2009, CLIN RESPIR J, V3, P102, DOI 10.1111/j.1752-699X.2009.00128.x; To T, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-204; Tucker KL, 2004, AM J CLIN NUTR, V79, P805; Ubbink JB, 1996, J CLIN INVEST, V98, P177, DOI 10.1172/JCI118763; van der Valk RJP, 2013, ALLERGY, V68, P788, DOI 10.1111/all.12146; Varraso R, 2012, CURR ALLERGY ASTHM R, V12, P201, DOI 10.1007/s11882-012-0253-8; Wang ZN, 2011, NATURE, V472, P57, DOI 10.1038/nature09922; Whitrow MJ, 2009, AM J EPIDEMIOL, V170, P1486, DOI 10.1093/aje/kwp315; Williams H, 2008, J ALLERGY CLIN IMMUN, V121, P947, DOI 10.1016/j.jaci.2007.11.004; Withers NJ, 1998, AM J RESP CRIT CARE, V158, P352, DOI 10.1164/ajrccm.158.2.9705079; Wolff GL, 1998, FASEB J, V12, P949, DOI 10.1096/fasebj.12.11.949; Woods RK, 2003, AM J CLIN NUTR, V78, P414, DOI 10.1093/ajcn/78.3.414; Wright AJA, 2007, BRIT J NUTR, V98, P667, DOI 10.1017/S0007114507777140; Yen CLE, 1999, FASEB J, V13, P135, DOI 10.1096/fasebj.13.1.135; Yetley EA, 2011, AM J CLIN NUTR, V94, p313S, DOI 10.3945/ajcn.111.013243; Yoshida Y, 2006, NUTRITION, V22, P303, DOI 10.1016/j.nut.2005.07.020; Zeisel SH, 2009, NUTR REV, V67, P615, DOI 10.1111/j.1753-4887.2009.00246.x	110	38	43	1	37	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2014	133	5					1246	1254		10.1016/j.jaci.2013.10.039	http://dx.doi.org/10.1016/j.jaci.2013.10.039			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AG5HS	24360248	Green Accepted			2022-12-18	WOS:000335450700002
J	Cifuentes, L; Vosseler, S; Blank, S; Seismann, H; Pennino, D; Darsow, U; Bredehorst, R; Ring, J; Mempel, M; Spillner, E; Ollert, MW				Cifuentes, Liliana; Vosseler, Sebastian; Blank, Simon; Seismann, Henning; Pennino, Davide; Darsow, Ulf; Bredehorst, Reinhard; Ring, Johannes; Mempel, Martin; Spillner, Edzard; Ollert, Markus W.			Identification of Hymenoptera venom-allergic patients with negative specific IgE to venom extract by using recombinant allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Cifuentes, Liliana; Vosseler, Sebastian; Darsow, Ulf; Spillner, Edzard; Ollert, Markus W.] Tech Univ Munich, Dept Dermatol & Allergy, D-80290 Munich, Germany; [Blank, Simon; Seismann, Henning; Bredehorst, Reinhard; Mempel, Martin] Univ Hamburg, Inst Biochem & Mol Biol, Hamburg, Germany; [Pennino, Davide] Tech Univ Munich, Ctr Allergy & Environm ZAUM, D-80290 Munich, Germany; [Pennino, Davide] Helmholtz Ctr, Munich, Germany; [Ring, Johannes] Univ Med Gottingen, Dept Dermatol Venereol & Allergol, Gottingen, Germany	Technical University of Munich; University of Hamburg; Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Gottingen	Cifuentes, L (corresponding author), Tech Univ Munich, Dept Dermatol & Allergy, D-80290 Munich, Germany.	liliana.cifuentes@lrz.tu-muenchen.de	Blank, Simon/M-7708-2013; Ring, Johannes/GLN-4341-2022	Ring, Johannes/0000-0001-8236-3152; Seismann, Henning/0000-0001-5199-2247; Ollert, Markus W./0000-0002-8055-0103; spillner, edzard/0000-0003-0999-5254				Blank S, 2010, J IMMUNOL, V184, P5403, DOI 10.4049/jimmunol.0803709; Hofmann SC, 2011, J ALLERGY CLIN IMMUN, V127, P265, DOI 10.1016/j.jaci.2010.06.042; JEEP S, 1992, ALLERGY, V47, P35, DOI 10.1111/j.1398-9995.1992.tb02247.x; Mittermann I, 2010, J ALLERGY CLIN IMMUN, V125, P1300, DOI 10.1016/j.jaci.2010.03.017; Muller UR, 2009, ALLERGY, V64, P543, DOI 10.1111/j.1398-9995.2008.01794.x; Rueff F, 1996, ALLERGY, V51, P216, DOI 10.1111/j.1398-9995.1996.tb04596.x; Seismann Henning, 2010, Clin Mol Allergy, V8, P7, DOI 10.1186/1476-7961-8-7	7	38	38	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2014	133	3					909	910		10.1016/j.jaci.2013.09.047	http://dx.doi.org/10.1016/j.jaci.2013.09.047			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EK	24290287				2022-12-18	WOS:000332397600044
J	Smolen, KK; Ruck, CE; Fortuno, ES; Ho, K; Dimitriu, P; Mohn, WW; Speert, DP; Cooper, PJ; Esser, M; Goetghebuer, T; Marchant, A; Kollmann, TR				Smolen, Kinga K.; Ruck, Candice E.; Fortuno, Edgardo S., III; Ho, Kevin; Dimitriu, Pedro; Mohn, William W.; Speert, David P.; Cooper, Philip J.; Esser, Monika; Goetghebuer, Tessa; Marchant, Arnaud; Kollmann, Tobias R.			Pattern recognition receptor-mediated cytokine response in infants across 4 continents	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Innate immunity; immune development; infectious disease; global	INNATE IMMUNE-RESPONSE; VACCINES; SYSTEM; INFECTIONS; MECHANISMS; COUNTRIES; DISTINCT; AGE	Background: Susceptibility to infection as well as response to vaccination varies among populations. To date, the underlying mechanisms responsible for these clinical observations have not been fully delineated. Because innate immunity instructs adaptive immunity, we hypothesized that differences between populations in innate immune responses may represent a mechanistic link to variation in susceptibility to infection or response to vaccination. Objective: Determine whether differences in innate immune responses exist among infants from different continents of the world. Methods: We determined the innate cytokine response following pattern recognition receptor (PRR) stimulation of whole blood from 2-year-old infants across 4 continents (Africa, North America, South America, and Europe). Results: We found that despite the many possible genetic and environmental exposure differences in infants across 4 continents, innate cytokine responses were similar for infants from North America, South America, and Europe. However, cells from South African infants secreted significantly lower levels of cytokines than did cells from infants from the 3 other sites, and did so following stimulation of extracellular and endosomal but not cytosolic PRRs. Conclusions: Substantial differences in innate cytokine responses to PRR stimulation exist among different populations of infants that could not have been predicted. Delineating the underlying mechanism(s) for these differences will not only aid in improving vaccine-mediated protection but possibly also provide clues for the susceptibility to infection in different regions of the world.	[Smolen, Kinga K.; Ruck, Candice E.; Kollmann, Tobias R.] Univ British Columbia, Dept Expt Med, Vancouver, BC V5Z 1M9, Canada; [Fortuno, Edgardo S., III; Ho, Kevin; Speert, David P.; Kollmann, Tobias R.] Univ British Columbia, Dept Pediat, Vancouver, BC V6T 1W5, Canada; [Dimitriu, Pedro; Mohn, William W.; Speert, David P.] Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V5Z 1M9, Canada; [Cooper, Philip J.] Ctr Invest FEPIS, Esmeraldas, Quininde, Ecuador; [Cooper, Philip J.] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England; [Cooper, Philip J.] Pontificia Univ Catolica Ecuador, Escuela Biol, Ctr Invest Enfermedades Infecciosas, Casilla, Quito, Ecuador; [Esser, Monika] NHLS, Dept Pathol, Div Med Microbiol, Immunol Unit, Matieland, South Africa; [Esser, Monika] Univ Stellenbosch, Matieland, South Africa; [Goetghebuer, Tessa] Ctr Hosp Univ St Pierre, Dept Paediat, Brussels, Belgium; [Marchant, Arnaud] Univ Libre Bruxelles, Inst Med Immunol, Gosselies, Belgium	University of British Columbia; University of British Columbia; University of British Columbia; Liverpool School of Tropical Medicine; University of Liverpool; Pontificia Universidad Catolica del Ecuador; Stellenbosch University; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles	Kollmann, TR (corresponding author), CFRI A5-147,950 W28th Ave, Vancouver, BC V5Z 4H4, Canada.	tkollm@mac.com	Smolen, Kinga/ABB-1903-2021	Cooper, Philip/0000-0002-6770-6871; Kollmann, Tobias/0000-0003-2403-9762; Fortuno, Edgardo/0000-0001-5294-1679; Smolen, Kinga/0000-0001-8650-3693	Career Award in the Biomedical Sciences from the Burroughs Wellcome Fund; Michael Smith Foundation for Health Research Career Investigator Award; Wellcome Trust [088862/Z/09/Z]; BC Children's Hospital (BCCH) Foundation; CIHR [CMF-108029]	Career Award in the Biomedical Sciences from the Burroughs Wellcome Fund(Burroughs Wellcome Fund); Michael Smith Foundation for Health Research Career Investigator Award(Michael Smith Foundation for Health Research); Wellcome Trust(Wellcome TrustEuropean Commission); BC Children's Hospital (BCCH) Foundation; CIHR(Canadian Institutes of Health Research (CIHR))	T.R.K. is supported in part by a Career Award in the Biomedical Sciences from the Burroughs Wellcome Fund, and a Michael Smith Foundation for Health Research Career Investigator Award. D. P. S. is a Sauder Family Professor of Pediatric Infectious Diseases. P.J.C is supported by the Wellcome Trust (088862/Z/09/Z). A. M. is a senior research associate at the Belgian Fund for Scientific Research. This work was in part supported by the BC Children's Hospital (BCCH) Foundation and CIHR CMF-108029.	[Anonymous], 2003, COR INF DEV IMM POL; [Anonymous], 2011, WORLD POP PROSP 2010; Arevshatian L, 2007, B WORLD HEALTH ORGAN, V85, P449, DOI 10.2471/BLT.06.031526; Belderbos ME, 2009, CLIN IMMUNOL, V133, P228, DOI 10.1016/j.clim.2009.07.003; Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8; Blencowe H, 2012, LANCET, V379, P2162, DOI 10.1016/S0140-6736(12)60820-4; Blimkie D, 2011, J IMMUNOL METHODS, V366, P89, DOI 10.1016/j.jim.2011.01.009; Bouxin G, 2005, J VEG SCI, V16, P355, DOI 10.1658/1100-9233(2005)016[0355:GAMAP]2.0.CO;2; Brown EM, 2013, NAT IMMUNOL, V14, P660, DOI 10.1038/ni.2611; Collado MC, 2012, GUT MICROBES, V3, P352, DOI 10.4161/gmic.21215; Cho P, 2013, GENES IMMUN, V14, P199, DOI 10.1038/gene.2013.5; Clemens J, 2005, NAT MED, V11, pS12, DOI 10.1038/nm1225; Cooper PJ, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-184; Corbett NP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015041; De Caceres M, 2007, ADV FUZZY SETS SYSTE, V2, P41, DOI DOI 10.1111/J.1654-1103.2005.TB02374.X; Djuardi Y, 2011, PARASITOLOGY, V138, P1508, DOI 10.1017/S0031182011000588; Djuardi Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014066; FINE PEM, 1995, LANCET, V346, P1339, DOI 10.1016/S0140-6736(95)92348-9; Flanagan KL, 2010, EXPERT REV VACCINES, V9, P665, DOI 10.1586/ERV.10.41; Graham JE, 2006, J BEHAV MED, V29, P389, DOI 10.1007/s10865-006-9057-4; Hostetter MK, 2012, NEW ENGL J MED, V366, P1328, DOI 10.1056/NEJMra1111421; Jansen K, 2008, J IMMUNOL METHODS, V336, P183, DOI 10.1016/j.jim.2008.04.013; Kollmann TR, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00081; Kollmann TR, 2012, IMMUNITY, V37, P771, DOI 10.1016/j.immuni.2012.10.014; Kollmann TR, 2009, J IMMUNOL, V183, P7150, DOI 10.4049/jimmunol.0901481; Levine MM, 2011, VACCINE, V29, pD116, DOI 10.1016/j.vaccine.2011.11.090; Levine MM, 2009, IMMUNOL CELL BIOL, V87, P274, DOI 10.1038/icb.2009.15; Levy O, 2013, VACCINE, V31, P2500, DOI 10.1016/j.vaccine.2012.10.016; Lewis D. B., 2011, INFECT DIS FETUS NEW, P80, DOI DOI 10.1016/B978-1-4160-6400-8.00004-3; Lisciandro JG, 2012, J ALLERGY CLIN IMMUN, V130, P1167, DOI 10.1016/j.jaci.2012.06.005; Lisciandro JG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036793; Netea MG, 2011, NEW ENGL J MED, V364, P60, DOI 10.1056/NEJMra1001976; Nguyen M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010407; Poland GA, 2008, VACCINE, V26, P6183, DOI 10.1016/j.vaccine.2008.06.057; Pulendran B, 2011, NAT IMMUNOL, V12, P509, DOI 10.1038/ni.2039; Reikie BA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044763; Shih DC, 2011, JOVE-J VIS EXP, DOI 10.3791/2397; Slogrove AL, 2010, J TROP PEDIATRICS, V56, P75, DOI 10.1093/tropej/fmp057; Teran R, 2011, CLIN IMMUNOL, V138, P299, DOI 10.1016/j.clim.2010.12.011; Turvey SE, 2010, J ALLERGY CLIN IMMUN, V125, pS24, DOI 10.1016/j.jaci.2009.07.016; van den Biggelaar AHJ, 2009, J ALLERGY CLIN IMMUN, V124, P544, DOI 10.1016/j.jaci.2009.03.040; World Health Organization, 2007, WHO CHILD GROWTH STA, DOI 10.1093/tropej/fmn002	42	38	38	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2014	133	3					818	+		10.1016/j.jaci.2013.09.038	http://dx.doi.org/10.1016/j.jaci.2013.09.038			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EK	24290283	Green Accepted, hybrid, Green Published			2022-12-18	WOS:000332397600026
J	Nguyen, JM; Holbrook, JT; Wei, CY; Gerald, LB; Teague, WG; Wise, RA				Nguyen, Jessica M.; Holbrook, Janet T.; Wei, Christine Y.; Gerald, Lynn B.; Teague, W. Gerald; Wise, Robert A.		Amer Lung Assoc Asthma Clinical Re	Validation and psychometric properties of the Asthma Control Questionnaire among children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; asthma control; Asthma Control Questionnaire; validity; minimally important difference	QUALITY-OF-LIFE; MINIMALLY IMPORTANT DIFFERENCES; CHILDHOOD ASTHMA; HEALTH-STATUS; OUTCOMES; RESPONSIVENESS; VERSIONS	Background: The Asthma Control Questionnaire (ACQ) is a patient-centered tool for evaluating asthma control. It has been validated in adults, but not well-validated among children. Objective: We evaluated the reliability, validity, and responsiveness to change of the ACQ for assessing asthma control in children ages 6 to 17 years. A threshold value for poor disease control and a minimally important difference were also determined. Methods: Data from 305 asthmatic children enrolled in a clinical trial were examined. The ACQ was administered at 8 visits. We analyzed results for the combined age group and for the 6- to 11-year-old and 12- to 17-year-old age groups separately. Results: Overall, the Cronbach alpha value (internal consistency) for the ACQ was 0.74 at baseline, and the intraclass correlation coefficient (test-retest reliability) for repeated questionnaires among stable patients was 0.53. The Pearson correlations between the ACQ and other asthma questionnaires were moderate to strong (-0.64 to -0.73). Mean ACQ scores were higher (worse) in patients whose peak flow decreased, who used more rescue medications, or who sought medical care for asthma than in patients who were stable (P < .0001 for all measures). Changes in ACQ scores were significantly different among patients with deteriorating, improving, or stable asthma symptoms (P <= .01). The optimal threshold indicating poor asthma control was 1.25 or greater. The minimally important difference was established to be 0.40. Results for the separate age groups were similar. Conclusion: The ACQ is a moderately reliable, valid, and responsive tool with adequate psychometric properties for assessing recent asthma control among children.	[Nguyen, Jessica M.; Wise, Robert A.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21218 USA; [Holbrook, Janet T.; Wei, Christine Y.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21218 USA; [Gerald, Lynn B.] Univ Arizona, Coll Publ Hlth, Dept Hlth Promot Sci, Tucson, AZ 85721 USA; [Teague, W. Gerald] Univ Virginia, Sch Med, Dept Pediat, Charlottesville, VA 22903 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of Arizona; University of Virginia	Wise, RA (corresponding author), Johns Hopkins Asthma & Allergy Ctr 4B72, Div Pulm & Crit Care Med, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	rwise@jhmi.edu		Wise, Robert/0000-0002-8353-2349	National Institutes of Health/National Heart, Lung, and Blood Institute [U01 HL080433, U01 HL080450]; American Lung Association; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL080433, U01HL080450] Funding Source: NIH RePORTER	National Institutes of Health/National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); American Lung Association; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The Study of Acid Reflux in Children with Asthma was supported by National Institutes of Health/National Heart, Lung, and Blood Institute grants U01 HL080433 and U01 HL080450 and the American Lung Association and is registered at ClinicalTrials. Gov (NCT00442013)	Cloutier MM, 2012, J ALLERGY CLIN IMMUN, V129, pS24, DOI 10.1016/j.jaci.2011.12.980; Guyatt GH, 2002, MAYO CLIN PROC, V77, P371, DOI 10.4065/77.4.371; Guyatt GH, 1997, PEDIATRICS, V99, P165, DOI 10.1542/peds.99.2.165; Hardin J. W., 2013, GEN ESTIMATING EQUAT; Hays Ron D, 2005, COPD, V2, P63; Holbrook JT, 2012, JAMA-J AM MED ASSOC, V307, P373, DOI 10.1001/jama.2011.2035; JAESCHKE R, 1989, CONTROL CLIN TRIALS, V10, P407, DOI 10.1016/0197-2456(89)90005-6; Juniper EF, 2010, EUR RESPIR J, V36, P1410, DOI 10.1183/09031936.00117509; Juniper EF, 2006, RESP MED, V100, P616, DOI 10.1016/j.rmed.2005.08.012; Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Juniper EF, 1996, QUAL LIFE RES, V5, P35, DOI 10.1007/BF00435967; Leidy Nancy Kline, 2005, COPD, V2, P157; Liu AH, 2007, J ALLERGY CLIN IMMUN, V119, P817, DOI 10.1016/j.jaci.2006.12.662; Norman GR, 2003, MED CARE, V41, P582, DOI 10.1097/00005650-200305000-00004; Revicki DA, 1998, CHEST, V114, P998, DOI 10.1378/chest.114.4.998; Revicki D, 2008, J CLIN EPIDEMIOL, V61, P102, DOI 10.1016/j.jclinepi.2007.03.012; Sastre J, 2010, J ASTHMA, V47, P865, DOI 10.3109/02770903.2010.491149; Schatz M, 2006, J ALLERGY CLIN IMMUN, V117, P549, DOI 10.1016/j.jaci.2006.01.011; Wyrwich KW, 1999, J CLIN EPIDEMIOL, V52, P861, DOI 10.1016/S0895-4356(99)00071-2; Yost KJ, 2005, EVAL HEALTH PROF, V28, P172, DOI 10.1177/0163278705275340	21	38	39	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2014	133	1					91	+		10.1016/j.jaci.2013.06.029	http://dx.doi.org/10.1016/j.jaci.2013.06.029			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	281MM	23932458	Green Accepted			2022-12-18	WOS:000329105700012
J	Ubel, C; Sopel, N; Graser, A; Hildner, K; Reinhardt, C; Zimmermann, T; Rieker, RJ; Maier, A; Neurath, MF; Murphy, KM; Finotto, S				Ubel, Caroline; Sopel, Nina; Graser, Anna; Hildner, Kai; Reinhardt, Cornelia; Zimmermann, Theodor; Rieker, Ralf Joachim; Maier, Anja; Neurath, Markus F.; Murphy, Kenneth M.; Finotto, Susetta			The activating protein 1 transcription factor basic leucine zipper transcription factor, ATF-like (BATF), regulates lymphocyte- and mast cell-driven immune responses in the setting of allergic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						BATF; asthma; T(H)2; T(H)17; mast cells; T cells	CD4(+) T-CELLS; C-KIT LIGAND; NEGATIVE REGULATOR; AIRWAY HYPERREACTIVITY; IN-VIVO; B-CELLS; LUNG; MICE; BET; JUN	Background: Mice without the basic leucine zipper transcription factor, ATF-like (BATF) gene (Batf(-/-)) lack T(H)17 and follicular helper T cells, which demonstrates that Batf is a transcription factor important for T- and B-cell differentiation. Objective: In this study we examined whether BATF expression would influence allergic asthma. Methods: In a cohort of preschool control children and children with asthma, we analyzed BATF mRNA expression using real-time PCR in PBMCs. In a murine model of allergic asthma, we analyzed differences in this allergic disease between wildtype, Batf transgenic, and Batf(-/-) mice. Results: In the absence of corticosteroid treatment, children with recurrent asthma have a significant increase in BATF mRNA expression in their PBMCs. Batf(-/-) mice display a significant reduction in the pathophysiologic responses seen in asthmatic wildtype littermates. Moreover, we discovered a decrease in IL-3 production and IL-3-dependent mast cell development in Batf(-/-) mice. By contrast, IFN-gamma was induced in lung CD4(+) and CD8(+) T cells. Intranasal delivery of anti-IFN-gamma antibodies induced airway hyperresponsiveness and inflammation in wild-type but not in Batf(-/-) mice. Transgenic overexpression of Batf under the control of the CD2 promoter/enhancer augmented lung inflammation and IgE levels in the setting of experimental asthma. Conclusion: BATF is increased in non-steroid-treated asthmatic children. Targeting BATF expression resulted in amelioration of the pathophysiologic responses seen in children with allergic asthma, and BATF has emerged as a novel target for antiasthma interventions.	[Ubel, Caroline; Sopel, Nina; Graser, Anna; Maier, Anja; Finotto, Susetta] Univ Erlangen Nurnberg, Dept Mol Pneumol, D-91052 Erlangen, Germany; [Hildner, Kai; Neurath, Markus F.] Univ Erlangen Nurnberg, Dept Med 1, D-91052 Erlangen, Germany; [Reinhardt, Cornelia; Zimmermann, Theodor] Univ Erlangen Nurnberg, Childrens Hosp, Dept Allergy & Pneumol, D-91052 Erlangen, Germany; [Rieker, Ralf Joachim] Univ Erlangen Nurnberg, Inst Pathol, D-91052 Erlangen, Germany; [Murphy, Kenneth M.] Washington Univ, Dept Pathol, St Louis, MO 63130 USA	University of Erlangen Nuremberg; University of Erlangen Nuremberg; University of Erlangen Nuremberg; University of Erlangen Nuremberg; Washington University (WUSTL)	Finotto, S (corresponding author), Univ Erlangen Nurnberg, Dept Mol Pneumol, Lab Cellular & Mol Lung Immunol, Hartmannstr 14,Rm 1-1025, D-91052 Erlangen, Germany.	susetta.finotto@uk-erlangen.de	Finotto, Susetta/H-2753-2019		department of Molecular Pneumology; European Grant "Predicta"-WP1-UK-ER; DFG; DFG at the University of Erlangen (Germany) [GK1660]	department of Molecular Pneumology; European Grant "Predicta"-WP1-UK-ER; DFG(German Research Foundation (DFG)); DFG at the University of Erlangen (Germany)	Supported by the department of Molecular Pneumology, the European Grant "Predicta"-WP1-UK-ER, a DFG grant for S. F., and a DFG grant (GK1660) at the University of Erlangen (Germany).	ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; Arinobu Yojiro, 2009, Allergology International, V58, P21, DOI 10.2332/allergolint.08-RAI-0067; Betz BC, 2010, J EXP MED, V207, P933, DOI 10.1084/jem.20091548; Boyman O, 2012, NAT REV IMMUNOL, V12, P180, DOI 10.1038/nri3156; Brand S, 2012, J ALLERGY CLIN IMMUN, V129, P1602, DOI 10.1016/j.jaci.2011.12.963; Caretto D, 2010, J IMMUNOL, V184, P30, DOI 10.4049/jimmunol.0903412; Doganci A, 2008, J IMMUNOL, V181, P1917, DOI 10.4049/jimmunol.181.3.1917; Ellyard JI, 2011, NAT IMMUNOL, V12, P519, DOI 10.1038/ni.2042; Finotto S, 1997, J CLIN INVEST, V99, P1721, DOI 10.1172/JCI119336; Finotto S, 2005, INT IMMUNOL, V17, P993, DOI 10.1093/intimm/dxh281; Finotto S, 2002, SCIENCE, V295, P336, DOI 10.1126/science.1065544; Finotto S, 2001, J ALLERGY CLIN IMMUN, V107, P279, DOI 10.1067/mai.2001.113049; Galli SJ, 2010, EUR J IMMUNOL, V40, P1843, DOI 10.1002/eji.201040559; Hartl D, 2007, J ALLERGY CLIN IMMUN, V119, P1258, DOI 10.1016/j.jaci.2007.02.023; Hausding M, 2011, INT IMMUNOL, V23, P1, DOI 10.1093/intimm/dxq451; Ise W, 2011, NAT IMMUNOL, V12, P536, DOI 10.1038/ni.2037; Koch S, 2013, SCI REP-UK, V3, DOI 10.1038/srep01754; Koltsida O, 2011, EMBO MOL MED, V3, P348, DOI 10.1002/emmm.201100142; Lewkowich IP, 2005, J EXP MED, V202, P1549, DOI 10.1084/jem.20051506; Li P, 2012, NATURE, V490, P543, DOI 10.1038/nature11530; Lloyd CM, 2010, NAT REV IMMUNOL, V10, P838, DOI 10.1038/nri2870; Malek TR, 2008, J CLIN IMMUNOL, V28, P635, DOI 10.1007/s10875-008-9235-y; Moisan J, 2007, J EXP MED, V204, P2825, DOI 10.1084/jem.20070994; Presser K, 2008, J IMMUNOL, V181, P7751, DOI 10.4049/jimmunol.181.11.7751; Saraiva M, 2010, NAT REV IMMUNOL, V10, P170, DOI 10.1038/nri2711; Sauer KA, 2006, NAT PROTOC, V1, P2870, DOI 10.1038/nprot.2006.435; Schnyder-Candrian S, 2006, J EXP MED, V203, P2715, DOI 10.1084/jem.20061401; Schraml BU, 2009, NATURE, V460, P405, DOI 10.1038/nature08114; Stassen M, 2012, ANN NY ACAD SCI, V1247, P56, DOI 10.1111/j.1749-6632.2011.06351.x; Staudt V, 2010, IMMUNITY, V33, P192, DOI 10.1016/j.immuni.2010.07.014; Stellato Cristiana, 2004, Proc Am Thorac Soc, V1, P255, DOI 10.1513/pats.200402-015MS; Tussiwand R, 2012, NATURE, V490, P502, DOI 10.1038/nature11531; Ukena D, 2008, DTSCH ARZTEBL INT, V105, P385, DOI 10.3238/arztebl.2008.0385; Wei P, 1998, MOL ENDOCRINOL, V12, P1322, DOI 10.1210/me.12.9.1322; Wilder JA, 2001, J LEUKOCYTE BIOL, V69, P538; Williams KL, 2001, EUR J IMMUNOL, V31, P1620, DOI 10.1002/1521-4141(200105)31:5<1620::AID-IMMU1620>3.0.CO;2-3; Yao Z, 2007, BLOOD, V109, P4368, DOI 10.1182/blood-2006-11-055756; Zhou XY, 2009, CURR OPIN IMMUNOL, V21, P281, DOI 10.1016/j.coi.2009.05.007	38	38	42	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2014	133	1					198	+		10.1016/j.jaci.2013.09.049	http://dx.doi.org/10.1016/j.jaci.2013.09.049			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	281MM	24290279				2022-12-18	WOS:000329105700027
J	Joseph, K; Tholanikunnel, BG; Bygum, A; Ghebrehiwet, B; Kaplan, AP				Joseph, Kusumam; Tholanikunnel, Baby G.; Bygum, Anette; Ghebrehiwet, Berhane; Kaplan, Allen P.			Factor XII-independent activation of the bradykinin-forming cascade: Implications for the pathogenesis of hereditary angioedema types I and II	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Bradykinin; factor XII; prekallikrein; kininogen; C1 inhibitor	MOLECULAR-WEIGHT KININOGEN; HUMAN HAGEMAN-FACTOR; PREKALLIKREIN; PLASMA; CLEAVAGE; INHIBITOR; COMPLEX; KALLIKREIN	Background: We have previously reported that prekallikrein expresses an active site when it is bound to high-molecular-weight kininogen (HK) and can digest HK to produce bradykinin. The reaction is stoichiometric and inhibited by C1 inhibitor (C1-INH) or corn trypsin inhibitor. Addition of heat shock protein 90 leads to conversion of prekallikrein to kallikrein in a zinc-dependent reaction. Objective: Our goal was to determine whether these reactions are demonstrable in plasma and distinguish them from activation through factor XII. Methods: Plasma was incubated in polystyrene plates and assayed for kallikrein formation. C1-INH was removed from factor XII-deficient plasma by means of immunoadsorption. Results: We demonstrate that prekallikrein-HK will activate to kallikrein in phosphate-containing buffers and that the rate is further accelerated on addition of heat shock protein 90. Prolonged incubation of plasma deficient in both factor XII and C1-INH led to conversion of prekallikrein to kallikrein and cleavage of HK, as was seen in plasma from patients with hereditary angioedema but not plasma from healthy subjects. Conclusions: These results indicate that C1-INH stabilizes the prekallikrein-HK complex to prevent HK cleavage either by prekallikrein or by prekallikrein-HK autoactivation to generate kallikrein. In patients with hereditary angioedema, kallikrein and bradykinin formation can occur without invoking factor XII activation, although the kallikrein formed can rapidly activate factor XII if it is surface bound.	[Joseph, Kusumam; Tholanikunnel, Baby G.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; [Kaplan, Allen P.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; [Bygum, Anette] Odense Univ Hosp, Dept Dermatol, Odense, Denmark; [Bygum, Anette] Odense Univ Hosp, Allergy Ctr, Odense, Denmark; [Ghebrehiwet, Berhane] SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA	Medical University of South Carolina; Medical University of South Carolina; University of Southern Denmark; Odense University Hospital; University of Southern Denmark; Odense University Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Joseph, K (corresponding author), Storm Eye Inst, Dept Biochem & Mol Biol, Rm 511,167 Ashley Ave, Charleston, SC 29425 USA.	josephk@musc.edu		Bygum, Anette/0000-0002-3004-0180	Shire Human Genetics Therapies, Lexington, Massachusetts; Shire; DYAX; CSL Behring; National Institutes of Health; National Institute of Allergy and Infectious Diseases; Abcam; Santa Cruz; HyCult; Robert Michael Educational Institute	Shire Human Genetics Therapies, Lexington, Massachusetts; Shire; DYAX; CSL Behring; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Abcam; Santa Cruz; HyCult; Robert Michael Educational Institute	Supported by Shire Human Genetics Therapies, Lexington, Massachusetts.; K. Joseph has received grants from Shire and has grants/grants pending from Shire, DYAX and CSL Behring. A. Bygum is a board member on the CSL Advisory board and has consultant arrangements with Shire Bradykinin Workshop, Viropharma Consulting, and SOBI. B. Ghebrehiwet has received grants from the National Institutes of Health and the National Institute of Allergy and Infectious Diseases; has consultant arrangements with Viropharma; and has received royalties from Abcam, Santa Cruz, and HyCult. A. P. Kaplan has received grants and travel support to meetings from Shire; has consultant arrangements with Genentech, Sanofi-Aventis, and DYAX; has grants/grants pending with CSL Behring, Shire, and DYAX; has received payment for lectures including service on speakers' bureaus from DYAX and the Robert Michael Educational Institute; and has received payment for development of educational presentations from the Robert Michael Educational Institute. B. G. Tholanikunnel declares no relevant conflicts of interest.	COCHRANE CG, 1973, J EXP MED, V138, P1564, DOI 10.1084/jem.138.6.1564; DUNN JT, 1982, J BIOL CHEM, V257, P1779; FIELDS T, 1983, J ALLERGY CLIN IMMUN, V72, P54, DOI 10.1016/0091-6749(83)90052-0; HOJIMA Y, 1980, THROMB RES, V20, P149, DOI 10.1016/0049-3848(80)90381-3; Joseph K, 2002, P NATL ACAD SCI USA, V99, P896, DOI 10.1073/pnas.022626899; Joseph K, 2009, J ALLERGY CLIN IMMUN, V124, P143, DOI 10.1016/j.jaci.2009.02.006; Kaplan AP, 2002, J ALLERGY CLIN IMMUN, V109, P195, DOI 10.1067/mai.2002.121316; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANDLE RJ, 1976, P NATL ACAD SCI USA, V73, P4179, DOI 10.1073/pnas.73.11.4179; REDDIGARI S, 1988, BLOOD, V71, P1334; Rojkjaer R, 1998, THROMB HAEMOSTASIS, V80, P74, DOI 10.1055/s-0037-1615142; SCOTT CF, 1980, J CLIN INVEST, V65, P413, DOI 10.1172/JCI109684; SHIBAYAMA Y, 1994, BRAZ J MED BIOL RES, V27, P1817; SHOEMAKER LR, 1994, CLIN EXP IMMUNOL, V95, P22; SILVERBERG M, 1980, J BIOL CHEM, V255, P7281; SILVERBERG M, 1982, BLOOD, V60, P64; THOMPSON RE, 1978, J EXP MED, V147, P488, DOI 10.1084/jem.147.2.488; WEISS R, 1986, BLOOD, V68, P239	18	38	38	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2013	132	2					470	475		10.1016/j.jaci.2013.03.026	http://dx.doi.org/10.1016/j.jaci.2013.03.026			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	194KL	23672780	Bronze			2022-12-18	WOS:000322631700026
J	Asai, Y; Greenwood, C; Hull, PR; Alizadehfar, R; Ben-Shoshan, M; Brown, SJ; Campbell, L; Michel, DL; Bussieres, J; Rousseau, F; Fujiwara, TM; Morgan, K; Irvine, AD; McLean, WHI; Clarke, A				Asai, Yuka; Greenwood, Celia; Hull, Peter R.; Alizadehfar, Reza; Ben-Shoshan, Moshe; Brown, Sara J.; Campbell, Linda; Michel, Deborah L.; Bussieres, Johanne; Rousseau, Francois; Fujiwara, T. Mary; Morgan, Kenneth; Irvine, Alan D.; McLean, W. H. Irwin; Clarke, Ann			Filaggrin gene mutation associations with peanut allergy persist despite variations in peanut allergy diagnostic criteria or asthma status	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							NULL MUTATIONS; RISK-FACTOR; PREVALENCE; SENSITIZATION		[Asai, Yuka] McGill Univ, Dept Med, Div Dermatol, Montreal, PQ, Canada; [Asai, Yuka; Clarke, Ann] McGill Univ, Dept Med, Div Clin Epidemiol, Montreal, PQ, Canada; [Greenwood, Celia] McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; [Greenwood, Celia] McGill Univ, Dept Oncol, Montreal, PQ, Canada; [Greenwood, Celia] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada; [Hull, Peter R.; Michel, Deborah L.] Univ Saskatchewan, Div Dermatol, Saskatoon, SK, Canada; [Alizadehfar, Reza; Ben-Shoshan, Moshe] McGill Univ, Dept Pediat, Div Allergy & Clin Immunol, Montreal, PQ H3A 2T5, Canada; [Brown, Sara J.; Campbell, Linda; McLean, W. H. Irwin] Univ Dundee, Dundee, Scotland; [Bussieres, Johanne; Rousseau, Francois] Univ Laval, Quebec City, PQ, Canada; [Fujiwara, T. Mary; Morgan, Kenneth] McGill Univ, Dept Human Genet, Montreal, PQ, Canada; [Fujiwara, T. Mary; Morgan, Kenneth] McGill Univ, Dept Med, Montreal, PQ, Canada; [Morgan, Kenneth] McGill Univ, Res Inst, McGill Univ Hlth Ctr, Montreal, PQ, Canada; [Irvine, Alan D.] Univ Dublin Trinity Coll, Dublin 2, Ireland; [Clarke, Ann] McGill Univ, Dept Med, Div Allergy Clin Immunol, Montreal, PQ, Canada	McGill University; McGill University; Lady Davis Institute; McGill University; McGill University; McGill University; University of Saskatchewan; McGill University; University of Dundee; Laval University; McGill University; McGill University; McGill University; Trinity College Dublin; McGill University	Asai, Y (corresponding author), McGill Univ, Dept Med, Div Dermatol, Montreal, PQ, Canada.	yuka.asai@mail.mcgill.ca	Brown, Sara J/AAF-7095-2019; Irvine, Alan D/A-3982-2008	Brown, Sara J/0000-0002-3232-5251; Irvine, Alan D/0000-0002-9048-2044; Hull, Peter/0000-0002-3896-9373; McLean, William Henry Irwin/0000-0001-5539-5757; Greenwood, Celia/0000-0002-2427-5696; Asai, Yuka/0000-0003-1674-3215; Michel, Deborah/0000-0001-5161-8677	CIHR Funding Source: Medline; Medical Research Council [G0700314] Funding Source: Medline; Wellcome Trust [086398/Z/08/Z, 098439, 092530/Z/10/Z, 090066/B/09/Z] Funding Source: Medline; MRC [G0700314] Funding Source: UKRI	CIHR(Canadian Institutes of Health Research (CIHR)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ben-Shoshan M, 2010, J ALLERGY CLIN IMMUN, V125, P1327, DOI 10.1016/j.jaci.2010.03.015; Berg ND, 2012, J ALLERGY CLIN IMMUN, V129, P374, DOI 10.1016/j.jaci.2011.08.045; Brown SJ, 2011, J ALLERGY CLIN IMMUN, V127, P661, DOI 10.1016/j.jaci.2011.01.031; Fox AT, 2009, J ALLERGY CLIN IMMUN, V123, P417, DOI 10.1016/j.jaci.2008.12.014; Girouard J, 2002, HUM MOL GENET, V11, P185, DOI 10.1093/hmg/11.2.185; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Liu AH, 2010, J ALLERGY CLIN IMMUN, V126, P798, DOI 10.1016/j.jaci.2010.07.026; Niggemann B, 2011, ALLERGY, V66, P980, DOI 10.1111/j.1398-9995.2011.02561.x; Palmer CNA, 2007, J ALLERGY CLIN IMMUN, V120, P64, DOI 10.1016/j.jaci.2007.04.001; Sicherer SH, 2000, J ALLERGY CLIN IMMUN, V106, P53, DOI [10.1067/mai.2000.108105, 10.1067/mai.2000.110158]; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; Strid J, 2005, CLIN EXP ALLERGY, V35, P757, DOI 10.1111/j.1365-2222.2005.02260.x	12	38	39	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2013	132	1					239	242		10.1016/j.jaci.2013.03.043	http://dx.doi.org/10.1016/j.jaci.2013.03.043			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	173BF	23684069	hybrid, Green Published			2022-12-18	WOS:000321052300038
J	Salazar, F; Sewell, HF; Shakib, F; Ghaemmaghami, AM				Salazar, Fabian; Sewell, Herb F.; Shakib, Farouk; Ghaemmaghami, Amir M.			The role of lectins in allergic sensitization and allergic disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						C-type lectin receptor; lectin; glycosylation; allergen type-I hypersensitivity; asthma; house dust mite; mannose receptor; DC-SIGN; Toll-like receptor; dendritic cells; galactins	SURFACTANT PROTEIN-D; HUMAN DENDRITIC CELLS; HOUSE-DUST MITE; NONINTEGRIN DC-SIGN; MANNAN-BINDING LECTIN; NF-KAPPA-B; ASPERGILLUS-FUMIGATUS; MANNOSE RECEPTOR; AIRWAY INFLAMMATION; MURINE MODEL	Allergic diseases are a global public health issue affecting millions of persons around the world. However, full understanding of the molecular basis of this group of chronic inflammatory disorders remains rather elusive. Recently, the role of carbohydrates on allergens and their counter structures on antigen-presenting cells (lectins) have been highlighted as crucial factors in allergen sensitization, which culminates in TH2 cell differentiation and the production of deleterious specific IgE antibodies. Here we review recent progress on the role of different lectins in patients with type I hypersensitivity or allergy, their interplay with other determinants of allergenicity, and ways of developing therapeutic modalities against newly identified targets.	[Salazar, Fabian; Sewell, Herb F.; Shakib, Farouk; Ghaemmaghami, Amir M.] Univ Nottingham, Fac Med & Hlth Sci, Nottingham NG7 2UH, England	University of Nottingham	Ghaemmaghami, AM (corresponding author), Univ Nottingham, Queens Med Ctr, Allergy Res Grp, Div Immunol, West Block,A Floor, Nottingham NG7 2UH, England.	amg@nottingham.ac.uk	Ghaemmaghami, Amir/S-2627-2019; Ghaemmaghami, Amir/AAP-2968-2020; Salazar, Fabian/AAW-2488-2020	Ghaemmaghami, Amir/0000-0003-3160-8759; Salazar Lizama, Fabian/0000-0001-5139-2292	Asthma UK [06/001]; Wellcome Trust V.I.P. fund; National Commission for Scientific and Technological Research (CONICYT), Chile	Asthma UK; Wellcome Trust V.I.P. fund(Wellcome Trust); National Commission for Scientific and Technological Research (CONICYT), Chile(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT))	Supported by Asthma UK (06/001) and the Wellcome Trust V.I.P. fund. F. Salazar is a recipient of a PhD scholarship from the National Commission for Scientific and Technological Research (CONICYT), Chile.	Al-Ghouleh A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033929; Altmann F, 2007, INT ARCH ALLERGY IMM, V142, P99, DOI 10.1159/000096114; Antony AB, 2002, J ALLERGY CLIN IMMUN, V110, P589, DOI 10.1067/mai.2002.127798; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Barrett NA, 2011, J EXP MED, V208, P593, DOI 10.1084/jem.20100793; Barrett NA, 2009, J IMMUNOL, V182, P1119, DOI 10.4049/jimmunol.182.2.1119; Bleijs DA, 2001, TRENDS IMMUNOL, V22, P457, DOI 10.1016/S1471-4906(01)01974-3; Borron PJ, 1998, J IMMUNOL, V161, P4599; Boscher C, 2011, CURR OPIN CELL BIOL, V23, P383, DOI 10.1016/j.ceb.2011.05.001; Brinker KG, 2003, AM J PHYSIOL-LUNG C, V284, pL232, DOI 10.1152/ajplung.00187.2002; Brinker KG, 2001, AM J PHYSIOL-LUNG C, V281, pL1453, DOI 10.1152/ajplung.2001.281.6.L1453; Brown GD, 2003, J EXP MED, V197, P1119, DOI 10.1084/jem.20021890; Calabozo B., 2002, Clinical and Experimental Allergy, V32, P1628, DOI 10.1046/j.1365-2222.2002.01530.x; Chen HY, 2006, J IMMUNOL, V177, P4991, DOI 10.4049/jimmunol.177.8.4991; Deb R, 2007, J BIOL CHEM, V282, P36808, DOI 10.1074/jbc.M702336200; del Pozo V, 2002, AM J RESP CRIT CARE, V166, P732, DOI 10.1164/rccm.2111031; Delacour D, 2009, TRAFFIC, V10, P1405, DOI 10.1111/j.1600-0854.2009.00960.x; Deslee G, 2002, J ALLERGY CLIN IMMUN, V110, P763, DOI 10.1067/mai.2002.129121; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Emara M, 2012, J BIOL CHEM, V287, P5756, DOI 10.1074/jbc.M111.312520; Emara M, 2011, J BIOL CHEM, V286, P13033, DOI 10.1074/jbc.M111.220657; Engering A, 2002, J IMMUNOL, V168, P2118, DOI 10.4049/jimmunol.168.5.2118; Erpenbeck VJ, 2005, AM J PHYSIOL-LUNG C, V288, pL692, DOI 10.1152/ajplung.00362.2004; Foetisch K, 2003, J ALLERGY CLIN IMMUN, V111, P889, DOI 10.1067/mai.2003.173; Furmonaviciene R, 2007, CLIN EXP ALLERGY, V37, P231, DOI 10.1111/j.1365-2222.2007.02651.x; Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787; Gazi U, 2009, IMMUNOBIOLOGY, V214, P554, DOI 10.1016/j.imbio.2008.11.004; Ge XN, 2010, J IMMUNOL, V185, P1205, DOI 10.4049/jimmunol.1000039; Geijtenbeek TBH, 2003, J EXP MED, V197, P7, DOI 10.1084/jem.20021229; Gill MA, 2012, J ALLERGY CLIN IMMUN, V129, P889, DOI 10.1016/j.jaci.2012.02.028; Gringhuis SI, 2007, IMMUNITY, V26, P605, DOI 10.1016/j.immuni.2007.03.012; Hattori T, 2009, IMMUNOGENETICS, V61, P731, DOI 10.1007/s00251-009-0403-x; Hickling TP, 2004, J LEUKOCYTE BIOL, V75, P27, DOI 10.1189/jlb.0703304; Himly M, 2002, FASEB J, V16, P106, DOI 10.1096/fj.02-0472fje; Homer RJ, 2002, AM J PHYSIOL-LUNG C, V283, pL52, DOI 10.1152/ajplung.00438.2001; Hsu DK, 2009, J INVEST DERMATOL, V129, P573, DOI 10.1038/jid.2008.276; Hsu SC, 2010, J BIOL CHEM, V285, P7903, DOI 10.1074/jbc.M109.058370; Huang HJ, 2011, MUCOSAL IMMUNOL, V4, P519, DOI 10.1038/mi.2011.17; Iacovacci P., 2002, Clinical and Experimental Allergy, V32, P1620, DOI 10.1046/j.1365-2222.2002.01516.x; Ilarregui JM, 2009, NAT IMMUNOL, V10, P981, DOI 10.1038/ni.1772; Jankovic D, 2002, IMMUNITY, V16, P429, DOI 10.1016/S1074-7613(02)00278-9; Jutel M, 2011, ALLERGY, V66, P725, DOI 10.1111/j.1398-9995.2011.02589.x; Katoh S, 2007, AM J RESP CRIT CARE, V176, P27, DOI 10.1164/rccm.200608-1243OC; Kaur S, 2005, J ALLERGY CLIN IMMUN, V116, P1381, DOI 10.1016/j.jaci.2005.08.028; Kaur S, 2006, CLIN EXP IMMUNOL, V143, P414, DOI 10.1111/j.1365-2249.2006.03007.x; Kaur S, 2006, CURR ALLERGY ASTHM R, V6, P377, DOI 10.1007/s11882-996-0007-6; Kayserova J, 2012, SCAND J IMMUNOL, V75, P305, DOI 10.1111/j.1365-3083.2011.02649.x; Kishore U, 2006, MOL IMMUNOL, V43, P1293, DOI 10.1016/j.molimm.2005.08.004; Kishore U, 2002, IMMUNOBIOLOGY, V205, P610, DOI 10.1078/0171-2985-00158; Kojima K, 2011, AM J RESP CRIT CARE, V184, P328, DOI 10.1164/rccm.201010-1566OC; Krop EJM, 2006, INT ARCH ALLERGY IMM, V139, P237, DOI 10.1159/000091169; Leonard R, 2005, J BIOL CHEM, V280, P7932, DOI 10.1074/jbc.M410407200; Li J, 2010, CLIN EXP IMMUNOL, V162, P251, DOI 10.1111/j.1365-2249.2010.04244.x; Li X, 2007, DNA SEQUENCE, V18, P190, DOI 10.1080/10425170701207166; Liu AH, 2002, J ALLERGY CLIN IMMUN, V109, P379, DOI 10.1067/mai.2002.122157; Liu FT, 2012, ANN NY ACAD SCI, V1253, P80, DOI 10.1111/j.1749-6632.2011.06386.x; Lopez E, 2006, J IMMUNOL, V176, P1943, DOI 10.4049/jimmunol.176.3.1943; Madan T, 1997, CLIN EXP IMMUNOL, V110, P241; Madan T, 2005, J IMMUNOL, V174, P6943, DOI 10.4049/jimmunol.174.11.6943; Madan T, 2001, J CLIN INVEST, V107, P467, DOI 10.1172/JCI10124; Malandain H, 2005, Eur Ann Allergy Clin Immunol, V37, P122; MALHOTRA R, 1993, BIOSCIENCE REP, V13, P79, DOI 10.1007/BF01145960; Mercer N, 2009, INT J IMMUNOPATH PH, V22, P207, DOI 10.1177/039463200902200123; MULLER UR, 1995, J ALLERGY CLIN IMMUN, V96, P395, DOI 10.1016/S0091-6749(95)70059-5; Nakahara S, 2007, CANCER METAST REV, V26, P605, DOI 10.1007/s10555-007-9095-6; Nigou J, 2001, J IMMUNOL, V166, P7477, DOI 10.4049/jimmunol.166.12.7477; Niki T, 2009, J BIOL CHEM, V284, P32344, DOI 10.1074/jbc.M109.035196; Ohtsubo K, 2006, CELL, V126, P855, DOI 10.1016/j.cell.2006.08.019; Okano M, 2001, J ALLERGY CLIN IMMUN, V108, P101, DOI 10.1067/mai.2001.115757; Osorio F, 2011, IMMUNITY, V34, P651, DOI 10.1016/j.immuni.2011.05.001; Pathak SK, 2005, J BIOL CHEM, V280, P42794, DOI 10.1074/jbc.M506471200; Pathak SK, 2012, J BIOL CHEM, V287, P13731, DOI 10.1074/jbc.M111.336545; Paul WE, 2010, NAT REV IMMUNOL, V10, P225, DOI 10.1038/nri2735; Puccetti P, 2007, NAT REV IMMUNOL, V7, P817, DOI 10.1038/nri2163; Reed CE, 2001, J ALLERGY CLIN IMMUN, V108, P157, DOI 10.1067/mai.2001.116862; Roth-Walter F, 2004, J ALLERGY CLIN IMMUN, V114, P1362, DOI 10.1016/j.jaci.2004.08.010; Royer PJ, 2010, J IMMUNOL, V185, P1522, DOI 10.4049/jimmunol.1000774; Saegusa J, 2009, AM J PATHOL, V174, P922, DOI 10.2353/ajpath.2009.080500; Salatino M, 2011, METHODS MOL BIOL, V677, P355, DOI 10.1007/978-1-60761-869-0_23; Sato K, 2006, J BIOL CHEM, V281, P38854, DOI 10.1074/jbc.M606542200; Schaub B, 2004, CLIN EXP ALLERGY, V34, P1819, DOI 10.1111/j.1365-2222.2004.02068.x; Schmid-Grendelmeier P, 2003, J ALLERGY CLIN IMMUN, V111, P1328, DOI 10.1067/mai.2003.1495; Schnare M, 2001, NAT IMMUNOL, V2, P947, DOI 10.1038/ni712; Shakib F, 2008, TRENDS IMMUNOL, V29, P633, DOI 10.1016/j.it.2008.08.007; Shreffler WG, 2006, J IMMUNOL, V177, P3677, DOI 10.4049/jimmunol.177.6.3677; Singh M, 2003, IMMUNOL LETT, V86, P299, DOI 10.1016/S0165-2478(03)00033-6; Singh SK, 2009, MOL IMMUNOL, V47, P164, DOI 10.1016/j.molimm.2009.09.026; Sperandio M, 2009, IMMUNOL REV, V230, P97, DOI 10.1111/j.1600-065X.2009.00795.x; Strait RT, 2006, J CLIN INVEST, V116, P833, DOI 10.1172/JCI25575; Strong P, 2003, CLIN EXP IMMUNOL, V134, P181, DOI 10.1046/j.1365-2249.2003.02281.x; Strong P, 2002, CLIN EXP IMMUNOL, V130, P19, DOI 10.1046/j.1365-2249.2002.01968.x; Sziksz E, 2010, INT ARCH ALLERGY IMM, V151, P308, DOI 10.1159/000250439; Tachado SD, 2007, J LEUKOCYTE BIOL, V81, P205, DOI 10.1189/jlb.1005580; Takeda K, 2003, AM J RESP CRIT CARE, V168, P783, DOI 10.1164/rccm.200304-548OC; Taylor PR, 2005, TRENDS IMMUNOL, V26, P104, DOI 10.1016/j.it.2004.12.001; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; Vailes LD, 1998, J ALLERGY CLIN IMMUN, V101, P274, DOI 10.1016/S0091-6749(98)70393-8; van Kooyk Y, 2003, NAT REV IMMUNOL, V3, P697, DOI 10.1038/nri1182; van Stijn CMW, 2010, MOL IMMUNOL, V47, P1544, DOI 10.1016/j.molimm.2010.01.014; Vinhas R, 2011, ALLERGY, V66, P1088, DOI 10.1111/j.1398-9995.2011.02598.x; Walter F, 2004, BIOCHEM BIOPH RES CO, V315, P281, DOI 10.1016/j.bbrc.2004.01.057; Wan H, 2001, CLIN EXP ALLERGY, V31, P279, DOI 10.1046/j.1365-2222.2001.00970.x; Wang JX, 2007, IMMUNOLOGY, V121, P174, DOI 10.1111/j.1365-2567.2007.02554.x; Wang JY, 1996, CLIN EXP IMMUNOL, V106, P367, DOI 10.1046/j.1365-2249.1996.d01-838.x; Wang JY, 1998, AM J RESP CRIT CARE, V158, P510, DOI 10.1164/ajrccm.158.2.9709111; Wicklein D, 2004, BIOL CHEM, V385, P397, DOI 10.1515/BC.2004.044; WILSHER ML, 1988, THORAX, V43, P354, DOI 10.1136/thx.43.5.354; Wilson IBH, 2002, CURR OPIN STRUC BIOL, V12, P569, DOI 10.1016/S0959-440X(02)00367-6; Yamamoto H, 2007, INT ARCH ALLERGY IMM, V143, P95, DOI 10.1159/000101414; Zhang JM, 2005, J LEUKOCYTE BIOL, V78, P665, DOI 10.1189/jlb.1204699; Zhou T, 2006, CELL MOL IMMUNOL, V3, P279; Zuberi RI, 2004, AM J PATHOL, V165, P2045, DOI 10.1016/S0002-9440(10)63255-5	112	38	39	1	26	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2013	132	1					27	36		10.1016/j.jaci.2013.02.001	http://dx.doi.org/10.1016/j.jaci.2013.02.001			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	173BF	23534971				2022-12-18	WOS:000321052300003
J	van Loosdregt, J; Spreafico, R; Rossetti, M; Prakken, BJ; Lotz, M; Albani, S				van Loosdregt, Jorg; Spreafico, Roberto; Rossetti, Maura; Prakken, Berent J.; Lotz, Martin; Albani, Salvatore			Hydroxychloroquine preferentially induces apoptosis of CD45RO(+) effector T cells by inhibiting autophagy: A possible mechanism for therapeutic modulation of T cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							RHEUMATOID-ARTHRITIS; SURVIVAL		[van Loosdregt, Jorg; Spreafico, Roberto; Rossetti, Maura; Albani, Salvatore] Sanford Burnham Med Res Inst, Inflammatory & Infect Dis Ctr, Translat Res Lab, La Jolla, CA USA; [van Loosdregt, Jorg; Prakken, Berent J.; Albani, Salvatore] Eureka Inst Translat Med, Siracusa, Italy; [Prakken, Berent J.] Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Ctr Mol & Cellular Intervent, Dept Immunol, Utrecht, Netherlands; [Lotz, Martin] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute; Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis; Scripps Research Institute	van Loosdregt, J (corresponding author), Sanford Burnham Med Res Inst, Inflammatory & Infect Dis Ctr, Translat Res Lab, La Jolla, CA USA.	salbani@sanfordburnham.org	Spreafico, Roberto/AAY-7867-2021; Rossetti, Maura/I-5905-2019	Spreafico, Roberto/0000-0001-8282-7658; Rossetti, Maura/0000-0003-3347-6200; van Loosdregt, Jorg/0000-0003-1411-3754	NIA NIH HHS [P01 AG007996, AG007996] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG007996] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ben-Zvi I, 2012, CLIN REV ALLERG IMMU, V42, P145, DOI 10.1007/s12016-010-8243-x; Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Lee JS, 2012, METHODS, V56, P375, DOI 10.1016/j.ymeth.2011.11.006; Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Munster T, 2002, ARTHRITIS RHEUM-US, V46, P1460, DOI 10.1002/art.10307; Pope RM, 2002, NAT REV IMMUNOL, V2, P527, DOI 10.1038/nri846; Pua HH, 2007, J EXP MED, V204, P25, DOI 10.1084/jem.20061303	9	38	38	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2013	131	5					1443	+		10.1016/j.jaci.2013.02.026	http://dx.doi.org/10.1016/j.jaci.2013.02.026			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	144AU	23541328	Green Accepted			2022-12-18	WOS:000318912200032
J	Wenande, EC; Skov, PS; Mosbech, H; Poulsen, LK; Garvey, LH				Wenande, Emily Cathrine; Skov, Per Stahl; Mosbech, Holger; Poulsen, Lars K.; Garvey, Lene H.			Inhibition of polyethylene glycol- induced histamine release by monomeric ethylene and diethylene glycol: A case of probable polyethylene glycol allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ANAPHYLAXIS; INJECTION		[Wenande, Emily Cathrine; Skov, Per Stahl; Mosbech, Holger; Poulsen, Lars K.; Garvey, Lene H.] Gentofte Univ Hosp, Allergy Clin, Copenhagen, Denmark; [Skov, Per Stahl] RefLab, Copenhagen, Denmark	University of Copenhagen; Herlev & Gentofte Hospital	Wenande, EC (corresponding author), Gentofte Univ Hosp, Allergy Clin, Copenhagen, Denmark.	lene.heise.garvey@regionh.dk	Wenande, Emily/N-2288-2016; Poulsen, Lars K/J-3065-2019	Wenande, Emily/0000-0002-5928-5042; Poulsen, Lars K/0000-0002-1730-847X				Girones MA, 2008, ALLERGOL IMMUNOPATH, V36, P110, DOI 10.1157/13120396; Dewachter P, 2005, ALLERGY, V60, P705, DOI 10.1111/j.1398-9995.2005.00783.x; Fruijtier-Polloth C, 2005, TOXICOLOGY, V214, P1, DOI 10.1016/j.tox.2005.06.001; Garvey LH, 2007, J ALLERGY CLIN IMMUN, V120, P409, DOI 10.1016/j.jaci.2007.04.029; Hyry H, 2006, ALLERGY, V61, P1021, DOI 10.1111/j.1398-9995.2006.01083.x; Knop K, 2010, ANGEW CHEM INT EDIT, V49, P6288, DOI 10.1002/anie.200902672; Savitz JA, 2011, MIL MED, V176, P944, DOI 10.7205/MILMED-D-09-00176; Shah S, 2012, J CLIN PHARMACOL, VXX, P1; Sohy C, 2008, ALLERGY, V63, P478, DOI 10.1111/j.1398-9995.2007.01610.x	9	38	39	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2013	131	5					1425	1427		10.1016/j.jaci.2012.09.037	http://dx.doi.org/10.1016/j.jaci.2012.09.037			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	144AU	23228247				2022-12-18	WOS:000318912200024
J	Cadman, RV; Lemanske, RF; Evans, MD; Jackson, DJ; Gern, JE; Sorkness, RL; Fain, SB				Cadman, Robert V.; Lemanske, Robert F., Jr.; Evans, Michael D.; Jackson, Daniel J.; Gern, James E.; Sorkness, Ronald L.; Fain, Sean B.			Pulmonary He-3 magnetic resonance imaging of childhood asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; pediatric; hyperpolarized magnetic resonance imaging; apparent diffusion coefficient	WHEEZING RHINOVIRUS ILLNESSES; IN-VIVO; LUNG MORPHOMETRY; MULTIDETECTOR CT; DIFFUSION MRI; RISK; GAS; ACQUISITION; SEVERITY; HEALTHY	Background: Magnetic resonance imaging (MRI) with He-3 does not require ionizing radiation and has been shown to detect regional abnormalities in lung ventilation and structure in adults with asthma, but the method has not been extended to children with asthma. Measurements of regional lung ventilation and microstructure in subjects with childhood asthma could advance our understanding of disease mechanisms. Objective: We sought to determine whether He-3 MRI in children can identify abnormalities related to the diagnosis of asthma or prior history of respiratory illness. Methods: Forty-four children aged 9 to 10 years were recruited from a birth cohort at increased risk of asthma and allergic diseases. For each subject, a time-resolved 3-dimensional image series and a 3-dimensional diffusion-weighted image were acquired in separate breathing maneuvers. The numbers and sizes of ventilation defects were scored, and regional maps and statistics of average He-3 diffusion lengths were calculated. Results: Children with mild-to-moderate asthma had lower average root-mean-square diffusion length ((X-rms) over bar) values (P = .004), increased regional SD of diffusion length values (P = .03), and higher defect scores (P = .03) than those without asthma. Children with histories of wheezing illness with rhinovirus infection before the third birthday had lower (X-rms) over bar values (P = .01) and higher defect scores (P = .05). Conclusion: MRI with He-3 detected more and larger regions of ventilation defect and a greater degree of restricted gas diffusion in children with asthma compared with those seen in children without asthma. These measures are consistent with regional obstruction and smaller and more regionally variable dimensions of the peripheral airways and alveolar spaces. (J Allergy Clin Immunol 2013;131:369-76.)	[Cadman, Robert V.; Fain, Sean B.] Univ Wisconsin Madison, Dept Med Phys, Sch Med & Publ Hlth, Madison, WI 53705 USA; [Lemanske, Robert F., Jr.; Jackson, Daniel J.; Gern, James E.; Sorkness, Ronald L.] Univ Wisconsin Madison, Dept Pediat Allergy Immunol & Rheumatol, Sch Med & Publ Hlth, Madison, WI 53705 USA; [Evans, Michael D.] Univ Wisconsin Madison, Dept Biostat & Med Informat, Sch Med & Publ Hlth, Madison, WI 53705 USA; [Gern, James E.; Sorkness, Ronald L.] Univ Wisconsin Madison, Dept Med Allergy Pulm & Crit Care, Sch Med & Publ Hlth, Madison, WI 53705 USA; [Fain, Sean B.] Univ Wisconsin Madison, Dept Radiol, Sch Med & Publ Hlth, Madison, WI 53705 USA; [Sorkness, Ronald L.] Univ Wisconsin Madison, Sch Pharm, Madison, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Fain, SB (corresponding author), Univ Wisconsin Madison, Dept Med Phys, Sch Med & Publ Hlth, 1111 Highland Ave,1133 WIMR, Madison, WI 53705 USA.	sfain@wisc.edu	Fain, Sean B./K-4260-2016	Fain, Sean B./0000-0001-5461-0646; Evans, Michael/0000-0001-7449-3993	National Institutes of Health [P01 HL070831, 5T32 CA009206-31, 1UL1RR025011]; Hartwell Foundation; National Institutes of Health (NIH); GE Healthcare; NIH; National Heart, Lung, and Blood Institute (NHLBI); Pharmaxis; Michigan Public Health Institute; Allegheny General Hospital; American Academy of Pediatrics; West Allegheny Health Systems; California Chapter 4 of the American Academy of Pediatrics; Colorado Allergy Society; Pennsylvania Allergy and Asthma Association; Harvard Pilgrim Health; California Society of Allergy; NYC Allergy Society; World Allergy Organization; American College of Chest Physicians; American Academy of Allergy, Asthma Immunology; Merck; AstraZeneca; GlaxoSmithKline; NIH/NHLBI; NATIONAL CANCER INSTITUTE [T32CA009206] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000427] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025011] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL070831] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Hartwell Foundation; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); GE Healthcare(General ElectricGE Healthcare); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Pharmaxis; Michigan Public Health Institute; Allegheny General Hospital(General Electric); American Academy of Pediatrics; West Allegheny Health Systems; California Chapter 4 of the American Academy of Pediatrics; Colorado Allergy Society; Pennsylvania Allergy and Asthma Association; Harvard Pilgrim Health; California Society of Allergy; NYC Allergy Society; World Allergy Organization; American College of Chest Physicians(General Electric); American Academy of Allergy, Asthma Immunology; Merck(Merck & Company); AstraZeneca(AstraZeneca); GlaxoSmithKline(GlaxoSmithKline); NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by National Institutes of Health grants P01 HL070831, 5T32 CA009206-31, and 1UL1RR025011 and by The Hartwell Foundation.; R. V. Cadman has received grants from the National Institutes of Health (NIH) and GE Healthcare. R. F. Lemanske, Jr, has received travel support and fees for participation in review activities from the NIH; has consultant arrangements with Merck, Sepracor, SA Boney and Associates, LTD, GlaxoSmithKline, the American Institute of Research, Genentech, Double Helix Development, and Boerhinger Ingelheim; is employed by the University of Wisconsin School of Medicine and Public Health; has received grants from the National Heart, Lung, and Blood Institute (NHLBI) and Pharmaxis; has received payment for lectures or service on speakers' bureaus from the Michigan Public Health Institute, Allegheny General Hospital, the American Academy of Pediatrics, West Allegheny Health Systems, California Chapter 4 of the American Academy of Pediatrics, Colorado Allergy Society, Pennsylvania Allergy and Asthma Association, Harvard Pilgrim Health, the California Society of Allergy, the NYC Allergy Society, the World Allergy Organization, and the American College of Chest Physicians; has received payment for manuscript preparation from the American Academy of Allergy, Asthma & Immunology; and has received royalties from Elsevier and UpToDate. M. D. Evans and R. L. Sorkness have received grants from the NIH. D. J. Jackson has received grants from the NIH and has consultant arrangements with Gilead. J. E. Gern is a board member for 3V BioSciences; has consultant arrangements with GlaxoSmithKline, Biota, Centocor, Boehringer Ingelheim, MedImmune, Gilead, Theraclone, Synairgen, and Pulmatrix; and has received grants from Merck, AstraZeneca, and GlaxoSmithKline. S. B. Fain has received grants from the NIH/NHLBI and GE Healthcare and has consultant arrangements with Xemed LLC.	Altes TA, 2001, J MAGN RESON IMAGING, V13, P378, DOI 10.1002/jmri.1054; Aysola R, 2010, J MAGN RESON IMAGING, V32, P1379, DOI 10.1002/jmri.22388; Aysola RS, 2008, CHEST, V134, P1183, DOI 10.1378/chest.07-2779; Busacker A, 2009, CHEST, V135, P48, DOI 10.1378/chest.08-0049; Carey MA, 2007, TRENDS ENDOCRIN MET, V18, P308, DOI 10.1016/j.tem.2007.08.003; de Jong PA, 2006, AM J RESP CRIT CARE, V173, P199, DOI 10.1164/rccm.200505-810OC; de Lange EE, 2006, CHEST, V130, P1055, DOI 10.1378/chest.130.4.1055; Eigen H, 2001, AM J RESP CRIT CARE, V163, P619, DOI 10.1164/ajrccm.163.3.2002054; Fain S, 2010, J MAGN RESON IMAGING, V32, P1398, DOI 10.1002/jmri.22375; Fain SB, 2008, ACAD RADIOL, V15, P753, DOI 10.1016/j.acra.2007.10.019; Fain SB, 2007, J MAGN RESON IMAGING, V25, P910, DOI 10.1002/jmri.20876; Fain SB, 2006, RADIOLOGY, V239, P875, DOI 10.1148/radiol.2393050111; Farah CS, 2012, J ALLERGY CLIN IMMUN, V129, P381, DOI 10.1016/j.jaci.2011.11.017; Gern JE, 2002, PEDIAT ALLERG IMM-UK, V13, P386, DOI 10.1034/j.1399-3038.2002.01093.x; Guilbert TW, 2011, J ALLERGY CLIN IMMUN, V128, P532, DOI 10.1016/j.jaci.2011.06.037; Holmes JH, 2008, MAGN RESON MED, V59, P1062, DOI 10.1002/mrm.21437; Holmnes JH, 2009, MAGN RESON MED, V62, P1543, DOI 10.1002/mrm.22150; Hopkins SR, 2007, J APPL PHYSIOL, V102, P1244, DOI 10.1152/japplphysiol.00738.2006; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Kirby M, 2010, RADIOLOGY, V256, P280, DOI 10.1148/radiol.10091937; Lemanske RF, 2002, PEDIAT ALLERG IMM-UK, V13, P38, DOI 10.1034/j.1399-3038.13.s.15.8.x; Matsuoka S, 2009, J THORAC IMAG, V24, P181, DOI 10.1097/RTI.0b013e3181b32bec; Narayanan M, 2012, AM J RESP CRIT CARE, V185, P186, DOI 10.1164/rccm.201107-1348OC; Niles DJ, 2012, RADIOLOGY; O'Halloran RL, 2008, MAGN RESON MED, V59, P132, DOI 10.1002/mrm.21439; O'Halloran RL, 2010, MAGN RESON MED, V63, P41, DOI 10.1002/mrm.22158; Saam BT, 2000, MAGN RESON MED, V44, P174, DOI 10.1002/1522-2594(200008)44:2<174::AID-MRM2>3.0.CO;2-4; Saglani S, 2007, AM J RESP CRIT CARE, V176, P858, DOI 10.1164/rccm.200702-212OC; Salerno M, 2002, RADIOLOGY, V222, P252, DOI 10.1148/radiol.2221001834; Samee S, 2003, J ALLERGY CLIN IMMUN, V111, P1205, DOI 10.1067/mai.2003.1544; Shanbhag DD, 2006, J MAGN RESON IMAGING, V24, P84, DOI 10.1002/jmri.20618; Spahn JD, 2004, AM J RESP CRIT CARE, V169, P784, DOI 10.1164/rccm.200309-1234OE; Sukstanskii AL, 2008, J MAGN RESON, V190, P200, DOI 10.1016/j.jmr.2007.10.015; Tashkin DP, 2009, J ALLERGY CLIN IMMUN, V124, pS78, DOI 10.1016/j.jaci.2009.10.002; Wang CB, 2008, J MAGN RESON IMAGING, V28, P80, DOI 10.1002/jmri.21408; Wanger J, 2005, EUR RESPIR J, V26, P511, DOI 10.1183/09031936.05.00035005; Woods JC, 2006, MAGN RESON MED, V56, P1293, DOI 10.1002/mrm.21076; Wright AL, 2006, PEDIATR PULM, V41, P318, DOI 10.1002/ppul.20373; Yablonskiy DA, 2002, P NATL ACAD SCI USA, V99, P3111, DOI 10.1073/pnas.052594699	39	38	40	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2013	131	2					369	+		10.1016/j.jaci.2012.10.032	http://dx.doi.org/10.1016/j.jaci.2012.10.032			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086CT	23246019	Green Accepted, Bronze			2022-12-18	WOS:000314661500013
J	Saito, J; Zhang, QL; Hui, C; Macedo, P; Gibeon, D; Menzies-Gow, A; Bhavsar, PK; Chung, KF				Saito, Junpei; Zhang, Qingling; Hui, Christopher; Macedo, Patricia; Gibeon, David; Menzies-Gow, Andrew; Bhavsar, Pankaj K.; Chung, Kian Fan			Sputum hydrogen sulfide as a novel biomarker of obstructive neutrophilic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							H2S		[Saito, Junpei; Hui, Christopher; Macedo, Patricia; Gibeon, David; Menzies-Gow, Andrew; Bhavsar, Pankaj K.; Chung, Kian Fan] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England; [Saito, Junpei; Hui, Christopher; Macedo, Patricia; Gibeon, David; Menzies-Gow, Andrew; Bhavsar, Pankaj K.; Chung, Kian Fan] Royal Brompton Hosp, Biomed Res Unit, London SW3 6LY, England; [Zhang, Qingling] Guangzhou Med Univ, State Key Lab Resp Dis, Guangzhou, Guangdong, Peoples R China	Imperial College London; Royal Brompton Hospital; Guangzhou Medical University; State Key Laboratory of Respiratory Disease	Saito, J (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England.	f.chung@imperial.ac.uk	Chung, Kian Fan/I-8456-2019; Chung, Kian Fan/B-1872-2012	Chung, Kian Fan/0000-0001-7101-1426; Chung, Kian Fan/0000-0001-7101-1426	Medical Research Council [G0801056B] Funding Source: researchfish; National Institute for Health Research [NF-SI-0509-10080] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))		Chen YH, 2009, CYTOKINE, V45, P117, DOI 10.1016/j.cyto.2008.11.009; Chen YH, 2005, CHEST, V128, P3205, DOI 10.1378/chest.128.5.3205; Dweik RA, 2011, AM J RESP CRIT CARE, V184, P602, DOI 10.1164/rccm.9120-11ST; Elrod JW, 2007, P NATL ACAD SCI USA, V104, P15560, DOI 10.1073/pnas.0705891104; Li L, 2008, TRENDS PHARMACOL SCI, V29, P84, DOI 10.1016/j.tips.2007.11.003; Perry MM, 2011, AM J RESP CELL MOL, V45, P746, DOI 10.1165/rcmb.2010-0304OC; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799; Shatalin K, 2011, SCIENCE, V334, P986, DOI 10.1126/science.1209855; Wang R, 2002, FASEB J, V16, P1792, DOI 10.1096/fj.02-0211hyp; Wang R, 2011, CURR OPIN NEPHROL HY, V20, P107, DOI 10.1097/MNH.0b013e3283430651	10	38	39	1	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2013	131	1					232	234		10.1016/j.jaci.2012.10.005	http://dx.doi.org/10.1016/j.jaci.2012.10.005			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	062YR	23146380				2022-12-18	WOS:000312961200035
J	Bonadonna, P; Lombardo, C; Bortolami, O; Bircher, A; Scherer, K; Barbaud, A; Passalacqua, G; Pagani, M				Bonadonna, Patrizia; Lombardo, Carla; Bortolami, Oscar; Bircher, Andreas; Scherer, Kathrin; Barbaud, Annick; Passalacqua, Giovanni; Pagani, Mauro			Hypersensitivity to proton pump inhibitors: Diagnostic accuracy of skin tests compared to oral provocation test	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CROSS-REACTIVITY; ANAPHYLAXIS; OMEPRAZOLE		[Bonadonna, Patrizia; Lombardo, Carla] Verona Univ Hosp, Allergy Unit, Verona, Italy; [Bortolami, Oscar] Verona Univ Hosp, Res Support Unit, Verona, Italy; [Bircher, Andreas; Scherer, Kathrin] Univ Basel Hosp, Allergy Unit, Dept Dermatol, CH-4031 Basel, Switzerland; [Barbaud, Annick] Univ Hosp Nancy, Dept Dermatol, Fournier Hosp, Nancy, France; [Passalacqua, Giovanni] Univ Genoa, DIMI, Genoa, Italy; [Pagani, Mauro] Azienda Osped C Poma, Asola Hosp, Dept Med, Mantua, Italy	University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Basel; CHU de Nancy; Universite de Lorraine; University of Genoa; Hospital Carlo Poma	Bonadonna, P (corresponding author), Verona Univ Hosp, Allergy Unit, Verona, Italy.	patrizia.bonadonna@ospedaleuniverona.it	, barbaud/AAZ-7250-2021; Bortolami, Oscar/E-9219-2016; Bortolami, Oscar/H-6559-2019	Bortolami, Oscar/0000-0002-4346-9672; Bortolami, Oscar/0000-0002-4346-9672; Scherer, Kathrin/0000-0002-5235-2556				Brockow K, 2002, ALLERGY, V57, P45; Confino-Cohen R, 2006, ANN ALLERG ASTHMA IM, V96, P33, DOI 10.1016/S1081-1206(10)61037-X; Demoly P, 1999, ALLERGY, V54, P999, DOI 10.1034/j.1398-9995.1999.00247.x; Garrido S, 2008, J INVEST ALLERG CLIN, V18, P140; Lobera T, 2009, J INVEST ALLERG CLIN, V19, P57; Ottervanger JP, 1996, J ALLERGY CLIN IMMUN, V97, P1413, DOI 10.1016/S0091-6749(96)70212-9; Pimiento AJP, 2006, J ALLERGY CLIN IMMUN, V117, P707, DOI 10.1016/j.jaci.2005.11.001; Rerkpattanapipat T, 2011, CURR OPIN ALLERGY CL, V11, P299, DOI 10.1097/ACI.0b013e328348a4e9; RING J, 1977, LANCET, V1, P466; Elfau MTS, 2010, J INVEST ALLERG CLIN, V20, P157; Thomson ABR, 2010, WORLD J GASTROENTERO, V16, P2323, DOI 10.3748/wjg.v16.i19.2323	11	38	41	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2012	130	2					547	549		10.1016/j.jaci.2012.04.048	http://dx.doi.org/10.1016/j.jaci.2012.04.048			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	981WC	22728084				2022-12-18	WOS:000307002200044
J	Du, R; Litonjua, AA; Tantisira, KG; Lasky-Su, J; Sunyaev, SR; Klanderman, BJ; Celedon, JC; Avila, L; Soto-Quiros, ME; Weiss, ST				Du, Rose; Litonjua, Augusto A.; Tantisira, Kelan G.; Lasky-Su, Jessica; Sunyaev, Shamil R.; Klanderman, Barbara J.; Celedon, Juan C.; Avila, Lydiana; Soto-Quiros, Manuel E.; Weiss, Scott T.			Genome-wide association study reveals class I MHC-restricted T cell-associated molecule gene (CRTAM) variants interact with vitamin D levels to affect asthma exacerbations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Gene-environment interaction; genome-wide association study; vitamin D; asthma exacerbation	ENVIRONMENT INTERACTION; D-RECEPTOR; CHILDHOOD ASTHMA; PREGNANCY; CHILDREN; POPULATION; INFECTIONS; RESPONSES; WHEEZE; TESTS	Background: It has recently been shown that vitamin D deficiency can increase asthma development and severity and that variations in vitamin D receptor genes are associated with asthma susceptibility. Objective: We sought to find genetic factors that might interact with vitamin D levels to affect the risk of asthma exacerbation. Methods: We conducted a genome-wide study of gene-vitamin D interaction on asthma exacerbations using population-based and family-based approaches on 403 subjects and trios from the Childhood Asthma Management Program. Twenty-three polymorphisms with significant interactions were studied in a replication analysis in 584 children from a Costa Rican cohort. Results: We identified 3 common variants in the class I MHC-restricted T cell-associated molecule gene (CRTAM) that were associated with an increased rate of asthma exacerbations based on the presence of a low circulating vitamin D level. These results were replicated in a second independent population (unadjusted combined interaction, P = .00028-.00097; combined odds ratio, 3.28-5.38). One variant, rs2272094, is a nonsynonymous coding polymorphism of CRTAM. Functional studies on cell lines confirmed the interaction of vitamin D and rs2272094 on CRTAM expression. CRTAM is highly expressed in activated human CD8(+) and natural killer T cells, both of which have been implicated in asthmatic patients. Conclusion: The findings highlight an important gene-environment interaction that elucidates the role of vitamin D and CD8(+) and natural killer T cells in asthma exacerbation in a genome-wide gene-environment interaction study that has been replicated in an independent population. The results suggest the potential importance of maintaining adequate vitamin D levels in subsets of high-risk asthmatic patients. (J Allergy Clin Immunol 2012;129:368-73.)	[Du, Rose] Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA; [Du, Rose; Litonjua, Augusto A.; Tantisira, Kelan G.; Lasky-Su, Jessica; Klanderman, Barbara J.; Celedon, Juan C.; Weiss, Scott T.] Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; [Litonjua, Augusto A.; Tantisira, Kelan G.; Weiss, Scott T.] Brigham & Womens Hosp, Ctr Genom Med, Boston, MA 02115 USA; [Du, Rose; Litonjua, Augusto A.; Tantisira, Kelan G.; Lasky-Su, Jessica; Sunyaev, Shamil R.; Klanderman, Barbara J.; Weiss, Scott T.] Harvard Univ, Sch Med, Boston, MA USA; [Celedon, Juan C.] Univ Pittsburgh, Div Pediat Pulm Med Allergy & Immunol, Dept Pediat, Childrens Hosp,UPMC,Sch Med, Pittsburgh, PA 15260 USA; [Avila, Lydiana; Soto-Quiros, Manuel E.] Hosp Nacl Ninos Dr Carlos Saenz Herrera, Div Pediat Pulmonol, San Jose, Costa Rica	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Du, R (corresponding author), Brigham & Womens Hosp, Dept Neurosurg, 75 Francis St, Boston, MA 02115 USA.	rdu@partners.org	Avila, Lydiana/D-5638-2015; Du, Rose/I-5402-2012; Du, Rose/AAJ-2873-2020	Avila, Lydiana/0000-0002-9579-1591; Du, Rose/0000-0003-2641-6496; Lasky-Su, Jessica/0000-0001-6236-4705; Litonjua, Augusto/0000-0003-0422-5875	National Institutes of Health (NIH) [R21HL089842, R01HL092197]; National Heart, Lung, and Blood Institute (NHLBI); NHLBI/NIH [U01 HL075419, U01 HL65899, P01 HL083069, R01 HL086601, T32 HL07427]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL089842, U01HL065899, R01HL086601, R00HL096840, U01HL075419, T32HL007427, P01HL083069, R37HL066289, R01HL092197] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by National Institutes of Health (NIH) grants R21HL089842 and R01HL092197. We acknowledge the Childhood Asthma Management Program (CAMP) investigators and research team, supported by the National Heart, Lung, and Blood Institute (NHLBI), for collection of CAMP Genetic Ancillary Study data. All work on data collected from the CAMP Genetic Ancillary Study was conducted at the Channing Laboratory of the Brigham and Women's Hospital under appropriate CAMP policies and human subjects' protections. The CAMP Genetics Ancillary Study is supported by U01 HL075419, U01 HL65899, P01 HL083069, R01 HL086601, and T32 HL07427 from the NHLBI/NIH.	Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Betts RJ, 2009, PHARMACOL THERAPEUT, V121, P123, DOI 10.1016/j.pharmthera.2008.09.001; Boles KS, 2005, BLOOD, V106, P779, DOI 10.1182/blood-2005-02-0817; Bosse Y, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-98; Botto LD, 2001, AM J EPIDEMIOL, V153, P1016, DOI 10.1093/aje/153.10.1016; Brehm JM, 2010, J ALLERGY CLIN IMMUN, V126, P52, DOI 10.1016/j.jaci.2010.03.043; Brehm JM, 2009, AM J RESP CRIT CARE, V179, P765, DOI 10.1164/rccm.200808-1361OC; Busse WW, 2010, LANCET, V376, P826, DOI 10.1016/S0140-6736(10)61380-3; Camargo CA, 2007, AM J CLIN NUTR, V85, P788, DOI 10.1093/ajcn/85.3.788; Chinellato I, 2011, EUR RESPIR J, V37, P1366, DOI 10.1183/09031936.00044710; Chinellato I, 2011, J PEDIATR-US, V158, P437, DOI 10.1016/j.jpeds.2010.08.043; Devereux G, 2007, AM J CLIN NUTR, V85, P853, DOI 10.1093/ajcn/85.3.853; Duca M, 2008, NUCLEIC ACIDS RES, V36, P5123, DOI 10.1093/nar/gkn493; Ege MJ, 2011, J ALLERGY CLIN IMMUN, V127, P138, DOI 10.1016/j.jaci.2010.09.041; Ege MJ, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Erkkola M, 2009, CLIN EXP ALLERGY, V39, P875, DOI 10.1111/j.1365-2222.2009.03234.x; Fairbrother WG, 2004, NUCLEIC ACIDS RES, V32, pW187, DOI 10.1093/nar/gkh393; Heidema J, 2008, J IMMUNOL, V181, P5551, DOI 10.4049/jimmunol.181.8.5551; Laird NM, 2000, GENET EPIDEMIOL, V19, pS36, DOI 10.1002/1098-2272(2000)19:1+<::AID-GEPI6>3.3.CO;2-D; Laird NM, 2006, NAT REV GENET, V7, P385, DOI 10.1038/nrg1839; Lake SL, 2003, HUM HERED, V55, P56, DOI 10.1159/000071811; Litonjua AA, 2007, J ALLERGY CLIN IMMUN, V120, P1031, DOI 10.1016/j.jaci.2007.08.028; McCarren M, 1998, J CLIN EPIDEMIOL, V51, P107, DOI 10.1016/S0895-4356(97)00246-1; MEEHAN MA, 1992, CELL IMMUNOL, V140, P400, DOI 10.1016/0008-8749(92)90206-5; Miyake Y, 2010, EUR RESPIR J, V35, P1228, DOI 10.1183/09031936.00100609; Parker KL, 1998, MOL CELL ENDOCRINOL, V140, P59, DOI 10.1016/S0303-7207(98)00030-6; Patino-Lopez G, 2006, J NEUROIMMUNOL, V171, P145, DOI 10.1016/j.jneuroim.2005.09.017; Poon AH, 2004, AM J RESP CRIT CARE, V170, P967, DOI 10.1164/rccm.200403-412oc; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Raby BA, 2004, AM J RESP CRIT CARE, V170, P1057, DOI 10.1164/rccm.200404-447OC; RCore Team, 2022, R LANG ENV STAT COMP; Sabatti C, 2009, NAT GENET, V41, P35, DOI 10.1038/ng.271; Sakaki T, 2005, FRONT BIOSCI, V10, P119; Sonuga-Barke EJS, 2008, AM J MED GENET B, V147B, P1359, DOI 10.1002/ajmg.b.30860; Takeuchi A, 2009, J IMMUNOL, V183, P4220, DOI 10.4049/jimmunol.0901248; Umetsu DT, 2006, NAT REV IMMUNOL, V6, P953, DOI 10.1038/nri1968; Walker VP, 2009, PEDIATR RES, V65, p106R, DOI 10.1203/PDR.0b013e31819dba91; Wang TT, 2004, J IMMUNOL, V173, P2909, DOI 10.4049/jimmunol.173.5.2909; Wjst M, 2006, PEDIAT ALLERG IMM-UK, V17, P477, DOI 10.1111/j.1399-3038.2006.00456.x; Xu ZL, 2009, NUCLEIC ACIDS RES, V37, pW600, DOI 10.1093/nar/gkp290; Yu SH, 2008, P NATL ACAD SCI USA, V105, P5207, DOI 10.1073/pnas.0711558105; Zhu Wensheng, 2009, BMC Proc, V3 Suppl 7, pS119; 2000, N ENGL J MED, V343, P1054	43	38	40	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2012	129	2					368	U145		10.1016/j.jaci.2011.09.034	http://dx.doi.org/10.1016/j.jaci.2011.09.034			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	887TC	22051697	Green Accepted, Green Published			2022-12-18	WOS:000299951700010
J	Leung, TF; Ko, FWS; Wong, GWK				Leung, Ting Fan; Ko, Fanny Wai-san; Wong, Gary Wing-kin			Roles of pollution in the prevalence and exacerbations of allergic diseases in Asia	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Air pollution; allergy; Asia; asthma; epidemiology	MIDDLE-SCHOOL CHILDREN; AIR-POLLUTION; RESPIRATORY SYMPTOMS; ASTHMA PREVALENCE; RISK-FACTORS; RHINITIS; OUTDOOR; CLIMATE; INDOOR; VISITS	The prevalence of asthma and allergic diseases has been found to be increasingly rapidly, especially in developing countries. Environmental factors have been found to be important contributors to the manifestations of allergic diseases. Air pollution has been extensively studied in different regions of the world. The levels of ambient air pollutants in many Asian countries are very high when compared with those in developed Western countries. However, the prevalence of asthma was relatively low across many Asian countries. Many studies have clearly documented that environmental air pollution is an important factor resulting in exacerbations of asthma. In particular, levels of traffic-related pollutants are increasing rapidly across many Asian countries in parallel with the level of urbanization and economic development. The loss of protective factors associated with a rural environment will further contribute to the adverse effect on patients with allergic diseases such as asthma. In this review the roles of air pollution were examined in relation to the inception and exacerbations of allergic diseases in Asia. (J Allergy Clin Immunol 2012; 129: 42-7.)	[Leung, Ting Fan; Wong, Gary Wing-kin] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Pediat, Shatin, Hong Kong, Peoples R China; [Ko, Fanny Wai-san] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital	Wong, GWK (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Pediat, 6-F Clin Sci Bldg, Shatin, Hong Kong, Peoples R China.	wingkinwong@cuhk.edu.hk	Wong, Gary WK/AAY-9207-2020; LEUNG, Ting Fan/E-7728-2013; Ko, Fanny W. S./B-8958-2016	Wong, Gary WK/0000-0001-5939-812X; LEUNG, Ting Fan/0000-0002-6469-1926; Ko, Fanny W. S./0000-0001-8454-0087	Research Grants Council [469908, 470909, 477110]; Hong Kong Government; Chinese University of Hong Kong	Research Grants Council(Hong Kong Research Grants Council); Hong Kong Government; Chinese University of Hong Kong(Chinese University of Hong Kong)	Supported by Research Grants Council General Research Funds (469908, 470909 and 477110), the Hong Kong Government, and Direct Grant for Research from the Chinese University of Hong Kong.	Abe T, 2009, AM J EMERG MED, V27, P153, DOI 10.1016/j.ajem.2008.01.013; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Cai H, 2011, SCI TOTAL ENVIRON, V409, P1935, DOI 10.1016/j.scitotenv.2011.01.025; Chen CH, 2006, J ASTHMA, V43, P287, DOI 10.1080/02770900600622935; Delfino RJ, 2008, ENVIRON HEALTH PERSP, V116, P550, DOI 10.1289/ehp.10911; Dong GH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022470; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Eriksson J, 2010, ALLERGY, V65, P1397, DOI 10.1111/j.1398-9995.2010.02397.x; Guo H, 2009, INDOOR AIR, V19, P206, DOI 10.1111/j.1600-0668.2008.00580.x; Guo YLL, 1999, ENVIRON HEALTH PERSP, V107, P1001, DOI 10.1289/ehp.991071001; Ho WC, 2007, ENVIRON RES, V104, P402, DOI 10.1016/j.envres.2007.01.007; Hwang BF, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-23; Hwang BF, 2005, THORAX, V60, P467, DOI 10.1136/thx.2004.033977; Hwang BF, 2010, CHEST, V138, P956, DOI 10.1378/chest.09-2600; Kim SY, 2007, INT ARCH OCC ENV HEA, V80, P701, DOI 10.1007/s00420-007-0182-3; Ko FWS, 2007, CLIN EXP ALLERGY, V37, P1312, DOI 10.1111/j.1365-2222.2007.02791.x; Lee MH, 2001, ANN ALLERG ASTHMA IM, V86, P691, DOI 10.1016/S1081-1206(10)62300-9; Lee YL, 2003, EUR RESPIR J, V21, P964, DOI 10.1183/09031936.03.00094602; Li Y, 2010, SCI TOTAL ENVIRON, V408, P1226, DOI 10.1016/j.scitotenv.2009.11.035; NG TP, 1994, INT J EPIDEMIOL, V23, P553, DOI 10.1093/ije/23.3.553; Padhi BK, 2008, INHAL TOXICOL, V20, P973, DOI 10.1080/08958370701866420 ; Pan GW, 2010, RESP MED, V104, P1903, DOI 10.1016/j.rmed.2010.07.018; Park JS, 2006, INDOOR AIR, V16, P129, DOI 10.1111/j.1600-0668.2005.00408.x; Pereira G, 2010, MED J AUSTRALIA, V193, P511, DOI 10.5694/j.1326-5377.2010.tb04034.x; Qian Z, 2007, INDOOR AIR, V17, P135, DOI 10.1111/j.1600-0668.2006.00463.x; Shima M, 2002, ARCH ENVIRON HEALTH, V57, P529, DOI 10.1080/00039890209602084; Shima M, 2000, INT J EPIDEMIOL, V29, P862, DOI 10.1093/ije/29.5.862; Takasaki K, 2009, EUR ARCH OTO-RHINO-L, V266, P673, DOI 10.1007/s00405-008-0793-7; Tang XJ, 2009, ENVIRON INT, V35, P1210, DOI 10.1016/j.envint.2009.06.002; VONMUTIUS E, 1992, BMJ-BRIT MED J, V305, P1395, DOI 10.1136/bmj.305.6866.1395; Watts J, 2006, LANCET, V368, P719, DOI 10.1016/S0140-6736(06)69267-2; Wilson D, 2008, RESP MED, V102, P1536, DOI 10.1016/j.rmed.2008.06.010; Wong GWK, 2008, PEDIATR PULM, V43, P107, DOI 10.1002/ppul.20755; Wong GWK, 2001, CLIN EXP ALLERGY, V31, P565, DOI 10.1046/j.1365-2222.2001.01063.x; Yura A, 2001, BRIT J DERMATOL, V145, P966, DOI 10.1046/j.1365-2133.2001.04506.x; Zhang FY, 2011, SCI TOTAL ENVIRON, V409, P2486, DOI 10.1016/j.scitotenv.2011.04.007; Zhao ZH, 2008, ENVIRON HEALTH PERSP, V116, P90, DOI 10.1289/ehp.10576	37	38	41	0	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2012	129	1					42	47		10.1016/j.jaci.2011.11.031	http://dx.doi.org/10.1016/j.jaci.2011.11.031			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	869XT	22196523	Bronze			2022-12-18	WOS:000298634000006
J	Aceves, SS				Aceves, Seema S.			Tissue remodeling in patients with eosinophilic esophagitis: What lies beneath the surface?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Asthma; eosinophilic esophagitis; tissue remodeling	GENE-EXPRESSION; CHILDREN		[Aceves, Seema S.] Univ Calif San Diego, Div Allergy, La Jolla, CA 92093 USA; [Aceves, Seema S.] Rady Childrens Hosp, San Diego, CA USA	University of California System; University of California San Diego; Rady Childrens Hospital San Diego	Aceves, SS (corresponding author), Univ Calif San Diego, Div Allergy, 9500 Gilman Dr,MC 0635, La Jolla, CA 92093 USA.	saceves@ucsd.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI092135] Funding Source: NIH RePORTER; NIAID NIH HHS [R01AI092135] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aceves SS, 2010, ALLERGY, V65, P109, DOI 10.1111/j.1398-9995.2009.02142.x; Aceves SS, 2010, J ALLERGY CLIN IMMUN, V126, P1198, DOI 10.1016/j.jaci.2010.08.050; Aceves SS, 2007, J ALLERGY CLIN IMMUN, V119, P206, DOI 10.1016/j.jaci.2006.10.016; Al-Muhsen S, 2011, J ALLERGY CLIN IMMUN, V128, P451, DOI 10.1016/j.jaci.2011.04.047; Blanchard C, 2006, J CLIN INVEST, V116, P536, DOI 10.1172/JCI26679; Fox Victor L, 2008, Gastrointest Endosc Clin N Am, V18, P45, DOI 10.1016/j.giec.2007.09.015; Hardie WD, 2010, CELL CYCLE, V9, P2769, DOI 10.4161/cc.9.14.12268; Kwiatek MA, 2011, GASTROENTEROLOGY, V140, P82, DOI 10.1053/j.gastro.2010.09.037; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Lucendo AJ, 2011, J ALLERGY CLIN IMMUN, V128, P1037, DOI 10.1016/j.jaci.2011.08.007; Mishra A, 2008, GASTROENTEROLOGY, V134, P204, DOI 10.1053/j.gastro.2007.10.002; Mulder DJ, 2009, GUT, V58, P166, DOI 10.1136/gut.2008.157628; Nurko S, 2009, AM J GASTROENTEROL, V104, P3050, DOI 10.1038/ajg.2009.543; Straumann A, 2010, GASTROENTEROLOGY, V139, P1526, DOI 10.1053/j.gastro.2010.07.048; Zuo L, 2010, J IMMUNOL, V185, P660, DOI 10.4049/jimmunol.1000471	15	38	39	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2011	128	5					1047	1049		10.1016/j.jaci.2011.09.026	http://dx.doi.org/10.1016/j.jaci.2011.09.026			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	842FJ	22036097				2022-12-18	WOS:000296578200018
J	Tison, BE; Nicholas, SK; Abramson, SL; Hanson, IC; Paul, ME; Seeborg, FO; Shearer, WT; Perez, MD; Noroski, LM; Chinen, J				Tison, Brian E.; Nicholas, Sarah K.; Abramson, Stuart L.; Hanson, Imelda C.; Paul, Mary E.; Seeborg, Filiz O.; Shearer, William T.; Perez, Maria D.; Noroski, Lenora M.; Chinen, Javier			Autoimmunity in a cohort of 130 pediatric patients with partial DiGeorge syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							22Q11.2 DELETION SYNDROME; METERED-DOSE INHALER; LARGE-VOLUME SPACER; FLUTICASONE PROPIONATE; LUNG DEPOSITION; CHILDREN; ASTHMA		[Tison, Brian E.; Nicholas, Sarah K.; Abramson, Stuart L.; Hanson, Imelda C.; Paul, Mary E.; Seeborg, Filiz O.; Shearer, William T.; Noroski, Lenora M.; Chinen, Javier] Baylor Coll Med, Dept Pediat, Sect Allergy & Immunol, Houston, TX 77030 USA; [Perez, Maria D.] Baylor Coll Med, Dept Rheumatol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Tison, BE (corresponding author), Baylor Coll Med, Dept Pediat, Sect Allergy & Immunol, Houston, TX 77030 USA.	chinej20@hotmail.com	Paul, Mary/AAA-2722-2021	Shearer, William/0000-0002-2483-2130				Anhoj J, 2000, AM J RESP CRIT CARE, V162, P1819; BESSMERTNY O, 2001, J PEDIAT PHARM THER, V6, P212; Dempsey OJ, 1999, CHEST, V116, P935, DOI 10.1378/chest.116.4.935; Gennery AR, 2002, ARCH DIS CHILD, V86, P422, DOI 10.1136/adc.86.6.422; Goodship J, 1998, ARCH DIS CHILD, V79, P348, DOI 10.1136/adc.79.4.348; Hedman A, 1997, ACTA PAEDIATR, V86, P226, DOI 10.1111/j.1651-2227.1997.tb08876.x; Jawad AF, 2001, J PEDIATR-US, V139, P715, DOI 10.1067/mpd.2001.118534; Kagimoto Seiichi, 1991, Acta Paediatrica Japonica, V33, P693; Kaloumenou I, 2008, THYROID, V18, P747, DOI 10.1089/thy.2007.0370; Krishnaswami S, 2000, J PHARMACEUT BIOMED, V22, P123, DOI 10.1016/S0731-7085(99)00246-0; Liang J, 2002, PHARMACOTHERAPY, V22, P947, DOI 10.1592/phco.22.12.947.33612; Lipworth BJ, 1997, THORAX, V52, P686, DOI 10.1136/thx.52.8.686; Liston A, 2008, NAT REV IMMUNOL, V8, P545, DOI 10.1038/nri2336; Wildhaber JH, 1999, J PEDIATR-US, V135, P28, DOI 10.1016/S0022-3476(99)70323-9	14	38	42	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2011	128	5					1115	1117		10.1016/j.jaci.2011.06.043	http://dx.doi.org/10.1016/j.jaci.2011.06.043			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	842FJ	21835443	Bronze			2022-12-18	WOS:000296578200031
J	Scott, L; Morphew, T; Bollinger, ME; Samuelson, S; Galant, S; Clement, L; O'Cull, K; Jones, F; Jones, CA				Scott, Lyne; Morphew, Tricia; Bollinger, Mary E.; Samuelson, Steve; Galant, Stanley; Clement, Loran; O'Cull, Karen; Jones, Felita; Jones, Craig A.			Achieving and maintaining asthma control in inner-city children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Pediatric asthma; inner city; asthma control; asthma morbidity	RANDOMIZED CLINICAL-TRIAL; CHILDHOOD ASTHMA; INHALED CORTICOSTEROIDS; UNDERSERVED CHILDREN; PEDIATRIC ASTHMA; UNITED-STATES; CARE; MANAGEMENT; MORBIDITY; DISPARITIES	Background: Despite guidelines-defined care, inner-city children of low socioeconomic status have poor asthma control. Objective: This study evaluated time to achieve control, maintenance of control, and factors associated with well controlled asthma for pediatric patients receiving specialty-based asthma care in mobile asthma clinics designed to reduce barriers to delivering effective asthma care (the Breathmobile Program). Methods: Existing clinical data collected from January 1998 to June 2008 for 7822 pediatric patients with asthma (34,339 visits) enrolled in similarly structured mobile asthma programs across the United States evaluated the effect of asthma control on the reduction of asthma-related morbidity, time to achieve asthma control, maintenance of asthma control, and factors associated with well controlled asthma. Results: Comparison of pre and post year data for subjects enrolled in the program for at least 1 year revealed reductions in the percentage of patients reporting emergency department visits (mean, 66%), hospitalizations (mean, 84%), and missed school days >= 5/year (mean, 78%). Well controlled asthma was achieved by visit 3 for an estimated 80% of patients. Factors contributing to well controlled asthma include non-African American race, visit interval <90 days, and adherence to prescribed therapy. Conclusion: This study demonstrates the ability to achieve and maintain asthma control in high-risk populations in association with intensive, accessible, guidelines-defined care with close follow-up. (J Allergy Clin Immunol 2011; 128: 56-63.)	[Scott, Lyne] Los Angeles Cty Univ So Calif, Med Ctr, Los Angeles, CA USA; [Morphew, Tricia; Jones, Felita] Asthma & Allergy Fdn Amer, Calif Chapter, Los Angeles, CA USA; [Bollinger, Mary E.] Univ Maryland, Sch Med, Div Pediat Pulmonol Allergy, Baltimore, MD 21201 USA; [Samuelson, Steve] Mobile Childrens Asthma Res & Educ CARE Fdn, Chicago, IL USA; [Galant, Stanley] Childrens Hosp Orange Cty, Breathmobile Program, Orange, CA USA; [Clement, Loran] Univ S Alabama, Dept Pediat, Mobile, AL 36688 USA; [O'Cull, Karen] Arrowhead Reg Med Ctr, Breathmobile Program, San Bernardino, CA USA; [Jones, Craig A.] Dept Vermont Hlth Access, Burlington, VT USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University System of Maryland; University of Maryland Baltimore; Childrens Hospital of Orange County; University of South Alabama	Scott, L (corresponding author), 1801 E Marengo St,Room 1G1, Los Angeles, CA 90033 USA.	lynescottmd@yahoo.com			Asthma and Allergy Foundation of America, California Chapter	Asthma and Allergy Foundation of America, California Chapter	Support for analysis of data was provided by the Asthma and Allergy Foundation of America, California Chapter.	Akinbami LJ, 2009, PEDIATRICS, V123, pS131, DOI 10.1542/peds.2008-2233C; Akinbami LJ, 2002, PEDIATRICS, V110, P315, DOI 10.1542/peds.110.2.315; Akinbami LJ, 2002, AMBUL PEDIATR, V2, P382, DOI 10.1367/1539-4409(2002)002<0382:RAIDIC>2.0.CO;2; Arruda L K, 2001, Curr Allergy Asthma Rep, V1, P466, DOI 10.1007/s11882-001-0035-1; Arruda L K, 2001, Curr Opin Pulm Med, V7, P14, DOI 10.1097/00063198-200101000-00003; Bai Y, 2007, J HEALTH CARE POOR U, V18, P54, DOI 10.1353/hpu.2007.0001; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Bollinger ME, 2010, ANN ALLERG ASTHMA IM, V105, P274, DOI 10.1016/j.anai.2010.07.012; Bruzzese JM, 2009, J ALLERGY CLIN IMMUN, V124, P195, DOI 10.1016/j.jaci.2009.05.040; Bryant-Stephens T, 2009, J ALLERGY CLIN IMMUN, V123, P1199, DOI 10.1016/j.jaci.2009.04.030; Burgess SW, 2008, RESPIROLOGY, V13, P559, DOI 10.1111/j.1440-1843.2008.01292.x; Butz AM, 2005, PUBLIC HEALTH NURS, V22, P189, DOI 10.1111/j.0737-1209.2005.220302.x; Butz AM, 2008, J ASTHMA, V45, P800, DOI 10.1080/02770900802290697; Carlstrom L, 2009, CURR ALLERGY ASTHM R, V9, P393, DOI 10.1007/s11882-009-0057-7; Chen E, 2007, AM J RESP CRIT CARE, V176, P644, DOI 10.1164/rccm.200610-1473OC; Cicutto L, 2009, J ALLERGY CLIN IMMUN, V124, P390, DOI 10.1016/j.jaci.2009.04.042; Claudio L, 2009, J HEALTH CARE POOR U, V20, P766, DOI 10.1353/hpu.0.0164; Corburn J, 2006, HEALTH PLACE, V12, P167, DOI 10.1016/j.healthplace.2004.11.002; Crain EF, 1998, ARCH PEDIAT ADOL MED, V152, P333; Denlinger LC, 2007, J ALLERGY CLIN IMMUN, V119, P3, DOI 10.1016/j.jaci.2006.10.015; *DEP HLTH SERV CDC, 2002, VITAL HLTH STAT 11, V246, P1; Eggleston PA, 2007, CHEST, V132, p782S, DOI 10.1378/chest.07-1906; Evans R, 1999, J PEDIATR-US, V135, P332, DOI 10.1016/S0022-3476(99)70130-7; Flores G, 2009, J ASTHMA, V46, P392, DOI 10.1080/02770900802712971; Gamble J, 2009, AM J RESP CRIT CARE, V180, P817, DOI 10.1164/rccm.200902-0166OC; Grineski S, 2008, J HEALTH CARE POOR U, V19, P227, DOI 10.1353/hpu.2008.0025; Gruchalla RS, 2009, J ALLERGY CLIN IMMUN, V124, P213, DOI 10.1016/j.jaci.2009.05.036; Halterman JS, 2008, AMBUL PEDIATR, V8, P43, DOI 10.1016/j.ambp.2007.10.005; Halterman JS, 2000, PEDIATRICS, V105, P272; Jones CA, 2007, J ALLERGY CLIN IMMUN, V119, P1445, DOI 10.1016/j.jaci.2007.02.031; Jones Craig A, 2005, Dis Manag, V8, P205, DOI 10.1089/dis.2005.8.205; Kattan M, 2006, PEDIATRICS, V117, pE1095, DOI 10.1542/peds.2005-2160; Kwong KYC, 2008, ANN ALLERG ASTHMA IM, V101, P144, DOI 10.1016/S1081-1206(10)60202-5; Kwong KYC, 2006, ANN ALLERG ASTHMA IM, V97, P288, DOI 10.1016/S1081-1206(10)60791-0; Lasmar L, 2009, ALLERGY, V64, P784, DOI 10.1111/j.1398-9995.2008.01877.x; Leaderer BP, 2002, ENVIRON HEALTH PERSP, V110, P419, DOI 10.1289/ehp.02110419; Markovitz BP, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-14; Matsui EC, 2008, IMMUNOL ALLERGY CLIN, V28, P665, DOI 10.1016/j.iac.2008.03.004; Matsui EC, 2006, ANN ALLERG ASTHMA IM, V97, P514, DOI 10.1016/S1081-1206(10)60943-X; Najada A, 2001, ANN ALLERG ASTHMA IM, V87, P335, DOI 10.1016/S1081-1206(10)62249-1; *NAT ASTHM ED PREV, 1997, NIH PUB; *NAT ASTHM ED PREV, 2002, NIH PUB; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Patel B, 2007, J ASTHMA, V44, P113, DOI 10.1080/02770900601182343; Phipatanakul W, 2005, ANN ALLERG ASTHMA IM, V94, P593, DOI 10.1016/S1081-1206(10)61139-8; Quinn K, 2006, AM J PUBLIC HEALTH, V96, P1599, DOI 10.2105/AJPH.2005.071514; Rand CS, 2000, J ALLERGY CLIN IMMUN, V105, P83, DOI 10.1016/S0091-6749(00)90182-9; Schatz M, 2005, J ALLERGY CLIN IMMUN, V116, P1307, DOI 10.1016/j.jaci.2005.09.027; SO Y, SAS GLOB FOR 2010 ST; Suglia SF, 2010, J EPIDEMIOL COMMUN H, V64, P1105, DOI 10.1136/jech.2008.082842corr1; SULLIVAN J, 2008, LEFT AM UNINSURED CH; Szefler S, 2008, LANCET, V372, P1065, DOI 10.1016/S0140-6736(08)61448-8; Szefler SJ, 2010, J ALLERGY CLIN IMMUN, V125, P521, DOI 10.1016/j.jaci.2010.01.025; Szefler SJ, 2010, J ALLERGY CLIN IMMUN, V125, P69, DOI 10.1016/j.jaci.2009.11.006; Teach SJ, 2006, PEDIATRICS, V117, pS152, DOI 10.1542/peds.2005-2000M; Turyk M, 2006, J ASTHMA, V43, P453, DOI 10.1080/02770900600758333; US Census Bureau, 2003, 2000 CENS POP HOUS S; Williams LK, 2004, J ALLERGY CLIN IMMUN, V114, P1288, DOI 10.1016/j.jaci.2004.09.028; Zhao Q, 2004, STAT MED, V23, P1621, DOI 10.1002/sim.1746	59	38	38	2	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2011	128	1					56	63		10.1016/j.jaci.2011.03.020	http://dx.doi.org/10.1016/j.jaci.2011.03.020			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	785RE	21531451	Bronze			2022-12-18	WOS:000292245600006
J	Altin, JA; Tian, L; Liston, A; Bertram, EM; Goodnow, CC; Cook, MC				Altin, John A.; Tian, Lei; Liston, Adrian; Bertram, Edward M.; Goodnow, Christopher C.; Cook, Matthew C.			Decreased T-cell receptor signaling through CARD11 differentially compromises forkhead box protein 3-positive regulatory versus T(H)2 effector cells to cause allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Card11; genetic variation; T-cell receptor signaling; nuclear factor kappa B; T(H)1/T(H)2; regulatory T cells; dermatitis; IgE	NF-KAPPA-B; IMMUNE DYSREGULATION; CUTTING EDGE; CARMA1; INTERLEUKIN-2; ENTEROPATHY; ACTIVATION; POLYENDOCRINOPATHY; RESPONSES; ZAP-70	Background: Allergy, the most common disease of immune dysregulation, has a substantial genetic component that is poorly understood. Although complete disruption of T-cell receptor (TCR) signaling causes profound immunodeficiency, little is known about the consequences of inherited genetic variants that cause partial quantitative decreases in particular TCR-signaling pathways, despite their potential to dysregulate immune responses and cause immunopathology. Objective: We sought to elucidate how an inherited decrease in TCR signaling through CARD11, a critical scaffold protein that signals to nuclear factor kappa B (NF-kappa B) transcription factors, results in spontaneous selective accumulation of large numbers of T(H)2 cells. Methods: "Unmodulated'' mice carry a Card11 single nucleotide variant that decreases but does not abolish TCR/CD28 signaling to induce targets of NF-kB. The consequences of this mutation on T-cell subset formation in vivo were examined, and its effects within effector versus regulatory T-cell subsets were dissected by the adoptive transfer of wild-type cells and by the examination of forkhead box protein 3 (Foxp3)-deficient unmodulated mice. Results: Unlike the pathology-free boundary points of complete Card11 sufficiency or deficiency, unmodulated mice have a specific allergic condition characterized by increased IgE levels and dermatitis. The single nucleotide variant partially decreases both the frequency of Foxp3(+) regulatory T cells and the efficiency of effector T-cell formation in vivo. These intermediate effects combine to cause a gradual and selective expansion of T(H)2 cells. Conclusions: Inherited reduction in the efficiency of TCR-NF-kappa B signaling has graded effects on T-cell activation and Foxp3(+) regulatory T-cell suppression that result in selective T(H)2 dysregulation and allergic disease. (J Allergy Clin Immunol 2011;127:1277-85.)	[Altin, John A.; Bertram, Edward M.; Goodnow, Christopher C.; Cook, Matthew C.] Australian Natl Univ, John Curtin Sch Med Res, Dept Immunol, Canberra, ACT, Australia; [Bertram, Edward M.; Goodnow, Christopher C.] Australian Natl Univ, Australian Phen Facil, Canberra, ACT, Australia; [Cook, Matthew C.] Australian Natl Univ, Sch Med, Canberra, ACT, Australia; [Tian, Lei; Liston, Adrian] VIB, Louvain, Belgium; [Tian, Lei; Liston, Adrian] Univ Louvain, Dept Expt Med, Louvain, Belgium; [Cook, Matthew C.] Canberra Hosp, Dept Immunol, Woden, ACT, Australia	Australian National University; John Curtin School of Medical Research; Australian National University; Australian National University; Flanders Institute for Biotechnology (VIB); Australian National University; Canberra Hospital	Goodnow, CC (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Bldg 131,Garran Rd, Acton, ACT, Australia.	Chris.Goodnow@anu.edu.au; Matthew.Cook@anu.edu.au	Cook, matthew/F-4151-2019; Liston, Adrian/G-8606-2013; tian, lei/HGU-7245-2022; Goodnow, Christopher C/V-8108-2018	Cook, matthew/0000-0002-3331-9363; Liston, Adrian/0000-0002-6272-4085; Goodnow, Christopher C/0000-0001-5296-6155	ACT Health & Medical Research Council; Australian National Health & Medical Research Council; Australian Research Council; VIB; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI054523, R01AI052127] Funding Source: NIH RePORTER	ACT Health & Medical Research Council; Australian National Health & Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Australian Research Council(Australian Research Council); VIB; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the ACT Health & Medical Research Council, the Australian National Health & Medical Research Council, and the Australian Research Council.; Disclosure of potential conflict of interest: A. Liston's wife is employed by UCB, and he receives research support from VIB. The rest of the authors have declared that they have no conflict of interest.	Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; Belkaid Y, 2002, NATURE, V420, P502, DOI 10.1038/nature01152; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; Caudy AA, 2007, J ALLERGY CLIN IMMUN, V119, P482, DOI 10.1016/j.jaci.2006.10.007; COFFMAN RL, 1986, J IMMUNOL, V136, P4538; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Fontenot JD, 2005, NAT IMMUNOL, V6, P1142, DOI 10.1038/ni1263; Gaide O, 2002, NAT IMMUNOL, V3, P836, DOI 10.1038/ni830; Geha RS, 2003, NAT REV IMMUNOL, V3, P721, DOI 10.1038/nri1181; GREEN JM, 1994, IMMUNITY, V1, P501, DOI 10.1016/1074-7613(94)90092-2; Gupta S, 2008, MOL IMMUNOL, V46, P213, DOI 10.1016/j.molimm.2008.08.275; Hara H, 2003, IMMUNITY, V18, P763, DOI 10.1016/S1074-7613(03)00148-1; Isomura I, 2009, J EXP MED, V206, P3001, DOI 10.1084/jem.20091411; Jun JE, 2003, IMMUNITY, V18, P751, DOI 10.1016/S1074-7613(03)00141-9; Lee JH, 2007, CLIN EXP IMMUNOL, V148, P53, DOI 10.1111/j.1365-2249.2007.03329.x; Lin W, 2005, J ALLERGY CLIN IMMUN, V116, P1106, DOI 10.1016/j.jaci.2005.08.046; Medoff BD, 2006, J IMMUNOL, V176, P7272, DOI 10.4049/jimmunol.176.12.7272; Miyara M, 2009, J ALLERGY CLIN IMMUN, V123, P749, DOI 10.1016/j.jaci.2009.03.001; Molinero LL, 2009, J IMMUNOL, V182, P6736, DOI 10.4049/jimmunol.0900498; Mottet C, 2003, J IMMUNOL, V170, P3939, DOI 10.4049/jimmunol.170.8.3939; Pfeifhofer C, 2003, J EXP MED, V197, P1525, DOI 10.1084/jem.20020234; Ruland J, 2001, CELL, V104, P33, DOI 10.1016/S0092-8674(01)00189-1; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; Sakaguchi N, 2003, NATURE, V426, P454, DOI 10.1038/nature02119; Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122; SCHAUB B, 2009, J ALLERGY CLIN IMMUN, V123, pE5, DOI DOI 10.1016/HACI.2009.01.056; Schaub B, 2008, J ALLERGY CLIN IMMUN, V121, P1491, DOI 10.1016/j.jaci.2008.04.010; Schaub Bianca, 2009, J Allergy Clin Immunol, V123, P774, DOI 10.1016/j.jaci.2009.01.056; Siggs OM, 2007, IMMUNITY, V27, P912, DOI 10.1016/j.immuni.2007.11.013; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; Tang QZ, 2003, J IMMUNOL, V171, P3348, DOI 10.4049/jimmunol.171.7.3348; Thome M, 2004, NAT REV IMMUNOL, V4, P348, DOI 10.1038/nri1352; Thornton AM, 1998, J EXP MED, V188, P287, DOI 10.1084/jem.188.2.287; Umetsu DT, 2006, IMMUNOL REV, V212, P238, DOI 10.1111/j.0105-2896.2006.00413.x; Wan YSY, 2007, NATURE, V445, P766, DOI 10.1038/nature05479; Wang DH, 2002, NAT IMMUNOL, V3, P830, DOI 10.1038/ni824; Wildin RS, 2002, J MED GENET, V39, P537, DOI 10.1136/jmg.39.8.537; Wildin RS, 2001, NAT GENET, V27, P18, DOI 10.1038/83707; Zheng Y, 2009, NATURE, V458, P351, DOI 10.1038/nature07674; Zhu JF, 2008, BLOOD, V112, P1557, DOI 10.1182/blood-2008-05-078154	43	38	39	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2011	127	5					1277	U296		10.1016/j.jaci.2010.12.1081	http://dx.doi.org/10.1016/j.jaci.2010.12.1081			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	756NG	21320717	Green Accepted			2022-12-18	WOS:000290018600024
J	Thomas, WR				Thomas, Wayne R.			The advent of recombinant allergens and allergen cloning	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen; cloning; recombinant; history; Dermatophagoides species; allergen structure	SHORT RAGWEED POLLEN; DUST MITE ALLERGEN; CDNA CLONING; IGE-BINDING; SEQUENCE-ANALYSIS; IMMUNE-RESPONSE; GRASS ALLERGEN; MAJOR ALLERGEN; VENOM ALLERGEN; PROTEIN	When the allergen nomenclature system was adopted in 1986, allergens were identified by their behavior on electrophoresis and chromatography and by reactivity to shared antisera. Not only was this unsatisfactory for standardization, but the processes of allergic sensitization and immunotherapy could not be studied in the framework of antigen processing and B-and T-cell epitopes. Recombinant technologies developed in the 1980s for cloning cDNA from low-abundance mRNA permitted the cloning of allergens, beginning with the major house dust mite allergen Der p 1 and hornet allergen Dol m 5. After this, a wave of cloning with IgE immunoscreening resulted in the cloning of Der p 2, Der p 5, Bet v 1, Bet v 2, and Dac g 2 along with Fel d 1 cloned after amino acid sequencing. Recombinant allergens have now been used to define the important allergens for a wide range of allergies and to develop new types of immunotherapy, some of which have shown efficacy in human trials. The clonally pure allergens have been used to solve the tertiary structures of allergens and from this how allergens might activate innate immunity. Proprietary recombinant allergens are now being used in improved diagnostic tests. (J Allergy Clin Immunol 2011;127:855-9.)	Univ Western Australia, Ctr Child Hlth Res, Telethon Inst Child Hlth Research, Subiaco, WA 6008, Australia	Telethon Kids Institute; University of Western Australia	Thomas, WR (corresponding author), Univ Western Australia, Ctr Child Hlth Res, Telethon Inst Child Hlth Research, 100 Roberts Rd, Subiaco, WA 6008, Australia.	wayne@ichr.uwa.edu.au			National Health and Medical Research Council of Australia	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	Supported by the National Health and Medical Research Council of Australia.	ARRUDA LK, 1990, J EXP MED, V172, P1529, DOI 10.1084/jem.172.5.1529; ARRUDA LK, 1995, J BIOL CHEM, V270, P19563, DOI 10.1074/jbc.270.33.19563; Arruda LK, 1997, AM J RESP CRIT CARE, V155, P343, DOI 10.1164/ajrccm.155.1.9001334; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; BURKS AW, 1995, J CLIN INVEST, V96, P1715, DOI 10.1172/JCI118216; Chapman MD, 2007, J ALLERGY CLIN IMMUN, V119, P414, DOI 10.1016/j.jaci.2006.11.001; CHUA KY, 1992, J ALLERGY CLIN IMMUN, V89, P95, DOI 10.1016/S0091-6749(05)80045-4; CHUA KY, 1990, INT ARCH ALLER A IMM, V91, P118, DOI 10.1159/000235101; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; FANG KSY, 1988, P NATL ACAD SCI USA, V85, P895, DOI 10.1073/pnas.85.3.895; Fersht AR, 2008, NAT REV MOL CELL BIO, V9, P650, DOI 10.1038/nrm2446; HACKETT CJ, 1985, J IMMUNOL, V135, P1391; Hansen KS, 2010, CURR ALLERGY ASTHM R, V10, P340, DOI 10.1007/s11882-010-0133-z; Kaiser L, 2007, J MOL BIOL, V370, P714, DOI 10.1016/j.jmb.2007.04.074; KING TP, 1979, J ALLERGY CLIN IMMUN, V64, P159, DOI 10.1016/0091-6749(79)90090-3; LAMB JR, 1983, J EXP MED, V157, P1434, DOI 10.1084/jem.157.5.1434; Maguire P, 1999, CLIN IMMUNOL, V93, P222, DOI 10.1006/clim.1999.4795; MARSH DG, 1982, J EXP MED, V155, P1439, DOI 10.1084/jem.155.5.1439; Monsalve RI, 1999, PROTEIN EXPRES PURIF, V16, P410, DOI 10.1006/prep.1999.1082; MORGENSTERN JP, 1991, P NATL ACAD SCI USA, V88, P9690, DOI 10.1073/pnas.88.21.9690; Oseroff C, 2010, J IMMUNOL, V185, P943, DOI 10.4049/jimmunol.1000405; PEREZ M, 1990, J BIOL CHEM, V265, P16210; RAFNAR T, 1991, J BIOL CHEM, V266, P1229; Russo Eugene, 2003, Nature, V421, P456, DOI 10.1038/nj6921-456a; SINGH MB, 1991, P NATL ACAD SCI USA, V88, P1384, DOI 10.1073/pnas.88.4.1384; SOLINGER AM, 1979, J EXP MED, V150, P830, DOI 10.1084/jem.150.4.830; Stanley JS, 1997, ARCH BIOCHEM BIOPHYS, V342, P244, DOI 10.1006/abbi.1997.9998; Thomas W.R., 1989, Advances in the Biosciences, V74, P139; Thomas WR, 2010, TRENDS MOL MED, V16, P321, DOI 10.1016/j.molmed.2010.04.008; THOMAS WR, 1988, INT ARCH ALLER A IMM, V85, P127, DOI 10.1159/000234488; TOVEY ER, 1989, J EXP MED, V170, P1457, DOI 10.1084/jem.170.4.1457; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; Valenta R, 2010, ANNU REV IMMUNOL, V28, P211, DOI 10.1146/annurev-immunol-030409-101218; WALSH DJ, 1989, INT ARCH ALLER A IMM, V90, P78, DOI 10.1159/000235004; Wopfner N, 2009, MOL IMMUNOL, V46, P2090, DOI 10.1016/j.molimm.2009.02.005; Wu CH, 1996, J BIOL CHEM, V271, P17937, DOI 10.1074/jbc.271.30.17937; YOUNG RA, 1983, SCIENCE, V222, P778, DOI 10.1126/science.6356359; YUUKI T, 1991, INT ARCH ALLER A IMM, V94, P354, DOI 10.1159/000235401	38	38	40	2	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2011	127	4					855	859		10.1016/j.jaci.2010.12.1084	http://dx.doi.org/10.1016/j.jaci.2010.12.1084			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743YL	21251702	Bronze			2022-12-18	WOS:000289055800003
J	McMurchy, AN; Gillies, J; Allan, SE; Passerini, L; Gambineri, E; Roncarolo, MG; Bacchetta, R; Levings, MK				McMurchy, Alicia N.; Gillies, Jana; Allan, Sarah E.; Passerini, Laura; Gambineri, Eleonora; Roncarolo, Maria Grazia; Bacchetta, Rosa; Levings, Megan K.			Point mutants of forkhead box P3 that cause immune dysregulation, polyendocrinopathy, enteropathy, X-linked have diverse abilities to reprogram T cells into regulatory T cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T regulatory cells; IPEX; FOXP3; autoimmunity; tolerance; IL-17	GROWTH-FACTOR-BETA; ROR-GAMMA-T; FOXP3 GENE; TARGET GENES; EXPRESSION; IPEX; ACTIVATION; TRANSCRIPTION; MUTATIONS; SCURFIN	Background: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) is a primary immunodeficiency with autoimmunity caused by mutations in forkhead box P3 (FOXP3), which encodes a transcription factor involved in regulatory T (Treg) cell function. The mechanistic basis for how different mutations in FOXP3 cause distinct manifestations of IPEX remains unclear. Objective: To determine whether 3 different point mutants of FOXP3 that cause severe or mild IPEX differ in their ability to reprogram conventional T cells into Treg cells. Methods: Human CD4(+) T cells were transduced with wild-type or point mutant forms of FOXP3, and changes in cell surface marker expression, cytokine production, proliferation and suppressive capacity were assessed. Ex vivo T H 17 cells were also transduced with different forms of FOXP3 to monitor changes in IL-17 production. Results: The forkhead mutant F373A failed to upregulate CD25 and CCR4, did not suppress cytokine production, and induced suppressive activity less effectively than wild-type FOXP3. In contrast, although the forkhead mutant R347H was also defective in upregulation of CD25, it suppressed the production of cytokines, conferred suppressive capacity on CD4(+) T cells, and suppressed IL-17 production. F324L, a mutant outside the forkhead domain associated with mild IPEX, was equivalent to wild-type FOXP3 in all aspects tested. Conclusion: Mutations in FOXP3 that cause IPEX do not uniformly abrogate the ability of FOXP3 to regulate transcription and drive the development of Treg cells. These data support the notion that factors in addition to functional changes in Treg cells, such as alterations in conventional T cells, are involved in the pathogenesis of IPEX. (J Allergy Clin Immunol 2010;126:1242-51.)	[McMurchy, Alicia N.; Gillies, Jana; Allan, Sarah E.; Levings, Megan K.] Univ British Columbia, Dept Surg, Vancouver, BC V5Z 4H4, Canada; [McMurchy, Alicia N.; Gillies, Jana; Allan, Sarah E.; Levings, Megan K.] Vancouver Coastal Hlth Res Inst, Immun & Infect Res Ctr, Vancouver, BC, Canada; [Passerini, Laura; Roncarolo, Maria Grazia; Bacchetta, Rosa] Ist Sci San Raffaele, San Raffaele Telethon Inst Gene Therapy, Div Regenerat Med Stem Cells & Gene Therapy, I-20132 Milan, Italy; [Roncarolo, Maria Grazia] Univ Vita Salute San Raffaele, Milan, Italy; [Gambineri, Eleonora] Univ Florence, Anna Meyer Childrens Hosp, Dept Sci Woman & Childs Hlth, I-50121 Florence, Italy	University of British Columbia; Vancouver Coastal Health Research Institute; Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; University of Florence; Azienda Ospedaliera Universitaria (AOU) MEYER	Levings, MK (corresponding author), Univ British Columbia, Dept Surg, Room A4-186,950 W 28th Ave, Vancouver, BC V5Z 4H4, Canada.	megan.levings@ubc.ca	Passerini, Laura/J-7791-2016; Gambineri, Eleonora/J-8747-2016	Passerini, Laura/0000-0002-4020-7386; Gambineri, Eleonora/0000-0002-4676-6541; RONCAROLO, Maria Grazia/0000-0002-2193-9186; McMurchy, Alicia Nicole/0000-0002-7033-8790; Levings, Megan/0000-0002-0305-5790	Immunity and Infection Research Centre, Michael Smith Foundation for Health Research (MSFHR) Unit; Canada Vanier Scholarship; MSFHR; CIHR [MOP-93793]; Italian Telethon Foundation, Rome; Canada Research Chair in Transplantation	Immunity and Infection Research Centre, Michael Smith Foundation for Health Research (MSFHR) Unit(Michael Smith Foundation for Health Research); Canada Vanier Scholarship; MSFHR(Michael Smith Foundation for Health Research); CIHR(Canadian Institutes of Health Research (CIHR)); Italian Telethon Foundation, Rome(Fondazione Telethon); Canada Research Chair in Transplantation	Supported by the CIHR (MOP-93793) and Stemcell Technologies Inc. Core support for flow cytometry and virus production was funded by the Immunity and Infection Research Centre, Michael Smith Foundation for Health Research (MSFHR) Unit. A.N.M. holds a Canada Vanier Scholarship, a MSFHR Junior Graduate Studentship, and a CIHR Transplantation Training Program award. R. B., L. P., and E. G. are supported by the Italian Telethon Foundation, Rome. M. K. L. holds a Canada Research Chair in Transplantation.	Allan SE, 2008, MOL THER, V16, P194, DOI 10.1038/sj.mt.6300341; Allan SE, 2007, INT IMMUNOL, V19, P345, DOI 10.1093/intimm/dxm014; Allan SE, 2008, EUR J IMMUNOL, V38, P3282, DOI 10.1002/eji.200838373; Allan SE, 2005, J CLIN INVEST, V115, P3276, DOI 10.1172/JCI24685; Amendola M, 2005, NAT BIOTECHNOL, V23, P108, DOI 10.1038/nbt1049; Bacchetta R, 2006, J CLIN INVEST, V116, P1713, DOI 10.1172/JCI25112; Baron U, 2007, EUR J IMMUNOL, V37, P2378, DOI 10.1002/eji.200737594; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Bettelli E, 2005, P NATL ACAD SCI USA, V102, P5138, DOI 10.1073/pnas.0501675102; Beysen D, 2008, HUM MOL GENET, V17, P2030, DOI 10.1093/hmg/ddn100; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; Buckner JH, 2008, ANN NY ACAD SCI, V1143, P151, DOI 10.1196/annals.1443.014; Chae WJ, 2006, P NATL ACAD SCI USA, V103, P9631, DOI 10.1073/pnas.0600225103; Chai JG, 2005, TRANSPLANTATION, V79, P1310, DOI 10.1097/01.TP.0000159147.56408.9C; Chatila TA, 2000, J CLIN INVEST, V106, pR75, DOI 10.1172/JCI11679; Crome SQ, 2009, EUR J IMMUNOL, V39, P1480, DOI 10.1002/eji.200838908; d'Hennezel E, 2009, NEW ENGL J MED, V361, P1710, DOI 10.1056/NEJMc0907093; Du JG, 2008, J IMMUNOL, V180, P4785, DOI 10.4049/jimmunol.180.7.4785; Floess S, 2007, PLOS BIOL, V5, P169, DOI 10.1371/journal.pbio.0050038; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Gambineri Eleonora, 2008, J Allergy Clin Immunol, V122, P1105, DOI 10.1016/j.jaci.2008.09.027; Gavin MA, 2006, P NATL ACAD SCI USA, V103, P6659, DOI 10.1073/pnas.0509484103; Gavin MA, 2007, NATURE, V445, P771, DOI 10.1038/nature05543; GODFREY VL, 1991, AM J PATHOL, V138, P1379; Hirahara K, 2006, J IMMUNOL, V177, P4488, DOI 10.4049/jimmunol.177.7.4488; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Kim HP, 2007, J EXP MED, V204, P1543, DOI 10.1084/jem.20070109; Kuczma M, 2009, J IMMUNOL, V183, P3731, DOI 10.4049/jimmunol.0800601; Lal G, 2009, J IMMUNOL, V182, P259, DOI 10.4049/jimmunol.182.1.259; Leonardo S, 2010, J IMMUNOL, V184; Levings MK, 2002, J EXP MED, V196, P1335, DOI 10.1084/jem.20021139; Li B, 2007, INT IMMUNOL, V19, P825, DOI 10.1093/intimm/dxm043; Li B, 2007, P NATL ACAD SCI USA, V104, P4571, DOI 10.1073/pnas.0700298104; Lim HW, 2005, J IMMUNOL, V175, P4180, DOI 10.4049/jimmunol.175.7.4180; Lin W, 2007, NAT IMMUNOL, V8, P359, DOI 10.1038/ni1445; Lopes JE, 2006, J IMMUNOL, V177, P3133, DOI 10.4049/jimmunol.177.5.3133; Louten J, 2009, J ALLERGY CLIN IMMUN, V123, P1004, DOI 10.1016/j.jaci.2009.04.003; Mahnke K, 2007, EUR J IMMUNOL, V37, P2117, DOI 10.1002/eji.200636841; Marson A, 2007, NATURE, V445, P931, DOI 10.1038/nature05478; Morgan ME, 2005, HUM IMMUNOL, V66, P13, DOI 10.1016/j.humimm.2004.05.016; Nagar M, 2008, INT IMMUNOL, V20, P1041, DOI 10.1093/intimm/dxn062; Ono M, 2007, NATURE, V446, P685, DOI 10.1038/nature05673; Pan F, 2009, SCIENCE, V325, P1142, DOI 10.1126/science.1176077; POLANSKY JK, 2010, J MOL MED; Polansky JK, 2008, EUR J IMMUNOL, V38, P1654, DOI 10.1002/eji.200838105; POWELL BR, 1982, J PEDIATR-US, V100, P731, DOI 10.1016/S0022-3476(82)80573-8; Probst-Kepper M, 2009, J CELL MOL MED, V13, P3343, DOI 10.1111/j.1582-4934.2009.00782.x; Scaillon M, 2009, J PEDIATR GASTR NUTR, V49, P368, DOI 10.1097/MPG.0b013e3181a159de; Schubert LA, 2001, J BIOL CHEM, V276, P37672, DOI 10.1074/jbc.M104521200; Seidel MG, 2009, BLOOD, V113, P5689, DOI 10.1182/blood-2009-02-206359; Torgerson TR, 2007, J ALLERGY CLIN IMMUN, V120, P744, DOI 10.1016/j.jaci.2007.08.044; Tran DQ, 2007, BLOOD, V110, P2983, DOI 10.1182/blood-2007-06-094656; Veldhoen M, 2006, J IMMUNOL, V176, P6202, DOI 10.4049/jimmunol.176.10.6202; Wang J, 2007, EUR J IMMUNOL, V37, P129, DOI 10.1002/eji.200636435; Wang R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002705; Wildin RS, 2002, J MED GENET, V39, P537, DOI 10.1136/jmg.39.8.537; Wildin RS, 2001, NAT GENET, V27, P18, DOI 10.1038/83707; Wu YQ, 2006, CELL, V126, P375, DOI 10.1016/j.cell.2006.05.042; Yang XO, 2008, IMMUNITY, V29, P44, DOI 10.1016/j.immuni.2008.05.007; Zhang FP, 2008, NAT IMMUNOL, V9, P1297, DOI 10.1038/ni.1663; Zheng Y, 2007, NATURE, V445, P936, DOI 10.1038/nature05563; Zheng Y, 2010, NATURE, V463, P808, DOI 10.1038/nature08750; Zhou L, 2008, NATURE, V453, P236, DOI 10.1038/nature06878	64	38	40	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2010	126	6					1242	1251		10.1016/j.jaci.2010.09.001	http://dx.doi.org/10.1016/j.jaci.2010.09.001			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	689RZ	21036387				2022-12-18	WOS:000284947800024
J	Vereda, A; Andreae, DA; Lin, J; Shreffler, WG; Ibanez, MD; Cuesta-Herranz, J; Bardina, L; Sampson, HA				Vereda, Andrea; Andreae, Doerthe A.; Lin, Jing; Shreffler, Wayne G.; Ibanez, Maria Dolores; Cuesta-Herranz, Javier; Bardina, Ludmilla; Sampson, Hugh A.			Identification of IgE sequential epitopes of lentil (Len c 1) by means of peptide microarray immunoassay	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Lentil allergy; peptide microarray; epitope recognition; epitope diversity; Len c 1	BETA-CONGLYCININ; PEANUT ALLERGEN; MAJOR ALLERGEN; ANAPHYLAXIS; CHICKPEA; IGG4	Background: Lentils are often responsible for allergic reactions to legumes in Mediterranean children. Although the primary sequence of the major allergen Len c 1 is known, the location of the IgE-binding epitopes remains undefined. Objective: We sought to identify IgE-binding epitopes of Len c 1 and relate epitope binding to clinical characteristics. Methods: One hundred thirty-five peptides corresponding to the primary sequence of Len c 1 were probed with sera from 33 patients with lentil allergy and 15 nonatopic control subjects by means of microarray immunoassay. Lentil-specific IgE levels, skin prick test responses, and clinical reactions to lentil were determined. Epitopes were defined as overlapping signal above interslide and intraslide cutoffs and confirmed by using inhibition assays with a peptide from the respective region. Hierarchic clustering of microarray data was used to correlate binding patterns with clinical findings. Results: The patients with lentil allergy specifically recognized IgE-binding epitopes located in the C-terminal region between peptides 107 and 135. Inhibition experiments confirmed the specificity of IgE binding in this region, identifying different epitopes. Linkage of cluster results with clinical data and lentil-specific IgE levels displayed a positive correlation between lentil-specific IgE levels, epitope recognition, and respiratory symptoms. Modeling based on the 3-dimensional structure of a homologous soy vicilin suggests that the Len c 1 epitopes identified are exposed on the surface of the molecule. Conclusion: Several IgE-binding sequential epitopes of Len c 1 have been identified. Epitopes are located in the C-terminal region and are predicted to be exposed on the surface of the protein. Epitope diversity is positively correlated with IgE levels, pointing to a more polyclonal IgE response. (J Allergy Clin Immunol 2010;126:596-601.)	[Vereda, Andrea; Andreae, Doerthe A.; Lin, Jing; Shreffler, Wayne G.; Bardina, Ludmilla; Sampson, Hugh A.] Mt Sinai Sch Med, Dept Pediat, Elliot & Roslyn Jaffe Food Allergy Inst, Div Allergy & Immunol, New York, NY USA; [Vereda, Andrea; Ibanez, Maria Dolores] Univ Nino Jesus, Hosp Infantil, Allergy Serv, Madrid, Spain; [Vereda, Andrea; Cuesta-Herranz, Javier] Fdn Jimenez Diaz, Serv Alergia, E-28040 Madrid, Spain	Icahn School of Medicine at Mount Sinai	Sampson, HA (corresponding author), Mt Sinai Sch Med, Dept Pediat, Elliot & Roslyn Jaffe Food Allergy Inst, Div Allergy & Immunol, Box 1198,1 Gustave L Levy Pl, New York, NY USA.	hugh.sampson@mssm.edu			World Allergy Organization; National Institutes of Health/National Institute of Allergy and Infectious Diseases; Food Allergy and Anaphylaxis Network; NATIONAL CENTER FOR RESEARCH RESOURCES [TL1RR029886, M01RR000071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI044236] Funding Source: NIH RePORTER	World Allergy Organization; National Institutes of Health/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Food Allergy and Anaphylaxis Network; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	A. V. was funded by the World Allergy Organization; H. A. S. and W. G. S. have received research support from the National Institutes of Health/National Institute of Allergy and Infectious Diseases and the Food Allergy and Anaphylaxis Network.	Barre A, 2005, BIOCHIMIE, V87, P499, DOI 10.1016/j.biochi.2005.02.011; Breiteneder H, 2004, J ALLERGY CLIN IMMUN, V113, P821, DOI [10.1016/j.jaci.2004.01.779, 10.1016/j.jaci.2004.01.079]; Cerecedo I, 2008, J ALLERGY CLIN IMMUN, V122, P589, DOI 10.1016/j.jaci.2008.06.040; Cuadrado C, 2009, MOL NUTR FOOD RES, V53, P1462, DOI 10.1002/mnfr.200800485; Flinterman AE, 2008, J ALLERGY CLIN IMMUN, V121, P737, DOI 10.1016/j.jaci.2007.11.039; Holzhauser T, 2009, J ALLERGY CLIN IMMUN, V123, P452, DOI 10.1016/j.jaci.2008.09.034; Ibanez M D, 2003, Allergol Immunopathol (Madr), V31, P151; Jaervinen KM, 2007, ALLERGY, V62, P758, DOI 10.1111/j.1398-9995.2007.01332.x; Jin T, 2009, MOL IMMUNOL, V46, P1796, DOI 10.1016/j.molimm.2009.01.023; Kalogeromitros D, 1996, ANN ALLERG ASTHMA IM, V77, P480, DOI 10.1016/S1081-1206(10)63354-6; Krishnan HB, 2009, J AGR FOOD CHEM, V57, P938, DOI 10.1021/jf802451g; Lin J, 2009, J ALLERGY CLIN IMMUN, V124, P315, DOI 10.1016/j.jaci.2009.05.024; Lin J, 2009, METHODS MOL BIOL, V524, P259, DOI 10.1007/978-1-59745-450-6_19; Lopez-Torrejon G, 2003, J ALLERGY CLIN IMMUN, V112, P1208, DOI 10.1016/j.jaci.2003.08.035; Matsuo H, 2005, J IMMUNOL, V175, P8116, DOI 10.4049/jimmunol.175.12.8116; Orhan F, 2008, J INVEST ALLERG CLIN, V18, P465; Ireneo MMS, 2008, ANN ALLERG ASTHMA IM, V101, P179; Sanchez-Monge R, 2000, J ALLERGY CLIN IMMUN, V106, P955, DOI 10.1067/mai.2000.109912; Sandin DI, 1999, ALLERGY, V54, P1209, DOI 10.1034/j.1398-9995.1999.00299.x; Shreffler WG, 2005, J ALLERGY CLIN IMMUN, V116, P893, DOI 10.1016/j.jaci.2005.06.033; Shreffler WG, 2004, J ALLERGY CLIN IMMUN, V113, P776, DOI 10.1016/j.jaci.2003.12.588; Wang J, 2010, J ALLERGY CLIN IMMUN, V125, P695, DOI 10.1016/j.jaci.2009.12.017	22	38	40	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2010	126	3					596	U21		10.1016/j.jaci.2010.06.023	http://dx.doi.org/10.1016/j.jaci.2010.06.023			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	646CF	20816193	Green Accepted			2022-12-18	WOS:000281512500028
J	Silverberg, JI; Norowitz, KB; Kleiman, E; Silverberg, NB; Durkin, HG; Joks, R; Smith-Norowitz, TA				Silverberg, Jonathan I.; Norowitz, Kevin B.; Kleiman, Edward; Silverberg, Nanette B.; Durkin, Helen G.; Joks, Rauno; Smith-Norowitz, Tamar A.			Association between varicella zoster virus infection and atopic dermatitis in early and late childhood: A case-control study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; varicella zoster virus; chickenpox; varicella vaccine; Varivax; eczema; atopy; asthma; allergic rhinitis; rhinoconjunctivitis; food allergy	FALSE DISCOVERY RATE; NASOPHARYNGEAL SECRETIONS; ICHTHYOSIS VULGARIS; IMMUNE-RESPONSES; CLINICAL-ASPECTS; SCHOOL-CHILDREN; RARE MUTATIONS; UNITED-STATES; RISK-FACTORS; FILAGGRIN	Background: Wild-type varicella zoster virus infection (WTVZV) early in childhood has been shown to protect against the development of asthma and atopy. Objective: To determine whether WTVZV in childhood protects against atopic dermatitis (AD). Methods: This retrospective, practice-based, case-control study randomly sampled 256 children and adolescents (age 1-18 years) with AD and 422 age-matched healthy controls from 2005 to 2007. Observations were made before the a priori hypothesis. Results: (1) A single episode of WTVZV in childhood is associated with decreased odds ratio (OR) of developing AD (conditional logistic regression; OR, 0.55; 95% CI, 0.34-0.89; P = .01). (2) When using intervals for age corresponding to bimodal distribution of age of WTVZV infection, the effects of WTVZV infection are significant when occurring at age 0 to 8 years (OR, 0.56; 95% CI, 0.35-0.90; P = .02), but not at 8 to 18 years (OR, 0.50; 95% CI, 0.19-1.31; P = .16). Considering 5-year intervals has similar findings. (3) WTVZV is associated with decreased odds of moderate AD (multinomial logistic regression; OR, 0.08, 95% CI, 0.04-0.15; P < .0001) or severe AD (OR, 0.04; 95% CI, 0.01-0.13; P < .0001). (4) WTVZV in children is associated with prolonged AD-free survival (Kaplan-Meier; median, 15.3 years; 95% CI, 10.9-18.0) compared with controls (median, 7.5 years; 95% CI, 4.8-11.9; log-rank test, P < .0001). (5) Children with WTVZV, compared with vaccine, who eventually develop AD require fewer pediatrician sick visits for management of AD (logistic regression; OR, 0.17; 95% CI, 0.06-0.51; P = .001). Conclusion: WTVZV in childhood protects up to 10 years of age against AD, delays onset of AD symptoms, and decreases AD severity and office visits. (J Allergy Clin Immunol 2010;126:300-5.)	[Silverberg, Jonathan I.; Durkin, Helen G.] Suny Downstate Med Ctr, Dept Pathol, Brooklyn, NY 11203 USA; [Silverberg, Jonathan I.; Kleiman, Edward; Durkin, Helen G.; Joks, Rauno] Suny Downstate Med Ctr, Dept Med, Brooklyn, NY 11203 USA; [Norowitz, Kevin B.; Smith-Norowitz, Tamar A.] Suny Downstate Med Ctr, Dept Pediat, Brooklyn, NY 11203 USA; [Silverberg, Jonathan I.] Suny Downstate Med Ctr, Sch Publ Hlth, Brooklyn, NY 11203 USA; [Silverberg, Jonathan I.; Durkin, Helen G.; Joks, Rauno; Smith-Norowitz, Tamar A.] Suny Downstate Med Ctr, Ctr Allergy & Asthma Res, Brooklyn, NY 11203 USA; [Silverberg, Jonathan I.; Silverberg, Nanette B.] Beth Israel Deaconess Med Ctr, Dept Dermatol, New York, NY 10003 USA; [Silverberg, Jonathan I.; Silverberg, Nanette B.] St Lukes Roosevelt Hosp, New York, NY USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Mount Sinai St. Luke's; Mount Sinai West	Silverberg, JI (corresponding author), Suny Downstate Med Ctr, Dept Pathol, Rm 4-18,Box 25,450 Clarkson Ave, Brooklyn, NY 11203 USA.	JonathanISilverberg@Gmail.com	silverberg, jonathan/ABH-2765-2021	silverberg, jonathan/0000-0003-3686-7805				[Anonymous], 1967, HDB METHODS APPL STA; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Becker Y, 2006, VIRUS GENES, V33, P235, DOI 10.1007/s11262-006-0064-x; Benjamini Y, 2001, ANN STAT, V29, P1165; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BerthJones J, 1997, BRIT J DERMATOL, V136, P498, DOI 10.1046/j.1365-2133.1997.d01-1224.x; Bonanni P, 2008, VACCINE, V26, P5619, DOI 10.1016/j.vaccine.2008.07.096; BUI RHD, 1987, J PEDIATR-US, V110, P87; Calvani M, 1997, PEDIATR ALLERGY IMMU, V8, P91, DOI 10.1111/j.1399-3038.1997.tb00150.x; Cassimos DC, 2008, PEDIATR INT, V50, P51, DOI 10.1111/j.1442-200X.2007.02509.x; Chow SC, 2003, SAMPLE SIZE CALCULAT; Comm Infect Dis, 2000, PEDIATRICS, V105, P136; Dakhama A, 2009, J ALLERGY CLIN IMMUN, V123, P138, DOI 10.1016/j.jaci.2008.10.012; DOTTERUD LK, 1994, ACTA DERM-VENEREOL, V74, P124; DOTTERUD LK, 1995, ACTA DERM-VENEREOL, V75, P50; FALK ES, 1993, ACTA DERM-VENEREOL, P10; Fohr C, 2005, BRIT J DERMATOL, V152, P202, DOI [10.1111/J.1365-2133.2005.06436.X, 10.1111/j.1365-2133.2004.06436.x]; Fujimura T, 1997, J ALLERGY CLIN IMMUN, V100, P274, DOI 10.1016/S0091-6749(97)70236-7; Garn H, 2007, IMMUNOBIOLOGY, V212, P441, DOI 10.1016/j.imbio.2007.03.006; Gillet Y, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-16; Halperin SA, 2009, VACCINE, V27, P2701, DOI 10.1016/j.vaccine.2009.02.044; Hambleton S, 2005, CURR OPIN INFECT DIS, V18, P235, DOI 10.1097/01.qco.0000168384.31766.89; Hanifin IM, 2007, DERMATITIS, V18, P82, DOI 10.2310/6620.2007.06034; Hanifin JM, 2001, EXP DERMATOL, V10, P11, DOI 10.1034/j.1600-0625.2001.100102.x; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Herd RM, 1996, BRIT J DERMATOL, V135, P18; Illi S, 2001, BMJ-BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; Irvine AD, 2006, J INVEST DERMATOL, V126, P1200, DOI 10.1038/sj.jid.5700365; Jenkins DE, 1998, J INFECT DIS, V178, P940, DOI 10.1086/515702; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Larsen FS, 1996, J AM ACAD DERMATOL, V34, P760, DOI 10.1016/S0190-9622(96)90009-2; LARSEN FS, 1993, MONOGR ALLERGY, V31, P9; LARSEN FS, 1992, ACTA DERM-VENEREOL, P7; Laughter D, 2000, J AM ACAD DERMATOL, V43, P649, DOI 10.1067/mjd.2000.107773; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Marin M, 2008, PEDIATRICS, V122, pE744, DOI 10.1542/peds.2008-0567; Martinez FD, 1999, J ALLERGY CLIN IMMUN, V103, P355, DOI 10.1016/S0091-6749(99)70456-2; Nguyen HQ, 2005, NEW ENGL J MED, V352, P450, DOI 10.1056/NEJMoa042271; Nilsson C, 2005, J ALLERGY CLIN IMMUN, V116, P438, DOI 10.1016/j.jaci.2005.04.027; O'Connell EJ, 2004, ALLERGY, V59, P7, DOI 10.1111/j.1398-9995.2004.00563.x; O'Regan GM, 2008, J ALLERGY CLIN IMMUN, V122, P689, DOI 10.1016/j.jaci.2008.08.002; O'Regan GM, 2008, CURR OPIN ALLERGY CL, V8, P406, DOI 10.1097/ACI.0b013e32830e6fb2; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Rodriguez E, 2009, J ALLERGY CLIN IMMUN, V123, P1361, DOI 10.1016/j.jaci.2009.03.036; Rodriguez S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005784; Rothe MJ, 1996, LANCET, V348, P769, DOI 10.1016/S0140-6736(05)65206-3; RUSSI JC, 1993, J CLIN MICROBIOL, V31, P819, DOI 10.1128/JCM.31.4.819-823.1993; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; Sandilands A, 2006, J INVEST DERMATOL, V126, P1770, DOI 10.1038/sj.jid.5700459; Saval P, 1993, Pediatr Allergy Immunol, V4, P117, DOI 10.1111/j.1399-3038.1993.tb00079.x; Schafer T, 1996, ALLERGY, V51, P532; Schafer T, 1999, ENVIRON RES, V81, P151, DOI 10.1006/enrs.1999.3964; Seward JF, 2002, JAMA-J AM MED ASSOC, V287, P606, DOI 10.1001/jama.287.5.606; SHAPIRO SS, 1965, BIOMETRIKA, V52, P591, DOI 10.1093/biomet/52.3-4.591; Silverberg Jonathan I., 2009, Pediatric Asthma Allergy & Immunology, V22, P15, DOI 10.1089/pai.2008.0515; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; TAYLOR B, 1984, LANCET, V2, P1255, DOI 10.1016/S0140-6736(84)92805-8; TOV HL, 2008, J ALLERGY CLIN IMMUN, V121, pS207; Verhagen J, 2006, J ALLERGY CLIN IMMUN, V117, P176, DOI 10.1016/j.jaci.2005.10.040; von Mutius E, 2007, IMMUNOBIOLOGY, V212, P433, DOI 10.1016/j.imbio.2007.03.002; Wang De-Yun, 2005, Ther Clin Risk Manag, V1, P115, DOI 10.2147/tcrm.1.2.115.62907; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; WELLIVER RC, 1981, NEW ENGL J MED, V305, P841, DOI 10.1056/NEJM198110083051501; Williams H, 2008, J ALLERGY CLIN IMMUN, V121, P947, DOI 10.1016/j.jaci.2007.11.004; Williams H, 2006, J ALLERGY CLIN IMMUN, V118, P209, DOI 10.1016/j.jaci.2006.04.043; Wuthrich B, 2003, J INVEST ALLERG CLIN, V13, P1; Wuthrich B, 1999, ANN ALLERG ASTHMA IM, V83, P464, DOI 10.1016/S1081-1206(10)62852-9; Zhou FJ, 2008, J INFECT DIS, V197, pS156, DOI 10.1086/522135; Zhou FJ, 2005, JAMA-J AM MED ASSOC, V294, P797, DOI 10.1001/jama.294.7.797	70	38	38	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2010	126	2					300	305		10.1016/j.jaci.2010.05.041	http://dx.doi.org/10.1016/j.jaci.2010.05.041			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	642IL	20624648				2022-12-18	WOS:000281203800015
J	Karp, CL				Karp, Christopher L.			Guilt by intimate association: What makes an allergen an allergen?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; allergenicity; T(H)2; asthma; innate immunity; pattern-recognition receptor; Toll-like receptor; adjuvant; LPS; protease; carbohydrate	HOUSE-DUST MITE; TOLL-LIKE RECEPTOR-2; IMMUNE-RESPONSES; INFLAMMATORY RESPONSE; CRYSTAL-STRUCTURE; DENDRITIC CELLS; MURINE MODEL; HAY-FEVER; IN-VIVO; ENDOTOXIN	Why specific, ubiquitous, otherwise innocuous environmental proteins tend to provoke maladaptive, T(H)2-polarized immune responses in susceptible hosts is a fundamental mechanistic question for those interested in the pathogenesis, therapy, and prevention of allergic disease. The current renaissance in the study of innate immunity has provided important insights into this question. The theme emerging from recent studies is that direct (dys)functional interactions with pathways of innate immune activation that evolved to signal the presence of microbial infection are central to the molecular basis for allergenicity. This article reviews these data. (J Allergy Clin Immunol 2010;125:955-60.)	[Karp, Christopher L.] Cincinnati Childrens Hosp Res Fdn, Div Mol Immunol, Dept Pediat, Cincinnati, OH USA; [Karp, Christopher L.] Univ Cincinnati, Coll Med, Cincinnati, OH 45221 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University of Cincinnati; University of Cincinnati	Karp, CL (corresponding author), CCHRF, Div Mol Immunol, 3333 Burnett Ave, Cincinnati, OH 45229 USA.	chris.karp@cchmc.org		Karp, Christopher/0000-0002-0832-2659	American Asthma Foundation; National Institutes of Health [AI088372]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI088372] Funding Source: NIH RePORTER	American Asthma Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by a Senior Investigator Award from the American Asthma Foundation and by National Institutes of Health grant AI088372.	Barrett NA, 2009, J IMMUNOL, V182, P1119, DOI 10.4049/jimmunol.182.2.1119; Becker S, 1999, AM J RESP CRIT CARE, V160, P1309, DOI 10.1164/ajrccm.160.4.9901062; Blander JM, 2006, NATURE, V440, P808, DOI 10.1038/nature04596; Braedel-Ruoff S, 2005, J ENDOTOXIN RES, V11, P89, DOI 10.1179/096805105X35189; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28, DOI 10.1046/j.1365-2222.1999.00479.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Broide D, 1998, J IMMUNOL, V161, P7054; Broide DH, 2001, J CLIN IMMUNOL, V21, P175, DOI 10.1023/A:1011078930363; Brutkiewicz RR, 2006, J IMMUNOL, V177, P769, DOI 10.4049/jimmunol.177.2.769; Dabbagh K, 2002, J IMMUNOL, V168, P4524, DOI 10.4049/jimmunol.168.9.4524; Deb R, 2007, J BIOL CHEM, V282, P36808, DOI 10.1074/jbc.M702336200; Derewenda U, 2002, J MOL BIOL, V318, P189, DOI 10.1016/S0022-2836(02)00027-X; Dziarski R, 2001, J IMMUNOL, V166, P1938, DOI 10.4049/jimmunol.166.3.1938; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; Eduard W, 2004, THORAX, V59, P381, DOI 10.1136/thx.2004.013326; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Elass E, 2005, INFECT IMMUN, V73, P7064, DOI 10.1128/IAI.73.10.7064-7068.2005; Ernst P, 2000, AM J RESP CRIT CARE, V161, P1563, DOI 10.1164/ajrccm.161.5.9908119; Gangloff M, 2004, TRENDS BIOCHEM SCI, V29, P294, DOI 10.1016/j.tibs.2004.04.008; Gehring U, 2002, AM J RESP CRIT CARE, V166, P939, DOI 10.1164/rccm.200203-256OC; Geijtenbeek TBH, 2009, NAT REV IMMUNOL, V9, P465, DOI 10.1038/nri2569; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Herrick CA, 2003, NAT REV IMMUNOL, V3, P405, DOI 10.1038/nri1084; Hessel EM, 2005, J EXP MED, V202, P1563, DOI 10.1084/jem.20050631; HEYMANN PW, 1989, J ALLERGY CLIN IMMUN, V83, P1055, DOI 10.1016/0091-6749(89)90447-8; Hollingsworth JW, 2005, AM J RESP CRIT CARE, V171, P806, DOI 10.1164/rccm.200407-953OC; HSU SC, 2010, J BIOL CHEM; Inohara N, 2002, TRENDS BIOCHEM SCI, V27, P219, DOI 10.1016/S0968-0004(02)02084-4; Iwasaki A, 2010, SCIENCE, V327, P291, DOI 10.1126/science.1183021; Jia HP, 2004, AM J PHYSIOL-LUNG C, V287, pL428, DOI 10.1152/ajplung.00377.2003; Kawasaki N, 2009, DIGEST ENDOSC, V21, P37, DOI 10.1111/j.1443-1661.2008.00816.x; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201, DOI 10.1046/j.1365-2222.2000.00800.x; Kim HM, 2007, CELL, V130, P906, DOI 10.1016/j.cell.2007.08.002; King C, 1998, J IMMUNOL, V161, P3645; Kouzaki H, 2009, J IMMUNOL, V183, P1427, DOI 10.4049/jimmunol.0900904; Liu YJ, 2009, ADV IMMUNOL, V101, P1, DOI 10.1016/S0065-2776(08)01001-8; Lotz S, 2004, J LEUKOCYTE BIOL, V75, P467, DOI 10.1189/jlb.0803360; Manukyan M, 2005, EUR J IMMUNOL, V35, P911, DOI 10.1002/eji.200425336; Martinez Fernando D, 2007, Proc Am Thorac Soc, V4, P221, DOI 10.1513/pats.200702-035AW; MAUNSELL K, 1968, LANCET, V1, P1267; McKerrow JH, 2006, ANNU REV PATHOL-MECH, V1, P497, DOI 10.1146/annurev.pathol.1.110304.100151; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641, DOI 10.1164/ajrccm.154.6.8970348; MICHEL O, 1989, J APPL PHYSIOL, V66, P1059, DOI 10.1152/jappl.1989.66.3.1059; Nathan AT, 2009, J ALLERGY CLIN IMMUN, V123, P612, DOI 10.1016/j.jaci.2008.12.006; Ohto U, 2007, SCIENCE, V316, P1632, DOI 10.1126/science.1139111; Park BS, 2009, NATURE, V458, P1191, DOI 10.1038/nature07830; Perrigoue JG, 2009, NAT IMMUNOL, V10, P697, DOI 10.1038/ni.1740; Phipps S, 2009, AM J RESP CRIT CARE, V179, P883, DOI 10.1164/rccm.200806-974OC; Pulendran B, 2001, J IMMUNOL, V167, P5067, DOI 10.4049/jimmunol.167.9.5067; Rallabhandi P, 2008, J BIOL CHEM, V283, P24314, DOI 10.1074/jbc.M804800200; Redecke V, 2004, J IMMUNOL, V172, P2739, DOI 10.4049/jimmunol.172.5.2739; Reese TA, 2007, NATURE, V447, P92, DOI 10.1038/nature05746; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; RYLANDER R, 1989, AM REV RESPIR DIS, V140, P981, DOI 10.1164/ajrccm/140.4.981; Schnare M, 2001, NAT IMMUNOL, V2, P947, DOI 10.1038/ni712; Serebrisky D, 2000, J IMMUNOL, V165, P5906, DOI 10.4049/jimmunol.165.10.5906; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; Shakib F, 1998, IMMUNOL TODAY, V19, P313, DOI 10.1016/S0167-5699(98)01284-5; Shreffler WG, 2006, J IMMUNOL, V177, P3677, DOI 10.4049/jimmunol.177.6.3677; Sokol CL, 2008, NAT IMMUNOL, V9, P310, DOI 10.1038/ni1558; Sokol CL, 2009, NAT IMMUNOL, V10, P713, DOI 10.1038/ni.1738; Sporri R, 2005, NAT IMMUNOL, V6, P163, DOI 10.1038/ni1162; Strohmeier GR, 2001, J IMMUNOL, V166, P2063, DOI 10.4049/jimmunol.166.3.2063; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Thomas WR, 2005, CURR ALLERGY ASTHM R, V5, P388, DOI 10.1007/s11882-005-0012-1; TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; Tulic MK, 2000, AM J RESP CELL MOL, V22, P604; Vercelli D, 2010, CURR OPIN ALLERGY CL; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187, DOI 10.1046/j.1365-2222.2000.00801.x; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Williams LK, 2005, ANN ALLERG ASTHMA IM, V94, P323, DOI 10.1016/S1081-1206(10)60983-0; Wills-Karp M, 2010, MUCOSAL IMMUNOL, V3, P104, DOI 10.1038/mi.2009.138; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; Yamashita Y, 2002, CLIN EXP ALLERGY, V32, P776, DOI 10.1046/j.1365-2222.2002.01334.x; Yarovinsky F, 2005, SCIENCE, V308, P1626, DOI 10.1126/science.1109893; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490; Yoshimoto T, 2009, NAT IMMUNOL, V10, P706, DOI 10.1038/ni.1737; Zhu JF, 2008, BLOOD, V112, P1557, DOI 10.1182/blood-2008-05-078154	82	38	39	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2010	125	5					955	960		10.1016/j.jaci.2010.03.002	http://dx.doi.org/10.1016/j.jaci.2010.03.002			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	596LO	20381850	Green Accepted			2022-12-18	WOS:000277686700001
J	Desai, SH; Chouksey, A; Poll, J; Berger, M				Desai, Shilpa H.; Chouksey, Akhil; Poll, John; Berger, Melvin			A pilot study of equal doses of 10% IGIV given intravenously or subcutaneously	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							IMMUNOGLOBULIN REPLACEMENT THERAPY; PRIMARY IMMUNODEFICIENCY; EFFICACY; SAFETY		[Desai, Shilpa H.] Case Western Reserve Univ, Sch Med, Cleveland, OH 44106 USA; [Chouksey, Akhil; Poll, John; Berger, Melvin] Univ Hosp Cleveland, Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital	Desai, SH (corresponding author), Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA.	Berger@UHhospitals.org						Aebersold P, 2005, INTRAVENOUS IMMUNOGL; Berger M, 2004, CLIN IMMUNOL, V112, P1, DOI 10.1016/j.clim.2004.02.002; Berger M, 2008, IMMUNOL ALLERGY CLIN, V28, P413, DOI 10.1016/j.iac.2008.01.008; Chapel HM, 2000, J CLIN IMMUNOL, V20, P94, DOI 10.1023/A:1006678312925; Choudhury A, 2005, ORAL ONCOL, V1, P120, DOI 10.1016/S1744-7895(05)80296-2; *EMEA CPMP, 2002, CPMPBPWG28300 EMEA; Ochs HD, 2006, J CLIN IMMUNOL, V26, P265, DOI 10.1007/s10875-006-9021-7; *US FDA, 2008, GUID IND SAF EFF PHA	8	38	38	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2009	124	4					854	856		10.1016/j.jaci.2009.07.051	http://dx.doi.org/10.1016/j.jaci.2009.07.051			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	506UV	19767071	Bronze			2022-12-18	WOS:000270802800038
J	Peters, JL; Suglia, SF; Platts-Mills, TAE; Hosen, J; Gold, DR; Wright, RJ				Peters, Junenette L.; Suglia, Shakira Franco; Platts-Mills, Thomas A. E.; Hosen, Jacob; Gold, Diane R.; Wright, Rosalind J.			Relationships among prenatal aeroallergen exposure and maternal and cord blood IgE: Project ACCESS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen; dust mite; cockroach; maternal; prenatal; cord blood; IgE; urban	DUST-MITE ALLERGEN; 1ST 2 YEARS; IMMUNOGLOBULIN-E; PROLIFERATIVE RESPONSES; ENVIRONMENTAL ALLERGENS; CYTOKINE PRODUCTION; IMMUNE-RESPONSES; INDOOR ALLERGENS; IN-UTERO; SENSITIZATION	Background: Whereas some evidence suggests that antigen sensitization may begin prenatally, the influence of maternal allergen exposure during pregnancy has not been fully elucidated. Objectives: We examined the relationship between prenatal maternal aeroallergen exposure and cord blood total IgE and the potential mediating/indirect effect of maternal immune response. Methods: This study was performed in 301 mother-infant pairs enrolled in the Asthma Coalition on Community, Environment, and Social Stress (ACCESS) project, a study examining the effects of prenatal and early life social and physical environmental exposures on urban asthma risk. Dust samples collected prenatally from mothers' bedrooms were analyzed for cockroach and dust mite allergens. Cord blood was analyzed for total IgE, and maternal serum collected during pregnancy for total and specific IgE. We assessed the relationship between prenatal exposure and cord blood total IgE and the potential mediation effect adjusting for maternal age, race, education, smoking status, and dust collection season; and child's sex and season of birth. Results: In multivariate models, elevated prenatal dust mite levels (>0.2 mu g/g) increased cord blood IgE concentrations by 29% (P = .08), and continuous dust mite concentration was associated with a significant nonlinear increase in cord blood IgE (P = .02). Elevated prenatal exposure to cockroach allergen (>2 U/g) was not associated with cord blood IgE, but showed a significant indirect relationship through maternal total IgE (beta = 0.23; 95% CI, 0.08-4.41). Conclusion: These results demonstrate that maternal prenatal exposure to household allergens may affect cord blood IgE, albeit the underlying mechanism may be allergen-specific. (J Allergy Clin Immunol 2009;123:1041-6.)	[Peters, Junenette L.; Suglia, Shakira Franco; Gold, Diane R.; Wright, Rosalind J.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Landmark Ctr, Boston, MA 02215 USA; [Platts-Mills, Thomas A. E.; Hosen, Jacob] Univ Virginia, Div Clin Immunol & Allergy, Charlottesville, VA 22903 USA; [Gold, Diane R.; Wright, Rosalind J.] Harvard Univ, Brigham & Womens Hosp, Channing Lab, Dept Med,Sch Med, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; University of Virginia; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Peters, JL (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Landmark Ctr, POB 15697,401 Pk Dr, Boston, MA 02215 USA.	jpeters@hsph.harvard.edu	Hosen, Jacob/F-9224-2013	Hosen, Jacob/0000-0003-2559-0687; /0000-0003-4542-4563; Platts-Mills, Thomas/0000-0002-1263-329X	National Institutes of Health [R01ES010932, U01HL072494, R01HL080674, AI-20565, R01AI35786, T32MH073122]; Robert Wood Johnson Foundation; Indoor Biotechnologies; ImClone; Phadia; Environmental protection Agency; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL072494, R01HL080674] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035786, R01AI020565] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010932] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH073122] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [R01MD006086] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF)); Indoor Biotechnologies; ImClone; Phadia(Phadia); Environmental protection Agency(United States Environmental Protection Agency); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	Supported by the National Institutes of Health R01ES010932, U01HL072494, R01HL080674, AI-20565,R01AI35786,T32MH073122.; Disclosure of potential conflict of interest: J. L. Peters has received research support from the National Institutes of Health and the Robert Wood Johnson Foundation. I A. E. Platts-Mills serves on the scientific advisory board for Indoor Biotechnologies and has received research support from Indoor Biotechnologies, ImClone, and Phadia. D. R. Gold has received research support from the National Institutes of Health and the Environmental protection Agency, and is a delegate to American Lung Association for the American Thoracic Society. R. J. Wright has received research support front the National Institutes of Health. The rest of the authors have declared that they have no conflict of interest.	AVRECH OM, 1994, INT ARCH ALLERGY IMM, V103, P160, DOI 10.1159/000236622; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Bonnelykke K, 2008, J ALLERGY CLIN IMMUN, V121, P646, DOI 10.1016/j.jaci.2007.12.1149; Chew GL, 2008, J ALLERGY CLIN IMMUN, V121, P240, DOI 10.1016/j.jaci.2007.08.024; Chew GL, 1999, ALLERGY, V54, P1058, DOI 10.1034/j.1398-9995.1999.00003.x; Cullinan P, 2004, THORAX, V59, P855, DOI 10.1136/thx.2003.019877; Dahlgren J, 2006, PEDIATR RES, V60, P147, DOI 10.1203/01.pdr.0000230026.74139.18; Dammann O, 1997, PEDIATR RES, V42, P1, DOI 10.1203/00006450-199707000-00001; Devereux G, 2002, CLIN EXP ALLERGY, V32, P43, DOI 10.1046/j.0022-0477.2001.01267.x; Ege MJ, 2008, J ALLERGY CLIN IMMUN, V122, P407, DOI 10.1016/j.jaci.2008.06.011; Eggleston PA, 2001, J ALLERGY CLIN IMMUN, V107, pS422, DOI 10.1067/mai.2001.113671; Eggleston PA, 2007, CHEST, V132, p782S, DOI 10.1378/chest.07-1906; Gergen PJ, 1999, J ALLERGY CLIN IMMUN, V103, P501, DOI 10.1016/S0091-6749(99)70477-X; Hagendorens MM, 2004, PEDIAT ALLERG IMM-UK, V15, P308, DOI 10.1111/j.1399-3038.2004.00169.x; HASTIE T, 1987, J AM STAT ASSOC, V82, P371, DOI 10.2307/2289439; Heinrich J, 2002, EUR RESPIR J, V20, P617, DOI 10.1183/09031936.02.02322001; HERBERT CA, 1995, AM J RESP CELL MOL, V12, P369, DOI 10.1165/ajrcmb.12.4.7695916; Herz U, 2001, INT ARCH ALLERGY IMM, V124, P193, DOI 10.1159/000053708; HEWITT CRA, 1995, J EXP MED, V182, P1537, DOI 10.1084/jem.182.5.1537; Holloway JA, 2000, LANCET, V356, P1900, DOI 10.1016/S0140-6736(00)03265-7; Jones CA, 2000, ALLERGY, V55, P2, DOI 10.1034/j.1398-9995.2000.00109.x; Jones CA, 1998, LANCET, V351, P1859, DOI 10.1016/S0140-6736(05)78805-X; Kaan A, 2000, ANN ALLERG ASTHMA IM, V84, P37, DOI 10.1016/S1081-1206(10)62738-X; Kerkhof M, 2005, PEDIAT ALLERG IMM-UK, V16, P10, DOI 10.1111/j.1399-3038.2005.00217.x; Kitch BT, 2000, ENVIRON HEALTH PERSP, V108, P301, DOI 10.2307/3454347; Lin YC, 2004, CLIN EXP ALLERGY, V34, P548, DOI 10.1111/j.1365-2222.2004.1928.x; Loibichler C., 2002, Clinical and Experimental Allergy, V32, P1546, DOI 10.1046/j.1365-2222.2002.01479.x; Lubin JH, 2004, ENVIRON HEALTH PERSP, V112, P1691, DOI 10.1289/ehp.7199; MacKinnon DP, 2007, ANNU REV PSYCHOL, V58, P593, DOI 10.1146/annurev.psych.58.110405.085542; Miles EA, 1996, CLIN EXP ALLERGY, V26, P780, DOI 10.1111/j.1365-2222.1996.tb00608.x; Miller RL, 2001, AM J RESP CRIT CARE, V164, P995, DOI 10.1164/ajrccm.164.6.2011107; Nambu M, 2003, BIOL NEONATE, V83, P102, DOI 10.1159/000067961; ODELRAM H, 1995, ALLERGY, V50, P585, DOI 10.1111/j.1398-9995.1995.tb01204.x; Ownby DR, 1996, PEDIATR ALLERGY IMMU, V7, P125, DOI 10.1111/j.1399-3038.1996.tb00119.x; Peden DB, 2000, ENVIRON HEALTH PERSP, V108, P475, DOI 10.2307/3454539; Peters JL, 2007, J URBAN HEALTH, V84, P185, DOI 10.1007/s11524-006-9146-2; PICCINNI MP, 1993, INT ARCH ALLERGY IMM, V102, P301, DOI 10.1159/000236541; Platts-Mills TAE, 2000, J ALLERGY CLIN IMMUN, V106, P441; Platts-Mills TAE, 2003, J ALLERGY CLIN IMMUN, V111, P123, DOI 10.1067/mai.2003.10; Pomes A, 2002, ALLERGY, V57, P673, DOI 10.1034/j.1398-9995.2002.02160.x; Preacher KJ, 2004, BEHAV RES METH INS C, V36, P717, DOI 10.3758/BF03206553; Preacher KJ, 2008, BEHAV RES METHODS, V40, P879, DOI 10.3758/BRM.40.3.879; Prescott SL, 1997, INT ARCH ALLERGY IMM, V113, P75, DOI 10.1159/000237512; Rowe J, 2007, J ALLERGY CLIN IMMUN, V119, P1164, DOI 10.1016/j.jaci.2007.02.016; Sarpong SB, 1996, J ALLERGY CLIN IMMUN, V97, P1393, DOI 10.1016/S0091-6749(96)70209-9; Schaub B, 2005, J CLIN IMMUNOL, V25, P329, DOI 10.1007/s10875-005-4180-5; Schiller JH, 2005, ANN ONCOL, V16, P27; SCHREYER P, 1989, GYNECOL OBSTET INVES, V27, P129, DOI 10.1159/000293638; Shakib F, 1998, IMMUNOL TODAY, V19, P313, DOI 10.1016/S0167-5699(98)01284-5; Shirakawa T, 1997, EUR J EPIDEMIOL, V13, P395, DOI 10.1023/A:1007361013917; Smillie FI, 2001, CLIN EXP ALLERGY, V31, P1194, DOI 10.1046/j.1365-2222.2001.01173.x; Szepfalusi Z, 2006, CLIN EXP ALLERGY, V36, P1130, DOI 10.1111/j.1365-2222.2006.02559.x; Tariq SM, 1999, CLIN EXP ALLERGY, V29, P1042; Thornton CA, 2003, CLIN EXP ALLERGY, V33, P306, DOI 10.1046/j.1365-2222.2003.01614.x; Tomee JFC, 1998, J ALLERGY CLIN IMMUN, V102, P75, DOI 10.1016/S0091-6749(98)70057-0; Torrent M, 2006, J ALLERGY CLIN IMMUN, V118, P742, DOI 10.1016/j.jaci.2006.04.059; Vance GHS, 2002, PEDIAT ALLERG IMM-UK, V13, P14, DOI 10.1034/j.1399-3038.13.s.15.5.x; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Warner JA, 2000, BRIT MED BULL, V56, P883, DOI 10.1258/0007142001903571; Wright RJ, 2008, CIENC SAUDE COLETIVA, V13, P1729, DOI 10.1590/S1413-81232008000600008	62	38	38	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2009	123	5					1041	1046		10.1016/j.jaci.2009.02.027	http://dx.doi.org/10.1016/j.jaci.2009.02.027			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	449CW	19361844	Green Accepted			2022-12-18	WOS:000266309400009
J	Ouyang, FX; Kumar, R; Pongracic, J; Story, RE; Liu, X; Wang, BY; Xing, HX; Liu, X; Li, ZP; Zhang, WB; Fang, YP; Zhang, SC; Xu, XP; Wang, XB				Ouyang, Fengxiu; Kumar, Rajesh; Pongracic, Jacqueline; Story, Rachel E.; Liu, Xin; Wang, Binyan; Xing, Houxun; Liu, Xue; Li, Zhiping; Zhang, Wenbin; Fang, Yaping; Zhang, Shanchun; Xu, Xiping; Wang, Xiaobin			Adiposity, serum lipid levels, and allergic sensitization in Chinese men and women	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						DEXA; body mass index; adiposity serum lipids; sensitization	BODY-MASS INDEX; METABOLIC SYNDROME; ASTHMA; ATOPY; OBESITY; RISK; POPULATION; PREVALENCE; IMMIGRANTS; MARKERS	Background: Obesity and allergic diseases have increased dramatically in recent decades. Although adiposity has been associated with asthma, associations with allergic sensitization have been inconsistent. Objective: To examine the association of adiposity and lipid profiles with allergic sensitization. Methods: This study included 1187 rural Chinese twins (653 men) age 18 to 39 years, with skin prick tests, anthropometric and dual-energy x-ray absorptiometry-assessed adiposity measures, and lipid assessments. Allergic sensitization was defined as positive SPT to >= 1 allergen (9 foods and 5 aeroallergens tested). We applied sex-stratified generalized estimating equations to assess the association of adiposity and serum lipids with allergic sensitization, and structural equation models to estimate the genetic/environmental influences on any observed associations. Results: Men had lower percent body fat (% BF) (13.9% vs. 28.8%) but higher rates of allergic sensitization (56.2% vs 36.7%) than women. M-en-in-the highest %BF quartile were 2.1 times more likely to be sensitized than the lowest quartile (95% CI, 1.3-3.5; P trend = .003). In men, the risk of allergic sensitization increased with high-density lipoprotein (HDL) <40 mg/dL (odds ratio = 4.0; 95% CI, 1.8-9.2) and higher low-density lipoprotein quartiles (P trend = .007). This appeared to be partially explained by shared genetic factors between serum lipid levels and allergic sensitization. In females, lower HDL was associated with increased risk of allergic sensitization. Conclusion: In this relatively lean Chinese population, higher %BF, lower HDL and higher LDL were associated with greater risk of allergic sensitization, most notable in men. The observed associations among adiposity, serum lipids, and allergic sensitization in men appear to be partially explained by common genetic influences on these traits. (J Allergy Clin Immunol 2009;123:940-8.)	[Wang, Xiaobin] Childrens Mem Hosp, Mary Ann & J Milburn Smith Child Hlth Res Program, Chicago, IL 60614 USA; [Ouyang, Fengxiu; Liu, Xin; Wang, Binyan; Fang, Yaping; Zhang, Shanchun; Wang, Xiaobin] Northwestern Univ, Dept Pediat, Feinberg Sch Med, Mary Ann & J Milburn Smith Child Hlth Res Program, Chicago, IL 60611 USA; [Ouyang, Fengxiu; Liu, Xin; Wang, Binyan; Fang, Yaping; Zhang, Shanchun; Wang, Xiaobin] Childrens Mem Res Ctr, Chicago, IL USA; [Kumar, Rajesh; Pongracic, Jacqueline; Story, Rachel E.] Northwestern Univ, Dept Pediat, Feinberg Sch Med, Div Allergy & Immunol, Chicago, IL 60611 USA; [Xing, Houxun; Liu, Xue; Li, Zhiping; Zhang, Wenbin; Fang, Yaping] Anhui Med Univ, Inst Biomed, Hefei, Peoples R China; [Xu, Xiping] Univ Illinois, Sch Publ Hlth, Ctr Populat Genet, Chicago, IL USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Anhui Medical University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Wang, XB (corresponding author), Childrens Mem Hosp, Mary Ann & J Milburn Smith Child Hlth Res Program, Chicago, IL 60614 USA.	xbwang@childrensmemorial.org		Kumar, Rajesh/0000-0002-1962-7108	National Institute of Child Health and Human Development [R01 HD049059]; National Heart, Lung, and Blood Institute [R01 HL0864619]; National Institute of Aging [R01 AG032227]; Food Allergy Project; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD049059] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000048] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL086461] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG032227] Funding Source: NIH RePORTER	National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Food Allergy Project; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Supported in part by grant R01 HD049059 from the National Institute of Child Health and Human Development; R01 HL0864619 from the National Heart, Lung, and Blood Institute; R01 AG032227 from the National Institute of Aging; and by the Food Allergy Project.	Brundtland GH, 2002, JAMA-J AM MED ASSOC, V288, P1974, DOI 10.1001/jama.288.16.1974; Burger D, 2002, ANN NY ACAD SCI, V966, P464, DOI 10.1111/j.1749-6632.2002.tb04248.x; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Feng Y, 2006, OBESITY, V14, P2089, DOI 10.1038/oby.2006.244; Ford ES, 2005, J ALLERGY CLIN IMMUN, V115, P897, DOI 10.1016/j.jaci.2004.11.050; Giltay EJ, 2000, J CLIN ENDOCR METAB, V85, P1648, DOI 10.1210/jc.85.4.1648; Grundy SM, 2005, CIRCULATION, V112, P2735, DOI 10.1161/CIRCULATIONAHA.105.169404; Hallstrand TS, 2005, J ALLERGY CLIN IMMUN, V116, P1235, DOI 10.1016/j.jaci.2005.09.016; Hancox RJ, 2005, AM J RESP CRIT CARE, V171, P440, DOI 10.1164/rccm.200405-623OC; Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485; Jarvis D, 2002, CLIN EXP ALLERGY, V32, P831, DOI 10.1046/j.1365-2222.2002.01380.x; Kay AB, 2001, NEW ENGL J MED, V344, P30, DOI 10.1056/NEJM200101043440106; Kolt GS, 2007, ASIA PAC J CLIN NUTR, V16, P663; LEUNG RC, 1994, MED J AUSTRALIA, V161, P418, DOI 10.5694/j.1326-5377.1994.tb127522.x; Linneberg A, 2001, CLIN EXP ALLERGY, V31, P1409, DOI 10.1046/j.1365-2222.2001.01178.x; Litonjua AA, 2008, J ALLERGY CLIN IMMUN, V121, P85, DOI [DOI 10.1016/HACI.2008.03.005, 10.1016/j.jaci.2008.03.005]; Litonjua AA, 2008, J ALLERGY CLIN IMMUN, V121, P1075, DOI 10.1016/j.jaci.2008.03.005; Macan J, 2007, CLIN EXP ALLERGY, V37, P1756, DOI 10.1111/j.1365-2222.2007.02836.x; McKeever TM, 2004, J ALLERGY CLIN IMMUN, V114, P1398, DOI 10.1016/j.jaci.2004.08.006; Pallasaho P, 2006, CLIN EXP ALLERGY, V36, P503, DOI 10.1111/j.1365-2222.2006.02460.x; Pietrobelli A, 1996, AM J PHYSIOL-ENDOC M, V271, pE941, DOI 10.1152/ajpendo.1996.271.6.E941; Rijsdijk Fruhling V, 2002, Brief Bioinform, V3, P119, DOI 10.1093/bib/3.2.119; Schachter LM, 2001, THORAX, V56, P4, DOI 10.1136/thorax.56.1.4; Schafer T, 2003, CLIN EXP ALLERGY, V33, P1360, DOI 10.1046/j.1365-2222.2003.01780.x; Shore SA, 2008, J ALLERGY CLIN IMMUN, V121, P1087, DOI 10.1016/j.jaci.2008.03.004; Snijder MB, 2006, INT J EPIDEMIOL, V35, P83, DOI 10.1093/ije/dyi253; Wang BY, 2007, PREV MED, V45, P358, DOI 10.1016/j.ypmed.2007.07.014; Wang H, 2008, ARCH DIS CHILD, V93, P738, DOI 10.1136/adc.2007.127589; WHO, 2004, LANCET, V363, P902; *WHO IASO IOTF, 2000, AS PAC PERSP REF OB; Xu BZ, 2002, EUR J PUBLIC HEALTH, V12, P166, DOI 10.1093/eurpub/12.3.166; Xuan W, 2002, THORAX, V57, P104, DOI 10.1136/thorax.57.2.104	32	38	39	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2009	123	4					940	948		10.1016/j.jaci.2008.11.032	http://dx.doi.org/10.1016/j.jaci.2008.11.032			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	431JW	19135238	Green Accepted			2022-12-18	WOS:000265058600024
J	Glaum, MC; Narula, S; Song, D; Zheng, Y; Anderson, AL; Pletcher, CH; Levinson, AI				Glaum, Mark C.; Narula, Shilpi; Song, Decheng; Zheng, Yi; Anderson, Amy L.; Pletcher, C. Hank; Levinson, Arnold I.			Toll-like receptor 7-induced naive human B-cell differentiation and immunoglobulin production	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						TLR-7; resiquimod; naive human B cells; immunoglobulin class-switch recombination; X-linked hyper-IgM syndrome	CLASS-SWITCH RECOMBINATION; ACQUIRED-IMMUNITY; HYPER-IGM; CPG DNA; LYMPHOCYTES; ACTIVATION; EXPRESSION; MEMORY; TLR9; INTERLEUKIN-10	Background: Toll-like receptors contribute to the establishment of adaptive immune responses. Objective: The reported studies were conducted to examine the effects of the Toll-like receptor (TLR)-7 ligand, resiquimod, on human naive B-cell differentiation. Methods: Naive human B cells were cultured with resiquimod in the presence or absence of IL-2 and IL-10. Secreted IgM and IgG were measured by ELISA, and IL-6, IL-10, and IFN-alpha were measured by a multiplex protein array. Cell proliferation was assessed by measuring [H-3]thymidine uptake. mRNA for activation-induced cytidine deaminase and I-gamma 1-C-mu circle transcripts was measured by means of RT-PCR. Results: Resiquimod induced the production of IgM and, to a lesser extent, IgG by naive human B cells in association with the secretion of IL-6 and IL-10, and a weak proliferative response. IL-2 and IL-10 synergized with resiquimod in markedly augmenting resiquimod-induced IgM and IgG production and proliferation. Resiquimod also stimulated production of IgG by B cells isolated from the blood of a patient with the X-linked hyper-IgM syndrome, with a greater response when these cells were costimulated with IL-2 and IL-10. The stimulated naive B cells from healthy volunteers displayed molecular evidence of immunoglobulin class-switch recombination-namely the appearance of activation-induced cytidine deaminase and I-gamma 1-C-mu, circle transcripts. Conclusion: Perturbation of TLR-7 on naive human B cells can lead to the induction of immunoglobulin class switch and IgG production in the absence of B-cell receptor cross-linking and CD40-CD40L interaction. The results are relevant to vaccine development and mechanisms by which microbial infection may lead to autoimmunity. (J Allergy Clin Immunol 2009;123:224-30.)	[Pletcher, C. Hank] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Glaum, Mark C.] Univ S Florida, Coll Med, Div Clin Immunol & Allergy, Tampa, FL USA; [Narula, Shilpi; Song, Decheng; Zheng, Yi; Anderson, Amy L.; Levinson, Arnold I.] Univ Penn, Sch Med, Allergy & Clin Immunol Sect, Philadelphia, PA 19104 USA	University of Pennsylvania; State University System of Florida; University of South Florida; University of Pennsylvania	Levinson, AI (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, 421 Curie Blvd,1014 BRB 2-3, Philadelphia, PA 19104 USA.	frog@mail.med.upenn.edu	Glaum, Mark/A-8860-2013		Immunology Research Fund, University of Pennsylvania School of Medicine	Immunology Research Fund, University of Pennsylvania School of Medicine	Supported by the Immunology Research Fund, University of Pennsylvania School of Medicine.	Agematsu K, 1998, J CLIN INVEST, V102, P853, DOI 10.1172/JCI3409; Bekeredjian-Ding IB, 2005, J IMMUNOL, V174, P4043, DOI 10.4049/jimmunol.174.7.4043; Bernasconi NL, 2002, SCIENCE, V298, P2199, DOI 10.1126/science.1076071; Bernasconi NL, 2003, BLOOD, V101, P4500, DOI 10.1182/blood-2002-11-3569; Bourke E, 2003, BLOOD, V102, P956, DOI 10.1182/blood-2002-11-3355; BURDIN N, 1995, J IMMUNOL, V154, P2533; Castigli E, 2007, J ALLERGY CLIN IMMUN, V120, P885, DOI 10.1016/j.jaci.2007.06.012; Chu VT, 2007, J IMMUNOL, V179, P5947, DOI 10.4049/jimmunol.179.9.5947; DEFRANCE T, 1992, J EXP MED, V175, P671, DOI 10.1084/jem.175.3.671; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; Genestier L, 2007, J IMMUNOL, V178, P7779, DOI 10.4049/jimmunol.178.12.7779; Hasbold J, 2004, NAT IMMUNOL, V5, P55, DOI 10.1038/ni1016; He B, 2004, J IMMUNOL, V173, P4479, DOI 10.4049/jimmunol.173.7.4479; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Jung J, 2002, J IMMUNOL, V169, P2368, DOI 10.4049/jimmunol.169.5.2368; Kinoshita K, 2001, P NATL ACAD SCI USA, V98, P12620, DOI 10.1073/pnas.221454398; Lau CM, 2005, J EXP MED, V202, P1171, DOI 10.1084/jem.20050630; Leadbetter EA, 2002, NATURE, V416, P603, DOI 10.1038/416603a; Lee J, 2003, P NATL ACAD SCI USA, V100, P6646, DOI 10.1073/pnas.0631696100; LEVINSON AI, 1986, J CLIN INVEST, V78, P612, DOI 10.1172/JCI112617; Litinskiy MB, 2002, NAT IMMUNOL, V3, P822, DOI 10.1038/ni829; Lund JM, 2004, P NATL ACAD SCI USA, V101, P5598, DOI 10.1073/pnas.0400937101; Manis JP, 2002, TRENDS IMMUNOL, V23, P31, DOI 10.1016/S1471-4906(01)02111-1; Okazaki IM, 2002, NATURE, V416, P340, DOI 10.1038/nature727; Olweus J, 1997, P NATL ACAD SCI USA, V94, P12551, DOI 10.1073/pnas.94.23.12551; Pasare C, 2004, SEMIN IMMUNOL, V16, P23, DOI 10.1016/j.smim.2003.10.006; Pasare C, 2005, NATURE, V438, P364, DOI 10.1038/nature04267; Pene J, 2004, J IMMUNOL, V172, P5154, DOI 10.4049/jimmunol.172.9.5154; ROUSSET F, 1991, J EXP MED, V173, P705, DOI 10.1084/jem.173.3.705; ROUSSET F, 1992, P NATL ACAD SCI USA, V89, P1890, DOI 10.1073/pnas.89.5.1890; Stavnezer J, 1996, ADV IMMUNOL, V61, P79, DOI 10.1016/S0065-2776(08)60866-4; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Tangye SG, 2002, J IMMUNOL, V169, P4298, DOI 10.4049/jimmunol.169.8.4298	35	38	40	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2009	123	1					224	230		10.1016/j.jaci.2008.09.018	http://dx.doi.org/10.1016/j.jaci.2008.09.018			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	399IP	18995892				2022-12-18	WOS:000262793900036
J	Del Prete, G; Chiumiento, L; Amedei, A; Piazza, M; D'Elios, MM; Codolo, G; de Bernard, M; Masetti, M; Bruschi, F				Del Prete, Gianfranco; Chiumiento, Lorena; Amedei, Amedeo; Piazza, Maria; D'Elios, Mario M.; Codolo, Gaia; de Bernard, Marina; Masetti, Massimo; Bruschi, Fabrizio			Immunosuppression of T(H)2 responses in Trichinelia spiralis infection by Helicobacter pylori neutrophil-activating protein	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T(H)2 response; T(H)2 immunosuppression; allergy; parasite infection; Trichinella spiralis; Helicobacter pylori neutrophil-activating protein; endogenous IL-12; mouse model; T(H)1/T(H)2 redirection	CYTOKINE PRODUCTION; INNATE RESISTANCE; ADAPTIVE IMMUNITY; INTERLEUKIN-12; IL-13; CELLS; IL-4R-ALPHA; MECHANISMS; EXPOSURE; DISEASE	Background: The Helicobacter pylori neutrophil-activating protein (HP-NAP) is able to induce IL-12 expression by cells of innate immunity and to shift to TO human allergen-specific T(H)2 cells in vitro. Objective: We performed an in vivo investigation of the ability of HP-NAP to downmodulate the T(H)2 response induced in mice by Trichinella spiralis infection. Methods: Groups of T spiralis-infected BALB/c mice received intraperitoneal PBS/rat IgG2b (control animals) or 10 jig of HP-NAP with or without anti-Toll-like receptor 2 antibody on days 10 and 28 after infection. Blood eosinophils, total and T spiralis-specific IgE levels, and cytokine levels were measured in the plasma up to day 42, when splenocytes were cultured for cytokine production. Results: Although control animals showed significant eosinophilia and increase of total and T spiralis-specific IgE, IL-4, and IL-5 levels from days 10 to 14, UP-NAP-treated animals showed less eosinophilia and total and excretory/secretory antigens of T spiralis-specific IgE in the blood. HP-NAP-treated animals also had higher IL-12 and IIFN-gamma plasma levels and lower IL-4 and IL-5 levels. The addition of anti-Toll-like receptor 2 antibody abrogated the anti-T(H)2/pro-T(H)1 activity of HP-NAP. Conclusion: This study provides evidence that HP-NAP enhances endogenous IL-12 and IFN-gamma response and exerts a powerful anti-T(H)2 activity in vivo, targeting both IL-5-induced eosinophilia and IL-4-mediated hyper-IgE responses induced by parasitic infection. Q Allergy Clin Immunol 2008;122:908-13.)	[Del Prete, Gianfranco; Amedei, Amedeo; D'Elios, Mario M.] Univ Florence, Dept Internal Med, I-50134 Florence, Italy; [Del Prete, Gianfranco; Amedei, Amedeo; D'Elios, Mario M.] Univ Careggi, Dept Biomed, Azienda Osped, Florence, Italy; [Chiumiento, Lorena; Piazza, Maria; Bruschi, Fabrizio] Univ Pisa, MBIE, Dept Expt Pathol, I-56100 Pisa, Italy; [Codolo, Gaia; de Bernard, Marina] Univ Padua, Dept Biol, I-35100 Padua, Italy; [Codolo, Gaia; de Bernard, Marina] Venetian Inst Mol Med, Padua, Italy; [Masetti, Massimo] Univ Pisa, Dept Biol, I-56100 Pisa, Italy	University of Florence; University of Florence; Azienda Ospedaliero Universitaria Careggi; University of Pisa; University of Padua; Veneto Institute Molecular Medicine; University of Pisa	Del Prete, G (corresponding author), Univ Florence, Dept Internal Med, Viale Morgagni 85, I-50134 Florence, Italy.	gdelprete@unifi.it	D'Elios, Mario Milco/Y-9573-2019; Amedei, Amedeo/G-5378-2011	D'Elios, Mario Milco/0000-0001-9160-0930; Amedei, Amedeo/0000-0002-6797-9343; CODOLO, GAIA/0000-0002-7793-2549; de Bernard, Marina/0000-0002-0091-4502	Italian Ministry of University and Research, Istituto Superiore di Sanita, Rome, Italy; University of Florence, Florence, Italy; University of Pisa, Pisa, Italy	Italian Ministry of University and Research, Istituto Superiore di Sanita, Rome, Italy; University of Florence, Florence, Italy; University of Pisa, Pisa, Italy	Supported in part by the following grants: Italian Ministry of University and Research, Istituto Superiore di Sanita, Rome, Italy; University of Florence, Florence, Italy and the University of Pisa, Pisa, Italy.	Amedei A, 2006, J CLIN INVEST, V116, P1092, DOI 10.1172/JCI27177; Atkins MB, 1997, CLIN CANCER RES, V3, P409; BRUSCHI F, 1992, EXP PARASITOL, V75, P1, DOI 10.1016/0014-4894(92)90116-R; Colombo MP, 2002, CYTOKINE GROWTH F R, V13, P155, DOI 10.1016/S1359-6101(01)00032-6; DElios MM, 1997, J IMMUNOL, V158, P962; DELPRETE G, 1988, J IMMUNOL, V140, P4193; DELPRETE GF, 1993, EUR J IMMUNOL, V23, P1445, DOI 10.1002/eji.1830230707; DELPRETE GF, 1991, J CLIN INVEST, V88, P346, DOI 10.1172/JCI115300; DUPOUYCAMET J, 2007, GUIDELINES SURVEILLA, P37; ELSE KJ, 1994, J EXP MED, V179, P347, DOI 10.1084/jem.179.1.347; Emson CL, 1998, J EXP MED, V188, P399, DOI 10.1084/jem.188.2.399; EVANS DJ, 1995, INFECT IMMUN, V63, P2213, DOI 10.1128/IAI.63.6.2213-2220.1995; Finkelman FD, 2004, IMMUNOL REV, V201, P139, DOI 10.1111/j.0105-2896.2004.00192.x; Freytag LC, 2005, VACCINE, V23, P1804, DOI 10.1016/j.vaccine.2004.11.010; Gangur V, 1999, INT ARCH ALLERGY IMM, V118, P387, DOI 10.1159/000024144; Gessner A, 2005, J IMMUNOL, V174, P1063, DOI 10.4049/jimmunol.174.2.1063; Grant RA, 1998, NAT STRUCT BIOL, V5, P294, DOI 10.1038/nsb0498-294; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Leonard JP, 1997, BLOOD, V90, P2541; Montecucco C, 2003, MICROBES INFECT, V5, P715, DOI 10.1016/S1286-4579(03)00124-2; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Oppmann B, 2000, IMMUNITY, V13, P715, DOI 10.1016/S1074-7613(00)00070-4; Romagnani S, 2000, J ALLERGY CLIN IMMUN, V105, P399, DOI 10.1067/mai.2000.104575; Scales HE, 2007, PARASITE IMMUNOL, V29, P81, DOI 10.1111/j.1365-3024.2006.00920.x; Takamoto M, 2001, PARASITOL RES, V87, P919; Tighe H, 2000, J ALLERGY CLIN IMMUN, V106, P124, DOI 10.1067/mai.2000.107927; Till SJ, 2004, J ALLERGY CLIN IMMUN, V113, P1025, DOI 10.1016/j.jaci.2004.03.024; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.iy.13.040195.001343; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; Turcanu V, 2003, J CLIN INVEST, V111, P1065, DOI 10.1172/JCI200316142; Urban JF, 1998, IMMUNITY, V8, P255, DOI 10.1016/S1074-7613(00)80477-X; URBAN JF, 1995, J IMMUNOL, V154, P4675; Wakelin D, 1996, INT J PARASITOL, V26, P471, DOI 10.1016/0020-7519(96)89377-5; Zanotti G, 2002, J MOL BIOL, V323, P125, DOI 10.1016/S0022-2836(02)00879-3	34	38	39	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2008	122	5					908	913		10.1016/j.jaci.2008.08.016	http://dx.doi.org/10.1016/j.jaci.2008.08.016			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	372ZF	18804852				2022-12-18	WOS:000260940100008
J	Chatila, TA; Li, N; Garcia-Llore, M; Kim, HJ; Nel, AE				Chatila, Talal A.; Li, Ning; Garcia-Llore, Maria; Kim, Hyon-Jeen; Nel, Andre E.			T-cell effector pathways in allergic diseases: Transcriptional mechanisms and therapeutic targets	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review							GROWTH-FACTOR-BETA; HYPER-IGE SYNDROME; ROR-GAMMA-T; RETINOIC-ACID; AIRWAY INFLAMMATION; GLUCOCORTICOID-RECEPTOR; FOXP3 EXPRESSION; ORPHAN RECEPTOR; MICE LACKING; IMMUNE DYSREGULATION	Originally interpreted within the framework of a binary T(H)1/T(H)2 paradigm, our knowledge of the pathogenesis of atopic diseases has broadened to incorporate the contribution of T regulatory cells and the newly described proinflammatory T(H)17 cell lineage. The commitment of peripheral T-cell clones to undergo differentiation into one of those lineages is shaped by self-reinforcing transcriptional circuitries that center on key transcriptional regulators: T-box expressed in T cells (T(H)1), GATA-3 (T(H)2), forkhead box p3 (T regulatory cells), and retinoid-related orphan receptor gamma tau/retinoid-related orphan receptor alpha (T(H)17). These circuits function both to establish the respective lineage phenotype and to enable epigenetic changes that maintain those phenotypes long-term. This evolving view of how signaling and transcriptional networks generate effector T-cell responses suggests novel therapeutic approaches to reprogram effector T-cell lineage commitment in allergic diseases in favor of tolerance induction.	[Chatila, Talal A.; Garcia-Llore, Maria] Univ Calif Los Angeles, David Geffen Sch Med, Div Immunol Allergy & Rheumatol, Dept Pediat, Los Angeles, CA 90095 USA; [Li, Ning; Kim, Hyon-Jeen] Univ Calif Los Angeles, David Geffen Sch Med, Div NanoMed, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Nel, AE (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Immunol Allergy & Rheumatol, Dept Pediat, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.	tchatila@mednet.ucla.edu; anel@mednet.ucla.edu	Nel, Andre E/J-2808-2012	Chatila, Talal/0000-0001-7439-2762	NIAID NIH HHS [2R01AI065617, U19 AI070453] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI065617, U19AI070453] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P942, DOI 10.1038/ni1496; Afkarian M, 2002, NAT IMMUNOL, V3, P549, DOI 10.1038/ni794; Afzali B, 2007, CLIN EXP IMMUNOL, V148, P32, DOI 10.1111/j.1365-2249.2007.03356.x; Akdis M, 2007, J ALLERGY CLIN IMMUN, V119, P780, DOI 10.1016/j.jaci.2007.01.022; Allan SE, 2008, MOL THER, V16, P194, DOI 10.1038/sj.mt.6300341; Allan SE, 2005, J CLIN INVEST, V115, P3276, DOI 10.1172/JCI24685; Ansel KM, 2006, ANNU REV IMMUNOL, V24, P607, DOI 10.1146/annurev.immunol.23.021704.115821; Apostolou I, 2004, J EXP MED, V199, P1401, DOI 10.1084/jem.20040249; Bacchetta R, 2007, J ALLERGY CLIN IMMUN, V120, P227, DOI 10.1016/j.jaci.2007.06.023; Barnes PJ, 2006, BRIT J PHARMACOL, V148, P245, DOI 10.1038/sj.bjp.0706736; Battaglia M, 2005, BLOOD, V105, P4743, DOI 10.1182/blood-2004-10-3932; Benson MJ, 2007, J EXP MED, V204, P1765, DOI 10.1084/jem.20070719; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Brustle A, 2007, NAT IMMUNOL, V8, P958, DOI 10.1038/ni1500; Calado DP, 2006, J IMMUNOL, V177, P5358, DOI 10.4049/jimmunol.177.8.5358; Caudy AA, 2007, J ALLERGY CLIN IMMUN, V119, P482, DOI 10.1016/j.jaci.2006.10.007; Chatila TA, 2007, CLIN EXP ALLERGY, V37, P1417, DOI 10.1111/j.1365-2222.2007.02814.x; Chatila TA, 2005, J ALLERGY CLIN IMMUN, V116, P949, DOI 10.1016/j.jaci.2005.08.047; Chatila TA, 2000, J CLIN INVEST, V106, pR75, DOI 10.1172/JCI11679; Chatila T, 2007, IMMUNITY, V27, P693, DOI 10.1016/j.immuni.2007.11.004; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Chen XL, 2004, CURR PHARM DESIGN, V10, P879, DOI 10.2174/1381612043452901; Cho HY, 2002, AM J RESP CELL MOL, V26, P175, DOI 10.1165/ajrcmb.26.2.4501; Cohen AC, 2006, J IMMUNOL, V177, P2770, DOI 10.4049/jimmunol.177.5.2770; Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590; D'Cruz LM, 2005, NAT IMMUNOL, V6, P1152, DOI 10.1038/ni1264; Djuretic IM, 2007, NAT IMMUNOL, V8, P145, DOI 10.1038/ni1424; Dzhagalov I, 2004, CELL MOL IMMUNOL, V1, P401; Elias KM, 2008, BLOOD, V111, P1013, DOI 10.1182/blood-2007-06-096438; Fahey JW, 2002, P NATL ACAD SCI USA, V99, P7610, DOI 10.1073/pnas.112203099; Fantini MC, 2004, J IMMUNOL, V172, P5149, DOI 10.4049/jimmunol.172.9.5149; Finotto S, 2005, INT IMMUNOL, V17, P993, DOI 10.1093/intimm/dxh281; Finotto S, 2002, SCIENCE, V295, P336, DOI 10.1126/science.1065544; Finotto S, 2001, J EXP MED, V193, P1247, DOI 10.1084/jem.193.11.1247; Floess S, 2007, PLOS BIOL, V5, P169, DOI 10.1371/journal.pbio.0050038; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Fontenot JD, 2005, NAT IMMUNOL, V6, P1142, DOI 10.1038/ni1263; Fortin A, 2007, ANNU REV GENOM HUM G, V8, P163, DOI 10.1146/annurev.genom.8.080706.092315; Gavin MA, 2007, NATURE, V445, P771, DOI 10.1038/nature05543; Happel KI, 2005, J EXP MED, V202, P761, DOI 10.1084/jem.20050193; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; He R, 2007, P NATL ACAD SCI USA, V104, P15817, DOI 10.1073/pnas.0706942104; He YW, 1998, IMMUNITY, V9, P797, DOI 10.1016/S1074-7613(00)80645-7; Hill JA, 2007, IMMUNITY, V27, P786, DOI 10.1016/j.immuni.2007.09.010; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; Hodge MR, 1996, SCIENCE, V274, P1903, DOI 10.1126/science.274.5294.1903; Holland SM, 2007, NEW ENGL J MED, V357, P1608, DOI 10.1056/NEJMoa073687; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Ito K, 2006, J ALLERGY CLIN IMMUN, V117, P522, DOI 10.1016/j.jaci.2006.01.032; Ito K, 2006, J EXP MED, V203, P7, DOI 10.1084/jem.20050466; Ivanov II, 2007, SEMIN IMMUNOL, V19, P409, DOI 10.1016/j.smim.2007.10.011; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Jee YK, 2005, J BIOL CHEM, V280, P23243, DOI 10.1074/jbc.M503659200; Jetten AM, 2001, PROG NUCLEIC ACID RE, V69, P205, DOI 10.1016/S0079-6603(01)69048-2; Joffre O, 2008, NAT MED, V14, P88, DOI 10.1038/nm1688; Kamanaka M, 2006, IMMUNITY, V25, P941, DOI 10.1016/j.immuni.2006.09.013; Kang SG, 2007, J IMMUNOL, V179, P3724, DOI 10.4049/jimmunol.179.6.3724; Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046; Kim HJ, 2007, J ALLERGY CLIN IMMUN, V119, P1225, DOI 10.1016/j.jaci.2007.01.016; Kim JI, 1999, IMMUNITY, V10, P745, DOI 10.1016/S1074-7613(00)80073-4; Korn T, 2007, NATURE, V448, P484, DOI 10.1038/nature05970; Kurebayashi S, 2000, P NATL ACAD SCI USA, V97, P10132, DOI 10.1073/pnas.97.18.10132; Laurence A, 2007, NAT IMMUNOL, V8, P903, DOI 10.1038/ni0907-903; Lee CC, 2008, MOL THER, V16, P60, DOI 10.1038/sj.mt.6300309; LEE GR, 2003, ANNU REV IMMUNOL, V21, P713; LeibundGut-Landmann S, 2007, NAT IMMUNOL, V8, P630, DOI 10.1038/ni1460; Lewis MD, 2007, MOL CELL BIOL, V27, P8510, DOI 10.1128/MCB.01615-07; Li B, 2007, INT IMMUNOL, V19, P825, DOI 10.1093/intimm/dxm043; Li B, 2007, P NATL ACAD SCI USA, V104, P4571, DOI 10.1073/pnas.0700298104; Li N, 2006, ANTIOXID REDOX SIGN, V8, P88, DOI 10.1089/ars.2006.8.88; Li N, 2004, J IMMUNOL, V173, P3467, DOI 10.4049/jimmunol.173.5.3467; Lin W, 2007, NAT IMMUNOL, V8, P359, DOI 10.1038/ni1445; Ma Q, 2006, AM J PATHOL, V168, P1960, DOI 10.2353/ajpath.2006.051113; MALEK T, 2007, ANN REV IMMUNOL 1206; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; Marie JC, 2005, J EXP MED, V201, P1061, DOI 10.1084/jem.20042276; Marson A, 2007, NATURE, V445, P931, DOI 10.1038/nature05478; Martins GA, 2005, J IMMUNOL, V175, P5981, DOI 10.4049/jimmunol.175.9.5981; Maynard CL, 2007, NAT IMMUNOL, V8, P931, DOI 10.1038/ni1504; MILNER JD, 2008, NATURE          0312; Minegishi Y, 2007, NATURE, V448, P1058, DOI 10.1038/nature06096; Minegishi Y, 2006, IMMUNITY, V25, P745, DOI 10.1016/j.immuni.2006.09.009; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Mucida D, 2005, J CLIN INVEST, V115, P1923, DOI 10.1172/JCI24487; Mucida D, 2007, SCIENCE, V317, P256, DOI 10.1126/science.1145697; Mullen AC, 2002, NAT IMMUNOL, V3, P652, DOI 10.1038/ni807; Mullen AC, 2001, SCIENCE, V292, P1907, DOI 10.1126/science.1059835; Murphy KM, 2002, NAT REV IMMUNOL, V2, P933, DOI 10.1038/nri954; Nakamura Y, 1999, J ALLERGY CLIN IMMUN, V103, P215, DOI 10.1016/S0091-6749(99)70493-8; Newton R, 2007, MOL PHARMACOL, V72, P799, DOI 10.1124/mol.107.038794; Nurieva R, 2007, NATURE, V448, P480, DOI 10.1038/nature05969; O'Garra A, 2004, J CLIN INVEST, V114, P1372, DOI 10.1172/JCI200423215; O'Garra A, 2007, NAT REV IMMUNOL, V7, P425, DOI 10.1038/nri2097; Ono M, 2007, NATURE, V446, P685, DOI 10.1038/nature05673; Ouyang W, 1998, IMMUNITY, V9, P745, DOI 10.1016/S1074-7613(00)80671-8; Ouyang WJ, 2000, IMMUNITY, V12, P27, DOI 10.1016/S1074-7613(00)80156-9; Pai SY, 2004, P NATL ACAD SCI USA, V101, P1993, DOI 10.1073/pnas.0308697100; Palm NW, 2007, NAT IMMUNOL, V8, P549, DOI 10.1038/ni0607-549; Pearce EL, 2003, SCIENCE, V302, P1041, DOI 10.1126/science.1090148; Peterson JD, 1998, P NATL ACAD SCI USA, V95, P3071, DOI 10.1073/pnas.95.6.3071; Raby BA, 2006, AM J RESP CRIT CARE, V173, P64, DOI 10.1164/rccm.200503-505OC; Rangasamy T, 2005, J EXP MED, V202, P47, DOI 10.1084/jem.20050538; Reiner SL, 2007, CELL, V129, P33, DOI 10.1016/j.cell.2007.03.019; Roncarolo MG, 2007, NAT REV IMMUNOL, V7, P585, DOI 10.1038/nri2138; Roth M, 2006, CURR DRUG TARGETS, V7, P589, DOI 10.2174/138945006776818638; Sakaguchi S, 2007, EUR J IMMUNOL, V37, pS116, DOI 10.1002/eji.200737593; Schaub B, 2006, J ALLERGY CLIN IMMUN, V117, P969, DOI 10.1016/j.jaci.2006.03.003; SCHRYDERCANDRIA. S, 2006, J EXP MED, V203, P2715; Schubert LA, 2001, J BIOL CHEM, V276, P37672, DOI 10.1074/jbc.M104521200; Steinman L, 2007, NAT MED, V13, P139, DOI 10.1038/nm1551; Sun CM, 2007, J EXP MED, V204, P1775, DOI 10.1084/jem.20070602; Sun ZM, 2000, SCIENCE, V288, P2369, DOI 10.1126/science.288.5475.2369; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Szabo SJ, 2002, SCIENCE, V295, P338, DOI 10.1126/science.1065543; Tang QZ, 2006, IMMUNOL REV, V212, P217, DOI 10.1111/j.0105-2896.2006.00421.x; Tao R, 2007, NAT MED, V13, P1299, DOI 10.1038/nm1652; Tone Y, 2008, NAT IMMUNOL, V9, P194, DOI 10.1038/ni1549; Torgerson TR, 2007, J ALLERGY CLIN IMMUN, V120, P744, DOI 10.1016/j.jaci.2007.08.044; Usui T, 2006, J EXP MED, V203, P755, DOI 10.1084/jem.20052165; van Beelen AJ, 2007, CURR OPIN ALLERGY CL, V7, P374, DOI 10.1097/ACI.0b013e3282ef869e; Veldhoen M, 2006, TRENDS IMMUNOL, V27, P358, DOI 10.1016/j.it.2006.06.001; Verbsky JW, 2007, CURR OPIN RHEUMATOL, V19, P252, DOI 10.1097/BOR.0b013e3280ad46bb; von Boehmer H, 2007, J EXP MED, V204, P1737, DOI 10.1084/jem.20071251; Weaver CT, 2006, IMMUNITY, V24, P677, DOI 10.1016/j.immuni.2006.06.002; Williams LM, 2007, NAT IMMUNOL, V8, P277, DOI 10.1038/ni1437; Wilson NJ, 2007, NAT IMMUNOL, V8, P950, DOI 10.1038/ni1497; Wing K, 2006, INT IMMUNOL, V18, P991, DOI 10.1093/intimm/dxl044; Wu YQ, 2006, CELL, V126, P375, DOI 10.1016/j.cell.2006.05.042; Yang XXO, 2008, IMMUNITY, V28, P29, DOI 10.1016/j.immuni.2007.11.016; Zeiser R, 2008, BLOOD, V111, P453, DOI 10.1182/blood-2007-06-094482; Zhang DH, 1999, IMMUNITY, V11, P473, DOI 10.1016/S1074-7613(00)80122-3; Zhang DH, 1997, J BIOL CHEM, V272, P21597, DOI 10.1074/jbc.272.34.21597; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8; Zheng Y, 2007, NATURE, V445, P936, DOI 10.1038/nature05563; Zheng Y, 2007, NAT IMMUNOL, V8, P457, DOI 10.1038/ni1455; Zhou LA, 2007, NAT IMMUNOL, V8, P967, DOI 10.1038/ni1488; Zhu JF, 2004, NAT IMMUNOL, V5, P1157, DOI 10.1038/ni1128; Zhu JF, 2006, CELL RES, V16, P3, DOI 10.1038/sj.cr.7310002	138	38	41	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2008	121	4					812	823		10.1016/j.jaci.2008.02.025	http://dx.doi.org/10.1016/j.jaci.2008.02.025			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286YY	18395547				2022-12-18	WOS:000254884000002
J	Ohnishi, H; Miyahara, N; Dakhama, A; Takeda, K; Mathis, S; Haribabu, B; Gelfand, EW				Ohnishi, Hiroshi; Miyahara, Nobuaki; Dakhama, Azzeddine; Takeda, Katsuyuki; Mathis, Steven; Haribabu, Bodduluri; Gelfand, Erwin W.			Corticosteroids enhance CD8(+) T cell-mediated airway hyperresponsiveness and allergic inflammation by upregulating leukotriene B-4 receptor 1	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						central memory T cell; CD122; CD25; corticosteroid-insensitive asthma; effector memory T cell	MOUSE IL-2 RECEPTOR; INSENSITIVE ASTHMA; EFFECTOR; BLT1; RECRUITMENT; EXPRESSION; GLUCOCORTICOIDS; MIGRATION; MICE; DIFFERENTIATION	Background: Leukotriene B-4 (LTB4) is a potent inflammatory lipid mediator that binds to LTB4 receptor 1 (BLT1). Ligation of BLT1 by LTB4 plays an important role in the recruitment of effector memory CD8(+) T cells into the airways of sensitized and challenged mice. Objectives: The effects of the corticosteroid dexamethasone (DEX) on BLT1-expressing effector memory CD8(+) T cells and effector memory CD8(+) T cell-mediated airway hyperresponsiveness (AHR) and allergic inflammation were determined. Methods: Effector memory CD8(+) T cells were generated from ovalbumin(257-264)-primed mononuclear cells from OT-1 mice in the presence of IL-2. In some cultures DEX was added. The effects of DEX on BLT1 expression, LTB4-induced Ca2+ influx, phosphorylation of extracellular signal-regulated kinase 1/2, chemotaxis, and effector memory CD8(+) T cell-mediated AHR were examined. Results: DEX-treated effector memory CD8(+) T cells showed significant increases in surface expression of BLT1, LTB4-induced intracellular Ca2+ influx, phosphorylation of extracellular signal-regulated kinase 1/2, and chemotaxis. Upregulation of BLT1 by DEX was accompanied by increased IL-2 receptor expression. Adoptive transfer of DEX-treated effector memory CD8(+) T cells into ovalbumin-sensitized and ovalbumin-challenged CD8(-/-) mice resulted in significant increases in AHR, allergic inflammation, goblet cell metaplasia, and numbers of both CD8(+) and CD4(+) T cells in the bronchoalveolar lavage fluid and lungs. Conclusions: Corticosteroids upregulate BLT1 on effector memory CD8(+) T cells and related signaling pathways and potentiate allergic airway inflammation and AHR induced by these cells.	[Ohnishi, Hiroshi; Miyahara, Nobuaki; Dakhama, Azzeddine; Takeda, Katsuyuki; Gelfand, Erwin W.] Natl Jewish Med & Res Ctr, Dept Pediat, Div Cell Biol, Denver, CO 80206 USA; [Mathis, Steven; Haribabu, Bodduluri] Univ Louisville, Hlth Sci Ctr, Dept Microbiol & Immunol, Louisville, KY 40292 USA; [Mathis, Steven; Haribabu, Bodduluri] Univ Louisville, Hlth Sci Ctr, James Graham Brown Canc Ctr, Louisville, KY 40292 USA	National Jewish Health; University of Louisville; University of Louisville	Gelfand, EW (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Cell Biol, 1400 Jackson St, Denver, CO 80206 USA.	gelfande@njc.org	Bodduluri, Haribabu/A-2584-2010	Bodduluri, Haribabu/0000-0002-8261-3294; Ohnishi, Hiroshi/0000-0002-7863-4519; Mathis, Steven/0000-0001-7704-1220	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577, R01HL061005] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL036577-21A15977, P01 HL036577, HL-61005, HL-36577] Funding Source: Medline; PHS HHS [A1-52381] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adcock IM, 2003, J ENDOCRINOL, V178, P347, DOI 10.1677/joe.0.1780347; Aiello RJ, 2002, ARTERIOSCL THROM VAS, V22, P443, DOI 10.1161/hq0302.105593; Back M, 2005, P NATL ACAD SCI USA, V102, P17501, DOI 10.1073/pnas.0505845102; Backman KS, 1997, CHEST, V112, P1234, DOI 10.1378/chest.112.5.1234; Bianchi M, 2000, P NATL ACAD SCI USA, V97, P9573, DOI 10.1073/pnas.160099797; Chan MTS, 1998, J ALLERGY CLIN IMMUN, V101, P594, DOI 10.1016/S0091-6749(98)70165-4; CORRIGAN CJ, 1993, AM REV RESPIR DIS, V147, P540, DOI 10.1164/ajrccm/147.3.540; Del Prete A, 2007, BLOOD, V109, P626, DOI 10.1182/blood-2006-02-003665; FERNANDEZRUIZ E, 1989, J IMMUNOL, V143, P4146; Gelfand EW, 2006, J ALLERGY CLIN IMMUN, V117, P577, DOI 10.1016/j.jaci.2005.12.1340; Goodarzi K, 2003, NAT IMMUNOL, V4, P965, DOI 10.1038/ni972; GRIFFITHS RJ, 1995, P NATL ACAD SCI USA, V92, P517, DOI 10.1073/pnas.92.2.517; Huang WW, 1998, J EXP MED, V188, P1063, DOI 10.1084/jem.188.6.1063; Islam SA, 2006, BLOOD, V107, P444, DOI 10.1182/blood-2005-06-2362; Kato K, 2000, J EXP MED, V192, P413, DOI 10.1084/jem.192.3.413; Kemeny DM, 1999, AM J RESP CRIT CARE, V160, pS33, DOI 10.1164/ajrccm.160.supplement_1.10; Kim ND, 2006, J EXP MED, V203, P829, DOI 10.1084/jem.20052349; Lamas M, 1997, CYTOKINE, V9, P973, DOI 10.1006/cyto.1997.0248; Lindsay MA, 1998, J LEUKOCYTE BIOL, V64, P555, DOI 10.1002/jlb.64.4.555; Loke Tuck-Kay, 2002, Curr Allergy Asthma Rep, V2, P144, DOI 10.1007/s11882-002-0009-y; Lundeen KA, 2006, J IMMUNOL, V177, P3439, DOI 10.4049/jimmunol.177.5.3439; Manjunath N, 2001, J CLIN INVEST, V108, P871, DOI 10.1172/JCI200113296; Marian E, 2006, CHEST, V129, P1523, DOI 10.1378/chest.129.6.1523; Masopust D, 2001, SCIENCE, V291, P2413, DOI 10.1126/science.1058867; Medoff BD, 2005, J EXP MED, V202, P97, DOI 10.1084/jem.20042481; Miyahara N, 2005, AM J RESP CRIT CARE, V172, P161, DOI 10.1164/rccm.200502-205OC; Miyahara N, 2005, J IMMUNOL, V174, P4979, DOI 10.4049/jimmunol.174.8.4979; Miyahara N, 2004, NAT MED, V10, P865, DOI 10.1038/nm1081; NEMOTO T, 1995, EUR J IMMUNOL, V25, P3001, DOI 10.1002/eji.1830251102; *NIH NAT HEART LUN, 2002, NHLBI WHO WORKSH REP; Obinata H, 2003, BIOCHEM BIOPH RES CO, V309, P114, DOI 10.1016/S0006-291X(03)01554-7; Oshiba A, 1996, J CLIN INVEST, V97, P1398, DOI 10.1172/JCI118560; Ott VL, 2003, NAT IMMUNOL, V4, P974, DOI 10.1038/ni971; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Stankova J, 2002, J IMMUNOL, V168, P3570, DOI 10.4049/jimmunol.168.7.3570; Suzuki S, 1999, J AM SOC NEPHROL, V10, P264; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635; Tager AM, 2000, J EXP MED, V192, P439, DOI 10.1084/jem.192.3.439; Tager AM, 2003, NAT IMMUNOL, V4, P982, DOI 10.1038/ni970; Tager AM, 2003, PROSTAG LEUKOTR ESS, V69, P123, DOI 10.1016/S0952-3278(03)00073-5; Takeda K, 1997, J EXP MED, V186, P449, DOI 10.1084/jem.186.3.449; Taniguchi H, 2002, J ASTHMA, V39, P217, DOI 10.1081/JAS-120002471; Taube C, 2006, J IMMUNOL, V176, P3157, DOI 10.4049/jimmunol.176.5.3157; Terawaki K, 2005, J IMMUNOL, V175, P4217, DOI 10.4049/jimmunol.175.7.4217; Ulrik CS, 1999, EUR RESPIR J, V14, P892, DOI 10.1034/j.1399-3003.1999.14d27.x; Wedzicha JA, 2003, THORAX, V58, P1, DOI 10.1136/thorax.58.1.1; Weninger W, 2001, J EXP MED, V194, P953, DOI 10.1084/jem.194.7.953; Woo CH, 2003, J IMMUNOL, V170, P6273, DOI 10.4049/jimmunol.170.12.6273; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	50	38	41	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2008	121	4					864	871		10.1016/j.jaci.2008.01.035	http://dx.doi.org/10.1016/j.jaci.2008.01.035			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286YY	18395551	Bronze			2022-12-18	WOS:000254884000009
J	Bardana, EJ				Bardana, Emil J.			Occupational asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; occupational asthma; reactive airways dysfunction syndrome; endotoxin	EXHALED NITRIC-OXIDE; GENE	A diversity of airborne dusts, gases, fumes, and vapors can induce dose-related respiratory symptoms in individuals exposed in the workplace. These agents can cause annoyance reactions, irritational effects, sensitization, or the induction of corrosive changes in the respiratory tract, depending on their composition, concentration, and duration of exposure. The prevalence of occupational asthma (OA) ranges from 9% to 15% of the asthmatic population. Factors that might influence the development of OA include the work environment, climatic conditions, genetic proclivities, tobacco and recreational drug use, respiratory infection, bronchial hyperresponsiveness, and endotoxin exposure. Pathogenetically, new-onset OA can be allergic or nonallergic in origin. The allergic variants are usually caused by high-molecular-weight allergens, such as grain dust and animal or fish protein. Selected low-molecular-weight agents are also capable of inducing allergic OA. Symptoms ensue after a latent period of months to years. Nonallergic OA can be precipitated by a brief high-level exposure to a potent irritant. Symptoms occur immediately or within a few hours of the exposure. Once the diagnosis of allergic OA is established, the worker should be removed from further exposure in the workplace. In nonallergic OA the worker can return to work if the exposure was clearly a nonrecurring event. If the diagnosis is made in a timely fashion, most workers experience improvement. Prevention is the best therapeutic intervention.	Oregon Hlth & Sci Univ, Portland, OR 97239 USA	Oregon Health & Science University	Bardana, EJ (corresponding author), Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd,OP34, Portland, OR 97239 USA.	bardanae@ohsu.edu						Alberts WM, 1996, CHEST, V109, P1618, DOI 10.1378/chest.109.6.1618; *AM LUNG ASS EP ST, 2006, AM LUNG ASS EP STAT; BARDANA EJ, 2003, J ALLERGY CLIN IMMUN, V111, P5530; Beach J, 2007, CHEST, V131, P569, DOI 10.1378/chest.06-0492; Berkman N, 2005, THORAX, V60, P383, DOI 10.1136/thx.2004.031104; Cockcroft DW, 2006, J ALLERGY CLIN IMMUN, V118, P551, DOI 10.1016/j.jaci.2006.07.012; Cristaudo A, 2005, ALLERGY, V60, P159, DOI 10.1111/j.1398-9995.2004.00521.x; Eduard W, 2004, THORAX, V59, P381, DOI 10.1136/thx.2004.013326; ENARSON DA, 1987, AM REV RESPIR DIS, V136, P613, DOI 10.1164/ajrccm/136.3.613; Gilliland FD, 2004, LANCET, V363, P119, DOI 10.1016/S0140-6736(03)15262-2; Hall W, 1998, LANCET, V352, P1611, DOI 10.1016/S0140-6736(98)05021-1; Heederik D, 2005, CURR OPIN ALLERGY CL, V5, P129, DOI 10.1097/01.all.0000162304.66986.7d; Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654, DOI 10.1164/ajrccm.154.3.8810601; LeVan TD, 2005, AM J RESP CRIT CARE, V171, P773, DOI 10.1164/rccm.200404-530OC; MALO JL, 1991, AM REV RESPIR DIS, V143, P528, DOI 10.1164/ajrccm/143.3.528; Mapp CE, 2005, CURR OPIN ALLERGY CL, V5, P113, DOI 10.1097/01.all.0000162301.74610.21; Mapp CE, 2002, J ALLERGY CLIN IMMUN, V109, P867, DOI 10.1067/mai.2002.123234; Mapp CE, 2005, AM J RESP CRIT CARE, V172, P280, DOI 10.1164/rccm.200311-1575SO; Martinez Fernando D, 2007, Proc Am Thorac Soc, V4, P26, DOI 10.1513/pats.200607-144JG; Nicholson PJ, 2005, OCCUP ENVIRON MED, V62, P290, DOI 10.1136/oem.2004.016287; Piipari R, 2005, CLIN EXP ALLERGY, V35, P1632, DOI 10.1111/j.1365-2222.2005.02386.x; Rachiotis G, 2007, THORAX, V62, P147, DOI 10.1136/thx.2006.061952; Schaller M, 2006, J ALLERGY CLIN IMMUN, V118, P295, DOI 10.1016/j.jaci.2006.05.025; Sigsgaard T, 2005, J ALLERGY CLIN IMMUN, V115, P1325, DOI 10.1016/j.jaci.2005.01.060; SIRACUSA A, 2006, SMOKING OCCUPATIONAL, V36, P577; Smith AD, 2004, AM J RESP CRIT CARE, V169, P473, DOI 10.1164/rccm.200310-1376OC; Tarlo SM, 2000, OCCUP MED, V15, P471; Wark PAB, 2006, THORAX, V61, P909, DOI 10.1136/thx.2005.045187	28	38	39	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2		2			S408	S411		10.1016/j.jaci.2007.08.005	http://dx.doi.org/10.1016/j.jaci.2007.08.005			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	266IB	18241692	Bronze			2022-12-18	WOS:000253426600011
J	Yang, KD; Ou, CY; Chang, JC; Chen, RF; Liu, CA; Liang, HM; Hsu, TY; Chen, LC; Huang, SK				Yang, Kuender D.; Ou, Chia-Yu; Chang, Jen-Chieh; Chen, Rong-Fu; Liu, Chieh-An; Liang, Hsiu-Mei; Hsu, Te-Yao; Chen, Li-Chen; Huang, Shau-Ku			Infant frequent wheezing correlated to Clara cell protein 10 (CC10) polymorphism and concentration, but not allergy sensitization, in a perinatal cohort study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						wheezing infants; cord blood IgE; gender; Clara cell 10-kd protein; polymorphism; asthma	RESPIRATORY-DISTRESS-SYNDROME; TOTAL IGE LEVELS; CORD BLOOD IGE; A38G POLYMORPHISM; DOUBLE-BLIND; ASTHMA; ASSOCIATION; CHILDREN; ATOPY; BRONCHIOLITIS	Background: Wheezing episodes are common in young infants. However, the molecular mechanism of wheezing is unclear, and very few therapeutic regimens are effective. Objective: This study investigated the genetic and environmental factors predisposing to infant wheezing in a birth cohort study. Methods: A cohort of 1211 pregnant women was recruited for this study. Infant wheezing episodes during the first 18 months of life were correlated to parental atopic history, parental smoking, prematurity, CB IgE levels, and the sequence variant (G+38A) of the Clara cell protein 10 (CC10) gene encoding a secretary anti-inflammatory CC10 protein. Results: Nine hundred eighty-three infants completed umbilical cord blood collection, and 813 infants completed the 18-month postnatal follow-up. Twenty-two percent of the infants experienced at least I wheezing episode, and 6.6 % of the infants experienced frequent wheezing (>= 3 episodes). Multivariate logistic regression showed that male sex and the CC10 G+38A polymorphism, but not prematurity, CB IgE level, passive smoking, or parental atopy, were predictors of frequent wheezing. Further studies found that infant frequent wheezing was significantly associated with the CC10 +38AA genotype and lower plasma CC10 levels at 18 months of age (P =.046), and infants with acute wheezing episodes had significantly lower CC10 levels than those without (P =.023). No association of wheezing episodes with allergic sensitization was observed in this cohort population. Conclusion: Infant frequent wheezing is associated with the CC-10 G+38A polymorphism and lower CC10 levels but not infant atopy. Clinical implications: Lower CC10 expression, but not allergy sensitization, is involved in the pathogenesis of infant frequent wheezing.	Chang Gung Mem Hosp, Dept Gynecol & Obstet, Kaohsiung, Taiwan; Chang Gung Univ, Chang Gung Mem Hosp, Kaohsiung Med Ctr, Dept Pediat, Kaohsiung, Taiwan; Chang Gung Univ, Chang Gung Mem Hosp, Kaohsiung Med Ctr, Dept Obstet, Kaohsiung, Taiwan; Chang Gung Univ, Chang Gung Childrens Hosp, Div Allergy Asthma & Rheumatol, Linkou, Taiwan; Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD USA	Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung University; Johns Hopkins University; Johns Hopkins Medicine	Ou, CY (corresponding author), Chang Gung Mem Hosp, Dept Gynecol & Obstet, Kaohsiung, Taiwan.	yangkd.yeh@msa.hinet.net	Chen, Rong-Fu/AAI-8593-2021; Huang, Shau-Ku/F-5509-2010	Chen, Rong-Fu/0000-0001-7529-5390; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052468] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI-052468] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERNARD A, 1994, PEDIATR RES, V36, P771, DOI 10.1203/00006450-199412000-00015; BERNARD A, 1992, CLIN CHIM ACTA, V207, P239, DOI 10.1016/0009-8981(92)90122-7; BERNARD A, 1995, TOXICOL LETT, V77, P145, DOI 10.1016/0378-4274(95)03284-3; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; Bradley JP, 2005, PEDIATRICS, V115, pE7, DOI 10.1542/peds.2004-0059; Broeckaert F, 2000, CLIN EXP ALLERGY, V30, P469; Candelaria PV, 2005, IMMUNOGENETICS, V57, P25, DOI 10.1007/s00251-005-0778-2; Chang JC, 2004, PEDIAT ALLERG IMM-UK, V15, P506, DOI 10.1111/j.1399-3038.2004.00161.x; Chen LC, 2001, J IMMUNOL, V167, P3025, DOI 10.4049/jimmunol.167.6.3025; Cookson WOC, 2000, HUM MOL GENET, V9, P2359, DOI 10.1093/hmg/9.16.2359; Gao PS, 1998, HUM GENET, V103, P57, DOI 10.1007/s004390050783; *GLOB IN ASTHM, 2006, GLOB STRAT ASTHM PRE; HAY JG, 1995, AM J PHYSIOL, V268, P565; HEIZMANN A, 2003, INT ARCH ALLERGY IMM, V131, P291; Heymann PW, 2004, J ALLERGY CLIN IMMUN, V114, P239, DOI 10.1016/j.jaci.2004.04.006; Hung CH, 2004, J ALLERGY CLIN IMMUN, V114, P664, DOI 10.1016/j.jaci.2004.05.042; Kaan A, 2000, ANN ALLERG ASTHMA IM, V84, P37, DOI 10.1016/S1081-1206(10)62738-X; Karmaus W, 2001, AM J EPIDEMIOL, V154, P909, DOI 10.1093/aje/154.10.909; Kurukulaaratchy RJ, 2003, EUR RESPIR J, V22, P767, DOI 10.1183/09031936.03.00005903; Laing IA, 1998, J MED GENET, V35, P463, DOI 10.1136/jmg.35.6.463; Laing IA, 2000, AM J RESP CRIT CARE, V161, P124, DOI 10.1164/ajrccm.161.1.9904073; Lannero E, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-3; Levine CR, 2005, PEDIATR RES, V58, P15, DOI 10.1203/01.PDR.0000156371.89952.35; Linneberg A, 2006, J ALLERGY CLIN IMMUN, V117, P184, DOI 10.1016/j.jaci.2005.09.042; Liu CA, 2003, J ALLERGY CLIN IMMUN, V112, P899, DOI 10.1016/j.jaci.2003.08.030; Malerba Giovanni, 2005, Journal of Applied Genetics, V46, P93; Mandal AK, 2004, J EXP MED, V199, P1317, DOI 10.1084/jem.20031666; Mansur AH, 2002, CLIN EXP ALLERGY, V32, P994, DOI 10.1046/j.1365-2222.2002.01426.x; Mattsson J, 2005, TRANSPLANTATION, V79, P1411, DOI 10.1097/01.TP.0000158354.39635.AB; Murray CS, 2006, LANCET, V368, P754, DOI 10.1016/S0140-6736(06)69285-4; Onay VU, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-114; Pilette C, 2001, AM J RESP CRIT CARE, V163, P185, DOI 10.1164/ajrccm.163.1.9912137; Ryan PH, 2005, J ALLERGY CLIN IMMUN, V116, P279, DOI 10.1016/j.jaci.2005.05.014; SCHONBERGER J, 2004, EUR J GEN PRACT, V10, P138; Sengler C, 2003, J ALLERGY CLIN IMMUN, V111, P515, DOI 10.1067/mai.2003.180; Shashikant BN, 2005, J APPL PHYSIOL, V99, P2204, DOI 10.1152/japplphysiol.00246.2005; Shijubo N, 2003, CURR PHARM DESIGN, V9, P1139, DOI 10.2174/1381612033455026; Siltanen M, 2004, PEDIATR PULM, V37, P43, DOI 10.1002/ppul.10402; SINGH G, 1990, BIOCHIM BIOPHYS ACTA, V1039, P348, DOI 10.1016/0167-4838(90)90270-P; Taussig LM, 2003, J ALLERGY CLIN IMMUN, V111, P661, DOI 10.1067/mai.2003.162; Wainwright C, 2003, NEW ENGL J MED, V349, P27, DOI 10.1056/NEJMoa022226; Woodruff PG, 2001, JAMA-J AM MED ASSOC, V286, P395, DOI 10.1001/jama.286.4.395; Yang KD, 2004, CLIN EXP ALLERGY, V34, P32, DOI 10.1111/j.1365-2222.2004.01776.x	43	38	40	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2007	120	4					842	848		10.1016/j.jaci.2007.07.009	http://dx.doi.org/10.1016/j.jaci.2007.07.009			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	220LH	17716718				2022-12-18	WOS:000250157700018
J	Kunzmann, S; Schmidt-Weber, C; Zingg, JM; Azzi, A; Kramer, BW; Blaser, K; Akdis, CA; Speer, CP				Kunzmann, Steffen; Schmidt-Weber, Carsten; Zingg, Jean-Marc; Azzi, Angelo; Kramer, Boris W.; Blaser, Kurt; Akdis, Cezmi A.; Speer, Christian P.			Connective tissue growth factor expression is regulated by histamine in lung fibroblasts: Potential role of histamine in airway remodeling	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; CTGF; Smad signaling; TGF-beta 1; vascular remodeling	NECROSIS-FACTOR-ALPHA; SMOOTH-MUSCLE-CELLS; FACTOR-BETA; TGF-BETA; ALLERGIC INFLAMMATION; ASTHMA; ACTIVATION; GENE; PROLIFERATION; RECEPTORS	Background: In the inflamed lung of allergic asthma, an aberrant injury-repair response is accompanied by structural changes in the airway, known as airway remodeling. TGF-beta and its downstream mediator connective tissue growth factor (CTGF) are playing a key role in these processes, resulting in irreversible airway remodelling. Objective: As histamine is a key mediator of allergic reactions, we investigated whether histamine is involved in airway remodeling. Methods: The effect of histamine and TGF-beta 1 on proliferation of lung fibroblast cells IMR-90 was studied by [H-3]-thymidine proliferation assay. The regulation of CTGF by histamine and TGF-beta 1 in lung fibroblasts was analyzed by RT-PCR, real-time PCR, Western blot analysis, and promoter analysis and characterized by specific histamine-receptor antagonists. Results: Histamine and TGF-beta 1 enhanced proliferation of lung fibroblast cells IMR-90. Both induced CTGF mRNA and protein expression with different time kinetics. Whereas TGF-beta 1 induced maximal CTGF expression after 12 hours (347% +/- 23%), histamine-induced maximal CTGF expression was lower and delayed (maximum expression of 204% +/- 11% after 48 hours). Histamine and TGF-beta 1 stimulated the CTGF promoter and the TGF-beta-response element in the CTGF promoter. The histamine-induced CTGF expression was mediated through the histamine receptor (HR1) and could be completely abolished by TNF-alpha. Conclusions: These findings demonstrate that histamine plays a potential role in the induction of airway remodeling mediated by the induction of lung fibroblasts proliferation and CTGF expression. Clinical implications: This mechanism could be important for prophylactic strategies aiming at airway remodeling and could be a new indication for antihistamine treatment.	Univ Wurzburg, Childrens Hosp, D-97080 Wurzburg, Germany; Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland; Univ Bern, Inst Biochem & Mol Med, Bern, Switzerland; Maastricht Univ Hosp, Dept Pediat, Maastricht, Netherlands	University of Wurzburg; Swiss Institute of Allergy & Asthma Research; University of Bern; Maastricht University; Maastricht University Medical Centre (MUMC)	Kunzmann, S (corresponding author), Univ Wurzburg, Childrens Hosp, Josef Schneider Str 2, D-97080 Wurzburg, Germany.	kunzinann_s@kinderklinik.uni-wuerzburg.de	Kramer, Boris/AAO-3183-2021; Zingg, Jean-Marc/H-6960-2019; Schmidt-Weber, Carsten B./AAU-1621-2021; Akdis, Cezmi/AAV-4844-2020	Schmidt-Weber, Carsten B./0000-0002-3203-8084; Akdis, Cezmi/0000-0001-8020-019X				Abraham DJ, 2000, J BIOL CHEM, V275, P15220, DOI 10.1074/jbc.275.20.15220; Akdis CA, 2006, EUR J PHARMACOL, V533, P69, DOI 10.1016/j.ejphar.2005.12.044; Akdis CA, 2003, J ALLERGY CLIN IMMUN, V112, P15, DOI 10.1067/mai.2003.1585; Balzar S, 2005, J ALLERGY CLIN IMMUN, V115, P110, DOI 10.1016/j.jaci.2004.09.034; Bartram U, 2004, CHEST, V125, P754, DOI 10.1378/chest.125.2.754; Berry MA, 2006, NEW ENGL J MED, V354, P697, DOI 10.1056/NEJMoa050580; Blom IE, 2002, MATRIX BIOL, V21, P473, DOI 10.1016/S0945-053X(02)00055-0; BOUCEK RJ, 1973, P SOC EXP BIOL MED, V144, P929; Brigstock David R., 2002, Angiogenesis, V5, P153, DOI 10.1023/A:1023823803510; Burgess JK, 2005, CLIN EXP PHARMACOL P, V32, P988, DOI 10.1111/j.1440-1681.2005.04296.x; Burgess JK, 2006, AM J PHYSIOL-LUNG C, V290, pL153, DOI 10.1152/ajplung.00287.2005; Burgess JK, 2003, AM J RESP CRIT CARE, V167, P71, DOI 10.1164/rccm.200205-416OC; Chen YJ, 2002, KIDNEY INT, V62, P1149, DOI 10.1111/j.1523-1755.2002.kid567.x; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Ehler E, 1996, CELL MOTIL CYTOSKEL, V34, P288, DOI 10.1002/(SICI)1097-0169(1996)34:4<288::AID-CM4>3.0.CO;2-4; ELIAS JA, 1991, J IMMUNOL, V146, P3437; FRIES KM, 1994, AM J RESP CELL MOL, V11, P552, DOI 10.1165/ajrcmb.11.5.7946384; Garbuzenko E, 2004, EXP LUNG RES, V30, P705, DOI 10.1080/01902140490517809; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; HAAKSMA EEJ, 1990, PHARMACOL THERAPEUT, V47, P73, DOI 10.1016/0163-7258(90)90046-5; Holmes A, 2001, J BIOL CHEM, V276, P10594, DOI 10.1074/jbc.M010149200; Howarth PH, 2005, THORAX, V60, P1012, DOI 10.1136/thx.2005.045260; JORDANA M, 1988, THORAX, V43, P552, DOI 10.1136/thx.43.7.552; Karagiannidis C, 2006, J ALLERGY CLIN IMMUN, V117, P111, DOI 10.1016/j.jaci.2005.09.017; Karjalainen EM, 2003, RESP MED, V97, P1045, DOI 10.1016/S0954-6111(03)00136-7; Kaufman J, 2001, CHEST, V120, p53S, DOI 10.1378/chest.120.1_suppl.S53; Kunzmann S, 2003, FASEB J, V17, P1089, DOI 10.1096/fj.02-1008com; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Leask A, 2001, J CLIN PATHOL-MOL PA, V54, P180, DOI 10.1136/mp.54.3.180; Leonardi A, 1999, EXP EYE RES, V68, P739, DOI 10.1006/exer.1999.0658; LORENZ W, 1975, AGENTS ACTIONS, V5, P402, DOI 10.1007/BF01972656; Oddera S, 2002, INT ARCH ALLERGY IMM, V129, P152, DOI 10.1159/000065877; PEARSON CA, 1988, EMBO J, V7, P2977, DOI 10.1002/j.1460-2075.1988.tb03160.x; PEAT JK, 1987, EUR J RESPIR DIS, V70, P171; PERKETT EA, 1990, J CLIN INVEST, V86, P1459, DOI 10.1172/JCI114862; Redington AE, 1997, AM J RESP CRIT CARE, V156, P642, DOI 10.1164/ajrccm.156.2.9605065; Sacco Oliviero, 2004, Paediatr Respir Rev, V5 Suppl A, pS35, DOI 10.1016/S1526-0542(04)90008-5; Schmidt-Weber CB, 2006, IMMUNOL ALLERGY CLIN, V26, P233, DOI 10.1016/j.iac.2006.02.011; Schmidt-Weber Carsten B, 2002, Curr Allergy Asthma Rep, V2, P259, DOI 10.1007/s11882-002-0028-8; Sempowski GD, 1997, J IMMUNOL, V158, P4670; SIMON RA, 1977, J ALLERGY CLIN IMMUN, V60, P312, DOI 10.1016/0091-6749(77)90111-7; Simons FER, 2004, NEW ENGL J MED, V351, P2203, DOI 10.1056/NEJMra033121; Trautmann A, 2000, J CLIN INVEST, V106, P25, DOI 10.1172/JCI9199; Vignola AM, 2000, J ALLERGY CLIN IMMUN, V105, P1041, DOI 10.1067/mai.2000.107195; Villacorta L, 2003, CIRC RES, V92, P104, DOI 10.1161/01.RES.0000049103.38175.1B; Wilson JW, 2006, CURR OPIN ALLERGY CL, V6, P51, DOI 10.1097/01.all.0000200505.54425.47	47	38	42	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2007	119	6					1398	1407		10.1016/j.jaci.2007.02.018	http://dx.doi.org/10.1016/j.jaci.2007.02.018			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	178PO	17412405				2022-12-18	WOS:000247232800015
J	Reese, G; Ballmer-Weber, BK; Wangorsch, A; Randow, S; Vieths, S				Reese, Gerald; Ballmer-Weber, Barbara K.; Wangorsch, Andrea; Randow, Stefanie; Vieths, Stefan			Allergenicity and antigenicity of wild-type and mutant, monomeric, and dimeric carrot major allergen Dau c 1: Destruction of conformation, not oligomerization, is the roadmap to save allergen vaccines	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Dau c 1; isoforms; carrot allergen; allergen vaccine; mutation; secondary structure; hypoallergenic variant; monomer; dimer; trimer	BIRCH POLLEN ALLERGEN; BET V 1; FOOD ALLERGY; CROSS-REACTIVITY; ANTIBODY-RESPONSES; EPITOPE ANALYSIS; IGE REACTIVITY; PRU AV-1; IMMUNOTHERAPY; PROTEIN	Background: Carrot allergy is caused by primary sensitization to birch pollen. Continuous carrot exposure results in additional Dau c 1-specific allergic responses. Thus, immunotherapy with birch pollen may not improve the food allergy. Objective: Evaluation of mutation and oligomerization of the major carrot allergen, Dan c 1, in regard to alteration of antibody binding capacities, structure, and the ability to induce blocking IgG antibodies. Methods: Measurement of IgE reactivities to monomers, dimers of wild-type and mutant Dan c 1.0104 and Dan c 1.0201, and Dan c 1.0104 trimer, their ability to induce blocking antibodies in mice, and their allergenic potency by histamine release. Results: The reactivity of human IgE to the mutant dimer was reduced on average by 81%. Sera of immunized Balb/c mice showed specific IgG similar to the human IgE antibody response; Dan c 1.01 was more antigenic than Dan c 1.02. Both wild-type and mutant Dan c 1 variants induced cross-reacting IgG, which blocked binding of human IgE. The mutants were more antigenic than the wild-type forms, and the dimers induced higher IgG responses in mice than the monomers. The results of the histamine release experiments corroborated the findings of the antibody binding studies. Conclusion: Destruction of native conformation rather than oligomerization is the appropriate strategy to reduce the allergenicity of Bet v I-homologous food allergens. Clinical implications: The dimer composed of mutants of Dau c 1.0104 and Dan c 1.0201 is a promising candidate vaccine for treatment of carrot allergy because of its high immunogenicity and drastically reduced allergenicity.	Paul Ehrlich Inst, Dept Allergol, D-63325 Langen, Germany; Univ Zurich Hosp, Dept Dermatol, Allergy Unit, Zurich, Switzerland	Paul Ehrlich Institute; University of Zurich; University Zurich Hospital	Reese, G (corresponding author), Paul Ehrlich Inst, Dept Allergol, Paul Ehrlich Str 51-59, D-63325 Langen, Germany.	reege@pei.de						Ballmer-Weber BK, 2005, CLIN EXP ALLERGY, V35, P970, DOI 10.1111/j.1365-2222.2005.02294.x; Ballmer-Weber BK, 2001, J ALLERGY CLIN IMMUN, V108, P301, DOI 10.1067/mai.2001.116430; Bohle B, 2005, CLIN EXP ALLERGY, V35, P1392, DOI 10.1111/j.1365-2222.2005.02332.x; Bolhaar STHP, 2004, CLIN EXP ALLERGY, V34, P761, DOI 10.1111/j.1365-2222.2004.1939.x; Bucher X, 2004, ALLERGY, V59, P1272, DOI 10.1111/j.1398-9995.2004.00626.x; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; Ferreira F, 1998, FASEB J, V12, P231, DOI 10.1096/fasebj.12.2.231; Gafvelin G, 2005, INT ARCH ALLERGY IMM, V138, P59, DOI 10.1159/000087358; Hansen KS, 2004, MOL NUTR FOOD RES, V48, P441, DOI 10.1002/mnfr.200400037; HELBLING A, 1993, ANN ALLERGY, V70, P495; Hoffmann-Sommergruber K, 1999, CLIN EXP ALLERGY, V29, P840, DOI 10.1046/j.1365-2222.1999.00529.x; Holm J, 2004, J IMMUNOL, V173, P5258, DOI 10.4049/jimmunol.173.8.5258; Kwok SC, 2003, J BIOL CHEM, V278, P35248, DOI 10.1074/jbc.M305306200; Lin XY, 1996, PLANT PHYSIOL, V112, P1365, DOI 10.1104/pp.112.3.1365; Ma Y, 2006, INT ARCH ALLERGY IMM, V139, P53, DOI 10.1159/000089756; Mahler V, 2004, CLIN EXP ALLERGY, V34, P115, DOI 10.1111/j.1365-2222.2004.01857.x; Mittag D, 2006, MOL IMMUNOL, V43, P268, DOI 10.1016/j.molimm.2005.02.008; Neudecker P, 2003, BIOCHEM J, V376, P97, DOI 10.1042/BJ20031057; Niederberger V, 2006, EXPERT REV VACCINES, V5, P103, DOI 10.1586/14760584.5.1.103; Reisinger J, 2005, J ALLERGY CLIN IMMUN, V116, P347, DOI 10.1016/j.jaci.2005.04.003; Scheurer S, 1999, MOL IMMUNOL, V36, P155, DOI 10.1016/S0161-5890(99)00033-4; Son DY, 1999, EUR J NUTR, V38, P201, DOI 10.1007/s003940050063; Vieths S, 2002, ANN NY ACAD SCI, V964, P47; Vrtala S, 2001, FASEB J, V15, P2045, DOI 10.1096/fj.00-0767fje; Wiche R, 2005, BIOCHEM J, V385, P319, DOI 10.1042/BJ20040842; Yamamoto M, 1997, PLANT CELL PHYSIOL, V38, P1080, DOI 10.1093/oxfordjournals.pcp.a029275	26	38	41	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2007	119	4					944	951		10.1016/j.jaci.2006.11.699	http://dx.doi.org/10.1016/j.jaci.2006.11.699			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	157OK	17292955				2022-12-18	WOS:000245729500025
J	Platts-Mills, TAE				Platts-Mills, Thomas A. E.			The role of indoor allergens in chronic allergic disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						indoor allergens; asthma; atopic dermatitis; mammalian allergens; total IgE; tolerance; modified T(H)2 response	MODIFIED TH2 RESPONSE; ASIAN LADY BEETLE; CAT ALLERGEN; AIRBORNE ENDOTOXIN; HARMONIA-AXYRIDIS; ATOPIC-DERMATITIS; ASTHMA; MITE; EXPOSURE; DUST		Univ Virginia, Asthma & Allerg Dis Ctr, Charlottesville, VA 22908 USA	University of Virginia	Platts-Mills, TAE (corresponding author), Univ Virginia, Asthma & Allerg Dis Ctr, Box 801355, Charlottesville, VA 22908 USA.	tap2z@virginia.edu		Platts-Mills, Thomas/0000-0002-1263-329X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI050989, R01AI020565, R37AI020565] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20565, AI50989] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aalberse RC, 2004, J ALLERGY CLIN IMMUN, V113, P983, DOI 10.1016/j.jaci.2004.02.046; Aalberse RC, 2002, IMMUNOLOGY, V105, P9, DOI 10.1046/j.0019-2805.2001.01341.x; Akdis CA, 2006, ALLERGY, V61, P969, DOI 10.1111/j.1398-9995.2006.01153.x; Albright DD, 2006, ANN ALLERG ASTHMA IM, V97, P521, DOI 10.1016/S1081-1206(10)60944-1; ALTOUNYAN REC, 1970, DISODIUM CROMOGLYCAT, P47; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Carneiro R, 2004, J INVEST DERMATOL, V122, P927, DOI 10.1111/j.0022-202X.2004.22407.x; Chapman MD, 2007, J ALLERGY CLIN IMMUN, V119, P414, DOI 10.1016/j.jaci.2006.11.001; Dawkins R., 2004, THE ANCESTORS TALE; Erwin EA, 2005, J ALLERGY CLIN IMMUN, V115, P74, DOI 10.1016/j.jaci.2004.10.030; Erwin EA, 2007, J ALLERGY CLIN IMMUN, V119, P359, DOI 10.1016/j.jaci.2006.12.648; Ghaemmaghami AM, 2001, EUR J IMMUNOL, V31, P1211, DOI 10.1002/1521-4141(200104)31:4&lt;1211::AID-IMMU1211&gt;3.0.CO;2-R; GLEICH GJ, 1975, SCIENCE, V190, P1106, DOI 10.1126/science.1188389; Homey B, 2006, J ALLERGY CLIN IMMUN, V118, P178, DOI 10.1016/j.jaci.2006.03.047; Horner AA, 2006, J ALLERGY CLIN IMMUN, V117, P1133, DOI 10.1016/j.jaci.2006.02.035; ISHIZAKA K, 1967, J IMMUNOL, V98, P490; Jeal H, 2006, AM J RESP CRIT CARE, V174, P21, DOI 10.1164/rccm.200506-964OC; Jeannin P, 1998, J IMMUNOL, V160, P3555; Kaiser L, 2003, J BIOL CHEM, V278, P37730, DOI 10.1074/jbc.M304740200; Mandal AK, 2005, J BIOL CHEM, V280, P32897, DOI 10.1074/jbc.M502375200; Matsui EC, 2005, CLIN EXP ALLERGY, V35, P1347, DOI 10.1111/j.1365-2222.2005.02331.x; MITCHELL EB, 1982, LANCET, V1, P127; Nakazawa T, 2007, J ALLERGY CLIN IMMUN, V119, P421, DOI 10.1016/j.jaci.2006.11.633; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Perzanowski MS, 2002, AM J RESP CRIT CARE, V166, P696, DOI 10.1164/rccm.2201035; Platts-Mills JA, 2005, J ALLERGY CLIN IMMUN, V116, P384, DOI 10.1016/j.jaci.2005.05.012; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Platts-Mills TAE, 2005, PLOS MED, V2, P122, DOI 10.1371/journal.pmed.0020034; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; PLATTSMILLS TAE, 1982, LANCET, V2, P675; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; PLATTSMILLS TAE, 2007, IN PRESS J ALLERGY C; PROUVOSTDANON A, 1977, EUR J IMMUNOL, V7, P342, DOI 10.1002/eji.1830070604; Reefer AJ, 2004, J IMMUNOL, V172, P2763, DOI 10.4049/jimmunol.172.5.2763; Salt BH, 2007, J ALLERGY CLIN IMMUN, V119, P508, DOI 10.1016/j.jaci.2006.11.006; Shreffler WG, 2006, J IMMUNOL, V177, P3677, DOI 10.4049/jimmunol.177.6.3677; Sohy C, 2005, ALLERGY, V60, P541, DOI 10.1111/j.1398-9995.2005.00742.x; Sporik R, 1999, THORAX, V54, P675, DOI 10.1136/thx.54.8.675; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; SVARTENGREN M, 1987, EXP LUNG RES, V12, P75, DOI 10.3109/01902148709068815; TOVEY ER, 1981, NATURE, V289, P592, DOI 10.1038/289592a0; TUFT L, 1949, J INVEST DERMATOL, V12, P211, DOI 10.1038/jid.1949.33; Tweedie S, 1997, MOL CELL BIOL, V17, P1469, DOI 10.1128/MCB.17.3.1469; van Ree R, 2007, J ALLERGY CLIN IMMUN, V119, P270, DOI 10.1016/j.jaci.2006.10.033; VOORHORS.R, 1967, J ALLERGY, V39, P325, DOI 10.1016/0021-8707(67)90045-7; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; WIDE L, 1967, LANCET, V2, P1105; WOOFOLK JA, 2007, J ALLERGY CLIN IMMUN, V119, P281; Yarbrough JA, 1999, J ALLERGY CLIN IMMUN, V104, P704, DOI 10.1016/S0091-6749(99)70347-7; Zhu L, 2005, NAT BIOTECHNOL, V23, P1159, DOI 10.1038/nbt1132	51	38	39	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2007	119	2					297	302		10.1016/j.jaci.2006.12.647	http://dx.doi.org/10.1016/j.jaci.2006.12.647			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137YB	17291849				2022-12-18	WOS:000244327900004
J	Denlinger, LC; Sorkness, CA; Chinchilli, VM; Lemanske, RF				Denlinger, Loren C.; Sorkness, Christine A.; Chinchilli, Vernon M.; Lemanske, Robert F., Jr.			Guideline-defining asthma clinical trials of the National Heart, Lung, and Blood Institute's Asthma Clinical Research Network and Childhood Asthma Research and Education Network	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; clinical trial; treatment guidelines	MILD PERSISTENT ASTHMA; INHALED CORTICOSTEROID TREATMENT; BETA(2)-ADRENERGIC RECEPTOR; FLUTICASONE PROPIONATE; IMPULSE OSCILLOMETRY; DOUBLE-BLIND; SALMETEROL; BUDESONIDE; ALBUTEROL; POLYMORPHISMS	Because of an increasing prevalence, morbidity, and mortality associated with asthma, the National Heart, Lung, and Blood Institute created the Asthma Clinical Research Network and the Childhood Asthma Research and Education Network to improve public health. The objectives of these clinical research networks are to conduct multiple, well-designed clinical trials for rapid evaluation of new and existing therapeutic approaches to asthma and to disseminate laboratory and clinical findings to the health care community. These trials comprise a large proportion of the data driving the treatment guidelines established and reviewed by the National Asthma Education and Prevention Program. This article will review the basic design and major findings of selected Asthma Clinical Research Network and Childhood Asthma Research and Education Network trials involving both adults and children with asthma. Collectively, these studies have helped refine the therapeutic role of existing controller medications, establish standard models for side-effect evaluation and risk-benefit models, validate symptom-based assessments for asthma control, and identify baseline characteristics that might predict individual patient responses. Remaining challenges include shaping the role of novel therapeutics in future guidelines, incorporating pharmacogenomic data in treatment decisions, and establishing better implementation strategies for translation to community settings, all with the goal of reducing the asthma burden on society.	Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat, Madison, WI 53792 USA; Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53792 USA; Univ Wisconsin, Sch Med & Publ Hlth, Dept Pharm, Madison, WI 53792 USA; Univ Wisconsin, Sch Pharm, Madison, WI 53792 USA; Penn State Univ, Coll Med, Dept Hlth Evaluat Sci, Hershey, PA USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Lemanske, RF (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat, Madison, WI 53792 USA.	rfl@medicine.wisc.edu			NHLBI NIH HHS [U10 HL064305, U10 HL051823, 5U10HL056443, U10 HL051831, 5U10HL064295, 5U10HL064287, U10 HL051834, U10 HL051845-07, 5U10HL064305, 5U10HL051834, 5U10HL051845, 5U10HL051810, U10 HL051831-10, U10 HL051845, U10 HL064313-07, U10 HL051810-10, U10 HL064307, U10 HL051843, U10 HL064287-05, 5U10HL051843, U10 HL064313, U10 HL064307-05, U10 HL051823-07, U10 HL064295, U10 HL064288, U10 HL064287, 5U10HL051823, 5U10HL064307, 5U10HL064313, U10 HL056443-08, U10 HL064288-01, U10 HL051834-10, 5U10HL064288, U10 HL064295-05, U10 HL064305-10, U10 HL051843-10, 5U10HL051831, U10 HL056443] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL064313, U10HL064305, U10HL051843, U10HL064307, U10HL064288, U10HL064287, U10HL051831, U10HL064295, U10HL051823, U10HL051845, U10HL051810, U10HL056443, U10HL051834] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; Allen DB, 1998, ACTA PAEDIATR, V87, P123, DOI 10.1080/08035259850157516; Bisgaard H, 2003, PEDIATR PULM, V36, P391, DOI 10.1002/ppul.10381; Boushey HA, 2005, AM J RESP CRIT CARE, V172, P412, DOI 10.1164/rccm.2505003; Boushey HA, 2005, NEW ENGL J MED, V352, P1519, DOI 10.1056/NEJMoa042552; CASTLE W, 1993, BRIT MED J, V306, P1034, DOI 10.1136/bmj.306.6884.1034; Chinchilli VM, 2001, CONTROL CLIN TRIALS, V22, p126S, DOI 10.1016/S0197-2456(01)00160-X; DALONZO GE, 1994, JAMA-J AM MED ASSOC, V271, P1412, DOI 10.1001/jama.271.18.1412; Drazen JM, 1996, NEW ENGL J MED, V335, P841, DOI 10.1056/NEJM199609193351202; Fabbri LM, 2005, NEW ENGL J MED, V352, P1589, DOI 10.1056/NEJMe058020; *GINA, 1998, GLOB IN ASTHM GLOB S; Goldman MD, 2002, PEDIATR PULM, V34, P312, DOI 10.1002/ppul.10168; GREEN SA, 1994, BIOCHEMISTRY-US, V33, P9414, DOI 10.1021/bi00198a006; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; Israel E, 2004, LANCET, V364, P1505, DOI 10.1016/S0140-6736(04)17273-5; Israel E, 2000, AM J RESP CRIT CARE, V162, P75, DOI 10.1164/ajrccm.162.1.9907092; Klug B, 1996, PEDIATR PULM, V21, P290; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; Lazarus SC, 2001, JAMA-J AM MED ASSOC, V285, P2583, DOI 10.1001/jama.285.20.2583; Lemanske RF, 2001, JAMA-J AM MED ASSOC, V285, P2594, DOI 10.1001/jama.285.20.2594; Marotta A, 2003, J ALLERGY CLIN IMMUN, V112, P317, DOI 10.1067/mai.2003.1627; Martin RJ, 2002, AM J RESP CRIT CARE, V165, P1377, DOI 10.1164/rccm.2105013; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MCFADDEN ER, 1995, J ALLERGY CLIN IMMUN, V95, P641, DOI 10.1016/S0091-6749(95)70166-4; National Asthma Education and Prevention Program (NAEPP), 1997, GUID DIAGN MAN ASTHM; O'Byrne PM, 2001, AM J RESP CRIT CARE, V164, P1392, DOI 10.1164/ajrccm.164.8.2104102; O'Byrne PM, 2005, AM J RESP CRIT CARE, V172, P410, DOI 10.1164/rccm.2505001; Pauwels RA, 2003, LANCET, V361, P1071, DOI 10.1016/S0140-6736(03)12891-7; PEARLMAN DS, 1992, NEW ENGL J MED, V327, P1420, DOI 10.1056/NEJM199211123272004; SELROOS O, 1995, CHEST, V108, P1228, DOI 10.1378/chest.108.5.1228; Sorkness CA, 2007, J ALLERGY CLIN IMMUN, V119, P64, DOI 10.1016/j.jaci.2006.09.042; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; Stoloff SW, 2004, J ALLERGY CLIN IMMUN, V113, P245, DOI 10.1016/j.jaci.2003.10.011; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; Taussig LM, 2003, J ALLERGY CLIN IMMUN, V111, P661, DOI 10.1067/mai.2003.162; Taylor DR, 2000, THORAX, V55, P762, DOI 10.1136/thorax.55.9.762; van Noord JA, 1999, THORAX, V54, P207, DOI 10.1136/thx.54.3.207; Wechsler ME, 2006, AM J RESP CRIT CARE, V173, P519, DOI 10.1164/rccm.200509-1519OC; Woolcock A, 1996, AM J RESP CRIT CARE, V153, P1481, DOI 10.1164/ajrccm.153.5.8630590; Zeiger RS, 2006, J ALLERGY CLIN IMMUN, V117, P45, DOI 10.1016/j.jaci.2005.10.012; Zhang J, 2002, EUR RESPIR J, V20, P1102, DOI 10.1183/09031936.02.02402001	45	38	38	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2007	119	1					3	11		10.1016/j.jaci.2006.10.015	http://dx.doi.org/10.1016/j.jaci.2006.10.015			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	127YL	17141853	Green Accepted			2022-12-18	WOS:000243622200001
J	Gaston, B; Kelly, R; Urban, P; Liu, L; Henderson, EM; Doctor, A; Teague, WG; Fitzpatrick, A; Erzurum, S; Hunt, JF				Gaston, Benjamin; Kelly, Robin; Urban, Peter; Liu, Lei; Henderson, Edward M.; Doctor, Allan; Teague, W. Gerald; Fitzpatrick, Anne; Erzurum, Serpil; Hunt, John F.			Buffering airway acid decreases exhaled nitric oxide in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						buffer; airway acid; nitric oxide; nitrite; asthma	CYSTIC-FIBROSIS AIRWAY; BRONCHOCONSTRICTION; HEALTHY; PH	Background: The human airway is believed to be acidified in asthma. In an acidic environment nitrite is converted to nitric oxide (NO). Objective: We hypothesized that buffering airway lining fluid acid would decrease the fraction of exhaled NO (F-ENO). Methods: We treated 28 adult nonsmoking subjects (9 healthy control subjects, 11 subjects with mild intermittent asthma, and 8 subjects with persistent asthma) with 3 mL of 10 mmol/L phosphate buffered saline (PBS) through a nebulizer and then serially measured F-ENO levels. Six subjects also received PBS mouthwash alone. Results: F-ENO levels decreased after buffer inhalation. The maximal decrease occurred between 15 and 30 minutes after treatment; F-ENO levels returned to pretreatment levels by 60 minutes. The decrease was greatest in subjects with persistent asthma (-7.1 +/- 1.0 ppb); this was more than in those with either mild asthma (-2.9 +/- 0.3 ppb) or healthy control subjects (-1.7 +/- 0.3 ppb, P <.001). Levels did not decrease in subjects who used PBS mouthwash. Conclusion: Neutralizing airway acid decreases F-ENO levels. The magnitude of this change is greatest in persistent asthma. These data suggest that airway pH is a determinant of F-ENO levels downstream from NO synthase activation. Clinical implications: Airway biochemistry modulates F-ENO levels. For example, nitrite is converted to NO in the airway, particularly the inflamed airway, by means of acid-based chemistry. Thus airway pH should be considered in interpreting clinical F-ENO values. In fact, PBS challenge testing integrates airway pH and F-ENO analysis, potentially improving the utility of F-ENO as a noninvasive test for the type and severity of asthmatic airway inflammation.	Univ Virginia, Sch Med, Dept Pediat Resp Med, Hlth Syst, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Biostat & Epidemiol, Charlottesville, VA USA; Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA; Cleveland Clin, Dept Med, Cleveland, OH 44106 USA	University of Virginia; University of Virginia; Emory University; Cleveland Clinic Foundation	Gaston, B (corresponding author), Univ Virginia, Sch Med, Dept Pediat Resp Med, Hlth Syst, Box 800386, Charlottesville, VA 22908 USA.	bmg3g@virginia.edu	Liu, Lei/B-4968-2009	Liu, Lei/0000-0003-1844-338X; Doctor, Allan/0000-0002-6096-6400; Fitzpatrick, Anne/0000-0002-2933-5926	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069170, R01HL059337] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 69170, 2R01 HL59337] Funding Source: Medline; PHS HHS [1U19A134607] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AHMED T, 1993, RESP MED, V87, P235, DOI 10.1016/0954-6111(93)90106-A; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; [Anonymous], 1999, Am J Respir Crit Care Med, V160, P2104; BENJAMIN N, 1999, NITRIC OXIDE INFECT, P215; Carraro S, 2006, AM J PHYSIOL-LUNG C, V290, pL827, DOI 10.1152/ajplung.00406.2005; Comhair SAA, 2005, AM J RESP CRIT CARE, V172, P306, DOI 10.1164/rccm.200502-180OC; DWEIK R, 2005, P AM THORAC SOC, V2, pA82; Dweik RA, 2001, P NATL ACAD SCI USA, V98, P2622, DOI 10.1073/pnas.051629498; Gaston B, 2002, AM J RESP CRIT CARE, V165, P387, DOI 10.1164/ajrccm.165.3.2106006; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; Gaston B, 2006, AM J RESP CRIT CARE, V173, P1186, DOI 10.1164/rccm.200510-1584PP; Gow AJ, 2002, J BIOL CHEM, V277, P9637, DOI 10.1074/jbc.C100746200; Hansel TT, 2003, FASEB J, V17, P1298, DOI 10.1096/fj.02-0633fje; Hunt JF, 2000, AM J RESP CRIT CARE, V161, P694, DOI 10.1164/ajrccm.161.3.9911005; Hunt JF, 2002, AM J RESP CRIT CARE, V165, P101, DOI 10.1164/ajrccm.165.1.2104131; HUNT JF, 2004, J ALLERGY CLIN IMMUN, V84, P731; Hunter CJ, 2004, NAT MED, V10, P1122, DOI 10.1038/nm1109; Kharitonov SA, 2003, EUR RESPIR J, V21, P433, DOI 10.1183/09031936.03.00066903a; Kostikas K, 2002, AM J RESP CRIT CARE, V165, P1364, DOI 10.1164/rccm.200111-068OC; LONNERHOLM G, 1982, PEDIATR RES, V16, P407; *NIH NAT HEART LUN, 2002, PUBL NIH NAT HEART L; PAGETBROWN A, 2004, AM J RESP CRIT CARE, V169, pA664; Que LG, 2005, SCIENCE, V308, P1618, DOI 10.1126/science.1108228; Ricciardolo FLM, 1999, AM J RESP CRIT CARE, V159, P557, DOI 10.1164/ajrccm.159.2.9804022; Ricciardolo FLM, 2004, PHYSIOL REV, V84, P731, DOI 10.1152/physrev.00034.2003; Snyder AH, 2002, AM J RESP CRIT CARE, V165, P922, DOI 10.1164/ajrccm.165.7.2105032; Tate S, 2002, THORAX, V57, P926, DOI 10.1136/thorax.57.11.926; WADSWORTH S, 1997, AM J PHYSIOL, V273, P427; Yoon SS, 2006, J CLIN INVEST, V116, P436, DOI 10.1172/JCI24684; Zetterquist W, 1999, EUR RESPIR J, V13, P327, DOI 10.1034/j.1399-3003.1999.13b18.x	30	38	39	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2006	118	4					817	822		10.1016/j.jaci.2006.06.040	http://dx.doi.org/10.1016/j.jaci.2006.06.040			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	097GD	17030232				2022-12-18	WOS:000241434200006
J	Barros, R; Moreira, A; Fonseca, J; Fonseca, J; Moreira, P; Fernandes, L; de Oliveira, JF; Delgado, L; Castel-Branco, MG				Barros, R; Moreira, A; Fonseca, J; Fonseca, J; Moreira, P; Fernandes, L; de Oliveira, JF; Delgado, L; Castel-Branco, MG			Obesity and airway inflammation in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							EXHALED NITRIC-OXIDE		Univ Porto, Fac Nutr & Food Sci, P-4100 Oporto, Portugal; Univ Porto, Hosp S Joao, Fac Med, P-4100 Oporto, Portugal	Universidade do Porto; Sao Joao Hospital; Universidade do Porto	Barros, R (corresponding author), Univ Porto, Fac Nutr & Food Sci, Rua Campo Alegre 823, P-4100 Oporto, Portugal.		Moreira, Pedro/K-5456-2012; Moreira, Pedro/U-3034-2019; Barros, Renata/AGC-2171-2022; Fernandes, Lia/A-2202-2012; Delgado, Luis/L-8035-2013; Moreira, André/AAH-9683-2020; Fonseca, João A./B-7562-2008	Moreira, Pedro/0000-0002-7035-7799; Moreira, Pedro/0000-0002-7035-7799; Barros, Renata/0000-0002-3043-1720; Fernandes, Lia/0000-0002-3391-0647; Delgado, Luis/0000-0003-2375-9071; Moreira, André/0000-0002-7294-9296; Fonseca, João A./0000-0002-0887-8796				Buchvald F, 2005, J ALLERGY CLIN IMMUN, V115, P1130, DOI 10.1016/j.jaci.2005.03.020; de Winter-de Groot KM, 2005, J ALLERGY CLIN IMMUN, V115, P419, DOI 10.1016/j.jaci.2004.11.025; Fantuzzi G, 2005, J ALLERGY CLIN IMMUN, V115, P911, DOI 10.1016/j.jaci.2005.02.023; Fonseca JA, 2005, CHEST, V128, P1258, DOI 10.1378/chest.128.3.1258; Ford ES, 2005, J ALLERGY CLIN IMMUN, V115, P897, DOI 10.1016/j.jaci.2004.11.050; Kazaks A, 2005, J ALLERGY CLIN IMMUN, V116, P929, DOI 10.1016/j.jaci.2005.06.005; King GG, 2005, EUR RESPIR J, V25, P896, DOI 10.1183/09031936.05.00104504; Leung TF, 2004, PEDIAT ALLERG IMM-UK, V15, P344, DOI 10.1111/j.1399-3038.2004.00164.x; Shore SA, 2005, J ALLERGY CLIN IMMUN, V115, P925, DOI 10.1016/j.jaci.2005.01.064; Slutsky AS, 1999, AM J RESP CRIT CARE, V160, P2104; Wong GWK, 2005, CLIN EXP ALLERGY, V35, P889, DOI 10.1111/j.1365-2222.2005.02263.x; World Health Organization, 2000, WHO TECHN REP SER, V894	12	38	38	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2006	117	6					1501	1502		10.1016/j.jaci.2006.02.027	http://dx.doi.org/10.1016/j.jaci.2006.02.027			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	053UX	16751020				2022-12-18	WOS:000238332300047
J	Barternes, KR; Cooper, KM; Drain, KL; Kita, H				Barternes, KR; Cooper, KM; Drain, KL; Kita, H			Secretory IgA induces antigen-independent eosinophil survival and cytokine production without inducing effector functions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						human; eosinophils; mucosa; secretory IgA; innate immunity; immunomodulation	PLATELET-ACTIVATING-FACTOR; FC-ALPHA RECEPTOR; ASTHMATIC AIRWAY; GENE-EXPRESSION; CELL-SURVIVAL; MAST-CELLS; DEGRANULATION; CHALLENGE; PATHWAYS; IL-5	Background: Eosinophils in human beings reside in tissues, especially the mucosal tissues of the gastrointestinal tract and inflamed airways. Secretory IgA (S-IgA) is the predominant antibody secreted by these tissues and likely plays a role in the innate immune response. Objective: Because eosinophils and S-IgA are often colocalized in mucosal tissues, we examined the potential regulatory effects of S-IgA without antigens on survival, gene expression, and effector functions of human eosinophils. Methods: Eosinophils were incubated with S-IgA in solution without antigens (soluble S-IgA) or with S-IgA immobilized to mimic multivalent antigen cross-linking. Eosinophil activation was monitored by superoxide anion generation and degranulation. Survival was assessed between 24 and 96 hours. Gene and protein expression were examined by microarray and ELISA. Eosinophil lysates were examined by immunoblot for extracellular signal-regulated kinase (ERK) phosphorylation. Results: Immobilized S-IgA stimulated eosinophil superoxide production and degranulation; soluble S-IgA did not. Although immobilized S-IgA inhibited eosinophil survival in vitro, soluble S-IgA enhanced survival; this involved autocrine production of GM-CSR Soluble S-IgA without antigens induced increases in mRNA levels of various cytokines, chemokines, signal transduction molecules, antiapoptotic factors, and cell surface markers. By using ELISA, we confirmed protein expression of selected mediators. Eosinophil interaction with soluble S-IgA likely involves FcciRI (CD89) and ERK pathway activation. Conclusion: Secretory IgA without multivalent antigens may regulate survival and gene expression of eosinophils. Eosinophils in mucosal tissues can be either primed for action (cytokine production and survival) or fully activated (degranulation and superoxide release) by different forms of S-IgA.	Mayo Clin, Div Allerg Dis, Dept Internal Med, Rochester, MN 55905 USA	Mayo Clinic	Kita, H (corresponding author), Mayo Clin, Div Allerg Dis, Dept Internal Med, Guggenheim Bldg 401A,200 1st St SW, Rochester, MN 55905 USA.	hirohito@mayo.edu		Cooper, Kate/0000-0001-8020-0149; Bartemes, Kathleen/0000-0003-4561-3233	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034486, R29AI034486, R56AI034486] Funding Source: NIH RePORTER; NIAID NIH HHS [AI34486] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABUGHAZALEH RI, 1989, J IMMUNOL, V142, P2393; Bartemes KR, 1999, J IMMUNOL, V162, P2982; Edwards AD, 2003, J IMMUNOL, V171, P47, DOI 10.4049/jimmunol.171.1.47; Flood-Page PT, 2003, AM J RESP CRIT CARE, V167, P199, DOI 10.1164/rccm.200208-789OC; GEORAS SN, 1992, AM J RESP CELL MOL, V7, P261, DOI 10.1165/ajrcmb/7.3.261; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177, DOI DOI 10.1016/S0065-2776(08)60351-X; Gonzalez-Espinosa C, 2003, J EXP MED, V197, P1453, DOI 10.1084/jem.20021806; Herr AB, 2003, J MOL BIOL, V327, P645, DOI 10.1016/S0022-2836(03)00149-9; HORIE S, 1994, J IMMUNOL, V152, P5457; Kalesnikoff J, 2001, IMMUNITY, V14, P801, DOI 10.1016/S1074-7613(01)00159-5; Kim JT, 1999, J IMMUNOL, V162, P4253; KITA H, 2003, MIDDLETONS ALLERGY P, P305; Kitaura J, 2004, J IMMUNOL, V173, P4317, DOI 10.4049/jimmunol.173.7.4317; Kitaura J, 2003, P NATL ACAD SCI USA, V100, P12911, DOI 10.1073/pnas.1735525100; Lacy P, 2000, CHEM IMMUNOL, V76, P134; Lee JJ, 2004, SCIENCE, V305, P1773, DOI 10.1126/science.1099472; Liu LY, 2002, J IMMUNOL, V169, P6452, DOI 10.4049/jimmunol.169.11.6452; LUM LG, 1979, J IMMUNOL, V122, P65; MALISZEWSKI CR, 1985, J IMMUNOL, V135, P3878; Matthews AN, 1998, P NATL ACAD SCI USA, V95, P6273, DOI 10.1073/pnas.95.11.6273; MESTECKY J, 1987, ADV IMMUNOL, V40, P153, DOI 10.1016/S0065-2776(08)60240-0; MONTEIRO RC, 1993, J CLIN INVEST, V92, P1681, DOI 10.1172/JCI116754; MONTEIRO RC, 1990, J EXP MED, V171, P597, DOI 10.1084/jem.171.3.597; Monteiro RC, 2003, ANNU REV IMMUNOL, V21, P177, DOI 10.1146/annurev.immunol.21.120601.141011; Motegi Y, 1998, J IMMUNOL, V161, P4340; Ohno I, 1996, AM J RESP CELL MOL, V15, P404, DOI 10.1165/ajrcmb.15.3.8810646; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Schmid-Grendelmeier P, 2002, J IMMUNOL, V169, P1021, DOI 10.4049/jimmunol.169.2.1021; Underdown B. J., 1994, HDB MUCOSAL IMMUNOLO, P79; WALLEN N, 1991, J IMMUNOL, V147, P3490; Wines BD, 1999, J IMMUNOL, V162, P2146; Wong CK, 2004, CRIT REV CL LAB SCI, V41, P79, DOI 10.1080/10408360490427624	32	38	38	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2005	116	4					827	835		10.1016/j.jaci.2005.07.014	http://dx.doi.org/10.1016/j.jaci.2005.07.014			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IF	16210057				2022-12-18	WOS:000235686600017
J	Simons, FER; Simons, KJ				Simons, FER; Simons, KJ			Levocetirizine: Pharmacokinetics and pharmacodynamics in children age 6 to 11 years	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						H-1-antihistamine; levocetirizine; pharmacokinetics; pharmacodynamics; wheal; flare; allergic rhinitis; urticaria; children	CLINICAL-PHARMACOLOGY; POPULATION PHARMACOKINETICS; CETIRIZINE; DISPOSITION; ABSORPTION; EFFICACY; THERAPY; INFANTS	Background: The pharmacokinetics and pharmaeodynamics of medications may differ between children and adults, necessitating different dose regimens for different age groups. Levocetirizine, the active enantiomer of cetirizine, is used in the treatment of allergic rhinitis and chronic urticaria in Europe. Its pbarmacokinetics and pharmacodynamics have not yet been studied prospectively in school-age children. Objectives: This study was performed to investigate levocetirizine pharmacokinetic disposition and pharmacodynamics in relation to skin reactivity to histamine in children aged 6 to 11 years. Methods: Blood samples were obtained at predose baseline and at defined intervals up to and including 28 hours after a 5-mg levocetirizine dose. Concurrently, epicutaneous tests with histamine phosphate, 1 mg/mL, were performed. Wheals and flares were traced at 10 minutes, and the areas were measured with a computerized digitizing system. Results: In children aged 8.6 +/- 0.4 years (+/- SEM), the peak levocetirizine concentration was 450 +/- 37 ng/mL, and the time at which peak concentrations occurred was 1.2 +/- 0.2 hours. The terminal elimination half-life was 5.7 +/- 0.2 hours, the oral clearance was 0.82 +/- 0.05 mL/min/kg, and the volume of distribution was 0.4 +/- 0.02 L/kg. Compared with predose areas, the wheals and flares produced by histamine phosphate were significantly decreased from 1 to 28 hours, inclusive (P < .05). Mean maximum inhibition of wheals and flares occurred from 2 to 10 hours (97% +/- 1%) and from 2 to 24 hours (93% +/- 1%), respectively. Conclusions: Levocefirizine had an onset of action within I hour and provided significant peripheral antihistamirtic activity for 28 hours after a single dose. Once-daily dosing may be optimal in children aged 6 to 11 years, as it is in adults.	Univ Manitoba, Fac Med, Canadian Inst Hlth Res, Natl Training Program Allergy & Asthma,Dept Immun, Winnipeg, MB R3T 2N2, Canada; Univ Manitoba, Fac Med, Fac Pharm, Dept Pediat & Child Hlth, Winnipeg, MB R3T 2N2, Canada	Institute for Work & Health; University of Manitoba; University of Manitoba	Simons, FER (corresponding author), 820 Sherbrook St, Winnipeg, MB R3A 1R9, Canada.	lmcniven@hsc.mb.ca						Bachert C, 2004, J ALLERGY CLIN IMMUN, V114, P838, DOI 10.1016/j.jaci.2004.05.070; Baltes E, 2001, FUNDAM CLIN PHARM, V15, P269, DOI 10.1046/j.1472-8206.2001.00035.x; Benedetti MS, 2001, EUR J CLIN PHARMACOL, V57, P571; Cranswick NE, 2004, CLIN PHARMACOL THER, V75, pP46, DOI 10.1016/j.clpt.2003.11.174; DESAGER JP, 1993, CLIN PHARMACOL THER, V53, P431, DOI 10.1038/clpt.1993.47; Devalia JL, 2001, ALLERGY, V56, P50, DOI 10.1034/j.1398-9995.2001.00726.x; HOLFORD NHG, 1981, CLIN PHARMACOKINET, V6, P429, DOI 10.2165/00003088-198106060-00002; Hussein Z, 2005, BRIT J CLIN PHARMACO, V59, P28, DOI 10.1111/j.1365-2125.2005.02242.x; Kearns GL, 2003, NEW ENGL J MED, V349, P1157, DOI 10.1056/NEJMra035092; Lin Chin-Chung, 1995, Am J Ther, V2, P504, DOI 10.1097/00045391-199506000-00011; Mentre F, 2001, J PHARMACOKINET PHAR, V28, P299, DOI 10.1023/A:1011583210549; PARIENTEKHAYAT A, 1995, INT J CLIN PHARM TH, V33, P340; POTTER PC, 2005, IN PRESS ANN ALLERGY; Salmond CH, 2005, J NEUROTRAUM, V22, P613, DOI 10.1089/neu.2005.22.613; SCHMIDTREDEMANN B, 1986, INT J CLIN PHARM TH, V24, P496; SIMONS FER, 1982, J ALLERGY CLIN IMMUN, V69, P376, DOI 10.1016/0091-6749(82)90149-X; Simons FER, 2005, PEDIAT ALLERG IMM-UK, V16, P97, DOI 10.1111/j.1399-3038.2005.00240.x; Simons FER, 2004, NEW ENGL J MED, V351, P2203, DOI 10.1056/NEJMra033121; Simons FER, 2003, J ALLERGY CLIN IMMUN, V111, P1244, DOI 10.1067/mai.2003.1496; Simons FER, 1996, J ALLERGY CLIN IMMUN, V98, P1062, DOI 10.1016/S0091-6749(96)80192-8; Simons FER, 1999, J ALLERGY CLIN IMMUN, V103, P223, DOI 10.1016/S0091-6749(99)70494-X; Simons FER, 2000, PEDIATR ALLERGY IMMU, V11, P116, DOI 10.1034/j.1399-3038.2000.00045.x; SIMONS FER, 1993, J PEDIATR-US, V122, P641; SIMONS FER, 1984, J PEDIATR-US, V104, P123; SIMONS FER, 2003, MIDDLETONS ALLERGY P, P834; SIMONS FER, 2002, HISTAMINE H1 ANTIHIS, P437; SIMONS KJ, 1990, J CLIN PHARMACOL, V30, P665, DOI 10.1002/j.1552-4604.1990.tb01871.x; Spicak V, 1997, CLIN PHARMACOL THER, V61, P325; Steinbrook R, 2002, NEW ENGL J MED, V347, P1462, DOI 10.1056/NEJMhpr021646; Tillement JP, 2003, BIOCHEM PHARMACOL, V66, P1123, DOI 10.1016/S0006-2952(03)00558-6; WATSON WTA, 1989, J ALLERGY CLIN IMMUN, V84, P457, DOI 10.1016/0091-6749(89)90358-8	31	38	41	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2005	116	2					355	361		10.1016/j.jaci.2005.04.010	http://dx.doi.org/10.1016/j.jaci.2005.04.010			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017ID	16083790				2022-12-18	WOS:000235686400018
J	Dirks, CG; Pedersen, MH; Platzer, MH; Bindsley-Jensen, C; Skov, PS; Poulsen, LK				Dirks, CG; Pedersen, MH; Platzer, MH; Bindsley-Jensen, C; Skov, PS; Poulsen, LK			Does absorption across the buccal mucosa explain early onset of food-induced allergic systemic reactions?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							PROTEIN		Natl Univ Hosp, Lab Med Allergol & Reflab, Allergy Clin, DK-2100 Copenhagen, Denmark; Odense Univ Hosp, Dept Dermatol, DK-5000 Odense, Denmark	University of Southern Denmark; Odense University Hospital	Dirks, CG (corresponding author), Natl Univ Hosp, Lab Med Allergol & Reflab, Allergy Clin, FIN 7551,Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	lkpallgy@inet.uni2.dk	Poulsen, Lars K/J-3065-2019; Bindslev-Jensen, Carsten/H-1877-2011	Poulsen, Lars K/0000-0002-1730-847X; Bindslev-Jensen, Carsten/0000-0002-8940-038X				HUSBY S, 1985, SCAND J IMMUNOL, V22, P83, DOI 10.1111/j.1365-3083.1985.tb01862.x; PAGANELLI R, 1980, J IMMUNOL METHODS, V37, P333, DOI 10.1016/0022-1759(80)90319-1; POULSEN LK, 2003, IMMUNOCHEMICAL BIOL, V94, P97; Wensing M, 2002, J ALLERGY CLIN IMMUN, V110, P915, DOI 10.1067/mai.2002.129235; Wilson SJ, 1935, AM J DIS CHILD, V50, P49, DOI 10.1001/archpedi.1935.01970070058005	5	38	39	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2005	115	6					1321	1323		10.1016/j.jaci.2005.03.027	http://dx.doi.org/10.1016/j.jaci.2005.03.027			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	935WZ	15940158	Bronze			2022-12-18	WOS:000229815400038
J	Joseph-Bowen, J; de Klerk, N; Holt, PG; Sly, PD				Joseph-Bowen, J; de Klerk, N; Holt, PG; Sly, PD			Relationship of asthma, atopy, and bronchial responsiveness to serum eosinophil cationic proteins in early childhood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						childhood asthma; eosinophilic cationic protein; atopy; skin prick tests; methacholine challenge	AIRWAY INFLAMMATION; CHILDREN; COHORT; HYPERRESPONSIVENESS; ASSOCIATION; MARKERS; LIFE; RISK	Background: The relationship between atopy, asthma, and eosinophilic inflammation is less clear in early childhood than later in life. Objective: We sought to determine the relationships between asthma, atopy, and serum eosinophil cationic protein (ECP), a biomarker of eosinophil activation, in 6-year-old children. Methods: Serum ECP levels were available from 968 six-year-old children who were part of a longitudinal birth cohort being assessed for asthma and atopy. Detailed clinical history and examination, lung function testing, methacholine challenge, and skin prick testing to 4 common allergens were undertaken. Subgroups of the children were compared by using t tests, ANOVA, chi(2) tests, and regression analysis. Results: One hundred ninety-one (19.7%) children had current asthma, with 114 (59.7%) of these being atopic. The mean serum ECP level for the entire group was 18.0 mug/L (range, 2.0-146.0 mug/L), with no difference between male and female patients. Serum ECP was higher in atopic children (20.5 +/- 18.4), those with asthma (22.4 +/- 19.6), and those with asthma and atopy (26.6 +/- 22.4; all P < .001 compared with children with no asthma or atopy [16.1 +/- 15.9]). Serum ECP levels, were highest in children with severe asthma (P < .001), especially in those with concurrent atopy. Severity of atopy, judged on the basis of wheal size or derived variables combining wheal size and the number of positive skin tests, was a major determinant of serum ECP. Heightened methacholine responsiveness was not associated with increased serum ECP levels. Conclusion: The higher serum ECP levels seen in 6-year-old children with current asthma and more severe atopy suggest that atopy and eosinophilic inflammation are important in driving this clinical phenotype and that this might represent asthma that persists.	Univ Western Australia, Telethon Inst Child Hlth Res, Nedlands, WA 6009, Australia; Univ Western Australia, Ctr Child Hlth Res, Nedlands, WA 6009, Australia	Telethon Kids Institute; University of Western Australia; University of Western Australia	Joseph-Bowen, J (corresponding author), Univ Western Australia, Telethon Inst Child Hlth Res, Nedlands, WA 6009, Australia.		de Klerk, Nicholas H/D-8388-2016; Study, Raine/K-4517-2013; Sly, Peter D/F-1486-2010; Holt, Patrick/H-1548-2011	de Klerk, Nicholas H/0000-0001-9223-0767; Sly, Peter D/0000-0001-6305-2201; Holt, Patrick/0000-0003-1193-0935				JAMES AL, 1989, AM REV RESPIR DIS, V139, P242, DOI 10.1164/ajrccm/139.1.242; Jeffery PK, 2000, RESP MED, V94, pS9, DOI 10.1016/S0954-6111(00)90127-6; Joseph-Bowen J, 2004, AM J RESP CRIT CARE, V169, P850, DOI 10.1164/rccm.200304-556OC; JUNTUNENBACKMAN K, 1993, J ALLERGY CLIN IMMUN, V92, P34, DOI 10.1016/0091-6749(93)90034-D; Kaleyias J, 2002, PEDIAT ALLERG IMM-UK, V13, P368, DOI 10.1034/j.1399-3038.2002.02077.x; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; Martinez FD, 1997, PEDIATR PULM, P9; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Morahan G, 2002, LANCET, V360, P455, DOI 10.1016/S0140-6736(02)09676-9; NEWNHAM JP, 1993, LANCET, V342, P887, DOI 10.1016/0140-6736(93)91944-H; Oddy WH, 1999, BMJ-BRIT MED J, V319, P815, DOI 10.1136/bmj.319.7213.815; PAPER P, 1993, ALLERGY          S14, V48, P48; Peat JK, 1996, ALLERGY, V51, P804, DOI 10.1111/j.1398-9995.1996.tb00026.x; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; Rao R, 1996, CLIN EXP ALLERGY, V26, P789; Rasmussen F, 2002, AM J RESP CRIT CARE, V165, P1480, DOI 10.1164/rccm.2108009; Rudin A, 2001, ALLERGY, V56, P1042, DOI 10.1034/j.1398-9995.2001.00991.x; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Ward C, 2002, THORAX, V57, P309, DOI 10.1136/thorax.57.4.309; Woolcock AJ, 2001, MED J AUSTRALIA, V175, P141, DOI 10.5694/j.1326-5377.2001.tb143062.x; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760; ZIMMERMAN B, 1993, CLIN EXP ALLERGY, V23, P564, DOI 10.1111/j.1365-2222.1993.tb00895.x; ZIMMERMAN B, 1993, CLIN EXP ALLERGY, V23, P8, DOI 10.1111/j.1365-2222.1993.tb00373.x	23	38	47	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2004	114	5					1040	1045		10.1016/j.jaci.2004.07.051	http://dx.doi.org/10.1016/j.jaci.2004.07.051			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	870HI	15536407				2022-12-18	WOS:000225047800007
J	Williams, LK; Peterson, EL; Ownby, DR; Johnson, CC				Williams, LK; Peterson, EL; Ownby, DR; Johnson, CC			The relationship between early fever and allergic sensitization at age 6 to 7 years	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						hygiene hypothesis; fever; allergy; allergic sensitization; atopy; seroatopy; infection; birth cohort	EARLY-LIFE; RESPIRATORY-INFECTIONS; HAY-FEVER; 1ST YEAR; ASTHMA; ATOPY; RISK; CHILDHOOD; CHILDREN; SIBLINGS	Background: The hygiene hypothesis suggests that early infections might protect against later allergic sensitization. Objective: The purpose of this study was to determine whether fevers before age 1 year were associated with allergic sensitization at age 6 to 7 years. Methods: Eight hundred thirty-five children from suburban Detroit, Michigan, were enrolled at birth. Clinic records from their first year were abstracted for episodes of fever, antibiotic use, and respiratory infections. Fever was defined as a rectal temperature of 38.3degreesC (101degreesF) or greater or its equivalent measured at another site. At age 6 to 7 years, 441 children underwent allergy testing. The primary outcome measures were atopy ( greater than or equal to 1 positive skin prick test result), seroatopy (> 1 positive allergen-specific IgE level), and allergic sensitization (either seroatopy or atopy). Results: By age 1 year, 207 (46.9%) of the 441 participants had a documented fever. Among children with 0, 1, or 2 or more fevers in the first year, 33.3%, 31.3%, and 26.0% demonstrated atopy at age 6 to 7 years, respectively (P =.504); 43.4%, 39.7%, and 25.0% had seroatopy, respectively (P =.032); and 50.0 %, 46.7%, and 31.3% had allergic sensitization, respectively (P.028). After adjusting for potential confounders, each febrile episode in the first year was associated with reduced odds for allergic sensitization (adjusted odds ratio, 0.69; 95% CI, 0.47-1.00). Febrile upper respiratory tract infections, in particular, were associated with lower odds of allergic sensitization (adjusted odds ratio, 0.55; 95 % CI, 0.31-0.97) per episode. Conclusion: This study provides direct support for the hygiene hypothesis because children with fevers before age 1 year were less likely to demonstrate allergic sensitivity at age 6 to 7 years.	Henry Ford Hlth Syst, Ctr Hlth Serv Res, Detroit, MI 48202 USA; Henry Ford Hlth Syst, Div Geriatr Med, Dept Internal Med, Detroit, MI 48202 USA; Henry Ford Hlth Syst, Dept Biostat & Res Epidemiol, Detroit, MI 48202 USA; Wayne State Univ, Natl Inst Environm Hlth Sci Ctr, Mol & Cellular Toxicol, Detroit, MI USA; Med Coll Georgia, Dept Pediat, Sect Allergy & Immunol, Augusta, GA 30912 USA	Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; Wayne State University; University System of Georgia; Augusta University	Williams, LK (corresponding author), Henry Ford Hlth Syst, Ctr Hlth Serv Res, 1 Ford Pl,3A, Detroit, MI 48202 USA.			Johnson, Christine Cole/0000-0002-6864-6604	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R03HL067427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI050681, R01AI024156, R01AI050681] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006639] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 67427] Funding Source: Medline; NIAID NIH HHS [AI 50681, AI 24156] Funding Source: Medline; NIEHS NIH HHS [P03ES06639] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Beasley R, 2000, J ALLERGY CLIN IMMUN, V105, pS466, DOI 10.1016/S0091-6749(00)90044-7; Bodner C, 2000, THORAX, V55, P383, DOI 10.1136/thorax.55.5.383; Braback L, 1998, CLIN EXP ALLERGY, V28, P936; BROWN RD, 1992, CLIN PEDIATR, V31, P523; Calvani M, 2002, EUR RESPIR J, V20, P391, DOI 10.1183/09031936.02.00274502; COGSWELL JJ, 1982, BRIT MED J, V284, P1011, DOI 10.1136/bmj.284.6321.1011; Craig JV, 2002, LANCET, V360, P603, DOI 10.1016/S0140-6736(02)09783-0; ELRADHI SA, 1994, FEVER PAEDIAT PRACTI, P15; Forastiere F, 1997, EPIDEMIOLOGY, V8, P566, DOI 10.1097/00001648-199709000-00015; Illi S, 2001, BMJ-BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; Johnson CC, 2002, EPIDEMIOL REV, V24, P154, DOI 10.1093/epirev/mxf013; Krabbe KS, 2001, CLIN DIAGN LAB IMMUN, V8, P333, DOI 10.1128/CDLI.8.2.333-338.2001; Kramer U, 1999, LANCET, V353, P450, DOI 10.1016/S0140-6736(98)06329-6; Mannino D M, 1998, MMWR CDC Surveill Summ, V47, P1; MARTINEZ FD, 1994, THORAX, V49, P1189, DOI 10.1136/thx.49.12.1189; Martinez FD, 1999, LANCET, V354, pS12, DOI 10.1016/S0140-6736(99)90437-3; MARTINEZ FD, 1995, THORAX, V50, P1067, DOI 10.1136/thx.50.10.1067; Matricardi PM, 1998, J ALLERGY CLIN IMMUN, V101, P439, DOI 10.1016/S0091-6749(98)70350-1; Matricardi PM, 1997, BRIT MED J, V314, P999, DOI 10.1136/bmj.314.7086.999; Netea MG, 2000, CLIN INFECT DIS, V31, pS178, DOI 10.1086/317513; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Ownby DR, 2000, AM J RESP CRIT CARE, V161, P1578, DOI 10.1164/ajrccm.161.5.9812156; Pajkrt D, 1997, J IMMUNOL, V158, P3971; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Prescott SL, 1998, J IMMUNOL, V160, P4730; Rasanen M, 1997, CLIN EXP ALLERGY, V27, P515, DOI 10.1111/j.1365-2222.1997.tb00739.x; ROMAGNANI S, 1992, IMMUNOL TODAY, V13, P379, DOI 10.1016/0167-5699(92)90083-J; Rona RJ, 1997, J ALLERGY CLIN IMMUN, V99, P454, DOI 10.1016/S0091-6749(97)70070-8; Sears MR, 2002, LANCET, V360, P901, DOI 10.1016/S0140-6736(02)11025-7; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shtrichman R, 2001, CURR OPIN MICROBIOL, V4, P251, DOI 10.1016/S1369-5274(00)00199-5; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Strachan DP, 1997, J ALLERGY CLIN IMMUN, V99, P6, DOI 10.1016/S0091-6749(97)81038-X; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; von Mutius E, 1999, EUR RESPIR J, V14, P4, DOI 10.1034/j.1399-3003.1999.14a03.x; VONMUTIUS E, 1994, BRIT MED J, V308, P692, DOI 10.1136/bmj.308.6930.692; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490	40	38	39	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2004	113	2					291	296		10.1016/j.jaci.2003.11.010	http://dx.doi.org/10.1016/j.jaci.2003.11.010			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	773EX	14767444				2022-12-18	WOS:000188885700017
J	Rodier, F; Gautrin, D; Ghezzo, H; Malo, JL				Rodier, F; Gautrin, D; Ghezzo, H; Malo, JL			Incidence of occupational rhinoconjunctivitis and risk factors in animal-health apprentices	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE-mediated hypersensitivity; occupational exposure; occupational rhinoconjunctivitis; occupational asthma; asthma	LABORATORY-ANIMALS; HOST DETERMINANTS; SENSITIZATION; RHINITIS; ASTHMA; METHACHOLINE; PREVALENCE; SYMPTOMS; EXPOSURE; AGENTS	Background: Exposure to laboratory animals often causes the appearance of immunologic sensitization and symptoms. Objective: Our aim was to determine the incidence of occupational rhinoconjunctivitis and the timing of symptoms and their determinants in apprentices starting exposure to laboratory animals. Methods: Data from 387 (92.8%) of 417 students entering career programs in animal health in 5 schools were kept for analysis. Questionnaires and skin prick tests with common and occupational inhalants were carried out on entry and at follow-up visits scheduled at 8, 20, 32, and 44 months, depending on the schools. Responsiveness to inhaled methacholine was assessed at entry. Results: Ninety-three (24%) subjects showed incident occupational rhinoconjunctivitis symptoms, and 37 (9.6%) had symptoms combined with skin sensitization to an animal-derived allergen. Symptoms such as sneezing, rhinorrhea, and itchy eyes tended to develop early in the course of exposure. In two thirds of the subjects, symptoms persisted at subsequent visits. In a multivariate analysis the determinants of the appearance of rhinoconjunctivitis with or without allergic sensitization included sensitization to grass pollens (odds ratio [OR], 1.78; 95% CI, 0.99-3.19), as well as nasal (rhinorrhea in contact with dust: OR, 1.79; 95% Cl, 1.05-3.05) and bronchial symptoms (chest tightness: OR, 3.31; 95% CI, 0.98-11.25; cough on exposure to strong odors: OR, 1.88; 95% CI, 0.98-3.59). Conclusion: The incidence of occupational rhinoconjunctivitis symptoms with or without immunologic sensitization is high in apprentices starting exposure to laboratory animals. Symptoms related to histamine release are common in the early course of exposure. Determinants include immunologic and target-organ susceptibility.	Hop Sacre Coeur, Dept Chest Med, Montreal, PQ H4J 1C5, Canada; Univ Montreal, Montreal, PQ H3C 3J7, Canada	Universite de Montreal; Universite de Montreal	Gautrin, D (corresponding author), Hop Sacre Coeur, Dept Chest Med, 5400 Gouin Blvd W, Montreal, PQ H4J 1C5, Canada.							Baraniuk JN, 2000, IMMUNOL ALLERGY CLIN, V20, P245, DOI 10.1016/S0889-8561(05)70147-8; BURNEY PGJ, 1989, EUR RESPIR J, V2, P940; Christiani DC, 1999, ASTHMA WORKPLACE, P331; Cullinan P, 1999, EUR RESPIR J, V13, P1139, DOI 10.1034/j.1399-3003.1999.13e33.x; Gautrin D, 2000, AM J RESP CRIT CARE, V162, P1222, DOI 10.1164/ajrccm.162.4.2001023; Gautrin D, 2002, ALLERGY, V57, P913, DOI 10.1034/j.1398-9995.2002.23636.x; Gautrin D, 2001, EUR RESPIR J, V17, P904, DOI 10.1183/09031936.01.17509040; Gautrin D, 1997, AM J RESP CRIT CARE, V155, P1841, DOI 10.1164/ajrccm.155.6.9196084; Gautrin D, 2001, AM J RESP CRIT CARE, V163, P899, DOI 10.1164/ajrccm.163.4.2008011; Gordon S, 1999, ASTHMA WORKPLACE, P399; Malo JL, 1997, EUR RESPIR J, V10, P1513, DOI 10.1183/09031936.97.10071513; MALO JL, 1983, AM REV RESPIR DIS, V128, P8, DOI 10.1164/arrd.1983.128.1.8; Monso E, 2000, AM J RESP CRIT CARE, V161, P1508, DOI 10.1164/ajrccm.161.5.9906113; Siracusa A, 2000, CLIN EXP ALLERGY, V30, P1519, DOI 10.1046/j.1365-2222.2000.00946.x; Troyanov S, 2000, EUR RESPIR J, V16, P9, DOI 10.1034/j.1399-3003.2000.16a03.x; Vignola AM, 2001, CLIN EXP ALLERGY, V31, P674, DOI 10.1046/j.1365-2222.2001.01115.x	16	38	39	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2003	112	6					1105	1111		10.1016/j.jaci.2003.08.011	http://dx.doi.org/10.1016/j.jaci.2003.08.011			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	752HC	14657867	Bronze			2022-12-18	WOS:000187154200012
J	Chitnis, T; Khoury, SJ				Chitnis, T; Khoury, SJ			Role of costimulatory pathways in the pathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						B7-1; B7-2; CD28; CD40; CD137 (4-IBB); CD154; (CD40 ligand); costimulation; CTLA-4 (CD152); CTLA41g; experimental autoimmune encephalomyelitis; inducible costimulatory molecule; multiple sclerosis; programmed death pathway 1; programmed death pathway ligand 1; programmed death pathway ligand 2; OX40 (CD134); OX40 ligand (CD134L)	MYELIN BASIC-PROTEIN; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; T-CELL PROLIFERATION; NECROSIS-FACTOR-ALPHA; LONG-TERM SURVIVAL; B-CELL; OX40 LIGAND; MONOCLONAL-ANTIBODY; IN-VITRO	Multiple sclerosis is an immune-mediated disorder of the central nervous system. T lymphocytes are thought to play a central role in the initiation and potentially in the propagation of this disease. Two signals are required for T-cell activation. The first signal consists of the interaction of the T-cell receptor with antigen presented by the MHC molecule on antigen-presenting cells. The second signal requires engagement of costimulatory receptors on T cells with their ligands on antigen-presenting cells. Several costimulatory pathways have been shown to play an important role in T-lymphocyte activation. Here we will review the current literature on the contribution of the B7-1/2-CD28/CTLA-4, inducible costimulatory molecule-B7h, programmed death pathway 1-programmed death pathway ligand 1/ligaDd 2, CD40-CD154, OX40-OX40 ligand, and CD137-CD137 ligand pathways to the pathogenesis of multiple sclerosis and their potential roles as therapeutic targets.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Khoury, SJ (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, 77 Ave Louis Pasteur,Rm 714, Boston, MA 02115 USA.			khoury, samia/0000-0003-3198-6063				Abrams JR, 2000, J EXP MED, V192, P681, DOI 10.1084/jem.192.5.681; Agata Y, 1996, INT IMMUNOL, V8, P765, DOI 10.1093/intimm/8.5.765; Akiba H, 1999, J IMMUNOL, V162, P7058; Alegre ML, 2001, NAT REV IMMUNOL, V1, P220, DOI 10.1038/35105024; Arima T, 1996, J IMMUNOL, V156, P4916; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; Balashov KE, 1997, P NATL ACAD SCI USA, V94, P599, DOI 10.1073/pnas.94.2.599; Becher B, 2000, J NEUROIMMUNOL, V102, P44, DOI 10.1016/S0165-5728(99)00152-6; Becher B, 2001, J EXP MED, V193, P967, DOI 10.1084/jem.193.8.967; Begolka WS, 1998, J IMMUNOL, V161, P4437; BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; Bretscher PA, 1999, P NATL ACAD SCI USA, V96, P185, DOI 10.1073/pnas.96.1.185; BRUNET JF, 1987, NATURE, V328, P267, DOI 10.1038/328267a0; Carter LL, 2002, EUR J IMMUNOL, V32, P634, DOI 10.1002/1521-4141(200203)32:3<634::AID-IMMU634>3.0.CO;2-9; CAYABYAB M, 1994, J IMMUNOL, V152, P1523; Chang TT, 1999, J EXP MED, V190, P733, DOI 10.1084/jem.190.5.733; Chitnis T, 2001, J CLIN INVEST, V108, P739, DOI 10.1172/JCI200112563; Chitnis T, 2001, J CLIN INVEST, V107, P575, DOI 10.1172/JCI11220; Constantinescu CS, 1999, J NEUROL SCI, V171, P60, DOI 10.1016/S0022-510X(99)00249-X; Coyle AJ, 2000, IMMUNITY, V13, P95, DOI 10.1016/S1074-7613(00)00011-X; Coyle AJ, 2001, NAT IMMUNOL, V2, P203, DOI 10.1038/85251; DALCANTO MC, 1995, MICROSC RES TECHNIQ, V32, P215, DOI 10.1002/jemt.1070320305; Dangond F, 1997, J NEUROIMMUNOL, V76, P132, DOI 10.1016/S0165-5728(97)00043-X; DeBenedette MA, 1997, J IMMUNOL, V158, P551; DESIMONE R, 1995, J NEUROPATH EXP NEUR, V54, P175; Dong C, 2001, NATURE, V409, P97, DOI 10.1038/35051100; Dong HD, 1999, NAT MED, V5, P1365; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Dyment DA, 2002, J NEUROIMMUNOL, V123, P193, DOI 10.1016/S0165-5728(01)00493-3; Eppihimer MJ, 2002, MICROCIRCULATION, V9, P133, DOI 10.1038/sj/mn/7800123; Filion LG, 2003, CLIN IMMUNOL, V106, P127, DOI 10.1016/S1521-6616(02)00028-1; FINCK BK, 1994, SCIENCE, V265, P1225, DOI 10.1126/science.7520604; Frasca L, 1997, EUR J IMMUNOL, V27, P3191, DOI 10.1002/eji.1830271216; FREEMAN GJ, 1993, SCIENCE, V262, P907, DOI 10.1126/science.7694362; Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027; FREEMAN GJ, 1991, J EXP MED, V174, P625, DOI 10.1084/jem.174.3.625; Fukazawa T, 1999, J NEUROL SCI, V171, P49, DOI 10.1016/S0022-510X(99)00251-8; Futagawa T, 2002, INT IMMUNOL, V14, P275, DOI 10.1093/intimm/14.3.275; Gallon L, 1997, J IMMUNOL, V159, P4212; GENE K, 1997, J CLIN INVEST, V99, P2664, DOI DOI 10.1172/JCI119455; Gerritse K, 1996, P NATL ACAD SCI USA, V93, P2499, DOI 10.1073/pnas.93.6.2499; GIMMI CD, 1993, P NATL ACAD SCI USA, V90, P6586, DOI 10.1073/pnas.90.14.6586; Girvin AR, 2000, J IMMUNOL, V164, P136, DOI 10.4049/jimmunol.164.1.136; Gramaglia I, 2000, EUR J IMMUNOL, V30, P392, DOI 10.1002/1521-4141(200002)30:2<392::AID-IMMU392>3.0.CO;2-H; Gramaglia I, 1998, J IMMUNOL, V161, P6510; Gramaglia I, 2000, J IMMUNOL, V165, P3043, DOI 10.4049/jimmunol.165.6.3043; Greenwald RJ, 2001, IMMUNITY, V14, P145, DOI 10.1016/S1074-7613(01)00097-8; Grewal IS, 1996, SCIENCE, V273, P1864, DOI 10.1126/science.273.5283.1864; Grohmann U, 2002, NAT IMMUNOL, V3, P1097, DOI 10.1038/ni846; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; Heinisch IVWM, 2000, EUR J IMMUNOL, V30, P3441, DOI 10.1002/1521-4141(2000012)30:12<3441::AID-IMMU3441>3.0.CO;2-L; Howard LM, 1999, J CLIN INVEST, V103, P281, DOI 10.1172/JCI5388; Hurtado JC, 1997, J IMMUNOL, V158, P2600; Hutloff A, 1999, NATURE, V397, P263, DOI 10.1038/16717; Ichikawa HT, 2002, J IMMUNOL, V169, P2781, DOI 10.4049/jimmunol.169.5.2781; Imura A, 1996, J EXP MED, V183, P2185, DOI 10.1084/jem.183.5.2185; Ishida M, 2002, IMMUNOL LETT, V84, P57, DOI 10.1016/S0165-2478(02)00142-6; Issazadeh S, 1998, J IMMUNOL, V161, P1104; ISSAZADEH S, 1995, J NEUROIMMUNOL, V61, P205, DOI 10.1016/0165-5728(95)00100-G; Jabs C, 2002, EUR J IMMUNOL, V32, P2687, DOI 10.1002/1521-4141(200209)32:9<2687::AID-IMMU2687>3.0.CO;2-1; JENKINS MK, 1991, J IMMUNOL, V147, P2461; Jensen J, 2001, EUR J NEUROL, V8, P321, DOI 10.1046/j.1468-1331.2001.00232.x; JOHNS LD, 1993, J NEUROIMMUNOL, V47, P1, DOI 10.1016/0165-5728(93)90278-7; Kaleeba JAR, 1998, INT IMMUNOL, V10, P453, DOI 10.1093/intimm/10.4.453; Kantarci OH, 2003, J NEUROIMMUNOL, V134, P133, DOI 10.1016/S0165-5728(02)00395-8; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; Karandikar NJ, 1996, J EXP MED, V184, P783, DOI 10.1084/jem.184.2.783; Karni A, 2002, J NEUROIMMUNOL, V125, P134, DOI 10.1016/S0165-5728(02)00018-8; Kelsall BL, 1996, ANN NY ACAD SCI, V795, P116, DOI 10.1111/j.1749-6632.1996.tb52660.x; Khoury SJ, 1996, J IMMUNOL, V157, P3700; KHOURY SJ, 1995, J IMMUNOL, V155, P4521; Kirk AD, 1997, P NATL ACAD SCI USA, V94, P8789, DOI 10.1073/pnas.94.16.8789; KLAUS SJ, 1994, J IMMUNOL, V152, P5643; Koch F, 1996, J EXP MED, V184, P741, DOI 10.1084/jem.184.2.741; Kopf M, 1999, IMMUNITY, V11, P699, DOI 10.1016/S1074-7613(00)80144-2; Krummel MF, 1996, J EXP MED, V183, P2533, DOI 10.1084/jem.183.6.2533; KUCHROO VK, 1995, CELL, V80, P707, DOI 10.1016/0092-8674(95)90349-6; KURUVILLA AP, 1991, P NATL ACAD SCI USA, V88, P2918, DOI 10.1073/pnas.88.7.2918; Kwon BS, 1997, J BIOL CHEM, V272, P14272, DOI 10.1074/jbc.272.22.14272; KWON BS, 1989, P NATL ACAD SCI USA, V86, P1963, DOI 10.1073/pnas.86.6.1963; Laman JD, 1998, J NEUROIMMUNOL, V86, P30, DOI 10.1016/S0165-5728(98)00024-1; Lane P, 2000, J EXP MED, V191, P201, DOI 10.1084/jem.191.2.201; Lane Peter J. L., 2001, Current Opinion in Pharmacology, V1, P409, DOI 10.1016/S1471-4892(01)00071-6; Latchman Y, 2001, NAT IMMUNOL, V2, P261, DOI 10.1038/85330; Lee HW, 2002, J IMMUNOL, V169, P4882, DOI 10.4049/jimmunol.169.9.4882; LENSCHOW DJ, 1995, J EXP MED, V181, P1145, DOI 10.1084/jem.181.3.1145; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; Lenz DC, 1999, J IMMUNOL, V163, P1763; Ligers A, 1999, J NEUROIMMUNOL, V97, P182, DOI 10.1016/S0165-5728(99)00072-7; Lim HY, 2002, CELL BIOL INT, V26, P271, DOI 10.1006/cbir.2001.0847; LINDSLEY MD, 1989, J IMMUNOL, V142, P2677; Ling V, 2000, J IMMUNOL, V164, P1653, DOI 10.4049/jimmunol.164.4.1653; LINSLEY PS, 1994, IMMUNITY, V1, P793, DOI 10.1016/S1074-7613(94)80021-9; Lublin FD, 1996, NEUROLOGY, V46, P907, DOI 10.1212/WNL.46.4.907; LUCAS PJ, 1995, J IMMUNOL, V154, P5757; Lucchinetti C, 2001, CURR OPIN NEUROL, V14, P259, DOI 10.1097/00019052-200106000-00002; Lucchinetti C, 2000, ANN NEUROL, V47, P707, DOI 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q; Mandelbrot DA, 1999, J EXP MED, V189, P435, DOI 10.1084/jem.189.2.435; Masterman T, 2002, J NEUROIMMUNOL, V131, P208, DOI 10.1016/S0165-5728(02)00274-6; McAdam AJ, 2000, J IMMUNOL, V165, P5035, DOI 10.4049/jimmunol.165.9.5035; McAdam AJ, 1998, IMMUNOL REV, V165, P231; McAdam AJ, 2001, NATURE, V409, P102, DOI 10.1038/35051107; Melero I, 1997, NAT MED, V3, P682, DOI 10.1038/nm0697-682; Mena E, 1999, ACTA NEUROL SCAND, V100, P92; Miller SD, 1995, IMMUNITY, V3, P739, DOI 10.1016/1074-7613(95)90063-2; Moreland LW, 2002, ARTHRITIS RHEUM, V46, P1470, DOI 10.1002/art.10294; Murata K, 2000, J EXP MED, V191, P365, DOI 10.1084/jem.191.2.365; Ndhlovu LC, 2001, J IMMUNOL, V167, P2991, DOI 10.4049/jimmunol.167.5.2991; Nguyen VT, 2002, J BIOL CHEM, V277, P13796, DOI 10.1074/jbc.M111906200; Nikcevich KM, 1997, J IMMUNOL, V158, P614; Nishimura H, 1998, INT IMMUNOL, V10, P1563, DOI 10.1093/intimm/10.10.1563; Nishimura H, 1996, INT IMMUNOL, V8, P773, DOI 10.1093/intimm/8.5.773; Nishimura H, 2000, J EXP MED, V191, P891, DOI 10.1084/jem.191.5.891; Nishimura H, 1999, IMMUNITY, V11, P141, DOI 10.1016/S1074-7613(00)80089-8; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; Nohara C, 2001, J IMMUNOL, V166, P2108, DOI 10.4049/jimmunol.166.3.2108; O'Keefe GM, 2002, J NEUROVIROL, V8, P496, DOI 10.1080/13550280290100941; Ohshima Y, 1997, J IMMUNOL, V159, P3838; Oliveira EML, 2003, J AUTOIMMUN, V20, P71, DOI 10.1016/S0896-8411(02)00106-3; Oliveira-dos-Santos AJ, 1999, J IMMUNOL, V162, P4490; PEACH RJ, 1994, J EXP MED, V180, P2049, DOI 10.1084/jem.180.6.2049; Perrin PJ, 1999, J IMMUNOL, V163, P1704; Perrin PJ, 2000, CLIN IMMUNOL, V94, P114, DOI 10.1006/clim.1999.4825; Pippig SD, 1999, J IMMUNOL, V163, P6520; POLLOK KE, 1994, EUR J IMMUNOL, V24, P367, DOI 10.1002/eji.1830240215; POLLOK KE, 1993, J IMMUNOL, V150, P771; RACKE MK, 1995, J CLIN INVEST, V96, P2195, DOI 10.1172/JCI118274; RAINE CS, 1994, ANN NEUROL, V36, pS61, DOI 10.1002/ana.410360716; RANHEIM EA, 1993, J EXP MED, V177, P925, DOI 10.1084/jem.177.4.925; Rogers PR, 2001, IMMUNITY, V15, P445, DOI 10.1016/S1074-7613(01)00191-1; Rottman JB, 2001, NAT IMMUNOL, V2, P605, DOI 10.1038/89750; Salama AD, 2003, J EXP MED, V198, P71, DOI 10.1084/jem.20022119; Saoulli K, 1998, J EXP MED, V187, P1849, DOI 10.1084/jem.187.11.1849; SAYEGH MH, 1995, J EXP MED, V181, P1869, DOI 10.1084/jem.181.5.1869; Schaub M, 1999, J NEUROIMMUNOL, V96, P158, DOI 10.1016/S0165-5728(99)00022-3; Scholz C, 1998, J IMMUNOL, V160, P1532; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; Sharpe AH, 2002, NAT REV IMMUNOL, V2, P116, DOI 10.1038/nri727; Shuford WW, 1997, J EXP MED, V186, P47, DOI 10.1084/jem.186.1.47; STUBER E, 1995, IMMUNITY, V2, P507, DOI 10.1016/1074-7613(95)90031-4; Stuber E, 1996, J EXP MED, V183, P979, DOI 10.1084/jem.183.3.979; Sun YL, 2002, J IMMUNOL, V168, P1457, DOI 10.4049/jimmunol.168.3.1457; Takahashi C, 1999, J IMMUNOL, V162, P5037; Teleshova N, 2000, SCAND J IMMUNOL, V51, P312; THOMPSON CB, 1989, P NATL ACAD SCI USA, V86, P1333, DOI 10.1073/pnas.86.4.1333; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; Vanderlugt CL, 2000, J IMMUNOL, V164, P670, DOI 10.4049/jimmunol.164.2.670; VanParijs L, 1996, IMMUNITY, V4, P321, DOI 10.1016/S1074-7613(00)80440-9; VERWEIJ CL, 1991, J BIOL CHEM, V266, P14179; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680; Walker LSK, 1999, J EXP MED, V190, P1115, DOI 10.1084/jem.190.8.1115; Walunas TL, 1996, J EXP MED, V183, P2541, DOI 10.1084/jem.183.6.2541; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; Weinberg AD, 1999, J IMMUNOL, V162, P1818; Wesemann DR, 2002, J IMMUNOL, V169, P2354, DOI 10.4049/jimmunol.169.5.2354; Wilcox RA, 2002, J CLIN INVEST, V109, P651, DOI 10.1172/JCI200214184; WILLIAMS K, 1994, EUR J IMMUNOL, V24, P3031, DOI 10.1002/eji.1830241217; Windhagen A, 1998, J NEUROIMMUNOL, V91, P1, DOI 10.1016/S0165-5728(98)00086-1; WINDHAGEN A, 1995, J EXP MED, V182, P1985, DOI 10.1084/jem.182.6.1985; YOKOCHI T, 1982, J IMMUNOL, V128, P823; Yoshinaga SK, 1999, NATURE, V402, P827, DOI 10.1038/45582; ZAMVIL SS, 1985, J EXP MED, V162, P2107, DOI 10.1084/jem.162.6.2107; Zhang J, 1992, Int Rev Immunol, V9, P183, DOI 10.3109/08830189209061790; ZHANG JW, 1994, J EXP MED, V179, P973, DOI 10.1084/jem.179.3.973	166	38	41	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2003	112	5					837	849		10.1016/j.jaci.2003.08.025	http://dx.doi.org/10.1016/j.jaci.2003.08.025			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743BV	14610467				2022-12-18	WOS:000186553300003
J	Adams, RJ; Weiss, ST; Fuhlbrigge, A				Adams, RJ; Weiss, ST; Fuhlbrigge, A			How and by whom care is delivered influences anti-inflammatory use in asthma: Results of a national population survey	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; population survey; asthma medication; quality of care; physician-patient communication	UNITED-STATES; MEDICATION USE; MANAGEMENT; ADHERENCE; GUIDELINES; EMERGENCY; ORGANIZATION; PERSPECTIVE; PHYSICIANS; EDUCATION	Background: Studies examining the influence of provider behavior and patterns of care delivery on the use of antiinflammatory asthma therapy have been limited to selected populations or have been unable to assess the appropriateness of therapy for individuals. We have previously reported the influence of sociodemographic variables and asthma severity on reported use of asthma medications in the United States. Objective: We sought to examine the influence of patterns of care delivery and clinician behavioral factors on the use of anti-inflammatory medication by patients with asthma. Methods: We performed a cross-sectional national random digit dial household telephone survey in 1998 of adult patients and parents of children with current asthma. Respondents were classified as having current asthma if they had a physician's diagnosis of asthma and were either taking medication for asthma or had asthma symptoms during the past year. Results: One or more persons met the study criteria for current asthma in 3273 (7.8%) households in which a screening questionnaire was completed. Of the 2509 persons (721 children <16 years of age) with current asthma interviewed, 507 (20.1%) reported current use of anti-inflammatory medication. In a multiple logistic regression model controlling for asthma symptoms, reported anti-inflammatory use was significantly associated with patients reporting their physician having an excellent ability to explain asthma management (odds ratio [OR], 1.47; 95% CI, 1.09-1.98), scheduling regular visits to a physician for asthma (OR, 1.30; 95% CI, 1.02-1.64), having a written asthma action plan (OR, 1.63; 95% CI, 1.29-2.06), and being of white, non-Hispanic ethnicity (OR, 1.53; 95% CI, 1.19-1.98), along with markers of greater asthma morbidity, missing 6 or more days from work or school in the past year (OR, 1.29; 95% CI, 1.01-1.65), and hospitalization for asthma in the past year (OR, 1.74; 95% CI, 1.19-2.53). Anti-inflammatory use was less likely to be reported with younger age (OR, 0.82; 95 % CI, 0.73-0.94), lower long-term asthma symptom burden (OR, 0.82; 95% CI, 0.71-0.94), use of 4 or fewer reliever inhaler canisters in the past year (OR, 0.50; 95 % CI, 0.43-0.58), and smoking (OR, 0.50; 95% CI, 0.37-0.68). Conclusion: How asthma care is delivered influences the use of anti-inflammatory medication. Strategies to increase regular evaluation by a physician interested in asthma, particularly for minority patients, and to increase a physician's ability to communicate asthma management to patients might improve use of anti-inflammatory therapy among patients with asthma.	Brigham & Womens Hosp, Channing Lab, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Adelaide, Dept Med, Adelaide, SA, Australia	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Adelaide	Fuhlbrigge, A (corresponding author), Brigham & Womens Hosp, Channing Lab, Dept Med, 181 Longwood Ave, Boston, MA 02115 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003919] Funding Source: NIH RePORTER; NHLBI NIH HHS [1 KO8 HL03919-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams RJ, 2002, J ALLERGY CLIN IMMUN, V110, P58, DOI 10.1067/mai.2002.125489; Adams S, 1997, SOC SCI MED, V45, P189, DOI 10.1016/S0277-9536(96)00333-4; Apter AJ, 1998, AM J RESP CRIT CARE, V157, P1810, DOI 10.1164/ajrccm.157.6.9712007; *BAYER I HEALTHC C, 2002, CHOIC CHANG; BECKER G, 1993, SOC SCI MED, V37, P305, DOI 10.1016/0277-9536(93)90262-3; BECKER MH, 1985, MED CARE, V23, P539, DOI 10.1097/00005650-198505000-00014; Campbell DA, 1996, AUST NZ J MED, V26, P356, DOI 10.1111/j.1445-5994.1996.tb01922.x; Clark NM, 1998, PEDIATRICS, V101, P831, DOI 10.1542/peds.101.5.831; Clark NM, 2000, BMJ-BRIT MED J, V320, P572, DOI 10.1136/bmj.320.7234.572; DALES RE, 1992, ARCH INTERN MED, V152, P2041, DOI 10.1001/archinte.152.10.2041; DiMatteo MR, 1982, ACHIEVING PATIENT CO; Eastwood AJ, 1996, QUAL HEALTH CARE, V5, P134, DOI 10.1136/qshc.5.3.134; Fuhlbrigge AL, 2002, AM J RESP CRIT CARE, V166, P1044, DOI 10.1164/rccm.2107057; GARDEN GMF, 1993, THORAX, V48, P501, DOI 10.1136/thx.48.5.501; GARRETT J, 1995, THORAX, V50, P303, DOI 10.1136/thx.50.3.303; GIBSON PG, 1993, MED J AUSTRALIA, V158, P775, DOI 10.5694/j.1326-5377.1993.tb121962.x; Goodman DC, 1999, PEDIATRICS, V104, P187, DOI 10.1542/peds.104.2.187; Halterman JS, 2000, PEDIATRICS, V105, P272; Kaplan SH, 1996, ANN INTERN MED, V124, P497, DOI 10.7326/0003-4819-124-5-199603010-00007; Kolbe J, 1996, CHEST, V110, P1463, DOI 10.1378/chest.110.6.1463; Lang DM, 1997, ARCH INTERN MED, V157, P1193, DOI 10.1001/archinte.157.11.1193; Legorreta AP, 1998, ARCH INTERN MED, V158, P457, DOI 10.1001/archinte.158.5.457; MORRIS LS, 1993, CLIN THER, V15, P593; *NAT ASTHM ED PREV, 1997, PUBL NAT ASTHM ED PR; National Asthma Campaign, 1999, ASTHM ADH GUID HLTH; Nestor A, 1998, ANN ALLERG ASTHMA IM, V81, P327, DOI 10.1016/S1081-1206(10)63124-9; Peat JK, 2001, THORAX, V56, P406, DOI 10.1136/thorax.56.5.406; RAND CS, 1992, AM REV RESPIR DIS, V146, P1559, DOI 10.1164/ajrccm/146.6.1559; Schmier JK, 1998, J ASTHMA, V35, P455, DOI 10.3109/02770909809070999; STRUNK RC, 1985, JAMA-J AM MED ASSOC, V254, P1193; TROSTLE JA, 1988, SOC SCI MED, V27, P1299, DOI 10.1016/0277-9536(88)90194-3; Vollmer WM, 1997, ARCH INTERN MED, V157, P1201, DOI 10.1001/archinte.157.11.1201; YELLOWLEES PM, 1989, CHEST, V95, P1298, DOI 10.1378/chest.95.6.1298	33	38	38	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2003	112	2					445	450		10.1067/mai.2003.1625	http://dx.doi.org/10.1067/mai.2003.1625			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	709WY	12897755				2022-12-18	WOS:000184650600033
J	Kerschenlohr, K; Decard, S; Darsow, U; Ollert, M; Wollenberg, A				Kerschenlohr, K; Decard, S; Darsow, U; Ollert, M; Wollenberg, A			Clinical and immunologic reactivity to aeroallergens in "intrinsic" atopic dermatitis patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							EPIDERMAL DENDRITIC CELLS; ALLERGY; ECZEMA		Univ Munich, Dept Dermatol & Allergy, Munich, Germany; Biederstein Tech Univ, Dept Dermatol & Allergy, Munich, Germany	University of Munich; Technical University of Munich	Kerschenlohr, K (corresponding author), Univ Munich, Dept Dermatol & Allergy, Marchioninistr 15, Munich, Germany.			Ollert, Markus W./0000-0002-8055-0103				Darsow U, 1999, J AM ACAD DERMATOL, V40, P187, DOI 10.1016/S0190-9622(99)70186-6; Darsow U, 2000, CLIN EXP DERMATOL, V25, P544, DOI 10.1046/j.1365-2230.2000.00695.x; Jeep S, 1996, ALLERGY, V51, P540, DOI 10.1111/j.1398-9995.1996.tb00110.x; Johansson SGO, 2001, ALLERGY, V56, P813, DOI 10.1034/j.1398-9995.2001.t01-1-00001.x; Majamaa H, 1999, ALLERGY, V54, P346, DOI 10.1034/j.1398-9995.1999.00834.x; Oppel T, 2000, BRIT J DERMATOL, V143, P1193, DOI 10.1046/j.1365-2133.2000.03887.x; Schmid P, 2001, ALLERGY, V56, P841, DOI 10.1034/j.1398-9995.2001.00144.x; Wollenberg A, 1999, CYTOMETRY, V37, P147, DOI 10.1002/(SICI)1097-0320(19991001)37:2<147::AID-CYTO8>3.0.CO;2-Y	8	38	42	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2003	111	1					195	197		10.1016/S0091-6749(03)70068-2	http://dx.doi.org/10.1016/S0091-6749(03)70068-2			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	636PR	12532120	Bronze			2022-12-18	WOS:000180465500032
J	Nagarkatti, R; Rao, CB; Rishi, JP; Chetiwal, R; Shandilya, V; Vijayan, V; Kumar, R; Pemde, HK; Sharma, SK; Sharma, S; Singh, AB; Gangal, SV; Ghosh, B				Nagarkatti, R; Rao, CB; Rishi, JP; Chetiwal, R; Shandilya, V; Vijayan, V; Kumar, R; Pemde, HK; Sharma, SK; Sharma, S; Singh, AB; Gangal, SV; Ghosh, B			Association of IFNG gene polymorphism with asthma in the Indian population	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; IFN-gamma; CA-repeat polymorphism; IFNG promoter; IgE; case-control study; Indian population	GAMMA GENE; DISEASE	Epidemiologic studies in India show that the prevalence of asthma is increasing, but no genetic studies have been reported on the Indian population thus far. We selected the IFNG locus on 12q21 as a candidate gene for asthma on the basis of its role in pathophysiology and positive linkage demonstrated in other populations. The aim of this study was to investigate association of a CA-repeat marker in this gene with asthma and total serum IgE levels in the North Indian population. The repeat region was PCR-amplified from patients and control subjects and analyzed through use of GeneScan. The distributions of allele sizes were found to be significantly different between patients and control subjects (Kolmogorov-Smirnov test, P < 10(-6)). Alleles 10 and 11 were found to be overrepresented in individuals with asthma, whereas alleles 13 and 15 were less likely in asthmatic individuals. We found that the CA-repeat polymorphism in the IFNG gene was significantly associated with total serum IgE levels (ANOVA, P < 10(-4) for control subjects and P=.0036 for patients). Furthermore, a previously reported promoter polymorphism at the -333 base pair position was not detected in our population. This is the first report on the association of a candidate gene with asthma from the Indian subcontinent.	Ctr Biochem Technol, Immunogenet Mol Lab, Delhi 110007, India; SMS Med Coll & Hosp, Jaipur, Rajasthan, India; Univ Delhi, Vallabhbhai Patel Chest Inst, Delhi 110007, India; Babu Jagjivan Ram Hosp, Delhi, India; All India Inst Med Sci, Delhi, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Genomics & Integrative Biology (IGIB); SMS Medical College & Hospital; University of Delhi; All India Institute of Medical Sciences (AIIMS) New Delhi	Ghosh, B (corresponding author), Ctr Biochem Technol, Immunogenet Mol Lab, Mall Rd, Delhi 110007, India.		Ghosh, Balaram/G-1248-2010	PEMDE, Harish/0000-0002-6605-1041; B-RAO, CHANDRIKA/0000-0003-3848-7945				Barnes KC, 1999, J ALLERGY CLIN IMMUN, V104, P485, DOI 10.1016/S0091-6749(99)70398-2; Bidwell J, 1999, GENES IMMUN, V1, P3, DOI 10.1038/sj.gene.6363645; Chung KF, 1999, THORAX, V54, P825, DOI 10.1136/thx.54.9.825; Giedraitis V, 1999, EUR J IMMUNOGENET, V26, P257, DOI 10.1046/j.1365-2370.1999.00140.x; Iwasaki H, 2001, J HUM GENET, V46, P32, DOI 10.1007/s100380170121; MARSH DG, 1995, INT ARCH ALLERGY IMM, V107, P25, DOI 10.1159/000236920; Nakao F, 2001, J ALLERGY CLIN IMMUN, V107, P499, DOI 10.1067/mai.2001.113051; Pravica V, 1999, EUR J IMMUNOGENET, V26, P1, DOI 10.1046/j.1365-2370.1999.00122.x; Smith KR, 2000, P NATL ACAD SCI USA, V97, P13286, DOI 10.1073/pnas.97.24.13286; Venkataraman C, 1999, J IMMUNOL, V162, P4053	10	38	41	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2002	110	3					410	412		10.1067/mai.2002.127859	http://dx.doi.org/10.1067/mai.2002.127859			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	592KM	12209087				2022-12-18	WOS:000177936900010
J	Fowler, SJ; Currie, GP; Lipworth, BJ				Fowler, SJ; Currie, GP; Lipworth, BJ			Step-down therapy with low-dose fluticasone-salmeterol combination or medium-dose hydrofluoroalkane 134a-beclomethasone alone	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma therapy; bronchial hyperreactivity; fluticasone propionate; salmeterol; beclomethasone	EXHALED NITRIC-OXIDE; QUALITY-OF-LIFE; BECLOMETHASONE DIPROPIONATE; AIRWAY INFLAMMATION; INHALED STEROIDS; DOUBLE-BLIND; ASTHMA; METHACHOLINE; BUDESONIDE; FORMOTEROL	Background: Options for step-down therapy include use of inhaled corticosteroids alone or in combination with a long-acting beta(2)-agonist. Objective: We sought to evaluate step-down therapy with a fluticasone propionate-salmeterol (FP-SM) combination administered through a dry powder inhaler (DPI; Advair Diskus) versus a medium dose of hydrofluoroalkane 143a-beclomethasone dipropionate (HFA-BDP) administered through a breath-actuated pressurized metered-dose inhaler (QVAR Autohaler). Methods: Thirty-nine patients with uncontrolled moderate-to-severe asthma were treated with 1000 mug of DPI-administered BDP twice daily (DPI-BDP) for 4 weeks and then randomized to 200 mug of HFA-BDP twice daily (n = 20) or 100 mug of FP and 50 mug of SM twice daily (FM-SM; n = 19) for 8 weeks in a double-blind, double-dummy, parallel-group design. We measured the provocative dose of methacholine producing a 20% fall in FEV1 (methacholine PD20) as the primary outcome, with secondary outcomes being lung function, surrogate inflammatory markers, diary card responses, quality of life, and safety. Results: There was a 0.9 (95% confidence interval, 0.5-1.2) doubling dose improvement in methacholine PD20 comparing asthma before versus after DPI-BDP. HFA-BDP maintained this improvement, whereas FP-SM produced a further significant improvement, amounting to a 1.1 (95% confidence interval, 0.2-2.1) doubling dose difference at 8 weeks for FP-SM versus HFA-BDP. Effects on FEV1, peak expiratory flow, and quality of life (symptoms and emotions) were similar to those on methacholine PD20, with a significant difference between FP-SM and HFA-BDP. Suppression of plasma and urinary cortisol and serum osteocalcin levels occurred with DPI-BDP, but values returned to baseline levels within 1 month of HFA-BDP or FP-SM administration. Conclusion: After high-dose inhaled corticosteroid, stepping down with the combination inhaler conferred further improvements in bronchoprotection, bronchodilatation, and clinical control, but not inflammatory markers, compared with that seen with a medium dose of inhaled corticosteroid.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol & Therapeut, Asthma & Allergy Res Grp, Dundee DD1 9SY, Scotland	University of Dundee	Lipworth, BJ (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol & Therapeut, Asthma & Allergy Res Grp, Dundee DD1 9SY, Scotland.			Fowler, Stephen/0000-0002-4524-1663; Currie, Graeme P/0000-0002-5711-9147				[Anonymous], 1987, Am Rev Respir Dis, V136, P1285; Aziz I, 2000, CHEST, V118, P1049, DOI 10.1378/chest.118.4.1049; BEACH JR, 1993, THORAX, V48, P239, DOI 10.1136/thx.48.3.239; Busse WW, 1999, J ALLERGY CLIN IMMUN, V104, P1215, DOI 10.1016/S0091-6749(99)70016-3; Busse WW, 1998, J ALLERGY CLIN IMMUN, V101, P457, DOI 10.1016/S0091-6749(98)70353-7; Calhoun WJ, 2001, AM J RESP CRIT CARE, V163, P881, DOI 10.1164/ajrccm.163.4.2001060; Fairfax A, 2001, ANN ALLERG ASTHMA IM, V86, P575, DOI 10.1016/S1081-1206(10)62907-9; GARDINER PV, 1994, AM J RESP CRIT CARE, V150, P1006, DOI 10.1164/ajrccm.150.4.7921429; Goldin JG, 1999, J ALLERGY CLIN IMMUN, V104, pS258, DOI 10.1016/S0091-6749(99)70043-6; GROVE A, 1995, LANCET, V346, P201, DOI 10.1016/S0140-6736(95)91265-7; Ichinose M, 2000, EUR RESPIR J, V15, P248, DOI 10.1034/j.1399-3003.2000.15b05.x; Jatakanon A, 1998, THORAX, V53, P91, DOI 10.1136/thx.53.2.91; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; JUNIPER EF, 1992, THORAX, V47, P76, DOI 10.1136/thx.47.2.76; Kemp JP, 1999, J ALLERGY CLIN IMMUN, V104, P1189, DOI 10.1016/S0091-6749(99)70012-6; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P1773, DOI 10.1164/ajrccm.153.6.8665033; KIPS JC, 2000, AM J RESP CRIT CARE, V161, P696; Kraft M, 1996, AM J RESP CRIT CARE, V154, P1505, DOI 10.1164/ajrccm.154.5.8912772; Lazarus SC, 2001, JAMA-J AM MED ASSOC, V285, P2583, DOI 10.1001/jama.285.20.2583; Leach CL, 1998, RESP MED, V92, P3, DOI 10.1016/S0954-6111(98)90211-6; Lipworth BJ, 1999, J ALLERGY CLIN IMMUN, V103, P88, DOI 10.1016/S0091-6749(99)70530-0; Lipworth BJ, 1999, ARCH INTERN MED, V159, P941, DOI 10.1001/archinte.159.9.941; Lipworth BJ, 2000, CHEST, V118, P321, DOI 10.1378/chest.118.2.321; Matz J, 2001, J ALLERGY CLIN IMMUN, V107, P783, DOI 10.1067/mai.2001.114709; OLSSON B, 1995, J AEROSOL MED, V8, pS13; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Pearson MG, 1997, THORAX, V52, pS1; Roberts JA, 1999, EUR RESPIR J, V14, P275, DOI 10.1034/j.1399-3003.1999.14b07.x; Shrewsbury S, 2000, BMJ-BRIT MED J, V320, P1368, DOI 10.1136/bmj.320.7246.1368; SONT JK, 1992, CLIN EXP ALLERGY, V22, P554, DOI 10.1111/j.1365-2222.1992.tb00165.x; van der Woude HJ, 2001, THORAX, V56, P529, DOI 10.1136/thorax.56.7.529; Wilding P, 1997, BRIT MED J, V314, P1441, DOI 10.1136/bmj.314.7092.1441; Wilson AM, 2000, AM J MED, V108, P269, DOI 10.1016/S0002-9343(99)00435-0; Woolcock A, 1996, AM J RESP CRIT CARE, V153, P1481, DOI 10.1164/ajrccm.153.5.8630590	34	38	43	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2002	109	6					929	935		10.1067/mai.2002.123869	http://dx.doi.org/10.1067/mai.2002.123869			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	566RU	12063520	Bronze			2022-12-18	WOS:000176442700006
J	Karim, MY; Masood, A				Karim, MY; Masood, A			Fresh-frozen plasma as a treatment for life-threatening ACE-inhibitor angloedema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ANGIOEDEMA; BRADYKININ		St Thomas Hosp, Dept Immunol, London SE1 7EH, England	Guy's & St Thomas' NHS Foundation Trust	Karim, MY (corresponding author), St Thomas Hosp, Dept Immunol, London SE1 7EH, England.		Karim, Mohammed Yousuf/AAI-6771-2020	Karim, Mohammed Yousuf/0000-0003-0912-1629				Agostoni A, 1999, IMMUNOPHARMACOLOGY, V44, P21, DOI 10.1016/S0162-3109(99)00107-1; Blais C, 1999, IMMUNOPHARMACOLOGY, V43, P293, DOI 10.1016/S0162-3109(99)00133-2; COOPER ES, 1994, JAMA-J AM MED ASSOC, V271, P777, DOI 10.1001/jama.1994.03510340067036; Gainer JV, 1996, J ALLERGY CLIN IMMUN, V98, P283, DOI 10.1016/S0091-6749(96)70151-3; HAUSER C, 1991, J AM ACAD DERMATOL, V24, P908, DOI 10.1016/0190-9622(91)70145-R; Kyrmizakis DE, 1998, AM J OTOLARYNG, V19, P394, DOI 10.1016/S0196-0709(98)90043-6; MEGERIAN CA, 1992, LARYNGOSCOPE, V102, P256; Nussberger J, 1998, LANCET, V351, P1693, DOI 10.1016/S0140-6736(97)09137-X; Vleeming W, 1998, DRUG SAFETY, V18, P171, DOI 10.2165/00002018-199818030-00003	9	38	38	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2002	109	2					370	371		10.1067/mai.2002.121313	http://dx.doi.org/10.1067/mai.2002.121313			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	528EZ	11842313	Bronze			2022-12-18	WOS:000174232600028
J	Uchida, Y; Kurasawa, K; Nakajima, H; Nakagawa, N; Tanabe, E; Sueishi, M; Saito, Y; Iwamoto, I				Uchida, Y; Kurasawa, K; Nakajima, H; Nakagawa, N; Tanabe, E; Sueishi, M; Saito, Y; Iwamoto, I			Increase of dendritic cells of type 2 (DC2) by altered response to IL-4 in atopic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						dendritic cells; DC1; DC2; atopy; T(H)2; IL-4	MOLECULAR PATHOLOGY; ALLERGIC DISEASE; T-CELLS; INTERLEUKIN-4; LYMPHOCYTES; STAT6		Chiba Univ, Sch Med, Dept Internal Med 2, Chiba 2608670, Japan; Toho Univ, Sch Med, Sakura Hosp, Dept Dermatol, Chiba 2748510, Japan; Shimoshizu Natl Hosp, Dept Internal Med, Chiba, Japan	Chiba University; Toho University	Kurasawa, K (corresponding author), Chiba Univ, Sch Med, Dept Internal Med 2, 1-8-1 Inohana, Chiba 2608670, Japan.		Nakajima, Hiroshi/AFU-9313-2022	Nakajima, Hiroshi/0000-0001-8595-9381				Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; Arpinati M, 2000, BLOOD, V95, P2484, DOI 10.1182/blood.V95.8.2484; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; CAUX C, 1992, NATURE, V360, P258, DOI 10.1038/360258a0; Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747; Christodoulopoulos P, 2000, J ALLERGY CLIN IMMUN, V105, P211, DOI 10.1016/S0091-6749(00)90068-X; Dickensheets HL, 1999, P NATL ACAD SCI USA, V96, P10800, DOI 10.1073/pnas.96.19.10800; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Gao PS, 2000, J MED GENET, V37, P380; Grouard G, 1997, J EXP MED, V185, P1101, DOI 10.1084/jem.185.6.1101; Hamid QA, 2000, J ALLERGY CLIN IMMUN, V105, P20, DOI 10.1016/S0091-6749(00)90172-6; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; Haque SJ, 2000, J BIOL CHEM, V275, P26500, DOI 10.1074/jbc.275.34.26500; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; JOHANSSON SG, 1968, IMMUNOLOGY, V14, P265; Kadowaki N, 2000, J EXP MED, V192, P219, DOI 10.1084/jem.192.2.219; Kohrgruber N, 1999, J IMMUNOL, V163, P3250; LEUNG DYM, 2000, J ALLERGY CLIN IMMUN, V105, P806; MACATONIA SE, 1995, J IMMUNOL, V154, P5071; Mitsuyasu H, 1998, NAT GENET, V19, P119, DOI 10.1038/472; Moser M, 2000, NAT IMMUNOL, V1, P199, DOI 10.1038/79734; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; NAKAJIMA H, 1992, AM REV RESPIR DIS, V146, P374, DOI 10.1164/ajrccm/146.2.374; NEIMS K, 1999, ANNU REV IMMUNOL, V17, P701; ODOHERTY U, 1994, IMMUNOLOGY, V82, P487; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; Robinson SP, 1999, EUR J IMMUNOL, V29, P2769, DOI 10.1002/(SICI)1521-4141(199909)29:09<2769::AID-IMMU2769>3.0.CO;2-2; Romagnani S, 2000, J ALLERGY CLIN IMMUN, V105, P399, DOI 10.1067/mai.2000.104575; SAGER N, 1992, J ALLERGY CLIN IMMUN, V89, P801, DOI 10.1016/0091-6749(92)90434-4; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143	33	38	39	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2001	108	6					1005	1011		10.1067/mai.2001.119741	http://dx.doi.org/10.1067/mai.2001.119741			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	505WK	11742280	Bronze			2022-12-18	WOS:000172938400018
J	Konno, S; Hizawa, N; Yamaguchi, E; Jinushi, E; Nishimura, M				Konno, S; Hizawa, N; Yamaguchi, E; Jinushi, E; Nishimura, M			(CCTTT)(n) repeat polymorphism in the NOS2 gene promoter is associated with atopy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy; asthma; nitric oxide synthase 2 (NOS2)	NITRIC-OXIDE SYNTHASE; HELPER TYPE-2 CELLS; AUTOIMMUNE-DISEASES; FUNCTIONAL-ANALYSIS; INHALANT ALLERGENS; ASTHMA; INDUCTION; CHILDHOOD; INFANCY	Background: Several studies have shown that nitric oxide (NO) plays a role in the regulation of the T(H)1/T(H)2 balance, indicating the potential for NO to contribute to the development of atopy and several other allergic diseases, including bronchial asthma. NO synthase 2 (NOS2) is critically involved in the synthesis of NO during several inflammatory states, and the gene encoding NOS2 is located at chromosome 17q11.2-q12, where 2 genome scans have identified a candidate locus for atopy and asthma. Objective: The 14-repeat allele of the (CCTTT)(n) repeat polymorphism in the NOS2 promoter region is a powerful enhancer of promoter activity in reporter constructs in vitro. We tested whether this potentially functional allele in the NOS2 gene influences the development of atopy and asthma. Methods: We studied a total of 497 unrelated Japanese subjects (141 nonatopic healthy controls, 102 atopic healthy controls, 56 nonatopic asthmatic subjects, and 198 atopic asthmatic subjects). The odds ratio (OR) was calculated for atopy and asthma in carriers of the 14-repeat allele through use of logistic regression models. Atopy was defined as a positive specific IgE level to at least 1 of 10 common inhaled allergens. Results: The 14-repeat allele was inversely associated with atopy (OR = 0.42, P < .01). The association remained significant when the model was controlled for asthmatic status (OR = 0.36, P < .01). This allele, however, was associated neither with the development of asthma nor with total serum IgE levels. Conclusion: Our findings suggest that the (CCTTT)(n) repeat polymorphism in the promoter of the NOS2 gene that affects promoter activity is a risk factor for the development of atopy, and this genetic effect seems independent of asthma.	Hokkaido Univ, Sch Med, Dept Med 1, Kita Ku, Sapporo, Hokkaido 0608638, Japan	Hokkaido University	Hizawa, N (corresponding author), Hokkaido Univ, Sch Med, Dept Med 1, Kita Ku, Kita 15 Nishi 7, Sapporo, Hokkaido 0608638, Japan.		Yamaguchi, Etsuro/AAB-3923-2020; Nishimura, Masaharu/A-4062-2012; Konno, Satoshi/G-1669-2012	Nishimura, Masaharu/0000-0002-6456-4361; 				Becker KG, 1998, P NATL ACAD SCI USA, V95, P9979, DOI 10.1073/pnas.95.17.9979; Bellamy R, 1997, CLIN GENET, V52, P192; BONDER C, 2000, THORAX, V55, P383; CECILLE S, 1999, J ALLERGY CLIN IMMUN, V103, P415; De Sanctis GT, 1999, J EXP MED, V189, P1621, DOI 10.1084/jem.189.10.1621; DESANCTIS GT, 1997, AM J PHYSIOL, V17, P883; Dizier MH, 2000, AM J RESP CRIT CARE, V162, P1812, DOI 10.1164/ajrccm.162.5.2002113; Gao PS, 2000, BIOCHEM BIOPH RES CO, V267, P761, DOI 10.1006/bbrc.1999.2030; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; Hizawa N, 2000, AM J RESP CRIT CARE, V161, P906, DOI 10.1164/ajrccm.161.3.9903128; Ho LP, 2000, CHEST, V118, P1327, DOI 10.1378/chest.118.5.1327; HOLT PG, 1995, PEDIAT ALLERG IMM-UK, V6, P1, DOI 10.1111/j.1399-3038.1995.tb00250.x; Johannesen J, 2000, DIABETES CARE, V23, P560, DOI 10.2337/diacare.23.4.560; Kolb H, 1998, IMMUNOL TODAY, V19, P556, DOI 10.1016/S0167-5699(98)01366-8; Kun JFJ, 1998, LANCET, V351, P265, DOI 10.1016/S0140-6736(05)78273-8; Kurz T, 2000, J ALLERGY CLIN IMMUN, V106, P925, DOI 10.1067/mai.2000.110557; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Marsh DG, 1997, NAT GENET, V15, P389; Martin J, 1999, LANCET, V353, P72, DOI 10.1016/S0140-6736(05)74833-9; MICHEL D, 1992, NUCLEIC ACIDS RES, V20, P439, DOI 10.1093/nar/20.3.439; Niedbala W, 1999, EUR J IMMUNOL, V29, P2498, DOI 10.1002/(SICI)1521-4141(199908)29:08<2498::AID-IMMU2498>3.0.CO;2-M; NUKAYA I, 1995, MICROBIOL IMMUNOL, V39, P709, DOI 10.1111/j.1348-0421.1995.tb03246.x; Ott J, 1999, ANAL HUMAN GENETIC L; Singh VK, 2000, IMMUNOL RES, V22, P1, DOI 10.1385/IR:22:1:1; Spitsin SV, 1996, MOL MED, V2, P226, DOI 10.1007/BF03401619; TAYLORROBINSON AW, 1994, EUR J IMMUNOL, V24, P980, DOI 10.1002/eji.1830240430; Warpeha KM, 1999, FASEB J, V13, P1825, DOI 10.1096/fasebj.13.13.1825; WEI XQ, 1995, NATURE, V375, P408, DOI 10.1038/375408a0; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; Xu WM, 1997, GENE, V204, P165, DOI 10.1016/S0378-1119(97)00538-6; Yabuhara A, 1997, CLIN EXP ALLERGY, V27, P1261, DOI 10.1111/j.1365-2222.1997.tb01170.x	31	38	39	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2001	108	5					810	814		10.1067/mai.2001.119030	http://dx.doi.org/10.1067/mai.2001.119030			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	498RG	11692109				2022-12-18	WOS:000172523800024
J	Dunzendorfer, S; Kaneider, NC; Kaser, A; Woell, E; Frade, JMR; Mellado, M; Martinez-Alonso, C; Wiedermann, CJ				Dunzendorfer, S; Kaneider, NC; Kaser, A; Woell, E; Frade, JMR; Mellado, M; Martinez-Alonso, C; Wiedermann, CJ			Functional expression of chemokine receptor 2 by normal human eosinophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophils; eosinophilic infiltration; chemokines; chemotaxis; receptor; signal transduction	PLATELET-ACTIVATING FACTOR; CHEMOTACTIC CYTOKINES; MIGRATION; BASOPHIL; PROTEIN; CHEMOATTRACTANT; NEUROPEPTIDE; RANTES	Background: Within the granulocytes, the CC chemokines preferentially activate basophils and eosinophils on binding to chemokine receptors (CCRs). In vivo administration of neutralizing anti-monocyte chemoattractant protein 1 (MCP-1) antibodies can block accumulation of eosinophils in the lungs of antigen-challenged animals. Objective: We studied a panel of chemokines for chemotactic activity in normal human eosinophils from healthy donors with a special focus on MCP-1, identified the respective receptor required for the biological response of eosinophils, and investigated mediators used for signal transduction. Methods: Cells were enriched by magnetic cell sorting. Receptor expression in cosinophils was shown by RT-PCR and fluorescence-activated cell sorting. The biological response was tested in chemotaxis and calcium mobilization assays. Results: Eosinophils have detectable mRNA for CCR2, and the receptor protein is expressed on cell surfaces. MCP-1 induces chemotaxis and calcium mobilization in eosinophils. The chemotactic activity of MCP-1 revealed a double-peaked dose-response curve; one of the peaks is abolished by addition of a blocking antibody to CCR2, but it is insensitive to blocking of CCR1 or CCR3. Specific enzyme inhibitors ruled out signaling characteristics of CCR2 in eosinophils. Conclusion: Normal human eosinophils express functional CCR2 on cell surfaces.	Univ Innsbruck, Dept Internal Med, Div Gen Internal Med, A-6020 Innsbruck, Austria; Univ Innsbruck, Dept Internal Med, Div Gastroenterol & Hepatol, A-6020 Innsbruck, Austria; Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Madrid, Spain	University of Innsbruck; University of Innsbruck; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Wiedermann, CJ (corresponding author), Univ Innsbruck, Dept Internal Med, Div Gen Internal Med, Anichstr 35, A-6020 Innsbruck, Austria.		Mellado, Mario/M-9893-2014; Frade, Jose Miguel Rodriguez/K-4266-2014; Mellado, Mario/Q-4752-2019; Wiedermann, Christian J./ABG-9521-2020	Mellado, Mario/0000-0001-6325-1630; Frade, Jose Miguel Rodriguez/0000-0002-7753-1462; Mellado, Mario/0000-0001-6325-1630; 				BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; BAGGIOLINI M, 1994, IMMUNOL TODAY, V15, P127, DOI 10.1016/0167-5699(94)90156-2; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; DAHINDEN CA, 1994, J EXP MED, V179, P751, DOI 10.1084/jem.179.2.751; Dunzendorfer S, 1998, BLOOD, V91, P1527, DOI 10.1182/blood.V91.5.1527.1527_1527_1532; Dunzendorfer S, 1998, J LEUKOCYTE BIOL, V64, P828, DOI 10.1002/jlb.64.6.828; Elsner J, 1996, EUR J IMMUNOL, V26, P1919, DOI 10.1002/eji.1830260837; Frade JMR, 1997, J IMMUNOL, V159, P5576; Gonzalo JA, 1998, J EXP MED, V188, P157, DOI 10.1084/jem.188.1.157; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HATZELMANN A, 1995, BRIT J PHARMACOL, V114, P821, DOI 10.1111/j.1476-5381.1995.tb13278.x; Jia GQ, 1996, J EXP MED, V184, P1939, DOI 10.1084/jem.184.5.1939; KAY AB, 1992, BRIT MED BULL, V48, P51, DOI 10.1093/oxfordjournals.bmb.a072541; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Luster AD, 1997, J LEUKOCYTE BIOL, V62, P620, DOI 10.1002/jlb.62.5.620; Melchers F, 1999, CELL, V99, P351, DOI 10.1016/S0092-8674(00)81521-4; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; Pettit EJ, 1998, PHYSIOL REV, V78, P949, DOI 10.1152/physrev.1998.78.4.949; Proudfoot AEI, 1999, J BIOL CHEM, V274, P32478, DOI 10.1074/jbc.274.45.32478; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; Schweizer RC, 1996, J LEUKOCYTE BIOL, V59, P347, DOI 10.1002/jlb.59.3.347; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Teixeira MM, 1997, BLOOD, V89, P4566, DOI 10.1182/blood.V89.12.4566; WEBER M, 1995, J IMMUNOL, V154, P4166; Weber M, 1996, J EXP MED, V183, P681, DOI 10.1084/jem.183.2.681; White JR, 1997, J LEUKOCYTE BIOL, V62, P667, DOI 10.1002/jlb.62.5.667; Yen HH, 1997, J LEUKOCYTE BIOL, V61, P529, DOI 10.1002/jlb.61.4.529	31	38	39	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2001	108	4					581	587		10.1067/mai.2001.118518	http://dx.doi.org/10.1067/mai.2001.118518			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	485NK	11590385				2022-12-18	WOS:000171760300018
J	Papi, A; Papadopoulos, NG; Stanciu, LA; Degitz, K; Holgate, ST; Johnston, SL				Papi, A; Papadopoulos, NG; Stanciu, LA; Degitz, K; Holgate, ST; Johnston, SL			Effect of desloratadine and loratadine on rhinovirus-induced intercellular adhesion molecule 1 upregulation and promoter activation in respiratory epithelial cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; rhinovirus; intercellular adhesion molecule 1; histamine H-1 receptor blockers	NF-KAPPA-B; TRANSCRIPTIONAL REGULATION; INHIBITORY ACTIVITY; ENDOTHELIAL-CELLS; UP-REGULATION; COMMON COLD; ICAM-1; INFECTION; RELEASE; EXPRESSION	Background: Rhinoviruses have been recently associated with the majority of asthma exacerbations for which current therapy is inadequate. Intercellular adhesion molecule 1 (ICAM-1) has a central role in airway inflammation in asthma, and it is the receptor for 90% of rhinoviruses. Rhinovirus infection of airway epithelium induces ICAM-1. Desloratadine and loratadine are compounds belonging to the new class of H-1-receptor blockers. Anti-inflammatory properties of antihistamines have been recently documented, although the underlying molecular mechanisms are not completely defined. Objective: We have investigated the effects of desloratadine and loratadine on rhinovirus-induced ICAM-1 expression, mRNA upregulation, and promoter activation. Methods: Cultured primary bronchial or transformed (A549) respiratory epithelial cells were pretreated with desloratadine and loratadine for 16 hours and infected with rhinovirus type 16 for 8 hours. ICAM-1 surface expression was evaluated with flow cytometry, and ICAM-1 mRNA was evaluated with specific RT-PCR. In A549 cells promoter activation was evaluated with a chloramphenicol acetyltransferase assay, and binding activity of nuclear factor kappaB in nuclear extracts was evaluated with an electrophoretic mobility shift assay. Results: Desloratadine and loratadine (0.1-10 mu mol/L) inhibited rhinovirus-induced ICAM-1 upregulation in both primary bronchial or transformed (A549) respiratory epithelial cells. In A549 cells the 2 compounds showed a dose-dependent inhibition with similar efficacy (inhibitory concentration of 50%, 1 mu mol/L). Desloratadine and loratadine also inhibited ICAM-1 mRNA induction caused by rhinovirus infection in a dose-dependent manner, and they completely inhibited rhinovirus-induced ICAM-1 promoter activation. Desloratadine also inhibited rhinovirus-induced nuclear factor kappaB activation. Desloratadine and loratadine had no direct effect on rhinovirus infectivity and replication in cultured epithelial cells. Conclusion: These effects are unlikely to be mediated by H-1-receptor antagonism and suggest a novel mechanism of action that may be important for the therapeutic control of virus-induced asthma exacerbations.	Univ Ferrara, Res Ctr Asthma & COPD, I-44100 Ferrara, Italy; Univ Southampton, Southampton, Hants, England; St Marys Hosp, Imperial Coll Sch Med, Natl Heart & Lung Inst, Dept Resp Med, London, England; Univ Munich, Dept Dermatol, D-8000 Munich, Germany	University of Ferrara; University of Southampton; Imperial College London; University of Munich	Papi, A (corresponding author), Univ Ferrara, Res Ctr Asthma & COPD, Via Savonarola 9, I-44100 Ferrara, Italy.		Johnston, Sebastian Lennox/I-2423-2012; Stanciu, Luminita A/B-8384-2012; N.G., Papadopoulos/L-8670-2013; Papadopoulos, Nikolaos/ABE-1774-2021; Papi, alberto/AAC-1888-2019	Johnston, Sebastian Lennox/0000-0003-3009-9200; N.G., Papadopoulos/0000-0002-4448-3468; Papadopoulos, Nikolaos/0000-0002-4448-3468; PAPI, ALBERTO/0000-0002-6924-4500; Papadopoulos, Nikolaos/0000-0002-2508-3872				Abdelaziz MM, 1998, J ALLERGY CLIN IMMUN, V101, P410, DOI 10.1016/S0091-6749(98)70256-8; Arnold R, 1999, CLIN EXP ALLERGY, V29, P1681, DOI 10.1046/j.1365-2222.1999.00630.x; AROLA M, 1990, ANN OTO RHINOL LARYN, V99, P451, DOI 10.1177/000348949009900607; BARNETT A, 1994, AGENTS ACTIONS, V43, P149, DOI 10.1007/BF01986682; CALHOUN WJ, 1994, J CLIN INVEST, V94, P2200, DOI 10.1172/JCI117581; DAMLE NK, 1992, J IMMUNOL, V148, P1985; Doull IJM, 1997, BMJ-BRIT MED J, V315, P858, DOI 10.1136/bmj.315.7112.858; DuBuske LM, 1996, J ALLERGY CLIN IMMUN, V98, pS307, DOI 10.1016/S0091-6749(96)80116-3; EDA R, 1993, ANN ALLERGY, V71, P373; FRAENKEL DJ, 1995, AM J RESP CRIT CARE, V151, P879; Genovese A, 1997, CLIN EXP ALLERGY, V27, P559, DOI 10.1111/j.1365-2222.1997.tb00745.x; Gern JE, 1997, AM J RESP CRIT CARE, V155, P1159, DOI 10.1164/ajrccm.155.3.9117003; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; GWALTNEY JM, 1994, NEW ENGL J MED, V330, P25, DOI 10.1056/NEJM199401063300105; HARIA M, 1994, DRUGS, V48, P617, DOI 10.2165/00003495-199448040-00009; HOGAN MB, 1997, ASTHMA, P537; JAHNKE A, 1994, FEBS LETT, V354, P220, DOI 10.1016/0014-5793(94)01130-3; Johnston SL, 1998, J IMMUNOL, V160, P6172; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654, DOI 10.1164/ajrccm.154.3.8810601; Johnston SL., 1997, DIAGNOSTIC PROCEDURE, P553; KLEINETEBBE J, 1994, J ALLERGY CLIN IMMUN, V93, P494, DOI 10.1016/0091-6749(94)90359-X; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; Lippert U, 1995, Exp Dermatol, V4, P272, DOI 10.1111/j.1600-0625.1995.tb00257.x; LOOK DC, 1994, J BIOL CHEM, V269, P8952; Molet S, 1997, CLIN EXP ALLERGY, V27, P1167; MULLER S, 1995, J INVEST DERMATOL, V104, P970, DOI 10.1111/1523-1747.ep12606225; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; Papadopoulos NG, 2000, J INFECT DIS, V181, P1875, DOI 10.1086/315513; Papi A, 1999, J BIOL CHEM, V274, P30041, DOI 10.1074/jbc.274.42.30041; Papi A, 1999, J BIOL CHEM, V274, P9707, DOI 10.1074/jbc.274.14.9707; Papi A, 2000, J ALLERGY CLIN IMMUN, V105, P318, DOI 10.1016/S0091-6749(00)90082-4; SIMONS FER, 1977, ALLERGY ALLERGIC DIS, P421; STANWAY G, 1994, ENCY VIROLOGY, V3, P1253; UNCAPHER CR, 1991, VIROLOGY, V180, P814, DOI 10.1016/0042-6822(91)90098-V; VAN SG, 1990, J IMMUNOL, V144, P4579; VIGNOLA AM, 1995, ALLERGY, V50, P200, DOI 10.1111/j.1398-9995.1995.tb01133.x; WILSON NM, 1990, ARCH DIS CHILD, V65, P407, DOI 10.1136/adc.65.4.407; Yoneda K, 1997, JPN J PHARMACOL, V73, P145, DOI 10.1254/jjp.73.145	39	38	42	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2001	108	2					221	228		10.1067/mai.2001.116861	http://dx.doi.org/10.1067/mai.2001.116861			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	465HY	11496238				2022-12-18	WOS:000170584600010
J	Reisman, RE				Reisman, RE			Insect sting allergy: The dilemma of the negative skin test reactor	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							VENOM IMMUNOTHERAPY; DIAGNOSTIC METHODS; HYPERSENSITIVITY; ANAPHYLAXIS; SEVERITY; SYMPTOMS		SUNY Buffalo, Sch Med, Buffalo, NY 14260 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Reisman, RE (corresponding author), Buffalo Med Grp, 295 Essjay Rd, Williamsville, NY 14221 USA.							BLAAUW PJ, 1985, J ALLERGY CLIN IMMUN, V75, P556, DOI 10.1016/0091-6749(85)90029-6; BOCK SA, 1978, J ALLERGY CLIN IMMUN, V62, P327, DOI 10.1016/0091-6749(78)90132-X; Goldberg A, 2000, J ALLERGY CLIN IMMUN, V106, P1184, DOI 10.1067/mai.2000.110927; Golden DBK, 1998, J ALLERGY CLIN IMMUN, V101, P298, DOI 10.1016/S0091-6749(98)70239-8; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; Lerch E, 1998, J ALLERGY CLIN IMMUN, V101, P606, DOI 10.1016/S0091-6749(98)70167-8; PARKER JL, 1982, J ALLERGY CLIN IMMUN, V69, P200, DOI 10.1016/0091-6749(82)90100-2; REISMAN RE, 1992, J ALLERGY CLIN IMMUN, V90, P335, DOI 10.1016/S0091-6749(05)80012-0; REISMAN RE, 1993, J ALLERGY CLIN IMMUN, V92, P831, DOI 10.1016/0091-6749(93)90060-S; REISMAN RE, 1987, ANN ALLERGY, V59, P429; WYPCH JI, 1984, INT ARCH ALLER A IMM, V73, P14	11	38	40	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2001	107	5					781	782						2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	434JX	11344342				2022-12-18	WOS:000168812300003
J	Sullivan, SD; Weiss, KB				Sullivan, SD; Weiss, KB			Health economics of asthma and rhinitis. II. Assessing the value of interventions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; allergic rhinitis; economics; cost-effectiveness analysis; costs	COST-EFFECTIVENESS ANALYSIS; BRONCHODILATOR DELIVERY METHODS; METERED-DOSE INHALER; FLUTICASONE PROPIONATE; DISEASE MANAGEMENT; SELF-MANAGEMENT; STRUCTURED TREATMENT; ALLERGIC RHINITIS; RANDOMIZED-TRIAL; OBSERVATION UNIT	Health care providers and payers are being asked to weigh data on the economic impact of new interventions along with clinical evidence when making decisions about the care of patients, The notion of incorporating formal health economic assessments into clinical and resource decisions is a difficult concept for many in the health fare sector. However, it is the reality in today's environment. To effectively participate in these ongoing discussions, clinicians and other decision makers must be able to understand and critically assess the evidence on economic impact of medical interventions. This second of 2 articles describes the elements of comparative economic evaluations, reviewing the published literature on asthma and rhinitis in an attempt to critically appraise the studies from the perspective of one who might use data for decision making. Unfortunately, the quality of the economic evidence in these two disease states is not extensive, Until better economic analyses are conducted and made available, the allocation of resources for asthma and allergic rhinitis will continue to primarily rely on expert opinion rather than evidence-based literature.	Rush Presbyterian St Lukes Med Ctr, Rush Primary Care Inst, Ctr Hlth Serv Res, Chicago, IL 60612 USA; Univ Washington, Sch Pharm, Dept Pharm Serv, Seattle, WA 98195 USA; Univ Washington, Sch Pharm, Dept Hlth Serv, Seattle, WA 98195 USA	Rush University; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Weiss, KB (corresponding author), Rush Presbyterian St Lukes Med Ctr, Rush Primary Care Inst, Ctr Hlth Serv Res, 1653 W Congress Pkwy, Chicago, IL 60612 USA.							ADELROTH E, 1988, LANCET, V1, P476; [Anonymous], 1996, COST EFFECTIVENESS H; Bailey R, 1998, CHEST, V113, P28, DOI 10.1378/chest.113.1.28; Balkrishnan R, 1998, CLIN THER, V20, P567, DOI 10.1016/S0149-2918(98)80066-0; Banta HD., 1993, HLTH CARE TECHNOLOGY; Barnes NC, 1999, RESP MED, V93, P402, DOI 10.1053/rmed.1999.0577; BARNES PJ, 1993, AM REV RESPIR DIS, V148, pS1, DOI 10.1164/ajrccm/148.4_Pt_2.S1; Barton S, 2000, BRIT MED J, V321, P255, DOI 10.1136/bmj.321.7256.255; BOLTON MB, 1991, J GEN INTERN MED, V6, P401, DOI 10.1007/BF02598160; Booth PC, 1996, PHARMACOECONOMICS, V10, P262, DOI 10.2165/00019053-199610030-00007; BOWTON DL, 1992, CHEST, V101, P305, DOI 10.1378/chest.101.2.305; Camargo C A Jr, 2000, Respir Care, V45, P756; CAMPBELL LM, 1993, BR J MED EC, V6, P67; CATES CJ, 1999, COCHRANE LIB; *CHILDH ASTHM MAN, 2000, NEW ENGLAND J MED, V0343; CLARK NM, 1986, J ALLERGY CLIN IMMUN, V78, P108, DOI 10.1016/0091-6749(86)90122-3; CONNETT GJ, 1993, BR J MED EC, V6, P127; COULET L, 1994, CHEST, V106, pS184; Curtin K, 1998, Eff Clin Pract, V1, P43; DETER HC, 1986, J PSYCHOSOM RES, V30, P173, DOI 10.1016/0022-3999(86)90047-4; Doan T, 1996, ANN ALLERG ASTHMA IM, V76, P513, DOI 10.1016/S1081-1206(10)63270-X; Drummond M.F., 2015, METHODS EC EVALUATIO, V4th; DRUMMOND N, 1994, BRIT MED J, V308, P559, DOI 10.1136/bmj.308.6928.559; Epstein RS, 1996, ANN INTERN MED, V124, P832, DOI 10.7326/0003-4819-124-9-199605010-00008; FIREMAN P, 1981, PEDIATRICS, V68, P341; FREUND DA, 1988, ANN ALLERGY, V60, P3; Gerdtham UG, 1996, MED CARE, V34, P1188, DOI 10.1097/00005650-199612000-00004; Ghosh CS, 1998, SOC SCI MED, V46, P1087, DOI 10.1016/S0277-9536(97)10047-8; Gilmet G. P., 2000, DIS MANAGEMENT, V3, P11; GLASSON J, 1995, JAMA-J AM MED ASSOC, V273, P330, DOI 10.1001/jama.1995.03520280076044; Gold MR, 1996, COST EFFECTIVENESS H; GREEN LW, 1974, HEALTH EDUC QUART, V2, P34, DOI 10.1177/10901981740020S106; Greineder DK, 1999, J ALLERGY CLIN IMMUN, V103, P436, DOI 10.1016/S0091-6749(99)70468-9; Haddix A, 1996, PREVENTION EFFECTIVE; Harris JM, 1996, ANN INTERN MED, V124, P838, DOI 10.7326/0003-4819-124-9-199605010-00009; Holzer SS, 1997, AM J MANAG C, V3, P891; Hunter DJ, 1997, BRIT MED J, V315, P50, DOI 10.1136/bmj.315.7099.50; JASPER AC, 1987, CHEST, V91, P614, DOI 10.1378/chest.91.4.614; Johansson G, 1999, PHARMACOECONOMICS, V16, P15, DOI 10.2165/00019053-199916002-00003; Jowers JR, 2000, AM J MANAG CARE, V6, P585; Kauppinen R, 1998, RESP MED, V92, P300, DOI 10.1016/S0954-6111(98)90113-5; Keith PK, 2000, ANN ALLERG ASTHMA IM, V84, P55, DOI 10.1016/S1081-1206(10)62741-X; Kelloway J S, 1997, Manag Care Interface, V10, P99; Kelly CS, 2000, ANN ALLERG ASTHMA IM, V84, P509, DOI 10.1016/S1081-1206(10)62514-8; Kelly CS, 2000, PEDIATRICS, V105, P1029, DOI 10.1542/peds.105.5.1029; Knoell DL, 1998, PHARMACOTHERAPY, V18, P1365; Kozma CM, 1996, CLIN THER, V18, P334, DOI 10.1016/S0149-2918(96)80014-2; KwanGett TS, 1997, ARCH PEDIAT ADOL MED, V151, P684, DOI 10.1001/archpedi.1997.02170440046008; Lahdensuo A, 1998, BRIT MED J, V316, P1138, DOI 10.1136/bmj.316.7138.1138; Langley PC, 1999, CLIN THER, V21, P236, DOI 10.1016/S0149-2918(00)88281-8; Lawrence G, 1995, Respir Care, V40, P39; Levenson T, 1997, ALLERGY ASTHMA PROC, V18, P73, DOI 10.2500/108854197778605455; LEWIS CE, 1984, PEDIATRICS, V74, P478; Liljas B, 1997, PHARMACOECONOMICS, V12, P267, DOI 10.2165/00019053-199712020-00017; Lord J, 1999, BRIT MED J, V319, P1470, DOI 10.1136/bmj.319.7223.1470; Lundback B, 2000, RESP MED, V94, P724, DOI 10.1053/rmed.2000.0876; Marks M K, 1997, Qual Manag Health Care, V6, P14; McCowan C, 1997, BRIT J GEN PRACT, V47, P156; McDowell KM, 1998, ARCH PEDIAT ADOL MED, V152, P977; MUHLHAUSER I, 1991, J INTERN MED, V230, P157; Munroe WP, 1997, CLIN THER, V19, P113, DOI 10.1016/S0149-2918(97)80078-1; *NAT ASTHM ED PREV, 1997, NIH PUBL; Neri M, 1996, ALLERGY, V51, P313, DOI 10.1111/j.1398-9995.1996.tb00091.x; O'Byrne P, 1996, CAN RESPIR J, V3, P169; O'Reilly JF, 1998, RESP MED, V92, P111, DOI 10.1016/S0954-6111(98)90041-5; Oconnor JFB, 1999, AM J GASTROENTEROL, V94, P1472; Orens D K, 1991, Respir Care, V36, P1099; Palmqvist M, 1999, PHARMACOECONOMICS, V16, P23, DOI 10.2165/00019053-199916002-00004; PERERA BJC, 1995, ARCH DIS CHILD, V72, P312, DOI 10.1136/adc.72.4.312; Pieters WR, 1999, PHARMACOECONOMICS, V16, P29, DOI 10.2165/00019053-199916002-00005; POPCOCK SJ, 2000, NEW ENGL J MED, V342, P1907; Price DB, 1998, RESP MED, V92, P351, DOI 10.1016/S0954-6111(98)90120-2; ROSS RN, 1988, CLIN THER, V10, P188; Rossiter LF, 2000, INQUIRY-J HEALTH CAR, V37, P188; Rutten-van Molken MPMH, 1998, PHARMACOECONOMICS, V14, P671, DOI 10.2165/00019053-199814060-00007; RUTTENVANMOLKEN MPMH, 1993, PHARMACOECONOMICS, V4, P257, DOI 10.2165/00019053-199304040-00004; RUTTENVANMOLKEN MPMH, 1995, AM J RESP CRIT CARE, V151, P975; Rydman RJ, 1998, MED CARE, V36, P599, DOI 10.1097/00005650-199804000-00015; Sackett DL., 1997, EVIDENCE BASED MED P; Santos R, 1999, AM J MANAG CARE, V5, pS225; Schadlich PK, 2000, PHARMACOECONOMICS, V17, P37, DOI 10.2165/00019053-200017010-00003; SCULPHER MJ, 1993, PHARMACOECONOMICS, V4, P345, DOI 10.2165/00019053-199304050-00005; Soondergaard B, 1992, Pharmacoeconomics, V1, P207; Stahl E, 2000, ANN ALLERG ASTHMA IM, V84, P397, DOI 10.1016/S1081-1206(10)62271-5; Suissa S, 1997, ANN INTERN MED, V126, P177, DOI 10.7326/0003-4819-126-3-199702010-00001; Sullivan S, 1996, AM J RESP CRIT CARE, V154, pS84, DOI 10.1164/ajrccm/154.3_Pt_2.S84; SUMMER W, 1989, ARCH INTERN MED, V149, P618, DOI 10.1001/archinte.149.3.618; Thomas K, 1996, NATL MED J INDIA, V9, P159; Thomas P, 1996, CLIN THER, V18, P939, DOI 10.1016/S0149-2918(96)80050-6; Torrance GW, 1987, METHODS EC EVALUATIO; TRAUTNER C, 1993, EUR RESPIR J, V6, P1485; Turner MO, 1996, ARCH INTERN MED, V156, P2113, DOI 10.1001/archinte.156.18.2113; van den Boom G, 1998, AM J RESP CRIT CARE, V158, P1730, DOI 10.1164/ajrccm.158.6.9709003; Warner KE, 1982, COST BENEFIT COST EF; Watanabe T, 1998, J CLIN PHARM THER, V23, P303, DOI 10.1046/j.1365-2710.1998.00163.x; Weiss KB, 2001, J ALLERGY CLIN IMMUN, V107, P3, DOI 10.1067/mai.2001.112262; Westley CR, 1997, ALLERGY ASTHMA PROC, V18, P15, DOI 10.2500/108854197778612835; WINDSOR RA, 1990, AM J PUBLIC HEALTH, V80, P1519, DOI 10.2105/AJPH.80.12.1519; ZWICKE DL, 1982, ANN EMERG MED, V11, P77, DOI 10.1016/S0196-0644(82)80301-6	99	38	40	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2001	107	2					203	210		10.1067/mai.2001.112851	http://dx.doi.org/10.1067/mai.2001.112851			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	403YV	11174182	Bronze			2022-12-18	WOS:000167071400001
J	Yamada, K; Elliott, WM; Hayashi, S; Brattsand, R; Roberts, C; Vitalis, TZ; Hogg, JC				Yamada, K; Elliott, WM; Hayashi, S; Brattsand, R; Roberts, C; Vitalis, TZ; Hogg, JC			Latent adenoviral infection modifies the steroid response in allergic lung inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						adenovirus; allergic eosinophilic inflammation; epithelial cells; steroid resistance	RESPIRATORY SYNCYTIAL VIRUS; AIRWAY INFLAMMATION; GUINEA-PIGS; INHALED GLUCOCORTICOIDS; ASTHMA; HYPERRESPONSIVENESS; PATHOGENESIS; EOSINOPHILIA; LYMPHOCYTES; INHIBITION	Background: Steroid-resistant asthma develops after adenoviral bronchiolitis. Objective: We sought to determine the effect of steroids on allergic lung inflammation in the presence of latent adenoviral infection. Methods: Guinea pigs with latent adenoviral (n = 12) or sham (n = 12) infections were sensitized and challenged with ovalbumin (OA) or sham sensitized and challenged with saline solution. The effect of steroids (20 mg/kg administered intraperitoneally) on OA-induced lung inflammation was examined by using quantitative histology as the outcome measure. Results: Latent adenoviral infection increased CD8(+) cells in the airway wall and CD8(+) cells, macrophages, B cells, and CD4(+) cells in the lung parenchyma. Ovalbumin challenge, on the other hand, increased eosinophils, macrophages, B cells, and CD4(+) cells in both the airway wall and lung parenchyma independent of the effect of latent adenoviral infection. In the sham-infected groups steroid treatment caused the expected reduction in the eosinophilic infiltrate induced by OA challenge in the airways without affecting the other cells. In the presence of both latent adenoviral infection and OA challenge, steroid treatment had no effect on allergen-induced eosinophilia but reduced CD8(+) cells in the airways and CD8(+) cells, CD4(+) cells, and B cells in the parenchyma. Conclusion: Latent adenoviral infection and OA challenge result in different types of lung inflammation, and the presence of latent adenoviral infection causes OA-induced eosinophilic airway inflammation to become steroid resistant.	Univ British Columbia, Pulm Res Lab, St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada; Astro Draco AB, Lund, Sweden	St. Paul's Hospital; University of British Columbia; University of Saskatchewan	Hogg, JC (corresponding author), Univ British Columbia, Pulm Res Lab, St Pauls Hosp, 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.							ANDERSSON P, 1982, BRIT J PHARMACOL, V76, P139, DOI 10.1111/j.1476-5381.1982.tb09199.x; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307; BASKIN MI, 1990, ANN INTERN MED, V113, P677, DOI 10.7326/0003-4819-113-9-677; Bramley AM, 1999, EUR RESPIR J, V14, P1061, DOI 10.1183/09031936.99.14510619; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405, DOI 10.1164/ajrccm/147.2.405; Chan MTS, 1998, J ALLERGY CLIN IMMUN, V101, P594, DOI 10.1016/S0091-6749(98)70165-4; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; DJUKANOVIC R, 1992, AM REV RESPIR DIS, V145, P669, DOI 10.1164/ajrccm/145.3.669; ELLIOTT WM, 1995, AM J RESP CELL MOL, V12, P642, DOI 10.1165/ajrcmb.12.6.7766428; FLEISS JL, 1986, DESIGN ANAL CLIN EXP, P91; Gern JE, 1996, J IMMUNOL, V157, P1605; GINSBERG HS, 1991, P NATL ACAD SCI USA, V88, P1651, DOI 10.1073/pnas.88.5.1651; GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P229, DOI 10.1111/j.1365-2818.1987.tb02837.x; HOGG JC, 1989, AM REV RESPIR DIS, V139, P1531, DOI 10.1164/ajrccm/139.6.1531; Howard C, 1998, UNBIASED STEREOLOGY; ISHIDA K, 1989, J APPL PHYSIOL, V67, P1133, DOI 10.1152/jappl.1989.67.3.1133; Jahnsen FL, 1999, J IMMUNOL, V163, P1545; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890, DOI 10.1164/ajrccm/145.4_Pt_1.890; Kamada AK, 1996, AM J RESP CRIT CARE, V153, P1739, DOI 10.1164/ajrccm.153.6.8665030; Leung DYM, 1999, J ALLERGY CLIN IMMUN, V104, pS99, DOI 10.1016/S0091-6749(99)70051-5; MACEK V, 1994, AM J RESP CRIT CARE, V150, P7, DOI 10.1164/ajrccm.150.1.8025775; Nickel R, 1999, J ALLERGY CLIN IMMUN, V104, P723, DOI 10.1016/S0091-6749(99)70281-2; NOLAN CR, 1986, NEW ENGL J MED, V315, P1516, DOI 10.1056/NEJM198612113152404; Olszewska-Pazdrak B, 1998, J VIROL, V72, P4756, DOI 10.1128/JVI.72.6.4756-4764.1998; POSTON RN, 1992, AM REV RESPIR DIS, V145, P918, DOI 10.1164/ajrccm/145.4_Pt_1.918; ROBERTS CR, 1991, AM J PHYSIOL, V261, pL92, DOI 10.1152/ajplung.1991.261.2.L92; Schwarze J, 1997, J CLIN INVEST, V100, P226, DOI 10.1172/JCI119516; STEGEMAN.H, 1967, CLIN CHIM ACTA, V18, P267, DOI 10.1016/0009-8981(67)90167-2; Vianna EO, 1998, J ALLERGY CLIN IMMUN, V102, P592, DOI 10.1016/S0091-6749(98)70274-X; Vitalis TZ, 1996, AM J RESP CELL MOL, V14, P225, DOI 10.1165/ajrcmb.14.3.8845172; Wang JH, 1996, AM J RESP CELL MOL, V14, P27, DOI 10.1165/ajrcmb.14.1.8534483; Xu Y, 2000, MOL CELL BIOL, V20, P2138, DOI 10.1128/MCB.20.6.2138-2146.2000	33	38	40	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2000	106	5					844	851		10.1067/mai.2000.110473	http://dx.doi.org/10.1067/mai.2000.110473			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	417ZK	11080705				2022-12-18	WOS:000167865200007
J	Kanbe, N; Kurosawa, M; Nagata, H; Yamashita, T; Kurimoto, F; Miyachi, Y				Kanbe, N; Kurosawa, M; Nagata, H; Yamashita, T; Kurimoto, F; Miyachi, Y			Production of fibrogenic cytokines by cord blood-derived cultured human mast cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Meeting on New Trends in Immunopharmacology 1998	JUL   25, 1998	TOKYO, JAPAN			mast cells; fibrogenic; cytokines; transforming growth factor-beta; platelet-derived growth factor; basic fibroblast growth factor	GROWTH-FACTOR-BETA; INDUCED PULMONARY FIBROSIS; MONONUCLEAR-CELLS; GENE-EXPRESSION; LINE HMC-1; ANTIBODIES; DOMAIN; IL-6	Background: Mast cells are a potential source of cytokines, but their contribution to nonallergic inflammatory conditions, such as fibrosis, remains unclear. Objective: We investigated whether cord blood-derived cultured human mast cells could produce fibrogenic cytokines by IgE-mediated activation. Methods: Mast cells were obtained from human cord blood mononuclear cells by culture with stem cell factor and IL-6, The mast cells were incubated with human myeloma IgE and were activated with anti-IgE. The expression of messenger RNA for fibrogenic cytokines was examined by the reverse-transcription polymerase chain reaction, and cytokine protein was assayed by enzyme-linked immunosorbent assay, or bioassay. Results: Cultured human mast cells constitutively expressed mRNA for transforming growth factor-beta(1), and its expression was not increased by anti-IgE stimulation. The cells released this factor into the culture medium spontaneously, which showed bioactivity after heat treatment. The mast cells also expressed mRNA for platelet-derived growth factor A, which was enhanced with a peak at 3 hours by stimulation with anti-IgE. Conditioned medium from nonactivated mast cells did not contain basic fibroblast growth factor, but this cytokine was released into the medium in a time-dependent manner after stimulation with anti-IgE. Conclusion: Human mast cells activated by IgE-mediated stimulation show production of fibrogenic cytokines that varies depending on the cytokine, which suggests possible involvement of mast cell cytokines in the development of fibrosis.	Hirosaki Univ, Sch Med, Dept Geriatr Med, Hirosaki, Aomori 0368562, Japan; Gunma Univ, Sch Med, Dept Dermatol, Maebashi, Gumma 371, Japan; Chiba Univ, Sch Med, Dept Otolaryngol, Chiba 280, Japan; Mitsubishi Kagaku Bio Clin Labs Inc, Res & Dev, Tokyo, Japan; Kyoto Univ, Grad Sch Med, Dept Dermatol, Kyoto, Japan	Hirosaki University; Gunma University; Chiba University; Mitsubishi Kagaku Bio-Clinical Laboratories; Kyoto University	Kurosawa, M (corresponding author), Hirosaki Univ, Sch Med, Dept Geriatr Med, 5 Zaifu Cho, Hirosaki, Aomori 0368562, Japan.		Kambe, Naotomo/H-3987-2017	Kambe, Naotomo/0000-0001-9610-4952				BIENENSTOCK J, 1987, AM REV RESPIR DIS, V135, P5; BROADLEY KN, 1989, LAB INVEST, V61, P571; BUTTERFIELD JH, 1988, LEUKEMIA RES, V12, P345, DOI 10.1016/0145-2126(88)90050-1; DAY R, 1987, AM REV RESPIR DIS, V136, P908, DOI 10.1164/ajrccm/136.4.908; GORDON JR, 1990, IMMUNOL TODAY, V11, P458, DOI 10.1016/0167-5699(90)90176-A; GORDON JR, 1994, J EXP MED, V180, P2027, DOI 10.1084/jem.180.6.2027; HAWKINS RA, 1985, ANN INTERN MED, V102, P182, DOI 10.7326/0003-4819-102-2-182; HU ZQ, 1994, IMMUNOLOGY, V82, P482; Igarashi Y, 1996, CLIN EXP ALLERGY, V26, P597; IRANI AMA, 1989, J HISTOCHEM CYTOCHEM, V37, P1509, DOI 10.1177/37.10.2674273; Kanbe N, 1998, ALLERGY, V53, P981, DOI 10.1111/j.1398-9995.1998.tb03800.x; Kanbe N, 1999, CLIN EXP ALLERGY, V29, P105; KATO M, 1995, J BIOL CHEM, V270, P12373, DOI 10.1074/jbc.270.21.12373; MIYAZONO K, 1987, J BIOL CHEM, V262, P4098; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; NILSSON G, 1995, SCAND J IMMUNOL, V42, P76, DOI 10.1111/j.1365-3083.1995.tb03628.x; NILSSON G, 1994, SCAND J IMMUNOL, V39, P489, DOI 10.1111/j.1365-3083.1994.tb03404.x; Persson U, 1997, J BIOL CHEM, V272, P21187, DOI 10.1074/jbc.272.34.21187; QU ZH, 1995, AM J PATHOL, V147, P564; RAGHOW R, 1989, J CLIN INVEST, V84, P1836, DOI 10.1172/JCI114369; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; ROBERTS AB, 1992, MOL REPROD DEV, V32, P91, DOI 10.1002/mrd.1080320203; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; Saito H, 1996, J IMMUNOL, V157, P343; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; YANAGIDA M, 1995, BLOOD, V86, P3705, DOI 10.1182/blood.V86.10.3705.bloodjournal86103705	26	38	40	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2000	106	1	2	S			S85	S90		10.1067/mai.2000.106777	http://dx.doi.org/10.1067/mai.2000.106777			6	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	339NF	10887339				2022-12-18	WOS:000088482600012
J	Gratzl, S; Palca, A; Schmitz, M; Simon, HU				Gratzl, S; Palca, A; Schmitz, M; Simon, HU			Treatment with IFN-alpha in corticosteroid-unresponsive asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IFN-alpha; asthma; corticosteroid	THERAPY		Univ Zurich, Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland; High Altitude Clin Davos Wolfgang, Davos, Switzerland	Swiss Institute of Allergy & Asthma Research; University of Zurich	Simon, HU (corresponding author), Univ Zurich, Swiss Inst Allergy & Asthma Res, Obere Str 22, CH-7270 Davos, Switzerland.		Simon, Hans-Uwe/AAU-7410-2020	Simon, Hans-Uwe/0000-0002-9404-7736				BUTTERFIELD JH, 1994, J ALLERGY CLIN IMMUN, V94, P1318, DOI 10.1016/0091-6749(94)90348-4; Grob JJ, 1998, LANCET, V351, P1905, DOI 10.1016/S0140-6736(97)12445-X; Oehling AG, 1997, ALLERGY, V52, P144, DOI 10.1111/j.1398-9995.1997.tb00968.x; Simon HU, 1999, NEW ENGL J MED, V341, P1112, DOI 10.1056/NEJM199910073411503; Simon HU, 1996, J EXP MED, V183, P1071, DOI 10.1084/jem.183.3.1071	5	38	38	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2000	105	5					1035	1036		10.1067/mai.2000.105317	http://dx.doi.org/10.1067/mai.2000.105317			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	316TW	10808188	Bronze			2022-12-18	WOS:000087185000026
J	Mautino, G; Capony, F; Bousquet, J; Vignola, AM				Mautino, G; Capony, F; Bousquet, J; Vignola, AM			Balance in asthma between matrix metalloproteinases and their inhibitors	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							AIRWAY INFLAMMATION; TISSUE INHIBITOR; SUBEPITHELIAL FIBROSIS; ALVEOLAR MACROPHAGES; BASEMENT-MEMBRANE; EXPRESSION; BIOPSIES		Inst Natl Sante & Rech Med U454, Hop Arnaud Villeneuve, Serv Malad Resp, F-34295 Montpellier 5, France; Consiglio Nazl Ric, Inst Fisiopatol Resp, Palermo, Italy	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; Consiglio Nazionale delle Ricerche (CNR)	Mautino, G (corresponding author), Inst Natl Sante & Rech Med U454, Hop Arnaud Villeneuve, Serv Malad Resp, F-34295 Montpellier 5, France.		Bousquet, Jean/O-4221-2019					Altraja A, 1996, AM J RESP CELL MOL, V15, P482, DOI 10.1165/ajrcmb.15.4.8879182; Bosse M, 1999, AM J RESP CRIT CARE, V159, P596, DOI 10.1164/ajrccm.159.2.9802045; Chetta A, 1996, AM J RESP CRIT CARE, V153, P910, DOI 10.1164/ajrccm.153.3.8630572; CLARK SD, 1987, J CLIN INVEST, V80, P1280, DOI 10.1172/JCI113203; Hoshino M, 1998, CLIN EXP ALLERGY, V28, P568; Hoshino M, 1998, J ALLERGY CLIN IMMUN, V102, P783, DOI 10.1016/S0091-6749(98)70018-1; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890, DOI 10.1164/ajrccm/145.4_Pt_1.890; Lemjabbar H, 1999, AM J RESP CRIT CARE, V159, P1298, DOI 10.1164/ajrccm.159.4.9708080; LUNDGREN R, 1988, EUR RESPIR J, V1, P883; Mautino G, 1999, LAB INVEST, V79, P39; Mautino G, 1999, AM J RESP CRIT CARE, V160, P324, DOI 10.1164/ajrccm.160.1.9808087; Mautino G, 1997, AM J RESP CELL MOL, V17, P583, DOI 10.1165/ajrcmb.17.5.2562; MURPHY G, 1992, AM J RESP CELL MOL, V7, P120, DOI 10.1165/ajrcmb/7.2.120; Ohno I, 1997, AM J RESP CELL MOL, V16, P212, DOI 10.1165/ajrcmb.16.3.9070604; Olivieri D, 1997, AM J RESP CRIT CARE, V155, P1864, DOI 10.1164/ajrccm.155.6.9196087; RAGHOW R, 1994, FASEB J, V8, P823, DOI 10.1096/fasebj.8.11.8070631; Reed CE, 1999, J ALLERGY CLIN IMMUN, V103, P539, DOI 10.1016/S0091-6749(99)70221-6; ROCHE WR, 1989, LANCET, V1, P520; SHAPIRO SD, 1991, J IMMUNOL, V146, P2724; Shapiro SD, 1999, AM J RESP CELL MOL, V20, P1100, DOI 10.1165/ajrcmb.20.6.f151; TRIGG CJ, 1994, AM J RESP CRIT CARE, V150, P17, DOI 10.1164/ajrccm.150.1.8025745; Vignola AM, 1998, AM J RESP CRIT CARE, V158, P1945, DOI 10.1164/ajrccm.158.6.9803014	23	38	41	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1999	104	3	1				530	533		10.1016/S0091-6749(99)70319-2	http://dx.doi.org/10.1016/S0091-6749(99)70319-2			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241EP	10482823				2022-12-18	WOS:000082870000011
J	Mori, A; Kaminuma, O; Mikami, T; Inoue, S; Okumura, Y; Akiyama, K; Okudaira, H				Mori, A; Kaminuma, O; Mikami, T; Inoue, S; Okumura, Y; Akiyama, K; Okudaira, H			Transcriptional control of the IL-5 gene by human helper T cells: IL-5 synthesis is regulated independently from IL-2 or IL-4 synthesis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Conference on New Trends in Immunopharmacology 1997	JUL 12, 1997	TOKYO, JAPAN	Novartis Pharma K K Tokyo		IL-5; T cell; gene transcription	MULTIPLE PROMOTER ELEMENTS; MOUSE INTERLEUKIN-5 GENE; BLOOD MONONUCLEAR-CELLS; BRONCHOALVEOLAR LAVAGE; PERIPHERAL-BLOOD; CYCLOSPORINE-A; INDUCIBLE ENHANCER; ATOPIC-DERMATITIS; BINDING-PROTEINS; NUCLEAR FACTOR	Background: IL-5 is fundamentally involved in eosinophilic inflammation. Control of IL-5 production may be effective for the management of allergic diseases, Objective: We aimed to find the transcriptional mechanisms that regulate the IL-5 gene to selectively control IL-5 synthesis. Methods: Allergen-specific T-cell clones and T-cell hybridomas were established from the peripheral blood Lymphocytes of patients with asthma, and the transcriptional regulation of the IL-5 gene was investigated with transient transfection and electrophoretic mobility shift analysis. Results: A human IL-5 promoter/enhancer-luciferase gene construct, pIL-5(-511)Luc, was transcribed on activation of IL-5-producing T-cell clones, but not IL-5-nonproducing clones. pIL-5(-511)Luc was transcribed by T-celI hybridomas derived from fusion between IL-5-producing T-cell clones and an IL-5 gene-nonexpressing T-cell line, but not by hybridomas derived from IL-5-nonproducing T-cell clones. IL-5 synthesis was not only induced by T-celI receptor stimulation but also by IL-2 receptor stimulation. Binding of NF-AT, NF-kappa B, and AP-I was induced by T-cell receptor (TcR) stimulation, although there was no significant upregulation of binding by IL-2 stimulation. Conclusion: IL-5 synthesis by human helper T cells is regulated at the transcriptional level. A unique transcriptional mechanism distinct from those regulating the IL-2 or IL-4 genes seems to control the IL-5 gene. Selective regulation of IL-5 gene transcription may be useful for treating eosinophlic inflammation.	Natl Sagamihara Hosp, Clin Res Ctr Allergy & Rheumatol, Sagamihara, Kanagawa 228, Japan; Univ Tokyo, Dept Med & Phys Therapy, Fac Med, Tokyo 113, Japan; Univ Tokyo, Fac Med, Dept Geriatr, Tokyo 113, Japan; Asahi Brewery Co Ltd, Biosci Res & Dev Lab, Ibaraki, Osaka, Japan	University of Tokyo; University of Tokyo; Asahi Group Holdings Ltd.	Mori, A (corresponding author), Natl Sagamihara Hosp, Clin Res Ctr Allergy & Rheumatol, 18-1 Sakuradai, Sagamihara, Kanagawa 228, Japan.							BOURKE PF, 1995, BLOOD, V85, P2069, DOI 10.1182/blood.V85.8.2069.bloodjournal8582069; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CORRIGAN CJ, 1993, AM REV RESPIR DIS, V147, P540, DOI 10.1164/ajrccm/147.3.540; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; GRUARTGOUILLEUX V, 1995, EUR J IMMUNOL, V25, P1431, DOI 10.1002/eji.1830250544; GULBENKIAN AR, 1992, AM REV RESPIR DIS, V146, P263, DOI 10.1164/ajrccm/146.1.263; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; Kaminuma O, 1997, AM J RESP CELL MOL, V16, P448, DOI 10.1165/ajrcmb.16.4.9115756; KAY AB, 1992, AM REV RESPIR DIS, V145, pS22, DOI 10.1164/ajrccm/145.2_Pt_2.S22; LEE HJ, 1995, J BIOL CHEM, V270, P17541, DOI 10.1074/jbc.270.29.17196; LEE HJ, 1993, J IMMUNOL, V151, P6135; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MAUSER PJ, 1993, AM REV RESPIR DIS, V148, P1623, DOI 10.1164/ajrccm/148.6_Pt_1.1623; MIZOGUCHI M, 1992, LANCET, V339, P1120, DOI 10.1016/0140-6736(92)90719-J; MORI A, 1995, INT ARCH ALLERGY IMM, V107, P366, DOI 10.1159/000237036; Mori A, 1996, INT IMMUNOL, V8, P1889, DOI 10.1093/intimm/8.12.1889; Mori A, 1997, BLOOD, V89, P2891, DOI 10.1182/blood.V89.8.2891; MORI A, 1994, INT ARCH ALLERGY IMM, V104, P32, DOI 10.1159/000236745; MORI A, 1995, INT IMMUNOL, V7, P449, DOI 10.1093/intimm/7.3.449; Mori A, 1997, J IMMUNOL, V158, P3659; MORI A, 1995, INT ARCH ALLERGY IMM, V107, P220, DOI 10.1159/000236983; MORI A, 1995, J IMMUNOL, V156, P2391; NAKAGAWA H, 1994, LANCET, V344, P883, DOI 10.1016/S0140-6736(94)92855-X; NAORA H, 1994, J IMMUNOL, V153, P3466; OHNISHI T, 1993, AM REV RESPIR DIS, V147, P901, DOI 10.1164/ajrccm/147.4.901; ONEILL EA, 1988, SCIENCE, V241, P1210, DOI 10.1126/science.3413485; PRIESCHL EE, 1995, J IMMUNOL, V154, P6112; RIEGEL JS, 1992, CHEM IMMUNOL, V51, P266; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; ROBINSON DS, 1993, J ALLERGY CLIN IMMUN, V92, P397, DOI 10.1016/0091-6749(93)90118-Y; ROONEY JW, 1995, IMMUNITY, V2, P473, DOI 10.1016/1074-7613(95)90028-4; SCHLEIMER RP, 1990, AM REV RESPIR DIS, V141, pS59; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SIEGEL MD, 1995, J BIOL CHEM, V270, P24548, DOI 10.1074/jbc.270.41.24548; SNYDER DS, 1982, J IMMUNOL, V129, P1803; STAYNOV DZ, 1992, IMMUNOLOGY, V75, P196; STRANICK KS, 1995, J BIOL CHEM, V270, P20575, DOI 10.1074/jbc.270.35.20575; TODD MD, 1993, J EXP MED, V177, P1663, DOI 10.1084/jem.177.6.1663; VACCA A, 1990, J BIOL CHEM, V265, P8075; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109; YAMAGATA T, 1995, MOL CELL BIOL, V15, P3830; YUUKI T, 1991, AGR BIOL CHEM TOKYO, V55, P1233, DOI 10.1080/00021369.1991.10870757	45	38	40	2	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1999	103	5	2	S			S429	S436		10.1016/S0091-6749(99)70158-2	http://dx.doi.org/10.1016/S0091-6749(99)70158-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	199TV	10329845	Bronze			2022-12-18	WOS:000080500200004
J	Jensen-Jarolim, E; Reider, N; Fritsch, R; Breiteneder, H				Jensen-Jarolim, E; Reider, N; Fritsch, R; Breiteneder, H			Fatal outcome of anaphylaxis to camomile-containing enema during labor: A case study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							REACTIVITY; BET-V-1		Univ Vienna, AKH, Dept Gen & Expt Pathol, A-1090 Vienna, Austria; Univ Innsbruck, Dept Dermatol, A-6020 Innsbruck, Austria	University of Vienna; University of Innsbruck	Jensen-Jarolim, E (corresponding author), Univ Vienna, AKH, Dept Gen & Expt Pathol, EBO 3Q,Waehringer Guertel 18-20, A-1090 Vienna, Austria.		Jensen-Jarolim, Erika/C-5120-2018	Jensen-Jarolim, Erika/0000-0003-4019-5765; Fritsch-Stork, ruth/0000-0003-0217-3629				BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; Ferreira F, 1996, J EXP MED, V183, P599, DOI 10.1084/jem.183.2.599; SUBIZA J, 1989, J ALLERGY CLIN IMMUN, V84, P353, DOI 10.1016/0091-6749(89)90420-X; Wen J, 1997, MOL PHYLOGENET EVOL, V8, P317, DOI 10.1006/mpev.1997.0447	5	38	40	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1998	102	6	1				1041	1042		10.1016/S0091-6749(98)70345-8	http://dx.doi.org/10.1016/S0091-6749(98)70345-8			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	150XE	9847448				2022-12-18	WOS:000077690700025
J	Suzuki, S; Suzuki, Y; Yamamoto, N; Matsumoto, Y; Shirai, A; Okubo, T				Suzuki, S; Suzuki, Y; Yamamoto, N; Matsumoto, Y; Shirai, A; Okubo, T			Influenza A virus infection increases IgE production and airway responsiveness in aerosolized antigen-exposed mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						virus infection; influenza A virus; IgE; airway hyperresponsiveness; CD8(+) cells; CD4(+) cells	T-CELLS; GUINEA-PIGS; ALLERGIC SENSITIZATION; ALVEOLAR MACROPHAGES; IMMUNE-RESPONSES; INHALED ANTIGEN; ASTHMA; INVIVO; OVALBUMIN; CHILDREN	Background: Respiratory viral infection is known clinically to promote sensitization to antigen inhalation and the development of asthma. Objective: The purpose of this investigation mas to determine whether influenza type A virus infection enhances inhalation sensitization and increases airway responsiveness in mice. Methods: Mice were infected by intranasal inoculation with influenza A viruses (strains: H1N1 and H3N2) or PBS. Animals were exposed to aerosols of of albumin on day 3. Two weeks after ovalbumin sensitization, mice were challenged with ovalbumin aerosols: 24 hours later, airway responsiveness (AR) to inhaled methacholine, levels of ovalbumin-specific IgE, and bronchoalveolar lavage fluid (BALF) were examined. Results: Neither influenza virus (H1N1 nor H3N2) alone nor ovalbumin sensitization alone caused changes in AR or IgE. However, ovalbumin sensitization after inoculation with either influenza A virus increased AR and levels of ovalbumin-specific IgE. On BALF-cell analysis, ovalbumin sensitization after inoculation with influenza virus A increased the number of lymphocytes but not the number of eosinophils. No difference in AR or IgE levels was observed between the 2 strains of influenza A viruses. Immmunostaining of BALF cells showed an increase in T cells, especially CD8(+) cells, with ovalbumin sensitization after inoculation with influenza virus A. Conclusion: Infection by influenza A virus enhances sensitization to inhaled antigens and airway responsiveness in mice by means of mechanisms including CD8(+) cells and antigen-specific IgE.	Yokohama City Univ, Sch Med, Dept Internal Med 1, Kanazawa Ku, Yokohama, Kanagawa 236, Japan	Yokohama City University	Suzuki, S (corresponding author), Yokohama City Univ, Sch Med, Dept Internal Med 1, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa 236, Japan.							AZOULAYDUPUIS E, 1984, J COMP PATHOL, V94, P273, DOI 10.1016/0021-9975(84)90046-X; BAUMGARTH N, 1994, J VIROL, V68, P7575, DOI 10.1128/JVI.68.11.7575-7581.1994; Baumgarth N, 1996, EUR J IMMUNOL, V26, P2189, DOI 10.1002/eji.1830260934; BRODER I, 1974, J ALLERGY CLIN IMMUN, V54, P100, DOI 10.1016/0091-6749(74)90038-4; BROIDE DH, 1991, J ALLERGY CLIN IMMUN, V88, P637, DOI 10.1016/0091-6749(91)90158-K; COYLE AJ, 1995, J EXP MED, V181, P1229, DOI 10.1084/jem.181.3.1229; DOLIN R, 1977, J INFECT DIS, V135, P714, DOI 10.1093/infdis/135.5.714; FOLKERTS G, 1993, AM REV RESPIR DIS, V147, P1569, DOI 10.1164/ajrccm/147.6_Pt_1.1569; FREIHORST J, 1988, P SOC EXP BIOL MED, V188, P191; FRICK OL, 1979, J ALLERGY CLIN IMMUN, V63, P228, DOI 10.1016/0091-6749(79)90106-4; GURWITZ D, 1981, J PEDIATR-US, V98, P551, DOI 10.1016/S0022-3476(81)80758-5; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Hamelmann E, 1997, AM J RESP CELL MOL, V16, P674, DOI 10.1165/ajrcmb.16.6.9191469; Hamelmann E, 1996, J EXP MED, V183, P1719, DOI 10.1084/jem.183.4.1719; HESSEL EM, 1995, EUR J PHARM-ENVIRON, V293, P401, DOI 10.1016/0926-6917(95)90061-6; HOLT PG, 1988, INT ARCH ALLER A IMM, V86, P121, DOI 10.1159/000234617; HOLT PG, 1993, J EXP MED, V177, P397, DOI 10.1084/jem.177.2.397; HOLTZMAN MJ, 1982, J APPL PHYSIOL, V53, P126, DOI 10.1152/jappl.1982.53.1.126; JOHNS K, 1990, AM REV RESPIR DIS, V142, P138, DOI 10.1164/ajrccm/142.1.138; KAY AB, 1992, BRIT MED BULL, V48, P51, DOI 10.1093/oxfordjournals.bmb.a072541; LARSEN GL, 1992, J CLIN INVEST, V89, P747, DOI 10.1172/JCI115651; Lebrec H, 1996, J TOXICOL ENV HEALTH, V49, P619; LEMANSKE RF, 1989, J CLIN INVEST, V83, P1, DOI 10.1172/JCI113843; LUKACHER AE, 1984, J EXP MED, V160, P814, DOI 10.1084/jem.160.3.814; MARTIN TR, 1988, J APPL PHYSIOL, V64, P2318, DOI 10.1152/jappl.1988.64.6.2318; MBOW ML, 1994, IMMUNOLOGY, V82, P596; MINOR TE, 1976, AM REV RESPIR DIS, V113, P149; MONTO AS, 1974, JAMA-J AM MED ASSOC, V227, P164, DOI 10.1001/jama.227.2.164; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; PATTEMORE PK, 1992, CLIN EXP ALLERGY, V22, P325, DOI 10.1111/j.1365-2222.1992.tb03094.x; PENE J, 1989, INT ARCH ALLER A IMM, V90, P32, DOI 10.1159/000235073; PENNOCK BE, 1979, J APPL PHYSIOL, V46, P399, DOI 10.1152/jappl.1979.46.2.399; RENZ H, 1993, J EXP MED, V177, P1175, DOI 10.1084/jem.177.4.1175; RENZ H, 1994, J IMMUNOL, V152, P351; RENZ H, 1992, J ALLERGY CLIN IMMUN, V89, P1127, DOI 10.1016/0091-6749(92)90296-E; SAKAMOTO M, 1984, J IMMUNOL, V132, P2614; SMITH JM, 1988, ALLERGY PRINCIPLES P, P891; TAYLOR KJ, 1987, THORAX, V42, P452, DOI 10.1136/thx.42.6.452; THEPEN T, 1992, CLIN EXP ALLERGY, V22, P1107, DOI 10.1111/j.1365-2222.1992.tb00137.x; WELLIVER RC, 1984, J IMMUNOL, V133, P1925; ZWEIMAN B, 1971, J ALLERGY CLIN IMMUN, V48, P283, DOI 10.1016/0091-6749(71)90029-7	41	38	41	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1998	102	5					732	740		10.1016/S0091-6749(98)70012-0	http://dx.doi.org/10.1016/S0091-6749(98)70012-0			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	139MR	9819289	Bronze, Green Published			2022-12-18	WOS:000077033400006
J	Simmons, MS; Nides, MA; Kleerup, EC; Chapman, KR; Milgrom, H; Rand, CS; Spector, SL; Tashkin, DP				Simmons, MS; Nides, MA; Kleerup, EC; Chapman, KR; Milgrom, H; Rand, CS; Spector, SL; Tashkin, DP			Validation of the Doser, a new device for monitoring metered-dose inhaler use	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						electronic medication monitoring; metered-dose inhaler; adherence; patient compliance	CLINICAL-TRIALS; MEDICATION; ASTHMA; ADHERENCE; NONCOMPLIANCE; CHRONOLOG; PRESSURE	Background: Electronic monitoring of medication use has proved valuable in both clinical and research settings. The Doser, a new and inexpensive commercially available device for monitoring metered-dose inhaler (MDI) use, displays 3 measures of daily use of an attached MDI: (1) the daily total of actuations, (2) the number of doses remaining in the MDI, and (3) the number of actuations on each of the preceding 30 days for later recall. Objective: We sought to validate the accuracy of the Doser with several commonly prescribed MDIs. Methods: In the laboratory, clinic personnel actuated an MDI with an attached Doser several times in succession on 3 consecutive days and recorded each of the 3 measures of MDI use (study 1), In study 2 clinic personnel carried an MDI and attached Doser with them for 4 weeks, actuating the MDI according to a prescribed protocol each morning and evening and again recording each of the 3 measures of daily use. In addition, during 2 weeks of study 2, a thermistor-based Nebulizer Chronolog was attached to the MDI to electronically record the date and time of each actuation, In study 3 clinic patients had both a Doser and Nebulizer Chronolog attached to their routinely used inhalers for 2 weeks and a Doser alone during a separate 2-week period. Results: In study 1 agreement was 99% to 100% among the 3 Doser measures, and each measure agreed with actual use by self-report 97% of the time. In study 2 agreement among the 3 Doser measures of use ranged from 98% to 99%, Agreement between each of the 3 Doser measures and the Nebulizer Chronolog ranged from 90% to 93%. Agreement between each of the 3 Doser measures and actual use ranged from 96% to 97%, and the Nebulizer Chronolog agreed with actual use 93% of the time, In study 3 Doser and Nebulizer Chronolog agreement with patient self-report were 85% and 80%, respectively, Agreement between the Doser and Nebulizer Chronolog was 76%. Several failures of the thermistor-based Nebulizer Chronolog occurred, and occasional mechanical problems occurred with the Doser, primarily on particular types of MDI canisters. Conclusion: The Doser provides an accurate measure of MDI use with most commonly prescribed medications and may be useful for monitoring MDI use by investigators, clinicians, and patients.	Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90095 USA; Toronto Hosp, Asthma Ctr, Toronto, ON M5T 2S8, Canada; Natl Jewish Med & Res Ctr, Denver, CO USA; Johns Hopkins Univ, Sch Med, Baltimore, MD USA; Allergy Res Fdn, Los Angeles, CA USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Toronto; University Toronto Affiliates; University Health Network Toronto; National Jewish Health; Johns Hopkins University	Tashkin, DP (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90095 USA.							BENDER B, 1997, AM J RESP CRIT CARE, V155, P259; Brueckner JW, 1997, J ALLERGY CLIN IMMUN, V100, P488, DOI 10.1016/S0091-6749(97)70140-4; CHANG JS, 1991, J OCUL PHARMACOL, V7, P117, DOI 10.1089/jop.1991.7.117; CHMELIK F, 1994, ANN ALLERGY, V73, P527; COUTTS JAP, 1992, ARCH DIS CHILD, V67, P332, DOI 10.1136/adc.67.3.332; MAWHINNEY H, 1991, ANN ALLERGY, V66, P294; MCKENNEY JM, 1992, J CLIN PHARMACOL, V32, P277, DOI 10.1002/j.1552-4604.1992.tb03837.x; Milgrom H, 1996, J ALLERGY CLIN IMMUN, V98, P1051, DOI 10.1016/S0091-6749(96)80190-4; NIDES MA, 1993, CHEST, V104, P501, DOI 10.1378/chest.104.2.501; RAND CS, 1992, AM REV RESPIR DIS, V146, P1559, DOI 10.1164/ajrccm/146.6.1559; ROVELLI M, 1989, TRANSPLANT P, V21, P833; RUDD P, 1995, AM HEART J, V130, P572, DOI 10.1016/0002-8703(95)90368-2; RUDD P, 1993, J GEN INTERN MED, V8, P659, DOI 10.1007/BF02598282; SAS Institute, 1990, SAS STAT US GUID VER; SAS INSTITUTE INC, 1990, SAS STAT US GUID VER, V1; SPECTOR SL, 1986, J ALLERGY CLIN IMMUN, V77, P65, DOI 10.1016/0091-6749(86)90325-8; Straka RJ, 1997, PHARMACOTHERAPY, V17, P126; TASHKIN DP, 1991, AM J MED, V91, pS33, DOI 10.1016/0002-9343(91)90260-5; Urquhart J, 1991, PATIENT COMPLIANCE M, P301; URQUHART J, 1988, DRUG INF J, V22, P363; WAMBOLDT F, 1997, AM J RESP CRIT CARE, V155, P259; WATERHOUSE DM, 1993, J CLIN ONCOL, V11, P1189, DOI 10.1200/JCO.1993.11.6.1189; WEEKS K, 1997, AM J RESP CRIT CARE, V155, P259	23	38	38	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1998	102	3					409	413		10.1016/S0091-6749(98)70128-9	http://dx.doi.org/10.1016/S0091-6749(98)70128-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	124ZN	9768581	hybrid			2022-12-18	WOS:000076212800012
J	Anibarro, B; Seoane, FJ				Anibarro, B; Seoane, FJ			Occupational conjunctivitis caused by sensitization to Anisakis simplex	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							URTICARIA		Hosp Severo Ochoa, Allergy Unit, Madrid, Spain	Severo Ochoa University Hospital	Anibarro, B (corresponding author), C Arzobispo Morcillo 42 9C, Madrid 28029, Spain.							AUDICANA MT, 1995, J ALLERGY CLIN IMMUN, V96, P558, DOI 10.1016/S0091-6749(95)70301-2; DelPozo MD, 1997, ALLERGY, V52, P576; KASUYA S, 1990, LANCET, V335, P665, DOI 10.1016/0140-6736(90)90455-E; Melillo G, 1997, ALLERGY, V52, P5, DOI 10.1111/j.1398-9995.1997.tb04814.x; Van Thiel P. H., 1960, Tropical and Geographical Medicine, V2, P97	5	38	39	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1998	102	2					331	332		10.1016/S0091-6749(98)70108-3	http://dx.doi.org/10.1016/S0091-6749(98)70108-3			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	113EH	9723684				2022-12-18	WOS:000075537100033
J	Di Lorenzo, G; Mansueto, P; Melluso, M; Candore, G; Colombo, A; Pellitteri, ME; Drago, A; Potestio, M; Caruso, C				Di Lorenzo, G; Mansueto, P; Melluso, M; Candore, G; Colombo, A; Pellitteri, ME; Drago, A; Potestio, M; Caruso, C			Allergic rhinitis to grass pollen: Measurement of inflammatory mediators of mast cell and eosinophils in native nasal fluid lavage and in serum out of and during pollen season	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophils; eosinophil cationic protein; histamine; tryptase; nasal lavage fluid; grass pollen	CATIONIC PROTEIN; HUMAN TRYPTASE; ASTHMA; CHALLENGE; IMMUNOASSAY; EXPOSURE; SYMPTOMS; SEMINARS; MEDICINE; RELEASE	Background: In allergic rhinitis, mast cells, activated by cross-linking of allergen to mast cell-bound specific IgE, release both vasoactive mediators related to the early nasal symptoms and chemotactic mediators that attract inflammatory cells, such as eosinophils, related to the late-phase response. Objective: We have analyzed, during and out of pollen season, in blood and nasal fluid from patients allergic to grass pollen, histamine and tryptase to monitor the early phase markers and eosinophil and eosinophil cationic protein (ECP) to monitor the late phase. Methods: Twenty patients were enrolled in the study. As a control, we studied 10 nonatopic subjects. Mediators and eosinophils were assessed in blood and nasal fluid. Histamine was tested only in nasal fluid. Results: During pollen season, tryptase but not histamine increased in nasal fluids from patients (2.96 vs 0.22 U/ml, p = 0.001) and correlated with symptom scores (r(s) = 0.63, p = 0.003). Tryptase was not detected in serum. Eosinophils increased in nasal cytology (17.0% vs 2.0%, p = 0.001) and in the blood (26.5 vs 12.7 x 10(6) L, p = 0.001) from patients, but they did not correlate with symptom scores. ECP increased only in the nasal lavage (16.33 vs 1.30 ng/ml, p = 0.001) and correlated with symptom scores (r(s) = 0.53, p = 0.016). Conclusions: Both ECP and tryptase increase in nasal secretion in natural disease. Therefore the measurement of tryptase and ECP levels in nasal fluid might be a useful clinical test for monitoring disease activity and the effects of therapeutic agents.	Univ Palermo, Ist Med Interna & Geriatria, I-90127 Palermo, Italy; Univ Palermo, Ist Patol Gen, Serv Tippizzaz Tissutale, I-90133 Palermo, Italy	University of Palermo; University of Palermo	Di Lorenzo, G (corresponding author), Univ Palermo, Ist Med Interna & Geriatria, Via Vespro 141, I-90127 Palermo, Italy.		Candore, Giuseppina GC/K-9496-2016; Mansueto, Pasquale/K-3458-2016	Di Lorenzo, Gabriele/0000-0002-0197-5665; Candore, Giuseppina/0000-0002-9966-934X; Mansueto, Pasquale/0000-0002-0406-0583				CASTELLS M, 1988, J ALLERGY CLIN IMMUN, V82, P348, DOI 10.1016/0091-6749(88)90005-X; DAHL R, 1990, RHINITIS ASTHMA SIMI, P203; DEGRAFFINTVELD C, 1996, CLIN EXP ALLERGY, V26, P966; DILORENZO G, 1995, CLIN EXP ALLERGY, V25, P951; DiLorenzo G, 1996, MEDIAT INFLAMM, V5, P113, DOI 10.1155/S0962935196000191; DILORENZO G, IN PRESS CLIN EXP IM; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P863, DOI 10.1164/ajrccm/142.4.863; DJUKANOVIC R, 1992, AM REV RESPIR DIS, V145, P669, DOI 10.1164/ajrccm/145.3.669; *EUR AC ALL CLIN I, 1989, ALLERGY, V10, P1; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; Kuna P, 1996, J ALLERGY CLIN IMMUN, V97, P104, DOI 10.1016/S0091-6749(96)70288-9; MELTZER EO, 1990, J ALLERGY CLIN IMMUN, V86, P221, DOI 10.1016/S0091-6749(05)80069-7; Mygind N, 1996, CLIN EXP ALLERGY, V26, P39, DOI 10.1111/j.1365-2222.1996.tb00658.x; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1991, NEW ENGL J MED, V325, P860; PLEEBLES RS, 1995, CHEM IMMUNOL, V62, P60; Rao R, 1996, CLIN EXP ALLERGY, V26, P789; RASP G, 1993, ALLERGY, V48, P72, DOI 10.1111/j.1398-9995.1993.tb00688.x; Schwartz LB, 1995, J CLIN INVEST, V96, P2702, DOI 10.1172/JCI118337; SCHWARTZ LB, 1987, ANN ALLERGY, V58, P226; SCHWARTZ LB, 1994, J CLIN IMMUNOL, V14, P190, DOI 10.1007/BF01533368; SVENSSON C, 1990, J ALLERGY CLIN IMMUN, V85, P828, DOI 10.1016/0091-6749(90)90064-B; ULRIK CS, 1995, CLIN EXP ALLERGY, V25, P820, DOI 10.1111/j.1365-2222.1995.tb00024.x; *UN ECP, 1995, N5250146401 UN ECP; VENGE P, 1994, ALLERGY, V49, P1, DOI 10.1111/j.1398-9995.1994.tb00765.x; VENGE P, 1995, RESP MED, V89, P1, DOI 10.1016/0954-6111(95)90062-4; WANG DY, 1995, INT ARCH ALLERGY IMM, V106, P278, DOI 10.1159/000236855; WELLER PF, 1991, NEW ENGL J MED, V324, P1110; WENZEL S, 1986, J IMMUNOL METHODS, V86, P139, DOI 10.1016/0022-1759(86)90277-2; WENZEL SE, 1988, AM REV RESPIR DIS, V137, P1002, DOI 10.1164/ajrccm/137.5.1002	31	38	40	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1997	100	6	1				832	837		10.1016/S0091-6749(97)70281-1	http://dx.doi.org/10.1016/S0091-6749(97)70281-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YQ151	9438494				2022-12-18	WOS:000071353600018
J	Nagai, H; Matsuo, A; Hiyama, H; Inagaki, N; Kawada, K				Nagai, H; Matsuo, A; Hiyama, H; Inagaki, N; Kawada, K			Immunoglobulin E production in mice by means of contact sensitization with a simple chemical, hapten	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Conference on New Trends in Immunopharmacology	JUL   06, 1996	TOKYO, JAPAN	Novartis Pharma KK, Tokyo, Japan		contact dermatitis; Th1 cell; Th2 cell; IgE; 2,4-dinitrofluorobenzene	ATOPIC-DERMATITIS; IGE; HYPERSENSITIVITY; ALLERGENS; EXPRESSION; IMMEDIATE; RESPONSES; ANTIGEN; ELISA	Production of IgE caused by repeated topical application of 2,4-dinitrofluorobenzene (DNFB) to the ears of BALB/c mice was investigated. Ear thickness increased in proportion to the number of applications. Eczematous changes of the skin included marked infiltration of neutrophils, eosinophils, and monocytes and hypertrophy of the epidermis. Ear thickness due to inflammation reached a maximum 24 hours after the second, third, fourth, and fifth applications. The strong expression of interferon-gamma and IL-2 messenger RNA (mRNA) in the skin lesions indicated the participation of Th1 type helper T cells in the delayed-type hypersensitivity reaction. After the fifth application, the mice showed an immediate cutaneous reaction in addition to the delayed-type hypersensitivity reaction. The immediate reaction appeared within 1 hour of application, Hapten-specific IgE also was detected in serum from the mice, and the expression of germline and productive C epsilon mRNA was detected in cervical lymph nodes, whereas productive C epsilon mRNA was detected in the spleen. These results indicate that five topical applications of DNFB to the ear produce local eczematous dermatitis and increase serum hapten-specific IgE level in mice, Eczematous dermatitis is mainly caused by Th1 type T cells, and IgE production is mediated by Th2 type T cells in the cervical lymph nodes. In addition, IgE class switching occurs in the cervical nodes and IgE production occurs in both Lymph nodes and spleen.	Gifu Pharmaceut Univ, Dept Pharmacol, Gifu 502, Japan; Gifu Coll Med Technol, Gifu, Japan	Gifu Pharmaceutical University	Nagai, H (corresponding author), Gifu Pharmaceut Univ, Dept Pharmacol, 5-6-1 Mitahora Higashi, Gifu 502, Japan.							ANNIE T, 1989, J IMMUNOL, V143, P2887; BORISH L, 1992, MED CLIN N AM, V76, P765, DOI 10.1016/S0025-7125(16)30325-X; Bruijnzeel-Koomen C, 1991, Clin Exp Allergy, V21 Suppl 1, P294, DOI 10.1111/j.1365-2222.1991.tb01745.x; CHAPMAN MD, 1983, J ALLERGY CLIN IMMUN, V72, P27, DOI 10.1016/0091-6749(83)90048-9; CHER DJ, 1987, J IMMUNOL, V138, P3688; DEARMAN RJ, 1992, TOXICOL APPL PHARM, V112, P190, DOI 10.1016/0041-008X(92)90187-W; DEARMAN RJ, 1991, IMMUNOLOGY, V72, P563; DEARMAN RJ, 1992, INT ARCH ALLERGY IMM, V97, P315, DOI 10.1159/000236139; HANIFIN JM, 1984, J ALLERGY CLIN IMMUN, V73, P211, DOI 10.1016/S0091-6749(84)80008-1; HIRANO T, 1989, J IMMUNOL METHODS, V119, P145, DOI 10.1016/0022-1759(89)90391-8; JUHLIN L, 1969, ARCH DERMATOL, V100, P12, DOI 10.1001/archderm.100.1.12; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; KITAGAKI H, 1995, J INVEST DERMATOL, V105, P749, DOI 10.1111/1523-1747.ep12325538; SAKAGUCHI M, 1989, J IMMUNOL METHODS, V116, P181, DOI 10.1016/0022-1759(89)90202-0; SALOGA J, 1994, AM J RESP CRIT CARE, V149, P65, DOI 10.1164/ajrccm.149.1.8111600; THYPHRONITIS G, 1993, J IMMUNOL, V151, P4128; UEHARA M, 1986, ACTA DERM-VENEREOL, V66, P404	17	38	39	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1997	100	6	2	S			S39	S44						6	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YR026	9440543				2022-12-18	WOS:000071449600003
J	Stanciu, LA; Shute, J; Promwong, C; Holgate, ST; Djukanovic, R				Stanciu, LA; Shute, J; Promwong, C; Holgate, ST; Djukanovic, R			Increased levels of IL-4 in CD8(+) T cells in atopic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic asthma; CD8(+) T cells; IL-4; IFN-gamma; Con A	MESSENGER-RNA EXPRESSION; PERIPHERAL-BLOOD; BRONCHOALVEOLAR LAVAGE; LYMPHOKINE SECRETION; CYTOKINE PRODUCTION; FUNCTIONAL SUBSETS; INTERLEUKIN-5; ACTIVATION; LYMPHOCYTES; CD4(+)	Background: In view of reports that CD8(+) T cells may produce T-H2-type cytokines and our own finding that levels of intracellular IL-4 are higher in CD8(+) than CD4(+) T cells in healthy nonatopic subjects, we have hypothesized that the capacity of CD8(+) T cells to produce IL-4 may be increased in atopic asthma, a disease characterized by high production of T-H2 cytokines. Methods: Levels of IL-4 and interferon-gamma were measured by ELISA in cell lysates and in 20- and 48-hour cultures of concanavalin A-stimulated purified peripheral blood CD8(+) T cells in seven patients with mild atopic asthma and seven healthy nonatopic subjects. Results: Resting CD8(+) T cells in patients with asthma contained significantly more IL-4 than those of healthy nonatopic subjects (median, 26 pg/10(6) cells; range, 17 to 84 pg/10(6) cells vs 16 pg/10(6) cells; 10 to 28 pg/10(6) cells), with no difference in intracellular interferon-gamma levels. In the healthy control subjects, but not in the patients with asthma, levels of intracellular IL-4 correlated negatively,vith levels of interferon-gamma in resting CD8(+) T cells (r(s) = -0.9411, p = 0.005). Stimulation with concanavalin A produced a consistent and significant increase in secretion of interferon-gamma, but not IL-4, with no difference between the two groups of subjects. Conclusion: The results of this study suggest that CD8(+) T cells from patients with asthma may be an important source of the T-H2-type cytokine IL-4. This capacity appears to be acquired in vivo, possibly by conditioning by IL-4 produced in the inflamed airways.	UNIV SOUTHAMPTON, DEPT MED, SOUTHAMPTON SO16 6YD, HANTS, ENGLAND	University of Southampton			Stanciu, Luminita A/B-8384-2012	Shute, Janis/0000-0002-6586-7583; Djukanovic, Ratko/0000-0001-6039-5612				[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; BRADDING P, 1994, AM J RESP CELL MOL, V10, P471, DOI 10.1165/ajrcmb.10.5.8179909; BROIDE DH, 1992, J ALLERGY CLIN IMMUN, V89, P958, DOI 10.1016/0091-6749(92)90218-Q; CONLON K, 1995, EUR J IMMUNOL, V25, P644, DOI 10.1002/eji.1830250303; CONLON K, 1995, EUR J IMMUNOL, V25, P751, DOI 10.1002/eji.1830250319; CORRIGAN CJ, 1993, AM REV RESPIR DIS, V147, P540, DOI 10.1164/ajrccm/147.3.540; COYLE AJ, 1995, J EXP MED, V181, P1229, DOI 10.1084/jem.181.3.1229; CROFT M, 1994, J EXP MED, V180, P1715, DOI 10.1084/jem.180.5.1715; ERARD F, 1993, SCIENCE, V260, P1802, DOI 10.1126/science.8511588; GONZALEZ S, 1994, J CLIN LAB ANAL, V8, P277, DOI 10.1002/jcla.1860080506; Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654, DOI 10.1164/ajrccm.154.3.8810601; JUNG T, 1995, EUR J IMMUNOL, V25, P2413, DOI 10.1002/eji.1830250843; KEMENY DM, 1994, IMMUNOL TODAY, V15, P107, DOI 10.1016/0167-5699(94)90152-X; Krug N, 1996, AM J RESP CELL MOL, V14, P319, DOI 10.1165/ajrcmb.14.4.8600935; LABERGE S, 1995, J IMMUNOL, V155, P2902; MAGGI E, 1994, J EXP MED, V180, P489, DOI 10.1084/jem.180.2.489; MATSUMOTO K, 1994, CHEST, V105, P681, DOI 10.1378/chest.105.3.681; MCMENAMIN C, 1993, J EXP MED, V178, P889, DOI 10.1084/jem.178.3.889; Meissner N, 1996, J ALLERGY CLIN IMMUN, V97, P904; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; OHEHIR RE, 1991, ANNU REV IMMUNOL, V9, P67, DOI 10.1146/annurev.iy.09.040191.000435; PAGANELLI R, 1995, J EXP MED, V181, P423, DOI 10.1084/jem.181.1.423; PARRONCHI P, 1992, J IMMUNOL, V149, P2977; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; RAMSAY AJ, 1993, IMMUNOL TODAY, V14, P155, DOI 10.1016/0167-5699(93)90277-R; RIEBER EP, 1994, J EXP MED, V179, P1385, DOI 10.1084/jem.179.4.1385; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588; Stanciu LA, 1996, J IMMUNOL METHODS, V189, P107, DOI 10.1016/0022-1759(95)00240-5; TILL S, 1995, EUR J IMMUNOL, V25, P2727, DOI 10.1002/eji.1830251002; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109; WEISS A, 1987, J IMMUNOL, V138, P2169; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; YING S, 1995, AM J RESP CELL MOL, V12, P477, DOI 10.1165/ajrcmb.12.5.7742012	36	38	40	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1997	100	3					373	378		10.1016/S0091-6749(97)70251-3	http://dx.doi.org/10.1016/S0091-6749(97)70251-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XX479	9314350	Bronze			2022-12-18	WOS:A1997XX47900015
J	Fujimura, T; Yamanashi, R; Masuzawa, M; Fujita, Y; Katsuoka, K; Nishiyama, S; Mitsuyama, M; Nomoto, K				Fujimura, T; Yamanashi, R; Masuzawa, M; Fujita, Y; Katsuoka, K; Nishiyama, S; Mitsuyama, M; Nomoto, K			Conversion of the CD4(+) T cell profile from T-H2-dominant type to T-H1-dominant type after varicella-zoster virus infection in atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; varicella; IL-12; cytokines; T-H1/T-H2	STIMULATORY FACTOR; IMMUNE-RESPONSES; IFN-GAMMA; CYTOKINE PRODUCTION; INTERFERON-GAMMA; LYMPHOCYTES-T; HELPER; SUBSETS; MICE; INTERLEUKIN-12	Skin lesions of atopic dermatitis were examined for cytokine expression by reverse transcription-polymerase chain reaction. The profile of mRNA for various cytokines revealed that both T-H1 and T-H2 types of CD4(+) T cells, probably including T-H0 type, infiltrate into the skin lesion. We observed that atopic skin lesions improved after varicella infection. In such lesions, expression of T-H1 type cytokines predominated. The peripheral blood T cells from atopic patients exhibited a differentiation into T-H2 type cells upon in vitro stimulation with mite antigen. In contrast they differentiated into T-H1 type cells upon stimulation by varicella antigen. Since IL-12 has been reported to switch the in vitro recall response of allergen-specific T cells of atopic donors from a T-H2- to a T-H1-like phenotype, we examined its local production in varicella lesions. IL-12 p35 and p40 mRNA were expressed in fresh lesions. Peripheral blood mononuclear cells from atopic patients expressed p40 mRNA upon in vitro stimulation with live varicella tester virus, but they did not show p40 mRNA without stimulation. This finding suggested that in atopic skin lesions containing the virus, IL-12 was produced and the cell type was changed to T-H1 type-predominance. These results suggested that patients with atopic dermatitis always have highly reactive CD4(+) T cells infiltrating into their skin, and that the snitch to T-H1 or T-H2 dominance is related to whether the lesion is improved or exacerbated.	NIIGATA UNIV, SCH MED, DEPT BACTERIOL, NIIGATA, JAPAN; KYUSHU UNIV, MED INST BIOREGULAT, DEPT IMMUNOL, FUKUOKA 812, JAPAN	Niigata University; Kyushu University	Fujimura, T (corresponding author), KITASATO UNIV, SCH MED, DEPT DERMATOL, 1-15-1 KITASATO, SAGAMIHARA, KANAGAWA 228, JAPAN.							CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHRETIEN I, 1990, EUR J IMMUNOL, V20, P243, DOI 10.1002/eji.1830200203; DELPRETE GF, 1991, J CLIN INVEST, V88, P346, DOI 10.1172/JCI115300; FINKELMAN FD, 1994, J EXP MED, V179, P1563, DOI 10.1084/jem.179.5.1563; Fujimura T, 1996, ACTA DERM-VENEREOL, V76, P321; GRANLUND H, 1995, BRIT J DERMATOL, V132, P106, DOI 10.1111/j.1365-2133.1995.tb08633.x; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; HSIEH CS, 1992, P NATL ACAD SCI USA, V89, P6065, DOI 10.1073/pnas.89.13.6065; KAWAMURA I, 1992, J IMMUNOL, V148, P2887; KOBAYASHI M, 1989, J EXP MED, V170, P827, DOI 10.1084/jem.170.3.827; LACOUR M, 1994, DERMATOLOGY, V188, P255, DOI 10.1159/000247161; MAGGI E, 1991, J IMMUNOL, V146, P1169; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; MOSMANN TR, 1991, IMMUNOL REV, V123, P209, DOI 10.1111/j.1600-065X.1991.tb00612.x; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MUNRO CS, 1994, BRIT J DERMATOL, V130, P376, DOI 10.1111/j.1365-2133.1994.tb02936.x; Ohyama Y, 1996, ARTHRITIS RHEUM, V39, P1376, DOI 10.1002/art.1780390816; OSWALD IP, 1994, J IMMUNOL, V153, P1707; Otter W. Den, 1993, British Journal of Dermatology, V128, P102, DOI 10.1111/j.1365-2133.1993.tb00157.x; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; PENE J, 1994, IMMUNOLOGY, V81, P58; PIRMEZ C, 1993, J CLIN INVEST, V91, P1390, DOI 10.1172/JCI116341; RAMBLINDHAUER C, 1991, ARCH DERMATOL RES, V283, P71, DOI 10.1007/BF00371611; REINER SL, 1994, J EXP MED, V179, P447, DOI 10.1084/jem.179.2.447; REINHOLD U, 1991, CLIN EXP IMMUNOL, V86, P444; REINHOLD U, 1990, CLIN EXP IMMUNOL, V79, P374; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; SAMPSON HA, 1991, IMMUNOLOGIC DISEASES, P229; SCOTT P, 1991, IMMUNOL TODAY, V12, P346, DOI 10.1016/0167-5699(91)90063-Y; SCOTT P, 1991, J IMMUNOL, V147, P3149; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; SHER A, 1992, IMMUNOL REV, V127, P183, DOI 10.1111/j.1600-065X.1992.tb01414.x; SIELING PA, 1994, J IMMUNOL, V153, P3639; TANG MLK, 1994, LANCET, V344, P983, DOI 10.1016/S0140-6736(94)91641-1; TANG MLK, 1994, CLIN EXP IMMUNOL, V97, P491; TAYLORROBINSON AW, 1993, SCIENCE, V260, P1931, DOI 10.1126/science.8100366; VANDERHEIJDEN FL, 1991, J INVEST DERMATOL, V97, P389, DOI 10.1111/1523-1747.ep12480966; VELUPILLAI P, 1994, P NATL ACAD SCI USA, V91, P18, DOI 10.1073/pnas.91.1.18; VERBOV J, 1986, PRACTITIONER, V230, P15; WIERENGA EA, 1991, J IMMUNOL, V147, P2942; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; WOLF SF, 1991, J IMMUNOL, V146, P3074; WU CY, 1993, J IMMUNOL, V151, P1938; YAMAMURA M, 1991, SCIENCE, V254, P277, DOI 10.1126/science.1925582; ZACHARY CB, 1985, BRIT J DERMATOL, V112, P149, DOI 10.1111/j.1365-2133.1985.tb00078.x; ZHANG M, 1994, J CLIN INVEST, V93, P1733, DOI 10.1172/JCI117157	48	38	38	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1997	100	2					274	282		10.1016/S0091-6749(97)70236-7	http://dx.doi.org/10.1016/S0091-6749(97)70236-7			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XR351	9275152	Bronze			2022-12-18	WOS:A1997XR35100021
J	PlattsMills, TAE; Woodfolk, JA; Chapman, MD; Heymann, PW				PlattsMills, TAE; Woodfolk, JA; Chapman, MD; Heymann, PW			Changing concepts of allergic disease: The attempt to keep up with real changes in lifestyles	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergens; asthma; causation; dust mite; exposure; hay fever; housing; outdoor; environment; sensitization	HOUSE-DUST MITE; FEL-D-I; RISK-FACTORS; ENVIRONMENTAL-CONTROL; INHALANT ALLERGENS; ASTHMATIC-CHILDREN; CHRONIC SINUSITIS; CHILDHOOD ASTHMA; IGE ANTIBODIES; GRASS-POLLEN	In the past 200 years, changes have occurred in the outdoor environment and in houses that have contributed to the increased prevalence of hay fever and asthma. Much evidence indicates that exposure to indoor allergens is an important cause of asthma. Changes in housing that have contributed to the increased prevalence and severity of asthma include ina eased temperature, decreased ventilation and permanent carpeting In addition to these changes, geographic differences in allergens, deficiencies in cleanliness, pool health care, passive smoke, and lack of exercise also contribute to the increase in severity of asthma that has occurred. The management of asthma includes controlling exposure to indoor allergens and seeking additional treatable causes of asthma (e.g., fungal allergens). Changes will continue to occur, and physicians who treat allergic diseases should become involved in the design of houses to limit exposure. Many questions regarding allergen measurement and control remain.			PlattsMills, TAE (corresponding author), UNIV VIRGINIA, HLTH SCI CTR, ASTHMA & ALLERGY DIS CTR, BOX 225, CHARLOTTESVILLE, VA 22908 USA.			Platts-Mills, Thomas/0000-0002-1263-329X; Chapman, Martin/0000-0002-0845-3632				ALEXANDER AG, 1992, LANCET, V339, P324, DOI 10.1016/0140-6736(92)91646-P; [Anonymous], 1966, HEALTH PHYS, V12, P173; ARSHAD SH, 1992, J ALLERGY CLIN IMMUN, V90, P235, DOI 10.1016/0091-6749(92)90077-F; ASIMOV I, 1953, CAVES STEEL; BALL BD, 1990, ANN ALLERGY, V65, P37; BANBRONSWIJK JEM, 1981, HOUSE DUST BIOL; BARDANA EJ, 1981, CRC CR REV CL LAB SC, V13, P85; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; Blackley CH., 1873, EXPT RES CAUSES NATU; Burge H, 1993, INDOOR ALLERGENS ASS; BURNEY PGJ, 1993, ASTHMA; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; CHARPIN D, 1991, AM REV RESPIR DIS, V143, P983, DOI 10.1164/ajrccm/143.5_Pt_1.983; CLARKE CW, 1979, CLIN ALLERGY, V9, P147, DOI 10.1111/j.1365-2222.1979.tb01535.x; COOKE RA, 1947, ALLERGY THEORY PRACT, P130; DEBLAY F, 1991, AM REV RESPIR DIS, V143, P1334, DOI 10.1164/ajrccm/143.6.1334; DENNING DW, 1991, CHEST, V100, P813, DOI 10.1378/chest.100.3.813; DEUELL B, 1991, J IMMUNOL, V147, P96; DUFF AL, 1993, PEDIATRICS, V92, P535; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; GERGEN PJ, 1990, JAMA-J AM MED ASSOC, V264, P1688, DOI 10.1001/jama.264.13.1688; GREENBERGER PA, 1987, CHEST, V91, pS165, DOI 10.1378/chest.91.6.165S; HAAHTELA T, 1990, BRIT MED J, V301, P266, DOI 10.1136/bmj.301.6746.266; HAGY GW, 1971, J ALLERGY CLIN IMMUN, V48, P200, DOI 10.1016/0091-6749(71)90066-2; HAMILOS DL, 1993, J ALLERGY CLIN IMMUN, V92, P39, DOI 10.1016/0091-6749(93)90035-E; HARLIN SL, 1988, J ALLERGY CLIN IMMUN, V81, P867, DOI 10.1016/0091-6749(88)90944-X; KEITH PK, 1994, J ALLERGY CLIN IMMUN, V93, P567, DOI 10.1016/S0091-6749(94)70068-0; Kern RA., 1921, MED CLIN N AM, V5, P751; KJELLMAN B, 1983, ALLERGY, V38, P65, DOI 10.1111/j.1398-9995.1983.tb00858.x; KORSGAARD J, 1983, AM REV RESPIR DIS, V128, P231; LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P718, DOI 10.1016/0091-6749(89)90300-X; LEMANSKE RF, 1989, J CLIN INVEST, V83, P1, DOI 10.1172/JCI113843; LIU MC, 1991, AM REV RESPIR DIS, V144, P51, DOI 10.1164/ajrccm/144.1.51; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; LUNDBACK B, 1993, ASTHMA CHRONIC BRONC; MARTINEZ FD, 1992, PEDIATRICS, V89, P21; MCDONALD LG, 1992, J ALLERGY CLIN IMMUN, V90, P599, DOI 10.1016/0091-6749(92)90132-L; MULLARKEY MF, 1988, NEW ENGL J MED, V318, P603, DOI 10.1056/NEJM198803103181004; MUNIR AKM, 1993, J ALLERGY CLIN IMMUN, V91, P1067, DOI 10.1016/0091-6749(93)90221-Z; NEWMAN LJ, 1994, JAMA-J AM MED ASSOC, V271, P363, DOI 10.1001/jama.271.5.363; OHMAN JL, 1973, J ALLERGY CLIN IMMUN, V52, P231, DOI 10.1016/0091-6749(73)90061-4; PEAT JK, 1993, CLIN EXP ALLERGY, V23, P812, DOI 10.1111/j.1365-2222.1993.tb00258.x; PEAT JK, 1987, CLIN ALLERGY, V17, P291, DOI 10.1111/j.1365-2222.1987.tb02017.x; Platts-Mills TAE, 1984, ASTHMA PHYSL IMMUNOP, P297; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P755, DOI 10.1016/S0091-6749(87)80261-0; PLATTSMILLS TAE, 1989, IMMUNOL ALLERGY CLIN, V9, P269; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P781, DOI 10.1016/0091-6749(87)90211-9; PLATTSMILLS TAE, 1982, CLIN ASPECTS IMMUNOL, P579; PLATTSMILLS TAE, 1989, J ALLERGYCLIN IMMUNO, V66, P769; POLLART SM, 1988, J ALLERGY CLIN IMMUN, V82, P224, DOI 10.1016/0091-6749(88)91003-2; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; PRICE JA, 1990, LANCET, V336, P895, DOI 10.1016/0140-6736(90)92268-M; RACKEMANN FM, 1947, AM J MED, V3, P601, DOI 10.1016/0002-9343(47)90204-0; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; Schor Juliet B., 1991, OVERWORKED AM; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; SMITH JM, 1969, BRIT MED J, V2, P723, DOI 10.1136/bmj.2.5659.723; SPENGLER JD, 1983, SCIENCE, V221, P9, DOI 10.1126/science.6857273; SPORIK R, 1992, CLIN EXP ALLERGY, V22, P897, DOI 10.1111/j.1365-2222.1992.tb02062.x; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; SPORIK R, 1991, Journal of Allergy and Clinical Immunology, V87, P291, DOI 10.1016/0091-6749(91)91888-Z; SPORIK R, IN PRESS AM J RESPIR; SVARTENGREN M, 1987, EXP LUNG RES, V12, P75, DOI 10.3109/01902148709068815; SWANSON MC, 1990, AM REV RESPIR DIS, V141, P1578, DOI 10.1164/ajrccm/141.6.1578; SWINEFORD O, 1973, ASTHMA HAY FEVER OTH; TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630; TOVEY ER, 1981, NATURE, V289, P592, DOI 10.1038/289592a0; VOORHORST R, 1969, HOUSE DUST MITE ATOP; WARD GW, 1989, LANCET, V1, P859; WARD GW, 1993, J ALLERGY CLIN IMMUN, V91, P226; WHARTON E, 1984, HOUSE OF MIRTH; Wise F, 1930, J AMER MED ASSOC, V95, P1504, DOI 10.1001/jama.1930.27210200002011a; Wyman M., 1872, AUTUMNAL CATARRH HAY	75	38	39	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1996	98	6	3	S			S297	S306		10.1016/S0091-6749(96)80115-1	http://dx.doi.org/10.1016/S0091-6749(96)80115-1			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WC448	8977541				2022-12-18	WOS:A1996WC44800003
J	Secord, EA; Kleiner, GI; Auci, DL; SmithNorowitz, T; Chice, S; Finkielstein, A; Nowakowski, M; Fikrig, S; Durkin, HG				Secord, EA; Kleiner, GI; Auci, DL; SmithNorowitz, T; Chice, S; Finkielstein, A; Nowakowski, M; Fikrig, S; Durkin, HG			IgE against HIV proteins in clinically healthy children with HIV disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HIV infection; IgE levels; opportunistic infections; CD4(+) T cells; Western blot	HUMAN-IMMUNODEFICIENCY-VIRUS; IMMUNOGLOBULIN-E; SERUM IGE; ANTIBODIES; INFECTION; ELEVATION; ANTIGENS; ATOPY; CELLS	Elevated serum IgE was detected in 26% (7 of 30) of children with HIV infection. The majority of children with elevated IgE were of one ethnic group (Puerto Rican) (4 of 7), compared with only 9% (2 of 23) in the normal to low IgE group (p = 0.02). Most of the children with elevated IgE had decreased circulating CD4(+) T cells (5 of 7 or 71%); but none had opportunistic infections, and none failed to thrive. Although similar numbers of children with normal to low IgE had decreased circulating CD4(+) T cells (19 of 23 or 83%), this group had opportunistic infections (6 of 23 26%) and failure to thrive (7 of 30 or 30%). There was no difference in incidence of allergic symptoms between groups. IgE antibody against HIV protein was detected by Western blot technique in the sera of three children with elevated serum IgE. Thus we have identified a group of children with HIV infection and elevated serum IgE of predominantly one ethnic group, who are without opportunistic infections or failure to thrive, some of whom produce HIV-specific IgE. This suggests that IgE may play a protective (perhaps late compensatory) role in HIV disease in genetically predisposed individuals.	SUNY HLTH SCI CTR,DEPT PEDIAT,BROOKLYN,NY 11203	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center								CAPRON M, 1994, SCIENCE, V264, P1876, DOI 10.1126/science.8009216; CARINI C, 1988, P NATL ACAD SCI USA, V85, P9214, DOI 10.1073/pnas.85.23.9214; CLERICI M, 1993, IMMUNOL TODAY, V107, P14; HOMBURGER HA, 1982, CLIN LAB ANN, V2, P1060; ISRAELBIET D, 1992, J ALLERGY CLIN IMMUN, V89, P68, DOI 10.1016/S0091-6749(05)80042-9; KHALIFE J, 1988, AIDS RES HUM RETROV, V4, P3, DOI 10.1089/aid.1988.4.3; MAGGI E, 1989, RES CLIN LAB, V19, P45; MAGGI E, 1992, J IMMUNOL, V148, P2142; NOWAKOWSKI M, 1992, ANN CLIN LAB SCI, V22, P377; Pizzo P. A., 1993, AIDS Clinical Care, V5, P9; RING J, 1986, ACTA DERM-VENEREOL, V66, P530; RUSSI JC, 1993, J CLIN MICROBIOL, V31, P819, DOI 10.1128/JCM.31.4.819-823.1993; SMALL CB, 1993, J INFECT DIS, V167, P283, DOI 10.1093/infdis/167.2.283; VIGANO A, 1995, J ALLERGY CLIN IMMUN, V95, P627, DOI 10.1016/S0091-6749(95)70326-8; WRIGHT DN, 1990, J ALLERGY CLIN IMMUN, V85, P445, DOI 10.1016/0091-6749(90)90154-V	15	38	39	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1996	98	5	1				979	984		10.1016/S0091-6749(96)80015-7	http://dx.doi.org/10.1016/S0091-6749(96)80015-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VU764	8939162				2022-12-18	WOS:A1996VU76400015
J	Widdicombe, JG				Widdicombe, JG			Sensory neurophysiology of the cough reflex	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						capsaicin; C fiber receptors; cough; cough receptors; neuropeptides; rapidly adapting receptors; tachykinins	AWAKE GUINEA-PIGS; SUBSTANCE-P; RESPIRATORY-TRACT; ANESTHETIZED CATS; BRONCHOCONSTRICTION; CAPSAICIN; LARYNGEAL; INNERVATION; RECEPTORS; IRRITANT	The epithelium of the larynx, trachea, and larger bronchi contains sensory nerves that are responsible for cough. Their two main categories are rapidly adapting receptors (RARs) and C fiber receptors. Both types respond to a wide variety of mechanical and chemical irritants. The RARs are the main sensory complex responsible for cough. C fiber receptors cause neurogenic inflammation by the release of tachykinins such as substance P. The reflex action of C fiber receptors seems to be inhibition of cough. However; the released tachykinins can stimulate RARs and promote of enhance the cough response. The strength and pattern of cough depends on the sites of the airway that are stimulated and the local and central reflex interactions of the RARs and C fiber receptors. Tachykinins seem to be involved in cough, but their role needs further study.	UNIV LONDON, ST GEORGE HOSP, SCH MED, DEPT PHYSIOL, LONDON, ENGLAND	St Georges University London; University of London								ADVENIER C, 1993, EUR J PHARMACOL, V250, P169, DOI 10.1016/0014-2999(93)90637-W; ARMSTRONG DJ, 1974, RESP PHYSIOL, V21, P47, DOI 10.1016/0034-5687(74)90006-1; BALUK P, 1993, AM J RESP CELL MOL, V8, P446, DOI 10.1165/ajrcmb/8.4.446; BALUK P, 1992, J COMP NEUROL, V319, P586, DOI 10.1002/cne.903190408; BARNES PJ, 1992, ASTHMA BASIC MECHANI, P359; Coleridge H.M., 1986, HDB PHYSL, P395, DOI [10.1002/cphy.cp030212, DOI 10.1002/CPHY.CP030212]; COLERIDGE JCG, 1984, REV PHYSIOL BIOCH P, V99, P1, DOI 10.1007/BFb0027715; DAS RM, 1979, J ANAT, V128, P259; DAS RM, 1978, J ANAT, V126, P123; FORSBERG K, 1990, J PHYSIOL-LONDON, V422, pP34; Forsberg K, 1988, Pulm Pharmacol, V1, P33, DOI 10.1016/0952-0600(88)90008-7; FOX AJ, 1993, J PHYSIOL-LONDON, V469, P21, DOI 10.1113/jphysiol.1993.sp019802; Gaylor JB, 1934, BRAIN, V57, P143, DOI 10.1093/brain/57.2.143; ICHINOSE M, 1992, LANCET, V340, P1248, DOI 10.1016/0140-6736(92)92948-F; Jackson D M, 1989, Pulm Pharmacol, V2, P179, DOI 10.1016/0952-0600(89)90018-5; JACKSON DM, 1988, BRIT J PHARMACOL, V93, P609, DOI 10.1111/j.1476-5381.1988.tb10317.x; JANCSO G, 1992, EXP PHYSIOL, V77, P405, DOI 10.1113/expphysiol.1992.sp003603; JOOS G, 1987, THORAX, V42, P779, DOI 10.1136/thx.42.10.779; KARLSSON JA, 1993, THORAX, V48, P396, DOI 10.1136/thx.48.4.396; KARLSSON JA, 1988, J APPL PHYSIOL, V65, P1007, DOI 10.1152/jappl.1988.65.3.1007; KATSUMATA U, 1989, TOHOKU J EXP MED, V158, P105, DOI 10.1620/tjem.158.105; KOHROGI H, 1988, J CLIN INVEST, V82, P2063, DOI 10.1172/JCI113827; KORPAS J, 1979, COUGH OTHER RESP REF, P1; Laitinen A, 1985, Eur J Respir Dis Suppl, V140, P1; MCDONALD DM, 1994, CL ALLER IM, V4, P321; MOHAMMED SP, 1993, J PHYSIOL-LONDON, V469, P51, DOI 10.1113/jphysiol.1993.sp019804; MORICE AH, 1987, LANCET, V2, P1116; Myers AC, 1996, J ALLERGY CLIN IMMUN, V98, pS107, DOI 10.1016/S0091-6749(96)80137-0; PRABHAKAR NR, 1987, ACTA PHYSIOL SCAND, V131, P63, DOI 10.1111/j.1748-1716.1987.tb08206.x; SEKIZAWA K, 1995, AM J RESP CRIT CARE, V151, P815; STOCKWELL M, 1993, J APPL PHYSIOL, V75, P613, DOI 10.1152/jappl.1993.75.2.613; STONE RA, 1993, J APPL PHYSIOL, V74, P396, DOI 10.1152/jappl.1993.74.1.396; TAKAHAMA K, 1993, REGUL PEPTIDES, V46, P236, DOI 10.1016/0167-0115(93)90045-A; TATAR M, 1988, J PHYSIOL-LONDON, V402, P411, DOI 10.1113/jphysiol.1988.sp017212; TATAR M, 1994, J APPL PHYSIOL, V76, P2672, DOI 10.1152/jappl.1994.76.6.2672; UJIIE Y, 1993, AM REV RESPIR DIS, V148, P1628, DOI 10.1164/ajrccm/148.6_Pt_1.1628; WIDDICOMBE JG, 1995, EUR RESPIR J, V8, P1193, DOI 10.1183/09031936.95.08071193; WIDDICOMBE JG, 1954, J PHYSIOL-LONDON, V123, P55, DOI 10.1113/jphysiol.1954.sp005033; WIDDICOMBE JG, 1954, J PHYSIOL-LONDON, V123, P71, DOI 10.1113/jphysiol.1954.sp005034; WINNING AJ, 1986, CLIN SCI, V71, P519, DOI 10.1042/cs0710519	40	38	43	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1996	98	5	2	S			S84	S89		10.1016/S0091-6749(96)80133-3	http://dx.doi.org/10.1016/S0091-6749(96)80133-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VW140	8939181	Bronze			2022-12-18	WOS:A1996VW14000017
J	Ferreira, FD; Mayer, P; Sperr, WR; Valent, P; Seiberler, S; Ebner, C; Liehl, E; Scheiner, O; Kraft, D; Valenta, R				Ferreira, FD; Mayer, P; Sperr, WR; Valent, P; Seiberler, S; Ebner, C; Liehl, E; Scheiner, O; Kraft, D; Valenta, R			Induction of IgE antibodies with predefined specificity in rhesus monkeys with recombinant birch pollen allergens, Bet v 1 and Bet v 2	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Type I allergy; recombinant tree pollen allergens; Bet v 1; profilin Bet v 2; IgE; rhesus monkeys	PHLEUM-PRATENSE POLLEN; MAJOR ALLERGEN; CEDAR POLLINOSIS; HAZEL POLLEN; TREE-POLLEN; IDENTIFICATION; PROFILIN; PURIFICATION; DIAGNOSIS; BASOPHILS	Background: Recombinant birch pollen allergens Bet v 1 and Bet v 2 (birch profilin) have been characterized in vitro previously. Objective: To establish a close-to-man model of type I allergy, recombinant birch pollen allergens were injected into rhesus monkeys. Methods: The allergens were expressed in Escherichia coli, purified to homogeneity and injected into rhesus monkeys with aluminium hydroxide as adjuvans. Tire development of type I allergy was monitored by measurement of specific IgE, in vitro histamine release tests, cellular proliferation assays, skin testing, and bronchial provocation tests. Results: Immunized results monkeys displayed symptoms of type I allergy comparable to those of allergic patients, and cross-reactivity of IgE antibodies with Bet v 1 and Bet v 2 homologous allergens was observed. Systemic application of corticosteroids during seconding immunizations suppressed specific antibody responses. Conclusion: Recombinant birch pollen allergens (Bet v 1 and Bet v 2) were effective to establish a close-to-man model of natural type I allergy in rhesus monkeys, allowing study of specific IgE regulation in vivo.	UNIV VIENNA,AKH,INST GEN & EXPTL PATHOL,A-1090 VIENNA,AUSTRIA; SALZBURG UNIV,INST GENET,A-5020 SALZBURG,AUSTRIA; SANDOZ GMBH,RES CTR,A-1235 VIENNA,AUSTRIA; UNIV VIENNA,DEPT HAEMATOL & HAEMOSTASEL,A-1090 VIENNA,AUSTRIA	University of Vienna; Salzburg University; Novartis; Sandoz; University of Vienna			Valent, Peter/B-8533-2016; Ferreira, Fatima/E-4889-2011; Test, PV/U-9451-2019; Sperr, Mast/V-4767-2019; Test, Test/Y-7921-2019; Gamperl, Susi/V-2715-2019; Ferreira, Fatima/AAB-4321-2019	Valent, Peter/0000-0003-0456-5095; Ferreira, Fatima/0000-0003-0989-2335; Sperr, Mast/0000-0002-7778-5219; Gamperl, Susi/0000-0003-0456-5095; Ferreira, Fatima/0000-0003-0989-2335; Sperr, Wolfgang/0000-0003-3288-8027; Valenta, Rudolf/0000-0001-5944-3365				BREITENBACH M, 1990, EPITOPES ATOPIC ALLE, P57; BREITENEDER H, 1992, J ALLERGY CLIN IMMUN, V90, P909, DOI 10.1016/0091-6749(92)90463-C; BREITENEDER H, 1993, EUR J BIOCHEM, V212, P355, DOI 10.1111/j.1432-1033.1993.tb17669.x; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; CHIBA N, 1990, INT ARCH ALLER A IMM, V93, P83, DOI 10.1159/000235284; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; EBNER C, 1991, J ALLERGY CLIN IMMUN, V88, P588, DOI 10.1016/0091-6749(91)90152-E; EBNER C, 1993, J IMMUNOL, V150, P1047; FANG KYS, 1989, P NATL ACAD SCI USA, V85, P895; FERREIRA FD, 1993, J BIOL CHEM, V268, P19574; GIRARD JP, 1970, INT ARCH ALLER A IMM, V37, P561, DOI 10.1159/000230245; HALPERN GM, 1989, ANN ALLERGY, V62, P255; HIRSCHWEHR R, 1992, J ALLERGY CLIN IMMUN, V90, P927, DOI 10.1016/0091-6749(92)90465-E; ISHIZAKA K, 1969, J IMMUNOL, V106, P443; ISHIZAKI T, 1987, ANN ALLERGY, V58, P265; JAROLIM E, 1989, ALLERGY, V44, P385, DOI 10.1111/j.1398-9995.1989.tb04169.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; PERPER RJ, 1972, INT ARCH ALLER A IMM, V43, P837, DOI 10.1159/000230901; ROHAC M, 1991, MOL IMMUNOL, V28, P897, DOI 10.1016/0161-5890(91)90054-N; SAKAGUCHI M, 1992, J MED PRIMATOL, V21, P323; SCHEINER O, 1992, ADVANCES IN ALLERGOLOGY AND CLINICAL IMMUNOLOGY, P115; SUTTON BJ, 1993, NATURE, V366, P421, DOI 10.1038/366421a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALENT P, 1989, P NATL ACAD SCI USA, V86, P5542, DOI 10.1073/pnas.86.14.5542; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; VALENTA R, 1991, J ALLERGY CLIN IMMUN, V88, P889, DOI 10.1016/0091-6749(91)90245-J; VALENTA R, 1991, J ALLERGY CLIN IMMUN, V87, P677, DOI 10.1016/0091-6749(91)90388-5; VALENTA R, 1993, J ALLERGY CLIN IMMUN, V91, P88, DOI 10.1016/0091-6749(93)90300-5; VALENTA R, 1992, INT ARCH ALLERGY IMM, V97, P287, DOI 10.1159/000236135; VALENTA R, 1993, J BIOL CHEM, V268, P22777; VALENTA R, 1993, VACCINES93 : MODERN APPROACHES TO NEW VACCINES INCLUDING PREVENTION OF AIDS, P37; VALENTA R, 1994, BIOCHEM BIOPH RES CO, V199, P106, DOI 10.1006/bbrc.1994.1201; VALLIER P, 1992, CLIN EXP ALLERGY, V22, P774, DOI 10.1111/j.1365-2222.1992.tb02818.x; VANREE R, 1992, INT ARCH ALLERGY IMM, V98, P97, DOI 10.1159/000236171; VRTALA S, 1993, J IMMUNOL, V151, P4773; Wuthrich B, 1991, ALLERGY CLIN IMMUNOL, V3, P41	37	38	38	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1996	97	1	1				95	103		10.1016/S0091-6749(96)70287-7	http://dx.doi.org/10.1016/S0091-6749(96)70287-7			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TR947	8568143				2022-12-18	WOS:A1996TR94700012
J	Yanagihara, Y; Ikizawa, K; Kajiwara, K; Koshio, T; Basaki, Y; Akiyama, K				Yanagihara, Y; Ikizawa, K; Kajiwara, K; Koshio, T; Basaki, Y; Akiyama, K			Functional significance of IL-4 receptor on B cells in IL-4-induced human IgE production	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	New Trends in Immunopharmacology 1994 Conference	JUL   23, 1994	TOKYO, JAPAN	Sandoz Pharm Ltd			HUMAN LYMPHOCYTES-B; PROTEIN-KINASE-C; PHOSPHATIDYLINOSITOL 3-KINASE; ANTISENSE OLIGONUCLEOTIDES; INTERLEUKIN-4 RECEPTOR; INTERFERON-GAMMA; EXPRESSION; INHIBITION; 3,4,5-TRISPHOSPHATE; IDENTIFICATION	IL-4 with the IgE-inducing activity is shown to upregulate the expression of IL-4 receptor (IL-4R) on lymphocytes. Antisense strategy was used that aimed at investigating the significance of IL-4-induced upregulation of IL-4R on B cells in human IgE production. When an antisense phosphorothioate oligodeoxynucleotide to IL-4R (S-oligo 1) was added to B cells together with IL-4, the agent selectively abrogated the upregulation of IL-4R without affecting its constitutive level expression. Moreover, S-oligo 1 had a suppressive effect on the T-cell-independent synthesis of IgE by B cells costimulated with IL-4 and anti-CD40 antibody. This suppression was accompanied by inhibition of mature but not germline C epsilon transcription. These findings indicate that constitutively expressed IL-4R provides a signal or signals responsible for the induction of germline C epsilon transcription and suggest that IL-4R upregulation may be required for the subsequent class switch recombination that leads to mature C epsilon transcription and IgE synthesis. The IL-4R signal transduction mechanism underlying germline C epsilon transcription was also analyzed in a human Burkitt lymphoma B-cell line, DND39. Induction of germline C epsilon transcripts in DND39 cells by IL-4 required at least two distinct signaling cascades. One was mediated by enhancement of tyrosine phosphorylation of a 57 kd protein associated with phospholipase C-gamma 1 (PLC-gamma 1) that resulted in PLC-gamma 1 activation inositol lipid hydrolysis, and protein kinase C delta translocation. The other was dependent on phosphatidylinositol 3-kinase, whose activation induced protein kinase C zeta translocation. In fact, kinase inhibitors such as herbimycin A, K-252a, and wortmannin were effective in inhibiting IL-1-induced germline C epsilon transcription. Therefore, in addition to activation of protein tyrosine kinases, coordinated actions of PLC-gamma 1 and phosphatidylinositol 3-kinase may be involved in IL-4-driven germline C epsilon transcription in DND39 cells.			Yanagihara, Y (corresponding author), NATL SAGAMIHARA HOSP,CLIN RES CTR ALLERGY,18-1 SAKURADAI,SAGAMIHARA,KANAGAWA 228,JAPAN.							ALBRECHT B, 1994, INT IMMUNOL, V6, P1143, DOI 10.1093/intimm/6.8.1143; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; DEPPER JM, 1985, P NATL ACAD SCI USA, V82, P4230, DOI 10.1073/pnas.82.12.4230; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; DIAZSANCHEZ D, 1994, J IMMUNOL, V153, P10; FOXWELL BMJ, 1989, EUR J IMMUNOL, V19, P1637, DOI 10.1002/eji.1830190918; GASCAN H, 1991, J IMMUNOL, V147, P8; GAUCHAT JF, 1990, J EXP MED, V172, P463, DOI 10.1084/jem.172.2.463; HARELBELLAN A, 1988, J EXP MED, V168, P2309, DOI 10.1084/jem.168.6.2309; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; ICHIKI T, 1993, J IMMUNOL, V150, P5408; IKIZAWA K, 1994, J ALLERGY CLIN IMMUN, V94, P620, DOI 10.1016/0091-6749(94)90138-4; IKIZAWA K, 1995, CLIN EXP IMMUNOL, V100, P383; IZUHARA K, 1993, J BIOL CHEM, V268, P13097; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KATIRA A, 1993, CLIN EXP IMMUNOL, V92, P347; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KOHLER I, 1993, EUR J IMMUNOL, V23, P3066, DOI 10.1002/eji.1830231204; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; LOH RKS, 1994, J ALLERGY CLIN IMMUN, V94, P784, DOI 10.1016/0091-6749(94)90187-2; MOZO L, 1993, J IMMUNOL, V150, P4261; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; OKADA T, 1994, J BIOL CHEM, V269, P3563; PAUL WE, 1991, BLOOD, V77, P1859; RENZ H, 1992, J INVEST DERMATOL, V99, P403, DOI 10.1111/1523-1747.ep12616114; ROUSSET F, 1988, J IMMUNOL, V140, P2625; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SIEGRIST CA, 1993, EUR J IMMUNOL, V23, P2903, DOI 10.1002/eji.1830231126; SMITH KA, 1985, P NATL ACAD SCI USA, V82, P864, DOI 10.1073/pnas.82.3.864; THYPHRONITIS G, 1989, P NATL ACAD SCI USA, V86, P5580, DOI 10.1073/pnas.86.14.5580; VALLE A, 1989, EUR J IMMUNOL, V19, P1463, DOI 10.1002/eji.1830190818; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WELHAM MJ, 1994, J BIOL CHEM, V269, P5865; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WU CY, 1991, J CLIN INVEST, V87, P870, DOI 10.1172/JCI115092; YANO H, 1993, J BIOL CHEM, V268, P25846; ZUBER CE, 1990, EUR J IMMUNOL, V20, P551, DOI 10.1002/eji.1830200314	39	38	40	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1995	96	6	2	S			1145	1151		10.1016/S0091-6749(95)70199-0	http://dx.doi.org/10.1016/S0091-6749(95)70199-0			7	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TQ509	8543771				2022-12-18	WOS:A1995TQ50900010
J	YAGAMI, T; SATO, M; NAKAMURA, A; SHONO, M				YAGAMI, T; SATO, M; NAKAMURA, A; SHONO, M			ONE OF THE RUBBER LATEX ALLERGENS IS A LYSOZYME	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						LYSOZYME; RUBBER LATEX ALLERGEN; LATER GLOVES; IMMUNOBLOTTING; CROSS-REACTION; DEFENSE-RELATED PROTEIN; DEFENSE RESPONSE	HEVEA-BRASILIENSIS LATEX; AMINO-ACID-SEQUENCE; CONTACT URTICARIA; NATURAL-RUBBER; PROTEINS; PURIFICATION; REACTIVITY; PLANTS; CHITINASES; DEFENSE	Background: Type I hypersensitivity reactions caused by latex products are ascribed to proteins eluted from them, bur little is known about the properties of these allergenic proteins. The reason for the cross-reaction between rubber latex and fruits is also not known. We have speculated that a series of defense-related proteins in plants is a cause of latex allergy and the cross-reaction. Objective: To verify our hypothesis, we selected a lysozyme as a representative defense-related protein and examined its relationship to latex allergy. Methods: Lysozymes eluted from latex gloves were detected with a cell-suspension clearing test. A chromatographically separated lysozyme was investigated for its physicochemical and enzymatic properties and allergenicity. Results: Lysozyme activity was detected in extracts from 12 ammoniated later and latex gloves. We separated a lysozyme (27 kd; isoelectric point, 9.5) using cation-exchange and gel filtration chromatography. This lysozyme was enzymatically very similar to fruit lysozymes and was demonstrated to be an allergen. Conclusions: One of the rubber later allergens is a lysozyme that has similarities to fruit lysozymes. This suggests the relevance of defense-related proteins to latex allergy and the cross-reaction.	SHONO CLIN DERMATOL,TOKYO,JAPAN		YAGAMI, T (corresponding author), NATL INST HLTH SCI,DIV MED DEVICES,SETAGAYA KU,1-18-1 KAMIYOGA,TOKYO 158,JAPAN.							ALENIUS H, 1991, INT ARCH ALLER A IMM, V96, P376, DOI 10.1159/000235525; ALENIUS H, 1993, INT ARCH ALLERGY IMM, V102, P61, DOI 10.1159/000236551; ALENIUS H, 1992, ALLERGY PROC, V13, P75, DOI 10.2500/108854192778878863; ARCHER BL, 1976, PHYTOCHEMISTRY, V15, P297, DOI 10.1016/S0031-9422(00)89007-X; AUDY P, 1990, PHYTOCHEMISTRY, V29, P1143, DOI 10.1016/0031-9422(90)85419-G; BERNASCONI P, 1985, FEBS LETT, V186, P263, DOI 10.1016/0014-5793(85)80721-3; BERNASCONI P, 1987, BIOCHIM BIOPHYS ACTA, V915, P254, DOI 10.1016/0167-4838(87)90307-4; BOWLES DJ, 1990, ANNU REV BIOCHEM, V59, P873, DOI 10.1146/annurev.bi.59.070190.004301; BROEKAERT W, 1990, P NATL ACAD SCI USA, V87, P7633, DOI 10.1073/pnas.87.19.7633; CEUPPENS JL, 1992, LANCET, V339, P493, DOI 10.1016/0140-6736(92)91101-D; CHAMBEYRON C, 1992, ALLERGY, V47, P92, DOI 10.1111/j.1398-9995.1992.tb05094.x; CHANDAN RC, 1981, J FOOD SCI, V46, P1278, DOI 10.1111/j.1365-2621.1981.tb03042.x; DAUZAC J, 1993, CURR PLANT SCI BIOT, V16, P205; DECORRES LF, 1990, CONTACT DERMATITIS, V23, P277; DURING K, 1993, PLANT MOL BIOL, V23, P209, DOI 10.1007/BF00021432; FUCHS T, 1992, ALLERGY PROC, V13, P61, DOI 10.2500/108854192778878881; GLAZER AN, 1969, J BIOL CHEM, V244, P3583; Hamann CP, 1993, AM J CONTACT DERMATI, V4, P4, DOI DOI 10.1097/01634989-199303000-00003; HOWARD JB, 1969, J BIOL CHEM, V244, P1399; HOWARD JB, 1967, J BIOL CHEM, V242, P5715; JAEGER D, 1992, J ALLERGY CLIN IMMUN, V89, P759, DOI 10.1016/0091-6749(92)90385-F; JEKEL PA, 1991, EUR J BIOCHEM, V200, P123, DOI 10.1111/j.1432-1033.1991.tb21057.x; KURUP VP, 1993, J ALLERGY CLIN IMMUN, V91, P1128, DOI 10.1016/0091-6749(93)90314-6; KUSH A, 1990, P NATL ACAD SCI USA, V87, P1787, DOI 10.1073/pnas.87.5.1787; LAVAUD F, 1992, LANCET, V339, P492, DOI 10.1016/0140-6736(92)91100-M; LEVY DA, 1992, ALLERGY, V47, P579, DOI 10.1111/j.1398-9995.1992.tb02378.x; LEVY DA, 1992, ALLERGY, V48, pS1; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYNN KR, 1989, PHYTOCHEMISTRY, V28, P1345, DOI 10.1016/S0031-9422(00)97743-4; MARTIN MN, 1991, PLANT PHYSIOL, V95, P469, DOI 10.1104/pp.95.2.469; METRAUX JP, 1989, P NATL ACAD SCI USA, V86, P896, DOI 10.1073/pnas.86.3.896; MRAIHI L, 1991, J ALLERGY CLIN IMMUN, V87, P129, DOI 10.1016/0091-6749(91)90224-C; NUTTER AF, 1979, BRIT J DERMATOL, V101, P597, DOI 10.1111/j.1365-2133.1979.tb15107.x; SAHAI AS, 1993, FEMS MICROBIOL REV, V11, P317, DOI 10.1111/j.1574-6976.1993.tb00004.x; SHONO M, 1993, JPN J DERMATOALLERGO, V1, P37; SHUGAR D, 1952, BIOCHIM BIOPHYS ACTA, V8, P302, DOI 10.1016/0006-3002(52)90045-0; SLATER JE, 1994, J ALLERGY CLIN IMMUN, V94, P139, DOI 10.1016/0091-6749(94)90031-0; SLATER JE, 1992, ANN ALLERGY, V68, P203; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STINTZI A, 1993, BIOCHIMIE, V75, P687, DOI 10.1016/0300-9084(93)90100-7; TATA S J, 1976, Journal of the Rubber Research Institute of Malaysia, V24, P233; TATA SJ, 1983, J RUBBER RES I MALAY, V31, P35; TOMAZIC VJ, 1992, CLIN IMMUNOL IMMUNOP, V64, P89, DOI 10.1016/0090-1229(92)90185-Q; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P362, DOI 10.1111/j.1600-0536.1988.tb02953.x; YAGAMI T, 1993, B NATL I HYG SCI, V111, P84	45	38	40	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1995	96	5	1				677	686		10.1016/S0091-6749(95)70267-9	http://dx.doi.org/10.1016/S0091-6749(95)70267-9			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TG528	7499685				2022-12-18	WOS:A1995TG52800014
J	DIB, G; GUERIN, B; BANKS, WA; LEYNADIER, F				DIB, G; GUERIN, B; BANKS, WA; LEYNADIER, F			SYSTEMIC REACTIONS TO THE SAMSUM ANT - AN IGE-MEDIATED HYPERSENSITIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						PACHYCONDYLA SENNAARENSIS; SAMSUM ANT; ANT ALLERGY; ANAPHYLAXIS TO ANT; HYMENOPTERA ALLERGY	IMPORTED FIRE ANT; MYRMECIA-PILOSULA; ALLERGY; VENOM; DIAGNOSIS; STINGS; TESTS	Background: In the United Arab Emirates the sting of the Pachycondyla sennaarensis ant (PSA) causes allergic reactions in certain persons. It is a common problem and is becoming a public health hazard. Up to now the diagnosis has been based only on the history, because the mechanism of the reaction was not yet established Objective: The aim of our study was to prepare an allergenic extract that would be used for skin tests and to prepare a reagent for specific IgE titration. Results of both skin tests and specific IgE were to be compared with the clinical history. Methods: We studied 31 patients with anaphylactic reactions and performed clinical examinations, skin tests, and specific IgE antibody titrations. A control group of 22 subjects wets also studied. Results: In 30 of 31 patients (97%) findings of PSA skin tests and/or specific IgE were positive. In the control groups PSA skin test results were negative in 86% and negative for specific IgE in 68%. Conclusion: The study shows that the mechanism of the reaction to the sting of the PSA is a type I IgE-mediated hypersensitivity and that the diagnosis can now be confirmed by skin rests and specific IgE determination.	LAB ALLERBIO,VARENNES EN ARGONNE,FRANCE; USDA ARS,GAINESVILLE,FL; UNIV PARIS 06,ROTHSCHILD HOSP,FAC MED ST ANTOINE,DEPT INTERNAL MED & ALLERGOL,PARIS,FRANCE	United States Department of Agriculture (USDA); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Rothschild - APHP; Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite	DIB, G (corresponding author), TAWAM HOSP,DEPT MED,POB 15258,ABU DHABI,U ARAB EMIRATES.							Axelsen N. H., 1973, SCAND J IMMUNOL S1, V2, P1; CLARKE PS, 1986, MED J AUSTRALIA, V145, P564, DOI 10.5694/j.1326-5377.1986.tb139498.x; Collingwood C.A., 1985, Fauna of Saudi Arabia, V7, P230; DEMOLY P, 1991, J ALLERGY CLIN IMMUN, V88, P758, DOI 10.1016/0091-6749(91)90183-O; DESHAZO RD, 1990, NEW ENGL J MED, V323, P462, DOI 10.1056/NEJM199008163230707; DIB G, 1992, LANCET, V339, P552, DOI 10.1016/0140-6736(92)90372-A; FORD SA, 1991, CLIN EXP ALLERGY, V21, P167, DOI 10.1111/j.1365-2222.1991.tb00826.x; GRASSI J, 1986, J ALLERGY CLIN IMMUN, V77, P808, DOI 10.1016/0091-6749(86)90378-7; HOFFMAN DR, 1988, J ALLERGY CLIN IMMUN, V82, P818, DOI 10.1016/0091-6749(88)90084-X; Kim Si-Chan, 1992, Yonsei Medical Journal, V33, P281; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOCKEY RF, 1974, J ALLERGY CLIN IMMUN, V54, P132, DOI 10.1016/0091-6749(74)90050-5; PAULL BR, 1983, J ALLERGY CLIN IMMUN, V71, P448, DOI 10.1016/0091-6749(83)90460-8; RHOADES RB, 1989, J ALLERGY CLIN IMMUN, V84, P159, DOI 10.1016/0091-6749(89)90319-9; RHOADES RB, 1977, J FLA MED ASSOC, V64, P247; SOLLEY GO, 1990, MED J AUSTRALIA, V153, P650, DOI 10.5694/j.1326-5377.1990.tb126312.x; STAFFORD CT, 1989, SOUTHERN MED J, V82, P1515, DOI 10.1097/00007611-198912000-00014; STAFFORD CT, 1992, J ALLERGY CLIN IMMUN, V90, P653, DOI 10.1016/0091-6749(92)90139-S; STAFFORD CT, 1990, ANN ALLERGY, V64, P368; STREET MD, 1994, CLIN EXP ALLERGY, V24, P590, DOI 10.1111/j.1365-2222.1994.tb00957.x; WHEELER WM, 1922, B AM MUS NATURAL HIS, V45, P84	21	38	39	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1995	96	4					465	472		10.1016/S0091-6749(95)70288-1	http://dx.doi.org/10.1016/S0091-6749(95)70288-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TA095	7560656				2022-12-18	WOS:A1995TA09500005
J	SCHWARTZ, HJ				SCHWARTZ, HJ			ELEVATED SERUM TRYPTASE IN EXERCISE-INDUCED ANAPHYLAXIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							PHYSICAL ALLERGY; FORM		CASE WESTERN RESERVE UNIV,SCH MED,DEPT MED,CLEVELAND,OH 44106; UNIV HOSP CLEVELAND,CTR AIRWAY DIS,CLEVELAND,OH	Case Western Reserve University; University Hospitals of Cleveland								CASALE TB, 1986, JAMA-J AM MED ASSOC, V255, P2049, DOI 10.1001/jama.255.15.2049; LEWIS J, 1981, J ALLERGY CLIN IMMUN, V68, P432, DOI 10.1016/0091-6749(81)90197-4; SCHWARTZ LB, 1987, NEW ENGL J MED, V316, P1622, DOI 10.1056/NEJM198706253162603; SCHWARTZ LB, 1990, J ALLERGY CLIN IMMUN, V86, P594, DOI 10.1016/S0091-6749(05)80222-2; SHEFFER AL, 1985, J ALLERGY CLIN IMMUN, V75, P479, DOI 10.1016/S0091-6749(85)80021-X; SHEFFER AL, 1980, J ALLERGY CLIN IMMUN, V66, P106, DOI 10.1016/0091-6749(80)90056-1; SHEFFER AL, 1988, NEW ENGL REG ALLERGY, V9, P215; SHEFFER AL, 1983, J ALLERGY CLIN IMMUN, V71, P311, DOI 10.1016/0091-6749(83)90085-4; SILVERS WS, 1992, ANN ALLERGY, V68, P58; YUNGINGER JW, 1991, J FORENSIC SCI, V36, P857	10	38	39	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1995	95	4					917	919		10.1016/S0091-6749(95)70139-7	http://dx.doi.org/10.1016/S0091-6749(95)70139-7			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QT468	7722176				2022-12-18	WOS:A1995QT46800021
J	MCFADDEN, ER				MCFADDEN, ER			PERSPECTIVES IN BETA(2)-AGONIST THERAPY - VOX CLAMANTIS IN DESERTO VEL LUX IN TENEBRIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							INHALED BETA-AGONIST; LONG-TERM TREATMENT; ASTHMATIC SUBJECTS; NEW-ZEALAND; PRESCRIBED FENOTEROL; BRONCHIAL HYPERRESPONSIVENESS; AIRWAY HYPERRESPONSIVENESS; BRONCHODILATOR TREATMENT; AEROSOLIZED TERBUTALINE; ADRENERGIC RECEPTORS		CASE WESTERN RESERVE UNIV,SCH MED,DEPT MED,CLEVELAND,OH 44106	Case Western Reserve University	MCFADDEN, ER (corresponding author), UNIV CLEVELAND HOSP,DIV PULM & CRIT CARE MED,CLEVELAND,OH 44106, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000080] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL037117] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1 RR 00080] Funding Source: Medline; NHLBI NIH HHS [HL 37117] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANGELICI E, 1984, AM REV RESPIR DIS, V129, P1014; BASS M, 1970, J AMER MED ASSOC, V212, P2075, DOI 10.1001/jama.212.12.2075; BEASLEY R, 1991, AUST NZ J MED, V21, P753, DOI 10.1111/j.1445-5994.1991.tb01385.x; BOOTH H, 1993, THORAX, V48, P121; BROOKS SM, 1972, AM REV RESPIR DIS, V105, P640; CASTLE W, 1993, BRIT MED J, V306, P1034, DOI 10.1136/bmj.306.6884.1034; CHERVINSKY P, 1969, ANN ALLERGY, V27, P611; CHEUNG D, 1992, NEW ENGL J MED, V327, P1198, DOI 10.1056/NEJM199210223271703; COCKCROFT DW, 1993, LANCET, V342, P833, DOI 10.1016/0140-6736(93)92695-P; COCKCROFT DW, 1992, J ALLERGY CLIN IMMUN, V90, P739, DOI 10.1016/0091-6749(92)90096-K; CONNOLLY MJ, 1985, THORAX, V40, P216; CONOLLY ME, 1982, J ALLERGY CLIN IMMUN, V70, P423, DOI 10.1016/0091-6749(82)90004-5; CRANE J, 1989, LANCET, V1, P917; CRANE J, 1992, BRIT MED J, V304, P1307, DOI 10.1136/bmj.304.6837.1307; DOLLERY CT, 1974, CLIN PHARMACOL THER, V15, P59; FABEL H, 1972, DEUT MED WOCHENSCHR, V97, P428, DOI 10.1055/s-0028-1107370; GIBSON GJ, 1978, BRIT J DIS CHEST, V72, P199, DOI 10.1016/0007-0971(78)90042-6; GRAINGER J, 1991, THORAX, V46, P105, DOI 10.1136/thx.46.2.105; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; HAAS JF, 1992, BRIT MED J, V304, P1634, DOI 10.1136/bmj.304.6842.1634; HARVEY JE, 1982, THORAX, V37, P280, DOI 10.1136/thx.37.4.280; INGRAM RH, 1970, AM REV RESPIR DIS, V101, P364; JACKSON R, 1988, CHEST, V94, P914, DOI 10.1378/chest.94.5.914; JENNE JW, 1977, J ALLERGY CLIN IMMUN, V59, P383, DOI 10.1016/0091-6749(77)90023-9; KALLENBACH J, 1979, SCAND J RESPIR DIS, V60, P44; KEIGHLEY JF, 1966, ANN INTERN MED, V65, P985, DOI 10.7326/0003-4819-65-5-985; KELLY HW, 1985, ANN ALLERGY, V54, P405; KEMP JP, 1984, J ALLERGY CLIN IMMUN, V73, P32, DOI 10.1016/0091-6749(84)90481-0; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; KNUDSON RJ, 1967, J APPL PHYSIOL, V22, P402, DOI 10.1152/jappl.1967.22.3.402; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; LAI CKW, 1987, AM REV RESPIR DIS, V140, P917; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; LARSSON S, 1977, J ALLERGY CLIN IMMUN, V59, P93, DOI 10.1016/0091-6749(77)90209-3; LEITCH AG, 1976, BRIT MED J, V1, P365, DOI 10.1136/bmj.1.6006.365; LIPWORTH BJ, 1989, AM REV RESPIR DIS, V140, P586, DOI 10.1164/ajrccm/140.3.586; LOFDAHL CG, 1991, EUR RESPIR J, V4, P1161; LOFDAHL CG, 1992, EUR RESPIR J, V5, P898; MANNING PJ, 1988, AM REV RESPIR DIS, V137, P1323, DOI 10.1164/ajrccm/137.6.1323; MANNING PJ, 1987, J APPL PHYSIOL, V63, P1572, DOI 10.1152/jappl.1987.63.4.1572; MCFADDEN ER, 1994, NEW ENGL J MED, V330, P1362, DOI 10.1056/NEJM199405123301907; MCFADDEN ER, 1968, NEW ENGL J MED, V278, P1027, DOI 10.1056/NEJM196805092781901; MCFADDEN ER, 1981, J ALLERGY CLIN IMMUN, V68, P91, DOI 10.1016/0091-6749(81)90164-0; MCFADDEN ER, 1993, ALLERGY PRINCIPLES P, P672; MITCHELL EA, 1989, THORAX, V44, P81, DOI 10.1136/thx.44.2.81; MIYAMOTO T, 1970, J ALLERGY, V45, P248, DOI 10.1016/0021-8707(70)90135-8; MULLEN M, 1993, JAMA-J AM MED ASSOC, V270, P1842, DOI 10.1001/jama.270.15.1842; NELSON HS, 1977, AM REV RESPIR DIS, V16, P871; NICKLAS RA, 1990, J ALLERGY CLIN IMMUN, V85, P959, DOI 10.1016/0091-6749(90)90084-H; NOGRADY SG, 1977, THORAX, V32, P559, DOI 10.1136/thx.32.5.559; OCALLAGHAN C, 1986, LANCET, V2, P1424, DOI 10.1016/S0140-6736(86)92735-2; OCONNOR BJ, 1992, NEW ENGL J MED, V327, P1204, DOI 10.1056/NEJM199210223271704; PAGE C, 1992, RESP MED, V86, P477, DOI 10.1016/S0954-6111(96)80005-9; PAGE CP, 1991, LANCET, V337, P717, DOI 10.1016/0140-6736(91)90289-2; PAUWELS R, 1985, J ALLERGY CLIN IMMUN, V76, P583, DOI 10.1016/0091-6749(85)90779-1; PEARCE N, 1990, THORAX, V45, P170, DOI 10.1136/thx.45.3.170; PEARLMAN DS, 1992, NEW ENGL J MED, V327, P1420, DOI 10.1056/NEJM199211123272004; PEEL ET, 1980, AM REV RESPIR DIS, V121, P973; PLUMMER AL, 1978, CHEST, V73, P949, DOI 10.1378/chest.73.6.949; RAES M, 1989, J ALLERGY CLIN IMMUN, V84, P874, DOI 10.1016/0091-6749(89)90382-5; RAMAGE L, 1994, RESP MED, V88, P363, DOI 10.1016/0954-6111(94)90042-6; REED CE, 1985, J ALLERGY CLIN IMMUN, V76, P335, DOI 10.1016/0091-6749(85)90650-5; REPSHER LH, 1984, CHEST, V85, P34, DOI 10.1378/chest.85.1.34; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SEARS MR, 1992, EUR RESPIR J, V5, P896; SEARS MR, 1987, BRIT MED J, V264, P477; SEARS MR, 1991, LANCET, V338, P1332; SLY RM, 1985, J ALLERGY CLIN IMMUN, V75, P443; SPEIZER FE, 1968, BRIT MED J, V1, P339, DOI 10.1136/bmj.1.5588.339; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; STILES GL, 1984, PHYSIOL REV, V64, P661, DOI 10.1152/physrev.1984.64.2.661; SUISSA S, 1994, AM J RESP CRIT CARE, V149, P604, DOI 10.1164/ajrccm.149.3.8118625; TAI E, 1967, LANCET, V1, P644; TAYLOR DR, 1993, THORAX, V48, P134, DOI 10.1136/thx.48.2.134; TRAUTLEIN J, 1976, J CLIN PHARMACOL, V16, P361, DOI 10.1002/j.1552-4604.1976.tb01533.x; VANSCHAYCK CP, 1990, J ALLERGY CLIN IMMUN, V86, P793, DOI 10.1016/S0091-6749(05)80185-X; VANSCHAYCK CP, 1991, BRIT MED J, V303, P1426, DOI 10.1136/bmj.303.6815.1426; VATHENEN AS, 1988, LANCET, V1, P554; WAHEDNA I, 1993, AM REV RESPIR DIS, V148, P707, DOI 10.1164/ajrccm/148.3.707; WEBER RW, 1982, J ALLERGY CLIN IMMUN, V70, P417, DOI 10.1016/0091-6749(82)90003-3; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683; WENG TR, 1970, AM REV RESPIR DIS, V101, P274; YARBROUGH J, 1985, ANN ALLERGY, V55, P55; 1993, J ALLERGY CLIN IMMUN, V91, P1234; 1992, 923091 US DEP HLTH H, P1; 1991, DEC P PULM ALL DRUGS; 1992, CURR PROBLEMS, V33, P658; 1991, 913042 US DEP HLTH H, P35	88	38	38	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1995	95	3					641	651		10.1016/S0091-6749(95)70166-4	http://dx.doi.org/10.1016/S0091-6749(95)70166-4			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QM017	7897145				2022-12-18	WOS:A1995QM01700001
J	OGAWA, M				OGAWA, M			HEMATOPOIESIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	New Trends in Immunopharmacology 1993 Conference	JUL   17, 1993	TOKYO, JAPAN			HEMATOPOIETIC STEM CELLS; HEMATOPOIETIC PROGENITORS; DIFFERENTIATION OF STEM CELLS; CYTOKINES; INTERLEUKIN; GROWTH FACTORS	COLONY-STIMULATING FACTOR; MURINE LYMPHOHEMATOPOIETIC PROGENITORS; PRIMITIVE STEM-CELLS; PAIRED PROGENITORS; GROWTH-FACTORS; FACTOR-I; INTERLEUKIN-3-DEPENDENT PROLIFERATION; HUMAN MEGAKARYOCYTOPOIESIS; DISPARATE DIFFERENTIATION; RECOMBINANT HUMAN	Cellular turnover of the hematopoietic system is supported by a small population of cells termed hematopoietic stem cells. Stem cells are capable of self-renewal and differentiation into individual lymphomyeloid lineages. Available evidence indicates that the decision of a stem cell to self-renew or differentiate and the decision of a multipotential progenitor to select a lineage pathway during differentiation (commitment) are intrinsic to the progenitors and are stochastic in nature. In contrast, proliferative kinetics of the progenitors, namely survival and expansion of the progenitors, appear to be controlled by a number of interacting cytokines. Whereas proliferation and maturation of committed progenitors are controlled by late-acting factors such as erythropoietin, macrophage colony-stimulating factor, granulocyte colony-stimulating factor, and interleukin-5, progenitors at earlier stages of development are controlled by a group of several overlapping cytokines. Interleukin-3, granulocyte/macrophage colony-stimulating factor, and interleukin-4 regulate proliferation of multipotential progenitors only after they are triggered to exit from dormancy state. Triggering of cycling of dormant primitive progenitors and proliferation of lymphohemopoietic primitive progenitors appear to require interactions of early acting cytokines including interleukin-6 granulocyte colony-stimulating factor, interleukin-11, interleukin-12 leukemia inhibitory factor and steel factor.	MED UNIV S CAROLINA,DEPT MED,CHARLESTON,SC 29425	Medical University of South Carolina	OGAWA, M (corresponding author), RALPH H JOHNSON DEPT VET AFFAIRS MED CTR,109 BEE ST,CHARLESTON,SC 29401, USA.				NIDDK NIH HHS [DK32294] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032294] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABKOWITZ JL, 1990, P NATL ACAD SCI USA, V87, P9062, DOI 10.1073/pnas.87.22.9062; ALLEN TD, 1976, DIFFERENTIATION, V6, P191, DOI 10.1111/j.1432-0436.1976.tb01486.x; BAUM CM, 1992, P NATL ACAD SCI USA, V89, P2804, DOI 10.1073/pnas.89.7.2804; BECKER AJ, 1965, BLOOD-J HEMATOL, V26, P296, DOI 10.1182/blood.V26.3.296.296; BODINE DM, 1991, BLOOD, V78, P914; BRADLEY TR, 1966, AUST J EXP BIOL MED, V44, P287, DOI 10.1038/icb.1966.28; BRIDDELL RA, 1992, BLOOD, V79, P332; BROXMEYER HE, 1988, J IMMUNOL, V141, P3852; BRUNO E, 1989, EXP HEMATOL, V17, P1038; CUMANO A, 1992, NATURE, V356, P612, DOI 10.1038/356612a0; DAI CH, 1991, BLOOD, V78, P2493; DANCEY JT, 1976, J CLIN INVEST, V58, P705, DOI 10.1172/JCI108517; DICK JE, 1985, CELL, V42, P71, DOI 10.1016/S0092-8674(85)80102-1; Erslev A., 1983, HEMATOLOGY, P365; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; HARA H, 1978, AM J HEMATOL, V4, P23, DOI 10.1002/ajh.2830040105; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; HIRAYAMA F, 1994, P NATL ACAD SCI USA, V91, P469, DOI 10.1073/pnas.91.2.469; HIRAYAMA F, 1992, P NATL ACAD SCI USA, V89, P5907, DOI 10.1073/pnas.89.13.5907; HIRAYAMA F, 1994, BLOOD, V83, P92; HODGSON GS, 1979, NATURE, V281, P381, DOI 10.1038/281381a0; IKEBUCHI K, 1988, P NATL ACAD SCI USA, V85, P3445, DOI 10.1073/pnas.85.10.3445; IKEBUCHI K, 1987, P NATL ACAD SCI USA, V84, P9035, DOI 10.1073/pnas.84.24.9035; ITOH Y, 1992, INT J HEMATOL, V55, P139; JOHNSON GR, 1981, EXPT HEMATOLOGY TODA, P13; KATAYAMA N, 1993, BLOOD, V81, P610; KAY HEM, 1965, LANCET, V2, P418; KELLER G, 1985, NATURE, V318, P149, DOI 10.1038/318149a0; KISHI K, 1989, J CELL PHYSIOL, V139, P463, DOI 10.1002/jcp.1041390303; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; KOIKE K, 1986, J CLIN INVEST, V77, P894, DOI 10.1172/JCI112387; KOIKE K, 1987, J CELL PHYSIOL, V131, P458, DOI 10.1002/jcp.1041310319; KOURY MJ, 1992, EXP HEMATOL, V20, P391; LAJTHA LG, 1979, DIFFERENTIATION, V14, P23, DOI 10.1111/j.1432-0436.1979.tb01007.x; LEARY AG, 1990, BLOOD, V75, P1960; LEARY AG, 1985, BLOOD, V66, P327; LEARY AG, 1984, J CLIN INVEST, V74, P2193, DOI 10.1172/JCI111645; LEARY AG, 1992, P NATL ACAD SCI USA, V89, P4013, DOI 10.1073/pnas.89.9.4013; LEARY AG, 1989, P NATL ACAD SCI USA, V86, P4535, DOI 10.1073/pnas.86.12.4535; LEMISCHKA IR, 1986, CELL, V45, P917, DOI 10.1016/0092-8674(86)90566-0; MERBERG DM, 1992, IMMUNOL TODAY, V13, P77, DOI 10.1016/0167-5699(92)90140-3; METCALF D, 1980, BLOOD, V55, P138; MUSASHI M, 1991, P NATL ACAD SCI USA, V88, P765, DOI 10.1073/pnas.88.3.765; MUSASHI M, 1991, BLOOD, V78, P1448; NAKAHATA T, 1982, J CELL PHYSIOL, V113, P455, DOI 10.1002/jcp.1041130314; NAKAHATA T, 1982, P NATL ACAD SCI-BIOL, V79, P3843, DOI 10.1073/pnas.79.12.3843; PESCHEL C, 1987, BLOOD, V70, P254; PLUZNIK DH, 1965, J CELL COMPAR PHYSL, V66, P319, DOI 10.1002/jcp.1030660309; RENNICK D, 1989, BLOOD, V73, P1828; RENNICK D, 1987, P NATL ACAD SCI USA, V84, P6889, DOI 10.1073/pnas.84.19.6889; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; SNODGRASS R, 1987, EMBO J, V6, P3955, DOI 10.1002/j.1460-2075.1987.tb02737.x; SONODA Y, 1988, P NATL ACAD SCI USA, V85, P4360, DOI 10.1073/pnas.85.12.4360; SUDA J, 1984, BLOOD, V64, P393; SUDA T, 1983, J CELL PHYSIOL, V117, P308, DOI 10.1002/jcp.1041170305; SUDA T, 1985, J CELL PHYSIOL, V124, P182, DOI 10.1002/jcp.1041240203; SUDA T, 1984, P NATL ACAD SCI-BIOL, V81, P2520, DOI 10.1073/pnas.81.8.2520; SUDA T, 1983, P NATL ACAD SCI-BIOL, V80, P6689, DOI 10.1073/pnas.80.21.6689; TILL JE, 1964, P NATL ACAD SCI USA, V51, P29, DOI 10.1073/pnas.51.1.29; TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892; TRENTIN JJ, 1970, REGULATION HEMATOPOI, V1, P161; TSUJI K, 1991, BLOOD, V78, P1223; TSUJI K, 1992, BLOOD, V79, P2855; VANZANT G, 1979, BLOOD, V53, P946; YIN T, 1992, BLOOD S, V80, pA151	65	38	38	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1994	94	3	2	S			645	650		10.1016/0091-6749(94)90142-2	http://dx.doi.org/10.1016/0091-6749(94)90142-2			6	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PH235	8083474				2022-12-18	WOS:A1994PH23500011
J	TAUTZ, C; RIHS, HP; THIELE, A; ZWOLLO, P; FREIDHOFF, LR; MARSH, DG; BAUR, X				TAUTZ, C; RIHS, HP; THIELE, A; ZWOLLO, P; FREIDHOFF, LR; MARSH, DG; BAUR, X			ASSOCIATION OF CLASS-II SEQUENCES ENCODING DR1 AND DQ5 SPECIFICITIES WITH HYPERSENSITIVITY TO CHIRONOMID ALLERGEN CHI-T-I	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALLERGY; HLA-D TYPING; POLYMERASE CHAIN REACTION; SEQUENCE-SPECIFIC OLIGONUCLEOTIDES	HUMAN IMMUNE-RESPONSE; NON-BITING MIDGES; SHORT RAGWEED ALLERGEN; AMB-A-V; ANTIGENIC DETERMINANTS; GENETIC-MARKER; POLLEN; HEMOGLOBINS; RESPONSIVENESS; DNA	A panel of 188 unrelated Caucasian subjects who were exposed to the larvae of Chironomus thummi (Diptera, nonbiting midges) was HLA-typed by polymerase chain reaction amplification of the second exons of the DRB, DQA1, and DQB1 genes followed by dot-blot hybridization with sequence-specific oligonucleotide probes. Type I sensitization to the allergen Chi t I and a large number of other inhalant allergens was determined by RAST and skin testing. Sixty-one individuals were found to be sensitized to Chi t I, of whom 24 were sensitive to this allergen and to no other allergens tested. Statistical analyses showed that only in the latter group were the HLA-D genes DRB1*0101, DQA1*0101, and DQB1*0501 associated with IgE-responsiveness to Chi t I. These results suggest that HLA associations responsiveness to certain allergens may be more striking in monosensitized subjects.	JOHNS HOPKINS ASTHMA & ALLERGY CTR, BALTIMORE, MD USA; RUHR UNIV BOCHUM, BERUFSGENOSSENSCHAFTL FORSCH INST ARBEITSMED, D-44789 BOCHUM, GERMANY	Johns Hopkins University; Johns Hopkins Medicine; Ruhr University Bochum								ANSARI AA, 1989, HUM IMMUNOL, V25, P59, DOI 10.1016/0198-8859(89)90070-0; BAUR X, 1982, J ALLERGY CLIN IMMUN, V69, P66, DOI 10.1016/0091-6749(82)90090-2; BAUR X, 1986, SCIENCE, V233, P351, DOI 10.1126/science.2425431; BEGOVICH AB, 1992, J IMMUNOL, V148, P249; BOUSQUET J, 1992, ACI NEWS, V4, P49; CRANSTON PS, 1983, ANN TROP MED PARASIT, V77, P527, DOI 10.1080/00034983.1983.11811746; FISCHER GF, 1992, HUM IMMUNOL, V33, P259, DOI 10.1016/0198-8859(92)90333-I; FREIDHOFF LR, 1988, TISSUE ANTIGENS, V31, P211, DOI 10.1111/j.1399-0039.1988.tb02083.x; HUANG SK, 1991, EUR J IMMUNOL, V21, P1469, DOI 10.1002/eji.1830210621; IGARASHI T, 1987, JPN J EXP MED, V57, P1; KAGEN S L, 1984, Journal of Allergy and Clinical Immunology, V73, P187; LIEBERS V, 1993, ALLERGY, V48, P236, DOI 10.1111/j.1398-9995.1993.tb00722.x; LIEBERS V, 1993, J ALLERGY CLIN IMMUN, V92, P334, DOI 10.1016/0091-6749(93)90177-H; LIEBERS V, 1991, INT ARCH ALLER A IMM, V95, P163, DOI 10.1159/000235423; MARCADET A, 1989, IMMUNOBIOLOGY HLA, V1, P553; MARSH DG, 1987, IMMUNOGENETICS, V26, P230, DOI 10.1007/BF00346517; MARSH DG, 1982, J EXP MED, V155, P1439, DOI 10.1084/jem.155.5.1439; MARSH DG, 1982, J EXP MED, V155, P1452, DOI 10.1084/jem.155.5.1452; MARSH DG, 1988, ADV BIOSCI, V74, P65; MAZUR G, 1988, MOL IMMUNOL, V25, P1005, DOI 10.1016/0161-5890(88)90007-7; MAZUR G, 1990, MONOGR ALLERGY, V28, P121; MAZUR G, 1989, ALLERGOLOGIE S, V12, P33; NEVINNYSTICKEL C, 1991, HUM IMMUNOL, V31, P7, DOI 10.1016/0198-8859(91)90042-8; PENE J, 1992, Journal of Allergy and Clinical Immunology, V89, P174; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOMMER R, 1989, NUCLEIC ACIDS RES, V17, P6749, DOI 10.1093/nar/17.16.6749; STEIGEMANN W, 1979, J MOL BIOL, V127, P309, DOI 10.1016/0022-2836(79)90332-2; TAUTZ C, 1992, IMMUNOBIOLOGY, V39, P91; TEE RD, 1985, CLIN ALLERGY, V15, P335, DOI 10.1111/j.1365-2222.1985.tb03001.x; TSUJI K, 1992, 11TH P HIST WORKSH C; WANK R, 1991, NATURE, V352, P723, DOI 10.1038/352723a0; WILLCOX HNA, 1978, IMMUNOGENETICS, V6, P209, DOI 10.1007/BF01563911; ZWOLLO P, 1989, J ALLERGY CLIN IMMUN, V83, P45, DOI 10.1016/0091-6749(89)90476-4; ZWOLLO P, 1991, IMMUNOGENETICS, V33, P141	35	38	38	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1994	93	5					918	925		10.1016/0091-6749(94)90386-7	http://dx.doi.org/10.1016/0091-6749(94)90386-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NL919	8182234				2022-12-18	WOS:A1994NL91900017
J	PETERSEN, A; BECKER, WM; SCHLAAK, M				PETERSEN, A; BECKER, WM; SCHLAAK, M			CHARACTERIZATION OF GRASS GROUP-I ALLERGENS IN TIMOTHY GRASS-POLLEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						GRASS POLLEN ALLERGENS; IMMUNOBLOTTING; MICROSEQUENCING; 2-DIMENSIONAL GEL ELECTROPHORESIS	GROUP-V ALLERGENS; PHL-P-V; PURIFICATION; NITROCELLULOSE; PROTEINS	Using Phl p V-depleted timothy grass pollen extract (Phleum pratense) as immunogen, we obtained a monoclonal antibody, QG 4, which recognized proteins of 33, 35, and 37 kd as determined by Western blotting. The antibody cross-reacted with pollen proteins of other grass species in the molecular weight range of 30 to 37 kd. By mean of two-dimensional polyacrylamide gel electrophoresis blot of timothy grass pollen extract, we demonstrated at least seven protein spots two of 37 kd with isoelectric points of 6.4 and 6.6; four of 35 kd with isoelectric points of 65, 68, 7.1, and 73, and one of 33 kd with an isoelectric point of 8.5. These protein spots were also detected by patients' pooled serum. Microsequencing of the 20 N-terminal amino acid residues revealed structures with sequence identities up to 90% to the well-established allergen, Lol p I of ryegrass (Lolium perenne). Therefore we assume that the monoclonal antibody QG 4 recognized the corresponding allergen Phl p I in timothy grass pollen.			PETERSEN, A (corresponding author), FORSCHUNGSINST BORSTEL,DIV ALLERGOL,PARKALLEE 22,D-23845 BORSTEL,GERMANY.							BECKER WM, 1988, BIOCH ENG, P440; CORNISHBOWDEN A, 1980, ANAL BIOCHEM, V105, P233, DOI 10.1016/0003-2697(80)90450-9; COTTAM GP, 1986, BIOCHEM J, V234, P305, DOI 10.1042/bj2340305; Goding JW, 1983, MONOCLONAL ANTIBODIE; GORG A, 1988, ELECTROPHORESIS, V9, P531, DOI 10.1002/elps.1150090913; HANCOCK K, 1983, ANAL BIOCHEM, V133, P157, DOI 10.1016/0003-2697(83)90237-3; HAWKES R, 1982, ANAL BIOCHEM, V119, P142, DOI 10.1016/0003-2697(82)90677-7; JOHNSON P, 1965, NATURE, V206, P935, DOI 10.1038/206935b0; KHYSEANDERSON J, 1984, J BIOCHEM BIOPH METH, V10, P203; LEARY JJ, 1983, P NATL ACAD SCI-BIOL, V80, P4045, DOI 10.1073/pnas.80.13.4045; MARSH DG, 1988, ALLERGY, V43, P161; MATTHIESEN F, 1991, CLIN EXP ALLERGY, V21, P309, DOI 10.1111/j.1365-2222.1991.tb01662.x; MATTHIESEN F, 1991, CLIN EXP ALLERGY, V21, P297, DOI 10.1111/j.1365-2222.1991.tb01661.x; MATTHIESEN F, 1992, ALLERGY S, V47, P31; Milstein C, 1980, Curr Top Dev Biol, V14, P1; Neville D M Jr, 1974, Methods Enzymol, V32, P92; OUCHTERLONY O, 1949, LANCET, V256, P346; PEREZ M, 1990, J BIOL CHEM, V265, P16210; PETERSEN A, 1992, INT ARCH ALLERGY IMM, V98, P105, DOI 10.1159/000236172; PETERSEN A, 1992, ELECTROPHORESIS, V13, P736, DOI 10.1002/elps.11501301158; PETERSEN A, 1991, Applied and Theoretical Electrophoresis, V2, P129; SINGH MB, 1991, P NATL ACAD SCI USA, V88, P1384, DOI 10.1073/pnas.88.4.1384; SONDERGAARD I, 1984, ALLERGY, V39, P473, DOI 10.1111/j.1398-9995.1984.tb01971.x; WEBER RW, 1981, ANN ALLERGY, V46, P208; WILLIAMSON AR, 1973, ANN NY ACAD SCI, V209, P210, DOI 10.1111/j.1749-6632.1973.tb47530.x; 1987, 220 PHARM DEV TECHN	26	38	38	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1993	92	6					789	796		10.1016/0091-6749(93)90055-K	http://dx.doi.org/10.1016/0091-6749(93)90055-K			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ML893	8258612	Bronze			2022-12-18	WOS:A1993ML89300003
J	BHAGAT, R; SHAH, A; JAGGI, OP; KHAN, ZU				BHAGAT, R; SHAH, A; JAGGI, OP; KHAN, ZU			CONCOMITANT ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS AND ALLERGIC ASPERGILLUS SINUSITIS WITH AN OPERATED ASPERGILLOMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									UNIV DELHI,VALLABHBHAI PATEL CHEST INST,DEPT CLIN RES,POB 2101,DELHI 110007,INDIA; UNIV DELHI,VALLABHBHAI PATEL CHEST INST,DEPT MED MYCOL,DELHI 110007,INDIA	University of Delhi; University of Delhi								LIGHT RW, 1990, PLEURAL DISEASES, P16; MURPHY D, 1981, BRIT J DIS CHEST, V75, P91, DOI 10.1016/S0007-0971(81)80013-7; SHAH A, 1990, ANN ALLERGY, V64, P507; SHAH A, 1989, J ASTHMA, V26, P109, DOI 10.3109/02770908909073239	4	38	38	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1993	91	5					1094	1096		10.1016/0091-6749(93)90224-4	http://dx.doi.org/10.1016/0091-6749(93)90224-4			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LC978	8491942	Bronze			2022-12-18	WOS:A1993LC97800018
J	MALO, JL; GHEZZO, H; TRUDEAU, C; LARCHEVEQUE, J; CARTIER, A				MALO, JL; GHEZZO, H; TRUDEAU, C; LARCHEVEQUE, J; CARTIER, A			SALMETEROL, A NEW INHALED BETA2-ADRENERGIC AGONIST, HAS A LONGER BLOCKING EFFECT THAN ALBUTEROL ON HYPERVENTILATION-INDUCED BRONCHOCONSTRICTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						BRONCHIAL PROVOCATION TESTS; ASTHMA; BRONCHI	COLD AIR INHALATION; ASTHMATIC SUBJECTS; SALBUTAMOL; FENOTEROL; DURATION; CURVE	The duration of the blocking effect of salmeterol (50-mu-g), albuterol (200-mu-g), and a placebo were compared in a double-blind study in 12 adult subjects with asthma who underwent hyperventilation tests with cold dry air (-20-degrees-C) on 4 study days. On the first day, the hyperventilation test was performed at various time intervals (baseline, 1, 4, 6, 8, 12, and 24 hours) with spontaneous functional recovery between each test to determine the within-day within-subject variability of the response. The response was assessed by interpolating the dose of cold dry air causing a 20% fall in FEV1. On the 3 remaining days, separated by an interval of at least 5 days, the active or placebo medication was administered after spontaneous recovery from the first hyperventilation test. Spirometry was assessed 15 minutes and 1 hour later. The hyperventilation test was then performed and repeated 4 hours after administration of the drug. The test was repeated 6, 8, 12, and 24 hours later to detect any significant blocking effect. The improvement in FEV1 15 minutes and 1 hour after the drug was administered was 19.8% and 20.4%, as compared to baseline for albuterol, and 16.3% and 16.8% for salmeterol (not significant). The mean duration of the blocking effect was 0.25 hour for the placebo, 3.5 hours for albuterol, and 15.9 hours for salmeterol (F = 24.5; p < 0.001; Newman-Keul's test was significant for every contrast). Eight of the 12 subjects still demonstrated some blocking effect 8 hours after taking salmeterol; this was true for only one subject receiving albuterol. We conclude that salmeterol has a significantly longer effect than albuterol on bronchoconstriction induced by hyperventilation.			MALO, JL (corresponding author), HOP SACRE COEUR, DEPT CHEST MED, 5400 W GOUIN, MONTREAL H4J 1C5, QUEBEC, CANADA.							[Anonymous], 1987, AM REV RESPIR DIS, V136, P1285; DENTE FL, 1986, RESPIRATION, V50, P196, DOI 10.1159/000195126; FITZPATRICK MF, 1990, BRIT MED J, V301, P1365, DOI 10.1136/bmj.301.6765.1365; JOHNSON M, 1990, LUNG, V168, P115, DOI 10.1007/BF02718123; KELLY HW, 1985, CLIN PHARMACY, V4, P383; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; LOFDAHL CG, 1991, EUR RESPIR J, V4, P218; MALO JL, 1989, AM REV RESPIR DIS, V140, P817, DOI 10.1164/ajrccm/140.3.817; MCCULLAGH P, 1980, J ROY STAT SOC B MET, V42, P109; McCullagh P., 1983, GEN LINEAR MODELS, DOI [10.1007/978-1-4899-3244-0, DOI 10.1007/978-1-4899-3244-0]; MENEELY GR, 1962, AM REV RESPIR DIS, V85, P762; MERLAND N, 1988, AM REV RESPIR DIS, V137, P1304, DOI 10.1164/ajrccm/137.6.1304; OBYRNE PM, 1983, AM REV RESPIR DIS, V128, P611; PAUWELS R, 1990, AM REV RESPIR DIS, V141, P469; RUFFIN RE, 1979, CLIN PHARMACOL THER, V25, P821; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SKIDMORE IF, 1984, DEV ANTIASTHMA DRUGS, P185; SMITH CM, 1988, CHEST, V94, P709, DOI 10.1378/chest.94.4.709; TESSIER P, 1987, AM REV RESPIR DIS, V136, P1418, DOI 10.1164/ajrccm/136.6.1418; TESSIER P, 1986, J ALLERGY CLIN IMMUN, V78, P379, DOI 10.1016/0091-6749(86)90021-7; TWENTYMAN OP, 1990, LANCET, V336, P1338, DOI 10.1016/0140-6736(90)92894-N; ULLMAN A, 1988, THORAX, V43, P674, DOI 10.1136/thx.43.9.674; ULLMAN A, 1990, AM REV RESPIR DIS, V142, P571, DOI 10.1164/ajrccm/142.3.571	23	38	38	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1992	89	2					567	574		10.1016/0091-6749(92)90324-U	http://dx.doi.org/10.1016/0091-6749(92)90324-U			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HD753	1346793				2022-12-18	WOS:A1992HD75300009
J	BACHELET, M; VINCENT, D; HAVET, N; MARRASHCHAHLA, R; PRADALIER, A; DRY, J; VARGAFTIG, BB				BACHELET, M; VINCENT, D; HAVET, N; MARRASHCHAHLA, R; PRADALIER, A; DRY, J; VARGAFTIG, BB			REDUCED RESPONSIVENESS OF ADENYLATE-CYCLASE IN ALVEOLAR MACROPHAGES FROM PATIENTS WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ADENYLATE CYCLASE; ALVEOLAR MACROPHAGES; ASTHMA	BETA-ADRENERGIC RECEPTORS; HETEROLOGOUS DESENSITIZATION; MONOPHOSPHATE; LYMPHOCYTES; LEUKOCYTES; SYSTEM	Alveolar macrophages from patients with asthma accumulated less cyclic adenosine monophosphate when these macrophages were exposed to isobutyl methylxanthine, salbutamol, or prostaglandin E2, compared to cells from control subjects without asthma, and the degree of the hyporesponsiveness was related to the severity of asthma. In addition, a significantly lower adenylate cyclase activity was observed in crude membrane fractions of macrophages from the group with asthma in the presence of salbutamol and prostaglandin E2. The refractoriness observed in patients with asthma is thus not accounted for by a specific beta-adrenergic desensitization at the adenylate cyclase receptor level but should rather be explained by a cyclic adenosine monophosphate-dependent postreceptor mechanism.	HOP ROTHSCHILD,SERV MED INTERNE,F-75571 PARIS 12,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Rothschild - APHP; UDICE-French Research Universities; Sorbonne Universite	BACHELET, M (corresponding author), INST PASTEUR,INSERM,U285,UNITE PHARMACOL CELLULAIRE,25 RUE DR ROUX,F-75724 PARIS 15,FRANCE.		Vargaftig, Bernardo Boris B.B.J./C-3323-2013					BACHELET M, 1989, Pulmonary Pharmacology, V2, P41, DOI 10.1016/S0952-0600(89)80008-0; BARNES PJ, 1980, NATURE, V285, P569, DOI 10.1038/285569a0; BARNES PJ, 1981, BRIT MED J, V282, P1207, DOI 10.1136/bmj.282.6271.1207; BROOKS SM, 1979, J ALLERGY CLIN IMMUN, V63, P401, DOI 10.1016/0091-6749(79)90213-6; CAPRON A, 1975, NATURE, V253, P474, DOI 10.1038/253474a0; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; GALANT SP, 1978, NEW ENGL J MED, V299, P933, DOI 10.1056/NEJM197810262991707; GARRITY M, 1983, J BIOL CHEM, V258, P8692; GILMAN AG, 1970, P NATL ACAD SCI USA, V67, P305, DOI 10.1073/pnas.67.1.305; GODARD P, 1982, J ALLERGY CLIN IMMUN, V70, P88, DOI 10.1016/0091-6749(82)90234-2; KOSCHEL K, 1980, EUR J BIOCHEM, V108, P163, DOI 10.1111/j.1432-1033.1980.tb04708.x; LI CY, 1973, J HISTOCHEM CYTOCHEM, V21, P1; LONGSDON PJ, 1972, J ALLERGY CLIN IMMUN, V50, P45; MAKINO S, 1977, J ALLERGY CLIN IMMUN, V59, P348, DOI 10.1016/0091-6749(77)90016-1; MITA H, 1983, INT ARCH ALLER A IMM, V70, P225, DOI 10.1159/000233328; NODA C, 1984, J BIOL CHEM, V259, P7747; SCHOCKEN DD, 1977, NATURE, V267, P856, DOI 10.1038/267856a0; SHELHAMER JH, 1980, J ALLERGY CLIN IMMUN, V66, P52, DOI 10.1016/0091-6749(80)90138-4; SIBLEY DR, 1985, NATURE, V317, P124, DOI 10.1038/317124a0; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STADEL JM, 1981, J CYCLIC NUCL PROT, V7, P37; SZENTIVANYI A, 1980, J ALLERGY CLIN IMMUN, V65, P5, DOI 10.1016/0091-6749(80)90170-0; ZIEGLER MG, 1976, NATURE, V261, P333, DOI 10.1038/261333a0	23	38	38	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1991	88	3	1				322	388		10.1016/0091-6749(91)90093-4	http://dx.doi.org/10.1016/0091-6749(91)90093-4			67	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GG126	1716272	Bronze			2022-12-18	WOS:A1991GG12600025
J	MOSS, RB				MOSS, RB			SENSITIZATION TO AZTREONAM AND CROSS-REACTIVITY WITH OTHER BETA-LACTAM ANTIBIOTICS IN HIGH-RISK PATIENTS WITH CYSTIC-FIBROSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							PENICILLIN ALLERGY; IMMEDIATE HYPERSENSITIVITY; SEMISYNTHETIC PENICILLINS; PULMONARY EXACERBATIONS; DESENSITIZATION	The immunogenicity, allergenicity, and cross-reactivity of aztreonam were investigated in 21 patients with cystic fibrosis (CF) (aged 5 to 39 years) with well-documented histories of allergic systemic reactions (SRs) to penicillin and/or cephalosporin antipseudomonal beta-lactam antibiotics (BLAs). Skin tests (STs) with penicilloyl-polylysine (PPL), penicillin minor determinant mixture, and antipseudomonal BLA were positive in 19 patients (90%). The BLA causing the most recent allergic reaction, minor determinant mixture, or PPL, was positive in 89%, 53%, and 32% of ST-positive patients, respectively. Serum PPL-specific IgE antibodies were not detectable, although PPL-specific IgG antibodies were found in 64% of patients tested. STs to aztreonam reagents were performed and were initially negative in 20 patients. One patient was ST positive to the polylysine conjugate of hydrolyzed aztreonam (SQ 27629), despite no prior exposure to aztreonam, and was not treated. Of 20 patients treated with aztreonam, four were demonstrated to be sensitized by exposure (one had an SR during initial treatment course, two had SRs on reexposure, and one patient was asymptomatic after intravenous desensitization) by positive aztreonam reagent skin responses on repeat testing. Aztreonyl-specific IgE and IgG serum antibodies were not detected in any patients, including patients with allergic reactions to aztreonam. Thus, aztreonam is generally well tolerated in high-risk patients with CF allergic to other BLAs and appears to have reduced immunogenicity by serologic testing. However, caution should be exercised with aztreonam in BLA-allergic patients with CF in light of 5% preexisting ST cross-reactivity and 20% sensitization rates found in this study.	STANFORD UNIV,MED CTR,SCH MED,DEPT PEDIAT,DIV ALLERGY & PULM DIS,STANFORD,CA 94305	Stanford University	MOSS, RB (corresponding author), CHILDRENS HOSP STANFORD,DEPT PEDIAT,DIV ALLERGY PULM,520 SAND HILL RD,PALO ALTO,CA 94304, USA.		Moss, Richard B./S-9218-2019	Moss, Richard B./0000-0003-3611-4221				ADKINSON NF, 1989, PROGRESS IN ALLERGY AND CLINICAL IMMUNOLOGY, P439; ADKINSON NF, 1985, REV INFECT DIS, V7, pS613; ADKINSON NF, 1984, ANTIMICROB AGENTS CH, V25, P93, DOI 10.1128/AAC.25.1.93; ADKINSON NF, 1986, MANUAL CLIN LABORATO, P692; ADKINSON NF, 1983, 11 P INT C ALL CLIN, P55; BLANCA M, 1989, J ALLERGY CLIN IMMUN, V83, P381, DOI 10.1016/0091-6749(89)90122-X; BOSSO JA, 1987, PEDIATR INFECT DIS J, V6, P393, DOI 10.1097/00006454-198704000-00010; BOSSO JA, 1988, PEDIATR INFECT DIS J, V7, P171, DOI 10.1097/00006454-198803000-00008; BROWN LA, 1982, J ALLERGY CLIN IMMUN, V69, P51, DOI 10.1016/0091-6749(82)90087-2; CHARTRAND SA, 1989, RESPIRATORY INFECTIO, P276; EARL HS, 1987, J ALLERGY CLIN IMMUN, V79, P477, DOI 10.1016/0091-6749(87)90365-4; GALANT S, 1987, J ALLERGY CLIN IMMUN, V79, P199; HILMAN BC, 1986, J ALLERGY CLIN IMMUN, V77, P167; LORIA RC, 1989, J ALLERGY CLIN IMMUN, V83, P735, DOI 10.1016/0091-6749(89)90007-9; MOSS RB, 1984, J PEDIATR-US, V104, P460, DOI 10.1016/S0022-3476(84)81117-8; MOSS RB, 1983, TXB CYSTIC FIBROSIS, P109; MOSS RB, IN PRESS REV INFECT; NEU HC, 1986, REV INFECT DIS, V8, pS237; SAXON A, 1984, J INFECT DIS, V149, P16, DOI 10.1093/infdis/149.1.16; SAXON A, 1987, ANN INTERN MED, V107, P204, DOI 10.7326/0003-4819-107-2-204; SAXON A, 1985, AM J MED, V78, P19, DOI 10.1016/0002-9343(85)90198-6; SAXON A, 1989, Pediatric Infectious Disease Journal, V8, pS124, DOI 10.1097/00006454-198909001-00008; SCHAAD UB, 1989, EUR J CLIN MICROBIOL, V8, P858, DOI 10.1007/BF01963771; SCULLY BE, 1985, REV INFECT DIS, V7, pS669; SOLLEY GO, 1982, J ALLERGY CLIN IMMUN, V69, P238, DOI 10.1016/0091-6749(82)90105-1; SULLIVAN TJ, 1981, J ALLERGY CLIN IMMUN, V68, P171, DOI 10.1016/0091-6749(81)90180-9; SULLIVAN TJ, 1982, J ALLERGY CLIN IMMUN, V69, P275, DOI 10.1016/S0091-6749(82)80004-3; VADINO WA, 1979, J PHARM SCI, V68, P1316, DOI 10.1002/jps.2600681032; VANDELLEN RG, 1981, J ALLERGY CLIN IMMUN, V68, P169, DOI 10.1016/0091-6749(81)90179-2; VANDELLEN RG, 1971, J ALLERGY, V47, P230, DOI 10.1016/S0091-6749(71)80468-2	30	38	38	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1991	87	1	1				78	88		10.1016/0091-6749(91)90215-A	http://dx.doi.org/10.1016/0091-6749(91)90215-A			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EX985	1991925				2022-12-18	WOS:A1991EX98500010
J	GENGO, FM; MANNING, C				GENGO, FM; MANNING, C			A REVIEW OF THE EFFECTS OF ANTIHISTAMINES ON MENTAL PROCESSES RELATED TO AUTOMOBILE DRIVING	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	CONF ON ADVANCEMENTS IN ANTIALLERGIC THERAPY : BEYOND CONVENTIONAL ANTIHISTAMINES	OCT 12-15, 1989	NAPLES, FL	PFIZER LAB			PSYCHOMOTOR PERFORMANCE; PSYCHOACTIVE-DRUGS; SKILLS PERFORMANCE; TERFENADINE; DIPHENHYDRAMINE; ALCOHOL; COMBINATION; HYDROXYZINE; DIAZEPAM; ETHANOL	The newer, second-generation H1-receptor antagonists have been shown to have potent antiallergic effects without inducing sleepiness. However, because traditional antihistamines may cause functional or cognitive impairment, the clinican still must consider warning patients about activities that could be hazardous. Because the effects of drugs on driving an automobile are difficult to measure directly, studies must use surrogate activities in a laboratory setting. Effects of antihistamines on the central nervous system are assessed with psychomotor tests, which are selected on the basis of their relativity to real-world activities, to develop a profile of mental processes that may be affected. This article reviews the psychomotor tests and study design used to characterize the intensity and duration of drug effects after single and multiple doses and in combination with other impairing agents such as ethanol. Several studies have been published that assess the effects of cetirizine, an H1-receptor blocker, on mental performance. In the study discussed here, diphenhydramine hydrochloride and hydroxyzine were used as positive controls to demonstrate that the period during which some traditional antihistamines impair performance is different than the period of reported drowsiness they induce. The results of this series of studies show that cetirizine induced minimal changes in mental performance tests and only following the highest (20 mg) dose studied.	SUNY BUFFALO,SCH MED,DEPT NEUROL,BUFFALO,NY 14214; SUNY BUFFALO,SCH PHARM,DEPT PHARM,BUFFALO,NY 14260	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	GENGO, FM (corresponding author), DENT NEUROL INST,DIV NEUROPHARMACOL,3 GATES CIRCLE,BUFFALO,NY 14209, USA.							BAUGH R, 1977, EUR J CLIN PHARMACOL, V12, P201, DOI 10.1007/BF00609861; BORNSTEIN RA, 1987, J NERV MENT DIS, V175, P229, DOI 10.1097/00005053-198704000-00007; BRAODBENT DE, 1984, BR J CLIN PHARM, V18, pS5; BURNS M, 1980, EUR J CLIN PHARMACOL, V17, P259, DOI 10.1007/BF00625799; CLARKE CH, 1978, BRIT J CLIN PHARMACO, V6, P31, DOI 10.1111/j.1365-2125.1978.tb01678.x; DEGIER JJ, 1984, BRIT J CLIN PHARMACO, V18, pS103; GENGO F, 1989, CLIN PHARMACOL THER, V45, P15, DOI 10.1038/clpt.1989.3; GENGO FM, 1987, CLIN PHARMACOL THER, V42, P265, DOI 10.1038/clpt.1987.145; GENGO FM, 1990, ANN ALLERGY, V64, P520; GENGO FM, 1987, ANN ALLERGY, V59, P53; GENGO FM, 1990, J CLIN PHARMACOL, V30, P748, DOI 10.1002/j.1552-4604.1990.tb03638.x; GOETZ DW, 1989, J ALLERGY CLIN IMMUN, V84, P316, DOI 10.1016/0091-6749(89)90414-4; HINDMARCH I, 1980, BRIT J CLIN PHARMACO, V10, P189, DOI 10.1111/j.1365-2125.1980.tb01745.x; KLINKNECHT RA, 1984, BR J CLIN PHARM, V18, pS39; KULSHRESTHA VK, 1978, BRIT J CLIN PHARMACO, V6, P25, DOI 10.1111/j.1365-2125.1978.tb01677.x; LINNOILA M, 1973, EUR J CLIN PHARMACOL, V5, P247, DOI 10.1007/BF00567013; LINNOILA M, 1973, EUR J CLIN PHARMACOL, V5, P186, DOI 10.1007/BF00564901; MANN P, 1983, ARRIVE ALIVE KEEP DR, P16; MOSER L, 1978, EUR J CLIN PHARMACOL, V14, P417, DOI 10.1007/BF00716383; MOSKOWITZ H, 1984, BRIT J CLIN PHARMACO, V18, pS51, DOI 10.1111/j.1365-2125.1984.tb02582.x; NICHOLSON AN, 1982, ARZNEIMITTEL-FORSCH, V32-2, P1191; NICHOLSON AN, 1982, BRIT J CLIN PHARMACO, V13, P199, DOI 10.1111/j.1365-2125.1982.tb01356.x; NICHOLSON AN, 1979, BRIT J CLIN PHARMACO, V8, P321, DOI 10.1111/j.1365-2125.1979.tb04712.x; OHANLON JF, 1988, CUTIS, V42, P10; OHANLON JF, 1984, BRIT J CLIN PHARMACO, V18, pS121, DOI 10.1111/j.1365-2125.1984.tb02590.x; OHANLON JF, 1986, DRUGS DRIVING; REINBERG A, 1978, EUR J CLIN PHARMACOL, V14, P245, DOI 10.1007/BF00560457; SEPPALA T, 1981, BRIT J CLIN PHARMACO, V12, P179; STARMER GA, 1984, BRIT J CLIN PHARMACO, V18, pS27, DOI 10.1111/j.1365-2125.1984.tb02580.x; WEINER M, 1982, ARZNEIMITTEL-FORSCH, V32-2, P1193; WOODS JR, 1989, ANN INTERN MED, V110, P560, DOI 10.7326/0003-4819-110-7-560	31	38	38	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1990	86	6	2	S			1034	1035		10.1016/S0091-6749(05)80250-7	http://dx.doi.org/10.1016/S0091-6749(05)80250-7			2	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	ER131	1979799				2022-12-18	WOS:A1990ER13100009
J	LYMPANY, P; KEMENY, DM; WELSH, KI; LEE, TH				LYMPANY, P; KEMENY, DM; WELSH, KI; LEE, TH			AN HLA-ASSOCIATED NONRESPONSIVENESS TO MELITTIN - A COMPONENT OF BEE VENOM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DEPT ALLERGY & ALLIED RESP DISORDERS,LONDON SE1 9RT,ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DEPT TISSUE TYPING,LONDON SE1 9RT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London				Lee, Tak/0000-0002-7554-4059				BIDWELL J, 1988, IMMUNOL TODAY, V9, P18, DOI 10.1016/0167-5699(88)91351-5; BIDWELL JL, 1987, MOL IMMUNOL, V24, P513, DOI 10.1016/0161-5890(87)90026-5; BLUMENTHAL MN, 1986, J ALLERGY CLIN IMMUN, V78, P962, DOI 10.1016/0091-6749(86)90286-1; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GUSTAFSSON K, 1984, NATURE, V309, P76, DOI 10.1038/309076a0; HECHT F, 1971, LANCET, V2, P496; HIRAYAMA K, 1987, NATURE, V327, P426, DOI 10.1038/327426a0; HYLDIGNIELSEN JJ, 1987, P NATL ACAD SCI USA, V84, P1644, DOI 10.1073/pnas.84.6.1644; JARISCH R, 1979, CLIN ALLERGY, V9, P535, DOI 10.1111/j.1365-2222.1979.tb02518.x; KEMENY DM, 1985, J IMMUNOL METHODS, V78, P217, DOI 10.1016/0022-1759(85)90079-1; KEMENY DM, 1980, CLIN ALLERGY, V10, P413, DOI 10.1111/j.1365-2222.1980.tb02124.x; KEMENY DM, 1983, J ALLERGY CLIN IMMUN, V71, P505, DOI 10.1016/0091-6749(83)90469-4; KEMENY DM, 1983, J ALLERGY CLIN IMMUN, V72, P376, DOI 10.1016/0091-6749(83)90503-1; KEMENY DM, 1981, J IMMUNOL METHODS, V49, P89; KIND LS, 1982, ALLERGY, V37, P225, DOI 10.1111/j.1398-9995.1982.tb01904.x; KING TP, 1976, ARCH BIOCHEM BIOPHYS, V172, P661, DOI 10.1016/0003-9861(76)90121-1; KING TP, 1984, J IMMUNOL, V133, P2668; KROEGEL C, 1981, MOL IMMUNOL, V18, P227, DOI 10.1016/0161-5890(81)90089-4; LARHAMMAR D, 1982, P NATL ACAD SCI-BIOL, V79, P3687, DOI 10.1073/pnas.79.12.3687; Mackler B F, 1972, Clin Allergy, V2, P317, DOI 10.1111/j.1365-2222.1972.tb01296.x; MARSH DG, 1974, P NATL ACAD SCI USA, V71, P3588, DOI 10.1073/pnas.71.9.3588; MARSH DG, 1979, P NATL ACAD SCI USA, V76, P2903, DOI 10.1073/pnas.76.6.2903; MARSH DG, 1980, J ALLERGY CLIN IMMUN, V65, P322, DOI 10.1016/0091-6749(80)90208-0; MARSH DG, 1981, NEW ENGL J MED, V305, P1551, DOI 10.1056/NEJM198112243052603; MARSH DG, 1982, J EXP MED, V155, P1439, DOI 10.1084/jem.155.5.1439; MARSH DG, 1981, INT ARCH ALLER A IMM, V66, P48, DOI 10.1159/000232866; MATSUSHITA S, 1987, J IMMUNOL, V138, P109; OUYANG C, 1979, TOXICON, V17, P197, DOI 10.1016/0041-0101(79)90305-2; PAULL BR, 1977, J ALLERGY CLIN IMMUN, V59, P334, DOI 10.1016/0091-6749(77)90056-2; SASAZUKI T, 1983, IMMUNOL REV, V70, P51, DOI 10.1111/j.1600-065X.1983.tb00709.x; SCHENNING L, 1984, EMBO J, V3, P447, DOI 10.1002/j.1460-2075.1984.tb01826.x; SETTIPANE GA, 1970, ACTA ALLERGOL, V25, P286, DOI 10.1111/j.1398-9995.1970.tb01264.x; SOBOTKA AK, 1974, J ALLERGY CLIN IMMUN, V53, P170, DOI 10.1016/0091-6749(74)90005-0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TERASAKI PI, 1964, NATURE, V204, P998, DOI 10.1038/204998b0; TROWSDALE J, 1975, IMMUNOL REV, V85, P5	36	38	38	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1990	86	2					160	170		10.1016/S0091-6749(05)80061-2	http://dx.doi.org/10.1016/S0091-6749(05)80061-2			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DV316	1974559	Bronze			2022-12-18	WOS:A1990DV31600004
J	MALO, JL; GHEZZO, H; LARCHEVEQUE, J; CARTIER, A				MALO, JL; GHEZZO, H; LARCHEVEQUE, J; CARTIER, A			LATE ASTHMATIC REACTIONS TO OCCUPATIONAL SENSITIZING AGENTS - FREQUENCY OF CHANGES IN NONSPECIFIC BRONCHIAL RESPONSIVENESS AND OF RESPONSE TO INHALED BETA-2-ADRENERGIC AGENT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											MALO, JL (corresponding author), HOP SACRE COEUR, DEPT CHEST MED, 5400 W GOUIN, MONTREAL H4J 1C5, QUEBEC, CANADA.							CARTIER A, 1986, J ALLERGY CLIN IMMUN, V78, P1185, DOI 10.1016/0091-6749(86)90270-8; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHUNG KF, 1986, THORAX, V41, P657, DOI 10.1136/thx.41.9.657; COCKCROFT DW, 1987, THORAX, V42, P302, DOI 10.1136/thx.42.4.302; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; COTE J, 1989, American Review of Respiratory Disease, V139, pA389; DEHAUT P, 1983, THORAX, V38, P516, DOI 10.1136/thx.38.7.516; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DURHAM SR, 1987, J ALLERGY CLIN IMMUN, V79, P398, DOI 10.1016/0091-6749(87)90161-8; FABBRI LM, 1987, AM REV RESPIR DIS, V136, P36, DOI 10.1164/ajrccm/136.1.36; GRANEEK BJ, 1987, B EUR PHYSIOPATH RES, V23, P577; HERXHEIMER H, 1952, INT ARCH ALLER A IMM, V3, P323, DOI 10.1159/000227979; HOWARTH PH, 1985, AM REV RESPIR DIS, V132, P986; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; KAY AB, 1987, ALLERGY INFLAMMATION; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; LAI CKW, 1989, AM REV RESPIR DIS, V140, P917, DOI 10.1164/ajrccm/140.4.917; LAM S, 1987, J ALLERGY CLIN IMMUN, V80, P44, DOI 10.1016/S0091-6749(87)80189-6; MACHADO L, 1985, ALLERGY, V40, P580, DOI 10.1111/j.1398-9995.1985.tb00886.x; MALO JL, 1989, J ALLERGY CLIN IMMUN, V83, P159, DOI 10.1016/0091-6749(89)90491-0; MALO JL, 1983, AM REV RESPIR DIS, V128, P8, DOI 10.1164/arrd.1983.128.1.8; MAPP CE, 1985, J ALLERGY CLIN IMMUN, V75, P568, DOI 10.1016/0091-6749(85)90031-4; MARSH WR, 1985, AM REV RESPIR DIS, V131, P875; MOIRA CY, 1986, AM REV RESPIR DIS, V133, P686; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; OBYRNE PM, 1986, CHEST, V90, P575, DOI 10.1378/chest.90.4.575; PAULI G, 1986, B EUR PHYSIOPATH RES, V22, P399; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; RACHIELE A, 1983, B EUR PHYSIOPATH RES, V19, P465; ROBERTSON DG, 1974, J ALLERGY CLIN IMMUN, V54, P244, DOI 10.1016/0091-6749(74)90067-0; RYAN G, 1981, AM REV RESPIR DIS, V123, P195; SLUITER HJ, 1989, BRONCHITIS, V4	35	38	39	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1990	85	5					834	842		10.1016/0091-6749(90)90065-C	http://dx.doi.org/10.1016/0091-6749(90)90065-C			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DD959	2332563				2022-12-18	WOS:A1990DD95900003
J	BALLOW, M; WHITE, W; DESBONNET, C				BALLOW, M; WHITE, W; DESBONNET, C			MODULATION OF INVITRO SYNTHESIS OF IMMUNOGLOBULIN AND THE INDUCTION OF SUPPRESSOR ACTIVITY BY THERAPY WITH INTRAVENOUS IMMUNE GLOBULIN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SUNY BUFFALO, DEPT PEDIAT, BUFFALO, NY 14260 USA; UNIV CONNECTICUT, SCH MED, DEPT PEDIAT, FARMINGTON, CT 06032 USA; UNIV CONNECTICUT, SCH MED, DEPT MED, FARMINGTON, CT 06032 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; University of Connecticut; University of Connecticut	BALLOW, M (corresponding author), BUFFALO CHILDRENS HOSP, DIV ALLERGY & IMMUNOL, 219 BRYANT ST, BUFFALO, NY 14222 USA.							ANTEL JP, 1981, CLIN EXP IMMUNOL, V43, P351; BLAESE RM, 1974, J EXP MED, V140, P1097, DOI 10.1084/jem.140.4.1097; CUNNINGHAMRUNDLES C, 1984, ANN INTERN MED, V101, P435, DOI 10.7326/0003-4819-101-4-435; DURANDY A, 1981, J CLIN INVEST, V67, P867, DOI 10.1172/JCI110104; HASHIMOTO F, 1986, CLIN EXP IMMUNOL, V65, P409; KAWADA K, 1987, EXP HEMATOL, V15, P133; SCHWARTZ SA, 1977, J CLIN INVEST, V59, P1176, DOI 10.1172/JCI108742; SIEGAL FP, 1976, J CLIN INVEST, V58, P109, DOI 10.1172/JCI108439; SIEGAL FP, 1978, NEW ENGL J MED, V299, P177; STOHL W, 1986, CLIN IMMUNOL IMMUNOP, V41, P273, DOI 10.1016/0090-1229(86)90111-X; STOHL W, 1986, J IMMUNOL, V136, P4407; TANNENBAUM AS, 1985, J ALLERGY CLIN IMMUN, V77, P4914; WALDMANN TA, 1974, LANCET, V2, P609; WHITE WB, 1985, NEW ENGL J MED, V312, P198, DOI 10.1056/NEJM198501243120402; WHITE WB, 1987, AM J MED, V83, P431, DOI 10.1016/0002-9343(87)90752-2	15	38	39	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1989	84	4	2	S			595	602		10.1016/0091-6749(89)90196-6	http://dx.doi.org/10.1016/0091-6749(89)90196-6			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AZ398	2571628				2022-12-18	WOS:A1989AZ39800005
J	FREUND, DA; STEIN, J; HURLEY, R; ENGEL, W; WOOMERT, A; LEE, B				FREUND, DA; STEIN, J; HURLEY, R; ENGEL, W; WOOMERT, A; LEE, B			SPECIALTY DIFFERENCES IN THE TREATMENT OF ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material											FREUND, DA (corresponding author), INDIANA UNIV,SCH PUBL & ENVIRONM AFFAIRS,BS404,INDIANAPOLIS,IN 46223, USA.								0	38	38	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1989	84	3					401	406		10.1016/0091-6749(89)90428-4	http://dx.doi.org/10.1016/0091-6749(89)90428-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AR199	2506264				2022-12-18	WOS:A1989AR19900021
J	TOMIOKA, M; STEAD, RH; NIELSEN, L; COUGHLIN, MD; BIENENSTOCK, J				TOMIOKA, M; STEAD, RH; NIELSEN, L; COUGHLIN, MD; BIENENSTOCK, J			NERVE GROWTH-FACTOR ENHANCES ANTIGEN AND OTHER SECRETAGOGUE-INDUCED HISTAMINE-RELEASE FROM RAT PERITONEAL MAST-CELLS IN THE ABSENCE OF PHOSPHATIDYLSERINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MCMASTER UNIV,DEPT PATHOL,ROOM 2N16,1200 MAIN ST W,HAMILTON L8N 3Z5,ONTARIO,CANADA; MCMASTER UNIV,DEPT NEUROSCI,HAMILTON L8N 3Z5,ONTARIO,CANADA	McMaster University; McMaster University								BEFUS AD, 1979, IMMUNOLOGY, V38, P95; BIENENSTOCK J, 1986, MAST CELL DIFFERENTI, P391; BOYLE MDP, 1985, J IMMUNOL, V134, P564; BRADSHAW RA, 1976, BIOCHEM PHARMACOL, V25, P1445, DOI 10.1016/0006-2952(76)90058-7; BRUNI A, 1982, FEBS LETT, V138, P190, DOI 10.1016/0014-5793(82)80438-9; CALISSANO P, 1984, HORMONAL PROTEINS PE, V12, P1; CHANDLER CE, 1980, J CELL PHYSIOL, V105, P275, DOI 10.1002/jcp.1041050211; CLAMAN HN, 1985, IMMUNOL TODAY, V6, P192, DOI 10.1016/0167-5699(85)90115-X; COHEN S, 1962, J BIOL CHEM, V237, P1555; COUGHLIN MD, 1985, DEV BIOL, V110, P392, DOI 10.1016/0012-1606(85)90098-3; DARLING TL, 1984, METHODS SERUM FREE C, P79; GEE AP, 1983, P NATL ACAD SCI-BIOL, V80, P7215, DOI 10.1073/pnas.80.23.7215; GINSBURG H, 1982, IMMUNOLOGY, V45, P371; GOTH A, 1971, SCIENCE, V173, P1034, DOI 10.1126/science.173.4001.1034; GOTO T, 1984, AM REV RESPIR DIS, V130, P797; GUDAT F, 1981, BRIT J PHARMACOL, V74, P533, DOI 10.1111/j.1476-5381.1981.tb10461.x; GUROFF G, 1981, J NEUROCHEM, V38, P342; HEINE H, 1975, ARCH DERMATOL FORSCH, V253, P225, DOI 10.1007/BF00561148; HETTI F, 1982, J NEUROSCI, V2, P1554; HIRATA F, 1979, P NATL ACAD SCI USA, V76, P4813, DOI 10.1073/pnas.76.10.4813; HUFF KR, 1979, BIOCHEM BIOPH RES CO, V89, P175, DOI 10.1016/0006-291X(79)90960-4; ISHIZAKA T, 1980, P NATL ACAD SCI-BIOL, V77, P1903, DOI 10.1073/pnas.77.4.1903; KNAUER KA, 1984, INT ARCH ALLER A IMM, V74, P29, DOI 10.1159/000233511; KORSCHING S, 1983, P NATL ACAD SCI-BIOL, V80, P3513, DOI 10.1073/pnas.80.11.3513; LEVIMONTALCINI R, 1961, REGIONAL NEUROCHEMIS, P362; LEVISCHAFFER F, 1985, J IMMUNOL, V135, P3454; LI AKC, 1980, P NATL ACAD SCI-BIOL, V77, P4379, DOI 10.1073/pnas.77.7.4379; MAZUREK N, 1986, FEBS LETT, V198, P315, DOI 10.1016/0014-5793(86)80428-8; MOBLEY WC, 1985, SCIENCE, V229, P284, DOI 10.1126/science.2861660; MOBLEY WC, 1976, BIOCHEMISTRY-US, V15, P5543, DOI 10.1021/bi00670a019; MORITA Y, 1981, J IMMUNOL, V127, P1339; NEWSON B, 1983, NEUROSCIENCE, V10, P565, DOI 10.1016/0306-4522(83)90153-7; PEARCE FL, 1986, J PHYSIOL-LONDON, V372, P379, DOI 10.1113/jphysiol.1986.sp016014; SHANAHAN F, 1985, J IMMUNOL, V135, P1331; SHELTON DL, 1984, P NATL ACAD SCI-BIOL, V81, P7951, DOI 10.1073/pnas.81.24.7951; SHORE PA, 1959, J PHARMACOL EXP THER, V127, P182; SIRAGANIAN RP, 1975, J IMMUNOL, V114, P886; SKOFITSCH G, 1985, HISTOCHEMISTRY, V82, P5, DOI 10.1007/BF00502084; STEAD RH, 1987, P NATL ACAD SCI USA, V84, P2975, DOI 10.1073/pnas.84.9.2975; SUGIYAMA K, 1985, ARCH ORAL BIOL, V30, P93, DOI 10.1016/0003-9969(85)90031-7; SULLIVAN TJ, 1976, AM J PATHOL, V85, P437; SULLIVAN TJ, 1975, J IMMUNOL, V15, P278; THOENEN H, 1985, SCIENCE, V229, P238, DOI 10.1126/science.2409599; WHITE JR, 1984, P NATL ACAD SCI-BIOL, V81, P3978, DOI 10.1073/pnas.81.13.3978	44	38	38	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1988	82	4					599	607		10.1016/0091-6749(88)90971-2	http://dx.doi.org/10.1016/0091-6749(88)90971-2			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q6399	2459178				2022-12-18	WOS:A1988Q639900011
J	CHARPIN, D; BENZARTI, M; HEMON, Y; SENFT, M; ALAZIA, M; ARNAUD, A; VERVLOET, D; CHARPIN, J				CHARPIN, D; BENZARTI, M; HEMON, Y; SENFT, M; ALAZIA, M; ARNAUD, A; VERVLOET, D; CHARPIN, J			ATOPY AND ANAPHYLACTIC REACTIONS TO SUXAMETHONIUM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOP ST MARGUERITE,DEPT ANAESTHESIOL,F-13277 MARSEILLE 9,FRANCE; HOP TIMONE,DEPT ANAESTHESIOL,MARSEILLE,FRANCE	UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	VERVLOET, D (corresponding author), HOP ST MARGUERITE,DEPT ALLERG & CHEST DIS,BP 29,F-13277 MARSEILLE 9,FRANCE.							ADKINSON NF, 1984, J ALLERGY CLIN IMMUN, V74, P567, DOI 10.1016/0091-6749(84)90108-8; Assem E S, 1972, Clin Allergy, V2, P325, DOI 10.1111/j.1365-2222.1972.tb01297.x; BIRNBAUM J, 1987, J ALLERGY CLIN IMMUN, V79, P235; Boileau S, 1985, Ann Fr Anesth Reanim, V4, P195, DOI 10.1016/S0750-7658(85)80200-8; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; ETTLIN R, 1986, INDIVIDUAL DISPOSITI; FISHER MM, 1983, ANESTH ANALG, V62, P559; FISHER MM, 1982, KLIN WOCHENSCHR, V60, P1017, DOI 10.1007/BF01716965; FISHER MM, 1987, BRIT J ANAESTH, V59, P690, DOI 10.1093/bja/59.6.690; GREEN GR, 1971, J ALLERGY CLIN IMMUN, V48, P331, DOI 10.1016/0091-6749(71)90079-0; HARLE DG, 1984, LANCET, V1, P930; Hatton F, 1983, ANN FR ANESTH, V2, P333; KRAFT D, 1977, CLIN ALLERGY, V7, P21, DOI 10.1111/j.1365-2222.1977.tb01420.x; LANGREHR D, 1982, KLIN WOCHENSCHR, V60, P1010, DOI 10.1007/BF01716964; LAXENAIRE M C, 1985, Annales Francaises d'Anesthesie et de Reanimation, V4, P30, DOI 10.1016/S0750-7658(85)80220-3; LAXENAIRE MC, 1982, KLIN WOCHENSCHR, V60, P1006, DOI 10.1007/BF01716963; MERRETT J, 1987, CLIN ALLERGY, V17, P409, DOI 10.1111/j.1365-2222.1987.tb02034.x; Moneret-Vautrin D A, 1985, Ann Fr Anesth Reanim, V4, P152, DOI 10.1016/S0750-7658(85)80191-X; MULLER U, 1973, INT ARCH ALLER A IMM, V44, P667, DOI 10.1159/000230969; RAJKA G, 1965, ACTA ALLERGOL, V20, P387, DOI 10.1111/j.1398-9995.1965.tb03071.x; SMITH JW, 1966, NEW ENGL J MED, V274, P998, DOI 10.1056/NEJM196605052741804; VERVLOET D, 1983, J ALLERGY CLIN IMMUN, V71, P552, DOI 10.1016/0091-6749(83)90436-0; VERVLOET D, 1985, J ALLERGY CLIN IMMUN, V75, P338, DOI 10.1016/0091-6749(85)90069-7	23	38	38	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1988	82	3	1				356	360		10.1016/0091-6749(88)90006-1	http://dx.doi.org/10.1016/0091-6749(88)90006-1			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q3229	3170984				2022-12-18	WOS:A1988Q322900006
J	TEE, RD; GORDON, DJ; HAWKINS, ER; NUNN, AJ; LACEY, J; VENABLES, KM; COOTER, RJ; MCCAFFERY, AR; TAYLOR, AJN				TEE, RD; GORDON, DJ; HAWKINS, ER; NUNN, AJ; LACEY, J; VENABLES, KM; COOTER, RJ; MCCAFFERY, AR; TAYLOR, AJN			OCCUPATIONAL ALLERGY TO LOCUSTS - AN INVESTIGATION OF THE SOURCES OF THE ALLERGEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BROMPTON HOSP, MRC, TUBERCULOSIS & CHEST DIS UNIT, LONDON SW3 6HP, ENGLAND; ROTHAMSTED EXPTL STN, DEPT PLANT PATHOL, HARPENDEN AL5 2JQ, HERTS, ENGLAND; TROP DEV & RES INST, LONDON, ENGLAND	Royal Brompton Hospital; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research	TEE, RD (corresponding author), BROMPTON HOSP, INST CARDIOTHORAC, DEPT OCCUPAT MED, LONDON SW3 6HP, ENGLAND.			Nunn, Andrew/0000-0002-9158-4595				ABBAS H. M., 1965, AGR PAKISTAN, V16, P325; BELLAS TE, 1982, INSECTS CAUSE INHALA; BESSOT JC, 1978, REV FR ALLERGOL, V18, P107; BURGE PS, 1980, CLIN ALLERGY, V10, P355, DOI 10.1111/j.1365-2222.1980.tb02119.x; CHAPMAN RF, 1985, COMPREHENSIVE INSECT, V4, P186; EDGE G, 1980, CLIN ALLERGY, V10, P347; Frankland A. W., 1953, Ann Allergy Minneapolis, V11, P445; FUCHS E, 1959, OCCUPATIONAL ALLER S, P52; GRONEMEYER W, 1958, DEUT MED WOCHENSCHR, V83, P30, DOI 10.1055/s-0028-1114156; Hunter-Jones P., 1966, NEW SCI, V31, P615; JOLY P, 1963, CR SOC BIOL, V157, P2299; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; TEE RD, 1985, J ALLERGY CLIN IMMUN, V76, P826, DOI 10.1016/0091-6749(85)90756-0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wirtz R.A., 1980, Bulletin of the Entomological Society of America, V26, P356; WIRTZ RA, 1984, ANNU REV ENTOMOL, V29, P47, DOI 10.1146/annurev.en.29.010184.000403	16	38	41	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1988	81	3					505	508		10.1016/0091-6749(88)90188-1	http://dx.doi.org/10.1016/0091-6749(88)90188-1			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M6181	3346482				2022-12-18	WOS:A1988M618100004
J	DYKEWICZ, MS; LAUFER, P; PATTERSON, R; ROBERTS, M; SOMMERS, HM				DYKEWICZ, MS; LAUFER, P; PATTERSON, R; ROBERTS, M; SOMMERS, HM			WOODMANS DISEASE - HYPERSENSITIVITY PNEUMONITIS FROM CUTTING LIVE TREES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611; KAISER PERMANENTE MED CTR,PARMA,OH; NW MEM HOSP,DEPT PATHOL,CHICAGO,IL 60611	Northwestern University; Kaiser Permanente; Northwestern Memorial Hospital					NIAID NIH HHS [AI 11403] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHLBOM G, 1982, EUR J RESPIR DIS, V63, P32; AVILA R, 1968, LANCET, V1, P620; BELIN L, 1980, EUR J RESPIR DIS, V61, P169; CAMPBELL JA, 1983, AM REV RESPIR DIS, V127, P495, DOI 10.1164/arrd.1983.127.4.495; COHEN HI, 1967, AM J MED, V43, P785, DOI 10.1016/0002-9343(67)90121-0; DEWECK AL, 1969, SCHWEIZ MED WSCHR, V99, P872; EMANUEL DA, 1966, NEW ENGL J MED, V274, P1413, DOI 10.1056/NEJM196606232742504; FERGUSSON RJ, 1984, THORAX, V39, P294, DOI 10.1136/thx.39.4.294; FINK JN, 1986, CHEST, V89, pS193, DOI 10.1378/chest.89.3_Supplement.193S; FINK JN, 1985, ALLERGIC DISEASES DI, P679; HOFFMAN DR, 1979, J ALLERGY CLIN IMMUN, V63, P213; HOWIE AD, 1976, THORAX, V31, P585, DOI 10.1136/thx.31.5.585; OUCHTERLONY O, 1958, PROG ALLERGY, V5, P1, DOI 10.1159/000273347; SALVAGGIO J, 1981, J ALLERGY CLIN IMMUN, V68, P327, DOI 10.1016/0091-6749(81)90131-7; SCHLUETER DP, 1972, ANN INTERN MED, V77, P907, DOI 10.7326/0003-4819-77-6-907; SEPULVEDA R, 1979, CLIN ALLERGY, V9, P359, DOI 10.1111/j.1365-2222.1979.tb02494.x; SOLLEY GO, 1980, J ALLERGY CLIN IMMUN, V65, P65, DOI 10.1016/0091-6749(80)90179-7; SOSMAN AJ, 1969, NEW ENGL J MED, V281, P977, DOI 10.1056/NEJM196910302811802; TERHO EO, 1980, SCAND J WORK ENV HEA, V6, P153, DOI 10.5271/sjweh.2627; Towey JW, 1932, J AMER MED ASSOC, V99, P453, DOI 10.1001/jama.1932.02740580021005; VANASSENDELFT AH, 1985, CHEST, V87, P394, DOI 10.1378/chest.87.3.394; VOLLER A, 1976, B WORLD HEALTH ORGAN, V53, P55; WIMANDER K, 1980, EUR J RESPIR DIS, V61, P163	23	38	38	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1988	81	2					455	460		10.1016/0091-6749(88)90917-7	http://dx.doi.org/10.1016/0091-6749(88)90917-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M0993	3123541				2022-12-18	WOS:A1988M099300015
J	GREENBERGER, PA; MEYERS, SN; KRAMER, BL; KRAMER, BL				GREENBERGER, PA; MEYERS, SN; KRAMER, BL; KRAMER, BL			EFFECTS OF BETA-ADRENERGIC AND CALCIUM-ANTAGONISTS ON THE DEVELOPMENT OF ANAPHYLACTOID REACTIONS FROM RADIOGRAPHIC CONTRAST-MEDIA DURING CARDIAC ANGIOGRAPHY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,DEPT MED,CARDIOL SECT,CHICAGO,IL 60611	Northwestern University; Northwestern University			Greenberger, Paul/L-2770-2019	Greenberger, Paul/0000-0003-3882-8498	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 11403] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANSELL G, 1980, INVEST RADIOL, V15, pS32, DOI 10.1097/00004424-198011001-00010; BARNES PJ, 1986, J ALLERGY CLIN IMMUN, V77, P791, DOI 10.1016/0091-6749(86)90375-1; BICKELL WH, 1984, ANN EMERG MED, V13, P189, DOI 10.1016/S0196-0644(84)80611-3; CLEAVELAND CR, 1972, ARCH INTERN MED, V130, P47, DOI 10.1001/archinte.130.1.47; COLEMAN WP, 1964, SOUTHERN MED J, V57, P1401, DOI 10.1097/00007611-196412000-00004; DAVIES P, 1975, BMJ-BRIT MED J, V2, P434, DOI 10.1136/bmj.2.5968.434; FISCHER HW, 1978, INVEST RADIOL, V13, P450, DOI 10.1097/00004424-197809000-00010; FLEISS JL, 1981, STAT METHODS RATES P, P33; JACOBS RL, 1981, J ALLERGY CLIN IMMUN, V68, P125, DOI 10.1016/0091-6749(81)90170-6; KARNEGIS JN, 1979, AM HEART J, V97, P291, DOI 10.1016/0002-8703(79)90427-7; LASSER EC, 1985, INVEST RADIOL, V1, pS79; LEE VY, 1983, THORAX, V38, P386, DOI 10.1136/thx.38.5.386; MADOWITZ JS, 1979, JAMA-J AM MED ASSOC, V241, P2813, DOI 10.1001/jama.241.26.2813; MIDDLETON E, 1985, CHEST, V87, pS79; PERUCCA E, 1981, CLIN PHARMACOL THER, V29, P425, DOI 10.1038/clpt.1981.59; SHEHADI WH, 1975, AM J ROENTGENOL, V124, P145, DOI 10.2214/ajr.124.1.145; WITTEN DM, 1973, AM J ROENTGENOL, V119, P832, DOI 10.2214/ajr.119.4.832	17	38	39	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1987	80	5					698	702		10.1016/0091-6749(87)90290-9	http://dx.doi.org/10.1016/0091-6749(87)90290-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K9930	2890682	Bronze			2022-12-18	WOS:A1987K993000010
J	HOFFMAN, DR				HOFFMAN, DR			ALLERGENS IN HYMENOPTERA VENOM .17. ALLERGENIC COMPONENTS OF SOLENOPSIS-INVICTA (IMPORTED FIRE ANT) VENOM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											HOFFMAN, DR (corresponding author), E CAROLINA UNIV,SCH MED,DEPT PATHOL,GREENVILLE,NC 27834, USA.							BAER H, 1979, TOXICON, V17, P397, DOI 10.1016/0041-0101(79)90267-8; BENJAMIN DC, 1984, ANNU REV IMMUNOL, V2, P51; BLUM MS, 1958, SCIENCE, V128, P306, DOI 10.1126/science.128.3319.306-a; BRAND JM, 1972, TOXICON, V10, P259, DOI 10.1016/0041-0101(72)90011-6; BUTCHER BT, 1985, J ALLERGY CLIN IMMUN, V75, P147, DOI 10.1016/0091-6749(85)90306-9; HOFFMAN DR, 1987, J ALLERGY CLIN IMMUN, V80, P307, DOI 10.1016/0091-6749(87)90036-4; HOFFMAN DR, 1987, CLIN REV ALLERG, V5, P75; HOFFMAN DR, 1979, ANN ALLERGY, V42, P224; MACCONNELL JG, 1976, TOXICON, V14, P69, DOI 10.1016/0041-0101(76)90122-7; NORDVALL SL, 1985, J ALLERGY CLIN IMMUN, V75, P122, DOI 10.1016/0091-6749(85)90207-6; PAULL B R, 1984, Journal of Allergy and Clinical Immunology, V73, P142; PAULL BR, 1983, J ALLERGY CLIN IMMUN, V71, P448, DOI 10.1016/0091-6749(83)90460-8; STAFFORD CT, 1987, J ALLERGY CLIN IMMUN, V79, P233; STROM GB, 1983, J ALLERGY CLIN IMMUN, V72, P46, DOI 10.1016/0091-6749(83)90051-9; SZEWCZYK B, 1985, ANAL BIOCHEM, V150, P403, DOI 10.1016/0003-2697(85)90528-7; WOOD CL, 1983, TOXICON, V21, P291, DOI 10.1016/0041-0101(83)90014-4	16	38	39	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1987	80	3	1				300	306		10.1016/0091-6749(87)90035-2	http://dx.doi.org/10.1016/0091-6749(87)90035-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K1036	3624682				2022-12-18	WOS:A1987K103600011
J	ZACH, MS; POLGAR, G				ZACH, MS; POLGAR, G			COLD AIR CHALLENGE OF AIRWAY HYPERREACTIVITY IN CHILDREN - DOSE-RESPONSE INTERRELATION WITH A REACTION PLATEAU	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									WAYNE STATE UNIV, DETROIT, MI 48202 USA; CHILDRENS HOSP MICHIGAN, DIV PULM DIS, DETROIT, MI 48201 USA	Wayne State University; Children's Hospital of Michigan	ZACH, MS (corresponding author), GRAZ UNIV, KINDERKLIN, AUENBRUGGERPL 30, A-8036 GRAZ, AUSTRIA.							BRINK C, 1980, BRIT J PHARMACOL, V69, P383, DOI 10.1111/j.1476-5381.1980.tb07026.x; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHUNG KF, 1982, AM REV RESPIR DIS, V126, P849; COCKCROFT DW, 1983, THORAX, V38, P55, DOI 10.1136/thx.38.1.55; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COCKCROFT DW, 1983, THORAX, V38, P523, DOI 10.1136/thx.38.7.523; DEAL EC, 1979, J APPL PHYSIOL, V46, P484, DOI 10.1152/jappl.1979.46.3.484; DEAL EC, 1980, AM REV RESPIR DIS, V121, P621; DEAL EC, 1979, J APPL PHYSIOL, V46, P467, DOI 10.1152/jappl.1979.46.3.467; DEAL EC, 1979, J APPL PHYSIOL, V46, P476, DOI 10.1152/jappl.1979.46.3.476; DEHAUT P, 1983, THORAX, V38, P516, DOI 10.1136/thx.38.7.516; FELARCA AB, 1966, J ALLERGY, V37, P223, DOI 10.1016/0021-8707(66)90117-1; GREEN M, 1974, J APPL PHYSIOL, V37, P793, DOI 10.1152/jappl.1974.37.6.793; HILL DJ, 1972, ARCH DIS CHILD, V47, P874, DOI 10.1136/adc.47.256.874; HYATT RE, 1979, LUNG TRANSITION HLTH, P73; KERREBIJN KF, 1981, PROGR RESPIR RES, V17, P143; MCFADDEN ER, 1973, NEW ENGL J MED, V288, P221, DOI 10.1056/NEJM197302012880501; MCLAUGHLIN FJ, 1983, PEDIATRICS, V72, P503; MCNICOL KN, 1973, BRIT MED J, V4, P7, DOI 10.1136/bmj.4.5883.7; MENEELY GR, 1962, AM REV RESPIR DIS, V85, P762; NADEL JA, 1961, J APPL PHYSIOL, V16, P717, DOI 10.1152/jappl.1961.16.4.717; NEIJENS HJ, 1982, B EUR PHYSIOPATH RES, V18, P427; OBYRNE PM, 1982, AM REV RESPIR DIS, V125, P281; OREHEK J, 1977, AM REV RESPIR DIS, V115, P937; POLGAR G, 1971, PULMONARY FUNCTION T, P186; SILVERMAN M, 1972, ARCH DIS CHILD, V47, P882, DOI 10.1136/adc.47.256.882; STEPHENS NL, 1977, ASTHMA PHYSL IMMUNOP, P150; STEPHENS NL, 1980, AIRWAY REACTIVITY ME, P110; STERK PJ, 1985, AM REV RESPIR DIS, V132, P865; STRAUSS RH, 1978, J CLIN INVEST, V61, P433, DOI 10.1172/JCI108954; STRAUSS RH, 1977, NEW ENGL J MED, V297, P743, DOI 10.1056/NEJM197710062971402; TAL A, 1984, J PEDIATR-US, V104, P516, DOI 10.1016/S0022-3476(84)80539-9; TOWNLEY RG, 1975, J ALLERGY CLIN IMMUN, V56, P427, DOI 10.1016/0091-6749(75)90061-5; VINCENC K, 1984, EUR J PHARMACOL, V98, P201, DOI 10.1016/0014-2999(84)90591-0; WOOLCOCK AJ, 1984, AM REV RESPIR DIS, V130, P71; ZACH M, 1984, PEDIATR RES, V18, P469, DOI 10.1203/00006450-198405000-00016; ZAPLETAL A, 1971, PEDIATRICS, V48, P64; ZAPLETAL A, 1982, B EUR PHYSIOPATH RES, V18, P31; 1983, B EUR PHYSIOPATHOL R, V19, P495	39	38	40	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1987	80	1					9	17		10.1016/S0091-6749(87)80184-7	http://dx.doi.org/10.1016/S0091-6749(87)80184-7			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	J2194	3598033				2022-12-18	WOS:A1987J219400002
J	MATTOLI, S; FORESI, A; CORBO, GM; VALENTE, S; CIAPPI, G				MATTOLI, S; FORESI, A; CORBO, GM; VALENTE, S; CIAPPI, G			EFFECTS OF 2 DOSES OF CROMOLYN ON ALLERGEN-INDUCED LATE ASTHMATIC RESPONSE AND INCREASED RESPONSIVENESS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CTR AUXOL ITALIANO PIANCAVALLO, DIV PNEUMOL PEDIAT, MILANO, ITALY	IRCCS Istituto Auxologico Italiano	MATTOLI, S (corresponding author), UNIV CATTOLICA SACRO CUORE, POLICLIN A GEMELLI, SERV FISIOPATOL RESP, LARGO S VITO 8, I-00168 ROME, ITALY.		Mattoli, Sabrina/H-8211-2014; CORBO, Giuseppe Maria/AAB-9964-2019	Mattoli, Sabrina/0000-0002-6866-604X; CORBO, Giuseppe Maria/0000-0002-8104-4659				ALTOUNYAN REC, 1970, DISODIUM CROMOGLYCAT, P47; BOOIJ-NOORD H, 1972, Clinical Allergy, V2, P43, DOI 10.1111/j.1365-2222.1972.tb01267.x; BOOIJNOORD H, 1971, J ALLERGY CLIN IMMUN, V48, P344, DOI 10.1016/0091-6749(71)90080-7; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1979, AM REV RESPIR DIS, V120, P1053; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COCKCROFT DW, 1986, J ALLERGY CLIN IMMUN, V77, P122; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; KNUDSON RJ, 1976, AM REV RESPIR DIS, V113, P587; KRELL RD, 1975, IMMUNOPHARMACOLOGY, P125; LAM S, 1979, J ALLERGY CLIN IMMUN, V63, P28, DOI 10.1016/0091-6749(79)90158-1; LOWHAGEN O, 1985, J ALLERGY CLIN IMMUN, V75, P343, DOI 10.1016/0091-6749(85)90070-3; MACINTYRE D, 1984, CLIN ALLERGY, V14, P311, DOI 10.1111/j.1365-2222.1984.tb02211.x; MATTOLI S, 1986, ANN ALLERGY, V57, P295; MATTOLI S, 1985, J ALLERGY CLIN IMMUN, V76, P214, DOI 10.1016/0091-6749(85)90704-3; MORMILE F, 1985, PROG RESPIR RES, V19, P256; PEPYS J, 1968, LANCET, V2, P134; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; PLATTSMILLS TAE, 1982, LANCET, V2, P675; RAK S, 1983, J ALLERGY CLIN IMMUN, V71, P149, DOI 10.1016/0091-6749(83)90367-6; ROBERTSON DG, 1974, J ALLERGY CLIN IMMUN, V54, P244, DOI 10.1016/0091-6749(74)90067-0; SHAMIYEH NB, 1971, J ECON ENTOMOL, V64, P53, DOI 10.1093/jee/64.1.53; Steel R.G., 1980, PRINCIPLES PROCEDURE, P481; VERVLOET D, 1982, J ALLERGY CLIN IMMUN, V69, P290, DOI 10.1016/S0091-6749(82)80006-7; WARNER JO, 1976, ARCH DIS CHILD, V51, P905, DOI 10.1136/adc.51.12.905	27	38	38	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1987	79	5					747	754		10.1016/0091-6749(87)90206-5	http://dx.doi.org/10.1016/0091-6749(87)90206-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	H4349	3106450				2022-12-18	WOS:A1987H434900009
J	KIRKEGAARD, J; MYGIND, N; MOLGAARD, F; GRAHNE, B; HOLOPAINEN, E; MALMBERG, H; BRONDBO, K; ROJNE, T				KIRKEGAARD, J; MYGIND, N; MOLGAARD, F; GRAHNE, B; HOLOPAINEN, E; MALMBERG, H; BRONDBO, K; ROJNE, T			ORDINARY AND HIGH-DOSE IPRATROPIUM IN PERENNIAL NONALLERGIC RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									RIGSHOSP,DEPT OTOLARYNGOL,OTOPATHOL LAB,DK-2100 COPENHAGEN O,DENMARK; CENT HOSP HELSINKI,DEPT OTOLARYNGOL,HELSINKI,FINLAND; BOEHRINGER INGELHEIM,DEPT MED,COPENHAGEN,FINLAND; AALBORG HOSP,DEPT OTOLARYNGOL,DK-9000 AALBORG,DENMARK; NATL HOSP NORWAY,DEPT OTOLARYNGOL,OSLO 1,NORWAY	Rigshospitalet; University of Helsinki; Helsinki University Central Hospital; Boehringer Ingelheim; Aalborg University; Aalborg University Hospital; University of Oslo; National Hospital Norway								Andersen, 1982, NOSE UPPER AIRWAY PH, P99; ANDERSEN I, 1971, ARCH ENVIRON HEALTH, V23, P408, DOI 10.1080/00039896.1971.10666029; BAIGELMAN W, 1977, CHEST, V71, P324, DOI 10.1378/chest.71.3.324; BAKER AP, 1975, AM REV RESPIR DIS, V111, P423; BOJSENMOELLER F, 1965, ANN OTO RHINOL LARYN, V74, P363, DOI 10.1177/000348946507400207; BOK HE, 1983, EUR J RESPIR DIS, V64, P486; BORUM P, 1978, Rhinology (Utrecht), V16, P225; BORUM P, 1979, CLIN OTOLARYNGOL, V4, P407, DOI 10.1111/j.1365-2273.1979.tb01773.x; BORUM P, 1983, CLIN OTOLARYNGOL, V8, P267, DOI 10.1111/j.1365-2273.1983.tb01440.x; BORUM P, 1979, J ALLERGY CLIN IMMUN, V63, P253, DOI 10.1016/0091-6749(79)90109-X; CERKEZ V, IN PRESS ANN OTOL; DECKERS W, 1975, POSTGRAD MED J, V51, P76; DOLOVICH J, 1985, J ALLERGY CLIN IMMUN, V75, P160, DOI 10.1016/0091-6749(85)90357-4; ENGELHARDT A, 1975, POSTGRAD MED J, V51, P82; JACKSON RT, 1981, ARCH OTOLARYNGOL, V107, P288; JOKINEN K, 1983, Rhinology (Utrecht), V21, P341; MALMBERG H, 1983, CLIN OTOLARYNGOL, V8, P273, DOI 10.1111/j.1365-2273.1983.tb01441.x; MUNCH EP, 1983, ALLERGY, V38, P517, DOI 10.1111/j.1398-9995.1983.tb02361.x; OHI M, 1984, Rhinology (Utrecht), V22, P241; PAKES GE, 1980, DRUGS, V20, P237, DOI 10.2165/00003495-198020040-00001; POPPIUS H, 1973, BMJ-BRIT MED J, V4, P134, DOI 10.1136/bmj.4.5885.134; SJOGREN I, 1984, ALLERGY, V39, P457, DOI 10.1111/j.1398-9995.1984.tb01968.x; STURGESS J, 1973, BRIT J EXP PATHOL, V54, P388; VANHAACKE NP, 1983, LANCET, P1258; WEINER N, 1980, P120	25	38	39	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1987	79	4					585	590		10.1016/S0091-6749(87)80153-7	http://dx.doi.org/10.1016/S0091-6749(87)80153-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	G9720	2951426				2022-12-18	WOS:A1987G972000006
J	GALVEZ, RA; MCLAUGHLIN, FJ; LEVISON, H				GALVEZ, RA; MCLAUGHLIN, FJ; LEVISON, H			THE ROLE OF THE METHACHOLINE CHALLENGE IN CHILDREN WITH CHRONIC COUGH	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOSP SICK CHILDREN,DEPT PEDIAT,DIV CHEST,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)								BANNER AS, 1985, AM REV RESPIR DIS, V131, P362; BRAMAN S, 1981, AM REV RESPIR DIS, V125, P133; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHAUSOW AM, 1983, J APPL PHYSIOL, V55, P541, DOI 10.1152/jappl.1983.55.2.541; CLOUTIER MM, 1981, PEDIATRICS, V67, P6; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; CORRAO WM, 1979, NEW ENGL J MED, V300, P633, DOI 10.1056/NEJM197903223001201; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; ESCHENBACHER WL, 1984, AM REV RESPIR DIS, V129, P211; FULLER RW, 1984, THORAX, V39, P766, DOI 10.1136/thx.39.10.766; GURWITZ D, 1981, J PEDIATR-US, V98, P551, DOI 10.1016/S0022-3476(81)80758-5; GURWITZ D, 1980, AM REV RESPIR DIS, V122, P95; HALL WJ, 1978, ANN INTERN MED, V88, P203, DOI 10.7326/0003-4819-88-2-203; HANNAWAY PJ, 1982, JAMA-J AM MED ASSOC, V247, P206, DOI 10.1001/jama.247.2.206; IRWIN RS, 1981, AM REV RESPIR DIS, V123, P413; KONIG P, 1981, AM J DIS CHILD, V135, P1053; MCNICHOL KN, 1973, BRIT MED J, V4, P12, DOI 10.1136/bmj.4.5883.12; MELLIS C M, 1977, American Review of Respiratory Disease, V115, P286; MITCHELL I, 1978, J PEDIATR-US, V93, P744, DOI 10.1016/S0022-3476(78)81070-1; MITSUHASHI M, 1985, PEDIATRICS, V75, P855; POE RH, 1980, AM REV RESPIR DIS, V126, P160; SACHA RF, 1985, ANN ALLERGY, V54, P195; SHAPIRO GG, 1982, J ALLERGY CLIN IMMUN, V69, P365, DOI 10.1016/0091-6749(82)90147-6; SMYTH JA, 1981, PEDIATRICS, V68, P336; SPELMAN R, 1984, J ROY COLL GEN PRACT, V34, P221; TOWNLEY RG, 1979, J ALLERGY CLIN IMMUN, V64, P569, DOI 10.1016/0091-6749(79)90014-9; WENG TR, 1969, AM REV RESPIR DIS, V99, P879	27	38	41	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1987	79	2					331	335		10.1016/0091-6749(87)90150-3	http://dx.doi.org/10.1016/0091-6749(87)90150-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	G1791	3546464				2022-12-18	WOS:A1987G179100005
J	FORESI, A; MATTOLI, S; CORBO, GM; VERGA, A; SOMMARUGA, A; CIAPPI, G				FORESI, A; MATTOLI, S; CORBO, GM; VERGA, A; SOMMARUGA, A; CIAPPI, G			LATE BRONCHIAL RESPONSE AND INCREASE IN METHACHOLINE HYPERRESPONSIVENESS AFTER EXERCISE AND DISTILLED WATER CHALLENGE IN ATOPIC SUBJECTS WITH ASTHMA WITH DUAL ASTHMATIC RESPONSE TO ALLERGEN INHALATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BAYROPHARM DHS LABS, MILANO, ITALY; UNIV CATTOLICA SACRO CUORE, POLICLIN A GEMELLI, IST CLIN MED, SERV FISIOPATOL RESP, I-00168 ROME, ITALY	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	FORESI, A (corresponding author), CTR AUXOL ITALIANO PIANCAVALLO, DIV PNEUMOL PEDIAT, CASELLA POSTALE, I-28044 INTRA NO, ITALY.		Mattoli, Sabrina/H-8211-2014; CORBO, Giuseppe Maria/AAB-9964-2019	Mattoli, Sabrina/0000-0002-6866-604X; CORBO, Giuseppe Maria/0000-0002-8104-4659				ANDERSON SD, 1981, THORAX, V36, P259, DOI 10.1136/thx.36.4.259; ANDERSON SD, 1983, THORAX, V38, P284, DOI 10.1136/thx.38.4.284; ATKINS PC, 1977, ANN INTERN MED, V86, P415, DOI 10.7326/0003-4819-86-4-415; BARNES PJ, 1981, CLIN SCI, V61, P159, DOI 10.1042/cs0610159; BIERMAN CW, 1980, J ALLERGY CLIN IMMUN, V65, P206; BIERMAN CW, 1984, J ALLERGY CLIN IMMUN, V74, P701, DOI 10.1016/0091-6749(84)90233-1; BIERMAN WC, 1984, J ALLERGY CLIN IMMUN, V73, P654; BLACK J L, 1984, American Review of Respiratory Disease, V129, pA263; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; EDMUNDS AT, 1978, AM REV RESPIR DIS, V117, P247; EGGLESTON PA, 1979, J ALLERGY CLIN IMMUN, V64, P642, DOI 10.1016/0091-6749(79)90028-9; ESCHENBACHER WL, 1984, AM REV RESPIR DIS, V129, P211; FELDMAN CH, 1982, AM REV RESPIR DIS, V125, P195; FINDLAY SR, 1980, AM REV RESPIR DIS, V122, P53; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P160, DOI 10.1016/0091-6749(82)90037-9; HAHN A, 1984, AM REV RESPIR DIS, V130, P575; HAHN AG, 1984, THORAX, V39, P919, DOI 10.1136/thx.39.12.919; HARGREAVE FE, 1974, CAN MED ASSOC J, V110, P415; HORN CR, 1984, CLIN ALLERGY, V14, P307, DOI 10.1111/j.1365-2222.1984.tb02210.x; IIKURA Y, 1985, J ALLERGY CLIN IMMUN, V75, P285, DOI 10.1016/0091-6749(85)90059-4; JOHNSON WR, 1980, SCI MED EXERCISE SPO, P125; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; KALINER M, 1974, J IMMUNOL, V112, P664; KILLIAN D, 1976, CLIN ALLERGY, V6, P219, DOI 10.1111/j.1365-2222.1976.tb01900.x; KNUDSON RJ, 1976, AM REV RESPIR DIS, V113, P587; LEE TH, 1982, J ALLERGY CLIN IMMUN, V70, P73, DOI 10.1016/0091-6749(82)90232-9; LEE TH, 1983, NEW ENGL J MED, V308, P1502, DOI 10.1056/NEJM198306233082504; LEE TH, 1982, J CLIN INVEST, V69, P889, DOI 10.1172/JCI110528; MATTOLI S, 1985, J ALLERGY CLIN IMMUN, V76, P214, DOI 10.1016/0091-6749(85)90704-3; MATTOLI S, 1985, ANN ALLERGY, V55, P289; MATTOLI S, 1986, J ALLERGY CLIN IMMUN, V77, P123; MATTOLI S, ANN ALLERGY; MORMILE F, 1985, PROG RESPIR RES, V19, P256; NAGY L, 1983, EUR J RESPIR DIS, V64, P161; NAGY L, 1982, NEW ENGL J MED, V306, P497, DOI 10.1056/NEJM198203043060901; PAPAGEORGIOU N, 1983, LANCET, V2, P1220; PEPYS J, 1968, LANCET, V2, P134; RUSSI EW, 1984, J APPL PHYSIOL, V57, P1182, DOI 10.1152/jappl.1984.57.4.1182; SCHENKEL E, 1982, J ALLERGY CLIN IMMUN, V70, P321, DOI 10.1016/0091-6749(82)90020-3; SCHOEFFEL RE, 1980, THORAX, V35, P164, DOI 10.1136/thx.35.3.164; SHAW RJ, 1985, ALLERGY, V40, P48, DOI 10.1111/j.1398-9995.1985.tb04154.x; SHEPPARD D, 1983, AM REV RESPIR DIS, V127, P691; SILVERMAN M, 1972, ARCH DIS CHILD, V47, P882, DOI 10.1136/adc.47.256.882; Steel R.G., 1980, PRINCIPLES PROCEDURE, P481; SUZUKI S, 1985, ANN ALLERGY, V54, P1366	46	38	38	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1986	78	6					1130	1139		10.1016/0091-6749(86)90262-9	http://dx.doi.org/10.1016/0091-6749(86)90262-9			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	F3026	3537091				2022-12-18	WOS:A1986F302600008
J	BLUMENTHAL, MN; YUNIS, E; MENDELL, N; ELSTON, RC				BLUMENTHAL, MN; YUNIS, E; MENDELL, N; ELSTON, RC			PREVENTIVE ALLERGY - GENETICS OF IGE-MEDIATED DISEASES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									LOUISIANA STATE UNIV,NEW ORLEANS,LA; SUNY STONY BROOK,LONG ISL,NY; HARVARD UNIV,BOSTON,MA 02115	Louisiana State University System; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Harvard University	BLUMENTHAL, MN (corresponding author), UNIV MINNESOTA,DEPT MED,CLIN IMMUNOL SECT,BOX 434,MAYO BLDG,MINNEAPOLIS,MN 55455, USA.							ALAGIDI SK, 1980, HUM BIOL, V52, P393; ALLANSMITH M, 1969, J IMMUNOL, V102, P1504; ALPER CA, 1976, J EXP MED, V144, P1111, DOI 10.1084/jem.144.4.1111; ALPER CA, 1972, J EXP MED, V135, P68, DOI 10.1084/jem.135.1.68; ALPER CA, 1982, CLIN IMMUNOL IMMUNOP, V24, P276, DOI 10.1016/0090-1229(82)90238-0; AWDEH ZL, 1979, NATURE, V282, P205, DOI 10.1038/282205a0; AWDEH ZL, 1983, P NATL ACAD SCI-BIOL, V80, P259, DOI 10.1073/pnas.80.1.259; AWDEH ZL, 1980, P NATL ACAD SCI-BIOL, V77, P3576, DOI 10.1073/pnas.77.6.3576; BAZARAL M, 1974, J ALLERGY CLIN IMMUN, V54, P288, DOI 10.1016/0091-6749(74)90015-3; BIAS W B, 1973, P39; Blumenthal M, 1977, Monogr Allergy, V11, P83; BLUMENTHAL MN, 1980, J ALLERGY CLIN IMMUN, V65, P403, DOI 10.1016/0091-6749(80)90231-6; BLUMENTHAL MN, 1981, J IMMUNOGENET, V8, P379; BLUMENTHAL MN, 1974, SCIENCE, V184, P1301, DOI 10.1126/science.184.4143.1301; BLUMENTHAL MN, 1981, AM J MED GENET, V10, P219, DOI 10.1002/ajmg.1320100304; BLUMENTHAL MN, 1977, INT C SERIES, V469; BLUMENTHAL MN, 1983, ALLERGY PRINCIPLES P, P11; BONNEY GE, 1984, AM J MED GENET, V18, P731, DOI 10.1002/ajmg.1320180420; BOUCHARD T, 1980, PROG CLIN BIOL R B C, V69, P227; BOYLE CR, 1979, BIOMETRICS, V35, P55, DOI 10.2307/2529936; Cooke RA, 1916, J IMMUNOL, V1, P201; COULTER KM, 1985, FEB AM AC ALL CHIC; CRONER S, 1982, ARCH DIS CHILD, V57, P364, DOI 10.1136/adc.57.5.364; CUDWORTH AG, 1976, BRIT MED J, V2, P846, DOI 10.1136/bmj.2.6040.846; DAWSON DV, 1984, AM J MED GENET, V18, P435, DOI 10.1002/ajmg.1320180313; DEWECK A, 1977, HLA DISEASE; DEWOLF WC, 1979, CLIN DIAGNOSIS MANAG, P1353; Elston R C, 1981, Adv Hum Genet, V11, P63; ELSTON RC, 1978, TWIN RES PSYCHOL MET, P189; Escobar V, 1978, Prog Clin Biol Res, V24 Pt C, P171; GERRARD JW, 1978, AM J HUM GENET, V30, P46; GLEICH GJ, 1983, ALLERGY, P271; HOPP RJ, 1984, J ALLERGY CLIN IMMUN, V73, P265, DOI 10.1016/S0091-6749(84)80018-4; KALFF MW, 1969, CLIN EXP IMMUNOL, V5, P469; LEE SK, 1980, PEDIATR RES, V14, P60; LEVINE BB, 1972, SCIENCE, V178, P1201, DOI 10.1126/science.178.4066.1201; MARSH DG, 1979, P NATL ACAD SCI USA, V76, P2903, DOI 10.1073/pnas.76.6.2903; MARSH DG, 1982, J EXP MED, V155, P1439, DOI 10.1084/jem.155.5.1439; MARSH DG, 1982, J EXP MED, V155, P1452, DOI 10.1084/jem.155.5.1452; MENDELL NR, 1978, CYTOGENET CELL GENET, V22, P330, DOI 10.1159/000130966; NORMAN PS, 1983, ALLERGY PRINCIPLES P, P295; PANDEY JP, 1979, LANCET, V1, P190; PANDEY JP, 1982, J IMMUNOGENET, V9, P25; PANDEY JP, 1981, J CLIN INVEST, V68, P1378, DOI 10.1172/JCI110387; PARKER CW, 1980, CLIN IMMUNOLOGY, P1372; RAO DC, 1980, AM J HUM GENET, V32, P620; RAPAPORT FT, 1962, ANN NY ACAD SCI, V99, P564, DOI 10.1111/j.1749-6632.1962.tb45337.x; ROITMANJOHNSON B, 1980, RECENT ADV CHRONOBIO; SALIER JP, 1981, SCIENCE, V213, P1400, DOI 10.1126/science.6973823; SISTONEN P, 1980, HUM HERED, V30, P155, DOI 10.1159/000153120; SMITH JM, 1983, ALLERGY PRINCIPLES P, P771; STOY PJ, 1981, J ALLERGY CLIN IMMUN, V68, P421, DOI 10.1016/0091-6749(81)90195-0; TERHORST C, 1977, P NATL ACAD SCI USA, V74, P4002, DOI 10.1073/pnas.74.9.4002; TURNER MW, 1981, IMMUNOLOGICAL CLIN A, P101; VAUGHAN W, 1954, PRACTICE ALLERGY, P74; WILCOX H, 1978, IMMUNOGENETICS, V6, P209; WITTINGHAM SJ, 1980, CLIN EXP IMMUNOL, V50, P8; WUTHRICH B, 1981, CLIN ALLERGY, V11, P147, DOI 10.1111/j.1365-2222.1981.tb01578.x; ZLOTNIK LH, 1983, AM J MED GENET, V15, P307, DOI 10.1002/ajmg.1320150214	59	38	38	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1986	78	5	2	S			962	968		10.1016/0091-6749(86)90286-1	http://dx.doi.org/10.1016/0091-6749(86)90286-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E9719	3537089				2022-12-18	WOS:A1986E971900007
J	THEOBALD, K; THIEL, H; KALLWEIT, C; ULMER, W; KONIG, W				THEOBALD, K; THIEL, H; KALLWEIT, C; ULMER, W; KONIG, W			DETECTION OF PROTEINS IN WHEAT-FLOUR EXTRACTS THAT BIND HUMAN-IGG, IGE, AND MOUSE MONOCLONAL-ANTIBODIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									RUHR UNIV BOCHUM,UNIV STR 150,POSTFACH 102148,D-4630 BOCHUM 1,FED REP GER; MARIEN HOSP,GELSENKIRCHEN,FED REP GER; RUHR UNIV BOCHUM,BERGMANNSHEIL CLIN,D-4630 BOCHUM,FED REP GER	Ruhr University Bochum; St. Marien Hospital; Ruhr University Bochum								BALDO BA, 1978, CLIN ALLERGY, V8, P109, DOI 10.1111/j.1365-2222.1978.tb00456.x; BALDO BA, 1980, ALLERGY, V35, P45, DOI 10.1111/j.1398-9995.1980.tb01716.x; BERGER E, 1958, BIBL PAEDIAT       S, V67, P1; BIENENSTOCK J, 1982, J ALLERGY CLIN IMMUN, V70, P407, DOI 10.1016/0091-6749(82)90001-X; Galfre G, 1981, Methods Enzymol, V73, P3; HAWKES R, 1982, ANAL BIOCHEM, V119, P142, DOI 10.1016/0003-2697(82)90677-7; KIEFFER M, 1981, J IMMUNOL METHODS, V42, P129, DOI 10.1016/0022-1759(81)90142-3; KOHLER G, 1981, IMMUNOLOGICAL METHOD, V2, P285; KONIG W, 1984, ARZNEIMITTEL-FORSCH, V34-1, P52; LUGHTENBERG B, 1975, FEBS LETT, V58, P254; MARCH SC, 1974, ANAL BIOCHEM, V60, P149, DOI 10.1016/0003-2697(74)90139-0; MATTHEWS TS, 1970, LANCET, V2, P893; MECHAM DK, 1978, BIOCHEM GENET, V16, P831, DOI 10.1007/BF00484739; Osborne TB., 1907, PUBLICATION CARNEGIE, V84; OSTERBALLE O, 1983, J ALLERGY CLIN IMMUN, V71, P40, DOI 10.1016/0091-6749(83)90545-6; SUTTON R, 1984, CLIN ALLERGY, V14, P93, DOI 10.1111/j.1365-2222.1984.tb02196.x; THEOBALD K, 1983, INT ARCH ALLER A IMM, V72, P84, DOI 10.1159/000234845; THIEL H, 1984, ALLERGOLOGIE, V7, P407; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONDERHAAR F, 1978, FEBS LETT, V94, P371, DOI 10.1016/0014-5793(78)80980-6; WALSH BJ, 1985, J ALLERGY CLIN IMMUN, V76, P23, DOI 10.1016/0091-6749(85)90799-7	21	38	38	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1986	78	3	1				470	477		10.1016/0091-6749(86)90035-7	http://dx.doi.org/10.1016/0091-6749(86)90035-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E1148	2428857				2022-12-18	WOS:A1986E114800016
J	ROHR, AS; SPECTOR, SL; SIEGEL, SC; KATZ, RM; RACHELEFSKY, GS				ROHR, AS; SPECTOR, SL; SIEGEL, SC; KATZ, RM; RACHELEFSKY, GS			CORRELATION BETWEEN A-MODE ULTRASOUND AND RADIOGRAPHY IN THE DIAGNOSIS OF MAXILLARY SINUSITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT PEDIAT,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles								AXELSSON A, 1970, ACTA OTO-LARYNGOL, V69, P302, DOI 10.3109/00016487009123368; MANN W, 1977, ARCH OTO-RHINO-LARYN, V215, P67, DOI 10.1007/BF00463193; Revonta M, 1980, Acta Otolaryngol Suppl, V370, P1; SPECTOR SL, 1981, J ALLERGY CLIN IMMUN, V67, P22, DOI 10.1016/0091-6749(81)90040-3; VVORANEN P, 1962, J LARYNGOL, V76, P359	5	38	38	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1986	78	1	1				58	61		10.1016/0091-6749(86)90115-6	http://dx.doi.org/10.1016/0091-6749(86)90115-6			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	D2996	3522707				2022-12-18	WOS:A1986D299600010
J	GIN, W; KAY, AB				GIN, W; KAY, AB			THE EFFECT OF CORTICOSTEROIDS ON MONOCYTE AND NEUTROPHIL ACTIVATION IN BRONCHIAL-ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BROMPTON HOSP, INST CARDIOTHORAC, DEPT ALLERGY & CLIN IMMUNOL, FULHAM RD, LONDON SW3 6HP, ENGLAND	Royal Brompton Hospital								ANWAR ARE, 1977, J IMMUNOL, V119, P976; ANWAR ARE, 1978, J IMMUNOL, V121, P1245; BERGER M, 1984, J CLIN INVEST, V74, P1566, DOI 10.1172/JCI111572; BOYLE W, 1968, TRANSPLANTATION, V6, P761, DOI 10.1097/00007890-196809000-00002; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P31; CARMICHAEL J, 1981, BRIT MED J, V282, P1419, DOI 10.1136/bmj.282.6274.1419; CARROLL M, 1983, CLIN EXP IMMUNOL, V54, P785; CARROLL MP, 1985, J ALLERGY CLIN IMMUN, V75, P290, DOI 10.1016/0091-6749(85)90060-0; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; Dunnill M S, 1971, Ciba Found Study Group, V38, P35; DUNNILL MS, 1982, PULMONARY PATHOLOGY, P58; DURHAM SR, 1984, NEW ENGL J MED, V311, P1398, DOI 10.1056/NEJM198411293112202; FEARON DT, 1983, J IMMUNOL, V130, P370; FRIES LF, 1983, J IMMUNOL, V131, P1240; GLASS EJ, 1980, CLIN EXP IMMUNOL, V39, P768; GONZALEZMOLINA A, 1977, J CLIN INVEST, V59, P616, DOI 10.1172/JCI108679; KAY AB, 1981, CLIN EXP IMMUNOL, V44, P576; KAY AB, 1984, CLIN EXP IMMUNOL, V57, P729; KLEMPNER MS, 1978, CLIN EXP IMMUNOL, V34, P137; KURLANDER RJ, 1982, J CLIN INVEST, V69, P1, DOI 10.1172/JCI110419; LACHMANN PJ, 1978, HDB EXPT IMMUNOLOGY, P1; LUKACS K, 1984, CLIN EXP IMMUNOL, V56, P321; PAPAGEORGIOU N, 1983, LANCET, V2, P1220; POZNANSKY MC, 1984, CLIN SCI, V67, P639, DOI 10.1042/cs0670639; RICHERSON HB, CLIN EXP IMMUNOL; SCHREIBER AD, 1975, J CLIN INVEST, V56, P1189, DOI 10.1172/JCI108196; YAM LT, 1971, AM J CLIN PATHOL, V55, P283	27	38	38	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	5					675	682		10.1016/0091-6749(85)90670-0	http://dx.doi.org/10.1016/0091-6749(85)90670-0			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AUU34	2932498				2022-12-18	WOS:A1985AUU3400004
J	TINKELMAN, DG; MOSS, BA; BUKANTZ, SC; SHEFFER, AL; DOBKEN, JH; CHODOSH, S; COHEN, BM; ROSENTHAL, RR; RAPPAPORT, I; BUCKLEY, CE; CHUSID, EL; DEUTSCH, AJ; SETTIPANE, GA; BURNS, RBP				TINKELMAN, DG; MOSS, BA; BUKANTZ, SC; SHEFFER, AL; DOBKEN, JH; CHODOSH, S; COHEN, BM; ROSENTHAL, RR; RAPPAPORT, I; BUCKLEY, CE; CHUSID, EL; DEUTSCH, AJ; SETTIPANE, GA; BURNS, RBP			A MULTICENTER TRIAL OF THE PROPHYLACTIC EFFECT OF KETOTIFEN, THEOPHYLLINE, AND PLACEBO IN ATOPIC ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									EASTERN VIRGINIA MED SCH,DEPT PEDIAT,NORFOLK,VA 23501; KINGS DAUGHTERS CHILDRENS HOSP,ALLERGY CLIN,NORFOLK,VA; UNIV S FLORIDA,COLL MED,DIV ALLERGY IMMUNOL,TAMPA,FL 33612; HARVARD UNIV,SCH MED,BOSTON,MA 02115; CORNELL UNIV,MED CTR,NEW YORK HOSP,DEPT PEDIAT,ALLERGY IMMUNOL & PULM DIS SECT,NEW YORK,NY 10021; BOSTON UNIV,SCH MED,BOSTON,MA 02118; UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,NEWARK,NJ 07103; ELIZABETH GEN HOSP,ELIZABETH,NJ; JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21205; DUKE UNIV,MED CTR,DURHAM,NC 27710; MT SINAI MED CTR,RESP CARE SERV,NEW YORK,NY; ALLERGY CTR ASTHMA,ATHENS,GA; BROWN UNIV,DEPT MED,PROVIDENCE,RI 02912; SANDOZ INC,E HANOVER,NJ 07936	Eastern Virginia Medical School; State University System of Florida; University of South Florida; Harvard University; Harvard Medical School; Cornell University; NewYork-Presbyterian Hospital; Boston University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Johns Hopkins University; Duke University; Icahn School of Medicine at Mount Sinai; Brown University; Novartis; Sandoz	TINKELMAN, DG (corresponding author), ATLANTA ALLERGY CLIN,PA 6667 VERNON WOODS DR,SUITE A-30,ATLANTA,GA 30328, USA.							ALTOUNYAN RE, 1967, ACTA ALLERGOL, V22, P487; BURNS RBP, 1983, J ASTHMA, V20, P105, DOI 10.3109/02770908309077073; CLARK TJH, 1972, LANCET, V1, P1361; CLARKE CW, 1980, BRIT J CLIN PHARMACO, V10, P473, DOI 10.1111/j.1365-2125.1980.tb01791.x; CRAPS L, 1978, CLIN ALLERGY, V8, P373, DOI 10.1111/j.1365-2222.1978.tb00472.x; DASTA J, 1979, AM J HOSP PHARM, V36, P613, DOI 10.1093/ajhp/36.5.613; DYSON AJ, 1980, BRIT MED J, V280, P360, DOI 10.1136/bmj.280.6211.360; GREENWOOD C, 1982, CHEST S S, V82, P45; Kumagai A, 1978, Triangle, V17, P135; LANE DJ, 1980, CLIN ALLERGY, V10, P519, DOI 10.1111/j.1365-2222.1980.tb02132.x; MARTIN U, 1978, ARZNEIMITTELFORSCH, V28-1, P770; TABACHNIK E, 1982, J PEDIATR-US, V100, P489, DOI 10.1016/S0022-3476(82)80467-8; WATT GD, 1980, J ALLERGY CLIN IMMUN, V66, P286, DOI 10.1016/0091-6749(80)90023-8	13	38	38	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	3					487	497		10.1016/0091-6749(85)90732-8	http://dx.doi.org/10.1016/0091-6749(85)90732-8			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ARC09	3897345				2022-12-18	WOS:A1985ARC0900012
J	ALLANSMITH, MR; BAIRD, RS; GREINER, JV; BLOCH, KJ				ALLANSMITH, MR; BAIRD, RS; GREINER, JV; BLOCH, KJ			LATE-PHASE REACTIONS IN OCULAR ANAPHYLAXIS IN THE RAT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									RETINA FDN, EYE RES INST, DEPT CORNEA RES, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, DEPT OPHTHALMOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, DEPT OPHTHALMOL, BOSTON, MA 02215 USA; MASSACHUSETTS GEN HOSP, GEN MED SERV, CLIN IMMUNOL UNIT, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, GEN MED SERV, ALLERGY UNIT, BOSTON, MA 02114 USA; GEORGETOWN UNIV, DEPT OPHTHALMOL, WASHINGTON, DC 20057 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Georgetown University				Greiner, Jack/0000-0003-1659-1020	NEI NIH HHS [EY-02099] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY002099] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Allansmith M, 1975, T AM ACAD OPHTHALMOL, V79, P128; ALLANSMITH MR, 1978, AM J OPHTHALMOL, V86, P250, DOI 10.1016/S0002-9394(14)76821-7; ALLANSMITH MR, 1981, IMMUNOLOGY, V44, P623; ALLANSMITH MR, 1979, INVEST OPHTH VIS SCI, V18, P863; ALLANSMITH MR, ARCH OPHTHALMOL; ALLANSMITH R, 1980, INVEST OPHTH VIS SCI, V19, P1521; ATKINS P, 1973, J ALLERGY CLIN IMMUN, V51, P263, DOI 10.1016/0091-6749(73)90128-0; BLOCH KJ, 1973, J IMMUNOL, V110, P197; DESHAZO RD, 1979, J IMMUNOL, V122, P692; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; FRIEDLAENDER MH, 1977, J IMMUNOL, V118, P1558; HOLLANDER M, 1973, NONPARAMETRIC STAT, P71; KLINE B. S., 1932, JOUR ALLERGY, V3, P531, DOI 10.1016/S0021-8707(32)90148-8; OERTEL H, 1981, J ALLERGY CLIN IMMUN, V68, P238, DOI 10.1016/0091-6749(81)90190-1; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; TANNENBAUM S, 1980, J IMMUNOL, V125, P325	16	38	39	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	1					49	55		10.1016/0091-6749(84)90483-4	http://dx.doi.org/10.1016/0091-6749(84)90483-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SB990	6693667				2022-12-18	WOS:A1984SB99000007
J	FARNAM, J; LAVASTIDA, MT; GRANT, JA; REDDI, RC; DANIELS, JC				FARNAM, J; LAVASTIDA, MT; GRANT, JA; REDDI, RC; DANIELS, JC			ANTINUCLEAR ANTIBODIES IN THE SERUM OF NORMAL PREGNANT-WOMEN - A PROSPECTIVE-STUDY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV TEXAS,MED BRANCH,DEPT INTERNAL MED,DIV IMMUNOL RHEUMATOL,GALVESTON,TX 77550; UNIV TEXAS,MED BRANCH,DEPT OBSTET & GYNECOL,GALVESTON,TX 77550	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	FARNAM, J (corresponding author), UNIV TEXAS,MED BRANCH,DEPT INTERNAL MED,DIV ALLERGY,GALVESTON,TX 77550, USA.							AARDEN LA, 1975, ANN NY ACAD SCI, V254, P505, DOI 10.1111/j.1749-6632.1975.tb29197.x; Bulmash J M, 1978, Obstet Gynecol Annu, V7, P153; CHAPLIN H, 1973, BRIT J HAEMATOL, V24, P219; DAVIS JS, 1981, TXB RHEUMATOLOGY, V1, P691; FINE LG, 1981, ANN INTERN MED, V94, P667, DOI 10.7326/0003-4819-94-5-667; FROELICH CJ, 1980, AM J MED, V69, P329; HESS EV, 1971, LANCET, V2, P871; HINKLE SC, 1979, ARTHRITIS RHEUM, V22, P201, DOI 10.1002/art.1780220217; HIRAHARA F, 1980, CLIN EXP IMMUNOL, V41, P353; KITZMILLER J L, 1978, Clinical Obstetrics and Gynecology, V21, P385, DOI 10.1097/00003081-197806000-00012; KOHLER PF, 1982, JAMA-J AM MED ASSOC, V248, P2646, DOI 10.1001/jama.248.20.2646; Levy D L, 1982, Obstet Gynecol Surv, V37, P122, DOI 10.1097/00006254-198202000-00025; NAKAMURA RM, 1978, AUTOANTIBODIES NUCLE; Northway J.D., 1972, CLIN IMMUNOL IMMUNOP, V1, P140, DOI [10.1016/0090-1229(72)90013-X, DOI 10.1016/0090-1229(72)90013-X]; POLISHUK WZ, 1971, LANCET, V2, P270; REYESLOPEZ PA, 1980, ARTHRITIS RHEUM, V23, P378, DOI 10.1002/art.1780230324; SRIDAMA V, 1982, NEW ENGL J MED, V307, P352, DOI 10.1056/NEJM198208053070606; THONG YH, 1973, NEW ENGL J MED, V289, P604, DOI 10.1056/NEJM197309202891203; ZULMAN JI, 1980, J RHEUMATOL, V7, P37	19	38	38	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	5					596	599		10.1016/0091-6749(84)90517-7	http://dx.doi.org/10.1016/0091-6749(84)90517-7			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SS045	6371103				2022-12-18	WOS:A1984SS04500010
J	WELSH, PW; BUTTERFIELD, JH; YUNGINGER, JW; AGARWAL, MK; GLEICH, GJ				WELSH, PW; BUTTERFIELD, JH; YUNGINGER, JW; AGARWAL, MK; GLEICH, GJ			ALLERGEN-CONTROLLED STUDY OF INTRANASAL IMMUNOTHERAPY FOR RAGWEED HAY-FEVER	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN, ALLERG DIS RES LAB, ROCHESTER, MN 55905 USA; MAYO MED SCH, DEPT IMMUNOL, ROCHESTER, MN 55901 USA; MAYO MED SCH, DEPT MED, ROCHESTER, MN 55901 USA; MAYO MED SCH, DEPT PEDIAT, ROCHESTER, MN 55901 USA; MAYO MED SCH, ALLERG DIS RES LAB, ROCHESTER, MN 55901 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011483] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 11483] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; COOK N, 1974, Journal of Laryngology and Otology, V88, P1169, DOI 10.1017/S0022215100079901; DEUSCHL H, 1977, ACTA ALLERGOL, V32, P248, DOI 10.1111/j.1398-9995.1977.tb01357.x; DIXON WJ, 1969, INTRO STATISTICAL AN, P341; GLEICH GJ, 1980, J ALLERGY CLIN IMMUN, V65, P20, DOI 10.1016/0091-6749(80)90172-4; GLEICH GJ, 1977, J ALLERGY CLIN IMMUN, V60, P188, DOI 10.1016/0091-6749(77)90123-3; GUERCIO JP, 1980, J ALLERGY CLIN IMMUN, V66, P61, DOI 10.1016/0091-6749(80)90139-6; HAMILTON RG, 1979, J IMMUNOL, V122, P1073; KARAU M, 1970, STATISTICAL REPORT P; LOWELL FC, 1965, NEW ENGL J MED, V273, P675, DOI 10.1056/NEJM196509232731302; MATHEWS KP, 1981, INT ARCH ALLER A IMM, V66, P218, DOI 10.1159/000232821; MEHTA S B, 1975, Clinical Allergy, V5, P279; NICKELSEN JA, 1981, J ALLERGY CLIN IMMUN, V68, P41, DOI 10.1016/0091-6749(81)90121-4; NICKELSEN JA, 1981, J ALLERGY CLIN IMMUN, V68, P33, DOI 10.1016/0091-6749(81)90120-2; OGDEN EC, 1967, J ALLERGY, V40, P1, DOI 10.1016/0021-8707(67)90053-6; SCHUMACHER MJ, 1981, J ALLERGY CLIN IMM S, V67, P8; SWINEFORD O, 1955, J ALLERGY, V26, P305, DOI 10.1016/0021-8707(55)90060-5; TAYLOR G, 1972, Clinical Allergy, V2, P125, DOI 10.1111/j.1365-2222.1972.tb01277.x; WELSH PW, 1981, J ALLERGY CLIN IMMUN, V67, P237, DOI 10.1016/0091-6749(81)90067-1	19	38	38	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	5					454	460		10.1016/0091-6749(83)90461-X	http://dx.doi.org/10.1016/0091-6749(83)90461-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QQ742	6601670				2022-12-18	WOS:A1983QQ74200004
J	FREYRIA, AM; PINET, A; BELLEVILLE, J; ELOY, R; TRAEGER, J				FREYRIA, AM; PINET, A; BELLEVILLE, J; ELOY, R; TRAEGER, J			EFFECTS OF 5 DIFFERENT CONTRAST AGENTS ON SERUM COMPLEMENT AND CALCIUM LEVELS AFTER EXCRETORY UROGRAPHY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOP EDOUARD HERRIOT,DEPT RADIOL,F-69374 LYON 2,FRANCE; HOP EDOUARD HERRIOT,INSERM,U80,F-69374 LYON 2,FRANCE; CARDIOVASC RES & ORGAN TRANSPLANTAT,INSERM,U37,BRON,FRANCE	CHU Lyon; CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)								ARROYAVE CM, 1979, J ALLERGY CLIN IMMUN, V63, P276, DOI 10.1016/0091-6749(79)90113-1; ARROYAVE CM, 1976, J IMMUNOL, V117, P1866; CAULFIELD JB, 1975, CIRCULATION, V52, P119, DOI 10.1161/01.CIR.52.1.119; GONSETTE RE, 1978, NEURORADIOLOGY, V16, P253, DOI 10.1007/BF00395264; GONSETTE RE, 1980, INVEST RADIOL S16, V15, P526; HASSELBACHER P, 1980, J ALLERGY CLIN IMMUN, V66, P217, DOI 10.1016/0091-6749(80)90042-1; KOLB WP, 1978, J IMMUNOL, V121, P1232; LASSER E, 1974, INVEST RADIOL, V9, P6; LASSER EC, 1979, AM J ROENTGENOL, V132, P171, DOI 10.2214/ajr.132.2.171; LIEBERMAN P, 1979, J ALLERGY CLIN IMMUN, V64, P13, DOI 10.1016/0091-6749(79)90076-9; Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2; NELSON RA, 1966, IMMUNOCHEMISTRY, V3, P111, DOI 10.1016/0019-2791(66)90292-8; SIMON RA, 1979, J ALLERGY CLIN IMMUN, V63, P281, DOI 10.1016/0091-6749(79)90114-3; STERNBERG JC, 1977, CLIN CHEM, V23, P1456; TILL G, 1978, INT ARCH ALLER A IMM, V56, P543, DOI 10.1159/000232070; TRONCHET J, 1958, Ann Biol Clin (Paris), V16, P459	16	38	38	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	4					397	403		10.1016/0091-6749(82)90152-X	http://dx.doi.org/10.1016/0091-6749(82)90152-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NL280	7069076				2022-12-18	WOS:A1982NL28000011
J	KAY, AB; LEE, TH				KAY, AB; LEE, TH			NEUTROPHIL CHEMOTACTIC FACTOR OF ANAPHYLAXIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material											KAY, AB (corresponding author), BROMPTON HOSP, INST CARDIOTHORAC, DEPT ALLERGY & CLIN IMMUNOL, LONDON SW3 6HP, ENGLAND.		Lee, Tak/AAA-9526-2020	Lee, Tak/0000-0002-7554-4059				ANDERSON SD, 1981, THORAX, V36, P259, DOI 10.1136/thx.36.4.259; ATKINS PC, 1979, J ALLERGY CLIN IMMUN, V64, P251, DOI 10.1016/0091-6749(79)90140-4; ATKINS PC, 1978, J ALLERGY CLIN IMMUN, V62, P149, DOI 10.1016/0091-6749(78)90099-4; ATKINS PC, 1977, ANN INTERN MED, V86, P415, DOI 10.7326/0003-4819-86-4-415; ATKINS PC, 1981, J ALLERGY CLIN IMMUN, V68, P286, DOI 10.1016/0091-6749(81)90153-6; BARNES PJ, 1981, CLIN SCI, V61, P159, DOI 10.1042/cs0610159; BEAVEN MA, 1972, CLIN CHIM ACTA, V37, P91, DOI 10.1016/0009-8981(72)90419-6; BIERMAN CW, 1980, J ALLERGY CLIN IMMUN, V65, P206; BROWN MJ, 1982, J ALLERGY CLIN IMMUN, V69, P20, DOI 10.1016/0091-6749(82)90082-3; BRUCE C, 1976, THORAX, V31, P724, DOI 10.1136/thx.31.6.724; CHURCH MK, 1982, CLIN ALLERGY, V12, P223, DOI 10.1111/j.1365-2222.1982.tb02522.x; COTES KL, 1978, LEUKOCYTE CHEMOTAXIS, P67; DEAL EC, 1978, J APPL PHYSIOL, V45, P238, DOI 10.1152/jappl.1978.45.2.238; DEAL EC, 1979, J APPL PHYSIOL, V46, P476, DOI 10.1152/jappl.1979.46.3.476; DEAL EC, 1980, J CLIN INVEST, V65, P659, DOI 10.1172/JCI109711; DUNER H, 1958, SCAND J CLIN LAB INV, V10, P394, DOI 10.3109/00365515809051243; FELDMAN CH, 1982, AM REV RESPIR DIS, V125, P195; GLEICH GJ, 1980, J ALLERGY CLIN IMMUN, V66, P295, DOI 10.1016/0091-6749(80)90024-X; GODFREY S, 1976, THORAX, V31, P137, DOI 10.1136/thx.31.2.137; GODFREY S, 1973, J ALLERGY CLIN IMMUN, V52, P199, DOI 10.1016/0091-6749(73)90058-4; HOWARTH PH, THORAX; KAY AB, 1970, CLIN EXP IMMUNOL, V6, P75; KAY AB, EUR J RESPIR DIS; KELLY MT, 1971, J CLIN INVEST, V50, P1044, DOI 10.1172/JCI106575; LEE TH, 1982, J ALLERGY CLIN IMMUN, V70, P73, DOI 10.1016/0091-6749(82)90232-9; LEE TH, 1982, FED PROC, V41, P734; LEE TH, 1982, J CLIN INVEST, V69, P889, DOI 10.1172/JCI110528; LEE TH, AGENTS ACTIONS; LEVINE L, 1981, P NATL ACAD SCI-BIOL, V78, P7692, DOI 10.1073/pnas.78.12.7692; LEWIS RA, 1981, BIOCH ACUTE ALLERGIC, P239; NAGAKURA T, THORAX; NAGY L, 1982, NEW ENGL J MED, V306, P497, DOI 10.1056/NEJM198203043060901; NARASBHAT K, 1976, J ALLERGY CLIN IMMUN, V58, P647, DOI 10.1016/0091-6749(76)90176-7; ODRISCOLL BR, UNPUB IMMUNOLOGICAL; PAPAGEORGIOU N, UNPUB NEUTROPHIL CHE; SCHENKEL E, 1982, J ALLERGY CLIN IMMUN, V70, P321, DOI 10.1016/0091-6749(82)90020-3; SCHWARTZ LB, 1981, BIOCH ACUTE ALLERGIC, P103; SHORE PA, 1959, J PHARMACOL EXP THER, V127, P182; SIRAGANIAN RP, 1975, J IMMUNOL METHODS, V7, P283, DOI 10.1016/0022-1759(75)90025-3; SOTER NA, 1980, NEW ENGL J MED, V302, P604, DOI 10.1056/NEJM198003133021104; SOTER NA, 1979, J INVEST DERMATOL, V72, P282; STEARNS DR, 1981, J APPL PHYSIOL, V50, P503, DOI 10.1152/jappl.1981.50.3.503; TERRAL C, 1979, MAST CELL ITS ROLE H, P123; WASSERMAN SI, 1982, CLIN EXP IMMUNOL, V47, P570; WASSERMAN SI, 1977, J CLIN INVEST, V60, P189, DOI 10.1172/JCI108756	45	38	38	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	5					317	320		10.1016/0091-6749(82)90019-7	http://dx.doi.org/10.1016/0091-6749(82)90019-7			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PQ105	6182176				2022-12-18	WOS:A1982PQ10500001
J	MARSH, DG; BELIN, L; BRUCE, CA; LICHTENSTEIN, LM; HUSSAIN, R				MARSH, DG; BELIN, L; BRUCE, CA; LICHTENSTEIN, LM; HUSSAIN, R			RAPIDLY RELEASED ALLERGENS FROM SHORT RAGWEED POLLEN .1. KINETICS OF RELEASE OF KNOWN ALLERGENS IN RELATION TO BIOLOGIC ACTIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV, SCH MED, DEPT MED, DIV CLIN IMMUNOL, BALTIMORE, MD 21218 USA; JOHNS HOPKINS UNIV, SCH MED, HOWARD HUGHES MED INST LAB, BALTIMORE, MD 21218 USA	Johns Hopkins University; Johns Hopkins University			Hussain, Rabia/E-9982-2015		NIAID NIH HHS [AI 08270, AI 09565] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI008270, R37AI008270] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AXELSON NH, 1973, MANUAL QUANTITATIVE; BAER H, 1974, J ALLERGY CLIN IMMUN, V54, P157, DOI 10.1016/0091-6749(74)90052-9; BAER H, 1970, J ALLERGY, V45, P347, DOI 10.1016/0021-8707(70)90043-2; BELIN L, 1971, INT ARCH ALLER A IMM, V40, P754, DOI 10.1159/000230460; BELIN L, 1972, INT ARCH ALLER A IMM, V42, P300, DOI 10.1159/000230613; BELIN LGA, 1977, CLIN ALLERGY, V7, P55, DOI 10.1111/j.1365-2222.1977.tb01425.x; BRIDGER GP, 1971, ANN OTO RHINOL LARYN, V80, P445, DOI 10.1177/000348947108000324; BRUCE CA, 1974, J ALLERGY CLIN IMMUN, V53, P230, DOI 10.1016/0091-6749(74)90085-2; CAMPBELL DH, 1970, METHOD IMMUNOL, P247; CRAIG LYMAN C, 1962, METHODS BIOCHEM ANALYSIS, V10, P175; Fabricant ND, 1941, ARCHIV OTOLARYNGOL, V34, P150; GOLDFARB AR, 1968, J IMMUNOL, V100, P902; HOWLETT BJ, 1973, J CELL SCI, V13, P603; ISHIZAKA K, 1970, J IMMUNOL, V105, P1459; KING TP, 1962, BIOCHEMISTRY-US, V1, P709, DOI 10.1021/bi00910a027; KING TP, 1964, BIOCHEMISTRY-US, V3, P458, DOI 10.1021/bi00891a026; KNOX RB, 1971, CYTOBIOS, V4, P49; LAPKOFF CB, 1974, INT ARCH ALLER A IMM, V46, P215, DOI 10.1159/000231125; LAURELL CB, 1972, SCAND J CLIN LAB INV, V29, P21, DOI 10.3109/00365517209102748; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LICHTENSTEIN LM, 1966, J ALLERGY, V38, P174, DOI 10.1016/0021-8707(66)90040-2; LOWENSTEIN H, UNPUBLISHED; MARSH DG, 1975, IMMUNOCHEMISTRY, V12, P539, DOI 10.1016/0019-2791(75)90081-6; MARSH DG, 1975, ANTIGENS, V3, P271; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; MORROWBROWN H, 1976, ACTA ALLERGOL, V31, P22; NORMAN PS, 1972, J ALLERGY CLIN IMMUN, V50, P31, DOI 10.1016/0091-6749(72)90077-2; NORMAN PS, 1968, J ALLERGY, V42, P93, DOI 10.1016/0021-8707(68)90139-1; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P94, DOI 10.1016/0091-6749(73)90081-X; NORMAN PS, 1976, MANUAL CLIN IMMUNOLO, P585; REISMAN RE, 1969, J ALLERGY, V44, P82, DOI 10.1016/0021-8707(69)90004-5; ROEBBER MG, 1975, ISOLATION STRUCTURE; UNDERDOWN BJ, 1969, BIOCHEMISTRY-US, V8, P980, DOI 10.1021/bi00831a031	33	38	38	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	3					206	216		10.1016/0091-6749(81)90063-4	http://dx.doi.org/10.1016/0091-6749(81)90063-4			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LG778	7462537				2022-12-18	WOS:A1981LG77800008
J	BLUMENTHAL, MN; MENDELL, N; YUNIS, E				BLUMENTHAL, MN; MENDELL, N; YUNIS, E			IMMUNOGENETICS OF ATOPIC DISEASES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									DUKE UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,DURHAM,NC 27710; HARVARD UNIV,DEPT IMMUNOL,BOSTON,MA 02115	Duke University; Harvard University	BLUMENTHAL, MN (corresponding author), UNIV MINNESOTA,DEPT MED,MINNEAPOLIS,MN 55455, USA.							BLUMENTHAL M, 1979, J ALLERGY CLIN IMMUN, V63, P169; BLUMENTHAL M, 1980, J ALLERGY CLIN IMMUN, V65, P203; BLUMENTHAL MN, 1974, SCIENCE, V181, P1201; DEWECK A, 1977, HLA DISEASE; DEWOLF WC, 1979, CLIN DIAGNOSIS MANAG, P1353; GERRARD JW, 1978, AM J HUM GENET, V30, P46; LEVINE BB, 1972, SCIENCE, V178, P1201, DOI 10.1126/science.178.4066.1201; MARSH DG, 1979, P NATL ACAD SCI USA, V76, P2903, DOI 10.1073/pnas.76.6.2903; OTT J, AM J HUM GENET; WILCOX H, 1978, IMMUNOGENETICS, V6, P209	10	38	38	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	65	6					403	405		10.1016/0091-6749(80)90231-6	http://dx.doi.org/10.1016/0091-6749(80)90231-6			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JV764	7372961				2022-12-18	WOS:A1980JV76400001
J	SOTER, NA; WASSERMAN, SI				SOTER, NA; WASSERMAN, SI			PHYSICAL URTICARIA-ANGIOEDEMA - AN EXPERIMENTAL-MODEL OF MAST-CELL ACTIVATION IN HUMANS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HARVARD UNIV,ROBERT B BRIGHAM HOSP,BOSTON,MA 02120; HARVARD UNIV,PETER BENT BRIGHAM HOSP,BOSTON,MA 02115; UNIV CALIF SAN DIEGO,SCH MED,DEPT MED,LA JOLLA,CA 92093	Harvard University; Harvard University; Brigham & Women's Hospital; University of California System; University of California San Diego	SOTER, NA (corresponding author), HARVARD UNIV,SCH MED,DEPT DERMATOL,BOSTON,MA 02115, USA.			Soter, Nicholas/0000-0003-3518-3209	NIAID NIH HHS [AI-14292] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ATKINS PC, 1977, ANN INTERN MED, V86, P415, DOI 10.7326/0003-4819-86-4-415; BACH MK, 1977, PROSTAGLANDINS, V14, P21, DOI 10.1016/0090-6980(77)90154-X; BAUGHMAN RD, 1963, ANN ALLERGY, V21, P248; BENTLEYPHILLIPS CB, 1976, LANCET, V2, P63; BENVENISTE J, 1974, NATURE, V249, P581, DOI 10.1038/249581a0; BLACK JW, 1972, NATURE, V236, P385, DOI 10.1038/236385a0; BOSWELL RN, 1978, J IMMUNOL, V120, P15; BROCKLEHURST WE, 1960, J PHYSIOL-LONDON, V151, P416, DOI 10.1113/jphysiol.1960.sp006449; CENTER DM, 1979, CLIN EXP IMMUNOL, V35, P112; CENTER DM, 1977, CLIN RES, V25, pA355; COMMENS CA, 1978, BRIT J DERMATOL, V98, P47, DOI 10.1111/j.1365-2133.1978.tb07332.x; COSTANZI JJ, 1969, J LAB CLIN MED, V74, P902; CRISSEY JT, 1965, J INVEST DERMATOL, V45, P329, DOI 10.1038/jid.1965.139; DAMAN L, 1978, J ALLERGY CLIN IMMUN, V61, P273, DOI 10.1016/0091-6749(78)90203-8; DEMOPOULOS CA, 1979, J BIOL CHEM, V254, P9355; DOUSA TP, 1974, J CLIN INVEST, V53, P334, DOI 10.1172/JCI107555; DRAZEN JM, 1979, J CLIN INVEST, V63, P1, DOI 10.1172/JCI109262; DRAZEN JM, 1974, J CLIN INVEST, V53, P1679, DOI 10.1172/JCI107719; EADY RAJ, 1978, LANCET, V1, P336; EBKEN RK, 1968, J ALLERGY, V41, P328; GELL PGH, 1963, CLINICAL ASPECTS IMM, P320; GOETZL EJ, 1975, P NATL ACAD SCI USA, V72, P4123, DOI 10.1073/pnas.72.10.4123; GOETZL EJ, 1977, J CLIN INVEST, V59, P179, DOI 10.1172/JCI108617; GOETZL EJ, 1978, LEUKOCYTE CHEMOTAXIS, P161; GREAVES M, 1977, BRIT J DERMATOL, V97, P225, DOI 10.1111/j.1365-2133.1977.tb15071.x; GREAVES MW, 1972, IMMUNOLOGY, V23, P239; HARBER LC, 1963, J INVEST DERMATOL, V41, P439, DOI 10.1038/jid.1963.138; HAWK JLM, 1980, BRIT J CLIN PHARMACO, V9, P183, DOI 10.1111/j.1365-2125.1980.tb05831.x; HENDERSON WR, 1979, J IMMUNOL, V122, P1322; HENDERSON WR, 1978, J CLIN INVEST, V61, P187, DOI 10.1172/JCI108917; HENSON PM, 1977, J CLIN INVEST, V60, P481, DOI 10.1172/JCI108799; HORIO T, 1978, ARCH DERMATOL, V114, P1761, DOI 10.1001/archderm.114.12.1761; IVE H, 1965, BRIT J DERMATOL, V77, P229, DOI 10.1111/j.1365-2133.1965.tb14637.x; JAKSCHIK BA, 1977, P NATL ACAD SCI USA, V74, P4577, DOI 10.1073/pnas.74.10.4577; KALZ F, 1950, ARCH DERMATOL SYPH, V61, P772, DOI 10.1001/archderm.1950.01530120063005; KAPLAN AP, 1976, J INVEST DERMATOL, V67, P327, DOI 10.1111/1523-1747.ep12514352; KAPLAN AP, 1978, J ALLERGY CLIN IMMUN, V61, P350, DOI 10.1016/0091-6749(78)90113-6; KAPLAN AP, 1975, J ALLERGY CLIN IMMUN, V55, P394, DOI 10.1016/0091-6749(75)90078-0; KAY AB, 1971, J IMMUNOL, V107, P899; KAY AB, 1971, J EXP MED, V133, P602, DOI 10.1084/jem.133.3.602; KIRBY JD, 1971, BRIT J DERMATOL, V85, P331; KRAVIS TC, 1977, J IMMUNOL, V118, P1569; LAGUNOFF D, 1970, EXP CELL RES, V61, P129, DOI 10.1016/0014-4827(70)90265-X; LAGUNOFF D, 1963, ANN NY ACAD SCI, V103, P185, DOI 10.1111/j.1749-6632.1963.tb53698.x; LAUNA N, 1970, J ALLERGY, V45, P266; LEWIS RA, 1980, FED PROC, V39, P905; LICHTENSTEIN LM, 1975, J PHARMACOL EXP THER, V192, P441; LYNCH SM, 1978, J IMMUNOL, V121, P1394; MATTHEWS CNA, 1979, BRIT J DERMATOL, V101, P57, DOI 10.1111/j.1365-2133.1979.tb15293.x; MCMANUS LM, 1979, J IMMUNOL, V123, P2835; MCNEILL JH, 1974, J PHARMACOL EXP THER, V188, P180; METCALFE DD, 1980, J INVEST DERMATOL, V74, P210, DOI 10.1111/1523-1747.ep12541737; METCALFE DD, 1979, J CLIN INVEST, V64, P1537, DOI 10.1172/JCI109613; MIKHAIL GR, 1964, J INVEST DERMATOL, V43, P249, DOI 10.1038/jid.1964.152; MOOREROBINSON M, 1968, BRIT J DERMATOL, V80, P794, DOI 10.1111/j.1365-2133.1968.tb11948.x; MURPHY RC, 1979, P NATL ACAD SCI USA, V76, P4275, DOI 10.1073/pnas.76.9.4275; NEWBALL HH, 1975, NATURE, V254, P635, DOI 10.1038/254635a0; NEWBALL HH, 1979, J CLIN INVEST, V64, P457, DOI 10.1172/JCI109483; NEWCOMB RW, 1973, AM J MED, V54, P174, DOI 10.1016/0002-9343(73)90221-0; Orange R P, 1969, Adv Immunol, V10, P105, DOI 10.1016/S0065-2776(08)60416-2; ORANGE RP, 1973, J IMMUNOL, V110, P760; PATTERSON R, 1972, J ALLERGY CLIN IMMUN, V50, P174, DOI 10.1016/0091-6749(72)90048-6; PHANUPHAK P, 1978, CLIN ALLERGY, V8, P429, DOI 10.1111/j.1365-2222.1978.tb01493.x; PINCKARD RN, 1979, J IMMUNOL, V123, P1847; PLAUT M, 1975, J CLIN INVEST, V55, P856, DOI 10.1172/JCI107997; RAMSAY CA, 1977, ARCH DERMATOL, V113, P1222, DOI 10.1001/archderm.113.9.1222; RICHELSON E, 1979, MAYO CLIN PROC, V54, P669; ROSE BRAM, 1941, JOUR ALLERGY, V12, P327, DOI 10.1016/S0021-8707(41)90260-5; RUDZKI E, 1970, ACTA ALLERGOL, V25, P70, DOI 10.1111/j.1398-9995.1970.tb01383.x; RYAN TJ, 1968, BRIT J DERMATOL, V80, P485, DOI 10.1111/j.1365-2133.1968.tb12334.x; SCHWARTZ LB, 1980, J INVEST DERMATOL, V74, P349, DOI 10.1111/1523-1747.ep12543620; SCHWARTZ LB, 1979, J IMMUNOL, V123, P1445; SCHWARTZ LB, 1980, CLIN RES, V28, pA559; SHELLEY WB, 1964, JAMA-J AM MED ASSOC, V189, P895; SHERMAN WB, 1950, J ALLERGY, V21, P414, DOI 10.1016/0021-8707(50)90017-7; SOLOMON LM, 1968, J INVEST DERMATOL, V51, P280, DOI 10.1038/jid.1968.128; SOTER NA, 1980, NEW ENGL J MED, V302, P604, DOI 10.1056/NEJM198003133021104; SOTER NA, 1977, J ALLERGY CLIN IMMUN, V59, P294, DOI 10.1016/0091-6749(77)90050-1; SOTER NA, 1979, J INVEST DERMATOL, V72, P282; SOTER NA, 1978, CLIN EXP IMMUNOL, V32, P46; SOTER NA, 1976, NEW ENGL J MED, V294, P687, DOI 10.1056/NEJM197603252941302; TINDALL JP, 1969, ARCH INTERN MED, V124, P129, DOI 10.1001/archinte.124.2.129; TROMOVITCH TA, 1967, CALIF MED, V106, P400; TROTTER C M, 1974, Clinical Allergy, V4, P421, DOI 10.1111/j.1365-2222.1974.tb01403.x; TURNBULL LW, 1977, IMMUNOLOGY, V32, P57; WANDERER AA, 1977, ARCH DERMATOL, V113, P1375, DOI 10.1001/archderm.113.10.1375; WASSERMAN SI, 1976, J CLIN INVEST, V57, P738, DOI 10.1172/JCI108332; WASSERMAN SI, 1977, J CLIN INVEST, V60, P189, DOI 10.1172/JCI108756; WASSERMAN SI, 1980, CLIN RES, V28, pA254; WASSERMAN SI, 1975, J IMMUNOL, V114, P645; WASSERMAN SI, 1977, J BIOL CHEM, V252, P7074; WEILER JM, 1978, J EXP MED, V147, P409, DOI 10.1084/jem.147.2.409; YURT R, 1977, J EXP MED, V146, P1405, DOI 10.1084/jem.146.5.1405; YURT RW, 1977, J BIOL CHEM, V252, P518	94	38	40	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	5					358	365		10.1016/0091-6749(80)90114-1	http://dx.doi.org/10.1016/0091-6749(80)90114-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KQ965	7002977				2022-12-18	WOS:A1980KQ96500003
J	PLAUT, M				PLAUT, M			HISTAMINE, H-1 AND H-2 ANTIHISTAMINES, AND IMMEDIATE HYPERSENSITIVITY REACTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material											PLAUT, M (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21239, USA.							ADAMS GK, 1979, J IMMUNOL, V122, P555; ASH ASF, 1966, BRIT J PHARM CHEMOTH, V27, P427, DOI 10.1111/j.1476-5381.1966.tb01674.x; AVELLA J, 1978, LANCET, V1, P624; BLACK JW, 1972, NATURE, V236, P385, DOI 10.1038/236385a0; BLACK JW, 1975, 6TH P INT C PHARM, V1, P3; Bovet D, 1937, CR SOC BIOL, V124, P547; CHAKRIN LW, 1974, AGENTS ACTIONS, V4, P297, DOI 10.1007/BF01964930; COMMENS CA, 1978, BRIT J DERMATOL, V99, P675, DOI 10.1111/j.1365-2133.1978.tb07062.x; Dale HH, 1919, J PHYSIOL-LONDON, V52, P355; Dale HH, 1910, J PHYSIOL-LONDON, V41, P318; DOUGLAS WW, 1975, PHARMACOL BASIS, P590; DRAZEN JM, 1978, AM REV RESPIR DIS, V117, P479; DULABH R, 1978, AGENTS ACTIONS, V8, P559, DOI 10.1007/BF01998882; DUNLOP LS, 1977, BRIT J PHARMACOL, V59, pP475; DURANT GJ, 1978, NATURE, V276, P403, DOI 10.1038/276403a0; DURANT GJ, 1975, J MED CHEM, V18, P905, DOI 10.1021/jm00243a009; HUTCHCROFT BJ, 1979, J ALLERGY CLIN IMMUN, V63, P376, DOI 10.1016/0091-6749(79)90209-4; KALINER M, 1978, AM REV RESPIR DIS, V118, P1015; KAPLAN AP, 1977, CLIN RES, V25, pA361; KAPLAN AP, 1975, J ALLERGY CLIN IMMUN, V55, P394, DOI 10.1016/0091-6749(75)90078-0; KNIKER WT, 1965, J EXP MED, V122, P83, DOI 10.1084/jem.122.1.83; KRELL RD, 1976, PHARMACOLOGIST, V18, P204; LICHTENSTEIN LM, 1975, J PHARMACOL EXP THER, V192, P441; MARKS R, 1977, BRIT J CLIN PHARMACO, V4, P367, DOI 10.1111/j.1365-2125.1977.tb00725.x; MASLINSKI C, 1975, AGENTS ACTIONS, V5, P89, DOI 10.1007/BF02027348; MAUDSLEY DV, 1973, NATURE-NEW BIOL, V245, P148, DOI 10.1038/newbio245148a0; OWEN DAA, 1977, GEN PHARMACOL, V8, P141, DOI 10.1016/0306-3623(77)90043-X; PARSONS ME, 1977, AGENTS ACTIONS, V7, P31, DOI 10.1007/BF01964878; PERPER RJ, 1972, INT ARCH ALLER A IMM, V43, P837, DOI 10.1159/000230901; PHANUPHAK P, 1978, CLIN ALLERGY, V8, P429, DOI 10.1111/j.1365-2222.1978.tb01493.x; PLAUT M, 1975, J CLIN INVEST, V55, P856, DOI 10.1172/JCI107997; PLAUT M, 1978, J ALLERGY CLIN IMMUN, V61, P132, DOI 10.1016/0091-6749(78)90252-X; PLAUT M, 1978, HDB EXP PHARM, V50, P345; POWELL JR, 1976, AM J PHYSIOL, V231, P1002, DOI 10.1152/ajplegacy.1976.231.4.1002; ROBERTS LJ, 1979, NEW ENGL J MED, V300, P236, DOI 10.1056/NEJM197902013000506; ROBERTSON I, 1978, BRIT J CLIN PHARMACO, V5, P319, DOI 10.1111/j.1365-2125.1978.tb01714.x; ROCKLIN RE, 1976, J CLIN INVEST, V57, P1051, DOI 10.1172/JCI108347; SCHWARTZ A, 1977, J IMMUNOL, V118, P159; SOSMAN J, 1976, SCIENCE, V194, P737; SOTER NA, 1976, NEW ENGL J MED, V294, P687, DOI 10.1056/NEJM197603252941302; Staub AM, 1937, CR SOC BIOL, V125, P818; THOMAS LL, 1978, BIOCHEM PHARMACOL, V27, P2562, DOI 10.1016/0006-2952(78)90327-1; VALENTINE MD, 1974, PRINCIPLES TECHNIQUE, P227; WOLFE JD, 1979, J ALLERGY CLIN IMMUN, V63, P208; WYLLIE JH, 1972, LANCET, V2, P1117; YAMAMOTO S, 1976, J INVEST DERMATOL, V67, P696, DOI 10.1111/1523-1747.ep12598572	46	38	38	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	63	6					371	375		10.1016/0091-6749(79)90208-2	http://dx.doi.org/10.1016/0091-6749(79)90208-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GY514	36419				2022-12-18	WOS:A1979GY51400001
J	LAKIN, JD; CAHILL, RA				LAKIN, JD; CAHILL, RA			GENERALIZED URTICARIA TO CYCLOPHOSPHAMIDE - TYPE-I HYPERSENSITIVITY TO AN IMMUNOSUPPRESSIVE AGENT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									USN,MED RES INST,DEPT CLIN & EXPTL IMMUNOL,TISSUE BANK DIV,BETHESDA,MD 20014; USN,MED RES INST,DEPT CLIN & EXPTL IMMUNOL,CLIN IMMUNOL DIV,BETHESDA,MD 20014	Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy; Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy								AISENBERG AC, 1973, CELL IMMUNOL, V7, P143, DOI 10.1016/0008-8749(73)90190-1; ARINOVICHE R, 1970, ANN RHEUM DIS, V29, P32, DOI 10.1136/ard.29.1.32; BACH JF, 1971, TRANSPLANT P, V3, P27; BROCK N, 1971, CANCER, V27, P1512, DOI 10.1002/1097-0142(197106)27:6<1512::AID-CNCR2820270636>3.0.CO;2-Q; CHEEMA A, 1972, AM J PATHOL, V66, P543; CURTIS JE, 1973, ARTHRITIS RHEUM, V16, P34, DOI 10.1002/art.1780160106; DECKER JL, 1973, ARTHRITIS RHEUM, V16, P89, DOI 10.1002/art.1780160115; DESWARTE RD, 1972, ALLERGIC DISEASES DI, P393; ELEKES F, 1974, PATH MICROBIOL, V40, P1; FAUCI AS, 1971, NEW ENGL J MED, V285, P1493, DOI 10.1056/NEJM197112302852701; FINCH SC, 1974, AM J MED, V56, P4, DOI 10.1016/0002-9343(74)90745-1; GELFAND MC, 1972, ARTHRITIS RHEUM-US, V15, P239, DOI 10.1002/art.1780150304; GELFAND MC, 1972, ARTHRITIS RHEUM-US, V15, P247, DOI 10.1002/art.1780150305; HERSH EM, 1965, CANCER RES, V25, P997; HOFFSTEN PE, 1974, J IMMUNOL, V112, P564; HRUBY MA, 1973, BLOOD, V42, P919, DOI 10.1182/blood.V42.6.919.919; HURD ER, 1973, ARTHRITIS RHEUM, V16, P84, DOI 10.1002/art.1780160114; ISHIZAKA K, 1972, J IMMUNOL, V109, P84; ISHIZAKA K, 1972, BIOLOGICAL ROLE IMMU, P103; ISHIZAKA K, 1973, MECHANISMS ALLERGY R, P63; JOKIPII AMM, 1973, CELL IMMUNOL, V9, P477, DOI 10.1016/0008-8749(73)90063-4; Kabat E. A., 1971, EXPT IMMUNOCHEMISTRY; KATZ DH, 1974, J IMMUNOL, V113, P974; KATZ SI, 1974, NATURE, V248, P612, DOI 10.1038/248612a0; KATZ SI, 1974, MAYO CLIN PROC, V49, P537; KIND LS, 1973, INT ARCH ALLER A IMM, V45, P780, DOI 10.1159/000231077; LAGRANGE PH, 1974, J EXP MED, V139, P1529, DOI 10.1084/jem.139.6.1529; LAKIN JD, 1975, ANN INTERN MED, V83, P204, DOI 10.7326/0003-4819-83-2-204; LAKIN JD, 1975, J ALLERGY CLIN IMMUN, V56, P94, DOI 10.1016/0091-6749(75)90113-X; LAKIN JD, 1975, J ALLERGY CLIN IMMUN, V55, P103; LAKIN JD, 1967, J IMMUNOL, V98, P745; LAKIN JD, TO BE PUBLISHED; LERMAN SP, 1970, J IMMUNOL, V105, P614; LIEBMAN IM, 1968, ACTA DERM-VENEREOL, V48, P391; LINNA TJ, 1972, INT ARCH ALLER A IMM, V42, P20, DOI 10.1159/000230590; MAGUIRE HC, 1961, J INVEST DERMATOL, V37, P427, DOI 10.1038/jid.1961.138; MAGUIRE HC, 1967, J INVEST DERMATOL, V48, P39, DOI 10.1038/jid.1967.6; MARBROOK J, 1971, INT ARCH ALLER A IMM, V41, P802, DOI 10.1159/000230572; MARSH DG, 1974, P NATL ACAD SCI USA, V71, P3588, DOI 10.1073/pnas.71.9.3588; MCKAY IR, 1973, ARTHRITIS RHEUM, V16, P455; OKUDAIRA H, 1974, J IMMUNOL, V113, P563; OKUMURA K, 1974, IMMUNOLOGY, V26, P257; PETROV RV, 1971, TRANSPLANT P, V3, P427; POLAK L, 1972, TRANSPLANTATION, V13, P310, DOI 10.1097/00007890-197203000-00018; POULTER LW, 1972, NATURE-NEW BIOL, V238, P17, DOI 10.1038/newbio238017a0; SANTOS GW, 1967, FED PROC, V26, P907; SANTOS GW, 1969, TRANSPLANT P, V1, P44; SANTOS GW, 1964, ANN NY ACAD SCI, V114, P404; SCHWARZE G, 1974, INT ARCH ALLER A IMM, V46, P629, DOI 10.1159/000231163; SKINNER MD, 1972, NEW ENGL J MED, V287, P221, DOI 10.1056/NEJM197208032870504; SPITZER A, 1972, PEDIATRICS, V50, P358; STARZL TE, 1973, TRANSPL P, V5, P511; STEINBER.AD, 1971, ANN INTERN MED, V75, P165, DOI 10.7326/0003-4819-75-2-165; STEWARD MW, 1973, P ROY SOC MED, V66, P808, DOI 10.1177/003591577306600838; STOCKMAN GD, 1972, J IMMUNOL, V108, P112; STRUCK RF, 1971, MOL PHARMACOL, V7, P519; SUGIURA K, 1961, CANCER RES, V21, P1421; TADA T, 1971, J IMMUNOL, V106, P1002; TADA T, 1971, J IMMUNOL, V106, P1012; TADA T, 1972, BIOLOGICAL ROLE IMMU, P89; TADA T, 1973, MECHANISMS ALLERGY, P43; TANIGUCH.M, 1971, J IMMUNOL, V107, P579; TRIPATHY SP, 1969, J EXP MED, V130, P17, DOI 10.1084/jem.130.1.17; TRIPATHY SP, 1969, J EXP MED, V130, P1, DOI 10.1084/jem.130.1.1; TURK JL, 1973, IMMUNOLOGY, V24, P751; TURK JL, 1972, IMMUNOLOGY, V23, P493; TURK JL, 1973, P ROY SOC MED, V66, P805, DOI 10.1177/003591577306600837; TURK JL, 1972, CLIN EXP IMMUNOL, V10, P285; WALKER SE, 1973, J LAB CLIN MED, V82, P619; WINKELSTEIN A, 1972, J LAB CLIN MED, V80, P506; WINKELSTEIN A, 1974, J LAB CLIN MED, V83, P504; WINKELSTEIN A, 1973, BLOOD, V41, P273, DOI 10.1182/blood.V41.2.273.273; 1970, N ENGL J MED, V283, P883	74	38	38	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	1					160	171		10.1016/0091-6749(76)90151-2	http://dx.doi.org/10.1016/0091-6749(76)90151-2			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BX744	985658				2022-12-18	WOS:A1976BX74400005
J	OHMAN, JL; BLOCH, KJ; KENDALL, S; LOWELL, FC				OHMAN, JL; BLOCH, KJ; KENDALL, S; LOWELL, FC			ALLERGENS OF MAMMALIAN ORIGIN .4. EVIDENCE FOR COMMON ALLERGENS IN CAT AND DOG SERUM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MASSACHUSETTS GEN HOSP,SERV MED,ALLERGY UNIT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,SERV MED,CLIN IMMUNOL UNIT,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,SERV MED,ARTHRITIS UNIT,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital								BRANDT R, 1973, INT ARCH ALLER A IMM, V45, P447, DOI 10.1159/000231062; HOLFORD-STREVENS V, 1973, Clinical Allergy, V3, P225, DOI 10.1111/j.1365-2222.1973.tb01325.x; HOLLEY JW, 1969, ACTA ALLERGOL, V24, P284, DOI 10.1111/j.1398-9995.1969.tb03744.x; KING TP, 1962, BIOCHEMISTRY-US, V1, P709, DOI 10.1021/bi00910a027; LYNCH NR, 1974, INT ARCH ALLER A IMM, V47, P818, DOI 10.1159/000231273; OHMAN JL, 1975, J ALLERGY CLIN IMMUN, V55, P16, DOI 10.1016/S0091-6749(75)80004-2; OHMAN JL, 1974, J IMMUNOL, V113, P1668; TUFT LOUIS, 1934, JOUR ALLERGY, V6, P25, DOI 10.1016/S0021-8707(34)90201-X; YMAN L, 1973, INT ARCH ALLER A IMM, V44, P358, DOI 10.1159/000230944	9	38	39	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	6					560	568		10.1016/0091-6749(76)90007-5	http://dx.doi.org/10.1016/0091-6749(76)90007-5			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BV054	819478				2022-12-18	WOS:A1976BV05400007
J	ZWEIMAN, B; SLOTT, RI; ATKINS, PC				ZWEIMAN, B; SLOTT, RI; ATKINS, PC			HISTOLOGIC STUDIES OF HUMAN-SKIN TEST RESPONSES TO RAGWEED AND COMPOUND 48-80	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									VET ADM HOSP,DEPT MED,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,PHILADELPHIA,PA 19174	University of Pennsylvania								ANDERSEN V, 1968, 12 P C INT SOC HEM N; ATKINS P, 1973, J ALLERGY CLIN IMMUN, V51, P263, DOI 10.1016/0091-6749(73)90128-0; BISHOP CR, 1968, J CLIN INVEST, V47, P249, DOI 10.1172/JCI105721; BOGGS DR, 1964, AM J PATHOL, V44, P763; CARPER HA, 1966, BLOOD-J HEMATOL, V27, P739, DOI 10.1182/blood.V27.5.739.739; CHAI H, 1973, J ALLERGY CLIN IMMUN, V51, P65, DOI 10.1016/S0091-6749(73)80001-6; CZARNETZKI BM, 1975, MAY AM FED CLIN RES; DALE, 1974, N ENG J MED, V291, P1154; DALE DC, 1975, J CLIN INVEST, V56, P808, DOI 10.1172/JCI108159; EDINGER D, 1962, NATURE, V196, P683; EDINGER D, 1964, J ALLERGY, V35, P77; ESSELLIER AF, 1954, BLOOD, V9, P531, DOI 10.1182/blood.V9.5.531.531; FEINBERG AR, 1967, J ALLERGY, V40, P73, DOI 10.1016/0021-8707(67)90100-1; FELARCA AB, 1971, J ALLERGY CLIN IMMUN, V48, P125, DOI 10.1016/0091-6749(71)90007-8; FELARCA AB, 1969, J ALLERGY, V43, P114, DOI 10.1016/0021-8707(69)90131-2; FOWLER JW, 1966, J ALLERGY, V37, P19, DOI 10.1016/0021-8707(66)90106-7; HERION JC, 1970, BLOOD-J HEMATOL, V36, P361, DOI 10.1182/blood.V36.3.361.361; HONSINGER RW, 1972, J ALLERGY CLIN IMMUN, V49, P142, DOI 10.1016/0091-6749(72)90108-X; HUDSON G, 1969, SEMIN HEMATOL, V5, P166; SLOTT RI, 1975, J ALLERGY CLIN IMMUN, V55, P232, DOI 10.1016/0091-6749(75)90142-6; SLOTT RI, 1974, J ALLERGY CLIN IMMUN, V54, P229, DOI 10.1016/0091-6749(74)90065-7; WASSERMAN SI, 1974, J IMMUNOL, V112, P351; ZWEIMAN B, IN PRESS	23	38	38	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	6					657	663		10.1016/0091-6749(76)90177-9	http://dx.doi.org/10.1016/0091-6749(76)90177-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CP077	993480				2022-12-18	WOS:A1976CP07700004
J	MALLEY, A; BAECHER, L; MACKLER, B; PERLMAN, F				MALLEY, A; BAECHER, L; MACKLER, B; PERLMAN, F			ISOLATION OF ALLERGENS FROM GREEN PEA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									OREGON REG PRIMATE RES CTR,DIV IMMUNE DIS,505 NW 185TH AVE,BEAVERTON,OR 97005	Oregon Health & Science University; Oregon National Primate Research Center								AAS K, 1967, INT ARCH ALLER A IMM, V32, P1, DOI 10.1159/000229911; CAMPBELL CH, 1964, METHODS IMMUNOLOGY, P146; CAMPBELL DH, 1964, MTHODS IMMUNOLOGY, P136; CAMPBELL DH, 1964, METHOD IMMUNOL, P143; DANIELSSON CE, 1952, ACTA CHEM SCAND, V6, P139, DOI 10.3891/acta.chem.scand.06-0139; DANIELSSON CE, 1952, ACTA CHEM SCAND, V6, P149, DOI 10.3891/acta.chem.scand.06-0149; DANIELSSON CE, 1950, ACTA CHEM SCAND, V4, P762, DOI 10.3891/acta.chem.scand.04-0762; ELSAYED S, 1971, INT ARCH ALLER A IMM, V40, P439, DOI 10.1159/000230426; JACOBS MB, 1951, CHEMISTRY TECHNOLOGY, V2; MALLEY A, 1970, J ALLERGY, V45, P14, DOI 10.1016/0021-8707(70)90013-4; MALLEY A, 1968, J IMMUNOL, V100, P915; MALLEY A, 1967, J IMMUNOL, V99, P825; ORNSTEIN L, 1964, ANN NY ACAD SCI, V121, P321, DOI 10.1111/j.1749-6632.1964.tb14207.x; PERLMAN F, 1964, S FOODS PROTEINS THE, P423; PERLMAN F, 1964, TOXIC CONSTITUENTS P, P319	15	38	42	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	56	4					282	290		10.1016/0091-6749(75)90102-5	http://dx.doi.org/10.1016/0091-6749(75)90102-5			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AS523	51864				2022-12-18	WOS:A1975AS52300005
J	BENNER, MH; LEE, HJ				BENNER, MH; LEE, HJ			ANAPHYLACTIC REACTION TO CHAMOMILE TEA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note																		ROWE ALBERT H., 1934, JOUR ALLERGY, V5, P383, DOI 10.1016/S0021-8707(34)90162-3; STERNBERG L, 1937, J ALLERGY, V8, P185	2	38	38	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	52	5					307	308		10.1016/0091-6749(73)90050-X	http://dx.doi.org/10.1016/0091-6749(73)90050-X			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R2087	4746793				2022-12-18	WOS:A1973R208700008
J	SYMEONIDES, PP; PASCHALOGLOU, C; PAPAGEORGIOU, S				SYMEONIDES, PP; PASCHALOGLOU, C; PAPAGEORGIOU, S			ALLERGIC REACTION AFTER INTERNAL FIXATION OF A FRACTURE USING A VITALLIUM PLATE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									GREEK AIR FORCE GEN HOSP, ATHENS, GREECE									CALNAN CD, 1956, BRIT J DERMATOL, V68, P229, DOI 10.1111/j.1365-2133.1956.tb12808.x; MCKENZIE AW, 1967, BMJ-BRIT MED J, V4, P36, DOI 10.1136/bmj.4.5570.36; STODDART JC, 1960, LANCET, V2, P741	3	38	38	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	51	4					251	252		10.1016/0091-6749(73)90145-0	http://dx.doi.org/10.1016/0091-6749(73)90145-0			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P3010	4689142				2022-12-18	WOS:A1973P301000008
J	TORSNEY, PJ				TORSNEY, PJ			TREATMENT FAILURE - INSECT DESENSITIZATION - CASE REPORTS OF FATALITIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									HAHNEMANN MED COLL & HOSP,DEPT MED,PHILADELPHIA,PA 19102	Drexel University								BROWN H, 1970, ARCH INTERN MED, V125, P665, DOI 10.1001/archinte.125.4.665; MUELLER HL, 1965, IMMUNOLOGIC DISEASES; REISMAN RE, 1970, J ALLERGY, V46, P254, DOI 10.1016/0021-8707(70)90029-8; TORSNEY PJ, 1968, NEW YORK STATE J MED, V68, P2765; 1965, JAMA, V193, P115	5	38	38	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	52	5					303	306		10.1016/0091-6749(73)90049-3	http://dx.doi.org/10.1016/0091-6749(73)90049-3			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R2087	4746792				2022-12-18	WOS:A1973R208700007
J	FALLIERS, CJ; MOLK, L; CARDOSO, RRD; CHAI, H; BANE, H				FALLIERS, CJ; MOLK, L; CARDOSO, RRD; CHAI, H; BANE, H			PULMONARY AND ADRENAL EFFECTS OF ALTERNATE-DAY CORTICOSTEROID THERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		AVIADO DM, 1970, J CLIN PHARMACOL N D, V10, P3; BONDY PK, 1969, DUNCANS DISEASES MET, P827; CHAI H, 1972, J ALLERGY CLIN IMMUN, V49, P126; FALLIERS CJ, 1971, ANN ALLERGY, V29, P239; FALLIERS CJ, 1970, CLIN PEDIATR, V9, P318, DOI 10.1177/000992287000900606; FALLIERS CJ, 1965, CLIN PEDIATR, V4, P441, DOI 10.1177/000992286500400804; FALLIERS CJ, 1970, ANN ALLERGY, V28, P513; FISHER DA, 1966, POSTGRAD MED, V39, P650, DOI 10.1080/00325481.1966.11695840; FRIEDMAN M, 1966, LANCET, V2, P568, DOI 10.1016/S0140-6736(66)93038-8; HARTER JG, 1963, NEW ENGL J MED, V269, P591, DOI 10.1056/NEJM196309192691201; KUMAR L, 1971, J PEDIATR-US, V79, P955, DOI 10.1016/S0022-3476(71)80190-7; MACGREGO.RR, 1969, NEW ENGL J MED, V280, P1427, DOI 10.1056/NEJM196906262802601; MARTIN MM, 1968, NEW ENGL J MED, V279, P273, DOI 10.1056/NEJM196808082790601; MORRIS HG, 1968, J CLIN INVEST, V47, P436, DOI 10.1172/JCI105740; MORRIS HG, 1971, J PEDIATR-US, V79, P480, DOI 10.1016/S0022-3476(71)80163-4; MURPHY BEP, 1967, J CLIN ENDOCR METAB, V27, P973, DOI 10.1210/jcem-27-7-973; OMALLEY BW, 1971, NEW ENGL J MED, V284, P370; PORTNER MM, 1970, J ALLERGY, V45, P109; Reindl K, 1969, Rass Neurol Veg, V23, P5; ROBINSON RH, 1962, BRIT MED J, P1579, DOI 10.1136/bmj.1.5292.1579; SADEGHIN.A, 1969, PEDIATRICS, V43, P277; SCHWARTZ HJ, 1968, ANN INTERN MED, V69, P493, DOI 10.7326/0003-4819-69-3-493; SIEGEL SC, 1965, J PEDIATR-US, V66, P927, DOI 10.1016/S0022-3476(65)80069-5; WEINBERG EG, TO BE PUBLISHED	24	38	38	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	49	3					156	+		10.1016/0091-6749(72)90109-1	http://dx.doi.org/10.1016/0091-6749(72)90109-1			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	L8566	5011089				2022-12-18	WOS:A1972L856600003
J	HONSINGER, RW; VANARSDE.PP; SILVERSTEIN, D				HONSINGER, RW; VANARSDE.PP; SILVERSTEIN, D			EOSINOPHIL AND ALLERGY - WHY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		ANDERSEN V, 1968, 12 P C INT SOC HEM N; ARCHER GT, 1963, J EXP MED, V118, P287, DOI 10.1084/jem.118.2.287; ARCHER GT, 1963, J EXP MED, V118, P277, DOI 10.1084/jem.118.2.277; ARCHER RK, 1963, EOSINOPHIL LEUKOCYTE; BARNHART MI, 1963, BLOOD, V21, P306, DOI 10.1182/blood.V21.3.306.306; BASTEN A, 1970, J EXP MED, V131, P1288, DOI 10.1084/jem.131.6.1288; CARPER HA, 1966, BLOOD, V27, P736; CHODIRKE.WB, 1967, J ALLERGY, V39, P126; CLINE MJ, 1968, BLOOD, V32, P922, DOI 10.1182/blood.V32.6.922.922; COHEN S, 1971, J EXP MED, V133, P133, DOI 10.1084/jem.133.1.133; COHEN SG, 1970, J ALLERGY, V46, P205, DOI 10.1016/0021-8707(70)90024-9; COHEN SG, 1965, J ALLERGY, V36, P415, DOI 10.1016/0021-8707(65)90135-8; COHEN SG, 1964, J ALLERGY, V35, P346, DOI 10.1016/0021-8707(64)90098-X; COHEN SG, 1963, P SOC EXP BIOL MED, V113, P29, DOI 10.3181/00379727-113-28266; CONNELL JT, 1968, J ALLERGY, V41, P1, DOI 10.1016/0021-8707(68)90002-6; DAWE CJ, 1953, ANAT REC, V116, P53, DOI 10.1002/ar.1091160106; ESSELLIER AF, 1954, BLOOD, V9, P531, DOI 10.1182/blood.V9.5.531.531; FEDORKO ME, 1968, BLOOD, V31, P188, DOI 10.1182/blood.V31.2.188.188; FELARCA AB, 1967, J ALLERGY, V40, P16, DOI 10.1016/0021-8707(67)90055-X; FELARCA AB, 1968, J ALLERGY, V41, P82, DOI 10.1016/0021-8707(68)90016-6; GOULD SE, 1963, LAB INVEST, V12, P737; HARDY WR, 1968, ANN INTERN MED, V68, P1220, DOI 10.7326/0003-4819-68-6-1220; HENRY WL, 1953, AM J PHYSIOL, V174, P455, DOI 10.1152/ajplegacy.1953.174.3.455; HERRON JC, 1970, BLOOD, V36, P361; HONSINGER RW, 1970, J ALLERGY, V45, P130; HUDSON G, 1968, Seminars in Hematology, V5, P166; HUNGERFORD GF, 1960, BLOOD, V16, P1642, DOI 10.1182/blood.V16.5.1642.1642; HUNTLEY CC, 1965, PEDIATRICS, V36, P425; KAY AB, 1970, CLIN EXP IMMUNOL, V6, P75; KAY AB, 1971, J EXP MED, V133, P602, DOI 10.1084/jem.133.3.602; KOCHWESE.J, 1968, ARCH INTERN MED, V121, P255, DOI 10.1001/archinte.121.3.255; KOSTAGE ST, 1967, P SOC EXP BIOL MED, V125, P413; LACHMANN PJ, 1970, IMMUNOLOGY, V19, P895; LANDS AM, 1967, NATURE, V214, P597, DOI 10.1038/214597a0; Leyden E., 1872, ARCH PATHOL ANAT PH, V54, P324; LITT M, 1962, J ALLERGY, V33, P532, DOI 10.1016/0021-8707(62)90021-7; LITT M, 1961, J IMMUNOL, V87, P522; LITT M, 1964, J CELL BIOL, V23, P355, DOI 10.1083/jcb.23.2.355; LITT M, 1964, J IMMUNOL, V93, P807; LITT M, 1963, AM J PATHOL, V42, P529; LITT M, 1968, EXCERPTA MEDICA  162, P38; LOWELL FC, 1967, J ALLERGY, V39, P110; LOWELL FC, 1967, J AMER MED ASSOC, V202, P875, DOI 10.1001/jama.202.9.875; MAUER AM, 1965, BLOOD-J HEMATOL, V26, P1; NAIMAN JL, 1964, AM J HUM GENET, V16, P195; Osgood EE, 1937, J AMER MED ASSOC, V109, P933, DOI 10.1001/jama.1937.02780380017005; PARISH WE, 1970, BRIT J DERMATOL, V82, P42, DOI 10.1111/j.1365-2133.1970.tb02193.x; PHIL E, 1967, SCAND J HAEMATOL, V4, P371; PRESENTEY B, 1969, AM J CLIN PATHOL, V51, P451; PROKOPOWICZ J, 1968, BIOCHIM BIOPHYS ACTA, V154, P91, DOI 10.1016/0005-2795(68)90262-6; RECANT L, 1950, J CLIN ENDOCRINOL, V10, P187, DOI 10.1210/jcem-10-2-187; REED CE, 1970, J ALLERGY, V46, P90, DOI 10.1016/0021-8707(70)90076-6; RENOLD AE, 1951, NEW ENGL J MED, V244, P754, DOI 10.1056/NEJM195105172442003; RIDDLE J, 1965, BLOOD, V25, P766; ROSENBERG EB, 1971, ANN INTERN MED, V75, P575, DOI 10.7326/0003-4819-75-4-575; RYTOEMAA T, 1961, NATURE, V192, P271, DOI 10.1038/192271b0; SABESIN SM, 1963, P SOC EXP BIOL MED, V112, P667, DOI 10.3181/00379727-112-28134; SALMON SE, 1970, NEW ENGL J MED, V282, P250, DOI 10.1056/NEJM197001292820505; SAMTER M, 1953, BLOOD, V8, P1078, DOI 10.1182/blood.V8.12.1078.1078; SAMTER M, 1947, J ALLERGY, V18, P221, DOI 10.1016/0021-8707(47)90045-2; Schlecht H, 1912, ARCH EXP PATHOL PHAR, V67, P137, DOI 10.1007/BF01997816; SCHWARTZ E, 1914, ERGEBN ALLG PATH, V17, P134; SCHWARTZ HJ, 1968, ANN INTERN MED, V69, P493, DOI 10.7326/0003-4819-69-3-493; SEEMAN PM, 1967, J CELL BIOL, V34, P745, DOI 10.1083/jcb.34.3.745; SMITHERS SR, 1967, 6 P M PAN AM HEALTH, P48; SOULSBY EJL, 1967, 6 P M APN AM HEALTH, P81; SPEIRS RS, 1958, ANN NY ACAD SCI, V73, P283, DOI 10.1111/j.1749-6632.1959.tb40804.x; SPEIRS RS, 1963, J IMMUNOL, V90, P561; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; THEVATHASAN OLIVER I., 1958, ACTA HAEMATOL, V19, P162; UHRBRAND H, 1958, ACTA MED SCAND, V160, P99; VAREKAMP H, 1965, ACTA ALLERGOL, V20, P171, DOI 10.1111/j.1398-9995.1965.tb03368.x; VAUGHN J, 1961, J ALLERGY, V32, P501, DOI 10.1016/0021-8707(61)90004-1; VERCAUTEREN R., 1951, ENZYMOLOGIA [HAGUE], V14, P340; VERZAR F, 1952, SCHWEIZ MED WSCHR, V82, P324; WARD PA, 1969, AM J PATHOL, V54, P121; WELSH RA, 1959, AM J PATHOL, V35, P1091; Wharton Jones T., 1846, PHILOS T ROY SOC LON, V136, P63; ZOLOV DM, 1969, INT ARCH ALLER A IMM, V35, P179, DOI 10.1159/000230170; ZUCKER-FRANKLIN DOROTHEA, 1968, SEMINAR HEMATOL, V5, P109	80	38	38	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	49	3					142	+		10.1016/0091-6749(72)90108-X	http://dx.doi.org/10.1016/0091-6749(72)90108-X			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	L8566	4110894				2022-12-18	WOS:A1972L856600002
J	KAWAI, T; MARSH, DG; NORMAN, PS; LICHTENSTEIN, LM				KAWAI, T; MARSH, DG; NORMAN, PS; LICHTENSTEIN, LM			ALLERGENS RESPONSIBLE FOR HOUSE DUST ALLERGY .1. COMPARISON OF DERMATOPHAGOIDES PTERONYSSINUS AND HOUSE DUST EXTRACTS BY ASSAY OF HISTAMINE-RELEASE FROM ALLERGIC HUMAN LEUKOCYTES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		FAIN A, 1967, Acarologia (Paris), V9, P179; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LICHTENSTEIN LM, 1969, J ALLERGY, V44, P307, DOI 10.1016/0021-8707(69)90035-5; LICHTENSTEIN LM, 1966, J CLIN INVEST, V45, P1126, DOI 10.1172/JCI105419; MARSH D, IN PRESS; MARSH DG, 1966, INT ARCH ALLER A IMM, V29, P521, DOI 10.1159/000229739; MAUNSELL K, 1968, LANCET, V1, P1267; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; MIYAMOTO T, 1968, J ALLERGY, V42, P14, DOI 10.1016/0021-8707(68)90128-7; PEPYS J, 1968, LANCET, V1, P1270; SASA M., 1950, JAP JOUR EXPTL MED, V20, P519; TRAVER JAY R., 1951, PROC ENT SOC WASHINGTON, V53, P1; UNDERDOWN BJ, 1969, BIOCHEMISTRY-US, V8, P980, DOI 10.1021/bi00831a031; VOORHORS.R, 1967, J ALLERGY, V39, P325, DOI 10.1016/0021-8707(67)90045-7; Voorhorst R., 1964, Allergie Asthma, V10, P329; VOORHORST R, 1958, OCCUPATIONAL ALLERGY, P260; [No title captured]	17	38	38	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	50	2					117	+		10.1016/0091-6749(72)90007-3	http://dx.doi.org/10.1016/0091-6749(72)90007-3			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N1795	4114293				2022-12-18	WOS:A1972N179500007
J	ROCKLIN, RE; DAVID, JR				ROCKLIN, RE; DAVID, JR			DETECTION IN-VITRO OF CELLULAR HYPERSENSITIVITY TO DRUGS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		AUGUSTIN R, 1961, ACTA ALLERGOL, V16, P473, DOI 10.1111/j.1398-9995.1961.tb02923.x; CHAPARAS SD, 1970, SCIENCE, V170, P637, DOI 10.1126/science.170.3958.637; DAVID JR, 1964, J IMMUNOL, V93, P264; DOLEN T, 1966, INT ARCH ALLER A IMM, V30, P405; GILL FA, 1967, J IMMUNOL, V98, P778; HALPERN B, 1967, J ALLERGY, V40, P168, DOI 10.1016/0021-8707(67)90006-8; HAN T, 1969, NEW ENGL J MED, V280, P547, DOI 10.1056/NEJM196903062801006; Nordqvist B, 1967, Trans St Johns Hosp Dermatol Soc, V53, P154; RIPPS CS, 1965, LANCET, V2, P951; ROBINSON BR, 1964, JAMA-J AM MED ASSOC, V189, P239; ROCKLIN RE, 1970, J IMMUNOL, V104, P95; ROCKLIN RE, 1970, 5 P LEUK CULT C, P639; SARKANY I, 1967, LANCET, V1, P743; SHELLEY WB, 1963, JAMA-J AM MED ASSOC, V184, P171, DOI 10.1001/jama.1963.03700160047006; SPITLER L, 1970, J EXP MED, V131, P133, DOI 10.1084/jem.131.1.133; VISCHER TL, 1966, LANCET, V2, P467	16	38	38	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1971	48	5					276	&		10.1016/0091-6749(71)90028-5	http://dx.doi.org/10.1016/0091-6749(71)90028-5			0	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K7978	5285777				2022-12-18	WOS:A1971K797800004
J	van der Made, CI; Potjewijd, J; Hoogstins, A; Willems, HPJ; Kwakernaak, AJ; de Sevaux, RGL; van Daele, PLA; Simons, A; Heijstek, M; Beck, DB; Netea, MG; van Paassen, P; Hak, AE; van der Veken, LT; van Gijn, ME; Hoischen, A; van de Veerdonk, FL; Leavis, HL; Rutgers, A				van der Made, Caspar, I; Potjewijd, Judith; Hoogstins, Annemiek; Willems, Huub P. J.; Kwakernaak, Arjan J.; de Sevaux, Ruud G. L.; van Daele, Paul L. A.; Simons, Annet; Heijstek, Marloes; Beck, David B.; Netea, Mihai G.; van Paassen, Pieter; Hak, A. Elizabeth; van der Veken, Lars T.; van Gijn, Marielle E.; Hoischen, Alexander; van de Veerdonk, Frank L.; Leavis, Helen L.; Rutgers, Abraham			Adult-onset autoinflammation caused by somatic mutations in UBA1: A Dutch case series of patients with VEXAS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						UBA1; VEXAS; autoinflammation; somatic variants	IMMUNODEFICIENCY; IDENTIFICATION; MOSAICISM	Background: A novel autoinflammatory syndrome was recently described in male patients who harbored somatic mutations in the X-chromosomal UBA1 gene. These patients were characterized by adult-onset, treatment-refractory inflammation with fever, cytopenia, dysplastic bone marrow, vacuoles in myeloid and erythroid progenitor cells, cutaneous and pulmonary inflammation, chondritis, and vasculitis, which is abbreviated as VEXAS. Objective: This study aimed to (retrospectively) diagnose VEXAS in patients who had previously been registered as having unclassified autoinflammation. We furthermore aimed to describe clinical experiences with this multifaceted, complex disease. Methods: A systematic reanalysis of whole-exome sequencing data from a cohort of undiagnosed patients with autoinflammation from academic hospitals in The Netherlands was performed. When no sequencing data were available, targeted Sanger sequencing was applied in cases with high clinical suspicion of VEXAS. Results: A total of 12 male patients who carried mutations in UBA1 were identified. These patients presented with adult-onset (mean age 67 years, range 47-79 years) autoinflammation with systemic symptoms, elevated inflammatory parameters, and multiorgan involvement, most typically involving the skin and bone marrow. Novel features of VEXAS included interstitial nephritis, cardiac involvement, stroke, and intestinal perforation related to treatment with tocilizumab. Although many types of treatment were initiated, most patients became treatment-refractory, with a high mortality rate of 50%. Conclusion: VEXAS should be considered in the differential diagnosis of males with adult-onset autoinflammation characterized by systemic symptoms and multiorgan involvement. Early diagnosis can prevent unnecessary diagnostic procedures and provide better prognostic information and more suitable treatment options, including stem cell transplantation. (J Allergy Clin Immunol 2022;149:432-9.)	[van der Made, Caspar, I; de Sevaux, Ruud G. L.; Netea, Mihai G.; Hoischen, Alexander; van de Veerdonk, Frank L.] Radboud Univ Nijmegen Med Ctr, Radboud Inst Mol Life Sci, Dept Internal Med, Nijmegen, Netherlands; [van der Made, Caspar, I; de Sevaux, Ruud G. L.; Netea, Mihai G.; Hoischen, Alexander; van de Veerdonk, Frank L.] Radboud Univ Nijmegen Med Ctr, Radboud Inst Mol Life Sci, Radboud Ctr Infect Dis, Nijmegen, Netherlands; [van der Made, Caspar, I; Simons, Annet; Hoischen, Alexander] Radboud Univ Nijmegen Med Ctr, Dept Human Genet, Nijmegen, Netherlands; [de Sevaux, Ruud G. L.] Radboud Univ Nijmegen Med Ctr, Dept Nephrol, Nijmegen, Netherlands; [Potjewijd, Judith; van Paassen, Pieter] Maastricht Univ Med Ctr, Dept Internal Med, Maastricht, Netherlands; [Hoogstins, Annemiek; Rutgers, Abraham] Univ Groningen, Univ Med Ctr Groningen, Dept Rheumatol & Clin Immunol, NL-9700 RB Groningen, Netherlands; [van Gijn, Marielle E.] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, Groningen, Netherlands; [Willems, Huub P. J.] Maxima Med Ctr, Dept Internal Med, Eindhoven, Netherlands; [Kwakernaak, Arjan J.; Hak, A. Elizabeth] Amsterdam Univ Med Ctr, Locat AMC Meibergdreef, Dept Internal Med, Amsterdam, Netherlands; [Kwakernaak, Arjan J.; Hak, A. Elizabeth] Amsterdam Univ Med Ctr, Locat AMC Meibergdreef, Dept Rheumatol & Clin Immunol, Amsterdam, Netherlands; [van Daele, Paul L. A.] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands; [van Daele, Paul L. A.] Erasmus MC, Dept Immunol, Rotterdam, Netherlands; [Heijstek, Marloes; Leavis, Helen L.] Univ Utrecht, Univ Med Ctr Utrecht, Dept Rheumatol & Clin Immunol, Utrecht, Netherlands; [van der Veken, Lars T.] Univ Utrecht, Univ Med Ctr Utrecht, Div Labs Pharm & Biomed Genet, Dept Genet, Utrecht, Netherlands; [Beck, David B.] NHGRI, NIH, Bethesda, MD 20892 USA	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Maastricht University; Maastricht University Medical Centre (MUMC); University of Groningen; University of Groningen; Maxima Medical Center; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Rutgers, A (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Rheumatol & Clin Immunol, NL-9700 RB Groningen, Netherlands.	A.Rutgers@umcg.nl	van der Made, Caspar/ABC-6046-2020; Hoischen, Alexander/AGF-7293-2022	van der Made, Caspar/0000-0003-0763-4017; Hoischen, Alexander/0000-0002-8072-4476	Solve-RD project of the European Union's Horizon 2020 Research and Innovation Programme [779257]; ERC Advanced Grant [833247]; Spinoza Grant of The Netherlands Organization; ZonMW Vidi Grant; Radboud Institute for Molecular Life Sciences; National Institutes of Health Intramural Research	Solve-RD project of the European Union's Horizon 2020 Research and Innovation Programme; ERC Advanced Grant(European Research Council (ERC)); Spinoza Grant of The Netherlands Organization; ZonMW Vidi Grant; Radboud Institute for Molecular Life Sciences; National Institutes of Health Intramural Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Supported by the Solve-RD project of the European Union's Horizon 2020 Research and Innovation Programme (grant 779257 [to A.H.] ) , an ERC Advanced Grant (no. 833247 [to M.G.N.] ) , a Spinoza Grant of The Netherlands Organization for Scientific Support (to M.G.N.) , a ZonMW Vidi Grant (to F.L.v.d.V.) , a Radboud Institute for Molecular Life Sciences PhD grant (to M.N.) , and the National Institutes of Health Intramural Research (to D.B.) .	Pereira DA, 2014, J ALLERGY CLIN IMMUN, V133, pAB274; Beck DB, 2020, NEW ENGL J MED, V383, P2628, DOI 10.1056/NEJMoa2026834; Boisson B, 2015, J EXP MED, V212, P939, DOI 10.1084/jem.20141130; Bourbon E, 2021, BLOOD, V137, P3682, DOI 10.1182/blood.2020010177; Damgaard RB, 2016, CELL, V166, P1215, DOI 10.1016/j.cell.2016.07.019; Ferrada MA, 2021, ARTHRITIS RHEUMATOL, V73, P1886, DOI 10.1002/art.41743; Gusdorf L, 2017, CURR RHEUMATOL REP, V19, DOI 10.1007/s11926-017-0673-5; HIRSCHHORN R, 1994, AM J HUM GENET, V55, P59; Kaiser C, 2012, RHEUMATOL INT, V32, P295, DOI 10.1007/s00296-011-2096-3; Kawasaki Y, 2017, ARTHRITIS RHEUMATOL, V69, P447, DOI 10.1002/art.39960; Louvrier C, 2020, J ALLERGY CLIN IMMUN, V145, P1254, DOI 10.1016/j.jaci.2019.11.035; MAGADURJOLY G, 1995, ANN RHEUM DIS, V54, P587, DOI 10.1136/ard.54.7.587; Mensa-Vilaro A, 2016, ARTHRITIS RHEUMATOL, V68, P1039, DOI 10.1002/art.39519; Poulter JA, 2021, BLOOD, V137, P3676, DOI 10.1182/blood.2020010286; Ramser J, 2008, AM J HUM GENET, V82, P188, DOI 10.1016/j.ajhg.2007.09.009; Revy P, 2019, NAT REV GENET, V20, P582, DOI 10.1038/s41576-019-0139-x; Rowczenio DM, 2016, ARTHRITIS RHEUMATOL, V68, P2044, DOI 10.1002/art.39683; Savic S, 2020, NAT REV RHEUMATOL, V16, P222, DOI 10.1038/s41584-020-0377-5; Singh A, 2020, GENES DIS, V7, P12, DOI 10.1016/j.gendis.2019.09.007; Strangfeld A, 2017, ANN RHEUM DIS, V76, P504, DOI 10.1136/annrheumdis-2016-209773; Zhou Q, 2016, NAT GENET, V48, P67, DOI 10.1038/ng.3459	21	37	37	8	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2022	149	1					432	+		10.1016/j.jaci.2021.05.014	http://dx.doi.org/10.1016/j.jaci.2021.05.014			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YO4PH	34048852	Green Published			2022-12-18	WOS:000747922700012
J	Lorenzini, T; Fliegauf, M; Klammer, N; Frede, N; Proietti, M; Bulashevska, A; Camacho-Ordonez, N; Varjosalo, M; Kinnunen, M; de Vries, E; van der Meer, JWM; Ameratunga, R; Roifman, CM; Schejter, YD; Kobbe, R; Hautala, T; Atschekzei, F; Schmidt, RE; Schroder, C; Stepensky, P; Shadur, B; Pedroza, LA; van der Flier, M; Martinez-Gallo, M; Gonzalez-Granado, LI; Allende, LM; Shcherbina, A; Kuzmenko, N; Zakharova, V; Neves, JF; Svec, P; Fischer, U; Ip, W; Bartsch, O; Baris, S; Klein, C; Geha, R; Chou, J; Alosaimi, M; Weintraub, L; Boztug, K; Hirschmugl, T; Vilela, MMD; Holzinger, D; Seidl, M; Lougaris, V; Plebani, A; Alsina, L; Piquer-Gibert, M; Deya-Martinez, A; Slade, CA; Aghamohammadi, A; Abolhassani, H; Hammarstrom, L; Kuismin, O; Helminen, M; Allen, HL; Thaventhiran, JE; Freeman, AF; Cook, M; Bakhtiar, S; Christiansen, M; Cunningham-Rundles, C; Patel, NC; Rae, W; Niehues, T; Brauer, N; Syrjanen, J; Seppanen, MRJ; Burns, SO; Tuijnenburg, P; Kuijpers, TW; Warnatz, K; Grimbacher, B				Lorenzini, Tiziana; Fliegauf, Manfred; Klammer, Nils; Frede, Natalie; Proietti, Michele; Bulashevska, Alla; Camacho-Ordonez, Nadezhda; Varjosalo, Markku; Kinnunen, Matias; de Vries, Esther; van der Meer, Jos W. M.; Ameratunga, Rohan; Roifman, Chaim M.; Schejter, Yael D.; Kobbe, Robin; Hautala, Timo; Atschekzei, Faranaz; Schmidt, Reinhold E.; Schroeder, Claudia; Stepensky, Polina; Shadur, Bella; Pedroza, Luis A.; van der Flier, Michiel; Martinez-Gallo, Monica; Ignacio Gonzalez-Granado, Luis; Allende, Luis M.; Shcherbina, Anna; Kuzmenko, Natalia; Zakharova, Victoria; Neves, Joao Farela; Svec, Peter; Fischer, Ute; Ip, Winnie; Bartsch, Oliver; Baris, Safa; Klein, Christoph; Geha, Raif; Chou, Janet; Alosaimi, Mohammed; Weintraub, Lauren; Boztug, Kaan; Hirschmugl, Tatjana; Dos Santos Vilela, Maria Marluce; Holzinger, Dirk; Seidl, Maximilian; Lougaris, Vassilios; Plebani, Alessandro; Alsina, Laia; Piquer-Gibert, Monica; Deya-Martinez, Angela; Slade, Charlotte A.; Aghamohammadi, Asghar; Abolhassani, Hassan; Hammarstrom, Lennart; Kuismin, Outi; Helminen, Merja; Allen, Hana Lango; Thaventhiran, James E.; Freeman, Alexandra F.; Cook, Matthew; Bakhtiar, Shahrzad; Christiansen, Mette; Cunningham-Rundles, Charlotte; Patel, Niraj C.; Rae, William; Niehues, Tim; Brauer, Nina; Syrjanen, Jaana; Seppanen, Mikko R. J.; Burns, Siobhan O.; Tuijnenburg, Paul; Kuijpers, Taco W.; Warnatz, Klaus; Grimbacher, Bodo		NIHR BioResource	Characterization of the clinical and immunologic phenotype and management of 157 individuals with 56 distinct heterozygous NFKB1 mutations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						NFKB1 variant; NFKB1 mutation; common variable immunodeficiency; reduced penetrance; NF-kappa B1-related phenotype; autosomal dominant	NF-KAPPA-B; NUCLEAR-FACTOR; NF-KAPPA-B1; HAPLOINSUFFICIENCY; IMMUNODEFICIENCY; CELLS	Background: An increasing number of NFKB1 variants are being identified in patients with heterogeneous immunologic phenotypes. Objective: To characterize the clinical and cellular phenotype as well as the management of patients with heterozygous NFKB1 mutations. Methods: In a worldwide collaborative effort, we evaluated 231 individuals harboring 105 distinct heterozygous NFKB1 variants. To provide evidence for pathogenicity, each variant was assessed in silico; in addition, 32 variants were assessed by functional in vitro testing of nuclear factor of kappa light polypeptide gene enhancer in B cells (NF-kappa B) signaling. Results: We classified 56 of the 105 distinct NFKB1 variants in 157 individuals from 68 unrelated families as pathogenic. Incomplete clinical penetrance (70%) and age-dependent severity of NFKB1-related phenotypes were observed. The phenotype included hypogammaglobulinemia (88.9%), reduced switched memory B cells (60.3%), and respiratory (83%) and gastrointestinal (28.6%) infections, thus characterizing the disorder as primary immunodeficiency. However, the high frequency of autoimmunity (57.4%), lymphoproliferation (52.4%), noninfectious enteropathy (23.1%), opportunistic infections (15.7%), autoinflammation (29.6%), and malignancy (16.8%) identified NF-kappa B1-related disease as an inborn error of immunity with immune dysregulation, rather than a mere primary immunodeficiency. Current treatment includes immunoglobulin replacement and immunosuppressive agents. Conclusions: We present a comprehensive clinical overview of the NF-kappa B1-related phenotype, which includes immunodeficiency, autoimmunity, autoinflammation, and cancer. Because of its multisystem involvement, clinicians from each and every medical discipline need to be made aware of this autosomal-dominant disease. Hematopoietic stem cell transplantation and NF-kappa B1 pathway-targeted therapeutic strategies should be considered in the future.	[Lorenzini, Tiziana; Fliegauf, Manfred; Klammer, Nils; Frede, Natalie; Proietti, Michele; Bulashevska, Alla; Camacho-Ordonez, Nadezhda; Warnatz, Klaus; Grimbacher, Bodo] Univ Freiburg, Med Ctr, Fac Med, Ctr Chron Immunodeficiency, Freiburg, Germany; [Lorenzini, Tiziana; Lougaris, Vassilios; Plebani, Alessandro] Univ Brescia, Pediat Clin, Dept Clin & Expt Sci, Brescia, Italy; [Lorenzini, Tiziana; Lougaris, Vassilios; Plebani, Alessandro] Univ Brescia, Inst Mol Med A Nocivelli, Dept Clin & Expt Sci, Brescia, Italy; [Lorenzini, Tiziana; Lougaris, Vassilios; Plebani, Alessandro] ASST Spedali Civili Brescia, Brescia, Italy; [Fliegauf, Manfred; Grimbacher, Bodo] Univ Freiburg, CIBSS Ctr Integrat Biol Signalling Studies, Freiburg, Germany; [Varjosalo, Markku; Kinnunen, Matias] Univ Helsinki, Inst Biotechnol, Helsinki, Finland; [de Vries, Esther] Tilburg Univ, Elisabeth Tweesteden Hosp, Lab Med Microbiol & Immunol, Tilburg, Netherlands; [de Vries, Esther] Tilburg Univ, Dept Tranzo, Tilburg, Netherlands; [van der Meer, Jos W. M.] Radboud Univ Nijmegen, Dept Internal Med, Med Ctr, Nijmegen, Netherlands; [Ameratunga, Rohan] Auckland City Hosp, Dept Virol & Immunol, Auckland, New Zealand; [Ameratunga, Rohan] Auckland City Hosp, Dept Clin Immunol, Auckland, New Zealand; [Roifman, Chaim M.; Schejter, Yael D.] Hosp Sick Children, Canadian Ctr Primary Immunodeficiency, Dept Pediat, Div Immunol & Allergy,Immunogen Lab, Toronto, ON, Canada; [Roifman, Chaim M.; Schejter, Yael D.] Univ Toronto, Toronto, ON, Canada; [Kobbe, Robin] Univ Med Ctr Hamburg, Dept Pediat, Hamburg, Germany; [Hautala, Timo] Oulu Univ Hosp, Dept Internal Med, Oulu, Finland; [Atschekzei, Faranaz; Schmidt, Reinhold E.; Schroeder, Claudia] Hannover Med Sch, Div Immunol & Rheumatol, Hannover, Germany; [Atschekzei, Faranaz; Schmidt, Reinhold E.; Grimbacher, Bodo] Hanover Med Sch, RESIST Cluster Excellence 2155, Satellite Ctr Freiburg, Freiburg, Germany; [Stepensky, Polina; Shadur, Bella] Hadassah Hebrew Univ, Bone Marrow Transplantat Dept, Med Ctr, Jerusalem, Israel; [Shadur, Bella] Garvan van Inst Med Res, Dept Immunol, Sydney, NSW, Australia; [Shadur, Bella] Univ New South Wales, Grad Res Sch, Sydney, NSW, Australia; [Pedroza, Luis A.] Univ San Francisco Quito, Colegio Ciencias Salud, Hosp Valles, Quito, Ecuador; [Pedroza, Luis A.] Univ San Francisco Quito, Inst Microbiol, Quito, Ecuador; [Pedroza, Luis A.] Baylor Coll Med, Dept Pediat, Sect Immunol Allergy & Rheumatol, Houston, TX 77030 USA; [van der Flier, Michiel] Radboud Univ Nijmegen, Dept Pediat Infect Dis & Immunol, Med Ctr, Nijmegen, Netherlands; [van der Flier, Michiel] Radboud Univ Nijmegen, Nijmegen Inst Infect Immun & Inflammat, Med Ctr, Nijmegen, Netherlands; [Martinez-Gallo, Monica] Autonomous Univ Barcelona UAB, Hosp Univ Vall dHebron HUVH, Vall Hebron Res Inst VHIR, Dept Cell Biol Physiol & Immunol,Immunol Div, Barcelona, Spain; [Martinez-Gallo, Monica] Jeffrey Model Fdn Excellence Ctr, Barcelona, Spain; [Ignacio Gonzalez-Granado, Luis] Univ Complutense Madrid, Sch Med, 12 Octubre Hlth Res Inst Imas12, Primary Immunodeficiencies Unit,Pediat, Madrid, Spain; [Allende, Luis M.] Hosp Univ 12 Octubre, Immunol Dept, Madrid, Spain; [Shcherbina, Anna; Kuzmenko, Natalia] Dmitry Rogachev Fed Res & Clin Ctr Pediat Hematol, Dept Clin Immunol Oncol & Immunol, Moscow, Russia; [Zakharova, Victoria] Dmitry Rogachev Natl Med & Res Ctr Pediat Hematol, Dept Hematopoiet Stem Cell Transplantat, Moscow, Russia; [Neves, Joao Farela] Ctr Hosp Lisboa Cent, Hosp Dona Estefania, Primary Immunodeficiencies Unit, Lisbon, Portugal; [Svec, Peter] Comenius Univ Children S Hosp, Dept Paediat Haematol & Oncol, Haematopoiet Stem Cell Transplantat Unit, Bratislava, Slovakia; [Fischer, Ute] Heinrich Heine Univ, Med Fac, Ctr Child & Adolescent Hlth, Dept Paediat Oncol Hematol & Clin Immunol, Dusseldorf, Germany; [Ip, Winnie] Great Ormond St Hosp Sick Children, Dept Immunol, London, England; [Ip, Winnie] Great Ormond St Hosp Sick Children, Mol & Cellular Immunol Unit, London, England; [Ip, Winnie] Univ Coll London UCL, Great Ormond St Inst Child Hlth, London, England; [Bartsch, Oliver] Johannes Gutenberg Univ Mainz, Inst Human Genet, Med Ctr, Mainz, Germany; [Baris, Safa] Marmara Univ, Dept Pediat, Div Allergy & Immunol, Sch Med, Istanbul, Turkey; [Klein, Christoph] Ludwig Maximilians Univ Munchen, Dr von Hauner Children S Hosp, Univ Hosp, Dept Pediat, Munich, Germany; [Geha, Raif; Chou, Janet; Alosaimi, Mohammed] Harvard Med Sch, Boston Childrens Hosp, Div Immunol, Boston, MA 02115 USA; [Geha, Raif; Chou, Janet; Alosaimi, Mohammed] Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA; [Weintraub, Lauren] Albany Med Ctr, Div Pediat Hematol, Albany, NY USA; [Weintraub, Lauren] Albany Med Ctr, Div Oncol, Albany, NY USA; [Boztug, Kaan; Hirschmugl, Tatjana] Med Univ Vienna, CeMM Res Ctr Mol Med, Austrian Acad Sci, Ludwig Boltzmann Inst Rare & Undiagnosed Dis,Dept, Vienna, Austria; [Boztug, Kaan; Hirschmugl, Tatjana] Med Univ Vienna, Dept Pediat, St Anna Kinderspital & Childrens Canc Res Inst, Vienna, Austria; [Dos Santos Vilela, Maria Marluce] Univ Estadual Campinas, UNICAMP, Ctr Invest Pediat, Lab Pediat Immunol,Fac Med Sci, Campinas, Brazil; [Holzinger, Dirk] Univ Duisburg Essen, Dept Pediat Hematol Oncol, Essen, Germany; [Seidl, Maximilian] Univ Freiburg, Univ Med Ctr, Ctr Chron Immunodeficiency & Mol Pathol, Dept Pathol, Freiburg, Germany; [Alsina, Laia; Piquer-Gibert, Monica; Deya-Martinez, Angela] Univ Barcelona, Pediat Allergy & Clin Immunol Dept, Hosp St Joan de Deu, Barcelona, Spain; [Alsina, Laia; Piquer-Gibert, Monica; Deya-Martinez, Angela] Univ Barcelona, Inst Recerca, Hosp St Joan de Deu, Barcelona, Spain; [Slade, Charlotte A.] Royal Melbourne Hosp, Dept Clin Immunol & Allergy, Melbourne, Vic, Australia; [Aghamohammadi, Asghar; Abolhassani, Hassan] Univ Tehran Med Sci, Res Ctr Immunodeficiencies, Pediat Ctr Excellence, Children S Med Ctr, Tehran, Iran; [Abolhassani, Hassan; Hammarstrom, Lennart] Karolinska Inst, Dept Lab Med, Karolinska Univ Hosp Huddinge, Div Clin Immunol, Stockholm, Sweden; [Kuismin, Outi] Med Res Ctr Oulu, PEDEGO Res Unit, Oulu, Finland; [Kuismin, Outi] Univ Oulu, Oulu, Finland; [Kuismin, Outi] Oulu Univ Hosp, Dept Clin Genet, Oulu, Finland; [Helminen, Merja] Univ Tampere, Tampere Ctr Child Hlth Res, Tampere, Finland; [Helminen, Merja] Tampere Univ Hosp, Tampere, Finland; [Allen, Hana Lango] Univ Cambridge, Dept Haematol, Cambridge, England; [Allen, Hana Lango] Cambridge Biomed Campus, NHS Blood & Transplant Cambridge, Cambridge, England; [Thaventhiran, James E.] Univ Cambridge, Dept Med, Cambridge, England; [Freeman, Alexandra F.] NIAID, Lab Clin Immunol & Microbiol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Cook, Matthew] Australian Natl Univ, Med Sch, Acton, Australia; [Cook, Matthew] Australian Natl Univ, John Curtin Sch Med Res, Acton, Australia; [Cook, Matthew] Canberra Hosp, Dept Immunol, Canberra, ACT, Australia; [Bakhtiar, Shahrzad] Univ Hosp Frankfurt, Div Pediat Stem Cell Transplantat & Immunol, Frankfurt, Germany; [Christiansen, Mette] Aarhus Univ Hosp Skejby, Int Ctr Immunodeficiency Dis, Aarhus, Denmark; [Christiansen, Mette] Aarhus Univ Hosp Skejby, Dept Clin Immunol, Aarhus, Denmark; [Cunningham-Rundles, Charlotte] Icahn Sch Med Mt Sinai, Div Clin Immunol, New York, NY 10029 USA; [Patel, Niraj C.] Atrium Hlth, Levine Childrens Hosp, Sect Infect Dis & Immunol, Dept Pediat, Charlotte, NC USA; [Rae, William] Univ Hosp Southampton NHS Fdn Trust, Southampton NIHR Wellcome Trust Clin Res Facil, Univ Hosp Southampton, Southampton, Hants, England; [Rae, William] Univ Hosp Southampton NHS Fdn Trust, NIHR Biomed Res Ctr, Univ Hosp Southampton, Dept Allergy Asthma & Clin Immunol, Southampton, Hants, England; [Niehues, Tim; Brauer, Nina] Helios Klinikum Krefeld, Dept Pediat Hematol & Oncol, Krefeld, Germany; [Syrjanen, Jaana] Tampere Univ Hosp, Dept Internal Med, Tampere, Finland; [Seppanen, Mikko R. J.] Univ Helsinki, New Childrens Hosp, Rare Dis Ctr, Helsinki, Finland; [Seppanen, Mikko R. J.] Univ Helsinki, Adult Immunodeficiency Unit, Inflammat Ctr, Helsinki, Finland; [Seppanen, Mikko R. J.] Helsinki Univ Hosp, Helsinki, Finland; [Burns, Siobhan O.] UCL, Royal Free London NHS Fdn Trust, Dept Immunol, Inst Immun & Transplantat, London, England; [Tuijnenburg, Paul; Kuijpers, Taco W.] Univ Amsterdam, Emma Childrens Hosp, Dept Pediat Immunol Rheumatol & Infect Dis, Amsterdam UMC, Meibergdreef 9, Amsterdam, Netherlands; [NIHR BioResource] Cambridge Biomed Campus, Cambridge Univ Hosp, NIHR BioResource, Cambridge, England; [Grimbacher, Bodo] Royal Free Hosp, Inst Immunol & Transplantat, London, England; [Grimbacher, Bodo] UCL, London, England; [Grimbacher, Bodo] DZIF German Ctr Infect Res, Satellite Ctr Freiburg, Freiburg, Germany; [Warnatz, Klaus; Grimbacher, Bodo] Univ Freiburg, Med Ctr, Fac Med, Ctr Chron Immunodeficiency,Rheumatol & Clin Immun, Freiburg, Germany	University of Freiburg; University of Brescia; University of Brescia; Hospital Spedali Civili Brescia; University of Freiburg; University of Helsinki; Elisabeth-TweeSteden Ziekenhuis (ETZ); Tilburg University; Tilburg University; Radboud University Nijmegen; Auckland City Hospital; Auckland City Hospital; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Oulu; Hannover Medical School; Hannover Medical School; Hebrew University of Jerusalem; Hadassah University Medical Center; University of New South Wales Sydney; Baylor College of Medicine; Radboud University Nijmegen; Radboud University Nijmegen; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Complutense University of Madrid; Hospital Universitario 12 de Octubre; Dmitry Rogachev National Medical Research Center Of Pediatric Hematology, Oncology & Immunology; Dmitry Rogachev National Medical Research Center Of Pediatric Hematology, Oncology & Immunology; Centro Hospitalar de Lisboa Central, EPE; Universidade de Lisboa; Heinrich Heine University Dusseldorf; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Johannes Gutenberg University of Mainz; Marmara University; University of Munich; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Albany Medical College; Albany Medical College; Austrian Academy of Sciences; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences; Medical University of Vienna; Medical University of Vienna; Saint Anna Children's Hospital; Universidade Estadual de Campinas; University of Duisburg Essen; University of Freiburg; University of Barcelona; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); University of Barcelona; Royal Melbourne Hospital; Tehran University of Medical Sciences; Karolinska Institutet; Karolinska University Hospital; University of Oulu; University of Oulu; Tampere University; Tampere University; Tampere University Hospital; University of Cambridge; University of Cambridge; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Australian National University; Australian National University; John Curtin School of Medical Research; Australian National University; Canberra Hospital; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Aarhus University; Aarhus University; Icahn School of Medicine at Mount Sinai; University of Southampton; University Hospital Southampton NHS Foundation Trust; University of Southampton; University Hospital Southampton NHS Foundation Trust; Helios Kliniken; Tampere University; Tampere University Hospital; University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of London; University College London; Royal Free London NHS Foundation Trust; Emma Children's Hospital; University of Amsterdam; University of Cambridge; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; German Center for Infection Research; University of Freiburg	Grimbacher, B (corresponding author), Univ Klinikum Freiburg, CCI Ctr Chron Immunodeficiency, Breisacher Str 115, D-79106 Freiburg, Germany.	bodo.grimbacher@uniklinik-freiburg.de	Ponsford, Mark J/ABA-3891-2020; Seidl, Maxmilian/ABF-3322-2021; Warnatz, Klaus/AAD-3464-2022; Martinez-Gallo, Monica/S-1368-2019; Ba, Sha/HGB-9711-2022; Gonzalez-Granado, Luis Ignacio/ABG-4515-2020; Cook, matthew/F-4151-2019; Abolhassani, Hassan/B-3465-2014; Boztug, Kaan/AAM-4161-2021; Alosaimi, Mohammed F/AAY-5814-2021; Bartsch, Oliver/ABE-2681-2020; Alsina, Laia/AID-4372-2022; Rae, William/AGX-6005-2022; Karim, Mohammed/G-9799-2016; van der Flier, Michiel/L-4307-2015; Booth, Claire/I-3667-2016; Varjosalo, Markku/K-6424-2015; Wood, Nicholas/C-2505-2009; Alsina, Laia/GQI-3516-2022; Simpson, Michael/F-4737-2011; Sargur, Ravishankar/C-2270-2009	Ponsford, Mark J/0000-0002-0236-1059; Seidl, Maxmilian/0000-0002-5559-4980; Martinez-Gallo, Monica/0000-0002-7340-2161; Gonzalez-Granado, Luis Ignacio/0000-0001-6917-8980; Cook, matthew/0000-0002-3331-9363; Abolhassani, Hassan/0000-0002-4838-0407; Boztug, Kaan/0000-0001-8387-9185; Alosaimi, Mohammed F/0000-0002-8025-3491; Seppanen, Mikko/0000-0001-9733-3650; Hautala, Timo/0000-0001-7889-1614; Karim, Mohammed/0000-0003-0912-1629; van der Flier, Michiel/0000-0003-1296-0159; Bradley, John/0000-0002-7774-8805; Urniaz, Rafal/0000-0003-0192-2165; james, roger/0000-0002-0058-1357; , Jesmeen/0000-0003-4169-8209; Deya-Martinez, Angela/0000-0002-8026-7674; Booth, Claire/0000-0002-2626-5037; Varjosalo, Markku/0000-0002-1340-9732; Kingston, Nathalie/0000-0002-9190-2231; Savic, Sinisa/0000-0001-7910-0554; Wood, Nicholas/0000-0002-9500-3348; Kuismin, Outi/0000-0002-0157-8985; /0000-0001-9586-8539; Alsina, Laia/0000-0002-3559-0018; Farela Neves, Joao/0000-0003-4740-6094; Yong, Patrick/0000-0003-1736-2756; Syrjanen, Jaana/0000-0002-7335-573X; Rae, William/0000-0003-0095-2514; Simpson, Michael/0000-0002-8539-8753; de Vries, Esther/0000-0003-4311-3550; Christiansen, Mette/0000-0001-5158-3670; Sargur, Ravishankar/0000-0002-8535-630X; /0000-0003-2885-4692; QASIM, WASEEM/0000-0001-8353-4494	German Research Foundation (DFG) [SFB1160]; Germany's Excellence Strategy [EXC-2189, 390939984, EXC 2155, 39087428]; E-rare program of the European Union [GR1617/14-1]; "Netzwerke Seltener Erkrankungen" of the German Ministry of Education and Research (BMBF) [GAIN_ 01GM1910A]; German Ministry of Education and Research (BMBF) [01E01303, 01ZX1306F]; MRC [MR/K020919/1, MR/L006197/1] Funding Source: UKRI	German Research Foundation (DFG)(German Research Foundation (DFG)); Germany's Excellence Strategy; E-rare program of the European Union; "Netzwerke Seltener Erkrankungen" of the German Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); German Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This study was supported by the German Research Foundation (DFG) (SFB1160 IMPATH to B.G.), and under Germany's Excellence Strategy (CIBSS -EXC-2189 Project ID 390939984 and RESIST -EXC 2155 -Project ID 39087428), by the E-rare program of the European Union, managed by the DFG, grant code GR1617/14-1/iPAD; by the "Netzwerke Seltener Erkrankungen" of the German Ministry of Education and Research (BMBF) (grant code: GAIN_ 01GM1910A); and by research funding from the German Ministry of Education and Research (BMBF, grant nos. 01E01303 and 01ZX1306F).	Ameratunga R, 2015, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00415; Beinke S, 2004, BIOCHEM J, V382, P393, DOI 10.1042/BJ20040544; Bertinchamp R, 2016, J ALLER CL IMM-PRACT, V4, P1147, DOI 10.1016/j.jaip.2016.07.002; Boztug H, 2016, J CLIN IMMUNOL, V36, P533, DOI 10.1007/s10875-016-0306-1; Collins PE, 2014, J BIOL CHEM, V289, P7059, DOI 10.1074/jbc.M114.551986; Cunningham-Rundles C, 1999, CLIN IMMUNOL, V92, P34, DOI 10.1006/clim.1999.4725; Dieli-Crimi R, 2018, CLIN IMMUNOL, V195, P49, DOI 10.1016/j.clim.2018.07.015; Etzioni A, 2017, J ALLERGY CLIN IMMUN, V139, P743, DOI 10.1016/j.jaci.2016.11.031; European Society for Immunodeficiences, CLIN WORK PART DIAGN; Fliegauf M, 2015, AM J HUM GENET, V97, P389, DOI 10.1016/j.ajhg.2015.07.008; Hayden MS, 2011, CELL RES, V21, P223, DOI 10.1038/cr.2011.13; Hoeger B, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01978; Isnardi I, 2010, BLOOD, V115, P5026, DOI 10.1182/blood-2009-09-243071; Kaustio M, 2017, J ALLERGY CLIN IMMUN, V140, P782, DOI 10.1016/j.jaci.2016.10.054; Keller B, 2017, J ALLERGY CLIN IMMUN, V139, P220, DOI 10.1016/j.jaci.2016.04.043; Lougaris V, 2017, CLIN IMMUNOL, V175, P99, DOI 10.1016/j.clim.2016.11.012; Maffucci P, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00220; O'Reilly LA, 2018, IMMUNITY, V48, P570, DOI 10.1016/j.immuni.2018.03.003; Oksenhendler E, 2008, CLIN INFECT DIS, V46, P1547, DOI 10.1086/587669; Patuzzo G, 2016, AUTOIMMUN REV, V15, P877, DOI 10.1016/j.autrev.2016.07.011; Pereira SG, 2008, INT J BIOCHEM CELL B, V40, P1425, DOI 10.1016/j.biocel.2007.05.004; Rae W, 2017, CLIN TRANSL IMMUNOL, V6, DOI 10.1038/cti.2017.38; Schipp C, 2016, HAEMATOLOGICA, V101, pE392, DOI 10.3324/haematol.2016.145136; Tuijnenburg P, 2018, J ALLERGY CLIN IMMUN, V142, P1285, DOI 10.1016/j.jaci.2018.01.039	24	37	37	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2020	146	4					901	911		10.1016/j.jaci.2019.11.051	http://dx.doi.org/10.1016/j.jaci.2019.11.051			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	OH2JO	32278790	Green Accepted, Green Submitted, Green Published			2022-12-18	WOS:000582395800021
J	Hosoki, K; Chakraborty, A; Sur, S				Hosoki, Koa; Chakraborty, Abhijit; Sur, Sanjiv			Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ACE2; asthma; allergic rhinitis; COVID-19; severe acute respiratory syndrome coronavirus 2; receptor-binding domain; TMPRSS2	ACUTE RESPIRATORY SYNDROME; ANGIOTENSIN-CONVERTING ENZYME-2; INDUCED ASTHMA EXACERBATIONS; CORONAVIRUS SPIKE PROTEIN; KAWASAKI-LIKE DISEASE; SARS-CORONAVIRUS; TRACT INFECTIONS; SYNCYTIAL VIRUS; PROTEOLYTIC ACTIVATION; TRANSMISSION DYNAMICS	The global pandemic caused by the newly described severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused worldwide suffering and death of unimaginable magnitude from coronavirus disease 2019 (COVID-19). The virus is transmitted through aerosol droplets, and causes severe acute respiratory syndrome. SARS-CoV-2 uses the receptor-binding domain of its spike protein S1 to attach to the host angiotensin-converting enzyme 2 receptor in lung and airway cells. Binding requires the help of another host protein, transmembrane protease serine S1 member 2. Several factors likely contribute to the efficient transmission of SARS-CoV-2. The receptor-binding domain of SARS-CoV-2 has a 10- to 20-fold higher receptor-binding capacity compared with previous pandemic coronaviruses. In addition, because asymptomatic persons infected with SARS-CoV-2 have high viral loads in their nasal secretions, they can silently and efficiently spread the disease. PCR-based tests have emerged as the criterion standard for the diagnosis of infection. Caution must be exercised in interpreting antibody-based tests because they have not yet been validated, and may give a false sense of security of being "immune" to SARS-CoV-2. We discuss how the development of some symptoms in allergic rhinitis can serve as clues for new onset COVID-19. There are mixed reports that asthma is a risk factor for severe COVID-19, possibly due to differences in asthma endotypes. The rapid spread of COVID-19 has focused the efforts of scientists on repurposing existing Food and Drug Administration approved drugs that inhibit viral entry, endocytosis, genome assembly, translation, and replication. Numerous clinical trials have been launched to identify effective treatments for COVID-19. Initial data from a placebo-controlled study suggest faster time to recovery in patients on remdesivir; it is now being evaluated in additional controlled studies. As discussed in this review, till effective vaccines and treatments emerge, it is important to understand the scientific rationale of pandemic-mitigation strategies such as wearing facemasks and social distancing, and implement them.	[Hosoki, Koa; Chakraborty, Abhijit; Sur, Sanjiv] Baylor Coll Med, Dept Med Immunol Allergy & Rheumatol, Houston, TX 77030 USA	Baylor College of Medicine	Sur, S (corresponding author), Baylor Coll Med, 1 Baylor Plaza, Houston, TX 77030 USA.	ssur@BCM.EDU	Chakraborty, Abhijit/N-2596-2018	Chakraborty, Abhijit/0000-0002-3822-5657; Hosoki, Koa/0000-0003-4228-2176	National Heart, Lung, and Blood Institute [5R01HL145477-02, 3R01HL145477-01S1]; Department of Defense [PR171425 W81XWH-18-1-0743]	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Department of Defense(United States Department of Defense)	This research was supported by the National Heart, Lung, and Blood Institute (grant nos. 5R01HL145477-02 and 3R01HL145477-01S1) and the Department of Defense (grant no. PR171425 W81XWH-18-1-0743).	Abd-Elsayed A, 2020, ANESTH ANALG, V131, P4, DOI 10.1213/ANE.0000000000004841; ABDULAI I, 2020, CELL, V181, DOI DOI 10.1016/J.AGSY.2020.102812; [Anonymous], SOL CLIN TRIAL COVID; Arabi YM, 2017, NEW ENGL J MED, V376, P584, DOI 10.1056/NEJMsr1408795; Bae S, 2020, ANN INTERN MED, V173, pW22, DOI 10.7326/M20-1342; Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI [10.1001/jama.2020.2565, 10.1056/NEJMoa2001316]; Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026; Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857; Bottcher E, 2006, J VIROL, V80, P9896, DOI 10.1128/JVI.01118-06; Broszeit F, 2019, CELL REP, V27, P3284, DOI 10.1016/j.celrep.2019.05.048; Canonica GW, 2008, WORLD ALLERGY ORGAN, V1, P138, DOI 10.1097/WOX.0b013e3181865faf; Cantini F, 2020, J INFECTION, V81, P318, DOI 10.1016/j.jinf.2020.04.017; Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282; Carenzo L, 2020, ANAESTHESIA, V75, P928, DOI 10.1111/anae.15072; Centers for Disease Control and Prevention, GROUPS HIGH RISK SEV; Centers for Disease Control and Prevention, 2018, SUMM HLTH STAT TABL; Centers for Disease Control and Prevention, INT GUID COLL HANDL; Centers for Disease Control and Prevention, HOSP RAT CHAR PAT HO; Chan JFW, 2020, CLIN INFECT DIS, V71, P2428, DOI 10.1093/cid/ciaa325; Chan JWM, 2003, THORAX, V58, P686, DOI 10.1136/thorax.58.8.686; Chan K. S., 2003, Hong Kong Medical Journal, V9, P399; Chen C., 2020, MEDRXIV, DOI [10.1101/2020.03.17.20037432, DOI 10.1101/2020.03.17.20037432]; Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7; Cheng ZKJ, 2020, INFECTION, V48, P155, DOI 10.1007/s15010-020-01401-y; Chinazzi M, 2020, SCIENCE, V368, P395, DOI 10.1126/science.aba9757; Chiu SS, 2005, CLIN INFECT DIS, V40, P1721, DOI 10.1086/430301; Chow EJ, 2020, JAMA-J AM MED ASSOC, V323, P2087, DOI 10.1001/jama.2020.6637; Chung JY, 2007, J MED VIROL, V79, P1238, DOI 10.1002/jmv.20926; Codispoti CD, 2020, ANN ALLERG ASTHMA IM, V125, P208, DOI 10.1016/j.anai.2020.05.009; Cohen J, 2020, SCIENCE, V368, P14, DOI 10.1126/science.368.6486.14; Conner SD, 2002, J CELL BIOL, V156, P921, DOI 10.1083/jcb.200108123; Coomes EA, 2020, REV MED VIROL, V30, DOI 10.1002/rmv.2141; Corne JM, 2002, LANCET, V359, P831, DOI 10.1016/S0140-6736(02)07953-9; COWART BJ, 1993, J ALLERGY CLIN IMMUN, V91, P747, DOI 10.1016/0091-6749(93)90194-K; de Wilde AH, 2018, CURR TOP MICROBIOL, V419, P1, DOI 10.1007/82_2017_25; de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81; Deng XF, 2017, P NATL ACAD SCI USA, V114, pE4251, DOI 10.1073/pnas.1618310114; Dhawale VS, 2016, TOXICOL APPL PHARM, V306, P17, DOI 10.1016/j.taap.2016.06.026; Ding QL, 2012, J ASTHMA, V49, P557, DOI 10.3109/02770903.2012.685540; Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747; Duan K., 2020, FEASIBILITY CONVALES, DOI [10.1101/2020.03.16.20036145, DOI 10.1101/2020.03.16.20036145]; El-Ekiaby A, 2006, AM J RESP CRIT CARE, V174, P508, DOI 10.1164/rccm.200603-431OC; Fauver Joseph R, 2020, medRxiv, DOI 10.1101/2020.03.25.20043828; Favalli EG, 2020, LANCET INFECT DIS, V20, P1012, DOI 10.1016/S1473-3099(20)30262-0; Feng S, 2020, LANCET RESP MED, V8, P434, DOI 10.1016/S2213-2600(20)30134-X; Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047; Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949; Gerna G, 2006, J MED VIROL, V78, P938, DOI 10.1002/jmv.20645; Giacomelli A, 2020, CLIN INFECT DIS, V71, P889, DOI 10.1093/cid/ciaa330; Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10; Gordon CJ, 2020, J BIOL CHEM, V295, P6785, DOI 10.1074/jbc.RA120.013679; Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419; Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031; Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016; Griggs TF, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0567-0; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Guo ZD, 2020, EMERG INFECT DIS, V26, P1586, DOI 10.3201/eid2607.200885; Gupta RS, 2006, J ALLERGY CLIN IMMUN, V117, P351, DOI 10.1016/j.jaci.2005.11.047; Haller O, 2015, TRENDS MICROBIOL, V23, P154, DOI 10.1016/j.tim.2014.12.003; Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570; Hamming I, 2007, J PATHOL, V212, P1, DOI 10.1002/path.2162; Hayashi T, 2004, J CLIN INVEST, V114, P270, DOI 10.1172/JCI200421275; HE X, 2020, NAT MED, V26, P672, DOI DOI 10.1038/S41591-020-0869-5; Heurich A, 2014, J VIROL, V88, P1293, DOI 10.1128/JVI.02202-13; Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191; Hu TY, 2020, NAT NANOTECHNOL, V15, P247, DOI 10.1038/s41565-020-0674-9; Huang N, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-4775-8; Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4; Hussain S, 2005, J VIROL, V79, P5288, DOI 10.1128/JVI.79.9.5288-5295.2005; Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712; Infectious Diseases Society of America, IDSA COVID 19 ANT TE; Iwabuchi K, 2020, COVID 19 3 CASES IMP; Iwata-Yoshikawa N, 2019, J VIROL, V93, DOI 10.1128/JVI.01815-18; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Jackson DJ, 2020, J ALLERGY CLIN IMMUN, V146, P203, DOI 10.1016/j.jaci.2020.04.009; Jackson DJ, 2014, AM J RESP CRIT CARE, V190, P1373, DOI 10.1164/rccm.201406-1039OC; Jeon S, ANTIMICROB AGENTS CH, DOI [10.1128/AAC.00810-20, DOI 10.1128/AAC.00810-20]; Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y; Johns Hopkins University, COR COVID 19 GLOB CA; JUNIPER EF, 1994, J ALLERGY CLIN IMMUN, V93, P413, DOI 10.1016/0091-6749(94)90349-2; Kampf G, 2020, J HOSP INFECT, V104, P246, DOI 10.1016/j.jhin.2020.01.022; Kawasaki T, 2006, P JPN ACAD B-PHYS, V82, P59, DOI 10.2183/pjab.82.59; Kesic MJ, 2012, RESP RES, V13, P82; Khetsuriani N, 2007, J ALLERGY CLIN IMMUN, V119, P314, DOI 10.1016/j.jaci.2006.08.041; Kim UJ, 2016, ANTIVIR THER, V21, P455, DOI 10.3851/IMP3002; Kistler A, 2007, J INFECT DIS, V196, P817, DOI 10.1086/520816; Kloepfer KM, 2014, J ALLERGY CLIN IMMUN, V133, P1301, DOI 10.1016/j.jaci.2014.02.030; Ko M., 2020, SCREENING FDA APPROV, DOI [10.1101/2020.02.25.965582, DOI 10.1101/2020.02.25.965582]; Kotaniemi-Syrjanen A, 2003, J ALLERGY CLIN IMMUN, V111, P66, DOI 10.1067/mai.2003.33; Krishnan JA, 2012, J ALLERGY CLIN IMMUN, V129, pS124, DOI 10.1016/j.jaci.2011.12.981; Kuo HC, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-38; Kupferschmidt K, 2020, SCIENCE, V367, P1412, DOI 10.1126/science.367.6485.1412; Kuruvilla ME, 2019, CLIN REV ALLERG IMMU, V56, P219, DOI 10.1007/s12016-018-8712-1; Lam TTY, 2020, NATURE, V583, P282, DOI 10.1038/s41586-020-2169-0; Lau SKP, 2006, J CLIN MICROBIOL, V44, P2063, DOI 10.1128/JCM.02614-05; Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504; Leach CL, 2006, J AEROSOL MED, V19, P117, DOI 10.1089/jam.2006.19.117; Lechien JR, 2020, EUR ARCH OTO-RHINO-L, V277, P2251, DOI 10.1007/s00405-020-05965-1; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Lescure FX, 2020, LANCET INFECT DIS, V20, P697, DOI 10.1016/S1473-3099(20)30200-0; Letko M, 2020, NAT MICROBIOL, V5, P562, DOI [10.1038/s41564-020-0688-y, 10.1101/2020.01.22.915660]; Li RY, 2020, SCIENCE, V368, P489, DOI [10.1126/science.abb3221, 10.1101/2020.02.14.20023127]; Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145; Li XC, 2020, J ALLERGY CLIN IMMUN, V146, P110, DOI 10.1016/j.jaci.2020.04.006; Lin L, 2020, GUT, V69, P997, DOI 10.1136/gutjnl-2020-321013; Lipsitch M, 2003, SCIENCE, V300, P1966, DOI 10.1126/science.1086616; Liu XP, 2020, INFLUENZA OTHER RESP, V14, P472, DOI 10.1111/irv.12740; Loisel DA, 2016, CLIN EXP ALLERGY, V46, P112, DOI 10.1111/cea.12642; Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8; Lukassen S, 2020, EMBO J, V39, DOI 10.15252/embj.20105114; Ma KL, 2020, COVID 19 MYOCARDITIS; Magagnoli J, 2020, MED-CAMBRIDGE, V1, P114, DOI [10.1101/2020.04.16.20065920, 10.1016/j.medj.2020.06.001]; Magalhaes GS, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00058; Mahase E, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m641; Malmstrom K, 2006, J ALLERGY CLIN IMMUN, V118, P591, DOI 10.1016/j.jaci.2006.04.032; Matsuyama S, INHALED CORTICOSTERO, DOI [10.1101/2020.0'3.11.087016, DOI 10.1101/2020.0'3.11.087016]; Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0; Meissner HC, 2016, NEW ENGL J MED, V374, P62, DOI 10.1056/NEJMra1413456; Miller EK, 2007, J INFECT DIS, V195, P773, DOI 10.1086/511821; Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004; Montgomery MT, AM J RESP CRIT CARE, DOI [10.1164/rcern.202003-08210C, DOI 10.1164/RCERN.202003-0821OC]; National Institute of Allergy and Infectious Diseases, COVLD 19 MERS SARS; National Institute of Health, COVID 19 TREATM GUID; Nave R, 2013, INT J GEN MED, V6, P99, DOI 10.2147/IJGM.S39134; New York State Department of Health, NYSDOH COVID 19 TRAC; Ong SWX, 2020, JAMA-J AM MED ASSOC, V323, P1610, DOI 10.1001/jama.2020.3227; Papadopoulos NG, 2002, THORAX, V57, P328, DOI 10.1136/thorax.57.4.328; Perrier A, 2019, J BIOL CHEM, V294, P14406, DOI 10.1074/jbc.RA119.008964; Peters U, 2018, J ALLERGY CLIN IMMUN, V141, P1169, DOI 10.1016/j.jaci.2018.02.004; Price D, 2015, CLIN TRANSL ALLERGY, V5, DOI 10.1186/s13601-015-0083-6; Rakes CP, 1999, AM J RESP CRIT CARE, V159, P785, DOI 10.1164/ajrccm.159.3.9801052; Ravanetti L, 2019, J ALLERGY CLIN IMMUN, V143, P1355, DOI 10.1016/j.jaci.2018.08.051; Recalcati S, 2020, J EUR ACAD DERMATOL, V34, pE346, DOI 10.1111/jdv.16533; Rhodes A, 2012, INTENS CARE MED, V38, P1647, DOI 10.1007/s00134-012-2627-8; Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4; Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2052, DOI 10.1001/jama.2020.6775; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; Rockx Barry, 2020, Science, V368, P1012, DOI 10.1126/science.abb7314; Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630; Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468; Rydzewski B, 2000, ACTA OTO-LARYNGOL, V120, P323; Sabir JSM, 2016, SCIENCE, V351, P81, DOI 10.1126/science.aac8608; Sandell C, 2010, J ALLERGY CLIN IMMUN, V144, P1624; Schaper F, 2015, CYTOKINE GROWTH F R, V26, P475, DOI 10.1016/j.cytogfr.2015.07.004; Schatz M, 2007, ALLERGY, V62, P9, DOI 10.1111/j.1398-9995.2007.01548.x; Shanawani H, 2006, CLIN CHEST MED, V27, P17, DOI 10.1016/j.ccm.2005.11.002; Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783; Shi T, 2015, J GLOB HEALTH, V5, P203, DOI 10.7189/jogh.05.020416; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076; Simmons G, 2013, ANTIVIR RES, V100, P605, DOI 10.1016/j.antiviral.2013.09.028; Skoner DR, 2001, J ALLERGY CLIN IMMUN, V108, pS2, DOI 10.1067/mai.2001.115569; Slejko JF, 2014, J ALLERGY CLIN IMMUN, V133, P1579, DOI 10.1016/j.jaci.2013.10.028; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Stuck BA, 2015, J ALLERGY CLIN IMMUN, V136, P1460, DOI 10.1016/j.jaci.2015.08.003; Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003; Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6; Taher YA, 2008, J ALLERGY CLIN IMMUN, V121, P983, DOI 10.1016/j.jaci.2007.11.021; Tan WC, 2003, AM J MED, V115, P272, DOI 10.1016/S0002-9343(03)00353-X; ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237; Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069; Torigoe M, 2018, CLIN IMMUNOL, V195, P1, DOI 10.1016/j.clim.2018.07.003; Tsai YJ, 2013, ALLERGY ASTHMA PROC, V34, P467, DOI 10.2500/aap.2013.34.3697; Vabret A, 2008, J PAEDIATR CHILD H, V44, P176, DOI 10.1111/j.1440-1754.2007.01246.x; Van Bever HP, 2004, PEDIAT ALLERG IMM-UK, V15, P206, DOI 10.1111/j.1399-3038.2004.00137.x; van Boheemen S, 2012, MBIO, V3, DOI 10.1128/mBio.00473-12; van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI [10.1056/NEJMc2004973, 10.1101/2020.03.09.20033217]; Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X; Viner RM, 2020, LANCET, V395, P1741, DOI 10.1016/S0140-6736(20)31129-6; Walk PA, 2002, EUR RESPIR J, V10, P68; Wallace DJ, 2015, AM J RESP CRIT CARE, V191, P410, DOI 10.1164/rccm.201409-1746OC; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Wang DW, 2020, J COASTAL RES, P1, DOI [10.1001/jama.2020.1585, 10.2112/JCR-SI109-001.1]; Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045; Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Weinheimer VK, 2012, J INFECT DIS, V206, P1685, DOI 10.1093/infdis/jis455; Werder RB, 2018, J ALLERGY CLIN IMMUN, V141, P1607, DOI 10.1016/j.jaci.2017.07.051; Wolfel R, 2020, NATURE, V588, pE35, DOI 10.1038/s41586-020-2984-3; World Health Organization, DRAFT LANDSC COVID 1; Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]; Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994; Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3; Wu Y, SCIENCE, DOI [10.1126/seience.abe2241., 10.1126/seience.abe2241, DOI 10.1126/SEIENCE.ABE2241]; Yamamoto M, 2016, ANTIMICROB AGENTS CH, V60, P6532, DOI 10.1128/AAC.01043-16; Yamaya M, 2020, RESPIR INVESTIG, V58, P155, DOI 10.1016/j.resinv.2019.12.005; Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762; Yao SL, 2017, J ASTHMA, V54, P476, DOI 10.1080/02770903.2016.1236943; YEAGER CL, 1992, NATURE, V357, P420, DOI 10.1038/357420a0; Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269; Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721; Zhang F., 2020, MEDRXIV, DOI 10.1101/2020.03.21.20040121; Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238; Zhang T., 2020, PANGOLIN HOMOLOGY AS, DOI [10.1101/2020.02.19.950253., 10.1101/2020.02.19.950253, DOI 10.1101/2020.02.19.950253]; Zheng XY, 2018, ARCH VIROL, V163, P845, DOI 10.1007/s00705-017-3700-y; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3; Zhou P, 2020, NATURE, V588, pE6, DOI [10.1038/s41586-020-2012-7, 10.1038/s41586-020-2951-z]; Zhou Z, 2020, CELL HOST MICROBE, V27, P883, DOI 10.1016/j.chom.2020.04.017; Zhu J, 2019, J ALLERGY CLIN IMMUN, V143, P114, DOI 10.1016/j.jaci.2018.04.003; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017; Zimmermann P, 2020, PEDIATR INFECT DIS J, V39, P469, DOI 10.1097/INF.0000000000002700	200	37	40	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2020	146	2					285	299		10.1016/j.jaci.2020.05.033	http://dx.doi.org/10.1016/j.jaci.2020.05.033			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MZ0TA	32624257	Green Published, Bronze			2022-12-18	WOS:000558835000013
J	Namazy, JA; Blais, L; Andrews, EB; Scheuerle, AE; Cabana, MD; Thorp, JM; Umetsu, DT; Veith, JH; Sun, D; Kaufman, DG; Covington, DL; Mukhopadhyay, S; Fogel, RB; Lopez-Leon, S; Spain, CV				Namazy, Jennifer A.; Blais, Lucie; Andrews, Elizabeth B.; Scheuerle, Angela E.; Cabana, Michael D.; Thorp, John M.; Umetsu, Dale T.; Veith, Joachim H.; Sun, Diana; Kaufman, Derrick G.; Covington, Deborah L.; Mukhopadhyay, Santanu; Fogel, Robert B.; Lopez-Leon, Sandra; Spain, C. Victor			Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Omalizumab; pregnancy; moderate to severe asthma; congenital anomalies	PERINATAL OUTCOMES; PRETERM DELIVERY; MATERNAL ASTHMA; UNITED-STATES; BIRTH-WEIGHT; SAFETY; IMPACT; CORTICOSTEROIDS; EXACERBATIONS; TORTICOLLIS	Background: The Observational Study of the Use and Safety of Xolair (omalizumab) during Pregnancy (EXPECT) pregnancy registry was a prospective observational study established in 2006 to evaluate perinatal outcomes in pregnant women exposed to omalizumab and their infants. Objective: This analysis compares EXPECT outcomes with those from a disease-matched population of pregnant women not treated with omalizumab. Data from a substudy of platelet counts among newborns are also presented. Methods: The EXPECT study enrolled 250 women with asthma exposed to omalizumab during pregnancy. The disease-matched external comparator cohort of women with moderate-to-severe asthma (n = 1153), termed the Quebec External Comparator Cohort (QECC), was created by using data from health care databases in Quebec, Canada. Outcome estimates were age adjusted based on the maternal age distribution of the EXPECT study. Results: Among singleton infants in the EXPECT study, the prevalence of major congenital anomalies was 8.1%, which was similar to the 8.9% seen in the QECC. In the EXPECT study 99.1% of pregnancies resulted in live births, which was similar to 99.3% in the QECC. Premature birth was identified in 15.0% of EXPECT infants and 11.3% in the QECC. Small for gestational age was identified in 9.7% of EXPECT infants and 15.8% in the QECC. Conclusion: There was no evidence of an increased risk of major congenital anomalies among pregnant women exposed to omalizumab compared with a disease-matched unexposed cohort. Given the observational nature of this registry, however, an absence of increased risk with omalizumab cannot be definitively established.	[Namazy, Jennifer A.] Scripps Clin, Div Allergy & Immunol, San Diego, CA USA; [Blais, Lucie] Univ Montreal, Fac Pharm, Montreal, PQ, Canada; [Andrews, Elizabeth B.] RTI Int, RTI Hlth Solut, Res Triangle Pk, NC USA; [Scheuerle, Angela E.] Univ Texas Southwestern Med Ctr Dallas, Dept Pediat, Div Genet & Metab, Dallas, TX 75390 USA; [Cabana, Michael D.] Univ Calif San Francisco, Div Gen Pediat, Dept Pediat Epidemiol & Biostat, San Francisco, CA 94143 USA; [Thorp, John M.] Univ N Carolina, Sch Med, Dept Obstet & Gynecol, Chapel Hill, NC USA; [Umetsu, Dale T.; Veith, Joachim H.; Sun, Diana; Kaufman, Derrick G.; Spain, C. Victor] Genentech Inc, San Francisco, CA USA; [Covington, Deborah L.] Evidera, Real World Evidence, Wilmington, DE USA; [Mukhopadhyay, Santanu] Novartis Pharma AG, Basel, Switzerland; [Fogel, Robert B.; Lopez-Leon, Sandra] Novartis Pharmaceut, E Hanover, NJ USA	Scripps Research Institute; Universite de Montreal; Research Triangle Institute; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of California System; University of California San Francisco; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Roche Holding; Genentech; Novartis; Novartis	Spain, CV (corresponding author), Genentech Inc, Real World Data, San Francisco, CA 94080 USA.	spainc@gene.com		Andrews, Elizabeth B./0000-0003-1131-5983	Genentech	Genentech(Roche HoldingGenentech)	Supported by Genentech.	Alexander GR, 1996, OBSTET GYNECOL, V87, P163, DOI 10.1016/0029-7844(95)00386-X; Bakhireva LN, 2008, ANN ALLERG ASTHMA IM, V101, P137, DOI 10.1016/S1081-1206(10)60201-3; Bakhireva LN, 2007, J ALLERGY CLIN IMMUN, V119, P618, DOI 10.1016/j.jaci.2006.12.618; Belanger K, 2010, OBSTET GYNECOL, V115, P559, DOI 10.1097/AOG.0b013e3181d06945; Blais L, 2006, PHARMACOEPIDEM DR S, V15, P245, DOI 10.1002/pds.1202; Blais L, 2015, THORAX, V70, P647, DOI 10.1136/thoraxjnl-2014-206634; Blais L, 2013, PHARMACOEPIDEM DR S, V22, P881, DOI 10.1002/pds.3446; Blais L, 2009, J ALLERGY CLIN IMMUN, V124, P1229, DOI 10.1016/j.jaci.2009.09.025; Bonham CA, 2018, CHEST, V153, P515, DOI 10.1016/j.chest.2017.08.029; Correa Adolfo, 2007, Birth Defects Res A Clin Mol Teratol, V79, P65; Corren J, 2009, CLIN EXP ALLERGY, V39, P788, DOI 10.1111/j.1365-2222.2009.03214.x; Cossette B, 2013, THORAX, V68, P724, DOI 10.1136/thoraxjnl-2012-203122; Dombrowski MP, 2004, OBSTET GYNECOL, V103, P5, DOI 10.1097/01.AOG.0000103994.75162.16; European Medicines Agency (EMA), XOL OM; Firoozi F, 2012, EUR J EPIDEMIOL, V27, P205, DOI 10.1007/s10654-012-9654-1; Genentech, OM XOL FULL PRESCR I; Kim SS, 2017, BJOG-INT J OBSTET GY, V124, P1708, DOI 10.1111/1471-0528.14613; Kramer MS, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.2.e35; KRAMER MS, 1987, B WORLD HEALTH ORGAN, V65, P663; Martin JA, 2016, NCHS DATA BRIEF, V2017, P1; Martin JA, 2013, MMWR-MORBID MORTAL W, V62, P136; Morris JK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194986; Namazy J, 2015, J ALLERGY CLIN IMMUN, V135, P407, DOI 10.1016/j.jaci.2014.08.025; Namazy JA, 2013, EUR RESPIR J, V41, P1082, DOI 10.1183/09031936.00195111; Nelson TS, 1988, DIS INFANCY ADULTHOO; Park-Wyllie L, 2000, TERATOLOGY, V62, P385, DOI 10.1002/1096-9926(200012)62:6<385::AID-TERA5>3.0.CO;2-Z; Paulozzi LJ, 1997, PEDIATRICS, V100, P831, DOI 10.1542/peds.100.5.831; PERLOW JH, 1992, AM J OBSTET GYNECOL, V167, P963, DOI 10.1016/S0002-9378(12)80020-2; Sairam S, 2001, ULTRASOUND OBST GYN, V17, P191, DOI 10.1046/j.1469-0705.2001.00333.x; Schatz M, 1997, J ALLERGY CLIN IMMUN, V100, P301, DOI 10.1016/S0091-6749(97)70241-0; Schatz M, 2018, ANN AM THORAC SOC, V15, P1131, DOI 10.1513/AnnalsATS.201806-400PP; Scheuerle A, 2002, PHARMACOEPIDEM DR S, V11, P465, DOI 10.1002/pds.726; Springer A, 2016, J PEDIAT UROL, V12, DOI DOI 10.1016/J.JPUR0L.2015.12.002; Stellwagen L, 2008, ARCH DIS CHILD, V93, P827, DOI 10.1136/adc.2007.124123; Thuot M, 2013, CAN RESPIR J, V20, P345, DOI 10.1155/2013/815143; Watemberg N, 2016, PEDIATR NEUROL, V59, P36, DOI 10.1016/j.pediatrneurol.2016.02.005	36	37	40	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2020	145	2					528	+		10.1016/j.jaci.2019.05.019	http://dx.doi.org/10.1016/j.jaci.2019.05.019			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KK6ZG	31145939	hybrid			2022-12-18	WOS:000512887400016
J	Gordon, EM; Yao, XL; Xu, HT; Karkowsky, W; Kaler, M; Kalchiem-Dekel, O; Barochia, AV; Gao, MX; Keeran, KJ; Jeffries, KR; Levine, SJ				Gordon, Elizabeth M.; Yao, Xianglan; Xu, Haitao; Karkowsky, William; Kaler, Maryann; Kalchiem-Dekel, Or; Barochia, Amisha V.; Gao, Meixia; Keeran, Karen J.; Jeffries, Kenneth R.; Levine, Stewart J.			Apolipoprotein E is a concentration-dependent pulmonary danger signal that activates the NLRP3 inflammasome and IL-1 beta secretion by bronchoalveolar fluid macrophages from asthmatic subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; apolipoprotein E; house dust mite; IL-1 beta; macrophages; NLRP3 inflammasome	NALP3 INFLAMMASOME; VASCULAR-PERMEABILITY; CHOLESTEROL EFFLUX; DEFICIENT MICE; P2X7 RECEPTOR; MOUSE MODEL; K+ EFFLUX; A-I; MECHANISMS; RESPONSES	Background: House dust mite (HDM)-challenged Apoe(-/-) mice display enhanced airway hyperreactivity and mucous cell metaplasia. Objective: We sought to characterize the pathways that induce apolipoprotein E (APOE) expression by bronchoalveolar lavage fluid (BALF) macrophages from asthmatic subjects and identify how APOE regulates IL-1 beta secretion. Methods: Macrophages were isolated from asthmatic BALF and derived from THP-1 cells and human monocytes. Results: HDM-derived cysteine and serine proteases induced APOE secretion from BALF macrophages through protease-activated receptor 2. APOE at concentrations of less than 2.5 nmol/L, which are similar to levels found in epithelial lining fluid from healthy adults, did not induce IL-1 beta release from BALF macrophages. In contrast, APOE at concentrations of 25 nmol/L or greater induced nucleotide-binding oligomerization domain, leucine-rich repeat-containing protein (NLRP) 3 and pro-IL-1 beta expression by BALF macrophages, as well as the caspase-1-mediated generation of mature IL-1 beta secreted from cells. HDM acted synergistically with APOE to both prime and activate the NLRP3 inflammasome. In a murine model of neutrophilic airway inflammation induced by HDM and polyinosinic-polycytidylic acid, APOE reached a concentration of 32 nmol/L in epithelial lining fluid, with associated increases in BALF IL-1 beta levels. APOE-dependent NLRP3 inflammasome activation in macrophages was primarily mediated through a potassium efflux-dependent mechanism. Conclusion: APOE can function as an endogenous, concentration-dependent pulmonary danger signal that primes and activates the NLPR3 inflammasome in BALF macrophages from asthmatic subjects to secrete IL-1 beta. This might represent a mechanism through which APOE amplifies pulmonary inflammatory responses when concentrations in the lung are increased to greater than normal levels, which can occur during viral exacerbations of HDM-induced asthma characterized by neutrophilic airway inflammation.	[Gordon, Elizabeth M.; Yao, Xianglan; Xu, Haitao; Karkowsky, William; Kaler, Maryann; Kalchiem-Dekel, Or; Barochia, Amisha V.; Gao, Meixia; Levine, Stewart J.] NHLBI, Lab Asthma & Lung Inflammat, Pulm Branch, NIH, Bldg 10,Room 6D03,MSC 1590, Bethesda, MD 20892 USA; [Keeran, Karen J.; Jeffries, Kenneth R.] NHLBI, Anim Surg & Resources Core Facil, Div Intramural Res, NIH, Bldg 10, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Levine, SJ (corresponding author), NHLBI, Lab Asthma & Lung Inflammat, Pulm Branch, NIH, Bldg 10,Room 6D03,MSC 1590, Bethesda, MD 20892 USA.	levines@nhlbi.nih.gov			Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL006197] Funding Source: NIH RePORTER	Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This research was funded by the Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.	Afonina IS, 2015, IMMUNITY, V42, P991, DOI 10.1016/j.immuni.2015.06.003; [Anonymous], [No title captured]; Arunachalam G, 2010, J INFLAMM-LOND, V7, DOI 10.1186/1476-9255-7-34; Baines KJ, 2011, J ALLERGY CLIN IMMUN, V127, P153, DOI 10.1016/j.jaci.2010.10.024; Baitsch D, 2011, ARTERIOSCL THROM VAS, V31, P1160, DOI 10.1161/ATVBAHA.111.222745; Barochia AV, 2015, AM J RESP CRIT CARE, V191, P990, DOI 10.1164/rccm.201411-1990OC; Boucher D, 2018, J EXP MED, V215, P827, DOI 10.1084/jem.20172222; Broz P, 2016, NAT REV IMMUNOL, V16, P407, DOI 10.1038/nri.2016.58; Calderon MA, 2015, J ALLERGY CLIN IMMUN, V136, P38, DOI 10.1016/j.jaci.2014.10.012; Chuang K, 2010, AM J SURG, V200, P391, DOI 10.1016/j.amjsurg.2009.10.017; Coll RC, 2015, NAT MED, V21, P248, DOI 10.1038/nm.3806; Crouchet E, 2017, GUT, V66, P896, DOI 10.1136/gutjnl-2015-311289; Dai X, 2011, J ALLERGY CLIN IMMUN, V127; De Alba J, 2015, CLIN SCI, V129, P973, DOI 10.1042/CS20150292; de Boer JD, 2014, INNATE IMMUN-LONDON, V20, P618, DOI 10.1177/1753425913503387; de Bont N, 1999, J LIPID RES, V40, P680; Di Virgilio F, 2017, IMMUNITY, V47, P15, DOI 10.1016/j.immuni.2017.06.020; Duewell P, 2010, NATURE, V464, P1357, DOI 10.1038/nature08938; GOLDIE RG, 1995, CLIN EXP PHARMACOL P, V22, P387, DOI 10.1111/j.1440-1681.1995.tb02028.x; Goldstein JL, 2009, ARTERIOSCL THROM VAS, V29, P431, DOI 10.1161/ATVBAHA.108.179564; Gregory LG, 2011, TRENDS IMMUNOL, V32, P402, DOI 10.1016/j.it.2011.06.006; Gross CJ, 2016, IMMUNITY, V45, P761, DOI 10.1016/j.immuni.2016.08.010; Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636; Hansbro PM, 2017, IMMUNOL REV, V278, P41, DOI 10.1111/imr.12543; Hansmann G, 2008, J CLIN INVEST, V118, P1846, DOI 10.1172/JCI32503; Hastie AT, 2010, J ALLERGY CLIN IMMUN, V125, P1028, DOI 10.1016/j.jaci.2010.02.008; He Y, 2016, TRENDS BIOCHEM SCI, V41, P1012, DOI 10.1016/j.tibs.2016.09.002; He Y, 2016, NATURE, V530, P354, DOI 10.1038/nature16959; Hornung V, 2008, NAT IMMUNOL, V9, P847, DOI 10.1038/ni.1631; Jacobsen NR, 2009, PART FIBRE TOXICOL, V6, DOI 10.1186/1743-8977-6-2; Kanazawa H, 2002, CHEST, V122, P166, DOI 10.1378/chest.122.1.166; Kanazawa H, 2002, THORAX, V57, P885, DOI 10.1136/thorax.57.10.885; Kattan OM, 2008, J IMMUNOL, V181, P1399, DOI 10.4049/jimmunol.181.2.1399; Kim RY, 2017, AM J RESP CRIT CARE, V196, P283, DOI 10.1164/rccm.201609-1830OC; Kim RY, 2015, THORAX, V70, P1199, DOI 10.1136/thoraxjnl-2014-206736; Kim SR, 2012, ALLERGY, V67, P869, DOI 10.1111/j.1398-9995.2012.02837.x; Levy O, 2015, EMBO MOL MED, V7, P211, DOI 10.15252/emmm.201404524; Li K, 2015, CIRC RES, V117, pe1, DOI 10.1161/CIRCRESAHA.117.305844; LIN CT, 1986, J CLIN INVEST, V78, P947, DOI 10.1172/JCI112685; Lin CY, 1999, J LIPID RES, V40, P1618; Mahley RW, 2009, J LIPID RES, V50, pS183, DOI 10.1194/jlr.R800069-JLR200; Mahmutovic PerssonI., 2018, RESP RES, V19, P16, DOI [10.1186/s12931-018-0725-z, DOI 10.1186/s12931-018-0725-z, DOI 10.1186/S12931-018-0725-Z]; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; MARUO K, 1991, BIOCHIM BIOPHYS ACTA, V1074, P62, DOI 10.1016/0304-4165(91)90040-N; Massaro D, 2008, AM J PHYSIOL-LUNG C, V294, pL991, DOI 10.1152/ajplung.00013.2008; Massaro D, 2011, PEDIATR RES, V70, P458, DOI 10.1203/PDR.0b013e31822f24df; Masters SL, 2010, NAT IMMUNOL, V11, P897, DOI 10.1038/ni.1935; MAZZONE T, 1994, J LIPID RES, V35, P1345; Mendivil CO, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123344; Munoz-Planillo R, 2013, IMMUNITY, V38, P1142, DOI 10.1016/j.immuni.2013.05.016; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Nomura J, 2015, J IMMUNOL, V195, P5718, DOI 10.4049/jimmunol.1402512; OHRUI T, 1992, J ALLERGY CLIN IMMUN, V89, P933, DOI 10.1016/0091-6749(92)90215-N; Orlowski GM, 2015, J IMMUNOL, V195, P1685, DOI 10.4049/jimmunol.1500509; Park EK, 2007, INFLAMM RES, V56, P45, DOI 10.1007/s00011-007-6115-5; Petrilli V, 2007, CELL DEATH DIFFER, V14, P1583, DOI 10.1038/sj.cdd.4402195; Pinkerton JW, 2017, MOL IMMUNOL, V86, P44, DOI 10.1016/j.molimm.2017.01.014; Randall TA, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061204; RENNARD SI, 1986, J APPL PHYSIOL, V60, P532, DOI 10.1152/jappl.1986.60.2.532; Robinson LE, 2014, J BIOL CHEM, V289, P31983, DOI 10.1074/jbc.M114.574699; Roselaar SE, 1998, J LIPID RES, V39, P1740; Rossios C, 2018, J ALLERGY CLIN IMMUN, V141, P560, DOI 10.1016/j.jaci.2017.02.045; Ryan AJ, 2002, AM J PHYSIOL-LUNG C, V283, pL310, DOI 10.1152/ajplung.00021.2002; Sharma D, 2016, J CELL BIOL, V213, P617, DOI 10.1083/jcb.201602089; Simpson JL, 2014, EUR RESPIR J, V43, P1067, DOI 10.1183/09031936.00105013; Smoak KA, 2010, CELL METAB, V11, P493, DOI 10.1016/j.cmet.2010.04.006; Starkhammar M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032110; STEWART GA, 1994, AM J IND MED, V25, P105, DOI 10.1002/ajim.4700250128; Stowell NC, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-43; Sundaram K, 2015, AM J RESP CELL MOL, V53, P400, DOI 10.1165/rcmb.2014-0370OC; Tall AR, 2015, NAT REV IMMUNOL, V15, P104, DOI 10.1038/nri3793; Tall AR, 2002, J CLIN INVEST, V110, P899, DOI 10.1172/JCI200216391; Van Oosten MV, 2001, J BIOL CHEM, V276, P8820, DOI 10.1074/jbc.M009915200; Venosa A, 2016, AM J RESP CELL MOL, V54, P436, DOI 10.1165/rcmb.2015-0120OC; Vigano E, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9761; Yamashita CM, 2014, RESPIRATION, V87, P416, DOI 10.1159/000358438; Yao XL, 2016, AM J RESP CELL MOL, V55, P159, DOI 10.1165/rcmb.2016-0060TR; Yao XL, 2010, AM J RESP CRIT CARE, V182, P1228, DOI 10.1164/rccm.201002-0308OC; Yaron JR, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.277; Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663; Zhu YJ, 2010, BIOCHEM J, V428, P47, DOI 10.1042/BJ20100016	81	37	39	4	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2019	144	2					426	+		10.1016/j.jaci.2019.02.027	http://dx.doi.org/10.1016/j.jaci.2019.02.027			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IN6LC	30872118	Bronze, Green Accepted			2022-12-18	WOS:000478789300012
J	Yang, TLB; Kim, BS				Yang, Ting-Lin B.; Kim, Brian S.			Pruritus in allergy and immunology	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Allergic contact dermatitis; atopic dermatitis; cytokine; eczema; histamine; itch; Janus kinase; mast cell; Mas-related G protein-coupled receptor; neuroimmunology; prurigo nodularis; pruritus	SEVERE ATOPIC-DERMATITIS; JANUS KINASE INHIBITOR; MAST-CELLS; RECEPTOR ANTAGONISTS; CONTACT-DERMATITIS; ADULT PATIENTS; ITCH; NODULARIS; OMALIZUMAB; URTICARIA	Although evolutionarily conserved to expel ectoparasites and aid in the clearance of toxins and noxious environmental stimuli from the host, the type 2 immune response can become pathologic in the setting of a variety of allergic disorders. Itch can be a behavioral extension of type 2 immunity by evoking scratching and, in the setting of disease, can become chronic and thus highly pathologic as well. Classically, our understanding of itch mechanisms has centered around the canonical IgE-mast cell-histamine axis. However, therapies aimed at blocking the histaminergic itch pathway have been largely ineffective, suggesting the existence of nonhistaminergic itch pathways. Indeed, recent advances in itch biology have provided critical new insight into a variety of novel therapeutic avenues for chronic itch in the setting of a number of allergic disorders. Here we highlight how these new developments will likely inform the problem of pruritus in a variety of well-established and emerging conditions in the field of allergy.	[Yang, Ting-Lin B.; Kim, Brian S.] Washington Univ, Sch Med, Ctr Study Itch, St Louis, MO USA; [Yang, Ting-Lin B.; Kim, Brian S.] Washington Univ, Sch Med, Dept Med, Div Dermatol, St Louis, MO 63110 USA; [Kim, Brian S.] Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA; [Kim, Brian S.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Kim, BS (corresponding author), 660 South Euclid Ave,Campus Box 8123, St Louis, MO 63110 USA.	briankim@wustl.edu	Kim, Brian/GZK-6649-2022	Kim, Brian/0000-0002-8100-7161	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) at the National Institutes of Health (NIH) [K08AR065577, R01AR070116]; American Skin Association (ASA); Doris Duke Charitable Foundation (DDCF) Clinical Scientist Development Award; LEO Pharma; Celgene; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR065577, R01AR070116] Funding Source: NIH RePORTER	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) at the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); American Skin Association (ASA); Doris Duke Charitable Foundation (DDCF) Clinical Scientist Development Award(Doris Duke Charitable Foundation (DDCF)); LEO Pharma(LEO Pharma); Celgene(Bristol-Myers SquibbCelgene Corporation); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Work in the Kim laboratory is supported by K08AR065577 and R01AR070116 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) at the National Institutes of Health (NIH), the American Skin Association (ASA), the Doris Duke Charitable Foundation (DDCF) Clinical Scientist Development Award, Celgene, and LEO Pharma.	ASKENASE PW, 1983, IMMUNOL TODAY, V4, P259, DOI 10.1016/0167-5699(83)90046-4; Bao Lei, 2013, JAKSTAT, V2, pe24137, DOI 10.4161/jkst.24137; Beck KM, 2019, JAMA DERMATOL, V155, P118, DOI 10.1001/jamadermatol.2018.3912; Beck L, 2018, ANN ALLERG ASTHMA IM, V121, pS21, DOI 10.1016/j.anai.2018.09.063; Beck LA, 2004, J ALLERGY CLIN IMMUN, V114, P527, DOI 10.1016/j.jaci.2004.06.032; Berger TG, 2011, SEMIN CUTAN MED SURG, V30, P113, DOI 10.1016/j.sder.2011.04.002; Bissonnette R, 2016, BRIT J DERMATOL, V175, P902, DOI 10.1111/bjd.14871; Cevikbas F, 2014, J ALLERGY CLIN IMMUN, V133, P448, DOI 10.1016/j.jaci.2013.10.048; Chang TW, 2006, J ALLERGY CLIN IMMUN, V117, P1203, DOI 10.1016/j.jaci.2006.04.005; de Silva NL, 2014, ALLERGY ASTHMA CL IM, V10, DOI 10.1186/1710-1492-10-24; Dudeck A, 2011, IMMUNITY, V34, P973, DOI 10.1016/j.immuni.2011.03.028; Eckman JA, 2008, J INVEST DERMATOL, V128, P1956, DOI 10.1038/jid.2008.55; Gaudenzio N, 2016, J CLIN INVEST, V126, P3981, DOI 10.1172/JCI85538; Gericke J, 2017, J ALLERGY CLIN IMMUN, V139, P1059, DOI 10.1016/j.jaci.2016.07.047; Gimenez-Rivera VA, 2016, J IMMUNOL, V197, P4240, DOI 10.4049/jimmunol.1600236; Grimbaldeston MA, 2007, NAT IMMUNOL, V8, P1095, DOI 10.1038/ni1503; Guttman-Yassky E, 2019, J ALLERGY CLIN IMMUN, V143, P155, DOI 10.1016/j.jaci.2018.08.022; Guttman-Yassky E, 2019, J AM ACAD DERMATOL, V80, P913, DOI 10.1016/j.jaad.2018.01.018; Haas S, 2010, J DERMATOL SCI, V58, P193, DOI 10.1016/j.jdermsci.2010.03.020; Iking A, 2013, J EUR ACAD DERMATOL, V27, P550, DOI 10.1111/j.1468-3083.2012.04481.x; Jenerowicz D, 2007, ACTA DERMATOVEN ALP, V16, P47; Kamo A, 2014, J INVEST DERMATOL, V134, P546, DOI 10.1038/jid.2013.351; Kaplan AP, 2017, ALLERGY ASTHMA IMMUN, V9, P477, DOI 10.4168/aair.2017.9.6.477; Kim BS, 2015, J INVEST DERMATOL, V135, P673, DOI 10.1038/jid.2014.401; Kimber I, 2002, INT IMMUNOPHARMACOL, V2, P201, DOI 10.1016/S1567-5769(01)00173-4; Kollmeier A, 2014, J PHARMACOL EXP THER, V350, P181, DOI 10.1124/jpet.114.215749; Kostner L, 2017, IMMUNOL ALLERGY CLIN, V37, P141, DOI 10.1016/j.iac.2016.08.014; Leonard A, 2019, CLIN REV ALLERG IMMU, V56, P1, DOI 10.1007/s12016-018-8685-0; Levy LL, 2015, J AM ACAD DERMATOL, V73, P395, DOI 10.1016/j.jaad.2015.06.045; Liang Y, 2000, J CUTAN PATHOL, V27, P359, DOI 10.1034/j.1600-0560.2000.027007359.x; Liu BY, 2016, P NATL ACAD SCI USA, V113, pE7572, DOI 10.1073/pnas.1606608113; Liu FT, 2011, CLIN REV ALLERG IMMU, V41, P298, DOI 10.1007/s12016-011-8252-4; Liu Q, 2009, CELL, V139, P1353, DOI 10.1016/j.cell.2009.11.034; Liu XY, 2014, MOL PAIN, V10, DOI 10.1186/1744-8069-10-4; Lotti T, 2008, DERMATOL THER, V21, P42, DOI 10.1111/j.1529-8019.2008.00168.x; Mack MR, 2018, TRENDS IMMUNOL, V39, P980, DOI 10.1016/j.it.2018.10.001; Matterne U, 2011, ACTA DERM-VENEREOL, V91, P674, DOI 10.2340/00015555-1159; Matthews SN, 1998, INT J DERMATOL, V37, P401, DOI 10.1046/j.1365-4362.1998.00507.x; Maurer M, 2013, NEW ENGL J MED, V368, P924, DOI 10.1056/NEJMoa1215372; McNeil B., TREATMENT XD IM 2014; McNeil BD, 2015, NATURE, V519, P237, DOI 10.1038/nature14022; Meixiong J, 2019, IMMUNITY, V50, P1163, DOI 10.1016/j.immuni.2019.03.013; Mishra SK, 2013, SCIENCE, V340, P968, DOI 10.1126/science.1233765; Mowad C, 2012, DERMATOLOGY; Nakagawa H, 2018, BRIT J DERMATOL, V178, P424, DOI 10.1111/bjd.16014; Oetjen LK, 2018, FEBS J, V285, P3138, DOI 10.1111/febs.14465; Oetjen LK, 2017, CELL, V171, P217, DOI 10.1016/j.cell.2017.08.006; Owens S, 2019, J ALLERGY CLIN IMMUN, V143, pAB128, DOI 10.1016/j.jaci.2018.12.387; Parnes JR, 2019, CLIN PHARM THER; Ruzicka T, 2017, NEW ENGL J MED, V376, P826, DOI 10.1056/NEJMoa1606490; Saini SS, 2015, J INVEST DERMATOL, V135, P67, DOI 10.1038/jid.2014.306; Schneider EH, 2016, NEUROPHARMACOLOGY, V106, P116, DOI 10.1016/j.neuropharm.2015.05.004; Simpson EL, 2018, J AM ACAD DERMATOL, V78, P863, DOI 10.1016/j.jaad.2018.01.017; Solinski HJ, 2019, CELL REP, V26, P3561, DOI 10.1016/j.celrep.2019.02.089; Sonkoly E, 2006, J ALLERGY CLIN IMMUN, V117, P411, DOI 10.1016/j.jaci.2005.10.033; Stander S, 2010, DERMATOLOGY, V221, P229, DOI 10.1159/000319862; Stander S, 2019, J AM ACAD DERMATOL, V80, P1395, DOI 10.1016/j.jaad.2019.01.052; Sun YG, 2007, NATURE, V448, P700, DOI 10.1038/nature06029; Thurmond RL, 2015, ANTIHISTAMINES ITCH, P257; Trier AM, 2018, CURR OPIN IMMUNOL, V54, P7, DOI 10.1016/j.coi.2018.05.005; Usatine RP, 2010, AM FAM PHYSICIAN, V82, P249; Weigelt N, 2010, J CUTAN PATHOL, V37, P578, DOI 10.1111/j.1600-0560.2009.01484.x; Werfel T, 2016, J ALLERGY CLIN IMMUN, V138, P336, DOI 10.1016/j.jaci.2016.06.010; Wilson SR, 2013, CELL, V155, P285, DOI 10.1016/j.cell.2013.08.057; Wollenberg A, 2016, J EUR ACAD DERMATOL, V30, P729, DOI 10.1111/jdv.13599; Wollenberg A, 2019, J ALLERGY CLIN IMMUN, V143, P135, DOI 10.1016/j.jaci.2018.05.029; Xu AZ, 2016, J AM ACAD DERMATOL, V74, P1017, DOI 10.1016/j.jaad.2015.11.029; Yosipovitch G, 2018, J AM ACAD DERMATOL, V78, P882, DOI 10.1016/j.jaad.2018.02.030; Zeidler C, 2018, DERMATOL CLIN, V36, P189, DOI 10.1016/j.det.2018.02.003	70	37	43	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2019	144	2					353	360		10.1016/j.jaci.2019.06.016	http://dx.doi.org/10.1016/j.jaci.2019.06.016			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IN6LC	31395149	Green Accepted, Bronze			2022-12-18	WOS:000478789300001
J	Carter, MC; Metcalfe, DD; Matito, A; Escribano, L; Butterfield, JH; Schwartz, LB; Bonadonna, P; Zanotti, R; Triggiani, M; Castells, M; Brockow, K				Carter, Melody C.; Metcalfe, Dean D.; Matito, Almudena; Escribano, Luis; Butterfield, Joseph H.; Schwartz, Lawrence B.; Bonadonna, Patrizia; Zanotti, Roberta; Triggiani, Massimo; Castells, Mariana; Brockow, Knut			Adverse reactions to drugs and biologics in patients with clonal mast cell disorders: A Work Group Report of the Mast Cells Disorder Committee, American Academy of Allergy, Asthma & Immunology	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mastocytosis; tryptase; Hymenoptera; anesthesia; nonsteroidal anti-inflammatory drugs; monoclonal antibodies; radiocontrast media; vaccines	ASPIRIN-SENSITIVE RHINOSINUSITIS; HYMENOPTERA VENOM ALLERGY; SYSTEMIC MASTOCYTOSIS; HISTAMINE-RELEASE; BONE-MARROW; INFLUENZA VACCINE; SERUM TRYPTASE; HYPERSENSITIVITY REACTIONS; PEDIATRIC MASTOCYTOSIS; GENERAL-ANESTHESIA	Providers caring for patients with mastocytosis are tasked with the decision to consider therapeutic options. This can come with some trepidation because information available in the public domain lists numerous mast cell (MC) activators based on data that do not discriminate between primates, rodents, and MC lines; do not consider dosage; and do not take into account previous exposure and resultant clinical findings. This being said, there is support in the literature for an enhanced MC response in some patients with mastocytosis and in cases in which there is a greater incidence of adverse reactions associated with certain antigens, such as venoms and drugs. Thus this report provides a comprehensive guide for those providers who must decide on therapeutic options in the management of patients with clonal MC disease.	[Carter, Melody C.; Metcalfe, Dean D.] NIAID, Lab Allerg Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Matito, Almudena] Hosp Virgen del Valle, Inst Estudios Mastocitosis Castilla La Mancha CLM, Toledo, Spain; [Escribano, Luis] USAL CSIC, Serv Gen Citometria, Ctr Invest Canc IBMCC, Salamanca, Spain; [Escribano, Luis] Univ Salamanca, Dept Med, Salamanca, Spain; [Escribano, Luis] IBSAL, Salamanca, Spain; [Matito, Almudena; Escribano, Luis] Spanish Network Mastocytois REMA, Toledo, Spain; [Butterfield, Joseph H.] Mayo Clin, Div Allerg Dis, Rochester, MN USA; [Butterfield, Joseph H.] Mayo Clin, Program Mast Cell & Eosinophil Disorders, Rochester, MN USA; [Schwartz, Lawrence B.] Virginia Commonwealth Univ, Dept Internal Med, Richmond, VA 23284 USA; [Bonadonna, Patrizia] Azienda Osped Univ Integrata Verona, Allergy Unit, Verona, Italy; [Bonadonna, Patrizia; Zanotti, Roberta] Azienda Osped Univ Integrata Verona, Multidisplinary Outpatients Clin Mastocytosis GIS, Verona, Italy; [Zanotti, Roberta] Azienda Osped Univ Integrata Verona, Dept Med, Haematol Unit, Verona, Italy; [Triggiani, Massimo] Univ Salerno, Div Allergy & Clin Immunol, Fisciano, Italy; [Castells, Mariana] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA; [Brockow, Knut] Tech Univ Munich, Dept Dermatol & Allergy Biederstein, Munich, Germany	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Complejo Hospitalario de Toledo; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Mayo Clinic; Mayo Clinic; Virginia Commonwealth University; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Salerno; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Technical University of Munich	Carter, MC (corresponding author), Bldg 10-11C207,10 Ctr Dr,MSC 1881, Bethesda, MD 20892 USA.	mcarter@niaid.nih.gov	Triggiani, Massimo/K-8271-2016	Triggiani, Massimo/0000-0001-7318-2093; Matito, Almudena/0000-0002-9547-4844	Division of Intramural Research of the National Institute of Allergy and Infectious Diseases/National Institutes of Health; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000249] Funding Source: NIH RePORTER	Division of Intramural Research of the National Institute of Allergy and Infectious Diseases/National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the Division of Intramural Research of the National Institute of Allergy and Infectious Diseases/National Institutes of Health.	Ahmad N, 2009, PEDIATR ANESTH, V19, P97, DOI 10.1111/j.1460-9592.2008.02904.x; Akin C, 2007, BLOOD, V110, P2331, DOI 10.1182/blood-2006-06-028100; Alvarez-Twose I, 2012, ALLERGY, V67, P813, DOI 10.1111/j.1398-9995.2012.02812.x; Alvarez-Twose I, 2014, J ALLERGY CLIN IMMUN, V133, P520, DOI 10.1016/j.jaci.2013.06.020; Alvarez-Twose I, 2010, J ALLERGY CLIN IMMUN, V125, P1269, DOI 10.1016/j.jaci.2010.02.019; Aun MV, 2014, J ALLER CL IMM-PRACT, V2, P414, DOI [10.1016/j.jaip.2014.03.014, 10.1016/j.jaip.2014.08.015]; Auvray L, 2001, ANN FR ANESTH, V20, P635; Baldo BA, 2012, ANAESTH INTENS CARE, V40, P216, DOI 10.1177/0310057X1204000204; BANDMANN HJ, 1983, HAUTARZT, V34, P217; Bankova LG, 2013, J ALLER CL IMM-PRACT, V1, P94, DOI 10.1016/j.jaip.2012.08.008; Bhole MV, 2012, BRIT J ANAESTH, V108, P903, DOI 10.1093/bja/aes162; Blunk JA, 2004, ANESTH ANALG, V98, P364, DOI 10.1213/01.ANE.0000097168.32472.0D; Bochenek G, 2003, J ALLERGY CLIN IMMUN, V111, P743, DOI 10.1067/mai.2003.1387; Bonadonna P, 2015, ALLERGY, V70, P755, DOI 10.1111/all.12617; Bonadonna P, 2014, J INVEST ALLERG CLIN, V24, P288; Bonadonna P, 2008, J ALLERGY CLIN IMMUN, V121, P256, DOI 10.1016/j.jaci.2007.10.014; Bonadonna P, 2013, J ALLER CL IMM-PRACT, V1, P474, DOI 10.1016/j.jaip.2013.06.014; Bonadonna P, 2009, J ALLERGY CLIN IMMUN, V123, P680, DOI 10.1016/j.jaci.2008.11.018; Bonifazi F, 2005, ALLERGY, V60, P1459, DOI 10.1111/j.1398-9995.2005.00960.x; Borgeat A, 1998, ANESTH ANALG, V86, P442, DOI 10.1097/00000539-199802000-00044; BOSSO JV, 1991, J ALLERGY CLIN IMMUN, V88, P830, DOI 10.1016/0091-6749(91)90238-J; Brennan PJ, 2009, J ALLERGY CLIN IMMUN, V124, P1259, DOI 10.1016/j.jaci.2009.09.009; Bridgman DE, 2013, ANAESTH INTENS CARE, V41, P116, DOI 10.1177/0310057X1304100120; Brockow K, 2008, ALLERGY, V63, P226, DOI 10.1111/j.1398-9995.2007.01569.x; Brockow K, 2005, ALLERGY, V60, P150, DOI 10.1111/j.1398-9995.2005.00745.x; Brockow K, 2013, ALLERGY, V68, P702, DOI 10.1111/all.12142; Brockow K, 2003, J AM ACAD DERMATOL, V48, P508, DOI 10.1067/mjd.2003.98; Brockow K, 2009, ALLERGY, V64, P234, DOI 10.1111/j.1398-9995.2008.01832.x; Brockow K, 2014, IMMUNOL ALLERGY CLIN, V34, P283, DOI 10.1016/j.iac.2014.01.003; Brockow K, 2012, ALLERGY, V67, P1323, DOI 10.1111/all.12013; Brockow K, 2012, CURR OPIN ALLERGY CL, V12, P354, DOI 10.1097/ACI.0b013e328355b7cb; Brodier C, 1993, Cah Anesthesiol, V41, P77; Broesby-Olsen S, 2018, ALLERGY, V73, P230, DOI 10.1111/all.13237; Broesby-Olsen S, 2016, AM J HEMATOL, V91, P1069, DOI 10.1002/ajh.24490; Brown SGA, 2012, J ALLERGY CLIN IMMUN, V130, P162, DOI 10.1016/j.jaci.2012.02.022; BUTTERFIELD JH, 1995, MAYO CLIN PROC, V70, P481, DOI 10.4065/70.5.481; Butterfield JH, 2008, INT ARCH ALLERGY IMM, V147, P338, DOI 10.1159/000144042; Butterfield JH, 2009, PROSTAG OTH LIPID M, V88, P122, DOI 10.1016/j.prostaglandins.2009.01.001; Caimmi S, 2010, CLIN EXP ALLERGY, V40, P805, DOI 10.1111/j.1365-2222.2010.03493.x; Carter MC, 2008, ANESTH ANALG, V107, P422, DOI 10.1213/ane.0b013e31817e6d7c; Carter MC, 2007, J ALLERGY CLIN IMMUN, V119, P1550, DOI 10.1016/j.jaci.2007.03.032; Casale TB, 2006, J ALLERGY CLIN IMMUN, V117, P134, DOI 10.1016/j.jaci.2005.09.036; Castells MC, 2015, J ALLER CL IMM-PRACT, V3, P350, DOI 10.1016/j.jaip.2015.03.015; Chung EY, 2010, PEDIATRICS, V125, pE1024, DOI 10.1542/peds.2009-2512; COLEMAN MA, 1980, ANESTH ANALG, V59, P704; CRAWHALL JC, 1987, CLIN INVEST MED, V10, P1; de Durana MDAD, 2003, ALLERGY, V58, P159, DOI 10.1034/j.1398-9995.2003.00056_2.x; de Olano DG, 2007, CLIN EXP ALLERGY, V37, P1547, DOI 10.1111/j.1365-2222.2007.02804.x; De Olano DG, 2008, J ALLERGY CLIN IMMUN, V121, P519, DOI 10.1016/j.jaci.2007.11.010; DESBOROUGH JP, 1990, BRIT J ANAESTH, V65, P833, DOI 10.1093/bja/65.6.833; Dewachter P, 2009, ANN FR ANESTH, V28, P61, DOI 10.1016/j.annfar.2008.09.022; Dewachter P, 2014, ANESTHESIOLOGY, V120, P753, DOI 10.1097/ALN.0000000000000031; Divekar R, 2015, ALLERGY, V70, P1230, DOI 10.1111/all.12668; DOBKIN ALLEN B., 1966, CAN ANAESTH SOC J, V13, P130, DOI 10.1007/BF03003441; Doenicke A, 1997, ANESTH ANALG, V84, P623, DOI 10.1097/00000539-199703000-00030; Dong SW, 2012, MINERVA ANESTESIOL, V78, P868; Douglass JA, 2010, ALLERGY, V65, P926, DOI 10.1111/j.1398-9995.2009.02259.x; Dysart BR, 1933, JAMA, V101; Elberink JNGO, 1997, J ALLERGY CLIN IMMUN, V99, P153, DOI 10.1016/S0091-6749(97)70314-2; Escribano L, 2002, ANN HEMATOL, V81, P677, DOI 10.1007/s00277-002-0575-z; Escribano L, 1999, LEUKEMIA LYMPHOMA, V35, P227, DOI 10.3109/10428199909145725; Gagnon R, 2010, J ALLERGY CLIN IMMUN, V126, P317, DOI 10.1016/j.jaci.2010.05.037; Greenblatt E P, 1990, J Clin Anesth, V2, P108, DOI 10.1016/0952-8180(90)90063-9; Greenhawt MJ, 2012, ANN ALLERG ASTHMA IM, V109, P426, DOI 10.1016/j.anai.2012.09.011; GUIN JD, 1982, MED CLIN N AM, V66, P831, DOI 10.1016/S0025-7125(16)31397-9; Gulen T, 2014, CLIN EXP ALLERGY, V44, P1179, DOI 10.1111/cea.12369; Gulen T, 2014, CLIN EXP ALLERGY, V44, P121, DOI 10.1111/cea.12225; HOSKING MP, 1987, ANESTH ANALG, V66, P344; Howe LE, 2011, ANN ALLERG ASTHMA IM, V106, P446, DOI 10.1016/j.anai.2011.01.024; James JM, 1998, J PEDIATR-US, V133, P624, DOI 10.1016/S0022-3476(98)70101-5; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Kattan JD, 2011, J ALLERGY CLIN IMMUN, V128, P215, DOI 10.1016/j.jaci.2011.04.046; KELSO JM, 1993, J ALLERGY CLIN IMMUN, V91, P867, DOI 10.1016/0091-6749(93)90344-F; Kelso JM, 2012, J ALLERGY CLIN IMMUN, V130, P25, DOI 10.1016/j.jaci.2012.04.003; Klein NJ, 2013, J ANESTH, V27, P588, DOI 10.1007/s00540-013-1563-2; Koh MJA, 2008, PEDIATR DERMATOL, V25, P381, DOI 10.1111/j.1525-1470.2008.00710.x; Kontou-Fili K, 2008, ALLERGY, V63, P376, DOI 10.1111/j.1398-9995.2007.01604.x; Kontou-Fili K, 2009, ALLERGY, V64, P1384, DOI 10.1111/j.1398-9995.2009.02045.x; KOOTTE AMM, 1983, NETH J MED, V26, P18; Koppert W, 2001, ANESTHESIOLOGY, V95, P659, DOI 10.1097/00000542-200109000-00019; KORS JW, 1993, J INTERN MED, V233, P255, DOI 10.1111/j.1365-2796.1993.tb00984.x; Kowalski ML, 2011, ALLERGY, V66, P818, DOI 10.1111/j.1398-9995.2011.02557.x; KWITTKEN PL, 1993, AM J DIS CHILD, V147, P128, DOI 10.1001/archpedi.1993.02160260018005; Lahat A, 2008, CLIN EXP IMMUNOL, V152, P320, DOI 10.1111/j.1365-2249.2008.03636.x; Lamson TW, 1932, JAMA, V99; LORCERIE B, 1989, LANCET, V2, P1155; Ludolph-Hauser D, 2001, LANCET, V357, P361, DOI 10.1016/S0140-6736(00)03647-3; LUMRY WR, 1983, J ALLERGY CLIN IMMUN, V71, P580, DOI 10.1016/0091-6749(83)90440-2; Luo CF, 2015, MOL MED REP, V12, P1082, DOI 10.3892/mmr.2015.3527; Malinovsky JM, 2016, PRESSE MED, V45, P753, DOI 10.1016/j.lpm.2016.05.011; MARONE G, 1992, MONOGR ALLERGY, V30, P54; Marone G, 2001, LEUKEMIA RES, V25, P583, DOI 10.1016/S0145-2126(01)00039-X; MARONE G, 1993, ANN FR ANESTH, V12, P116, DOI 10.1016/S0750-7658(05)81020-2; Matito A, 2015, INT ARCH ALLERGY IMM, V167, P47, DOI 10.1159/000436969; Matsuo H, 2005, CLIN EXP ALLERGY, V35, P461, DOI 10.1111/j.1365-2222.2005.02213.x; Mertes PM, 2011, J ALLERGY CLIN IMMUN, V128, P366, DOI 10.1016/j.jaci.2011.03.003; Michel J, 2016, ALLERGY, V71, P651, DOI 10.1111/all.12850; Morita E, 2007, J DERMATOL SCI, V47, P109, DOI 10.1016/j.jdermsci.2007.03.004; Morrow JD, 1999, J INVEST DERMATOL, V113, P93, DOI 10.1046/j.1523-1747.1999.00624.x; MULLER U, 1990, ALLERGY, V45, P597, DOI 10.1111/j.1398-9995.1990.tb00945.x; Nagata H, 1997, INT ARCH ALLERGY IMM, V113, P184, DOI 10.1159/000237541; Nakayama T, 2000, J ALLERGY CLIN IMMUN, V106, P591, DOI 10.1067/mai.2000.108433; Parente R, 2017, PEDIAT ALLERG IMM-UK, V28, P93, DOI 10.1111/pai.12647; Pereira-Santos MC, 2008, CLIN EXP ALLERGY, V38, P291, DOI 10.1111/j.1365-2222.2007.02887.x; Pfeffer I, 2011, J DTSCH DERMATOL GES, V9, P230, DOI 10.1111/j.1610-0387.2010.07562.x; PLESKOW WW, 1983, J ALLERGY CLIN IMMUN, V71, P574, DOI 10.1016/0091-6749(83)90439-6; Poulton JK, 1999, CUTIS, V63, P37; Quintas-Cardama A, 2010, LEUKEMIA LYMPHOMA, V51, P540, DOI 10.3109/10428190903470869; Ravi A, 2014, J ALLER CL IMM-PRACT, V2, P775, DOI 10.1016/j.jaip.2014.06.011; Roberts L J 2nd, 1982, Trans Assoc Am Physicians, V95, P36; Roberts L J 2nd, 1982, Adv Shock Res, V8, P145; ROBERTS LJ, 1980, NEW ENGL J MED, V303, P1400, DOI 10.1056/NEJM198012113032405; ROSOW CE, 1984, ANESTHESIOLOGY, V60, P489, DOI 10.1097/00000542-198405000-00020; Roush SW, 2007, JAMA-J AM MED ASSOC, V298, P2155, DOI 10.1001/jama.298.18.2155; Rueff F, 2006, CURR OPIN ALLERGY CL, V6, P284, DOI 10.1097/01.all.0000235903.10548.63; Russell M, 2004, VACCINE, V23, P664, DOI 10.1016/j.vaccine.2004.06.042; Sakaguchi M, 1996, J ALLERGY CLIN IMMUN, V98, P1058, DOI 10.1016/S0091-6749(96)80191-6; Sakaguchi M, 1997, J ALLERGY CLIN IMMUN, V99, P263, DOI 10.1016/S0091-6749(97)70108-8; Sakaguchi M, 2001, ALLERGY, V56, P536, DOI 10.1034/j.1398-9995.2001.056006536.x; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; Sanchez-Matas I, 2009, ALLERGY, V64, P551, DOI DOI 10.1111/j.1398-9995.2009.02078.x; Schena D, 2016, BRIT J DERMATOL, V174, P411, DOI 10.1111/bjd.14004; SCOTT HW, 1983, ANN SURG, V197, P507, DOI 10.1097/00000658-198305000-00002; Seitz CS, 2014, ALLERGY ASTHMA CL IM, V10, DOI 10.1186/1710-1492-10-19; Siebenhaar F, 2014, IMMUNOL ALLERGY CLIN, V34, P433, DOI 10.1016/j.iac.2014.01.012; Simioni L, 2013, ANN ALLERG ASTHMA IM, V110, P51, DOI 10.1016/j.anai.2012.09.014; Simons FER, 2010, J ALLERGY CLIN IMMUN, V125, pS161, DOI 10.1016/j.jaci.2009.12.981; Slater JE, 2011, J ALLERGY CLIN IMMUN, V128, P434, DOI 10.1016/j.jaci.2011.06.028; SMITH GB, 1987, ANAESTHESIA, V42, P861, DOI 10.1111/j.1365-2044.1987.tb04112.x; Sokol KC, 2014, J ALLER CL IMM-PRACT, V2, P266, DOI 10.1016/j.jaip.2014.03.009; Solensky R, 2010, ANN ALLERG ASTHMA IM, V105, P259, DOI 10.1016/j.anai.2010.08.002; Sonneck K, 2007, INT ARCH ALLERGY IMM, V142, P158, DOI 10.1159/000096442; STELLATO C, 1991, ANESTHESIOLOGY, V74, P1078, DOI 10.1097/00000542-199106000-00016; STELLATO C, 1992, ANESTHESIOLOGY, V77, P932, DOI 10.1097/00000542-199211000-00016; STELLATO C, 1995, CHEM IMMUNOL, V62, P108; STELLATO C, 1991, BRIT J ANAESTH, V67, P751, DOI 10.1093/bja/67.6.751; Takazawa T, 2016, J ANESTH, V30, P290, DOI 10.1007/s00540-015-2105-x; Tirel O, 2001, ANN FR ANESTH, V20, P874, DOI 10.1016/S0750-7658(01)00536-6; Tramer MR, 2006, BRIT MED J, V333, P675, DOI 10.1136/bmj.38905.634132.AE; Valabhji J, 2000, J ROY SOC MED, V93, P141, DOI 10.1177/014107680009300309; Valent P, 2007, EUR J CLIN INVEST, V37, P435, DOI 10.1111/j.1365-2362.2007.01807.x; Valent P, 2017, BLOOD, V129, P1420, DOI 10.1182/blood-2016-09-731893; Valent P, 2012, INT ARCH ALLERGY IMM, V157, P215, DOI 10.1159/000328760; Vaughan STA, 1998, ANAESTHESIA, V53, P804, DOI 10.1046/j.1365-2044.1998.00536.x; Weingarten TN, 2009, ANAESTH INTENS CARE, V37, P646, DOI 10.1177/0310057X0903700415; Wong JT, 2000, J ALLERGY CLIN IMMUN, V105, P997, DOI 10.1067/mai.2000.104571; Yanagi H, 1996, ACTA ANAESTH SCAND, V40, P1138, DOI 10.1111/j.1399-6576.1996.tb05577.x; Zanoni G, 2017, CLIN EXP ALLERGY, V47, P593, DOI 10.1111/cea.12882; Zanotti R, 2015, J ALLERGY CLIN IMMUN, V136, P135, DOI 10.1016/j.jaci.2014.11.035; Zanotti R, 2011, HAEMATOL-HEMATOL J, V96, P482, DOI 10.3324/haematol.2010.034553; Zent O, 2004, VACCINE, V23, P579, DOI 10.1016/j.vaccine.2004.07.016; Zheng W, 2007, ANN ALLERG ASTHMA IM, V99, P574, DOI 10.1016/S1081-1206(10)60391-2	153	37	38	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2019	143	3					880	893		10.1016/j.jaci.2018.10.063	http://dx.doi.org/10.1016/j.jaci.2018.10.063			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HN6CQ	30528617	hybrid			2022-12-18	WOS:000460272900006
J	Mahler, V; Esch, RE; Kleine-Tebbe, J; Lavery, WJ; Plunkett, G; Vieths, S; Bernstein, DI				Mahler, Vera; Esch, Robert E.; Kleine-Tebbe, Joerg; Lavery, William J.; Plunkett, Greg; Vieths, Stefan; Bernstein, David I.			Understanding differences in allergen immunotherapy products and practices in North America and Europe	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Allergen immunotherapy; allergen; allergoid; diagnostic; European Medicines Agency; European Union; extracts; Food and Drug Administration; practices; regulatory; subcutaneous; sublingual; United States	EAACI AIT GUIDELINES; SUBCUTANEOUS IMMUNOTHERAPY; DIAGNOSIS; EXTRACTS; ASTHMA	Allergen immunotherapy (AIT) is thought to be clinically effective and safe in treating allergic rhinitis, asthma, and stinging insect allergy in Europe and North America. However, there are intercontinental differences in AIT therapeutic products in terms of their application and regulation. In North America unmodified standardized and nonstandardized aqueous aeroallergen extracts are approved and used almost exclusively for subcutaneous immunotherapy, whereas more product options are available in Europe, including adsorbed allergens, chemically modified allergens, or both. Both liquid extracts and tablets are approved for sublingual immunotherapy in Europe. Nevertheless, within the European Union, there are major differences in AIT products approved and used in individual countries. There are major differences in the clinical approach to subcutaneous immunotherapy in polysensitized patients; in the United States mixed extracts containing multiple aeroallergens are used, whereas European allergists preferably administer separate injections of single allergen sources or homologous groups deemed to be clinically relevant. Moreover, the regulatory approach differs between the European Union and United States. In contrast to the United States, where common allergen standards exist based on biologic activity, no common standards exist in Europe. In terms of development of new investigational products, the United States has followed the European example for phase II and III studies; no formal US Food and Drug Administration guidance has been issued.	[Mahler, Vera; Vieths, Stefan] Paul Ehrlich Inst, Paul Ehrlich Str 51-59, D-63225 Langen, Germany; [Esch, Robert E.] Lenoir Rhyne Univ, Sch Nat Sci, Hickory, NC USA; [Kleine-Tebbe, Joerg] Outpatient Clin & Res Ctr, Allergy & Asthma Ctr Westend, Berlin, Germany; [Lavery, William J.; Bernstein, David I.] Univ Cincinnati, Coll Med, Div Immunol, Allergy Sect, Cincinnati, OH 45267 USA	Paul Ehrlich Institute; University System of Ohio; University of Cincinnati	Vieths, S (corresponding author), Paul Ehrlich Inst, Paul Ehrlich Str 51-59, D-63225 Langen, Germany.; Bernstein, DI (corresponding author), Univ Cincinnati, Coll Med, Div Immunol Allergy & Rheumatol, 231 Albert Sabin Way,Rm 7507, Cincinnati, OH 45267 USA.	stefan.vieths@pei.de; BERNSTDD@ucmail.uc.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI060515] Funding Source: NIH RePORTER; NIAID NIH HHS [T32 AI060515] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abramson MJ, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001186.pub2; Bachert C, 2015, WORLD ALLERGY ORGAN, V8, DOI 10.1186/s40413-015-0078-8; Bernstein DI, 2004, J ALLERGY CLIN IMMUN, V113, P1129, DOI 10.1016/j.jaci.2004.02.006; Bonertz A, 2018, ALLERGY, V73, P816, DOI 10.1111/all.13357; Bonertz A, 2018, ALLERGY, V73, P64, DOI 10.1111/all.13266; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Brozek JL, 2017, J ALLERGY CLIN IMMUN, V140, P950, DOI 10.1016/j.jaci.2017.03.050; Calderon M, 2012, ALLERGY, V67, P462, DOI 10.1111/j.1398-9995.2012.02785.x; Center for Biologics Evaluation and Research, 2011, FED REGISTER, V76, P59407; Codina R, 2017, ANN ALLERG ASTHMA IM, V118, P148, DOI 10.1016/j.anai.2016.02.005; Cox L, 2011, J ALLERGY CLIN IMMUN, V127, DOI 10.1016/j.jaci.2010.09.034; Durham SR, 2016, J ALLERGY CLIN IMMUN, V137, P339, DOI 10.1016/j.jaci.2015.12.1298; Englert L, 2012, BUNDESGESUNDHEITSBLA, V55, P351, DOI 10.1007/s00103-011-1434-7; Epstein TG, 2013, ANN ALLERG ASTHMA IM, V110, P274, DOI 10.1016/j.anai.2013.01.015; Golden DBK, 2017, ANN ALLERG ASTHMA IM, V118, P28, DOI 10.1016/j.anai.2016.10.031; Greenhawt M, 2017, ANN ALLERG ASTHMA IM, V118, P276, DOI 10.1016/j.anai.2016.12.009; Halken S, 2017, PEDIAT ALLERG IMM-UK, V28, P728, DOI 10.1111/pai.12807; James LK, 2011, J ALLERGY CLIN IMMUN, V127, P509, DOI 10.1016/j.jaci.2010.12.1080; Kaul S, 2017, Pharmeur Bio Sci Notes, V2017, P69; Kleine-Tebbe J, 2016, IMMUNOL ALLERGY CLIN, V36, P191, DOI 10.1016/j.iac.2015.08.012; Li JT, 2016, J ALLERGY CLIN IMMUN, V137, P369, DOI 10.1016/j.jaci.2015.06.046; Massaro Ilaria, 2017, Clin Mol Allergy, V15, P15, DOI 10.1186/s12948-017-0071-6; Matricardi PM, 2016, PEDIAT ALLERG IMM-UK, V27, P1, DOI 10.1111/pai.12563; Muraro A, 2018, ALLERGY, V73, P739, DOI 10.1111/all.13420; Nelson HS, 1996, J ALLERGY CLIN IMMUN, V97, P1193, DOI 10.1016/S0091-6749(96)70184-7; Nordic Council of Medicines, REG ALL PREP, V23; Pajno GB, 2018, ALLERGY, V73, P799, DOI 10.1111/all.13319; Roberts G, 2018, ALLERGY, V73, P765, DOI 10.1111/all.13317; Ryan D, 2018, ALLERGY, V73, P827, DOI 10.1111/all.13264; Slater JE, 2012, J ALLERGY CLIN IMMUN, V129, P1014, DOI 10.1016/j.jaci.2012.01.066; Slater JE, 2014, ALLERGY PRINCIPLES P, P470; Sturm GJ, 2018, ALLERGY, V73, P744, DOI 10.1111/all.13262; TURKELTAUB PC, 1982, J ALLERGY CLIN IMMUN, V70, P343, DOI 10.1016/0091-6749(82)90023-9; Virchow JC, 2016, JAMA-J AM MED ASSOC, V315, P1715, DOI 10.1001/jama.2016.3964; White JF, 2005, ANN ALLERG ASTHMA IM, V94, P240, DOI 10.1016/S1081-1206(10)61302-6; Zimmer J, 2017, ALLERGOL IMMUNOPATH, V45, P4, DOI 10.1016/j.aller.2017.09.002; Zimmer J, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0599-4	37	37	37	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2019	143	3					813	830		10.1016/j.jaci.2019.01.024	http://dx.doi.org/10.1016/j.jaci.2019.01.024			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HN6CQ	30850069	Bronze			2022-12-18	WOS:000460272900001
J	Nakajima, S; Nomura, T; Common, J; Kabashima, K				Nakajima, Saeko; Nomura, Takashi; Common, John; Kabashima, Kenji			Insights into atopic dermatitis gained from genetically defined mouse models	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; genetically defined mouse models; skin barrier; immune dysfunction; T(H)2 cell response; pruritis; microbiome	INNATE LYMPHOID-CELLS; THYMIC STROMAL LYMPHOPOIETIN; SKIN BARRIER FUNCTION; STAPHYLOCOCCUS-AUREUS; STRATUM-CORNEUM; EPIDERMAL BARRIER; T-CELLS; TOPICAL APPLICATION; CASPASE-14-DEFICIENT MICE; ANTIMICROBIAL DEFENSE	Atopic dermatitis (AD) is characterized by severe pruritus and recurrent eczema with a chronic disease course. Impaired skin barrier function, hyperactivated T(H)2 cell-type inflammation, and pruritus-induced scratching contribute to the disease pathogenesis of AD. Skin microbial alterations complicate the pathogenesis of AD further. Mouse models are a powerful tool to analyze such intricate pathophysiology of AD, with a caution that anatomy and immunology of the skin differ between human subjects and mice. Here we review recent understanding of AD etiology obtained using mouse models, which address the epidermal barrier, skin microbiome, T-H(2) immune response, and pruritus.	[Nakajima, Saeko; Nomura, Takashi; Kabashima, Kenji] Kyoto Univ, Grad Sch Med, Dept Dermatol, 54 Shogoin Kawahara, Kyoto 6068507, Japan; [Common, John; Kabashima, Kenji] SRIS, 8A Biomed Grove,06-16 Immunos, Singapore 138648, Singapore; [Kabashima, Kenji] ASTAR, Singapore Immunol Network, Singapore, Singapore	Kyoto University; Agency for Science Technology & Research (A*STAR); A*STAR - Singapore Immunology Network (SIgN)	Kabashima, K (corresponding author), Kyoto Univ, Grad Sch Med, Dept Dermatol, 54 Shogoin Kawahara, Kyoto 6068507, Japan.; Common, J (corresponding author), SRIS, 8A Biomed Grove,06-16 Immunos, Singapore 138648, Singapore.	john.common@sris.a-star.edu.sg; kaba@kuhp.kyoto-u.ac.jp	Common, John/Q-6412-2018; Nakajima, Saeko/AAB-1577-2021	Common, John/0000-0002-3280-7365; Nakajima, Saeko/0000-0003-0831-1447	JSPS KAKENHI [18F18096]; Funding for Research to Expedite Effective drug discovery by Goverment, Academia and Private partnership (GAPFREE2) [100160600081]; Advanced Research & Development Programs for Medical Innovation (AMED-PRIME) [18m6010014h0002]	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Funding for Research to Expedite Effective drug discovery by Goverment, Academia and Private partnership (GAPFREE2); Advanced Research & Development Programs for Medical Innovation (AMED-PRIME)	This work was supported by JSPS KAKENHI grant no. 18F18096; by Funding for Research to Expedite Effective drug discovery by Goverment, Academia and Private partnership (GAPFREE2) no. 100160600081; and by Advanced Research & Development Programs for Medical Innovation (AMED-PRIME) no. 18m6010014h0002.	Amano W, 2015, J ALLERGY CLIN IMMUN, V136, P667, DOI 10.1016/j.jaci.2015.03.051; Baurecht H, 2018, J ALLERGY CLIN IMMUN, V141, P1668, DOI 10.1016/j.jaci.2018.01.019; Bieber T, 2012, ALLERGY, V67, P1475, DOI 10.1111/all.12049; Blaydon DC, 2011, NEW ENGL J MED, V365, P1502, DOI 10.1056/NEJMoa1100721; Bonefeld CM, 2016, IMMUNOL LETT, V179, P25, DOI 10.1016/j.imlet.2016.01.005; Breuer K, 2005, CLIN EXP ALLERGY, V35, P1088, DOI 10.1111/j.1365-2222.2005.02295.x; Brown SJ, 2009, BRIT J DERMATOL, V161, P884, DOI 10.1111/j.1365-2133.2009.09339.x; Brown SJ, 2012, J INVEST DERMATOL, V132, P751, DOI 10.1038/jid.2011.393; Bruggen MC, 2016, J INVEST DERMATOL, V136, P2396, DOI 10.1016/j.jid.2016.07.017; Brunner PM, 2018, J ALLERGY CLIN IMMUN, V141, P2094, DOI 10.1016/j.jaci.2018.02.040; Byrd AL, 2018, NAT REV MICROBIOL, V16, P143, DOI 10.1038/nrmicro.2017.157; Byrd AL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal4651; Cai SCS, 2012, BRIT J DERMATOL, V166, P200, DOI 10.1111/j.1365-2133.2011.10541.x; Cai YH, 2011, IMMUNITY, V35, P596, DOI 10.1016/j.immuni.2011.08.001; Carretero M, 2016, J INVEST DERMATOL, V136, P136, DOI 10.1038/JID.2015.362; Chan LS, 2001, J INVEST DERMATOL, V117, P977, DOI 10.1046/j.0022-202x.2001.01484.x; Chiba T, 2012, ALLERGY, V67, P936, DOI 10.1111/j.1398-9995.2012.02844.x; Chng KR, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2016.106, 10.1038/nmicrobiol.2016.106]; CHRISTOPHERS E, 1987, ARCH DERMATOL RES, V279, pS48, DOI 10.1007/BF00585919; Cornelissen C, 2012, EUR J CELL BIOL, V91, P552, DOI 10.1016/j.ejcb.2011.07.006; Cowden JM, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-86; Cruz MS, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01304; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V127; Descargues P, 2005, NAT GENET, V37, P56, DOI 10.1038/ng1493; Dillon SR, 2004, NAT IMMUNOL, V5, P752, DOI 10.1038/ni1084; Egawa G, 2018, ALLERGOL INT, V67, P3, DOI 10.1016/j.alit.2017.10.002; Egawa G, 2016, J ALLERGY CLIN IMMUN, V138, P350, DOI 10.1016/j.jaci.2016.06.002; Elias PM, 2001, ARCH DERMATOL, V137, P1079; Engler RJM, 2002, J ALLERGY CLIN IMMUN, V110, P357, DOI 10.1067/mai.2002.128052; Ewald DA, 2017, J ALLERGY CLIN IMMUN, V139, P562, DOI 10.1016/j.jaci.2016.08.029; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; Feingold KR, 2014, BBA-MOL CELL BIOL L, V1841, P280, DOI 10.1016/j.bbalip.2013.11.007; Fleury OM, 2017, INFECT IMMUN, V85, DOI 10.1128/IAI.00994-16; Floudas A, 2017, J IMMUNOL, V199, P707, DOI 10.4049/jimmunol.1602185; Foster EL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022029; Francis NA, 2017, ANN FAM MED, V15, P124, DOI 10.1370/afm.2038; Furuse M, 2002, J CELL BIOL, V156, P1099, DOI 10.1083/jcb.200110122; Fyhrquist N, 2014, J ALLERGY CLIN IMMUN, V134, P1301, DOI 10.1016/j.jaci.2014.07.059; Gao PS, 2009, J ALLERGY CLIN IMMUN, V124, P507, DOI 10.1016/j.jaci.2009.07.034; Geoghegan JA, 2018, TRENDS MICROBIOL, V26, P484, DOI 10.1016/j.tim.2017.11.008; Glatz M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192443; Grether-Beck S, 2012, J INVEST DERMATOL, V132, P1561, DOI 10.1038/jid.2012.42; Halim TYF, 2014, IMMUNITY, V40, P425, DOI 10.1016/j.immuni.2014.01.011; Hamid Q, 1996, J ALLERGY CLIN IMMUN, V98, P225, DOI 10.1016/S0091-6749(96)70246-4; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; Hatano Y, 2010, J ALLERGY CLIN IMMUN, V125, P160, DOI 10.1016/j.jaci.2009.06.049; Hidaka T, 2017, NAT IMMUNOL, V18, P64, DOI 10.1038/ni.3614; Hoff S, 2015, CLIN IMMUNOL, V156, P128, DOI 10.1016/j.clim.2014.12.001; Hoste E, 2013, J INVEST DERMATOL, V133, P742, DOI 10.1038/jid.2012.350; Hou MH, 2013, EXP DERMATOL, V22, P210, DOI 10.1111/exd.12102; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Howell MD, 2009, J ALLERGY CLIN IMMUN, V124, pR7, DOI 10.1016/j.jaci.2009.07.012; Imai Y, 2013, P NATL ACAD SCI USA, V110, P13921, DOI 10.1073/pnas.1307321110; Imamachi N, 2009, P NATL ACAD SCI USA, V106, P11330, DOI 10.1073/pnas.0905605106; IMOKAWA G, 1991, J INVEST DERMATOL, V96, P523, DOI 10.1111/1523-1747.ep12470233; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Janssens M, 2012, J LIPID RES, V53, P2755, DOI 10.1194/jlr.P030338; Jonca N, 2011, EUR J DERMATOL, V21, P35, DOI 10.1684/ejd.2011.1264; Kabashima K, 2018, J ALLERGY CLIN IMMUN, V142, P1121, DOI 10.1016/j.jaci.2018.03.018; Kabashima K, 2017, CURR OPIN IMMUNOL, V48, P99, DOI 10.1016/j.coi.2017.08.010; Kabashima K, 2013, J DERMATOL SCI, V70, P3, DOI 10.1016/j.jdermsci.2013.02.001; Kamo A, 2011, J DERMATOL SCI, V62, P91, DOI 10.1016/j.jdermsci.2011.01.004; Kanzaki H, 1996, J DERMATOL SCI, V12, P132, DOI 10.1016/0923-1811(95)00472-6; Karuppagounder V, 2015, CYTOKINE, V76, P206, DOI 10.1016/j.cyto.2015.05.016; Kawasaki H, 2012, J ALLERGY CLIN IMMUN, V129, P1538, DOI 10.1016/j.jaci.2012.01.068; Kennedy EA, 2017, J ALLERGY CLIN IMMUN, V139, P166, DOI 10.1016/j.jaci.2016.07.029; Kido-Nakahara M, 2017, IMMUNOL ALLERGY CLIN, V37, P113, DOI 10.1016/j.iac.2016.08.007; Kim BS, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005374; Kimura M, 1998, J ALLERGY CLIN IMMUN, V101, P84, DOI 10.1016/S0091-6749(98)70197-6; Kobayashi T, 2015, IMMUNITY, V42, P756, DOI 10.1016/j.immuni.2015.03.014; Komatsu N, 2007, EXP DERMATOL, V16, P513, DOI 10.1111/j.1600-0625.2007.00562.x; Kong HDH, 2012, GENOME RES, V22, P850, DOI 10.1101/gr.131029.111; Kubica M, 2014, EXP DERMATOL, V23, P561, DOI 10.1111/exd.12458; Kubo A, 2012, J CLIN INVEST, V122, P440, DOI 10.1172/JCI57416; Lai YP, 2010, J INVEST DERMATOL, V130, P2211, DOI 10.1038/jid.2010.123; Leclerc EA, 2009, J CELL SCI, V122, P2699, DOI 10.1242/jcs.050302; Leung DYM, 2014, J ALLERGY CLIN IMMUN, V134, P769, DOI 10.1016/j.jaci.2014.08.008; Leung DYM, 2011, J ALLERGY CLIN IMMUN, V127, P965, DOI 10.1016/j.jaci.2011.02.010; Leung DY, 2011, J ALLERGY CLIN IMMUN, V127, pe1; LEUNG DYM, 1993, J CLIN INVEST, V92, P1374, DOI 10.1172/JCI116711; LEYDEN JJ, 1974, BRIT J DERMATOL, V90, P525, DOI 10.1111/j.1365-2133.1974.tb06447.x; Leyvraz C, 2005, J CELL BIOL, V170, P487, DOI 10.1083/jcb.200501038; Liew FY, 2010, NAT REV IMMUNOL, V10, P103, DOI 10.1038/nri2692; Linehan JL, 2018, CELL, V172, P784, DOI 10.1016/j.cell.2017.12.033; Liu HY, 2017, CELL HOST MICROBE, V22, P653, DOI 10.1016/j.chom.2017.10.006; Mathes EF, 2013, PEDIATRICS, V132, pE149, DOI 10.1542/peds.2012-3175; Matsuda H, 1997, INT IMMUNOL, V9, P461, DOI 10.1093/intimm/9.3.461; Matsui T, 2006, J BIOL CHEM, V281, P27512, DOI 10.1074/jbc.M603559200; Matsumoto M, 2008, P NATL ACAD SCI USA, V105, P6720, DOI 10.1073/pnas.0709345105; McAleer MA, 2013, J ALLERGY CLIN IMMUN, V131, P280, DOI 10.1016/j.jaci.2012.12.668; Mestas J, 2004, J IMMUNOL, V172, P2731, DOI 10.4049/jimmunol.172.5.2731; Miller Lloyd S, 2008, Adv Dermatol, V24, P71; Mollanazar NK, 2016, CLIN REV ALLERG IMMU, V51, P263, DOI 10.1007/s12016-015-8488-5; Moniaga CS, 2013, AM J PATHOL, V182, P841, DOI 10.1016/j.ajpath.2012.11.039; Moniaga CS, 2010, AM J PATHOL, V176, P2385, DOI 10.2353/ajpath.2010.090957; Morita E, 1999, J DERMATOL SCI, V19, P37, DOI 10.1016/S0923-1811(98)00047-4; Murota H, 2016, EUR J PAIN, V20, P47, DOI 10.1002/ejp.777; Murota H, 2012, J ALLERGY CLIN IMMUN, V130, P671, DOI 10.1016/j.jaci.2012.05.027; Myles IA, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120608; Myles IA, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.86955; Nagelkerken L, 2008, J INVEST DERMATOL, V128, P1165, DOI 10.1038/sj.jid.5701182; Naik S, 2012, SCIENCE, V337, P1115, DOI 10.1126/science.1225152; Nakagawa S, 2017, CELL HOST MICROBE, V22, P667, DOI 10.1016/j.chom.2017.10.008; Nakajima S, 2014, J INVEST DERMATOL, V134, P2122, DOI 10.1038/jid.2014.51; Nakajima S, 2012, J ALLERGY CLIN IMMUN, V129, P1048, DOI 10.1016/j.jaci.2012.01.063; Nakamizo S, 2015, SEMIN IMMUNOPATHOL, V37, P73, DOI 10.1007/s00281-014-0452-6; Nakamura Y, 2013, NATURE, V503, P397, DOI 10.1038/nature12655; Nakashima C, 2018, EXP DERMATOL, V27, P327, DOI 10.1111/exd.13533; Nakatsuji T, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah4680; Negi O, 2012, J DERMATOL SCI, V66, P37, DOI 10.1016/j.jdermsci.2012.01.007; Niebuhr M, 2010, J ALLERGY CLIN IMMUN, V126, P1176, DOI 10.1016/j.jaci.2010.07.041; Nomura T, 2018, INT IMMUNOL, V30, P419, DOI 10.1093/intimm/dxy015; Novak N, 2011, CURR PROBL DERMATOL, V41, P47, DOI 10.1159/000323295; Ny A, 2004, ACTA DERM-VENEREOL, V84, P18, DOI 10.1080/0001555031004924; Oetjen LK, 2017, CELL, V171, P217, DOI 10.1016/j.cell.2017.08.006; Oh J, 2013, GENOME RES, V23, P2103, DOI 10.1101/gr.159467.113; Oji V, 2010, AM J HUM GENET, V87, P274, DOI 10.1016/j.ajhg.2010.07.005; Oldhoff JM, 2005, ALLERGY, V60, P693, DOI 10.1111/j.1398-9995.2005.00791.x; Otsuka A, 2014, J ALLERGY CLIN IMMUN, V133, pe1; Otsuka A, 2017, IMMUNOL REV, V278, P246, DOI 10.1111/imr.12545; Otsuka A, 2014, J ALLERGY CLIN IMMUN, V133, P139, DOI 10.1016/j.jaci.2013.07.027; Oyoshi MK, 2015, J ALLERGY CLIN IMMUN, V135, P1511, DOI 10.1016/j.jaci.2014.12.1923; Oyoshi MK, 2009, J ALLERGY CLIN IMMUN, V124, P485, DOI 10.1016/j.jaci.2009.05.042; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Park YH, 2012, J INVEST DERMATOL, V132, P476, DOI 10.1038/jid.2011.333; Pasparakis M, 2014, NAT REV IMMUNOL, V14, P289, DOI 10.1038/nri3646; Paternoster L, 2018, J ALLERGY CLIN IMMUN, V141, P964, DOI 10.1016/j.jaci.2017.09.044; Potaczek DP, 2012, CLIN EXP ALLERGY, V42, P852, DOI 10.1111/j.1365-2222.2011.03953.x; Potaczek DP, 2017, EPIGENOMICS-UK, V9, P539, DOI 10.2217/epi-2016-0162; Ruzicka T, 2017, NEW ENGL J MED, V376, P826, DOI 10.1056/NEJMoa1606490; Salgado G, 2017, DIFFERENTIATION, V98, P14, DOI 10.1016/j.diff.2017.09.004; Sasakawa T, 2001, INT ARCH ALLERGY IMM, V126, P239, DOI 10.1159/000049520; Sasaki T, 2013, J ALLERGY CLIN IMMUN, V132, P1111, DOI 10.1016/j.jaci.2013.08.027; Saunders SP, 2016, J ALLERGY CLIN IMMUN, V137, P482, DOI 10.1016/j.jaci.2015.06.045; Saunders SP, 2013, J ALLERGY CLIN IMMUN, V132, P1121, DOI 10.1016/j.jaci.2013.08.046; Savinko T, 2012, J INVEST DERMATOL, V132, P1392, DOI 10.1038/jid.2011.446; Scharschmidt TC, 2015, IMMUNITY, V43, P1011, DOI 10.1016/j.immuni.2015.10.016; Scharschmidt TC, 2009, J ALLERGY CLIN IMMUN, V124, P496, DOI 10.1016/j.jaci.2009.06.046; Scharschmidt TC, 2009, J INVEST DERMATOL, V129, P2435, DOI 10.1038/jid.2009.104; Schwartz DR, 1999, P NATL ACAD SCI USA, V96, P4680, DOI 10.1073/pnas.96.8.4680; Sehra S, 2016, EUR J IMMUNOL, V46, P2609, DOI 10.1002/eji.201646421; Sehra S, 2010, J IMMUNOL, V184, P3186, DOI 10.4049/jimmunol.0901860; Serezani APM, 2017, J ALLERGY CLIN IMMUN, V139, P142, DOI 10.1016/j.jaci.2016.07.012; Simpson EL, 2016, NEW ENGL J MED, V375, P2335, DOI 10.1056/NEJMoa1610020; Simpson EL, 2018, J INVEST DERMATOL, V138, P2224, DOI 10.1016/j.jid.2018.03.1517; Sonkoly E, 2006, J ALLERGY CLIN IMMUN, V117, P411, DOI 10.1016/j.jaci.2005.10.033; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Spaulding AR, 2013, CLIN MICROBIOL REV, V26, P422, DOI 10.1128/CMR.00104-12; Stanley JR, 2006, NEW ENGL J MED, V355, P1800, DOI 10.1056/NEJMra061111; Staumont-Salle D, 2008, J ALLERGY CLIN IMMUN, V121, P962, DOI 10.1016/j.jaci.2007.12.1165; Syed AK, 2015, INFECT IMMUN, V83, P3428, DOI 10.1128/IAI.00401-15; Tauber M, 2016, J ALLERGY CLIN IMMUN, V137, P1272, DOI 10.1016/j.jaci.2015.07.052; Terada M, 2006, P NATL ACAD SCI USA, V103, P8816, DOI 10.1073/pnas.0602900103; Tominaga M, 2014, J DERMATOL, V41, P205, DOI 10.1111/1346-8138.12317; Tominaga M, 2009, J DERMATOL SCI, V55, P40, DOI 10.1016/j.jdermsci.2009.03.007; Urashima R, 1998, VIRCHOWS ARCH, V432, P363, DOI 10.1007/s004280050179; Vasilopoulos Y, 2011, J DERMATOL SCI, V61, P131, DOI 10.1016/j.jdermsci.2010.11.013; Volz T, 2014, J INVEST DERMATOL, V134, P96, DOI 10.1038/jid.2013.291; Walsh NC, 2017, ANNU REV PATHOL-MECH, V12, P187, DOI 10.1146/annurev-pathol-052016-100332; Wanke I, 2013, EXP DERMATOL, V22, P153, DOI 10.1111/exd.12083; Weidinger S, 2016, LANCET, V387, P1109, DOI 10.1016/S0140-6736(15)00149-X; Wilson SR, 2013, CELL, V155, P285, DOI 10.1016/j.cell.2013.08.057; Yagi R, 2002, J IMMUNOL, V168, P2020, DOI 10.4049/jimmunol.168.4.2020; Yockey LJ, 2013, J INVEST DERMATOL, V133, P2714, DOI 10.1038/jid.2013.228; Yoo J, 2005, J EXP MED, V202, P541, DOI 10.1084/jem.20041503; Zeeuwen PLJM, 2017, J ALLERGY CLIN IMMUN, V139, P1368, DOI 10.1016/j.jaci.2016.09.017; Zheng T, 2009, J INVEST DERMATOL, V129, P742, DOI 10.1038/jid.2008.295	167	37	37	1	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2019	143	1					13	25		10.1016/j.jaci.2018.11.014	http://dx.doi.org/10.1016/j.jaci.2018.11.014			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HG4BD	30612664	Bronze			2022-12-18	WOS:000454918300002
J	Fettelschoss-Gabriel, A; Fettelschoss, V; Thoms, F; Giese, C; Daniel, M; Olomski, F; Kamarachev, J; Birkmann, K; Buhler, M; Kummer, M; Zeltins, A; Marti, E; Kundig, TM; Bachmann, MF				Fettelschoss-Gabriel, Antonia; Fettelschoss, Victoria; Thoms, Franziska; Giese, Christoph; Daniel, Michelle; Olomski, Florian; Kamarachev, Jivko; Birkmann, Katharina; Buhler, Maya; Kummer, Martin; Zeltins, Andris; Marti, Eliane; Kundig, Thomas M.; Bachmann, Martin F.			Treating insect-bite hypersensitivity in horses with active vaccination against IL-5	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic dermatitis; eosinophils; vaccination	SEVERE EOSINOPHILIC ASTHMA; VIRUS-LIKE PARTICLES; SWEET ITCH; CULICOIDES-HYPERSENSITIVITY; ICELANDIC HORSES; MONOCLONAL-ANTIBODY; CHEMOKINE EOTAXIN; ATOPIC-DERMATITIS; BRITISH-COLUMBIA; SUMMER ECZEMA	Background: Insect-bite hypersensitivity is the most common allergic dermatitis in horses. Excoriated skin lesions are typical symptoms of this seasonal and refractory chronic disease. On a cellular level, the skin lesions are characterized by massive eosinophil infiltration caused by an underlying allergic response. Objective: To target these cells and treat disease, we developed a therapeutic vaccine against equine IL-5 (eIL-5), the master regulator of eosinophils. Methods: The vaccine consisted of eIL-5 covalently linked to a virus-like particle derived from cucumber mosaic virus containing the tetanus toxoid universal T-cell epitope tt830-843 (CMVTT). Thirty-four Icelandic horses were recruited and immunized with 400 mu g of eIL-5-CMVTT formulated in PBS without adjuvant (19 horses) or PBS alone (15 horses). Results: The vaccine was well tolerated and did not reveal any safety concerns but was able to induce anti-eIL-5 autoantibody titers in 17 of 19 horses. This resulted in a statistically significant reduction in clinical lesion scores when compared with previous season levels, as well as levels in placebo-treated horses. Protection required a minimal threshold of anti-eIL-5 antibodies. Clinical improvement by disease scoring showed that 47% and 21% of vaccinated horses reached 50% and 75% improvement, respectively. In the placebo group no horse reached 75% improvement, and only 13% reached 50% improvement. Conclusion: Our therapeutic vaccine inducing autoantibodies against self IL-5 brings biologics to horses, is the first successful immunotherapeutic approach targeting a chronic disease in horses, and might facilitate development of a similar vaccine against IL-5 in human subjects.	[Fettelschoss-Gabriel, Antonia; Fettelschoss, Victoria; Thoms, Franziska; Daniel, Michelle; Olomski, Florian] Univ Hosp Zurich, Dept Dermatol, Schlieren, Switzerland; [Fettelschoss-Gabriel, Antonia; Fettelschoss, Victoria] Evax AG, Munchwilen, Switzerland; [Giese, Christoph] Swiss Fed Inst Technol, Inst Mol Biol & Biophys, Zurich, Switzerland; [Kamarachev, Jivko; Kundig, Thomas M.] Univ Hosp Zurich, Dept Dermatol, Zurich, Switzerland; [Birkmann, Katharina; Buhler, Maya; Kummer, Martin] Thurlandpraxis, Niederuzwil, Switzerland; [Zeltins, Andris] Latvian Biomed Res & Study Ctr, Riga, Latvia; [Marti, Eliane] Univ Bern, Clin Immunol Grp, Vetsuisse Fac, Dept Clin Res VPH, Bern, Switzerland; [Bachmann, Martin F.] Univ Bern, Inselspital, RIA Immunol, Bern, Switzerland; [Bachmann, Martin F.] Univ Oxford, Nuffield Dept Med, Jenner Inst, Henry Wellcome Bldg Mol Physiol, Oxford, England	University of Zurich; University Zurich Hospital; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; University Zurich Hospital; Latvian Biomedical Research & Study Centre; University of Bern; University of Bern; University Hospital of Bern; University of Oxford; Jenner Institute	Fettelschoss-Gabriel, A (corresponding author), Wagistr 14, CH-8952 Schlieren, Switzerland.	Antonia.gabriel@usz.ch	Zeltins, Andris/AAI-1017-2021; Gabriel, Antonia/AAD-2355-2019	Gabriel, Antonia/0000-0002-6189-172X	Swiss National Science Foundation (SNF) [CRSII3_154490]; Stiftung und Verein Forschung fur das Pferd/Pro Pferd [2014/02]; Commission for Technology and Innovation (CTI) [25758.1 PFLS-LS]; Benchmark Vaccines Limited, UK	Swiss National Science Foundation (SNF)(Swiss National Science Foundation (SNSF)); Stiftung und Verein Forschung fur das Pferd/Pro Pferd; Commission for Technology and Innovation (CTI); Benchmark Vaccines Limited, UK	Supported by funding of the Swiss National Science Foundation (SNF grant CRSII3_154490), Stiftung und Verein Forschung fur das Pferd/Pro Pferd (grant 2014/02), the Commission for Technology and Innovation (CTI grant 25758.1 PFLS-LS), and Benchmark Vaccines Limited, UK, through a licensing agreement with Evax AG.	ANDERSON GS, 1991, J MED ENTOMOL, V28, P685, DOI 10.1093/jmedent/28.5.685; Anderson GS, 1996, J MED ENTOMOL, V33, P458, DOI 10.1093/jmedent/33.3.458; [Anonymous], 2012, Gastroenterol Hepatol (N Y), V8, P131; Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868; Bachmann MF, 2004, NAT REV DRUG DISCOV, V3, P81, DOI 10.1038/nrd1284; BAKER KP, 1978, EQUINE VET J, V10, P243, DOI 10.1111/j.2042-3306.1978.tb02271.x; Bandeira-Melo C, 2002, J EXP MED, V196, P841, DOI 10.1084/jem.20020516; Benarafa C, 2002, VET REC, V151, P691; Bjornsdottir S, 2006, ACTA VET SCAND, V48, DOI 10.1186/1751-0147-48-3; BRAVERMAN Y, 1983, VET REC, V112, P521, DOI 10.1136/vr.112.22.521; BROSTROM H, 1987, EQUINE VET J, V19, P229, DOI 10.1111/j.2042-3306.1987.tb01389.x; Cavelti-Weder C, 2016, MOL THER, V24, P1003, DOI 10.1038/mt.2015.227; Chackerian B, 2007, EXPERT REV VACCINES, V6, P381, DOI 10.1586/14760584.6.3.381; COLLINS PD, 1995, J EXP MED, V182, P1169, DOI 10.1084/jem.182.4.1169; Cunningham FM, 2008, VET J, V177, P334, DOI 10.1016/j.tvjl.2007.10.005; CZECH W, 1992, BRIT J DERMATOL, V126, P351, DOI 10.1111/j.1365-2133.1992.tb00677.x; FADOK VA, 1990, EQUINE VET J, V22, P236, DOI 10.1111/j.2042-3306.1990.tb04259.x; Foster AP, 1998, VET REC, V143, P189, DOI 10.1136/vr.143.7.189; GREINER EC, 1990, MED VET ENTOMOL, V4, P375, DOI 10.1111/j.1365-2915.1990.tb00454.x; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; HALLDORDSOTTIR S, 1991, EQUINE VET J, V23, P296, DOI 10.1111/j.2042-3306.1991.tb03721.x; Hellberg W, 2009, VET IMMUNOL IMMUNOP, V132, P62, DOI 10.1016/j.vetimm.2009.09.016; Jegerlehner A, 2010, VACCINE, V28, P5503, DOI 10.1016/j.vaccine.2010.02.103; Jonsdottir S, 2016, VET IMMUNOL IMMUNOP, V172, P14, DOI 10.1016/j.vetimm.2016.02.017; Kopf M, 1996, IMMUNITY, V4, P15, DOI 10.1016/S1074-7613(00)80294-0; KUROTAKI T, 1994, J COMP PATHOL, V110, P145, DOI 10.1016/S0021-9975(08)80186-7; Kurotaki T, 2002, J VET MED SCI, V64, P539, DOI 10.1292/jvms.64.539; Legrand F, 2015, J ALLER CL IMM-PRACT, V3, P167, DOI 10.1016/j.jaip.2015.01.013; Leon-Ferre Roberto A, 2013, Clin Adv Hematol Oncol, V11, P317; MARTI E, 1992, EQUINE VET J, V24, P113, DOI 10.1111/j.2042-3306.1992.tb02794.x; McKelvie J, 1999, EQUINE VET J, V31, P466, DOI 10.1111/j.2042-3306.1999.tb03852.x; MILBURN MV, 1993, NATURE, V363, P172, DOI 10.1038/363172a0; Mukherjee M, 2014, WORLD ALLERGY ORGAN, V7, DOI 10.1186/1939-4551-7-32; Oldhoff JM, 2005, ALLERGY, V60, P693, DOI 10.1111/j.1398-9995.2005.00791.x; Ortega HG, 2016, LANCET RESP MED, V4, P549, DOI 10.1016/S2213-2600(16)30031-5; Park YM, 2010, ALLERGY ASTHMA IMMUN, V2, P87, DOI 10.4168/aair.2010.2.2.87; Pavord ID, 2017, LANCET RESP MED, V5, P362, DOI 10.1016/S2213-2600(17)30132-7; Pichler WJ, 2003, ANN INTERN MED, V139, P683, DOI 10.7326/0003-4819-139-8-200310210-00012; Pumpens P, 2016, INTERVIROLOGY, V59, P74, DOI 10.1159/000449503; QUINN PJ, 1983, EQUINE VET J, V15, P266, DOI 10.1111/j.2042-3306.1983.tb01788.x; RIEK R. F., 1953, AUSTRALIAN VET JOUR, V29, P177, DOI 10.1111/j.1751-0813.1953.tb13937.x; Robinson DS, 2013, EXPERT REV RESP MED, V7, P13, DOI [10.1586/ers.12.84, 10.1586/ERS.12.84]; Schaffartzik A, 2012, VET IMMUNOL IMMUNOP, V147, P113, DOI 10.1016/j.vetimm.2012.03.017; Schmid F, 2005, PROTEIN FOLDING HANDBOOK, P22, DOI 10.1002/9783527619498.ch2; Smith DA, 2011, CLIN PHARMACOKINET, V50, P215, DOI 10.2165/11584340-000000000-00000; Steenholdt C, 2011, ALIMENT PHARM THER, V34, P51, DOI 10.1111/j.1365-2036.2011.04682.x; Steinman A, 2003, VET REC, V152, P748, DOI 10.1136/vr.152.24.748; STRATH M, 1992, EXP HEMATOL, V20, P229; Van Grevenhof EM, 2007, EQUINE VET J, V39, P69, DOI 10.2746/042516407X153020; Walford HH, 2014, J ASTHMA ALLERGY, V7, P53, DOI 10.2147/JAA.S39119; Zeltins A, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0030-8; Zeltins A, 2013, MOL BIOTECHNOL, V53, P92, DOI 10.1007/s12033-012-9598-4; Zou Y, 2010, VACCINE, V28, P3192, DOI 10.1016/j.vaccine.2010.02.048	53	37	37	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2018	142	4					1194	+		10.1016/j.jaci.2018.01.041	http://dx.doi.org/10.1016/j.jaci.2018.01.041			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GV7RG	29627082	Green Accepted, Green Published, hybrid			2022-12-18	WOS:000446327300019
J	Mahdavinia, M; Engen, PA; LoSavio, PS; Naqib, A; Khan, RJ; Tobin, MC; Mehta, A; Kota, R; Preite, NZ; Codispoti, CD; Tajudeen, BA; Schleimer, RP; Green, SJ; Keshavarzian, A; Batra, PS				Mahdavinia, Mahboobeh; Engen, Phillip A.; LoSavio, Phillip S.; Naqib, Ankur; Khan, Rafsa J.; Tobin, Mary C.; Mehta, Arpita; Kota, Raj; Preite, Nailliw Z.; Codispoti, Christopher D.; Tajudeen, Bobby A.; Schleimer, Robert P.; Green, Stefan J.; Keshavarzian, Ali; Batra, Pete S.			The nasal microbiome in patients with chronic rhinosinusitis: Analyzing the effects of atopy and bacterial functional pathways in 111 patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									[Mahdavinia, Mahboobeh; Khan, Rafsa J.; Tobin, Mary C.; Mehta, Arpita; Kota, Raj; Preite, Nailliw Z.; Codispoti, Christopher D.] Rush Univ, Med Ctr, Dept Internal Med, Div Allergy Immunol, Chicago, IL 60612 USA; [Engen, Phillip A.; Preite, Nailliw Z.; Keshavarzian, Ali] Rush Univ, Dept Internal Med, Med Ctr, Div Gastroenterol Hepatol & Nutr, Chicago, IL 60612 USA; [LoSavio, Phillip S.; Tajudeen, Bobby A.; Batra, Pete S.] Rush Univ, Med Ctr, Dept Otorhinolaryngol Head & Neck Surg, Chicago, IL 60612 USA; [LoSavio, Phillip S.; Tajudeen, Bobby A.; Batra, Pete S.] Rush Univ, Med Ctr, Rush Sinus Program, Chicago, IL 60612 USA; [Naqib, Ankur; Green, Stefan J.] Univ Illinois, Res Resources Ctr, DNA Serv Facil, Chicago, IL USA; [Green, Stefan J.] Univ Illinois, Dept Biol Sci, Chicago, IL USA; [Schleimer, Robert P.] Northwestern Univ, Dept Internal Med, Feinberg Sch Med, Div Allergy & Immunol, Chicago, IL 60611 USA	Rush University; Rush University; Rush University; Rush University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Northwestern University; Feinberg School of Medicine	Mahdavinia, M (corresponding author), Rush Univ, Med Ctr, Dept Internal Med, Div Allergy Immunol, Chicago, IL 60612 USA.	Mahboobeh_mahdavinia@rush.edu		Mahdavinia, mahboobeh/0000-0003-4004-203X; Zanini Preite, Nailliw/0000-0002-0675-9080	Medtronic and internal departmental - Rush University; Brinson Foundation; Ernest S. Bazley Foundation; National Institute of Allergy and Infectious Diseases [U19 AI106683]; National Heart, Lung, and Blood Institute [R37 HL068546]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL068546] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI106683] Funding Source: NIH RePORTER	Medtronic and internal departmental - Rush University; Brinson Foundation; Ernest S. Bazley Foundation; National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was conducted by a research grant from Medtronic and internal departmental funding by Rush University (principal investigators: Mahboobeh Mahdavinia, MD, PhD, and Pete S. Batra, MD, FACS). M.M. is supported by a Brinson Foundation award. R.P.S. is supported in part by the Ernest S. Bazley Foundation, U19 AI106683 from the National Institute of Allergy and Infectious Diseases, and R37 HL068546 from the National Heart, Lung, and Blood Institute.	Bachert Claus, 2007, Clin Allergy Immunol, V20, P163; Biesbroek G, 2014, AM J RESP CRIT CARE, V190, P1283, DOI 10.1164/rccm.201407-1240OC; Chng KR, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2016.106, 10.1038/nmicrobiol.2016.106]; Huang MT, 2017, SCI REP-UK, V7, DOI 10.1038/srep43535; Lal D, 2017, INT FORUM ALLERGY RH, V7, P561, DOI 10.1002/alr.21934; Langille MGI, 2013, NAT BIOTECHNOL, V31, P814, DOI 10.1038/nbt.2676; Mahdavinia M, 2016, CLIN EXP ALLERGY, V46, P21, DOI 10.1111/cea.12666; Ramakrishnan VR, 2015, J ALLERGY CLIN IMMUN, V136, P334, DOI 10.1016/j.jaci.2015.02.008; Stefka AT, 2014, P NATL ACAD SCI USA, V111, P13145, DOI 10.1073/pnas.1412008111; Stephenson MF, 2010, J OTOLARYNGOL-HEAD N, V39, P182, DOI 10.2310/7070.2009.090060; Wiesner DL, 2016, J IMMUNOL, V196, P365, DOI 10.4049/jimmunol.1501871	11	37	39	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2018	142	1					287	290		10.1016/j.jaci.2018.01.033	http://dx.doi.org/10.1016/j.jaci.2018.01.033			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GM1OC	29452201	Green Accepted, Bronze			2022-12-18	WOS:000437837500033
J	Mehta, N; Devarakonda, MV				Mehta, Neil; Devarakonda, Murthy V.			Machine learning, natural language programming, and electronic health records: The next step in the artificial intelligence journey?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Machine learning; artificial intelligence; electronic health records; natural language processing; medical computer science			[Mehta, Neil] Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Educ Informat & Technol, NA2-24,9500 Euclid Ave, Cleveland, OH 44195 USA; [Devarakonda, Murthy V.] Arizona State Univ, Coll Hlth Solut, Dept Biomed Informat, Scottsdale, AZ USA	Case Western Reserve University; Cleveland Clinic Foundation; Arizona State University	Mehta, N (corresponding author), Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Educ Informat & Technol, NA2-24,9500 Euclid Ave, Cleveland, OH 44195 USA.	mehtan@ccf.org	Mehta, Neil/AAL-9824-2020	Mehta, Neil/0000-0001-8342-4252	IBM	IBM(International Business Machines (IBM))	N. Mehta received a grant from IBM. M. V. Devarakonda declares no relevant conflicts of interest.	Bodenreider O, 2004, NUCLEIC ACIDS RES, V32, pD267, DOI 10.1093/nar/gkh061; Cohen AM, 2005, BRIEF BIOINFORM, V6, P57, DOI 10.1093/bib/6.1.57; Demner-Fushman D, 2017, J AM MED INFORM ASSN, V24, P841, DOI 10.1093/jamia/ocw177; Devarakonda MV, AUTOMATED PROBLEM LI; Ferrucci D, 2013, ARTIF INTELL, V199, P93, DOI 10.1016/j.artint.2012.06.009; Li Dingcheng, 2013, AMIA Jt Summits Transl Sci Proc, V2013, P142; Lighthill J., LIGHTHILL REPORT ART; McCarthy J., PROPOSAL DARTMOUTH S; Nof SY, 2009, SPRINGER HDB AUTOMAT, P1841; Page David, 2012, Proc Conf AAAI Artif Intell, V2012, P790; Pierce J, 1416 AUT LANG PROC A; Roland A, 2002, HIST COMP, P13; Savova GK, 2010, J AM MED INFORM ASSN, V17, P507, DOI 10.1136/jamia.2009.001560; Schroff F., FACENET UNIFIED EMBE; Shachak A, 2009, J GEN INTERN MED, V24, P341, DOI 10.1007/s11606-008-0892-6; Turing A.M., 1950, MIND, V49, P433	16	37	38	11	44	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2018	141	6					2019	+		10.1016/j.jaci.2018.02.025	http://dx.doi.org/10.1016/j.jaci.2018.02.025			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GI7SD	29518424	Bronze			2022-12-18	WOS:000434701600007
J	Nagashima, H; Okuyama, Y; Fujita, T; Takeda, T; Motomura, Y; Moro, K; Hidaka, T; Omori, K; Sakurai, T; Machiyama, T; Ndhlovu, LC; Riccardi, C; So, T; Ishii, N				Nagashima, Hiroyuki; Okuyama, Yuko; Fujita, Tsuyoshi; Takeda, Takeo; Motomura, Yasutaka; Moro, Kazuyo; Hidaka, Takanori; Omori, Koki; Sakurai, Tsuyoshi; Machiyama, Tomoaki; Ndhlovu, Lishomwa C.; Riccardi, Carlo; So, Takanori; Ishii, Naoto			GITR cosignal in ILC2s controls allergic lung inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							INNATE LYMPHOID-CELLS; ACTIVATION; LIGAND		[Nagashima, Hiroyuki; Okuyama, Yuko; Fujita, Tsuyoshi; Takeda, Takeo; Omori, Koki; Sakurai, Tsuyoshi; Machiyama, Tomoaki; So, Takanori; Ishii, Naoto] Tohoku Univ, Grad Sch Med, Dept Microbiol & Immunol, Sendai, Miyagi, Japan; [Motomura, Yasutaka; Moro, Kazuyo] RIKEN Ctr Integrat Med Sci, Lab Innate Immune Syst, Yokohama, Kanagawa, Japan; [Hidaka, Takanori] Tohoku Univ, Grad Sch Med, Dept Dermatol, Sendai, Miyagi, Japan; [Ndhlovu, Lishomwa C.] Univ Hawaii, John A Burns Sch Med, Hawaii Ctr AIDS, Dept Trop Med, Honolulu, HI 96822 USA; [Riccardi, Carlo] Univ Perugia, Dept Med, Pharmacol Sect, Perugia, Italy; [So, Takanori] Univ Toyama, Mol Cell Biol Lab, Grad Sch Med & Pharmaceut Sci, Toyama, Japan	Tohoku University; RIKEN; Tohoku University; University of Hawaii System; University of Perugia; University of Toyama	Ishii, N (corresponding author), Tohoku Univ, Grad Sch Med, Dept Microbiol & Immunol, Sendai, Miyagi, Japan.	ishiin@med.tohoku.ac.jp	Riccardi, Carlo/N-4610-2014; Nagashima, Hiroyuki/AAL-3128-2021; n, l/AAX-3992-2020; So, Takanori/R-6175-2019	Riccardi, Carlo/0000-0001-9257-3997; So, Takanori/0000-0003-3004-8526; Nagashima, Hiroyuki/0000-0001-8405-6746; Ndhlovu, Lishomwa/0000-0001-5427-4187; Moro, Kazuyo/0000-0002-7377-1303; Ishii, Naoto/0000-0002-0549-8245; Takeda, Takeo/0000-0001-9445-7332	JSPS KAKENHI [16K15508, 17K08875]; Yamaguchi Educational and Scholarship Foundation; Daiichi-Sankyo Foundation of Life Science	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Yamaguchi Educational and Scholarship Foundation; Daiichi-Sankyo Foundation of Life Science	This study was supported in part by JSPS KAKENHI (grant nos. 16K15508 and 17K08875), the Yamaguchi Educational and Scholarship Foundation (T.S.), and the Daiichi-Sankyo Foundation of Life Science (T.S.).	Eberl G, 2015, SCIENCE, V348, DOI 10.1126/science.aaa6566; Kamachi F, 2015, BIOCHEM BIOPH RES CO, V463, P739, DOI 10.1016/j.bbrc.2015.06.005; Klose CSN, 2016, NAT IMMUNOL, V17, P765, DOI 10.1038/ni.3489; Matute-Bello G, 2011, AM J RESP CELL MOL, V44, P725, DOI 10.1165/rcmb.2009-0210ST; McKenzie GJ, 1998, IMMUNITY, V9, P423, DOI 10.1016/S1074-7613(00)80625-1; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Mohapatra A, 2016, MUCOSAL IMMUNOL, V9, P275, DOI 10.1038/mi.2015.59; Morita H, 2016, J ALLERGY CLIN IMMUN, V138, P1253, DOI 10.1016/j.jaci.2016.09.011; Moro K, 2015, NAT PROTOC, V10, P792, DOI 10.1038/nprot.2015.047; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Murata K, 2002, J IMMUNOL, V169, P4628, DOI 10.4049/jimmunol.169.8.4628; Ronchetti S, 2002, BLOOD, V100, P350, DOI 10.1182/blood-2001-12-0276; Spits H, 2012, ANNU REV IMMUNOL, V30, P647, DOI 10.1146/annurev-immunol-020711-075053; SUDA T, 1994, J EXP MED, V179, P873, DOI 10.1084/jem.179.3.873; Turner JE, 2013, J EXP MED, V210, P2951, DOI 10.1084/jem.20130071; Wilhelm C, 2011, NAT IMMUNOL, V12, P1071, DOI 10.1038/ni.2133	16	37	39	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2018	141	5					1939	+		10.1016/j.jaci.2018.01.028	http://dx.doi.org/10.1016/j.jaci.2018.01.028			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GF7KX	29427641	Bronze			2022-12-18	WOS:000432148200053
J	Deckers, J; Sichien, D; Plantinga, M; Van Moorleghem, J; Vanheerswynghels, M; Hoste, E; Malissen, B; Dombrowicz, D; Guilliams, M; De Bosscher, K; Lambrecht, BN; Hammad, H				Deckers, Julie; Sichien, Dorine; Plantinga, Maud; Van Moorleghem, Justine; Vanheerswynghels, Manon; Hoste, Esther; Malissen, Bernard; Dombrowicz, David; Guilliams, Martin; De Bosscher, Karolien; Lambrecht, Bart N.; Hammad, Hamida			Epicutaneous sensitization to house dust mite allergen requires interferon regulatory factor 4-dependent dermal dendritic cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Epicutaneous sensitization; house dust mite; allergy; airway inflammation; skin dendritic cells	CD4(+) T-CELLS; LANGERHANS CELLS; TYPE-2 IMMUNITY; PROTEASE ACTIVITY; C57BL/6 MICE; SKIN BARRIER; LYMPH-NODES; IN-VIVO; P 2; ANTIGEN	Background: Exposure to allergens, such as house dust mite (HDM), through the skin often precedes allergic inflammation in the lung. It was proposed that T(H)2 sensitization through the skin occurs when skin barrier function is disrupted by, for example, genetic predisposition, mechanical damage, or the enzymatic activity of allergens. Objective: We sought to study how HDM applied to unmanipulated skin leads to T(H)2 sensitization and to study which antigen-presenting cells mediate this process. Methods: HDM was applied epicutaneously by painting HDM on unmanipulated ear skin or under an occlusive tape. HDM challenge was through the nose. Mouse strains lacking different dendritic cell (DC) populations were used, and 1-DER T cells carrying a transgenic T-cell receptor reactive to Der p 1 allergen were used as a readout for antigen presentation. The T(H)2-inducing capacity of sorted skin-derived DC subsets was determined by means of adoptive transfer to naive mice. Results: Epicutaneous HDM application led to T(H)2 sensitization and eosinophilic airway inflammation upon intranasal HDM challenge. Skin sensitization did not require prior skin damage or enzymatic activity within HDM extract, yet was facilitated by applying the allergen under an occlusive tape. Primary proliferation of 1-DER T cells occurred only in the regional skin-draining lymph nodes. Epicutaneous sensitization was found to be driven by 2 variants of interferon regulatory factor 4-dependent dermal type 2 conventional DC subsets and not by epidermal Langerhans cells. Conclusion: These findings identify skin type 2 conventional DCs as crucial players in T(H)2 sensitization to common inhaled allergens that enter the body through the skin and can provoke features of allergic asthma.	[Deckers, Julie; Sichien, Dorine; Plantinga, Maud; Van Moorleghem, Justine; Vanheerswynghels, Manon; Hoste, Esther; Guilliams, Martin; Lambrecht, Bart N.; Hammad, Hamida] VIB Ctr Inflammat Res, Ghent, Belgium; [Deckers, Julie; Plantinga, Maud; Van Moorleghem, Justine; Vanheerswynghels, Manon; Lambrecht, Bart N.; Hammad, Hamida] Univ Ghent, Dept Internal Med, Ghent, Belgium; [Deckers, Julie; De Bosscher, Karolien] VIB Ctr Med Biotechnol, Nucl Receptor Lab, Receptor Res Labs, Ghent, Belgium; [Deckers, Julie; De Bosscher, Karolien] Univ Ghent, Dept Biochem, Ghent, Belgium; [Sichien, Dorine; Hoste, Esther; Guilliams, Martin] Univ Ghent, Dept Biomed Mol Biol, Ghent, Belgium; [Plantinga, Maud; Lambrecht, Bart N.] Erasmus Univ, Med Ctr Rotterdam, Dept Pulm Med, Rotterdam, Netherlands; [Malissen, Bernard] Ctr Immunol Marseille Luminy, Marseille, France; [Dombrowicz, David] Univ Lille Nord France, INSERM, U1011, Inst Pasteur Lille, Lille, France	Flanders Institute for Biotechnology (VIB); Ghent University; Ghent University; Flanders Institute for Biotechnology (VIB); Ghent University; Ghent University; Erasmus University Rotterdam; Erasmus MC; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille	Hammad, H (corresponding author), VIB Inflammat Res Ctr, Technol Pk 927, B-9052 Ghent, Belgium.	hamida.hammad@ugent.be	Hammad, Hamida/J-9391-2015; Guilliams, Martin/N-7803-2013; Hoste, Esther/AAG-2218-2020; Lambrecht, Bart N/K-2484-2014; Dombrowicz, David/F-7044-2013; Malissen, Bernard/AAK-4659-2020	Hammad, Hamida/0000-0003-3762-8603; Guilliams, Martin/0000-0003-3525-7570; Hoste, Esther/0000-0002-3181-431X; Lambrecht, Bart N/0000-0003-4376-6834; Dombrowicz, David/0000-0002-0485-8923; Malissen, Bernard/0000-0003-1340-9342; Sichien, Dorine/0000-0002-7298-3005; De Bosscher, Karolien/0000-0001-5059-9718	ERC; University of Ghent MRP grant (GROUP-ID consortium); FWO	ERC(European Research Council (ERC)European Commission); University of Ghent MRP grant (GROUP-ID consortium); FWO(FWO)	Supported by an ERC consolidator grant (to B.N.L.), a University of Ghent MRP grant (GROUP-ID consortium; to B.N.L.), a FWO project grant (to H.H.), and a joined FWO project grant (to H.H. and K.D.B.).	Bajana S, 2012, J IMMUNOL, V189, P3368, DOI 10.4049/jimmunol.1102613; Bennett CL, 2005, J CELL BIOL, V169, P569, DOI 10.1083/jcb.200501071; Boralevi F, 2008, ALLERGY, V63, P205, DOI 10.1111/j.1398-9995.2007.01556.x; Bursch LS, 2007, J EXP MED, V204, P3147, DOI 10.1084/jem.20071966; CARSWELL F, 1987, INT ARCH ALLER A IMM, V82, P453, DOI 10.1159/000234252; Chen SY, 2014, CUTAN OCUL TOXICOL, V33, P63, DOI 10.3109/15569527.2013.821615; Coquet JM, 2015, IMMUNITY, V43, P318, DOI 10.1016/j.immuni.2015.07.015; de Aguero MG, 2012, J CLIN INVEST, V122, P1700, DOI 10.1172/JCI59725; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; de Kleer IM, 2016, IMMUNITY, V45, P1285, DOI 10.1016/j.immuni.2016.10.031; Dullaers M, 2017, J ALLERGY CLIN IMMUN, V140, P76, DOI 10.1016/j.jaci.2016.09.020; Everts B, 2016, J EXP MED, V213, P35, DOI 10.1084/jem.20150235; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; Galand C, 2016, J ALLERGY CLIN IMMUN, V138, P1356, DOI 10.1016/j.jaci.2016.03.056; Gao Y, 2013, IMMUNITY, V39, P722, DOI 10.1016/j.immuni.2013.08.028; Georas SN, 2014, J ALLERGY CLIN IMMUN, V134, P509, DOI 10.1016/j.jaci.2014.05.049; Ginhoux F, 2006, NAT IMMUNOL, V7, P265, DOI 10.1038/ni1307; Gregory LG, 2011, TRENDS IMMUNOL, V32, P402, DOI 10.1016/j.it.2011.06.006; Guilliams M, 2016, IMMUNITY, V45, P669, DOI 10.1016/j.immuni.2016.08.015; Guilliams M, 2014, NAT REV IMMUNOL, V14, P571, DOI 10.1038/nri3712; Guilliams M, 2010, EUR J IMMUNOL, V40, P2089, DOI 10.1002/eji.201040498; Guilliams M, 2010, BLOOD, V115, P1958, DOI 10.1182/blood-2009-09-245274; Hammad H, 2015, IMMUNITY, V43, P29, DOI 10.1016/j.immuni.2015.07.007; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Henri S, 2010, IMMUNOL CELL BIOL, V88, P366, DOI 10.1038/icb.2010.34; Hondowicz BD, 2016, IMMUNITY, V44, P155, DOI 10.1016/j.immuni.2015.11.004; Hoste E, 2011, J INVEST DERMATOL, V131, P2233, DOI 10.1038/jid.2011.153; Igyarto BZ, 2011, IMMUNITY, V35, P260, DOI 10.1016/j.immuni.2011.06.005; Igyarto BZ, 2009, J IMMUNOL, V183, P5085, DOI 10.4049/jimmunol.0901884; Iida H, 2014, ALLERGOL INT, V63, P219, DOI 10.2332/allergolint.13-OA-0621; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Ivanov S, 2016, J CLIN INVEST, V126, P1581, DOI 10.1172/JCI84518; Kay AB, 2001, NEW ENGL J MED, V344, P30, DOI 10.1056/NEJM200101043440106; Khare A, 2013, J IMMUNOL, V191, P25, DOI 10.4049/jimmunol.1300193; Kissenpfennig A, 2005, IMMUNITY, V22, P643, DOI 10.1016/j.immuni.2005.04.004; KleinJan A, 2006, J ALLERGY CLIN IMMUN, V118, P1117, DOI 10.1016/j.jaci.2006.05.030; Kubo A, 2012, J CLIN INVEST, V122, P440, DOI 10.1172/JCI57416; Kubo A, 2009, J EXP MED, V206, P2937, DOI 10.1084/jem.20091527; Kumamoto Y, 2016, ELIFE, V5, DOI 10.7554/eLife.17979; Kumamoto Y, 2013, IMMUNITY, V39, P733, DOI 10.1016/j.immuni.2013.08.029; Kuo IH, 2013, J INVEST DERMATOL, V133, P988, DOI 10.1038/jid.2012.437; Lambrecht Bart N, 2014, Ann Am Thorac Soc, V11 Suppl 5, pS236, DOI 10.1513/AnnalsATS.201405-218AW; Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049; Lambrecht BN, 2012, ANNU REV IMMUNOL, V30, P243, DOI 10.1146/annurev-immunol-020711-075021; Lambrecht BN, 2011, CURR OPIN IMMUNOL, V23, P769, DOI 10.1016/j.coi.2011.09.004; Lugt BV, 2014, NAT IMMUNOL, V15, P161, DOI 10.1038/ni.2795; Malissen B, 2014, NAT REV IMMUNOL, V14, P417, DOI 10.1038/nri3683; Martinez-Lopez M, 2015, EUR J IMMUNOL, V45, P119, DOI 10.1002/eji.201444651; McLean WHI, 2008, J ALLERGY CLIN IMMUN, V121, P1294, DOI 10.1016/j.jaci.2008.02.039; Mesnil C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053242; Nakajima S, 2012, J ALLERGY CLIN IMMUN, V129, P1048, DOI 10.1016/j.jaci.2012.01.063; Noti M, 2014, J ALLERGY CLIN IMMUN, V133, P1390, DOI 10.1016/j.jaci.2014.01.021; Ohl L, 2004, IMMUNITY, V21, P279, DOI 10.1016/j.immuni.2004.06.014; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Persson EK, 2013, IMMUNITY, V38, P958, DOI 10.1016/j.immuni.2013.03.009; Plantinga M, 2013, IMMUNITY, V38, P322, DOI 10.1016/j.immuni.2012.10.016; Poulin LF, 2007, J EXP MED, V204, P3119, DOI 10.1084/jem.20071724; Ravichandran S, 2011, NANOTOXICOLOGY, V5, P675, DOI 10.3109/17435390.2010.537381; Raymond M, 2009, J ALLERGY CLIN IMMUN, V124, P1333, DOI 10.1016/j.jaci.2009.07.021; Rodriguez E, 2009, J ALLERGY CLIN IMMUN, V123, P1361, DOI 10.1016/j.jaci.2009.03.036; Rydnert F, 2014, IMMUNOL CELL BIOL, V92, P557, DOI 10.1038/icb.2014.23; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; Schafer T, 1999, J ALLERGY CLIN IMMUN, V104, P1280, DOI 10.1016/S0091-6749(99)70025-4; Schiavoni G, 2004, BLOOD, V103, P2221, DOI 10.1182/blood-2003-09-3007; Semmrich M, 2012, MUCOSAL IMMUNOL, V5, P150, DOI 10.1038/mi.2011.61; Shimura S, 2016, J INVEST DERMATOL, V136, P1408, DOI 10.1016/j.jid.2016.02.810; Shklovskaya E, 2008, J IMMUNOL, V181, P418, DOI 10.4049/jimmunol.181.1.418; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Stremnitzer C, 2014, ALLERGY, V69, P741, DOI 10.1111/all.12399; Stremnitzer C, 2015, J INVEST DERMATOL, V135, P1790, DOI 10.1038/jid.2015.58; Strid J, 2005, CLIN EXP ALLERGY, V35, P757, DOI 10.1111/j.1365-2222.2005.02260.x; Strid J, 2004, EUR J IMMUNOL, V34, P2100, DOI 10.1002/eji.200425196; Szalai K, 2012, EXP DERMATOL, V21, P842, DOI 10.1111/exd.12015; Tamoutounour S, 2013, IMMUNITY, V39, P925, DOI 10.1016/j.immuni.2013.10.004; Tordesillas L, 2014, J CLIN INVEST, V124, P4965, DOI 10.1172/JCI75660; Tussiwand R, 2015, IMMUNITY, V42, P916, DOI 10.1016/j.immuni.2015.04.017; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Wan H, 2001, CLIN EXP ALLERGY, V31, P279, DOI 10.1046/j.1365-2222.2001.00970.x; Williams JW, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3990; WOOD LC, 1992, J CLIN INVEST, V90, P482, DOI 10.1172/JCI115884; Yockey LJ, 2013, J INVEST DERMATOL, V133, P2714, DOI 10.1038/jid.2013.228	82	37	40	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2017	140	5					1364	+		10.1016/j.jaci.2016.12.970	http://dx.doi.org/10.1016/j.jaci.2016.12.970			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FL5RV	28189772	Bronze			2022-12-18	WOS:000414304300016
J	Frischmeyer-Guerrerio, PA; Masilamani, M; Gu, WJ; Brittain, E; Wood, R; Kim, J; Nadeau, K; Jarvinen, KM; Grishin, A; Lindblad, R; Sampson, HA				Frischmeyer-Guerrerio, Pamela A.; Masilamani, Madhan; Gu, Wenjuan; Brittain, Erica; Wood, Robert; Kim, Jennifer; Nadeau, Kari; Jarvinen, Kirsi M.; Grishin, Alexander; Lindblad, Robert; Sampson, Hugh A.			Mechanistic correlates of clinical responses to omalizumab in the setting of oral immunotherapy for milk allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Oral immunotherapy; food allergy; milk allergy; omalizumab; desensitization; sustained unresponsiveness; basophil activation; biomarker; regulatory T cells	BASOPHIL ACTIVATION TEST; COWS MILK; PEANUT; CELL; IGE; SUPPRESSION; EXPRESSION; CHILDREN; CD63	Background: In our recent clinical trial, the addition of omalizumab to oral immunotherapy (OIT) for milk allergy improved safety, but no significant clinical benefit was detected. Objective: We sought to investigate mechanisms by which omalizumab modulates immunity in the context of OIT and to identify baseline biomarkers that predict subgroups of patients most likely to benefit from omalizumab. Methods: Blood was obtained at baseline and multiple time points during a placebo-controlled trial of OIT for milk allergy in which subjects were randomized to receive omalizumab or placebo. Immunologic outcomes included measurement of basophil CD63 expression and histamine release and casein-specific CD4(+) regulatory T-cell proliferation. Biomarkers were analyzed in relationship to measurements of safety and efficacy. Results: Milk-induced basophil CD63 expression was transiently reduced in whole blood samples from both omalizumab- and placebo-treated subjects. However, IgE-dependent histamine release increased in washed cell preparations from omalizumab-but not placebo-treated subjects. No increase in regulatory T-cell frequency was evident in either group. Subjects with lower rates of adverse reactions, regardless of arm, experienced better clinical outcomes. Pre-OIT basophil reactivity positively associated with occurrence of symptoms during OIT, whereas the baseline milk IgE/total IgE ratio correlated with the likelihood of achieving sustained unresponsiveness. A combination of baseline basophil and serologic biomarkers defined a subset of patients in which adjunctive therapy with omalizumab was associated with attainment of sustained unresponsiveness and a reduction in adverse reactions. Conclusions: Combining omalizumab therapy with milk OIT led to distinct alterations in basophil reactivity but not T-cell responses. Baseline biomarkers can identify subjects most likely to benefit from adjunctive therapy with omalizumab.	[Frischmeyer-Guerrerio, Pamela A.] NIAID, Lab Allerg Dis, Food Allergy Res Unit, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Masilamani, Madhan; Kim, Jennifer; Grishin, Alexander; Sampson, Hugh A.] Icahn Sch Med Mt Sinai, Dept Pediat, Div Allergy & Immunol, New York, NY 10029 USA; [Gu, Wenjuan] Leidos Biomed Res, Clin Res Directorate, Clin Monitoring Res Program, NCI Campus, Frederick, MD USA; [Brittain, Erica] NIH, Biostat Res Branch, Div Clin Res, Bldg 10, Bethesda, MD 20892 USA; [Wood, Robert] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Allergy & Immunol, Baltimore, MD 21205 USA; [Nadeau, Kari] Stanford Sch Med, Sean N Parker Ctr Allergy & Asthma Res, Dept Med, Stanford, CA USA; [Nadeau, Kari] Stanford Sch Med, Sean N Parker Ctr Allergy & Asthma Res, Dept Pediat, Stanford, CA USA; [Jarvinen, Kirsi M.] Univ Rochester, Med Ctr, Sch Med & Dent, Dept Pediat,Div Allergy & Immunol, Rochester, NY USA; [Lindblad, Robert] EMMES Corp, Rockville, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; Johns Hopkins University; Stanford University; Stanford University; University of Rochester; Emmes Corporation	Sampson, HA (corresponding author), Icahn Sch Med Mt Sinai, Dept Pediat, Jaffe Food Allergy Inst, Box 1089, New York, NY 10029 USA.	hugh.sampson@mssm.edu	Guerrerio, Pamela/S-9360-2019; Masilamani, Madhan/H-3691-2019	Masilamani, Madhan/0000-0001-8181-8848; Grishin, Alexander/0000-0003-4799-4324	National Institute of Allergy and Infectious Diseases (NIAID) [AI-44236]; National Center for Advancing Translational Sciences, National Institutes of Health (NIH) [RR-026134, UL1 TR 001079]; Food Allergy Research and Education; Division of Intramural Research, NIAID, NIH; National Cancer Institute (NCI)/NIH [HHSN26120080000IE]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI044236, P01AI044236, ZIAAI001202] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Advancing Translational Sciences, National Institutes of Health (NIH); Food Allergy Research and Education; Division of Intramural Research, NIAID, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Cancer Institute (NCI)/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Omalizumab (Xolair) and omalizumab placebo for the trial were kindly provided by Genentech. The study was supported by grant AI-44236 from the National Institute of Allergy and Infectious Diseases (NIAID) and RR-026134 (Mount Sinai) and UL1 TR 001079 (Johns Hopkins) from the National Center for Advancing Translational Sciences, National Institutes of Health (NIH) and a supplemental grant from Food Allergy Research and Education. P.A.F.-G. is supported by the Division of Intramural Research, NIAID, NIH. This project was funded in in part with federal funds from the National Cancer Institute (NCI)/NIH under contract no. HHSN26120080000IE (to W.G.). The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government.	Bedoret D, 2012, MUCOSAL IMMUNOL, V5, P267, DOI 10.1038/mi.2012.5; Berin MC, 2016, IMMUNOL ALLERGY CLIN, V36, P87, DOI 10.1016/j.iac.2015.08.002; Burks AW, 2012, NEW ENGL J MED, V367, P233, DOI 10.1056/NEJMoa1200435; Chinthrajah RS, 2016, J ALLERGY CLIN IMMUN, V137, P984, DOI 10.1016/j.jaci.2016.02.004; Eckman JA, 2010, J ALLERGY CLIN IMMUN, V125, P889, DOI 10.1016/j.jaci.2009.09.012; Feuille E, 2016, ANN NUTR METAB, V68, P19, DOI 10.1159/000445391; Ford LS, 2013, J ALLERGY CLIN IMMUN, V131, P180, DOI 10.1016/j.jaci.2012.06.003; Gorelik M, 2015, J ALLERGY CLIN IMMUN, V135, P1283, DOI 10.1016/j.jaci.2014.11.010; Gruchalla RS, 2016, PEDIAT ALLERG IMM-UK, V27, P328, DOI 10.1111/pai.12508; Holgate S, 2005, J ALLERGY CLIN IMMUN, V115, P459, DOI 10.1016/j.jaci.2004.11.053; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Jones Stacie M, 2009, J Allergy Clin Immunol, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Keet CA, 2012, J ALLERGY CLIN IMMUN, V129, pe1; Keet CA, 2012, J ALLERGY CLIN IMMUN, V129, P448, DOI 10.1016/j.jaci.2011.10.023; Kim EH, 2011, J ALLERGY CLIN IMMUN, V127, P640, DOI 10.1016/j.jaci.2010.12.1083; KNOL EF, 1991, J ALLERGY CLIN IMMUN, V88, P328, DOI 10.1016/0091-6749(91)90094-5; MacGlashan D, 2010, CLIN EXP ALLERGY, V40, P1365, DOI 10.1111/j.1365-2222.2010.03572.x; MacGlashan DW, 2013, J ALLERGY CLIN IMMUN, V132, P906, DOI 10.1016/j.jaci.2013.04.056; MacGlashan DW, 2012, J ALLERGY CLIN IMMUN, V130, P1130, DOI 10.1016/j.jaci.2012.05.038; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; Macglashan jr DW, 2013, J ALLERGY CLIN IMMUN, V132, pe1; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P432, DOI 10.1016/0091-6749(76)90124-X; Prussin C, 2003, J ALLERGY CLIN IMMUN, V112, P1147, DOI 10.1016/j.jaci.2003.10.003; Rubio A, 2011, ALLERGY, V66, P92, DOI 10.1111/j.1398-9995.2010.02432.x; Sampson H. A., 2004, NOVART FDN SYMP, V257, P207; Sampson Hugh A, 2004, Novartis Found Symp, V257, P161; Santos AF, 2015, J ALLERGY CLIN IMMUN, V135, P179, DOI 10.1016/j.jaci.2014.09.001; Savage JH, 2012, J ALLERGY CLIN IMMUN, V130, P1123, DOI 10.1016/j.jaci.2012.05.039; Schroeder JT, 2013, J ALLERGY CLIN IMMUN, V132, P1428, DOI 10.1016/j.jaci.2013.08.033; SHUSTER J, 1983, CONTROL CLIN TRIALS, V4, P209, DOI 10.1016/S0197-2456(83)80026-9; Syed A, 2014, J ALLERGY CLIN IMMUN, V133, P500, DOI 10.1016/j.jaci.2013.12.1037; Vickery BP, 2014, J ALLERGY CLIN IMMUN, V133, P468, DOI 10.1016/j.jaci.2013.11.007; Wood RA, 2016, J ALLERGY CLIN IMMUN, V137, P973, DOI 10.1016/j.jaci.2016.01.001; Wood RA, 2016, J ALLERGY CLIN IMMUN, V137, P1103, DOI 10.1016/j.jaci.2015.10.005; Zaidi AK, 2010, J ALLERGY CLIN IMMUN, V125, P902, DOI 10.1016/j.jaci.2009.12.996	35	37	40	1	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2017	140	4					1043	+		10.1016/j.jaci.2017.03.028	http://dx.doi.org/10.1016/j.jaci.2017.03.028			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FI7JL	28414061	Green Accepted, Bronze			2022-12-18	WOS:000412172900016
J	Kreiner, E; Waage, J; Standl, M; Brix, S; Pers, TH; Alves, AC; Warrington, NM; Tiesler, CMT; Fuertes, E; Franke, L; Hirschhorn, JN; James, A; Simpson, A; Tung, JY; Koppelman, GH; Postma, DS; Pennell, CE; Jarvelin, MR; Custovic, A; Timpson, N; Ferreira, MA; Strachan, DP; Henderson, J; Hinds, D; Bisgaard, H; Bonnelykke, K				Kreiner, Eskil; Waage, Johannes; Standl, Marie; Brix, Susanne; Pers, Tune H.; Alves, Alexessander Couto; Warrington, Nicole M.; Tiesler, Carla M. T.; Fuertes, Elaine; Franke, Lude; Hirschhorn, Joel N.; James, Alan; Simpson, Angela; Tung, Joyce Y.; Koppelman, Gerard H.; Postma, Dirkje S.; Pennell, Craig E.; Jarvelin, Marjo-Riitta; Custovic, Adnan; Timpson, Nicholas; Ferreira, Manuel A.; Strachan, David P.; Henderson, John; Hinds, David; Bisgaard, Hans; Bonnelykke, Klaus			Shared genetic variants suggest common pathways in allergy and autoimmune diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; single nucleotide polymorphism; autoimmune disease; autoimmunity; genetic association studies	GENOME-WIDE ASSOCIATION; NF-KAPPA-B; SUSCEPTIBILITY LOCI; T-CELLS; 1,25-DIHYDROXYVITAMIN D-3; RHEUMATOID-ARTHRITIS; HAY-FEVER; METAANALYSIS; RISK; ASTHMA	Background: The relationship between allergy and autoimmune disorders is complex and poorly understood. Objective: We sought to investigate commonalities in genetic loci and pathways between allergy and autoimmune diseases to elucidate shared disease mechanisms. Methods: We meta-analyzed 2 genome-wide association studies on self-reported allergy and sensitization comprising a total of 62,330 subjects. These results were used to calculate enrichment for single nucleotide polymorphisms (SNPs) previously associated with autoimmune diseases. Furthermore, we probed for enrichment within genetic pathways and of transcription factor binding sites and characterized commonalities in variant burden on tissue-specific regulatory sites by calculating the enrichment of allergy SNPs falling in gene regulatory regions in various cells using Encode Roadmap DNase-hypersensitive site data. Finally, we compared the allergy data with those of all known diseases. Results: Among 290 loci previously associated with 16 autoimmune diseases, we found a significant enrichment of loci also associated with allergy (P = 1.4e-17) encompassing 29 loci at a false discovery rate of less than 0.05. Such enrichment seemed to be a general characteristic for autoimmune diseases. Among the common loci, 48% had the same direction of effect for allergy and autoimmune diseases. Additionally, we observed an enrichment of allergy SNPs falling within immune pathways and regions of chromatin accessible in immune cells that was also represented in patients with autoimmune diseases but not those with other diseases. Conclusion: We identified shared susceptibility loci and commonalities in pathways between allergy and autoimmune diseases, suggesting shared disease mechanisms. Further studies of these shared genetic mechanisms might help in understanding the complex relationship between these diseases, including the parallel increase in disease prevalence.	[Kreiner, Eskil; Waage, Johannes; Bisgaard, Hans; Bonnelykke, Klaus] Univ Copenhagen, Copenhagen Prospect Studies Asthma Childhood, COPSAC, Copenhagen, Denmark; [Standl, Marie; Tiesler, Carla M. T.; Fuertes, Elaine] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Epidemiol 1, Neuherberg, Germany; [Brix, Susanne] Univ Copenhagen, Novo Nordisk Fdn Ctr Basic Metab Res, Copenhagen, Denmark; [Pers, Tune H.; Hirschhorn, Joel N.] Boston Childrens Hosp, Div Endocrinol, Boston, MA USA; [Pers, Tune H.; Hirschhorn, Joel N.] Boston Childrens Hosp, Ctr Basic & Translat Obes Res, Boston, MA USA; [Pers, Tune H.; Hirschhorn, Joel N.] Broad Inst MIT & Harvard, Med & Populat Genet Program, Cambridge, MA USA; [Alves, Alexessander Couto] Imperial Coll London, Sch Publ Hlth, Dept Epidemiol & Biostat, London, England; [Warrington, Nicole M.] Univ Queensland, Brisbane, Qld 4072, Australia; [Warrington, Nicole M.] Univ Queensland, Diamantina Inst, Translat Res Inst, Brisbane, Qld 4072, Australia; [Warrington, Nicole M.; Pennell, Craig E.] Univ Western Australia, Sch Womens & Infants Hlth, Perth, WA, Australia; [Tiesler, Carla M. T.] Ludwig Maximilians Univ Munchen, Dr Van Hauner Childrens Hosp, Munich, Germany; [Franke, Lude] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, Groningen, Netherlands; [Hirschhorn, Joel N.] Harvard Med Sch, Dept Genet, Boston, MA USA; [James, Alan] Sir Charles Gairdner Hosp, Busselton Populat Med Res Fdn, Perth, WA, Australia; [James, Alan] Univ West Australia, Sch Med & Pharmacol, Nedlands, WA, Australia; [James, Alan] West Australian Sleep Disorders Res Inst, Dept Pulm Physiol, Nedlands, WA, Australia; [Simpson, Angela] Univ Manchester, Manchester Acad Hlth Sci Ctr, Univ Hosp South Manchester, NHS Fdn Trust, Manchester, Lancs, England; [Tung, Joyce Y.; Hinds, David] 23andMe, Mountain View, CA USA; [Koppelman, Gerard H.] Univ Groningen, Univ Med Ctr Groningen, Dept Pediat Pulmonol & Pediat Allergol, Beatrix Childrens Hosp,GRIAC Res Inst, Groningen, Netherlands; [Postma, Dirkje S.] Univ Groningen, Univ Med Ctr Groningen, Dept Pulm Med & TB, GRIAC Res Inst, Groningen, Netherlands; [Jarvelin, Marjo-Riitta] Imperial Coll London, Sch Publ Hlth, Ctr Environm & Hlth, MRC,Hlth Protect Agcy HPA,Dept Epidemiol & Biosta, London, England; [Jarvelin, Marjo-Riitta] Ctr Life Course Epidemiol, Fac Med, Oulu, Finland; [Jarvelin, Marjo-Riitta] Univ Oulu, Bioctr Oulu, Oulu, Finland; [Jarvelin, Marjo-Riitta] Oulu Univ Hosp, Unit Primary Care, Oulu, Finland; [Jarvelin, Marjo-Riitta] Natl Inst Hlth & Welf, Dept Children & Young People & Families, Oulu, Finland; [Custovic, Adnan] Univ Manchester, Manchester Acad Hlth Sci Ctr, Univ Hosp South Manchester, NHS Fdn Trust, Manchester, Lancs, England; [Timpson, Nicholas] MRC Integrat Epidemiol Unit, Bristol, Avon, England; [Henderson, John] Univ Bristol, Sch Social & Community Med, Bristol, Avon, England; [Ferreira, Manuel A.] QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia; [Strachan, David P.] St Georges Univ London, Populat Hlth Res Inst, London, England; [Pers, Tune H.] Statens Serum Inst, Dept Epidemiol Res, Copenhagen, Denmark	University of Copenhagen; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Novo Nordisk Foundation; University of Copenhagen; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Imperial College London; University of Queensland; University of Queensland; University of Western Australia; University of Munich; University of Groningen; Harvard University; Harvard Medical School; University of Western Australia; University of Western Australia; Oxford University Hospitals NHS Foundation Trust; University of Manchester; Wythenshawe Hospital NHS Foundation Trust; University of Groningen; University of Groningen; Health Protection Agency; Imperial College London; University of Oulu; University of Oulu; Finland National Institute for Health & Welfare; Oxford University Hospitals NHS Foundation Trust; University of Manchester; Wythenshawe Hospital NHS Foundation Trust; University of Bristol; QIMR Berghofer Medical Research Institute; St Georges University London; Statens Serum Institut	Bisgaard, H (corresponding author), Univ Copenhagen, Herlev & Gentofte Hosp, Copenhagen Prospect Studies Asthma Childhood, COPSAC, Copenhagen, Denmark.	bisgaard@copsac.com	Fox, Laura J/C-6249-2016; Custovic, Adnan/A-2435-2012; Warrington, Nicole/P-4868-2014; Timpson, Nicholas John/O-7548-2015; Pedersen, Susanne Brix/B-3484-2009; Koppelman, Gerard/AAG-9187-2020; Pennell, Craig/ABD-6902-2020; Attrill, Lauren/V-1688-2018; Bisgaard, Hans/N-4761-2016; Franke, Lude/P-7036-2016	Custovic, Adnan/0000-0001-5218-7071; Warrington, Nicole/0000-0003-4195-775X; Timpson, Nicholas John/0000-0002-7141-9189; Pedersen, Susanne Brix/0000-0001-8951-6705; Pennell, Craig/0000-0002-0937-6165; Bisgaard, Hans/0000-0003-4131-7592; Bonnelykke, Klaus/0000-0003-2003-1018; Fuertes, Elaine/0000-0003-0205-9025; Koppelman, Gerard/0000-0001-8567-3252; Franke, Lude/0000-0002-5159-8802; Simpson, Angela/0000-0003-2733-6666; Pers, Tune/0000-0003-0207-4831; Hinds, David/0000-0002-4911-803X; Standl, Marie/0000-0002-5345-2049; Kreiner, Eskil/0000-0003-1204-2438; Couto Alves, Alex/0000-0001-8519-7356	Medical Research Council; Netherlands Lung Foundation; Stichting Astma Bestrijding; Ubbo Emmius Foundation; TEVA, The Netherlands; AstraZeneca; Chiesi; Genentech; GlaxoSmithKline; Roche; National Health Medical Research Council; Telethon; Telethon-Perth Children's Hospital Research Fund; Novartis; Regeneron/Sanofi; ALK-Abello; Bayer; Thermo Fisher; National Health Medical Research Council of Australia [613627]; Wellcome; 23andMe; National Heart, Lung, and Blood Institute [1R43HL115873-01]; Danish Ministry of Health; Lundbeck Foundation; Danish Strategic Research Foundation; MRC [MR/K002449/1, G0401540, MC_UU_12013/3, MR/N01104X/1, MR/K002449/2, MR/N01104X/2, G1001799, G0601361] Funding Source: UKRI; Lundbeck Foundation [R163-2013-16235, R190-2014-3904] Funding Source: researchfish; Medical Research Council [G1000758, MC_UU_12013/3, MR/N01104X/2, G0601361, G1001799, MR/N01104X/1, G9815508, MR/K002449/1, G1000758B, G0401540, MR/K002449/2] Funding Source: researchfish; NNF Center for Basic Metabolic Research [Pers Group] Funding Source: researchfish; Novo Nordisk Fonden [NNF16OC0021496] Funding Source: researchfish; Asthma UK [MRC-Asthma UK Centre, MRC-AsthmaUKCentre] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Netherlands Lung Foundation; Stichting Astma Bestrijding; Ubbo Emmius Foundation; TEVA, The Netherlands(Teva Pharmaceutical Industries); AstraZeneca(AstraZeneca); Chiesi(Chiesi Pharmaceuticals Inc); Genentech(Roche HoldingGenentech); GlaxoSmithKline(GlaxoSmithKline); Roche(Roche Holding); National Health Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Telethon(Fondazione Telethon); Telethon-Perth Children's Hospital Research Fund; Novartis(Novartis); Regeneron/Sanofi(Regeneron); ALK-Abello; Bayer(Bayer AG); Thermo Fisher; National Health Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Wellcome; 23andMe; National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Danish Ministry of Health; Lundbeck Foundation(Lundbeckfonden); Danish Strategic Research Foundation(Danske Strategiske Forskningsrad (DSF)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Lundbeck Foundation(Lundbeckfonden); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NNF Center for Basic Metabolic Research(Novo Nordisk Foundation); Novo Nordisk Fonden(Novo Nordisk Foundation); Asthma UK	E. Kreiner is employed at Novo Nordisk A/S. A. Simpson has received a grant from the Medical Research Council. J. Y. Tung is employed by and receives stock/stock options from 23andMe. G. H. Koppelman has received grants from the Netherlands Lung Foundation, Stichting Astma Bestrijding, Ubbo Emmius Foundation, and TEVA, The Netherlands. D. S. Postma has consultant arrangements with Astra Zeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Takeda, and TEVA and has received grants from AstraZeneca, Chiesi, Genentech, GlaxoSmithKline, and Roche. C. E. Pennell has received grants from the National Health Medical Research Council, Telethon, and Telethon-Perth Children's Hospital Research Fund; is employed by the University of Western Australia; and has received travel support for invited presentations from Raine Study Core Funds, Haematology Association of Australia, Global Obstetric Update, March of Dimes and Burrows Wellcome. A. Custovic has received personal fees from Novartis, Regeneron/Sanofi, ALK-Abello, Bayer, and Thermo Fisher. M. A. Ferreira has received a grant from the National Health Medical Research Council of Australia (Project Grant 613627). J. Henderson has received grants from the Medical Research Council, Wellcome, and 23andMe. D. Hinds has received a grant from the National Heart, Lung, and Blood Institute (grant 1R43HL115873-01) and is employed by and has received stock/stock options from 23andMe. H. Bisgaard has received grants from the Danish Ministry of Health, the Lundbeck Foundation, and the Danish Strategic Research Foundation and has consultant arrangements with Chiesi Pharmaceuticals and Boehringer Ingelheim. K. Bonnelykke has received grants from the Danish Ministry of Health, the Lundbeck Foundation, and the Danish Strategic Research Foundation. The rest of the authors declare that they have no relevant conflicts of interest.	Allen HL, 2010, NATURE, V467, P832, DOI 10.1038/nature09410; Ananieva O, 2008, NAT IMMUNOL, V9, P1028, DOI 10.1038/ni.1644; Andersson R, 2014, NATURE, V507, P455, DOI 10.1038/nature12787; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Barrett JC, 2009, NAT GENET, V41, P703, DOI 10.1038/ng.381; Bergamaschi R, 2009, NEUROL SCI, V30, P115, DOI 10.1007/s10072-009-0036-8; Bhatt D, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00071; Bonnelykke K, 2013, NAT GENET, V45, P902, DOI 10.1038/ng.2694; Chen RQ, 2014, IMMUNITY, V41, P325, DOI 10.1016/j.immuni.2014.08.002; Chevalier N, 2011, J IMMUNOL, V186, P5556, DOI 10.4049/jimmunol.1002828; Clark RI, 2013, CELL, V155, P435, DOI 10.1016/j.cell.2013.09.007; Cotsapas C, 2013, TRENDS IMMUNOL, V34, P22, DOI 10.1016/j.it.2012.09.001; Cotsapas C, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002254; Du W, 2014, J IMMUNOL S, V192, P607; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Elangovan RI, 2014, J HUM GENET, V59, P211, DOI 10.1038/jhg.2014.3; Farh KKH, 2015, NATURE, V518, P337, DOI 10.1038/nature13835; Ferreira MAR, 2014, J ALLERGY CLIN IMMUN, V133, P1564, DOI 10.1016/j.jaci.2013.10.030; Ferreira MAR, 2011, LANCET, V378, P1006, DOI 10.1016/S0140-6736(11)60874-X; Franke A, 2010, NAT GENET, V42, P1118, DOI 10.1038/ng.717; Fujita N, 2004, CELL, V119, P75, DOI 10.1016/j.cell.2004.09.014; Gohlke PR, 2009, AUTOIMMUNITY, V42, P183, DOI 10.1080/08916930802668586; Gudbjartsson DF, 2009, NAT GENET, V41, P342, DOI 10.1038/ng.323; Han JW, 2009, NAT GENET, V41, P1234, DOI 10.1038/ng.472; Hinds DA, 2013, NAT GENET, V45, P907, DOI 10.1038/ng.2686; Hirota T, 2012, NAT GENET, V44, P1222, DOI 10.1038/ng.2438; Jeffery LE, 2009, J IMMUNOL, V183, P5458, DOI 10.4049/jimmunol.0803217; Jostins L, 2012, NATURE, V491, P119, DOI 10.1038/nature11582; Koch S, 2015, CLIN EXP ALLERGY, V45, P1356, DOI 10.1111/cea.12493; Kofler DM, 2014, J CLIN INVEST, V124, P2513, DOI 10.1172/JCI72973; Lee SU, 2012, IMMUNOL REV, V247, P107, DOI 10.1111/j.1600-065X.2012.01116.x; Li XN, 2012, J ALLERGY CLIN IMMUN, V130, P861, DOI 10.1016/j.jaci.2012.04.041; Lloyd CM, 2010, NAT REV IMMUNOL, V10, P838, DOI 10.1038/nri2870; Maier LM, 2006, J ALLERGY CLIN IMMUN, V117, P1306, DOI 10.1016/j.jaci.2005.12.1354; Maurano MT, 2012, SCIENCE, V337, P1190, DOI 10.1126/science.1222794; Mells GF, 2011, NAT GENET, V43, P329, DOI 10.1038/ng.789; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Nair RP, 2009, NAT GENET, V41, P199, DOI 10.1038/ng.311; Palmer MT, 2011, J BIOL CHEM, V286, P997, DOI 10.1074/jbc.M110.163790; Paternoster L, 2012, NAT GENET, V44, P187, DOI 10.1038/ng.1017; Pers TH, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6890; Petukhova L, 2010, NATURE, V466, P113, DOI 10.1038/nature09114; Pittet LA, 2011, AM J RESP CELL MOL, V45, P573, DOI 10.1165/rcmb.2010-0210OC; Rabin RL, 2008, CLIN EXP IMMUNOL, V153, P19, DOI 10.1111/j.1365-2249.2008.03679.x; Rudwaleit M, 2002, ANN RHEUM DIS, V61, P968, DOI 10.1136/ard.61.11.968; Sawcer S, 2011, NATURE, V476, P214, DOI 10.1038/nature10251; Sevelsted A, 2015, PEDIATRICS, V135, pE92, DOI 10.1542/peds.2014-0596; Sirota M, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000792; Stahl EA, 2010, NAT GENET, V42, P508, DOI 10.1038/ng.582; Steinman L, 2007, NAT MED, V13, P139, DOI 10.1038/nm1551; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Takimoto T, 2010, J IMMUNOL, V185, P842, DOI 10.4049/jimmunol.0904100; Terrados G, 2012, NUCLEIC ACIDS RES, V40, P7844, DOI 10.1093/nar/gks544; Urayama KY, 2012, JNCI-J NATL CANCER I, V104, P240, DOI 10.1093/jnci/djr516; Verhoef CM, 1998, ANN RHEUM DIS, V57, P275, DOI 10.1136/ard.57.5.275; Wang J, 2009, INT IMMUNOL, V21, P227, DOI 10.1093/intimm/dxn143; Welter D, 2014, NUCLEIC ACIDS RES, V42, pD1001, DOI 10.1093/nar/gkt1229; Yan H, 1996, EMBO J, V15, P1064, DOI 10.1002/j.1460-2075.1996.tb00444.x; Yoshida T, 2010, CURR OPIN IMMUNOL, V22, P154, DOI 10.1016/j.coi.2010.02.011; Zhernakova A, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002004	60	37	37	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2017	140	3					771	781		10.1016/j.jaci.2016.10.055	http://dx.doi.org/10.1016/j.jaci.2016.10.055			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FF8CA	28188724	Green Submitted, Green Accepted, Bronze			2022-12-18	WOS:000409241500016
J	Chen, W; Wang, T; Pino-Yanes, M; Forno, E; Liang, LM; Yan, Q; Hu, DL; Weeks, DE; Baccarelli, A; Acosta-Perez, E; Eng, C; Han, YY; Boutaoui, N; Laprise, C; Davies, GA; Hopkin, JM; Moffatt, MF; Cookson, WOCM; Canino, G; Burchard, EG; Celedon, JC				Chen, Wei; Wang, Ting; Pino-Yanes, Maria; Forno, Erick; Liang, Liming; Yan, Qi; Hu, Donglei; Weeks, Daniel E.; Baccarelli, Andrea; Acosta-Perez, Edna; Eng, Celeste; Han, Yueh-Ying; Boutaoui, Nadia; Laprise, Catherine; Davies, Gwyneth A.; Hopkin, Julian M.; Moffatt, Miriam F.; Cookson, William O. C. M.; Canino, Glorisa; Burchard, Esteban G.; Celedon, Juan C.			An epigenome-wide association study of total serum IgE in Hispanic children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Epigenome-wide association study; total IgE; Hispanic; children	DNA METHYLATION; ALLERGIC-ASTHMA; LUNG-FUNCTION; ANCESTRY; LATINOS; PROTEIN	Background: Total IgE is a therapeutic target in patients with allergic diseases. DNA methylation in white blood cells (WBCs) was associated with total IgE levels in an epigenome-wide association study of white subjects. Whether DNA methylation of eosinophils explains these findings is insufficiently understood. Methods: We tested for association between genome-wide DNA methylation in WBCs and total IgE levels in 2 studies of Hispanic children: the Puerto Rico Genetics of Asthma and Lifestyle Study (PR-GOAL; n = 306) and the Genes-environments and Admixture in Latino Americans (GALA II) study (n = 573). Whole-genome methylation of DNA from WBCs was measured by using the Illumina Infinium HumanMethylation450 BeadChip. Total IgE levels were measured by using the UniCAP 100 system. InPR-GOALWBCtypes (ie, neutrophils, eosinophils, basophils, lymphocytes, and monocytes) in peripheral blood were measured by using Coulter Counter techniques. In the GALA II study WBC types were imputed. Multivariable linear regression was used for the analysis of DNA methylation and total IgE levels, which was first conducted separately for each cohort, and then results from the 2 cohorts were combined in a meta-analysis. Results: CpG sites in multiple genes, including novel findings and results previously reported in white subjects, were significantly associated with total IgE levels. However, adjustment for WBC types resulted in markedly fewer significant sites. Top findings from this adjusted meta-analysis were in the genes ZFPM1 (P = 1.5 x 10(-12)), ACOT7 (P = 2.5 x 10(-11)), and MND1 (P = 1.4 x 10(-9)). Conclusions: In an epigenome-wide association study adjusted for WBC types (including eosinophils), methylation changes in genes enriched in pathways relevant to asthma and immune responses were associated with total IgE levels among Hispanic children.	[Chen, Wei; Wang, Ting; Forno, Erick; Yan, Qi; Han, Yueh-Ying; Boutaoui, Nadia; Celedon, Juan C.] UPMC, Childrens Hosp Pittsburgh, Div Pediat Pulm Med Allergy & Immunol, Pittsburgh, PA 15224 USA; [Weeks, Daniel E.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15260 USA; [Weeks, Daniel E.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15260 USA; [Pino-Yanes, Maria] Inst Salud Carlos III, CIBER Enfermedades Resp, Madrid, Spain; [Liang, Liming] Harvard Sch Publ Hlth, Dept Epidemiol & Biostat, Boston, MA USA; [Baccarelli, Andrea] Harvard Sch Publ Hlth, Dept Environm Med, Boston, MA USA; [Hu, Donglei; Eng, Celeste; Burchard, Esteban G.] Univ Calif San Francisco, Dept Therapeut Sci & Bioengn, San Francisco, CA 94143 USA; [Acosta-Perez, Edna; Canino, Glorisa] Univ Puerto Rico, Behav Sci Res Inst, San Juan, PR 00936 USA; [Acosta-Perez, Edna; Canino, Glorisa] Univ Puerto Rico, Dept Pediat, San Juan, PR 00936 USA; [Laprise, Catherine] Univ Quebec Chicoutimi, Saguenay, PQ, Canada; [Davies, Gwyneth A.; Hopkin, Julian M.] Swansea Univ, Med Sch, Inst Life Sci, Swansea, W Glam, Wales; [Moffatt, Miriam F.; Cookson, William O. C. M.] Imperial Coll, Natl Heart & Lung Inst, London, England	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; Instituto de Salud Carlos III; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; University of California System; University of California San Francisco; University of Puerto Rico; University of Puerto Rico Medical Sciences Campus; University of Puerto Rico; University of Puerto Rico Medical Sciences Campus; University of Quebec; University of Quebec Chicoutimi; Swansea University; Imperial College London	Celedon, JC (corresponding author), UPMC, Childrens Hosp Pittsburgh, Div Pulm Med Allergy & Immunol, 4401 Penn Ave, Pittsburgh, PA 15224 USA.	juan.celedon@chp.edu	Forno, Erick/I-1476-2019; Weeks, Daniel E/B-2995-2012; Chen, Wei/AAX-5994-2020; Pérez, Edna Acosta/AAW-6672-2021; Cookson, William/HHC-1790-2022; Pino-Yanes, Maria/C-8498-2017; Davies, Gwyneth/C-3838-2017; Wang, Ting/L-8427-2017	Forno, Erick/0000-0001-6497-9885; Weeks, Daniel E/0000-0001-9410-7228; Chen, Wei/0000-0001-7196-8703; Pino-Yanes, Maria/0000-0003-0332-437X; Davies, Gwyneth/0000-0003-1218-1008; Wang, Ting/0000-0003-4712-6658; acosta, edna/0000-0001-7101-3157; Laprise, Catherine/0000-0001-5526-9945	National Institutes of Health (NIH) [HL079966, HL117191]; Heinz Endowments; NIH [HL088133, HL004464, HL117004, ES015794, ES24844, TRDRP 24RT 0025, MD006902, GM007546, HL125666]; RWJF Amos Medical Faculty Development Award; American Asthma Foundation; Sandler Foundation; Instituto de Salud Carlos III within the ERACoSysMed 1st Joint Transnational Call (SysPharmPedia 99) from the European Union, under the Horizon [AC15/00015]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079966, R01HL117191, K08HL125666] Funding Source: NIH RePORTER; Medical Research Council [G1000758, G1000758B] Funding Source: researchfish; Wellcome Trust [096964/Z/11/Z] Funding Source: researchfish; Asthma UK [MRC-Asthma UK Centre, MRC-AsthmaUKCentre] Funding Source: researchfish	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Heinz Endowments; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); RWJF Amos Medical Faculty Development Award; American Asthma Foundation; Sandler Foundation; Instituto de Salud Carlos III within the ERACoSysMed 1st Joint Transnational Call (SysPharmPedia 99) from the European Union, under the Horizon; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Wellcome Trust(Wellcome TrustEuropean Commission); Asthma UK	PR-GOAL was supported by grants HL079966 and HL117191 from the National Institutes of Health (NIH) and by the Heinz Endowments. The GALA II study was supported by grants HL088133, HL004464, HL117004, ES015794, ES24844, TRDRP 24RT 0025, MD006902, and GM007546 from the NIH. E.G.B. was also supported by the RWJF Amos Medical Faculty Development Award, the American Asthma Foundation, and the Sandler Foundation. E.F.'s contribution was supported by grant HL125666 from the NIH. C.L. is the chairholder of the Canada Research Chair in the Environment and Genetics of Respiratory Disorders and Allergy. E.P.-Y. was supported by the grant AC15/00015 by Instituto de Salud Carlos III within the ERACoSysMed 1st Joint Transnational Call (SysPharmPedia 99) from the European Union, under the Horizon 2020.	Brehm JM, 2012, J ALLERGY CLIN IMMUN, V129, P1484, DOI 10.1016/j.jaci.2012.03.035; Celedon JC, 2004, CHEST, V125, P85, DOI 10.1378/chest.125.1.85; Chen WL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137979; Clay CC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090401; Dyskova T, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/121378; Everson TM, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0213-8; Feleszko W, 2014, ARCH DIS CHILD, V99, P985, DOI 10.1136/archdischild-2013-305444; Gorentla BK, 2015, J ALLERGY CLIN IMMUN, V135, pAB283, DOI 10.1016/j.jaci.2014.12.1863; Granada M, 2012, J ALLERGY CLIN IMMUN, V129, P840, DOI 10.1016/j.jaci.2011.09.029; Houseman EA, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-86; Jacobs TS, 2014, J ALLERGY CLIN IMMUN, V134, P737, DOI 10.1016/j.jaci.2014.03.028; Kim H, 2012, INT J PHARMACEUT, V434, P243, DOI 10.1016/j.ijpharm.2012.05.067; Kitamura N, 2011, INT ARCH ALLERGY IMM, V155, P53, DOI 10.1159/000327292; Liang LM, 2015, NATURE, V520, P670, DOI 10.1038/nature14125; Marabita F, 2013, EPIGENETICS-US, V8, P333, DOI 10.4161/epi.24008; Matsuoka T, 2000, SCIENCE, V287, P2013, DOI 10.1126/science.287.5460.2013; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Nickel R, 2005, CLIN EXP ALLERGY, V35, P619, DOI 10.1111/j.1365-2222.2005.02237.x; Nishimura KK, 2013, AM J RESP CRIT CARE, V188, P309, DOI 10.1164/rccm.201302-0264OC; Pino-Yanes M, 2015, J ALLERGY CLIN IMMUN, V135, P1502, DOI 10.1016/j.jaci.2014.10.033; Pino-Yanes M, 2015, J ALLERGY CLIN IMMUN, V135, P228, DOI 10.1016/j.jaci.2014.07.053; Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847; Rosser FJ, 2014, AM J RESP CRIT CARE, V189, P1316, DOI 10.1164/rccm.201401-0186PP; Saaf AM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004017; Seong K, 2011, J CONTROL RELEASE, V152, P257, DOI 10.1016/j.jconrel.2011.02.025; Simon D, 2007, J ALLERGY CLIN IMMUN, V119, P1291, DOI 10.1016/j.jaci.2007.02.010; Stokes JR, 2015, J ALLER CL IMM-PRACT, V3, P162, DOI 10.1016/j.jaip.2014.10.010; Teschendorff AE, 2013, BIOINFORMATICS, V29, P189, DOI 10.1093/bioinformatics/bts680; Uller L, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-16; Wang T, 2015, EPIGENETICS-US, V10, P662, DOI 10.1080/15592294.2015.1057384; Wu C., 2016, EPIGENETICS; Yang IV, 2015, J ALLERGY CLIN IMMUN, V136, P69, DOI 10.1016/j.jaci.2015.01.025; Yang IV, 2012, AM J RESP CRIT CARE, V185, P620, DOI 10.1164/rccm.201108-1503OC; Yatagai Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080941	34	37	38	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2017	140	2					571	577		10.1016/j.jaci.2016.11.030	http://dx.doi.org/10.1016/j.jaci.2016.11.030			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FC5BK	28069425	Green Accepted, Bronze			2022-12-18	WOS:000406855500029
J	Ellis, AK; Frankish, CW; O'Hehir, RE; Armstrong, K; Steacy, L; Larche, M; Hafner, RP				Ellis, Anne K.; Frankish, Charles W.; O'Hehir, Robyn E.; Armstrong, Kristen; Steacy, Lisa; Larche, Mark; Hafner, Roderick P.			Treatment with grass allergen peptides improves symptoms of grass pollen-induced allergic rhinoconjunctivitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen challenge; allergen peptides; allergy; allergic rhinoconjunctivitis; allergic rhinitis; environmental exposure unit; epitope; grass; immunotherapy; synthetic peptide immunoregulatory epitope	SUBLINGUAL IMMUNOTHERAPY; FOLLOW-UP; UNITED-STATES; NATIONAL-HEALTH; T-CELLS; EFFICACY; RHINITIS; ASTHMA; SAFETY; CHILDREN	Background: Synthetic peptide immunoregulatory epitopes are a new class of immunotherapy to treat allergic rhinoconjunctivitis (ARC). Grass allergen peptides, comprising 7 synthetic T-cell epitopes derived from Cyn d 1, Lol p 5, Dac g 5, Hol l 5, and Phl p 5, is investigated for treatment of grass pollen-induced ARC. Objective: We sought to evaluate the efficacy, safety, and tolerability of intradermally administered grass allergen peptides. Methods: A multicenter, randomized, double-blind, placebocontrolled study evaluated 3 regimens of grass allergen peptides versus placebo in patients with grass pollen-induced allergy (18-65 years). After a 4-day baseline challenge to rye grass in the environmental exposure unit (EEU), subjects were randomized to receive grass allergen peptides at 6 nmol at 2-week intervals for a total of 8 doses (8x6Q2W), grass allergen peptides at 12 nmol at 4-week intervals for a total of 4 doses (4x12Q4W), or grass allergen peptides at 12 nmol at 2-week intervals for a total of 8 doses (8x12Q2W) or placebo and treated before the grass pollen season. The primary efficacy end point was change from baseline in total rhinoconjunctivitis symptom score across days 2 to 4 of a 4-day posttreatment challenge (PTC) in the EEU after the grass pollen season. Secondary efficacy end points and safety were also assessed. Results: Two hundred eighty-two subjects were randomized. Significantly greater improvement (reduction of total rhinoconjunctivitis symptom score from baseline to PTC) occurred across days 2 to 4 with grass allergen peptide 8x6Q2W versus placebo (25.4 vs 23.8, respectively; P = .0346). Greater improvement at PTC also occurred for grass allergen peptide 8x6Q2W versus placebo (P = .0403) in patients with more symptomatic ARC. No safety signals were detected. Conclusion: Grass allergen peptide 8x6Q2W significantly improved ARC symptoms after rye grass allergen challenge in an EEU with an acceptable safety profile.	[Ellis, Anne K.] Queens Univ, Dept Med, Kingston, ON, Canada; [Ellis, Anne K.] Queens Univ, Dept Biomed & Mol Sci, Kingston, ON, Canada; [Frankish, Charles W.] Univ Ottawa, Dept Med, Ottawa, ON, Canada; [O'Hehir, Robyn E.] Alfred Hosp, Dept Allergy Immunol & Resp Med, Melbourne, Vic, Australia; [O'Hehir, Robyn E.] Monash Univ, Melbourne, Vic, Australia; [Armstrong, Kristen] Adiga Life Sci, Hamilton, ON, Canada; [Ellis, Anne K.; Steacy, Lisa] Kingston Gen Hosp, Allergy Res Unit, Kingston, ON, Canada; [Larche, Mark] McMaster Univ, St Josephs Healthcare, Hamilton, ON, Canada; [Hafner, Roderick P.] Circassia Ltd, Oxford Sci Pk, Oxford, England	Queens University - Canada; Queens University - Canada; University of Ottawa; Florey Institute of Neuroscience & Mental Health; Monash University; Queens University - Canada; McMaster University	Ellis, AK (corresponding author), Queens Univ, Dept Med, Kingston Gen Hosp, Watkins D1,76 Stuart St, Kingston, ON K7L 2V7, Canada.	ellisa@KGH.KARI.NET	O'Hehir, Robyn E/H-3627-2011	O'Hehir, Robyn E/0000-0002-3489-7595; Larche, Mark/0000-0002-1439-7593	Circassia	Circassia	We acknowledge the editorial assistance provided by Ken Kauffman and Patricia C. Abramo of Adelphi Communications New York in the preparation of this manuscript (funded by Circassia).	Aalberse RC, 2002, IMMUNOLOGY, V105, P9, DOI 10.1046/j.0019-2805.2001.01341.x; Akdis M, 2009, CURR OPIN IMMUNOL, V21, P700, DOI 10.1016/j.coi.2009.07.012; Anolik R, 2014, ANN ALLERG ASTHMA IM, V113, P101, DOI 10.1016/j.anai.2014.04.008; Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; Bachert C, 2015, WORLD ALLERGY ORGAN, V8, DOI 10.1186/s40413-015-0078-8; Barnes ML, 2010, CLIN EXP ALLERGY, V40, P242, DOI 10.1111/j.1365-2222.2009.03381.x; Blaiss M, 2011, J ALLERGY CLIN IMMUN, V127, P64, DOI 10.1016/j.jaci.2010.11.034; Blaiss MS, 2014, ANN ALLERG ASTHMA IM, V112, P322, DOI 10.1016/j.anai.2014.02.006; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Bousquet J, 2011, ALLERGY, V66, P765, DOI 10.1111/j.1398-9995.2011.02590.x; Calabrese EJ, 2005, CRIT REV TOXICOL, V35, P89, DOI 10.1080/10408440590917044; Calderon MA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001936.pub2; Canonica GW, 2007, ALLERGY, V62, P317, DOI 10.1111/j.1398-9995.2006.01312.x; Canonica GW, 2014, WORLD ALLERGY ORGAN, V7, DOI 10.1186/1939-4551-7-6; Couroux P, 2015, CLIN EXP ALLERGY, V45, P974, DOI 10.1111/cea.12488; Cox L, 2010, J ALLERGY CLIN IMMUN, V125, P569, DOI 10.1016/j.jaci.2009.10.060; Day J. H., 2006, Clinical and Experimental Allergy Reviews, V6, P31, DOI 10.1111/j.1365-2222.2005.00099.x; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; Di Bona D, 2015, JAMA INTERN MED, V175, P1301, DOI 10.1001/jamainternmed.2015.2840; Didier A, 2014, EXPERT REV CLIN IMMU, V10, P1309, DOI 10.1586/1744666X.2014.957677; Dretzke J, 2013, J ALLERGY CLIN IMMUN, V131, P1361, DOI 10.1016/j.jaci.2013.02.013; Durham SR, 2012, J ALLERGY CLIN IMMUN, V129, P717, DOI 10.1016/j.jaci.2011.12.973; Elenburg S, 2014, WORLD ALLERGY ORGAN, V7, DOI 10.1186/1939-4551-7-24; Ellis AK, 2014, AAAAI ANN MARCH 4 SA; Ellis Anne K, 2013, Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess, V97, P91; Ellis AK, 2013, ANN ALLERG ASTHMA IM, V111, P323, DOI 10.1016/j.anai.2013.07.019; Esch RE, 2008, J ALLERGY CLIN IMMUN, V122, P659, DOI 10.1016/j.jaci.2008.07.018; Fitzhugh DJ, 2011, IMMUNOL ALLERGY CLIN, V31, P149, DOI 10.1016/j.iac.2011.03.003; Gordon BR, 2011, OTOLARYNG CLIN N AM, V44, P765, DOI 10.1016/j.otc.2011.03.006; Howarth P, 2012, ALLERGY, V67, P321, DOI 10.1111/j.1398-9995.2011.02759.x; Jacobsen L, 2007, ALLERGY, V62, P943, DOI 10.1111/j.1398-9995.2007.01451.x; Jutel M, 2014, ALLERGY, V69, P31; Kiel MA, 2013, J ALLERGY CLIN IMMUN, V132, P353, DOI 10.1016/j.jaci.2013.03.013; Larche M, 2005, PHARMACOL THERAPEUT, V108, P353, DOI 10.1016/j.pharmthera.2005.05.004; Larche M, 2007, J ALLERGY CLIN IMMUN, V119, P906, DOI 10.1016/j.jaci.2007.02.015; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Muller U, 1998, J ALLERGY CLIN IMMUN, V101, P747, DOI 10.1016/S0091-6749(98)70402-6; Muma W., 2012, ONTARIO GRASSES; Nelson H, 2015, J ALLER CL IMM-PRACT, V3, P256, DOI 10.1016/j.jaip.2014.09.018; Nelson HS, 2014, EXPERT REV CLIN IMMU, V10, P1437, DOI 10.1586/1744666X.2014.963556; Nelson HS, 2011, J ALLERGY CLIN IMMUN, V127, P72, DOI 10.1016/j.jaci.2010.11.035; Niggemann B, 2006, ALLERGY, V61, P855, DOI 10.1111/j.1398-9995.2006.01068.x; North ML, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0514-4; Oldfield WLG, 2002, LANCET, V360, P47, DOI 10.1016/S0140-6736(02)09332-7; Pablos I, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0603-z; Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x; Patel D, 2013, J ALLERGY CLIN IMMUN, V131, P103, DOI 10.1016/j.jaci.2012.07.028; Pene J, 1998, J ALLERGY CLIN IMMUN, V102, P571, DOI 10.1016/S0091-6749(98)70294-5; Rolland Jennifer M., 2013, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, V12, P201; Rolland JM, 2009, PHARMACOL THERAPEUT, V121, P273, DOI 10.1016/j.pharmthera.2008.11.007; Salo PM, 2014, J ALLERGY CLIN IMMUN, V134, P350, DOI 10.1016/j.jaci.2013.12.1071; Schmitt J, 2015, J ALLERGY CLIN IMMUN, V136, P1511, DOI 10.1016/j.jaci.2015.07.038; Shamji MH, 2015, EAACI ANN M BARC SPA; Sikora JM, 2013, ANN ALLERG ASTHMA IM, V110, P194, DOI 10.1016/j.anai.2012.12.014; Singh K, 2010, J ALLERGY CLIN IMMUN, V126, P778, DOI 10.1016/j.jaci.2010.06.050; Smith TRF, 2004, ALLERGY, V59, P1097, DOI 10.1111/j.1398-9995.2004.00601.x; Tankersley MS, 2011, CURR ALLERGY ASTHM R, V11, P115, DOI 10.1007/s11882-010-0172-5; Tarzi M, 2006, CLIN EXP ALLERGY, V36, P465, DOI 10.1111/j.1365-2222.2006.02469.x; van Ree R, 1998, J ALLERGY CLIN IMMUN, V102, P184, DOI 10.1016/S0091-6749(98)70084-3; Verhoef A, 2005, PLOS MED, V2, P253, DOI 10.1371/journal.pmed.0020078; Weber RW, 2003, J ALLERGY CLIN IMMUN, V112, P229, DOI 10.1067/mai.2003.1683; White JF, 2003, ANN ALLERG ASTHMA IM, V91, P425, DOI 10.1016/S1081-1206(10)61509-8; Worm M, 2011, J ALLERGY CLIN IMMUN, V127, P89, DOI 10.1016/j.jaci.2010.11.029	63	37	38	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2017	140	2					486	496		10.1016/j.jaci.2016.11.043	http://dx.doi.org/10.1016/j.jaci.2016.11.043			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FC5BK	28236469				2022-12-18	WOS:000406855500021
J	Serezani, APM; Bozdogan, G; Sehra, S; Walsh, D; Krishnamurthy, P; Potchanant, EAS; Nalepa, G; Goenka, S; Turner, MJ; Spandau, DF; Kaplan, MH				Serezani, Ana P. M.; Bozdogan, Gunseli; Sehra, Sarita; Walsh, Daniel; Krishnamurthy, Purna; Potchanant, Elizabeth A. Sierra; Nalepa, Grzegorz; Goenka, Shreevrat; Turner, Matthew J.; Spandau, Dan F.; Kaplan, Mark H.			IL-4 impairs wound healing potential in the skin by repressing fibronectin expression	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Keratinocyte; atopic dermatitis; wound healing; IL-4; RNA sequencing; fibronectin	ATOPIC-DERMATITIS SKIN; HUMAN KERATINOCYTES; TH2 CYTOKINES; FOLLOW-UP; T-CELLS; RECEPTOR; GROWTH; INTERLEUKIN-4; INFLAMMATION; ACTIVATION	Background: Atopic dermatitis (AD) is characterized by intense pruritis and is a common childhood inflammatory disease. Many factors are known to affect AD development, including the pleiotropic cytokine IL-4. Yet little is known regarding the direct effects of IL-4 on keratinocyte function. Objective and Methods: In this report RNA sequencing and functional assays were used to define the effect of the allergic environment on primary keratinocyte function and wound repair in mice. Results: Acute or chronic stimulation by IL-4 modified expression of more than 1000 genes expressed in human keratinocytes that are involved in a broad spectrum of nonoverlapping functions. Among the IL-4-induced changes, repression of fibronectin critically impaired the human keratinocyte wound response. Moreover, in mouse models of spontaneous and induced AD-like lesions, there was delayed re-epithelialization. Importantly, topical treatment with fibronectin restored the epidermal repair response. Conclusion: Keratinocyte gene expression is critically shaped by IL-4, altering cell fate decisions, which are likely important for the clinical manifestations and pathology of allergic skin disease.	[Serezani, Ana P. M.; Bozdogan, Gunseli; Sehra, Sarita; Walsh, Daniel; Krishnamurthy, Purna; Potchanant, Elizabeth A. Sierra; Nalepa, Grzegorz; Goenka, Shreevrat; Kaplan, Mark H.] Indiana Univ Sch Med, Dept Pediat, HB Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; [Potchanant, Elizabeth A. Sierra; Nalepa, Grzegorz] Indiana Univ Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; [Potchanant, Elizabeth A. Sierra; Nalepa, Grzegorz] Indiana Univ Sch Med, Div Pediat Hematol Oncol, Bone Marrow Failure Program, Indianapolis, IN 46202 USA; [Potchanant, Elizabeth A. Sierra; Nalepa, Grzegorz] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; [Turner, Matthew J.; Spandau, Dan F.] Indiana Univ Sch Med, Dept Dermatol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington	Kaplan, MH (corresponding author), Indiana Univ, Wells Ctr, Pediat, 1044 West Walnut St,Rm 202, Indianapolis, IN 46202 USA.	mkaplan2@iupui.edu	Bozdogan, Gunseli/X-3032-2018	Sierra, Elizabeth/0000-0003-0040-5916; Lab, Nalepa/0000-0002-7560-1906	Public Health Service grant [R01 AI095282, R01 ES020866]; NIH K12-Indiana Pediatric Scientist Award [5T32H0069047-04]; VA [CDA2 CX001019]; Riley Children's Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD068371, T32HD069047] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007910] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI095282] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES020866] Funding Source: NIH RePORTER	Public Health Service grant(United States Department of Health & Human ServicesUnited States Public Health Service); NIH K12-Indiana Pediatric Scientist Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); VA(US Department of Veterans Affairs); Riley Children's Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by Public Health Service grants R01 AI095282 (to M.H.K.), R01 ES020866 (to D.F.S.), VA CDA2 CX001019 (to M.J.T.), NIH K12-Indiana Pediatric Scientist Award, and T32 (5T32H0069047-04; to G.N.). Support provided by the HB Wells Center was in part from the Riley Children's Foundation.	Albanesi C, 2007, J IMMUNOL, V179, P984, DOI 10.4049/jimmunol.179.2.984; Allen JE, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002003; Amon Ulrich, 1994, Journal of Dermatology (Tokyo), V21, P982; Beltrani VS, 2005, CURR OPIN ALLERGY CL, V5, P413, DOI 10.1097/01.all.0000182544.37724.b5; Bergmann RL, 1998, CLIN EXP ALLERGY, V28, P965; Brauweiler AM, 2015, J INVEST DERMATOL, V135, P2550, DOI 10.1038/jid.2015.181; BROWN LF, 1993, AM J PATHOL, V142, P793; Bruns HA, 2003, J IMMUNOL, V170, P3478, DOI 10.4049/jimmunol.170.7.3478; De Benedetto Anna, 2011, J Allergy Clin Immunol, V127, P773, DOI 10.1016/j.jaci.2010.10.018; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V128, P242, DOI 10.1016/j.jaci.2011.02.014; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V127, P773, DOI 10.1016/j.jaci.2010.10.018; de Koning HD, 2012, BRIT J DERMATOL, V166, P1245, DOI 10.1111/j.1365-2133.2012.10885.x; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Elmariah SB, 2013, CELL, V155, P267, DOI 10.1016/j.cell.2013.09.038; Gustafsson D, 2000, ALLERGY, V55, P240, DOI 10.1034/j.1398-9995.2000.00391.x; Howell MD, 2006, IMMUNITY, V24, P341, DOI 10.1016/j.immuni.2006.02.006; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Kagami S, 2005, CLIN EXP IMMUNOL, V141, P459, DOI 10.1111/j.1365-2249.2005.02875.x; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kim BE, 2008, CLIN IMMUNOL, V126, P332, DOI 10.1016/j.clim.2007.11.006; KIMURA T, 1989, J AM ACAD DERMATOL, V21, P579, DOI 10.1016/S0190-9622(89)80235-X; Knipper JA, 2015, IMMUNITY, V43, P803, DOI 10.1016/j.immuni.2015.09.005; Kobayashi T, 2015, IMMUNITY, V42, P756, DOI 10.1016/j.immuni.2015.03.014; Krishnamurthy P, 2014, J ALLERGY CLIN IMMUN, V133, P577, DOI 10.1016/j.jaci.2013.09.031; Kuhn C, 1999, INT J CANCER, V80, P431, DOI 10.1002/(SICI)1097-0215(19990129)80:3<431::AID-IJC16>3.3.CO;2-X; Leoni G, 2015, MUCOSAL IMMUNOL, V8, P959, DOI 10.1038/mi.2015.63; Leung DYM, 2011, J ALLERGY CLIN IMMUN, V127, P965, DOI 10.1016/j.jaci.2011.02.010; Leung DY, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Lewkowich IP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003879; Li-Korotky HS, 2007, ARCH OTOLARYNGOL, V133, P919, DOI 10.1001/archotol.133.9.919; Lim EJ, 2011, J BIOL CHEM, V286, P13193, DOI 10.1074/jbc.M110.210724; Lin FB, 2014, J INVEST DERMATOL, V134, P1119, DOI 10.1038/jid.2013.420; Livant DL, 2000, J CLIN INVEST, V105, P1537, DOI 10.1172/JCI8527; Malaisse J, 2014, J INVEST DERMATOL, V134, P2174, DOI 10.1038/jid.2014.147; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; Omori-Miyake M, 2014, J INVEST DERMATOL, V134, P1342, DOI 10.1038/jid.2013.503; Owczarek W, 2010, CYTOKINE, V50, P181, DOI 10.1016/j.cyto.2010.02.016; Pellerin L, 2013, J ALLERGY CLIN IMMUN, V131, P1094, DOI 10.1016/j.jaci.2012.12.1566; Renard E, 2012, J MOL MED, V90, P649, DOI 10.1007/s00109-011-0842-3; Ricci G, 2006, J AM ACAD DERMATOL, V55, P765, DOI 10.1016/j.jaad.2006.04.064; Rouse BT, 2010, NAT REV IMMUNOL, V10, P514, DOI 10.1038/nri2802; Sehra S, 2008, CRIT REV IMMUNOL, V28, P15, DOI 10.1615/CritRevImmunol.v28.i1.20; Sehra S, 2010, J IMMUNOL, V184, P3186, DOI 10.4049/jimmunol.0901860; Sehrawat S, 2010, J GERONTOL SOC WORK, V53, P64, DOI 10.1080/01634370802609254; Sehrawat S, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000882; Suarez-Farinas M, 2011, J ALLERGY CLIN IMMUN, V127, P954, DOI 10.1016/j.jaci.2010.12.1124; Tanaka M, 1997, BRIT J DERMATOL, V136, P966, DOI 10.1111/j.1365-2133.1997.tb03946.x; Wang Q, 2015, J ALLERGY CLIN IMMUN, V135, P781, DOI 10.1016/j.jaci.2014.09.015; Wills-Karp M, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1.51.pe55; Wynn TA, 2012, NAT MED, V18, P1028, DOI 10.1038/nm.2807; Zhu J, 2014, J INVEST DERMATOL, V134, P895, DOI 10.1038/jid.2013.484	52	37	39	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2017	139	1					142	+		10.1016/j.jaci.2016.07.012	http://dx.doi.org/10.1016/j.jaci.2016.07.012			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EK5WM	27554818	Green Accepted, Green Submitted, Bronze			2022-12-18	WOS:000393996800016
J	Vento-Tormo, R; Alvarez-Errico, D; Garcia-Gomez, A; Hernandez-Rodriguez, J; Bujan, S; Basagana, M; Hernandez-Rodriguez, J; Bujan, S; Basagana, M; Mendez, M; Yague, J; Juan, M; Arostegui, JI; Ballestar, E				Vento-Tormo, Roser; Alvarez-Errico, Damiana; Garcia-Gomez, Antonio; Hernandez-Rodriguez, Jose; Bujan, Segundo; Basagana, Maria; Hernandez-Rodriguez, Jose; Bujan, Segundo; Basagana, Maria; Mendez, Maria; Yague, Jordi; Juan, Manel; Arostegui, Juan I.; Ballestar, Esteban			DNA demethylation of inflammasome-associated genes is enhanced in patients with cryopyrinassociated periodic syndromes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cryopyrin-associated periodic syndromes; familial Mediterranean fever; autoinflammatory diseases; inflammasome; epigenetics; DNA methylation; active demethylation	CELLS; 5-HYDROXYMETHYLCYTOSINE; LIPOPOLYSACCHARIDE; INTERLEUKIN-1-BETA; DIFFERENTIATION; MONOCYTES; BLOCKADE; CRYSTALS	Background: Inflammasomes are cytosolic multiprotein complexes in macrophages. They assemble after infection-or stress-associated stimuli, activating both caspase-1-mediated inflammatory cytokine secretion and pyroptosis. Increased inflammasome activity resulting from gene mutations is related to monogenic autoinflammatory syndromes. However, variable penetrance among patients with the same gene mutations suggests involvement of additional mechanisms associated with inflammasome gene regulation. Objective: We sought to investigate the role of DNA demethylation in activating inflammasome genes during macrophage differentiation and monocyte activation in healthy control subjects and patients with autoinflammatory syndrome. Methods: Inflammasome-related genes were tested for DNA methylation and mRNA levels by using bisulfite pyrosequencing and quantitative RT-PCR in monocytes in vitro differentiated to macrophages and exposed to inflammatory conditions. The contribution of Tet methylcytosine dioxygenase 2 (TET2) and nuclear factor kappa B to DNA demethylation was tested by using chromatin immunoprecipitation, small interfering RNA-mediated downregulation, and pharmacologic inhibition. Results: We observed that inflammasome-related genes are rapidly demethylated in both monocyte-to-macrophage differentiation and on monocyte activation. Demethylation associates with increased gene expression, and both mechanisms are impaired when TET2 and nuclear factor kB are downregulated. We analyzed DNA methylation levels of inflammasome-related genes in patients with cryopyrin-associated periodic syndromes (CAPS) and familial Mediterranean fever, 2 archetypical monogenic autoinflammatory syndromes. Under the above conditions, monocytes fromuntreated patients with CAPS undergo more efficient DNA demethylation than those of healthy subjects. Interestingly, patients with CAPS treated with anti-IL-1 drugs display methylation levels similar to those of healthy control subjects. Conclusion: Our study is the first to demonstrate the involvement of DNA methylation-associated alterations in patients with monogenic autoinflammatory disease and opens up possibilities for novel clinical markers.	[Vento-Tormo, Roser; Alvarez-Errico, Damiana; Garcia-Gomez, Antonio; Ballestar, Esteban] Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Programme PEBC, Chromatin & Dis Grp, Avda Gran Via 199-203, Barcelona 08908, Spain; [Hernandez-Rodriguez, Jose] Hosp Clin Barcelona, Dept Autoimmune Dis, IDIBAPS, Autoinflammatory Dis Clin Unit, Barcelona, Spain; [Hernandez-Rodriguez, Jose] Hosp Clin Barcelona, Dept Autoimmune Dis, IDIBAPS, Vasculitis Res Unit, Barcelona, Spain; [Bujan, Segundo] Hosp Valle De Hebron, Internal Med Autoimmune & Syst Dis Serv, Barcelona, Spain; [Basagana, Maria] Univ Autonoma Barcelona, Hosp Univ Germans Trias & Pujol, Dept Allergy, Badalona, Spain; [Mendez, Maria] Univ Autonoma Barcelona, Hosp Univ Germans Trias & Pujol, Dept Pediat, Badalona, Spain; [Yague, Jordi; Juan, Manel; Arostegui, Juan I.] Hosp Clin Barcelona, IDIBAPS, Dept Immunol CDB, Barcelona, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Hospital Universitari Vall d'Hebron; Autonomous University of Barcelona; Hospital Germans Trias i Pujol; Autonomous University of Barcelona; Hospital Germans Trias i Pujol; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Alvarez-Errico, D; Ballestar, E (corresponding author), Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Programme PEBC, Chromatin & Dis Grp, Avda Gran Via 199-203, Barcelona 08908, Spain.	dalvarez@idibell.cat; eballestar@idibell.cat	Ballestar, Esteban/ABG-8561-2020; Alvarez, Damiana/AAU-4160-2020; Hernandez-Rodriguez, Jose/AAF-7003-2021; Juan, Manel/Q-2931-2019; Alvarez Errico, Damiana/R-5964-2018; Hernandez-Rodriguez, Jose/L-2073-2017	Alvarez_Errico, Damiana/0000-0002-7921-5164; Arostegui, Juan Ignacio/0000-0003-4757-504X; Ballestar, Esteban/0000-0002-1400-2440; Garcia, Antonio/0000-0003-0527-7351; Yague Ribes, Jordi/0000-0002-1935-4488; Hernandez-Rodriguez, Jose/0000-0002-2357-2015; YAGUE, JORDI/0000-0001-8210-1929; Juan, Manel/0000-0002-3064-1648	Instituto de Salud Carlos III [SAF2014-55942-R]; FEDER funds/European Regional Development Fund (ERDF)-a way	Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); FEDER funds/European Regional Development Fund (ERDF)-a way	Supported by grant SAF2014-55942-R from the Instituto de Salud Carlos III, organisms ascribed to the Ministerio de Economia y Competitividad and cofunded by FEDER funds/European Regional Development Fund (ERDF)-a way to build Europe.	Booth MJ, 2013, NAT PROTOC, V8, P1841, DOI 10.1038/nprot.2013.115; de la Rica L, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-014-0561-5; Fleetwood AJ, 2007, J IMMUNOL, V178, P5245, DOI 10.4049/jimmunol.178.8.5245; Gattorno M, 2007, ARTHRITIS RHEUM, V56, P3138, DOI 10.1002/art.22842; Geissmann F, 2010, SCIENCE, V327, P656, DOI 10.1126/science.1178331; Giamarellos-Bourboulis EJ, 2009, ANN RHEUM DIS, V68, P273, DOI 10.1136/ard.2007.082222; Guo HT, 2015, NAT MED, V21, P677, DOI 10.1038/nm.3893; Hernandez-Rodriguez J, 2016, AUTOIMMUN REV, V15, P9, DOI 10.1016/j.autrev.2015.08.008; Klug M, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-5-r46; Klug M, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-6-r63; Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516; Martinon F, 2015, NAT REV RHEUMATOL, V11, P11, DOI 10.1038/nrrheum.2014.158; Serbina NV, 2006, NAT IMMUNOL, V7, P311, DOI 10.1038/ni1309; Srinivasula SM, 2002, J BIOL CHEM, V277, P21119, DOI 10.1074/jbc.C200179200; Vanaja SK, 2015, TRENDS CELL BIOL, V25, P308, DOI 10.1016/j.tcb.2014.12.009; Vento-Tormo R, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-015-0863-2	16	37	40	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2017	139	1					202	+		10.1016/j.jaci.2016.05.016	http://dx.doi.org/10.1016/j.jaci.2016.05.016			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EK5WM	27394913	Bronze			2022-12-18	WOS:000393996800022
J	Perzanowski, MS; Ronmark, E; James, HR; Hedman, L; Schuyler, AJ; Bjerg, A; Lundback, B; Platts-Mills, TAE				Perzanowski, Matthew S.; Ronmark, Eva; James, Hayley R.; Hedman, Linnea; Schuyler, Alexander J.; Bjerg, Anders; Lundback, Bo; Platts-Mills, Thomas A. E.			Relevance of specific IgE antibody titer to the prevalence, severity, and persistence of asthma among 19-year-olds in northern Sweden	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE titer; IgE antibodies; mammalian allergen; asthma severity; cat ownership	HOUSE-DUST MITE; OBSTRUCTIVE LUNG-DISEASE; ALLERGIC SENSITIZATION; CHILDHOOD ASTHMA; EARLY EXPOSURE; RISK-FACTORS; FOLLOW-UP; P-I; F-I; CAT	Background: Although sensitization to indoor allergens is strongly associated with asthma, there are questions as to how this relates to asthma symptoms. Objective: We sought to study the relevance of IgE antibodies to cat and dog allergens in an area in which (1) the climate discourages cockroach, fungal, and mite growth and (2) dander allergens are known to be present in schools and houses without animals. Methods: IgE to 8 allergens was tested in 963 sera from a population-based study on 19-year-olds, and associations with asthma symptoms, diagnosis, and treatment were examined. In positive sera IgE to specific cat and dog allergens was also assayed. Results: IgE specific for animal dander had the highest prevalence and strongest relationship to asthma diagnosis. Furthermore, asthma severity, as judged by the frequency of symptoms and use of treatment, was directly associated with the titer of IgE antibodies to animal dander. Among the 103 subjects who had current asthma at age 19 years, 50 had asthma before age 12 years. Among those 50, the odds ratios for asthma related to any IgE antibodies to animal dander or high-titer IgE antibodies (>= 17.5 IU/mL) were 9.2 (95% CI, 4.9-17) and 13 (95% CI, 6.9-25), respectively. In multivariable analysis IgE antibodies to Fel d 1 and Can f 5 were each associated with current asthma. Conclusion: High-titer IgE antibodies to cat and dog allergens were strongly associated with the diagnosis, severity, and persistence of asthma; however, a large proportion of patients with current asthma did not live in a house with a cat or dog.	[Perzanowski, Matthew S.] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA; [Ronmark, Eva; Hedman, Linnea] Umea Univ, OLIN Unit, Dept Publ Hlth & Clin Med, Umea, Sweden; [James, Hayley R.; Schuyler, Alexander J.; Platts-Mills, Thomas A. E.] Univ Virginia, Div Allergy & Immunol, Charlottesville, VA USA; [Bjerg, Anders; Lundback, Bo] Univ Gothenburg, Sahlgrenska Acad, Krefting Res Ctr, Dept Med, Gothenburg, Sweden	Columbia University; Umea University; University of Virginia; University of Gothenburg	Platts-Mills, TAE (corresponding author), Box 801355, Charlottesville, VA 22908 USA.	tap2z@virginia.edu	Bjerg, Anders/GRR-3443-2022	Hedman, Linnea/0000-0002-1630-3167; Platts-Mills, Thomas/0000-0002-1263-329X	National Institutes of Health [R01-AI-20565, U19-AI-070364]; Swedish Heart-Lung Foundation; Swedish Research Council; Swedish Asthma-Allergy Foundation; Swedish Foundation for Health Care Science and Allergy Research (Vardal); Visare Norr, Umea University; Norrbotten County Council; Phadia/Thermo Fisher; GlaxoSmithKline World Wide Epidemiology; ALK-Abello (Horsholm, Denmark);  [P30-ES-09089]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070364, R01AI020565] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009089] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Asthma-Allergy Foundation; Swedish Foundation for Health Care Science and Allergy Research (Vardal); Visare Norr, Umea University; Norrbotten County Council; Phadia/Thermo Fisher; GlaxoSmithKline World Wide Epidemiology(GlaxoSmithKline); ALK-Abello (Horsholm, Denmark); ; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by National Institutes of Health grants R01-AI-20565 and U19-AI-070364 to T.A.E.P.-M., as well as P30-ES-09089 to M.S.P., and grants to E.R. from the Swedish Heart-Lung Foundation, the Swedish Research Council, the Swedish Asthma-Allergy Foundation, the Swedish Foundation for Health Care Science and Allergy Research (Vardal), Visare Norr, Umea University, and Norrbotten County Council. Phadia/Thermo Fisher provided unrestricted support for IgE assays. Additional funding was provided by GlaxoSmithKline World Wide Epidemiology and ALK-Abello (Horsholm, Denmark).	Almqvist C, 2001, AM J RESP CRIT CARE, V163, P694, DOI 10.1164/ajrccm.163.3.2006114; Andersson M, 2013, PEDIATRICS, V132, pE435, DOI 10.1542/peds.2013-0741; Backlund AB, 2006, ALLERGY, V61, P549, DOI 10.1111/j.1398-9995.2006.01027.x; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Bener A, 1995, Allerg Immunol (Paris), V27, P190; BRUNEKREEF B, 1992, INT J EPIDEMIOL, V21, P338, DOI 10.1093/ije/21.2.338; Carlsen KCL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043214; Cornmins SP, 2012, AM J RESP CRIT CARE, V185, P723, DOI 10.1164/rccm.201111-2017OC; Custovic A, 2003, J ALLERGY CLIN IMMUN, V111, P402, DOI 10.1067/mai.2003.55; Custovic A, 2004, THORAX, V59, P825, DOI 10.1136/thx.2004.027334; Erwin EA, 2005, J ALLERGY CLIN IMMUN, V115, P74, DOI 10.1016/j.jaci.2004.10.030; Erwin EA, 2005, J ALLERGY CLIN IMMUN, V115, P1029, DOI 10.1016/j.jaci.2004.12.1131; Erwin EA, 2007, J ALLERGY CLIN IMMUN, V119, P359, DOI 10.1016/j.jaci.2006.12.648; Fujimura KE, 2014, P NATL ACAD SCI USA, V111, P805, DOI 10.1073/pnas.1310750111; Fujimura KE, 2010, J ALLERGY CLIN IMMUN, V126, DOI 10.1016/j.jaci.2010.05.042; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; Gronlund H, 2009, J ALLERGY CLIN IMMUN, V123, P1189, DOI 10.1016/j.jaci.2009.03.011; Hedman Linnea, 2012, Clin Transl Allergy, V2, P1, DOI 10.1186/2045-7022-2-1; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Konradsen JR, 2015, J ALLERGY CLIN IMMUN, V135, P616, DOI 10.1016/j.jaci.2014.08.026; Kurukulaaratchy RJ, 2012, RESP MED, V106, P329, DOI 10.1016/j.rmed.2011.12.006; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Lodge CJ, 2012, CLIN EXP ALLERGY, V42, P1377, DOI 10.1111/j.1365-2222.2012.04032.x; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; Mattsson L, 2009, J ALLERGY CLIN IMMUN, V123, P362, DOI 10.1016/j.jaci.2008.11.021; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; MUNIR AKM, 1993, J ALLERGY CLIN IMMUN, V91, P1067, DOI 10.1016/0091-6749(93)90221-Z; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Perzanowski MS, 1999, J ALLERGY CLIN IMMUN, V103, P1018, DOI 10.1016/S0091-6749(99)70173-9; Perzanowski MS, 1998, J ALLERGY CLIN IMMUN, V101, P626, DOI 10.1016/S0091-6749(98)70170-8; Perzanowski MS, 2002, AM J RESP CRIT CARE, V166, P696, DOI 10.1164/rccm.2201035; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; PLATTSMILLS TAE, 1978, J IMMUNOL, V120, P1201; Posthumus J, 2013, J ALLERGY CLIN IMMUN, V131, P923, DOI 10.1016/j.jaci.2012.12.665; Ronmark E, 2009, J ALLERGY CLIN IMMUN, V124, P357, DOI 10.1016/j.jaci.2009.05.011; Ronmark E, 2003, J ALLERGY CLIN IMMUN, V112, P747, DOI 10.1016/S0091-6749(03)01866-9; Ronmark E, 2002, RESP MED, V96, P1006, DOI 10.1053/rmed.2002.1391; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; ROWNTREE S, 1987, J ALLERGY CLIN IMMUN, V80, P622, DOI 10.1016/0091-6749(87)90017-0; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Smith W, 2004, CLIN EXP ALLERGY, V34, P1732, DOI 10.1111/j.1365-2222.2004.02090.x; SPORIK R, 1992, CLIN EXP ALLERGY, V22, P897, DOI 10.1111/j.1365-2222.1992.tb02062.x; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Stern DA, 2004, CLIN EXP ALLERGY, V34, P1563, DOI 10.1111/j.1365-2222.2004.02088.x; Svanes C, 2003, J ALLERGY CLIN IMMUN, V112, P289, DOI 10.1067/mai.2003.1596; Varraso R, 2005, AM J RESP CRIT CARE, V171, P334, DOI 10.1164/rccm.200405-674OC; von Hertzen L, 2009, AM J RESP CRIT CARE, V180, P113, DOI 10.1164/rccm.200807-1001CO; Wegienka G, 2011, CLIN EXP ALLERGY, V41, P979, DOI 10.1111/j.1365-2222.2011.03747.x	50	37	37	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2016	138	6					1582	1590		10.1016/j.jaci.2016.05.017	http://dx.doi.org/10.1016/j.jaci.2016.05.017			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EF0MK	27430609	Green Accepted, Bronze			2022-12-18	WOS:000390019300013
J	Lucendo, AJ; Arias, A; Gonzalez-Cervera, J; Olalla, JM; Molina-Infante, J				Lucendo, Alfredo J.; Arias, Angel; Gonzalez-Cervera, Jesus; Maria Olalla, Jose; Molina-Infante, Javier			Dual response to dietary/topical steroid and proton pump inhibitor therapy in adult patients with eosinophilic esophagitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CONSENSUS RECOMMENDATIONS; PREVALENCE; MANAGEMENT; DIAGNOSIS; CHILDREN		[Lucendo, Alfredo J.] Hosp Gen Tomelloso, Dept Gastroenterol, Tomelloso, Spain; [Arias, Angel] Hosp Gen La Mancha Ctr, Res Unit, Alcazar De San Juan, Spain; [Gonzalez-Cervera, Jesus] Hosp Gen Tomelloso, Dept Allergy, Tomelloso, Spain; [Maria Olalla, Jose] Hosp Gen La Mancha Ctr, Dept Pathol, Alcazar De San Juan, Spain; [Molina-Infante, Javier] Hosp San Pedro de Alcantara, Dept Gastroenterol, Caceres, Spain		Lucendo, AJ (corresponding author), Hosp Gen Tomelloso, Dept Gastroenterol, Tomelloso, Spain.	alucendo@vodafone.es	Lucendo, Alfredo J/C-1958-2009; Arias, Ángel J/E-5885-2016	Lucendo, Alfredo J/0000-0003-1183-1072; Arias, Ángel J/0000-0003-1006-0958; Gonzalez-Cervera, Jesus/0000-0002-7444-9076				Arias A, 2013, EUR J GASTROEN HEPAT, V25, P208, DOI 10.1097/MEG.0b013e32835a4c95; ATTWOOD SEA, 1993, DIGEST DIS SCI, V38, P109, DOI 10.1007/BF01296781; Dellon ES, 2014, CLIN GASTROENTEROL H, V12, P589, DOI 10.1016/j.cgh.2013.09.008; Dellon ES, 2013, AM J GASTROENTEROL, V108, P679, DOI 10.1038/ajg.2013.71; Furuta GT, 2007, GASTROENTEROLOGY, V133, P1342, DOI 10.1053/j.gastro.2007.08.017; Hruz P, 2011, J ALLERGY CLIN IMMUN, V128, P1349, DOI 10.1016/j.jaci.2011.09.013; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Papadopoulou A, 2014, J PEDIATR GASTR NUTR, V58, P107, DOI 10.1097/MPG.0b013e3182a80be1; STRAUMANN A, 1994, SCHWEIZ MED WSCHR, V124, P1419	9	37	38	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2016	137	3					931	934		10.1016/j.jaci.2015.07.033	http://dx.doi.org/10.1016/j.jaci.2015.07.033			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DG2LB	26371836	Bronze			2022-12-18	WOS:000371897500039
J	Mehta, AK; Duan, W; Doerner, AM; Traves, SL; Broide, DH; Proud, D; Zuraw, BL; Croft, M				Mehta, Amit K.; Duan, Wei; Doerner, Astrid M.; Traves, Suzanne L.; Broide, David H.; Proud, David; Zuraw, Bruce L.; Croft, Michael			Rhinovirus infection interferes with induction of tolerance to aeroantigens through OX40 ligand, thymic stromal lymphopoietin, and IL-33	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; epithelial cell; OX40 ligand; RV1B; RV16; thymic stromal lymphopoietin; peripherally induced regulatory T cell	INNATE LYMPHOID-CELLS; REGULATORY T-CELLS; EPITHELIAL-CELLS; AIRWAY INFLAMMATION; DENDRITIC CELLS; CUTTING EDGE; ALLERGIC INFLAMMATION; LUNG INFLAMMATION; ASTHMA; EXPRESSION	Background: Rhinovirus infection at an early age has been associated with development of asthma, but how rhinovirus influences the immune response is not clear. Objective: Tolerance to inhaled antigen is mediated through induction of regulatory T (Treg) cells, and we examined whether rhinovirus infection of the respiratory tract can block airway tolerance by modulating Treg cells. Methods: The immune response to intranasal ovalbumin in mice was assessed with concomitant infection with RV1B, and the factors induced in vivo were compared with those made by human lung epithelial cells infected in vitro with RV16. Results: RV1B infection of mice abrogated tolerance induced by inhalation of soluble ovalbumin, suppressing the normal generation of forkhead box protein 3-positive Treg cells while promoting TH2 cells. Furthermore, RV1B infection led to susceptibility to asthmatic lung disease when mice subsequently re-encountered aeroantigen. RV1B promoted early in vivo expression of the TNF family protein OX40 ligand on lung dendritic cells that was dependent on the innate cytokine thymic stromal lymphopoietin (TSLP) and also induced another innate cytokine, IL-33. Inhibiting each of these pathways allowed the natural development of Treg cells while minimizing TH2 differentiation and restored tolerance in the face of RV1B infection. In accordance, RV16 infection of human lung epithelial cells upregulated TSLP and IL-33 expression. Conclusions: These results suggest that infection of the respiratory epithelium with rhinovirus can antagonize tolerance to inhaled antigen through combined induction of TSLP, IL-33, and OX40 ligand and that this can lead to susceptibility to asthmatic lung inflammation.	[Mehta, Amit K.; Duan, Wei; Croft, Michael] La Jolla Inst Allergy & Immunol, Div Immune Regulat, La Jolla, CA 92037 USA; [Doerner, Astrid M.; Zuraw, Bruce L.] Univ Calif San Diego, Vet Med Res Fdn, La Jolla, CA 92093 USA; [Doerner, Astrid M.; Broide, David H.; Zuraw, Bruce L.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Traves, Suzanne L.; Proud, David] Univ Calgary, Fac Med, Airway Inflammat Res Grp, Snyder Inst Chron Dis,Dept Physiol & Pharmacol, Calgary, AB T2N 1N4, Canada	La Jolla Institute for Immunology; University of California System; University of California San Diego; Veterans Medical Research Foundation; University of California System; University of California San Diego; University of Calgary	Croft, M (corresponding author), La Jolla Inst Allergy & Immunol, Div Immune Regulat, 9420 Athena Circle, La Jolla, CA 92037 USA.	mick@lji.org	Mehta, Amit Kumar/D-7585-2016	Broide, David/0000-0001-8405-9090	National Institutes of Health [AI070535, AI103021]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070535, R01AI103021] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants AI070535 and AI103021 (to M.C.).	Al-Shami A, 2005, J EXP MED, V202, P829, DOI 10.1084/jem.20050199; Barnden MJ, 1998, IMMUNOL CELL BIOL, V76, P34, DOI 10.1046/j.1440-1711.1998.00709.x; Bartlett NW, 2008, NAT MED, V14, P199, DOI 10.1038/nm1713; Carpino N, 2004, MOL CELL BIOL, V24, P2584, DOI 10.1128/MCB.24.6.2584-2592.2004; Chang YJ, 2011, NAT IMMUNOL, V12, P631, DOI 10.1038/ni.2045; Chen ZG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051268; Chu DK, 2013, J ALLERGY CLIN IMMUN, V131, P187, DOI 10.1016/j.jaci.2012.08.002; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Croft M, 2010, ANNU REV IMMUNOL, V28, P57, DOI 10.1146/annurev-immunol-030409-101243; Doherty TA, 2012, AM J PHYSIOL-LUNG C, V303, pL577, DOI 10.1152/ajplung.00174.2012; Doherty TA, 2009, AM J PHYSIOL-LUNG C, V296, pL229, DOI 10.1152/ajplung.90543.2008; Duan W, 2011, J IMMUNOL, V187, P6499, DOI 10.4049/jimmunol.1101398; Duan W, 2010, J ALLERGY CLIN IMMUN, V126, P1284, DOI 10.1016/j.jaci.2010.09.021; Duan W, 2008, J IMMUNOL, V181, P8650, DOI 10.4049/jimmunol.181.12.8650; Enoksson M, 2013, BLOOD, V121, P530, DOI 10.1182/blood-2012-05-434209; Gauvreau GM, 2014, NEW ENGL J MED, V370, P2102, DOI 10.1056/NEJMoa1402895; Gern JE, 1997, AM J RESP CRIT CARE, V155, P1159, DOI 10.1164/ajrccm.155.3.9117003; Gramaglia I, 1998, J IMMUNOL, V161, P6510; Hammad H, 2008, NAT REV IMMUNOL, V8, P193, DOI 10.1038/nri2275; Han JY, 2012, J ALLERGY CLIN IMMUN, V130, P1175, DOI 10.1016/j.jaci.2012.08.033; Hardman CS, 2013, EUR J IMMUNOL, V43, P488, DOI 10.1002/eji.201242863; Hershenson MB, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/405876; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Jember AGH, 2001, J EXP MED, V193, P387, DOI 10.1084/jem.193.3.387; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Kato A, 2007, CURR OPIN IMMUNOL, V19, P711, DOI 10.1016/j.coi.2007.08.004; Kato A, 2007, J IMMUNOL, V179, P1080, DOI 10.4049/jimmunol.179.2.1080; Khare A, 2013, J IMMUNOL, V191, P25, DOI 10.4049/jimmunol.1300193; Kurowska-Stolarska M, 2008, J IMMUNOL, V181, P4780, DOI 10.4049/jimmunol.181.7.4780; Lei LY, 2011, J IMMUNOL, V186, P2254, DOI 10.4049/jimmunol.1002503; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Liew FY, 2010, NAT REV IMMUNOL, V10, P103, DOI 10.1038/nri2692; Nagarkar DR, 2010, J IMMUNOL, V185, P2525, DOI 10.4049/jimmunol.1000286; Nagarkar DR, 2009, J IMMUNOL, V183, P6698, DOI 10.4049/jimmunol.0900298; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Newcomb DC, 2008, AM J RESP CRIT CARE, V177, P1111, DOI 10.1164/rccm.200708-1243OC; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; Papadopoulos NG, 2000, J INFECT DIS, V181, P1875, DOI 10.1086/315513; Proud D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040762; Proud D, 2011, IMMUNOL REV, V242, P186, DOI 10.1111/j.1600-065X.2011.01033.x; Rakes CP, 1999, AM J RESP CRIT CARE, V159, P785, DOI 10.1164/ajrccm.159.3.9801052; Rank MA, 2009, J ALLERGY CLIN IMMUN, V123, P1047, DOI 10.1016/j.jaci.2009.02.026; Rochman I, 2007, J IMMUNOL, V178, P6720, DOI 10.4049/jimmunol.178.11.6720; Rogers PR, 2001, IMMUNITY, V15, P445, DOI 10.1016/S1074-7613(01)00191-1; Salek-Ardakani S, 2003, J EXP MED, V198, P315, DOI 10.1084/jem.20021937; Sanders SP, 1998, J VIROL, V72, P934, DOI 10.1128/JVI.72.2.934-942.1998; Seshasayee D, 2007, J CLIN INVEST, V117, P3868, DOI 10.1172/JCI33559; Sims JE, 2000, J EXP MED, V192, P671, DOI 10.1084/jem.192.5.671; Smithgall MD, 2008, INT IMMUNOL, V20, P1019, DOI 10.1093/intimm/dxn060; So T, 2006, P NATL ACAD SCI USA, V103, P3740, DOI 10.1073/pnas.0600205103; So T, 2007, J IMMUNOL, V179, P1427, DOI 10.4049/jimmunol.179.3.1427; Soroosh P, 2013, J EXP MED, V210, P775, DOI 10.1084/jem.20121849; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Wos M, 2008, AM J RESP CRIT CARE, V177, P1082, DOI 10.1164/rccm.200607-973OC; Yasuda K, 2012, P NATL ACAD SCI USA, V109, P3451, DOI 10.1073/pnas.1201042109; Ying S, 2008, J IMMUNOL, V181, P2790, DOI 10.4049/jimmunol.181.4.2790; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247	59	37	39	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2016	137	1					278	+		10.1016/j.jaci.2015.05.007	http://dx.doi.org/10.1016/j.jaci.2015.05.007			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DA3UK	26100084	Green Accepted, Bronze			2022-12-18	WOS:000367724300019
J	Homburg, U; Renz, H; Timmer, W; Hohlfeld, JM; Seitz, F; Luer, K; Mayer, A; Wacker, A; Schmidt, O; Kuhlmann, J; Turowska, A; Roller, J; Kutz, K; Schluter, G; Krug, N; Garn, H				Homburg, Ursula; Renz, Harald; Timmer, Wolfgang; Hohlfeld, Jens M.; Seitz, Friedeborg; Lueer, Katrin; Mayer, Alexandra; Wacker, Anja; Schmidt, Oliver; Kuhlmann, Jens; Turowska, Agnieszka; Roller, Julia; Kutz, Klaus; Schlueter, Gerhard; Krug, Norbert; Garn, Holger			Safety and tolerability of a novel inhaled GATA3 mRNA targeting DNAzyme in patients with T(H)2-driven asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							GATA-3-SPECIFIC DNAZYME; ACTIVATION; EXPRESSION; TOXICITY; EXPOSURE; HGD40		[Homburg, Ursula; Kuhlmann, Jens; Turowska, Agnieszka] Sterna Biol GmbH, Marburg, Germany; [Renz, Harald; Garn, Holger] Univ Giessen, Univ Marburg, Fac Med, Inst Lab Med & Pathobiochem Mol Diagnost, Marburg, Germany; [Renz, Harald; Garn, Holger] Marburg Lung Ctr UGMLC, Marburg, Germany; [Hohlfeld, Jens M.; Lueer, Katrin; Krug, Norbert] Fraunhofer Inst Toxicol & Expt Med, Dept Clin Airway Res, Hannover, Germany; [Seitz, Friedeborg; Mayer, Alexandra] CRS Clin Res Serv Mannheim GmbH, Mannheim, Germany; [Wacker, Anja; Schmidt, Oliver] Engelhard Arzneimittel GmbH, Niederdorfelden, Germany; [Roller, Julia] Vectura GmbH, Gauting, Germany; [Kutz, Klaus] AccelPharm, Basel, Switzerland	Justus Liebig University Giessen; Philipps University Marburg; Fraunhofer Gesellschaft	Homburg, U (corresponding author), Sterna Biol GmbH, Marburg, Germany.	garn@staff.uni-marburg.de		Hohlfeld, Jens/0000-0003-2646-6186; Garn, Holger/0000-0002-5178-4023				Alton EW, 2012, NUCLEIC ACID THER, V22, P246, DOI 10.1089/nat.2012.0345; Dicke T, 2012, NUCLEIC ACID THER, V22, P117, DOI 10.1089/nat.2011.0294; Finotto S, 2001, J EXP MED, V193, P1247, DOI 10.1084/jem.193.11.1247; Fuhst R, 2013, PULM PHARMACOL THER, V26, P281, DOI 10.1016/j.pupt.2012.12.005; Klein-Hessling S, 2003, J IMMUNOL, V170, P2956, DOI 10.4049/jimmunol.170.6.2956; Sel S, 2008, J ALLERGY CLIN IMMUN, V121, P910, DOI 10.1016/j.jaci.2007.12.1175; Silverman SK, 2005, NUCLEIC ACIDS RES, V33, P6151, DOI 10.1093/nar/gki930; Turowska A, 2013, TOXICOL APPL PHARM, V272, P365, DOI 10.1016/j.taap.2013.06.020; Wenzel S, 2007, LANCET, V370, P1422, DOI 10.1016/S0140-6736(07)61600-6	9	37	38	1	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2015	136	3					797	+		10.1016/j.jaci.2015.02.018	http://dx.doi.org/10.1016/j.jaci.2015.02.018			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CQ9EA	25842286	Bronze			2022-12-18	WOS:000360913300033
J	Tsuji, G; Okiyama, N; Villarroel, VA; Katz, SI				Tsuji, Gaku; Okiyama, Naoko; Villarroel, Vadim A.; Katz, Stephen I.			Histone deacetylase 6 inhibition impairs effector CD8 T-cell functions during skin inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CD8 T cell; histone deacetylase 6; contact hypersensitivity; graft-versus-host-disease	VERSUS-HOST-DISEASE; SIGNALING PATHWAYS; LYMPHOCYTES; RECEPTOR; INDUCTION; MICE	Background: Broad-spectrum histone deacetylase (HDAC) inhibitors are useful in the treatment of allergic and autoimmune diseases and malignancy. However, use of more specific HDAC inhibitors might limit the toxicities caused by HDAC inhibition. HDAC6, a member of the HDAC family, is highly expressed on CD8 T cells and has been shown to regulate immune responses through interactions between T cells and antigen-presenting cells. However, the mechanism by which HDAC6 inhibition affects the activation and functions of CD8 T cells is unclear. Objectives: We investigated the role or roles of HDAC6 in CD8 T-cell activation and functions during skin inflammation in vitro and in vivo and examined the mechanism by which HDAC6 inhibition modifies T-cell receptor signaling in vitro. Methods: We assessed the clinical and biological effects of ACY1215, an HDAC6-specific inhibitor, by using murine CD8 T cellrelated skin disease models, including contact hypersensitivity (CHS) and experimental graft-versus-host disease (GVHD)-like disease. Results: ACY-1215, an HDAC6 inhibitor, prevented the development of CHS and GVHD-like disease in vivo by modulating CD8 T-cell activation and functions; abrogated the induction of effector T cells from naive CD8 T cells by means of anti-CD3/CD28 antibody-or antigen-specific stimulation in vitro; and enhanced the binding of acetylated heat shock protein 90 to lymphocyte-specific protein tyrosine kinase in vitro, disrupting lymphocyte-specific protein tyrosine kinase phosphorylation and leading to impairment of the mitogenactivated protein kinase pathway. Conclusion: HDAC6, a key modifier of T-cell receptor signaling, might represent a novel target for the treatment of CD8 T cellrelated skin diseases, including CHS and GVHD.	[Tsuji, Gaku; Okiyama, Naoko; Villarroel, Vadim A.; Katz, Stephen I.] NCI, Dermatol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Katz, SI (corresponding author), NCI, Dermatol Branch, Ctr Canc Res, NIH, Bldg 10, Bethesda, MD 20892 USA.	katzs@od.niams.nih.gov	Okiyama, Naoko/AAP-7906-2020	Okiyama, Naoko/0000-0002-5398-0773	Center for Cancer Research of the National Cancer Institute, National Institutes of Health	Center for Cancer Research of the National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by the Center for Cancer Research of the National Cancer Institute, National Institutes of Health.	Aoyagi S, 2005, TRENDS CELL BIOL, V15, P565, DOI 10.1016/j.tcb.2005.09.003; Asada H, 1997, J INVEST DERMATOL, V108, P406, DOI 10.1111/1523-1747.ep12289700; Biedermann BC, 2002, LANCET, V359, P2078, DOI 10.1016/S0140-6736(02)08907-9; Bouloc A, 1998, J INVEST DERMATOL, V111, P44, DOI 10.1046/j.1523-1747.1998.00236.x; Brownlie RJ, 2013, NAT REV IMMUNOL, V13, P257, DOI 10.1038/nri3403; de Zoeten EF, 2011, MOL CELL BIOL, V31, P2066, DOI 10.1128/MCB.05155-11; Gilhar A, 2006, AUTOIMMUN REV, V5, P64, DOI 10.1016/j.autrev.2005.07.001; Hartson SD, 1996, BIOCHEMISTRY-US, V35, P13451, DOI 10.1021/bi961332c; Li NN, 2008, P NATL ACAD SCI USA, V105, P4796, DOI 10.1073/pnas.0712051105; Miyagawa F, 2012, P NATL ACAD SCI USA, V109, P12123, DOI 10.1073/pnas.1201453109; Ogg GS, 1998, J EXP MED, V188, P1203, DOI 10.1084/jem.188.6.1203; Okiyama N, 2014, J INVEST DERMATOL, V134, P992, DOI 10.1038/jid.2013.476; Raji N, 2012, AM SOC HEM ATL GA DE; Reddy P, 2004, P NATL ACAD SCI USA, V101, P3921, DOI 10.1073/pnas.0400380101; Rincon M, 2001, CURR OPIN IMMUNOL, V13, P339, DOI 10.1016/S0952-7915(00)00224-7; Santo L, 2012, BLOOD, V119, P2579, DOI 10.1182/blood-2011-10-387365; Serrador JM, 2004, IMMUNITY, V20, P417, DOI 10.1016/S1074-7613(04)00078-0; Shibaki A, 2004, J INVEST DERMATOL, V123, P109, DOI 10.1111/j.0022-202X.2004.22701.x; Villarroel VA, 2014, J INVEST DERMATOL, V134, P1552, DOI 10.1038/jid.2014.2; Vishwakarma S, 2013, INT IMMUNOPHARMACOL, V16, P72, DOI 10.1016/j.intimp.2013.03.016; Yorgin PD, 2000, J IMMUNOL, V164, P2915, DOI 10.4049/jimmunol.164.6.2915	21	37	39	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2015	135	5					1228	1239		10.1016/j.jaci.2014.10.002	http://dx.doi.org/10.1016/j.jaci.2014.10.002			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CH4DA	25458911	Green Accepted			2022-12-18	WOS:000353980700016
J	Petitdemange, C; Wauquier, N; Vieillard, V				Petitdemange, Caroline; Wauquier, Nadia; Vieillard, Vincent			Control of immunopathology during chikungunya virus infection	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chikungunya virus; immune responses; immunotherapy; vaccination	INNATE IMMUNE-RESPONSE; REUNION ISLAND; AEDES-ALBOPICTUS; E2 GLYCOPROTEIN; NEUTRALIZING ANTIBODIES; NONHUMAN-PRIMATES; MOUSE MODEL; DISEASE; MICE; OUTBREAK	After several decades of epidemiologic silence, chikungunya virus (CHIKV) has recently re-emerged, causing explosive outbreaks and reaching the 5 continents. Transmitted through the bite of Aedes species mosquitoes, CHIKV is responsible for an acute febrile illness accompanied by several characteristic symptoms, including cutaneous rash, myalgia, and arthralgia, with the latter sometimes persisting for months or years. Although CHIKV has previously been known as a relatively benign disease, more recent epidemic events have brought waves of increased morbidity and fatality, leading it to become a serious public health problem. The host's immune response plays a crucial role in controlling the infection, but it might also contribute to the promotion of viral spread and immunopathology. This review focuses on the immune responses to CHIKV in human subjects with an emphasis on early antiviral immune responses. We assess recent developments in the understanding of their possible Janus-faced effects in the control of viral infection and pathogenesis. Although preventive vaccination and specific therapies are yet to be developed, exploring this interesting model of virus-host interactions might have a strong effect on the design of novel therapeutic options to minimize immunopathology without impairing beneficial host defenses.	[Petitdemange, Caroline; Wauquier, Nadia; Vieillard, Vincent] Univ Paris 06, Sorbonne Univ, CR7, CIMI Paris, Paris, France; [Wauquier, Nadia] Metabiota, San Francisco, CA USA; [Vieillard, Vincent] INSERM, U1135, CIMI Paris, Paris, France; [Vieillard, Vincent] CNRS, ERL 8255, CIMI Paris, Paris, France	UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite	Vieillard, V (corresponding author), Hop La Pitie Salpetriere, Ctr Immunol & Infect Dis CIMI Paris, 83 Blvd Hop, F-75013 Paris, France.	vincent.vieillard@upmc.fr	Vieillard, Vincent/P-3001-2017	Wauquier, Nadia/0000-0002-2874-7574				Akahata W, 2010, NAT MED, V16, P334, DOI 10.1038/nm.2105; Akhrymuk I, 2012, J VIROL, V86, P7180, DOI 10.1128/JVI.00541-12; Ansumana R, 2013, EMERG INFECT DIS, V19, P1108, DOI 10.3201/eid1907.121563; Arankalle VA, 2007, J GEN VIROL, V88, P1967, DOI 10.1099/vir.0.82714-0; Baba M, 2013, J INFECT DEV COUNTR, V7, P51, DOI 10.3855/jidc.2411; Borgherini G, 2007, CLIN INFECT DIS, V44, P1401, DOI 10.1086/517537; Burt FJ, 2012, LANCET, V379, P662, DOI 10.1016/S0140-6736(11)60281-X; Caron M, 2012, CLIN INFECT DIS, V55, pE45, DOI 10.1093/cid/cis530; Chang LJ, 2014, LANCET, V384, P2046, DOI 10.1016/S0140-6736(14)61185-5; Chen WQ, 2015, J VIROL, V89, P581, DOI 10.1128/JVI.02034-14; Chow A, 2011, J INFECT DIS, V203, P149, DOI 10.1093/infdis/jiq042; Couderc T, 2009, J INFECT DIS, V200, P516, DOI 10.1086/600381; Dupuis-Maguiraga L, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001446; Economopoulou A, 2009, EPIDEMIOL INFECT, V137, P534, DOI 10.1017/S0950268808001167; Fric J, 2013, J INFECT DIS, V207, P319, DOI 10.1093/infdis/jis674; Garcia-Arriaza J, 2014, J VIROL, V88, P3527, DOI 10.1128/JVI.03418-13; Gerardin P, 2008, PLOS MED, V5, P413, DOI 10.1371/journal.pmed.0050060; Gibney KB, 2011, CLIN INFECT DIS, V52, pE121, DOI 10.1093/cid/ciq214; Gorchakov R, 2012, J VIROL, V86, P6084, DOI 10.1128/JVI.06449-11; Hallengard D, 2014, J VIROL, V88, P2858, DOI 10.1128/JVI.03453-13; Her ZS, 2015, EMBO MOL MED, V7, P24, DOI 10.15252/emmm.201404459; Her ZS, 2010, J IMMUNOL, V184, P5903, DOI 10.4049/jimmunol.0904181; Hoarau JJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084695; Hoarau JJ, 2010, J IMMUNOL, V184, P5914, DOI 10.4049/jimmunol.0900255; Jost S, 2013, ANNU REV IMMUNOL, V31, P163, DOI 10.1146/annurev-immunol-032712-100001; Kam YW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095647; Kam YW, 2012, EMBO MOL MED, V4, P330, DOI 10.1002/emmm.201200213; Kam YW, 2012, J INFECT DIS, V205, P1147, DOI 10.1093/infdis/jis033; Kelvin AA, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001279; Khan K, 2014, PLOS CURR OUTBRE JUN; Kishishita N, 2015, J CLIN MICROBIOL, V53, P184, DOI 10.1128/JCM.02744-14; Komatsu N, 2012, ADV IMMUNOL, V115, P45, DOI 10.1016/B978-0-12-394299-9.00002-3; Kulkarni S, 2008, SEMIN IMMUNOL, V20, P343, DOI 10.1016/j.smim.2008.06.003; Kumar S, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-313; Labadie K, 2010, J CLIN INVEST, V120, P894, DOI 10.1172/JCI40104; Lee CY, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002390; Leo YS, 2009, EMERG INFECT DIS, V15, P836, DOI 10.3201/eid1505.081390; Leparc-Goffart I, 2014, LANCET, V383, P514, DOI 10.1016/S0140-6736(14)60185-9; Leroy EM, 2009, EMERG INFECT DIS, V15, P591, DOI 10.3201/eid1504.080664; LEVITT NH, 1986, VACCINE, V4, P157, DOI 10.1016/0264-410X(86)90003-4; Lewthwaite P, 2009, EMERG INFECT DIS, V15, P329, DOI 10.3201/eid1502.080902; Lindsey NP, 2015, AM J TROP MED HYG, V92, P82, DOI 10.4269/ajtmh.14-0442; Litzba N, 2008, J VIROL METHODS, V149, P175, DOI 10.1016/j.jviromet.2008.01.004; Long KM, 2013, J VIROL, V87, P5697, DOI 10.1128/JVI.01611-12; Lum FM, 2013, J IMMUNOL, V190, P6295, DOI 10.4049/jimmunol.1300304; LUMSDEN W. H. R., 1955, TANGANYIKA TERRITORY IN 1952 53 II TRANS ROY SOC TROP MED AND HYG, V49, P33, DOI 10.1016/0035-9203(55)90081-X; Mallilankaraman K, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000928; Malmberg KJ, 2012, EUR J IMMUNOL, V42, P3141, DOI 10.1002/eji.201243050; Morrison TE, 2011, AM J PATHOL, V178, P32, DOI 10.1016/j.ajpath.2010.11.018; Ng LFP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004261; Nitatpattana N, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-183; Nkoghe D, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001517; Olowokure B, 2014, LANCET INFECT DIS, V14, P1039, DOI 10.1016/S1473-3099(14)70948-X; Pal P, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003312; Pal P, 2014, J VIROL, V88, P8213, DOI 10.1128/JVI.01032-14; Palha N, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003619; Petitdemange C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108798; Petitdemange C, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002268; Plante K, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002142; Renault P, 2007, AM J TROP MED HYG, V77, P727; Rezza G, 2007, LANCET, V370, P1840, DOI 10.1016/S0140-6736(07)61779-6; ROBINSON M C, 1955, Trans R Soc Trop Med Hyg, V49, P28, DOI [10.1016/0035-9203(55)90080-8, 10.1016/0035-9203(57)90022-6]; Rudd PA, 2012, J VIROL, V86, P9888, DOI 10.1128/JVI.00956-12; Rulli NE, 2011, J INFECT DIS, V204, P1026, DOI 10.1093/infdis/jir470; Schwartz O, 2010, NAT REV MICROBIOL, V8, P491, DOI 10.1038/nrmicro2368; Sebastian MR, 2009, INDIAN J PEDIATR, V76, P185, DOI 10.1007/s12098-009-0049-6; Silva LA, 2014, J VIROL, V88, P2385, DOI 10.1128/JVI.03116-13; Sissoko D, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000389; Solignat M, 2009, VIROLOGY, V393, P183, DOI 10.1016/j.virol.2009.07.024; Sourisseau M, 2007, PLOS PATHOG, V3, P804, DOI 10.1371/journal.ppat.0030089; Spuul P, 2011, J VIROL, V85, P4739, DOI 10.1128/JVI.00085-11; Staples JE, 2014, NEW ENGL J MED, V371, P887, DOI 10.1056/NEJMp1407698; Staples JE, 2009, CLIN INFECT DIS, V49, P942, DOI 10.1086/605496; Suhrbier A, 2012, NAT REV RHEUMATOL, V8, P420, DOI 10.1038/nrrheum.2012.64; Teo TH, 2013, J IMMUNOL, V190, P259, DOI 10.4049/jimmunol.1202177; Thiberville SD, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002004; Tsetsarkin KA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5084; Tsetsarkin KA, 2011, CURR OPIN VIROL, V1, P310, DOI 10.1016/j.coviro.2011.07.004; Tsetsarkin KA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006835; van den Doel P, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003101; Venugopalan A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111305; Waldock J, 2013, PATHOG GLOB HEALTH, V107, P224, DOI 10.1179/2047773213Y.0000000100; Warter L, 2011, J IMMUNOL, V186, P3258, DOI 10.4049/jimmunol.1003139; Wauquier N, 2011, J INFECT DIS, V204, P115, DOI 10.1093/infdis/jiq006; Weaver SC, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002921; WHITE A, 1972, APPL MICROBIOL, V23, P951, DOI 10.1128/AEM.23.5.951-952.1972	86	37	37	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2015	135	4					846	855		10.1016/j.jaci.2015.01.039	http://dx.doi.org/10.1016/j.jaci.2015.01.039			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CF0MQ	25843597				2022-12-18	WOS:000352238600001
J	Shi, MH; Shi, GC; Tang, J; Kong, DP; Bao, Y; Xiao, B; Zuo, CJ; Wang, T; Wang, QS; Shen, YJ; Wang, H; Funk, CD; Zhou, J; Yu, Y				Shi, Maohua; Shi, Guochao; Tang, Juan; Kong, Deping; Bao, Yao; Xiao, Bing; Zuo, Caojian; Wang, Tai; Wang, Qingsong; Shen, Yujun; Wang, Hui; Funk, Colin D.; Zhou, Jie; Yu, Ying			Myeloid-derived suppressor cell function is diminished in aspirin-triggered allergic airway hyperresponsiveness in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Myeloid-derived suppressor cells; aspirin-intolerant asthma; T(H)2; COX; prostaglandin; arginase	PROSTAGLANDIN E-2; INTOLERANT ASTHMA; BONE-MARROW; EPITHELIAL-CELLS; DENDRITIC CELLS; CANCER; RESPONSES; DISEASE; RISK; LUNG	Background: Myeloid-derived suppressor cells (MDSCs) have recently been implicated in the pathogenesis of asthma, but their regulation in patients with aspirin-intolerant asthma (AIA) remains unclear. Objective: We sought to characterize MDSC accumulation and pathogenic functions in allergic airway inflammation mediated by COX-1 deficiency or aspirin treatment in mice. Methods: Allergic airway inflammation was induced in mice by means of ovalbumin challenge. The distribution and function of MDSCs in mice were analyzed by using flow cytometry and pharmacologic/gene manipulation approaches. Results: CD11b(+)Gr1(high)Ly6G(+)Ly6C(int) MDSCs (polymorphonuclear MDSCs [PMN-MDSCs]) recruited to the lungs are negatively correlated with airway inflammation in allergen-challenged mice. Aspirin-treated and COX-1 knockout (KO) mice showed significantly lower accumulation of PMN-MDSCs in the inflamed lung and immune organs accompanied by increased T(H)2 airway responses. The T(H)2-suppressive function of PMN-MDSCs was notably impaired by COX-1 deletion or inhibition, predominantly through downregulation of arginase-1. COX-1-derived prostaglandin E-2 promoted PMN-MDSC generation in bone marrow through E prostanoid 2 and 4 receptors (EP2 and EP4), whereas the impaired arginase-1 expression in PMN-MDSCs in COX-1 KO mice was mediated by dysregulation of the prostaglandin E-2/EP4/cyclic AMP/protein kinase A pathway. EP4 agonist administration alleviated allergy-induced airway hyperresponsiveness in COX-1 KO mice. Moreover, the immunosuppressive function of PMN-MDSCs from patients with AIA was dramatically decreased compared with that from patients with aspirin-tolerant asthma. Conclusion: The immunosuppressive activity of PMN-MDSCs was diminished in both allergen-challenged COX-1 KO mice and patients with AIA, probably through an EP4-mediated signaling pathway, indicating that activation of PMN-MDSCs might be a promising therapeutic strategy for asthma, particularly AIA.	[Shi, Maohua; Tang, Juan; Kong, Deping; Xiao, Bing; Zuo, Caojian; Wang, Tai; Wang, Qingsong; Shen, Yujun; Wang, Hui; Yu, Ying] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Nutr Sci, Key Lab Food Safety Res, Shanghai 200031, Peoples R China; [Shi, Maohua; Zhou, Jie] Sun Yat Sen Univ, Zhongshan Sch Med, Inst Human Virol, Guangzhou 510275, Guangdong, Peoples R China; [Shi, Guochao; Bao, Yao] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Dept Pulm Med, Shanghai 200030, Peoples R China; [Funk, Colin D.] Queens Univ, Dept Biomed & Mol Sci, Kingston, ON, Canada; [Wang, Hui; Yu, Ying] Minist Hlth, Key Lab Food Safety Risk Assessment, Beijing, Peoples R China; [Zhou, Jie] Sun Yat Sen Univ, Key Lab Trop Dis Control, Chinese Minist Educ, Guangzhou 510275, Guangdong, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Sun Yat Sen University; Shanghai Jiao Tong University; Queens University - Canada; Sun Yat Sen University	Yu, Y (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Nutr Sci, 294 Taiyuan Rd, Shanghai 200031, Peoples R China.	zhouj72@mail.sysu.edu.cn; yuying@sibs.ac.cn	bao, yao/GQQ-1119-2022	Funk, Colin/0000-0001-7029-4233	Ministry of Science and Technology of China [2012CB945100, 2011CB503906, 2011ZX09307-302-01, 2012CB524900, 2012BAK01B00]; National Natural Science Foundation of China [81030004, 81072397, 31200860, 31270921]; NSFC-CIHR [81161120538/CCI117951]; Knowledge Innovation Program [KSCX2-EWR-09]; Shanghai Institutes for Biological Sciences of the Chinese Academy of Sciences [2012KIP514]; Clinical Research Center at Institute for the Nutritional Sciences, Shanghai Institutes for Biological Sciences [CRC2010007]; Natural Science Foundation of Guangdong [S2011020006072]; Guangdong Innovative Research Team Program [2009010058]; Program of the Chinese Academy of Sciences [2010OHTP10]; Pujiang Talents Program of Shanghai Municipality [11PJ1411100]; Heart and Stroke Foundation of Ontario [HSF CI-7406]	Ministry of Science and Technology of China(Ministry of Science and Technology, China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NSFC-CIHR(Canadian Institutes of Health Research (CIHR)); Knowledge Innovation Program(Knowledge Innovation Program of the Chinese Academy of Sciences); Shanghai Institutes for Biological Sciences of the Chinese Academy of Sciences; Clinical Research Center at Institute for the Nutritional Sciences, Shanghai Institutes for Biological Sciences; Natural Science Foundation of Guangdong(National Natural Science Foundation of Guangdong Province); Guangdong Innovative Research Team Program; Program of the Chinese Academy of Sciences(Chinese Academy of Sciences); Pujiang Talents Program of Shanghai Municipality; Heart and Stroke Foundation of Ontario(Heart & Stroke Foundation of Ontario)	Supported by grants from the Ministry of Science and Technology of China (2012CB945100, 2011CB503906, 2011ZX09307-302-01, 2012CB524900, and 2012BAK01B00) and the National Natural Science Foundation of China (81030004, 81072397, 31200860, and 31270921), a NSFC-CIHR joint grant (81161120538/CCI117951), the Knowledge Innovation Program (KSCX2-EWR-09) and Postdoctoral Research Program at the Shanghai Institutes for Biological Sciences (2012KIP514) of the Chinese Academy of Sciences, the Clinical Research Center at Institute for the Nutritional Sciences, Shanghai Institutes for Biological Sciences (CRC2010007), the Natural Science Foundation of Guangdong (S2011020006072), and the Guangdong Innovative Research Team Program (2009010058). Y. Y. was supported by the One Hundred Talents Program of the Chinese Academy of Sciences (2010OHTP10) and Pujiang Talents Program of Shanghai Municipality (11PJ1411100). C. D. F. holds a Tier 1 Canada Research Chair and Career Investigator award from the Heart and Stroke Foundation of Ontario (HSF CI-7406).	Arora M, 2010, MUCOSAL IMMUNOL, V3, P578, DOI 10.1038/mi.2010.41; Arora M, 2011, INT IMMUNOPHARMACOL, V11, P827, DOI 10.1016/j.intimp.2011.01.034; Cripps JG, 2011, INT IMMUNOPHARMACOL, V11, P789, DOI 10.1016/j.intimp.2011.01.026; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; El-Zein M, 2010, ANN ALLERG ASTHMA IM, V104, P378, DOI 10.1016/j.anai.2010.03.003; Farooque SP, 2009, ANNU REV PHYSIOL, V71, P465, DOI 10.1146/annurev.physiol.010908.163114; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Gauvreau GM, 1999, AM J RESP CRIT CARE, V159, P31, DOI 10.1164/ajrccm.159.1.9804030; Gavett SH, 1999, J CLIN INVEST, V104, P721, DOI 10.1172/JCI6890; Haile LA, 2008, GASTROENTEROLOGY, V135, P871, DOI 10.1053/j.gastro.2008.06.032; Harrington LS, 2008, FASEB J, V22, P4005, DOI 10.1096/fj.08-107979; Ingram JL, 2012, J ALLERGY CLIN IMMUN, V130, P829, DOI 10.1016/j.jaci.2012.06.034; Jinnai N, 2004, HUM MOL GENET, V13, P3203, DOI 10.1093/hmg/ddh332; Kim SR, 2013, J ALLERGY CLIN IMMUN, V132, P1397, DOI 10.1016/j.jaci.2013.08.041; Kocieda VP, 2012, J BIOL CHEM, V287, P36922, DOI 10.1074/jbc.M112.402958; Kowalski ML, 2000, AM J RESP CRIT CARE, V161, P391, DOI 10.1164/ajrccm.161.2.9902034; Lesokhin AM, 2012, CANCER RES, V72, P876, DOI 10.1158/0008-5472.CAN-11-1792; Lu TY, 2011, J CLIN INVEST, V121, P4015, DOI 10.1172/JCI45862; Lundequist A, 2010, J IMMUNOL, V184, P433, DOI 10.4049/jimmunol.0902835; Michaud DS, 2012, CANCER CAUSE CONTROL, V23, P1317, DOI 10.1007/s10552-012-0009-8; MODOLELL M, 1995, EUR J IMMUNOL, V25, P1101, DOI 10.1002/eji.1830250436; Montero AJ, 2012, J IMMUNOTHER, V35, P107, DOI 10.1097/CJI.0b013e318242169f; Obermajer N, 2011, BLOOD, V118, P5498, DOI 10.1182/blood-2011-07-365825; Park BL, 2010, BMB REP, V43, P445, DOI 10.5483/BMBRep.2010.43.6.445; Park HW, 2007, CLIN EXP ALLERGY, V37, P1609, DOI 10.1111/j.1365-2222.2007.02820.x; Peranzoni E, 2010, CURR OPIN IMMUNOL, V22, P238, DOI 10.1016/j.coi.2010.01.021; Pierzchalska M, 2007, J PHYSIOL PHARMACOL, V58, P207; Pierzchalska M, 2003, J ALLERGY CLIN IMMUN, V111, P1041, DOI 10.1067/mai.2003.1491; Poh TW, 2009, CANCER RES, V69, P3554, DOI 10.1158/0008-5472.CAN-08-3806; Qu P, 2012, IMMUNOL INVEST, V41, P562, DOI 10.3109/08820139.2012.685538; Raber P, 2012, IMMUNOL INVEST, V41, P614, DOI 10.3109/08820139.2012.680634; Roca-Ferrer J, 2011, J ALLERGY CLIN IMMUN, V128, P66, DOI 10.1016/j.jaci.2011.01.065; Rodriguez PC, 2005, J EXP MED, V202, P931, DOI 10.1084/jem.20050715; Roncarolo F, 2012, CANCER CAUSE CONTROL, V23, P617, DOI 10.1007/s10552-012-9928-7; Smyth EM, 2009, J LIPID RES, V50, pS423, DOI 10.1194/jlr.R800094-JLR200; SZCZEKLIK A, 1975, BRIT MED J, V1, P67, DOI 10.1136/bmj.1.5949.67; Toh B, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001162; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Wang L, 2013, J IMMUNOL, V190, P794, DOI 10.4049/jimmunol.1202088; Watanabe J, 2003, J BIOL CHEM, V278, P42361, DOI 10.1074/jbc.M307752200; Ying S, 2006, J ALLERGY CLIN IMMUN, V117, P312, DOI 10.1016/j.jaci.2005.10.037	41	37	38	2	27	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2014	134	5					1163	+	1174.e1	10.1016/j.jaci.2014.04.035	http://dx.doi.org/10.1016/j.jaci.2014.04.035			28	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AT4UN	24948368	Bronze			2022-12-18	WOS:000344938900022
J	Wu, YCB; James, LK; Vander Heiden, JA; Uduman, M; Durham, SR; Kleinstein, SH; Kipling, D; Gould, HJ				Wu, Yu-Chang B.; James, Louisa K.; Vander Heiden, Jason A.; Uduman, Mohamed; Durham, Stephen R.; Kleinstein, Steven H.; Kipling, David; Gould, Hannah J.			Influence of seasonal exposure to grass pollen on local and peripheral blood IgE repertoires in patients with allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Next-generation sequencing; peripheral blood and nasal mucosal IgE repertoires; allergic rhinitis	CLASS SWITCH RECOMBINATION; HEAVY-CHAIN; ANTIBODY REPERTOIRE; ATOPIC-DERMATITIS; VARIABLE REGION; ANTIGEN-DRIVEN; NASAL-MUCOSA; GENE USAGE; B-CELLS; TRANSCRIPTS	Background: Previous studies of immunoglobulin gene sequences in patients with allergic diseases using low-throughput Sanger sequencing have limited the analytic depth for characterization of IgE repertoires. Objectives: We used a high-throughput, next-generation sequencing approach to characterize immunoglobulin heavy-chain gene (IGH) repertoires in patients with seasonal allergic rhinitis (AR) with the aim of better understanding the underlying disease mechanisms. Methods: IGH sequences in matched peripheral blood and nasal biopsy specimens from nonallergic healthy control subjects (n = 3) and patients with grass pollen-related AR taken in season (n = 3) or out of season (n = 4) were amplified and pyrosequenced on the 454 GS FLX + System. Results: A total of 97,610 IGH (including 8,135 IgE) sequences were analyzed. Use of immunoglobulin heavy-chain variable region gene families 1 (IGHV1) and 5 (IGHV5) was higher in IgE clonotypic repertoires compared with other antibody classes independent of atopic status. IgE repertoires measured inside the grass pollen season were more diverse and more mutated (particularly in the biopsy specimens) and had more evidence of antigen-driven selection compared with those taken outside of the pollen season or from healthy control subjects. Clonal relatedness was observed for IgE between the blood and nasal biopsy specimens. Furthermore in patients with AR, but not healthy control subjects, we found clonal relatedness between IgE and IgG classes. Conclusion: This is the first report that exploits next-generation sequencing to determine local and peripheral blood IGH repertoires in patients with respiratory allergic disease. We demonstrate that natural pollen exposure was associated with changes in IgE repertoires that were suggestive of ongoing germinal center reactions. Furthermore, these changes were more often apparent in nasal biopsy specimens compared with peripheral blood and in patients with AR compared with healthy control subjects.	[Wu, Yu-Chang B.; James, Louisa K.; Gould, Hannah J.] Kings Coll London, Randall Div Cell & Mol Biophys, London SE1 1UL, England; [Wu, Yu-Chang B.; James, Louisa K.; Durham, Stephen R.; Gould, Hannah J.] MRC, London, England; [Wu, Yu-Chang B.; James, Louisa K.; Durham, Stephen R.; Gould, Hannah J.] Asthma UK Ctr, London, England; [Vander Heiden, Jason A.; Kleinstein, Steven H.] Yale Univ, Interdept Program Computat Biol & Bioinformat, New Haven, CT USA; [Uduman, Mohamed; Kleinstein, Steven H.] Yale Sch Med, Dept Pathol, New Haven, CT USA; [Durham, Stephen R.] Imperial Coll London, Natl Heart & Lung Inst, Allergy & Clin Immunol, London, England; [Kipling, David] Cardiff Univ, Sch Med, Inst Canc & Genet, Cardiff, Wales	University of London; King's College London; Yale University; Yale University; Imperial College London; Cardiff University	Wu, YCB (corresponding author), Kings Coll London, Randall Div Cell & Mol Biophys, New Hunts House,Guys Campus, London SE1 1UL, England.	yu-chang.wu@kcl.ac.uk	WU, YU-CHANG BRYAN/K-9566-2019; James, Louisa/C-9831-2010; Wu, Bryan Yu-Chang/L-3996-2019	WU, YU-CHANG BRYAN/0000-0003-3191-3163; James, Louisa/0000-0002-2252-4636; Gould, Hannah/0000-0003-0411-688X; Uduman, Mohamed/0000-0002-9725-0705	National Library of Medicine of the National Institutes of Health (National Institutes of Health) [T15 LM07056]; Biomedical Research Centre; London Law Trust; National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust; King's College London; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI104739] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [T15LM007056] Funding Source: NIH RePORTER; Medical Research Council [G1000758B, G1000758, G1100090] Funding Source: researchfish; Asthma UK [AUK-PG-2013-183, MRC-AsthmaUKCentre] Funding Source: researchfish; MRC [G1100090] Funding Source: UKRI	National Library of Medicine of the National Institutes of Health (National Institutes of Health); Biomedical Research Centre; London Law Trust; National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust; King's College London; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Asthma UK; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	J.A.V.H. has received research support from the National Library of Medicine of the National Institutes of Health (National Institutes of Health grant T15 LM07056). H.J.G., Y.-C.B.W., and L.K.J. are supported by Biomedical Research Centre (Programme Grant: IgE Structure, Function & Regulation). L.K.J. has received research support from the London Law Trust. Y.-C.B. W. has received research support from the Translational and Experimental Medicine/Cluster 4 Early Career Award from the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health.	Ademokun A, 2011, AGING CELL, V10, P922, DOI 10.1111/j.1474-9726.2011.00732.x; Boyd SD, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000540; Briney BS, 2012, GENES IMMUN, V13, P469, DOI 10.1038/gene.2012.20; Cameron L, 2003, J IMMUNOL, V171, P3816, DOI 10.4049/jimmunol.171.7.3816; Coker HA, 2005, J ALLERGY CLIN IMMUN, V116, P445, DOI 10.1016/j.jaci.2005.04.032; CROUZIER R, 1995, J IMMUNOL, V154, P4526; Davies JM, 2013, J ALLERGY CLIN IMMUN, V131, P972, DOI 10.1016/j.jaci.2012.12.1569; Davies JM, 2004, CLIN EXP ALLERGY, V34, P429, DOI 10.1111/j.1365-2222.2004.01900.x; Durham SR, 1997, EUR J IMMUNOL, V27, P2899, DOI 10.1002/eji.1830271123; Edwards MR, 2002, J IMMUNOL, V168, P6305, DOI 10.4049/jimmunol.168.12.6305; Eibensteiner P, 2000, IMMUNOLOGY, V101, P112, DOI 10.1046/j.1365-2567.2000.00078.x; Felsenstein J., 2005, CLADISTICS; GANZER U, 1988, ORL J OTO-RHINO-LARY, V50, P257, DOI 10.1159/000276000; Gawad C, 2012, BLOOD, V120, P4407, DOI 10.1182/blood-2012-05-429811; Georgiou G, 2014, NAT BIOTECHNOL, V32, P158, DOI 10.1038/nbt.2782; Gevaert P, 2013, ALLERGY, V68, P55, DOI 10.1111/all.12054; Gould HJ, 2008, NAT REV IMMUNOL, V8, P205, DOI 10.1038/nri2273; He J, 2011, ONCOTARGET, V2, P178; HILL MO, 1973, ECOLOGY, V54, P427, DOI 10.2307/1934352; Holgate ST, 2004, CLIN EXP ALLERGY, V34, P632, DOI 10.1111/j.1365-2222.2004.1916.x; Jiang N, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004794; Kashiwakura JI, 2012, ALLERGY ASTHMA IMMUN, V4, P332, DOI 10.4168/aair.2012.4.6.332; Kerzel S, 2010, J IMMUNOL, V185, P2253, DOI 10.4049/jimmunol.0902942; Larimore K, 2012, J IMMUNOL, V189, P3221, DOI 10.4049/jimmunol.1201303; Lavinder JJ, 2014, P NATL ACAD SCI USA, V111, P2259, DOI 10.1073/pnas.1317793111; Levin M, 2013, INT ARCH ALLERGY IMM, V161, P122, DOI 10.1159/000345421; Lim A, 2007, J ALLERGY CLIN IMMUN, V120, P696, DOI 10.1016/j.jaci.2007.05.035; Mroczek ES, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00096; Niederberger V, 2002, EUR J IMMUNOL, V32, P576, DOI 10.1002/1521-4141(200202)32:2<576::AID-IMMU576>3.0.CO;2-U; Parameswaran P, 2013, CELL HOST MICROBE, V13, P691, DOI 10.1016/j.chom.2013.05.008; Ravn U, 2013, METHODS, V60, P99, DOI 10.1016/j.ymeth.2013.03.001; Snow RE, 1997, EUR J IMMUNOL, V27, P162, DOI 10.1002/eji.1830270124; Snow RE, 1999, IMMUNOLOGY, V98, P646, DOI 10.1046/j.1365-2567.1999.00910.x; Takhar P, 2007, J ALLERGY CLIN IMMUN, V119, P213, DOI 10.1016/j.jaci.2006.09.045; VANDERSTOEP N, 1993, J EXP MED, V177, P99, DOI 10.1084/jem.177.1.99; Volpe Joseph M, 2008, Immunome Res, V4, P3, DOI 10.1186/1745-7580-4-3; von Budingen HC, 2012, J CLIN INVEST, V122, P4533, DOI 10.1172/JCI63842; Weinstein JA, 2009, SCIENCE, V324, P807, DOI 10.1126/science.1170020; Wu XL, 2011, SCIENCE, V333, P1593, DOI 10.1126/science.1207532; Wu YC, 2010, BLOOD, V116, P1070, DOI 10.1182/blood-2010-03-275859; Wu YCB, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00081; Xiong HZ, 2012, J EXP MED, V209, P353, DOI 10.1084/jem.20111941; Yaari G, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks457; Yang PL, 1999, J MOL BIOL, V294, P1191, DOI 10.1006/jmbi.1999.3197; Zhu J, 2013, P NATL ACAD SCI USA, V110, P6470, DOI 10.1073/pnas.1219320110	45	37	37	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2014	134	3					604	612		10.1016/j.jaci.2014.07.010	http://dx.doi.org/10.1016/j.jaci.2014.07.010			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GR	25171866	Green Published, hybrid			2022-12-18	WOS:000341372400013
J	Keles, S; Jabara, HH; Reisli, I; McDonald, DR; Barlan, I; Hanna-Wakim, R; Dbaibo, G; Lefranc, G; Al-Herz, W; Geha, RS; Chatila, TA				Keles, Sevgi; Jabara, Haifa H.; Reisli, Ismail; McDonald, Douglas R.; Barlan, Isil; Hanna-Wakim, Rima; Dbaibo, Ghassan; Lefranc, Gerard; Al-Herz, Waleed; Geha, Raif S.; Chatila, Talal A.			Plasmacytoid dendritic cell depletion in DOCK8 deficiency: Rescue of severe herpetic infections with IFN-alpha 2b therapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							HYPER-IGE SYNDROME; MUTATIONS; DEDICATOR; SURVIVAL		[Keles, Sevgi; Reisli, Ismail] Necmettin Erbakan Univ, Meram Med Fac, Div Pediat Immunol & Allergy, Konya, Turkey; [Keles, Sevgi; Jabara, Haifa H.; McDonald, Douglas R.; Geha, Raif S.; Chatila, Talal A.] Harvard Univ, Sch Med, Dept Pediat, Div Immunol,Boston Childrens Hosp, Boston, MA 02115 USA; [Barlan, Isil] Marmara Univ, Fac Med, Div Pediat Allergy & Immunol, Istanbul, Turkey; [Hanna-Wakim, Rima; Dbaibo, Ghassan] Amer Univ Beirut, Div Pediat Infect Dis, Beirut, Lebanon; [Lefranc, Gerard] Univ Montpellier 2, Montpellier, France; [Lefranc, Gerard] CNRS UPR 1142, Inst Human Genet, Montpellier, France; [Al-Herz, Waleed] Kuwait Univ, Fac Med, Dept Pediat, Kuwait, Kuwait	Necmettin Erbakan University; Selcuk University; Harvard University; Boston Children's Hospital; Harvard Medical School; Marmara University; American University of Beirut; Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Kuwait University	Keles, S (corresponding author), Necmettin Erbakan Univ, Meram Med Fac, Div Pediat Immunol & Allergy, Konya, Turkey.	sevgi.keles@childrens.harvard.edu; talal.chatila@childrens.harvard.edu	Dbaibo, Ghassan S./X-2978-2019	Chatila, Talal/0000-0001-7439-2762	NIAID NIH HHS [1R21AI087627, R01 AI085090, R21 AI087627, 1R01AI100315, 5R01AI065617, R01 AI100315] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI100315, R01AI065617, R01AI085090, R21AI087627] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Crawford G, 2013, BLOOD, V122, P2052, DOI 10.1182/blood-2013-02-482331; Engelhardt KR, 2009, J ALLERGY CLIN IMMUN, V124, P1289, DOI 10.1016/j.jaci.2009.10.038; Harada Y, 2012, BLOOD, V119, P4451, DOI 10.1182/blood-2012-01-407098; Jabara HH, 2012, NAT IMMUNOL, V13, P612, DOI 10.1038/ni.2305; Mizesko MC, 2013, J ALLERGY CLIN IMMUN, V131, P840, DOI 10.1016/j.jaci.2012.12.1568; Ozarmagan G, 2005, ACTA DERM-VENEREOL, V85, P433, DOI 10.1080/00015550510030041; Randall KL, 2011, J EXP MED, V208, P2305, DOI 10.1084/jem.20110345; Reizis B, 2011, ANNU REV IMMUNOL, V29, P163, DOI 10.1146/annurev-immunol-031210-101345; Zhang Q, 2009, NEW ENGL J MED, V361, P2046, DOI 10.1056/NEJMoa0905506	9	37	39	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2014	133	6					1753	1755		10.1016/j.jaci.2014.03.032	http://dx.doi.org/10.1016/j.jaci.2014.03.032			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AI2FI	24767873	Green Accepted			2022-12-18	WOS:000336672500030
J	Chen, K; Wu, W; Mathew, D; Zhang, YH; Browne, SK; Rosen, LB; McManus, MP; Pulsipher, MA; Yandell, M; Bohnsack, JF; Jorde, LB; Notarangelo, LD; Walter, JE				Chen, Karin; Wu, Wilfred; Mathew, Divij; Zhang, Yuhua; Browne, Sarah K.; Rosen, Lindsey B.; McManus, Meghann P.; Pulsipher, Michael A.; Yandell, Mark; Bohnsack, John F.; Jorde, Lynn B.; Notarangelo, Luigi D.; Walter, Jolan E.			Autoimmunity due to RAG deficiency and estimated disease incidence in RAG1/2 mutations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							IMMUNODEFICIENCY; AUTOANTIBODIES; RECOMBINATION; LYMPHOPENIA		[Chen, Karin; Bohnsack, John F.] Univ Utah, Sch Med, Dept Pediat, Div Allergy Immunol & Rheumatol, Salt Lake City, UT 84112 USA; [Wu, Wilfred; Yandell, Mark; Jorde, Lynn B.] Univ Utah, Dept Human Genet, Salt Lake City, UT USA; [Mathew, Divij; Notarangelo, Luigi D.; Walter, Jolan E.] Harvard Univ, Sch Med, Div Immunol, Boston, MA USA; [Mathew, Divij; Notarangelo, Luigi D.; Walter, Jolan E.] Harvard Univ, Sch Med, Boston Childrens Hosp, Manton Ctr Orphan Dis Res, Boston, MA USA; [Zhang, Yuhua] Rutgers State Univ, RUCDR, Piscataway, NJ USA; [Browne, Sarah K.; Rosen, Lindsey B.] NIAID, Immunopathogenesis Sect, Lab Clin Infect Dis, NIH, Bethesda, MD 20892 USA; [McManus, Meghann P.; Pulsipher, Michael A.] Univ Utah, Sch Med, Div Hematol Blood & Marrow Transplantat, Salt Lake City, UT USA; [Notarangelo, Luigi D.] Harvard Univ, Sch Med, Harvard Stem Cell Inst, Boston, MA USA; [Walter, Jolan E.] Massachusetts Gen Hosp Children, Pediat Immunodeficiency Program, Div Allergy, Boston, MA USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Rutgers State University New Brunswick; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Utah System of Higher Education; University of Utah; Harvard University; Harvard Medical School	Chen, K (corresponding author), Univ Utah, Sch Med, Dept Pediat, Div Allergy Immunol & Rheumatol, Salt Lake City, UT 84112 USA.	karin.chen@hsc.utah.edu	Notarangelo, Luigi D/F-9718-2016	Notarangelo, Luigi D/0000-0002-8335-0262	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI103035, U54AI082973, P01AI076210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM104390, R01GM059290] Funding Source: NIH RePORTER; NIAID NIH HHS [5P01AI076210-04, P01 AI076210, K08 AI103035, 1K08AI103035-01, U54AI082973] Funding Source: Medline; NIGMS NIH HHS [R01 GM104390, GM59290] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632; Asai E, 2011, CLIN IMMUNOL, V138, P172, DOI 10.1016/j.clim.2010.11.005; Avila EM, 2010, PEDIATRICS, V126, pE1248, DOI 10.1542/peds.2009-3171; Bell CJ, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001756; Buckley RH, 2012, J ALLERGY CLIN IMMUN, V129, P597, DOI 10.1016/j.jaci.2011.12.964; Burbelo PD, 2010, BLOOD, V116, P4848, DOI 10.1182/blood-2010-05-286161; de Villartay JP, 2005, J CLIN INVEST, V115, P3291, DOI 10.1172/JCI25178; Gruber TA, 2009, PEDIATR TRANSPLANT, V13, P244, DOI 10.1111/j.1399-3046.2008.00970.x; Kuijpers TW, 2011, BLOOD, V117, P5892, DOI 10.1182/blood-2011-01-329052; Kwan A, 2013, J ALLERGY CLIN IMMUN, V132, P140, DOI 10.1016/j.jaci.2013.04.024; Meager A, 2006, PLOS MED, V3, P1152, DOI 10.1371/journal.pmed.0030289; Niehues T, 2010, CLIN IMMUNOL, V135, P183, DOI 10.1016/j.clim.2010.01.013; Safaeil S, 2011, IRAN J ALLERGY ASTHM, V10, P129, DOI 010.02/ijaai.129132; Schatz DG, 2011, NAT REV IMMUNOL, V11, P251, DOI 10.1038/nri2941; Sheehan WJ, 2009, J ALLERGY CLIN IMMUN, V123, P966, DOI 10.1016/j.jaci.2008.12.007; Sobacchi C, 2006, HUM MUTAT, V27, P1174, DOI 10.1002/humu.20408; Villa A, 2001, BLOOD, V97, P81, DOI 10.1182/blood.V97.1.81	17	37	37	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2014	133	3					880	+		10.1016/j.jaci.2013.11.038	http://dx.doi.org/10.1016/j.jaci.2013.11.038			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EK	24472623	Green Accepted, Bronze			2022-12-18	WOS:000332397600033
J	Wood, RA; Togias, A; Wildfire, J; Visness, CM; Matsui, EC; Gruchalla, R; Hershey, G; Liu, AH; O'Connor, GT; Pongracic, JA; Zoratti, E; Little, F; Granada, M; Kennedy, S; Durham, SR; Shamji, MH; Busse, WW				Wood, Robert A.; Togias, Alkis; Wildfire, Jeremy; Visness, Cynthia M.; Matsui, Elizabeth C.; Gruchalla, Rebecca; Hershey, Gurjit; Liu, Andrew H.; O'Connor, George T.; Pongracic, Jacqueline A.; Zoratti, Edward; Little, Frederic; Granada, Mark; Kennedy, Suzanne; Durham, Stephen R.; Shamji, Mohamed H.; Busse, William W.			Development of cockroach immunotherapy by the Inner-City Asthma Consortium	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cockroach; immunotherapy; sublingual immunotherapy; subcutaneous immunotherapy; inner city asthma	SUBLINGUAL IMMUNOTHERAPY; ALLERGEN; CHILDREN	Background: Cockroach allergy is a key contributor to asthma morbidity in children living in urban environments. Objective: We sought to document immune responses to cockroach allergen and provide direction for the development of immunotherapy for cockroach allergy. Methods: Four pilot studies were conducted: (1) an open-label study to assess the safety of cockroach sublingual immunotherapy (SLIT) in adults and children; (2) a randomized, double-blind biomarker study of cockroach SLIT versus placebo in adults; (3) a randomized, double-blind biomarker study of 2 doses of cockroach SLIT versus placebo in children; and (4) an open-label safety and biomarker study of cockroach subcutaneous immunotherapy (SCIT) in adults. Results: The adult SLIT trial (n = 54; age, 18-54 years) found a significantly greater increase in cockroach-specific IgE levels between the active and placebo groups (geometric mean ratio, 1.92; P < .0001) and a trend toward increased cockroach-specific IgG(4) levels in actively treated subjects (P = .09) but no evidence of functional blocking antibody response. The pediatric SLIT trial (n = 99; age, 5-17 years) found significant differences in IgE, IgG, and IgG(4) responses between both active groups and the placebo group but no consistent differences between the high-and low-dose groups. In the SCIT study the treatment resulted in significant changes from baseline in cockroach IgE, IgG(4), and blocking antibody levels. The safety profile of cockroach immunotherapy was reassuring in all studies. Conclusions: The administration of cockroach allergen by means of SCIT is immunologically more active than SLIT, especially with regard to IgG(4) levels and blocking antibody responses. No safety concerns were raised in any age group. These pilot studies suggest that immunotherapy with cockroach allergen is more likely to be effective with SCIT.	[Wood, Robert A.; Matsui, Elizabeth C.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; [Togias, Alkis] NIAID, Div Allergy Immunol & Transplantat, NIH, Bethesda, MD 20892 USA; [Wildfire, Jeremy; Visness, Cynthia M.; Kennedy, Suzanne] Rho Fed Syst Div, Chapel Hill, NC USA; [Gruchalla, Rebecca] Univ Texas Dallas, Dept Med, SW Med Sch, Dallas, TX 75230 USA; [Gruchalla, Rebecca] Univ Texas Dallas, Dept Pediat, SW Med Sch, Dallas, TX 75230 USA; [Hershey, Gurjit] Cincinnati Childrens Hosp, Dept Pediat, Cincinnati, OH USA; [Liu, Andrew H.] Natl Jewish Hlth, Denver, CO USA; [Liu, Andrew H.] Univ Colorado, Sch Med, Denver, CO USA; [O'Connor, George T.; Little, Frederic; Granada, Mark] Boston Univ, Sch Med, Dept Med, Boston, MA USA; [Pongracic, Jacqueline A.] Ann & Robert H Lurie Childrens Hosp Chicago, Dept Pediat, Chicago, IL USA; [Zoratti, Edward] Henry Ford Hlth Syst, Dept Med, Detroit, MI USA; [Durham, Stephen R.; Shamji, Mohamed H.] Univ London Imperial Coll Sci Technol & Med, London, England; [Busse, William W.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Cincinnati Children's Hospital Medical Center; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Boston University; Ann & Robert H. Lurie Children's Hospital of Chicago; Henry Ford Health System; Henry Ford Hospital; Imperial College London; University of Wisconsin System; University of Wisconsin Madison	Wood, RA (corresponding author), Johns Hopkins Univ Hosp, CMSC 1102,600 N Wolfe St, Baltimore, MD 21287 USA.	rwood@jhmi.edu	Shamji, Mohamed/AAU-8811-2020; Shamji, Mohamed/AAD-1788-2019	Shamji, Mohamed/0000-0003-3425-3463; O'Connor, George/0000-0002-6476-3926; Matsui, Elizabeth/0000-0001-8134-5593	National Institute of Allergy and Infectious Diseases, National Institutes of Health [NO1-AI-25496, NO1-AI-25482, HHSN272200900052C, HHSN2722010000521]; National Center for Research Resources, National Institutes of Health [RR00052, 1UL1RR025771, UL1 RR024982, UL1 TR000077-04]; National Center for Advancing Translational Sciences, National Institutes of Health [RR00052, 1UL1RR025771, UL1 RR024982, UL1 TR000077-04]; MRC [G0601303] Funding Source: UKRI; Medical Research Council [G1000758B, G1000758, G0601303] Funding Source: researchfish; Asthma UK [MRC-AsthmaUKCentre] Funding Source: researchfish; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001079, UL1TR000077, UL1TR001105] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024982, UL1RR025771] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI025496] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Research Resources, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Center for Advancing Translational Sciences, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Asthma UK; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, under contract nos. NO1-AI-25496, NO1-AI-25482, HHSN272200900052C, and HHSN2722010000521 and from the National Center for Research Resources and National Center for Advancing Translational Sciences, National Institutes of Health, under grants RR00052, 1UL1RR025771, UL1 RR024982, and UL1 TR000077-04. Immunologic extracts were donated for some studies by Greer Pharmaceuticals (Lenoir, NC).	Brown SGA, 2004, J ALLERGY CLIN IMMUN, V114, P371, DOI 10.1016/j.jaci.2004.04.029; Bush RK, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Bush RK, 2011, J ALLERGY CLIN IMMUN, V127, P974, DOI 10.1016/j.jaci.2010.11.045; Dahl R, 2008, J ALLERGY CLIN IMMUN, V121, P512, DOI 10.1016/j.jaci.2007.10.039; Esch RE, 2008, ANN ALLERG ASTHMA IM, V100, P475, DOI 10.1016/S1081-1206(10)60474-7; Frew AJ, 2008, NEW ENGL J MED, V358, P2259, DOI 10.1056/NEJMct0708337; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; O'Hehir RE, 2009, AM J RESP CRIT CARE, V180, P936, DOI 10.1164/rccm.200905-0686OC; Radulovic S, 2011, ALLERGY, V66, P740, DOI 10.1111/j.1398-9995.2011.02583.x; Radulovic S, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002893.pub2; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Shamji MH, 2012, ALLERGY, V67, P217, DOI 10.1111/j.1398-9995.2011.02745.x; Shamji MH, 2006, J IMMUNOL METHODS, V317, P71, DOI 10.1016/j.jim.2006.09.004; Slater JE, 2007, CLIN EXP ALLERGY, V37, P1033, DOI 10.1111/j.1365-2222.2007.02751.x; Srivastava D, 2011, EUR J CLIN INVEST, V41, P879, DOI 10.1111/j.1365-2362.2011.02480.x; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x	16	37	37	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2014	133	3					846	+		10.1016/j.jaci.2013.08.047	http://dx.doi.org/10.1016/j.jaci.2013.08.047			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EK	24184147	Green Accepted			2022-12-18	WOS:000332397600029
J	Seite, JF; Goutsmedt, C; Youinou, P; Pers, JO; Hillion, S				Seite, Jean-Francois; Goutsmedt, Carole; Youinou, Pierre; Pers, Jacques-Olivier; Hillion, Sophie			Intravenous immunoglobulin induces a functional silencing program similar to anergy in human B cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Intravenous immunoglobulin; B cells; anergy; chronic inflammatory diseases; autoimmunity; immune tolerance	ANTIGEN RECEPTOR; TOLERANCE; ACTIVATION; MATURE; CD22; IVIG; INTERNALIZATION; AUTOIMMUNITY; MAINTENANCE; INHIBITION	Background: Chronic inflammatory and autoimmune diseases are largely due to inappropriate response of hyperactive or autoreactive B cells. These autoreactive B cells can evade central tolerance checkpoints and migrate to the periphery, where they would be silenced by anergy. Such anergic cells are characterized by B-cell receptor (BCR) desensitization and altered downstream signaling. Objective: We sought to determine whether intravenous immunoglobulin (IVIg) induces a nonresponsive state of B cells and to address the similarities of this mechanism to those described in anergy. Methods: Human B cells were stimulated with anti-IgM antibody, and effects of IVIg on several parameters, such as calcium release, tyrosine phosphorylation, BCR aggregation, BCR internalization, or transcriptional activity, were studied by using flow cytometry, confocal microscopy, Western blotting, and a quantitative PCR array. Results: IVIg-treated B cells show defects in activating coreceptor expression, calcium signaling, and BCR aggregation on engagement by antigen. IVIg also induces suppression of phosphoinositide 3-kinase signaling, which plays a central role in determining B-cell fate. All these events ultimately lead to profound modifications in gene expression, resulting in long-term functional but reversible silencing of IVIg-treated B cells. Conclusion: Our findings provide insights into the effectiveness of IVIg in treating autoimmune or inflammatory pathologies associated with the loss of B-cell tolerance. Furthermore, these data provide a model to explore the complexity of positive versus negative selection in B cells.	[Seite, Jean-Francois; Goutsmedt, Carole; Youinou, Pierre; Pers, Jacques-Olivier; Hillion, Sophie] Univ Bretagne Occidentale, Univ Europeenne Bretagne, EA2216, Brest, France	Universite de Bretagne Occidentale	Pers, JO (corresponding author), Brest Univ, Med Sch Hosp, Immunol Lab, BP824, F-29609 Brest, France.	pers@univ-brest.fr	HILLION, Sophie/I-9747-2019; Pers, Jacques-Olivier/AGG-7221-2022		CSL Behring	CSL Behring	Supported by a grant from CSL Behring.	Anthony RM, 2008, P NATL ACAD SCI USA, V105, P19571, DOI 10.1073/pnas.0810163105; Batista FD, 2001, NATURE, V411, P489, DOI 10.1038/35078099; Blery M, 2006, J EXP MED, V203, P1773, DOI 10.1084/jem.20060552; Borde M, 2006, IMMUNOL REV, V210, P105, DOI 10.1111/j.0105-2896.2006.00370.x; Browne CD, 2009, IMMUNITY, V31, P749, DOI 10.1016/j.immuni.2009.08.026; Cambier JC, 2007, NAT REV IMMUNOL, V7, P633, DOI 10.1038/nri2133; Chaturvedi A, 2011, NAT IMMUNOL, V12, P1119, DOI 10.1038/ni.2116; Clark MR, 2011, MOL IMMUNOL, V48, P1281, DOI 10.1016/j.molimm.2010.10.024; Depoil D, 2008, NAT IMMUNOL, V9, P63, DOI 10.1038/ni1547; Duty JA, 2009, J EXP MED, V206, P139, DOI 10.1084/jem.20080611; Feuerstein N, 1999, J IMMUNOL, V163, P5287; Gauld SB, 2005, NAT IMMUNOL, V6, P1160, DOI 10.1038/ni1256; Ghielmetti M, 2006, MOL IMMUNOL, V43, P939, DOI 10.1016/j.molimm.2005.06.024; Glynne R, 2000, IMMUNOL REV, V176, P216; Goodnow CC, 1996, P NATL ACAD SCI USA, V93, P2264, DOI 10.1073/pnas.93.6.2264; Gross AJ, 2009, J IMMUNOL, V182, P5382, DOI 10.4049/jimmunol.0803941; Halverson R, 2004, NAT IMMUNOL, V5, P645, DOI 10.1038/ni1076; Healy JI, 1997, IMMUNITY, V6, P419, DOI 10.1016/S1074-7613(00)80285-X; Hippen KL, 2005, J IMMUNOL, V175, P909, DOI 10.4049/jimmunol.175.2.909; Kessel A, 2011, J CLIN IMMUNOL, V31, P30, DOI 10.1007/s10875-010-9469-3; Koelsch K, 2007, J CLIN INVEST, V117, P1558, DOI 10.1172/JCI27628; Maddur MS, 2011, J ALLERGY CLIN IMMUN, V127, P823, DOI 10.1016/j.jaci.2010.12.1102; Massoud AH, 2012, J ALLERGY CLIN IMMUN, V129, P1656, DOI 10.1016/j.jaci.2012.02.050; Miller AT, 2009, J IMMUNOL, V182, P4696, DOI 10.4049/jimmunol.0802850; Noorchashm H, 1999, INT IMMUNOL, V11, P765, DOI 10.1093/intimm/11.5.765; Nossal GJV, 1996, J EXP MED, V183, P1953, DOI 10.1084/jem.183.5.1953; O'Keefe TL, 1999, J EXP MED, V189, P1307, DOI 10.1084/jem.189.8.1307; O'Neill SK, 2011, IMMUNITY, V35, P746, DOI 10.1016/j.immuni.2011.10.011; O'Neill SK, 2009, P NATL ACAD SCI USA, V106, P6262, DOI 10.1073/pnas.0812922106; Proulx DP, 2009, IMMUNOL LETT, V124, P18, DOI 10.1016/j.imlet.2009.03.012; Pugh-Bernard AE, 2001, J CLIN INVEST, V108, P1061, DOI 10.1172/JCI200112462; Reichlin A, 2004, J EXP MED, V199, P855, DOI 10.1084/jem.20031140; Seite JF, 2011, J AUTOIMMUN, V37, P190, DOI 10.1016/j.jaut.2011.05.014; Seite JF, 2010, BLOOD, V116, P1698, DOI 10.1182/blood-2009-12-261461; Smith KGC, 1998, J EXP MED, V187, P807, DOI 10.1084/jem.187.5.807; Vilen BJ, 1999, IMMUNITY, V10, P239, DOI 10.1016/S1074-7613(00)80024-2; Vilen BJ, 1997, J IMMUNOL, V159, P231; Wardemann H, 2003, SCIENCE, V301, P1374, DOI 10.1126/science.1086907; Weintraub BC, 2000, J EXP MED, V191, P1443, DOI 10.1084/jem.191.8.1443; Winter O, 2012, J IMMUNOL, V189, P5105, DOI 10.4049/jimmunol.1202317; Yarkoni Y, 2010, IMMUNOL REV, V237, P249, DOI 10.1111/j.1600-065X.2010.00936.x; Zhuang QL, 2002, J ALLERGY CLIN IMMUN, V110, P480, DOI 10.1067/mai.2002.127284; Zhuang QL, 2001, J ALLERGY CLIN IMMUN, V108, P229, DOI 10.1067/mai.2001.116291	43	37	40	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2014	133	1					181	+		10.1016/j.jaci.2013.08.042	http://dx.doi.org/10.1016/j.jaci.2013.08.042			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	281MM	24139609				2022-12-18	WOS:000329105700025
J	Haque, R; Hakim, A; Moodley, T; Torrego, A; Essilfie-Quaye, S; Jazrawi, E; Johnson, M; Barnes, PJ; Adcock, IM; Usmani, OS				Haque, Rubaiyat; Hakim, Amir; Moodley, Thunicia; Torrego, Alfonso; Essilfie-Quaye, Sarah; Jazrawi, Elen; Johnson, Malcolm; Barnes, Peter J.; Adcock, Ian M.; Usmani, Omar Sharif			Inhaled long-acting beta(2) agonists enhance glucocorticoid receptor nuclear translocation and efficacy in sputum macrophages in COPD	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Long-acting beta(2) agonist; corticosteroid; glucocorticoid receptor; sputum; COPD; macrophage	OBSTRUCTIVE PULMONARY-DISEASE; SALMETEROL/FLUTICASONE PROPIONATE; INFLAMMATORY INDEXES; ASTHMA MANAGEMENT; SALMETEROL; FLUTICASONE; CORTICOSTEROIDS; BUDESONIDE; FORMOTEROL; BUDESONIDE/FORMOTEROL	Background: Combination inhaled therapy with long-acting beta(2) agonists (LABAs) and corticosteroids is beneficial in treating asthma and chronic obstructive pulmonary disease (COPD). Objective: In asthma, LABAs enhance glucocorticoid receptor (GR) nuclear translocation in the presence of corticosteroids. Whether this biological mechanism occurs in COPD, a relatively corticosteroid-resistant disease, is uncertain. Methods: Eight patients with mild/moderate COPD participated in a double-blind, placebo-controlled, crossover study and inhaled single doses of fluticasone propionate (FP) 100 mu g, FP 500 mu g, salmeterol xinafoate (SLM) 50 mu g, and combination FP 100 mu g + SLM 50 mu g. One hour postinhalation, sputum was induced, nuclear proteins isolated from purified macrophages, and levels of activated nuclear GR quantified by using a GR-glucocorticoid response element ELISA-based assay. Results: Nuclear GR significantly increased after the inhalation of FP 500 mu g(P<.01), but not after the inhalation of FP 100 mu g or SLM 50 mu g, compared with placebo. Interestingly, SLM in combination with FP 100 mu g increased nuclear GR levels equivalent to those of FP 500 mu g alone. This was significantly greater than either FP 100 mg (P<.05) or SLM 50 mu g (P<.01) alone. In vitro in a human macrophage cell line, SLM(10(-8) mol/L) enhanced FP (10(-9) mol/L)-induced mitogen-activated protein kinase phosphatase-1 mRNA (5.8 +/- 0.6 vs 8.4 +/- 1.1 x 10(-6) copies, P<.05) and 2 x glucocorticoid response element-luciferase reporter gene activity (250.1 +/- 5.6 vs 103.1 +/- 23.6-fold induction, P<.001). Addition of SLM (10(-9) mol/L) to FP (10(-11) mol/L) significantly enhanced FP-mediated suppression of IL-1 beta-induced CXCL8 (P<.05). Conclusions: Addition of SLM 50 mu g to FP 100 mu g enhanced GR nuclear translocation equivalent to that seen with a 5-fold higher dose of FP in sputum macrophages from patients with COPD. This may account for the superior clinical effects of combination LABA/corticosteroid treatment compared with either as monotherapy observed in COPD.	[Usmani, Omar Sharif] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Airway Dis Sect, London SW3 6LY, England; [Usmani, Omar Sharif] Royal Brompton Hosp, London SW3 6LY, England	Imperial College London; Royal Brompton Hospital	Usmani, OS (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Airway Dis Sect, Guy Scadding Bldg,Dovehouse St, London SW3 6LY, England.	o.usmani@imperial.ac.uk	Adcock, Ian/L-3217-2019	Adcock, Ian/0000-0003-2101-8843; Barnes, Peter/0000-0002-5122-4018; hakim, amir/0000-0002-4884-3141; Essilfie-Quaye, Sarah/0000-0002-5483-6642	GlaxoSmithKline (UK); National Institute for Health Research (NIHR) Respiratory Disease Biomedical Research Unit at the Royal Brompton; Harefield NHS Foundation Trust; Imperial College London; UK NIHR; MRC [MC_PC_13033] Funding Source: UKRI; Medical Research Council [MC_PC_13033] Funding Source: researchfish; National Institute for Health Research [CDF-2011-04-053, NF-SI-0611-10148] Funding Source: researchfish	GlaxoSmithKline (UK)(GlaxoSmithKline); National Institute for Health Research (NIHR) Respiratory Disease Biomedical Research Unit at the Royal Brompton; Harefield NHS Foundation Trust; Imperial College London(General Electric); UK NIHR(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	Supported by an unrestricted grant from GlaxoSmithKline (UK). This project was supported by the National Institute for Health Research (NIHR) Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London. Omar Sharif Usmani is a recipient of a UK NIHR Career Development Fellowship.	Adcock Ian M., 2002, Journal of Allergy and Clinical Immunology, V110, pS261, DOI 10.1067/mai.2002.129705; Barnes NC, 2006, AM J RESP CRIT CARE, V173, P736, DOI 10.1164/rccm.200508-1321OC; Barnes PJ, 2006, BRIT J PHARMACOL, V148, P245, DOI 10.1038/sj.bjp.0706736; Barnes PJ, 2013, J ALLERGY CLIN IMMUN, V131, P636, DOI 10.1016/j.jaci.2012.12.1564; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Bathoorn E, 2008, COPD, V5, P282, DOI 10.1080/15412550802363360; Beasley R, 1999, J ALLERGY CLIN IMMUN, V104, pS18, DOI 10.1016/S0091-6749(99)70270-8; Bourbeau J, 2007, THORAX, V62, P938, DOI 10.1136/thx.2006.071068; Calverley P, 2003, LANCET, V361, P449, DOI 10.1016/S0140-6736(03)12459-2; Calverley PMA, 2007, NEW ENGL J MED, V356, P775, DOI 10.1056/NEJMoa063070; Calverley PM, 2003, EUR RESPIR J, V22, P912, DOI 10.1183/09031936.03.00027003; Celli BR, 2008, AM J RESP CRIT CARE, V178, P332, DOI 10.1164/rccm.200712-1869OC; Cosio BG, 2004, J EXP MED, V200, P689, DOI 10.1084/jem.20040416; Culpitt SV, 2002, AM J RESP CRIT CARE, V165, P1371, DOI 10.1164/rccm.2105106; Ducharme FM, 2011, COCHRANE DB SYST REV, V5; Eickelberg O, 1999, J BIOL CHEM, V274, P1005, DOI 10.1074/jbc.274.2.1005; Gibson PG, 2007, J ALLERGY CLIN IMMUN, V119, P344, DOI 10.1016/j.jaci.2006.10.043; Giembycz MA, 2008, BRIT J PHARMACOL, V153, P1090, DOI 10.1038/sj.bjp.0707627; Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2018, GLOBAL STRATEGY DIAG; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; Johnson M, 2006, J ALLERGY CLIN IMMUN, V117, P18, DOI 10.1016/j.jaci.2005.11.012; Johnson M, 2008, COPD, V5, P369, DOI 10.1080/15412550802522924; Juniper EF, 1999, EUR RESPIR J, V14, P1038, DOI 10.1183/09031936.99.14510389; Kaur M, 2008, MOL PHARMACOL, V73, P203, DOI 10.1124/mol.107.040121; Keatings VM, 1997, AM J RESP CRIT CARE, V155, P542, DOI 10.1164/ajrccm.155.2.9032192; Kobayashi Y, 2012, PULM PHARMACOL THER, V25, P201, DOI 10.1016/j.pupt.2012.02.005; Matz J, 2001, J ALLERGY CLIN IMMUN, V107, P783, DOI 10.1067/mai.2001.114709; Mortaz E, 2008, J MOL MED, V86, P1045, DOI 10.1007/s00109-008-0360-0; Nannini L, 2007, COCHRANE DB SYST REV, V4; Nannini LJ, 2007, COCHRANE DB SYST REV, V4; Nie M, 2005, J IMMUNOL, V175, P478, DOI 10.4049/jimmunol.175.1.478; Pang LH, 2000, AM J RESP CELL MOL, V23, P79, DOI 10.1165/ajrcmb.23.1.3985; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Roth M, 2002, LANCET, V360, P1293, DOI 10.1016/S0140-6736(02)11319-5; Shrewsbury S, 2000, BMJ-BRIT MED J, V320, P1368, DOI 10.1136/bmj.320.7246.1368; Soriano JB, 2007, CHEST, V131, P682, DOI 10.1378/chest.06-1696; Suissa S, 2013, CHEST, V143, P1208, DOI 10.1378/chest.12-2881; Szafranski W, 2003, EUR RESPIR J, V21, P74, DOI 10.1183/09031936.03.00031402; Usmani OS, 2005, AM J RESP CRIT CARE, V172, P704, DOI 10.1164/rccm.200408-1041OC; Weigel NL, 2007, MOL ENDOCRINOL, V21, P2311, DOI 10.1210/me.2007-0101; Wells KE, 2012, J ALLERGY CLIN IMMUN, V129, P1274, DOI 10.1016/j.jaci.2011.12.974; Woolcock A, 1996, AM J RESP CRIT CARE, V153, P1481, DOI 10.1164/ajrccm.153.5.8630590; Yang IA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002991.pub2	43	37	38	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2013	132	5					1166	1173		10.1016/j.jaci.2013.07.038	http://dx.doi.org/10.1016/j.jaci.2013.07.038			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	242JH	24070494	Green Submitted			2022-12-18	WOS:000326235600019
J	Fernandez-Boyanapalli, R; Goleva, E; Kolakowski, C; Min, E; Day, B; Leung, DYM; Riches, DWH; Bratton, DL; Sutherland, ER				Fernandez-Boyanapalli, Ruby; Goleva, Elena; Kolakowski, Christena; Min, Elysia; Day, Brian; Leung, Donald Y. M.; Riches, David W. H.; Bratton, Donna L.; Sutherland, E. Rand			Obesity impairs apoptotic cell clearance in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; obesity; inflammation; macrophage; oxidative stress; steroid	ADIPOSE-TISSUE MACROPHAGES; BODY-MASS INDEX; INTERFERON-GAMMA; ALVEOLAR MACROPHAGES; OXIDATIVE STRESS; ALTERNATIVE ACTIVATION; GENE-EXPRESSION; LUNG-FUNCTION; INFLAMMATION; EFFEROCYTOSIS	Background: Asthma in obese adults is typically more severe and less responsive to glucocorticoids than asthma in nonobese adults. Objective: We sought to determine whether the clearance of apoptotic inflammatory cells (efferocytosis) by airway macrophages was associated with altered inflammation and reduced glucocorticoid sensitivity in obese asthmatic patients. Methods: We investigated the relationship of efferocytosis by airway (induced sputum) macrophages and blood monocytes to markers of monocyte programming, in vitro glucocorticoid response, and systemic oxidative stress in a cohort of adults with persistent asthma. Results: Efferocytosis by airway macrophages was assessed in obese (n = 14) and nonobese (n = 19) asthmatic patients. Efferocytosis by macrophages was 40% lower in obese than nonobese subjects, with a mean efferocytic index of 1.77 (SD, 1.07) versus 3.00 (SD, 1.25; P < .01). A similar reduction of efferocytic function was observed in blood monocytes of obese participants. In these monocytes there was also a relative decrease in expression of markers of alternative (M2) programming associated with efferocytosis, including peroxisome proliferator-activated receptor delta and CX3 chemokine receptor 1. Macrophage efferocytic index was significantly correlated with dexamethasone-induced mitogen-activated protein kinase phosphatase 1 expression (p = 0.46, P < .02) and baseline glucocorticoid receptor a expression (p = 0.44, P < .02) in PBMCs. Plasma 4-hydroxynonenal levels were increased in obese asthmatic patients at 0.33 ng/mL (SD, 0.15 ng/mL) versus 0.16 ng/mL (SD, 0.08 ng/mL) in nonobese patients (P = .006) and was inversely correlated with macrophage efferocytic index (p = 5 20.67, P = .02). Conclusions: Asthma in obese adults is associated with impaired macrophage/monocyte efferocytosis. Impairment of this antiinflammatory process is associated with altered monocyte/macrophage programming, reduced glucocorticoid responsiveness, and systemic oxidative stress. (J Allergy Clin Immunol 2013; 131:1041-7.)	[Fernandez-Boyanapalli, Ruby; Goleva, Elena; Leung, Donald Y. M.; Riches, David W. H.; Bratton, Donna L.] Natl Jewish Hlth, Sch Med, Dept Pediat, Denver, CO USA; [Kolakowski, Christena; Min, Elysia; Day, Brian; Sutherland, E. Rand] Natl Jewish Hlth, Sch Med, Dept Med, Denver, CO USA; [Leung, Donald Y. M.; Bratton, Donna L.] Univ Colorado, Sch Med, Dept Pediat, Denver, CO USA; [Riches, David W. H.; Sutherland, E. Rand] Univ Colorado, Sch Med, Dept Med, Denver, CO USA; [Riches, David W. H.] Univ Colorado, Sch Med, Dept Immunol, Denver, CO USA	National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Sutherland, ER (corresponding author), 1400 Jackson St,J-201, Denver, CO 80206 USA.	sutherlande@njhealth.org			National Jewish Health Translational Pilot Program [HL090982]; Catherine Kramer Scientist in Pediatric Medicine [HL34303, AI058228, UL1 RR025780]; Max Goldenberg Foundation; Walter S. and Lucienne B. Driskill Charitable Foundation; Eugene F. and Easton M. Crawford Charitable Lead Unitrust; Crawford Charitable Lead Unitrust; National Institutes of Health (NIH) [RO1 ES017582, U54 ES015678]; Cystic Fibrosis Foundation; Saber Pharmaceuticals [6,231,894]; Aeolus Pharmaceuticals [5,994,339, 6,127,356, 6,479,477, 6,583,132, 6,916,799, 7,189,707, 7,470,677, 7,820,644, 8,217,026]; Catherine Kramer Foundation; National Jewish Health; American Thoracic Society; American Academy of Allergy, Asthma Immunology; Boehringer-Ingelheim; Novartis; National Institutes of Health; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL090982, P01HL034303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI058228, R56AI058228] Funding Source: NIH RePORTER	National Jewish Health Translational Pilot Program; Catherine Kramer Scientist in Pediatric Medicine; Max Goldenberg Foundation; Walter S. and Lucienne B. Driskill Charitable Foundation; Eugene F. and Easton M. Crawford Charitable Lead Unitrust; Crawford Charitable Lead Unitrust; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cystic Fibrosis Foundation(Italian Cystic Fibrosis Research Foundation); Saber Pharmaceuticals; Aeolus Pharmaceuticals; Catherine Kramer Foundation; National Jewish Health; American Thoracic Society; American Academy of Allergy, Asthma Immunology; Boehringer-Ingelheim(Boehringer Ingelheim); Novartis(Novartis); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by HL090982, the National Jewish Health Translational Pilot Program, HL34303, AI058228, UL1 RR025780, Catherine Kramer Scientist in Pediatric Medicine, the Max Goldenberg Foundation, the Walter S. and Lucienne B. Driskill Charitable Foundation, and the Eugene F. and Easton M. Crawford Charitable Lead Unitrust.; Disclosure of potential conflict of interest: R. Fernandez-Boyanapalli has been supported by one or more grants from the Crawford Charitable Lead Unitrust. E. Goleva has been supported by one or more grants from the National Institutes of Health (NIH). B. Day has consultancy arrangements with Aeolus Pharmaceuticals; has received one or more grants from or has one or more grants pending with the NIH (RO1 ES017582 and U54 ES015678) and the Cystic Fibrosis Foundation; has one or more patents (planned, pending, or issued) with Saber Pharmaceuticals (US#6,231,894) and Aeolus Pharmaceuticals (US#5,994,339; #6,127,356; #6,479,477; # 6,583,132; # 6,916,799; # 7,189,707; # 7,470,677; # 7,820,644; # 8,217,026); and owns stock/stock options in Aeolus Pharmaceuticals. D. L. Bratton has been supported by one or more grants from the Catherine Kramer Foundation (endowed chair in pediatric medicine); has been supported by one or more grants from National Jewish Health (Translational Pilot Grant Program support for the investigation); is employed by National Jewish Health; and has received one or more payments for lecturing from or is on the speakers' bureau for the American Thoracic Society and the American Academy of Allergy, Asthma & Immunology. E. R. Sutherland has consultancy arrangements with Forest Laboratories, GlaxoSmithKline, Merck/Schering-Plough, Novartis (inactive), Dey (inactive), and Genentech; is employed by National Jewish Health; has received one or more grants from or has one or more grants pending with Boehringer-Ingelheim, Novartis, and the National Institutes of Health; and has received one or more payments for the development of educational presentations for Genentech. The rest of the authors declare that they have no relevant conflicts of interest.	Agrawal A, 2011, AM J RESP CELL MOL, V44, P270, DOI 10.1165/rcmb.2010-0141TR; [Anonymous], 2007, 3 US DEP HLTH HUM SE; Asada K, 2004, AM J RESP CRIT CARE, V169, P195, DOI 10.1164/rccm.200207-740OC; Berry MA, 2006, NEW ENGL J MED, V354, P697, DOI 10.1056/NEJMoa050580; Bhavsar P, 2008, THORAX, V63, P784, DOI 10.1136/thx.2007.090027; Boniface S, 2003, CLIN EXP ALLERGY, V33, P1238, DOI 10.1046/j.1365-2222.2003.01762.x; Borges VM, 2009, AM J PHYSIOL-LUNG C, V297, pL586, DOI 10.1152/ajplung.90569.2008; Bratton DL, 2011, TRENDS IMMUNOL, V32, P350, DOI 10.1016/j.it.2011.04.009; Busse WW, 2005, AM J RESP CRIT CARE, V172, P807, DOI 10.1164/rccm.200407-966WS; Cho SH, 2005, AM J RESP CRIT CARE, V171, P224, DOI 10.1164/rccm.200310-1416OC; Cottrell L, 2011, AM J RESP CRIT CARE, V183, P441, DOI 10.1164/rccm.201004-0603OC; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Dixon AE, 2006, J ASTHMA, V43, P553, DOI 10.1080/02770900600859123; Fahy JV, 2001, AM J RESP CRIT CARE, V163, P1470, DOI 10.1164/ajrccm.163.6.9901105; Fernandez-Boyanapalli R, 2010, BLOOD, V116, P4512, DOI 10.1182/blood-2010-02-272005; Fernandez-Boyanapalli RF, 2009, BLOOD, V113, P2047, DOI 10.1182/blood-2008-05-160564; Fitzpatrick AM, 2011, PEDIATR RES, V69, P154, DOI 10.1203/PDR.0b013e3182026370; Fitzpatrick AM, 2009, J ALLERGY CLIN IMMUN, V123, P146, DOI 10.1016/j.jaci.2008.10.047; Forno E, 2011, J ALLERGY CLIN IMMUN, V127, P741, DOI 10.1016/j.jaci.2010.12.010; Frasch SC, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.181800; Freire-de-Lima CG, 2006, J BIOL CHEM, V281, P38376, DOI 10.1074/jbc.M605146200; Furukawa S, 2004, J CLIN INVEST, V114, P1752, DOI [10.1172/JCI21625, 10.1172/JCI20042162S]; Geissmann F, 2010, SCIENCE, V327, P656, DOI 10.1126/science.1178331; Gilmour JS, 2006, J IMMUNOL, V176, P7605, DOI 10.4049/jimmunol.176.12.7605; Goleva E, 2008, J ALLERGY CLIN IMMUN, V122, P550, DOI 10.1016/j.jaci.2008.07.007; Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007; Hakonarson H, 2005, P NATL ACAD SCI USA, V102, P14789, DOI 10.1073/pnas.0409904102; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Hauk PJ, 2006, J ALLERGY CLIN IMMUN, V117, pS194, DOI 10.1016/j.jaci.2005.12.767; Heasman SJ, 2004, EUR J IMMUNOL, V34, P1752, DOI 10.1002/eji.200324698; Hodge S, 2003, IMMUNOL CELL BIOL, V81, P289, DOI 10.1046/j.1440-1711.2003.t01-1-01170.x; Huynh MLN, 2005, AM J RESP CRIT CARE, V172, P972, DOI 10.1164/rccm.200501-035OC; Ingersoll MA, 2010, BLOOD, V115, pE10, DOI 10.1182/blood-2009-07-235028; Jin M, 2004, AM J RESP CELL MOL, V31, P322, DOI 10.1165/rcmb.2004-0080OC; Kang K, 2008, CELL METAB, V7, P485, DOI 10.1016/j.cmet.2008.04.002; Keaney JF, 2003, ARTERIOSCL THROM VAS, V23, P434, DOI 10.1161/01.ATV.0000058402.34138.11; Kiss RS, 2006, CURR BIOL, V16, P2252, DOI 10.1016/j.cub.2006.09.043; Knolle MD, 2009, EXPERT OPIN THER TAR, V13, P523, DOI [10.1517/14728220902889788, 10.1517/14728220902889788 ]; Korns D, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00057; Kumar Rakesh K., 2006, Inflammation & Allergy Drug Targets, V5, P253, DOI 10.2174/187152806779010909; Lara A, 2008, AM J RESP CRIT CARE, V178, P673, DOI 10.1164/rccm.200710-1542OC; Li LB, 2006, J LEUKOCYTE BIOL, V79, P818, DOI 10.1189/jlb.0805466; Litonjua AA, 2003, ANN ALLERG ASTHMA IM, V90, P422, DOI 10.1016/S1081-1206(10)61827-3; Lumeng CN, 2007, J CLIN INVEST, V117, P175, DOI 10.1172/JCI29881; Majai G, 2007, EUR J IMMUNOL, V37, P1343, DOI 10.1002/eji.200636398; McPhillips K, 2007, J IMMUNOL, V178, P8117, DOI 10.4049/jimmunol.178.12.8117; Medeiros AI, 2009, J EXP MED, V206, P61, DOI 10.1084/jem.20082058; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Mukundan L, 2009, NAT MED, V15, P1266, DOI 10.1038/nm.2048; O'Neill HC, 2010, FREE RADICAL BIO MED, V48, P1188, DOI 10.1016/j.freeradbiomed.2010.01.039; Odegaard JI, 2008, CELL METAB, V7, P496, DOI 10.1016/j.cmet.2008.04.003; Odegaard JI, 2007, NATURE, V447, P1116, DOI 10.1038/nature05894; Ohashi K, 2010, J BIOL CHEM, V285, P6153, DOI 10.1074/jbc.M109.088708; Olefsky JM, 2010, ANNU REV PHYSIOL, V72, P219, DOI 10.1146/annurev-physiol-021909-135846; Ouchi N, 2011, NAT REV IMMUNOL, V11, P85, DOI 10.1038/nri2921; Peters SP, 2010, NEW ENGL J MED, V363, P1715, DOI 10.1056/NEJMoa1008770; Ravichandran KS, 2010, J EXP MED, V207, P1807, DOI 10.1084/jem.20101157; Shore SA, 2010, J APPL PHYSIOL, V108, P735, DOI 10.1152/japplphysiol.00749.2009; Silkoff Philip E, 2006, Proc Am Thorac Soc, V3, P131; Sutherland ER, 2008, AM J RESP CRIT CARE, V178, P682, DOI 10.1164/rccm.200801-076OC; Sutherland ER, 2010, AM J RESP CRIT CARE, V181, P699, DOI 10.1164/rccm.200911-1710OC; Sutherland ER, 2010, ALLERGY ASTHMA PROC, V31, P20, DOI 10.2500/aap.2010.31.3307; Sutherland ER, 2009, J ALLERGY CLIN IMMUN, V123, P1328, DOI 10.1016/j.jaci.2009.04.005; Truyen E, 2006, THORAX, V61, P202, DOI 10.1136/thx.2005.052399; Vandivier RW, 2006, CHEST, V129, P1673, DOI 10.1378/chest.129.6.1673; Webster JC, 2001, P NATL ACAD SCI USA, V98, P6865, DOI 10.1073/pnas.121455098; Wentworth JM, 2010, DIABETES, V59, P1648, DOI 10.2337/db09-0287; Yamauchi T, 2007, NAT MED, V13, P332, DOI 10.1038/nm1557; Zeyda M, 2007, INT J OBESITY, V31, P1420, DOI 10.1038/sj.ijo.0803632; Zimmermann N, 2003, J CLIN INVEST, V111, P1863, DOI 10.1172/JCI200317912	71	37	38	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2013	131	4					1041	+		10.1016/j.jaci.2012.09.028	http://dx.doi.org/10.1016/j.jaci.2012.09.028			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	120QT	23154082	Green Accepted, Bronze			2022-12-18	WOS:000317187200011
J	Gupta, RS; Springston, EE; Smith, B; Pongracic, J; Holl, JL; Warrier, MR				Gupta, Ruchi S.; Springston, Elizabeth E.; Smith, Bridget; Pongracic, Jacqueline; Holl, Jane L.; Warrier, Manoj R.			Parent report of physician diagnosis in pediatric food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; diagnosis; oral food challenge; serum specific IgE; skin prick test; pediatrics; urticaria; angioedema; eczema	CHILDREN; ANAPHYLAXIS; PREVALENCE; MANAGEMENT; KNOWLEDGE; ATTITUDES; BELIEFS	Background: Childhood food allergy is a serious health problem. However, little is known about the frequency and manner in which it is currently diagnosed. Objective: To describe parent report of physician practices in the diagnosis of pediatric food allergy. Methods: Data from children with food allergy were identified for analysis from a representative survey administered in US households with children from June 2009 to February 2010. Analyses were performed at the level of the allergy. Demographic characteristics, symptom prevalence, and diagnostic methods were calculated as weighted proportions. Adjusted models were estimated to examine the association of reaction history and allergenic food with odds of physician diagnosis and testing. Results: Food allergies (n = 3,218) to 9 common allergens were reported among 2,355 children in a sample of 38,480. We found that 70.4% of reported food allergy was diagnosed by a physician. Among physician-diagnosed food allergy, 32.6% was not evaluated with diagnostic testing, 47.3% was assessed with a skin prick test, 39.9% with a serum specific IgE test, and 20.2% with an oral food challenge. Odds of physician diagnosis and testing were significantly higher for severe versus mild/moderate food allergy. Urticaria and angioedema were not reported as symptoms in 40.7% and 34.6% of severe food allergies, respectively. Conclusion: Thirty percent of parent-reported food allergies in this study were not diagnosed by a physician. One in 5 physician-diagnosed allergies was evaluated with oral food challenge. Understanding parent report of practices in food allergy provides insight into ways in which to streamline the diagnosis and management of care. (J Allergy Clin Immunol 2013;131:150-6.)	[Gupta, Ruchi S.; Springston, Elizabeth E.; Holl, Jane L.] Northwestern Univ, Ctr Healthcare Studies, Feinberg Sch Med, Chicago, IL 60611 USA; [Gupta, Ruchi S.] Childrens Mem Hosp, Smith Child Hlth Res Program, Chicago, IL 60614 USA; [Gupta, Ruchi S.; Pongracic, Jacqueline; Holl, Jane L.] Northwestern Univ, Dept Pediat, Feinberg Sch Med, Chicago, IL 60611 USA; [Smith, Bridget] Loyola Stritch Sch Med, Program Hlth Serv Res, Maywood, IL USA; [Smith, Bridget] Edward Hines Jr VA Hosp, Ctr Management Complex Chron Care, Hines, IL USA; [Pongracic, Jacqueline] Childrens Mem Hosp, Div Allergy & Immunol, Chicago, IL 60614 USA; [Warrier, Manoj R.] St Louis Univ, Sch Med, Div Allergy & Immunol, St Louis, MO USA; [Warrier, Manoj R.] Allergy Asthma & Sinus Care Ctr, St Louis, MO USA	Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Loyola University Chicago; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; Ann & Robert H. Lurie Children's Hospital of Chicago; Saint Louis University	Gupta, RS (corresponding author), Northwestern Univ, Ctr Healthcare Studies, Feinberg Sch Med, 750 N Lake Shore Dr,10th Fl, Chicago, IL 60611 USA.	rugupta@childrensmemorial.org			Food Allergy Initiative, New York, NY; Food Allergy Initiative; Loyola University	Food Allergy Initiative, New York, NY; Food Allergy Initiative; Loyola University	Supported by the Food Allergy Initiative, New York, NY.; R. S. Gupta has received research support, travel support, and payment for writing/reviewing this manuscript from the Food Allergy Initiative. B. Smith has received consulting fees from Loyola University. The rest of the authors declare that they have no relevant conflicts of interest.; We thank the Food Allergy Initiative and Dave and Denise Bunning for their support of this research. We also thank to Drs Xiaobin Wang and Rajesh Kumar for their valuable guidance in data analysis and manuscript review and Ms Claudia Lao for her assistance in manuscript preparation.	[Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Branum AM, 2009, PEDIATRICS, V124, P1549, DOI 10.1542/peds.2009-1210; Branum Amy M, 2008, NCHS Data Brief, P1; Chafen JJS, 2010, JAMA-J AM MED ASSOC, V303, P1848, DOI 10.1001/jama.2010.582; Eigenmann PA, 2000, J ALLERGY CLIN IMMUN, V105, P587, DOI 10.1067/mai.2000.104255; Grundy J, 2002, J ALLERGY CLIN IMMUN, V110, P784, DOI 10.1067/mai.2002.128802; Gupta RS, 2011, PEDIATRICS, V128, pE9, DOI 10.1542/peds.2011-0204; Gupta RS, 2010, PEDIAT ALLERG IMM-UK, V21, P927, DOI 10.1111/j.1399-3038.2010.01005.x; Gupta RS, 2010, PEDIATRICS, V125, P126, DOI 10.1542/peds.2009-1116; Heeringa SG, 2017, APPL SURVEY DATA ANA, VSecond, DOI DOI 10.1201/9781315153278; Hu W, 2008, HEALTH EXPECT, V11, P208, DOI 10.1111/j.1369-7625.2008.00506.x; Lieberman JA, 2010, AM J RHINOL ALLERGY, V24, P439, DOI 10.2500/ajra.2010.24.3515; Lin RY, 2008, ANN ALLERG ASTHMA IM, V101, P387, DOI 10.1016/S1081-1206(10)60315-8; Luccioli S, 2008, PEDIATRICS, V122, pS105, DOI 10.1542/peds.2008-1315n; Nowak-Wegrzyn A, 2008, J ALLERGY CLIN IMMUN, V122, P342, DOI 10.1016/j.jaci.2008.05.043; Pongracic JA, 2012, J ALLERGY CLIN IMMUN, V129, P564, DOI 10.1016/j.jaci.2011.09.024; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Sicherer SH, 2012, PEDIATRICS, V129, P193, DOI 10.1542/peds.2011-2382; Sicherer SH, 2004, J ALLERGY CLIN IMMUN, V114, P1146, DOI 10.1016/j.jaci.2004.07.034; Vierk KA, 2007, J ALLERGY CLIN IMMUN, V119, P1504, DOI 10.1016/j.jaci.2007.03.011; Webb LM, 2006, ANN ALLERG ASTHMA IM, V97, P39, DOI 10.1016/S1081-1206(10)61367-1; Wilson BG, 2008, ANN ALLERG ASTHMA IM, V100, P250, DOI 10.1016/S1081-1206(10)60450-4; Yocum MW, 1999, J ALLERGY CLIN IMMUN, V104, P452, DOI 10.1016/S0091-6749(99)70392-1	23	37	38	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2013	131	1					150	156		10.1016/j.jaci.2012.07.016	http://dx.doi.org/10.1016/j.jaci.2012.07.016			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	062YR	22947345				2022-12-18	WOS:000312961200019
J	Bauer, RN; Brighton, LE; Mueller, L; Xiang, ZD; Rager, JE; Fry, RC; Peden, DB; Jaspers, I				Bauer, Rebecca N.; Brighton, Luisa E.; Mueller, Loretta; Xiang, Zhidan; Rager, Julia E.; Fry, Rebecca C.; Peden, David B.; Jaspers, Ilona			Influenza enhances caspase-1 in bronchial epithelial cells from asthmatic volunteers and is associated with pathogenesis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Epithelial cell; asthma; influenza; antiviral; inflammasome; caspase-1; innate immunity	VIRUS-INDUCED ASTHMA; FACTOR-KAPPA-B; NUCLEAR-FACTOR; IMMUNE-RESPONSE; VIRAL-INFECTION; RISK-FACTORS; A H1N1; EXACERBATIONS; ACTIVATION; INFLAMMATION	Background: The leading cause of asthma exacerbation is respiratory viral infection. Innate antiviral defense pathways are altered in the asthmatic epithelium, yet involvement of inflammasome signaling in virus-induced asthma exacerbation is not known. Objective: This study compared influenza-induced activation of inflammasome and innate immune signaling in human bronchial epithelial cells from volunteers with and without asthma and investigated the role of caspase-1 in epithelial cell antiviral defense. Methods: Differentiated primary human bronchial epithelial cells from volunteers with and without asthma were infected with influenza Avirus. An inflammasome-specific quantitative real-time polymerase chain reaction array was used to compare baseline and influenza-induced gene expression profiles. Cytokine secretion, innate immune gene expression, and viral replication were compared between human bronchial epithelial cells from volunteers with and without asthma. Immunofluorescence microscopy was used to evaluate caspase-1 and PYCARD colocalization. Tracheal epithelial cells from caspase-1-deficient or wild-type mice were infected with influenza and assessed for antiviral gene expression and viral replication. Results: Human bronchial epithelial cells from asthmatic volunteers had altered influenza-induced expression of inflammasome-related and innate immune signaling components, which correlated with enhanced production of IL-1 beta, IL-6, and TNF-alpha. Specifically, influenza-induced caspase-1 expression was enhanced and localization differed in human bronchial epithelial cells from asthmatic volunteers compared to volunteers without asthma. Influenza-infected tracheal epithelial cells from caspase-1-deficient mice had reduced expression of antiviral genes and viral replication. Conclusion: Caspase-1 plays an important role in the airway epithelial cell response to influenza infection, which is enhanced in asthmatic volunteers, and may contribute to the enhanced influenza-related pathogenesis observed in vivo. (J Allergy Clin Immunol 2012; 130: 958-67.)	[Bauer, Rebecca N.; Jaspers, Ilona] Univ N Carolina, Curriculum Toxicol, Gillings Sch Publ Hlth, Chapel Hill, NC USA; [Brighton, Luisa E.; Jaspers, Ilona] Univ N Carolina, Dept Pediat, Gillings Sch Publ Hlth, Chapel Hill, NC USA; [Brighton, Luisa E.; Mueller, Loretta; Peden, David B.; Jaspers, Ilona] Univ N Carolina, Ctr Environm Med Asthma & Lung Biol, Gillings Sch Publ Hlth, Chapel Hill, NC USA; [Xiang, Zhidan] Univ N Carolina, Dept Genet, Gillings Sch Publ Hlth, Chapel Hill, NC USA; [Rager, Julia E.; Fry, Rebecca C.] Univ N Carolina, Dept Environm Sci & Engn, Gillings Sch Publ Hlth, Chapel Hill, NC USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Jaspers, I (corresponding author), 104 Mason Farm Rd, Chapel Hill, NC 27510 USA.	ilona_jaspers@med.unc.edu	xiang, zhidan/I-6671-2015; Jaspers, Ilona/AAZ-5035-2020	xiang, zhidan/0000-0003-1694-5503; Fry, Rebecca/0000-0003-0899-9018; Peden, David/0000-0003-4526-4627	National Institute for Allergy and Infectious Diseases [U19A1O77347]; National Institute of Environmental Health Sciences [ES013611]; US Environmental Protection Agency through Center for Environmental Medicine, Asthma, and Lung Biology at The University of North Carolina at Chapel Hill [CR83346301]; Swiss National Science Foundation; National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIH); MedImmune; US Environmental Protection Agency; Aquinox Pharmaceuticals; NIH; Flight Attendant Medical Research Institute (FAMRI); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI077437] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES010126, T32ES007126, R01ES013611] Funding Source: NIH RePORTER	National Institute for Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); US Environmental Protection Agency through Center for Environmental Medicine, Asthma, and Lung Biology at The University of North Carolina at Chapel Hill; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); MedImmune(AstraZenecaMedimmune); US Environmental Protection Agency(United States Environmental Protection Agency); Aquinox Pharmaceuticals; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Flight Attendant Medical Research Institute (FAMRI); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported in part by the National Institute for Allergy and Infectious Diseases grant no. U19A1O77347, the National Institute of Environmental Health Sciences grant no. ES013611, and in part by the US Environmental Protection Agency through cooperative agreement CR83346301 with the Center for Environmental Medicine, Asthma, and Lung Biology at The University of North Carolina at Chapel Hill.; L. Mueller has received research support from the Swiss National Science Foundation. D.B. Peden has received research support from the National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIH), MedImmune, the US Environmental Protection Agency, and Aquinox Pharmaceuticals. I. Jaspers has received research support from the NIH and the Flight Attendant Medical Research Institute (FAMRI). The rest of the authors declare that they have no relevant conflicts of interest.	Allen IC, 2009, IMMUNITY, V30, P556, DOI 10.1016/j.immuni.2009.02.005; Beck MA, 2001, FASEB J, V15, P1481, DOI 10.1096/fj.00-0721fje; Bian ZM, 2009, INVEST OPHTH VIS SCI, V50, P6006, DOI 10.1167/iovs.09-3628; Bochkov YA, 2010, MUCOSAL IMMUNOL, V3, P69, DOI 10.1038/mi.2009.109; Brightling C, 2008, J ALLERGY CLIN IMMUN, V121, P5, DOI 10.1016/j.jaci.2007.10.028; Brough D, 2007, J CELL SCI, V120, P772, DOI 10.1242/jcs.03377; Bryan NB, 2009, J IMMUNOL, V182, P3173, DOI 10.4049/jimmunol.0802367; Ciencewicki J, 2006, AM J PHYSIOL-LUNG C, V290, pL1154, DOI 10.1152/ajplung.00318.2005; Contoli M, 2005, CLIN EXP ALLERGY, V35, P137, DOI 10.1111/j.1365-2222.2005.02163.x; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Culley FJ, 2006, J VIROL, V80, P8151, DOI 10.1128/JVI.00496-06; Davis BK, 2011, ANNU REV IMMUNOL, V29, P707, DOI 10.1146/annurev-immunol-031210-101405; Dulek DE, 2011, BBA-GEN SUBJECTS, V1810, P1080, DOI 10.1016/j.bbagen.2011.01.012; Fernandes-Alnemri T, 2007, CELL DEATH DIFFER, V14, P1590, DOI 10.1038/sj.cdd.4402194; Fleege Laura, 2009, Minn Med, V92, P38; Gern JE, 2003, J PEDIATR-US, V142, pS9, DOI 10.1067/mpd.2003.20; Gern JE, 2003, J PEDIAT, V142, pS13; Hackett TL, 2011, AM J RESP CELL MOL, V45, P1090, DOI 10.1165/rcmb.2011-0031OC; Hart LA, 1998, AM J RESP CRIT CARE, V158, P1585, DOI 10.1164/ajrccm.158.5.9706116; Horvath KM, 2011, AM J RESP CELL MOL, V45, P237, DOI 10.1165/rcmb.2010-0190OC; Ichinohe T, 2010, NAT IMMUNOL, V11, P404, DOI 10.1038/ni.1861; Jackson DJ, 2011, J ALLERGY CLIN IMMUN, V128, P1165, DOI 10.1016/j.jaci.2011.10.024; Janssen-Heininger Yvonne M W, 2009, Proc Am Thorac Soc, V6, P249, DOI 10.1513/pats.200806-054RM; Jaspers I, 2007, FREE RADICAL BIO MED, V42, P1826, DOI 10.1016/j.freeradbiomed.2007.03.017; Jaspers I, 2005, TOXICOL SCI, V85, P990, DOI 10.1093/toxsci/kfi141; Jaspers I, 2001, AM J RESP CELL MOL, V24, P769, DOI 10.1165/ajrcmb.24.6.4344; Jaspers I, 2009, PART FIBRE TOXICOL, V6, DOI 10.1186/1743-8977-6-22; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Kanneganti TD, 2010, NAT REV IMMUNOL, V10, P688, DOI 10.1038/nri2851; Kayagaki N, 2011, NATURE, V479, P117, DOI 10.1038/nature10558; Kesic MJ, 2011, FREE RADICAL BIO MED, V51, P444, DOI 10.1016/j.freeradbiomed.2011.04.027; Lamkanfi M, 2004, J BIOL CHEM, V279, P24785, DOI 10.1074/jbc.M400985200; Lamkanfi M, 2011, NAT REV IMMUNOL, V11, P213, DOI 10.1038/nri2936; Lee CW, 2004, J VIROL METHODS, V119, P151, DOI 10.1016/j.jviromet.2004.03.014; Li W, 2007, EXP BIOL MED, V232, P412; Libster R, 2010, NEW ENGL J MED, V362, P45, DOI 10.1056/NEJMoa0907673; Lopez-Souza N, 2009, J ALLERGY CLIN IMMUN, V123, P1384, DOI 10.1016/j.jaci.2009.03.010; Masumoto J, 1999, J BIOL CHEM, V274, P33835, DOI 10.1074/jbc.274.48.33835; Murray Clare S, 2004, Proc Am Thorac Soc, V1, P99, DOI 10.1513/pats.2306027; Neveu WA, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-28; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; O'Riordan S, 2010, CAN MED ASSOC J, V182, P39, DOI 10.1503/cmaj.091724; Poeck H, 2010, NAT IMMUNOL, V11, P63, DOI 10.1038/ni.1824; Reich M, 2006, NAT GENET, V38, P500, DOI 10.1038/ng0506-500; Roberson EC, 2012, AM J RESP CELL MOL, V46, P573, DOI 10.1165/rcmb.2010-0460OC; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Thomas PG, 2009, IMMUNITY, V30, P566, DOI 10.1016/j.immuni.2009.02.006; Tillie-Leblond I, 1999, AM J RESP CRIT CARE, V159, P487, DOI 10.1164/ajrccm.159.2.9805115; Venge J, 1996, J ALLERGY CLIN IMMUN, V97, P1110, DOI 10.1016/S0091-6749(96)70265-8; Wang SY, 1998, CELL, V92, P501, DOI 10.1016/S0092-8674(00)80943-5; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Wark PAB, 2007, J ALLERGY CLIN IMMUN, V120, P586, DOI 10.1016/j.jaci.2007.04.046; Werts C, 2007, EUR J IMMUNOL, V37, P2499, DOI 10.1002/eji.200737069; You YJ, 2002, AM J PHYSIOL-LUNG C, V283, pL1315, DOI 10.1152/ajplung.00169.2002	55	37	38	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2012	130	4					958	+		10.1016/j.jaci.2012.07.013	http://dx.doi.org/10.1016/j.jaci.2012.07.013			24	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017MT	23021143	Green Accepted			2022-12-18	WOS:000309594800018
J	Rothenberg, ME; Aceves, S; Bonis, PA; Collins, MH; Gonsalves, N; Gupta, SK; Hirano, I; Liacouras, CA; Putnam, PE; Spergel, JM; Straumann, A; Wershil, BK; Furuta, GT				Rothenberg, Marc E.; Aceves, Seema; Bonis, Peter A.; Collins, Margaret H.; Gonsalves, Nirmala; Gupta, Sandeep K.; Hirano, Ikuo; Liacouras, Chris A.; Putnam, Phil E.; Spergel, Jonathan M.; Straumann, Alex; Wershil, Barry K.; Furuta, Glenn T.			Working with the US Food and Drug Administration: Progress and timelines in understanding and treating patients with eosinophilic esophagitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Eosinophils; esophagitis; symptoms; therapy	PLACEBO-CONTROLLED TRIAL; REPORTED OUTCOMES; CHILDREN		[Rothenberg, Marc E.; Collins, Margaret H.; Putnam, Phil E.] Univ Cincinnati, Cincinnati Childrens Hosp, Med Ctr, Dept Pediat, Cincinnati, OH 45221 USA; [Aceves, Seema] Univ Calif San Diego, Rady Childrens Hosp, San Diego, CA 92103 USA; [Bonis, Peter A.] Tufts Univ, Div Gastroenterol, Medford, MA 02155 USA; [Gonsalves, Nirmala; Hirano, Ikuo] Northwestern Univ, Feinberg Sch Med, Div Gastroenterol, Chicago, IL 60611 USA; [Gupta, Sandeep K.] Indiana Univ, Riley Childrens Hosp, Indianapolis, IN 46204 USA; [Liacouras, Chris A.] Univ Penn, Perelman Sch Med, Childrens Hosp Philadelphia, Div Gastroenterol, Philadelphia, PA 19104 USA; [Spergel, Jonathan M.] Univ Penn, Perelman Sch Med, Childrens Hosp Philadelphia, Div Allergy & Immunol, Philadelphia, PA 19104 USA; [Straumann, Alex] Univ Basel, CH-4003 Basel, Switzerland; [Wershil, Barry K.] Northwestern Univ, Feinberg Sch Med, Ann & Robert H Lurie Childrens Hosp Chicago, Evanston, IL 60208 USA; [Furuta, Glenn T.] Univ Colorado, Digest Hlth Inst,Mucosal Inflammat Program, Childrens Hosp Colorado,Denver Sch Med, Gastrointestinal Eosinophil Dis Program, Aurora, CO USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Rady Childrens Hospital San Diego; University of California System; University of California San Diego; Tufts University; Northwestern University; Feinberg School of Medicine; Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Basel; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Rothenberg, ME (corresponding author), Childrens Hosp, Med Ctr, Dept Pediat, 3333 Burnet Ave,ML7028, Cincinnati, OH 45229 USA.	Marc.Rothenberg@cchmc.org		Gonsalves, Nirmala/0000-0003-0722-6099; Spergel, Jonathan/0000-0002-4658-5353	NIAID NIH HHS [R37 AI045898] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI045898] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Dohil R, 2010, GASTROENTEROLOGY, V139, P418, DOI 10.1053/j.gastro.2010.05.001; Fiorentino R, 2012, J ALLERGY CLIN IMMUN, V130, P613, DOI 10.1016/j.jaci.2012.07.011; Konikoff MR, 2006, GASTROENTEROLOGY, V131, P1381, DOI 10.1053/j.gastro.2006.08.033; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Patrick DL, 2007, VALUE HEALTH, V10, pS125, DOI 10.1111/j.1524-4733.2007.00275.x; Rolla G, 2011, NEW ENGL J MED, V365, P1446, DOI 10.1056/NEJMc1109235; Sasinowski F.J., 2011, QUANTUM EFFECTIVENES; Sherrill JD, 2011, J ALLERGY CLIN IMMUN, V128, P23, DOI 10.1016/j.jaci.2011.03.046; Valderas JM, 2008, QUAL LIFE RES, V17, P179, DOI 10.1007/s11136-007-9295-0; Wechsler ME, 2011, NEW ENGL J MED, V365, P119, DOI 10.1056/NEJMoa1103319	10	37	37	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2012	130	3					617	619		10.1016/j.jaci.2012.06.051	http://dx.doi.org/10.1016/j.jaci.2012.06.051			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	001LZ	22935588	Green Accepted			2022-12-18	WOS:000308463500007
J	Ahrens, B; Niggemann, B; Wahn, U; Beyer, K				Ahrens, Birgit; Niggemann, Bodo; Wahn, Ulrich; Beyer, Kirsten			Organ-specific symptoms during oral food challenge in children with food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							T-CELLS		[Ahrens, Birgit; Wahn, Ulrich; Beyer, Kirsten] Univ Med, Dept Pediat Pneumol & Immunol, Berlin, Germany; [Niggemann, Bodo] German Red Cross Hosp Westend, Div Pediat Allergol & Pneumol, Berlin, Germany		Ahrens, B (corresponding author), Univ Med, Dept Pediat Pneumol & Immunol, Berlin, Germany.	kirsten.beyer@charite.de						Beyer KB, 2001, J ALLERGY CLIN IMMUN, V107, P1077, DOI 10.1067/mai.2001.115480; Blazquez AB, 2010, GASTROENTEROLOGY, V138, P275, DOI 10.1053/j.gastro.2009.09.016; Cassani B, 2011, GASTROENTEROLOGY, V141, P2109, DOI 10.1053/j.gastro.2011.09.015; Celik-Bilgili S, 2005, CLIN EXP ALLERGY, V35, P268, DOI 10.1111/j.1365-2222.2005.02150.x; Du Toit G, 2009, PEDIAT ALLERG IMM-UK, V20, P309, DOI 10.1111/j.1399-3038.2009.00887.x; Niggemann B, 2010, ALLERGY, V65, P2, DOI 10.1111/j.1398-9995.2009.02170.x; Pease JE, 2011, BIOCHEM J, V434, P11, DOI 10.1042/BJ20101132; Post S, 2012, THORAX, V67, P488, DOI 10.1136/thoraxjnl-2011-200606; Pumphrey RSH, 2000, CLIN EXP ALLERGY, V30, P1144, DOI 10.1046/j.1365-2222.2000.00864.x; Shek LPC, 2005, ALLERGY, V60, P912, DOI 10.1111/j.1398-9995.2005.00705.x; Spergel JM, 2004, ANN ALLERG ASTHMA IM, V92, P217, DOI 10.1016/S1081-1206(10)61550-5; Venter C, 2006, J ALLERGY CLIN IMMUN, V117, P1118, DOI 10.1016/j.jaci.2005.12.1352	12	37	38	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2012	130	2					549	551		10.1016/j.jaci.2012.05.045	http://dx.doi.org/10.1016/j.jaci.2012.05.045			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	981WC	22846754				2022-12-18	WOS:000307002200045
J	Tse, SM; Kelly, HW; Litonjua, AA; Van Natta, ML; Weiss, ST; Tantisira, KG				Tse, Sze Man; Kelly, H. William; Litonjua, Augusto A.; Van Natta, Mark L.; Weiss, Scott T.; Tantisira, Kelan G.		Childhood Asthma Management Progra	Corticosteroid use and bone mineral accretion in children with asthma: Effect modification by vitamin D	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; vitamin D; bone mineral density; corticosteroids	NUTRITION EXAMINATION SURVEY; X-RAY ABSORPTIOMETRY; 25-HYDROXYVITAMIN D; ORAL CORTICOSTEROIDS; INDUCED OSTEOPOROSIS; CHILDHOOD ASTHMA; BODY-COMPOSITION; NATIONAL-HEALTH; DENSITY; ADULTS	Background: The adverse effects of corticosteroids on bone mineral accretion (BMA) have been well documented. Vitamin D insufficiency, a prevalent condition in the pediatric population, has also been associated with decreased bone mineral density (BMD). Objective: We sought to determine whether children with asthma who have lower vitamin D levels are more susceptible to the negative effects of corticosteroids on BMD over time. Methods: Children aged 5 to 12 years with mild-to-moderate asthma who participated in the Childhood Asthma Management Program were followed for a mean of 4.3 years. Total doses of inhaled corticosteroids and oral corticosteroids (OCSs) were recorded, serum 25-hydroxyvitamin D3 levels were measured at the beginning of the trial, and serial dual-energy x-ray absorptiometry scans of the lumbar spine were performed. Annual BMA rates were defined as follows: [(BMD at 4 years' follow-up 2 BMD at baseline)/4 years]. Results: BMA was calculated for 780 subjects. In boys baseline vitamin D levels significantly modified the relationship between OCSs and BMA (vitamin D x 3 OCS interaction, P = .023). Stratification by vitamin D levels showed a decrease in BMA with increased use of OCSs in vitamin D-insufficient boys only (P < .001). Compared with vitamin D-sufficient boys, vitamin D-insufficient boys exposed to more than 2 courses of OCSs per year had twice the decrease in BMA rate (relative to boys who were OCS unexposed). Conclusions: Vitamin D levels significantly modified the effect of OCSs on BMA in boys. Further research is needed to examine whether vitamin D supplementation in children with poorly controlled asthma might confer benefits to bone health. (J Allergy Clin Immunol 2012;130:53-60.)	[Tse, Sze Man; Litonjua, Augusto A.; Weiss, Scott T.; Tantisira, Kelan G.] Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; [Tse, Sze Man; Litonjua, Augusto A.; Weiss, Scott T.; Tantisira, Kelan G.] Harvard Univ, Sch Med, Boston, MA USA; [Kelly, H. William] Univ New Mexico, Dept Pediat, Hlth Sci Ctr, Albuquerque, NM 87131 USA; [Van Natta, Mark L.] Johns Hopkins Ctr Clin Trials, Baltimore, MD USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of New Mexico; University of New Mexico's Health Sciences Center; Johns Hopkins University	Tse, SM (corresponding author), Brigham & Womens Hosp, Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA.	reszt@channing.harvard.edu		Litonjua, Augusto/0000-0003-0422-5875	National Heart, Lung, and Blood Institute and General Clinical Research Center from the National Center for Research Resources [M01RR00051, M01RR0099718-24, M01RR02719-14, RR00036]; National Institutes of Health [P50 HL67664, T32 HL07427, R21 HL089842]; National Heart, Lung, and Blood Institute; National Institutes of Health (NIH); NIH;  [NO1-HR-16044];  [16045];  [16046];  [16047];  [16048];  [16049];  [16050];  [16051];  [16052]; DIVISION OF LUNG DISEASES [N01HR016048, N01HR016044, N01HR016045, N01HR016047, N01HR016049, N01HR016051, N01HR016050, N01HR016052, N01HR016046] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000041] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051, M01RR002719] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007427, P50HL067664, R21HL089842] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute and General Clinical Research Center from the National Center for Research Resources; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; ; ; ; ; ; ; ; ; DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The Childhood Asthma Management Program is supported by contracts NO1-HR-16044, 16045, 16046, 16047, 16048, 16049, 16050, 16051, and 16052 with the National Heart, Lung, and Blood Institute and General Clinical Research Center grants M01RR00051, M01RR0099718-24, M01RR02719-14, and RR00036 from the National Center for Research Resources. Additional support for this research came from grants P50 HL67664, T32 HL07427, and R21 HL089842 from the National Institutes of Health and the National Heart, Lung, and Blood Institute. This article is subject to the National Institutes of Health's Public Access Policy (http://publicaccess.nih.gov).; H. W. Kelly is on the GlaxoSmithKline Steering Committee for FDA mandated LABA safety study in children and the AstraZeneca, Novartis, and Merck Steering Committees for FDA-mandated LABA safety trials in adults. A. Litonjua has received research support from the National Institutes of Health (NIH) and receives author royalties from UpToDate, Inc. K. Tantisira has received research support from the NIH. The rest of the authors declare that they have no relevant conflicts of interest.	[Anonymous], 2008, LIF ASTHM PREV PERC; Bagger YZ, 2006, OSTEOPOROSIS INT, V17, P471, DOI 10.1007/s00198-005-0009-6; Bahceciler NN, 2002, J ASTHMA, V39, P151, DOI 10.1081/JAS-120002196; BARALDI E, 1994, EUR RESPIR J, V7, P710, DOI 10.1183/09031936.94.07040710; Baxter-Jones ADG, 2011, J BONE MINER RES, V26, P1729, DOI 10.1002/jbmr.412; Bischoff-Ferrari HA, 2004, AM J MED, V116, P634, DOI 10.1016/j.amjmed.2003.12.029; Brehm JM, 2010, J ALLERGY CLIN IMMUN, V126, P52, DOI 10.1016/j.jaci.2010.03.043; Brehm JM, 2009, AM J RESP CRIT CARE, V179, P765, DOI 10.1164/rccm.200808-1361OC; Brown JJ, 2005, J PAEDIATR CHILD H, V41, P553, DOI 10.1111/j.1440-1754.2005.00718.x; Callewaert F, 2009, FASEB J, V23, P232, DOI 10.1096/fj.08-113456; Canalis E, 2007, OSTEOPOROSIS INT, V18, P1319, DOI 10.1007/s00198-007-0394-0; Carnevale V, 2010, BONE, V47, P626, DOI 10.1016/j.bone.2010.06.013; Cranney A, 2008, AM J CLIN NUTR, V88, p513S, DOI 10.1093/ajcn/88.2.513S; GENANT HK, 1994, J BONE MINER RES, V9, P1503; Ginde AA, 2009, ARCH INTERN MED, V169, P384, DOI 10.1001/archinternmed.2008.560; Gutierrez OM, 2011, OSTEOPOROSIS INT, V22, P1745, DOI 10.1007/s00198-010-1383-2; Hofmann JN, 2010, CANCER EPIDEM BIOMAR, V19, P927, DOI 10.1158/1055-9965.EPI-09-1121; Holick MF, 2006, J CLIN INVEST, V116, P2062, DOI 10.1172/JCI29449; Holick MF, 2009, ANN EPIDEMIOL, V19, P73, DOI 10.1016/j.annepidem.2007.12.001; HOLLIS BW, 1993, CLIN CHEM, V39, P529; Huybers S, 2007, AM J PHYSIOL-GASTR L, V292, pG92, DOI 10.1152/ajpgi.00317.2006; Jia D, 2006, ENDOCRINOLOGY, V147, P5592, DOI 10.1210/en.2006-0459; Jorde R, 2010, AM J EPIDEMIOL, V171, P903, DOI 10.1093/aje/kwq005; Kelly HW, 2008, PEDIATRICS, V122, pE53, DOI 10.1542/peds.2007-3381; Lindberg MK, 2001, J ENDOCRINOL, V171, P229, DOI 10.1677/joe.0.1710229; Looker AC, 2010, J BONE MINER RES, V25, P64, DOI 10.1359/jbmr.090706; Matsumoto H, 2001, CHEST, V120, P1468, DOI 10.1378/chest.120.5.1468; O'Mahony L, 2011, NUTRIENTS, V3, P1023, DOI 10.3390/nu3121023; Rajasekaran K, 2010, AM J RHINOL ALLERGY, V24, P215, DOI 10.2500/ajra.2010.24.3445; Roux C, 2003, PEDIATRICS, V111, pE706, DOI 10.1542/peds.111.6.e706; Turner S, 2009, ARCH DIS CHILD, V94, P16, DOI 10.1136/adc.2008.140681; US Department of Health and Human Services. National Asthma Education and Prevention Program, 2007, NIH PUBL; van der Sluis IM, 2002, ARCH DIS CHILD, V87, P341, DOI 10.1136/adc.87.4.341; Van Staa TP, 2003, J BONE MINER RES, V18, P913, DOI 10.1359/jbmr.2003.18.5.913; Wasilewska A, 2010, PEDIATR NEPHROL, V25, P2067, DOI 10.1007/s00467-010-1583-1; 2000, N ENGL J MED, V343, P1054	36	37	40	1	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2012	130	1					53	+		10.1016/j.jaci.2012.04.005	http://dx.doi.org/10.1016/j.jaci.2012.04.005			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	977GN	22608570	Green Accepted, Green Published			2022-12-18	WOS:000306644800007
J	Marron, TU; Martinez-Gallo, M; Yu, JE; Cunningham-Rundles, C				Marron, Thomas U.; Martinez-Gallo, Monica; Yu, Joyce E.; Cunningham-Rundles, Charlotte			Toll-like receptor 4-, 7-, and 8-activated myeloid cells from patients with X-linked agammaglobulinemia produce enhanced inflammatory cytokines	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Bruton tyrosine kinase; X-linked agammaglobulinemia; Toll-like receptors; MyD88 adapter-like protein; Toll-IL-1 receptor domain-containing adapter protein	BRUTONS TYROSINE KINASE; VARIABLE IMMUNE-DEFICIENCY; KAPPA-B ACTIVATION; QUALITY-OF-LIFE; DENDRITIC CELLS; SIGNAL-TRANSDUCTION; AUTOIMMUNE-DISEASE; BTK INHIBITOR; RESPONSES; EXPRESSION	Background: Bruton tyrosine kinase (BTK) is a component of signaling pathways downstream from Toll-like receptors (TLRs) 2, 4, 7, 8, and 9. Previous work in BTK-deficient mice, cell lines, and cultured cells from patients with X-linked agammaglobulinemia (XLA) suggested defective TLR-driven cytokine production. Objective: We sought to compare TLR-4-, TLR-7-, and TLR-8-induced cytokine production of primary cells from patients with XLA with that seen in control cells. Methods: PBMCs from patients with XLA, freshly isolated plasmacytoid dendritic cells, monocytes, and monocytoid dendritic cells were activated with TLR-4, TLR-7, and TLR-8 agonists. Signaling intermediates and intracellular and secreted cytokine levels were compared with those seen in control cells. Results: Although TLR-4, TLR-7, and TLR-8 activation of nuclear factor kappa B and mitogen-activated protein kinase pathways in cells from patients with XLA and control cells were comparable, TLR-activated freshly isolated monocytes and monocytoid dendritic cells from patients with XLA produced significantly more TNF-alpha, IL-6, and IL-10 than control cells. TLR-7/8-activated plasmacytoid dendritic cells produced normal amounts of IFN-alpha. In murine models BTK regulates the degradation of Toll-IL-1 receptor domain-containing adaptor protein, terminating TLR-4-induced cytokine production. Although this might explain the heightened TLR-4-driven cytokine production we observed, Toll-IL-1 receptor domain-containing adaptor protein degradation is intact in cells from patients with XLA, excluding this explanation. Conclusion: In contrast to previous studies with BTK-deficient mice, cell lines, and cultured cells from patients with XLA suggesting impaired TLR-driven cytokine production, these data suggest that BTK inhibits TLR-induced cytokine production in primary human cells. (J Allergy Clin Immunol 2012; 129: 184-90.)	[Cunningham-Rundles, Charlotte] Mt Sinai Sch Med, Dept Med, Inst Immunol, New York, NY 10029 USA; [Cunningham-Rundles, Charlotte] Mt Sinai Sch Med, Dept Med, Inst Immunol, New York, NY 10029 USA; [Cunningham-Rundles, Charlotte] Mt Sinai Sch Med, Dept Pediat, Inst Immunol, New York, NY 10029 USA; [Martinez-Gallo, Monica] Vall Hebron Univ Hosp, Barcelona, Spain; [Yu, Joyce E.] Weill Cornell Med Ctr, Dept Pediat, New York, NY USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Hospital Universitari Vall d'Hebron; Cornell University	Cunningham-Rundles, C (corresponding author), Mt Sinai Sch Med, Dept Med, Inst Immunol, 1425 Madison Ave, New York, NY 10029 USA.	Charlotte.Cunningham-Rundles@mssm.edu	Martinez-Gallo, Monica/S-1368-2019	Martinez-Gallo, Monica/0000-0002-7340-2161	National Institutes of Health [AI 101093, AI-467320, AI-48693]; National Institute of Allergy and Infectious Diseases [03-22]; Jeffrey Modell Foundation; David S. Gottesman Immunology Chair; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI061093, R21AI101093, R18AI048693] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Jeffrey Modell Foundation; David S. Gottesman Immunology Chair; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants AI 101093, AI-467320, and AI-48693; National Institute of Allergy and Infectious Diseases contract no. 03-22, the Jeffrey Modell Foundation, and the David S. Gottesman Immunology Chair.	Avalos AM, 2010, AUTOIMMUNITY, V43, P76, DOI 10.3109/08916930903374618; Bayry J, 2004, P NATL ACAD SCI USA, V101, P14210, DOI 10.1073/pnas.0402183101; Conley ME, 2009, CURR OPIN IMMUNOL, V21, P466, DOI 10.1016/j.coi.2009.07.003; CONLEY ME, 1985, J IMMUNOL, V134, P3070; Cunningham-Rundles C, 2006, J IMMUNOL, V176, P1978, DOI 10.4049/jimmunol.176.3.1978; Cunningham-Rundles C, 2005, CLIN IMMUNOL, V115, P147, DOI 10.1016/j.clim.2004.12.007; Danks L, 2011, J BONE MINER RES, V26, P182, DOI 10.1002/jbmr.210; de Diego RP, 2006, J ALLERGY CLIN IMMUN, V117, P1462, DOI 10.1016/j.jaci.2006.01.037; Di Paolo JA, 2011, NAT CHEM BIOL, V7, P41, DOI 10.1038/NCHEMBIO.481; Doyle SL, 2007, J BIOL CHEM, V282, P36953, DOI 10.1074/jbc.M707682200; Doyle SL, 2005, J BIOL CHEM, V280, P23496, DOI 10.1074/jbc.C500053200; Dunne A, 2010, J BIOL CHEM, V285, P18276, DOI 10.1074/jbc.M109.098137; Ellmeier W, 2000, J EXP MED, V192, P1611, DOI 10.1084/jem.192.11.1611; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Gagliardi MC, 2003, CLIN EXP IMMUNOL, V133, P115, DOI 10.1046/j.1365-2249.2003.t01-1-02178.x; Gilbert C, 2003, J IMMUNOL, V170, P5235, DOI 10.4049/jimmunol.170.10.5235; GO NF, 1990, J EXP MED, V172, P1625, DOI 10.1084/jem.172.6.1625; Gray P, 2006, J BIOL CHEM, V281, P10489, DOI 10.1074/jbc.M508892200; Hasan M, 2008, IMMUNOLOGY, V123, P239, DOI 10.1111/j.1365-2567.2007.02693.x; Hennessy EJ, 2010, NAT REV DRUG DISCOV, V9, P293, DOI 10.1038/nrd3203; Honigberg LA, 2010, P NATL ACAD SCI USA, V107, P13075, DOI 10.1073/pnas.1004594107; Horwood NJ, 2006, J IMMUNOL, V176, P3635, DOI 10.4049/jimmunol.176.6.3635; Horwood NJ, 2003, J EXP MED, V197, P1603, DOI 10.1084/jem.20021845; Howard V, 2006, CLIN IMMUNOL, V118, P201, DOI 10.1016/j.clim.2005.11.002; Islam TC, 2002, EUR J IMMUNOL, V32, P982, DOI 10.1002/1521-4141(200204)32:4<982::AID-IMMU982>3.0.CO;2-I; Jefferies CA, 2003, J BIOL CHEM, V278, P26258, DOI 10.1074/jbc.M301484200; Jyonouchi H, 2008, EUR J PEDIATR, V167, P317, DOI 10.1007/s00431-007-0493-0; Lee KG, 2008, J BIOL CHEM, V283, P11189, DOI 10.1074/jbc.M708516200; Lijeroos M, 2007, CELL SIGNAL, V19, P625, DOI 10.1016/j.cellsig.2006.08.013; Lindvall JM, 2005, IMMUNOL REV, V203, P200, DOI 10.1111/j.0105-2896.2005.00225.x; Mangla A, 2004, BLOOD, V104, P1191, DOI 10.1182/blood-2004-01-0207; Mansell A, 2006, NAT IMMUNOL, V7, P148, DOI 10.1038/ni1299; Marron TU, 2010, CLIN IMMUNOL, V137, P74, DOI 10.1016/j.clim.2010.06.011; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; Murray PR, 2010, ARCH DERMATOL, V146, P523, DOI 10.1001/archdermatol.2010.86; Pisitkun P, 2006, SCIENCE, V312, P1669, DOI 10.1126/science.1124978; Quan PL, 2010, EMERG INFECT DIS, V16, P918, DOI 10.3201/eid1606.091536; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Reynolds JM, 2010, IMMUNITY, V32, P692, DOI 10.1016/j.immuni.2010.04.010; ROIFMAN CM, 1986, AM J MED, V80, P590, DOI 10.1016/0002-9343(86)90812-0; Schmidt NW, 2006, J IMMUNOL, V177, P7203, DOI 10.4049/jimmunol.177.10.7203; Sochorova K, 2007, BLOOD, V109, P2553, DOI 10.1182/blood-2006-07-037960; STUCKEY M, 1978, LANCET, V2, P917, DOI 10.1016/S0140-6736(78)91632-X; Sukumaran S, 2011, INT J RHEUMATOL, V2011, DOI 10.1155/2011/175973; Taneichi H, 2008, CLIN IMMUNOL, V126, P148, DOI 10.1016/j.clim.2007.10.005; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; Uckun FM, 2010, EXPERT OPIN THER PAT, V20, P1457, DOI 10.1517/13543776.2010.517750; van den Akker E, 2004, BIOL CHEM, V385, P409; Verbruggen G, 2005, ANN RHEUM DIS, V64, P1075, DOI 10.1136/ard.2004.030049; VIHINEN M, 1994, P NATL ACAD SCI USA, V91, P12803, DOI 10.1073/pnas.91.26.12803; WEBSTER ADB, 1976, BRIT MED J, V1, P1314, DOI 10.1136/bmj.1.6021.1314; Winkelstein JA, 2008, MEDICINE, V87, P253, DOI 10.1097/MD.0b013e318187ed81; Winkelstein JA, 2006, MEDICINE, V85, P193, DOI 10.1097/01.md.0000229482.27398.ad; Yu JE, 2009, J ALLERGY CLIN IMMUN, V124, P349, DOI 10.1016/j.jaci.2009.05.019; Zorn CN, 2009, CELL SIGNAL, V21, P79, DOI 10.1016/j.cellsig.2008.09.010	55	37	38	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2012	129	1					184	U263		10.1016/j.jaci.2011.10.009	http://dx.doi.org/10.1016/j.jaci.2011.10.009			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	869XT	22088613	Green Accepted			2022-12-18	WOS:000298634000024
J	de Koning, HD; Schalkwijk, J; van der Meer, JWM; Simon, A				de Koning, Heleen D.; Schalkwijk, Joost; van der Meer, Jos W. M.; Simon, Anna			Successful canakinumab treatment identifies IL-1 beta as a pivotal mediator in Schnitzler syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[de Koning, Heleen D.; van der Meer, Jos W. M.; Simon, Anna] Radboud Univ Nijmegen, Med Ctr, Dept Gen Internal Med, NL-6525 ED Nijmegen, Netherlands; [de Koning, Heleen D.; Schalkwijk, Joost] Radboud Univ Nijmegen, Med Ctr, Dept Dermatol, NL-6525 ED Nijmegen, Netherlands; [de Koning, Heleen D.; Schalkwijk, Joost; van der Meer, Jos W. M.; Simon, Anna] Nijmegen Inst Infect Inflammat & Immun N4i, Nijmegen, Netherlands; [de Koning, Heleen D.; Schalkwijk, Joost] NCMLS, Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen	de Koning, HD (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Gen Internal Med, NL-6525 ED Nijmegen, Netherlands.	h.dekoning@derma.umcn.nl	Schalkwijk, Joost/R-7509-2019; van der Meer, Jos W.M./C-8521-2013; de Koning, Heleen/A-5374-2011; Simon, Anna/D-3757-2009; Schalkwijk, Joost/N-1774-2013	Schalkwijk, Joost/0000-0002-1308-1319; van der Meer, Jos W.M./0000-0001-5120-3690; Simon, Anna/0000-0002-6141-7921; 				Besada E, 2010, CLIN RHEUMATOL, V29, P567, DOI 10.1007/s10067-010-1375-9; de Koning HD, 2006, ANN RHEUM DIS, V65, P542, DOI 10.1136/ard.2005.045245; de Koning HD, 2007, SEMIN ARTHRITIS RHEU, V37, P137, DOI 10.1016/j.semarthrit.2007.04.001; Hoffman HM, 2009, J ALLERGY CLIN IMMUN, V124, P1129, DOI 10.1016/j.jaci.2009.11.001; Lachmann HJ, 2009, NEW ENGL J MED, V360, P2416, DOI 10.1056/NEJMoa0810787; Lachmann HJ, 2009, J EXP MED, V206, P1029, DOI 10.1084/jem.20082481; Lipsker D, 2001, MEDICINE, V80, P37, DOI 10.1097/00005792-200101000-00004; Ryan JG, 2008, J ALLERGY CLIN IMMUN, V121, P260, DOI 10.1016/j.jaci.2007.09.021	8	37	38	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2011	128	6					1352	1354		10.1016/j.jaci.2011.05.023	http://dx.doi.org/10.1016/j.jaci.2011.05.023			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	865WX	21704363				2022-12-18	WOS:000298342700029
J	Busse, WW				Busse, William W.			Asthma diagnosis and treatment: Filling in the information gaps	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; asthma diagnosis; asthma management; asthma heterogeneity	EXHALED NITRIC-OXIDE; SPUTUM EOSINOPHIL COUNTS; STEP-DOWN THERAPY; AIRWAY HYPERRESPONSIVENESS; FLUTICASONE PROPIONATE/SALMETEROL; PERSISTENT ASTHMA; CLUSTER-ANALYSIS; ANTI-IGE; EXACERBATIONS; OMALIZUMAB	Current approaches to the diagnosis and management of asthma are based on guideline recommendations, which have provided a framework for the efforts. Asthma, however, is emerging as a heterogeneous disease, and these features need to be considered in both the diagnosis and management of this disease in individual patients. These diverse or phenotypic features add complexity to the diagnosis of asthma, as well as attempts to achieve control with treatment. Although the diagnosis of asthma is often based on clinical information, it is important to pursue objective criteria as well, including an evaluation for reversibility of airflow obstruction and bronchial hyperresponsiveness, an area with new diagnostic approaches. Furthermore, there exist a number of treatment gaps (ie, exacerbations, step-down care, use of antibiotics, and severe disease) in which new direction is needed to improve care. A major morbidity in asthmatic patients occurs with exacerbations and in patients with severe disease. Novel approaches to treatment for these conditions will be an important advance to reduce the morbidity associated with asthma. (J Allergy Clin Immunol 2011;128:740-50.)	[Busse, William W.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Busse, WW (corresponding author), Univ Wisconsin Hosp, Dept Med, K4-910 CSC,MC 9988,600 Highland Ave, Madison, WI 53792 USA.	wwb@medicine.wisc.edu			National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases; NIH/National Heart, Lung, and Blood Institute	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH/National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	W. W. Busse is on the advisory boards for Centocor and Merck; has consultant arrangements with AstraZeneca, Novartis, GlaxoSmithKline, Amgen, MedImmune, and Genentech; and receives research support from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases and the NIH/National Heart, Lung, and Blood Institute.	Anderson SD, 2010, CHEST, V138, p25S, DOI 10.1378/chest.10-0116; Anderson SD, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-4; [Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; [Anonymous], 2006, LANCET, V368, P705; Bacharier LB, 2002, J ALLERGY CLIN IMMUN, V109, P916, DOI 10.1067/mai.2002.124665; Barnett SBL, 2011, J ALLERGY CLIN IMMUN, V127, P145, DOI 10.1016/j.jaci.2010.10.020; Bateman ED, 2006, J ALLERGY CLIN IMMUN, V117, P563, DOI 10.1016/j.jaci.2005.11.036; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Bisgaard H, 2010, BMJ-BRIT MED J, V341; Black PN, 2001, AM J RESP CRIT CARE, V164, P536, DOI 10.1164/ajrccm.164.4.2011040; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Busse WW, 2010, LANCET, V376, P826, DOI 10.1016/S0140-6736(10)61380-3; Busse WW, 2010, CHEST, V138, p4S, DOI 10.1378/chest.10-0100; Chowdhury BA, 2011, NEW ENGL J MED, V364, P2473, DOI 10.1056/NEJMp1104375; Chowdhury BA, 2010, NEW ENGL J MED, V362, P1169, DOI 10.1056/NEJMp1002074; Cockcroft DW, 2006, J ALLERGY CLIN IMMUN, V118, P551, DOI 10.1016/j.jaci.2006.07.012; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Corren J, 2011, N ENGL J MED; Deykin A, 2005, J ALLERGY CLIN IMMUN, V115, P720, DOI 10.1016/j.jaci.2004.12.1129; Dweik RA, 2010, AM J RESP CRIT CARE, V181, P1033, DOI 10.1164/rccm.200905-0695OC; Fahy JV, 2001, AM J RESP CRIT CARE, V163, P1470, DOI 10.1164/ajrccm.163.6.9901105; FAHY JV, 1995, J ALLERGY CLIN IMMUN, V95, P843, DOI 10.1016/S0091-6749(95)70128-1; FitzGerald JM, 2004, THORAX, V59, P550, DOI 10.1136/thx.2003.014936; Foresi A, 2005, CHEST, V127, P117, DOI 10.1378/chest.127.1.117; Fowler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P929, DOI 10.1067/mai.2002.123869; Gielen V, 2010, EUR RESPIR J, V36, P646, DOI 10.1183/09031936.00095809; Godard P, 2008, RESP MED, V102, P1124, DOI 10.1016/j.rmed.2008.03.014; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Hanania NA, 2011, ANN INTERN MED, V154, P573, DOI 10.7326/0003-4819-154-9-201105030-00002; Hargreave FE, 2011, CHEST, V139, P1270, DOI 10.1378/chest.11-0618; Harrison TW, 2004, LANCET, V363, P271, DOI 10.1016/S0140-6736(03)15384-6; Haselkorn T, 2009, J ALLERGY CLIN IMMUN, V124, pe1, DOI DOI 10.1016/J.JACI.2009.07.035.PUBMED; Haselkorn T, 2009, J ALLERGY CLIN IMMUN, V124, P895, DOI 10.1016/j.jaci.2009.07.035; Holgate ST, 2006, J ALLERGY CLIN IMMUN, V117, P496, DOI 10.1016/j.jaci.2006.01.039; Holgate ST, 2005, CLIN EXP ALLERGY, V35, P408, DOI 10.1111/j.1365-2222.2005.02191.x; Holgate ST, 2011, J ALLERGY CLIN IMMUN, V128, P495, DOI 10.1016/j.jaci.2011.06.052; Humbert M, 2005, ALLERGY, V60, P309, DOI 10.1111/j.1398-9995.2004.00772.x; Innes AL, 2011, AM J RESP CRIT CARE, V183, P189, DOI 10.1164/rccm.201003-0488OC; Johnston NW, 2006, J ALLERGY CLIN IMMUN, V117, P557, DOI 10.1016/j.jaci.2005.11.034; Kelly HW, 2011, J ALLERGY CLIN IMMUN, V128, P278, DOI 10.1016/j.jaci.2011.05.002; Koenig SM, 2008, J ASTHMA, V45, P681, DOI 10.1080/02770900802168695; Kozyrskyj AL, 2006, PEDIATRICS, V117, pE1104, DOI 10.1542/peds.2005-2443; Kraft M, 2002, CHEST, V121, P1782, DOI 10.1378/chest.121.6.1782; Lamblin C, 1998, AM J RESP CRIT CARE, V157, P394, DOI 10.1164/ajrccm.157.2.97-02099; Lanier B, 2009, J ALLERGY CLIN IMMUN, V124, P1210, DOI 10.1016/j.jaci.2009.09.021; Lemanske RF, 2010, NEW ENGL J MED, V362, P975, DOI 10.1056/NEJMoa1001278; Lopez-Boado YS, 2008, CURR OPIN PHARMACOL, V8, P286, DOI 10.1016/j.coph.2008.01.010; Majid H, 2010, CURR OPIN PULM MED, V16, P42, DOI 10.1097/MCP.0b013e328332ca46; Message SD, 2008, P NATL ACAD SCI USA, V105, P13562, DOI 10.1073/pnas.0804181105; Moore WC, 2006, J ALLERGY CLIN IMMUN, V117, P487, DOI 10.1016/j.jaci.2006.01.033; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; *NAT ASTHM ED PREV, 1997, NIH PUBL; National Asthma Education and Prevention Program, 1991, NIH BETH PUBL, V91-3642; National Asthma Education and Prevention Program National Heart Lung and Blood Institute, 2007, NIH PUBL; O'Byrne PM, 2005, AM J RESP CRIT CARE, V171, P129, DOI 10.1164/rccm.200407-884OC; Ordonez CL, 2000, AM J RESP CRIT CARE, V161, P1185, DOI 10.1164/ajrccm.161.4.9812061; Pare PD, 2003, AM J RESP CRIT CARE, V168, P913, DOI 10.1164/rccm.2307005; Pare PD, 2007, CAN J PHYSIOL PHARM, V85, P653, DOI 10.1139/Y07-051; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Petsky HL, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006340.pub3; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Schneider Antonius, 2009, BMC Pulm Med, V9, P31, DOI 10.1186/1471-2466-9-31; Shaw DE, 2007, AM J RESP CRIT CARE, V176, P231, DOI 10.1164/rccm.200610-1427OC; Smith AD, 2005, AM J RESP CRIT CARE, V172, P453, DOI 10.1164/rccm.200411-1498OC; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043, DOI 10.1164/ajrccm.159.4.9806052; Sutherland ER, 2010, J ALLERGY CLIN IMMUN, V126, P747, DOI 10.1016/j.jaci.2010.07.024; Suzuki T, 2002, AM J RESP CRIT CARE, V165, P1113, DOI 10.1164/ajrccm.165.8.2103094; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Szefler S, 2008, LANCET, V372, P1065, DOI 10.1016/S0140-6736(08)61448-8; Szefler SJ, 2011, J ALLERGY CLIN IMMUN, V128, P485, DOI 10.1016/j.jaci.2011.07.010; Thomas A, 2011, J ALLERGY CLIN IMMUN; Vanderweil SG, 2008, ACAD EMERG MED, V15, P736, DOI 10.1111/j.1553-2712.2008.00167.x; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Wenzel SE, 2007, J ALLERGY CLIN IMMUN, V119, P14, DOI 10.1016/j.jaci.2006.10.025; Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Yawn BP, 2007, MAYO CLIN PROC, V82, P414, DOI 10.4065/82.4.414	84	37	39	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2011	128	4					740	750		10.1016/j.jaci.2011.08.014	http://dx.doi.org/10.1016/j.jaci.2011.08.014			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	841UA	21875745				2022-12-18	WOS:000296538100007
J	Dall'Antonia, F; Gieras, A; Devanaboyina, SC; Valenta, R; Keller, W				Dall'Antonia, Fabio; Gieras, Anna; Devanaboyina, Siva Charan; Valenta, Rudolf; Keller, Walter			Prediction of IgE-binding epitopes by means of allergen surface comparison and correlation to cross-reactivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; cross-reactivity; x-ray structures; IgE binding; epitope prediction; allergen surfaces; hypoallergenic derivatives; allergen-specific immunotherapy	BIRCH POLLEN ALLERGEN; BET V 1; B-CELL EPITOPES; X-RAY CRYSTALLOGRAPHY; PLANT FOOD ALLERGENS; CRYSTAL-STRUCTURE; MAJOR ALLERGEN; ANTIGENIC DETERMINANTS; 3-DIMENSIONAL STRUCTURE; CONFORMATIONAL EPITOPE	Background: The experimental determination of conformational allergen epitopes recognized by IgE is a difficult task because they often involve discontinuous amino acid residues, being separated in the primary allergen sequence, and require the correct allergen fold. Objective: We sought to develop a computational tool for the localization of conformational IgE epitopes by using a structure-based comparison of allergen surfaces and IgE cross-reactivity data. Methods: Our approach involves the quantitative analysis of geometric and physicochemical surface parameters and the subsequent correlation of surface similarity scores to immunologic data. The software tool Surface comparison-based Prediction of Allergenic Discontinuous Epitopes (SPADE) is able to predict the IgE epitopes of an allergen given the availability of at least 2 structural models and IgE reactivity data. Results: We report on the application of our tool to 3 allergen families: the lipocalins, the group 10 pathogenesis-related proteins, and the group 2/3 grass pollen allergens. First, we succeeded in the partial relocalization of IgE epitopes of bovine beta-lactoglobulin and grass pollen Phl p 2 as known from the x-ray structures of their antibody complexes. Second, we measured the relative binding of anti-Bet v 1 IgE to 10 homologous proteins and correlated these data to surface comparison results involving Bet v 1, 5 of the homologs, and 2 hypoallergenic Bet v 1 isoforms. Thereby we predicted IgE-reactive surface portions in agreement with IgE epitope-mapping studies. Conclusion: Our approach is the first for the prediction of IgE epitopes by combining structural and IgE cross-reactivity data. It should be useful for the development of point-mutated or structurally disrupted allergen derivatives for allergen-specific immunotherapy. (J Allergy Clin Immunol 2011;128:872-9.)	[Dall'Antonia, Fabio; Devanaboyina, Siva Charan; Keller, Walter] Karl Franzens Univ Graz, Inst Mol Biosci, Dept Biol Struct, A-8010 Graz, Austria; [Gieras, Anna; Valenta, Rudolf] Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Dept Pathophysiol, Christian Doppler Lab Allergy Res,Div Immunopatho, Vienna, Austria; [Dall'Antonia, Fabio] Hamburg Outstn, European Mol Biol Lab, Hamburg, Germany; [Devanaboyina, Siva Charan] Univ Texas SW Med Ctr Dallas, Dept Immunol, Dallas, TX 75390 USA	University of Graz; Medical University of Vienna; European Molecular Biology Laboratory (EMBL); University of Texas System; University of Texas Southwestern Medical Center Dallas	Keller, W (corresponding author), Karl Franzens Univ Graz, Inst Mol Biosci, Dept Biol Struct, Humboldtstr 50-3, A-8010 Graz, Austria.	walter.keller@uni-graz.at	Gieras, Anna/S-8345-2019; Keller, Walter/AAW-1501-2021	Keller, Walter/0000-0002-2261-958X; Valenta, Rudolf/0000-0001-5944-3365; Gieras, Anna/0000-0002-5147-2281	Fonds zur Forderung der wissenschaftlichen Forschung in Osterreich (FWF) [M1009-B13]; Christian Doppler Research Association [SFB F1805, F1815]; Biomay, Vienna, Austria; Austrian Science Fund; Austrian Science Fund, Biomay (Vienna)	Fonds zur Forderung der wissenschaftlichen Forschung in Osterreich (FWF)(Austrian Science Fund (FWF)); Christian Doppler Research Association; Biomay, Vienna, Austria; Austrian Science Fund(Austrian Science Fund (FWF)); Austrian Science Fund, Biomay (Vienna)(Austrian Science Fund (FWF))	Supported by the Fonds zur Forderung der wissenschaftlichen Forschung in Osterreich (FWF) through the Lise-Meitner fellowship M1009-B13 and the SFB F1805, F1815 "Molecular and immunological strategies for the prevention, diagnosis and treatment of type-I allergies," by the Christian Doppler Research Association, and by Biomay, Vienna, Austria.; F. Dall'Antonia, A. Gieras, and W. Keller have received research support from the Austrian Science Fund. R. Valenta has received research support from the Austrian Science Fund, Biomay (Vienna), the Christian Doppler Research Association, and Phadia (Uppsala) and has served as a legal consultant/expert witness for Phadia and Biomay on the topics of allergy diagnosis and therapy. S. C. Devanaboyina has declared no conflict of interest.	Aalberse Rob C, 2007, Clin Mol Allergy, V5, P2, DOI 10.1186/1476-7961-5-2; Andersen PH, 2006, PROTEIN SCI, V15, P2558, DOI 10.1110/ps.062405906; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Biesiadka J, 2002, J MOL BIOL, V319, P1223, DOI 10.1016/S0022-2836(02)00385-6; Binkowski TA, 2004, NUCLEIC ACIDS RES, V32, pW555, DOI 10.1093/nar/gkh390; BLACK SD, 1991, ANAL BIOCHEM, V193, P72, DOI 10.1016/0003-2697(91)90045-U; Breiteneder H, 2004, J ALLERGY CLIN IMMUN, V113, P821, DOI [10.1016/j.jaci.2004.01.779, 10.1016/j.jaci.2004.01.079]; Chaudhuri BN, 1999, ACTA CRYSTALLOGR D, V55, P753, DOI 10.1107/S0907444998017211; DeLano W. L, 2002, PYMOL MOL GENETICS G; Dolinsky TJ, 2007, NUCLEIC ACIDS RES, V35, pW522, DOI 10.1093/nar/gkm276; Ferreira F, 1996, J EXP MED, V183, P599, DOI 10.1084/jem.183.2.599; Focke M, 2004, CLIN EXP ALLERGY, V34, P1525, DOI 10.1111/j.1365-2222.2004.02081.x; Furmonaviciene R, 2005, BIOINFORMATICS, V21, P4201, DOI 10.1093/bioinformatics/bti700; Gajhede M, 1996, NAT STRUCT BIOL, V3, P1040, DOI 10.1038/nsb1296-1040; Gieras A, 2011, J IMMUNOL, V186, P5333, DOI 10.4049/jimmunol.1000804; Gustchina A, 2005, J MOL BIOL, V348, P433, DOI 10.1016/j.jmb.2005.02.062; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; Jenkins JA, 2005, J ALLERGY CLIN IMMUN, V115, P163, DOI 10.1016/j.jaci.2004.10.026; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; Kaneta Y, 2002, INFORM SCIENCES, V146, P41, DOI 10.1016/S0020-0255(02)00213-X; Kawabata T, 2003, NUCLEIC ACIDS RES, V31, P3367, DOI 10.1093/nar/gkg581; Kulkarni-Kale U, 2005, NUCLEIC ACIDS RES, V33, pW168, DOI 10.1093/nar/gki460; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Li M, 2008, J BIOL CHEM, V283, P22806, DOI 10.1074/jbc.M800937200; Lovell SC, 2000, PROTEINS, V40, P389, DOI 10.1002/1097-0134(20000815)40:3<389::AID-PROT50>3.0.CO;2-2; Mari A, 2005, INT ARCH ALLERGY IMM, V138, P88, DOI 10.1159/000087848; Markovic-Housley Z, 2003, J MOL BIOL, V325, P123, DOI 10.1016/S0022-2836(02)01197-X; Markovic-Housley Z, 2000, STRUCTURE, V8, P1025, DOI 10.1016/S0969-2126(00)00511-6; Mirza O, 2000, J IMMUNOL, V165, P331, DOI 10.4049/jimmunol.165.1.331; Neudecker P, 2001, J BIOL CHEM, V276, P22756, DOI 10.1074/jbc.M101657200; Niemi M, 2007, STRUCTURE, V15, P1413, DOI 10.1016/j.str.2007.09.012; Oksanen E, 2006, ACTA CRYSTALLOGR D, V62, P1369, DOI 10.1107/S0907444906031519; Oliveira KMG, 2001, EUR J BIOCHEM, V268, P477, DOI 10.1046/j.1432-1327.2001.01918.x; Padavattan S, 2007, J MOL BIOL, V368, P742, DOI 10.1016/j.jmb.2007.02.036; Padavattan S, 2009, J IMMUNOL, V182, P2141, DOI 10.4049/jimmunol.0803018; Pasternak O, 2006, PLANT CELL, V18, P2622, DOI 10.1105/tpc.105.037119; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; Petersen A, 2006, CLIN EXP ALLERGY, V36, P840, DOI 10.1111/j.1365-2222.2006.02505.x; Ponomarenko J, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-514; Radauer C, 2008, J ALLERGY CLIN IMMUN, V121, P847, DOI 10.1016/j.jaci.2008.01.025; Rouvinen J, 1999, J BIOL CHEM, V274, P2337, DOI 10.1074/jbc.274.4.2337; Rubinstein ND, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-287; Saha S, 2006, PROTEINS, V65, P40, DOI 10.1002/prot.21078; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; Schirmer T, 2005, J MOL BIOL, V351, P1101, DOI 10.1016/j.jmb.2005.06.054; Shatsky M, 2004, PROTEINS, V56, P143, DOI 10.1002/prot.10628; Spangfort MD, 2003, J IMMUNOL, V171, P3084, DOI 10.4049/jimmunol.171.6.3084; Stern DA, 2007, J ALLERGY CLIN IMMUN, V119, P351, DOI 10.1016/j.jaci.2006.10.013; Sun J, 2009, NUCLEIC ACIDS RES, V37, pW612, DOI 10.1093/nar/gkp417; Suutari TJ, 2006, J INVEST ALLERG CLIN, V16, P296; Swoboda I, 2007, J IMMUNOL, V178, P6290, DOI 10.4049/jimmunol.178.10.6290; THORNTON JM, 1986, EMBO J, V5, P409, DOI 10.1002/j.1460-2075.1986.tb04226.x; Valenta R, 1996, IMMUNOL CELL BIOL, V74, P187, DOI 10.1038/icb.1996.26; Valenta R, 2002, NAT REV IMMUNOL, V2, P446, DOI 10.1038/nri824; Valenta R, 2001, IMMUNOL REV, V179, P119, DOI 10.1034/j.1600-065X.2001.790112.x; Valenta R, 2010, ANNU REV IMMUNOL, V28, P211, DOI 10.1146/annurev-immunol-030409-101218; Vieths S, 2002, ANN NY ACAD SCI, V964, P47; WESTHOF E, 1984, NATURE, V311, P123, DOI 10.1038/311123a0; Westritschnig K, 2004, J IMMUNOL, V172, P5684, DOI 10.4049/jimmunol.172.9.5684; Zaborsky N, 2010, J IMMUNOL, V184, P725, DOI 10.4049/jimmunol.0902080	61	37	39	2	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2011	128	4					872	U298		10.1016/j.jaci.2011.07.007	http://dx.doi.org/10.1016/j.jaci.2011.07.007			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	841UA	21872913				2022-12-18	WOS:000296538100026
J	Tovey, ER; Marks, GB				Tovey, Euan R.; Marks, Guy B.			It's time to rethink mite allergen avoidance	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen avoidance; prevention; house dust mite; aeroallergen	HOUSE-DUST MITE; RANDOMIZED-CONTROLLED-TRIAL; AIRBORNE CAT ALLERGEN; EXHALED NITRIC-OXIDE; DOUBLE-BLIND TRIAL; ASTHMATIC-CHILDREN; VACUUM CLEANERS; ENVIRONMENTAL-CONTROL; HIGH-ALTITUDE; AIRWAY INFLAMMATION	The role of allergen exposure in the etiology of allergic sensitization and asthma is complex. Advice on strategies to avoid domestic allergens remains contentious because trials of interventions aimed to prevent asthma or reduce symptoms have often failed to demonstrate benefits. Asthma management guidelines differ widely in their recommendations, while Web-based information often claims benefits associated with products. In this rostrum we argue that although many factors have a role in both the etiology and the exacerbation of asthma, allergen exposure probably remains an important contributor to the manifestations of the disease. Currently, there is no evidence-based framework for effective domestic allergen avoidance interventions to reduce chronic aeroallergen exposure. The development of an effective approach to allergen avoidance requires a better understanding of (a) the physical nature of chronic aeroallergen exposure and methods for measuring and reducing this, (b) the interaction between allergen exposure and innate immune modulators at different disease stages, and (c) markers enabling the identification of individuals who would benefit from this. The strategic risk of overemphasizing other novel mechanisms and approaches to asthma management is that we will prematurely abandon and fail to improve an existing approach that could have a significant impact on the development, progression, and symptoms of the disease. (J Allergy Clin Immunol 2011;128:723-7.)	[Tovey, Euan R.] Woolcock Inst Med Res, Sydney, NSW 2050, Australia; Univ Sydney, Sydney, NSW 2006, Australia	University of Sydney; Woolcock Institute of Medical Research; University of Sydney	Tovey, ER (corresponding author), Woolcock Inst Med Res, Box M77,Missenden Rd Post Off, Sydney, NSW 2050, Australia.	ert@med.usyd.edu.au	Tovey, Euan R/G-8604-2017; Marks, Guy B./F-5058-2013	Tovey, Euan R/0000-0002-1802-7266; Marks, Guy B./0000-0002-8976-8053	National Health and Medical Research Council of Australia	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	Both E. R. Tovey and G. B. Marks are supported by fellowships funded by the National Health and Medical Research Council of Australia.	Ahluwalia SK, 2011, CURR OPIN ALLERGY CL, V11, P137, DOI 10.1097/ACI.0b013e3283445921; Almqvist C, 2007, CLIN EXP ALLERGY, V37, P1296, DOI 10.1111/j.1365-2222.2007.02796.x; [Anonymous], 2007, 3 NAT HEART LUNG BLO; Arlian LG, 2003, J ALLERGY CLIN IMMUN, V111, P1269, DOI 10.1067/mai.2003.1547; Arlian LG, 2001, J ALLERGY CLIN IMMUN, V107, P99, DOI 10.1067/mai.2001.112119; Bisgaard H, 2010, J ALLERGY CLIN IMMUN, V126, P187, DOI 10.1016/j.jaci.2010.07.011; Blackhall K, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002986; Bloomfield SF, 2006, CLIN EXP ALLERGY, V36, P402, DOI 10.1111/j.1365-2222.2006.02463.x; Bobb C, 2010, CLIN EXP ALLERGY, V40, P143, DOI 10.1111/j.1365-2222.2009.03350.x; Bodini A, 2004, PEDIAT ALLERG IMM-UK, V15, P26, DOI 10.1046/j.0905-6157.2003.00097.x; Bonnelykke K, 2010, PEDIAT ALLERG IMM-UK, V21, P954, DOI 10.1111/j.1399-3038.2010.01073.x; Brodtkorb TH, 2010, CLIN RESPIR J, V4, P104, DOI 10.1111/j.1752-699X.2009.00156.x; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Carswell F, 1996, CLIN EXP ALLERGY, V26, P386, DOI 10.1111/j.1365-2222.1996.tb00554.x; Causer SM, 2008, TEXT RES J, V78, P105, DOI 10.1177/0040517507083438; Causer SM, 2004, J OCCUP ENVIRON HYG, V1, P237, DOI 10.1080/15459620490432169; Choi SY, 2008, ANN ALLERG ASTHMA IM, V100, P583, DOI 10.1016/S1081-1206(10)60060-9; Colloff M., 2009, DUST MITES; COLLOFF MJ, 1995, CLIN EXP ALLERGY, V25, P1061, DOI 10.1111/j.1365-2222.1995.tb03252.x; Corsi RL, 2008, J OCCUP ENVIRON HYG, V5, P232, DOI 10.1080/15459620801901165; Custovic A, 2003, J ALLERGY CLIN IMMUN, V111, P402, DOI 10.1067/mai.2003.55; Custovic A, 2011, J ALLERGY CLIN IMMUN, V127, P1480, DOI 10.1016/j.jaci.2011.03.014; Custovic A, 2011, RESPIROLOGY, V16, P379, DOI 10.1111/j.1440-1843.2010.01916.x; De Lucca SD, 2000, J ALLERGY CLIN IMMUN, V106, P874, DOI 10.1067/mai.2000.110804; Douwes J, 2003, AM J EPIDEMIOL, V158, P203, DOI 10.1093/aje/kwg149; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Erwin EA, 2007, J ALLERGY CLIN IMMUN, V119, pS311, DOI 10.1016/j.jaci.2006.12.586; Erwin EA, 2005, J ALLERGY CLIN IMMUN, V115, P74, DOI 10.1016/j.jaci.2004.10.030; Ferro AR, 2004, ENVIRON SCI TECHNOL, V38, P1759, DOI 10.1021/es0263893; Fox AT, 2009, J ALLERGY CLIN IMMUN, V123, P417, DOI 10.1016/j.jaci.2008.12.014; Fujimura KE, 2010, J ALLERGY CLIN IMMUN, V126, DOI 10.1016/j.jaci.2010.05.042; Gaffin JM, 2009, CURR OPIN ALLERGY CL, V9, P128, DOI 10.1097/ACI.0b013e32832678b0; Gehring U, 2007, EUR RESPIR J, V29, P1144, DOI 10.1183/09031936.00118806; Global Strategy for Asthma Management and Prevention, 2009, GLOB IN ASTHM; Gomes C, 2007, ATMOS ENVIRON, V41, P5257, DOI 10.1016/j.atmosenv.2006.07.061; Gore RB, 2010, THORAX, V65, pA87, DOI 10.1136/thx.2010.150961.27; Gore RB, 2006, ALLERGY, V61, P119, DOI 10.1111/j.1398-9995.2005.00946.x; Gore RB, 2003, J ALLERGY CLIN IMMUN, V111, P784, DOI 10.1067/mai.2003.1378; Gore RB, 2002, CLIN EXP ALLERGY, V32, P856, DOI 10.1046/j.1365-2222.2002.01403.x; Gotzsche PC, 2008, ALLERGY, V63, P646, DOI 10.1111/j.1398-9995.2008.01690.x; Haahtela T, 2008, ALLERGY, V63, P634, DOI 10.1111/j.1398-9995.2008.01712.x; Hacker DW, 2005, INDOOR AIR, V15, P420, DOI 10.1111/j.1600-0668.2005.00387.x; Ho SM, 2010, J ALLERGY CLIN IMMUN, V126, P453, DOI 10.1016/j.jaci.2010.07.030; Htut T, 2001, J ALLERGY CLIN IMMUN, V107, P55, DOI 10.1067/mai.2001.111240; Huss-Marp J, 2007, J ALLERGY CLIN IMMUN, V120, P471, DOI 10.1016/j.jaci.2007.03.039; Jartti T, 2010, PEDIAT ALLERG IMM-UK, V21, P1008, DOI 10.1111/j.1399-3038.2010.01059.x; Jarvis D, 2007, J ALLERGY CLIN IMMUN, V119, P697, DOI 10.1016/j.jaci.2006.10.042; Jeal H, 2010, CLIN EXP ALLERGY, V40, P1593, DOI 10.1111/j.1365-2222.2010.03609.x; Johnsen CR, 1997, INDOOR BUILT ENVIRON, V6, P174, DOI 10.1177/1420326X9700600308; Karagiannidis C, 2006, SCAND J IMMUNOL, V63, P304, DOI 10.1111/j.1365-3083.2006.01739.x; Karlsson AS, 2004, J ALLERGY CLIN IMMUN, V113, P1172, DOI 10.1016/j.jaci.2003.12.590; Karmaus W, 2002, J EPIDEMIOL COMMUN H, V56, P209, DOI 10.1136/jech.56.3.209; Krieger J, 2010, J PUBLIC HEALTH MAN, V16, pS11, DOI 10.1097/PHH.0b013e3181ddcbd9; Krop EJM, 2011, ALLERGY, V66, P517, DOI 10.1111/j.1398-9995.2010.02508.x; Lang A, 2010, PEDIAT ALLERG IMM-UK, V21, P945, DOI 10.1111/j.1399-3038.2010.01072.x; Lau JY, 2006, J ALLERGY CLIN IMMUN, V117, pS30, DOI 10.1016/j.jaci.2005.12.125; Linneberg A, 2008, INT ARCH ALLERGY IMM, V147, P93, DOI 10.1159/000135695; Lowe AJ, 2007, CLIN EXP ALLERGY, V37, P536, DOI 10.1111/j.1365-2222.2007.02691.x; Ly NP, 2011, J ALLERGY CLIN IMMUN, V127, P1087, DOI 10.1016/j.jaci.2011.02.015; MacDonald C, 2007, ENVIRON HEALTH PERSP, V115, P1691, DOI 10.1289/ehp.10382; MARKS GB, 1994, CLIN EXP ALLERGY, V24, P1078, DOI 10.1111/j.1365-2222.1994.tb02746.x; Marks GB, 2006, J ALLERGY CLIN IMMUN, V118, P53, DOI 10.1016/j.jaci.2006.04.004; Marriott C., 2004, Journal of Allergy and Clinical Immunology, V113, pS231, DOI 10.1016/j.jaci.2004.01.289; Martin PE, 2011, J ALLERGY CLIN IMMUN, V127, P1473; McCormack MC, 2009, ENVIRON HEALTH PERSP, V117, P294, DOI 10.1289/ehp.11770; McDonald E, 2002, CHEST, V122, P1535, DOI 10.1378/chest.122.5.1535; MCDONALD LG, 1992, J ALLERGY CLIN IMMUN, V90, P599, DOI 10.1016/0091-6749(92)90132-L; Milanese M, 2004, J ALLERGY CLIN IMMUN, V114, P505, DOI 10.1016/j.jaci.2004.05.041; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Montoya LD, 2001, ATMOS ENVIRON, V35, P859, DOI 10.1016/S1352-2310(00)00379-4; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Morris RJ, 2006, ALLERGY ASTHMA PROC, V27, P63; Muche-Borowski C, 2009, ALLERGOLOGIE, V32, P383; Mukai C, 2009, AEROSOL SCI TECH, V43, P1022, DOI 10.1080/02786820903131073; Murakami S, 2004, INDOOR AIR, V14, P144, DOI 10.1111/j.1600-0668.2004.00283.x; Murray CS, 2006, THORAX, V61, P376, DOI 10.1136/thx.2005.042523; Nagappa AN, 2009, J YOUNG PHARM, V1, P278, DOI 10.4103/0975-1483.57075; Niven RM, 1999, J ALLERGY CLIN IMMUN, V103, P756, DOI 10.1016/S0091-6749(99)70416-1; NOGRADY SG, 1983, THORAX, V38, P919, DOI 10.1136/thx.38.12.919; Nurmatov U, 2011, J ALLERGY CLIN IMMUN, V127, P724, DOI 10.1016/j.jaci.2010.11.001; O'Meara T, 2000, CLIN REV ALLERG IMMU, V18, P341, DOI 10.1385/CRIAI:18:3:341; O'Rourke SD, 2002, J ALLERGY CLIN IMMUN, V109, pS47, DOI 10.1016/S0091-6749(02)81228-3; Ober C, 2011, TRENDS GENET, V27, P107, DOI 10.1016/j.tig.2010.12.004; Oryszczyn MP, 2009, CLIN EXP ALLERGY, V39, P1515, DOI 10.1111/j.1365-2222.2009.03288.x; Park JW, 2002, J INVEST ALLERG CLIN, V12, P293; Pedroletti C, 2009, RESP MED, V103, P1313, DOI 10.1016/j.rmed.2009.03.020; Peroni DG, 2002, CLIN EXP ALLERGY, V32, P850, DOI 10.1046/j.1365-2222.2002.01372.x; Peters M, 2006, THORAX, V61, P134, DOI 10.1136/thx.2005.049403; Piacentini GL, 2007, J ALLERGY CLIN IMMUN, V120, P1226, DOI 10.1016/j.jaci.2007.06.045; Piacentini GL, 1999, J ALLERGY CLIN IMMUN, V104, P1323, DOI 10.1016/S0091-6749(99)70031-X; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; PLATTSMILLS TAE, 1982, LANCET, V2, P675; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; Poninska J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016933; Prescott SL, 2007, J ALLERGY CLIN IMMUN, V120, P255, DOI 10.1016/j.jaci.2007.04.027; PRICE JA, 1990, LANCET, V336, P895, DOI 10.1016/0140-6736(90)92268-M; Qian J, 2008, AEROSOL SCI TECH, V42, P566, DOI 10.1080/02786820802220274; Qian J, 2008, J AIR WASTE MANAGE, V58, P502, DOI 10.3155/1047-3289.58.4.502; Rabinovitch N, 2005, J ALLERGY CLIN IMMUN, V116, P1053, DOI 10.1016/j.jaci.2005.08.045; Raja S, 2010, ENVIRON INT, V36, P8, DOI 10.1016/j.envint.2009.09.001; Recer GM, 2004, CLIN EXP ALLERGY, V34, P268, DOI 10.1111/j.1365-2222.2004.01863.x; Rim D, 2009, BUILD ENVIRON, V44, P1840, DOI 10.1016/j.buildenv.2008.12.009; Rosati JA, 2008, AEROSOL SCI TECH, V42, P472, DOI 10.1080/02786820802187069; SAKAGUCHI M, 1993, J ALLERGY CLIN IMMUN, V92, P797, DOI 10.1016/0091-6749(93)90056-L; SAKAGUCHI M, 1989, INT ARCH ALLER A IMM, V90, P190, DOI 10.1159/000235022; Sakaguchi M, 1996, J ALLERGY CLIN IMMUN, V97, P1040, DOI 10.1016/S0091-6749(96)70255-5; SAKAGUCHI M, 1992, ALLERGY, V47, P55, DOI 10.1111/j.1398-9995.1992.tb02250.x; Sakaguchi M, 1995, AEROBIOLOGIA, V11, P265, DOI 10.1007/BF02447207; Salo PM, 2006, J ALLERGY CLIN IMMUN, V118, P892, DOI 10.1016/j.jaci.2006.07.037; Schram-Bijkerk D, 2006, ALLERGY, V61, P640, DOI 10.1111/j.1398-9995.2006.01079.x; Scottish Intercollegiate Guidelines Network Healthcare Improvement Scotland, 2013, MAN SCH NAT CLIN GUI; Sercombe JK, 2007, INT J HYG ENVIR HEAL, V210, P43, DOI 10.1016/j.ijheh.2006.06.006; Siebers RW, 2002, ALLERGY, V57, P465, DOI 10.1034/j.1398-9995.2002.23643.x; Simpson A, 2005, CURR OPIN ALLERGY CL, V5, P223, DOI 10.1097/01.all.0000168785.51711.27; Simpson A, 2009, CURR ALLERGY ASTHM R, V9, P363, DOI 10.1007/s11882-009-0053-y; Sordillo JE, 2010, CLIN EXP ALLERGY, V40, P902, DOI 10.1111/j.1365-2222.2010.03509.x; Sordillo JE, 2011, J ALLERGY CLIN IMMUN, V127, P1165; Stillerman A, 2010, ANN ALLERG ASTHMA IM, V104, P440, DOI 10.1016/j.anai.2010.03.006; Sublett JL, 2010, J ALLERGY CLIN IMMUN, V125, P32, DOI 10.1016/j.jaci.2009.08.036; Svanes C, 2003, J ALLERGY CLIN IMMUN, V112, P289, DOI 10.1067/mai.2003.1596; Takaro TK, 2011, AM J PUBLIC HEALTH, V101, P55, DOI 10.2105/AJPH.2010.300008; Torrent M, 2006, J ALLERGY CLIN IMMUN, V118, P742, DOI 10.1016/j.jaci.2006.04.059; Tovey E, 1999, J ALLERGY CLIN IMMUN, V103, P179, DOI 10.1016/S0091-6749(99)70488-4; Tovey ER, 2007, CLIN EXP ALLERGY, V37, P1199, DOI 10.1111/j.1365-2222.2007.02770.x; TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630; Tovey ER, 2001, J ALLERGY CLIN IMMUN, V108, P369, DOI 10.1067/mai.2001.117799; Tovey ER, 2008, J ALLERGY CLIN IMMUN, V122, P114, DOI 10.1016/j.jaci.2008.05.010; Tovey ER, 2008, CURR ALLERGY ASTHM R, V8, P126, DOI 10.1007/s11882-008-0022-x; van den Oord R, 2009, BRIT MED J, V339, P86; van Schayck OCP, 2007, J ALLERGY CLIN IMMUN, V119, P1323, DOI 10.1016/j.jaci.2007.02.024; van Strien RT, 2004, INDOOR AIR, V14, P174, DOI 10.1111/j.1600-0668.2004.00217.x; VERRALL B, 1988, ANN ALLERGY, V61, P117; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; Vyszenski-Moher DL, 2002, ANN ALLERG ASTHMA IM, V88, P578, DOI 10.1016/S1081-1206(10)61889-3; Warner JO, 2009, PEDIATR ALLERGY IMMU, V20, P509, DOI 10.1111/j.1399-3038.2009.00942.x; WARNER JA, 1993, THORAX, V48, P330, DOI 10.1136/thx.48.4.330; Warner JA, 2000, J ALLERGY CLIN IMMUN, V105, P75, DOI 10.1016/S0091-6749(00)90181-7; Weiss ST, 2011, J ALLERGY CLIN IMMUN, V127, P1128, DOI 10.1016/j.jaci.2011.02.025; Winkins A., 2005, ALLERGIE KONKRET, V2, P16; Wood Robert A, 2002, Curr Allergy Asthma Rep, V2, P397, DOI 10.1007/s11882-002-0073-3; Woodcock A, 2004, AM J RESP CRIT CARE, V170, P433, DOI 10.1164/rccm.200401-083OC; WOODFOLK JA, 1993, J ALLERGY CLIN IMMUN, V91, P829, DOI 10.1016/0091-6749(93)90339-H; Wright GR, 2009, ALLERGY, V64, P1671, DOI 10.1111/j.1398-9995.2009.02098.x; Xu Y, 2010, BUILD ENVIRON, V45, P330, DOI 10.1016/j.buildenv.2009.06.010; Yu CH, 2009, J ENVIRON MONITOR, V11, P205, DOI 10.1039/b807821a; ZWEMER RJ, 1973, ANN ALLERGY, V31, P284	146	37	43	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2011	128	4					723	U370		10.1016/j.jaci.2011.07.009	http://dx.doi.org/10.1016/j.jaci.2011.07.009			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	841UA	21855978	Bronze			2022-12-18	WOS:000296538100003
J	Weiss, ST				Weiss, Scott T.			Bacterial components plus vitamin D: The ultimate solution to the asthma (autoimmune disease) epidemic?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Asthma; microbiome; vitamin D	REGULATORY T-CELLS; GUT MICROBIOTA COMPOSITION; IMMUNE-RESPONSES; INTESTINAL MICROFLORA; ATOPIC-DERMATITIS; CONTROLLED-TRIAL; DENDRITIC CELLS; PROBIOTICS; INFANTS; INDUCTION		[Weiss, Scott T.] Harvard Univ, Sch Med, Channing Lab, Dept Med, Boston, MA 02115 USA; [Weiss, Scott T.] Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; [Weiss, Scott T.] Partners Hlth Care, Partners Ctr Personalized Genet Med, Boston, MA USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Partners Healthcare System	Weiss, ST (corresponding author), Harvard Univ, Sch Med, Channing Lab, Dept Med, 181 Longwood Ave, Boston, MA 02115 USA.	scott.weiss@channing.harvard.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL091528] Funding Source: NIH RePORTER; NHLBI NIH HHS [U01 HL091528-03, U01 HL091528-02, U01 HL091528-01A1, U01 HL091528, U01 HL091528-04] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adlerberth I, 2007, J ALLERGY CLIN IMMUN, V120, P343, DOI 10.1016/j.jaci.2007.05.018; Adorini L, 2004, SEMIN IMMUNOL, V16, P127, DOI 10.1016/j.smim.2003.12.008; Benson AK, 2010, P NATL ACAD SCI USA, V107, P18933, DOI 10.1073/pnas.1007028107; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342, DOI 10.1046/j.1365-2222.1999.00560.x; Borriello SP, 2003, CLIN INFECT DIS, V36, P775, DOI 10.1086/368080; Bottcher MF, 2000, CLIN EXP ALLERGY, V30, P1590, DOI 10.1046/j.1365-2222.2000.00982.x; Cadwell K, 2010, CELL, V141, P1135, DOI 10.1016/j.cell.2010.05.009; Diaz Heijtz R, 2011, P NATL ACAD IN PRESS; DOBZHANSKY T, 1964, AM ZOOL, V4, P443; Edwards CA, 2002, BRIT J NUTR, V88, pS11, DOI [10.1079/BJN2002625, 10.1079/BJNBJN2002580]; Forno Erick, 2008, Clin Mol Allergy, V6, P11, DOI 10.1186/1476-7961-6-11; Froicu M, 2006, IMMUNOLOGY, V117, P310, DOI 10.1111/j.1365-2567.2005.02290.x; Griffin MD, 2004, J STEROID BIOCHEM, V89-90, P443, DOI 10.1016/j.jsbmb.2004.03.039; Guarner J, 2003, AM J CLIN PATHOL, V120, P845, DOI 10.1309/LBRNGF9MJW2MHT97; Harmsen HJM, 2000, J PEDIATR GASTR NUTR, V30, P61, DOI 10.1097/00005176-200001000-00019; Isolauri E, 2000, CLIN EXP ALLERGY, V30, P1604, DOI 10.1046/j.1365-2222.2000.00943.x; Kalliomaki M, 2003, LANCET, V361, P1869, DOI 10.1016/S0140-6736(03)13490-3; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Litonjua AA, 2007, J ALLERGY CLIN IMMUN, V120, P1031, DOI 10.1016/j.jaci.2007.08.028; Ly NP, 2011, J ALLERGY CLIN IMMUN, V127, P1087, DOI 10.1016/j.jaci.2011.02.015; Maslowski KM, 2011, NAT IMMUNOL, V12, P5, DOI 10.1038/ni0111-5; McLoughlin RM, 2011, J ALLERGY CLIN IMMUN, V127, P1097, DOI 10.1016/j.jaci.2011.02.012; Mora JR, 2008, NAT REV IMMUNOL, V8, P685, DOI 10.1038/nri2378; Noverr MC, 2004, TRENDS MICROBIOL, V12, P562, DOI 10.1016/j.tim.2004.10.008; Penders J, 2007, ALLERGY, V62, P1223, DOI 10.1111/j.1398-9995.2007.01462.x; Penders J, 2007, GUT, V56, P661, DOI 10.1136/gut.2006.100164; Prescott SL, 2005, CLIN EXP ALLERGY, V35, P1557, DOI 10.1111/j.1365-2222.2005.02376.x; Rask C, 2005, SCAND J IMMUNOL, V61, P529, DOI 10.1111/j.1365-3083.2005.01598.x; Sepp E, 1997, ACTA PAEDIATR, V86, P956, DOI 10.1111/j.1651-2227.1997.tb15178.x; Strauch UG, 2005, GUT, V54, P1546, DOI 10.1136/gut.2004.059451; Taher YA, 2008, J IMMUNOL, V180, P5211, DOI 10.4049/jimmunol.180.8.5211; Weiss ST, 1997, ASTHMA, P244; Weston S, 2005, ARCH DIS CHILD, V90, P892, DOI 10.1136/adc.2004.060673; Xystrakis E, 2006, J CLIN INVEST, V116, P146, DOI 10.1172/JCI21759; Zhu BL, 2010, PROTEIN CELL, V1, P718, DOI 10.1007/s13238-010-0093-z	35	37	38	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2011	127	5					1128	1130		10.1016/j.jaci.2011.02.025	http://dx.doi.org/10.1016/j.jaci.2011.02.025			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	756NG	21411129	Green Accepted, Bronze, Green Published			2022-12-18	WOS:000290018600005
J	He, R; Oyoshi, MK; Wang, JYT; Hodge, MR; Jin, H; Geha, RS				He, Rui; Oyoshi, Michiko K.; Wang, James Y. T.; Hodge, Martin R.; Jin, Haoli; Geha, Raif S.			The prostaglandin D-2 receptor CRTH2 is important for allergic skin inflammation after epicutaneous antigen challenge	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CRTH2; prostaglandin D-2; atopic dermatitis	EOSINOPHILIC AIRWAY INFLAMMATION; HELPER TYPE-2 CELLS; HUMAN TH2 CELLS; ATOPIC-DERMATITIS; LANGERHANS CELLS; MURINE MODEL; RT-PCR; CHEMOATTRACTANT; EXPRESSION; MOLECULE	Background: Cutaneous prostaglandin (PG) D-2 levels increase after scratching. Chemoattractant receptor-homologous molecule expressed on receptor on T(H)2 cells (CRTH2) mediates chemotaxis to PGD(2) and is expressed on T(H)2 cells and eosinophils, which infiltrate skin lesions in patients with atopic dermatitis. Objective: We sought to examine the role of CRTH2 in a murine model of atopic dermatitis. Methods: CRTH2(-/-) mice and wild-type control animals were epicutaneously sensitized by means of repeated application of ovalbumin (OVA) to tape-stripped skin for 7 weeks and then challenged by means of OVA application to tape-stripped previously unsensitized skin for 1 week. Skin histology was assessed by means of hematoxylin and eosin staining and immunohistochemistry. Cytokine mRNA expression was examined by means of quantitative RT-PCR. Levels of PGD2, antibody, and cytokines were measured by means of ELISA. Results: PGD(2) levels significantly increased in skin 24 hours after tape stripping, although not in skin subjected to repeated sensitization with OVA. Allergic skin inflammation developed normally at sites of chronic epicutaneous sensitization with OVA in CRTH2(-/-) mice but was severely impaired in previously unsensitized skin challenged with OVA, as evidenced by significantly decreased skin infiltration with eosinophils and CD4(+) cells and impaired T(H)2 cytokine mRNA expression. Impaired skin inflammation at sites of acute OVA challenge in CRTH2(-/-) mice was not due to an impaired systemic response to epicutaneous sensitization because OVA-specific IgG1 and IgE antibody levels and OVA-driven splenocyte secretion of cytokines in these mice were comparable with those seen in wild-type control animals. Conclusions: CRTH2 promotes allergic skin inflammation in response to cutaneous exposure to antigen in previously sensitized mice. (J Allergy Clin Immunol 2010;126:784-90.)	[He, Rui; Oyoshi, Michiko K.; Wang, James Y. T.; Jin, Haoli; Geha, Raif S.] Childrens Hosp, Div Immunol, Boston, MA 02115 USA; [He, Rui; Oyoshi, Michiko K.; Wang, James Y. T.; Jin, Haoli; Geha, Raif S.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [Hodge, Martin R.] Biogen Idec Inc, Cambridge, MA USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Biogen	Geha, RS (corresponding author), Childrens Hosp, Div Immunol, Room 10210,Karp Family Res Bldg,1 Blackfan Circle, Boston, MA 02115 USA.	raif.geha@childrens.harvard.edu	He, Rui/P-7302-2019	He, Rui/0000-0001-5288-9786; Wang, James/0000-0003-2711-0827	Atopic Dermatitis and Vaccinia Immunization Network; National Institutes of Health/National Institute of Allergy and Infectious Diseases [NO1 (AI 40030)]; USPHS [AR-047417]; National Institutes of Health; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047417] Funding Source: NIH RePORTER	Atopic Dermatitis and Vaccinia Immunization Network(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institutes of Health/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); USPHS(United States Department of Health & Human ServicesUnited States Public Health Service); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported by the Atopic Dermatitis and Vaccinia Immunization Network, National Institutes of Health/National Institute of Allergy and Infectious Diseases contract NO1 (AI 40030), and a USPHS grant AR-047417 to R. S. G.; Disclosure of potential conflict of interest: R. S. G. receives research support from the National Institutes of Health. The rest of the authors have declared that they have no conflict of interest. All other authors declare no conflicts of interest.	Boehme SA, 2009, INT IMMUNOL, V21, P621, DOI 10.1093/intimm/dxp031; Boehme SA, 2009, INT IMMUNOL, V21, P1, DOI 10.1093/intimm/dxn118; Cameron L, 2009, ALLERGY, V64, P1478, DOI 10.1111/j.1398-9995.2009.02053.x; Chevalier E, 2005, J IMMUNOL, V175, P2056, DOI 10.4049/jimmunol.175.4.2056; Cosmi L, 2000, EUR J IMMUNOL, V30, P2972, DOI 10.1002/1521-4141(200010)30:10<2972::AID-IMMU2972>3.0.CO;2-#; Gervais FG, 2001, J ALLERGY CLIN IMMUN, V108, P982, DOI 10.1067/mai.2001.119919; Hata AN, 2004, PHARMACOL THERAPEUT, V103, P147, DOI 10.1016/j.pharmthera.2004.06.003; Hijnen D, 2005, J INVEST DERMATOL, V125, P1149, DOI 10.1111/j.0022-202X.2005.23932.x; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; Huang JL, 2004, HUM MOL GENET, V13, P2691, DOI 10.1093/hmg/ddh279; Iwasaki M, 2002, J INVEST DERMATOL, V119, P609, DOI 10.1046/j.1523-1747.2002.01862.x; Laouini D, 2005, J ALLERGY CLIN IMMUN, V116, P390, DOI 10.1016/j.jaci.2005.03.042; Lukacs NW, 2008, AM J PHYSIOL-LUNG C, V295, pL767, DOI 10.1152/ajplung.90351.2008; Ma W, 2002, J CLIN INVEST, V109, P621, DOI 10.1172/JCI200214097; Matsuoka T, 2000, SCIENCE, V287, P2013, DOI 10.1126/science.287.5460.2013; Monneret G, 2001, BLOOD, V98, P1942, DOI 10.1182/blood.V98.6.1942; Nagata K, 1999, FEBS LETT, V459, P195, DOI 10.1016/S0014-5793(99)01251-X; Nagata K, 1999, J IMMUNOL, V162, P1278; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; ROBERTS LJ, 1980, NEW ENGL J MED, V303, P1400, DOI 10.1056/NEJM198012113032405; ROSENBACH T, 1990, J INVEST DERMATOL, V95, P104, DOI 10.1111/1523-1747.ep12874064; RUZICKA T, 1987, J IMMUNOL, V138, P539; Satoh T, 2006, J IMMUNOL, V177, P2621, DOI 10.4049/jimmunol.177.4.2621; Schratl P, 2007, J IMMUNOL, V179, P4792, DOI 10.4049/jimmunol.179.7.4792; Shiraishi Y, 2005, J PHARMACOL EXP THER, V312, P954, DOI 10.1124/jpet.104.078212; Shiraishi Y, 2008, J IMMUNOL, V180, P541, DOI 10.4049/jimmunol.180.1.541; Shirasaki H, 2009, ANN ALLERG ASTHMA IM, V102, P110, DOI 10.1016/S1081-1206(10)60239-6; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Spergel JM, 1999, J CLIN INVEST, V103, P1103, DOI 10.1172/JCI5669; Spik I, 2005, J IMMUNOL, V174, P3703, DOI 10.4049/jimmunol.174.6.3703; Sugimoto M, 2007, PROSTAG LEUKOTR ESS, V76, P93, DOI 10.1016/j.plefa.2006.11.007; Tanaka K, 2004, BIOCHEM BIOPH RES CO, V316, P1009, DOI 10.1016/j.bbrc.2004.02.151; Uller L, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-16; Vinall SL, 2007, IMMUNOLOGY, V121, P577, DOI 10.1111/j.1365-2567.2007.02606.x; Wang JH, 2009, MOL BIOL REP, V36, P1549, DOI 10.1007/s11033-008-9349-6; Xue LZ, 2009, J IMMUNOL, V182, P7580, DOI 10.4049/jimmunol.0804090; Xue LZ, 2005, J IMMUNOL, V175, P6531, DOI 10.4049/jimmunol.175.10.6531; Yahara H, 2010, J EUR ACAD DERMATOL, V24, P75, DOI 10.1111/j.1468-3083.2009.03267.x; Yawalkar N, 1999, J INVEST DERMATOL, V113, P43, DOI 10.1046/j.1523-1747.1999.00619.x; Zheng XY, 2003, J DERMATOL, V30, P26	40	37	37	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2010	126	4					784	790		10.1016/j.jaci.2010.07.006	http://dx.doi.org/10.1016/j.jaci.2010.07.006			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	658SP	20713302	Green Accepted			2022-12-18	WOS:000282510000016
J	Dratva, J; Schindler, C; Curjuric, I; Stolz, D; Macsali, F; Gomez, FR; Zemp, E				Dratva, Julia; Schindler, Christian; Curjuric, Ivan; Stolz, Daiana; Macsali, Ferenc; Gomez, Francisco Real; Zemp, Elisabeth		SAPALDIA Team	Perimenstrual increase in bronchial hyperreactivity in premenopausal women: Results from the population-based SAPALDIA 2 cohort	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; bronchial hyperreactivity; epidemiology; menstruation; methacholine challenge test; oral contraceptives; premenstrual	BODY-MASS INDEX; MENSTRUAL-CYCLE; PREMENSTRUAL ASTHMA; AIRWAY RESPONSIVENESS; EMERGENCY-DEPARTMENT; IMMUNE-RESPONSE; LUNG-DISEASES; SEX-HORMONES; NITRIC-OXIDE; METHACHOLINE	Background: Studies on perimenstrual asthma are inconsistent, and different methodologies limit comparisons. Objective: To investigate cyclic variations in bronchial hyperreactivity (BHR) to methacholine in premenopausal women in a population-based cohort and assess effect modification by oral contraceptives (OCs). Methods: Day of menstruation cycle at the time of methacholine challenge was calculated in 571 menstruating women without hormonal treatment, age 28 to 58 years, on the basis of questionnaire data from the Swiss cohort study on Air Pollution And Lung Disease In Adults (SAPALDIA) cohort 2001/2002. A window of risk was defined 3 days before and after the first day of menstruation. Logistic and linear regression analyses were performed adjusting for main predictors of BHR and stratifying for asthma status. The impact of OCs was studied in the same sample enlarged by 130 women taking OCs. Results: The prevalence of BHR was 13% (fall of >= 20% in FEV1 up to a maximal cumulative dose of 2 mg), and 6% had asthma. A total of 143 women had undergone methacholine challenge within the risk window. We observed a significant increase in BHR within the window of risk (odds ratio [OR], 2.3; 95% CI, 1.27-4.29). A cyclic association pattern was confirmed by trigonometric functions. Effect modification by asthma status and oral contraceptive use was found, with lower OR in subjects without asthma and OR <1 in women using OCs. Conclusion: The data provide evidence of a systematic variation in BHR during the menstruation cycle, supporting the hypothesis of a hormonal influence. OCs appear to have a protective effect. Cyclicity of BHR could be of clinical importance in view of future medication recommendations and timing of respiratory function tests in women. (J Allergy Clin Immunol 2010;125:823-9.)	[Dratva, Julia; Schindler, Christian; Curjuric, Ivan; Zemp, Elisabeth] Swiss Trop Inst, Inst Social & Prevent Med, CH-4051 Basel, Switzerland; [Stolz, Daiana] Univ Basel Hosp, Clin Pulm Med & Resp Cell Res, CH-4031 Basel, Switzerland; [Macsali, Ferenc; Gomez, Francisco Real] Haukeland Hosp, Dept Gynecol & Obstet, N-5021 Bergen, Norway	University of Basel; Swiss Tropical & Public Health Institute; University of Basel; University of Bergen; Haukeland University Hospital	Dratva, J (corresponding author), Swiss Trop Inst, Inst Social & Prevent Med, Steinengraben 49, CH-4051 Basel, Switzerland.	julia.dratva@unibas.ch	Schindler, Christian/D-3472-2015	Stolz, Daiana/0000-0003-0099-882X; Gomez Real, Francisco/0000-0001-5407-3270	Swiss National Science Foundation [4026-28099, 3347CO-108796, 3247BO-104283, 3247BO-104288, 3247BO-104284, 32-65896.01, 32-59302.99, 32-52720.97, 32-4253.94]; Federal Office for Forest, Environment and Landscape; Federal Office of Public Health; Federal Office of Roads and Transport; Cantonal Governments of Aargau, Basel-Stadt, Basel-Landschaft, Geneva, Lucerne, Ticino, and Zurich; Swiss Lung League; Cantonal Lung Leagues of Basel Stadt/Basel Landschaft, Geneva, Ticino, and Zurich	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Federal Office for Forest, Environment and Landscape; Federal Office of Public Health; Federal Office of Roads and Transport; Cantonal Governments of Aargau, Basel-Stadt, Basel-Landschaft, Geneva, Lucerne, Ticino, and Zurich; Swiss Lung League; Cantonal Lung Leagues of Basel Stadt/Basel Landschaft, Geneva, Ticino, and Zurich	SAPALDIA is supported by the Swiss National Science Foundation (grant nos. 402628099, 3347CO-108796, 3247BO-104283, 3247BO-104288, 3247BO-104284, 32-65896.01, 32-59302.99, 32-52720.97, and 32-4253.94); the Federal Office for Forest, Environment and Landscape; the Federal Office of Public Health; the Federal Office of Roads and Transport: the Cantonal Governments of Aargau, Basel-Stadt, Basel-Landschaft, Geneva, Lucerne, Ticino, and Zurich; the Swiss Lung League; and the Cantonal Lung Leagues of Basel Stadt/Basel Landschaft, Geneva, Ticino, and Zurich.	Ackermann-Liebrich U, 2005, SOZ PRAVENTIV MED, V50, P245, DOI 10.1007/s00038-005-4075-5; Agarwal AK, 1997, J ASTHMA, V34, P539, DOI 10.3109/02770909709055398; Almqvist C, 2008, ALLERGY, V63, P47, DOI 10.1111/j.1398-9995.2007.01524.x; Balzano G, 2001, ALLERGY, V56, P13, DOI 10.1034/j.1398-9995.2001.00128.x; Bouman A, 2005, HUM REPROD UPDATE, V11, P411, DOI 10.1093/humupd/dmi008; Bouman A, 2001, FERTIL STERIL, V76, P555, DOI 10.1016/S0015-0282(01)01971-9; Brenner BE, 2005, THORAX, V60, P806, DOI 10.1136/thx.2004.033928; Cameron IT, 1998, HUM REPROD UPDATE, V4, P565, DOI 10.1093/humupd/4.5.565; Chandler MHH, 1997, PHARMACOTHERAPY, V17, P224; Chwalisz K, 2000, HUM REPROD, V15, P96, DOI 10.1093/humrep/15.suppl_3.96; Critchley HOD, 2001, CLIN ENDOCRINOL, V55, P701, DOI 10.1046/j.1365-2265.2001.01432.x; Derimanov GS, 1998, ANN ALLERG ASTHMA IM, V81, P243, DOI 10.1016/S1081-1206(10)62820-7; Ensom MHH, 2003, PHARMACOTHERAPY, V23, P561, DOI 10.1592/phco.23.5.561.32201; Ensom MHH, 2003, ANN PHARMACOTHER, V37, P1610, DOI 10.1345/aph.1D090; Forbes L, 1999, EUR RESPIR J, V14, P1028, DOI 10.1183/09031936.99.14510289; GIBBS CJ, 1984, THORAX, V39, P833, DOI 10.1136/thx.39.11.833; Gluck JC, 2006, IMMUNOL ALLERGY CLIN, V26, P63, DOI 10.1016/j.iac.2005.10.008; Hanania Nicola A, 2005, Crit Care Med, V33, pS319, DOI 10.1097/01.CCM.0000182789.14710.A1; HANLEY SP, 1981, BRIT J DIS CHEST, V75, P306, DOI 10.1016/0007-0971(81)90010-3; Jarvis D, 2002, EUR RESPIR J, V20, P1071, DOI 10.1183/09031936.02.00046802; Jayet PY, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-131; JUNIPER EF, 1987, AM REV RESPIR DIS, V135, P1039; Kunzli N, 2005, SWISS MED WKLY, V135, P503; de Oliveira APL, 2007, AM J PHYSIOL-CELL PH, V293, pC1120, DOI 10.1152/ajpcell.00286.2006; Macsali F, 2009, J ALLERGY CLIN IMMUN, V123, P391, DOI 10.1016/j.jaci.2008.10.041; Martin BW, 1997, SOZ PRAVENTIV MED, V42, P67, DOI 10.1007/BF01318136; MASCALI F, 2009, ERS C EUR RESP SOC V; Murphy VE, 2008, J ASTHMA, V45, P696, DOI 10.1080/02770900802207279; Murphy VE, 2005, EUR RESPIR J, V25, P731, DOI 10.1183/09031936.05.00085704; O'Byrne PM, 2009, CLIN EXP ALLERGY, V39, P181, DOI 10.1111/j.1365-2222.2008.03172.x; OCONNOR G, 1987, AM REV RESPIR DIS, V136, P1412, DOI 10.1164/ajrccm/136.6.1412; Oguzulgen IK, 2002, J ASTHMA, V39, P517, DOI 10.1081/JAS-120004921; PAULI BD, 1989, AM REV RESPIR DIS, V140, P358, DOI 10.1164/ajrccm/140.2.358; Salam MT, 2006, J ALLERGY CLIN IMMUN, V117, P1001, DOI 10.1016/j.jaci.2006.02.004; Shames RS, 1998, ANN ALLERG ASTHMA IM, V81, P65, DOI 10.1016/S1081-1206(10)63111-0; Skobeloff EM, 1996, ARCH INTERN MED, V156, P1837, DOI 10.1001/archinte.156.16.1837; Soules M R, 2001, Menopause, V8, P402, DOI 10.1097/00042192-200111000-00004; Suzuki Kazuo, 2007, Allergol Int, V56, P249, DOI 10.2332/allergolint.O-06-475; Tan KS, 1997, AM J RESP CRIT CARE, V155, P1273, DOI 10.1164/ajrccm.155.4.9105066; Tan KS, 1997, THORAX, V52, P608, DOI 10.1136/thx.52.7.608; Tan KS, 1997, CHEST, V111, P847, DOI 10.1378/chest.111.4.847; Tantisira KG, 2008, AM J RESP CRIT CARE, V178, P325, DOI 10.1164/rccm.200708-1174OC; TROISI RJ, 1995, AM J RESP CRIT CARE, V152, P1183, DOI 10.1164/ajrccm.152.4.7551368; Varraso R, 2005, AM J RESP CRIT CARE, V171, P334, DOI 10.1164/rccm.200405-674OC; Vrieze A, 2003, J ALLERGY CLIN IMMUN, V112, P271, DOI 10.1067/mai.2003.1676; WEINMANN GG, 1987, J ALLERGY CLIN IMMUN, V79, P634, DOI 10.1016/S0091-6749(87)80160-4; Zimmerman JL, 2000, AM J RESP CRIT CARE, V162, P512, DOI 10.1164/ajrccm.162.2.9910105	47	37	37	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2010	125	4					823	829		10.1016/j.jaci.2009.12.938	http://dx.doi.org/10.1016/j.jaci.2009.12.938			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	584XP	20227756				2022-12-18	WOS:000276787900006
J	Szefler, SJ; Gergen, PJ; Mitchell, H; Morgan, W				Szefler, Stanley J.; Gergen, Peter J.; Mitchell, Herman; Morgan, Wayne			Achieving asthma control in the inner city: Do the National Institutes of Health Asthma Guidelines really work?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Asthma; childhood asthma; inner-city asthma; exhaled nitric oxide; asthma guidelines	URBAN CHILDREN; MANAGEMENT; DISEASE; DISPARITIES; ADHERENCE; MORBIDITY; BELIEFS; ADULTS; TRIAL; CARE	For children living in inner cities, asthma tends to be more frequent and severe. To characterize, understand, and treat children with asthma living in the inner city more effectively, the National Institute of Allergy and Infectious Diseases established an Inner-City Asthma Program in 1991. In addition, the revised National Asthma Education and Prevention Program Expert Panel 3 report was introduced with new concepts for asthma management that are now centered on asthma control. The purpose of this review is to highlight features of the National Institute of Allergy and Infectious Diseases Inner-City Asthma Consortium Asthma Control Evaluation study that enhance our knowledge regarding the application of the asthma guidelines and to provide a summary of lessons learned from that important study. We recognized that asthma symptoms and exacerbations are theoretically linked to underlying inflammation of airways but are not direct indicators of inflammation. Based on the observations from the Asthma Control Evaluation study, we were impressed that a systematic guidelines-based approach improved asthma control significantly over the course of the 1-year treatment period. (J Allergy Clin Immunol 2010;125:521-6.)	[Szefler, Stanley J.] Natl Jewish Hlth, Div Pediat Clin Pharmacol, Dept Pediat, Denver, CO 80206 USA; [Szefler, Stanley J.] Natl Jewish Hlth, Div Allergy & Immunol, Dept Pediat, Denver, CO 80206 USA; [Szefler, Stanley J.] Univ Colorado, Denver Sch Med, Boulder, CO 80309 USA; [Gergen, Peter J.] NIAID, NIH, Bethesda, MD 20892 USA; [Mitchell, Herman] Rho Inc, Chapel Hill, NC USA; [Morgan, Wayne] Univ Arizona, Coll Med, Dept Pediat, Tucson, AZ 85721 USA	National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Rho; University of Arizona	Szefler, SJ (corresponding author), Natl Jewish Hlth, Div Pediat Clin Pharmacol, Dept Pediat, 1400 Jackson St,Room J304 Molly Blank Bldg, Denver, CO 80206 USA.	szeflers@njhealth.org			NIH/NHLBI Childhood Management Program (CAMP); NHLBI Childhood Asthma Research and Education (CARE); NIH/NHLBI Asthma Clin Res Network (ACRN); NIH/NIAID Inner City Asthma Consortium (ICAC); GlaxoSmithKline; NJH.NHLBI Asthma Net; NEEHS/EPA Childhood Environmental Health Center; NIH/NIAID; NIH/University of Wisconsin and Novartis; Public Health Services [HR-16048, HL64288, HL 51834, AI-25496, HL081335, HL075416]; National Institutes of Health and National Center for Research Resources [1 UL1 RR025780]; Colorado Cancer, Cardiovascular, and Pulmonary Disease Program; DIVISION OF LUNG DISEASES [N01HR016048] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025780] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL081335, U10HL064288, U10HL051834, U01HL075416] Funding Source: NIH RePORTER	NIH/NHLBI Childhood Management Program (CAMP)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI Childhood Asthma Research and Education (CARE)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH/NHLBI Asthma Clin Res Network (ACRN)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH/NIAID Inner City Asthma Consortium (ICAC)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); GlaxoSmithKline(GlaxoSmithKline); NJH.NHLBI Asthma Net(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NEEHS/EPA Childhood Environmental Health Center; NIH/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH/University of Wisconsin and Novartis(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Public Health Services(United States Department of Health & Human ServicesUnited States Public Health Service); National Institutes of Health and National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Colorado Cancer, Cardiovascular, and Pulmonary Disease Program; DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Companies/Organizations: S. J. Szefler is a consultant for GlaxoSmithKline, Genentech, Merck, Boehringer-Ingelheim, Novartis, Schering Plough; and has received research support from the NIH/NHLBI Childhood Management Program (CAMP), NHLBI Childhood Asthma Research and Education (CARE), NIH/NHLBI Asthma Clin Res Network (ACRN), NIH/NIAID Inner City Asthma Consortium (ICAC), GlaxoSmithKline, NJH.NHLBI Asthma Net, and NEEHS/EPA Childhood Environmental Health Center grant. P. J. Gergen declares he has no conflicts of interest. H. Mitchell has received research support from the NIH/NIAID. W. Morgan is a consultant, and is Chair for the Data Safety Monitoring Board for the Cystic Fibrosis Foundation; is a consultant and is Chair for the North American Scientific Advisory Group for the Epidemiologic Study of Cystic Fibrosis for Genentech; is a consultant for Novartis; and has received research support from the NIH/University of Wisconsin and Novartis.; Supported in part by Public Health Services research grants HR-16048, HL64288, HL 51834, AI-25496, HL081335, and HL075416; the Colorado CTSA grant 1 UL1 RR025780 from the National Institutes of Health and National Center for Research Resources; and the Colorado Cancer, Cardiovascular, and Pulmonary Disease Program.	Akinbami LJ, 2009, PEDIATRICS, V123, pS131, DOI 10.1542/peds.2008-2233C; [Anonymous], 2007, J ALLERGY CLIN IMM S, V120, pS94; Bruzzese JM, 2009, J ALLERGY CLIN IMMUN, V124, P195, DOI 10.1016/j.jaci.2009.05.040; Bryant-Stephens T, 2009, J ALLERGY CLIN IMMUN, V123, P1199, DOI 10.1016/j.jaci.2009.04.030; Busse WW, 2007, J ALLERGY CLIN IMMUN, V119, P43, DOI 10.1016/j.jaci.2006.10.021; Canino G, 2009, J ALLERGY CLIN IMMUN, V123, P1209, DOI 10.1016/j.jaci.2009.02.043; Cicutto L, 2009, J ALLERGY CLIN IMMUN, V124, P390, DOI 10.1016/j.jaci.2009.04.042; Cloutier MM, 2005, J PEDIATR-US, V146, P591, DOI 10.1016/j.jpeds.2004.12.017; *CO GUID COLL, ASTHM; Conn KM, 2005, AMBUL PEDIATR, V5, P306, DOI 10.1367/A05-004R1.1; Evans R, 1999, J PEDIATR-US, V135, P332, DOI 10.1016/S0022-3476(99)70130-7; EVANS R, 1987, CHEST S, V91, P65; Frey U, 2008, LANCET, V372, P1088, DOI 10.1016/S0140-6736(08)61450-6; GERGEN PJ, 1990, JAMA-J AM MED ASSOC, V264, P1688, DOI 10.1001/jama.264.13.1688; Halm EA, 2006, CHEST, V129, P573, DOI 10.1378/chest.129.3.573; Jones CA, 2007, J ALLERGY CLIN IMMUN, V119, P1445, DOI 10.1016/j.jaci.2007.02.031; Kattan M, 2007, J ALLERGY CLIN IMMUN, V120, P618, DOI 10.1016/j.jaci.2007.05.014; Mansour ME, 2000, PEDIATRICS, V106, P512, DOI 10.1542/peds.106.3.512; McIvor RA, 2008, LANCET, V372, P1021, DOI 10.1016/S0140-6736(08)61423-3; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; *NIH NAT ASTHM ED, NIH PUBL; Ponieman D, 2009, ANN ALLERG ASTHMA IM, V103, P38, DOI 10.1016/S1081-1206(10)60141-X; Riekert KA, 2003, PEDIATRICS, V111, DOI 10.1542/peds.111.3.e214; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Szefler S, 2008, LANCET, V372, P1065, DOI 10.1016/S0140-6736(08)61448-8; Szefler SJ, 2007, J ALLERGY CLIN IMMUN, V119, P24, DOI 10.1016/j.jaci.2006.10.036; COLORADO IMPROVING P	27	37	37	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2010	125	3					521	526		10.1016/j.jaci.2010.01.025	http://dx.doi.org/10.1016/j.jaci.2010.01.025			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	573BK	20226288				2022-12-18	WOS:000275883200003
J	O'Byrne, PM; van der Linde, J; Cockcroft, DW; Gauvreau, GM; Brannan, JD; FitzGerald, M; Watson, RM; Milot, J; Davis, B; O'Connor, M; Hart, L; Korducki, L; Hamilton, AL; Boulet, LP				O'Byrne, Paul M.; van der Linde, Just; Cockcroft, Donald W.; Gauvreau, Gail M.; Brannan, John D.; FitzGerald, Mark; Watson, Richard M.; Milot, Joanne; Davis, Beth; O'Connor, Megan; Hart, Lorna; Korducki, Lawrence; Hamilton, Alan L.; Boulet, Louis-Philippe			Prolonged bronchoprotection against inhaled methacholine by inhaled BI 1744, a long-acting beta(2)-agonist, in patients with mild asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; long-acting inhaled beta(2)-agonists; methacholine; functional antagonists; bronchodilators	EXERCISE-INDUCED ASTHMA; AIRWAY RESPONSIVENESS; LUNG-FUNCTION; SALMETEROL; FORMOTEROL; HISTAMINE; TACHYPHYLAXIS; SALBUTAMOL; PROTECTION; TOLERANCE	Background: Long-acting beta(2)-agonists are an established controller medication in asthma. BI 1744 is a novel L/long-acting beta(2)-agonist with a preclinical profile that suggests 24-hour bronchodilation and bronchoprotection may be achieved. Objective: To examine the bronchoprotective effects of single doses of BI 1744 against methacholine provocation in subjects with mild asthma. Methods: Thirty-one subjects with mild asthma were randomized to receive single doses of BI 1744 (2, 5, 10, 20 mu g) or placebo on separate days according to a double-blind, 5-way crossover design. Methacholine challenges were performed at 30 minutes and at 4, 8, 24, and 32 hours after each single dose of medication, and the results were expressed as PC20 FEV1. Results: All doses of BI 1744 produced statistically significant increases in the methacholine PC20 compared with placebo as long as 32 hours. The mean (geometric SEM) methacholine PC20 24 hours after dosing with placebo was 1.73 (1.13) mg/mL, which increased after 2 mu g to 3.86 (1.14) mg/mL, after 5 mu g to 5.67 (1.14) mg/mL, after 10 mu g to 9.42 (1.13) mg/mL, and after 20 mu g to 13.71 (1.14) mg/mL (all P < .0001). After 32 hours, the methacholine PC20 value remained significantly increased for all doses. No safety or tolerability concerns were identified. Conclusion: BI 1744 provides significant bronchoprotection against inhaled methacholine for up to 32 hours after single-dose administration. (J Allergy Clin Immunol 2009;124:1217-21.)	[O'Byrne, Paul M.] McMaster Univ, Med Ctr, Dept Med, Hamilton, ON L8N 3Z5, Canada; [Milot, Joanne; Boulet, Louis-Philippe] Univ Laval, Quebec City, PQ, Canada; [Cockcroft, Donald W.; Davis, Beth] Univ Saskatoon, Saskatoon, SK, Canada; [FitzGerald, Mark] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Hart, Lorna; Korducki, Lawrence; Hamilton, Alan L.] Boehringer Ingelheim Inc, Burlington, ON, Canada	McMaster University; Laval University; University of Saskatchewan; University of British Columbia; Boehringer Ingelheim	O'Byrne, PM (corresponding author), McMaster Univ, Med Ctr, Dept Med, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	obyrnep@mcmaster.ca		O'Byrne, Paul/0000-0003-0979-281X; Brannan, John/0000-0001-7243-7998	AllerGen Network of Centers or Excellence Clinical Investigator Collaborative; Boehringer Ingelheim Inc.; Michael Smith Foundation	AllerGen Network of Centers or Excellence Clinical Investigator Collaborative; Boehringer Ingelheim Inc.(Boehringer Ingelheim); Michael Smith Foundation(Michael Smith Foundation for Health Research)	Supported as part of the AllerGen Network of Centers or Excellence Clinical Investigator Collaborative and by Boehringer Ingelheim Inc.; M.F. is a BC Lung CIHR/Scientist and a Michael Smith Foundation for Health Research Distinguished Scholar.	AHRENS RC, 1987, J ALLERGY CLIN IMMUN, V79, P876, DOI 10.1016/0091-6749(87)90235-1; American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; ANDERSON GP, 1993, LIFE SCI, V52, P2145, DOI 10.1016/0024-3205(93)90729-M; ANDERSON SD, 1993, EUR RESPIR J, V6, P1090; BALL DI, 1991, BRIT J PHARMACOL, V104, P665, DOI 10.1111/j.1476-5381.1991.tb12486.x; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Bhagat R, 1996, J ALLERGY CLIN IMMUN, V97, P47, DOI 10.1016/S0091-6749(96)70282-8; BHAGAT R, 1995, CHEST, V108, P1235, DOI 10.1378/chest.108.5.1235; Celli BR, 2008, AM J RESP CRIT CARE, V178, P332, DOI 10.1164/rccm.200712-1869OC; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; DEROM EY, 1992, J ALLERGY CLIN IMMUN, V89, P811, DOI 10.1016/0091-6749(92)90435-5; DEVRIES K, 1962, INT ARCH ALLER A IMM, V20, P93, DOI 10.1159/000229248; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; Inman MD, 1998, J ALLERGY CLIN IMMUN, V101, P342, DOI 10.1016/S0091-6749(98)70246-5; Lipworth B, 1998, AM J MED, V104, P431, DOI 10.1016/S0002-9343(98)00086-2; LIPWORTH BJ, 1989, AM REV RESPIR DIS, V140, P586, DOI 10.1164/ajrccm/140.3.586; MANNING PJ, 1987, J APPL PHYSIOL, V63, P1572, DOI 10.1152/jappl.1987.63.4.1572; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; Newman SP, 1998, CHEST, V113, P957, DOI 10.1378/chest.113.4.957; O'Byrne PM, 2005, AM J RESP CRIT CARE, V171, P129, DOI 10.1164/rccm.200407-884OC; OBYRNE PM, 1982, THORAX, V37, P913, DOI 10.1136/thx.37.12.913; ORGEL HA, 1985, J ALLERGY CLIN IMMUN, V75, P55, DOI 10.1016/0091-6749(85)90012-0; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; RABE KF, 1993, AM REV RESPIR DIS, V147, P1436, DOI 10.1164/ajrccm/147.6_Pt_1.1436; RAMSDALE EH, 1991, AM REV RESPIR DIS, V143, P998, DOI 10.1164/ajrccm/143.5_Pt_1.998; Simons FER, 1997, PEDIATRICS, V99, P655, DOI 10.1542/peds.99.5.655; STEVENS WH, 1990, J APPL PHYSIOL, V69, P875, DOI 10.1152/jappl.1990.69.3.875	28	37	37	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2009	124	6					1217	1221		10.1016/j.jaci.2009.08.047	http://dx.doi.org/10.1016/j.jaci.2009.08.047			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	536VH	20004781				2022-12-18	WOS:000273071500012
J	Patel, NC; Chinen, J; Rosenblatt, HM; Hanson, IC; Krance, RA; Paul, ME; Abramson, SL; Noroski, LM; Davis, CM; Seeborg, FO; Foster, SB; Leung, KS; Brown, BS; Ritz, J; Shearer, WT				Patel, Niraj C.; Chinen, Javier; Rosenblatt, Howard M.; Hanson, I. Celine; Krance, Robert A.; Paul, Mary E.; Abramson, Stuart L.; Noroski, Lenora M.; Davis, Carla M.; Seeborg, Filiz O.; Foster, Samuel B.; Leung, Kathryn S.; Brown, Betty S.; Ritz, Jerome; Shearer, William T.			Outcomes of patients with severe combined immunodeficiency treated with hematopoietic stem cell transplantation with and without preconditioning	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hematopoietic stem cell transplantation; graft-versus-host disease; severe combined immunodeficiency; immune reconstitution; primary immunodeficiency; conditioning	BONE-MARROW-TRANSPLANTATION; IMMUNE RECONSTITUTION; SINGLE-CENTER; DEFICIENCY; BMT	Background: The effect of pretransplantation conditioning on the long-term outcomes of patients receiving hematopoietic stem cell transplantation for severe combined immunodeficiency (SCID) has not been completely determined. Objective: We sought to assess the outcomes of 23 mostly conditioned patients with SCID and compare their outcomes with those of 25 previously reported nonconditioned patients with SCID who underwent transplantation. Methods: In the present study we reviewed the medical records of these 23 consecutive, mostly conditioned patients with SCID who underwent transplantation between 1998 and 2007. Results: Eighteen patients (median age at transplantation, 10 months; range, 0.8-108 months) received haploidentical mismatched related donor, matched unrelated donor, or mismatched unrelated donor transplants, 17 of whom received pretransplantation conditioning (with I not conditioned); 13 (72%) patients engrafted with donor cells and survive at a median of 3.8 years (range, 1.8-9.8 year); 5 (38%) of 13 patients require intravenous immunoglobulin; and 6 of 6 age-eligible children attend school. Of 5 recipients (median age at transplantation, 7 months; range, 2-23 months) of matched related donor transplants, all 5 engrafted and survive at a median of 7.5 years (range, 1.5-9.5 year), I recipient requires intravenous immunoglobulin, and 3 of 3 age-eligible children attend school. Gene mutations were known in 16 cases: mutation in the common gamma chain of the IL-2 receptor (IL2RG) in 7 patients, mutation in the alpha chain of the IL-7 receptor (IL7RA) in 4 patients, mutation in the recombinase-activating gene (RAG1) in 2 patients, adenosine deaminase deficiency (ADA) in 2 patients, and adenylate kinase 2 (AK2) in I patient. Early outcomes and quality of life of the previous nonconditioned versus the present conditioned cohorts were not statistically different, but longer-term follow-up is necessary for confirmation. Conclusions: Hematopoietic stem cell transplantation in patients with SCED results in engraftment, long-term survival, and a good quality of life for the majority of patients with or without pretransplantation conditioning. (J Allergy Clin Immunol 2009;124:1062-9.)	[Patel, Niraj C.; Chinen, Javier; Hanson, I. Celine; Paul, Mary E.; Abramson, Stuart L.; Noroski, Lenora M.; Davis, Carla M.; Seeborg, Filiz O.; Foster, Samuel B.; Brown, Betty S.; Shearer, William T.] Texas Childrens Hosp, Dept Pediat, Sect Allergy & Immunol, Baylor Coll Med, Houston, TX 77039 USA; [Rosenblatt, Howard M.] Dell Childrens Med Ctr Cent Texas, Austin, TX USA; [Krance, Robert A.; Leung, Kathryn S.] Texas Childrens Hosp, Sect Hematol & Oncol, Baylor Coll Med, Houston, TX 77039 USA; [Ritz, Jerome] Harvard Univ, Sch Med, Div Hematol Malignancies, Boston, MA USA; [Ritz, Jerome] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Ritz, Jerome] Harvard Univ, Sch Med, Harvard Stem Cell Inst, Boston, MA USA	Baylor College of Medicine; Baylor College of Medicine; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	Shearer, WT (corresponding author), Texas Childrens Hosp, Dept Pediat, Sect Allergy & Immunol, Baylor Coll Med, 6621 Fannin,FC 330-01, Houston, TX 77039 USA.	wtsheare@texaschildrenshospital.org	Paul, Mary/AAA-2722-2021	Shearer, William/0000-0002-2483-2130	Pfizer; Astella; Novartis; CSL Behring; Food Allergy and Anaphylaxis Network; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI069441] Funding Source: NIH RePORTER	Pfizer(Pfizer); Astella; Novartis(Novartis); CSL Behring; Food Allergy and Anaphylaxis Network; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	R. A. Krance has received research support from Pfizer and Astella. S. L. Abramson has received research support from Novartis and CSL Behring. C. M. Davis has received research support from the Food Allergy and Anaphylaxis Network.	Antoine C, 2003, LANCET, V361, P553, DOI 10.1016/S0140-6736(03)12513-5; Bertrand Y, 1999, J PEDIATR-US, V134, P740, DOI 10.1016/S0022-3476(99)70291-X; BREARD J, 1980, J IMMUNOL, V124, P1943; Buckley RH, 1999, NEW ENGL J MED, V340, P508, DOI 10.1056/NEJM199902183400703; Buckley RH, 2004, ANNU REV IMMUNOL, V22, P625, DOI 10.1146/annurev.immunol.22.012703.104614; BUCKLEY RH, 1986, J IMMUNOL, V136, P2398; Dickinson AM, 1997, BONE MARROW TRANSPL, V19, P323, DOI 10.1038/sj.bmt.1700669; Fischer A, 2005, IMMUNOL REV, V203, P98, DOI 10.1111/j.0105-2896.2005.00223.x; Grunebaum E, 2006, JAMA-J AM MED ASSOC, V295, P508, DOI 10.1001/jama.295.5.508; Haddad E, 1999, BLOOD, V94, P2923, DOI 10.1182/blood.V94.8.2923.420k44_2923_2930; Keever-Taylor CA, 2001, BIOL BLOOD MARROW TR, V7, P620, DOI 10.1053/bbmt.2001.v7.pm11760150; Mazzolari E, 2007, J ALLERGY CLIN IMMUN, V120, P892, DOI 10.1016/j.jaci.2007.08.007; Neven B, 2009, BLOOD, V113, P4114, DOI 10.1182/blood-2008-09-177923; Patel NC, 2008, J ALLERGY CLIN IMMUN, V122, P1185, DOI 10.1016/j.jaci.2008.10.030; RAILEY MD, J PEDIAT IN PRESS; Sarzotti-Kelsoe M, 2009, BLOOD, V114, P1445, DOI 10.1182/blood-2009-01-199323; Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003	17	37	39	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2009	124	5					1062	1069		10.1016/j.jaci.2009.08.041	http://dx.doi.org/10.1016/j.jaci.2009.08.041			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	523XI	19895994	Green Accepted			2022-12-18	WOS:000272108000029
J	Ohgiya, Y; Arakawa, F; Akiyama, H; Yoshioka, Y; Hayashi, Y; Sakai, S; Ito, S; Yamakawa, Y; Ohgiya, S; Ikezawa, Z; Teshima, R				Ohgiya, Yoko; Arakawa, Fumihiro; Akiyama, Hiroshi; Yoshioka, Yasuo; Hayashi, Yoshiki; Sakai, Shinobu; Ito, Sumio; Yamakawa, Yuko; Ohgiya, Satoru; Ikezawa, Zenro; Teshima, Reiko			Molecular cloning, expression, and characterization of a major 38-kd cochineal allergen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cochineal; allergen; cDNA; IgE; food allergy; carmine; immunoblotting; cloning; recombinant	OCCUPATIONAL ASTHMA; INHALED CARMINE; ANAPHYLAXIS; RESPONSES; IDENTIFICATION; INGESTION; DYE	Background: Carmine is a natural red pigment obtained from dried gravid female cochineal insects (Dactylopius coccus or Coccus cacti). There have been several reports of allergies to carmine, but the major allergens responsible have not been identified. Objective: To identify the major allergenic proteins in cochineal. Methods: Immunoblots of purified cochineal extract were probed with sera from 3 patients with allergy. Partial amino acid sequences were determined for the proteins bound by IgE, and the corresponding cDNA, containing a complete coding region, was cloned by 5' and 3' rapid cDNA extension and PCR. The recombinant protein was expressed in yeast and subjected to immunoblotting. Results: We identified a full-length cDNA encoding a protein, which we named CC38K, with 335 amino acids and a molecular mass calculated as 38 kd. This amino acid sequence included all the partial amino acid sequences obtained from the purified proteins identified by IgE from patients with allergy. Recombinant CC38K protein was recognized by patients' sera, indicating that this is a major allergen present in carmine. The CC38K sequence showed homology to phospholipases. Conclusion: We have, for the first time, identified the major allergen in cochineal extract. This protein may be a phospholipase or related enzyme, both of which are known to be allergens in other insects. (J Allergy Clin Immunol 2009; 123:1157-62.)	[Akiyama, Hiroshi] Natl Inst Hlth Sci, Div Novel Foods & Immunochem, Setagaya Ku, Tokyo 1588501, Japan; [Ohgiya, Yoko] Sapporo City Inst Publ Hlth, Sapporo, Hokkaido 0038505, Japan; [Arakawa, Fumihiro; Ito, Sumio] San Ei Gen FFI Inc, Osaka, Japan; [Yamakawa, Yuko; Ikezawa, Zenro] Yokohama City Univ, Grad Sch Med, Dept Environm Immunodermatol, Yokohama, Kanagawa 232, Japan; [Ohgiya, Satoru] Natl Inst Adv Ind Sci & Technol, Res Inst Genome Based Biofactory, Sapporo, Hokkaido, Japan; [Ohgiya, Satoru] Hokkaido Univ, Grad Sch Sci, Sapporo, Hokkaido, Japan	National Institute of Health Sciences - Japan; San-Ei Gen F.F.I., Inc.; Yokohama City University; National Institute of Advanced Industrial Science & Technology (AIST); Hokkaido University	Akiyama, H (corresponding author), Natl Inst Hlth Sci, Div Novel Foods & Immunochem, Setagaya Ku, 1-18-1 Kamiyoga, Tokyo 1588501, Japan.	akiyama@nihs.go.jp	Ohgiya, Satoru/V-3117-2018	Ohgiya, Satoru/0000-0001-8257-8284	Ministry of Health, Labor and Welfare of Japan; Japan Food Chemical Research Foundation; National Institute of Public Health, Wako, Japan	Ministry of Health, Labor and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Japan Food Chemical Research Foundation(Japan Food Chemical Research Foundation); National Institute of Public Health, Wako, Japan	Supported in part by grants from the Ministry of Health, Labor and Welfare of Japan and the Japan Food Chemical Research Foundation. Supported by a training program for building research capacity in the field of epidemiology and public health science in the National Institute of Public Health, Wako, Japan.	Acero S, 1998, ALLERGY, V53, P897, DOI 10.1111/j.1398-9995.1998.tb03998.x; ANGEL F, 2005, INT ARCH ALLERGY IMM, V138, P243; Anibarro Belen, 2003, Int J Occup Med Environ Health, V16, P133; Baldwin JL, 1997, ANN ALLERG ASTHMA IM, V79, P415, DOI 10.1016/S1081-1206(10)63035-9; BEAUDOUIN E, 1995, ANN ALLERG ASTHMA IM, V74, P427; Beer HD, 1998, BBA-GENE STRUCT EXPR, V1399, P173, DOI 10.1016/S0167-4781(98)00104-3; BURGE PS, 1979, CLIN ALLERGY, V9, P185, DOI 10.1111/j.1365-2222.1979.tb01540.x; Chung K, 2001, ALLERGY, V56, P73, DOI 10.1034/j.1398-9995.2001.00693.x; DiCello MC, 1999, ALLERGY ASTHMA PROC, V20, P377, DOI 10.2500/108854199778251816; DIETEMANNMOLARD A, 1991, LANCET, V338, P460, DOI 10.1016/0140-6736(91)91096-D; DURHAM SR, 1987, J ALLERGY CLIN IMMUN, V79, P398, DOI 10.1016/0091-6749(87)90161-8; *IPCS INCHEM JECFA, IPCS INCHEM JECFA MO, P996; KAGI MK, 1994, LANCET, V344, P60, DOI 10.1016/S0140-6736(94)91083-9; Kume A, 1999, ENV DERMATOL, V6, P148; LENZ D, 1983, Revue Francaise des Maladies Respiratoires, V11, P487; Lizaso MT, 2000, ANN ALLERG ASTHMA IM, V84, P549, DOI 10.1016/S1081-1206(10)62521-5; Park G R, 1981, J R Army Med Corps, V127, P85; QUIRCE S, 1994, J ALLERGY CLIN IMMUN, V93, P44, DOI 10.1016/0091-6749(94)90231-3; Sahara T, 2002, J BIOL CHEM, V277, P50015, DOI 10.1074/jbc.M209258200; SAHARA T, 2007, BIOSCI IND, V65, P130; SARKANY I, 1961, T ST JOHNS HOSP DERM, V48, P39; Shibata N, 2006, FEMS MICROBIOL LETT, V256, P137, DOI 10.1111/j.1574-6968.2006.00106.x; STUCKER W, 1996, ALLERGO J, V5, P143; TE PF, 2000, INT ARCH ALLERGY IMM, V123, P99; TENABENE A, 1987, Archives des Maladies Professionnelles de Medecine du Travail et de Securite Sociale, V48, P569; Wuthrich B, 1997, ALLERGY, V52, P1133, DOI 10.1111/j.1398-9995.1997.tb00189.x; YAMAKAWA Y, 2004, HOSP RES REP, V10, P39; 2006, FED REG, V71, P4839	28	37	38	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2009	123	5					1157	1162		10.1016/j.jaci.2008.12.1111	http://dx.doi.org/10.1016/j.jaci.2008.12.1111			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	449CW	19249084				2022-12-18	WOS:000266309400026
J	Kavadas, FD; Giliani, S; Gu, YP; Mazzolari, E; Bates, A; Pegoiani, E; Roifman, CM; Notarangelo, LD				Kavadas, Fotini D.; Giliani, Silvia; Gu, Yiping; Mazzolari, Evelina; Bates, Andrea; Pegoiani, Eleonora; Roifman, Chaim M.; Notarangelo, Luigi D.			Variability of clinical and laboratory features among patients with ribonuclease mitochondrial RNA processing endoribonuclease gene mutations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cartilage hair hypoplasia; RNase mitochondrial RNA processing endoribonuclease; severe combined immunodeficiency; Omenn syndrome; CD8 lymphopenia	CARTILAGE-HAIR-HYPOPLASIA; BONE-MARROW-TRANSPLANTATION; CELL-CYCLE PROGRESSION; RMRP MUTATIONS; IMMUNE-DEFICIENCY; JAPANESE PATIENTS; OMENN-SYNDROME; MANIFESTATIONS; COMPONENT; SPECTRUM	Background: Cartilage hair hypoplasia is an autosomal recessive type of metaphyseal chondrodysplasia, caused by mutations in the ribonuclease mitochondrial RNA processing (RMRP) gene. Typical features of cartilage hair hypoplasia include short stature, a predisposition to malignancy, and a variable degree of impairment of cellular immunity. Objective: We sought to describe the heterogeneity of clinical and immunologic phenotype in 12 consecutive patients with RMRP mutations who were referred to 2 different institutions for immunologic evaluation. Methods: We have retrospectively analyzed the clinical and laboratory features in 12 patients with molecular defects in the RMRP gene. T-cell repertoire was investigated by quantitating V beta families' expression and analyzing their diversity. T-cell receptor excision circle analysis was used to study thymic output. Results: All 12 patients had significant immune abnormalities, leading to severe immune deficiency in 9. CD8 lymphocytopenia was identified as a novel phenotype associated with RMRP mutations. Significant, even intrafamilial, phenotypic heterogeneity was observed. In 3 cases, severe immunodeficiency was the only phenotypic manifestation associated with RMRP mutations, a novel finding. Mutations leading to significant immune defects were most often located in the promoter, and the first case of a compound heterozygote for 2 such mutations is reported. Conclusion: This report broadens the spectrum of phenotypes associated with RMRP mutations and suggests that mutations in this gene should be considered when evaluating patients with combined immune deficiency, regardless of the presence of other manifestations. (J Allergy Clin Immunol 2008;122:1178-84.)	[Kavadas, Fotini D.; Gu, Yiping; Bates, Andrea; Roifman, Chaim M.] Univ Toronto, Hosp Sick Children, Div Immunol & Allergy, Toronto, ON M5S 1A1, Canada; [Giliani, Silvia; Mazzolari, Evelina; Pegoiani, Eleonora; Notarangelo, Luigi D.] Univ Brescia, Div Pediat Hematol Oncol, I-25121 Brescia, Italy; [Giliani, Silvia; Mazzolari, Evelina; Pegoiani, Eleonora; Notarangelo, Luigi D.] Hosp Sick Children, Angelo Nocivelli Inst Mol Med, Toronto, ON M5G 1X8, Canada; [Notarangelo, Luigi D.] Harvard Univ, Sch Med, Childrens Hosp Boston, Div Immunol, Cambridge, MA 02138 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Brescia; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Harvard University; Boston Children's Hospital	Roifman, CM (corresponding author), Hosp Sick Children, Div Allergy Immunol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	chaim.roifman@sickkids.ca; luigi.notarangelo@childrens.harvard.edu	Notarangelo, Luigi D/F-9718-2016; Giliani, Silvia/AAX-8843-2020	Notarangelo, Luigi D/0000-0002-8335-0262; Giliani, Silvia/0000-0001-8137-4642	Canadian Immunodeficiency Society; Canadian Centre for Primary Immunodeficiency; Donald and Audrey Campbell Chair of Immunology; "Angelo Nocivelli" Foundation; European Union [006411]	Canadian Immunodeficiency Society; Canadian Centre for Primary Immunodeficiency; Donald and Audrey Campbell Chair of Immunology; "Angelo Nocivelli" Foundation; European Union(European Commission)	Supported by the Canadian Immunodeficiency Society. the Canadian Centre for Primary Immunodeficiency, the Donald and Audrey Campbell Chair of Immunology, the "Angelo Nocivelli" Foundation, and the European Union, grant 006411 (EURO-POLICY-PID) to L-D.N.	ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; Berthet F, 1996, EUR J PEDIATR, V155, P286; Bonafe L, 2005, PLOS GENET, V1, P444, DOI 10.1371/journal.pgen.0010047; Bonafe L, 2002, CLIN GENET, V61, P146, DOI 10.1034/j.1399-0004.2002.610210.x; Cai T, 2002, GENETICS, V161, P1029; Gill T, 2004, MOL CELL BIOL, V24, P945, DOI 10.1128/MCB.24.3.945-953.2004; Guggenheim R, 2006, BONE MARROW TRANSPL, V38, P751, DOI 10.1038/sj.bmt.1705520; Hermanns P, 2005, HUM MOL GENET, V14, P3723, DOI 10.1093/hmg/ddi403; Hermanns P, 2006, AM J MED GENET A, V140A, P2121, DOI 10.1002/ajmg.a.31331; Hirose Y, 2006, J HUM GENET, V51, P706, DOI 10.1007/s10038-006-0015-3; Katamura K, 1999, CLIN EXP IMMUNOL, V115, P124; Kuijpers TW, 2003, J MED GENET, V40, P761, DOI 10.1136/jmg.40.10.761; Makitie O, 2000, J PEDIATR-US, V137, P487, DOI 10.1067/mpd.2000.108102; MAKITIE O, 1995, J MED GENET, V32, P39, DOI 10.1136/jmg.32.1.39; Makitie O, 1998, EUR J PEDIATR, V157, P816, DOI 10.1007/s004310050943; MAKITIE O, 1993, EUR J PEDIATR, V152, P211, DOI 10.1007/BF01956147; MAZZOLARI E, 2008, IMMUNOL RES     0701; MCKUSICK VA, 1965, B J HOPKINS HOSP, V116, P231; Munoz-Robles J, 2006, IMMUNOBIOLOGY, V211, P753, DOI 10.1016/j.imbio.2006.05.001; Nakashima E, 2003, AM J MED GENET A, V123A, P253, DOI 10.1002/ajmg.a.20281; Nakashima E, 2007, AM J MED GENET A, V143A, P2675, DOI 10.1002/ajmg.a.32053; Ridanpaa M, 2002, EUR J HUM GENET, V10, P439, DOI 10.1038/sj.ejhg.5200824; Ridanpaa M, 2001, CELL, V104, P195, DOI 10.1016/S0092-8674(01)00205-7; Roifman CM, 2006, J ALLERGY CLIN IMMUN, V117, P897, DOI 10.1016/j.jaci.2006.01.003; ROIFMAN CM, 1989, J EXP MED, V170, P2177, DOI 10.1084/jem.170.6.2177; Sharfe N, 1997, J CLIN INVEST, V100, P3036, DOI 10.1172/JCI119858; Signorini S, 1999, BLOOD, V94, P3468, DOI 10.1182/blood.V94.10.3468.422k34_3468_3478; SULISALO T, 1995, HUM GENET, V95, P157, DOI 10.1007/BF00209394; Thiel CT, 2007, AM J HUM GENET, V81, P519, DOI 10.1086/521034; Thiel CT, 2005, AM J HUM GENET, V77, P795, DOI 10.1086/497708; TURUL T, 2008, EUR J PEDIAT    0529	31	37	37	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2008	122	6					1178	1184		10.1016/j.jaci.2008.07.036	http://dx.doi.org/10.1016/j.jaci.2008.07.036			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	383ZA	18804272				2022-12-18	WOS:000261711800017
J	Abe, J; Ebata, R; Jibiki, T; Yasukawa, K; Saito, H; Terai, M				Abe, Jun; Ebata, Ryota; Jibiki, Toshiaki; Yasukawa, Kumi; Saito, Hirohisa; Terai, Masaru			Elevated granulocyte colony-stimulating factor levels predict treatment failure in patients with Kawasaki disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Kawasaki disease; vasculitis; neutrophil; PRV-I; G-CSF; microarray; inflammation; IVIG; biomarker	ENDOTHELIAL-CELLS; GAMMA-GLOBULIN; G-CSF; INVOLVEMENT; RELEASE	Background: Kawasaki disease (KD) is an acute vasculitis in young children, frequently associated with coronary artery aneurysms. The intravenous infusion of high-dose IgG (IVIG) effectively reduces the systemic inflammation and the incidence of coronary artery lesions, although the precise underlying mechanisms are unknown. Objective: We performed expression profiling of whole blood cells to investigate the mechanisms underlying the effect of IVIG and to identify biomarkers associated with unresponsiveness to IVIG. Methods: We compared the transcript abundance among pre-IVIG and post-IVIG patients and febrile control patients. Then we analyzed the mRNA levels and the protein levels among the different cohort of patients with KD who were either responsive or nonresponsive to the initial WIG. Results: A total of 298 transcripts were overrepresented or underrepresented in the pre-IVIG patients compared with post-IVIG patients and febrile controls, of which 15 transcripts were differentially expressed in nonresponsive patients with KD compared with responsive patients before IVIG. The protein levels of polycythemia rubra vera 1, which was one of the most variably expressed transcripts in pre-IVIG patients, and the serum granulocyte colony-stimulating factor levels were significantly higher in nonresponsive patients than in responsive patients before the initial IVIG administration. Conclusion: These findings suggest that the variable gene expression profiles were correlated to the responses of patients with KD to IVIG administration. Polycythemia rubra vera I and granulocyte colony-stimulating factor levels may be good biomarkers for predicting response to TVIG in patients with KD. (J Allergy Clin Immunol 2008;122:1008-13.)	[Abe, Jun] Natl Res Inst Child Hlth & Dev, Dept Allergy & Immunol, Setagaya Ku, Tokyo 1578535, Japan; [Ebata, Ryota; Yasukawa, Kumi] Chiba Univ, Grad Sch Med, Chiba, Japan; [Jibiki, Toshiaki] Chiba Kaihin Municipal Hosp, Chiba, Japan; [Terai, Masaru] Tokyo Womens Med Univ, Chiba, Japan; [Terai, Masaru] Yachiyo Med Ctr, Chiba, Japan	National Center for Child Health & Development - Japan; Chiba University; Tokyo Women's Medical University	Abe, J (corresponding author), Natl Res Inst Child Hlth & Dev, Dept Allergy & Immunol, Setagaya Ku, 2-10-1 Ohkura, Tokyo 1578535, Japan.	jabe@nch.go.jp	Ebata, Ryota/AAQ-5832-2021	Ebata, Ryota/0000-0001-8471-1042; Saito, Hirohisa/0000-0002-6630-8337	Japan Health Sciences Foundation [KH21013]; National Institute of Biomedical Innovation [ID05-24]	Japan Health Sciences Foundation; National Institute of Biomedical Innovation(National Institute of Biomedical Innovation)	Supported in part by a grant from the Japan Health Sciences Foundation (KH21013) and a grant from the National Institute of Biomedical Innovation (ID05-24).	Abe J, 2005, J IMMUNOL, V174, P5837, DOI 10.4049/jimmunol.174.9.5837; *AFF TECHN NOT, 2003, GLOB RED PROT METH P; BROUDY VC, 1987, J IMMUNOL, V139, P464; Burns JC, 2005, J INFECT DIS, V192, P344, DOI 10.1086/430953; Egami K, 2006, J PEDIATR-US, V149, P237, DOI 10.1016/j.jpeds.2006.03.050; FURUSHO K, 1984, LANCET, V2, P1055; Hirai H, 2006, NAT IMMUNOL, V7, P732, DOI 10.1038/ni1354; Inoue Y, 1999, PEDIATR INT, V41, P330, DOI 10.1046/j.1442-200x.1999.01074.x; KAWASAKI T, 1967, JAP J ALLERG, V16, P178, DOI DOI 10.4070/KCJ.2018.0214; Kim T, 2007, EUR J PEDIATR, V166, P421, DOI 10.1007/s00431-006-0251-8; Kobayashi T, 2006, CIRCULATION, V113, P2606, DOI 10.1161/CIRCULATIONAHA.105.592865; McCrindle BW, 2007, CIRCULATION, V116, P174, DOI 10.1161/CIRCULATIONAHA.107.690875; Nakajima T, 2004, J ALLERGY CLIN IMMUN, V113, P528, DOI 10.1016/j.jaci.2003.12.036; Newburger JW, 2004, CIRCULATION, V110, P2747, DOI 10.1161/01.CIR.0000145143.19711.78; NIWA Y, 1984, J PEDIATR-US, V104, P56, DOI 10.1016/S0022-3476(84)80589-2; Samada K, 2002, EUR J PEDIATR, V161, P538, DOI 10.1007/s00431-002-1018-5; Sano T, 2007, EUR J PEDIATR, V166, P131, DOI 10.1007/s00431-006-0223-z; Stanford SJ, 2000, BRIT J PHARMACOL, V129, P835, DOI 10.1038/sj.bjp.0703151; Stroncek DF, 2005, J TRANSL MED, V3, P1, DOI 10.1186/1479-5876-3-36; Suzuki H, 2001, PEDIATR INT, V43, P115, DOI 10.1046/j.1442-200x.2001.01362.x; Takahashi K, 2005, PEDIATR INT, V47, P305, DOI 10.1111/j.1442-200x.2005.02049.x; Temerinac S, 2000, BLOOD, V95, P2569; The Japan Kawasaki disease research committee, 2002, DIAGN GUID KAW DIS; Theilgaard-Monch K, 2005, BLOOD, V105, P1785, DOI 10.1182/blood-2004-08-3346; Theilgaard-Monch K, 2006, BLOOD, V108, P353, DOI 10.1182/blood-2005-09-3890; ZSEBO KM, 1988, BLOOD, V71, P99	26	37	39	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2008	122	5					1008	1013		10.1016/j.jaci.2008.09.011	http://dx.doi.org/10.1016/j.jaci.2008.09.011			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	372ZF	18930517	Bronze			2022-12-18	WOS:000260940100023
J	Wang, L; Joad, JP; Zhong, CY; Pinkerton, KE				Wang, Lei; Joad, Jesse P.; Zhong, Caiyun; Pinkerton, Kent E.			Effects of environmental tobacco smoke exposure on pulmonary immune response in infant monkeys	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						environmental tobacco smoke; lung development; T(H)1; immune response	CELL ALPHA-CHEMOATTRACTANT; ANTIGEN-PRESENTING CELLS; T-BET; TRANSCRIPTION FACTOR; DIFFERENTIAL EXPRESSION; RECEPTOR EXPRESSION; CYTOKINE PRODUCTION; INTERFERON-GAMMA; GENE-EXPRESSION; 1ST YEAR	Background: Exposure to environmental tobacco smoke (ETS) in early life has adverse effects on lung development and increases asthma incidence and susceptibility to infection. We have previously reported that perinatal and postnatal exposure to ETS in infant monkeys leads to an impaired T(H)1 immune response in peripheral blood. Objective: Determine whether ETS exposure during the perinatal period alters pulmonary immune maturation in the neonatal lung. Methods: Nonhuman primates were exposed to ETS from gestation day 50 to 13 months postnatal age (perinatal ETS) or from 6 to 13 months (postnatal ETS). Control animals were only exposed to filtered air. T(H)1 and T(H)2-related cytokines, chemokines, and their corresponding receptors as well as transcription factors were analyzed in lung tissues at 13 months. Results: Animals exposed to ETS beginning in utero exhibited more profound alterations in T(H)1 factors compared with animals exposed to ETS beginning at 6 months postnatal age. In perinatal ETS-exposed monkeys, mRNA for IFN-gamma, IL-2, IFN-gamma-inducible protein 10, monokine induced by IFN-gamma, IFN-gamma-inducible T-cell chemoattractant, CXC chemokine receptor 3, IL-12 bioactive p70 subunit, and T-bet were significantly downregulated, whereas in postnatal ETS-exposed monkeys, only IFN-gamma, CXC chemokine receptor 3, and IL-12p70 were significantly downregulated. ETS effects on T(H)2 factors were less apparent and more variable: mRNA for thymus and activation-regulated chemokine was increased, and IL-10 protein was reduced. Conclusions: Environmental tobacco smoke exposure during early life enhances a local TH2 immunity by impairing normal pulmonary TH1 immune maturation. This effect was greater in animals beginning ETS exposure in utero.	[Wang, Lei; Zhong, Caiyun; Pinkerton, Kent E.] Univ Calif Davis, Ctr Hlth & Environm, Davis, CA 95616 USA; [Joad, Jesse P.; Pinkerton, Kent E.] Univ Calif Davis, Dept Pediat, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Pinkerton, KE (corresponding author), Univ Calif Davis, Ctr Hlth & Environm, Old Davis Rd, Davis, CA 95616 USA.	kepinkerton@ucdavis.edu			National Institutes of Health [R01 ES011634];  [ES05707];  [P51 RR00169]; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000169] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011634] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; ; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by grants from the National Institutes of Health (R01 ES011634, ES05707 and P51 RR00169)	Adkins P, 2001, J IMMUNOL, V166, P918, DOI 10.4049/jimmunol.166.2.918; Bardelli C, 2005, BRIT J PHARMACOL, V145, P385, DOI 10.1038/sj.bjp.0706198; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Bonfield TL, 1999, J ALLERGY CLIN IMMUN, V104, P72, DOI 10.1016/S0091-6749(99)70116-8; Chtanova T, 2001, J IMMUNOL, V167, P3057, DOI 10.4049/jimmunol.167.6.3057; Cole KE, 1998, J EXP MED, V187, P2009, DOI 10.1084/jem.187.12.2009; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; FARBER JM, 1990, P NATL ACAD SCI USA, V87, P5238, DOI 10.1073/pnas.87.14.5238; Farber JM, 1997, J LEUKOCYTE BIOL, V61, P246, DOI 10.1002/jlb.61.3.246; Farrar JD, 2001, J EXP MED, V193, P643, DOI 10.1084/jem.193.5.643; Gleeson M, 2004, FEMS IMMUNOL MED MIC, V42, P21, DOI 10.1016/j.femsim.2004.06.012; Glimcher LH, 2000, GENE DEV, V14, P1693; GORTMAKER SL, 1982, AM J PUBLIC HEALTH, V72, P574, DOI 10.2105/AJPH.72.6.574; Jacobs M, 2000, IMMUNOLOGY, V100, P494, DOI 10.1046/j.1365-2567.2000.00053.x; Kapsenberg ML, 1999, CLIN EXP ALLERGY, V29, P33, DOI 10.1046/j.1365-2222.1999.00006.x-i2; Kim E, 2005, IMMUNOL LETT, V99, P24, DOI 10.1016/j.imlet.2004.11.025; Kishikawa H, 2001, J IMMUNOL, V167, P4414, DOI 10.4049/jimmunol.167.8.4414; Ko FWS, 2007, CLIN EXP IMMUNOL, V147, P526, DOI 10.1111/j.1365-2249.2006.03315.x; Kraan TCTMV, 1997, J IMMUNOL, V158, P5560; KRAAN TCTMV, 1995, J EXP MED, V181, P775, DOI 10.1084/jem.181.2.775; KRAEMER MJ, 1983, JAMA-J AM MED ASSOC, V249, P1022, DOI 10.1001/jama.249.8.1022; Lambert C, 2007, J BIOL CHEM, V282, P19666, DOI 10.1074/jbc.M611527200; Leem JH, 2005, J ASTHMA, V42, P463, DOI 10.1080/02770900500200733; Lu B, 1999, EUR J IMMUNOL, V29, P3804, DOI 10.1002/(SICI)1521-4141(199911)29:11<3804::AID-IMMU3804>3.0.CO;2-9; LUSTER AD, 1987, J EXP MED, V166, P1084, DOI 10.1084/jem.166.4.1084; MALEFYT RD, 1991, J EXP MED, V174, P1209; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MUNK ME, 1995, EUR RESPIR J, V8, pS668; Murphy PM, 2002, PHARMACOL REV, V54, P227, DOI 10.1124/pr.54.2.227; Neurath MF, 2002, J EXP MED, V195, P1129, DOI 10.1084/jem.20011956; O'Garra A, 2000, CURR BIOL, V10, pR492, DOI 10.1016/S0960-9822(00)00556-X; Peden DB, 2000, ENVIRON HEALTH PERSP, V108, P475, DOI 10.2307/3454539; PEDREIRA FA, 1985, PEDIATRICS, V75, P594; Phaybouth V, 2006, AM J PHYSIOL-LUNG C, V290, pL222, DOI 10.1152/ajplung.00148.2005; Pinkerton KE, 2006, CLIN EXP PHARMACOL P, V33, P269, DOI 10.1111/j.1440-1681.2006.04357.x; Rabin RL, 1999, J IMMUNOL, V162, P3840; Ritter M, 2005, BIOCHEM BIOPH RES CO, V334, P254, DOI 10.1016/j.bbrc.2005.06.084; Robinson DS, 2002, CURR BIOL, V12, pR322, DOI 10.1016/S0960-9822(02)00830-8; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Seymour BWP, 1997, J IMMUNOL, V159, P6169; Smit JJ, 2006, EUR J PHARMACOL, V533, P277, DOI 10.1016/j.ejphar.2005.12.064; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; TEAGUE SV, 1994, INHAL TOXICOL, V6, P79, DOI 10.3109/08958379409029697; TRINCHIERI G, 1994, BLOOD, V84, P4008, DOI 10.1182/blood.V84.12.4008.bloodjournal84124008; Vassallo R, 2005, J IMMUNOL, V175, P2684, DOI 10.4049/jimmunol.175.4.2684; Vogel CFA, 2003, J BIOCHEM MOL TOXIC, V17, P305, DOI 10.1002/jbt.10096; Wang L, 2007, J ALLERGY CLIN IMMUN, V120, P445, DOI 10.1016/j.jaci.2007.03.028; Weng YM, 1998, J BIOL CHEM, V273, P18288, DOI 10.1074/jbc.273.29.18288; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; WILSON CB, 1986, J CLIN INVEST, V77, P860, DOI 10.1172/JCI112383; Zhang DH, 1997, J BIOL CHEM, V272, P21597, DOI 10.1074/jbc.272.34.21597; Zhao DXM, 2002, J IMMUNOL, V169, P1556, DOI 10.4049/jimmunol.169.3.1556	53	37	38	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2008	122	2					400	406		10.1016/j.jaci.2008.04.011	http://dx.doi.org/10.1016/j.jaci.2008.04.011			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337HO	18502491				2022-12-18	WOS:000258426300029
J	Nakashima, T; Yokoyama, A; Onari, Y; Shoda, H; Haruta, Y; Hattori, N; Naka, T; Kohno, N				Nakashima, Taku; Yokoyama, Akihito; Onari, Yojiro; Shoda, Hiroyasu; Haruta, Yoshinori; Hattori, Noboru; Naka, Tetsuji; Kohno, Nobuoki			Suppressor of cytokine signaling 1 inhibits pulmonary inflammation and fibrosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						pulmonary fibrosis; suppressor of cytokine signaling; tumor necrosis factor alpha; adenoviral vector; bleomycin	LUNG INJURY; TNF-ALPHA; BLEOMYCIN; MICE; EXPRESSION; CELLS; SOCS1; MAINTENANCE; DEFICIENT; PHENOTYPE	Background: Suppressor of cytokine signaling (SOCS) proteins are inhibitors of cytokine signaling. Our previous study suggested that SOCS1 regulates collagen synthesis by lung fibroblasts, suggesting a role of SOCS1 in the pathophysiology of pulmonary fibrosis. Objectives: We sought to investigate the role of SOCS1 in pulmonary inflammation and fibrosis in vivo. Methods: SOCS1-haplodeficient mice treated with bleomycin (BLM) were evaluated for pulmonary inflammation and fibrosis compared with wild-type mice. The human study group was composed of 18 patients with interstitial lung disease. Lung specimens obtained by means of open lung biopsy were investigated to determine whether the severity of fibrosis was associated with decreased SOCS1 expression. Finally, we further analyzed the effect of exogenous SOCS1 on BLM-induced lung injury based on adenoviral SOCS1 gene transfer to the lung. Results: SOCS1-haplodeficient mice treated with BLM showed markedly enhanced pulmonary inflammation and fibrosis compared with wild-type mice. Using human lung specimens, we found that SOCS1 mRNA levels inversely correlated with duration of the disease. SOCS1 expression was significantly less in lung tissue from patients with idiopathic pulmonary fibrosis (IPF) compared with that in non-IPF patients. Moreover, SOCS1 expression was significantly less in severe fibrotic lesions (lower lobe) than in less fibrotic lesions (upper lobe). Adenoviral SOCS1 gene transfer to murine lungs significantly decreased lymphocytic inflammation, pulmonary fibrosis, and mortality because of BLM-induced lung injury. Exogenous SOCS1 inhibited expression of various cytokines, including TNF-alpha, which might play a key role. Conclusions: These results suggest that SOCS1 might act as a suppressor for pulmonary fibrosis. SOCS1 might be a target of IPF treatment.	[Yokoyama, Akihito; Shoda, Hiroyasu] Kochi Univ, Dept Hematol & Resp Med, Kochi 7838505, Japan; [Nakashima, Taku; Onari, Yojiro; Haruta, Yoshinori; Hattori, Noboru; Kohno, Nobuoki] Hiroshima Univ, Grad Sch Biomed Sci, Dept Mol & Internal Med, Hiroshima 730, Japan; [Naka, Tetsuji] Natl Inst Biomed Innovat, Lab Immune Signal Project, Osaka, Japan	Kochi University; Hiroshima University; National Institute of Health Sciences - Japan	Yokoyama, A (corresponding author), Kochi Univ, Dept Hematol & Resp Med, Kohasu Oko Cho, Kochi 7838505, Japan.	ayokoyama@kochi-u.ac.jp	Hiyama, Eiso/A-2013-2019; Nakashima, Taku/D-1517-2011	Hiyama, Eiso/0000-0001-9179-5037; Nakashima, Taku/0000-0002-0035-674X				Agostini Carlo, 2006, Proc Am Thorac Soc, V3, P357, DOI 10.1513/pats.200601-010TK; *AM THOR SOC EUR R, 2001, CRIT CARE MED, V165, P277; Belperio JA, 2002, AM J RESP CELL MOL, V27, P419, DOI 10.1165/rcmb.2002-0009OC; Chua F, 2005, AM J RESP CELL MOL, V33, P9, DOI 10.1165/rcmb.2005-0062TR; Egwuagu CE, 2002, J IMMUNOL, V168, P3181, DOI 10.4049/jimmunol.168.7.3181; Fujimoto M, 2003, TRENDS IMMUNOL, V24, P659, DOI 10.1016/j.it.2003.10.008; Hattori N, 2000, J CLIN INVEST, V106, P1341, DOI 10.1172/JCI10531; Irifune K, 2003, EUR RESPIR J, V21, P11, DOI 10.1183/09031936.03.00291203; Isomaki P, 2007, RHEUMATOLOGY, V46, P1538, DOI 10.1093/rheumatology/kem198; Kimura A, 2004, INT IMMUNOL, V16, P991, DOI 10.1093/intimm/dxh102; King TE, 2005, AM J RESP CRIT CARE, V172, P268, DOI 10.1164/rccm.200503-483OE; Kolb M, 2001, AM J RESP CRIT CARE, V163, P770, DOI 10.1164/ajrccm.163.3.2006084; Li YH, 2006, J IMMUNOL, V177, P1679, DOI 10.4049/jimmunol.177.3.1679; Lundblad LKA, 2005, AM J RESP CRIT CARE, V171, P1363, DOI 10.1164/rccm.200410-1349OC; Mukhopadhyay S, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-125; Naka T, 1998, P NATL ACAD SCI USA, V95, P15577, DOI 10.1073/pnas.95.26.15577; Oikonomou N, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000108; OLASHINIA M, 2007, CLIN EXP ALLERGY, V37, P735; Seki Y, 2003, NAT MED, V9, P1047, DOI 10.1038/nm896; Severgnini M, 2005, AM J RESP CRIT CARE, V171, P858, DOI 10.1164/rccm.200407-981OC; Shimabukuro DW, 2003, CRIT CARE MED, V31, pS524, DOI 10.1097/01.CCM.0000081437.06466.B3; Shoda H, 2007, BIOCHEM BIOPH RES CO, V353, P1004, DOI 10.1016/j.bbrc.2006.12.128; Strieter RM, 2004, J CLIN INVEST, V114, P165, DOI 10.1172/JCI200422398; Winkler MK, 2002, AM J PHYSIOL-LUNG C, V283, pL1, DOI 10.1152/ajplung.00489.2001; Xu JG, 2006, AM J PHYSIOL-LUNG C, V291, pL658, DOI 10.1152/ajplung.00006.2006; Yasukawa H, 2003, J CLIN INVEST, V111, P469, DOI 10.1172/JCI200316491; Yoshida T, 2004, J EXP MED, V199, P1701, DOI 10.1084/jem.20031675; Yoshimura A, 2007, NAT REV IMMUNOL, V7, P454, DOI 10.1038/nri2093	28	37	38	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2008	121	5					1269	1276		10.1016/j.jaci.2008.02.003	http://dx.doi.org/10.1016/j.jaci.2008.02.003			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	302IJ	18355908				2022-12-18	WOS:000255961700029
J	Mertsching, E; Bafetti, L; Hess, H; Perper, S; Giza, K; Allen, LC; Negrou, E; Hathaway, K; Hopp, B; Chung, J; Perret, D; Shields, M; Saxon, A; Kehry, MR				Mertsching, Elisabeth; Bafetti, Lisa; Hess, Henry; Perper, Stuart; Giza, Keith; Allen, Lisa Chan; Negrou, Ella; Hathaway, Karen; Hopp, BS'Jennifer; Chung, Julie; Perret, Daniel; Shields, Michael; Saxon, Andrew; Kehry, Marilyn R.			A mouse Fc gamma-Fc epsilon protein that inhibits mast cells through activation of Fc gamma RIIB, SH2 domain-containing inositol phosphatase 1, and SH2 domain-containing protein tyrosine phosphatases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						fc gamma RIIB; mast cell inhibition; Fc epsilon RI signaling	AFFINITY IGE RECEPTOR; NEGATIVE REGULATION; IN-VIVO; KINASE; ANAPHYLAXIS; SYK; PHOSPHORYLATION; EXPRESSION; SHIP	Background: A human Fc gamma-Fc epsilon fusion protein (GE2) designed to inhibit Fc epsilon RI signaling by coaggregating Fc epsilon RI with the inhibitory receptor Fc gamma RIIB has been shown to inhibit mast cell activation and block cutaneous anaphylaxis. A critical issue remained as to whether the mechanism of GE2 inhibition is competition for IgE binding or inhibitory signaling through Fc gamma RIIB. Objective: Our aim was to define the in vitro and in vivo mechanism of action of a mouse homolog of GE2 (mGE) and to assess the potential of human GE2 (hGE2) for therapeutic administration. Methods: The in vitro activity of mGE on mediator release and signaling pathways was characterized in IgE-sensitized bone marrow-derived mast cells (BMMCs). The in vivo activity of mGE was examined in mouse passive cutaneous and passive systemic anaphylaxis models, and the therapeutic activity of hGE2 was evaluated in Ascaris suum-sensitized cynomolgus monkeys. Results: mGE inhibited release of histamine and cytokines by BMMCs from wild-type mice but not by BMMCs from Fc gamma RIIB-deficient mice. In mice mGE blocked IgE-dependent anaphylaxis mediated by mast cells with sustained efficacy. In BMMCs mGE decreased spleen tyrosine kinase and extracellular signal-regulated kinases 1/2 phosphorylation and induced Fc gamma RIIB phosphorylation and the subsequent recruitment of SH2 domain-containing inositol polyphosphate 5' phosphatase (SHIP) 1 and SH2 domain-containing protein tyrosine phosphatase (SHP) 1/2 phosphatases. When administered therapeutically, hGE2 protected sensitized monkeys from local anaphylaxis for 3 weeks. Conclusion: mGE-mediated inhibition of mast cell activation is associated with inhibitory signaling through Fc gamma RIIB that results from activation of SHIP-1 and SHP-1/2 phosphatases.	[Mertsching, Elisabeth; Bafetti, Lisa; Negrou, Ella; Hathaway, Karen; Hopp, BS'Jennifer; Chung, Julie; Perret, Daniel; Shields, Michael; Kehry, Marilyn R.] Biogen Idec Inc, San Diego, CA 92130 USA; [Hess, Henry; Perper, Stuart; Giza, Keith] Biogen Idec Inc, Cambridge, MA USA; [Allen, Lisa Chan; Saxon, Andrew] Univ Calif Los Angeles, Sch Med, Dept Med, Div Clin Immunol Allergy,Hart & Louise Lyon Lab, Los Angeles, CA 90024 USA	Biogen; Biogen; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Mertsching, E (corresponding author), Biogen Idec Inc, 5200 Res Pl, San Diego, CA 92130 USA.	clisabeth.mertsching@biogenidec.com						Bruhns P, 2005, CURR OPIN IMMUNOL, V17, P662, DOI 10.1016/j.coi.2005.09.012; Costello PS, 1996, ONCOGENE, V13, P2595; Dombrowicz D, 1996, J IMMUNOL, V157, P1645; Dustin LB, 1999, J IMMUNOL, V162, P2717; Fitzgerald KA, 2006, CELL, V125, P834, DOI 10.1016/j.cell.2006.05.014; Fong DC, 1996, IMMUNOL LETT, V54, P83, DOI 10.1016/S0165-2478(96)02654-5; Freeman J, 1914, LANCET, V1, P1178; Kawakami T, 2002, NAT REV IMMUNOL, V2, P773, DOI 10.1038/nri914; Kepley CL, 2000, J ALLERGY CLIN IMMUN, V106, P337, DOI 10.1067/mai.2000.107931; Kepley CL, 2004, J BIOL CHEM, V279, P35139, DOI 10.1074/jbc.M404318200; Kraft S, 2006, TRENDS IMMUNOL, V27, P88, DOI 10.1016/j.it.2005.11.008; Lesourne R, 2001, J BIOL CHEM, V276, P6327, DOI 10.1074/jbc.M006537200; Malbec O, 1998, J IMMUNOL, V160, P1647; Noon L, 1911, LANCET, V1, P1572; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Prussin C, 2006, J ALLERGY CLIN IMMUN, V117, pS450, DOI 10.1016/j.jaci.2005.11.016; Ravetch JV, 2001, ANNU REV IMMUNOL, V19, P275, DOI 10.1146/annurev.immunol.19.1.275; Siraganian RP, 2003, CURR OPIN IMMUNOL, V15, P639, DOI 10.1016/j.coi.2003.09.010; Stassen M, 2001, J IMMUNOL, V166, P4391, DOI 10.4049/jimmunol.166.7.4391; Strait RT, 2006, J CLIN INVEST, V116, P833, DOI 10.1172/JCI25575; Takai T, 1996, NATURE, V379, P346, DOI 10.1038/379346a0; Ujike A, 1999, J EXP MED, V189, P1573, DOI 10.1084/jem.189.10.1573; Xie ZH, 2000, J IMMUNOL, V164, P1521, DOI 10.4049/jimmunol.164.3.1521; Zhang J, 1996, J EXP MED, V184, P71, DOI 10.1084/jem.184.1.71; Zhang K, 2004, J ALLERGY CLIN IMMUN, V114, P321, DOI 10.1016/j.jaci.2004.03.058; Zhu DC, 2002, NAT MED, V8, P518, DOI 10.1038/nm0502-518	26	37	39	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2					441	447		10.1016/j.jaci.2007.08.051	http://dx.doi.org/10.1016/j.jaci.2007.08.051			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	265CX	17949802				2022-12-18	WOS:000253337800025
J	Kanters, D; ten Hove, W; Luijk, B; van Aalst, C; Schweizer, RC; Lammers, JWJ; Leufkens, HGM; Raaijmakers, JAM; Bracke, M; Koenderman, L				Kanters, Deon; ten Hove, Willem; Luijk, Bart; van Aalst, Corneli; Schweizer, Rene C.; Lammers, Jan-Willem J.; Leufkens, Hubert G. M.; Raaijmakers, Jan A. M.; Bracke, Madelon; Koenderman, Leo			Expression of activated Fc gamma Rll discriminates between multiple granulocyte-priming phenotypes in peripheral blood of allergic asthmatic subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						priming; allergen challenge; neutrophils; eosinophils; allergic asthma; gene expression; peripheral blood	HUMAN EOSINOPHILS; NEUTROPHILIC INFLAMMATION; L-SELECTIN; AIRWAY; CYTOKINE; MATRIX-METALLOPROTEINASE-9; CHALLENGE; ALPHA; RESPONSIVENESS; ANTIBODIES	Background: Allergic asthma is associated with chronic airway and systemic immune responses. Systemic responses include priming of peripheral blood eosinophils, which is enhanced after allergen challenge. In a subpopulation of asthmatic subjects, neutrophils are associated with bronchial inflammation. Objective: We sought to monitor systemic granulocyte priming in allergic asthmatic subjects as a consequence of chronic and acute inflammatory signals initiated by allergen challenge. Methods: Blood was taken at baseline and 6 to 24 hours after allergen challenge in asthmatic subjects with and without late asthmatic responses. Systemic granulocyte priming was studied by using expression of cellular markers, such as alpha-chain of Mac-1 (alpha m)/CD11b, L-selectin/CD62L, and an activation epitope present on Fc gamma RII/CD32 recognized by monoclonal phage antibody A17. Results: Eosinophils of asthmatic subjects have a primed phenotype identified by cell-surface markers. Neutrophils of these patients were subtly primed, which was only identified after activation with N-formyl-methionyl-leucyl-phenylaianine. After allergen challenge, an acute increase in eosinophil priming characterized by enhanced expression of activated Fc gamma RII was found in patients experiencing a late asthmatic response and not in patients with a single early asthmatic response. In contrast, expression of alpha m/CD11b and L-selectin on granulocytes was not different between control and asthmatic subjects and was not affected by allergen challenge. Interestingly, expression of both adhesion molecules was positively correlated, and alpha m expression on eosinophils and neutrophils correlated positively with bronchial hyperresponsiveness. Conclusion: Different phases, phenotypes, or both of allergic asthma are associated with distinct priming profiles of inflammatory cells in peripheral blood. Clinical implications: Insight in differences of systemic innate responses will lead to better definition of asthma subtypes and to better designs of new therapeutic options.	Univ Med Ctr Utrecht, Dept Pulm Dis, NL-3584 CX Utrecht, Netherlands; Univ Utrecht, Fac Sci, Utrecht Inst Pharmaceut Sci, Div Pharmacoepidemiol & Pharmacotherapy, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University	Koenderman, L (corresponding author), Univ Med Ctr Utrecht, Dept Pulm Dis, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.	L.Koenderman@umcutrecht.nl	Koenderman, Leo/AAE-7870-2020	Koenderman, Leo/0000-0002-5636-6453				AALBERS R, 1993, CHEST, V103, P1178, DOI 10.1378/chest.103.4.1178; Abraham B, 2003, EUR RESPIR J, V22, P470, DOI 10.1183/09031936.03.00261903; Bancalari L, 1997, ALLERGY, V52, P32, DOI 10.1111/j.1398-9995.1997.tb02543.x; BCOHNER BS, 2000, J ALLERGY CLIN IMM S, V106, pS292; Bentley AM, 1997, CLIN EXP ALLERGY, V27, P71, DOI 10.1111/j.1365-2222.1997.tb01830.x; Bracke M, 2000, J LEUKOCYTE BIOL, V68, P655; Bracke M, 1997, J IMMUNOL, V159, P1459; Bracke M, 2001, BLOOD, V97, P3478, DOI 10.1182/blood.V97.11.3478; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Cataldo DD, 2002, CHEST, V122, P1553, DOI 10.1378/chest.122.5.1553; COCKCROFT DW, 1987, THORAX, V42, P302, DOI 10.1136/thx.42.4.302; COCKCROFT DW, 1987, AM REV RESPIR DIS, V135, P264; Cundall M, 2003, J ALLERGY CLIN IMMUN, V112, P1064, DOI 10.1016/j.jaci.2003.08.013; Douwes J, 2002, THORAX, V57, P643, DOI 10.1136/thorax.57.7.643; EBISAWA M, 1994, J IMMUNOL, V152, P4590; Gibson PG, 2001, CHEST, V119, P1329, DOI 10.1378/chest.119.5.1329; Grutters JC, 1999, EUR RESPIR J, V14, P915, DOI 10.1034/j.1399-3003.1999.14d31.x; Holgate ST, 2004, CYTOKINE, V28, P152, DOI 10.1016/j.cyto.2004.07.010; IERINO FL, 1993, J IMMUNOL, V150, P1794; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532, DOI 10.1164/ajrccm.160.5.9806170; Kelly EAB, 2000, AM J RESP CRIT CARE, V162, P1157; Koenderman L, 1996, EUR RESPIR J, V9, pS119; Koenderman L, 2000, J LEUKOCYTE BIOL, V68, P58; KOENDERMAN L, 1993, BLOOD, V81, P2413; KOH YY, 1993, AM J RESP CELL MOL, V8, P493, DOI 10.1165/ajrcmb/8.5.493; Lantero S, 2000, EUR RESPIR J, V16, P940, DOI 10.1183/09031936.00.16594000; Luijk B, 2005, J ALLERGY CLIN IMMUN, V115, P997, DOI 10.1016/j.jaci.2005.02.002; Mann BS, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-59; MENGELERS HJ, 1994, AM J RESP CRIT CARE, V149, P345, DOI 10.1164/ajrccm.149.2.8306028; MENGELERS HJJ, 1993, CLIN EXP ALLERGY, V23, P196, DOI 10.1111/j.1365-2222.1993.tb00882.x; MOSER R, 1992, BLOOD, V79, P2937; *NAT HERAT LUNG BL, 2002, NIH PUBL; NEELEY SP, 1993, AM J RESP CELL MOL, V8, P633, DOI 10.1165/ajrcmb/8.6.633; Nocker RET, 1999, INT ARCH ALLERGY IMM, V119, P45, DOI 10.1159/000024174; Oudijk EJD, 2005, THORAX, V60, P538, DOI 10.1136/thx.2004.034009; Pals CEGM, 2000, J ALLERGY CLIN IMMUN, V105, P760, DOI 10.1067/mai.2000.104382; Ritz SA, 2002, TRENDS IMMUNOL, V23, P396, DOI 10.1016/S1471-4906(02)02278-0; SCHWEIZER RC, 1994, BLOOD, V83, P3697; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; Taube C, 2003, J IMMUNOL, V170, P4301, DOI 10.4049/jimmunol.170.8.4301; Thomas PS, 2001, IMMUNOL CELL BIOL, V79, P132, DOI 10.1046/j.1440-1711.2001.00980.x; THORNE KJI, 1990, J IMMUNOL METHODS, V133, P47, DOI 10.1016/0022-1759(90)90317-O; Veen JCCMI, 1998, CLIN EXP ALLERGY, V28, P606; WARRINGA RAJ, 1992, BLOOD, V79, P1836; WARRINGA RAJ, 1993, J ALLERGY CLIN IMMUN, V91, P1198, DOI 10.1016/0091-6749(93)90323-8; WEERSINK EJM, 1994, RESP MED, V88, P103, DOI 10.1016/0954-6111(94)90021-3; Wenzel SE, 2003, J ALLERGY CLIN IMMUN, V111, P1345, DOI 10.1067/mai.2003.1464; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737, DOI 10.1164/ajrccm.156.3.9610046	48	37	37	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2007	120	5					1073	1081		10.1016/j.jaci.2007.06.021	http://dx.doi.org/10.1016/j.jaci.2007.06.021			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	231TZ	17697704	Bronze			2022-12-18	WOS:000250973400014
J	Santamaria, F; Montella, S; De Stefano, S; Sperli, F; Barbarano, F; Spadaro, R; Franzese, A				Santamaria, Francesca; Montella, Silvia; De Stefano, Sara; Sperli, Francesco; Barbarano, Federico; Spadaro, Raella; Franzese, Adriana			Asthma, atopy, and airway inflammation in obese children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							EXHALED NITRIC-OXIDE; BODY-MASS INDEX; SAMPLE; ADOLESCENTS		Univ Naples Federico 2, Dept Pediat, Naples, Italy	University of Naples Federico II	Santamaria, F (corresponding author), Univ Naples Federico 2, Dept Pediat, Naples, Italy.	santamar@unina.it	Santamaria, Francesca/AAC-3503-2022	Montella, Silvia/0000-0002-3133-1166				Appleton SL, 2006, J ALLERGY CLIN IMMUN, V118, P1284, DOI 10.1016/j.jaci.2006.08.011; Armitage P., 2001, STAT METHODS MED RES; Barros R, 2006, J ALLERGY CLIN IMMUN, V117, P1501, DOI 10.1016/j.jaci.2006.02.027; de Winter-de Groot KM, 2005, J ALLERGY CLIN IMMUN, V115, P419, DOI 10.1016/j.jaci.2004.11.025; Fantuzzi G, 2005, J ALLERGY CLIN IMMUN, V115, P911, DOI 10.1016/j.jaci.2005.02.023; Gilliland FD, 2003, AM J EPIDEMIOL, V158, P406, DOI 10.1093/aje/kwg175; Jouaville LF, 2003, CLIN EXP ALLERGY, V33, P1506, DOI 10.1046/j.1365-2222.2003.01800.x; Kazaks A, 2005, J ALLERGY CLIN IMMUN, V116, P929, DOI 10.1016/j.jaci.2005.06.005; Leung TF, 2004, PEDIAT ALLERG IMM-UK, V15, P344, DOI 10.1111/j.1399-3038.2004.00164.x; McLachlan CR, 2007, J ALLERGY CLIN IMMUN, V119, P634, DOI 10.1016/j.jaci.2006.10.029; Moody A, 2000, J ALLERGY CLIN IMMUN, V105, P895, DOI 10.1067/mai.2000.105318; Santamaria F, 2005, J ALLERGY CLIN IMMUN, V116, P1163, DOI 10.1016/j.jaci.2005.07.018; SCHLESSELMAN JJ, 1973, J CHRON DIS, V26, P553, DOI 10.1016/0021-9681(73)90060-X; Weiss R, 2004, NEW ENGL J MED, V350, P2362, DOI 10.1056/NEJMoa031049	14	37	39	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2007	120	4					965	967		10.1016/j.jaci.2007.06.002	http://dx.doi.org/10.1016/j.jaci.2007.06.002			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	220LH	17637474				2022-12-18	WOS:000250157700039
J	Byrd, JB; Shreevatsa, A; Putlur, P; Foretia, D; McAlexander, L; Sinha, T; Does, MD; Brown, NJ				Byrd, James Brian; Shreevatsa, Ajai; Putlur, Pradeep; Foretia, Denis; McAlexander, Laurie; Sinha, Tuhin; Does, Mark D.; Brown, Nancy J.			Dipeptidyl peptidase IV deficiency increases susceptibility to angiotensin-converting enzyme inhibitor-induced peritracheal edema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						angioedema; angiotensin-converting enzyme inhibitor; dipeptidyl peptidase IV; trachea; larynx; magnetic resonance imaging; pharmacogenetics; substance P; neurokinin; spantide	IMPROVED GLUCOSE-TOLERANCE; SUBSTANCE-P; PLASMA EXTRAVASATION; CARDIOVASCULAR EVENTS; INSULIN-SECRETION; AMINOPEPTIDASE-M; NASAL-MUCOSA; ANGIOEDEMA; INFLAMMATION; MICE	Background: Serum dipeptidyl peptidase IV (DPPIV) activity is decreased in some individuals with ACE inhibitor-associated angioedema. ACE and DPPIV degrade substance P, an edema-forming peptide. The contribution of impaired degradation of substance P by DPPIV to the pathogenesis of ACE inhibitor-associated angioedema is unknown. Objectives: We sought to determine whether DPPIV deficiency results in increased edema formation during ACE inhibition. We also sought to develop an animal model using magnetic resonance imaging to quantify ACE inhibitor-induced edema. Methods: The effect of genetic DPPIV deficiency on peritracheal edema was assessed in F344 rats after treatment with saline, captopril (2.5 mg/kg), or captopril plus the neurokinin receptor antagonist spantide (100 mu g/kg) by using serial T2-weighted magnetic resonance imaging. Results: Serum dipeptidyl peptidase activity was dramatically decreased in DPPIV-deficient rats (P < .001). The volume of peritracheal edema was significantly greater in captopril-treated DPPIV-deficient rats than in saline-treated DPPIV-deficient rats (P = .001), saline-treated rats of the normal substrain (P < .001), or captopril-treated rats of the normal substrain (P = .001). Cotreatment with spantide attenuated peritracheal edema in captopril-treated DPPIV-deficient rats (P = .005 vs captopril-treated DPPIV-deficient rats and P = .57 vs saline-treated DPPIV-deficient rats). Conclusions: DPPIV deficiency predisposes to peritracheal edema formation when ACE is inhibited through a neurokinin receptor-dependent mechanism. Magnetic resonance imaging is useful for modeling ACE inhibitor-associated angioedema in rats. Clinical implications: Genetic or environmental factors that decrease DPPIV activity might increase the risk of ACE inhibitor-associated angioedema.	Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Inst Imaging Sci, Nashville, TN 37240 USA; Vanderbilt Univ, Sch Engn, Dept Biomed Engn, Nashville, TN 37240 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Brown, NJ (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, 550 Robinson Res Bldg, Nashville, TN 37232 USA.	j.brown@vanderbilt.edu	Byrd, James Brian/H-6674-2019; Does, Mark/G-8975-2011	Byrd, James Brian/0000-0002-0509-3520; Foretia, Denis/0000-0002-9824-3494	NHLBI NIH HHS [HL076133, HL079184] Funding Source: Medline; NIBIB NIH HHS [R01 EB001744-03, R01 EB001744] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079184, T32HL076133] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB001744] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		AHMAD S, 1992, J PHARMACOL EXP THER, V260, P1257; Ahren B, 2004, J CLIN ENDOCR METAB, V89, P2078, DOI 10.1210/jc.2003-031907; Ahren B, 2002, DIABETES CARE, V25, P869, DOI 10.2337/diacare.25.5.869; Aschner P, 2006, DIABETES CARE, V29, P2632, DOI 10.2337/dc06-0703; Campos MM, 2000, NEUROPEPTIDES, V34, P314, DOI 10.1054/npep.2000.0823; Conarello SL, 2003, P NATL ACAD SCI USA, V100, P6825, DOI 10.1073/pnas.0631828100; Dahlof B, 2005, LANCET, V366, P895, DOI 10.1016/S0140-6736(05)67185-1; Emanueli C, 1998, HYPERTENSION, V31, P1299, DOI 10.1161/01.HYP.31.6.1299; Grouzmann E, 2002, FASEB J, V16, P1132, DOI 10.1096/fj.01-0939fje; Herman GA, 2006, J CLIN ENDOCR METAB, V91, P4612, DOI 10.1210/jc.2006-1009; KOPP UC, 1997, P AM J PHYSL S, V272, pR2009; Kostis JB, 2005, ARCH INTERN MED, V165, P1637, DOI 10.1001/archinte.165.14.1637; Kostis OB, 2004, AM J HYPERTENS, V17, P103, DOI 10.1016/j.amjhyper.2003.09.014; Lefebvre J, 2002, HYPERTENSION, V39, P460, DOI 10.1161/hy0202.103054; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; Marguet D, 2000, P NATL ACAD SCI USA, V97, P6874, DOI 10.1073/pnas.120069197; MATSAS R, 1983, P NATL ACAD SCI-BIOL, V80, P3111, DOI 10.1073/pnas.80.10.3111; MENTLEIN R, 1993, EUR J BIOCHEM, V214, P829, DOI 10.1111/j.1432-1033.1993.tb17986.x; Moreau ME, 2005, J PHARMACOL EXP THER, V315, P1065, DOI 10.1124/jpet.105.088005; Nagakura T, 2001, BIOCHEM BIOPH RES CO, V284, P501, DOI 10.1006/bbrc.2001.4999; NAGATSU T, 1976, ANAL BIOCHEM, V74, P466, DOI 10.1016/0003-2697(76)90227-X; Ogasawara T, 2001, ORAL SURG ORAL MED O, V92, P473, DOI 10.1067/moe.2001.116508; Pala L, 2005, DIABETOLOGIA, V48, P1168, DOI 10.1007/s00125-005-1749-8; PETERSSON G, 1993, J PHARMACOL EXP THER, V264, P509; SCHAPIRA M, 1983, NEW ENGL J MED, V308, P1050, DOI 10.1056/NEJM198305053081802; Sulpizio AC, 2004, J PHARMACOL EXP THER, V309, P1141, DOI 10.1124/jpet.103.064105; WANG LH, 1991, PEPTIDES, V12, P1357, DOI 10.1016/0196-9781(91)90220-J; WATANABE Y, 1987, EXPERIENTIA, V43, P400, DOI 10.1007/BF01940426; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; Yusuf S, 2000, NEW ENGL J MED, V342, P145	30	37	37	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2007	120	2					403	408		10.1016/j.jaci.2007.04.012	http://dx.doi.org/10.1016/j.jaci.2007.04.012			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	198VF	17531305				2022-12-18	WOS:000248654900028
J	Jones, CA; Clement, LT; Morphew, T; Kwong, KYC; Hanley-Lopez, J; Lifson, F; Opas, L; Guterman, JJ				Jones, Craig A.; Clement, Loran T.; Morphew, Tricia; Kwong, Kenny Yat Choi; Hanley-Lopez, Jean; Lifson, Francene; Opas, Lawrence; Guterman, Jeffrey J.			Achieving and maintaining asthma control in an urban pediatric disease management program: The Breathmobile Program	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; asthma control; Breathmobile; children; inner city; urban; disease management; schools	PREVALENCE; MONTELUKAST; CHILDREN; SYMPTOMS; BECLOMETHASONE; FLUTICASONE; MORBIDITY; PLACEBO	Background: National guidelines suggest that, with appropriate care, most patients can control their asthma. The probabilities of children achieving and maintaining control with ongoing care are unknown. Objective: We sought to evaluate the degree to which children in a lower socioeconomic urban setting achieve and maintain control of asthma with regular participation in a disease management program that provides guideline-based care. Methods: Interdisciplinary teams of asthma specialists use mobile clinics to offer ongoing care at schools and county clinics. A guideline-derived construct of asthma control is recorded at each visit. Results: Two thousand one hundred eighty-five enrollees were eligible to evaluate the time to first achieve control, and 1591 patients were eligible to evaluate subsequent control maintenance. Depending on severity, 70% to 87% of patients with persistent asthma achieved control by visit 3, and 89% to 98% achieved control by visit 6. Subsequent control maintenance was highly variable. Thirty-nine percent of patients displayed well-controlled asthma (control at >90% of subsequent visits), whereas 13% displayed difficult-to-control asthma (<50% of subsequent visits). Patients from each baseline severity category were found in each group. Maintenance of control was influenced by physician-estimated compliance with the treatment plan, baseline severity, and the interval between clinic visits. Conclusions: Many children can achieve asthma control with regular visit intervals and guideline-based care; however, long-term control can be highly variable among patients in all severity categories. Clinical implications: These findings highlight the need and feasibility for systematically tracking each patient's clinical response to individualize therapy and guide the use of population management strategies.	Univ So Calif, Los Angeles Cty Med Ctr, Keck Sch Med, Div Allergy & Immunol, Los Angeles, CA 90033 USA; Univ So Calif, Los Angeles Cty Med Ctr, Keck Sch Med, Dept Pediat, Los Angeles, CA 90033 USA; Univ S Alabama, Coll Med, Dept Pediat, Mobile, AL USA; Asthma & Allergy Fdn Amer, So Calif Chapter, Los Angeles, CA USA; Olive View UCLA Med Ctr, Los Angeles Cty Dept Hlth Serv, Los Angeles, CA USA; Univ Calif Los Angeles, Geffen Sch Med, Los Angeles, CA USA	University of Southern California; University of Southern California; University of South Alabama; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Jones, CA (corresponding author), 1801 E Marengo,Room 1G1,Gen Labs Bldg, Los Angeles, CA 90033 USA.	craigj@usc.edu						Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Breysse PN, 2005, ENVIRON RES, V98, P167, DOI 10.1016/j.envres.2004.07.018; Crain EF, 1998, ARCH PEDIAT ADOL MED, V152, P333; Grant EN, 2000, AM J PUBLIC HEALTH, V90, P1923, DOI 10.2105/AJPH.90.12.1923; Grant EN, 1999, ANN ALLERG ASTHMA IM, V83, P113, DOI 10.1016/S1081-1206(10)62621-X; Israel E, 2004, LANCET, V364, P1505, DOI 10.1016/S0140-6736(04)17273-5; Israel E, 2002, J ALLERGY CLIN IMMUN, V110, P847, DOI 10.1067/mai.2002.129413; Israel E, 2005, J ALLERGY CLIN IMMUN, V115, pS532, DOI 10.1016/j.jaci.2005.01.029; Jones CA, 2004, CHEST, V125, P924, DOI 10.1378/chest.125.3.924; Jones Craig A, 2005, Dis Manag, V8, P205, DOI 10.1089/dis.2005.8.205; Lara M, 2003, J ASTHMA, V40, P289, DOI 10.1081/JAS-120018331; Leickly FE, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.5.e8; Malmstrom K, 1999, ANN INTERN MED, V130, P487, DOI 10.7326/0003-4819-130-6-199903160-00005; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; National cholesterol education program National heart lung and blood institute National institutes of health, 2002, 3 REP NAT CHOL ED PR; Newacheck PW, 2000, ARCH PEDIAT ADOL MED, V154, P287, DOI 10.1001/archpedi.154.3.287; *NIH, 1997, NIH PUBL; *NIH, 1991, NIH PUBL; Persky VW, 1998, ANN ALLERG ASTHMA IM, V81, P266, DOI 10.1016/S1081-1206(10)62824-4; Simon PA, 2003, J ASTHMA, V40, P535, DOI 10.1081/JAS-120018788; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; SZEFLER SJ, 2002, J ALLERGY CLIN IMMUN, V109, P466; Tantisira KG, 2004, HUM MOL GENET, V13, P1353, DOI 10.1093/hmg/ddh149; Tantisira KG, 2004, P NATL ACAD SCI USA, V101, P18099, DOI 10.1073/pnas.0408532102; Webber MP, 2002, PEDIATR PULM, V34, P105, DOI 10.1002/ppul.10146; Wechsler ME, 2006, AM J RESP CRIT CARE, V173, P519, DOI 10.1164/rccm.200509-1519OC; Wechsler ME, 2005, AM J RESP CRIT CARE, V172, P12, DOI 10.1164/rccm.200412-1635OE; Wright RJ, 2004, AM J PUBLIC HEALTH, V94, P625, DOI 10.2105/AJPH.94.4.625; Zeiger RS, 2006, J ALLERGY CLIN IMMUN, V117, P45, DOI 10.1016/j.jaci.2005.10.012	30	37	39	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2007	119	6					1445	1453		10.1016/j.jaci.2007.02.031	http://dx.doi.org/10.1016/j.jaci.2007.02.031			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	178PO	17416407				2022-12-18	WOS:000247232800021
J	Foley, SC; Hamid, Q				Foley, Susan C.; Hamid, Qutayba			Images in allergy and immunology: Neutrophils in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							AIRWAY INFLAMMATION; MATRIX-METALLOPROTEINASE-9; EXPRESSION; ASSOCIATION; OBSTRUCTION; SEVERITY		McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada	McGill University	Hamid, Q (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.	qutayba.hamid@mcgill.ca						BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; Chu HW, 2000, J ALLERGY CLIN IMMUN, V106, P1115; Cundall M, 2003, J ALLERGY CLIN IMMUN, V112, P1064, DOI 10.1016/j.jaci.2003.08.013; Fukakusa M, 2005, J ALLERGY CLIN IMMUN, V115, P280, DOI 10.1016/j.jaci.2004.10.036; Hauber HP, 2003, J ALLERGY CLIN IMMUN, V112, P58, DOI 10.1067/mai.2003.1612; Hoshino M, 1998, J ALLERGY CLIN IMMUN, V102, P783, DOI 10.1016/S0091-6749(98)70018-1; Little SA, 2002, AM J MED, V112, P446, DOI 10.1016/S0002-9343(02)01047-1; Louis R, 2000, AM J RESP CRIT CARE, V161, P9, DOI 10.1164/ajrccm.161.1.9802048; SOUSSIGOUNNI A, 2001, J IMMUNOL, V166, P2768; SOUSSIGOUNNI A, 2001, FASEB J, V15, P940; Vignola AM, 1998, AM J RESP CRIT CARE, V158, P1945, DOI 10.1164/ajrccm.158.6.9803014; Wenzel SE, 2003, J ALLERGY CLIN IMMUN, V111, P1345, DOI 10.1067/mai.2003.1464; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737, DOI 10.1164/ajrccm.156.3.9610046; Woodruff PG, 2001, J ALLERGY CLIN IMMUN, V108, P753, DOI 10.1067/mai.2001.119411	14	37	43	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2007	119	5					1282	1286		10.1016/j.jaci.2007.02.006	http://dx.doi.org/10.1016/j.jaci.2007.02.006			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167CB	17412406				2022-12-18	WOS:000246427200041
J	Linehan, MF; Frank, TL; Hazell, ML; Francis, HC; Morris, JA; Baxter, DN; Niven, RM				Linehan, Mary F.; Frank, Timothy L.; Hazell, Michelle L.; Francis, Helen C.; Morris, Julie A.; Baxter, David N.; Niven, Robert M.			Is the prevalence of wheeze in children altered by neonatal BCG vaccination?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						wheeze; children; BCG; questionnaire; prevalence	ATOPIC DISEASE; RESPIRATORY SYMPTOMS; TUBERCULIN RESPONSES; IMMUNE-RESPONSE; ASTHMA; SCHOOLCHILDREN; IMMUNIZATION; ASSOCIATION; CHILDHOOD; COMMUNITY	Background: The prevalence of asthma and atopic disease has increased in recent decades, but precise reasons for this increase are unknown. BCG vaccination is thought to be among a group of vaccines capable of manipulating the immune system toward T(H)1 dominance and therefore reducing the likelihood of atopic disease. Objective: The aim of this study was to determine the influence of neonatal BCG vaccination on the prevalence of wheeze in a large community population of children. Method: In a historical cohort study, a parent-completed questionnaire was used to identify the prevalence of wheeze in BCG-vaccinated and nonvaccinated children in Manchester, England. Results: There were 2414 participants aged between 6 and 11 years. In a univariate analysis neonatal BCG vaccination was associated with a significantly lower prevalence of wheeze (odds ratio, 0.69; 95% CI, 0.55-0.86), and statistical significance was retained when the analysis was adjusted for potential confounders (odds ratio, 0.68; 95% CI, 0.53-0.87). Conclusion: These results demonstrate an association between asthma symptom prevalence and neonatal BCG vaccination, relating to a possible 27% reduction in prevalence, and are therefore of considerable public health importance. Clinical implications: The capacity of neonatal BCG vaccination to reduce the prevalence of respiratory symptoms in children warrants further investigation.	NW Lung Res Ctr, Gen Practice Res Unit, Manchester, Lancs, England; Wythenshawe Hosp, S Manchester NHS Trust, Manchester M23 9LT, Lancs, England; Univ Manchester, Manchester M13 9PL, Lancs, England	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; University of Manchester	Linehan, MF (corresponding author), Wythenshawe Hosp, NW Lung Res Ctr, Gen Practice Res Unit, Manchester M23 9LT, Lancs, England.	linehanmary@yahoo.co.uk	frank, timothy/AAF-9833-2020	Frank, Timothy/0000-0002-1580-8980; Niven, Robert/0000-0003-2249-960X				Aaby P, 2000, CLIN EXP ALLERGY, V30, P644, DOI 10.1046/j.1365-2222.2000.00803.x; Alm JS, 1997, LANCET, V350, P400, DOI 10.1016/S0140-6736(97)02207-1; Annus T, 2004, ALLERGY, V59, P1068, DOI 10.1111/j.1398-9995.2004.00557.x; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Cane RS, 2000, ARCH DIS CHILD, V82, P327, DOI 10.1136/adc.82.4.327; da Cunha SS, 2004, ALLERGY, V59, P857; DEMEO DL, 2002, ASTHMA COPD, P7; El Biaze M, 2003, ALLERGY, V58, P844, DOI 10.1034/j.1398-9995.2003.00282.x; Elphick HE, 2001, ARCH DIS CHILD, V84, P35, DOI 10.1136/adc.84.1.35; Frank PI, 2005, BRIT J GEN PRACT, V55, P596; Garcia-Marcosa L, 2005, INT ARCH ALLERGY IMM, V137, P303, DOI 10.1159/000086461; *GEN HOUS SURV, 2003, SAMPL DES RESP; Gruber C, 2002, PEDIAT ALLERG IMM-UK, V13, P177, DOI 10.1034/j.1399-3038.2002.01006.x; Hensley MJ, 2003, PEDIATR PULM, V36, P509, DOI 10.1002/ppul.10360; HOLT PG, 1994, LANCET, V344, P456, DOI 10.1016/S0140-6736(94)91776-0; Larche M, 2003, J ALLERGY CLIN IMMUN, V111, P450, DOI 10.1067/mai.2003.169; Linehan MF, 2005, ARCH DIS CHILD, V90, P516, DOI 10.1136/adc.2004.061879; Marks GB, 2003, J ALLERGY CLIN IMMUN, V111, P541, DOI 10.1067/mai.2003.171; Martinez FD, 1998, EUR RESPIR J, V12, p3S; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; Mommers M, 2004, PEDIATR PULM, V38, P329, DOI 10.1002/ppul.20089; Ota MOC, 2003, CLIN EXP ALLERGY, V33, P731, DOI 10.1046/j.1365-2222.2003.01599.x; Pahari A, 2002, Indian Pediatr, V39, P254; Racila DM, 2005, J ALLERGY CLIN IMMUN, V116, P1202, DOI 10.1016/j.jaci.2005.08.050; Renz H, 2004, CLIN EXP ALLERGY, V34, P167, DOI 10.1111/j.1365-2222.2004.01875.x; ROMAGNANI S, 1992, IMMUNOL TODAY, V13, P379, DOI 10.1016/0167-5699(92)90083-J; Sander B, 1995, IMMUNOLOGY, V86, P512; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; *SPSS INC, 2001, SPSS VERS 10 1 4 WIN; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; von Mutius E, 2000, THORAX, V55, P449, DOI 10.1136/thorax.55.6.449; Wong GWK, 2001, THORAX, V56, P770, DOI 10.1136/thorax.56.10.770; Yu ITS, 2004, ARCH DIS CHILD, V89, P544, DOI 10.1136/adc.2003.033688	33	37	38	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2007	119	5					1079	1085		10.1016/j.jaci.2006.12.672	http://dx.doi.org/10.1016/j.jaci.2006.12.672			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167CB	17379292				2022-12-18	WOS:000246427200005
J	Hong, SJ; Kim, HB; Kang, MJ; Lee, SY; Kim, JH; Kim, BS; Jang, SO; Shin, HD; Park, CS				Hong, Soo-Jong; Kim, Hyo-Bin; Kang, Mi-Jin; Lee, So-Yeon; Kim, Ja-Hyung; Kim, Bong-Seong; Jang, Seong-Ok; Shin, Hyung-Doo; Park, Choon-Sik			TNF-alpha (-308 G/A) and CD14(-159T/C) polymorphisms in the bronchial responsiveness of Korean children with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						tumor necrosis factor alpha; CD14; asthma; bronchial hyperreactivity; polymorphism; atopy	TUMOR-NECROSIS-FACTOR; ATOPIC ASTHMA; PROMOTER POLYMORPHISM; GENE POLYMORPHISM; CD14 GENE; ASSOCIATION; TNF-ALPHA-308; RECEPTOR; ALLELES; ALLERGY	Background: TNF-alpha is a pivotal proinflammatory cytokine increased in asthmatic airways. The TNF-alpha gene family might be linked to asthma or bronchial hyperresponsiveness (BHR), and TNF-alpha production might be modulated by CD14(+) cells. Objective: We investigated the association between asthma susceptibility or asthma-related phenotypes and TNF-alpha (-308G/A) polymorphism and examined the combined effect with CD14 (-159T/C) polymorphism in Korean children. Methods: Asthmatic (n = 788) and control (n = 153) children were evaluated for asthma phenotypes. Genotypes were determined by using the single-base extension method and PCR-restriction fragment length polymorphism. Results: There was no difference between asthmatic children and control subjects in terms of the allele frequencies of TNF-alpha (-308G/A) and CD14 (-159T/C). Significantly lower PC20 values were seen in asthmatic (P = .016) children with the TNF-a risk allele (-308A). Higher frequencies of 1 or 2 copies of the risk allele were found in asthmatic children with moderate-to-severe BHR to methacholine and exercise compared with control children (adjusted odds ratio of 2.57 [95% CI, 1.30-5.08] and adjusted odds ratio of 2.04 [95% CI 0.99-4.20], respectively). In addition, asthmatic children with risk alleles at both loci had significantly greater BHR than those homozygous for the common alleles (P = .018). Conclusion: The TNF-alpha promoter polymorphism (-308GIA) might be associated with severe BHR in Korean children with asthma. In addition, these children show a synergistic effect between the TNF-a promoter (-308A) and CD14 promoter (-159C) polymorphisms in terms of BHR. Clinical implications: The TNF-alpha polymorphism might be a disease-modifying gene in asthma and modulated by the CD14 gene.	Soonchunhyang Univ, Bucheon Hosp, Div Allergy & Resp Med, Dept Internal Med, Puchon 420021, Gyeonggi Do, South Korea; Univ Ulsan, Coll Med, Dept Pediat, Seoul, South Korea; Univ Ulsan, Asan Inst Life Sci, Seoul, South Korea; Hallym Univ, Coll Med, Dept Pediat, Hangang Sacred Heart Hosp, Seoul, South Korea; SNP Genet Inc, Dept Genet Epidemiol, Seoul, South Korea	Soonchunhyang University; University of Ulsan; University of Ulsan; Hallym University; SNP Genetics	Park, CS (corresponding author), Soonchunhyang Univ, Bucheon Hosp, Div Allergy & Resp Med, Dept Internal Med, 1174,Jung Dong, Puchon 420021, Gyeonggi Do, South Korea.	mdcspark@unitel.co.kr	Hong, Soo-Jong/AAR-1788-2020	Hong, Soo-Jong/0000-0003-1409-2113				Albuquerque RV, 1998, CLIN EXP ALLERGY, V28, P578; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; Baldini M, 1999, AM J RESP CELL MOL, V20, P976, DOI 10.1165/ajrcmb.20.5.3494; Berry MA, 2006, NEW ENGL J MED, V354, P697, DOI 10.1056/NEJMoa050580; Buckova D, 2002, J INVEST ALLERG CLIN, V12, P192; Busse William W., 2000, Journal of Allergy and Clinical Immunology, V106, P1033; Castro J, 2000, J INVEST ALLERG CLIN, V10, P149; Chagani T, 1999, AM J RESP CRIT CARE, V160, P278, DOI 10.1164/ajrccm.160.1.9808032; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; Di Somma C, 2003, HUM IMMUNOL, V64, P359, DOI 10.1016/S0198-8859(02)00819-4; Dobrovolskaia MA, 2002, MICROBES INFECT, V4, P903, DOI 10.1016/S1286-4579(02)01613-1; El Bahlawan L, 2003, CHEST, V123, p374S, DOI 10.1378/chest.123.3_suppl.374S-a; Gao J, 2006, THORAX, V61, P466, DOI 10.1136/thx.2005.051284; Gao PS, 1999, CLIN GENET, V56, P164; Howarth PH, 2005, THORAX, V60, P1012, DOI 10.1136/thx.2005.045260; KAM L, 1997, P NATL ACAD SCI USA, V173, P209; Kay AB, 2001, NEW ENGL J MED, V344, P30, DOI 10.1056/NEJM200101043440106; Kim HB, 2006, J ALLERGY CLIN IMMUN, V117, P1191, DOI 10.1016/j.jaci.2005.12.1361; KIPS JC, 1992, AM REV RESPIR DIS, V145, P332, DOI 10.1164/ajrccm/145.2_Pt_1.332; Knight JC, 2003, NAT GENET, V33, P469, DOI 10.1038/ng1124; Koppelman GH, 2001, AM J RESP CRIT CARE, V163, P965, DOI 10.1164/ajrccm.163.4.2004164; Koppelman GH, 2000, ASTHMA, P146; Landmann R, 2000, MICROBES INFECT, V2, P295, DOI 10.1016/S1286-4579(00)00298-7; Lee SG, 2004, CLIN EXP ALLERGY, V34, P1202, DOI 10.1111/j.1365-2222.2004.02015.x; Lin YC, 2002, ALLERGY, V57, P831, DOI 10.1034/j.1398-9995.2002.23719.x; Louis E, 1998, CLIN EXP IMMUNOL, V113, P401; Louis R, 2000, EUR RESPIR J, V16, P604, DOI 10.1034/j.1399-3003.2000.16d06.x; MANOGUE KR, 1991, CYTOKINE HDB, P241; MING WJ, 1987, J IMMUNOL, V138, P1469; Moffatt MF, 1997, HUM MOL GENET, V6, P551, DOI 10.1093/hmg/6.4.551; Moffatt MF, 1999, THORAX, V54, P757, DOI 10.1136/thx.54.9.757; Noguchi E, 2002, AM J RESP CRIT CARE, V166, P43, DOI 10.1164/rccm.2110052; Randolph AG, 2005, AM J RESP CRIT CARE, V172, P687, DOI 10.1164/rccm.200501-122OC; Sengler C, 2003, CLIN EXP ALLERGY, V33, P166, DOI 10.1046/j.1365-2222.2003.01549.x; Shin HD, 2004, HUM MOL GENET, V13, P397, DOI 10.1093/hmg/ddh036; SHULMAN DI, 1992, J PEDIATR GASTR NUTR, V14, P3, DOI 10.1097/00005176-199201000-00002; Thomas PS, 2002, THORAX, V57, P774, DOI 10.1136/thorax.57.9.774; THOMAS PS, 1995, AM J RESP CRIT CARE, V152, P76, DOI 10.1164/ajrccm.152.1.7599866; Ulbrich H, 2003, TRENDS PHARMACOL SCI, V24, P640, DOI 10.1016/j.tips.2003.10.004; Vercelli D, 2002, J ALLERGY CLIN IMMUN, V109, P14, DOI 10.1067/mai.2002.121015; Wa TCLK, 1999, CLIN EXP ALLERGY, V29, P1204; Wang TN, 2004, CLIN EXP ALLERGY, V34, P184, DOI 10.1111/j.1365-2222.2004.01867.x; Wedzicha JA, 2003, THORAX, V58, P1, DOI 10.1136/thorax.58.1.1; Wilson AG, 1997, P NATL ACAD SCI USA, V94, P3195, DOI 10.1073/pnas.94.7.3195; Winchester EC, 2000, HUM GENET, V107, P591, DOI 10.1007/s004390000410; Witte JS, 2002, EUR J HUM GENET, V10, P82, DOI 10.1038/sj.ejhg.5200746; Xu JF, 2001, AM J HUM GENET, V68, P1437, DOI 10.1086/320589; ZIEGLERHEITBROCK HWL, 1993, IMMUNOL TODAY, V14, P121, DOI 10.1016/0167-5699(93)90212-4	49	37	39	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2007	119	2					398	404		10.1016/j.jaci.2006.10.031	http://dx.doi.org/10.1016/j.jaci.2006.10.031			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137YB	17196641				2022-12-18	WOS:000244327900018
J	Sanchez-Monge, R; Blanco, C; Lopez-Torrejon, G; Cumplido, J; Recas, M; Figueroa, J; Carrillo, T; Salcedo, G				Sanchez-Monge, Rosa; Blanco, Carlos; Lopez-Torrejon, Gema; Cumplido, Jose; Recas, Munia; Figueroa, Javier; Carrillo, Teresa; Salcedo, Gabriel			Differential allergen sensitization patterns in chestnut allergy with or without associated latex-fruit syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chestnut; food allergy; latex-fruit syndrome; lipid transfer protein; class I chitinase; hevein; mugwort pollen; peach	LIPID-TRANSFER PROTEINS; PLANT-DERIVED FOODS; CLASS-I CHITINASES; CROSS-REACTIVITY; CLINICAL-FEATURES; ARTEMISIA POLLEN; HEVEA LATEX; IDENTIFICATION; BINDING; IGE	Background: Chestnut allergy has been almost exclusively considered in the context of the latex-fruit syndrome. Chestnut allergens not linked to latex hypersensitivity have not been studied. Objective: We sought to explore whether differences in sensitization patterns between chestnut allergy with or without associated latex-fruit syndrome can be detected. Methods: Twelve patients sensitized to chestnut but not to latex and 3 control patients with latex-chestnut allergy were analyzed. A major chestnut allergen was purified and characterized. IgE immunoblotting, specific IgE determination, and skin prick tests with 5 isolated allergens involved in food allergy or latex-fruit syndrome were also performed. Results: A major 9-kd allergen was detected in chestnut extract, isolated, and identified as lipid transfer protein (LTP) Cas s 8. Specific IgE to this allergen was found in 91% (by means of IgE immunoblotting) and 58% (by means of ELISA) of sera from patients with chestnut but not latex allergy. Moreover, 66% of these patients had positive skin prick test responses to Cas s 8. Additionally, allergenic Ups from peach fruit and Artemisia vulgaris pollen were also reactive. In contrast, avocado class I chitinase and latex hevein, allergens associated with the latex-fruit syndrome, showed no reaction. The opposite situation was exhibited by patients with latex-chestnut allergy. Conclusions: Patients with chestnut allergy with or without associated latex hypersensitivity present different patterns of major allergens (LTPs and class I chitinases, respectively). Clinical implications: LTPs and class I chitinases can be used as diagnostic tools in patients with chestnut allergy to predict whether an associated latex sensitization and a risk of potential cross-reactivity with other plant foods and pollens exist.	UPM, Unidad Bioquim, Dept Biotechnol, ETS Ingn Agron, Madrid 28040, Spain; Univ Dr Negrin, Las Palmas Gran Canaria, Spain	Universidad Politecnica de Madrid	Salcedo, G (corresponding author), UPM, Unidad Bioquim, Dept Biotechnol, ETS Ingn Agron, Ciudad Univ, Madrid 28040, Spain.	gabriel.salcedo@upm.es	Blanco, Carlos/B-3895-2012	Blanco, Carlos/0000-0002-2893-6594; Lopez-Torrejon, Gema/0000-0003-2588-4378				Asero R, 2005, J ALLERGY CLIN IMMUN, V115, P1312, DOI 10.1016/j.jaci.2005.02.018; Beezhold DH, 2003, ANN ALLERG ASTHMA IM, V90, P439, DOI 10.1016/S1081-1206(10)61830-3; Bjorksten B, 2004, CLIN EXP ALLERGY, V34, P673, DOI 10.1111/j.1365-2222.2004.1936.x; Blanco C, 1999, J ALLERGY CLIN IMMUN, V103, P507, DOI 10.1016/S0091-6749(99)70478-1; Blanco C, 2003, CURR ALLERGY ASTHM R, V3, P47, DOI 10.1007/s11882-003-0012-y; BLANCO C, 1994, ANN ALLERGY, V73, P309; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen ZP, 1997, J ALLERGY CLIN IMMUN, V99, P402, DOI 10.1016/S0091-6749(97)70059-9; Chen ZP, 1998, J ALLERGY CLIN IMMUN, V102, P476, DOI 10.1016/S0091-6749(98)70138-1; DECORRES LF, 1993, ANN ALLERGY, V70, P35; Diaz-Perales A, 1998, J ALLERGY CLIN IMMUN, V102, P127, DOI 10.1016/S0091-6749(98)70063-6; Diaz-Perales A, 2003, J ALLERGY CLIN IMMUN, V111, P628, DOI 10.1067/mai.2003.75; Diaz-Perales A, 2000, CLIN EXP ALLERGY, V30, P1403, DOI 10.1046/j.1365-2222.2000.00909.x; Figueroa J, 2005, ALLERGY, V60, P48, DOI 10.1111/j.1398-9995.2005.00644.x; Garcia-Selles FJ, 2002, INT ARCH ALLERGY IMM, V128, P115, DOI 10.1159/000059401; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee SK, 2005, J KOREAN MED SCI, V20, P573, DOI 10.3346/jkms.2005.20.4.573; Mikkola JH, 1998, J ALLERGY CLIN IMMUN, V102, P1005, DOI 10.1016/S0091-6749(98)70339-2; Palacin A, 2006, J ALLERGY CLIN IMMUN, V117, P1423, DOI 10.1016/j.jaci.2006.01.026; RODRIGUEZ M, 1993, ANN ALLERGY, V70, P31; Roux KH, 2003, INT ARCH ALLERGY IMM, V131, P234, DOI 10.1159/000072135; Salcedo G, 2001, CURR OPIN ALLERGY CL, V1, P177, DOI 10.1097/00130832-200104000-00010; SANCHEZMADRID F, 1984, J IMMUNOL METHODS, V73, P367, DOI 10.1016/0022-1759(84)90412-5; Sicherer SH, 2005, J ALLERGY CLIN IMMUN, V116, P153, DOI 10.1016/j.jaci.2005.03.017; Yagami T, 1998, J ALLERGY CLIN IMMUN, V101, P379, DOI 10.1016/S0091-6749(98)70251-9	25	37	38	0	7	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2006	118	3					705	710		10.1016/j.jaci.2006.04.058	http://dx.doi.org/10.1016/j.jaci.2006.04.058			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086BV	16950291				2022-12-18	WOS:000240649000025
J	Liu, SM; Xavier, R; Good, KL; Chtanova, T; Newton, R; Sisavanh, M; Zimmer, S; Deng, CY; Silva, DG; Frost, MJ; Tangye, SG; Rolph, MS; Mackay, CR				Liu, Sue M.; Xavier, Ramnik; Good, Kim L.; Chtanova, Tatyana; Newton, Rebecca; Sisavanh, Mary; Zimmer, Sabine; Deng, Chaoyang; Silva, Diego G.; Frost, Melinda J.; Tangye, Stuart G.; Rolph, Michael S.; Mackay, Charles R.			Immune cell transcriptome datasets reveal novel leukocyte subset-specific genes and genes associated with allergic processes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; gene profiling; leukocyte-specific; toll-like receptors	HUMAN MAST-CELLS; B-CELLS; DENDRITIC CELL; T-CELLS; MICROARRAY EXPRESSION; ASTHMA PATHOGENESIS; BONE-MARROW; RECEPTOR; RESPONSES; MOUSE	Background: The precise function of various resting and activated leukocyte subsets remains unclear. For instance, mast cells, basophils, and eosinophils play important roles in allergic inflammation but also participate in other immunologic responses. One strategy to understand leukocyte subset function is to define the expression and function of subset-restricted molecules. Objective: To use a microarray dataset and bioinformatics strategies to identify novel leukocyte markers as well as genes associated with allergic or innate responses. Methods: By using Affymetrix microarrays, we generated an immune transcriptome dataset composed of gene profiles from all of the major leukocyte subsets, including rare enigmatic subsets such as mast cells, basophils, and plasma cells. We also assessed whether analysis of genes expressed commonly by certain groups of leukocytes, such as allergic leukocytes, might identify genes associated with particular responses. Results: Transcripts highly restricted to a single leukocyte subset were readily identified (> 2000 subset-specific transcripts), many of which have not been associated previously with leukocyte functions. Transcripts expressed exclusively by allergy-related leukocytes revealed well known as well as novel molecules, many of which presumably contribute to allergic responses. Likewise, Nearest Neighbor Analysis of genes coexpressed with Toll-like receptors identified genes of potential relevance for innate immunity. Conclusion: Gene profiles from all of the major human leukocyte subsets provide a powerful means to identify genes associated with single leukocyte subsets, or different types of immune response. Clinical implications: A comprehensive dataset of gene expression profiles of human leukocytes should provide new targets or biomarkers for human inflammatory diseases.	Garvan Inst Med Res, Immunol & Inflammat Res Program, Sydney, NSW 2010, Australia; Univ Sydney, Cooperat Res Ctr Asthma, Sydney, NSW 2006, Australia; Univ New S Wales, Fac Med, St Vincents Clin Sch, Sydney, NSW, Australia; Massachusetts Gen Hosp, Dept Med & Mol Biol, Boston, MA 02114 USA; Centenary Inst Canc Med & Cell Biol, Camperdown, NSW, Australia; MIT, Ctr Canc Res, Cambridge, MA 02139 USA; Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2601, Australia	Garvan Institute of Medical Research; University of Sydney; University of New South Wales Sydney; Harvard University; Massachusetts General Hospital; University of Sydney; Centenary Institute; Massachusetts Institute of Technology (MIT); Australian National University; John Curtin School of Medical Research	Mackay, CR (corresponding author), Garvan Inst Med Res, Immunol & Inflammat Res Program, 384 Victoria St, Sydney, NSW 2010, Australia.	c.mackay@garvan.org.au	Tangye, Stuart G/H-4023-2014; Mackay, Charles R/A-9673-2008	Tangye, Stuart G/0000-0002-5360-5180; Mackay, Charles R/0000-0002-6338-7340; Chtanova, Tatyana/0000-0003-3419-4483; Liu, Sue Min/0000-0003-1504-1115; Good-Jacobson, Kim/0000-0003-1891-7274	NIDDK NIH HHS [P30 DK040561-11, P30 DK040561] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK040561] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abbas AR, 2005, GENES IMMUN, V6, P319, DOI 10.1038/sj.gene.6364173; AIDA Y, 1990, J IMMUNOL, V145, P3017; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Avery DT, 2003, J CLIN INVEST, V112, P286, DOI 10.1172/JCI200318025; Benoist C, 2002, NATURE, V420, P875, DOI 10.1038/nature01324; Chtanova T, 2004, J IMMUNOL, V173, P68, DOI 10.4049/jimmunol.173.1.68; Chtanova T, 2005, J IMMUNOL, V175, P7837, DOI 10.4049/jimmunol.175.12.7837; Chtanova T, 2001, J IMMUNOL, V167, P3057, DOI 10.4049/jimmunol.167.6.3057; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Edwards JCW, 2004, NEW ENGL J MED, V350, P2572, DOI 10.1056/NEJMoa032534; Ellyard JI, 2004, BLOOD, V103, P3805, DOI 10.1182/blood-2003-09-3109; Feske S, 2001, NAT IMMUNOL, V2, P316, DOI 10.1038/86318; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Fulkerson PC, 2004, P NATL ACAD SCI USA, V101, P1987, DOI 10.1073/pnas.0308544100; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; HANSEL TT, 1989, J IMMUNOL METHODS, V122, P97, DOI 10.1016/0022-1759(89)90339-6; Huang Q, 2001, SCIENCE, V294, P870, DOI 10.1126/science.294.5543.870; Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283; Jeffrey KL, 2006, NAT IMMUNOL, V7, P274, DOI 10.1038/ni1310; Koopman LA, 2003, J EXP MED, V198, P1201, DOI 10.1084/jem.20030305; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; LANZAVECCHIA A, 1985, NATURE, V314, P537, DOI 10.1038/314537a0; Manger ID, 2000, CURR OPIN IMMUNOL, V12, P215, DOI 10.1016/S0952-7915(99)00077-1; Mootha VK, 2003, P NATL ACAD SCI USA, V100, P605, DOI 10.1073/pnas.242716699; Mukai K, 2005, IMMUNITY, V23, P191, DOI 10.1016/j.immuni.2005.06.011; Nagata K, 1999, FEBS LETT, V459, P195, DOI 10.1016/S0014-5793(99)01251-X; Nakajima T, 2002, BLOOD, V100, P3861, DOI 10.1182/blood-2002-02-0602; Nakajima T, 2001, BLOOD, V98, P1127, DOI 10.1182/blood.V98.4.1127; Nau GJ, 2002, P NATL ACAD SCI USA, V99, P1503, DOI 10.1073/pnas.022649799; Ng LG, 2004, J IMMUNOL, V173, P807, DOI 10.4049/jimmunol.173.2.807; Ochi H, 1999, J EXP MED, V190, P267, DOI 10.1084/jem.190.2.267; Ohl L, 2003, J EXP MED, V197, P1199, DOI 10.1084/jem.20030169; Oliveira SHP, 2002, BLOOD, V100, P4291, DOI 10.1182/blood.V100.13.4291; REFF ME, 1994, BLOOD, V83, P435; Rolph MS, 2006, PHARMACOL THERAPEUT, V109, P284, DOI 10.1016/j.pharmthera.2005.08.009; Sallusto F, 2004, CURR OPIN IMMUNOL, V16, P724, DOI 10.1016/j.coi.2004.09.012; Sallusto F, 2000, IMMUNOL REV, V177, P134, DOI 10.1034/j.1600-065X.2000.17717.x; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Sayama Koichi, 2002, BMC Immunol, V3, P5, DOI 10.1186/1471-2172-3-5; Sehmi R, 1997, J CLIN INVEST, V100, P2466, DOI 10.1172/JCI119789; Shaffer AL, 2001, IMMUNITY, V15, P375, DOI 10.1016/S1074-7613(01)00194-7; Spik I, 2005, J IMMUNOL, V174, P3703, DOI 10.4049/jimmunol.174.6.3703; Staudt LM, 2003, NEW ENGL J MED, V348, P1777, DOI 10.1056/NEJMra020067; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Tangye SG, 2003, J IMMUNOL, V170, P686, DOI 10.4049/jimmunol.170.2.686; Tureci O, 2003, FASEB J, V17, P836, DOI 10.1096/fj.02-0724com; Underhill GH, 2003, BLOOD, V101, P4013, DOI 10.1182/blood-2002-08-2673; Zimmermann N, 2003, J CLIN INVEST, V111, P1863, DOI 10.1172/JCI200317912	48	37	43	0	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2006	118	2					496	503		10.1016/j.jaci.2006.04.040	http://dx.doi.org/10.1016/j.jaci.2006.04.040			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	075IH	16890777				2022-12-18	WOS:000239877700028
J	Horner, AA				Horner, Anthony A.			Toll-like receptor ligands and atopy: A coin with at least two sides	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						hygiene hypothesis; toll-like receptor; peptidoglycan; LPS; immunostimulatory sequence oligodeoxynucleotide; CpG motif; asthma; allergy	INDUCE DIFFERENT CLASSES; HEAT-KILLED LISTERIA; HOUSE-DUST MITE; DENDRITIC CELLS; CUTTING EDGE; TUBERCULOSIS INFECTION; INVERSE ASSOCIATION; IMMUNE-RESPONSES; BCG VACCINATION; BACTERIAL-DNA	Allergic disease prevalence rates have increased dramatically in affluent countries over the last half century. One proposed explanation is that decreased exposures to microbes caused by modern public health practices has led to deficiencies in an important source of immune education and a consequent increase in the risk of pathogenic immune responses to environmental antigens. Recently, it has become clear that innate responses to microbes are mediated in large part by Toll-like receptors (TLRs), which recognize a diverse family of ligands produced by viruses, bacteria, and fungi. In this perspectives article we will review experimental evidence suggesting that TLRs also play a dominant role in innate responses to noninfectious immunostimulatory materials present in environments of daily living. We will further discuss how ligands for different TLRs can polarize the T-H bias of adaptive responses in opposing directions. Finally, we will consider how TLRs might contribute to the genesis of atopy and the clinical potential of pharmacologic interventions that target TLRs for the prevention and treatment of allergic diseases.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA; Univ Calif San Diego, Sam & Rose Stein Inst Aging, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Horner, AA (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr,Mail Code 0663, La Jolla, CA 92093 USA.	ahorner@ucsd.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI040682, R01AI061772] Funding Source: NIH RePORTER; NIAID NIH HHS [AI40682, AI61772] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abreu MT, 2005, J IMMUNOL, V174, P4453, DOI 10.4049/jimmunol.174.8.4453; Agrawal S, 2003, J IMMUNOL, V171, P4984, DOI 10.4049/jimmunol.171.10.4984; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Bauer S, 2001, P NATL ACAD SCI USA, V98, P9237, DOI 10.1073/pnas.161293498; Beutler B, 2004, NATURE, V430, P257, DOI 10.1038/nature02761; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342, DOI 10.1046/j.1365-2222.1999.00560.x; Bjorksten Bengt, 2005, Current Drug Targets - Inflammation and Allergy, V4, P599, DOI 10.2174/156801005774322135; Boasen J, 2005, J ALLERGY CLIN IMMUN, V116, P185, DOI 10.1016/j.jaci.2005.03.015; Boguniewicz M, 2001, SEMIN CUTAN MED SURG, V20, P217, DOI 10.1053/sder.2001.29379; Bohle B, 1999, EUR J IMMUNOL, V29, P2344, DOI 10.1002/(SICI)1521-4141(199907)29:07<2344::AID-IMMU2344>3.0.CO;2-R; Bottcher MF, 2000, CLIN EXP ALLERGY, V30, P1590, DOI 10.1046/j.1365-2222.2000.00982.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Broide DH, 2001, J CLIN IMMUNOL, V21, P175, DOI 10.1023/A:1011078930363; Brugnolo F, 2003, J ALLERGY CLIN IMMUN, V111, P380, DOI 10.1067/mai.2003.102; Chisholm D, 2004, J ALLERGY CLIN IMMUN, V113, P448, DOI 10.1016/j.jaci.2003.12.011; Creticos PS, 2000, J ALLERGY CLIN IMMUN, V105, pS70, DOI 10.1016/S0091-6749(00)90645-6; Didierlaurent A, 2004, J IMMUNOL, V172, P6922, DOI 10.4049/jimmunol.172.11.6922; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Frew AJ, 2005, J ALLERGY CLIN IMMUN, V115, P1197, DOI 10.1016/j.jaci.2005.03.006; Frick OL, 2005, ALLERGY, V60, P243, DOI 10.1111/j.1398-9995.2004.00711.x; Garcia-Marcosa L, 2005, INT ARCH ALLERGY IMM, V137, P303, DOI 10.1159/000086461; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gereda JE, 2001, J ALLERGY CLIN IMMUN, V107, P790, DOI 10.1067/mai.2001.115245; Halperin SA, 2003, VACCINE, V21, P2461, DOI 10.1016/S0264-410X(03)00045-8; Hansen G, 2000, J IMMUNOL, V164, P223, DOI 10.4049/jimmunol.164.1.223; Hayashi T, 2004, J CLIN INVEST, V114, P270, DOI 10.1172/JCI200421275; Herz U, 1998, J ALLERGY CLIN IMMUN, V102, P867, DOI 10.1016/S0091-6749(98)70030-2; Homer AA, 2001, J ALLERGY CLIN IMMUN, V108, P417, DOI 10.1067/mai.2001.117795; HOMER AA, 2003, CURR OPIN IMMUNOL, V15, P614; HOMER AA, 2002, J ALLERGY CLIN IMMUN, V110, P413; HOMER AA, 2002, J ALLERGY CLIN IMMUN, V110, P706; Horner AA, 2001, J IMMUNOL, V167, P1584, DOI 10.4049/jimmunol.167.3.1584; Huss K, 2001, J ALLERGY CLIN IMMUN, V107, P48, DOI 10.1067/mai.2001.111146; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Janssen R, 2001, IMMUNOLOGY, V102, P441, DOI 10.1046/j.1365-2567.2001.01207.x; Kaisho T, 2002, INT IMMUNOL, V14, P695, DOI 10.1093/intimm/dxf039; Kaisho T, 2006, J ALLERGY CLIN IMMUN, V117, P979, DOI 10.1016/j.jaci.2006.02.023; Kobayashi H, 1999, CELL IMMUNOL, V198, P69, DOI 10.1006/cimm.1999.1572; Krause TG, 2003, JAMA-J AM MED ASSOC, V289, P1012, DOI 10.1001/jama.289.8.1012; Kruisselbrink A, 2001, CLIN EXP IMMUNOL, V126, P2, DOI 10.1046/j.1365-2249.2001.01642.x; Li XM, 2003, J ALLERGY CLIN IMMUN, V112, P159, DOI 10.1067/mai.2003.1622; Marks GB, 2003, J ALLERGY CLIN IMMUN, V111, P541, DOI 10.1067/mai.2003.171; Matsui K, 2002, CLIN EXP ALLERGY, V32, P783, DOI 10.1046/j.1365-2222.2002.01357.x; McCurdy JD, 2003, J IMMUNOL, V170, P1625, DOI 10.4049/jimmunol.170.4.1625; Medzhitov R, 2000, IMMUNOL REV, V173, P89, DOI 10.1034/j.1600-065X.2000.917309.x; Mellor AL, 2005, J IMMUNOL, V175, P5601, DOI 10.4049/jimmunol.175.9.5601; Moseman EA, 2004, J IMMUNOL, V173, P4433, DOI 10.4049/jimmunol.173.7.4433; Moynagh PN, 2005, TRENDS IMMUNOL, V26, P469, DOI 10.1016/j.it.2005.06.009; Obihara CC, 2005, ALLERGY, V60, P1121, DOI 10.1111/j.1398-9995.2005.00834.x; Patel M, 2005, J IMMUNOL, V174, P7558, DOI 10.4049/jimmunol.174.12.7558; Perzanowski MS, 2006, J ALLERGY CLIN IMMUN, V117, P1082, DOI 10.1016/j.jaci.2005.12.1348; Platts-Mills TAE, 2004, SPRINGER SEMIN IMMUN, V25, P271, DOI 10.1007/s00281-003-0149-8; PLATTSMILLS TAE, 1991, INT ARCH ALLER A IMM, V94, P339, DOI 10.1159/000235398; Pulendran B, 2001, J IMMUNOL, V167, P5067, DOI 10.4049/jimmunol.167.9.5067; PURKERSON JM, 1994, J EXP MED, V179, P1877, DOI 10.1084/jem.179.6.1877; Racila DM, 2005, J ALLERGY CLIN IMMUN, V116, P1202, DOI 10.1016/j.jaci.2005.08.050; Rautava S, 2005, J ALLERGY CLIN IMMUN, V116, P31, DOI 10.1016/j.jaci.2005.02.010; Re F, 2001, J BIOL CHEM, V276, P37692, DOI 10.1074/jbc.M105927200; Rhee CS, 2004, IMMUNOLOGY, V113, P106, DOI 10.1111/j.1365-2567.2004.01930.x; Rifkin IR, 2005, IMMUNOL REV, V204, P27, DOI 10.1111/j.0105-2896.2005.00239.x; Roy SR, 2003, J ALLERGY CLIN IMMUN, V112, P571, DOI 10.1067/mai.2003.1711; Saxon A, 2005, NAT IMMUNOL, V6, P223, DOI 10.1038/ni0305-223; Schaub B, 2006, J ALLERGY CLIN IMMUN, V117, P969, DOI 10.1016/j.jaci.2006.03.003; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Simons FER, 2004, J ALLERGY CLIN IMMUN, V113, P1144, DOI 10.1016/j.jaci.2004.03.003; Supajatura V, 2002, J CLIN INVEST, V109, P1351, DOI 10.1172/JCI200214704; Takabayashi K, 2003, J IMMUNOL, V170, P3898, DOI 10.4049/jimmunol.170.7.3898; Tighe H, 2000, EUR J IMMUNOL, V30, P1939, DOI 10.1002/1521-4141(200007)30:7<1939::AID-IMMU1939>3.0.CO;2-#; Tsalik EL, 2005, ANN ALLERG ASTHMA IM, V95, P403, DOI 10.1016/S1081-1206(10)61163-5; Tulic MK, 2000, AM J RESP CELL MOL, V22, P604; Tulic MK, 2004, J ALLERGY CLIN IMMUN, V113, P235, DOI 10.1016/j.jaci.2003.11.001; van Strien RT, 2004, J ALLERGY CLIN IMMUN, V113, P860, DOI 10.1016/j.jaci.2004.01.078; Wang LL, 2002, J CLIN INVEST, V110, P1175, DOI 10.1172/JCI200215536; Yarovinsky F, 2005, SCIENCE, V308, P1626, DOI 10.1126/science.1109893; Zuany-Amorim C, 2002, NAT MED, V8, P625, DOI 10.1038/nm0602-625	75	37	42	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2006	117	5					1133	1140		10.1016/j.jaci.2006.02.035	http://dx.doi.org/10.1016/j.jaci.2006.02.035			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	041EM	16675343				2022-12-18	WOS:000237436300026
J	Nakajima-Adachi, H; Ebihara, A; Kikuchi, A; Ishida, T; Sasaki, K; Hirano, K; Watanabe, H; Asai, K; Takahashi, Y; Kanamori, Y; Shimojo, N; Matsuda, H; Kohno, Y; Hachimura, S; Kaminogawa, S				Nakajima-Adachi, Haruyo; Ebihara, Ayumi; Kikuchi, Akira; Ishida, Tsuyoshi; Sasaki, Kiyomi; Hirano, Kiyomi; Watanabe, Hiroko; Asai, Kazumi; Takahashi, Yoshimasa; Kanamori, Yutaka; Shimojo, Naoki; Matsuda, Hiroshi; Kohno, Yoichi; Hachimura, Satoshi; Kaminogawa, Shuichi			Food antigen causes T(H)2-dependent enteropathy followed by tissue repair in T-cell receptor transgenic mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T-cell receptor transgenic mouse; food-sensitive intestinal inflammation; ovalbumin; food antigen intake; antigen-specific T cells; IgE; mast cell; T(H)2; histamine; tissue repair	SMALL-INTESTINAL-MUCOSA; COWS-MILK; MURINE MODEL; IGE; LYMPHOCYTES; FREQUENCY; DISEASE; ALLERGY	Background: Clarification of the mechanisms underlying the development of food-sensitive intestinal inflammation will provide an important clue to combating food allergies. Objective: To establish a model of intestinal inflammation caused by oral administration of antigen without additional treatments, we focused on the ovalbumin (OVA) 23-3 T-cell receptor transgenic mouse, which had been reported to have high serum antigen-specific IgE responses to the feeding of an egg white diet. Methods: Changes in body weight of mice fed an egg white diet were monitored throughout tire 28-day experimental period. After the 28-day feeding, intestinal tissues were harvested for histologic examination. Endogenous production of cytokines and histamine in the jejunum, and production of cytokines secreted by OVA-specific CD4(+) T cells purified from mesenteric lymph nodes, were analyzed. Results: Egg white diet-fed OVA23-3 mice developed weight loss and inflammation with villous atrophy and goblet cell hyperplasia, especially in the jejunum. A further characteristic feature was evidence of weight recovery and tissue repair. Jejunal inflammation was also observed in egg white diet-fed recombination activating gene (RAG)-2-deficient OVA23-3 mice. In addition, tissue sections revealed significant infiltration of specific IgE-positive cells and IgE-positive degranulating mast cells. Higher levels of IL-4 and significant levels of histamine were detected in the tissues. In the supernatant of OVA-stimulated T cells, IL-10 levels were also markedly elevated. Conclusion: We report that high-dose and continuous intake of primitive OVA alone induces enteropathy containing regions under repair in OVA23-3 mice. Antigen-specific T cells and inflammatory cells primed by T(H)2- responses play important roles in regulation of development and improvement of the disease. Clinical implications: Long-term antigen intake causes T(H)2-dependent and food-sensitive enteropathy followed by tissue repair.	Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Bunkyo Ku, Tokyo 1138657, Japan; Nippon Telegraph & Tel E Corp, Kanto Med Ctr, Dept Diagnost Pathol, Tokyo, Japan; Chiba Univ, Dept Pediat, Chiba, Japan; Kanagawa Prefectural Inst Publ Hlth, Div Chem, Kanagawa, Japan; Natl Inst Infect Dis, Dept Immunol, Tokyo, Japan; Univ Tokyo, Dept Pediat Surg, Tokyo 1138657, Japan; Tokyo Univ Agr & Technol, Grad Sch, Div Anim Sci, Inst Symbiot Sci & Technol, Tokyo, Japan; Nihon Univ, Coll Bioresource Sci, Dept Food Sci & Technol, Kanagawa, Japan	University of Tokyo; Kanto Medical Center NTT EC; Nippon Telegraph & Telephone Corporation; Chiba University; National Institute of Infectious Diseases (NIID); University of Tokyo; Tokyo University of Agriculture & Technology; Nihon University	Nakajima-Adachi, H (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	aryu@mail.ecc.u-tokyo.ac.jp	Matsuda, Hiroshi/C-8358-2013	Matsuda, Hiroshi/0000-0003-3189-6842; Takahashi, Yoshimasa/0000-0001-6342-4087				Akdis CA, 2003, J ALLERGY CLIN IMMUN, V112, P15, DOI 10.1067/mai.2003.1585; Allam JP, 2003, J ALLERGY CLIN IMMUN, V112, P141, DOI 10.1067/mai.2003.1607; Asai K, 2002, J IMMUNOL, V169, P4723, DOI 10.4049/jimmunol.169.9.4723; Brandt EB, 2003, J CLIN INVEST, V112, P1666, DOI 10.1172/JCI19785; Dohi T, 2003, GASTROENTEROLOGY, V124, P672, DOI 10.1053/gast.2003.50092; Dupont C, 2000, J PEDIATR GASTR NUTR, V30, pS50, DOI 10.1097/00005176-200001001-00008; Forbes E, 2004, GASTROENTEROLOGY, V127, P105, DOI 10.1053/j.gastro.2004.03.057; Hauer AC, 1997, PEDIATR RES, V42, P629, DOI 10.1203/00006450-199711000-00014; Helm RM, 2002, ANN NY ACAD SCI, V964, P139; Iqbal N, 2002, J EXP MED, V195, P71, DOI 10.1084/jem.2001889; Kweon MN, 2000, J CLIN INVEST, V106, P199, DOI 10.1172/JCI8490; Li XM, 1999, J ALLERGY CLIN IMMUN, V103, P206, DOI 10.1016/S0091-6749(99)70492-6; MALUENDA C, 1984, J PEDIATR GASTR NUTR, V3, P349, DOI 10.1097/00005176-198406000-00008; Nakajima H, 1996, J ALLERGY CLIN IMMUN, V97, P1342, DOI 10.1016/S0091-6749(96)70203-8; Nakajima-Adachi H, 1998, J ALLERGY CLIN IMMUN, V101, P660, DOI 10.1016/S0091-6749(98)70175-7; Newberry RD, 1999, NAT MED, V5, P900, DOI 10.1038/11341; Ohtsuka Y, 1996, PEDIATR RES, V39, P862, DOI 10.1203/00006450-199605000-00020; Ohtsuka Y, 1999, PEDIATR RES, V45, P300, DOI 10.1203/00006450-199903000-00002; Sampson HA, 2001, GASTROENTEROLOGY, V120, P1026, DOI 10.1053/gast.2001.23031; SATO T, 1994, EUR J IMMUNOL, V24, P1512, DOI 10.1002/eji.1830240708; Shida K, 2000, J ALLERGY CLIN IMMUN, V105, P788, DOI 10.1067/mai.2000.104934; SHINER M, 1975, LANCET, V1, P136; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; vanHalteren AGS, 1997, J ALLERGY CLIN IMMUN, V99, P94, DOI 10.1016/S0091-6749(97)81049-4; YAMANAKA H, 1989, J FOOD HYG SOC JPN, V30, P396; Yoshida M, 2002, GASTROENTEROLOGY, V123, P1949, DOI 10.1053/gast.2002.37049	26	37	38	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2006	117	5					1125	1132		10.1016/j.jaci.2006.01.016	http://dx.doi.org/10.1016/j.jaci.2006.01.016			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	041EM	16675342				2022-12-18	WOS:000237436300025
J	Yamashita, N; Tashimo, H; Matsuo, Y; Ishida, H; Yoshiura, K; Sato, K; Yamashita, N; Kakiuchi, T; Ohta, K				Yamashita, Naomi; Tashimo, Hiroyuki; Matsuo, Yukiko; Ishida, Hirofumi; Yoshiura, Kenta; Sato, Katsuaki; Yamashita, Naohide; Kakiuchi, Terutaka; Ohta, Ken			Role of CCL21 and CCL19 in allergic inflammation in the ovalbumin-specific murine asthmatic model	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; airway hyperresponsiveness; CCL21; dendritic cells; airway inflammation	LYMPHOID-ORGAN CHEMOKINE; MICE LACKING EXPRESSION; DENDRITIC CELLS; AIRWAY RESPONSIVENESS; T-CELLS; SENSITIZATION; INTERLEUKIN-5; IMMUNOLOGY; TOLERANCE; MIGRATION	Background: Dendritic cells are the most powerful of the antigen-presenting cells and are known to play important roles in sensitization and inflammation in allergen-specific asthma. Various cytokines and chemokines are involved in the maturation and activation of dendritic cells. Among them is CC chemokine ligand (CCL)21, a key chemokine in the entry of naive T cells and antigen-stimulated dendritic cells into the T-cell zones of secondary lymphoid organs, which is a critical process in antigen-specific T-cell activation. Objective: We studied the role of CCL21 in airway inflammation in asthma by using BALB/c-pit/pit (pit) juice, which possess genetic defects in expression of both CCL21 and CCL19. Methods: Pit and control BALB/c mice were immunized with ovalbumin and alum 4 times and thereafter were subjected to a 2-week regimen of ovalbumin inhalation. Results: In pit mice, ovalbumin-specific IgE response was delayed compared with control BALB/c mice, but they had the same level of response after final immunization. Although airway inflammation and response to acetylcholine were significantly reduced compared with BALB/c mice, significant eosinophilic inflammation and hyperresponsiveness were also observed in pit mice after 2 weeks of inhalation. Four weeks after cessation of inhalation, airway inflammation and hyperresponsiveness in pit mice were greater than in BALB/c mice. At the time of resolution of airway inflammation, IL-10 production was enhanced in BALB/c mice but not in pit mice. Conclusion: The chemokines CCL21 and CCL19 were critical for resolution of airway inflammation. Clinical implications: The findings about the chemokines for induction and resolution of inflammation are key to establishing a new strategy for asthma immunotherapy.	Musashino Univ, Dept Pharmacol, Pharmaceut Sci Res Inst, Tokyo, Japan; Teikyo Univ, Sch Med, Dept Med, Tokyo 173, Japan; RIKEN, Res Ctr Allergy & Immunol, Yokohama, Kanagawa, Japan; Univ Tokyo, Dept Adv Med Sci, Inst Med Sci, Tokyo, Japan; Toho Univ, Sch Med, Dept Immunol, Tokyo, Japan	Teikyo University; RIKEN; University of Tokyo; Toho University	Yamashita, N (corresponding author), Musashino Univ, Dept Pharmacol, Pharmaceut Sci Res Inst, 1-1-20 Shinmachi, Tokyo, Japan.	naoyama@musashino-u.ac.jp	Yamashita, Naomi/F-5045-2011					Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Bromley SK, 2005, NAT IMMUNOL, V6, P895, DOI 10.1038/ni1240; Chinen J, 2005, J ALLERGY CLIN IMMUN, V116, P411, DOI 10.1016/j.jaci.2005.05.010; Chinen J, 2004, J ALLERGY CLIN IMMUN, V114, P398, DOI 10.1016/j.jaci.2004.05.036; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; Cyster JG, 1999, SCIENCE, V286, P2098, DOI 10.1126/science.286.5447.2098; Debes GF, 2005, NAT IMMUNOL, V6, P889, DOI 10.1038/ni1238; Forster R, 1999, CELL, V99, P23, DOI 10.1016/S0092-8674(00)80059-8; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Gajewska BU, 2001, J CLIN INVEST, V108, P577, DOI 10.1172/JCI200112627; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Gunn MD, 1999, J EXP MED, V189, P451, DOI 10.1084/jem.189.3.451; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Huehn J, 2004, J EXP MED, V199, P303, DOI 10.1084/jem.20031562; Itakura M, 2001, J IMMUNOL, V166, P2071, DOI 10.4049/jimmunol.166.3.2071; Johnston B, 2003, J IMMUNOL, V171, P2960, DOI 10.4049/jimmunol.171.6.2960; Lambrecht BN, 2001, CURR OPIN ALLERGY CL, V1, P51, DOI 10.1097/00130832-200102000-00010; Lambrecht BN, 2000, CLIN EXP ALLERGY, V30, P214; McGeachy MJ, 2005, J IMMUNOL, V175, P3025, DOI 10.4049/jimmunol.175.5.3025; McHugh RS, 2002, J ALLERGY CLIN IMMUN, V110, P693, DOI 10.1067/mai.2002.129339; Morel PA, 2003, CLIN EXP IMMUNOL, V133, P1, DOI 10.1046/j.1365-2249.2003.02161.x; Mori S, 2001, J EXP MED, V193, P207, DOI 10.1084/jem.193.2.207; Nakano H, 1998, BLOOD, V91, P2886, DOI 10.1182/blood.V91.8.2886.2886_2886_2895; Nakano H, 2001, J IMMUNOL, V166, P361, DOI 10.4049/jimmunol.166.1.361; Nakano H, 2001, J EXP MED, V194, P1171, DOI 10.1084/jem.194.8.1171; Palucka K, 2002, CURR OPIN IMMUNOL, V14, P420, DOI 10.1016/S0952-7915(02)00365-5; Sallusto F, 2000, IMMUNOL REV, V177, P134, DOI 10.1034/j.1600-065X.2000.17717.x; Sanchez-Sanchez N, 2004, BLOOD, V104, P619, DOI 10.1182/blood-2003-11-3943; Stampfli MR, 1999, AM J RESP CELL MOL, V21, P586; Umetsu DT, 2003, J ALLERGY CLIN IMMUN, V112, P480, DOI 10.1067/mai.2003.1717; Vermaelen K, 2003, AM J RESP CELL MOL, V29, P405, DOI 10.1165/rcmb.2003-0008OC; Vogel G, 1998, SCIENCE, V282, P2168, DOI 10.1126/science.282.5397.2168a; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Yamashita N, 2002, CELL IMMUNOL, V219, P92, DOI 10.1016/S0008-8749(02)00565-8; Yamashita N, 2001, J ALLERGY CLIN IMMUN, V107, P135, DOI 10.1067/mai.2001.111433; Zemann B, 2003, J ALLERGY CLIN IMMUN, V111, P1069, DOI [10.1067/mai.2003.1411, 10.1067/mai.2003/1411]	36	37	40	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2006	117	5					1040	1046		10.1016/j.jaci.2006.01.009	http://dx.doi.org/10.1016/j.jaci.2006.01.009			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	041EM	16675330				2022-12-18	WOS:000237436300010
J	Miyahara, S; Miyahara, N; Takeda, K; Joetham, A; Gelfand, EW				Miyahara, S; Miyahara, N; Takeda, K; Joetham, A; Gelfand, EW			Physiologic assessment of allergic rhinitis in mice: Role of the high-affinity IgE receptor (Fc epsilon RI)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						rodent; rhinitis; hyperresponsiveness; allergy	EOSINOPHILIC AIRWAY INFLAMMATION; CD8(+) T-CELLS; MAST-CELL; IMMUNOGLOBULIN-E; LEUKOTRIENE B-4; MURINE MODEL; NASAL-MUCOSA; GUINEA-PIGS; HYPERRESPONSIVENESS; ASTHMA	Background: There have been few reports using animal models to study the development of allergic rhinitis. Characterization of such a model in mice would be advantageous given the availability of reagents and gene-manipulated strains. Objective: We sought to develop a murine model of allergic rhinitis in the absence of lower airway changes. Methods: After sensitization and challenge, both wild-type and Fe epsilon RI-deficient mice were studied for their ability to develop early- and late-phase nasal responses. In the invasive approach, direct measurements of nasal airway resistance (R-NA) were obtained; in the noninvasive approach using whole-body plethysmography, respiratory frequency and expiratory and inspiratory times were monitored. In both approaches, nasal responses were determined either acutely after challenge (early phase) or 24 hours after challenge (late phase). Results: After challenge of sensitized mice, R-NA significantly increased. In parallel, respiratory frequency significantly decreased and was highly correlated with the increases in R-NA-Sensitized wild-type mice had an early-phase nasal response and persistent nasal blockage (late-phase response) after allergen challenge. In contrast, sensitized and challenged Fc epsilon RI alpha-chain-deficient mice did not have an early-phase nasal reaction and exhibited reduced nasal blockage and lower IL-13 levels in nasal tissue homogenates. Conclusions: These data indicate that Fc epsilon RI is essential to development of an early-phase nasal response and contributes to the development of the late-phase nasal response. These invasive and noninvasive approaches provide new opportunities to evaluate the mechanisms underlying the development of nasal responses to allergen and to assess various therapeutic interventions.	Natl Jewish Med & Res Ctr, Dept Pediat, Div Cell Biol, Denver, CO 80206 USA	National Jewish Health	Gelfand, EW (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Cell Biol, 1400 Jackson St, Denver, CO 80206 USA.	gelfande@njc.org			NHLBI NIH HHS [HL-36577, HL-61005] Funding Source: Medline; NIAID NIH HHS [AI-42246] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577, R01HL061005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI042246, R01AI042246] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Asakura K, 1998, INT ARCH ALLERGY IMM, V116, P49, DOI 10.1159/000023924; BELLOFIORE S, 1987, AM REV RESPIR DIS, V136, P363, DOI 10.1164/ajrccm/136.2.363; BURD PR, 1995, J EXP MED, V181, P1373, DOI 10.1084/jem.181.4.1373; CORRADO OJ, 1987, BRIT J CLIN PHARMACO, V24, P283, DOI 10.1111/j.1365-2125.1987.tb03171.x; DIAZSANCHEZ D, 1994, J CLIN INVEST, V94, P1417, DOI 10.1172/JCI117478; Dombrowicz D, 1997, J CLIN INVEST, V99, P915, DOI 10.1172/JCI119256; DOMBROWICZ D, 1993, CELL, V75, P969, DOI 10.1016/0092-8674(93)90540-7; EPSTEIN MAF, 1978, RESP PHYSIOL, V32, P105, DOI 10.1016/0034-5687(78)90103-2; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; GAWIN AZ, 1991, J APPL PHYSIOL, V71, P2460, DOI 10.1152/jappl.1991.71.6.2460; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hamelmann E, 1999, AM J RESP CELL MOL, V21, P480, DOI 10.1165/ajrcmb.21.4.3659; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; ILIOPOULOS O, 1990, J ALLERGY CLIN IMMUN, V86, P851, DOI 10.1016/S0091-6749(05)80146-0; Iwasaki M, 2003, J ALLERGY CLIN IMMUN, V112, P134, DOI 10.1067/mai.2003.1554; JULIUSSON S, 1987, CLIN ALLERGY, V17, P301, DOI 10.1111/j.1365-2222.1987.tb02018.x; KleinJan A, 1997, J ALLERGY CLIN IMMUN, V99, P515, DOI 10.1016/S0091-6749(97)70079-4; Lee JJ, 2004, SCIENCE, V305, P1773, DOI 10.1126/science.1099472; Mayr SI, 2002, J IMMUNOL, V169, P2061, DOI 10.4049/jimmunol.169.4.2061; Miyahara N, 2004, NAT MED, V10, P865, DOI 10.1038/nm1081; MIZUNO H, 1991, JPN J PHARMACOL, V55, P321, DOI 10.1254/jjp.55.321; MYGIND N, 1984, CLIN REV ALLERG, V2, P173; Mygind N, 1987, Eur J Respir Dis Suppl, V153, P26; NACLERIO RM, 1991, NEW ENGL J MED, V325, P860; Ott VL, 2003, NAT IMMUNOL, V4, P974, DOI 10.1038/ni971; Pillow JJ, 2001, J APPL PHYSIOL, V91, P2730, DOI 10.1152/jappl.2001.91.6.2730; Saito H, 2001, IMMUNOLOGY, V104, P226, DOI 10.1046/j.1365-2567.2001.01253.x; SHERWOOD JE, 1993, J ALLERGY CLIN IMMUN, V92, P435, DOI 10.1016/0091-6749(93)90122-V; Skoner DR, 2001, J ALLERGY CLIN IMMUN, V108, pS2, DOI 10.1067/mai.2001.115569; TADA T, 1970, Journal of Immunology, V104, P377; Tager AM, 2003, NAT IMMUNOL, V4, P982, DOI 10.1038/ni970; Takeda K, 1997, J EXP MED, V186, P449, DOI 10.1084/jem.186.3.449; Taube C, 2004, J IMMUNOL, V172, P6398, DOI 10.4049/jimmunol.172.10.6398; Taube C, 2002, J IMMUNOL, V169, P6482, DOI 10.4049/jimmunol.169.11.6482; Tiniakov RL, 2003, J APPL PHYSIOL, V94, P1821, DOI 10.1152/japplphysiol.00930.2002; van de Rijn M, 1998, J ALLERGY CLIN IMMUN, V102, P65, DOI 10.1016/S0091-6749(98)70056-9; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258	37	37	40	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2005	116	5					1020	1027		10.1016/j.jaci.2005.08.020	http://dx.doi.org/10.1016/j.jaci.2005.08.020			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IG	16275370				2022-12-18	WOS:000235686700011
J	Boasen, J; Chisholm, D; Lebet, L; Akira, S; Horner, AA				Boasen, J; Chisholm, D; Lebet, L; Akira, S; Horner, AA			House dust extracts elicit Toll-like receptor-dependent dendritic cell responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						hygiene hypothesis; Toll-like receptor; house dust; endotoxin; dendritic cell; allergy; autommuinity; autoinflammatory	ENDOTOXIN; INFECTION; EXPOSURE; PATHOGENESIS; DISEASE; ASTHMA	Background: Laboratory and epidemiological studies have provided indirect but compelling evidence that Toll-like receptors (TLRs) play an important role in innate host responsiveness to ambient immunostimulatory factors. However, little direct evidence exists. Objective: To determine whether house dust extracts activate dendritic cells by TLR-dependent mechanisms. Methods: In initial studies, bone marrow-derived dendritic cells were cultured with sterile house dust extracts, and cytokine production and costimulatory molecule expression were evaluated. In additional experiments, the TLR dependence of these responses was assessed. Results: House dust extract-activated bone marrow-derived dendritic cells were found to produce IL-6 and IL-12 in a concentration-dependent manner and to increase their expression of CD40, CD80, CD86, and MHC class II molecules. Furthermore, correlations were seen between the relative bioactivities of house dust extracts and their endotoxin levels. Finally, bone marrow-derived dendritic cells from TLR (2, 49 and 9)-deficient mice all demonstrated attenuated responses, and MyD88 deficient bone marrow-derived dendritic cells were almost completely nonresponsive to house dust extracts. Conclusion: These investigations provide direct evidence that TLR signaling pathways play a central role in at least a subset of dendritic cell responses to noninfectious factors ubiquitous in living environments.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sam & Rose Stein Inst Res Aging, La Jolla, CA 92093 USA; Osaka Univ, Dept Host Def, Res Inst Microbial Dis, Osaka, Japan	University of California System; University of California San Diego; University of California System; University of California San Diego; Osaka University	Horner, AA (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	ahorner@ucsd.edu	Akira, Shizuo/C-3134-2009; Boasen, Jared/R-3207-2017	Boasen, Jared/0000-0003-3825-3612	NIAID NIH HHS [AI61772, AI40682] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI061772, P01AI040682] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Chisholm D, 2004, J ALLERGY CLIN IMMUN, V113, P448, DOI 10.1016/j.jaci.2003.12.011; Danese S, 2004, AUTOIMMUN REV, V3, P394, DOI 10.1016/j.autrev.2004.03.002; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787; Gazzinelli RT, 2004, IMMUNOL REV, V201, P9, DOI 10.1111/j.0105-2896.2004.00174.x; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Horner AA, 2003, CURR OPIN IMMUNOL, V15, P614, DOI 10.1016/j.coi.2003.09.021; Horner AA, 2002, J ALLERGY CLIN IMMUN, V110, P706, DOI 10.1067/mai.2002.129122; Kaisho T, 2002, INT IMMUNOL, V14, P695, DOI 10.1093/intimm/dxf039; Kaisho T, 2001, J IMMUNOL, V166, P5688, DOI 10.4049/jimmunol.166.9.5688; Marshall AL, 2004, DIABETIC MED, V21, P1035, DOI 10.1111/j.1464-5491.2004.01282.x; Martinez FD, 1999, LANCET, V354, pS12, DOI 10.1016/S0140-6736(99)90437-3; Matricardi PM, 2002, J ALLERGY CLIN IMMUN, V110, P381, DOI 10.1067/mai.2002.126658; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Philpott DJ, 2004, MOL IMMUNOL, V41, P1099, DOI 10.1016/j.molimm.2004.06.012; Picard C, 2003, SCIENCE, V299, P2076, DOI 10.1126/science.1081902; Rachmilewitz D, 2004, GASTROENTEROLOGY, V126, P520, DOI 10.1053/j.gastro.2003.11.019; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Ronaghy A, 2002, J IMMUNOL, V168, P51, DOI 10.4049/jimmunol.168.1.51; Roy SR, 2003, J ALLERGY CLIN IMMUN, V112, P571, DOI 10.1067/mai.2003.1711; Shi HN, 2004, CAN J GASTROENTEROL, V18, P493, DOI 10.1155/2004/690421; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; van Strien RT, 2004, J ALLERGY CLIN IMMUN, V113, P860, DOI 10.1016/j.jaci.2004.01.078; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; Zhang DK, 2004, SCIENCE, V303, P1522, DOI 10.1126/science.1094351; Zuany-Amorim C, 2002, NAT MED, V8, P625, DOI 10.1038/nm0602-625	29	37	44	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2005	116	1					185	191		10.1016/j.jaci.2005.03.015	http://dx.doi.org/10.1016/j.jaci.2005.03.015			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IC	15990793	Bronze			2022-12-18	WOS:000235686300028
J	Gauvreau, GM; Plitt, JR; Baatjes, A; MacGlashan, DW				Gauvreau, GM; Plitt, JR; Baatjes, A; MacGlashan, DW			Expression of functional cysteinyl leukotriene receptors by human basophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						basophil; cysteinyl leukotriene receptor type 1; cysteinyl leukotriene receptor type 2; mRNA; viability; chemotaxis	HUMAN MAST-CELLS; ALLERGEN INHALATION; ATOPIC ASTHMATICS; CYTOSOLIC CALCIUM; CYSLT(1) RECEPTOR; PERIPHERAL-BLOOD; HUMAN EOSINOPHIL; MESSENGER-RNA; D-4; RELEASE	Background: Synthesis of leukotriene (LT) C-4 by basophils and mast cells is an important component of IgE-mediated inflammation, resulting in increased levels of the cysteinyl leukotrienes (cysLTs) LTC4, LTD4, and LTE4. Receptors for cysLTs are expressed on a variety of peripheral blood leukocytes, but of interest, they are also expressed on cells that synthesize LTC4, such as eosinophils and mast cells. Objective: We examined human basopbils for expression and function of cysLT receptor type 1 (cysLT1) and cysLT receptor type 2 (cysLT2). Methods: Basophils were purified from human blood and analyzed by means of RT-PCR, Western blotting, and flow cytometry for receptor expression. Basophils were also examined for functional responses to LTD4, including cytosolic calcium flux, histamine release, viability, and chemotaxis. Results: We found that basophils express mRNA for cysLT1 and cysLT2. CysLT1 and cysLT2 were also detectable by means of flow cytometry, but only cysLT2 was detectable by means of Western blotting with available antibodies. Increases in cytosolic calcium induced by LTD4-Stimulated basophils were inhibited by the cysLT1 receptor antagonist zafirlukast, confirming the presence of functional cysLT1 receptors on basophils. There was no significant effect of LTD4 on histamine release; however, LTD4 decreased CD95 (Fas) expression on basophils in several-day cultures. Conclusions: We have demonstrated that basophils express the cysLT receptors cysLT1 and cysLT2, and some functional responses to LTD4 can be observed.	Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD 21224 USA; McMaster Univ, Dept Med, Hamilton, ON L8S 4L8, Canada	Johns Hopkins University; Johns Hopkins Medicine; McMaster University	MacGlashan, DW (corresponding author), Johns Hopkins Asthma & Allergy Ctr, Room 3A38,5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	dmacglas@welch.jhu.edu						ADELROTH E, 1986, NEW ENGL J MED, V315, P480, DOI 10.1056/NEJM198608213150803; ANDERSON ME, 1982, P NATL ACAD SCI-BIOL, V79, P1088, DOI 10.1073/pnas.79.4.1088; Baswick EN, 2000, AM J RESP CRIT CARE, V161, pA832; Bautz F, 2001, BLOOD, V97, P3433, DOI 10.1182/blood.V97.11.3433; Braccioni F, 2002, J ALLERGY CLIN IMMUN, V110, P96, DOI 10.1067/mai.2002.125000; Calhoun WJ, 1998, AM J RESP CRIT CARE, V157, P1381, DOI 10.1164/ajrccm.157.5.9609014; CHAN CC, 1994, J PHARMACOL EXP THER, V269, P891; Cockcroft DW, 1985, AIRWAY RESPONSIVENES, P22; DAVIDSON AB, 1987, AM REV RESPIR DIS, V135, P333; DONNELLY AL, 1995, AM J RESP CRIT CARE, V151, P1734, DOI 10.1164/ajrccm.151.6.7767514; Dunzendorfer S, 2001, J ALLERGY CLIN IMMUN, V108, P581, DOI 10.1067/mai.2001.118518; Figueroa DJ, 2001, AM J RESP CRIT CARE, V163, P226, DOI 10.1164/ajrccm.163.1.2003101; Fregonese L, 2002, CLIN EXP ALLERGY, V32, P745, DOI 10.1046/j.1365-2222.2002.01384.x; Gauvreau GM, 2000, AM J RESP CRIT CARE, V161, P1473, DOI 10.1164/ajrccm.161.5.9908090; Gauvreau GM, 2001, AM J RESP CRIT CARE, V164, P1495, DOI 10.1164/ajrccm.164.8.2102033; GRIFFIN M, 1983, NEW ENGL J MED, V308, P436, DOI 10.1056/NEJM198302243080807; Irani AMA, 1998, J ALLERGY CLIN IMMUN, V101, P354, DOI 10.1016/S0091-6749(98)70248-9; Lee E, 1999, AM J RESP CRIT CARE, V159, pA328; Lee YS, 2004, PROG EL RES, V48, P27, DOI 10.2528/PIER03120304; Lynch KR, 1999, NATURE, V399, P789; Macfarlane AJ, 2000, AM J RESP CRIT CARE, V161, P1553, DOI 10.1164/ajrccm.161.5.9906068; Macfarlane AJ, 2000, J ALLERGY CLIN IMMUN, V105, P99, DOI 10.1016/S0091-6749(00)90184-2; MACGLASHAN D, 1994, J IMMUNOL, V152, P3006; MACGLASHAN D, 1991, J IMMUNOL, V147, P2259; MACGLASHAN DW, 1986, J IMMUNOL, V136, P2231; MACGLASHAN DW, 1993, J ALLERGY CLIN IMMUN, V91, P605, DOI 10.1016/0091-6749(93)90266-I; MAROM ZVI, 1982, AM REV RESPIR DIS, V126, P449; Mellor EA, 2001, P NATL ACAD SCI USA, V98, P7964, DOI 10.1073/pnas.141221498; Mita H, 2001, CLIN EXP ALLERGY, V31, P1714, DOI 10.1046/j.1365-2222.2001.01184.x; Pizzichini E, 1999, EUR RESPIR J, V14, P12, DOI 10.1034/j.1399-3003.1999.14a04.x; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; SPADA CS, 1994, J LEUKOCYTE BIOL, V55, P183, DOI 10.1002/jlb.55.2.183; Takasaki J, 2000, BIOCHEM BIOPH RES CO, V274, P316, DOI 10.1006/bbrc.2000.3140	33	37	40	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2005	116	1					80	87		10.1016/j.jaci.2005.03.014	http://dx.doi.org/10.1016/j.jaci.2005.03.014			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IC	15990778				2022-12-18	WOS:000235686300013
J	Michel, O; Murdoch, R; Bernard, A				Michel, O; Murdoch, R; Bernard, A			Inhaled LPS induces blood release of Clara cell specific protein (CC16) in human beings	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						LPS; lung permeability; Clara cell protein (CC16)	KAPPA-B ACTIVATION; LIPOPOLYSACCHARIDE LPS; AIRWAY NEUTROPHILIA; ENDOTOXIN; SERUM; INHALATION; EXPOSURE; RESPONSIVENESS; LYMPHOCYTES; EXPRESSION	Background: Animal models of lung inflammation have validated the plasma 16-kd Clara cell protein (CC16) as a peripheral marker of the permeability of the alveolocapillary barrier. Objective: We investigated in human beings whether inhaled LPS induced a rise in airways permeability measured by the plasma changes in CC16. Methods: The CC16 was measured in plasma from 15 subjects exposed to LPS by inhalation, during which the kinetics and the dose-response relationship of LIPS-induced CC16 were evaluated. Because LPS-induced response involves macrophages activation, the protective effect of oral methylprednisolone was also evaluated. Results: An inhalation of 50 mu g LPS induced a significant (P < .001) rise in CC16 after 6 hours (from 7.24 [+/- 0.68] mu g/L to 10.69 [+/- 0.99] mu g/L) that normalized at 24 hours (6.65 [+/- 0.33] mu g/L). The CC16 response was dose-related, with the no-response threshold 0.5 mu g LPS. A 6-day treatment with 20 mg/d methylprednisolone inhibited significantly (P < .001) the CC16 response to 50 mu g LPS. Conclusion: Exposure to LIPS by inhalation in healthy subjects induces an intravascular leakage of CC16 that can be blocked by corticosteroids. These observations further validate plasma CC16 as a noninvasive test of the alveolocapillary barrier permeability.	Free Univ Brussels, Hop Univ St Pierre, Clin Allergol & Resp Dis, Brussels, Belgium; GlaxoSmithKline, Clin Pharmacol & Discovery Med, Greenford, Middx, England; Catholic Univ Louvain, Fac Med, Unit Ind Toxicol & Occupat Med, Louvain, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel; GlaxoSmithKline; Universite Catholique Louvain	Michel, O (corresponding author), CHU St Pierre, Rue Haute 322, B-1000 Brussels, Belgium.	omichel@ulb.ac.be	BERNARD, Alfred M/A-6511-2010; michel, olivier/G-5016-2010	BERNARD, Alfred M/0000-0003-3171-3743; michel, olivier/0000-0002-1528-1277				Alexis NE, 2003, J ALLERGY CLIN IMMUN, V112, P353, DOI 10.1067/mai.2003.1651; Allenby MI, 2002, J ALLERGY CLIN IMMUN, V109, pS30, DOI 10.1016/S0091-6749(02)81172-1; Arsalane K, 2000, AM J RESP CRIT CARE, V161, P1624, DOI 10.1164/ajrccm.161.5.9812157; Arsalane K, 1999, TOXICOL APPL PHARM, V159, P169, DOI 10.1006/taap.1999.8738; BERNARD A, 1992, CLIN CHIM ACTA, V207, P239, DOI 10.1016/0009-8981(92)90122-7; BERNARD A, 1993, CLIN CHIM ACTA, V223, P189, DOI 10.1016/0009-8981(93)90077-H; Bernard A, 2003, OCCUP ENVIRON MED, V60, P385, DOI 10.1136/oem.60.6.385; Bernard A, 1997, OCCUP ENVIRON MED, V54, P63, DOI 10.1136/oem.54.1.63; BLOMBERG A, 2003, EUR RESPIR J, V22, P1; Boehlecke B, 2003, J ALLERGY CLIN IMMUN, V112, P1241, DOI 10.1016/j.jaci.2003.08.052; Braga CR, 2004, J INVEST ALLERG CLIN, V14, P142; Broeckaert F, 1999, LANCET, V353, P900, DOI 10.1016/S0140-6736(99)00540-1; Broeckaert F, 2000, CLIN EXP ALLERGY, V30, P469; BURRELL R, 1988, AM REV RESPIR DIS, V137, P100, DOI 10.1164/ajrccm/137.1.100; Carbonnelle S, 2002, BIOMARKERS, V7, P464, DOI 10.1080/13547500210166612; DIERYNCK I, 1995, AM J RESP CELL MOL, V12, P205, DOI 10.1165/ajrcmb.12.2.7865218; Dubin W, 1996, AM J PHYSIOL-LUNG C, V270, pL736, DOI 10.1152/ajplung.1996.270.5.L736; Ferretti S, 2003, J IMMUNOL, V170, P2106, DOI 10.4049/jimmunol.170.4.2106; FISCHER P, 1977, CIRC SHOCK, V4, P387; Hasday JD, 1999, CHEST, V115, P829, DOI 10.1378/chest.115.3.829; HELLEDAY R, 2003, EUR ESP J S45, V22, pS75; Hermans C, 1999, AM J RESP CRIT CARE, V159, P646, DOI 10.1164/ajrccm.159.2.9806064; Hermans C, 1998, CLIN CHIM ACTA, V272, P101, DOI 10.1016/S0009-8981(98)00006-0; Johnston CJ, 1997, AM J RESP CELL MOL, V17, P147, DOI 10.1165/ajrcmb.17.2.2676; Koay MA, 2002, AM J RESP CELL MOL, V26, P572, DOI 10.1165/ajrcmb.26.5.4748; Mango GW, 1998, AM J PHYSIOL-LUNG C, V275, pL348, DOI 10.1152/ajplung.1998.275.2.L348; MICHEL O, 1989, J APPL PHYSIOL, V66, P1059, DOI 10.1152/jappl.1989.66.3.1059; Michel O, 2003, J ENDOTOXIN RES, V9, P293, DOI 10.1179/096805103225002539; Michel O, 1997, AM J RESP CRIT CARE, V156, P1157, DOI 10.1164/ajrccm.156.4.97-02002; Nord M, 2002, TRANSPLANTATION, V73, P1264, DOI 10.1097/00007890-200204270-00013; O'Grady NP, 2001, AM J RESP CRIT CARE, V163, P1591, DOI 10.1164/ajrccm.163.7.2009111; PARRILLO JE, 1979, ANNU REV PHARMACOL, V19, P179, DOI 10.1146/annurev.pa.19.040179.001143; PLOPPER CG, 1997, LUNG, P515; Poynter ME, 2003, J IMMUNOL, V170, P6257, DOI 10.4049/jimmunol.170.12.6257; Rylander R., 1997, INT J OCCUP ENV HEAL, V3, pS1, DOI 10.1179/oeh.1997.3.1.1.; SANDSTROM T, 1992, EUR RESPIR J, V5, P992; Sengler C, 2003, J ALLERGY CLIN IMMUN, V111, P515, DOI 10.1067/mai.2003.180; SINGH G, 1984, J HISTOCHEM CYTOCHEM, V32, P49, DOI 10.1177/32.1.6418790; Tulic MK, 2000, AM J RESP CELL MOL, V22, P604; WALLENSTEIN S, 1980, CIRC RES, V47, P1, DOI 10.1161/01.RES.47.1.1	40	37	43	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2005	115	6					1143	1147		10.1016/j.jaci.2005.01.067	http://dx.doi.org/10.1016/j.jaci.2005.01.067			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	935WZ	15940126				2022-12-18	WOS:000229815400006
J	Jongepier, H; Koppelman, GH; Nolte, IM; Bruinenberg, M; Bleecker, ER; Meyers, DA; Meerman, GJT; Postma, DS				Jongepier, H; Koppelman, GH; Nolte, IM; Bruinenberg, M; Bleecker, ER; Meyers, DA; Meerman, GJT; Postma, DS			Polymorphisms in SPINK5 are not associated with asthma in a Dutch population	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; polymorphism; SPINK-5; allergy; atopic dermatitis	SERINE-PROTEASE INHIBITOR; NETHERTON-SYNDROME; ATOPIC-DERMATITIS; GENE; MUTATIONS; FAMILIES; EXPRESSION; JAPANESE; DISEASE; LEKTI	Background: Asthma and allergic phenotypes are complex genetic diseases with known linkage to chromosome 5q. This region has many candidate genes, including serine protease inhibitor Kazal type 5 (SPINK5), which has been associated with asthma and atopic dermatitis in family-based studies of children with atopic dermatitis. Objective: We sought to investigate whether single nucleotide polymorphisms in SPINK5 are associated with asthma, atopic phenotypes, and atopic dermatitis. Methods: We investigated whether single nucleotide polymorphisms in SPINK5 (ie, -785 A/G, Asn368Ser, and Lys420Glu) are associated with asthma, atopic phenotypes, and atopic dermatitis in 200 families ascertained by a proband with asthma (nonaffected spouses served as a matched control population) and an independent set of 252 trios with asthma. Results: We found no association with asthma, atopic phenotypes, and atopic dermatitis after correction for multiple testing. Conclusion: The negative results in this study suggest that SPINK5 is not associated with asthma or atopic phenotypes in individuals ascertained by a proband with asthma. This is consistent with the finding that SPINK5 is not expressed in the lung. Because our patients were ascertained for asthma, a role of SPINK5 in atopic dermatitis cannot be excluded.	Univ Groningen Hosp, Beatrix Childrens Hosp, Dept Pulmonol, NL-9700 RB Groningen, Netherlands; Univ Groningen Hosp, Beatrixoord, Dept Pulm Rehabil, NL-9700 RB Groningen, Netherlands; Univ Groningen Hosp, Dept Pulmonol, NL-9700 RB Groningen, Netherlands; Univ Groningen, Dept Med Biol, NL-9700 AB Groningen, Netherlands; Univ Groningen, Dept Med Genet, NL-9700 AB Groningen, Netherlands; Wake Forest Univ, Sch Med, Ctr Human Genom, Winston Salem, NC 27109 USA	University of Groningen; University of Groningen; University of Groningen; University of Groningen; University of Groningen; Wake Forest University	Postma, DS (corresponding author), Univ Groningen Hosp, Beatrix Childrens Hosp, Dept Pulmonol, Hanzepl 1,POB 30-001, NL-9700 RB Groningen, Netherlands.	d.s.postma@int.azg.nl	Koppelman, Gerard/AAG-9187-2020	Koppelman, Gerard/0000-0001-8567-3252				Abecasis GR, 2000, AM J HUM GENET, V66, P279, DOI 10.1086/302698; Amelung PJ, 1997, CHEST, V111, pS77, DOI 10.1378/chest.111.6_Supplement.77S; Bitoun E, 2003, HUM MOL GENET, V12, P2417, DOI 10.1093/hmg/ddg247; Bitoun E, 2002, J INVEST DERMATOL, V118, P352, DOI 10.1046/j.1523-1747.2002.01603.x; Chavanas S, 2000, AM J HUM GENET, V66, P914, DOI 10.1086/302824; Chavanas S, 2000, NAT GENET, V25, P141, DOI 10.1038/75977; DEVRIES K, 1962, INT ARCH ALLER A IMM, V20, P93, DOI 10.1159/000229248; Howard TD, 2001, AM J RESP CELL MOL, V25, P377, DOI 10.1165/ajrcmb.25.3.4483; Howard TD, 2002, AM J HUM GENET, V70, P230, DOI 10.1086/338242; Janson C, 1997, EUR RESPIR J, V10, P1795, DOI 10.1183/09031936.97.10081795; Kabesch M, 2004, CLIN EXP ALLERGY, V34, P340, DOI 10.1111/j.1365-2222.2004.01860.x; Kabesch M, 2003, J ALLERGY CLIN IMMUN, V112, P893, DOI 10.1016/j.jaci.2003.08.033; Kato A, 2003, BRIT J DERMATOL, V148, P665, DOI 10.1046/j.1365-2133.2003.05243.x; Koppelman GH, 2001, AM J RESP CRIT CARE, V163, P965, DOI 10.1164/ajrccm.163.4.2004164; Koppelman GH, 2002, J ALLERGY CLIN IMMUN, V109, P498, DOI 10.1067/mai.2002.122235; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Mitsudo K, 2003, BIOCHEMISTRY-US, V42, P3874, DOI 10.1021/bi027029v; Morita K, 2003, J DERMATOL SCI, V31, P81, DOI 10.1016/S0923-1811(03)00038-0; Nishio Y, 2003, GENES IMMUN, V4, P515, DOI 10.1038/sj.gene.6363889; Panhuysen CIM, 1998, AM J RESP CRIT CARE, V157, P1734, DOI 10.1164/ajrccm.157.6.9606088; PANHUYSEN CIM, 1995, CLIN EXP ALLERGY, V25, P35, DOI 10.1111/j.1365-2222.1995.tb00418.x; REIHSAUS E, 1993, AM J RESP CELL MOL, V8, P334, DOI 10.1165/ajrcmb/8.3.334; Spielman RS, 1996, AM J HUM GENET, V59, P983; Walley AJ, 2001, NAT GENET, V29, P175, DOI 10.1038/ng728; Xu JF, 2002, HUM GENET, V111, P573, DOI 10.1007/s00439-002-0819-y; Xu JF, 2000, AM J HUM GENET, V67, P1163, DOI 10.1086/321190	26	37	37	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2005	115	3					486	492		10.1016/j.jaci.2004.12.013	http://dx.doi.org/10.1016/j.jaci.2004.12.013			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	907AN	15753894				2022-12-18	WOS:000227687000009
J	Openshaw, PJM; Yamaguchi, Y; Tregoning, JS				Openshaw, PJM; Yamaguchi, Y; Tregoning, JS			Childhood infections, the developing immune system, and the origins of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						common cold; bronchiolitis; developmental immunity; childhood asthma; respiratory syncytial vints	RESPIRATORY SYNCYTIAL VIRUS; DENDRITIC CELLS; ALLERGIC DISEASE; EARLY-LIFE; T-CELLS; AGE; RISK; BRONCHIOLITIS; INCREASES; HYGIENE	Asthma is an immune-mediated inflammatory condition characterized by increased responsiveness to bronchoconstrictive stimuli. Viruses have been shown to play an important role in asthma, with viral infection being present during about 85% of exacerbations. However, the role they play in the onset of asthma is more controversial. Some respiratory viral infections might be protective, but there is a strong association between respiratory syncytial virus-induced bronchiolitis in infancy and recurrent wheeze up to 12 years of age. Both the respiratory tract and the immune system undergo rapid maturation during the first year of life, and it seems that postnatal development is affected by and affects responses to viral infections. Understanding postnatal developmental changes in the immune system might help to explain the origins and pathogenesis of asthma and thus the effectiveness or ineffectiveness of specific asthma therapies.	Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Resp Med, London W2 1PG, England	Imperial College London	Openshaw, PJM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Resp Med, St Marys Campus, London W2 1PG, England.	p.openshaw@imperial.ac.uk	Openshaw, Peter/AAL-9442-2020	Openshaw, Peter/0000-0002-7220-2555; Tregoning, John/0000-0001-8093-8741				Adkins B, 2004, NAT REV IMMUNOL, V4, P553, DOI 10.1038/nri1394; Barends M, 2004, CLIN EXP ALLERGY, V34, P488, DOI 10.1111/j.1365-2222.2004.01906.x; Beyer M, 2004, J ALLERGY CLIN IMMUN, V113, P127, DOI 10.1016/j.jaci.2003.10.057; Culley FJ, 2002, J EXP MED, V196, P1381, DOI 10.1084/jem.20020943; Dahl ME, 2004, NAT IMMUNOL, V5, P337, DOI 10.1038/ni1041; de Lafaille MAC, 2002, CURR OPIN IMMUNOL, V14, P771; Muthukkumar S, 2000, J IMMUNOL, V165, P4803, DOI 10.4049/jimmunol.165.9.4803; Openshaw PJM, 2003, PEDIATR INFECT DIS J, V22, pS58, DOI 10.1097/00006454-200302001-00009; Peebles R. Stokes Jr., 2004, Journal of Allergy and Clinical Immunology, V113, pS15, DOI 10.1016/j.jaci.2003.10.033; Qureshi MH, 2001, J IMMUNOL, V166, P5704, DOI 10.4049/jimmunol.166.9.5704; Schwarze J, 2004, AM J RESP CRIT CARE, V169, P801, DOI 10.1164/rccm.200308-1203OC; Siegrist CA, 2001, VACCINE, V19, P3331, DOI 10.1016/S0264-410X(01)00028-7; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Stene LC, 2001, LANCET, V357, P607, DOI 10.1016/S0140-6736(00)04067-8; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Wenzel SE, 2002, AM J MED, V112, P627, DOI 10.1016/S0002-9343(02)01095-1; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579	18	37	40	1	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2004	114	6					1275	1277		10.1016/j.jaci.2004.08.024	http://dx.doi.org/10.1016/j.jaci.2004.08.024			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	877NN	15577822				2022-12-18	WOS:000225577400003
J	van den Berge, M; Polosa, R; Kerstjens, HAM; Postma, DS				van den Berge, M; Polosa, R; Kerstjens, HAM; Postma, DS			The role of endogenous and exogenous AMP in asthma and chronic obstructive pulmonary disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						AMP; adenosine; hyperresponsiveness; inflammation	HUMAN MAST-CELL; INHALED FLUTICASONE PROPIONATE; METHACHOLINE-INDUCED BRONCHOCONSTRICTION; BRONCHOALVEOLAR LAVAGE FLUID; ADENOSINE RECEPTOR SUBTYPES; BRONCHIAL BIOPSY SPECIMENS; DEAMINASE-DEFICIENT MICE; AIRWAY INFLAMMATION; ENDOTHELIAL-CELLS; LEUKOTRIENE D-4	Bronchial hyperresponsiveness is present in virtually all patients with asthma and in more than two thirds of patients with chronic obstructive pulmonary disease. Thus far, methacholine and histamine are usually used to measure bronchial hyperresponsiveness. Both are direct stimuli, because they act directly on airway smooth muscle. Another possible stimulus to measure bronchial hyperresponsiveness is AMP. AMP is an indirect stimulus, because it acts via the release of histamine and other mediators from immunologically primed mast cells. There is increasing interest in the role of AMP as a bronchoconstrictor stimulus because it has been suggested that the concentration of AMP causing the FEV1 to decrease by 20% (PC20 AMP) may be used as a noninvasive marker of airway inflammation. The aim of this article was to review the literature assessing AMP's value in asthma and chronic obstructive pulmonary disease.	Univ Groningen Hosp, Dept Pulmonol, NL-9700 RB Groningen, Netherlands	University of Groningen	Postma, DS (corresponding author), Univ Groningen Hosp, Dept Pulm Dis, Hanzepl 1, NL-9700 RB Groningen, Netherlands.	D.S.Postma@iut.azg.nl	Kerstjens, Huib/N-4754-2017	Kerstjens, Huib/0000-0001-7705-7927				AALBERS R, 1993, EUR RESPIR J, V6, P840; Alvarez MJ, 2000, ALLERGY, V55, P355, DOI 10.1034/j.1398-9995.2000.00312.x; Anthonisen NR, 2002, AM J RESP CRIT CARE, V166, P675, DOI 10.1164/rccm.2112096; AVITAL A, 1995, THORAX, V50, P511, DOI 10.1136/thx.50.5.511; Aziz I, 1998, EUR RESPIR J, V12, P580, DOI 10.1183/09031936.98.12030580; Barnes PJ, 2003, PHARMACOL THERAPEUT, V97, P87, DOI 10.1016/S0163-7258(02)00324-8; Barnes PJ, 2002, EUR RESPIR J, V19, P182, DOI 10.1183/09031936.02.00283202; BARNES PJ, 1995, AM J RESP CRIT CARE, V152, P838, DOI 10.1164/ajrccm.152.3.7663795; Benckhuijsen J, 1996, PEDIATR PULM, V22, P147, DOI 10.1002/(SICI)1099-0496(199609)22:3<147::AID-PPUL2>3.0.CO;2-M; Blease K, 1998, AM J RESP CELL MOL, V18, P620, DOI 10.1165/ajrcmb.18.5.3052; BOOTSMA GP, 1995, THORAX, V50, P1044, DOI 10.1136/thx.50.10.1044; Bradding P, 1996, ANN NY ACAD SCI, V796, P272, DOI 10.1111/j.1749-6632.1996.tb32589.x; BRADDING P, 1994, AM J RESP CELL MOL, V10, P471, DOI 10.1165/ajrcmb.10.5.8179909; BRADDING P, 1993, J IMMUNOL, V151, P3853; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; BROWN HM, 1972, BRIT MED J, V1, P585, DOI 10.1136/bmj.1.5800.585; Chanez P, 1997, AM J RESP CRIT CARE, V155, P1529, DOI 10.1164/ajrccm.155.5.9154853; CHONG LK, 1995, AM J RESP CELL MOL, V13, P540, DOI 10.1165/ajrcmb.13.5.7576689; Chunn JL, 2001, J IMMUNOL, V167, P4676, DOI 10.4049/jimmunol.167.8.4676; Cockcroft DW, 2001, AM J RESP CRIT CARE, V163, P1514, DOI 10.1164/ajrccm.163.7.2103055b; COLLIS MG, 1993, TRENDS PHARMACOL SCI, V14, P360; Compton SJ, 1999, INT ARCH ALLERGY IMM, V118, P204, DOI 10.1159/000024068; Crimi E, 1998, AM J RESP CRIT CARE, V157, P4, DOI 10.1164/ajrccm.157.1.9703002; CRIMI N, 1988, ALLERGY, V43, P179; CRONSTEIN BN, 1990, J CLIN INVEST, V85, P1150, DOI 10.1172/JCI114547; CUSHLEY MJ, 1985, EUR J RESPIR DIS, V67, P185; Diamant Z, 1997, AM J RESP CRIT CARE, V155, P1247, DOI 10.1164/ajrccm.155.4.9105062; Doull IJM, 1997, PEDIATR PULM, V23, P404, DOI 10.1002/(SICI)1099-0496(199706)23:6<404::AID-PPUL2>3.3.CO;2-N; DRIVER AG, 1993, AM REV RESPIR DIS, V148, P91, DOI 10.1164/ajrccm/148.1.91; Egbagbe E, 1997, THORAX, V52, P239, DOI 10.1136/thx.52.3.239; Evans DJ, 1997, NEW ENGL J MED, V337, P1412, DOI 10.1056/NEJM199711133372002; FELSCH A, 1995, J IMMUNOL, V155, P333; Feoktistov I, 1998, TRENDS PHARMACOL SCI, V19, P148, DOI 10.1016/S0165-6147(98)01179-1; FEOKTISTOV I, 1995, J CLIN INVEST, V96, P1979, DOI 10.1172/JCI118245; Fowler SJ, 2000, AM J RESP CRIT CARE, V162, P1318, DOI 10.1164/ajrccm.162.4.9912103; Fozard JR, 2002, EUR J PHARMACOL, V438, P183, DOI 10.1016/S0014-2999(02)01305-5; FULLER RW, 1991, CHEST, V100, P670, DOI 10.1378/chest.100.3.670; Gauvreau GM, 2001, AM J RESP CRIT CARE, V164, P1495, DOI 10.1164/ajrccm.164.8.2102033; GIBSON PG, 1993, AM REV RESPIR DIS, V148, P80, DOI 10.1164/ajrccm/148.1.80; Grashoff WFH, 1997, AM J PATHOL, V151, P1785; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; GROOT CAR, 1992, EUR RESPIR J, V5, P1075; He SH, 1998, BRIT J PHARMACOL, V125, P1491, DOI 10.1038/sj.bjp.0702223; Hirata N, 1998, AM J RESP CELL MOL, V18, P12, DOI 10.1165/ajrcmb.18.1.2704; Hofstra WB, 2000, PEDIATR PULM, V29, P415, DOI 10.1002/(SICI)1099-0496(200006)29:6<415::AID-PPUL1>3.0.CO;2-7; Joos GF, 2003, EUR RESPIR J, V21, P1050, DOI 10.1183/09031936.03.00008403; KALENDERIAN R, 1988, CHEST, V94, P119, DOI 10.1378/chest.94.1.119; KANNER RE, 1994, AM J RESP CRIT CARE, V150, P956, DOI 10.1164/ajrccm.150.4.7921469; Ketchell RI, 2002, J ALLERGY CLIN IMMUN, V110, P603, DOI 10.1067/mai.2002.128486; Ketchell RI, 2002, EUR RESPIR J, V19, P611, DOI 10.1183/09031936.02.00332001; Klotz KN, 1998, N-S ARCH PHARMACOL, V357, P1; LANGE P, 1989, EUR RESPIR J, V2, P811; Lim S, 2001, AM J RESP CRIT CARE, V164, P273, DOI 10.1164/ajrccm.164.2.2006043; Luijk B, 2004, EUR RESPIR J, V23, P559, DOI 10.1183/09031936.04.00043504; MANN JS, 1986, J APPL PHYSIOL, V61, P1667, DOI 10.1152/jappl.1986.61.5.1667; MARQUARDT DL, 1994, AGENTS ACTIONS, V43, P7, DOI 10.1007/BF02005755; MARQUARDT R, 1976, Z KARDIOL, V65, P585; Martinez-Garcia MA, 2002, PULM PHARMACOL THER, V15, P157, DOI 10.1006/pupt.2001.0334; Meijer RJ, 1999, THORAX, V54, P894, DOI 10.1136/thx.54.10.894; Morali T, 2001, J ASTHMA, V38, P673, DOI 10.1081/JAS-100107545; Mulder A, 1999, AM J RESP CRIT CARE, V159, P1562, DOI 10.1164/ajrccm.159.5.9810095; Nyce JW, 1997, NATURE, V385, P721, DOI 10.1038/385721a0; OCONNOR BJ, 1992, NEW ENGL J MED, V327, P1204, DOI 10.1056/NEJM199210223271704; OCONNOR BJ, 1992, AM REV RESPIR DIS, V146, P560, DOI 10.1164/ajrccm/146.3.560; OCONNOR BJ, 1994, AM J RESP CRIT CARE, V150, P381, DOI 10.1164/ajrccm.150.2.8049819; OOSTERHOFF Y, 1993, AM REV RESPIR DIS, V147, P553, DOI 10.1164/ajrccm/147.3.553; OOSTERHOFF Y, 1993, J ALLERGY CLIN IMMUN, V92, P773, DOI 10.1016/0091-6749(93)90023-9; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; PEACHELL PT, 1988, J IMMUNOL, V140, P571; PHILLIPS GD, 1990, AM REV RESPIR DIS, V141, P9, DOI 10.1164/ajrccm/141.1.9; PHILLIPS GD, 1988, CLIN SCI, V75, P429, DOI 10.1042/cs0750429; Pizzichini E, 1998, AM J RESP CRIT CARE, V158, P1511, DOI 10.1164/ajrccm.158.5.9804028; Polosa R, 2000, EUR RESPIR J, V15, P30, DOI 10.1034/j.1399-3003.2000.15a07.x; POLOSA R, 1995, AM J RESP CRIT CARE, V151, P624; POSTMA DS, 1991, AM REV RESPIR DIS, V143, P1458, DOI 10.1164/ajrccm/143.6.1458; Postma DS, 1998, AM J RESP CRIT CARE, V158, pS187, DOI 10.1164/ajrccm.158.supplement_2.13tac170; Prosperini G, 2002, J ALLERGY CLIN IMMUN, V110, P855, DOI 10.1067/mai.2002.130050; Reynolds CJ, 2002, CLIN EXP ALLERGY, V32, P1174, DOI 10.1046/j.1365-2745.2002.01443.x; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; Rutgers SR, 1999, CLIN EXP ALLERGY, V29, P1287; Rutgers SR, 2000, CLIN EXP ALLERGY, V30, P657; Rutgers SR, 1998, AM J RESP CRIT CARE, V157, P880, DOI 10.1164/ajrccm.157.3.9709100; Shrewsbury S, 2000, BMJ-BRIT MED J, V320, P1368, DOI 10.1136/bmj.320.7246.1368; SOLER M, 1994, EUR RESPIR J, V7, P1973; Sont JK, 1996, THORAX, V51, P496, DOI 10.1136/thx.51.5.496; SULLIVAN P, 1994, LANCET, V343, P1006, DOI 10.1016/S0140-6736(94)90127-9; Suzuki H, 1998, BIOCHEM BIOPH RES CO, V242, P697, DOI 10.1006/bbrc.1997.8040; Tashkin DP, 1996, AM J RESP CRIT CARE, V153, P1802, DOI 10.1164/ajrccm.153.6.8665038; Taylor DA, 1999, AM J RESP CRIT CARE, V160, P237, DOI 10.1164/ajrccm.160.1.9809046; Taylor DA, 1997, AM J RESP CRIT CARE, V156, P1731, DOI 10.1164/ajrccm.156.6.9703047; van den Berge M, 2004, CLIN EXP ALLERGY, V34, P71, DOI 10.1111/j.1365-2222.2004.01832.x; Van den Berge M, 2001, AM J RESP CRIT CARE, V164, P1127, DOI 10.1164/ajrccm.164.7.2102135; Van dn Berge M, 2001, AM J RESP CRIT CARE, V163, P1546, DOI 10.1164/ajrccm.163.7.2010145; VATHENEN AS, 1991, THORAX, V46, P811, DOI 10.1136/thx.46.11.811; Walker BAM, 1997, AM J RESP CELL MOL, V16, P531, DOI 10.1165/ajrcmb.16.5.9160835; WALLS AF, 1995, INT ARCH ALLERGY IMM, V107, P372, DOI 10.1159/000237039; Weersink EJM, 1997, AM J RESP CRIT CARE, V155, P1241, DOI 10.1164/ajrccm.155.4.9105061; WIGGS BR, 1992, AM REV RESPIR DIS, V145, P1251, DOI 10.1164/ajrccm/145.6.1251; Woolcock A, 1996, AM J RESP CRIT CARE, V153, P1481, DOI 10.1164/ajrccm.153.5.8630590; Zhong HY, 2001, J PHARMACOL EXP THER, V298, P433	101	37	38	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2004	114	4					737	746		10.1016/j.jaci.2004.05.071	http://dx.doi.org/10.1016/j.jaci.2004.05.071			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	861SO	15480309	Bronze			2022-12-18	WOS:000224439100003
J	Brass, DM; Savov, JD; Whitehead, GS; Maxwell, AB; Schwartz, DA				Brass, DM; Savov, JD; Whitehead, GS; Maxwell, AB; Schwartz, DA			LPS binding protein is important in the airway response to inhaled endotoxin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						endotoxin; LPS binding protein; neutrophil	LIPOPOLYSACCHARIDE LPS; SOLUBLE CD14; EXPOSURE; DUST; ASTHMA; INFLAMMATION; EXPRESSION; DISEASE; LUNGS; MICE	Background: Inhaled endotoxin is a risk factor for asthma exacerbation, and endotoxin inhalation by itself recapitulates many of the classical features of asthma in mice, including reversible airflow obstruction and inflammation, airways hyperresponsiveness, and airway remodeling. Objective: Our objective was to determine the importance of LPS binding protein (LBP) in the response to inhaled LPS. Methods: We challenged LBP-deficient mice (C57BL/6(LBP-/-)) and C57BL/6 mice with inhaled endotoxin for 4 hours, 5 days, or 4 weeks, followed by 3 days of recovery. Results: LBP in the lung was significantly increased in LPS-exposed C57BL/6 mice from all 3 groups. Only LPS-exposed C57BL/6 mice had significantly enhanced airway responsiveness to inhaled methacholine. Total lavage cells in LPS-exposed C57BL/6(LBP-/-) mice were significantly reduced compared with those seen in LPS-exposed C57BL/6 mice; however, the percentage of PMNs was similarly increased in both the C57BL/6 and C57BL/6(LBP-/-) mice. TNF-alpha, IL-1beta, and IL-6 protein concentrations in whole-lung lavage fluid from C57BL/6(LBP-/-) mice were also significantly reduced when compared with those seen in C57BL/6 mice. In C57BL/6(LBP-/-) mice submucosal cell proliferation was significantly reduced in the 1-week group when compared with that seen in similarly exposed C57BL/6 mice. The 4-week exposed C57BL/6 mice had significantly thickened airway submucosa and significantly increased lavaged TGF-beta(1) protein compared with that seen in C57BL/6(LBP-/-) Mice. Conclusions: These findings indicate that LBP is one of the critical molecules regulating the acute and chronic airway response to inhaled LPS.	Duke Univ, Med Ctr, Div Pulm Allergy & Crit Care Med, Durham, NC 27710 USA	Duke University	Brass, DM (corresponding author), Duke Univ, Med Ctr, Div Pulm Allergy & Crit Care Med, Res Dr,Room 275 MSRB,DUMC Box 2629, Durham, NC 27710 USA.	brass001@mc.duke.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL066611, U01HL066604] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U19ES011375, P30ES011961, R01ES007498, Z01ES101945] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL66604, HL66611] Funding Source: Medline; NIEHS NIH HHS [ES012496, ES11375, ES011961, ES07498] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Brass DM, 1999, AM J PATHOL, V154, P853, DOI 10.1016/S0002-9440(10)65332-1; BRASS DM, 2003, AM J PHYSIOL-LUNG C, V6, P6; Braun-Fahrlander C, 2003, CURR OPIN ALLERGY CL, V3, P325, DOI 10.1097/01.all.0000092600.10871.e0; Dentener MA, 2000, AM J RESP CELL MOL, V23, P146, DOI 10.1165/ajrcmb.23.2.3855; Dubin W, 1996, AM J PHYSIOL-LUNG C, V270, pL736, DOI 10.1152/ajplung.1996.270.5.L736; George CLS, 2001, AM J PHYSIOL-LUNG C, V280, pL203, DOI 10.1152/ajplung.2001.280.2.L203; Jack RS, 1997, NATURE, V389, P742, DOI 10.1038/39622; KENNEDY SM, 1987, AM REV RESPIR DIS, V135, P194; Kline JN, 2000, J APPL PHYSIOL, V89, P1172, DOI 10.1152/jappl.2000.89.3.1172; Martin TR, 1997, AM J RESP CRIT CARE, V155, P937, DOI 10.1164/ajrccm.155.3.9117029; Martin TR, 2000, AM J RESP CELL MOL, V23, P128, DOI 10.1165/ajrcmb.23.2.f189; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641, DOI 10.1164/ajrccm.154.6.8970348; Michel O, 2003, J ENDOTOXIN RES, V9, P293, DOI 10.1179/096805103225002539; Rizzo MC, 1997, PEDIAT ALLERG IMM-UK, V8, P121; Savov JD, 2002, AM J PHYSIOL-LUNG C, V283, pL952, DOI 10.1152/ajplung.00420.2001; Vernooy JHJ, 2002, AM J RESP CELL MOL, V26, P152, DOI 10.1165/ajrcmb.26.1.4652; Wohlford-Lenane CL, 1999, AM J PHYSIOL-LUNG C, V276, pL736, DOI 10.1152/ajplung.1999.276.5.L736; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Wurfel MM, 1997, J EXP MED, V186, P2051, DOI 10.1084/jem.186.12.2051; Yu M, 2002, TOXICOL SCI, V68, P488, DOI 10.1093/toxsci/68.2.488	20	37	37	2	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2004	114	3					586	592		10.1016/j.jaci.2004.04.043	http://dx.doi.org/10.1016/j.jaci.2004.04.043			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	853AX	15356561				2022-12-18	WOS:000223799600018
J	Min, HK; Moxley, G; Neale, MC; Schwartz, LB				Min, HK; Moxley, G; Neale, MC; Schwartz, LB			Effect of sex and haplotype on plasma tryptase levels in healthy adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						tryptase; mast cells	MAST-CELL TRYPTASE	Background: The total level of alpha-tryptase and beta-tryptase in serum or plasma is used as a clinical indicator of the mast cell burden. Objective: The effect of the tryptase haplotype and of sex on the total tryptase level of healthy individuals was determined. Methods: A novel hot-stop PCR technique was used to determine the tryptase genotype, and a standard fluoroenzyme immunoassay was used to measure total plasma tryptase levels in 106 healthy subjects. Mx modeling and the QTL association routine of Mendel 5.0 were used to analyze the data. Results: Tryptase haplotypes exhibit a 1 (betaalpha/betaalpha):2 (betabeta/betabeta) distribution, monomorphic for beta at 1 position and allelic for beta and alpha at the other position. The betaalpha haplotype has a frequency of 0.49. The Bet haplotype increases total tryptase levels by 0.5 ng/mL from the overall mean, whereas female sex increases the level by 0.2 ng/mL from the mean. Conclusion: The tryptase haplotype and sex each have a statistically significant effect on the total plasma tryptase level of healthy subjects.	Virginia Commonwealth Univ, Div Rheumatol Allergy & Immunol, Dept Internal Med, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Psychiat, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University	Schwartz, LB (corresponding author), Virginia Commonwealth Univ, Div Rheumatol Allergy & Immunol, Dept Internal Med, POB 980263, Richmond, VA 23298 USA.	lbschwar@vcu.edu	Neale, Michael/AAD-5056-2020; Neale, Michael C/B-1418-2008		NIAID NIH HHS [AI20487] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020487, R21AI020487, R01AI020487] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abecasis GR, 2000, BIOINFORMATICS, V16, P182, DOI 10.1093/bioinformatics/16.2.182; Caughey GH, 2000, J IMMUNOL, V164, P6566, DOI 10.4049/jimmunol.164.12.6566; Daniels RJ, 2001, HUM MOL GENET, V10, P339, DOI 10.1093/hmg/10.4.339; Guida M, 2000, PHARMACOGENETICS, V10, P389, DOI 10.1097/00008571-200007000-00002; JOGIEBRAHIM S, 2004, IN PRESS J ALLERGY C; Lange K, 2001, AM J HUM GENET, V69, P504; NEALE MC, 1999, STAT MODELING; Sakai K, 1996, J CLIN INVEST, V97, P988, DOI 10.1172/JCI118523; Schwartz LB, 1995, J CLIN INVEST, V96, P2702, DOI 10.1172/JCI118337; Schwartz LB, 2003, J IMMUNOL, V170, P5667, DOI 10.4049/jimmunol.170.11.5667; Schwartz LB, 2002, CL ALLER IM, V16, P3; SCHWARTZ LB, 1994, J CLIN IMMUNOL, V14, P190, DOI 10.1007/BF01533368; Soto D, 2002, CLIN EXP ALLERGY, V32, P1000, DOI 10.1046/j.1365-2222.2002.01416.x; Sperr WR, 2002, LEUKEMIA LYMPHOMA, V43, P1097, DOI 10.1080/10428190290021470; Sperr WR, 2001, BLOOD, V98, P2200, DOI 10.1182/blood.V98.7.2200; Ueijma H, 2000, NAT GENET, V25, P375, DOI 10.1038/78040; VANDERLINDEN PWG, 1992, J ALLERGY CLIN IMMUN, V90, P110, DOI 10.1016/S0091-6749(06)80017-5	17	37	37	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2004	114	1					48	51		10.1016/j.jaci.2004.04.008	http://dx.doi.org/10.1016/j.jaci.2004.04.008			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	836DA	15241343				2022-12-18	WOS:000222534300007
J	Cunningham-Rundles, C; Sidi, P; Estrella, L; Doucette, J				Cunningham-Rundles, C; Sidi, P; Estrella, L; Doucette, J			Identifying undiagnosed primary immunodeficiency diseases in minority subjects by using computer sorting of diagnosis codes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						primary immune deficiency; ICD-9; minority health; algorithm	COMMON VARIABLE IMMUNODEFICIENCY; IGA DEFICIENCY; NATIONAL-REGISTRY; CHILDREN; MORTALITY	Background: Primary immunodeficiency diseases occur in all populations, but these diagnoses are rarely made in minority subjects in the United States. Objective: We sought to develop and validate a method to identify. patients without diagnoses but with immunodeficiency in an urban hospital with a substantial minority patient population. Methods: We developed a scoring algorithm on the basis of International Classification of Disease, Ninth Revision (ICD-9) codes to identify all hospitalized patients age 60 years or less who had been given a diagnosis of 2 or more of 174 ICD-9-coded complications associated with immunodeficiency. Codes v ere weighted for severity and expressed as a sum for all admissions between October 1, 1995, and December 31, 2002. Patients with, for example, cancer or HIV or those after transplantation or major surgery were excluded. Demographic features of subjects with aggregated ICD-9 codes suggestive of immunodeficiency were compared with those of other inpatients: 59 computer-selected subjects were then tested for immune defects. Results: The computer-identified group contained 533 patients (0.4% of all inpatients), who had been hospitalized 2683 times. The median age was 6.6 years. Sixty-five percent were African American or Hispanic, and 61% were insured by Medicaid, which is significantly more than other inpatients younger than 60 years of age (median age, 32.6 years; 37% minority, 27% insured by Medicaid; P < .0001). Primary immunodeficiency was found in 17 (29%) of the 59 subjects tested. Thirteen other patients had secondary immune defects, and 86% of immunodeficient subjects were Hispanic or African American. Conclusions: An ICD-9-based scoring algorithm identifies patients demographically different from other hospitalized subjects who have multiple illnesses suggestive of immunodeficiency. This group contains undiagnosed minority patients with immunodeficiency.	Mt Sinai Med Ctr, Dept Med & Pediat, New York, NY 10029 USA; Mt Sinai Med Ctr, Dept Informat Technol, New York, NY 10029 USA; Mt Sinai Med Ctr, Dept Community & Prevent Med, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Cunningham-Rundles, C (corresponding author), Mt Sinai Sch Med, 1425 Madison Ave, New York, NY 10029 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R18AI048693] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 48693, AI 467320] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bertoni AG, 2002, DIABETES CARE, V25, P471, DOI 10.2337/diacare.25.3.471; Buckley Rebecca H, 2002, Curr Allergy Asthma Rep, V2, P356, DOI 10.1007/s11882-002-0067-1; Buckley RH, 1997, J PEDIATR-US, V130, P378, DOI 10.1016/S0022-3476(97)70199-9; Coleman LT, 1995, J THORAC IMAG, V10, P268, DOI 10.1097/00005382-199524000-00004; CONLEY ME, 1996, IMMUNOLOGIC DISORDER, P201; CORTI MC, 1995, JAMA-J AM MED ASSOC, V274, P539, DOI 10.1001/jama.274.7.539; Cunningham-Rundles C, 1999, CLIN IMMUNOL, V92, P34, DOI 10.1006/clim.1999.4725; CUNNINGHAMRUNDL.C, 1996, IMMUNOLOGIC DISORDER, P201; FASTH A, 1982, J CLIN IMMUNOL, V2, P86, DOI 10.1007/BF00916891; Finkelstein MM, 1999, CAN FAM PHYSICIAN, V45, P344; FLETCHER MA, 1997, MANUAL CLIN LAB IMMU, P313; Flores G, 2002, JAMA-J AM MED ASSOC, V288, P82, DOI 10.1001/jama.288.1.82; Flori NM, 1997, J CLIN IMMUNOL, V17, P333, DOI 10.1023/A:1027382916924; Folds James D., 2003, Journal of Allergy and Clinical Immunology, V111, pS702; Grimbacher B, 1999, NEW ENGL J MED, V340, P692, DOI 10.1056/NEJM199903043400904; Hall W. Dallas, 1999, Ethnicity and Disease, V9, P333; Herman-Giddens ME, 1999, JAMA-J AM MED ASSOC, V282, P463, DOI 10.1001/jama.282.5.463; Hong R, 1998, SEMIN HEMATOL, V35, P282; Jirapongsananuruk O, 1999, CLIN EXP IMMUNOL, V118, P1; KANOH T, 1986, VOX SANG, V50, P81, DOI 10.1111/j.1423-0410.1986.tb04851.x; KIDD PG, 1997, MANUAL CLIN LAB IMMU, P245; LUZI G, 1983, J CLIN IMMUNOL, V3, P316, DOI 10.1007/BF00915792; McCarthy EP, 2000, MED CARE, V38, P868, DOI 10.1097/00005650-200008000-00010; MCGEADY SJ, 1987, J PEDIATR-US, V110, P47, DOI 10.1016/S0022-3476(87)80286-X; Nietert PJ, 1999, J PEDIAT HEMATOL ONC, V21, P389, DOI 10.1097/00043426-199909000-00010; Noroski LM, 1998, CLIN IMMUNOL IMMUNOP, V86, P237, DOI 10.1006/clin.1997.4469; Ochs HD, 1996, MEDICINE, V75, P287, DOI 10.1097/00005792-199611000-00001; Owayed AF, 2000, ARCH PEDIAT ADOL MED, V154, P190, DOI 10.1001/archpedi.154.2.190; Pasteur MC, 2000, AM J RESP CRIT CARE, V162, P1277, DOI 10.1164/ajrccm.162.4.9906120; *PRACT MAN INF COR, 1998, ICD 9 CM INT CLASS D, V3; *PRACT MAN INF COR, 1998, ICD 9 CM INT CLASS D, V2; *PRACT MAN INF COR, 1998, ICD 9 CM INT CLASS D, V1; Rand CS, 2000, J ALLERGY CLIN IMMUN, V105, P83, DOI 10.1016/S0091-6749(00)90182-9; ROSEN FS, 1995, NEW ENGL J MED, V333, P431, DOI 10.1056/NEJM199508173330707; RYSER O, 1988, J CLIN IMMUNOL, V8, P479, DOI 10.1007/BF00916954; Schroeder HW, 1998, MOL MED, V4, P72, DOI 10.1007/BF03401731; Seto B, 2001, AM J MED SCI, V322, P246, DOI 10.1097/00000441-200111000-00002; Shohat T, 1999, AM J PUBLIC HEALTH, V89, P1855, DOI 10.2105/AJPH.89.12.1855; TIWARI JL, 1985, HLA DISEASE ASS, P1; UMETSU DT, 1985, NEW ENGL J MED, V313, P1247, DOI 10.1056/NEJM198511143132002; Vorechovsky I, 2000, J IMMUNOL, V164, P4408, DOI 10.4049/jimmunol.164.8.4408; VOWELLS SJ, 1995, J IMMUNOL METHODS, V178, P89, DOI 10.1016/0022-1759(94)00247-T; Whaley K, 1997, SEMIN LIVER DIS, V17, P297, DOI 10.1055/s-2007-1007206; Winkelstein JA, 2000, MEDICINE, V79, P155, DOI 10.1097/00005792-200005000-00003	44	37	37	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2004	113	4					747	755		10.1016/j.jaci.2004.01.761	http://dx.doi.org/10.1016/j.jaci.2004.01.761			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	814DY	15100683				2022-12-18	WOS:000220956600025
J	Cao, Y; Tao, JQ; Bates, SR; Beers, MF; Haczku, A				Cao, Y; Tao, JQ; Bates, SR; Beers, MF; Haczku, A			IL-4 induces production of the lung collectin surfactant protein-D	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						lung; T(H)2 cytokine; interleukin; surfactant protein; epithelial cells	AIRWAY INFLAMMATION; EXPRESSION; ALVEOLAR; CELLS	Background: Surfactant protein (SP)-D is an epithelial cell product of the distal air spaces that aids uptake and clearance of inhaled pathogens and allergens. Allergic airway inflammation significantly increases SP-D levels in the bronchoalveolar lavage fluid in asthmatic patients and mouse models, but the mechanisms involved remain unknown. Objective: To investigate the effects of the T(H)2-type cytokine IL-4 on SP-D production by isolated pulmonary epithelial cells. Methods: Rat type II alveolar epithelial cells were purified and cultured with dexamethasone, cAMP, and isobutyl-l-methyl-xanthine (DCI). The effects of IL-4 on SP-D expression were investigated at the protein and mRNA levels by means of Western and Northern blot analyses. Results: In contrast to a lamellar body protein ABCA3 and surfactant protein-A, expression of SP-D significantly declined when cells were cultured in medium alone for 24 hours. The presence of DCI in the culture medium restored SP-D levels, which were enhanced by 2-fold after addition of recombinant IL-4. The enhancing effects of IL-4 were concentration-dependent, with maximum effects observed at 20 ng/mL (1.43 nmol/L). IL-4 did not rescue cycloheximide-induced decrease of intracellular SP-D levels and did not inhibit extracellular release of SP-D. However, IL-4 significantly augmented DCI-induced SP-D mRNA expression by approximately 2.5-fold over control levels. Conclusions: IL-4 selectively upregulates SP-D expression, and it may act at the level of mRNA in isolated pulmonary epithelial cells. Since SP-D has a potent anti-inflammatory function, this mechanism may be part of a negative feedback loop providing a regulatory link between adaptive and innate immunity during allergic inflammation.	Univ Penn, Med Ctr, Dept Med, Pulm Allegy & Crit Care Div, Philadelphia, PA 19104 USA; Univ Penn, Inst Environm Med, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Haczku, A (corresponding author), Univ Penn, Med Ctr, Dept Med, Pulm Allegy & Crit Care Div, 421 Curie Blvd,BRB 2-3 840, Philadelphia, PA 19104 USA.		HACZKU, ANGELA/A-8486-2013	HACZKU, ANGELA/0000-0002-1301-4941; Cao, Richard/0000-0002-8743-9125	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064520, P01HL019737] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-64520, HL-19737] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aderibigbe AO, 1999, AM J RESP CELL MOL, V20, P219, DOI 10.1165/ajrcmb.20.2.3348; Atochina EN, 2000, AM J PHYSIOL-LUNG C, V278, pL599, DOI 10.1152/ajplung.2000.278.3.L599; Bates SR, 2002, AM J PHYSIOL-LUNG C, V282, pL267, DOI 10.1152/ajplung.00227.2001; Beers MF, 1999, J LAB CLIN MED, V133, P423, DOI 10.1016/S0022-2143(99)90019-7; Borron PJ, 1998, J IMMUNOL, V161, P4599; BRUSSELLE G, 1995, AM J RESP CELL MOL, V12, P254, DOI 10.1165/ajrcmb.12.3.7873190; Bry K, 1996, SEMIN PERINATOL, V20, P194, DOI 10.1016/S0146-0005(96)80048-6; Corry DB, 1998, MOL MED, V4, P344, DOI 10.1007/BF03401741; Crouch E, 2001, ANNU REV PHYSIOL, V63, P521, DOI 10.1146/annurev.physiol.63.1.521; Crouch E C, 2000, Respir Res, V1, P93; Crouch EC, 1998, BBA-MOL BASIS DIS, V1408, P278, DOI 10.1016/S0925-4439(98)00073-8; FINKELMAN FD, 1988, J IMMUNOL, V141, P2335; Foster PS, 2002, PHARMACOL THERAPEUT, V94, P253, DOI 10.1016/S0163-7258(02)00220-6; Haczku A, 2001, AM J RESP CELL MOL, V25, P45, DOI 10.1165/ajrcmb.25.1.4391; Haley KJ, 2002, AM J PHYSIOL-LUNG C, V282, pL573, DOI 10.1152/ajplung.00117.2001; He YC, 2002, J BIOL CHEM, V277, P19530, DOI 10.1074/jbc.M201126200; Homer RJ, 2002, AM J PHYSIOL-LUNG C, V283, pL52, DOI 10.1152/ajplung.00438.2001; HOPPE HJ, 1994, PROTEIN SCI, V3, P1143, DOI 10.1002/pro.5560030801; Ikegami M, 2000, AM J PHYSIOL-LUNG C, V278, pL75, DOI 10.1152/ajplung.2000.278.1.L75; Jain-Vora S, 1998, INFECT IMMUN, V66, P4229; Kasper M, 2002, CLIN EXP ALLERGY, V32, P1251, DOI 10.1046/j.1365-2745.2002.01423.x; Madsen J, 2000, J IMMUNOL, V164, P5866, DOI 10.4049/jimmunol.164.11.5866; McIntosh JC, 1996, AM J RESP CELL MOL, V15, P509, DOI 10.1165/ajrcmb.15.4.8879185; Mishra A, 2001, J BIOL CHEM, V276, P8453, DOI 10.1074/jbc.M009481200; Mulugeta S, 2002, J BIOL CHEM, V277, P22147, DOI 10.1074/jbc.M201812200; NILSSON G, 1995, EUR J IMMUNOL, V25, P870, DOI 10.1002/eji.1830250337; Pantelidis P, 2003, TISSUE ANTIGENS, V61, P317, DOI 10.1034/j.1399-0039.2003.00038.x; WALI A, 1993, AM J PHYSIOL, V264, pL431, DOI 10.1152/ajplung.1993.264.5.L431; Wang JY, 2001, CLIN EXP ALLERGY, V31, P652, DOI 10.1046/j.1365-2222.2001.01031.x; Zen K, 1998, AM J PHYSIOL-LUNG C, V275, pL172, DOI 10.1152/ajplung.1998.275.1.L172	30	37	40	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2004	113	3					439	444		10.1016/j.jaci.2003.11.031	http://dx.doi.org/10.1016/j.jaci.2003.11.031			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	802DM	15007344				2022-12-18	WOS:000220144200014
J	Brix, S; Bovetto, L; Fritsche, R; Barkholt, V; Frokiaer, H				Brix, S; Bovetto, L; Fritsche, R; Barkholt, V; Frokiaer, H			Immunostimulatory potential of beta-lactoglobulin preparations: Effects caused by endotoxin contamination	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						beta-lactoglobulin; bioactive; immunomodulatory; endotoxin; lipopolysaccharide; milk proteins	CELL PROLIFERATIVE RESPONSES; COWS MILK; CORD-BLOOD; CYTOKINE PROFILE; LIPID-A; INTERFERON-GAMMA; DENDRITIC CELLS; IMMUNE-SYSTEM; SPLEEN-CELLS; T-CELLS	Background: The immunomodulating potential residing in cow's milk proteins is currently receiving increasing attention because of growing interest in functional foods and the complex problem of cow's milk allergy. One of the major cow's milk allergens, whey protein beta-lactoglobulin, has previously been shown to mediate cellular activation in both human and murine immune cells. Objective: We examined the response to different beta-lactoglobulin preparations in naive immune cells. Methods: Splenocytes and cells from mesenteric lymph nodes derived from BALB/c mice bred and maintained on a milk-free diet were cultured in vitro with different beta-lactoglobulin preparations. Cell proliferation, cytokine production, and increases in intracellular glutathione were used as cellular activation markers. Moreover, the effect of beta-lactoglobulin on cytokine production in murine bone-marrow-derived dendritic cells was examined. Results: We observed that some commercial beta-lactoglobulin preparations induced pronounced proliferation of both spleen cells and cells from mesenteric lymph nodes; production of TNF-alpha, IL-6, IL-1beta, and IL-10; and an increased level of intracellular glutathione in spleen cell cultures. Furthermore, TNF-alpha, IL-6, IL-1beta, and IL-10 production was induced in murine bone-marrow-derived dendritic cells. Purification of beta-lactoglobulin from raw milk using nondenaturating conditions, however, revealed that the beta-lactoglobulin per se did not possess the immunomodulatory activity. Eventually, the immunostimulatory effect was found to be caused by endotoxin contamination. Conclusion: These results identify endotoxin as the main immunostimulatory component present in some commercial beta-lactoglobulin preparations. Moreover, the present study makes it evident that immunomodulatory effects attributed to beta-lactoglobulin need to be reassessed.	Tech Univ Denmark, Bioctr, DK-2800 Lyngby, Denmark; Nestec Ltd, Nestle Res Ctr, Lausanne, Switzerland	Technical University of Denmark; Nestle SA	Frokiaer, H (corresponding author), Tech Univ Denmark, Bioctr, DK-2800 Lyngby, Denmark.		Pedersen, Susanne Brix/B-3484-2009	Pedersen, Susanne Brix/0000-0001-8951-6705; Frokiaer, Hanne/0000-0003-1472-9698				ANDERSSON J, 1973, J EXP MED, V137, P943, DOI 10.1084/jem.137.4.943; BARKHOLT V, 1989, ANAL BIOCHEM, V177, P318, DOI 10.1016/0003-2697(89)90059-6; Beyer K, 2002, J ALLERGY CLIN IMMUN, V109, P707, DOI 10.1067/mai.2002.122503; BOUNOUS G, 1989, CLIN INVEST MED, V12, P154; Catala M, 2002, MOL CELL BIOCHEM, V231, P75, DOI 10.1023/A:1014489108199; Christensen HR, 2002, J IMMUNOL, V168, P171, DOI 10.4049/jimmunol.168.1.171; Cross ML, 2000, BRIT J NUTR, V84, pS81; Docena GH, 1996, ALLERGY, V51, P412, DOI 10.1111/j.1398-9995.1996.tb04639.x; Ebert EC, 2001, DIGEST DIS SCI, V46, P661, DOI 10.1023/A:1005684123481; Eigenmann PA, 1999, J ALLERGY CLIN IMMUN, V103, P931, DOI 10.1016/S0091-6749(99)70441-0; Exner R, 2000, WIEN KLIN WOCHENSCHR, V112, P610; Gao JJ, 2001, INFECT IMMUN, V69, P751, DOI 10.1128/IAI.69.2.751-757.2001; Goodier MR, 2000, J IMMUNOL, V165, P139, DOI 10.4049/jimmunol.165.1.139; HILL DJ, 1993, ALLERGY, V48, P75, DOI 10.1111/j.1398-9995.1993.tb00689.x; Hoffman KM, 1997, J ALLERGY CLIN IMMUN, V99, P360, DOI 10.1016/S0091-6749(97)70054-X; Jenmalm MC, 1999, PEDIATR ALLERGY IMMU, V10, P168, DOI 10.1034/j.1399-3038.1999.00016.x; Jones AC, 1996, PEDIATR ALLERGY IMMU, V7, P109, DOI 10.1111/j.1399-3038.1996.tb00117.x; Kopp MV, 2000, PEDIATR ALLERGY IMMU, V11, P4, DOI 10.1034/j.1399-3038.2000.00053.x; Kopp MV, 2001, CLIN EXP ALLERGY, V31, P1536, DOI 10.1046/j.1365-2222.2001.01198.x; Loser C, 2000, BRIT J NUTR, V84, pS55; Lu SC, 2000, CURR TOP CELL REGUL, V36, P95; MATTERN T, 1994, J IMMUNOL, V153, P2996; MattsbyBaltzer I, 1996, PEDIATR RES, V40, P257, DOI 10.1203/00006450-199608000-00011; Miles EA, 1996, CLIN EXP ALLERGY, V26, P780, DOI 10.1111/j.1365-2222.1996.tb00608.x; Nagata S, 2000, J IMMUNOL, V165, P5315, DOI 10.4049/jimmunol.165.9.5315; OTANI H, 1995, BIOSCI BIOTECH BIOCH, V59, P1166, DOI 10.1271/bbb.59.1166; Papadopoulos NG, 1999, INT ARCH ALLERGY IMM, V119, P64, DOI 10.1159/000024177; Petsch D, 2000, J BIOTECHNOL, V76, P97, DOI 10.1016/S0168-1656(99)00185-6; PIASTRA M, 1994, INT ARCH ALLERGY IMM, V104, P358, DOI 10.1159/000236692; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Prescott SL, 1998, J IMMUNOL, V160, P4730; Sopo SM, 1999, PEDIATR ALLERGY IMMU, V10, P249, DOI 10.1034/j.1399-3038.1999.00045.x; Sousa CRE, 1999, J IMMUNOL, V162, P6552; Srimal S, 1996, BIOCHEM J, V315, P679, DOI 10.1042/bj3150679; STOECK M, 1989, J IMMUNOL, V143, P3258; Suri RM, 1998, J IMMUNOL METHODS, V214, P149, DOI 10.1016/S0022-1759(98)00048-9; Szepfalusi Z, 1997, CLIN EXP ALLERGY, V27, P28, DOI 10.1046/j.1365-2222.1997.d01-417.x; Ulevitch RJ, 1999, CURR OPIN IMMUNOL, V11, P19, DOI 10.1016/S0952-7915(99)80004-1; Wal JM, 1998, ALLERGY, V53, P1013, DOI 10.1111/j.1398-9995.1998.tb03811.x; WAL JM, 1995, RECENT ADV MUCOSAL I, P879; WARNER JA, 1994, CLIN EXP ALLERGY, V24, P423, DOI 10.1111/j.1365-2222.1994.tb00930.x; Wong KF, 1998, J DAIRY SCI, V81, P1825, DOI 10.3168/jds.S0022-0302(98)75752-2	42	37	38	0	9	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2003	112	6					1216	1222		10.1016/j.jaci.2003.08.047	http://dx.doi.org/10.1016/j.jaci.2003.08.047			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	752HC	14657886				2022-12-18	WOS:000187154200029
J	Allen, TM; Altfeld, M				Allen, TM; Altfeld, M			HIV-1 superinfection	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HIV-1; superinfection; recombination; cytotoxic T lymphocyte; viral evolution	HUMAN-IMMUNODEFICIENCY-VIRUS; CYTOTOXIC T-LYMPHOCYTES; CROSS-CLADE; DUAL INFECTION; TYPE-1 INFECTION; CELL RECOGNITION; SUBTYPE-B; RECOMBINATION; IDENTIFICATION; RESPONSES	During the past year, a number of reports have described HIV-1 superinfection in human subjects, defined as the reinfection of an individual with a second heterologous strain of HIV-1. These reports have challenged the assumption that HIV-1-specific immune responses generated during primary infection are protective against subsequent infection and have raised concern, not only with respect to HIV-1-positive individuals engaging in unsafe sex but also from the standpoint of developing effective vaccines. Herein we review the published reports of HIV-1 superinfection and highlight studies providing additional insight into the potential for HIV-1 superinfections to affect the global epidemic.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Partners AIDS Res Ctr, Charlestown, MA USA	Harvard University; Massachusetts General Hospital	Altfeld, M (corresponding author), Massachusetts Gen Hosp, Partners AIDS Res Ctr, Bldg 149,13th St,5th Floor, Charlestown, MA 02129 USA.		Allen, Todd/F-5473-2011; Altfeld, Marcus/AAE-7306-2019	Allen, Todd/0000-0002-6609-1318; Altfeld, Marcus/0000-0001-5972-2997				ALTER HJ, 1984, SCIENCE, V226, P549, DOI 10.1126/science.6093251; Altfeld M, 2002, NATURE, V420, P434, DOI 10.1038/nature01200; Altfeld M, 2000, CURR OPIN IMMUNOL, V12, P375, DOI 10.1016/S0952-7915(00)00103-5; ANGEL JB, 2000, 7 C RETR OPP INF; ARTENSTEIN AW, 1995, J INFECT DIS, V171, P805, DOI 10.1093/infdis/171.4.805; Becker-Pergola G, 2000, AIDS RES HUM RETROV, V16, P1099, DOI 10.1089/088922200414938; Belda FJ, 1998, AIDS RES HUM RETROV, V14, P911, DOI 10.1089/aid.1998.14.911; BENSON RE, 1993, J EXP MED, V177, P1561, DOI 10.1084/jem.177.6.1561; BENVENISTE RE, 1988, J VIROL, V62, P2091, DOI 10.1128/JVI.62.6.2091-2101.1988; Betts MR, 1997, J VIROL, V71, P8908, DOI 10.1128/JVI.71.11.8908-8911.1997; Blackard JT, 2002, CLIN INFECT DIS, V34, P1108, DOI 10.1086/339547; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; Buseyne F, 1998, VIROLOGY, V250, P316, DOI 10.1006/viro.1998.9373; Butto S, 1997, AIDS, V11, P694; Cao HY, 2000, J INFECT DIS, V182, P1350, DOI 10.1086/315868; Cao HY, 1997, J VIROL, V71, P8615, DOI 10.1128/JVI.71.11.8615-8623.1997; DAAR ES, 2002, 9 C RETR OPP INF; DIAZ RS, 1995, J VIROL, V69, P3273, DOI 10.1128/JVI.69.6.3273-3281.1995; Dorrell L, 1999, J VIROL, V73, P1708, DOI 10.1128/JVI.73.2.1708-1714.1999; Dorrell L, 2001, EUR J IMMUNOL, V31, P1747, DOI 10.1002/1521-4141(200106)31:6<1747::AID-IMMU1747>3.3.CO;2-C; Douek DC, 2002, NATURE, V417, P95, DOI 10.1038/417095a; Fleury H, 2003, AIDS RES HUM RETROV, V19, P41, DOI 10.1089/08892220360473952; Flores I, 1999, EMERG INFECT DIS, V5, P481, DOI 10.3201/eid0503.990328; FRANCIS DP, 1984, LANCET, V2, P1276; Fukada K, 2002, AIDS, V16, P701, DOI 10.1097/00002030-200203290-00005; FULTZ PN, 1990, CURR OPIN IMMUNOL, V2, P403, DOI 10.1016/0952-7915(89)90150-7; FULTZ PN, 1987, J VIROL, V61, P4026, DOI 10.1128/JVI.61.12.4026-4029.1987; Gotch F, 1998, CURR OPIN IMMUNOL, V10, P388, DOI 10.1016/S0952-7915(98)80109-X; Goulder PJR, 2002, NEW ENGL J MED, V347, P756, DOI 10.1056/NEJMe020091; Janini LM, 1998, J INFECT DIS, V177, P227, DOI 10.1086/517360; Janini LM, 1996, VIRUS GENES, V13, P69, DOI 10.1007/BF00576981; Jetzt AE, 2000, J VIROL, V74, P1234, DOI 10.1128/JVI.74.3.1234-1240.2000; Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991; Joag SV, 1996, J VIROL, V70, P3189, DOI 10.1128/JVI.70.5.3189-3197.1996; Jost S, 2002, NEW ENGL J MED, V347, P731, DOI 10.1056/NEJMoa020263; Jung A, 2002, NATURE, V418, P144, DOI 10.1038/418144a; Kalams SA, 1998, J EXP MED, V188, P2199, DOI 10.1084/jem.188.12.2199; Koelsch KK, 2003, AIDS, V17, pF11, DOI 10.1097/00002030-200305020-00001; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; Levy JA, 2003, LANCET, V361, P98, DOI 10.1016/S0140-6736(03)12242-8; Liitsola K, 2000, AIDS RES HUM RETROV, V16, P1047, DOI 10.1089/08892220050075309; Lole KS, 1999, J VIROL, V73, P152, DOI 10.1128/JVI.73.1.152-160.1999; Lynch JA, 1998, J INFECT DIS, V178, P1040, DOI 10.1086/515652; Mamadou S, 2003, AIDS RES HUM RETROV, V19, P77, DOI 10.1089/08892220360474005; Mamadou S, 2002, AIDS RES HUM RETROV, V18, P723, DOI 10.1089/088922202760072357; McAdam S, 1998, AIDS, V12, P571, DOI 10.1097/00002030-199806000-00005; McCutchan FE, 2002, AIDS RES HUM RETROV, V18, P1135, DOI 10.1089/088922202320567879; McCutchan FE, 2000, AIDS, V14, pS31; McMichael AJ, 2002, NATURE, V420, P371, DOI 10.1038/420371a; Mellquist JL, 1999, AIDS RES HUM RETROV, V15, P217, DOI 10.1089/088922299311637; MURPHEYCORB M, 1986, NATURE, V321, P435, DOI 10.1038/321435a0; Najera R, 2002, AIDS, V16, pS3, DOI 10.1097/00002030-200216004-00002; NICOL I, 1989, INTERVIROLOGY, V30, P258, DOI 10.1159/000150101; Novembre FJ, 2001, J VIROL, V75, P1533, DOI 10.1128/JVI.75.3.1533-1539.2001; Otten RA, 1999, J INFECT DIS, V180, P673, DOI 10.1086/314968; PEETERS M, 2000, MOL IMMUNOLOGY COMPE; Perrin L, 2003, LANCET INFECT DIS, V3, P22, DOI 10.1016/S1473-3099(03)00484-5; Ramos A, 1999, EMERG INFECT DIS, V5, P65, DOI 10.3201/eid0501.990108; Ramos A, 2002, J VIROL, V76, P7444, DOI 10.1128/JVI.76.15.7444-7452.2002; Reimann KA, 1996, J VIROL, V70, P3198, DOI 10.1128/JVI.70.5.3198-3206.1996; Reimann KA, 1996, J VIROL, V70, P6922, DOI 10.1128/JVI.70.10.6922-6928.1996; ROBERTSON DL, 1995, NATURE, V374, P124, DOI 10.1038/374124b0; Rowland-Jones SL, 1999, IMMUNOL LETT, V66, P9, DOI 10.1016/S0165-2478(98)00179-5; SALA M, 1995, AIDS RES HUM RETROV, V11, P653, DOI 10.1089/aid.1995.11.653; Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857; TADDEO B, 1993, VIROLOGY, V194, P441, DOI 10.1006/viro.1993.1283; Volsky DJ, 1996, J VIROL, V70, P3823, DOI 10.1128/JVI.70.6.3823-3833.1996; Walker BD, 2001, NAT IMMUNOL, V2, P473, DOI 10.1038/88656; Wei Q, 1998, J VIROL, V72, P3005, DOI 10.1128/JVI.72.4.3005-3017.1998; Wilson SE, 1998, AIDS RES HUM RETROV, V14, P925, DOI 10.1089/aid.1998.14.925; Wyand MS, 1999, J VIROL, V73, P8356, DOI 10.1128/JVI.73.10.8356-8363.1999; XIN KQ, 1995, LANCET, V346, P1372, DOI 10.1016/S0140-6736(95)92391-8; Yang RG, 2003, J VIROL, V77, P685, DOI 10.1128/JVI.77.1.685-695.2003; Yirrell DL, 2002, AIDS, V16, P279, DOI 10.1097/00002030-200201250-00018; Zhuang JL, 2002, J VIROL, V76, P11273, DOI 10.1128/JVI.76.22.11273-11282.2002	75	37	38	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2003	112	5					829	835		10.1016/j.jaci.2003.08.037	http://dx.doi.org/10.1016/j.jaci.2003.08.037			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743BV	14610465	Bronze			2022-12-18	WOS:000186553300002
J	Ober, AI; MacLean, JA; Hannaway, PJ				Ober, AI; MacLean, JA; Hannaway, PJ			Life-threatening anaphylaxis to venom immunotherapy in a patient taking an angiotensin-converting enzyme inhibitor	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									N Shore Med Ctr, Salem, MA 01970 USA		Ober, AI (corresponding author), N Shore Med Ctr, 114R Highland Ave, Salem, MA 01970 USA.							*AM AC ALL ASTHM I, 1999, J ALLERGY CLIN IMMUN, V103, P963; HERMANN K, 1994, INT ARCH ALLERGY IMM, V104, P379, DOI 10.1159/000236695; Hermann K, 1997, INT ARCH ALLERGY IMM, V112, P251, DOI 10.1159/000237462; *JOINT TASK FORC P, 1998, J ALLERGY CLIN IMMUN, V101, pS465; Joint Task Force on Practice Parameters, 2003, Ann Allergy Asthma Immunol, V90, P1; Kemp SF, 1997, ANN ALLERG ASTHMA IM, V78, P527, DOI 10.1016/S1081-1206(10)63212-7; REID MJ, 1993, J ALLERGY CLIN IMMUN, V92, P6, DOI 10.1016/0091-6749(93)90030-J; SCHAEFER RM, 1994, CLIN NEPHROL, V42, pS44; TUNONDELARA JM, 1992, LANCET, V340, P908, DOI 10.1016/0140-6736(92)93314-D; VONTSCHIRSCHNIT.M, 1993, J ALLERGY CLIN IMMUN, V91, P823	10	37	38	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2003	112	5					1008	1009		10.1016/S0091-6749(03)01940-7	http://dx.doi.org/10.1016/S0091-6749(03)01940-7			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743BV	14610496				2022-12-18	WOS:000186553300027
J	Hunt, LW; Kelkar, P; Reed, CE; Yunginger, JW				Hunt, LW; Kelkar, P; Reed, CE; Yunginger, JW			Management of occupational allergy to natural rubber latex in a medical center: The importance of quantitative latex allergen measurement and objective follow-up	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Meeting on Natural Rubber Latex Sensitivity	FEB 09-10, 2001	SAN FRANCISCO, CA	Malaysian Rubber Res Inst		latex allergens; latex aeroallergens; immunoassay; environmental control; incidence; intervention measures; health care workers	HEALTH-CARE WORKERS; AIRBORNE ALLERGENS; ASTHMA; GLOVES; AEROALLERGEN; CHALLENGE; IMMUNOTHERAPY; SENSITIZATION; PREVALENCE; HOSPITALS	When our employees began coming to the Occupational Health Service, Dermatology, and Allergy Clinics with symptoms of allergy to rubber gloves 12 years ago, the Mayo Clinic initiated 3 responses. (1) The Allergic Disease Research Laboratory adapted well-established technology to measure both the IgE antibody specific to natural rubber allergens, and by use of this IgE antibody, the allergens in rubber products and in the air of the workplace. (2) The Division of Allergic Diseases and Internal Medicine reviewed the prevalence and severity of the problem. (3) The Clinical Practice Committee appointed a multidisciplinary task force to implement measures to reduce exposure. The 3 sections of this article describe the Mayo Clinic's experience of successful control of this occupational health problem. Use of only gloves with low or undetectable allergen content greatly reduced the concentration of allergen in the work site, reduced the number of new cases of occupational allergy to rubber, and allowed individuals with latex allergy to work at their usual jobs.	Mayo Clin & Mayo Fdn, Allerg Dis Res Lab, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Pediat, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Internal Med, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Yunginger, JW (corresponding author), Mayo Clin & Mayo Fdn, Allerg Dis Res Lab, 200 1st St SW, Rochester, MN 55905 USA.							Allmers H, 1998, J ALLERGY CLIN IMMUN, V102, P841, DOI 10.1016/S0091-6749(98)70026-0; ANDERSON MC, 1986, RAST INHIBITION PROC; AXELSSON JGK, 1987, ALLERGY, V42, P46, DOI 10.1111/j.1398-9995.1987.tb02186.x; BAUR X, 1993, LANCET, V342, P1148, DOI 10.1016/0140-6736(93)92127-F; Baur X, 1998, J ALLERGY CLIN IMMUN, V101, P24, DOI 10.1016/S0091-6749(98)70188-5; Baur X, 1997, ALLERGY, V52, P661, DOI 10.1111/j.1398-9995.1997.tb01046.x; Baur X, 1998, AM J IND MED, V33, P114; Baur X, 1998, CLIN EXP ALLERGY, V28, P537; BEAUDOUIN E, 1990, REV FR ALLERGOL, V30, P157, DOI 10.1016/S0335-7457(05)80230-8; BUBAK ME, 1992, MAYO CLIN PROC, V67, P1075, DOI 10.1016/S0025-6196(12)61122-7; Charous BL, 2000, ANN ALLERG ASTHMA IM, V85, P285, DOI 10.1016/S1081-1206(10)62531-8; Glovsky MM, 1997, ALLERGY ASTHMA PROC, V18, P163, DOI 10.2500/108854197778984392; Hamilton RG, 2000, J ALLERGY CLIN IMMUN, V105, P839, DOI 10.1067/mai.2000.105224; Heilman DK, 1996, J ALLERGY CLIN IMMUN, V98, P325, DOI 10.1016/S0091-6749(96)70157-4; Hermesch C B, 1999, J Dent Educ, V63, P814; HUNT LW, 1995, J OCCUP ENVIRON MED, V37, P1204, DOI 10.1097/00043764-199510000-00011; Hunt LW, 1996, J OCCUP ENVIRON MED, V38, P765, DOI 10.1097/00043764-199608000-00011; JOKANKI R, 1999, CONTACT DERMATITIS, V40, P329; JONES RT, 1994, ANN ALLERGY, V73, P321; Jones RT, 1998, J ALLERGY CLIN IMMUN, V102, P694, DOI 10.1016/S0091-6749(98)70290-8; KAJALA V, 1999, OCCUP MED, V49, P3; Kelly K, 2000, J ALLERGY CLIN IMMUN, V105, pS52, DOI 10.1016/S0091-6749(00)90588-8; KURTZ KM, 2000, J ALLERGY CLIN IMMUN, V107, P78; Laoprasert N, 1998, J ALLERGY CLIN IMMUN, V102, P998, DOI 10.1016/S0091-6749(98)70338-0; Leynadier F, 2000, J ALLERGY CLIN IMMUN, V106, P585, DOI 10.1067/mai.2000.109173; Liss GM, 1997, OCCUP ENVIRON MED, V54, P335, DOI 10.1136/oem.54.5.335; LUNDBERG M, 1995, ALLERGY, V50, P378, DOI 10.1111/j.1398-9995.1995.tb01165.x; Miguel AG, 1996, ENVIRON HEALTH PERSP, V104, P1180, DOI 10.2307/3432911; NELSON HS, 1998, ALLERGY PRINCIPLES P, P1050; Page EH, 2000, J OCCUP ENVIRON MED, V42, P613, DOI 10.1097/00043764-200006000-00010; Pereira C, 1999, ALLERGY, V54, P291, DOI 10.1034/j.1398-9995.1999.00954.x; Phillips VL, 1999, AM J PUBLIC HEALTH, V89, P1024, DOI 10.2105/AJPH.89.7.1024; PISATI G, 1994, EUR RESPIR J, V7, P332, DOI 10.1183/09031936.94.07020332; Raulf-Heimsoth M, 2000, CLIN EXP ALLERGY, V30, P110; REED CE, 1999, ASTHMA WORKPLACE, P235; SALKIE ML, 1993, ARCH PATHOL LAB MED, V117, P897; Shahnaz M, 1999, J ALLERGY CLIN IMMUN, V103, pS160; SLATER JE, 1989, NEW ENGL J MED, V320, P1126, DOI 10.1056/NEJM198904273201707; Sri-Akajunt N, 2000, ANN OCCUP HYG, V44, P79, DOI 10.1093/annhyg/44.2.79; SUSSMAN GL, 1991, JAMA-J AM MED ASSOC, V265, P2844, DOI 10.1001/jama.265.21.2844; Sussman GL, 1998, J ALLERGY CLIN IMMUN, V101, P171, DOI 10.1016/S0091-6749(98)70381-1; Sussman GL, 1998, J ALLERGY CLIN IMMUN, V102, P333, DOI 10.1016/S0091-6749(98)70110-1; SWANSON MC, 1994, J ALLERGY CLIN IMMUN, V94, P445, DOI 10.1016/0091-6749(94)90199-6; SWANSON MC, 2000, CAN J ALLERGY CLIN I, V5, P328; TARLO SM, 1994, J ALLERGY CLIN IMMUN, V93, P985, DOI 10.1016/S0091-6749(94)70045-1; *TASK FORC ALL REA, 1993, J ALLERGY CLIN IMMUN, V92, P16; Toci G, 1998, J ALLERGY CLIN IMMUN, V101, pS161; Turjanmaa K, 2000, J ALLERGY CLIN IMMUN, V105, pS373, DOI 10.1016/S0091-6749(00)91520-3; TURJANMAA K, 1995, IMMUNOL ALLERGY CLIN, V15, P71; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; VANDENPLAS O, 1995, AM J RESP CRIT CARE, V151, P54, DOI 10.1164/ajrccm.151.1.7812572; Vandenplas O, 1996, THORAX, V51, P452, DOI 10.1136/thx.51.4.452; VANDENPLAS O, 1995, AM J RESP CRIT CARE, V151, P887; Vandenplas O, 1999, ASTHMA WORKPLACE, P425; WILLIAMS PB, 1995, J ALLERGY CLIN IMMUN, V95, P88, DOI 10.1016/S0091-6749(95)70156-7; Woods Julia A., 1997, Journal of Emergency Medicine, V15, P71, DOI 10.1016/S0736-4679(96)00256-9; YASSIN MS, 1994, ANN ALLERGY, V72, P245; Yunginger JW, 1999, ANN ALLERG ASTHMA IM, V83, P630, DOI 10.1016/S1081-1206(10)62885-2; YUNGINGER JW, 1994, J ALLERGY CLIN IMMUN, V93, P836, DOI 10.1016/0091-6749(94)90374-3; YUNGINGER JW, 1997, MANUAL CLIN LAB IMMU, P868	60	37	40	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2002	110	2		S			S96	S106		10.1067/mai.2002.125442	http://dx.doi.org/10.1067/mai.2002.125442			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	586ET	12170249				2022-12-18	WOS:000177572200014
J	Just, J; Fournier, L; Momas, I; Zambetti, C; Sahraoui, F; Grimfeld, A				Just, J; Fournier, L; Momas, I; Zambetti, C; Sahraoui, F; Grimfeld, A			Clinical significance of bronchoalveolar eosinophils in childhood asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; child; infant; bronchoalveolar lavage; eosinophils; neutrophils	INFLAMMATION; LAVAGE	To evaluate the relationship between clinical parameters and differential cell counts, bronchoalveolar lavage was performed in 79 asthmatic infants and children with unusual asthma. Multivariate analysis showed significant associations between (1) allergic asthma and the presence of alveolar eosinophils and (2) persistent and longer asthma and an increased number of alveolar neutrophils. Our results provide the first evidence that in asthmatic infants and children eosinophilic inflammation is related to allergic sensitization.	Hop Enfants Armand Trousseau, Policlin Pneumol Pediat, Serv Pneumol Pediat, F-75571 Paris 12, France; Univ Paris 05, Lab Hyg & Sante Publ, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Universite Paris Cite	Just, J (corresponding author), Hop Enfants Armand Trousseau, Policlin Pneumol Pediat, Serv Pneumol Pediat, 26,Ave Dr Arnold Netter, F-75571 Paris 12, France.			momas, isabelle/0000-0003-4344-3787				BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Fayon M, 1999, ACTA PAEDIATR, V88, P1216, DOI 10.1080/080352599750030310; Gibson PG, 1998, J ALLERGY CLIN IMMUN, V102, pS100, DOI 10.1016/S0091-6749(98)70039-9; JAKATANON A, 1999, AM J RESP CRIT CARE, V160, P1532; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Martinez FD, 1997, PEDIATR PULM, P9; MIDULLA F, 1995, PEDIATR PULM, V20, P112, DOI 10.1002/ppul.1950200211; Ordonez CL, 2000, AM J RESP CRIT CARE, V161, P1185, DOI 10.1164/ajrccm.161.4.9812061; Stevenson EC, 1997, CLIN EXP ALLERGY, V27, P1027, DOI 10.1111/j.1365-2222.1997.tb01254.x; TABACHNIK E, 1981, J ALLERGY CLIN IMMUN, V67, P339, DOI 10.1016/0091-6749(81)90077-4	10	37	37	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2002	110	1					42	44		10.1067/mai.2002.123304	http://dx.doi.org/10.1067/mai.2002.123304			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	574CF	12110817	Bronze			2022-12-18	WOS:000176870300009
J	Luccioli, S; Brody, DT; Hasan, S; Keane-Myers, A; Prussin, C; Metcalfe, DD				Luccioli, S; Brody, DT; Hasan, S; Keane-Myers, A; Prussin, C; Metcalfe, DD			IgE(+), Kit(-), I-A/I-E- myeloid cells are the initial source of IL-4 after antigen challenge in a mouse model of allergic pulmonary inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mast cells; basophils; asthma; IL-4; IgE; Fc receptors	EOSINOPHILIC AIRWAY INFLAMMATION; CD4(+) T-CELLS; FC-EPSILON-RI; MURINE MODEL; MAST-CELLS; SCHISTOSOMA-MANSONI; PERIPHERAL-BLOOD; DEFICIENT MICE; ASTHMA; INTERLEUKIN-4	Background: IL-4 is generated within hours after antigen lung challenge and influences events that take place early in the induction of pulmonary inflammation. However, the cells responsible for this early IL-4 production in the lung are unknown. Objectives: We sought to characterize the initial inflammatory events in the lung after antigen challenge and to identify cells responsible for producing 11-4 at early time points. Methods: Mice were sensitized with ovalbumin or passive IgE and challenged intranasally. Histologic measures of inflammation were used, and lung tissue cytokine production was analyzed by means of RT-PCR. Cells producing IL-4 were characterized by means of in situ hybridization and flow cytometry. Results: IL-4 mRNA was detectable 100 minutes after challenge in sensitized animals. Blockade of this early IL-4 down-regulated vascular cell adhesion molecule I mRNA expression and attenuated the early recruitment of eusinophils to the lung. CD4-depleted and mast cell-deficient mice both expressed early IL-4. Cellular analysis revealed the presence of IL-4 protein at 100 minutes exclusively in IgE myeloid cells that did not express CD3, Kit, or I-AA-E. Moreover, IL-4 production induced by means of passive IgE sensitization and abrogated in FcR gamma-chain-deficient mice supports the conclusion that this IL-4 production is dependent on IgE/gamma-chain interaction. Conclusion: IL-4 production by an IgE/gamma-chain-dependent mechanism occurs rapidly after allergen challenge. At these early time points, IL-4 is produced by a myeloid cell with the characteristics of a mouse basophil (IgE(+), Kit(-), I-A/I-E-). These data thus suggest that strategies targeting basophils should be considered in the treatment of early lung inflammation.	NIAID, Lab Allerg Dis, NIH, Rockville, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Luccioli, S (corresponding author), NIAID, Lab Allerg Dis, NIH, Twinbrook 2,Room 203,12441 Parklawn Dr, Rockville, MD 20852 USA.			Prussin, Calman/0000-0002-3917-3326	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000709, Z01AI000888] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AOKI I, 1995, P NATL ACAD SCI USA, V92, P2534, DOI 10.1073/pnas.92.7.2534; Barnes PJ, 2001, J ALLERGY CLIN IMMUN, V108, pS72, DOI 10.1067/mai.2001.116435; Blyth DI, 1996, AM J RESP CELL MOL, V14, P425, DOI 10.1165/ajrcmb.14.5.8624247; BRUSSELLE GG, 1994, CLIN EXP ALLERGY, V24, P73, DOI 10.1111/j.1365-2222.1994.tb00920.x; Buttner C, 1997, AM J RESP CELL MOL, V17, P315; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; COYLE AJ, 1995, AM J RESP CELL MOL, V13, P54, DOI 10.1165/ajrcmb.13.1.7598937; Devouassoux G, 1999, J ALLERGY CLIN IMMUN, V104, P811, DOI 10.1016/S0091-6749(99)70292-7; Dombrowicz D, 2001, CURR OPIN IMMUNOL, V13, P716, DOI 10.1016/S0952-7915(01)00284-9; Dombrowicz D, 1998, IMMUNITY, V8, P517, DOI 10.1016/S1074-7613(00)80556-7; DVORAK AM, 1982, BLOOD, V59, P1279; Dvorak AM, 2000, BLOOD, V96, P1616, DOI 10.1182/blood.V96.4.1616.h8001608e_1616_1617; FINKELMAN FD, 1988, J IMMUNOL, V141, P2335; GAVETT SH, 1994, AM J RESP CELL MOL, V10, P587, DOI 10.1165/ajrcmb.10.6.8003337; Gleich GJ, 2000, J ALLERGY CLIN IMMUN, V105, P651, DOI 10.1067/mai.2000.105712; GUO CB, 1994, AM J RESP CELL MOL, V10, P384, DOI 10.1165/ajrcmb.10.4.7510984; Haile S, 1999, EUR RESPIR J, V13, P961, DOI 10.1034/j.1399-3003.1999.13e06.x; Henderson WR, 2000, J IMMUNOL, V164, P1086, DOI 10.4049/jimmunol.164.2.1086; IADEMARCO MF, 1995, J CLIN INVEST, V95, P264, DOI 10.1172/JCI117650; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; Korsgren M, 1999, J EXP MED, V189, P553, DOI 10.1084/jem.189.3.553; Koshino T, 1996, J ASTHMA, V33, P89, DOI 10.3109/02770909609054536; Lantz CS, 1997, J IMMUNOL, V158, P2517; Launois P, 1995, EUR J IMMUNOL, V25, P3298, DOI 10.1002/eji.1830251215; LUKACS NW, 1994, AM J RESP CELL MOL, V10, P526, DOI 10.1165/ajrcmb.10.5.8179915; MACGLASHAN D, 1994, J IMMUNOL, V152, P3006; Mehlhop PD, 1997, P NATL ACAD SCI USA, V94, P1344, DOI 10.1073/pnas.94.4.1344; Noben-Trauth N, 2000, J IMMUNOL, V165, P3620, DOI 10.4049/jimmunol.165.7.3620; Ohkawara Y, 1997, AM J RESP CELL MOL, V16, P510, DOI 10.1165/ajrcmb.16.5.9160833; Pauwels RA, 1997, AM J RESP CRIT CARE, V156, pS78, DOI 10.1164/ajrccm.156.4.12-tac-1; Pivniouk VI, 1999, J CLIN INVEST, V103, P1737; Prussin C, 1995, J IMMUNOL METHODS, V188, P117, DOI 10.1016/0022-1759(95)00209-X; Romagnani S, 2000, J ALLERGY CLIN IMMUN, V105, P399, DOI 10.1067/mai.2000.104575; SABIN EA, 1995, J IMMUNOL, V155, P4844; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; Schroeder JT, 2000, J ALLERGY CLIN IMMUN, V105, pS85, DOI 10.1016/S0091-6749(00)90686-9; SEDER RA, 1991, P NATL ACAD SCI USA, V88, P2835, DOI 10.1073/pnas.88.7.2835; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; Takeda K, 1997, J EXP MED, V186, P449, DOI 10.1084/jem.186.3.449; URBINA C, 1981, INT ARCH ALLER A IMM, V66, P158, DOI 10.1159/000232814; Williams CMM, 2000, J EXP MED, V192, P455, DOI 10.1084/jem.192.3.455; Williams CMM, 2000, J ALLERGY CLIN IMMUN, V105, P847, DOI 10.1067/mai.2000.106485; WILLIAMS ME, 1993, EUR J IMMUNOL, V23, P1910, DOI 10.1002/eji.1830230827; Wills-Karp M, 2000, IMMUNOPHARMACOLOGY, V48, P263, DOI 10.1016/S0162-3109(00)00223-X	44	37	37	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2002	110	1					117	124		10.1067/mai.2002.125828	http://dx.doi.org/10.1067/mai.2002.125828			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	574CF	12110830				2022-12-18	WOS:000176870300022
J	Reich, K; Hugo, S; Middel, P; Blaschke, V; Heine, A; Gutgesell, C; Williams, R; Neumann, C				Reich, K; Hugo, S; Middel, P; Blaschke, V; Heine, A; Gutgesell, C; Williams, R; Neumann, C			Evidence for a role of Langerhans cell-derived IL-16 in atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; Langerhans cells; keratinocytes; IL-16; chemotaxis; CD4(+) cells; real-time RT-PCE; tacrolimus	DENDRITIC CELLS; INCREASED EXPRESSION; T-CELLS; INTERLEUKIN-16; CYTOKINE; ACTIVATION; PRECURSOR; EOTAXIN; TISSUE; LIGAND	Background: The factors controlling infiltration of inflammatory cells into atopic dermatitis (AD) lesions remain to be fully explored. Recently, epidermal cells in lesional AD were reported to contain increased messenger (m)RNA levels of IL-16, a cytokine that induces chemotactic responses in CD4(+) T cells, monocytes, and eosinophils. Objectives: We sought to determine the expression of IL-16 in epidermal cells in normal skin and skin from AD lesions and to investigate whether Langerhans cell (LC)-derived IL-16 may contribute to the initiation of atopic eczema. Methods: The cutaneous expression of IL-16 was investigated by in situ hybridization and immunohistochemistry. Expression of IL-16 was also investigated in freshly isolated LCs and in keratinocytes by intracellular cytokine staining, quantitative real-time RT-PCR, and ELISA. Results: Low levels of IL-16 mRNA, but no stored IL-16 protein, were detected in keratinocytes and LCs isolated from normal skin. Synthesis, storage, and secretion of IL-16 could be induced in LCs, but not keratinocytes, by activation with phorbol ester and ionomycin. In normal skin (n = 10) neither keratinocytes nor LCs expressed IL-16. In contrast, IL-16 was contained in approximately 40% of CD1a(+) LCs in patients with active AD (n = 16). IL-16 expression in LCs in patients with AD correlated with the number of infiltrating CD4+ cells (r = .72, P = .0017) and was completely downregulated parallel to the clinical response of AD lesions to topical treatment with FK506. Conclusion: LC-derived IL-16 may participate in the recruitment and activation of inflammatory cells in AD.	Univ Gottingen, Dept Dermatol, D-37075 Gottingen, Germany; Univ Gottingen, Dept Pathol, D-37075 Gottingen, Germany; Univ Tubingen, Dept Surg, Tubingen, Germany	University of Gottingen; University of Gottingen; Eberhard Karls University of Tubingen	Reich, K (corresponding author), Univ Gottingen, Dept Dermatol, Von Siebold Str 3, D-37075 Gottingen, Germany.							AOYAMA H, 1995, BRIT J DERMATOL, V133, P494, DOI 10.1111/j.1365-2133.1995.tb02691.x; Baier M, 1997, P NATL ACAD SCI USA, V94, P5273, DOI 10.1073/pnas.94.10.5273; Blaschke V, 1999, J INVEST DERMATOL, V113, P658, DOI 10.1046/j.1523-1747.1999.00717.x; Blaschke V, 2000, J IMMUNOL METHODS, V246, P79, DOI 10.1016/S0022-1759(00)00304-5; Center DM, 1996, IMMUNOL TODAY, V17, P476, DOI 10.1016/0167-5699(96)10052-I; Chupp GL, 1998, J IMMUNOL, V161, P3114; CRUIKSHANK WW, 1995, AM J RESP CELL MOL, V13, P738, DOI 10.1165/ajrcmb.13.6.7576712; de Saint-Vis B, 1998, J IMMUNOL, V160, P1666; Hessel EM, 1998, J IMMUNOL, V160, P2998; Homey B, 1998, J IMMUNOL, V160, P5331; Junghans V, 1996, Exp Dermatol, V5, P316, DOI 10.1111/j.1600-0625.1996.tb00135.x; Kaser A, 1999, J IMMUNOL, V163, P3232; Laberge S, 2000, J ALLERGY CLIN IMMUN, V106, P293; Laberge S, 1998, J ALLERGY CLIN IMMUN, V102, P645, DOI 10.1016/S0091-6749(98)70282-9; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; Parada NA, 1998, J IMMUNOL, V160, P2115; Parnia S, 2000, J ALLERGY CLIN IMMUN, V105, P892, DOI 10.1067/mai.2000.106570; Reich K, 2001, J IMMUNOL, V167, P6321, DOI 10.4049/jimmunol.167.11.6321; Schluesener HJ, 1996, J NEUROSCI RES, V44, P606; Simon J C, 1995, Exp Dermatol, V4, P155, DOI 10.1111/j.1600-0625.1995.tb00239.x; Stingl G, 1997, INT ARCH ALLERGY IMM, V113, P24, DOI 10.1159/000237499; Taha RA, 2000, J ALLERGY CLIN IMMUN, V105, P1002, DOI 10.1067/mai.2000.106483; Wollenberg A, 1996, J INVEST DERMATOL, V106, P446, DOI 10.1111/1523-1747.ep12343596; Yawalkar N, 1999, J INVEST DERMATOL, V113, P43, DOI 10.1046/j.1523-1747.1999.00619.x; Yoshimoto T, 2000, BLOOD, V95, P2869, DOI 10.1182/blood.V95.9.2869.009k18_2869_2874; Zhang YJ, 1998, J BIOL CHEM, V273, P1144, DOI 10.1074/jbc.273.2.1144	26	37	41	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2002	109	4					681	687		10.1067/mai.2002.122234	http://dx.doi.org/10.1067/mai.2002.122234			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	543YZ	11941319				2022-12-18	WOS:000175132600018
J	Vercelli, D				Vercelli, D			The functional genomics of CD14 and its role in IgE responses: An integrated view	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						allergy; asthma; CD14; functional genomics; hygiene hypothesis; IgE; single nucleotide polymorphism	MONOCYTE RECEPTOR GENE; T-CELL DEVELOPMENT; PROMOTER POLYMORPHISM; MYOCARDIAL-INFARCTION; INFLAMMATORY RESPONSE; REGULATORY REGION; INNATE IMMUNITY; CODING REGION; RISK-FACTOR; ASTHMA	Several studies in recent years have suggested that there is a strong genetic component in the pathogenesis of IgE-mediated diseases. Epidemiologic studies have identified a number of genes that carry single base changes (single nucleotide poly-morphisms) associated with parameters of allergy. What remain to be established are the mechanisms whereby genetic variation results in dysregulation of IgE-mediated responses. This is the task of functional genomics. In this article, some of the most powerful approaches that have been devised to provide a mechanistic explanation for the effects of genetic variation on the regulation of gene expression and function are discussed. Recent data on the impact of genetic variation on the regulation of CD14 are explored in the context of the potential role played by this gene in the pathogenesis of allergy. Also discussed is the notion, that taken individually, each instance of variation might result in small effects. It is the combination of variations in the same gene and/or in genes arrayed along one functional pathway that might eventually lead to dysregulation strong enough to cause disease. In this scenario, the environment is likely to play an essential role in determining the functional outcome of genetic variation.	Univ Arizona, Coll Med, Arizona Resp Ctr, Tucson, AZ 85724 USA	University of Arizona	Vercelli, D (corresponding author), Univ Arizona, Coll Med, Arizona Resp Ctr, 1501 N Campbell Ave, Tucson, AZ 85724 USA.				NHLBI NIH HHS [R01 HL66391-01, U01-HL66803] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL066803, R01HL066391] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agarwal S, 1998, IMMUNITY, V9, P765, DOI 10.1016/S1074-7613(00)80642-1; Agarwal S, 1999, J ALLERGY CLIN IMMUN, V103, P990, DOI 10.1016/S0091-6749(99)70168-5; AMELUNG PJ, 2000, AM J RESP CRIT CARE, V161, pA927; Baldini M, 1999, AM J RESP CELL MOL, V20, P976, DOI 10.1165/ajrcmb.20.5.3494; BALDINI M, 2000, AM J RESP CRIT CARE, V161, pA928; Bix M, 1998, SCIENCE, V281, P1352, DOI 10.1126/science.281.5381.1352; Burchard EG, 1999, AM J RESP CRIT CARE, V160, P919, DOI 10.1164/ajrccm.160.3.9812024; Chakravarti A, 2001, NATURE, V409, P822, DOI 10.1038/35057281; Cok SJ, 2001, J BIOL CHEM, V276, P23179, DOI 10.1074/jbc.M008461200; Correia JD, 2001, J BIOL CHEM, V276, P21129, DOI 10.1074/jbc.M009164200; Drysdale CM, 2000, P NATL ACAD SCI USA, V97, P10483, DOI 10.1073/pnas.97.19.10483; Eldridge MW, 2000, J ALLERGY CLIN IMMUN, V105, P475, DOI 10.1067/mai.2000.104552; Emson CL, 1998, J EXP MED, V188, P399, DOI 10.1084/jem.188.2.399; Fukunaga K, 2001, EUR RESPIR J, V17, P59, DOI 10.1183/09031936.01.17100590; GADD S, 1989, TISSUE ANTIGENS, V33, P197; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Grasemann H, 2000, BIOCHEM BIOPH RES CO, V272, P391, DOI 10.1006/bbrc.2000.2794; Graves PE, 2000, J ALLERGY CLIN IMMUN, V105, P506, DOI 10.1067/mai.2000.104940; Grogan JL, 2001, IMMUNITY, V14, P205, DOI 10.1016/S1074-7613(01)00103-0; Hata Y, 1998, J BIOL CHEM, V273, P19294, DOI 10.1074/jbc.273.30.19294; Hizawa N, 2001, J ALLERGY CLIN IMMUN, V108, P74, DOI 10.1067/mai.2001.116119; Hobbs K, 1998, AM J RESP CRIT CARE, V158, P1958, DOI 10.1164/ajrccm.158.6.9804011; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Holloway JW, 2000, CLIN EXP ALLERGY, V30, P1097; Hubacek JA, 1999, CIRCULATION, V99, P3218, DOI 10.1161/01.CIR.99.25.3218; Hural JA, 2000, J IMMUNOL, V165, P3239, DOI 10.4049/jimmunol.165.6.3239; Jacquelin B, 2001, J BIOL CHEM, V276, P23518, DOI 10.1074/jbc.M102019200; Jarvelainen HA, 2001, HEPATOLOGY, V33, P1148, DOI 10.1053/jhep.2001.24236; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kelly BL, 2000, J IMMUNOL, V165, P2982, DOI 10.4049/jimmunol.165.6.2982; Kruse S, 2000, AM J HUM GENET, V66, P1522, DOI 10.1086/302901; LeVan TD, 2001, J IMMUNOL, V167, P5838, DOI 10.4049/jimmunol.167.10.5838; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; Martinez FD, 1999, J ALLERGY CLIN IMMUN, V103, P355, DOI 10.1016/S0091-6749(99)70456-2; Martinez FD, 1999, LANCET, V354, pS12, DOI 10.1016/S0140-6736(99)90437-3; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; MEYERS DA, 1997, IGE REGULATION MOL M, P61; MICHEL O, 1992, AM REV RESPIR DIS, V146, P352, DOI 10.1164/ajrccm/146.2.352; Moffatt MF, 1999, CURR OPIN IMMUNOL, V11, P606, DOI 10.1016/S0952-7915(99)00024-2; Nakao F, 2001, J ALLERGY CLIN IMMUN, V107, P499, DOI 10.1067/mai.2001.113051; Nickel RG, 2000, J IMMUNOL, V164, P1612, DOI 10.4049/jimmunol.164.3.1612; Ober C, 2000, AM J HUM GENET, V66, P517, DOI 10.1086/302781; Oettgen HC, 2001, J ALLERGY CLIN IMMUN, V107, P429, DOI 10.1067/mai.2001.113759; Pan Z, 2000, J BIOL CHEM, V275, P36430, DOI 10.1074/jbc.M003192200; Price SJ, 2001, J BIOL CHEM, V276, P7549, DOI 10.1074/jbc.M010242200; PROKIPCAK RD, 1994, J BIOL CHEM, V269, P9261; PUGIN J, 1994, IMMUNITY, V1, P509, DOI 10.1016/1074-7613(94)90093-0; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; Romagnani S, 2000, J ALLERGY CLIN IMMUN, V105, P399, DOI 10.1067/mai.2000.104575; Rosenwasser LJ, 1999, INT ARCH ALLERGY IMM, V118, P268, DOI 10.1159/000024096; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; SHARP PM, 1995, PHILOS T R SOC B, V349, P241, DOI 10.1098/rstb.1995.0108; Shimada K, 2000, AM J CARDIOL, V86, P682, DOI 10.1016/S0002-9149(00)01054-7; Shirakawa T, 2000, IMMUNOL TODAY, V21, P60, DOI 10.1016/S0167-5699(99)01492-9; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; Spiteri MA, 2000, ALLERGY, V55, P15, DOI 10.1034/j.1398-9995.2000.00502.x; Strachan DP, 1997, PEDIAT ALLERG IMM-UK, V8, P161, DOI 10.1111/j.1399-3038.1997.tb00156.x; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Szalai C, 2001, J ALLERGY CLIN IMMUN, V108, P375, DOI 10.1067/mai.2001.117930; Townsend MJ, 2000, IMMUNITY, V13, P573, DOI 10.1016/S1074-7613(00)00056-X; Trabetti E, 1999, J MED GENET, V36, P323; Tulic MK, 2000, AM J RESP CELL MOL, V22, P604; Ulevitch RJ, 1999, CURR OPIN IMMUNOL, V11, P19, DOI 10.1016/S0952-7915(99)80004-1; Unkelbach K, 1999, ARTERIOSCL THROM VAS, V19, P932, DOI 10.1161/01.ATV.19.4.932; Vercelli D, 2001, INT ARCH ALLERGY IMM, V124, P20, DOI 10.1159/000053658; Vercelli D, 2001, J ENDOTOXIN RES, V7, P45, DOI 10.1179/096805101101532521; Vercelli D, 2001, CURR OPIN ALLERGY CL, V1, P61, DOI 10.1097/01.all.0000010986.58020.8d; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187, DOI 10.1046/j.1365-2222.2000.00801.x; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; von Mutius E, 2000, J ALLERGY CLIN IMMUN, V105, P9, DOI 10.1016/S0091-6749(00)90171-4; Walley AJ, 2001, NAT GENET, V29, P175, DOI 10.1038/ng728; Werner T, 2000, Methods Mol Biol, V132, P337; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Winchester EC, 2000, HUM GENET, V107, P591, DOI 10.1007/s004390000410; Yan L, 2000, PHARMACOGENETICS, V10, P261, DOI 10.1097/00008571-200004000-00007; Zee RYL, 2001, ATHEROSCLEROSIS, V154, P699, DOI 10.1016/S0021-9150(00)00698-5; Zhang BP, 1999, CIRCULATION, V99, P1788, DOI 10.1161/01.CIR.99.14.1788	78	37	40	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2002	109	1					14	21		10.1067/mai.2002.121015	http://dx.doi.org/10.1067/mai.2002.121015			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	519RM	11799359				2022-12-18	WOS:000173739300002
J	Nagase, H; Miyamasu, M; Yamaguchi, M; Kawasaki, H; Ohta, K; Yamamoto, K; Morita, Y; Hirai, K				Nagase, H; Miyamasu, M; Yamaguchi, M; Kawasaki, H; Ohta, K; Yamamoto, K; Morita, Y; Hirai, K			Glucocorticoids preferentially upregulate functional CXCR4 expression in eosinophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CXCR4; CCR3; eosinophils; neutrophils; dexamethasone; glucocorticoid; stromal cell-derived factor 1 alpha; eotaxin; chemotaxis; Ca2+ influx	EPITHELIAL-CELLS; EOTAXIN RECEPTOR; FACTOR-1 SDF-1; CC-CHEMOKINE; CLONING; CHEMOATTRACTANT; RESPONSES; CYTOKINES; RANTES	Background: Chemokines play an important role in accumulation of eosinophils at allergic inflammatory sites. Systemic administration of glucocorticoids (GCCs) attenuates tissue eosinophilia. In vivo chemokine actions are regulated at levels of both ligand production and receptor expression. The inhibitory effects of GCCs on the production of eosinophil-active chemokines, such as eotaxin, have been web established. However, no data exist regarding the effects of GCCs on expression of chemokine receptors in eosinophils per se. Objective: The objective of this study was to investigate the regulation of chemokine receptor expression in eosinophils by GCCs. Methods: Chemokine receptor expression was analyzed by using flow cytometry and reverse transcriptase PCR, Intracellular Ca2+ influx and chemotaxis were also analyzed. Results: Eosinophil CCR3 expression was slightly downregulated by 24-hour treatment with dexamethasone (DEX). On the other hand, DEX-treated eosinophils showed markedly increased CXCR4 expression (similar to6 fold) in a time- and dose-dependent fashion. In contrast to eosinophils, CXCR4 expression in neutrophils was only marginally. affected by DEX. In DEX-treated eosinophils, stromal cell-derived factor Ig a natural ligand for CXCR4, induced a higher level of Ca2+ influx and chemotaxis compared with untreated cells. Conclusion: GCCs upregulate the expression of CXCR4 in eosinophils but not in neutrophils. Because stromal cell-derived fatter la may play a role in baseline trafficking of eosinophils into extravascular tissues rather than recruiting them directly to inflammatory sites, upregulation of CXCR4 by GCCs may mediate the antiallergic property of these drugs by sequestering eosinophils from the circulation to extravascular tissues.	Univ Tokyo, Grad Sch Med, Dept Bioregulatory Funct, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Grad Sch Med, Dept Resp Med, Tokyo 1138655, Japan; Univ Tokyo, Grad Sch Med, Dept Allergy & Rheumatol, Tokyo 1138655, Japan; Univ Tokyo, Inst Med Sci, Dept Clin Immunol, Tokyo, Japan; Univ Tokyo, Inst Med Sci, Ctr AIDS Res, Tokyo, Japan; Teikyo Univ, Sch Med, Dept Internal Med, Tokyo 173, Japan	University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo; Teikyo University	Hirai, K (corresponding author), Univ Tokyo, Grad Sch Med, Dept Bioregulatory Funct, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.		Yamamoto, Kazuhiko/N-5096-2015; Nagase, Hiroyuki/Y-4367-2019	Nagase, Hiroyuki/0000-0002-0296-5901				BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307; BASCOM R, 1988, AM REV RESPIR DIS, V138, P406, DOI 10.1164/ajrccm/138.2.406; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Chelucci C, 1999, BLOOD, V94, P1590, DOI 10.1182/blood.V94.5.1590.417k35_1590_1600; Coulomb-L'Hermine A, 1999, P NATL ACAD SCI USA, V96, P8585, DOI 10.1073/pnas.96.15.8585; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; ELWOOD W, 1992, AM REV RESPIR DIS, V145, P1289, DOI 10.1164/ajrccm/145.6.1289; GLEICH GJ, 1993, ANNU REV MED, V44, P85, DOI 10.1146/annurev.me.44.020193.000505; John M, 1997, J IMMUNOL, V158, P1841; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; Lilly CM, 1997, J CLIN INVEST, V99, P1767, DOI 10.1172/JCI119341; MIYAMASU M, 1995, J IMMUNOL, V154, P1339; Nagasawa T, 1999, Adv Immunol, V71, P211; Nagase H, 1999, ALLERGY, V54, P944, DOI 10.1034/j.1398-9995.1999.00184.x; Nagase H, 2000, J IMMUNOL, V164, P5935, DOI 10.4049/jimmunol.164.11.5935; *NAT ASTHM ED PREV, 1997, NIH PUBL; PETERSON AP, 1981, J ALLERGY CLIN IMMUN, V68, P212, DOI 10.1016/0091-6749(81)90186-X; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; RYTOMAA T, 1960, ACTA PATHOLOGIC S140, V50; Sato K, 1999, BLOOD, V93, P34, DOI 10.1182/blood.V93.1.34.424k27_34_42; SCHLEIMER RP, 1990, AM REV RESPIR DIS S, V141, P59; SCHWEIZER RC, 1994, BLOOD, V83, P3697; Stellato C, 1999, J IMMUNOL, V163, P5624; Stellato C, 1997, J CLIN INVEST, V99, P926, DOI 10.1172/JCI119257; WALLEN N, 1991, J IMMUNOL, V147, P3490	25	37	39	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2000	106	6					1132	1139						8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	384ER	11112897				2022-12-18	WOS:000165930300016
J	Geiser, M; Leupin, N; Maye, I; Hof, VI; Gehr, P				Geiser, M; Leupin, N; Maye, I; Hof, VI; Gehr, P			Interaction of fungal spores with the lungs: Distribution and retention of inhaled puffball (Calvatia excipuliformis) spores	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						aerosol; basidiospores; disector; fractionator; hamster; lung; macrophages; retention; surfactant; stereology	INTRAPULMONARY CONDUCTING AIRWAYS; BASIDIOMYCETE ALLERGY; ALVEOLAR MACROPHAGES; PARTICLE INHALATION; DENDRITIC CELLS; SKIN-TEST; FRACTIONATOR; PREVALENCE; CLEARANCE; SYMPTOMS	Background: The biologic responses to inhaled airborne fungal spores, which are well-known allergen carriers, would be better understood if we had an insight into their pattern of distribution and interaction with lung structures. Objectives: To investigate the retention characteristics of inhaled basidiospores, which often represent the major portion of the spore load in air-sampling surveys and to analyze their regional distribution within and interaction with the lungs. Methods: Intubated and anesthetized Syrian Golden hamsters inhaled aerosols of puffball (Calvatia excipuliformis) spores, with an aerodynamic diameter of 3.1 mu m, either by spontaneous breathing (group A, n = 3) or by continuous negative-pressure ventilation (group B, n = 4). Lungs were fixed by intravascular perfusion of fixative solution within 29 minutes of the initial inhalation, and tissue samples were then professed for light and electron microscopy, Results: Stereological (fractionator) analysis of lung tissue revealed that the greatest number of spores was deposited within the alveoli (67.2% in group A and 89.8% in group B), The intrapulmonary conducting airways retained an intermediate proportion (32.3% in group A and 10.0% in group B), whereas the extrapulmonary mainstem bronchi and trachea held the lowest proportion (0.5% or less). Deposited spores were lodged within the aqueous lining layer and in close proximity to the epithelial cells. Within the intrapulmonary conducting airways, 22.3% of the spores in group A and 9.0% of those in group B had been engulfed by macrophages. Conclusion: This study demonstrates that inhaled 3-mu m-diameter basidiospores become distributed over a large surface area. It also reveals that such particles are displaced by surfactant (surface forces) into the aqueous lining layer of airways and alveoli, thereby facilitating subsequent phagocytosis by macrophages. This interaction of spores with lung structures may be important for the development of respiratory allergies induced by airborne fungal allergens.	Univ Bern, Inst Anat, Div Histol, CH-3000 Bern 9, Switzerland; Univ Hosp Bern, Inst Pathophysiol, CH-3010 Bern, Switzerland	University of Bern; University of Bern; University Hospital of Bern	Geiser, M (corresponding author), Univ Bern, Inst Anat, Div Histol, Buhlstr 26, CH-3000 Bern 9, Switzerland.		Gehr, Peter/I-1991-2014; Leupin, Nicolas/AAF-5119-2019					ADAMS KF, 1968, ACTA ALLERGOL, V23, P265, DOI 10.1111/j.1398-9995.1968.tb04059.x; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BRAIN JD, 1985, HANDB PHYSIOL, V1, P447; Chatfield C., 1980, INTRO MULTIVARIATE A; CRUZORIVE LM, 1990, J MICROSC-OXFORD, V160, P89, DOI 10.1111/j.1365-2818.1990.tb03050.x; Epton MJ, 1997, THORAX, V52, P528, DOI 10.1136/thx.52.6.528; GAENG DP, 1995, INT J CANCER, V62, P784, DOI 10.1002/ijc.2910620623; GEHR P, 1978, RESP PHYSIOL, V32, P121, DOI 10.1016/0034-5687(78)90104-4; Gehr P, 1990, J AEROSOL MED, V3, P27, DOI DOI 10.1089/JAM.1990.3.27; GEISER M, 1994, AM J RESP CELL MOL, V10, P594, DOI 10.1165/ajrcmb.10.6.8003338; GEISER M, 1995, J AEROSOL MED, V8, P149, DOI 10.1089/jam.1995.8.149; GEISER M, 1990, J MICROSC-OXFORD, V160, P75, DOI 10.1111/j.1365-2818.1990.tb03049.x; Geiser M, 2000, J AEROSOL MED, V13, P43, DOI 10.1089/jam.2000.13.43; GEISER M, 2000, LUNG BIOL HEALTH DIS, V143, P291; GREGORY PH, 1952, NATURE, V170, P414, DOI 10.1038/170414a0; GREGORY PH, 1957, J GEN MICROBIOL, V17, P135, DOI 10.1099/00221287-17-1-135; Helbling A, 1998, J ALLERGY CLIN IMMUN, V102, P853, DOI 10.1016/S0091-6749(98)70028-4; HOF VI, 1989, J AEROSOL MED, V2, P247; HOLT PG, 1987, IMMUNOLOGY, V62, P349; Horner WE, 1998, ALLERGY, V53, P1114, DOI 10.1111/j.1398-9995.1998.tb03830.x; HORNER WE, 1993, J ALLERGY CLIN IMMUN, V92, P306, DOI 10.1016/0091-6749(93)90174-E; Inglis J K, 1980, INTRO LAB ANIMAL SCI; KREYLING WG, 1990, AM J RESP CELL MOL, V2, P413, DOI 10.1165/ajrcmb/2.5.413; LEHRER SB, 1994, ALLERGY, V49, P460, DOI 10.1111/j.1398-9995.1994.tb00840.x; LEHRER SB, 1986, J ALLERGY CLIN IMMUN, V78, P478, DOI 10.1016/0091-6749(86)90036-9; MASPERO JF, 1995, J ALLERGY CLIN IMMUN, V95, P185; Maye I, 1999, AM J RESP CRIT CARE, V159, pA616; MCWILLIAM AS, 2000, LUNG BIOL HEALTH DIS, V143, P473; Pinkerton K. E., 1992, TREATISE PULMONARY T, VI, P121; SALVAGGIO J, 1971, J ALLERGY CLIN IMMUN, V48, P96, DOI 10.1016/0091-6749(71)90091-1; SCHERLE W, 1970, Mikroskopie, V26, P57; Schulz H, 2000, LUNG BIOL HEALTH DIS, P229; SCHURCH S, 1990, RESP PHYSIOL, V80, P17, DOI 10.1016/0034-5687(90)90003-H; SOROKIN SP, 1975, ANAT REC, V181, P581, DOI 10.1002/ar.1091810304; SPRENGER JD, 1988, J ALLERGY CLIN IMMUN, V82, P1076, DOI 10.1016/0091-6749(88)90146-7; STERIO DC, 1984, J MICROSC-OXFORD, V134, P127, DOI 10.1111/j.1365-2818.1984.tb02501.x; STONE KC, 1992, AM J RESP CELL MOL, V6, P235, DOI 10.1165/ajrcmb/6.2.235; Waber U, 1999, EXP LUNG RES, V25, P113, DOI 10.1080/019021499270330	38	37	37	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2000	106	1	1				92	100		10.1067/mai.2000.107753	http://dx.doi.org/10.1067/mai.2000.107753			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337ZH	10887311				2022-12-18	WOS:000088393300013
J	Nopp, A; Hallden, G; Lundahl, J; Johansson, E; Vrtala, S; Valenta, R; Gronneberg, R; van Hage-Hamsten, M				Nopp, A; Hallden, G; Lundahl, J; Johansson, E; Vrtala, S; Valenta, R; Gronneberg, R; van Hage-Hamsten, M			Comparison of inflammatory responses to genetically engineered hypoallergenic derivatives of the major birch pollen allergen Bet v 1 and to recombinant Bet v 1 wild type in skin chamber fluids collected from birch pollen-allergic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						recombinant birch pollen allergens; rBet v 1; hyopallergenic derivatives; skin blister chambers; eosinophils; CD69; eosinophil cationic protein	EOSINOPHIL ACTIVITY MARKERS; ATOPIC SUBJECTS; INDUCED ACCUMULATION; PERIPHERAL-BLOOD; MESSENGER-RNA; IN-VITRO; EXPRESSION; ASTHMA; ANTIBODIES; BASOPHILS	Background: Nearly 60% of birth pollen-allergic patients react exclusively to Bet v 1, With use of the skin blister model, previously only established for installation of crude allergens, we have for the First time characterized the inflammatory response in vivo to recombinant birch pollen allergen, rBet v 1, molecules (rBet v 1 wild type, fragments and trimer), Objective: Our purpose was to examine whether challenge with rBet vl derivatives (fragments and trimer) compared with rBet v 1 wild type differs with respect to influx of activated eosinophils and detectable levels of cytokines/chemokines related to allergic inflammation in skin chambers applied to birch pollen-allergic patients. Methods: The skin blister chambers were filled for 2 hours with rBet v 1, the derivatives or PBS and heparin (negative control), The fluids were analyzed after 2 and 8 hours. The number of eosinophils was determined and EG2 and CD69 expression measured by flow cytometry. Cytokines and mediators were analyzed by ELISA and RIA techniques. Results: Comparable numbers of eosinophils were recruited to the chambers challenged with rBet vl molecules, but the eosinophils from the rBet vl wild-type challenged chambers showed a significantly higher expression of CD69. The levels of eotaxin were similar in all 4 chambers, whereas rBet v 1 wild type induced significantly higher levels of histamine, eosinophil cationic protein, and GM-CSF than the derivatives did. Recombinant Bet v 1 trimer elicited significantly lower levels of IL-4 compared with rBet vl wild type. Conclusion: Genetically engineered hypoallergenic rBet v derivatives recruited eosinophils analogously with rBet v 1 wild type. However, the derivatives exhibited a lower capacity to activate eosinophils and to release proinflammatory mediators and T helper type 2-derived cytokines, The derivatives may therefore be candidate molecules for specific immunotherapy of birch pollen allergy with reduced risk of inducing allergenic or inflammatory side effects.	Karolinska Hosp, Div Clin Immunol, S-17176 Stockholm, Sweden; Huddinge Univ Hosp, Dept Resp Med & Allergol, Stockholm, Sweden; Karolinska Inst, Stockholm, Sweden; Univ Vienna, Vienna Gen Hosp, Mol Immunopathol Grp, Dept Gen & Expt Pathol, Vienna, Austria	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska Institutet; University of Vienna	Nopp, A (corresponding author), Karolinska Hosp, Div Clin Immunol, S-17176 Stockholm, Sweden.		van Hage, Marianne/A-9678-2017	van Hage, Marianne/0000-0003-3091-1596; Valenta, Rudolf/0000-0001-5944-3365; Nopp, Anna/0000-0003-1389-8676; Vrtala, Susanne/0000-0003-4250-8243				BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; CHARLESWORTH EN, 1991, J IMMUNOL, V146, P671; Chung KF, 1999, THORAX, V54, P825, DOI 10.1136/thx.54.9.825; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; Elfman L, 1997, INT ARCH ALLERGY IMM, V113, P249, DOI 10.1159/000237561; FAHY JV, 1993, AM REV RESPIR DIS, V147, P1126, DOI 10.1164/ajrccm/147.5.1126; Fernvik E, 1999, INFLAMM RES, V48, P28, DOI 10.1007/s000110050383; Fernvik E, 1996, ALLERGY, V51, P697; Fernvik E, 1999, CLIN EXP ALLERGY, V29, P1516; Fernvik E, 2000, INFLAMMATION, V24, P73, DOI 10.1023/A:1006940109869; Fernvik E, 1999, ALLERGY, V54, P455; HALLDEN G, 1989, J IMMUNOL METHODS, V124, P103, DOI 10.1016/0022-1759(89)90191-9; Hallden G, 1999, ANN ALLERG ASTHMA IM, V83, P413, DOI 10.1016/S1081-1206(10)62839-6; HARTNELL A, 1993, IMMUNOLOGY, V80, P281; HED J, 1993, ALLERGY, V48, P87, DOI 10.1111/j.1398-9995.1993.tb04707.x; HoffmannSommergruber K, 1997, PROTEIN EXPRES PURIF, V9, P33, DOI 10.1006/prep.1996.0671; Irani AMA, 1998, J ALLERGY CLIN IMMUN, V101, P354, DOI 10.1016/S0091-6749(98)70248-9; JAROLIM E, 1989, ALLERGY, V44, P385, DOI 10.1111/j.1398-9995.1989.tb04169.x; KITA H, 1991, J EXP MED, V174, P745, DOI 10.1084/jem.174.3.745; MOQBEL R, 1995, J IMMUNOL, V155, P4939; Nakajima H, 1999, J LEUKOCYTE BIOL, V66, P447, DOI 10.1002/jlb.66.3.447; NISHIKAWA K, 1992, J ALLERGY CLIN IMMUN, V90, P169, DOI 10.1016/0091-6749(92)90068-D; Nopp A, 2000, ALLERGY, V55, P148, DOI 10.1034/j.1398-9995.2000.00363.x; PAULI G, IN PRESS CLIN EXP AL; Raud J, 1996, J ALLERGY CLIN IMMUN, V97, P1151, DOI 10.1016/S0091-6749(96)70270-1; Rothenberg ME, 1999, AM J RESP CELL MOL, V21, P291, DOI 10.1165/ajrcmb.21.3.f160; SKEDINGER M, 1995, ANN ALLERG ASTHMA IM, V75, P250; Synek M, 1996, AM J RESP CRIT CARE, V154, P224, DOI 10.1164/ajrccm.154.1.8680684; TAI PC, 1984, NATURE, V309, P182, DOI 10.1038/309182a0; van Hage-Hamsten M, 1999, J ALLERGY CLIN IMMUN, V104, P969, DOI 10.1016/S0091-6749(99)70077-1; VOWELS BR, 1995, J ALLERGY CLIN IMMUN, V96, P92, DOI 10.1016/S0091-6749(95)70037-4; Vrtala S, 1999, INT ARCH ALLERGY IMM, V118, P218, DOI 10.1159/000024075; Vrtala S, 1997, J CLIN INVEST, V99, P1673, DOI 10.1172/JCI119330; WARDLAW AJ, 1994, POSTGRAD MED J, V70, P536, DOI 10.1136/pgmj.70.826.536; Yamada N, 1995, J ALLERGY CLIN IMMUN, V96, P1069, DOI 10.1016/S0091-6749(95)70192-3; Ying S, 1999, J IMMUNOL, V163, P3976; Zweiman B, 1997, J ALLERGY CLIN IMMUN, V100, P104, DOI 10.1016/S0091-6749(97)70201-X	37	37	39	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2000	106	1	1				101	109		10.1067/mai.2000.106924	http://dx.doi.org/10.1067/mai.2000.106924			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337ZH	10887312				2022-12-18	WOS:000088393300014
J	Andersson, JA; Uddman, R; Cardell, LO				Andersson, JA; Uddman, R; Cardell, LO			Carbon monoxide is endogenously produced in the human nose and paranasal sinuses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						carbon monoxide; heme oxygenase; paranasal sinuses	EXHALED NITRIC-OXIDE; HEME OXYGENASE; AIR; FORMS; CO	Background: Carbon monoxide (CO) has recently emerged as an endogenously produced gaseous mediator that, like nitric oxide (NO), appears to be involved in both upper and lower airway inflammation. In healthy subjects a large part of the exhaled NO seems to originate from the nasal airways, and the paranasal sinuses have been described as a dominating site for NO production. Objective: The current study was designed to investigate whether CO could also be produced in the nose and paranasal sinuses. Methods: The occurrence in the nasal mucosa of the enzyme heme oxygenase, the rate limiting step for CO production, was analyzed with use:of immunocytochemistry. CO in exhaled and sampled air was measured with an infrared analyzer. Forty-two healthy subjects and two patients with a tracheostoma volunteered for the study. Results: Heme oxygenase-like immunoreactivity was seen in the respiratory epithelium, in connection with seromucous glands and in the vascular smooth muscle of the nose. When CO was continuously sampled from one nostril during normal breathing through the mouth, stable levels of CO could be measured within 40 seconds in all subjects tested (n = 33), Repeated measurements indicated only minor variations in the values obtained. Sampling through a drainage tube inserted into the maxillary sinus revealed CO levels comparable to the levels obtained by sampling through the nose (n = 6), Breathing through the nose increased the CO levels obtained in the exhaled air (n=33, P<.001). Conclusion: These results imply that the nose and paranasal sinuses contribute to the CO production of the human airways.	Malmo Univ Hosp, Dept Otorhinolaryngol, S-20502 Malmo, Sweden	Lund University; Skane University Hospital	Cardell, LO (corresponding author), Malmo Univ Hosp, Dept Otorhinolaryngol, S-20502 Malmo, Sweden.							BORLAND C, 1993, THORAX, V48, P1160, DOI 10.1136/thx.48.11.1160; Canning BJ, 1998, AM J RESP CELL MOL, V18, P279, DOI 10.1165/ajrcmb.18.2.3029; Cardell LO, 1998, BRIT J PHARMACOL, V124, P1065, DOI 10.1038/sj.bjp.0701878; Cardell LO, 1998, PULM PHARMACOL THER, V11, P309, DOI 10.1006/pupt.1998.0152; CRUSE I, 1988, J BIOL CHEM, V263, P3348; GERLACH H, 1994, LANCET, V343, P518, DOI 10.1016/S0140-6736(94)91465-6; GUSTAFSSON LE, 1991, BIOCHEM BIOPH RES CO, V181, P852, DOI 10.1016/0006-291X(91)91268-H; Horvath I, 1998, THORAX, V53, P867, DOI 10.1136/thx.53.10.867; JARVIS MJ, 1980, BRIT MED J, V281, P484, DOI 10.1136/bmj.281.6238.484; LUNDBERG JON, 1994, EUR RESPIR J, V7, P1501, DOI 10.1183/09031936.94.07081501; LUNDBERG JON, 1995, NAT MED, V1, P370, DOI 10.1038/nm0495-370; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; MAINES MD, 1986, J BIOL CHEM, V261, P411; PAREDI P, 1998, EUR RESPIR J, V28, P127; RATTAN S, 1993, AM J PHYSIOL, V265, pG799, DOI 10.1152/ajpgi.1993.265.4.G799; RODGERS PA, 1994, SEMIN PERINATOL, V18, P2; VREMAN HJ, 1988, ANAL BIOCHEM, V168, P31, DOI 10.1016/0003-2697(88)90006-1; Yamara M, 1999, EUR RESPIR J, V13, P757, DOI 10.1034/j.1399-3003.1999.13d10.x; Yamaya M, 1998, AM J RESP CRIT CARE, V158, P311, DOI 10.1164/ajrccm.158.1.9711066; Zayasu K, 1997, AM J RESP CRIT CARE, V156, P1140, DOI 10.1164/ajrccm.156.4.96-08056	20	37	39	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2000	105	2	1				269	273		10.1016/S0091-6749(00)90075-7	http://dx.doi.org/10.1016/S0091-6749(00)90075-7			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	285RQ	10669846	Bronze			2022-12-18	WOS:000085402200010
J	Rhyoo, C; Sanders, SP; Leopold, DA; Proud, D				Rhyoo, C; Sanders, SP; Leopold, DA; Proud, D			Sinus mucosal IL-8 gene expression in chronic rhinosinusitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chronic rhinosinusitis; IL-8; gene expression; reverse-transcription polymerase chain reaction; sinus computed tomography; pathophysiology	TUMOR-NECROSIS-FACTOR; COLONY-STIMULATING FACTOR; AIRWAY EPITHELIAL-CELLS; INTERLEUKIN-8 EXPRESSION; OUTCOMES RESEARCH; STAGING SYSTEMS; MESSENGER-RNA; IN-VITRO; EOSINOPHILIA; LYMPHOCYTES	Background: Epithelial hyperplasia and mucosal infiltration of leukocytes are common features of chronic rhinosinusitis, The epithelium can produce chemoattractant cytokines that may contribute to leukocyte infiltration in rhinosinusitis, Objective: We sought to determine whether mucosal IL-8 gene expression is increased in chronic rhinosinusitis and to relate IL-8 gene expression to disease severity. Methods: We used both a noncompetitive and a quantitative, competitive reverse transcription-polymerase chain reaction to examine IL-8 gene expression in samples of sinus mucosal tissue obtained during surgery from 22 patients with chronic rhinosinusitis and 9 normal control subjects. IL-I gene expression was related to disease severity assessed by sinus computed tomography (CT) scores and to symptom scores assessed by means of a questionnaire. Results: Sinus mucosal IL-8 gene expression was not detected in any of the control subjects but was present in 12 of 22 (55%) patients with rhinosinusitis. Sinus CT scores and symptom scores were both significantly higher in patients with positive mucosal IL-8 gene expression than in subjects with no detectable IL-I gene expression. Positive IL-8 gene expression was not predicted by history of prior surgery nor by atopic or asthmatic status. In 9 subjects with positive IL-8 gene expression, levels of mRNA expression, assessed by competitive reverse transcription-polymerase chain reaction, correlated significantly (rho = 0.72, P <.05) with sinus CT scores. Conclusion: Sinus mucosal expression of the gene for IL-8 is increased in patients with chronic rhinosinusitis, and the level of IL-8 gene expression correlates with disease severity.	Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Div Clin Immunol & Allergy, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Proud, D (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.				NIAID NIH HHS [AI 37163] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI037163] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BECKER S, 1993, AM J RESP CELL MOL, V8, P20, DOI 10.1165/ajrcmb/8.1.20; CARENFELT C, 1979, ANN OTO RHINOL LARYN, V8, P16; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CROMWELL O, 1992, IMMUNOLOGY, V77, P330; DOUGLASS JA, 1994, AM J RESP CRIT CARE, V150, P1108, DOI 10.1164/ajrccm.150.4.7921444; GLIKLICH RE, 1994, AM J RHINOL, V8, P291, DOI 10.2500/105065894781874197; HAMILOS DL, 1993, J ALLERGY CLIN IMMUN, V92, P39, DOI 10.1016/0091-6749(93)90035-E; HAMILOS DL, 1995, J ALLERGY CLIN IMMUN, V96, P537, DOI 10.1016/S0091-6749(95)70298-9; HARLIN SL, 1988, J ALLERGY CLIN IMMUN, V81, P867, DOI 10.1016/0091-6749(88)90944-X; Hoover GE, 1997, J ALLERGY CLIN IMMUN, V100, P185, DOI 10.1016/S0091-6749(97)70223-9; Ikeda K, 1996, AM J RHINOL, V10, P217, DOI 10.2500/105065896782103117; Kaliner MA, 1997, J ALLERGY CLIN IMMUN, V99, pS829, DOI 10.1016/S0091-6749(97)70041-1; Kennedy D W, 1992, Laryngoscope, V102, P1; KWON OJ, 1994, IMMUNOLOGY, V81, P389; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; LEONARD EJ, 1990, AM J RESP CELL MOL, V2, P479, DOI 10.1165/ajrcmb/2.6.479; LEVINE SJ, 1993, AM J PHYSIOL, V265, pL360, DOI 10.1152/ajplung.1993.265.4.L360; LINDLEY I, 1988, P NATL ACAD SCI USA, V85, P9199, DOI 10.1073/pnas.85.23.9199; Lund Valerie J., 1993, Rhinology (Utrecht), V31, P183; Lund VJ, 1997, OTOLARYNG HEAD NECK, V117, pS35, DOI 10.1016/S0194-5998(97)70005-6; MARINI M, 1992, J ALLERGY CLIN IMMUN, V89, P1001, DOI 10.1016/0091-6749(92)90223-O; MASSION PP, 1994, J CLIN INVEST, V93, P26, DOI 10.1172/JCI116954; MATSUSHIMA K, 1988, J EXP MED, V167, P1883, DOI 10.1084/jem.167.6.1883; Metson R, 1997, OTOLARYNG HEAD NECK, V117, P372, DOI 10.1016/S0194-5998(97)70129-3; Minshall EM, 1997, AM J RESP CELL MOL, V17, P683, DOI 10.1165/ajrcmb.17.6.2865; NEWMAN LJ, 1994, JAMA-J AM MED ASSOC, V271, P363, DOI 10.1001/jama.271.5.363; PICCIRILLO JF, 1994, OTOLARYNG HEAD NECK, V111, P764, DOI 10.1016/S0194-5998(94)70565-8; PROUD D, 1998, ALLERGY PRINCIPLES P, P306; Sanders SP, 1998, J VIROL, V72, P934, DOI 10.1128/JVI.72.2.934-942.1998; SUBAUSTE MC, 1995, J CLIN INVEST, V96, P549, DOI 10.1172/JCI118067; Suzuki H, 1996, J ALLERGY CLIN IMMUN, V98, P659, DOI 10.1016/S0091-6749(96)70100-8; TAKEUCHI K, 1995, AM J OTOLARYNG, V16, P98, DOI 10.1016/0196-0709(95)90039-X; Taub DD, 1996, J CLIN INVEST, V97, P1931, DOI 10.1172/JCI118625; Tomee JFC, 1997, J INFECT DIS, V176, P300, DOI 10.1086/517272; WARRINGA RAJ, 1993, J ALLERGY CLIN IMMUN, V91, P1198, DOI 10.1016/0091-6749(93)90323-8	35	37	40	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1999	103	3	1				395	400		10.1016/S0091-6749(99)70462-8	http://dx.doi.org/10.1016/S0091-6749(99)70462-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	176WU	10069871				2022-12-18	WOS:000079175700006
J	Kelso, JM				Kelso, JM			The gelatin story	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							IMMEDIATE-TYPE; MEASLES; VACCINE; ANAPHYLAXIS; CHILDREN; RUBELLA; MUMPS; IGE		USN, Med Ctr, Dept Internal Med, Div Allergy, San Diego, CA 92134 USA	United States Department of Defense; United States Navy	Kelso, JM (corresponding author), USN, Med Ctr, Dept Clin Res, San Diego, CA 92134 USA.							[Anonymous], 1991, PHYS DESK REF; [Anonymous], 1998, PHYS DESK REF; Borish L, 1997, J ALLERGY CLIN IMMUN, V99, P161, DOI 10.1016/S0091-6749(97)70090-3; FREEMAN MK, 1979, ANAESTHESIA, V34, P341, DOI 10.1111/j.1365-2044.1979.tb04933.x; HAENEY MR, 1992, BRIT MED J, V305, P870, DOI 10.1136/bmj.305.6858.870-c; HERMAN JJ, 1983, J PEDIATR-US, V102, P196, DOI 10.1016/S0022-3476(83)80519-8; KELSO JM, 1993, J ALLERGY CLIN IMMUN, V91, P867, DOI 10.1016/0091-6749(93)90344-F; Kumagai T, 1997, J ALLERGY CLIN IMMUN, V100, P130, DOI 10.1016/S0091-6749(97)70204-5; LUND N, 1973, BRIT J ANAESTH, V45, P929, DOI 10.1093/bja/45.8.929; Lundsgaard-Hansen P, 1980, Dev Biol Stand, V48, P251; Nakayama T, 1999, J ALLERGY CLIN IMMUN, V103, P321, DOI 10.1016/S0091-6749(99)70508-7; Ohsaki M, 1999, J ALLERGY CLIN IMMUN, V103, P276, DOI 10.1016/S0091-6749(99)70502-6; SADDLER JM, 1987, ANAESTHESIA, V42, P998, DOI 10.1111/j.1365-2044.1987.tb05376.x; Sakaguchi M, 1999, J ALLERGY CLIN IMMUN, V103, P349, DOI 10.1016/S0091-6749(99)70512-9; Sakaguchi M, 1996, J ALLERGY CLIN IMMUN, V98, P1058, DOI 10.1016/S0091-6749(96)80191-6; Sakaguchi M, 1997, J ALLERGY CLIN IMMUN, V99, P263, DOI 10.1016/S0091-6749(97)70108-8; Sakai Y, 1998, BIOL PHARM BULL, V21, P330; VERVLOET D, 1983, J ALLERGY CLIN IMMUN, V71, P535, DOI 10.1016/0091-6749(83)90433-5; WISBORG K, 1993, BRIT J ANAESTH, V47, P1116	19	37	40	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1999	103	2	1				200	202		10.1016/S0091-6749(99)70490-2	http://dx.doi.org/10.1016/S0091-6749(99)70490-2			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167JW	9949308	Bronze			2022-12-18	WOS:000078630100003
J	Ledford, D; Apter, A; Brenner, AM; Rubin, K; Prestwood, K; Frieri, M; Lukert, B				Ledford, D; Apter, A; Brenner, AM; Rubin, K; Prestwood, K; Frieri, M; Lukert, B			Osteoporosis in the corticosteroid-treated patient with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						osteoporosis; asthma; corticosteroid; inhaled corticosteroid; bone density	BONE-MINERAL DENSITY; INHALED BECLOMETHASONE DIPROPIONATE; GLUCOCORTICOID-INDUCED OSTEOPOROSIS; LOW-DOSE CORTICOSTEROIDS; RHEUMATOID-ARTHRITIS; POSTMENOPAUSAL WOMEN; CYCLICAL ETIDRONATE; CALCIUM SUPPLEMENTATION; REPLACEMENT THERAPY; INDUCED OSTEOPENIA	Osteoporosis affects 40% of white women older than 45 years of age and 15% of white men older than 50 years of age, resulting in approximately 1.5 million annual fractures in the United States. Systemic corticosteroid therapy increases the probability of osteoporosis, even with alternate-day dosing and with dosages sufficiently low so as not to affect the hypothalamic-pituitary-adrenal axis. Inhaled corticosteroid therapy may affect bone density if high-dose therapy is given to select individuals. The potential of increasing osteoporosis with inhaled corticosteroid asthma therapy is a concern because of the availability of more potent inhaled corticosteroid agents and recommendations that inhaled corticosteroid therapy be initiated earlier in the course of asthma, This article provides suggestions, on the basis of the medical literature and consensus of the authors when specific information was not available, for assessing and treating osteoporosis in subjects with asthma, Suggested risk categories are "low risk" (inhaled corticosteroid dosage of less than or equal to 800 mu g of beclomethasone dipropionate [BDP]/day in adults or less than or equal to 400 mu g BDP or equivalent in children), "moderate risk" (inhaled BDP >800 mu g/day in adults or >400 mu g/day in children), and "high risk" (systemic corticosteroid therapy 4 times a year or daily or alternate-day systemic corticosteroid therapy). Dosage of nasal corticosteroid probably should be added to the orally inhaled corticosteroid for total burden of inhaled corticosteroid. Potential treatment strategies based on risk factors and bone density if indicated are offered to assist physicians treating patients with asthma.	Univ S Florida, Vet Affairs Med Ctr, Dept Internal Med, Div Clin Immunol & Allergy, Tampa, FL 33612 USA; James A Haley Vet Hosp, Tampa, FL 33612 USA; Univ Connecticut, Sch Med, Dept Med, Sect Allergy & Immunol, Farmington, CT USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Natl Jewish Med & Res Ctr, Div Clin Immunol & Allergy, Denver, CO 80262 USA; Univ Connecticut, Sch Med, Dept Pediat, Div Pediat Endocrinol, Farmington, CT 06032 USA; Univ Connecticut, Sch Med, Dept Med, Div Geriatr, Farmington, CT 06032 USA; SUNY Stony Brook, Nassau Cty Med Ctr, Dept Med, Div Allergy & Immunol, E Meadow, NY USA; Univ Kansas, Med Ctr, Dept Med, Div Endocrinol, Kansas City, KS 66103 USA	State University System of Florida; University of South Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; University of Connecticut; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Connecticut; University of Connecticut; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Kansas; University of Kansas Medical Center	Ledford, D (corresponding author), Univ S Florida, Vet Affairs Med Ctr, Dept Internal Med, Div Clin Immunol & Allergy, 13000 Bruce B Downs Blvd,VAR IIID, Tampa, FL 33612 USA.		Lukert, Barbara/AAW-5298-2021					ABRAMS SA, 1993, J PEDIATR-US, V123, P326, DOI 10.1016/S0022-3476(05)81714-7; Adachi JD, 1997, NEW ENGL J MED, V337, P382, DOI 10.1056/NEJM199708073370603; ADINOFF AD, 1983, NEW ENGL J MED, V309, P265, DOI 10.1056/NEJM198308043090502; BACHRACH LK, 1990, PEDIATRICS, V86, P440; BARALDI E, 1994, EUR RESPIR J, V7, P710, DOI 10.1183/09031936.94.07040710; BAUER RL, 1988, AM J EPIDEMIOL, V127, P145, DOI 10.1093/oxfordjournals.aje.a114774; BILEZIKIAN JP, 1994, JAMA-J AM MED ASSOC, V272, P1942, DOI 10.1001/jama.1994.03520240070044; BOULET LP, 1994, J ALLERGY CLIN IMMUN, V94, P796, DOI 10.1016/0091-6749(94)90145-7; BUCKLEY LM, 1995, J RHEUMATOL, V22, P1055; *CONC DEV C, 1993, AM J MED, V95, pS1; COOPER C, 1992, OSTEOPOROSIS INT, V2, P285, DOI 10.1007/BF01623184; Cooper Cyrus, 1997, American Journal of Medicine, V103, p12S, DOI 10.1016/S0002-9343(97)90022-X; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301; DELMAS PD, 1992, BONE, V13, P517; DIAMOND T, 1995, AM J MED, V98, P459, DOI 10.1016/S0002-9343(99)80345-3; DYKMAN TR, 1985, ARTHRITIS RHEUM, V28, P361, DOI 10.1002/art.1780280402; EISMAN JA, 1995, CALCIFIED TISSUE INT, V56, pS48, DOI 10.1007/BF03354655; FAULKNER KG, 1997, J BONE MINER RES, V12, pS142; FUCHSYOUNG R, 1995, ANN NY ACAD SCI, V761, P355, DOI 10.1111/j.1749-6632.1995.tb31392.x; GARNERO P, 1994, J CLIN ENDOCR METAB, V79, P780, DOI 10.1210/jc.79.3.780; GENNARI C, 1985, BONE MINERAL RES ANN, V3, P213; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; HALL GM, 1994, ARTHRITIS RHEUM, V37, P1499, DOI 10.1002/art.1780371014; HANANIA NA, 1995, J ALLERGY CLIN IMMUN, V96, P571, DOI 10.1016/S0091-6749(95)70254-7; HANSON DA, 1992, J BONE MINER RES, V7, P1251; Hawker GA, 1996, J RHEUMATOL, V23, P2; HERGENROEDER AC, 1995, J PEDIATR-US, V126, P683, DOI 10.1016/S0022-3476(95)70393-4; HERRALA J, 1994, BONE, V15, P621, DOI 10.1016/8756-3282(94)90309-3; Hochberg MC, 1996, ARTHRITIS RHEUM-US, V39, P1791; HOPP RJ, 1995, ANN ALLERG ASTHMA IM, V75, P143; JACKSON JA, 1990, MEDICINE, V69, P137, DOI 10.1097/00005792-199005000-00002; JOHNSTON CC, 1991, NEW ENGL J MED, V324, P1105; JOHNSTON CC, 1992, NEW ENGL J MED, V327, P82, DOI 10.1056/NEJM199207093270204; Kamada AK, 1996, AM J RESP CRIT CARE, V153, P1739, DOI 10.1164/ajrccm.153.6.8665030; KELLY P, 1990, OSTEOPOROSIS INT, V1, P14; KENNY AM, 1995, J CLIN ENDOCR METAB, V80, P3287, DOI 10.1210/jc.80.11.3287; KINBERG KA, 1994, J ALLERGY CLIN IMMUN, V94, P490, DOI 10.1016/0091-6749(94)90205-4; KNUTSSON U, 1995, J ENDOCRINOL, V144, P301, DOI 10.1677/joe.0.1440301; KONIG P, 1993, J PEDIATR-US, V122, P219, DOI 10.1016/S0022-3476(06)80116-2; KRIEPE RE, 1995, PEDIATR ANN, V24, P308; LACROIX AZ, 1990, NEW ENGL J MED, V322, P286, DOI 10.1056/NEJM199002013220502; LOCASCIO V, 1990, BONE MINER, V8, P39, DOI 10.1016/0169-6009(91)90139-Q; Lonzer MD, 1996, CLIN PEDIATR, V35, P185, DOI 10.1177/000992289603500402; LUENGO M, 1990, AM REV RESPIR DIS, V142, P104, DOI 10.1164/ajrccm/142.1.104; LUKERT BP, 1990, ANN INTERN MED, V112, P352, DOI 10.7326/0003-4819-112-5-352; LUKERT BP, 1986, J CLIN ENDOCR METAB, V62, P1056, DOI 10.1210/jcem-62-5-1056; LUKERT BP, 1992, J BONE MINER RES, V7, P1063; LUKERT BP, 1994, RHEUM DIS CLIN N AM, V20, P630; Martinati LC, 1996, AM J RESP CRIT CARE, V153, P232, DOI 10.1164/ajrccm.153.1.8542121; Matkovic V, 1996, J CLIN ENDOCR METAB, V81, P2013, DOI 10.1210/jc.81.6.2013; MELTON LJ, 1993, BONE, V14, pS1; MELTON LJ, 1989, AM J EPIDEMIOL, V129, P1000, DOI 10.1093/oxfordjournals.aje.a115204; MELTON LJ, 1993, OSTEOPOROTIC SYNDROM, P17; MULDER H, 1994, BRIT J RHEUMATOL, V33, P348; Norman Michael E., 1996, P275; ORWALL E, 1996, OSTEOPOROSIS MEN; OTT SM, 1990, J CLIN ENDOCR METAB, V71, P1083; OTT SM, 1991, NEW ENGL J MED, V325, P1647; Pedersen S, 1997, ALLERGY, V52, P1, DOI 10.1111/j.1398-9995.1997.tb05047.x; *PHS NIH, 1997, 2 PHS NIH; Rachelefsky GS, 1998, J ALLERGY CLIN IMMUN, V101, pS236; Raisz LG, 1997, ANN INTERN MED, V126, P458, DOI 10.7326/0003-4819-126-6-199703150-00007; Reid IR, 1996, ARCH INTERN MED, V156, P1173, DOI 10.1001/archinte.156.11.1173; REID IR, 1988, LANCET, V1, P143; REID IR, 1993, NEW ENGL J MED, V328, P460, DOI 10.1056/NEJM199302183280702; REIMER LG, 1975, J ALLERGY CLIN IMMUN, V55, P224, DOI 10.1016/0091-6749(75)90141-4; RIGGS BL, 1982, J CLIN INVEST, V70, P716, DOI 10.1172/JCI110667; RUBIN K, 1993, J PEDIATR-US, V123, P863, DOI 10.1016/S0022-3476(05)80381-6; RUEGSEGGER P, 1983, EUR J CLIN PHARMACOL, V25, P615, DOI 10.1007/BF00542348; SAITO JK, 1995, CALCIFIED TISSUE INT, V57, P115, DOI 10.1007/BF00298431; SAMBROOK P, 1993, NEW ENGL J MED, V328, P1747, DOI 10.1056/NEJM199306173282404; SCHWARTZMAN MS, 1987, AM J MED, V82, P224, DOI 10.1016/0002-9343(87)90060-X; SCOTT JC, 1997, JCR-J CLIN RHEUMATOL, V3, pS9; SEEMAN E, 1994, J BONE MINER RES, V9, P739; Simons FER, 1997, NEW ENGL J MED, V337, P1659, DOI 10.1056/NEJM199712043372304; SLEMENDA CW, 1994, J PEDIATR-US, V125, P201, DOI 10.1016/S0022-3476(94)70193-8; STRUYS A, 1995, AM J MED, V99, P235, DOI 10.1016/S0002-9343(99)80154-5; THOMAS KA, 1991, J PEDIATR ORTHOPED, V11, P48, DOI 10.1097/01241398-199101000-00011; TOOGOOD JH, 1991, J ALLERGY CLIN IMMUN, V88, P572, DOI 10.1016/0091-6749(91)90150-M; TOOGOOD JH, 1995, J ALLERGY CLIN IMMUN, V96, P157, DOI 10.1016/S0091-6749(95)70003-X; Uitterlinden AG, 1998, NEW ENGL J MED, V338, P1016, DOI 10.1056/NEJM199804093381502; VERSTRAETEN A, 1986, ANN RHEUM DIS, V45, P852, DOI 10.1136/ard.45.10.852; WARADY BD, 1994, J RHEUMATOL, V21, P530; WHITE CM, 1992, AM J DIS CHILD, V146, P31, DOI 10.1001/archpedi.1992.02160130033016; *WHO, 1994, WHO TECHN REP SER, V843, P5; 1998, MED LETT DRUGS THER, V40, P29	87	37	39	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1998	102	3					353	362		10.1016/S0091-6749(98)70120-4	http://dx.doi.org/10.1016/S0091-6749(98)70120-4			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	124ZN	9768573	Bronze			2022-12-18	WOS:000076212800004
J	Volovitz, B; Soferman, R; Blau, H; Nussinovitch, M; Varsano, I				Volovitz, B; Soferman, R; Blau, H; Nussinovitch, M; Varsano, I			Rapid induction of clinic response with a short-term high-dose starting schedule of budesonide nebulizing suspension in young children with recurrent wheezing episodes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						inhaled corticosteroids; budesonide nebulizing suspension; dose schedule; treatment; children; wheezing; asthma	SEVERE INFANTILE ASTHMA; INHALED BUDESONIDE; CHILDHOOD; MODERATE; TODDLERS	Background: There ape no data currently available on the correct schedule Tor the initiation of treatment with nebulized suspension of budesonide in children with recurrent wheezing episodes. We compared the efficacy and safety of starting with a high dose followed by a stepwise decrease to a continuous low dose. Methods: In a double-blind design, 42 children aged 6 months to 3 years were randomly allocated to receive either a high starting dose of 1 mg budesonide twice daily followed by a stepwise decrease of 25% every second day for 1 week (group B) or a low dose of 0.25 mg twice daily for 1 week (group B). Efficacy was assessed with daily symptom scores and the systemic effect of the corticosteroids with the adrenocorticoatropic hormone test. Results: The two groups were comparable for all parameters evaluated. During the first week of treatment, there was a significant decrease in asthmatic symptomatology only in group A: a 59% decrease for wheezing (p = 0.0001), 39% for diurnal cough (p = 0.036), and 39% for nocturnal cough (p = 0.04). Mean time to clinical response was 3.0 days int group A and 5.7 days in group B (p = 0.02). This early improvement was sustained for the rest of the follow-up period. The high dose starting schedule was not associated with anp change in serum cortisol level. Conclusions: The administration of nebulized suspension of budesonide at a high starting dose schedule followed by a rapid (1 week) stepwise decrease yields a significant early improvement in asthma symptoms and causes no change in serum cortisol levels.	Schneider Childrens Med Ctr Israel, Dept Pediat C, Asthma Clin, IL-49202 Petah Tikva, Israel; Schneider Childrens Med Ctr Israel, Pulm Unit, IL-49202 Petah Tikva, Israel; Tel Aviv Univ, Dana Childrens Hosp, Sackler Sch Med, Asthma Clin, IL-69978 Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine	Volovitz, B (corresponding author), Schneider Childrens Med Ctr Israel, Dept Pediat C, Asthma Clin, 14 Kaplan St, IL-49202 Petah Tikva, Israel.							BARNES PJ, 1989, NEW ENGL J MED, V321, P1517; BISGAARD H, 1990, LANCET, V336, P649, DOI 10.1016/0140-6736(90)92147-A; CARLSEN KCL, 1992, ARCH DIS CHILD, V67, P1077; deBlic J, 1996, J ALLERGY CLIN IMMUN, V98, P14, DOI 10.1016/S0091-6749(96)70221-X; DEJONGSTE JC, 1989, LANCET, V1, P1388; GODFREY S, 1987, LANCET, V2, P851; ILANGOVAN P, 1993, ARCH DIS CHILD, V68, P356, DOI 10.1136/adc.68.3.356; REED CE, 1991, NEW ENGL J MED, V325, P425, DOI 10.1056/NEJM199108083250610; TOOGOOD JH, 1989, J ALLERGY CLIN IMMUN, V84, P688, DOI 10.1016/0091-6749(89)90297-2; VANBEVER HP, 1990, PEDIATR PULM, V9, P177, DOI 10.1002/ppul.1950090310; VARSANO I, 1990, J ALLERGY CLIN IMMUN, V85, P914, DOI 10.1016/0091-6749(90)90077-H; VOLOVITZ B, 1993, NEW ENGL J MED, V329, P1703, DOI 10.1056/NEJM199312023292305; WEBB MSC, 1986, ARCH DIS CHILD, V61, P1108, DOI 10.1136/adc.61.11.1108; Wennergren G, 1996, ACTA PAEDIATR, V85, P183, DOI 10.1111/j.1651-2227.1996.tb13989.x	14	37	38	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1998	101	4	1				464	469		10.1016/S0091-6749(98)70405-1	http://dx.doi.org/10.1016/S0091-6749(98)70405-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZH469	9564798				2022-12-18	WOS:000073113500007
J	Volcheck, GW; Gleich, GJ; Kita, H				Volcheck, GW; Gleich, GJ; Kita, H			Pro- and anti-inflammatory effects of beta adrenergic agonists on eosinophil response to IL-5.	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract									Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA	Mayo Clinic									0	37	37	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1998	101	1	2			153	S35	S35						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YW339					2022-12-18	WOS:000071924800154
J	Bagley, CJ; Lopez, AF; Vadas, MA				Bagley, CJ; Lopez, AF; Vadas, MA			New frontiers for IL-5	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							HUMAN INTERLEUKIN-5; ASTHMA		INST MED & VET SCI,HANSON CTR CANC RES,DEPT HUMAN IMMUNOL,ADELAIDE,SA 5000,AUSTRALIA	Institute Medical & Veterinary Science Australia			Vadas, Mathew/R-1378-2019; Lopez, Angel F/E-2260-2011	Lopez, Angel F/0000-0001-7430-0135				Bagley CJ, 1996, J BIOL CHEM, V271, P31922, DOI 10.1074/jbc.271.50.31922; Bentley AM, 1996, AM J RESP CRIT CARE, V153, P551, DOI 10.1164/ajrccm.153.2.8564096; Dickason RR, 1996, NATURE, V379, P652, DOI 10.1038/379652a0; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; HERCUS TR, 1994, P NATL ACAD SCI USA, V91, P5838, DOI 10.1073/pnas.91.13.5838; Li J, 1996, J BIOL CHEM, V271, P31729, DOI 10.1074/jbc.271.49.31729; MAUSER PJ, 1995, AM J RESP CRIT CARE, V152, P467, DOI 10.1164/ajrccm.152.2.7633694; MILBURN MV, 1993, NATURE, V363, P172, DOI 10.1038/363172a0; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; SUR S, 1995, J ALLERGY CLIN IMMUN, V96, P661, DOI 10.1016/S0091-6749(95)70265-2; Sur S, 1996, J ALLERGY CLIN IMMUN, V97, P1272, DOI 10.1016/S0091-6749(96)70195-1; TAVERNIER J, 1995, P NATL ACAD SCI USA, V92, P5194, DOI 10.1073/pnas.92.11.5194	12	37	38	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1997	99	6	1				725	728		10.1016/S0091-6749(97)80002-4	http://dx.doi.org/10.1016/S0091-6749(97)80002-4			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XH193	9215236	Bronze			2022-12-18	WOS:A1997XH19300001
J	Castells, MC; Friend, DS; Bunnell, CA; Hu, XZ; Kraus, M; Osteen, RT; Austen, KF				Castells, MC; Friend, DS; Bunnell, CA; Hu, XZ; Kraus, M; Osteen, RT; Austen, KF			The presence of membrane-bound stem cell factor on highly immature nonmetachromatic mast cells in the peripheral blood of a patient with aggressive systemic mastocytosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						systemic mastocytosis; tryptase; chymase; CPA; c-kit; SCF; mast cell progenitors; peripheral blood	LIGAND-INDEPENDENT ACTIVATION; C-KIT; TYROSINE KINASE; GROWTH-FACTOR; EXPRESSION; PROGENITOR; TRYPTASE; DISEASE; MUTANT; CD34+	Background: Systemic mastocytosis is characterized by mast cell infiltration of bone marrow and tissues in the absence of identified circulating bone marrow-derived progenitors. A 58-year-old man was first seen with aggressive systemic mastocytosis manifested by urticaria pigmentosa, hepatosplenomegaly, generalized bone lesions, anemia, thrombocytopenia, monoclonal gammopathy, and increased urine histamine levels. Objectives and Methods: A rapidly progressive anemia and thrombocytopenia dictated a splenectomy. We sought to identify the mast cell progenitors in the peripheral blood and to provide evidence of their maturation in tissues with immunohistochemical and ultrastructural analyses. Results: The peripheral blood contained 1% to 3% nonmetachromatic mononuclear cells with eccentric nuclei that expressed the mast cell proteases, tryptase and carboxypeptidase A, along with c-kit, stem cell factor (SCF) and high-affinity IgE receptor (Fc epsilon RI), but not chymase. Similar mononuclear cells colocalized in the spleen and lymph nodes with mature, metachromatic mast cells that expressed tryptase, chymase, carboxypeptidase A, c-kit, SCF, and Fc epsilon RI. Electron microscopy disclosed at each site, a mature mast cell population with electron-dense scroll-poor granules. Conclusions: The peripheral blood of a patient with aggressive systemic mastocytosis contained immature mononuclear cells of the mast cell lineage that express c-kit, SCF, tryptase, carboxypeptidase A, and Fc epsilon RI. These cells were also found in the skin, spleen, and lymph nodes where they presumably expand, differentiate, and mature, assuming the mast cell phenotype for those tissues characterized by metachromasia, expression of a full range of mast cell-related secretory granule proteases, and ultrastructural appearance. The presence of SCF on the surface membrane of the circulating highly immature mast cells suggests an autocrine regulation of the c-kit-SCF interaction.	HARVARD UNIV, SCH MED, DEPT MED, CAMBRIDGE, MA 02138 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, CAMBRIDGE, MA 02138 USA; HARVARD UNIV, SCH MED, DEPT SURG, CAMBRIDGE, MA 02138 USA; BRIGHAM & WOMENS HOSP, DEPT HEMATOL ONCOL, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT PATHOL, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT SURG, DIV SURG ONCOL, BOSTON, MA 02115 USA	Harvard University; Harvard University; Harvard University; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	Castells, MC (corresponding author), BRIGHAM & WOMENS HOSP, DEPT MED, DIV RHEUMATOL & IMMUNOL, SEELEY G MUDD BLDG, ROOM 607, BOSTON, MA 02115 USA.				NIAID NIH HHS [AI07306, AI22531, AI31599] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI031599, R01AI022531, R37AI022531, U01AI031599] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGIS H, 1993, J IMMUNOL, V151, P4221; ALDENBORG F, 1994, HISTOCHEM J, V26, P587, DOI 10.1007/BF00158593; AUSTEN KF, 1992, NEW ENGL J MED, V326, P639, DOI 10.1056/NEJM199202273260912; BECKSTEAD JH, 1981, BLOOD, V57, P1088; CASTELLS MC, 1987, J IMMUNOL, V138, P2184; CAULFIELD JP, 1980, J CELL BIOL, V85, P299, DOI 10.1083/jcb.85.2.299; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; GURISH MF, 1995, IMMUNITY, V3, P175, DOI 10.1016/1074-7613(95)90087-X; HORAN RF, 1991, J INVEST DERMATOL, V96, pS5, DOI 10.1111/1523-1747.ep12468899; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; ISHIZAKA T, 1993, CURR OPIN IMMUNOL, V5, P937, DOI 10.1016/0952-7915(93)90109-6; LAMMIE A, 1994, J HISTOCHEM CYTOCHEM, V42, P1417, DOI 10.1177/42.11.7523489; LAWRENCE JB, 1991, AM J MED, V91, P612, DOI 10.1016/0002-9343(91)90214-I; LONGLEY BJ, 1993, NEW ENGL J MED, V328, P1302, DOI 10.1056/NEJM199305063281803; MCNEIL HP, 1992, J IMMUNOL, V149, P2466; METCALFE DD, 1991, J INVEST DERMATOL, V96, pS2, DOI 10.1111/1523-1747.ep12468882; NAKAHATA T, 1995, BIOL MOL ASPECTS MAS, P8; PARKER RI, 1991, J INVEST DERMATOL, V96, pS47, DOI 10.1111/1523-1747.ep12469034; PARKER RI, 1991, J INVEST DERMATOL, V96, pS52, DOI 10.1111/1523-1747.ep12469045; REYNOLDS DS, 1992, J CLIN INVEST, V89, P273, DOI 10.1172/JCI115571; ROBERTS LJ, 1980, NEW ENGL J MED, V303, P1400, DOI 10.1056/NEJM198012113032405; ROTTEM M, 1994, BLOOD, V84, P2489; SAITO H, 1995, BIOL MOL ASPECTS MAS, P50; STEVENS RL, 1994, P NATL ACAD SCI USA, V91, P128, DOI 10.1073/pnas.91.1.128; TRAVIS WD, 1988, MEDICINE, V67, P345, DOI 10.1097/00005792-198811000-00001; TSUJIMURA T, 1994, BLOOD, V83, P2619; TSUJIMURA T, 1991, BLOOD, V78, P1942; VALENT P, 1989, BLOOD, V73, P1778; WEIDNER N, 1990, LAB INVEST, V63, P63	30	37	50	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1996	98	4					831	840		10.1016/S0091-6749(96)70133-1	http://dx.doi.org/10.1016/S0091-6749(96)70133-1			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VM665	8876560				2022-12-18	WOS:A1996VM66500017
J	Bernstein, DI; Creticos, PS; Busse, WW; Cohen, R; Graft, DF; Howland, WC; Lumry, WR; Pedinoff, AJ; Ratner, PH; Lim, J; Stokes, A; McNally, C				Bernstein, DI; Creticos, PS; Busse, WW; Cohen, R; Graft, DF; Howland, WC; Lumry, WR; Pedinoff, AJ; Ratner, PH; Lim, J; Stokes, A; McNally, C			Comparison of triamcinolone acetonide nasal inhaler with astemizole in the treatment of ragweed-induced allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						triamcinolone acetonide; astemizole; allergic rhinitis; antihistamine; nasal corticosteroid	POLLEN-INDUCED RHINOCONJUNCTIVITIS; BECLOMETHASONE DIPROPIONATE; ORAL ANTIHISTAMINE; HAY-FEVER; STEROID SPRAY; EFFICACY; TERFENADINE; LORATADINE	Background: Few clinical trails have directly compared the efficacy of antihistamines with topical nasal corticosteroids. Objective: The study was performed to compare the efficacy and safety of triamcinolone acetonide nasal spray at a dose of 110 mu g in each nostril once daily with 10 mg of oral astemizole once daily for the treatment of seasonal allergic rhinitis. Methods: A multicenter, double-blind, parallel-group study was conducted in 239 patients who were randomized to receive either triamcinolone acetonide or astemizole. A 5-day, drug-free, lead-in period was followed by 4 weeks of double-blind treatment. One hundred four patients treated with triamcinolone and 105 patients with astemizole could be evaluated. Results: Overall, triamcinolone acetonide was more effective than astemizole in reducing total nasal symptoms, nasal stuffiness, nasal itching, and sneezing (p less than or equal to 0.01). Triamcinolone acetonide was superior to astemizole at weeks 1, 2, and 3 in reduction of the total nasal symptom score (p less than or equal to 0.0401) and in reduction of nasal stuffness (p less than or equal to 0.05). Improvements in individual nasal symptoms (itching, postnasal drip, runny nose, and sneezing) were greater for triamcinolone acetonide at week 2 (p less than or equal to 0.01). Ocular symptoms improved from baseline in both groups. When pollen counts were correlated to mean nasal rhinitis scores, the triamcinolone acetonide group showed continued improvement from week 2 to week 2. This study demonstrated that once daily administration of triamcinolone acetonide was more effective than astemizole for controlling nasal symptoms of seasonal allergic rhinitis, especially during the peak pollination period.			Bernstein, DI (corresponding author), UNIV CINCINNATI,COLL MED,DIV IMMUNOL,ML563,231 BETHESDA AVE,CINCINNATI,OH 45267, USA.							BACKHOUSE CI, 1986, J INT MED RES, V14, P34; BESWICK KBJ, 1985, CURR MED RES OPIN, V9, P560, DOI 10.1185/03007998509109635; BROGDEN RN, 1984, DRUGS, V28, P99, DOI 10.2165/00003495-198428020-00002; DELCARPIO J, 1989, J ALLERGY CLIN IMMUN, V84, P741; FINDLAY S, 1992, ANN ALLERGY, V68, P228; FROLUND L, 1991, CLIN OTOLARYNGOL, V16, P527, DOI 10.1111/j.1365-2273.1991.tb00965.x; Gatley M S, 1968, J R Coll Gen Pract, V16, P39; HOWARTH PH, 1984, BRIT J CLIN PHARMACO, V18, P1; HOWARTH PH, 1984, THORAX, V39, P668, DOI 10.1136/thx.39.9.668; JUNIPER EF, 1989, J ALLERGY CLIN IMMUN, V83, P627, DOI 10.1016/0091-6749(89)90075-4; JUNIPER EF, 1988, J ALLERGY CLIN IMMUN, V82, P670, DOI 10.1016/0091-6749(88)90981-5; KNIGHT A, 1985, J OTOLARYNGOL, V14, P85; SALOMONSSON P, 1988, ALLERGY, V43, P214; SIEGEL SC, 1988, J ALLERGY CLIN IMMUN, V81, P984, DOI 10.1016/0091-6749(88)90166-2; SIMONS FER, 1994, NEW ENGL J MED, V330, P1663; WOOD SF, 1986, CLIN ALLERGY, V16, P195, DOI 10.1111/j.1365-2222.1986.tb00766.x	16	37	37	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1996	97	3					749	755		10.1016/S0091-6749(96)80151-5	http://dx.doi.org/10.1016/S0091-6749(96)80151-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UA975	8613630				2022-12-18	WOS:A1996UA97500004
J	Larsen, JN; Lowenstein, H				Larsen, JN; Lowenstein, H			Allergen nomenclature	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							POLLEN		ALK LABS,RES,DK-2970 HORSHOLM,DENMARK									CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; King T.P., 1994, ALLERGY CLIN IMMUNOL, V6, P38; KING TP, 1978, BIOCHEMISTRY-US, V17, P5165, DOI 10.1021/bi00617a016; KING TP, 1994, B WORLD HEALTH ORGAN, V72, P797; KING TP, 1995, J ALLERGY CLIN IMMUN, V96, P5, DOI 10.1016/S0091-6749(95)70027-7; KING TP, 1976, ARCH BIOCHEM BIOPHYS, V172, P661, DOI 10.1016/0003-9861(76)90121-1; LOWENSTEIN H, 1980, ALLERGY, V35, P188, DOI 10.1111/j.1398-9995.1980.tb01739.x; MARSH DG, 1986, J ALLERGY CLIN IMMUN, V80, P639; RAFNAR T, 1991, J BIOL CHEM, V266, P1229; STANWORTH D R, 1990, Bulletin of the World Health Organization, V68, P109	10	37	39	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1996	97	2					577	578						2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TW087	8621841				2022-12-18	WOS:A1996TW08700001
J	BRUGNAMI, G; MARABINI, A; SIRACUSA, A; ABBRITTI, G				BRUGNAMI, G; MARABINI, A; SIRACUSA, A; ABBRITTI, G			WORK-RELATED LATE ASTHMATIC RESPONSE INDUCED BY LATEX ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						LATEX RUBBER; IMMEDIATE HYPERSENSITIVITY; LATE ASTHMATIC RESPONSE; URTICARIA; ANGIOEDEMA; ASTHMA; OCCUPATIONAL DISEASES; RHINITIS; PROVOCATION TESTS; FOLLOW-UP STUDIES	OCCUPATIONAL-ASTHMA; CONTACT URTICARIA; RUBBER; GLOVES; BRONCHOPROVOCATION	Background: The occupational uses of latex gloves may De associated with asthma. Hypersensitivity to latex has been shown to be IgE-mediated. The asthmatic reaction to Inter is usually early; however, the natural history of Enter asthma is still unknown. Objective: The purposes Of this study were to investigate asthmatic responses induced by natural rubber. latex and to assess the long-term respiratory consequences of latex-induced asthma after removal from exposure. Methods: This report describes the clinical and immunologic study of sis nurses with work-related respiratory and skirt disorders induced by the use of latex gloves. To determine whether the symptoms induced by latex gloves were IgE-mediated, we assessed later IgE antibody levels by skin prick tests (SPTs) and RASTs with Inter extracts. To confirm work-related latex reactions, we assessed respiratory symptoms, skin reactions, and FEV(1) respiratory symptoms, skit? reactions, and FEV(1) after a glove exposure test and nt? inhalation provocation test with Inter gloves. All subjects were followed up for 7 months to 7 years after the first observation. Results: All subjects had positive SPT and RAST responses to Inter extracts, positive double prick test responses to Inter gloves, and negative SPT responses to cornstarch and common allergens. Ten atopic and ID nonatopic control subjects had negative SPT responses to latex and cornstarch extracts and,negative double prick test responses to Inter gloves. In three subjects later allergy was associated with allergy to fruit (banana and chestnut). After the glove exposure test, four of six subjects had contact urticaria, all had rhinoconjunctivitis, and two had a late asthmatic response. The inhalation provocation? test was performed on four subjects: all had rhinoconjunctivitis, two had urticaria and late asthmatic response, and one had laryngeal edema. A late asthmatic response was recorded in foul subjects. Three subjects continued to have chronic asthma, and foul subjects had increased nonspecific bronchial responsiveness 7,months to 7 years after being assigned to duties not involving latex gloves. Conclusions: This study of six nurses shows that later is a potential cause of occupational asthma, I rhinoconjunctivitis, and urticaria-angioedema. Latex seems to include antigens that elicit IgE-mediated hypersensitivity and may cause a late asthmatic reaction. Occupational asthma caused by latex may lead to permanent respiratory disability, even after removal from exposure.	UNIV PERUGIA, TOXICOL SECT, I-06100 PERUGIA, ITALY; UNIV PERUGIA, DEPT CLIN MED PATHOL & PHARMACOL, I-06122 PERUGIA, ITALY	University of Perugia; University of Perugia								ANDRI L, 1992, GIORN IT ALLERGOL IM, V2, P315; ANIBARRO B, 1993, ALLERGY, V48, P130, DOI 10.1111/j.1398-9995.1993.tb00698.x; ANTONICELLI L, 1993, GIORN ITAL ALLERGOL, V3, P55; AXELSSON JGK, 1987, ALLERGY, V42, P46, DOI 10.1111/j.1398-9995.1987.tb02186.x; BAUR X, 1990, LANCET, V335, P912, DOI 10.1016/0140-6736(90)90508-3; BOUSQUET J, 1990, J ALLERGY CLIN IMMUN, V85, P1039, DOI 10.1016/0091-6749(90)90048-9; CARTIER A, 1989, J ALLERGY CLIN IMMUN, V84, P823, DOI 10.1016/0091-6749(89)90346-1; CEUPPENS JL, 1992, LANCET, V339, P493, DOI 10.1016/0140-6736(92)91101-D; Chan-Yeung Moira, 1993, P299; CHANYEUNG M, 1982, AM J MED, V72, P411, DOI 10.1016/0002-9343(82)90497-1; DEZOTTI R, 1992, BRIT J IND MED, V49, P596; DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; JEAGER D, 1992, J ALLERGY CLIN IMMUN, V89, P759; LAGIER F, 1990, LANCET, V336, P516, DOI 10.1016/0140-6736(90)92076-T; LAGIER F, 1992, J ALLERGY CLIN IMMUN, V90, P319, DOI 10.1016/S0091-6749(05)80009-0; MAPP CE, 1988, AM REV RESPIR DIS, V137, P1326, DOI 10.1164/ajrccm/137.6.1326; MRAIHI L, 1991, J ALLERGY CLIN IMMUN, V87, P129, DOI 10.1016/0091-6749(91)90224-C; NUTTER AF, 1979, BRIT J DERMATOL, V101, P597, DOI 10.1111/j.1365-2133.1979.tb15107.x; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; PISATI G, 1994, EUR RESPIR J, V7, P332, DOI 10.1183/09031936.94.07020332; SEATON A, 1988, BRIT MED J, V296, P531, DOI 10.1136/bmj.296.6621.531-a; SIRACUSA A, 1992, AM REV RESPIR DIS, V146, P408, DOI 10.1164/ajrccm/146.2.408; SLATER JE, 1989, NEW ENGL J MED, V320, P1126, DOI 10.1056/NEJM198904273201707; TARLO SM, 1990, J ALLERGY CLIN IMMUN, V85, P626, DOI 10.1016/0091-6749(90)90103-B; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; WRANGSJO K, 1988, CONTACT DERMATITIS, V19, P264, DOI 10.1111/j.1600-0536.1988.tb02925.x	26	37	40	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1995	96	4					457	464		10.1016/S0091-6749(95)70287-3	http://dx.doi.org/10.1016/S0091-6749(95)70287-3			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TA095	7560655	Bronze			2022-12-18	WOS:A1995TA09500004
J	DOCKHORN, R; VANDENBURGT, JA; EKHOLM, BP; DONNELL, D; CULLEN, MT				DOCKHORN, R; VANDENBURGT, JA; EKHOLM, BP; DONNELL, D; CULLEN, MT			CLINICAL EQUIVALENCE OF A NOVEL NON-CHLOROFLUOROCARBON-CONTAINING SALBUTAMOL SULFATE METERED-DOSE INHALER AND A CONVENTIONAL CHLOROFLUOROCARBON INHALER IN PATIENTS WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SALBUTAMOL; ASTHMA; HYDROFLUOROALKANE; HFA-134A; BRONCHODILATOR		Background: New formulations of non-chlorofluorocarbon-containing propellants for pressurized metered-dose inhaler delivery systems must be developed in response to the forthcoming ban on chlorofluorocarbon (CFC) production. Objective: This study compared the bronchodilator effects of 100, 200, and 300 mu g (base equivalent) of salbutamol in a novel CFC-free propellant system (Airomir in the 3M CFC-Free System; 3M Pharmaceuticals, St. Paul Minn.; 108 mu g of salbutamol sulfate or 90 mu g of salbutamol base equivalent per inhalation) with that of 100 and 200 mu g of salbutamol base in a conventional CFC propellant system (Ventolin, CFC-11/12; Allen and Hanburys, Division of Glaxo Inc., Research Triangle Park, N.C.; 90 mu g of salbutamol base per inhalation) and placebo. Methods: Twenty-six patients with chronic, stable asthma, who had a forced expiratory volume in 1 second (FEV(1)) between 50.0% and 75.0% of predicted normal value entered this randomized double-blind, double-dummy, 6-period, crossover study. FEV(1) was measured before and at multiple time points (ranging from 10 to 480 minutes) after administration of one, two, and three inhalations of salbutamol/CFC-free (100, 200, and 300 mu g); one and two inhalations of salbutamol/CFC (100 and 200 mu g); and placebo. Safety parameters included adverse events, heart rate, blood pressure, physical examinations, electrocardiograms, and clinical laboratory tests. Parametric analysis of variance models appropriate for a 6-period crossover design were used, along with multiple comparisons according to Tukey's method. Results: All active treatments produced significantly (p < 0.0001) greater bronchodilation than placebo. The bronchodilator effect, as measured by FEV(1) (peak percent change, peak as a percent of predicted value duration, and area under the curve) after two inhalations of salbutamol/CFC-free was clinically comparable to two inhalations of salbutamol/CFC, with no clinically meaningful differences in safety parameters between the two delivery systems or between different dose levels. Conclusion: These results suggest that salbutamol/CFC-free may offer a suitable alternative for salbutamol/CFC when the need arises to change front CFC-containing salbutamol products.	THREE M CO,PHARMACEUT,ST PAUL,MN 55144; INT MED TECH CONSULTANTS INC,LENEXA,KS; THREE M HLTH CARE,LOUGHBOROUGH,LEICS,ENGLAND	3M								[Anonymous], 1987, Am Rev Respir Dis, V136, P1285; BOULDEN ME, 1994, SPRAY TECHNOL MARKET, V4, P32; LEACH CL, 1995, IN PRESS AEROSOL SCI; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; WONG BJO, 1993, J ALLERGY CLIN IMMUN, V92, P373, DOI 10.1016/0091-6749(93)90115-V; 1989, SAS STAT USERS GUIDE, V1; 1994, SCRIP, V943, P26	7	37	38	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1995	96	1					50	56		10.1016/S0091-6749(95)70032-3	http://dx.doi.org/10.1016/S0091-6749(95)70032-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RK383	7622763				2022-12-18	WOS:A1995RK38300007
J	OWNBY, DR; ADINOFF, AD				OWNBY, DR; ADINOFF, AD			THE APPROPRIATE USE OF SKIN TESTING AND ALLERGEN IMMUNOTHERAPY IN YOUNG-CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							BONE-MARROW TRANSPLANTATION; SYSTEMIC REACTIONS; TEST REACTIVITY; INFANCY; ASTHMA; AGE; ADJUSTMENT; ISSUES; STRESS		HENRY FORD HLTH SYST,DIV CLIN IMMUNOL & ALLERGY,DETROIT,MI; UNIV COLORADO,SCH MED,DENVER,CO; COLORADO ALLERGY & ASTHMA CLIN,AURORA,CO	Henry Ford Health System; Henry Ford Hospital; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								BERNSTEIN JM, 1993, ALLERGY PRINCIPLES P, P1471; CAREY TN, 1933, J ALLERGY, V5, P488; CRETICOS PS, 1993, J ALLERGY CLIN IMMUN, V91, P227; GARDNER GG, 1977, PEDIATRICS, V60, P625; GREEN BL, 1991, J AM ACAD CHILD PSY, V30, P945, DOI 10.1097/00004583-199111000-00012; HEJJAOUI A, 1990, J ALLERGY CLIN IMMUN, V85, P473, DOI 10.1016/0091-6749(90)90157-Y; MACLEAN WE, 1992, J PEDIATR PSYCHOL, V17, P159, DOI 10.1093/jpepsy/17.2.159; MALLING HJ, 1993, ALLERGY, V48, P9; MATHESON A, 1952, PEDIATRICS, V10, P181; MENARDO JL, 1985, J ALLERGY CLIN IMMUN, V75, P646, DOI 10.1016/0091-6749(85)90088-0; NIR Y, 1985, POST TRAUMATIC STRES, P240; OWNBY DR, 1988, PEDIATR CLIN N AM, V35, P995; PERRIN JM, 1989, PEDIATRICS, V83, P26; PETERSON L, 1989, J CONSULT CLIN PSYCH, V57, P380, DOI 10.1037/0022-006X.57.3.380; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P755, DOI 10.1016/S0091-6749(87)80261-0; PYNOOS RS, 1987, ARCH GEN PSYCHIAT, V44, P1057; RASNAKE LK, 1989, J DEV BEHAV PEDIATR, V10, P169; SKASSABROCIEK W, 1987, J ALLERGY CLIN IMMUN, V80, P711, DOI 10.1016/0091-6749(87)90292-2; STEWART GE, 1992, J ALLERGY CLIN IMMUN, V90, P567, DOI 10.1016/0091-6749(92)90129-P; STUBER ML, 1991, J AM ACAD CHILD PSY, V30, P952, DOI 10.1097/00004583-199111000-00013; Sulzberger MB, 1940, ARCH DERMATOL SYPH, V41, P1029, DOI 10.1001/archderm.1940.01490120031004; TERR LC, 1983, AM J PSYCHIAT, V140, P1543; VANMETRE TE, 1993, ALLERGY PRINCIPLES P, P1489; ZEIGER RS, 1985, J ALLERGY CLIN IMMUN, V75, P633, DOI 10.1016/0091-6749(85)90086-7; 1993, CLIN EXP ALLERGY S3, V23, P1	25	37	37	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1994	94	4					662	665		10.1016/0091-6749(94)90171-6	http://dx.doi.org/10.1016/0091-6749(94)90171-6			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	PM273	7930297				2022-12-18	WOS:A1994PM27300002
J	TOMEE, JFC; KAUFFMAN, HF; KLIMP, AH; DEMONCHY, JGR; KOETER, GH; DUBOIS, AEJ				TOMEE, JFC; KAUFFMAN, HF; KLIMP, AH; DEMONCHY, JGR; KOETER, GH; DUBOIS, AEJ			IMMUNOLOGICAL SIGNIFICANCE OF A COLLAGEN-DERIVED CULTURE FILTRATE CONTAINING PROTEOLYTIC ACTIVITY IN ASPERGILLUS-RELATED DISEASES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						PROTEASE; CULTURE FILTRATES; ASPERGILLUS FUMIGATUS; ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ASPERGILLOMA; IMMUNOLOGY; DETECTION; IGG ANTIBODY; FUNGAL ELASTASE	ELASTASE PRODUCTION; FUMIGATUS; PROTEINASE; ANTIBODIES; STANDARDIZATION; PURIFICATION; INHIBITION; PROTEASES; EXTRACTS; FLAVUS	Background: Despite increasing evidence implicating fungal proteases in the virulence of pulmonary fungal diseases, routine fungal culture media do not favor protease production. Hence, filtrates that serve as the source of antigen for serologic determinations are poor in proteases, and consequently the immunologic significance of these enzymes is unknown. Methods: A clinical isolate of Aspergillus fumigatus was cultured on collagen medium, resulting in excretion of high levels of fungal proteases in the culture filtrate. This was compared with standard culture filtrates by diverse analytic techniques including immunoblotting with sera of patients with pulmonary aspergilloma (PA) and allergic bronchopulmonary aspergillosis (ABPA). Results: Protein profiles of collagen medium filtrate showed several (glyco)proteins not found in conventional culture filtrates, including a prominent 32 kd glycoprotein, which coisolated in gel filtration and ion-exchange chromatography with elastase activity, as well as 67 kd and 94 kd (glyco)proteins. Intense IgG binding was seen with the 32 kd glycoprotein when ABPA and PA sera were used. The 94 kd protein showed intense binding with PA sera but not with ABPA sera, whereas for the 67 kd glycoprotein the reverse tended to be the case. Conclusion: Fungal culture on collagen media results in the production of filtrates with high pretense activity, containing unique (glyco)proteins of which at least one (32 kd) is closely associated with fungal elastase activity. These constituents are immunologically relevant, eliciting IgG production in patients with PA and ABPA, suggesting production of these (glyco)proteins during disease in vivo. The use of collagen media filtrates may enhance our serodiagnostic capacity in patients with fungal pulmonary diseases.	UNIV GRONINGEN HOSP,DEPT ALLERGOL,9700 RB GRONINGEN,NETHERLANDS	University of Groningen								BEAUMONT F, 1985, ALLERGY, V40, P173, DOI 10.1111/j.1398-9995.1985.tb00213.x; COHEN BL, 1977, GENETICS PHYSL ASPER, P281; DENNING DW, 1992, INFECT IMMUN, V60, P5153, DOI 10.1128/IAI.60.12.5153-5156.1992; DION WM, 1950, CAN J RES C, V28, P577, DOI 10.1139/cjr50c-034; FROSCO M, 1992, INFECT IMMUN, V60, P728, DOI 10.1128/IAI.60.3.728-734.1992; FROSCO M, 1992, INFECT IMMUN, V60, P735, DOI 10.1128/IAI.60.3.735-741.1992; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; KAUFFMAN HF, 1984, J ALLERGY CLIN IMMUN, V73, P567, DOI 10.1016/0091-6749(84)90512-8; KAUFFMAN HF, 1983, J ALLERGY CLIN IMMUN, V72, P255, DOI 10.1016/0091-6749(83)90029-5; KAUFFMAN HF, 1980, INT ARCH ALLER A IMM, V62, P252, DOI 10.1159/000232521; KAUFFMAN HF, 1985, INT ARCH ALLER A IMM, V76, P168, DOI 10.1159/000233685; KAUFFMAN HF, 1984, MOULD ALLERGY WORKSH, P43; KOTHARY MH, 1984, INFECT IMMUN, V43, P320, DOI 10.1128/IAI.43.1.320-325.1984; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MONOD M, 1991, J MED MICROBIOL, V35, P23, DOI 10.1099/00222615-35-1-23; Nakagawa Y., 1970, METHOD ENZYMOL, V19, P581; REED C, 1978, J ALLERGY CLIN IMMUN, V61, P227, DOI 10.1016/0091-6749(78)90189-6; REICHARD U, 1990, J MED MICROBIOL, V33, P243, DOI 10.1099/00222615-33-4-243; RHODES JC, 1991, J MED VET MYCOL, V29, P407; RHODES JC, 1988, DIAGN MICR INFEC DIS, V10, P165, DOI 10.1016/0732-8893(88)90036-3; ROBINSON BWS, 1990, J ALLERGY CLIN IMMUN, V86, P726, DOI 10.1016/S0091-6749(05)80176-9; Shotton D. M., 1970, METHOD ENZYMOL, V19, P113, DOI 10.1016/0076-6879(70)19009-4; VANDERHEIDE S, 1984, J ALLERGY CLIN IMMUN, V73, P813, DOI 10.1016/0091-6749(84)90452-4; VANWART HE, 1981, ANAL BIOCHEM, V113, P356, DOI 10.1016/0003-2697(81)90089-0; WASHBURN RG, 1986, J INFECT DIS, V154, P944, DOI 10.1093/infdis/154.6.944; WOLTERS GHJ, 1990, HORM METAB RES, V25, P20; ZHU WS, 1990, DIAGN MICR INFEC DIS, V13, P491, DOI 10.1016/0732-8893(90)90081-6	28	37	40	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1994	93	4					768	778		10.1016/0091-6749(94)90257-7	http://dx.doi.org/10.1016/0091-6749(94)90257-7			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NH497	8163786				2022-12-18	WOS:A1994NH49700010
J	OBRIEN, RM; THOMAS, WR; TAIT, BD				OBRIEN, RM; THOMAS, WR; TAIT, BD			AN IMMUNOGENETIC ANALYSIS OF T-CELL REACTIVE REGIONS ON THE MAJOR ALLERGEN FROM THE HOUSE-DUST MITE, DER P I, WITH RECOMBINANT TRUNCATED FRAGMENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HOUSE DUST MITE; DERMATOPHAGOIDES PTERONYSSINUS; T-CELL EPITOPES; PROLIFERATION ASSAY; HLA; IMMUNOGENETICS; ALLERGY; RECOMBINANT	DERMATOPHAGOIDES-PTERONYSSINUS; HISTOCOMPATIBILITY COMPLEX; SEQUENCE-ANALYSIS; IGE; DETERMINANT; ANTIGEN; HISTAMINE; PATTERNS; EXTRACTS; RELEASE	Proliferation assays were used to localize the T-cell reactive sites on the major allergen from the house dust mite Dermatophagoides pteronyssinus, Der p I. Seven overlapping recombinant fragments of the Der p I molecule, synthesized with the pGEX expression vector system, were used to stimulate peripheral blood lymphocytes from 35 HDM-sensitive individuals. The fusion fragments were from 39 to 114 amino acids in length and spanned the entire Der p I molecule. Significant proliferative responses to one or more of the fragments were evident in 18 of the allergic individuals, and each of the fragments led to T-cell stimulation in at least one of the subjects. Although T-cell reactive regions were located throughout the molecule, in 12 of the 18 responsive individuals, major immunogenic sites were contained within the 56 amino acids of the N-terminus, and in 11 of these individuals T-cell reactive regions were only present between amino acid positions 1 and 94. In two individuals reactive sites could be mapped in the C-terminal half of the molecule, and in five subjects, epitopes were present in both N- and C-terminal regions. HLA class I and class II DR and DQ specificities were determined serologically in 16 of the 18 individuals, and no strong pattern of association between HLA type and the T-cell immunogenic region could be detected.	PRINCESS MARGARET HOSP CHILDREN,WESTERN AUSTRALIAN RES INST CHILD HLTH,PERTH,AUSTRALIA; ROYAL MELBOURNE HOSP,TISSUE TYPING LAB,PARKVILLE,VIC 3050,AUSTRALIA	Telethon Kids Institute; University of Western Australia; Royal Melbourne Hospital	OBRIEN, RM (corresponding author), UNIV MELBOURNE,WESTERN HOSP,DEPT MED,GORDON ST,FOOTSCRAY,VIC 3011,CANADA.							BARNETT AJ, 1989, CLIN EXP IMMUNOL, V76, P24; BROWN LE, 1991, INT IMMUNOL, V3, P1307, DOI 10.1093/intimm/3.12.1307; CARABALLO L, 1991, HUM IMMUNOL, V32, P157, DOI 10.1016/0198-8859(91)90051-A; CARABALLO LR, 1990, TISSUE ANTIGENS, V35, P182, DOI 10.1111/j.1399-0039.1990.tb01777.x; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; DILWORTH RJ, 1991, CLIN EXP ALLERGY, V21, P25, DOI 10.1111/j.1365-2222.1991.tb00800.x; EISENLOHR LC, 1992, J EXP MED, V175, P481, DOI 10.1084/jem.175.2.481; FRIEDHOFF LR, 1990, GENETIC ENV FACTORS, P53; GAMMON G, 1991, J EXP MED, V173, P609, DOI 10.1084/jem.173.3.609; GREENE WK, 1991, J IMMUNOL, V147, P3768; HOYNE GF, 1993, IMMUNOLOGY, V78, P65; ISHIKAWA T, 1985, INT ARCH ALLER A IMM, V77, P210, DOI 10.1159/000233789; ISHIZAKA K, 1984, ANNU REV IMMUNOL, V2, P159, DOI 10.1146/annurev.immunol.2.1.159; Lett-Brown M A, 1989, Year Immunol, V5, P195; LIU Z, 1991, J IMMUNOL, V146, P438; OBRIEN RM, 1992, J ALLERGY CLIN IMMUN, V89, P1021, DOI 10.1016/0091-6749(92)90225-Q; OHEHIR RE, 1991, ANNU REV IMMUNOL, V9, P67, DOI 10.1146/annurev.iy.09.040191.000435; ORANGE RP, 1971, J EXP MED, V134, pS136; PLAUT M, 1990, J IMMUNOL, V144, P4497; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; Stewart G.A., 1989, Advances in the Biosciences, V74, P297; TOVEY ER, 1987, J ALLERGY CLIN IMMUN, V79, P93, DOI 10.1016/S0091-6749(87)80022-2; VANDERZEE JS, 1988, J ALLERGY CLIN IMMUN, V81, P884, DOI 10.1016/0091-6749(88)90946-3; YOUNG RP, 1992, ALLERGY, V47, P8; YSSEL H, 1992, J IMMUNOL, V148, P738	25	37	40	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1994	93	3					628	634		10.1016/S0091-6749(94)70074-5	http://dx.doi.org/10.1016/S0091-6749(94)70074-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ND140	7512103	Bronze			2022-12-18	WOS:A1994ND14000009
J	TESHIMA, R; IKEBUCHI, H; SAWADA, J; MIYACHI, S; KITANI, S; IWAMA, M; IRIE, M; ICHINOE, M; TERAO, T				TESHIMA, R; IKEBUCHI, H; SAWADA, J; MIYACHI, S; KITANI, S; IWAMA, M; IRIE, M; ICHINOE, M; TERAO, T			ISOLATION AND CHARACTERIZATION OF A MAJOR ALLERGENIC COMPONENT (GP55) OF ASPERGILLUS-FUMIGATUS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASPERGILLUS FUMIGATUS; IGE-BINDING PROTEIN; GLYCOPROTEIN; N-LINKED OLIGOSACCHARIDES; N-TERMINAL SEQUENCE	IMMUNOCHEMICAL CHARACTERIZATION; ANTIGENS; FRACTIONS; BINDING; PEPTIDE; PROTEIN; SERA	IgE class antibodies specific for antigens in a water-soluble extract of Aspergillus fumigatus (strain NHL-5759) were analyzed by immunoblotting with sera from patients with allergic bronchopulmonary aspergillosis. All the sera tested were reactive with a major 50 to 60 kd protein in the extract. This allergen, designated gp55, was purified by gel filtration and preparative sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The antigen was found to be present in the water-soluble extract in the form of a complex composed of approximately eight molecules of gp55. The carbohydrate and phosphate content of the purified antigen were 23.1% and 0.46%, respectively. The molar ratio of mannose to galactose residues was 2.76:1, and the protein was glycosylated predominantly with N-linked oligosaccharides. The serologic activity of the gp55 antigen was abolished by treatment with nonspecific protease (Pronase) but not by treatment with sodium metaperiodate or endoglycosidases. Thus the major antigenic site of the glycoprotein is located within its peptide moiety. The antigen itself displayed no chymotryptic or tryptic activity. The amino acid sequence of the 20 N-terminal residues of the antigen (ATPHEPVFFSWDAGAVTSFP) is different from that of any other protein previously reported.	KANTO CHUO HOSP,DEPT MED,TOKYO,JAPAN; HOSHI COLL PHARM,DEPT MICROBIOL,TOKYO,JAPAN; UNIV TOKYO,SCH MED,DEPT MED & PHYS THERAPY,TOKYO 113,JAPAN; NATL INST HYG SCI,DIV MICROBIOL,TOKYO 158,JAPAN	Hoshi University; University of Tokyo; National Institute of Health Sciences - Japan	TESHIMA, R (corresponding author), NATL INST HYG SCI,DIV BIOCHEM & IMMUNOCHEM,1-18-1 KAMIYOGA,SETAGAYA KU,TOKYO 158,JAPAN.		Kitani, Seiichi/O-1848-2014					Ames BN., 1966, METHOD ENZYMOL, V8, P115, DOI DOI 10.1016/0076-6879(66)08014-5; ANDERSON CJ, 1980, J ALLERGY CLIN IMMUN, V65, P140, DOI 10.1016/0091-6749(80)90199-2; ARRUDA LK, 1990, J EXP MED, V172, P1529, DOI 10.1084/jem.172.5.1529; BARDANA E, 1980, CRC CRIT REV CLIN LA, V13, P85; CALVANICO NJ, 1981, CLIN EXP IMMUNOL, V45, P662; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Elson LA, 1933, BIOCHEM J, V27, P1824, DOI 10.1042/bj0271824; FRATAMICO PM, 1991, INFECT IMMUN, V59, P309, DOI 10.1128/IAI.59.1.309-315.1991; HARVEY C, 1986, CLIN EXP IMMUNOL, V65, P206; HARVEY C, 1987, CLIN EXP IMMUNOL, V70, P247; HEARN VM, 1980, J GEN MICROBIOL, V119, P41; HEARN VM, 1979, J GEN MICROBIOL, V112, P35, DOI 10.1099/00221287-112-1-35; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; KATO H, 1980, J BIOCHEM-TOKYO, V88, P183; KIM SJ, 1978, AM REV RESPIR DIS, V118, P547; KIM SJ, 1978, AM REV RESPIR DIS, V118, P553; KURAP VP, 1983, INFECT IMMUN, V41, P698; KURUP VP, 1986, J ALLERGY CLIN IMMUN, V78, P1166, DOI 10.1016/0091-6749(86)90267-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LLOYD KO, 1972, BIOCHEMISTRY-US, V21, P3884; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mackenzie D. W. R., 1991, Japanese Journal of Medical Mycology, V32, P95; PIECHURA JE, 1990, CAN J MICROBIOL, V36, P33, DOI 10.1139/m90-006; REIJULA KE, 1991, J ALLERGY CLIN IMMUN, V87, P683, DOI 10.1016/0091-6749(91)90389-6; RINALDI MG, 1983, REV INFECT DIS, V5, P1061; SCHONHEYDER H, 1985, SABOURAUDIA, V23, P339; ZACHARIUS RM, 1969, ANAL BIOCHEM, V30, P148, DOI 10.1016/0003-2697(69)90383-2	27	37	40	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1993	92	5					698	706		10.1016/0091-6749(93)90013-6	http://dx.doi.org/10.1016/0091-6749(93)90013-6			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MG982	8227861				2022-12-18	WOS:A1993MG98200011
J	COCKCROFT, DW; MCPARLAND, CP; OBYRNE, PM; MANNING, P; FRIEND, JL; RUTHERFORD, BC; SWYSTUN, VA				COCKCROFT, DW; MCPARLAND, CP; OBYRNE, PM; MANNING, P; FRIEND, JL; RUTHERFORD, BC; SWYSTUN, VA			BECLOMETHASONE GIVEN AFTER THE EARLY ASTHMATIC RESPONSE INHIBITS THE LATE RESPONSE AND THE INCREASED METHACHOLINE RESPONSIVENESS AND CROMOLYN DOES NOT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						BECLOMETHASONE; CROMOLYN; ALLERGEN INHALATION TESTS; LATE ASTHMATIC RESPONSE; ALLERGEN-INDUCED INCREASE IN AIRWAY RESPONSIVENESS	BRONCHIAL RESPONSIVENESS; AIRWAY RESPONSIVENESS; ALLERGEN CHALLENGE; HISTAMINE; SODIUM; BRONCHOCONSTRICTION; HYPERRESPONSIVENESS; CROMOGLYCATE; REACTIVITY	Background: Single doses of inhaled beclomethasone or inhaled cromolyn, given before allergen inhalation, inhibit allergen-induced late asthmatic responses (LARs) and increased airway responsiveness (DELTA log methacholine PC20). We hypothesized that when given 2 hours after allergen, beclomethasone might work better than cromolyn. Methods: In 10 patients with mild, stable, atopic asthma with LARs or DELTA log PC20 or both, we performed a double-blind, double-dummy, random-order trial comparing a single dose of inhaled beclomethasone (500 mug), cromolyn (20 mg), and placebo, administered 2 hours after allergen challenge on LAR and DELTA log PC20. Results: The treatment effect on LAR was significant (p < 0.001). The LAR after beclomethasone (7.3% +/- 6.1%) was significantly less than after cromolyn (20.4% +/- 15.2%) or placebo (26.4% +/- 8.2%); cromolyn was not different from placebo. There was a borderline treatment effect on DELTA log PC20 (p = 0.056) with beclomethasone (0.12 +/- 0.31) less than placebo (0.37 +/- 0.39) but not less than cromolyn (0.34 +/- 0.18). Conclusion: Beclomethasone (500 mug) administered 2 hours after allergen challenge markedly inhibited the LAR and had a small effect on allergen-induced airway responsiveness. Cromolyn (20 mg) was not effective on maximal LAR; a small effect on the early part of the LAR was suggested.	MCMASTER UNIV,MED CTR,DIV RESP MED,HAMILTON L8S 4L8,ONTARIO,CANADA; UNIV SASKATCHEWAN,DEPT MED,DIV RESP MED,SASKATOON S7N 0W0,SASKATCHEWAN,CANADA	McMaster University; University of Saskatchewan				O'Byrne, Paul/0000-0003-0979-281X				AALBERS R, 1991, J ALLERGY CLIN IMMUN, V87, P993, DOI 10.1016/0091-6749(91)90422-K; ANDERSSON P, 1988, INT ARCH ALLER A IMM, V87, P32, DOI 10.1159/000234645; BOOIJ-NOORD H, 1972, Clinical Allergy, V2, P43, DOI 10.1111/j.1365-2222.1972.tb01267.x; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; COCKCROFT DW, 1987, THORAX, V42, P302, DOI 10.1136/thx.42.4.302; COCKCROFT DW, 1983, CHEST, V84, P505, DOI 10.1378/chest.84.4.505; COCKCROFT DW, 1987, AM REV RESPIR DIS, V135, P264; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; COLE JWL, 1966, BIOMETRICS, V22, P810, DOI 10.2307/2528076; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DURHAM SR, 1988, J ALLERGY CLIN IMMUN, V82, P764, DOI 10.1016/0091-6749(88)90077-2; GIBSON PG, 1992, CLIN EXP ALLERGY, V22, P525, DOI 10.1111/j.1365-2222.1992.tb00161.x; HUTSON PA, 1988, AM REV RESPIR DIS, V138, P1157, DOI 10.1164/ajrccm/138.5.1157; KIRBY JG, 1989, J APPL PHYSIOL, V66, P578, DOI 10.1152/jappl.1989.66.2.578; MATTOLI S, 1986, ANN ALLERGY, V57, P295; MATTOLI S, 1987, J ALLERGY CLIN IMMUN, V79, P747, DOI 10.1016/0091-6749(87)90206-5; MURPHY KR, 1986, AM REV RESPIR DIS, V134, P62; PEPYS J, 1968, LANCET, V2, P134; Steel R. G. D., 1990, PRINCIPLES PROCEDURE, P137; WONG B J O, 1992, Journal of Allergy and Clinical Immunology, V89, P176	21	37	37	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1993	91	6					1163	1168		10.1016/0091-6749(93)90319-B	http://dx.doi.org/10.1016/0091-6749(93)90319-B			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LG740	8509579				2022-12-18	WOS:A1993LG74000008
J	DIAMENT, MJ				DIAMENT, MJ			THE DIAGNOSIS OF SINUSITIS IN INFANTS AND CHILDREN - X-RAY, COMPUTED-TOMOGRAPHY, AND MAGNETIC-RESONANCE-IMAGING - DIAGNOSTIC-IMAGING OF PEDIATRIC SINUSITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	SYMP ON MECHANISMS, DIAGNOSIS, AND TREATMENT OF SINUSITIS IN CHILDREN AND ADULTS	JAN 24-25, 1992	SCOTTSDALE, AZ	ALLEN & HANBURYS		PARANASAL SINUSES; SINUSITIS; INFANTS AND CHILDREN; X-RAY; COMPUTED TOMOGRAPHY; MAGNETIC RESONANCE IMAGING	PARA-NASAL SINUSES; PARANASAL SINUSES; CT; ABNORMALITIES; RADIOGRAPHS; DISEASE	Plain film radiographic examination, the historical standard, is rapidly being supplanted by computed tomography (CT) and magnetic resonance imaging (MRI) in the diagnosis of sinusitis. In particular, many endoscopic surgeons consider CT to be a mandatory part of the preoperative evaluation. MRI is useful for cases complicated by orbital or intracranial extension. However, because of considerations of cost, the need for sedation, and for CT radiation exposure, conventional x-ray films will continue to play an important role in the diagnosis and management of medically treated sinus disease. Incidental sinus abnormalities in children without apparent symptoms are usually the result of resolving, uncomplicated upper respiratory tract infection. Opacification, moderate-to-severe mucosal thickening, or air fluid levels in patients with persistent symptoms indicate sinusitis. Sinus imaging in children, whatever the modality, is demanding both in obtaining technically adequate studies and interpreting findings. Poor-quality examinations usually overestimate the presence and severity of disease. Ideally, children should be referred to centers with expertise in pediatric ear, nose, and throat imaging.	UNIV CALIF LOS ANGELES,CTR HLTH SCI,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	DIAMENT, MJ (corresponding author), VALLEY PRESBYTERIAN HOSP,15107 VANOWEN BLVD,VAN NUYS,CA 91405, USA.							BABBEL R, 1991, AM J ROENTGENOL, V157, P1093; CONNER BL, 1989, ANN ALLERGY, V62, P457; COOKE LD, 1991, J LARYNGOL OTOL, V105, P278, DOI 10.1017/S0022215100115609; DIAMENT MJ, 1987, J COMPUT ASSIST TOMO, V11, P426, DOI 10.1097/00004728-198705000-00011; FERNBACH SK, 1981, NEURORADIOLOGY, V22, P7, DOI 10.1007/BF00344603; FUJIOKA M, 1978, RADIOLOGY, V129, P133, DOI 10.1148/129.1.133; GLASIER CM, 1986, AM J NEURORADIOL, V7, P861; GROSS GW, 1991, AM J ROENTGENOL, V156, P367, DOI 10.2214/ajr.156.2.1898816; HAWKINS DB, 1989, OTOLARYNG CLIN N AM, V22, P553; KOVATCH AL, 1984, PEDIATRICS, V73, P306; Maresh MM, 1940, AM J DIS CHILD, V60, P841, DOI 10.1001/archpedi.1940.02000040060005; Maresh MM, 1940, AM J DIS CHILD, V60, P55, DOI 10.1001/archpedi.1940.02000010064005; MCALISTER WH, 1989, AM J ROENTGENOL, V153, P1259, DOI 10.2214/ajr.153.6.1259; RAK KM, 1991, AM J ROENTGENOL, V156, P381, DOI 10.2214/ajr.156.2.1898819; SHOPFNER CE, 1973, AM J ROENTGENOL, V118, P176, DOI 10.2214/ajr.118.1.176; SILVERMAN FN, 1985, CAFFEYS PEDIATRIC XR, P97; ZINREICH SJ, 1987, RADIOLOGY, V163, P769, DOI 10.1148/radiology.163.3.3575731	17	37	42	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1992	90	3	2	S			442	444		10.1016/0091-6749(92)90166-Y	http://dx.doi.org/10.1016/0091-6749(92)90166-Y			3	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JP521	1527334				2022-12-18	WOS:A1992JP52100007
J	WAGENMANN, M; NACLERIO, RM				WAGENMANN, M; NACLERIO, RM			COMPLICATIONS OF SINUSITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	SYMP ON MECHANISMS, DIAGNOSIS, AND TREATMENT OF SINUSITIS IN CHILDREN AND ADULTS	JAN 24-25, 1992	SCOTTSDALE, AZ	ALLEN & HANBURYS		SINUSITIS; INFECTION; INTRAORBITAL; INTRACRANIAL	ORBITAL COMPLICATIONS	Even though they seldomly occur, the complications of sinusitis may be life-threatening. Complications can be local, orbital, and intracranial problems or combinations thereof. Orbital complications are the most frequent, and children with acute ethmoiditis are especially prone to them. To prevent permanent loss of vision, immediate and intense therapy is most important. Intracranial complications can have few symptoms, and discordance between symptoms and severity is not uncommon, which involves the importance of early radiologic diagnosis with computed tomographic or magnetic resonance imaging scans. Orbital and intracranial complications of sinusitis are medical emergencies and must be treated by specialists. Whenever possible, the underlying sinus infection should be drained at the same time. All physicians treating acute and chronic sinusitis must keep the potentially life-threatening complications of sinusitis in mind and remain suspicious because early recognition and treatment are crucial in these cases.	JOHNS HOPKINS UNIV,SCH MED,DEPT OTOLARYNGOL HEAD & NECK SURG,BALTIMORE,MD 21205	Johns Hopkins University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031335] Funding Source: NIH RePORTER; NIAID NIH HHS [AI31335] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CHANDLER JR, 1970, LARYNGOSCOPE, V80, P1414, DOI 10.1288/00005537-197009000-00007; GWALTNEY JM, 1981, ANN OTO RHINOL LARYN, V90, P68, DOI 10.1177/00034894810903S216; HADLEY JA, 1991, AM J RHINOL, V5, P181; JOHNSON JT, 1986, OTOLARYNGOLOGY HEAD, V1, P887; KENNEDY DW, 1989, LARYNGOSCOPE, V99, P885; MANIGLIA AJ, 1984, LARYNGOSCOPE, V94, P1050; MANIGLIA AJ, 1989, ARCH OTOLARYNGOL, V115, P1424; PATT BS, 1991, OTOLARYNG HEAD NECK, V104, P789, DOI 10.1177/019459989110400604; REMMLER D, 1980, LARYNGOSCOPE, V90, P1814, DOI 10.1288/00005537-198011000-00009	9	37	39	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1992	90	3	2	S			552	554		10.1016/0091-6749(92)90184-4	http://dx.doi.org/10.1016/0091-6749(92)90184-4			3	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JP521	1527349				2022-12-18	WOS:A1992JP52100025
J	GARCIAORTEGA, P; MARTINEZ, J; MARTINEZ, A; PALACIOS, R; BELMONTE, J; RICHART, C				GARCIAORTEGA, P; MARTINEZ, J; MARTINEZ, A; PALACIOS, R; BELMONTE, J; RICHART, C			MERCURIALIS-ANNUA POLLEN - A NEW SOURCE OF ALLERGIC SENSITIZATION AND RESPIRATORY-DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						MERCURIALIS-ANNUA; WEED POLLENS; SENSITIZATION TO UNKNOWN ALLERGENS; ALLERGIC ASTHMA; ALLERGIC RHINITIS; IMMUNOBLOTTING	ASTHMA; REACTIVITY	Sensitization to Mercurialis annua pollen in 13 patients admitted for allergy study of asthma, rhinitis, or rhinoconjunctivitis is described. Twelve of these patients were also sensitized to other common aeroallergens. In five patients, a relationship was found between exposure to M. annua pollen and elicitation of symptoms. All patients were prick test and RAST positive to an extract of M. annua pollen. Nasal provocation test proved positive in 10 of 12 patients, and bronchial provocation test was positive in the only patient in whom it was performed. Two late responses were recorded. Immunoblotting of the 13 sera revealed two different groups of relevant allergens: one of isoelectric point 10.2, reacting with 12 of the 13 sera, and the other allergen of isoelectric point 5.0 to 5.5, reacting with 11 of the 13 sera. M. annua pollen is able to induce both sensitization and clinical disease in atopic patients. Since sensitization to this pollen accounts for 8.5% of total positive skin tested patients in the same period, we believe M. annua pollen should be considered as a relevant allergen and thus included in skin test batteries. Some patients labeled as having "intrinsic" asthma or rhinitis might be sensitized to this and other previously unknown allergens.	UNIV BARCELONA,HOSP JOAN 13,DEPT MED,DIV 7,ALLERGY UNIT,TARRAGONA,SPAIN; IFIDESA ARISTEGUI,DEPT RES & DEV,BILBAO,SPAIN; UNIV AUTONOMA BARCELONA,DEPT BOT,BARCELONA,SPAIN	University of Barcelona; Autonomous University of Barcelona			Belmonte, Jordina/AAD-9687-2020; RICHART, CRISTOBAL C/S-9158-2017	Belmonte, Jordina/0000-0002-6419-9595; RICHART, CRISTOBAL C/0000-0003-0852-6739; MARTINEZ, JORGE/0000-0001-7002-0056				ANTO JM, 1989, NEW ENGL J MED, V320, P1097, DOI 10.1056/NEJM198904273201701; ARIANO R, 1990, Clinical and Experimental Allergy, V20, P124; BELMONTE J, 1988, THESIS U AUTONOMA BA, P694; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P102; CHAPMAN MD, 1988, CHEST, V94, P185, DOI 10.1378/chest.94.1.185; CHUNG CW, 1954, J BIOL CHEM, V208, P395; Clement P A, 1984, Rhinology, V22, P151; EKRAMODDOULLAH AKM, 1982, MOL IMMUNOL, V19, P1527, DOI 10.1016/0161-5890(82)90263-2; ELKON KB, 1989, HDB IMMUNOBLOTTING P, P51; LELONG M, 1980, REV FR ALLERGOL, V20, P149, DOI 10.1016/S0335-7457(80)80007-4; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALLING HJ, 1987, ALLERGY, V42, P196, DOI 10.1111/j.1398-9995.1987.tb02200.x; Meusel H., 1978, VERGLEICHENDE CHOROL; SHEN HD, 1988, CLIN ALLERGY, V18, P401, DOI 10.1111/j.1365-2222.1988.tb02888.x; TUTIN TG, 1980, FLORA EUROPAEA, P212; VALDES B, 1987, ATLAS POLINICO ANDAL, P215; VOLKIN E, 1957, METHOD BIOCHEM ANAL, V1, P298; WIDE L, 1967, LANCET, V2, P1105; 1983, B EUR PHYSIOPATHOL R, V19, P495	20	37	37	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1992	89	5					987	993		10.1016/0091-6749(92)90221-M	http://dx.doi.org/10.1016/0091-6749(92)90221-M			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HU542	1583253				2022-12-18	WOS:A1992HU54200009
J	MULLOL, J; RAPHAEL, GD; LUNDGREN, JD; BARANIUK, JN; MERIDA, M; SHELHAMER, JH; KALINER, MA				MULLOL, J; RAPHAEL, GD; LUNDGREN, JD; BARANIUK, JN; MERIDA, M; SHELHAMER, JH; KALINER, MA			COMPARISON OF HUMAN NASAL MUCOSAL SECRETION INVIVO AND INVITRO	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						RESPIRATORY GLYCOCONJUGATES; LACTOFERRIN; EXPLANT CULTURE; ALBUMIN; METHACHOLINE; ATROPINE; HISTAMINE; ALPHA-AGONISTS; BETA-AGONISTS	PATHO-PHYSIOLOGY; MUCOUS GLYCOPROTEINS; HUMAN AIRWAYS; RHINITIS; RELEASE; HISTAMINE; PROTEIN; LOCALIZATION; LACTOFERRIN; STIMULATION	The secretion of proteins from the human nasal mucosa induced by histamine, alpha-adrenergic, beta-adrenergic, and cholinergic agonists was studied in vivo and in vitro. Glandular secretion of lactoferrin, lysozyme (in vivo only), and respiratory glycoconjugates (RGCs) was measured. Vascular permeability was determined in vivo by albumin secretion in relationship to the other proteins. Muscarinic stimulation by methacholine induced significant glandular secretion (lactoferrin, lysozyme and/or RCGs) both in vivo and in vitro, confirming that muscarinic receptors are stimulated directly. Histamine induced predominantly vascular permeability in vivo but caused some glandular secretion as well. However, in vitro, histamine had no effect on glandular secretion, suggesting that histamine acts predominantly on the nasal vascular bed and only affects glandular secretion through reflex actions. Phenylephrine, an alpha-adrenergic agonist, selectively stimulated lysozyme release in vivo, and both RGCs and lactoferrin release in vitro. Thus, alpha-adrenergic stimulation has some direct, albeit minimal, capacity to stimulate mucosal glands. Beta-Adrenergic agonists had no effect on glandular secretion or vascular permeability either in vivo or in vitro. Therefore, glandular secretion is directly stimulated by alpha-adrenergic and cholinergic agonists, but not by beta-adrenergic agonists. The stimulation of glandular secretion by histamine is indirect and mediated through the action of neural reflexes.	NIAID,CLIN INVEST LAB,ALLERG DIS SECT,BLDG 10,RM 11-C-205,9000 ROCKVILLE PIKE,BETHESDA,MD 20892; NIH,CTR CLIN,DEPT CRIT CARE MED,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)			Lundgren, Jens/AAE-6876-2019	Baraniuk, James Nicholas/0000-0002-1866-4177; Lundgren, Jens/0000-0001-8901-7850				BARANIUK J N, 1988, American Review of Respiratory Disease, V137, P231; BASBAUM C, 1985, J CELL BIOL, V101, P232; BASBAUM CB, 1986, ARCH BIOCHEM BIOPHYS, V249, P363, DOI 10.1016/0003-9861(86)90012-3; BASBAUM CB, 1981, CELL TISSUE RES, V220, P481, DOI 10.1007/BF00216752; BOAT TF, 1975, CHEST, V67, pS32, DOI 10.1378/chest.67.2.32S; BORSON DB, 1980, J APPL PHYSIOL, V49, P1027, DOI 10.1152/jappl.1980.49.6.1027; BOWES D, 1981, THORAX, V36, P108, DOI 10.1136/thx.36.2.108; CREETH JM, 1977, BIOCHEM J, V167, P557, DOI 10.1042/bj1670557; DAVIS B, 1979, CLIN RES, V27, P55; DRUCE HM, 1985, J ALLERGY CLIN IMMUN, V76, P445, DOI 10.1016/0091-6749(85)90725-0; DRUCE HM, 1984, J APPL PHYSIOL, V57, P1276, DOI 10.1152/jappl.1984.57.4.1276; LIEDTKE CM, 1982, CHEST, V81, pS20, DOI 10.1378/chest.81.5_Supplement.20S; LOPEZVIDRIERO MT, 1977, THORAX, V32, P734, DOI 10.1136/thx.32.6.734; MEREDITH SD, 1989, J ALLERGY CLIN IMMUN, V84, P920, DOI 10.1016/0091-6749(89)90390-4; METCALF JA, 1986, LABORATORY MANUAL NE, P149; PATOW CA, 1984, AM J OTOLARYNG, V5, P334, DOI 10.1016/S0196-0709(84)80003-4; PATOW CA, 1984, OTOLARYNG HEAD NECK, V92, P424, DOI 10.1177/019459988409200410; PHIPPS RJ, 1982, CHEST, V81, pS19, DOI 10.1378/chest.81.5_Supplement.19S; PHIPPS RJ, 1980, AM REV RESPIR DIS, V121, P359; PHIPPS RJ, 1982, CLIN SCI, V63, P23, DOI 10.1042/cs0630023; PLATSHON LF, 1978, J CLIN INVEST, V62, P1113, DOI 10.1172/JCI109230; RAPHAEL G, 1989, J ALLERGY CLIN IMMUN, V83, P110, DOI 10.1016/0091-6749(89)90484-3; RAPHAEL GD, 1988, AM REV RESPIR DIS, V138, P413, DOI 10.1164/ajrccm/138.2.413; RAPHAEL GD, 1989, J CLIN INVEST, V84, P1528, DOI 10.1172/JCI114329; RAPHAEL GD, 1989, AM REV RESPIR DIS, V139, P791, DOI 10.1164/ajrccm/139.3.791; SHELHAMER JH, 1984, EXP LUNG RES, V7, P149, DOI 10.3109/01902148409069675; SHELHAMER JH, 1980, J CLIN INVEST, V66, P1400, DOI 10.1172/JCI109993; TOMMOY M, 1983, CELL TISSUE RES, V228, P549; UEKI I, 1980, AM REV RESPIR DIS, V121, P351; WOODWARD H, 1982, BIOCHEMISTRY-US, V21, P694, DOI 10.1021/bi00533a017	30	37	41	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1992	89	2					584	592		10.1016/0091-6749(92)90326-W	http://dx.doi.org/10.1016/0091-6749(92)90326-W			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HD753	1740587				2022-12-18	WOS:A1992HD75300011
J	KUROHARA, ML; KWONG, FK; LEBHERZ, TB; KLAUSTERMEYER, WB				KUROHARA, ML; KWONG, FK; LEBHERZ, TB; KLAUSTERMEYER, WB			METRONIDAZOLE HYPERSENSITIVITY AND ORAL DESENSITIZATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							IMMEDIATE HYPERSENSITIVITY; MEDIATORS		UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								PATTERSON R, 1988, J ALLERGY CLIN IMMUN, V81, P380, DOI 10.1016/0091-6749(88)90905-0; SERAFIN WE, 1987, NEW ENGL J MED, V317, P30, DOI 10.1056/NEJM198707023170106; SULLIVAN TJ, 1982, J ALLERGY CLIN IMMUN, V69, P275, DOI 10.1016/S0091-6749(82)80004-3; SULLIVAN TJ, 1984, J ALLERGY CLIN IMMUN, V74, P594, DOI 10.1016/0091-6749(84)90112-X; WASSERMAN SI, 1983, J ALLERGY CLIN IMMUN, V72, P101, DOI 10.1016/0091-6749(83)90512-2	5	37	40	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1991	88	2					279	280		10.1016/0091-6749(91)90341-K	http://dx.doi.org/10.1016/0091-6749(91)90341-K			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GB225	1880329	Bronze			2022-12-18	WOS:A1991GB22500020
J	BACKER, V; DIRKSEN, A; BACHMORTENSEN, N; HANSEN, KK; MOSFELDTLAURSEN, E; WENDELBOE, D				BACKER, V; DIRKSEN, A; BACHMORTENSEN, N; HANSEN, KK; MOSFELDTLAURSEN, E; WENDELBOE, D			THE DISTRIBUTION OF BRONCHIAL RESPONSIVENESS TO HISTAMINE AND EXERCISE IN 527 CHILDREN AND ADOLESCENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						BRONCHIAL RESPONSIVENESS; DISTRIBUTION; HISTAMINE CHALLENGE; EXERCISE; CHILDREN	INHALED HISTAMINE; AIRWAY HYPERRESPONSIVENESS; AUSTRALIAN SCHOOLCHILDREN; RESPIRATORY SYMPTOMS; ASTHMATIC-CHILDREN; METHACHOLINE; PREVALENCE; REACTIVITY; POPULATION; CHALLENGE	The aim of the study was to describe the bronchial responsiveness to inhaled histamine and exercise in a randomly selected group of 527 children and adolescents from Copenhagen, aged between 7 to 16 years. The distribution of the bronchial responsiveness was described as (1) the provoking concentration that causes a 20% reduction in FEV1. (2) the dose-response slope (DRS), that is, the linear slope of the dose-response curve, and (3) reduction in FEV1 after 6 minutes of exercise on a treadmill. The distribution of the concentration that causes a 20% reduction in FEV1 in the responsive range was not significantly different from a unimodal distribution, although the findings were skewed toward the less responsive end of the range (p > 0.05). The subjects with asthma represented a subgroup within the responsive distribution tail rather than a separate distribution peak. In asymptomatic individuals, the values of DRS were distributed symmetrically on a logarithmic scale. The deviation from normal was such that the standard deviation only slightly underestimated the "normal" range. The distribution of the bronchial response to exercise was found to be significantly different from a normal distribution. However, a significant relationship was found between the bronchial response to inhaled histamine and exercise (p < 0.0001). We conclude that there is a log-normal distribution of the bronchial response to inhaled histamine in a random sample of children and adolescents.	UNIV COPENHAGEN,RIGSHOSP,DEPT INTERNAL MED B,RESP PHYSIOL LAB,DK-2100 COPENHAGEN,DENMARK; UNIV COPENHAGEN,RIGSHOSP,DEPT PEDIAT GGK,DK-2100 COPENHAGEN,DENMARK; UNIV COPENHAGEN,RIGSHOSP,DEPT INTERNAL MED,TTA ALLERGY UNIT,DK-2100 COPENHAGEN,DENMARK; UNIV COPENHAGEN,RIGSHOSP,RESP PHYSIOL LAB,DK-2100 COPENHAGEN,DENMARK	Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen			Backer, Vibeke/I-9573-2014; Backer, Vibeke/AAQ-9379-2021	Backer, Vibeke/0000-0002-7806-7219; 				ANDERTON RC, 1979, J ALLERGY CLIN IMMUN, V63, P315, DOI 10.1016/0091-6749(79)90125-8; BACKER V, 1989, ALLERGY, V44, P214, DOI 10.1111/j.1398-9995.1989.tb02265.x; BRAMAN SS, 1987, CHEST, V91, P671, DOI 10.1378/chest.91.5.671; COCKCROFT DW, 1983, CHEST, V83, P751, DOI 10.1378/chest.83.5.751; COCKCROFT DW, 1988, ANN ALLERGY, V60, P465; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; FORESI A, 1986, CHEST, V90, P822, DOI 10.1378/chest.90.6.822; FOURIE PR, 1988, PEDIATR PULM, V4, P2, DOI 10.1002/ppul.1950040103; GODFREY S, 1975, J ALLERGY CLIN IMMUN, V56, P1, DOI 10.1016/0091-6749(75)90029-9; HOPP RJ, 1985, J ALLERGY CLIN IMMUN, V76, P609, DOI 10.1016/0091-6749(85)90783-3; HOPP RJ, 1990, AM REV RESPIR DIS, V141, P2, DOI 10.1164/ajrccm/141.1.2; KONIG P, 1973, ARCH DIS CHILD, V48, P513, DOI 10.1136/adc.48.7.513; MELLIS CM, 1978, AM REV RESPIR DIS, V117, P911; OCONNOR G, 1987, AM REV RESPIR DIS, V136, P1412, DOI 10.1164/ajrccm/136.6.1412; OCONNOR GT, 1989, AM REV RESPIR DIS, V140, P225, DOI 10.1164/ajrccm/140.1.225; PEAT JK, 1989, CLIN EXP ALLERGY, V19, P299, DOI 10.1111/j.1365-2222.1989.tb02387.x; PRIDE NB, 1989, EUR RESPIR J, V1, P87; PRIDE NB, 1989, EUR RESPIR J, V1, P485; RAMSDALE EH, 1985, THORAX, V40, P422, DOI 10.1136/thx.40.6.422; SALOME CM, 1987, CLIN ALLERGY, V17, P271, DOI 10.1111/j.1365-2222.1987.tb02015.x; SEARS M R, 1984, Australian and New Zealand Journal of Medicine, V14, P542; SEARS MR, 1986, THORAX, V41, P283, DOI 10.1136/thx.41.4.283; TATTERSFIELD AE, 1988, EUR RESPIR J, V1, P476; TOWNLEY RG, 1986, J ALLERGY CLIN IMMUN, V77, P101, DOI 10.1016/0091-6749(86)90330-1; WOOLCOCK AJ, 1987, THORAX, V42, P361, DOI 10.1136/thx.42.5.361; ZAPLETAL A, 1987, METHODS REFERENCE VA, P1	26	37	37	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1991	88	1					68	76		10.1016/0091-6749(91)90302-5	http://dx.doi.org/10.1016/0091-6749(91)90302-5			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FY204	2071786	Bronze			2022-12-18	WOS:A1991FY20400008
J	EGGLESTON, PA; ANSARI, AA; ZIEMANN, B; ADKINSON, NF; CORN, M				EGGLESTON, PA; ANSARI, AA; ZIEMANN, B; ADKINSON, NF; CORN, M			OCCUPATIONAL CHALLENGE STUDIES WITH LABORATORY WORKERS ALLERGIC TO RATS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT ENVIRONM HLTH SCI,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT IMMUNOL & INFECT DIS,BALTIMORE,MD 21218	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030532] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021073] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30532] Funding Source: Medline; NIAID NIH HHS [AI21073] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAUMGARTEN CR, 1986, J IMMUNOL, V137, P977; BEESON MF, 1983, CLIN ALLERGY, V13, P433, DOI 10.1111/j.1365-2222.1983.tb02619.x; BOWES SM, 1989, AEROSOL SCI TECH, V11, P157, DOI 10.1080/02786828908959308; BRODER I, 1974, J ALLERGY CLIN IMMUN, V53, P127, DOI 10.1016/0091-6749(74)90001-3; BRUCE CA, 1975, J ALLERGY CLIN IMMUN, V56, P331, DOI 10.1016/0091-6749(75)90126-8; CARTIER A, 1984, J ALLERGY CLIN IMMUN, V74, P261, DOI 10.1016/0091-6749(84)90256-2; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; COCKCROFT A, 1981, LANCET, V1, P827; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1979, AM REV RESPIR DIS, V120, P1053; CORN M, 1988, ANN OCCUP HYG     S1, V32, P435; EGGLESTON PA, 1989, J ALLERGY CLIN IMMUN, V84, P347, DOI 10.1016/0091-6749(89)90419-3; FINDLAY SR, 1983, AM REV RESPIR DIS, V128, P1008; FREIDHOFF LR, 1983, J ALLERGY CLIN IMMUN, V72, P274, DOI 10.1016/0091-6749(83)90032-5; GROSS NJ, 1980, J ALLERGY CLIN IMMUN, V66, P158, DOI 10.1016/0091-6749(80)90064-0; HOUNAM RF, 1971, INHALED PARTICLES, V3, P71; IMANARI T, 1976, DHEW NIH76791 PUBL, P205; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; NIINIMAA V, 1980, RESP PHYSIOL, V42, P61, DOI 10.1016/0034-5687(80)90104-8; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; PLATTSMILLS TAE, 1986, J ALLERGY CLIN IMMUN, V77, P850, DOI 10.1016/0091-6749(86)90383-0; PRICE JA, 1988, CLIN ALLERGY, V18, P95, DOI 10.1111/j.1365-2222.1988.tb02848.x; SALTIN B, 1967, J APPL PHYSIOL, V23, P353, DOI 10.1152/jappl.1967.23.3.353; SCHUMACHER MJ, 1981, J ALLERGY CLIN IMMUN, V68, P310, DOI 10.1016/0091-6749(81)90157-3; SIRAGANIAN R, 1974, ANAL BIOCHEM, V57, P283; STUART BO, 1984, ENVIRON HEALTH PERSP, V55, P369, DOI 10.2307/3429715; TOWNLEY RG, 1965, J ALLERGY, V36, P121, DOI 10.1016/0021-8707(65)90161-9; VAN ARSDEL P P Jr, 1959, Acta Genet Stat Med, V9, P101; VANMETRE TE, 1986, J ALLERGY CLIN IMMUN, V78, P62, DOI 10.1016/0091-6749(86)90116-8; WOOLCOCK AJ, 1985, AIRWAY RESPONSIVENES, P80	31	37	37	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1990	86	1					63	72		10.1016/S0091-6749(05)80124-1	http://dx.doi.org/10.1016/S0091-6749(05)80124-1			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DQ688	2196304				2022-12-18	WOS:A1990DQ68800010
J	OHNISHI, M; RUHNO, J; BIENENSTOCK, J; DOLOVICH, J; DENBURG, JA				OHNISHI, M; RUHNO, J; BIENENSTOCK, J; DOLOVICH, J; DENBURG, JA			HEMATOPOIETIC GROWTH-FACTOR PRODUCTION BY CULTURED-CELLS OF HUMAN NASAL POLYP EPITHELIAL SCRAPINGS - KINETICS, CELL SOURCE, AND RELATIONSHIP TO CLINICAL STATUS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MCMASTER UNIV,DEPT MED,HAMILTON L8S 4L8,ONTARIO,CANADA; MCMASTER UNIV,DEPT PATHOL,HAMILTON L8S 4L8,ONTARIO,CANADA; MCMASTER UNIV,DEPT PEDIAT,HAMILTON L8S 4L8,ONTARIO,CANADA	McMaster University; McMaster University; McMaster University								BAGBY GC, 1986, J CLIN INVEST, V78, P1316, DOI 10.1172/JCI112717; BEFUS AD, 1982, J IMMUNOL, V128, P2475; CAUNA N, 1972, ANN OTO RHINOL LARYN, V81, P41, DOI 10.1177/000348947208100105; DENBURG JA, 1980, IMMUNOLOGY, V41, P195; DENBURG JA, 1985, CLIN RES, V33, pA160; DENBURG JA, 1986, LYMPHOKINE RES, V5, P261; DENBURG JA, 1980, J CLIN INVEST, V65, P390, DOI 10.1172/JCI109682; DENBURG JA, 1985, J ALLERGY CLIN IMMUN, V76, P466, DOI 10.1016/0091-6749(85)90728-6; DENBURG JA, IN PRESS INT ARCH AL; DENBURG JA, 1986, MAST CELL DIFFERENTI, P379; DONOVAN R, 1970, INT ARCH ALLER A IMM, V37, P154, DOI 10.1159/000230229; DRAKELEE AB, 1984, J LARYNGOL OTOL, V98, P285, DOI 10.1017/S0022215100146584; ENERBACK L, 1986, INT ARCH ALLER A IMM, V80, P44, DOI 10.1159/000234024; Enerback L., 1981, MONOGR ALLERGY, V17, P222; FUNG MC, 1984, NATURE, V307, P233, DOI 10.1038/307233a0; GRAPPER RM, 1983, J IMMUNOL, V131, P923; GUYGRAND D, 1984, J EXP MED, V160, P12, DOI 10.1084/jem.160.1.12; HAIG DM, 1983, P NATL ACAD SCI-BIOL, V80, P4499, DOI 10.1073/pnas.80.14.4499; HAIG DM, 1982, NATURE, V300, P189; HASTIE R, 1979, LAB INVEST, V40, P554; HUTTTAYLOR SR, 1988, BLOOD, V71, P209; KITAMURA Y, 1978, BLOOD, V52, P447; KITAMURA Y, 1977, NATURE, V268, P442, DOI 10.1038/268442a0; KITAMURA Y, 1979, J EXP MED, V150, P482, DOI 10.1084/jem.150.3.482; LECHNER JF, 1981, CANCER RES, V41, P2294; LEVISCHAFFER F, 1987, J IMMUNOL, V139, P494; LUGER TA, 1985, J IMMUNOL, V134, P915; MYGIND N, 1975, INT ARCH ALLER A IMM, V49, P99, DOI 10.1159/000231383; NAGATA S, 1986, NATURE, V319, P415, DOI 10.1038/319415a0; NAKANO T, 1985, J EXP MED, V162, P1025, DOI 10.1084/jem.162.3.1025; OHNISHI M, 1988, J ALLERGY CLIN IMMUN, V81, P1149, DOI 10.1016/0091-6749(88)90883-4; OHNISHI M, IN PRESS AM REV RESP; OKUDA M, 1977, ARCH OTO-RHINO-LARYN, V214, P283, DOI 10.1007/BF00457469; OTSUKA H, 1985, J ALLERGY CLIN IMMUN, V76, P695, DOI 10.1016/0091-6749(85)90673-6; OTSUKA H, 1986, AM REV RESPIR DIS, V133, P757; OTSUKA H, 1986, J ALLERGY CLIN IMMUN, V78, P365, DOI 10.1016/S0091-6749(86)80091-4; OTSUKA H, 1987, AM REV RESPIR DIS, V136, P710, DOI 10.1164/ajrccm/136.3.710; OTSUKA H, 1977, ARCH OTORHINOLARYNGO, V233, P227; OWEN WF, 1987, J EXP MED, V166, P129, DOI 10.1084/jem.166.1.129; ROTHENBERG ME, 1987, SCIENCE, V237, P645, DOI 10.1126/science.3110954; SCHLEIMER RP, 1985, J ALLERGY CLIN IMMUN, V76, P369, DOI 10.1016/0091-6749(85)90656-6; SETTIPANE GA, 1977, J ALLERGY CLIN IMMUN, V59, P17, DOI 10.1016/0091-6749(77)90171-3; TANNO Y, 1987, INT ARCH ALLER A IMM, V83, P1, DOI 10.1159/000234322; WU R, 1985, AM REV RESPIR DIS, V132, P311; YANKASKAS JR, 1985, AM REV RESPIR DIS, V132, P1281	45	37	37	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1989	83	6					1091	1100		10.1016/0091-6749(89)90451-X	http://dx.doi.org/10.1016/0091-6749(89)90451-X			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC235	2659645				2022-12-18	WOS:A1989AC23500013
J	REISMAN, RE; LANTNER, R				REISMAN, RE; LANTNER, R			FURTHER OBSERVATIONS OF STOPPING VENOM IMMUNOTHERAPY - COMPARISON OF PATIENTS STOPPED BECAUSE OF A FALL IN SERUM VENOM SPECIFIC IGE TO INSIGNIFICANT LEVELS WITH PATIENTS STOPPED PREMATURELY BY SELF-CHOICE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											REISMAN, RE (corresponding author), SUNY BUFFALO, BUFFALO GEN HOSP, DEPT MED, ALLERGY RES LAB, 100 HIGH ST, BUFFALO, NY 14203 USA.							GEORGITIS JW, 1985, J ALLERGY CLIN IMMUN, V76, P803, DOI 10.1016/0091-6749(85)90752-3; GOLDEN DBK, 1986, J ALLERGY CLIN IMMUN, V77, P435, DOI 10.1016/0091-6749(86)90177-6; GOLDEN DBK, 1987, J ALLERGY CLIN IMMUN, V79, P126; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; LIGHT WC, 1976, CLIN ALLERGY, V6, P293, DOI 10.1111/j.1365-2222.1976.tb01909.x; RANDOLPH CC, 1986, J ALLERGY CLIN IMMUN, V77, P823, DOI 10.1016/0091-6749(86)90379-9; REISMAN RE, 1985, J ALLERGY CLIN IMMUN, V75, P731, DOI 10.1016/0091-6749(85)90103-4; SAVLIWALA MN, 1987, J ALLERGY CLIN IMMUN, V80, P741, DOI 10.1016/0091-6749(87)90296-X; SCHUBERTH KC, 1987, J ALLERGY CLIN IMMUN, V79, P126; SCHUBERTH KC, 1982, J PEDIATR-US, V100, P546, DOI 10.1016/S0022-3476(82)80750-6; VALENTINE MD, 1984, J ALLERGY CLIN IMMUN, V73, P299, DOI 10.1016/0091-6749(84)90397-X	11	37	37	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1989	83	6					1049	1054		10.1016/0091-6749(89)90446-6	http://dx.doi.org/10.1016/0091-6749(89)90446-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC235	2732405				2022-12-18	WOS:A1989AC23500007
J	ZUBER, P; PECOUD, A				ZUBER, P; PECOUD, A			EFFECT OF LEVOCABASTINE, A NEW H-1 ANTAGONIST, IN A CONJUNCTIVAL PROVOCATION TEST WITH ALLERGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CHU VAUDOIS,DEPT MED,DIV ALLERGY & CLIN IMMUNOL,CH-1011 LAUSANNE,SWITZERLAND	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)								ALLANSMITH MR, 1984, J ALLERGY CLIN IMMUN, V73, P49, DOI 10.1016/0091-6749(84)90483-4; BISGAARD H, 1985, ALLERGY, V40, P417, DOI 10.1111/j.1398-9995.1985.tb02680.x; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; DVORACEK JE, 1984, J ALLERGY CLIN IMMUN, V73, P363, DOI 10.1016/0091-6749(84)90409-3; EASTY D, 1973, CLIN ALLERGY, V2, P100; FOGLEHANSSON M, 1979, ACTA OTOLARYNGOL S, V360, P33; FRIEDLAENDER MH, 1985, J ALLERGY CLIN IMMUN, V76, P645, DOI 10.1016/0091-6749(85)90664-5; HARGREAVE FE, 1974, CAN MED ASSOC J, V110, P415; HERXHEIMER H, 1952, INT ARCH ALLER A IMM, V3, P323, DOI 10.1159/000227979; KIRKEGAARD J, 1982, ALLERGY, V37, P203, DOI 10.1111/j.1398-9995.1982.tb01897.x; KOLLY M, 1986, BRIT J CLIN PHARMACO, V22, P389, DOI 10.1111/j.1365-2125.1986.tb02907.x; MOLLER C, 1984, ALLERGY, V39, P37, DOI 10.1111/j.1398-9995.1984.tb01931.x; NICOD L, 1985, PROG RESPIR RES, V19, P226; Noon L, 1911, LANCET, V1, P1572; PIPKORN U, 1985, ALLERGY, V40, P491, DOI 10.1111/j.1398-9995.1985.tb00255.x; STOKBROEKX RA, 1986, DRUG DEVELOP RES, V8, P87, DOI 10.1002/ddr.430080111	16	37	37	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1988	82	4					590	594		10.1016/0091-6749(88)90969-4	http://dx.doi.org/10.1016/0091-6749(88)90969-4			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q6399	2902114	Bronze			2022-12-18	WOS:A1988Q639900009
J	MELTZER, EO; STORMS, WW; PIERSON, WE; CUMMINS, LH; ORGEL, HA; PERHACH, JL; HEMSWORTH, GR				MELTZER, EO; STORMS, WW; PIERSON, WE; CUMMINS, LH; ORGEL, HA; PERHACH, JL; HEMSWORTH, GR			EFFICACY OF AZELASTINE IN PERENNIAL ALLERGIC RHINITIS - CLINICAL AND RHINOMANOMETRIC EVALUATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											MELTZER, EO (corresponding author), ALLERGY & ASTHMA MED GRP & RES CTR,3444 KEARNY VILLA RD,SAN DIEGO,CA 92123, USA.							ATKINS P, 1984, J ALLERGY CLIN IMMUN, V75, P167; CHAND N, 1985, J ALLERGY CLIN IMMUN, V75, P194, DOI 10.1016/0091-6749(85)90495-6; CHAND N, 1983, J ALLERGY CLIN IMMUN, V71, P149, DOI 10.1016/0091-6749(83)90365-2; CHAND N, 1985, PHARMACOLOGIST, V27, P162; CONNELL JT, 1985, ANN ALLERGY, V55, P392; CONNELL JT, 1982, ANN ALLERGY, V49, P179; CONNELL JT, 1979, ANN ALLERGY, V42, P278; DIAMANTIS W, 1984, Journal of Allergy and Clinical Immunology, V73, P184; Diamantis W., 1981, PHARMACOLOGIST, V23, P149; DIAMOND L, 1981, ANN ALLERGY, V47, P87; FALLIERS CJ, 1980, ANN ALLERGY, V45, P75; KEMP JP, 1985, ANN ALLERGY, V54, P502; KEMP JP, 1987, J ALLERGY CLIN IMMUN, V79, P893, DOI 10.1016/0091-6749(87)90238-7; OLLIER S, 1986, J ALLERGY CLIN IMMUN, V78, P358, DOI 10.1016/S0091-6749(86)80090-2; PERHACH J, 1984, Journal of Allergy and Clinical Immunology, V73, P144; STORMS W, 1985, J ALLERGY CLIN IMMUN, V75, P167, DOI 10.1016/0091-6749(85)90386-0; WEILER JM, 1986, J ALLERGY CLIN IMMUN, V77, P180; WIHL JA, 1985, J ALLERGY CLIN IMMUN, V75, P720, DOI 10.1016/0091-6749(85)90100-9	18	37	40	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1988	82	3	1				447	455		10.1016/0091-6749(88)90018-8	http://dx.doi.org/10.1016/0091-6749(88)90018-8			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q3229	3170993				2022-12-18	WOS:A1988Q322900019
J	WALDEN, SM; PROUD, D; BASCOM, R; LICHTENSTEIN, LM; KAGEYSOBOTKA, A; ADKINSON, NF; NACLERIO, RM				WALDEN, SM; PROUD, D; BASCOM, R; LICHTENSTEIN, LM; KAGEYSOBOTKA, A; ADKINSON, NF; NACLERIO, RM			EXPERIMENTALLY INDUCED NASAL ALLERGIC RESPONSES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,DEPT MED,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,DIV CLIN IMMUNOL,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,DEPT OTOLARYNGOL,BALTIMORE,MD 21218	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University					NHLBI NIH HHS [HL 32272] Funding Source: Medline; NIAID NIH HHS [AI 08270] Funding Source: Medline; NINDS NIH HHS [NS 22488] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032272] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI008270, R37AI008270] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022488] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADKINSON NF, 1977, J LAB CLIN MED, V90, P1043; BASCOM R, 1986, CLIN RES, V34, pA625; BASCOM R, 1986, J ALLERGY CLIN IMMUN, V77, P246; BAUMGARTEN CR, 1986, J IMMUNOL, V137, P1323; BAUMGARTEN CR, 1986, J IMMUNOL, V137, P977; BROWN MS, 1987, ARCH OTOLARYNGOL, V113, P179; CASALE TB, 1987, J ALLERGY CLIN IMMUN, V79, P246; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; FERREIRA SH, 1971, NATURE-NEW BIOL, V231, P237, DOI 10.1038/newbio231237a0; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P160, DOI 10.1016/0091-6749(82)90037-9; GOETZL EJ, 1981, MED CLIN N AM, V65, P809, DOI 10.1016/S0025-7125(16)31499-7; GOMEZ E, 1986, J ALLERGY CLIN IMMUN, V78, P637, DOI 10.1016/0091-6749(86)90082-5; HAYES EC, 1983, J IMMUNOL, V131, P429; ILIOPOULOS O, 1987, J ALLERGY CLIN IMMUN, V790, P253; IMANARI T, 1976, DHEW NIH76791 PUBL, P205; LAVKER RM, 1985, J IMMUNOL, V135, P2868; LEIKAUF GD, 1985, AM J PHYSIOL, V248, pF48, DOI 10.1152/ajprenal.1985.248.1.F48; MARONE G, 1979, J IMMUNOL, V123, P1659; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; PATERSON NAM, 1981, J ALLERGY CLIN IMMUN, V67, P426, DOI 10.1016/0091-6749(81)90095-6; PETERS SP, 1985, AM REV RESPIR DIS, V132, P367; PETERS SP, 1984, J IMMUNOL, V132, P1972; PIPKORN U, 1987, J CLIN INVEST, V80, P957, DOI 10.1172/JCI113188; PIPKORN U, 1987, NEW ENGL J MED, V316, P1506, DOI 10.1056/NEJM198706113162403; PROUD D, 1983, J CLIN INVEST, V72, P1678, DOI 10.1172/JCI111127; SCHULMAN ES, 1981, AM REV RESPIR DIS, V124, P402; SHEPHARD EG, 1985, BRIT J CLIN PHARMACO, V19, P459, DOI 10.1111/j.1365-2125.1985.tb02671.x; SIRAGANIAN R, 1974, ANAL BIOCHEM, V57, P283; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0	30	37	37	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1988	81	5	2	S			940	949		10.1016/0091-6749(88)90157-1	http://dx.doi.org/10.1016/0091-6749(88)90157-1			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N7037	3372915				2022-12-18	WOS:A1988N703700002
J	FALTHMAGNUSSON, K; KJELLMAN, NIM; MAGNUSSON, KE				FALTHMAGNUSSON, K; KJELLMAN, NIM; MAGNUSSON, KE			ANTIBODIES IGG, IGA, AND IGM TO FOOD ANTIGENS DURING THE 1ST 18 MONTHS OF LIFE IN RELATION TO FEEDING AND DEVELOPMENT OF ATOPIC DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									LINKOPING UNIV,FAC HLTH SCI,DEPT PEDIAT,S-58183 LINKOPING,SWEDEN; LINKOPING UNIV,FAC HLTH SCI,DEPT MED MICROBIOL,S-58183 LINKOPING,SWEDEN	Linkoping University; Linkoping University				Magnusson, Karl-Eric/0000-0002-7809-8437				ANDERSSON U, 1981, ACTA PAEDIATR SCAND, V70, P837, DOI 10.1111/j.1651-2227.1981.tb06236.x; BRAMBELL FWR, 1970, TRANSMISSION PASSIVE, P242; BRANDTZAEG P, 1987, FOOD ALLERGY INTOLER, P119; BUSINCO L, 1983, CLIN ALLERGY, V13, P503, DOI 10.1111/j.1365-2222.1983.tb02631.x; CANT A, 1985, BRIT MED J, V291, P932, DOI 10.1136/bmj.291.6500.932; CASIMIR G, 1985, J ALLERGY CLIN IMMUN, V75, P206, DOI 10.1016/0091-6749(85)90541-X; CHANDRA RK, 1986, CLIN ALLERGY, V16, P563, DOI 10.1111/j.1365-2222.1986.tb01995.x; DANNAEUS A, 1977, ACTA PAEDIATR SCAND, V66, P31, DOI 10.1111/j.1651-2227.1977.tb07803.x; ENGVALL E, 1972, J IMMUNOL, V109, P129; FALLSTROM SP, 1978, INT ARCH ALLER A IMM, V56, P97, DOI 10.1159/000232011; FALLSTROM SP, 1986, CLIN ALLERGY, V16, P417, DOI 10.1111/j.1365-2222.1986.tb01976.x; FALTHMAGNUSSON K, 1987, ALLERGY, V42, P64, DOI 10.1111/j.1398-9995.1987.tb02189.x; FALTHMAGNUSSON K, 1987, J ALLERGY CLIN IMMUN, V80, P868, DOI 10.1016/S0091-6749(87)80279-8; FIRER MA, 1982, CLIN ALLERGY, V12, P385, DOI 10.1111/j.1365-2222.1982.tb02543.x; GERRARD JW, 1986, ANN ALLERGY, V56, P351; JACOBSSON I, 1985, ACTA PAEDIATR SCAND, V74, P342; JARRETT EEE, 1977, LANCET, V2, P223; JARRETT EEE, 1984, IMMUNOLOGY, V53, P365; KILSHAW PJ, 1984, INT ARCH ALLER A IMM, V75, P8, DOI 10.1159/000233582; KJELLMAN NIM, 1979, CLIN ALLERGY, V9, P347, DOI 10.1111/j.1365-2222.1979.tb02493.x; KLETTER B, 1971, INT ARCH ALLER A IMM, V40, P667, DOI 10.1159/000230448; KLETTER B, 1971, INT ARCH ALLER A IMM, V40, P656, DOI 10.1159/000230447; KULANGARA AC, 1980, IRCS MED SCI-BIOCHEM, V8, P19; MAY CD, 1977, CLIN ALLERGY, V7, P583, DOI 10.1111/j.1365-2222.1977.tb01489.x; Shannon WR, 1921, AM J DIS CHILD, V22, P223	25	37	38	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1988	81	4					743	749		10.1016/0091-6749(88)91048-2	http://dx.doi.org/10.1016/0091-6749(88)91048-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N0650	3356852				2022-12-18	WOS:A1988N065000017
J	SKASSABROCIEK, W; BOUSQUET, J; MONTES, F; VERDIER, M; SCHWAB, D; LHERMINIER, M; MICHEL, FB				SKASSABROCIEK, W; BOUSQUET, J; MONTES, F; VERDIER, M; SCHWAB, D; LHERMINIER, M; MICHEL, FB			DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF LORATADINE, MEQUITAZINE, AND PLACEBO IN THE SYMPTOMATIC TREATMENT OF SEASONAL ALLERGIC RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOP AIGUELONGUE,MALAD RESP CLIN,F-34059 MONTPELLIER,FRANCE; LABS UNICET,LEVALLOIS PERRET,FRANCE				Bousquet, Jean/O-4221-2019					BARNETT A, 1984, AGENTS ACTIONS, V14, P590, DOI 10.1007/BF01978891; BATENHORST RL, IN PRESS EUR J CLIN; BOUSQUET J, 1985, CLIN ALLERGY, V15, P29, DOI 10.1111/j.1365-2222.1985.tb02251.x; CALLIER J, 1981, CURR THER RES, V29, P1981; COUR P, 1974, Pollen et Spores, V16, P103; DUGUE P, 1982, ARZNEIMITTEL-FORSCH, V32-2, P1206; LEOPHONTE P, 1984, ALLERGIE IMMUNOLOGIE, V3, P213; NICHOLSON AN, 1983, LANCET, V2, P211; NORMAN PS, 1983, J ALLERGY CLIN IMMUN, V72, P421, DOI 10.1016/0091-6749(83)90577-8; NORMAN PS, 1985, J ALLERGY CLIN IMMUN, V76, P366, DOI 10.1016/0091-6749(85)90655-4; ROMAN IJ, 1986, ANN ALLERGY, V57, P253; ROSSONI G, 1984, ARCH INT PHARMACOD T, V268, P128; WILSON JD, 1983, CLIN ALLERGY, V13, P131, DOI 10.1111/j.1365-2222.1983.tb02580.x	13	37	37	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1988	81	4					725	730		10.1016/0091-6749(88)91045-7	http://dx.doi.org/10.1016/0091-6749(88)91045-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N0650	2965719				2022-12-18	WOS:A1988N065000014
J	OKAYAMA, M; YAFUSO, N; NOGAMI, H; LIN, YN; HORIO, S; HIDA, W; INOUE, H; TAKISHIMA, T				OKAYAMA, M; YAFUSO, N; NOGAMI, H; LIN, YN; HORIO, S; HIDA, W; INOUE, H; TAKISHIMA, T			A NEW METHOD OF INHALATION CHALLENGE WITH PROPRANOLOL - COMPARISON WITH METHACHOLINE-INDUCED BRONCHOCONSTRICTION AND ROLE OF VAGAL NERVE ACTIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TOHOKU UNIV,SCH MED,DEPT INTERNAL MED 1,SENDAI,MIYAGI 980,JAPAN	Tohoku University				Inoue, Hiroshi/0000-0002-9969-2152				GAYRARD P, 1975, THORAX, V30, P657, DOI 10.1136/thx.30.6.657; GILMAN AG, 1985, GOODMAN GILMANS PHAR, P133; GIMENO F, 1972, AM REV RESPIR DIS, V105, P68; GRIECO MH, 1971, J ALLERGY CLIN IMMUN, V48, P143, DOI 10.1016/0091-6749(71)90009-1; HARRISON LI, 1986, AM REV RESPIR DIS, V134, P254; IND P W, 1984, American Review of Respiratory Disease, V129, pA10; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; LANGER I, 1967, J PHYSL, V190, P41; LIU YN, 1985, AM REV RESPIR DIS, V132, P278; MACDONALD AG, 1967, BRIT J ANAESTH, V39, P919, DOI 10.1093/bja/39.12.919; MCNEILL RS, 1964, LANCET, V2, P1101; PAK CCF, 1982, AM REV RESPIR DIS, V125, P331; RICHARDSON PS, 1969, BMJ-BRIT MED J, V3, P143, DOI 10.1136/bmj.3.5663.143; SEKIZAWA K, 1985, J APPL PHYSIOL, V58, P1164, DOI 10.1152/jappl.1985.58.4.1164; SHINDOH C, 1985, AM REV RESPIR DIS, V132, P671; TAKISHIMA T, 1981, CHEST, V80, P600, DOI 10.1378/chest.80.5.600; TAMURA G, 1985, J ALLERGY CLIN IMMUN, V75, P47, DOI 10.1016/0091-6749(85)90011-9; ZAID G, 1966, NEW ENGL J MED, V275, P580, DOI 10.1056/NEJM196609152751103	18	37	38	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1987	80	3	1				291	299		10.1016/0091-6749(87)90034-0	http://dx.doi.org/10.1016/0091-6749(87)90034-0			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K1036	3305663				2022-12-18	WOS:A1987K103600010
J	BUTCHER, BT; SALVAGGIO, JE				BUTCHER, BT; SALVAGGIO, JE			OCCUPATIONAL ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TULANE UNIV,MED CTR,DEPT MED,CLIN IMMUNOL SECT,NEW ORLEANS,LA 70118	Tulane University								ANTWEILER H, 1959, ANN OCCUP HYG, V1, P152; BALFOURLYNN L, 1981, ARCH DIS CHILD, V56, P450, DOI 10.1136/adc.56.6.450; BANKS DE, 1986, CHEST, V89, P389, DOI 10.1378/chest.89.3.389; BAUR X, 1982, CLIN ALLERGY, V12, P9, DOI 10.1111/j.1365-2222.1982.tb03121.x; BROOKS SM, 1985, CHEST, V88, P376, DOI 10.1378/chest.88.3.376; BURGE PS, 1982, EUR J RESPIR DIS, V63, P65; BUTCHER BT, 1980, J ALLERGY CLIN IMMUN, V66, P213, DOI 10.1016/0091-6749(80)90041-X; BUTCHER BT, 1982, EUR J RESPIR DIS, V63, P82; BUTCHER BT, 1976, J ALLERGY CLIN IMMUN, V58, P89, DOI 10.1016/0091-6749(76)90110-X; BUTCHER BT, 1983, CLIN ALLERGY, V13, P31, DOI 10.1111/j.1365-2222.1983.tb02563.x; BUTCHER BT, 1982, J ALLERGY CLIN IMMUN, V70, P231, DOI 10.1016/0091-6749(82)90058-6; BUTCHER BT, 1984, OCCUPATIONAL LUNG DI, P111; CARROLL KB, 1976, CLIN ALLERGY, V6, P99, DOI 10.1111/j.1365-2222.1976.tb01886.x; CHANYEUNG M, 1982, AM J MED, V72, P411, DOI 10.1016/0002-9343(82)90497-1; CHANYEUNG M, 1977, AM REV RESPIR DIS, V116, P1023; CHANYEUNG M, 1973, AM REV RESPIR DIS, V108, P1094; Coca AF, 1923, J IMMUNOL, V8, P163; COOMBS RRA, 1968, LANCET, V1, P1115; DAVIES RJ, 1977, J ALLERGY CLIN IMMUN, V60, P233; DOLOVICH J, 1984, BRIT J IND MED, V41, P51; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; EVANS E, 1974, BRIT J IND MED, V31, P28; FABBRI LM, 1984, ANN ALLERGY, V53, P172; Figley KD, 1928, J AMER MED ASSOC, V90, P79, DOI 10.1001/jama.1928.02690290009003; FINK JN, 1984, J ALLERGY CLIN IMMUN, V74, P1, DOI 10.1016/0091-6749(84)90077-0; HUNTER D, 1945, BRIT J IND MED, V2, P92; ISHIZAKA K, 1966, J IMMUNOL, V97, P840; Johansson S.G.O., 1967, NOBEL S, P193; JONES RN, 1982, AM REV RESPIR DIS, V125, P199; KARASEK SR, 1911, PRELIMINARY REPORT I; KARR RM, 1978, J ALLERGY CLIN IMMUN, V62, P143, DOI 10.1016/0091-6749(78)90098-2; KOBAYASHI S, 1974, ALLERGOLOGY; KUMAR P, 1981, NEW ENGL J MED, V305, P1531, DOI 10.1056/NEJM198112173052515; LEGGE RT, 1936, IND MED, V5, P300; MALO JL, 1983, J ALLERGY CLIN IMMUN, V72, P413, DOI 10.1016/0091-6749(83)90508-0; MATHEWS KP, 1982, JAMA-J AM MED ASSOC, V248, P2587, DOI 10.1001/jama.248.20.2587; NEWHOUSE ML, 1970, LANCET, V1, P689; Pepys J, 1972, Clin Allergy, V2, P391, DOI 10.1111/j.1365-2222.1972.tb01303.x; PEPYS J, 1979, CLIN ALLERGY, V9, P645, DOI 10.1111/j.1365-2222.1979.tb00491.x; PEPYS J, 1978, ALLERGY PRINCIPLES P, P812; RAMAZZINI B, 1964, MORBIS ARTIFICUM; ROBERTS AE, 1951, AMA ARCH IND HYG OCC, V4, P549; SACHARIAE H, 1981, ALLERGY, V36, P513; SALVAGGIO J, 1979, NIH79387 PUBL; SCHILLING RSF, 1956, LANCET, V2, P261; SLAVIN RG, 1971, J ALLERGY CLIN IMMUN, V48, P262, DOI 10.1016/0091-6749(71)90026-1; STJERNBERG N, 1985, EUR J RESPIR DIS, V67, P41; TSE KS, 1982, CLIN ALLERGY, V12, P249, DOI 10.1111/j.1365-2222.1982.tb02525.x; WEILL H, 1979, J ALLERGY CLIN IMMUN, V64, P646; ZEISS CR, 1977, J ALLERGY CLIN IMMUN, V60, P96, DOI 10.1016/0091-6749(77)90033-1; ZEISS CR, 1983, ANN INTERN MED, V98, P8, DOI 10.7326/0003-4819-98-1-8; 1956, US DEP LABOR LISTING	52	37	37	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1986	78	4	1				547	556		10.1016/0091-6749(86)90068-0	http://dx.doi.org/10.1016/0091-6749(86)90068-0			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E5682	3534048				2022-12-18	WOS:A1986E568200001
J	NIELSON, CP; CROWLEY, JJ; CUSACK, BJ; VESTAL, RE				NIELSON, CP; CROWLEY, JJ; CUSACK, BJ; VESTAL, RE			THERAPEUTIC CONCENTRATIONS OF THEOPHYLLINE AND ENPROFYLLINE POTENTIATE CATECHOLAMINE EFFECTS AND INHIBIT LEUKOCYTE ACTIVATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WASHINGTON,DEPT MED,DIV GERONTOL & GERIATR MED,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	NIELSON, CP (corresponding author), VET ADM MED CTR,CLIN PHARMACOL & GERONTOL UNIT,500 W FT ST,BOISE,ID 83702, USA.				NATIONAL INSTITUTE ON AGING [R01AG002901] Funding Source: NIH RePORTER; NIA NIH HHS [AG02901] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BOYUM A, 1968, SCAND J CLIN LAB S97, V21, P1; BUTCHER RW, 1962, J BIOL CHEM, V237, P1244; CHARIBITRON A, 1983, CELL BIOL INT REP, V7, P303, DOI 10.1016/0309-1651(83)90065-6; CRONSTEIN BN, 1983, J EXP MED, V158, P1160, DOI 10.1084/jem.158.4.1160; CRONSTEIN BN, 1985, J IMMUNOL, V135, P1366; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; FREDHOLM BB, 1980, EUR J RESPIR DIS, V61, P29; FREDHOLM BB, 1982, EUR J PHARMACOL, V81, P673, DOI 10.1016/0014-2999(82)90359-4; HORAN TD, 1982, CLIN IMMUNOL IMMUNOP, V22, P259, DOI 10.1016/0090-1229(82)90042-3; KOLBECK RC, 1979, LUNG, V156, P173, DOI 10.1007/BF02714008; LAURSEN LC, 1983, EUR J CLIN PHARMACOL, V24, P323, DOI 10.1007/BF00610048; LEHMEYER JE, 1978, CLIN IMMUNOL IMMUNOP, V9, P482, DOI 10.1016/0090-1229(78)90144-7; MARONE G, 1980, J IMMUNOL, V125, P2277; MILLER JP, 1973, BIOCHEMISTRY-US, V12, P1010, DOI 10.1021/bi00729a035; NIELSON C, 1985, FED PROC, V44, P580; NIELSON CP, 1985, CLIN RES, V33, pA529; PERSSON CGA, 1981, ACTA PHARMACOL TOX, V49, P317; POLSON JB, 1978, CLIN EXP PHARMACOL P, V5, P535; PRYZWANSKY KB, 1981, SCIENCE, V211, P407, DOI 10.1126/science.6261328; SCHELLFR.E, 1974, FEBS LETT, V48, P37, DOI 10.1016/0014-5793(74)81056-2; TOLL JBC, 1984, ALLERGY, V39, P515, DOI 10.1111/j.1398-9995.1984.tb00872.x; WELLS JN, 1983, TRENDS PHARM SCI, V17, P385	22	37	37	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1986	78	4	1				660	667		10.1016/0091-6749(86)90086-2	http://dx.doi.org/10.1016/0091-6749(86)90086-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E5682	2430004				2022-12-18	WOS:A1986E568200016
J	ANDERSON, JA				ANDERSON, JA			THE ESTABLISHMENT OF COMMON LANGUAGE CONCERNING ADVERSE REACTIONS TO FOODS AND FOOD-ADDITIVES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HENRY FORD HOSP,DIV ALLERGY & IMMUNOL,DETROIT,MI 48202	Henry Ford Health System; Henry Ford Hospital	ANDERSON, JA (corresponding author), HENRY FORD HOSP,DEPT PEDIAT,2799 W GRAND BLVD,DETROIT,MI 48202, USA.							ANDERSON JA, 1980, ALLERGIC DISEASES IN, P690; ANDERSON JA, 1982, JAMA, V248, P2637; ANDERSON JA, 1984, NIH842442 PUBL, P4; ANDERSSON R, 1984, ENERG ECON, V6, P122, DOI 10.1016/0140-9883(84)90027-6; BIERMAN CW, 1980, ALLERGIC DISEASES IN, pR13; HANSON LA, 1984, NUTR REV, V42, P137; MAY CD, 1984, NUTR REV, V42, P72, DOI 10.1111/j.1753-4887.1984.tb02293.x; MIDDLETON E, 1983, ALLERGY PRINCIPLES P, pR21; SAMTER M, 1969, EXCERPTS CLASSICS AL, P8; Shaffer J.H., 1959, MECHANISMS HYPERSENS; VAUGHAN WT, 1954, PRACTICE ALLERGY, P9; VAUGHAN WT, 1954, PRACTICE ALLERGY, P271; 1984, JR COLL PHYSICIANS L, V18, P83; 1968, DORLANDS MED DICT, P1364; 1968, WEBSTERS NEW COLLEGI, P29	15	37	37	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1986	78	1	2	S			140	144		10.1016/0091-6749(86)90004-7	http://dx.doi.org/10.1016/0091-6749(86)90004-7			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	D2997	3722641	Bronze			2022-12-18	WOS:A1986D299700004
J	LONGBOTTOM, JL; AUSTWICK, PKC				LONGBOTTOM, JL; AUSTWICK, PKC			ANTIGENS AND ALLERGENS OF ASPERGILLUS-FUMIGATUS .1. CHARACTERIZATION BY QUANTITATIVE IMMUNOELECTROPHORETIC TECHNIQUES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											LONGBOTTOM, JL (corresponding author), BROMPTON HOSP,INST CARDIOTHORAC,DEPT ALLERGY & CLIN IMMUNOL,FULHAM RD,LONDON SW3 6HP,ENGLAND.							AXELSEN NH, 1973, INFECT IMMUN, V7, P949, DOI 10.1128/IAI.7.6.949-960.1973; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; GREENBERGER PA, 1984, J ALLERGY CLIN IMMUN, V74, P645, DOI 10.1016/0091-6749(84)90223-9; HASLAM P, 1976, CLIN ALLERGY, V6, P277, DOI 10.1111/j.1365-2222.1976.tb01908.x; HEARN VM, 1980, J MED MICROBIOL, V13, P451, DOI 10.1099/00222615-13-3-451; HEARN VM, 1980, MYKOSEN, V23, P549; JACOBY B, 1977, CLIN ALLERGY, V7, P117, DOI 10.1111/j.1365-2222.1977.tb01432.x; KAHN ZU, 1984, INT ARCH ALLERGY APP, V73, P205; KAUFFMAN HF, 1983, J ALLERGY CLIN IMMUN, V72, P255, DOI 10.1016/0091-6749(83)90029-5; KAUFFMAN HF, 1980, INT ARCH ALLER A IMM, V62, P252, DOI 10.1159/000232521; KIM SJ, 1978, AM REV RESPIR DIS, V118, P553; KROLL J, 1983, SCAND J IMMUNOL S10, V17, P171; KURUP VP, 1978, MICROBIOS, V19, P191; Longbottom J L, 1978, Mykosen Suppl, V1, P207; LONGBOTTOM JL, 1983, CLIN EXP IMMUNOL, V53, P354; LONGBOTTOM JL, 1983, J ALLERGY CLIN IMMUN, V72, P668, DOI 10.1016/0091-6749(83)90627-9; LONGBOTTOM JL, 1964, J PATHOL BACTERIOL, V88, P141, DOI 10.1002/path.1700880119; LONGBOTTOM JL, 1964, THESIS U LONDON; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALO JL, 1981, CLIN ALLERGY, V11, P333, DOI 10.1111/j.1365-2222.1981.tb01603.x; MALO JL, 1977, THORAX, V32, P269, DOI 10.1136/thx.32.3.269; MALO JL, 1979, CLIN ALLERGY, V9, P377, DOI 10.1111/j.1365-2222.1979.tb02496.x; PEPYS J, 1978, HDB EXPT IMMUNOLOGY, pCH41; REED C, 1978, J ALLERGY CLIN IMMUN, V61, P227, DOI 10.1016/0091-6749(78)90189-6; SALVAGGIO J, 1981, J ALLERGY CLIN IMMUN, V68, P327, DOI 10.1016/0091-6749(81)90131-7; SCHONHEYDER H, 1983, INT ARCH ALLER A IMM, V70, P108, DOI 10.1159/000233306; SEPULVEDA R, 1979, CLIN ALLERGY, V9, P359, DOI 10.1111/j.1365-2222.1979.tb02494.x; WALLENBECK I, 1984, INT ARCH ALLER A IMM, V73, P166, DOI 10.1159/000233459; WILSON EV, 1983, SABOURAUDIA, V21, P195; 1979, BIORAD PROTEIN ASSAY	30	37	37	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1986	78	1	1				9	17		10.1016/0091-6749(86)90108-9	http://dx.doi.org/10.1016/0091-6749(86)90108-9			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	D2996	3522708	Bronze			2022-12-18	WOS:A1986D299600003
J	CARTIER, A; LEMIRE, I; LARCHEVEQUE, J; GHEZZO, H; MARTIN, RR; MALO, JL				CARTIER, A; LEMIRE, I; LARCHEVEQUE, J; GHEZZO, H; MARTIN, RR; MALO, JL			THEOPHYLLINE PARTIALLY INHIBITS BRONCHOCONSTRICTION CAUSED BY INHALED HISTAMINE IN SUBJECTS WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOP SACRE COEUR, DEPT CHEST MED, 5400 W GOUIN BLVD, MONTREAL H4J 1C5, QUEBEC, CANADA	Universite de Montreal								[Anonymous], 1979, AM REV RESPIR DIS, V119, P831; BARNES PJ, 1983, THORAX, V38, P481, DOI 10.1136/thx.38.7.481; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COCKCROFT DW, 1977, THORAX, V32, P429, DOI 10.1136/thx.32.4.429; DECOTIIS B A, 1980, American Review of Respiratory Disease, V121, P125; EISER NM, 1983, B EUR PHYSIOPATH RES, V19, P495; FISCHER RD, 1950, STATISTICAL METHODS, P99; GODFREY S, 1983, ASTHMA, P57; HENDELES L, 1983, PHARMACOTHERAPY, V3, P2; KERSHNER RP, 1981, J AM STAT ASSOC, V76, P612, DOI 10.2307/2287519; KNUDSON RJ, 1976, AM REV RESPIR DIS, V113, P587; LEMIRE I, 1984, J ALLERGY CLIN IMMUN, V73, P234, DOI 10.1016/S0091-6749(84)80013-5; MCWILLIAMS BC, 1984, AM REV RESPIR DIS, V130, P193; MENEELY GR, 1962, AM REV RESPIR DIS, V85, P762; RUFFIN RE, 1981, J ALLERGY CLIN IMMUN, V67, P285, DOI 10.1016/0091-6749(81)90023-3; RYAN G, 1981, AM REV RESPIR DIS, V123, P195; SPECTOR SL, 1978, CHEST, V73, P976, DOI 10.1378/chest.73.6.976; THOMSON NC, 1981, J ALLERGY CLIN IMMUN, V68, P392, DOI 10.1016/0091-6749(81)90138-X; WALTERS EH, 1983, THORAX, V38, P188, DOI 10.1136/thx.38.3.188	21	37	37	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1986	77	4					570	575		10.1016/0091-6749(86)90347-7	http://dx.doi.org/10.1016/0091-6749(86)90347-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	A9381	3958384				2022-12-18	WOS:A1986A938100007
J	BALLOW, M; DONSHIK, PC; MENDELSON, L				BALLOW, M; DONSHIK, PC; MENDELSON, L			COMPLEMENT PROTEINS AND C-3 ANAPHYLATOXIN IN THE TEARS OF PATIENTS WITH CONJUNCTIVITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CONNECTICUT,CTR HLTH,DEPT SURG,FARMINGTON,CT 06032	University of Connecticut	BALLOW, M (corresponding author), UNIV CONNECTICUT,CTR HLTH,DEPT PEDIAT,DIV OPHTHALMOL,FARMINGTON,CT 06032, USA.				NATIONAL EYE INSTITUTE [R01EY002036] Funding Source: NIH RePORTER; NEI NIH HHS [EY-5189, EY-2036] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALLANSMITH M, 1963, J ALLERGY, V34, P535, DOI 10.1016/0021-8707(63)90095-9; ALLANSMITH MR, 1978, J ALLERGY CLIN IMMUN, V61, P154, DOI 10.1016/0091-6749(78)90325-1; ALLANSMITH MR, 1979, AM J OPHTHALMOL, V87, P544, DOI 10.1016/0002-9394(79)90247-2; Allansmith MR, 1982, EYE IMMUNOLOGY, P118; BALLOW M, 1980, J ALLERGY CLIN IMMUN, V66, P112, DOI 10.1016/0091-6749(80)90057-3; BALLOW M, 1983, AM J OPHTHALMOL, V95, P161, DOI 10.1016/0002-9394(83)90009-0; BERNSTEIN JM, 1978, CLIN EXP IMMUNOL, V33, P340; BLUESTONE R, 1975, BRIT J OPHTHALMOL, V59, P279, DOI 10.1136/bjo.59.5.279; BOKISCH VA, 1970, J CLIN INVEST, V49, P2427, DOI 10.1172/JCI106462; BOKISCH VA, 1969, J EXP MED, V129, P1109, DOI 10.1084/jem.129.5.1109; BUNCH TW, 1974, MAYO CLIN PROC, V49, P715; CHANDLER JW, 1974, INVEST OPHTH VISUAL, V13, P151; CHENOWITH DE, 1980, FUTURE PERSPECTIVES, P443; DEUSCHL H, 1974, CLIN EXP IMMUNOL, V16, P401; DONSHIK PC, 1983, AM J OPHTHALMOL, V96, P460, DOI 10.1016/S0002-9394(14)77909-7; EASTY DL, 1979, MAST CELL ITS ROLE H, P493; EINSTEIN LP, 1977, J CLIN INVEST, V60, P963, DOI 10.1172/JCI108876; FEARON DT, 1981, IMMUNE COMPLEXES CLI; HADLER NM, 1973, ARTHRITIS RHEUM, V16, P507, DOI 10.1002/art.1780160411; JOHNSON AR, 1975, IMMUNOLOGY, V28, P1067; LICHTENSTEIN LM, 1968, J IMMUNOL, V101, P317; MATHEWS KP, 1981, J ALLERGY CLIN IMMUN, V68, P46, DOI 10.1016/0091-6749(81)90122-6; MONDINO BJ, 1983, ARCH OPHTHALMOL-CHIC, V101, P465; MONDINO BJ, 1983, INVEST OPHTH VIS SCI, V24, P380; MULLEREBERHARD HJ, 1983, BIOL IMMUNOLOGIC DIS, P129; MULLEREBERHARD HJ, 1980, ADV IMMUNOL, V29, P3; PEREIRA AB, 1980, J IMMUNOL, V125, P763; RICE NSC, 1973, CLIN IMMUNOL ALLERGY, P139; VOLLOTA EH, 1973, J EXP MED, V137, P1109; WEHLER C, 1984, MOL IMMUNOL, V18, P157; WHALEY K, 1980, J EXP MED, V151, P501, DOI 10.1084/jem.151.3.501; YAMAMOTO GK, 1979, AM J OPHTHALMOL, V17, P58	32	37	37	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	3					473	476		10.1016/0091-6749(85)90729-8	http://dx.doi.org/10.1016/0091-6749(85)90729-8			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ARC09	3875643				2022-12-18	WOS:A1985ARC0900009
J	CRAPS, LP				CRAPS, LP			IMMUNOLOGICAL AND THERAPEUTIC ASPECTS OF KETOTIFEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											CRAPS, LP (corresponding author), SANDOZ LTD,DIV PHARMACEUT,CH-4002 BASEL,SWITZERLAND.							BORGE P, 1982, RES CLIN FORUMS, V4, P79; BRETZ U, 1983, EUR J PHARMACOL, V86, P321, DOI 10.1016/0014-2999(83)90180-2; CRAPS L, 1983, PHARMATHERAPEUTICA, V3, P314; CRAPS L, 1981, PHARMATHERAPEUTICA, V3, P18; CRAPS LP, 1985, BRONCHIAL ASTHMA MEC, P734; DAVIES RJ, 1983, 11TH P INT C ALL CLI, P213; DEBELIC M, 1981, DEUT MED WOCHENSCHR, V106, P1704, DOI 10.1055/s-2008-1070580; GIRARD JP, 1977, ACTA ALLERGOL, V32, P27; JENNE JW, 1982, J ALLERGY CLIN IMMUN, V70, P413, DOI 10.1016/0091-6749(82)90002-1; KOETER GH, 1982, EUR J RESPIR DIS, V63, P72; MACLAY WP, 1984, BRIT MED J, V288, P911, DOI 10.1136/bmj.288.6421.911; MARCELLE R, 1977, J PHARMACOL-PARIS, V8, P560; MARTIN U, 1978, ARZNEIMITTELFORSCH, V28-1, P770; MARTIN U, 1981, N-S ARCH PHARMACOL, V316, P186, DOI 10.1007/BF00505315; Martin U, 1981, PHARM BIOCH PROPERTI, V3, P424; MARTIN U, 1977, ALLERGOL IMMUNOPA S5, V5, P5; MORLEY, 1984, LANCET, V2, P1142; NAGY L, 1985, RESPIRATION, V47, P21, DOI 10.1159/000194744; PHILLIPS MJ, 1980, RESPIRATION, V39, P26, DOI 10.1159/000195035; PLATTSMILLS TAE, 1982, LANCET, V2, P675; PODLESKI WK, 1984, AGENTS ACTIONS, V15, P177, DOI 10.1007/BF01972346; RADERMECKER M, 1980, ALLERGOL IMMUNOPATH, V8, P384; ROMANSKI B, 1982, ASTHMA BRONCHIALE BR, P111; ROSS WJ, 1979, J MED CHEM, V22, P412, DOI 10.1021/jm00190a011; SAUNDERS RN, 1983, THROMB HAEMOSTASIS, V50, pA1493	25	37	39	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	2					389	393		10.1016/0091-6749(85)90659-1	http://dx.doi.org/10.1016/0091-6749(85)90659-1			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	APE89	4019961				2022-12-18	WOS:A1985APE8900023
J	LARSEN, GL				LARSEN, GL			LATE-PHASE REACTIONS - OBSERVATIONS ON PATHOGENESIS AND PREVENTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material											LARSEN, GL (corresponding author), UNIV COLORADO,SCH MED,NATL JEWISH CTR IMMUNOL,DEPT PEDIAT,1400 JACKSON ST,DENVER,CO 80206, USA.							BEHRENS BL, 1984, AM REV RESPIR DIS, V130, P1134; BEHRENS BL, 1985, CHEST, V87, pS153, DOI 10.1378/chest.87.5_Supplement.153S; BOOIJNOORD H, 1971, J ALLERGY CLIN IMMUN, V48, P344, DOI 10.1016/0091-6749(71)90080-7; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; Coombs R.R.A., 1963, CLIN ASPECTS IMMUNOL, Vpublication, P317; DELEHUNT JC, 1984, AM REV RESPIR DIS, V130, P748; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DESHAZO RD, 1979, J IMMUNOL, V122, P692; DOLOVICH J, 1972, J ALLERGY CLIN IMMUN, V49, P43, DOI 10.1016/0091-6749(72)90122-4; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; DVORACEK JE, 1984, J ALLERGY CLIN IMMUN, V73, P363, DOI 10.1016/0091-6749(84)90409-3; GLEICH GJ, 1984, ANNU REV IMMUNOL, V2, P429, DOI 10.1146/annurev.immunol.2.1.429; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P160, DOI 10.1016/0091-6749(82)90037-9; GWYNN CM, 1982, LANCET, V1, P254; HARGREAVE FE, 1974, CAN MED ASSOC J, V110, P415; HERXHEIMER H, 1952, INT ARCH ALLER A IMM, V3, P323, DOI 10.1159/000227979; KALINER MM, 1984, J ALLERGY CLIN IMMUN, V73, P311, DOI 10.1016/0091-6749(84)90401-9; LANES S, 1985, American Review of Respiratory Disease, V131, pA45; MARSH WR, 1985, AM REV RESPIR DIS, V131, P875; METZGER WJ, 1985, CHEST, V87, pS155, DOI 10.1378/chest.87.5_Supplement.155S; METZGER WJ, 1985, CLIN REV ALLERG, V3, P145, DOI 10.1007/BF02992980; MURPHY K R, 1985, American Review of Respiratory Disease, V131, pA6; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; NAGY L, 1982, NEW ENGL J MED, V306, P497, DOI 10.1056/NEJM198203043060901; NAKAGAWA T, 1983, INT ARCH ALLER A IMM, V71, P122, DOI 10.1159/000233374; OERTEL HL, 1981, J IMMUNOL, V127, P1398; PAGE CP, 1985, AGENTS ACTIONS, V16, P30, DOI 10.1007/BF01999636; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; PEPYS J, 1968, ALLERGOLOGIE, P221; PINCKARD RN, 1972, J ALLERGY CLIN IMMUN, V49, P301; PRICE JF, 1984, CLIN ALLERGY, V14, P209, DOI 10.1111/j.1365-2222.1984.tb02200.x; ROBERTSON DG, 1974, J ALLERGY CLIN IMMUN, V54, P244, DOI 10.1016/0091-6749(74)90067-0; ROCKLIN RE, 1983, J ALLERGY CLIN IMMUN, V72, P323, DOI 10.1016/0091-6749(83)90492-X; SCHENKEL E, 1982, J ALLERGY CLIN IMMUN, V70, P321, DOI 10.1016/0091-6749(82)90020-3; SHAMPAIN MP, 1982, AM REV RESPIR DIS, V126, P493; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; TANNENBAUM S, 1980, J IMMUNOL, V125, P325; TURNER MW, 1984, CLIN ALLERGY, V14, P221, DOI 10.1111/j.1365-2222.1984.tb02201.x; VANLOVEREN H, 1983, J EXP MED, V157, P1604, DOI 10.1084/jem.157.5.1604; WARNER JO, 1978, LANCET, V2, P912; WARNER JO, 1976, ARCH DIS CHILD, V51, P905, DOI 10.1136/adc.51.12.905; ZETTERSTROM O, 1978, CLIN ALLERGY, V8, P77, DOI 10.1111/j.1365-2222.1978.tb00452.x; ZVAIFLER NJ, 1969, J EXP MED, V130, P907, DOI 10.1084/jem.130.4.907	45	37	37	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	5					665	669		10.1016/0091-6749(85)90668-2	http://dx.doi.org/10.1016/0091-6749(85)90668-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AUU34	3902940				2022-12-18	WOS:A1985AUU3400002
J	NORMAN, PS				NORMAN, PS			ALLERGIC RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											NORMAN, PS (corresponding author), GOOD SAMARITAN HOSP,DIV CLIN IMMUNOL,5601 LOCH RAVEN BLVD,CINCINNATI,OH 45220, USA.							AALBERSE RC, 1983, J IMMUNOL, V130, P722; AAS K, 1974, ACTA ALLERGOL, V29, P238; AAS K, 1971, ACTA PAEDIATR SCAND, V60, P264, DOI 10.1111/j.1651-2227.1971.tb06655.x; ATKINS PC, 1977, ANN INTERN MED, V86, P415, DOI 10.7326/0003-4819-86-4-415; AUSTEN KF, 1963, ADV IMMUNOL, V3, P1, DOI 10.1016/S0065-2776(08)60810-X; BAUMGARTEN C, UNPUB J CLIN INVEST; BELIN LGA, 1977, CLIN ALLERGY, V7, P55, DOI 10.1111/j.1365-2222.1977.tb01425.x; BERG T, 1971, INT ARCH ALLER A IMM, V40, P770, DOI 10.1159/000230461; BOHROD MG, 1955, PROG ALLERGY, V4, P31; CHAPMAN MD, 1980, INT ARCH ALLER A IMM, V61, P431, DOI 10.1159/000232471; CONNELL JT, 1968, J ALLERGY, V41, P123, DOI 10.1016/0021-8707(68)90053-1; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; CONNELL JT, 1969, J ALLERGY, V43, P22, DOI 10.1016/0021-8707(69)90017-3; CRETICOS P, UNPUB J CLIN INVEST; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; DEVEY ME, 1976, CLIN ALLERGY, V6, P227, DOI 10.1111/j.1365-2222.1976.tb01901.x; DOLOVICH J, 1970, International Archives of Allergy and Applied Immunology, V38, P337; DOUGLAS WW, 1975, PHARM BASIS THERAPEU; EGGLESTON PA, 1978, INT ARCH ALLER A IMM, V57, P193, DOI 10.1159/000232103; Fabricant ND, 1941, ARCHIV OTOLARYNGOL, V34, P297; FABRICANT ND, 1961, ARCH OTOLARYNGOL, V32, P271; Fleming A, 1922, P R SOC LOND B-CONTA, V93, P306, DOI 10.1098/rspb.1922.0023; FRANKLAND AW, 1954, LANCET, V1, P1055; FRANKLAND AW, 1955, INT ARCH ALLER A IMM, V6, P45, DOI 10.1159/000228145; Freeman J, 1911, LANCET, V2, P814; FRIESEN GL, 1984, IMMUNOL ALLERGY PRAC, V6, P163; Fry F.A., 1973, J AEROSOL SCI, V4, P113; FUCHS AM, 1959, J ALLERGY, V30, P66, DOI 10.1016/0021-8707(59)90060-7; Grove RC, 1933, ARCHIV OTOLARYNGOL, V18, P622; GROVE RC, 1939, J ALLERGY, V11, P271; HASTIE R, 1979, LAB INVEST, V40, P554; HATCH TF, 1961, BACTERIOL REV, V25, P237, DOI 10.1128/MMBR.25.3.237-240.1961; Heetderks DR, 1927, AM J MED SCI, V174, P231, DOI 10.1097/00000441-192708000-00008; HELM RM, 1984, J ALLERGY CLIN IMMUN, V73, P790, DOI 10.1016/0091-6749(84)90449-4; HOLMES TH, 1951, PSYCHOSOM MED, V13, P71, DOI 10.1097/00006842-195103000-00001; INNES LM, 1975, PHARM BASIS THERAPEU; Jahnke V, 1972, Z Laryngol Rhinol Otol, V51, P152; JOHANSSON SG, 1971, INT ARCH ALLER A IMM, V41, P443, DOI 10.1159/000230538; KERN RA, 1933, J ALLERGY, V4, P485; KOIVIKKO A, 1984, Journal of Allergy and Clinical Immunology, V73, P142; LEE TH, 1982, J CLIN INVEST, V69, P889, DOI 10.1172/JCI110528; LENZ H, 1972, ARCH KLIN EXP OHREN, V202, P242; LEVY DA, 1967, J IMMUNOL, V99, P1068; LICHTENS.LM, 1968, AM J MED, V44, P514, DOI 10.1016/0002-9343(68)90052-1; LICHTENSTEIN LM, 1971, ANN INTERN MED, V75, P663, DOI 10.7326/0003-4819-75-5-663; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LICHTENSTEIN LM, 1967, J ALLERGY, V40, P160, DOI 10.1016/0021-8707(67)90005-6; LICHTENSTEIN LM, 1966, J ALLERGY, V38, P174, DOI 10.1016/0021-8707(66)90040-2; LICHTENSTEIN LM, 1966, J CLIN INVEST, V45, P1126, DOI 10.1172/JCI105419; LINDBLAD JH, 1961, J ALLERGY, V32, P392, DOI 10.1016/0021-8707(61)90016-8; LOEW E R, 1952, BMQ, V3, P1; LOWELL FC, 1963, J ALLERGY, V34, P165, DOI 10.1016/0021-8707(63)90069-8; MACGLASHAN DW, 1983, FED PROC, V42, P2504; MIDDLETON E, 1983, ALLERGY PRINCIPLES P; MYGIND N, 1975, POSTGRAD MED J, V51, P107; Mygind N., 1979, NASAL ALLERGY; NACLERIO R, UNPUB N ENGL J MED; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1984, ARCH OTOLARYNGOL, V110, P25; NAGY L, 1982, NEW ENGL J MED, V306, P497, DOI 10.1056/NEJM198203043060901; NICHOLSON AN, 1983, LANCET, V2, P211; Noon L, 1911, LANCET, V1, P1572; NORMAN PS, 1972, J ALLERGY CLIN IMMUN, V50, P31, DOI 10.1016/0091-6749(72)90077-2; NORMAN PS, 1974, MED CLIN N AM, V58, P111, DOI 10.1016/S0025-7125(16)32181-2; NORMAN PS, 1968, J ALLERGY, V42, P93, DOI 10.1016/0021-8707(68)90139-1; NORMAN PS, 1971, J ALLERGY, V47, P273, DOI 10.1016/S0091-6749(71)80005-2; NORMAN PS, 1966, MOD TREAT, V3, P881; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; NORMAN PS, 1978, J ALLERGY CLIN IMMUN, V61, P370, DOI 10.1016/0091-6749(78)90116-1; NORMAN PS, 1976, J ALLERGY CLIN IMMUN, V57, P221; OKAZAKI T, 1977, PROSTAGLANDINS, V13, P681, DOI 10.1016/0090-6980(77)90239-8; OKUDA M, 1977, ARCH OTO-RHINO-LARYN, V214, P283, DOI 10.1007/BF00457469; OKUDA M, 1982, RHINOLOGY S, V19, P115; OSTERBALLE O, 1980, ALLERGY, V35, P473, DOI 10.1111/j.1398-9995.1980.tb01795.x; PATTERSON R, 1972, ALLERGIC DISEASES DI; PENCE HL, 1976, J ALLERGY CLIN IMMUN, V58, P39, DOI 10.1016/0091-6749(76)90105-6; PETERS S, T ASS AM PHYSICIANS; PHANUPHAK P, 1980, AM J MED, V68, P479, DOI 10.1016/0002-9343(80)90285-5; PIENKOWSKI M, J ALLERGY CLIN IMMUN; PLATTSMILLS TAE, 1976, J CLIN INVEST, V57, P1041, DOI 10.1172/JCI108346; Proctor DF, 1963, NOSE PARANASAL SINUS; PROETZ AW, 1943, ESSAYS APPLIED PHYSL; PROUD D, 1983, J CLIN INVEST, V72, P1678, DOI 10.1172/JCI111127; RAPPAPORT BZ, 1953, J ALLERGY, V24, P35, DOI 10.1016/0021-8707(53)90059-8; ROCKLIN RE, 1980, NEW ENGL J MED, V302, P1213, DOI 10.1056/NEJM198005293022201; ROSEN RD, 1966, J IMMUNOL, V97, P369; ROSENBERG GL, 1983, J ALLERGY CLIN IMMUN, V71, P302, DOI 10.1016/0091-6749(83)90084-2; SADAN N, 1969, NEW ENGL J MED, V280, P623, DOI 10.1056/NEJM196903202801201; SCHLEIMER RP, 1982, J IMMUNOL, V129, P1632; Sheldon J. M., 1967, MANUAL CLIN ALLERGY; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; SLOME D, 1957, LECT SCI BASIS MED, V5, P451; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; SPIEGELMAN J, 1961, ANN ALLERGY, V19, P613; SPIEGELMAN J, 1968, J ALLERGY, V42, P193, DOI 10.1016/S0021-8707(68)90116-0; STEENSEN H, 1981, ALLERGY, V36, P245, DOI 10.1111/j.1398-9995.1981.tb01570.x; STEIN MR, 1978, J ALLERGY CLIN IMMUN, V62, P211, DOI 10.1016/0091-6749(78)90209-9; STRENIUS B, 1971, CLIN ALLERGY, V1, P37; TAYLOR WW, 1978, J ALLERGY CLIN IMMUN, V61, P283, DOI 10.1016/0091-6749(78)90048-9; TOGIAS AG, UNPUB J CLIN INVEST; TURKELTAUB PC, 1982, J ALLERGY CLIN IMMUN, V70, P343, DOI 10.1016/0091-6749(82)90023-9; TURKELTAUB PC, 1976, J ALLERGY CLIN IMMUN, V58, P597, DOI 10.1016/0091-6749(76)90206-2; VANDERGIESSEN M, 1976, INT ARCH ALLER A IMM, V50, P625, DOI 10.1159/000231566; VIANDER M, 1978, CLIN ALLERGY, V8, P387, DOI 10.1111/j.1365-2222.1978.tb00474.x; WARNER JO, 1978, LANCET, V2, P912; WIDE L, 1967, LANCET, V2, P1105; WIHL JA, 1977, ACTA OTO-LARYNGOL, V84, P281, DOI 10.3109/00016487709123968; WINKENWERDER WL, 1937, B J HOPKINS HOSP, V2, P90; WOLF S, 1950, J ALLERGY, V21, P1, DOI 10.1016/0021-8707(50)90028-1; WRIGHT J, 1985, AM J MED SCI, V109, P516; YANG WH, 1979, J ALLERGY CLIN IMMUN, V63, P300, DOI 10.1016/0091-6749(79)90123-4; [No title captured]; 1962, MED LETT DRUGS THER, V4, P50	113	37	38	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	5					531	545		10.1016/0091-6749(85)90024-7	http://dx.doi.org/10.1016/0091-6749(85)90024-7			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AHV07	3886762	Bronze			2022-12-18	WOS:A1985AHV0700001
J	SCHWARTZ, LB; FOLEY, JV; AUSTEN, KF; SOTER, NA; SHEPARD, R; MURPHY, GF				SCHWARTZ, LB; FOLEY, JV; AUSTEN, KF; SOTER, NA; SHEPARD, R; MURPHY, GF			LOCALIZATION OF TRYPTASE TO HUMAN CUTANEOUS MAST-CELLS AND KERATINOCYTES BY IMMUNOFLUORESCENCE AND IMMUNOPEROXIDASE CYTO-CHEMISTRY WITH MONOCLONAL ANTITRYPTASE ANTIBODY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT IMMUNOL, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT RHEUMATOL, BOSTON, MA 02115 USA; NYU MED CTR, DEPT DERMATOL, NEW YORK, NY 10016 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; New York University	SCHWARTZ, LB (corresponding author), VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT MED, ALLERGY & CLIN IMMUNOL SECT, BOX 263, RICHMOND, VA 23298 USA.			Soter, Nicholas/0000-0003-3518-3209	NIAID NIH HHS [AI-20487, AI-10356, AI-20852] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020487, R21AI020487, R01AI020487] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		EISENGER M, 1979, P NATL ACAD SCI USA, V76, P5340; FITZPATRICK T B, 1963, Dermatol Wochenschr, V147, P481; FRAKI JE, 1975, ARCH DERMATOL FORSCH, V253, P261, DOI 10.1007/BF00561152; GLENNER GG, 1960, NATURE, V185, P846, DOI 10.1038/185846a0; JOHNSON GD, 1978, HDB EXPT IMMUNOLOGY; MAIER M, 1983, J IMMUNOL, V130, P2352; MORSE MA, 1980, J HISTOCHEM CYTOCHEM, V28, P677, DOI 10.1177/28.7.6993554; MOTTAZ JH, 1967, J INVEST DERMATOL, V49, P605, DOI 10.1038/jid.1967.187; MURPHY GF, 1981, LAB INVEST, V45, P465; REINHERZ EL, 1980, P NATL ACAD SCI-BIOL, V77, P1588, DOI 10.1073/pnas.77.3.1588; ROBERTS LJ, 1980, NEW ENGL J MED, V303, P1400, DOI 10.1056/NEJM198012113032405; Schreier M., 1980, HYBRIDOMA TECHNIQUES; SCHWARTZ LB, 1983, J IMMUNOL, V130, P1891; SCHWARTZ LB, 1981, J IMMUNOL, V126, P1290; SCHWARTZ LB, 1985, J IMMUNOL, V134, P526; SCHWARTZ LB, 1981, J BIOL CHEM, V256, P1939; SCHWARTZ LB, 1982, CLIN ASPECTS IMMUNOL, P130; SOTER NA, 1979, NEW ENGL J MED, V301, P465, DOI 10.1056/NEJM197908303010903; TANAKA T, 1983, J BIOL CHEM, V258, P3552; TOKI N, 1979, J INVEST DERMATOL, V73, P297, DOI 10.1111/1523-1747.ep12531717	20	37	37	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	2					182	188		10.1016/0091-6749(85)90699-2	http://dx.doi.org/10.1016/0091-6749(85)90699-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	APE88	3894479				2022-12-18	WOS:A1985APE8800011
J	RUFFIN, RE; MCINTYRE, E; CROCKETT, AJ; ZIELONKA, K; ALPERS, JH				RUFFIN, RE; MCINTYRE, E; CROCKETT, AJ; ZIELONKA, K; ALPERS, JH			COMBINATION BRONCHODILATOR THERAPY IN ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											RUFFIN, RE (corresponding author), FLINDERS UNIV S AUSTRALIA,MED CTR,DEPT MED,BEDFORD PK,SA 5042,AUSTRALIA.		McIntyre, Ellen/E-5264-2015; Crockett, Alan J/F-4553-2013; Crockett, Alan Joseph/K-3859-2019	McIntyre, Ellen/0000-0002-2230-1619; 				COCHRAN WG, 1957, EXPT DESIGNS, P75; CORR D, 1980, American Review of Respiratory Disease, V121, P123; GROSS NJ, 1975, AM REV RESPIR DIS, V112, P823; LARSSON S, 1977, AM REV RESPIR DIS, V116, P861; LIGHTBODY IM, 1978, BRIT J DIS CHEST, V72, P181, DOI 10.1016/0007-0971(78)90039-6; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; NIE NH, 1975, SPPS STATISTICAL PAC; PETRIE GR, 1975, BRIT MED J, V1, P430, DOI 10.1136/bmj.1.5955.430; POPPIUS H, 1972, B PHYSIO-PATHOL RESP, V8, P643; RUFFIN RE, 1978, CHEST, V74, P256, DOI 10.1378/chest.74.3.256; RUFFIN RE, 1978, LUNG, V155, P141, DOI 10.1007/BF02730688; RUFFIN RE, 1977, J ALLERGY CLIN IMMUN, V59, P136, DOI 10.1016/0091-6749(77)90215-9; Sergysels R, 1976, Acta Tuberc Pneumol Belg, V67, P163; SNEDECOR GW, 1967, STATISTICAL METHODS, P93; ULMER WT, 1973, ARZNEIMITTEL-FORSCH, V23, P468; Verstraeten J M, 1974, Acta Tuberc Pneumol Belg, V65, P395; WARD MJ, 1981, BRIT MED J, V282, P598, DOI 10.1136/bmj.282.6264.598; WOLFE JD, 1978, NEW ENGL J MED, V298, P363, DOI 10.1056/NEJM197802162980703	18	37	37	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	1					60	65		10.1016/0091-6749(82)90089-6	http://dx.doi.org/10.1016/0091-6749(82)90089-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MZ377	6459357	Bronze			2022-12-18	WOS:A1982MZ37700011
J	SHERMAN, B; WEINBERGER, M; CHENWALDEN, H; WENDT, H				SHERMAN, B; WEINBERGER, M; CHENWALDEN, H; WENDT, H			FURTHER-STUDIES OF THE EFFECTS OF INHALED GLUCOCORTICOIDS ON PITUITARY-ADRENAL-FUNCTION IN HEALTHY-ADULTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SHERING AG,BERLIN,FED REP GER	Schering AG	SHERMAN, B (corresponding author), UNIV IOWA,HOSP & CLIN,CLIN RES CTR,IOWA CITY,IA 52242, USA.				NCRR NIH HHS [RR59] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		HARRIS D M, 1973, Clinical Allergy, V3, P243, DOI 10.1111/j.1365-2222.1973.tb01329.x; HSU TH, 1970, J CLIN ENDOCR METAB, V30, P443, DOI 10.1210/jcem-30-4-443; MIKLE AW, 1969, J CLIN ENDOCRINOL ME, V29, P985; Mutzel W, 1977, Arzneimittelforschung, V27, P2230; MYGIND N, 1973, ACTA ALLERGOL, V28, P211, DOI 10.1111/j.1398-9995.1973.tb01327.x; NASSIF E, 1980, J ALLERGY CLIN IMMUN, V65, P219; NUGENT CA, 1966, J CLIN ENDOCR METAB, V26, P1116, DOI 10.1210/jcem-26-10-1116; Wendt H, 1977, Arzneimittelforschung, V27, P2236; WYATT R, 1978, NEW ENGL J MED, V299, P1387, DOI 10.1056/NEJM197812212992504	9	37	37	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	2					208	212		10.1016/0091-6749(82)90101-4	http://dx.doi.org/10.1016/0091-6749(82)90101-4			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NC581	7056952				2022-12-18	WOS:A1982NC58100007
J	SMALL, P; BLACK, M; FRENKIEL, S				SMALL, P; BLACK, M; FRENKIEL, S			EFFECTS OF TREATMENT WITH BECLOMETHASONE DIPROPIONATE IN SUB-POPULATIONS OF PERENNIAL RHINITIS PATIENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MCGILL UNIV,JEWISH GEN HOSP,DEPT OTORHINOLARYNGOL,MONTREAL H3T 1E2,QUEBEC,CANADA	McGill University	SMALL, P (corresponding author), MCGILL UNIV,JEWISH GEN HOSP,DEPT MED,DIV CLIN IMMUNOL,MONTREAL H3T 1E2,QUEBEC,CANADA.							BROWN H M, 1974, Clinical Allergy, V4, P331, DOI 10.1111/j.1365-2222.1974.tb01394.x; CHATTERJEE S S, 1974, Clinical Allergy, V4, P343, DOI 10.1111/j.1365-2222.1974.tb01395.x; COCKCROFT DW, 1976, CAN MED ASS J, V18, P523; COHAN RH, 1976, J ALLERGY CLIN IMMUN, V58, P121, DOI 10.1016/0091-6749(76)90147-0; GIBSON GJ, 1974, BRIT MED J, V4, P503, DOI 10.1136/bmj.4.5943.503; HANSEN IB, 1974, ACTA ALLERGOL, V29, P281, DOI 10.1111/j.1398-9995.1974.tb01655.x; HARDING SM, 1976, CLIN ALLERGY, V6, P369, DOI 10.1111/j.1365-2222.1976.tb01918.x; HARRIS DM, 1974, CLIN ALLERGY, V4, P291, DOI 10.1111/j.1365-2222.1974.tb01387.x; HILLAS J, 1980, CLIN ALLERGY, V10, P253, DOI 10.1111/j.1365-2222.1980.tb02104.x; INCAUDO G, 1980, J ALLERGY CLIN IMMUN, V65, P41, DOI 10.1016/0091-6749(80)90175-X; JACOBS RL, 1981, J ALLERGY CLIN IMMUN, V67, P253, DOI 10.1016/0091-6749(81)90019-1; JOHANSSON SG, 1968, IMMUNOLOGY, V14, P265; LOFKVIST T, 1975, ACTA ALLERGOL, V30, P227, DOI 10.1111/j.1398-9995.1975.tb01345.x; MULLARKEY MF, 1980, J ALLERGY CLIN IMMUN, V65, P122, DOI 10.1016/0091-6749(80)90196-7; MULLARKEY MF, 1981, J ALLERGY CLIN IMMUN, V67, P251, DOI 10.1016/0091-6749(81)90018-X; MYGIND N, 1973, BRIT MED J, V4, P464, DOI 10.1136/bmj.4.5890.464; Mygind N, 1978, NASAL ALLERGY; PRAHL P, 1975, ARCH DIS CHILD, V50, P875, DOI 10.1136/adc.50.11.875; RUFF F, 1975, POSTGRAD MED J, V51, P54; SCHULZ JI, 1978, CLIN ALLERGY, V8, P313, DOI 10.1111/j.1365-2222.1978.tb00466.x; SMITH JM, 1975, BRIT MED J, V2, P255, DOI 10.1136/bmj.2.5965.255; TARLO SM, 1977, J ALLERGY CLIN IMMUN, V59, P232, DOI 10.1016/0091-6749(77)90155-5; VILSVIK J S, 1975, Clinical Allergy, V5, P291, DOI 10.1111/j.1365-2222.1975.tb01865.x; 1980, CLIN ALLERGY, V10, P239	24	37	38	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	3					178	182		10.1016/0091-6749(82)90039-2	http://dx.doi.org/10.1016/0091-6749(82)90039-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PG384	7108069				2022-12-18	WOS:A1982PG38400004
J	GRANT, JA; GOLDBLUM, RM; RAHR, R; THUESON, DO; FARNAM, J; GILLASPY, J				GRANT, JA; GOLDBLUM, RM; RAHR, R; THUESON, DO; FARNAM, J; GILLASPY, J			ENZYME-LINKED IMMUNOSORBENT-ASSAY (ELISA) FOR IMMUNOGLOBULIN-G ANTIBODIES AGAINST INSECT VENOMS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV TEXAS,MED BRANCH,DEPT PEDIAT,GALVESTON,TX 77550; UNIV TEXAS,MED BRANCH,DEPT PREVENT MED & COMMUNITY HLTH,GALVESTON,TX 77550	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	GRANT, JA (corresponding author), UNIV TEXAS,MED BRANCH,DEPT INTERNAL MED,GALVESTON,TX 77550, USA.				NCRR NIH HHS [RR-73] Funding Source: Medline; NIAID NIH HHS [AI-00110, AI-12621] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ENGVALL E, 1972, J IMMUNOL, V109, P129; FINDLAY SR, 1977, J ALLERGY CLIN IMMUN, V60, P230, DOI 10.1016/0091-6749(77)90135-X; FORSTER J, 1979, KLIN WOCHENSCHR, V57, P421, DOI 10.1007/BF01480482; GILLASPY J E, 1979, Southwestern Entomologist, V4, P96; GRANT JA, 1980, 10 P INT C IMM OXF, P435; HAMILTON RG, 1979, J IMMUNOL, V122, P1073; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; LESSOF MH, 1978, JOHNS HOPKINS MED J, V142, P1; LICHTENS.LM, 1968, AM J MED, V44, P514, DOI 10.1016/0002-9343(68)90052-1; LICHTENSTEIN LM, 1979, J ALLERGY CLIN IMMUN, V64, P5, DOI 10.1016/0091-6749(79)90075-7; MIYACHI S, 1979, INT ARCH ALLER A IMM, V60, P148, DOI 10.1159/000232336; NORMAN PS, 1980, J ALLERGY CLIN IMMUN, V65, P87, DOI 10.1016/0091-6749(80)90191-8; PAULL BR, 1977, J ALLERGY CLIN IMMUN, V59, P334, DOI 10.1016/0091-6749(77)90056-2; PAULL BR, 1978, J IMMUNOL, V120, P1917; SAVIGNY D, 1980, J IMMUNOASSAY, V1, P105; SIRAGANIAN RP, 1975, J IMMUNOL METHODS, V7, P283, DOI 10.1016/0022-1759(75)90025-3; SOBOTKA AK, 1976, J ALLERGY CLIN IMMUN, V57, P29, DOI 10.1016/0091-6749(76)90076-2; SOBOTKA AK, 1976, J IMMUNOL, V117, P84; YUNGINGER JW, 1979, J ALLERGY CLIN IMMUN, V63, P340, DOI 10.1016/0091-6749(79)90129-5	19	37	37	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	2					112	118		10.1016/0091-6749(81)90168-8	http://dx.doi.org/10.1016/0091-6749(81)90168-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MD162	6166648				2022-12-18	WOS:A1981MD16200006
J	CHAPLIN, MD; COOPER, WC; SEGRE, EJ; OREN, J; JONES, RE; NERENBERG, C				CHAPLIN, MD; COOPER, WC; SEGRE, EJ; OREN, J; JONES, RE; NERENBERG, C			CORRELATION OF FLUNISOLIDE PLASMA-LEVELS TO EOSINOPENIC RESPONSE IN HUMANS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SYNTEX RES CORP,INST CLIN MED & PHARMACEUT SCI,PALO ALTO,CA 94304	Syntex Corporation	CHAPLIN, MD (corresponding author), SYNTEX RES CORP,INST PHARMACOL & METAB,DEPT DRUG METAB,PALO ALTO,CA 94304, USA.							BICKERMANN HA, 1963, JAMA-J AM MED ASSOC, V184, P533, DOI 10.1001/jama.1963.03700200055010; BLACKWELL EW, 1974, BRIT J PHARMACOL, V50, P587, DOI 10.1111/j.1476-5381.1974.tb08593.x; BLOOM FL, 1977, ANN ALLERGY, V38, P408; BROCKBANK W, 1958, LANCET, V1, P187; BROWN HM, 1972, BRIT MED J, V1, P585, DOI 10.1136/bmj.1.5800.585; CHAPLIN MD, 1980, CLIN PHARMACOL THER, V27, P402, DOI 10.1038/clpt.1980.54; CHOOKANG YFJ, 1974, POSTGRAD MED J     S, P73; CLARK TJH, 1972, LANCET, V1, P1361; COSTELLO JF, 1974, THORAX, V29, P571, DOI 10.1136/thx.29.5.571; CREPEA SB, 1963, J ALLERGY, V34, P119, DOI 10.1016/0021-8707(63)90065-0; CURRY SH, 1975, BRIT J CLIN PHARMACO, V2, P267, DOI 10.1111/j.1365-2125.1975.tb01586.x; DUGGAN DE, 1975, CLIN PHARMACOL THER, V18, P205; FOULDS WS, 1955, LANCET, V1, P234; GADDIE J, 1973, LANCET, V2, P280; GELFAND ML, 1951, NEW ENGL J MED, V245, P293, DOI 10.1056/NEJM195108232450804; HARRIS DM, 1975, POSTGRAD MED J, V51, P20; LINDER WR, 1964, ARCH INTERN MED, V113, P655, DOI 10.1001/archinte.1964.00280110035006; LOWELL FC, 1976, J ALLERGY CLIN IMMUN, V57, P257; MACFARLANE JCW, 1951, BRIT MED J, V2, P1187, DOI 10.1136/bmj.2.4741.1187; MELTZER EO, 1979, J ALLERGY CLIN IMMUN, V63, P162; MYGIND N, 1973, ACTA ALLERGOL, V28, P211, DOI 10.1111/j.1398-9995.1973.tb01327.x; NERENBERG C, 1979, 26TH ANN M AM PHARM, V9, P142; NOVEY HS, 1965, ARCH INTERN MED, V115, P602, DOI 10.1001/archinte.1960.03860170084018; RAJTORA D, 1975, J ALLERGY CLIN IMMUN, V55, P121; SHAPRIO GG, 1979, J ALLERGY CLIN IMMUN, V63, P163; SHENFIELD GM, 1976, BRIT J CLIN PHARMACO, V3, P583, DOI 10.1111/j.1365-2125.1976.tb04879.x; SIEGEL SC, 1964, PEDIATRICS, V33, P245; TOOGOOD JH, 1977, J ALLERGY CLIN IMMUN, V59, P298, DOI 10.1016/0091-6749(77)90051-3; TURKELTAUB PC, 1976, J ALLERGY CLIN IMMUN, V58, P597, DOI 10.1016/0091-6749(76)90206-2; WEBB DR, 1979, ANN ALLERGY, V42, P80; WILLIAMS MH, 1974, AM REV RESPIR DIS, V109, P538; WILLIAMS MH, 1975, JAMA-J AM MED ASSOC, V231, P406, DOI 10.1001/jama.231.4.406; Winer BJ., 1971, STAT PRINCIPLES EXPT, V2nd ed; WYATT R, 1978, NEW ENGL J MED, V299, P1387, DOI 10.1056/NEJM197812212992504; 1975, LANCET, V2, P469	35	37	38	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	65	6					445	453		10.1016/0091-6749(80)90238-9	http://dx.doi.org/10.1016/0091-6749(80)90238-9			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JV764	7372965	Bronze			2022-12-18	WOS:A1980JV76400008
J	SPECTOR, SL; ENGLISH, G; JONES, L				SPECTOR, SL; ENGLISH, G; JONES, L			CLINICAL AND NASAL BIOPSY RESPONSE TO TREATMENT OF PERENNIAL RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									COLORADO GEN HOSP,DENVER,CO		SPECTOR, SL (corresponding author), NATL JEWISH HOSP & RES CTR,DENVER,CO 80206, USA.							ANDERSEN I, 1974, ARCH ENV HLTH, V20, P319; ANDERSEN IB, 1972, AM REV RESPIR DIS, V106, P438, DOI 10.1164/arrd.1972.106.3.438; BROSTOFF J, 1969, J ALLERGY, V44, P77, DOI 10.1016/0021-8707(69)90003-3; CONNELL JF, 1979, NASAL HYPERSENSITIVI, P397; CONNELL JT, 1976, ALLERGIC RHINITIS, P481; DAVIDSON W D, 1975, Clinical Allergy, V5, P381, DOI 10.1111/j.1365-2222.1975.tb01877.x; DEWEESE DE, 1973, TXB OTOLARYNGOLOGY, P214; HANSEN IB, 1974, ACTA ALLERGOL, V29, P281, DOI 10.1111/j.1398-9995.1974.tb01655.x; HARDING SM, 1976, CLIN ALLERGY, V6, P369, DOI 10.1111/j.1365-2222.1976.tb01918.x; JACOBS RL, 1979, J ALLERGY CLIN IMMUN, V63, P202; JONES LM, 1979, ANN ALLERGY, V42, P139; KAMMERMEYER JK, 1977, J ALLERGY CLIN IMMUN, V59, P287, DOI 10.1016/0091-6749(77)90049-5; LOFKVIST T, 1976, ACTA ALLERGOL, V31, P227, DOI 10.1111/j.1398-9995.1976.tb01683.x; MALM L, 1976, ACTA ALLERGOL, V31, P245, DOI 10.1111/j.1398-9995.1976.tb01685.x; MCKENNA EL, 1974, LARYNGOSCOPE, V84, P112, DOI 10.1288/00005537-197401000-00010; MULLARKEY MF, 1979, J ALLERGY CLIN IMMUN, V63, P201; MYGIND N, 1978, ACTA OTO-LARYNGOL, V85, P437; NORMAN PS, 1967, J ALLERGY, V40, P57, DOI 10.1016/0021-8707(67)90060-3; PROCTOR DF, 1976, PHARMACOL THER, V2, P491; SIEGEL S, 1956, NONPARAMETRIC STAT, P75; TAYLOR G, 1973, J ALLERGY CLIN IMMUN, V52, P193, DOI 10.1016/0091-6749(73)90057-2; TURKELTAUB PC, 1976, J ALLERGY CLIN IMMUN, V58, P597, DOI 10.1016/0091-6749(76)90206-2; WINER BJ, 1971, STATISTICAL PRINCIPL, P539	23	37	37	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	2					129	137		10.1016/0091-6749(80)90060-3	http://dx.doi.org/10.1016/0091-6749(80)90060-3			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KD119	7400477	Bronze			2022-12-18	WOS:A1980KD11900007
J	HASSELBACHER, P				HASSELBACHER, P			BINDING OF IMMUNOGLOBULIN AND ACTIVATION OF COMPLEMENT BY ASBESTOS FIBERS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									DARTMOUTH COLL,HITCHCOCK ARTHRITIS CTR,HANOVER,NH 03755	Dartmouth College	HASSELBACHER, P (corresponding author), DARTMOUTH COLL,SCH MED,CONNECT TISSUE DIS SECT,HANOVER,NH 03755, USA.								0	37	37	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	4					294	298		10.1016/0091-6749(79)90147-7	http://dx.doi.org/10.1016/0091-6749(79)90147-7			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HQ469	479482				2022-12-18	WOS:A1979HQ46900011
J	NOYES, JH; BOYD, GK; SETTIPANE, GA				NOYES, JH; BOYD, GK; SETTIPANE, GA			ANAPHYLAXIS TO SUNFLOWER SEED	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									RHODE ISL HOSP,DEPT MED,PROVIDENCE,RI 02902; BROWN UNIV,PROGRAM MED,PROVIDENCE,RI 02912	Lifespan Health Rhode Island; Rhode Island Hospital; Brown University	NOYES, JH (corresponding author), RHODE ISL HOSP,DEPT PHARMACOL,DIV ALLERGY,PROVIDENCE,RI 02902, USA.							AUSTEN KF, 1965, J AMER MED ASSOC, V192, P108, DOI 10.1001/jama.1965.03080150038007; BENDERSKY G, 1960, JAMA-J AM MED ASSOC, V173, P255, DOI 10.1001/jama.1960.73020210003009a; BUSH RK, 1977, CLIN ALLERGY, V7, P369, DOI 10.1111/j.1365-2222.1977.tb01465.x; COLEMAN WP, 1964, DERM TROP, V3, P91; COLLINS-WILLIAMS C., 1955, ANN ALLERGY, V13, P415; Dang R W, 1967, Hawaii Med J, V27, P149; DANNAEUS S, 1977, ACTA PAEDIATRICA SCA, V66, P31; GIFFORD CG, 1976, PAEDIATRICIAN, V5, P215; GOLBERT TM, 1969, J ALLERGY, V44, P96, DOI 10.1016/0021-8707(69)90005-7; GOLDSTEIN GB, 1970, J ALLERGY, V46, P270, DOI 10.1016/0021-8707(70)90068-7; HILL AF, 1952, EC BOTANY, P519; LINAWEAVER WE, 1976, AM J DIS CHILD, V130, P207, DOI 10.1001/archpedi.1976.02120030097019; McCord CP, 1962, IND MED SURG, V31, P365; MITCHELL JC, 1971, BRIT J DERMATOL, V84, P139, DOI 10.1111/j.1365-2133.1971.tb06857.x; RUBIN JM, 1965, J AMER MED ASSOC, V193, P397, DOI 10.1001/jama.1965.03090050073027; SCHUR S, 1974, J ALLERGY CLIN IMMUN, V54, P174, DOI 10.1016/0091-6749(74)90054-2; Storrs F J, 1976, Cutis, V18, P681; TORSNEY PJ, 1964, J ALLERGY, V35, P514, DOI 10.1016/0021-8707(64)90083-8; 1973, PEDIATRICS, V51, P136	19	37	39	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	63	4					242	244		10.1016/0091-6749(79)90107-6	http://dx.doi.org/10.1016/0091-6749(79)90107-6			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GR842	429702				2022-12-18	WOS:A1979GR84200003
J	CHRYSSANTHOPOULOS, C; BARBORIAK, JJ; FINK, JN; STEKIEL, WJ; MAKSUD, MG				CHRYSSANTHOPOULOS, C; BARBORIAK, JJ; FINK, JN; STEKIEL, WJ; MAKSUD, MG			ADRENERGIC RESPONSES OF ASTHMATIC AND NORMAL SUBJECTS TO SUBMAXIMAL AND MAXIMAL WORK LEVELS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MED COLL WISCONSIN,DEPT PHARMACOL,MILWAUKEE,WI 53233; MED COLL WISCONSIN,DEPT PEDIAT,MILWAUKEE,WI 53233; MED COLL WISCONSIN,DEPT MED,MILWAUKEE,WI 53233; UNIV WISCONSIN,MILWAUKEE,WI 53201; VET ADM CTR,RES SERV,WOOD,WI 53193; MED COLL WISCONSIN,DEPT PHYSIOL,MILWAUKEE,WI 53233	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; University of Wisconsin System; University of Wisconsin Milwaukee; Medical College of Wisconsin								ANDERSON SD, 1976, SCAND J RESPIR DIS, V57, P41; ANTON AH, 1962, J PHARMACOL EXP THER, V138, P360; BANISTER EW, 1972, J APPL PHYSIOL, V33, P674; BARBORIAK J J, 1973, Clinical Allergy, V3, P83, DOI 10.1111/j.1365-2222.1973.tb01312.x; BIANCO S, 1974, BMJ-BRIT MED J, V4, P18, DOI 10.1136/bmj.4.5935.18; CHRYSSANTHOPOUL.C, UNPUBLISHED; GALBO H, 1976, J APPL PHYSIOL, V40, P855, DOI 10.1152/jappl.1976.40.6.855; GODFREY S, 1974, EXERCISE TESTING CHI, P112; GRIFFITHS J, 1972, Chest, V62, P527; GROSS GN, 1974, CHEST, V66, P397, DOI 10.1378/chest.66.4.397; HAGGENDAL J, 1970, SCAN J CLIN INVEST, V26, P336; IRVING MH, 1974, NATURE, V248, P531, DOI 10.1038/248531a0; JOHNSON HG, 1975, J IMMUNOL, V114, P514; JONES RHT, 1966, BMJ-BRIT MED J, V2, P976, DOI 10.1136/bmj.2.5520.976; JONES RS, 1963, ARCH DIS CHILD, V38, P539, DOI 10.1136/adc.38.202.539; JONES RS, 1972, THORAX, V27, P572, DOI 10.1136/thx.27.5.572; KERR JW, 1970, BMJ-BRIT MED J, V2, P139, DOI 10.1136/bmj.2.5702.139; KIRKPATRICK CH, 1967, AM REV RESPIR DIS, V96, P692; KORRY RC, 1963, AM REV RESPIR DIS, V87, P228; LOGSDON PJ, 1973, J ALLERGY CLIN IMMUN, V52, P148, DOI 10.1016/0091-6749(73)90031-6; LUND A, 1949, ACTA PHARMACOL TOX, V5, P231; MASUDA M, 1966, J PSYCHOSOM RES, V10, P255, DOI 10.1016/0022-3999(66)90092-4; MATHE AA, 1969, NEW ENGL J MED, V281, P234, DOI 10.1056/NEJM196907312810503; MCNEILL RS, 1964, LANCET, V2, P1101; MERRILLS R. J., 1963, ANALYT BIOCHEM, V6, P272, DOI 10.1016/0003-2697(63)90135-0; MIDDLETON E, 1968, J ALLERGY, V42, P288, DOI 10.1016/0021-8707(68)90022-1; MOOREHOUSE LE, 1976, PHYSIOLOGY EXERCISE, P89; NELSON HS, 1975, PEDIATR CLIN N AM, V22, P53; PATEL KR, 1976, J ALLERGY CLIN IMMUN, V57, P285, DOI 10.1016/0091-6749(76)90084-1; PATEL KR, 1973, CLIN ALLERGY, V3, P439, DOI 10.1111/j.1365-2222.1973.tb01351.x; REED CE, 1968, J ALLERGY, V42, P238, DOI 10.1016/S0021-8707(68)90119-6; SOIFER MM, 1976, J ALLERGY CLIN IMMUN, V57, P577, DOI 10.1016/0091-6749(76)90009-9; SUTHERLAND EW, 1968, CIRCULATION, V37, P279, DOI 10.1161/01.CIR.37.2.279; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; VANE JR, 1969, BRIT J PHARMACOL, V35, P209, DOI 10.1111/j.1476-5381.1969.tb07982.x; VENDSALU A, 1960, ACTA PHYSIOL SC S173, V49, P57; [No title captured]	37	37	37	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	61	1					17	22		10.1016/0091-6749(78)90468-2	http://dx.doi.org/10.1016/0091-6749(78)90468-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EH112	618943				2022-12-18	WOS:A1978EH11200003
J	KARR, RM; DAVIES, RJ; BUTCHER, BT; LEHRER, SB; WILSON, MR; DHARMARAJAN, V; SALVAGGIO, JE				KARR, RM; DAVIES, RJ; BUTCHER, BT; LEHRER, SB; WILSON, MR; DHARMARAJAN, V; SALVAGGIO, JE			OCCUPATIONAL ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TULANE UNIV, SCH MED, DEPT INTERNAL MED, CLIN IMMUNOL SECT, NEW ORLEANS, LA 70112 USA	Tulane University								ANDRASCH RH, 1975, J ALLERGY CLIN IMMUN, V55, P130; ARROYAVE CM, 1977, CLIN ALLERGY, V7, P173, DOI 10.1111/j.1365-2222.1977.tb01439.x; BARNES R, 1970, MED J AUSTRALIA, V1, P850, DOI 10.5694/j.1326-5377.1970.tb116783.x; BATAWI MAE, 1964, BRIT J IND MED, V21, P231; BOHNER CB, 1940, J ALLERGY, V12, P290; BOUHUYS AL, 1974, BYSSINOSIS, pCH17; BUTCHER BT, 1977, AM REV RESPIR DIS, V116, P411, DOI 10.1164/arrd.1977.116.3.411; BUTCHER BT, 1976, J ALLERGY CLIN IMMUN, V58, P89, DOI 10.1016/0091-6749(76)90110-X; CARROLL KB, 1976, CLIN ALLERGY, V6, P99, DOI 10.1111/j.1365-2222.1976.tb01886.x; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHANYEUNG M, 1973, AM REV RESPIR DIS, V108, P1094; COLTEN HR, 1975, J ALLERGY CLIN IMMUN, V55, P130; COOMBS RRA, 1968, LANCET, V1, P1115; COULSON EJ, 1950, J ALLERGY, V21, P554, DOI 10.1016/0021-8707(50)90107-9; COWAN D W, 1963, J Air Pollut Control Assoc, V13, P546; DAVIES R J, 1975, Clinical Allergy, V5, P99, DOI 10.1111/j.1365-2222.1975.tb01841.x; DAVIES RJ, 1976, AM REV RESPIR DIS, V114, P1011; DAVIES RJ, 1977, J ALLERGY CLIN IMMUN, V60, P223, DOI 10.1016/0091-6749(77)90134-8; DAVIES RJ, 1974, CLIN ALLERGY, V4, P227; DOLOVICH J, 1977, ANN ALLERGY, V38, P382; FAWCETT IW, 1976, CLIN ALLERGY, V6, P577, DOI 10.1111/j.1365-2222.1976.tb01944.x; FEINBERG SM, 1945, J ALLERGY, V16, P209, DOI 10.1016/0021-8707(45)90001-3; FIGLEY KD, 1950, J ALLERGY, V21, P545, DOI 10.1016/0021-8707(50)90106-7; FRANKLAND AE, 1974, ALLERGOLOGIE, P123; FREEDMAN SO, 1964, J ALLERGY, V35, P97, DOI 10.1016/0021-8707(64)90023-1; GANDEVIA B, 1970, MED J AUSTRALIA, V2, P332, DOI 10.5694/j.1326-5377.1970.tb50018.x; GELFAND HH, 1963, J ALLERGY, V34, P374, DOI 10.1016/0021-8707(63)90056-X; GREENE SA, 1976, CLIN ALLERGY, V6, P105, DOI 10.1111/j.1365-2222.1976.tb01887.x; HENDRICK DJ, 1976, CLIN ALLERGY, V6, P241, DOI 10.1111/j.1365-2222.1976.tb01903.x; HENDRICK DJ, 1977, BRIT J IND MED, V34, P11; HUNTER D, 1945, BRIT J IND MED, V2, P92; Introna F, 1966, Minerva Medicoleg, V86, P176; KALINER M, 1973, J EXP MED, V138, P1077, DOI 10.1084/jem.138.5.1077; KAMMERMEYER JK, 1973, J ALLERGY CLIN IMMUN, V52, P73, DOI 10.1016/0091-6749(73)90079-1; KARR RM, UNPUBLISHED; KOBAYASHI S, 1974, ALLERGOLOGIE, P124; LAYTON LL, 1968, INT ARCH ALLER A IMM, V33, P417, DOI 10.1159/000230057; LEHRER SB, UNPUBLISHED; LINCOLN TA, 1974, J OCCUP ENVIRON MED, V16, P465; MACCIA CA, 1976, AM REV RESPIR DIS, V113, P701; MCCONNELL LH, 1973, ANN INTERN MED, V78, P888, DOI 10.7326/0003-4819-78-6-888; NARASBHAT K, 1976, J ALLERGY CLIN IMMUN, V58, P647, DOI 10.1016/0091-6749(76)90176-7; Pepys J, 1972, Clin Allergy, V2, P391, DOI 10.1111/j.1365-2222.1972.tb01303.x; PEPYS J, 1972, Clinical Allergy, V2, P189, DOI 10.1111/j.1365-2222.1972.tb01282.x; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; PEPYS J, 1973, Clinical Allergy, V3, P143, DOI 10.1111/j.1365-2222.1973.tb01318.x; PEPYS J, ALLERGY PRINCIPLES P; PETERS JM, 1971, AM REV RESPIR DIS, V104, P432, DOI 10.1164/arrd.1971.104.3.432; RAMAZZINI B, 1940, MORBUS ARTIFICUM DIA; REILLY DA, 1968, ANALYST, V93, P178, DOI 10.1039/an9689300178; SCHEEL LD, 1964, AM IND HYG ASSOC J, V25, P197; SEATON A, 1975, OCCUPATIONAL LUNG DI, P251; STEVENSON DD, 1976, CLIN ALLERGY, V6, P493, DOI 10.1111/j.1365-2222.1976.tb01934.x; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; TWAROG FJ, 1977, J ALLERGY CLIN IMMUN, V59, P35, DOI 10.1016/0091-6749(77)90174-9; WEINER A, 1961, ANN ALLERGY, V19, P397; ZEISS CR, 1977, J ALLERGY CLIN IMMUN, V60, P96, DOI 10.1016/0091-6749(77)90033-1; 1973, PUBLIC HLTH SERVICE	58	37	37	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	61	1					54	65		10.1016/0091-6749(78)90474-8	http://dx.doi.org/10.1016/0091-6749(78)90474-8			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EH112	618946				2022-12-18	WOS:A1978EH11200009
J	BUSH, RK; EHRLICH, EN; REED, CE				BUSH, RK; EHRLICH, EN; REED, CE			THYROID DISEASE AND ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WISCONSIN,SCH MED,DEPT INTERNAL MED,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison								COPINSCHI G, 1971, HORM METAB RES, V3, P437, DOI 10.1055/s-0028-1094119; COULOMBE P, 1976, METABOLISM, V25, P973, DOI 10.1016/0026-0495(76)90126-8; COULOMBE P, 1976, J CLIN ENDOCR METAB, V42, P125, DOI 10.1210/jcem-42-1-125; DAZORD A, 1972, J CLIN ENDOCR METAB, V35, P24, DOI 10.1210/jcem-35-1-24; FEINBERG SM, 1944, ALLERGY CLIN PRACTIC, P90; FILIPP G, 1973, ANN ALLERGY, V31, P272; HELLMAN L, 1961, J CLIN ENDOCR METAB, V21, P1231, DOI 10.1210/jcem-21-10-1231; KARLBERG BE, 1974, J CLIN ENDOCR METAB, V39, P96, DOI 10.1210/jcem-39-1-96; Kasperlik-Zaluska A, 1968, Gruzlica, V36, P581; KENNY FM, 1967, J CLIN ENDOCR METAB, V27, P1616, DOI 10.1210/jcem-27-11-1616; MARTIN MM, 1963, J CLIN ENDOCR METAB, V23, P242, DOI 10.1210/jcem-23-3-242; MURRAY JF, 1959, ANN INTERN MED, V51, P309, DOI 10.7326/0003-4819-51-2-309; NOTH RH, 1974, J CLIN ENDOCR METAB, V39, P614, DOI 10.1210/jcem-39-3-614; RUDER H, 1971, J CLIN ENDOCR METAB, V33, P382, DOI 10.1210/jcem-33-3-382; SATOYOSHI E, 1963, NEUROLOGY, V13, P645, DOI 10.1212/WNL.13.8.645; SCHWARTZ HJ, 1966, ANN ALLERGY, V24, P235; SETTIPANE GA, 1972, J ALLERGY CLIN IMMUN, V49, P348, DOI 10.1016/0091-6749(72)90133-9; SPAULDING SW, 1975, MED CLIN N AM, V59, P1123, DOI 10.1016/S0025-7125(16)31962-9; STOCK JM, 1974, NEW ENGL J MED, V290, P529, DOI 10.1056/NEJM197403072901001; STOFFER SS, 1973, J CLIN ENDOCR METAB, V36, P587, DOI 10.1210/jcem-36-3-587	20	37	39	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	5					398	401		10.1016/0091-6749(77)90025-2	http://dx.doi.org/10.1016/0091-6749(77)90025-2			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DF215	853177	Bronze			2022-12-18	WOS:A1977DF21500011
J	OLENCHOCK, SA; BURRELL, R				OLENCHOCK, SA; BURRELL, R			ROLE OF PRECIPITINS AND COMPLEMENT ACTIVATION IN ETIOLOGY OF ALLERGIC LUNG-DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									W VIRGINIA UNIV, MED CTR, DEPT MICROBIOL, MORGANTOWN, WV 26505 USA	West Virginia University								ALTMAN PL, 1964, BIOLOGY DATA BOOK, P260; AMOS RE, 1967, PHYTOPATHOLOGY, V57, P32; BANASZAK EF, 1970, NEW ENGL J MED, V283, P271, DOI 10.1056/NEJM197008062830601; BARTELS H, 1959, PFLUG ARCH GES PHYS, V268, P334, DOI 10.1007/BF00380734; BERRENS L, 1974, ANN NY ACAD SCI, V221, P153, DOI 10.1111/j.1749-6632.1974.tb28213.x; BICE DE, 1975, J ALLERGY CLIN IMMUN, V55, P71; BOWER VE, 1961, J RES NAT BUR STAND, VA 65, P267, DOI 10.6028/jres.065A.031; BURRELL R, 1974, EXPT IMMUNOLOGY, P40; BURRELL RG, 1966, PHYTOPATHOLOGY, V56, P422; CALDWELL JR, 1973, J ALLERGY CLIN IMMUN, V52, P225, DOI 10.1016/0091-6749(73)90060-2; CARPENTER CB, 1966, IMMUNOLOGY, V10, P355; CHMELIK F, 1974, J ALLERGY CLIN IMMUN, V54, P180, DOI 10.1016/0091-6749(74)90055-4; COCHRANE CG, 1970, J IMMUNOL, V105, P55; DAVIDSON JT, 1966, J APPL PHYSIOL, V21, P1094, DOI 10.1152/jappl.1966.21.3.1094; DAVIES B H, 1975, Clinical Allergy, V5, P217, DOI 10.1111/j.1365-2222.1975.tb01855.x; DUNNETT CW, 1955, J AM STAT ASSOC, V50, P1096, DOI 10.2307/2281208; EDWARDS J H, 1974, Clinical Allergy, V4, P379, DOI 10.1111/j.1365-2222.1974.tb01399.x; EMANUEL DA, 1975, CHEST, V67, P293, DOI 10.1378/chest.67.3.293; EMANUEL DA, 1964, AM J MED, V37, P392, DOI 10.1016/0002-9343(64)90195-0; FLAHERTY DK, 1974, J ALLERGY CLIN IMMUN, V53, P329, DOI 10.1016/0091-6749(74)90116-X; GORDON MA, 1971, AM J CLIN PATHOL, V56, P471; GRANT IWB, 1972, BRIT MED J, V1, P530, DOI 10.1136/bmj.1.5799.530; HANSEN PJ, 1974, INT ARCH ALLER A IMM, V47, P498, DOI 10.1159/000231244; HOLLINGDALE MR, 1974, J HYG-CAMBRIDGE, V72, P79, DOI 10.1017/S002217240002324X; KAWAI T, 1973, CLIN EXP IMMUNOL, V15, P123; MAJOR PC, 1972, FED PROC, V31, pA664; MARX JJ, 1975, J ALLERGY CLIN IMMUN, V55, P70; Mayer M., 1961, EXPT IMMUNOCHEMISTRY, V2nd ed.; MERINO VL, 1973, AM REV RESPIR DIS, V107, P809; MOORE VL, 1974, J ALLERGY CLIN IMMUN, V53, P319, DOI 10.1016/0091-6749(74)90115-8; MORGAN WKC, 1975, OCCUPATIONAL LUNG DI, P302; NORTHUP S, 1975, FED PROC, V34, P839; PALMER KNV, 1973, AM REV RESPIR DIS, V107, P940; Pepys J, 1969, HYPERSENSITIVITY DIS; RENT R, 1975, J IMMUNOL, V114, P120; RICHERSON HB, 1972, J LAB CLIN MED, V79, P745; RICHERSON HB, 1974, ANN NY ACAD SCI, V221, P340, DOI 10.1111/j.1749-6632.1974.tb28236.x; STUKA AJ, 1967, J BACTERIOL, V94, P914, DOI 10.1128/JB.94.4.914-918.1967; WEISBROT IM, 1974, AM J CLIN PATHOL, V61, P923; WENZEL FJ, 1971, J ALLERGY CLIN IMMUN, V48, P224, DOI 10.1016/0091-6749(71)90069-8	40	37	37	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	1					76	88		10.1016/0091-6749(76)90109-3	http://dx.doi.org/10.1016/0091-6749(76)90109-3			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BX742	7583				2022-12-18	WOS:A1976BX74200009
J	RYO, UY; TOWNLEY, RG				RYO, UY; TOWNLEY, RG			COMPARISON OF RESPIRATORY AND CARDIOVASCULAR EFFECTS OF ISOPROTERENOL, PROPRANOLOL, AND PRACTOLOL IN ASTHMATIC AND NORMAL SUBJECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CREIGHTON UNIV,SCH MED,DEPT MED,OMAHA,NB 68178	Creighton University								ADOLPHSON RL, TO BE PUBLISHED; BARRETT AM, 1968, ARCH EXP PATHOL PH, V259, P152; BERNECKER, 1970, LANCET, V2, P662; BEUMER H M, 1969, Pharmacologia Clinica, V1, P172, DOI 10.1007/BF00456941; BLINKS JR, 1967, ANN NY ACAD SCI, V139, P673, DOI 10.1111/j.1749-6632.1967.tb41237.x; BRICK I, 1968, BRIT J PHARMACOL, V34, P127, DOI 10.1111/j.1476-5381.1968.tb07956.x; DOLLERY CT, 1969, CLIN PHARMACOL THER, V10, P765; DUBOIS AB, 1956, J CLIN INVEST, V35, P327, DOI 10.1172/JCI103282; DUNLOP D, 1968, BRIT J PHARMACOL, V32, P201, DOI 10.1111/j.1476-5381.1968.tb00444.x; Frullani F, 1969, Minerva Anestesiol, V35, P1130; FURCHGOT.RF, 1967, ANN NY ACAD SCI, V139, P553, DOI 10.1111/j.1749-6632.1967.tb41229.x; GRIECO MH, 1970, B NEW YORK ACAD MED, V46, P597; GUIRGIS HM, 1969, THORAX, V24, P613, DOI 10.1136/thx.24.5.613; HARLEY D, 1968, NATURE, V219, P861; HARRIS A, 1966, AM J CARDIOL, V18, P431, DOI 10.1016/0002-9149(66)90066-X; HERXHEIMER H, 1967, J PHYSIOL-LONDON, V190, P41; JENKINS AV, 1970, BRIT J ANAESTH, V42, P59, DOI 10.1093/bja/42.1.59; LANDS AM, 1964, P SOC EXP BIOL MED, V116, P331; LANDS AM, 1967, NATURE, V214, P597, DOI 10.1038/214597a0; LANGER I, 1967, J PHYSL, V190, P41; MCDONALD AG, 1968, BRIT J ANAESTH, V40, P508; MCGEADY S, 1968, J ALLERGY, V41, P108; MCNEILL RS, 1966, AM J CARDIOL, V18, P473, DOI 10.1016/0002-9149(66)90072-5; MCNEILL RS, 1964, LANCET, V2, P1101; MEIER J, 1966, DEUT MED WOCHENSCHR, V91, P145, DOI 10.1055/s-0028-1110536; MORAN NC, 1966, PHARMACOL REV, V18, P503; MORAN NC, 1967, ANN NY ACAD SCI, V139, P649, DOI 10.1111/j.1749-6632.1967.tb41235.x; NICKERSO.M, 1967, ANN NY ACAD SCI, V139, P571, DOI 10.1111/j.1749-6632.1967.tb41230.x; OUELLETTE J J, 1967, Journal of Allergy, V39, P160, DOI 10.1016/0021-8707(67)90033-0; PALMER KNV, 1969, LANCET, V2, P1092; PATON DM, 1969, AM HEART J, V77, P707, DOI 10.1016/0002-8703(69)90560-2; POWLES R, 1969, THORAX, V24, P616, DOI 10.1136/thx.24.5.616; RYO U Y, 1970, Federation Proceedings, V29, P321; SCHAMROTH L, 1966, AM J CARDIOL, V18, P438, DOI 10.1016/0002-9149(66)90067-1; SEATON A, 1966, BMJ-BRIT MED J, V1, P1522, DOI 10.1136/bmj.1.5502.1522; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; TOWNLEY RG, 1965, J ALLERGY, V36, P121, DOI 10.1016/0021-8707(65)90161-9; TOWNLEY RG, 1967, J ALLERGY, V39, P177, DOI 10.1016/0021-8707(67)90036-6; TOWNLEY RG, 1972, PRACTICE MEDICINE; ZAID G, 1966, NEW ENGL J MED, V275, P580, DOI 10.1056/NEJM196609152751103	40	37	37	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	1					12	24		10.1016/0091-6749(76)90074-9	http://dx.doi.org/10.1016/0091-6749(76)90074-9			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BC141	1245680				2022-12-18	WOS:A1976BC14100002
J	WELTMAN, JK; FRACKELTON, AR; SZARO, RP; ROTMAN, B				WELTMAN, JK; FRACKELTON, AR; SZARO, RP; ROTMAN, B			GALACTOSIDASE IMMUNOSORBENT TEST FOR HUMAN IMMUNOGLOBULIN-E	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MIRIAM HOSP,EXPTL IMMUNOL & BIOPHYS LAB,PROVIDENCE,RI 02906; BROWN UNIV,DIV BIOMED SCI,PROVIDENCE,RI 02912	Lifespan Health Rhode Island; Miriam Hospital; Brown University								AVRAMEAS S, 1969, IMMUNOCHEMISTRY, V6, P43, DOI 10.1016/0019-2791(69)90177-3; BERG T, 1969, INT ARCH ALLER A IMM, V36, P219, DOI 10.1159/000230745; CAPEL PJA, 1975, J IMMUNOL METHODS, V7, P77, DOI 10.1016/0022-1759(75)90132-5; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; Cuatrecasas P., 1971, METHOD ENZYMOL, V22, P345; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; HOFFMAN DR, 1973, J ALLERGY CLIN IMMUN, V51, P303, DOI 10.1016/0091-6749(73)90132-2; ISHIZAKA K, 1967, J IMMUNOL, V99, P1187; JOHANSSO.SG, 1967, LANCET, V2, P951; JOHANSSON SG, 1968, INT ARCH ALLER A IMM, V34, P1; JOHANSSON SG, 1968, IMMUNOLOGY, V14, P265; KING TP, 1962, BIOCHEMISTRY-US, V1, P709, DOI 10.1021/bi00910a027; Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2; ROTMAN B, 1961, P NATL ACAD SCI USA, V47, P1981, DOI 10.1073/pnas.47.12.1981; Rotman B., 1973, FLUORESCENCE TECHNIQ, P333; ROTMAN MB, 1970, LACTOSE OPERON, P279; WIDE L, 1967, LANCET, V2, P1105	17	37	37	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	3					426	431		10.1016/0091-6749(76)90123-8	http://dx.doi.org/10.1016/0091-6749(76)90123-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CD454	987089				2022-12-18	WOS:A1976CD45400009
J	TANNENBAUM, H; RUDDY, S; SCHUR, PH				TANNENBAUM, H; RUDDY, S; SCHUR, PH			ACUTE ANAPHYLAXIS ASSOCIATED WITH SERUM COMPLEMENT DEPLETION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HARVARD UNIV,MED SCH,DEPT MED,BOSTON,MA; ROBERT B BRIGHAM HOSP,DEPT MED,125 PARKER HILL AVE,BOSTON,MA 02120	Harvard University; Harvard Medical School								ADRIANI J, 1970, ANESTH ANALG, V49, P182; AGNELLO V, 1970, IMMUNOLOGY, V19, P909; CAMPBELL DH, 1970, METHOD IMMUNOL, P279; DESWARTE RD, 1972, ALLERGIC DISEASES DI, P393; DUPREE E, 1974, J ALLERGY CLIN IMMUN, V53, P75; EYRE, 1971, LANCET, V1, P264; GUPTA SK, 1959, BRIT MED J, V1, P695, DOI 10.1136/bmj.1.5123.695; HOLTI G, 1965, Dent Pract Dent Rec, V15, P294; HOWSE CR, COMMUNICATION; ISHIZAKA K, 1967, J ALLERGY, V39, P254, DOI 10.1016/0021-8707(67)90019-6; Ishizaka K., 1971, PROGR IMMUNOLOGY, V1st, P859; ISHIZAKA T, 1969, J IMMUNOL, V102, P884; KAY AB, 1971, J IMMUNOL, V107, P899; KENT JF, 1963, AM J TROP MED HYG, V12, P103, DOI 10.4269/ajtmh.1963.12.103; LEHNER T, 1971, LANCET, V1, P1245; LEWIS EJ, 1971, ANN INTERN MED, V75, P555, DOI 10.7326/0003-4819-75-4-555; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LYNAS RFA, 1969, ANESTHESIOLOGY, V31, P380; MORRISSET L M, 1957, U S Armed Forces Med J, V8, P740; NOBLE DS, 1961, LANCET, V2, P1436; ORANGE RP, 1971, BIOCHEMISTRY ACUTE A, P189; Pelot G, 1966, J Urol Nephrol (Paris), V72, P819; RUDDY S, 1972, NEW ENGL J MED, V287, P642, DOI 10.1056/NEJM197209282871306; RUDDY S, 1972, NEW ENGL J MED, V287, P489, DOI 10.1056/NEJM197209072871005; RUDDY S, 1970, IMMUNOLOGY, V18, P943; RUDDY S, 1972, NEW ENGL J MED, V287, P592, DOI 10.1056/NEJM197209212871206; RUDDY S, 1972, NEW ENGL J MED, V287, P545, DOI 10.1056/NEJM197209142871106; RUDDY S, LABORATORY DIAGNOSTI; SCHUR PH, 1968, ANNU REV MED, V19, P1, DOI 10.1146/annurev.me.19.020168.000245; SCHUR PH, 1970, NEW ENGL J MED, V283, P631, DOI 10.1056/NEJM197009172831205; SCHUR PH, 1973, B RHEUM DIS, V22, P666; SCHUR PH, UNPUBLISHED OBSERVAT; Shields P W, 1972, Aust Dent J, V17, P51; STECHSCHULTE DJ, 1973, J IMMUNOL, V111, P1585; WALDMAN HB, 1967, J AM DENT ASSOC, V74, P747, DOI 10.14219/jada.archive.1967.0111; Walker R T, 1971, J R Nav Med Serv, V57, P53; WELLINS SL, 1969, ORAL SURG ORAL MED O, V28, P761, DOI 10.1016/0030-4220(69)90425-3	37	37	37	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	56	3					226	234		10.1016/0091-6749(75)90094-9	http://dx.doi.org/10.1016/0091-6749(75)90094-9			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AQ290	50336	Bronze			2022-12-18	WOS:A1975AQ29000008
J	SWEET, LC; ANDERSON, JA; CALLIES, QC; COATES, EO				SWEET, LC; ANDERSON, JA; CALLIES, QC; COATES, EO			HYPERSENSITIVITY PNEUMONITIS RELATED TO A HOME FURNACE HUMIDIFIER	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note																		BANASZAK EF, 1970, NEW ENGL J MED, V283, P271, DOI 10.1056/NEJM197008062830601; FINK JN, 1971, ANN INTERN MED, V74, P80, DOI 10.7326/0003-4819-74-1-80; HARGREAVE FE, 1966, LANCET, V1, P444; Pepys J, 1966, Clin Exp Immunol, V1, P377; REED CC, 1965, JAMA, V261, P261; RIDDLE HFV, 1968, THORAX, V23, P271, DOI 10.1136/thx.23.3.271; SAKULA A, 1967, BRIT MED J, V3, P708, DOI 10.1136/bmj.3.5567.708; SALVAGGIO J, 1969, AM J MED, V46, P538, DOI 10.1016/0002-9343(69)90073-4; STUDDERT TC, 1953, BMJ-BRIT MED J, V1, P1305, DOI 10.1136/bmj.1.4823.1305	9	37	37	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1971	48	3					171	&		10.1016/0091-6749(71)90013-3	http://dx.doi.org/10.1016/0091-6749(71)90013-3			0	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K3234	4998685				2022-12-18	WOS:A1971K323400007
J	Roth-Walter, F; Afify, SM; Pacios, LF; Blokhuis, BR; Redegeld, F; Regner, A; Petje, LM; Fiocchi, A; Untersmayr, E; Dvorak, Z; Hufnagl, K; Pali-Scholl, I; Jensen-Jarolim, E				Roth-Walter, Franziska; Afify, Sheriene Moussa; Pacios, Luis F.; Blokhuis, Bart R.; Redegeld, Frank; Regner, Andreas; Petje, Lisa-Marie; Fiocchi, Alessandro; Untersmayr, Eva; Dvorak, Zdenek; Hufnagl, Karin; Pali-Scholl, Isabella; Jensen-Jarolim, Erika			Cow's milk protein beta-lactoglobulin confers resilience against allergy by targeting complexed iron into immune cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen; allergy; beta-lactoglobulin; BLG; Bos d 5; cow's milk; iron; ligand; lipocalin; milk; quercetin; tolerance	ARYL-HYDROCARBON RECEPTOR; MEMBRANE-RECEPTOR; CELLULAR INTERNALIZATION; ANTIMICROBIAL ACTIVITY; INNATE IMMUNITY; IN-VITRO; T-CELLS; BINDING; LIPOCALIN; ACTIVATION	Background: Beta-lactoglobulin (BLG) is a bovine lipocalin in milk with an innate defense function. The circumstances under which BLG is associated with tolerance of or allergy to milk are not understood. Objective: Our aims were to assess the capacity of ligand-free apoBLG versus loaded BLG (holoBLG) to protect mice against allergy by using an iron-quercetin complex as an exemplary ligand and to study the molecular mechanisms of this protection. Methods: Binding of iron-quercetin to BLG was modeled and confirmed by spectroscopy and docking calculations. Serum IgE binding to apoBLG and holoBLG in children allergic to milk and children tolerant of milk was assessed. Mice were intranasally treated with apoBLG versus holoBLG and analyzed immunologically after systemic challenge. Aryl hydrocarbon receptor (AhR) activation was evaluated with reporter cells and Cyp1A1 expression. Treated human PBMCs and human mast cells were assessed by fluorescence-activated cell sorting and degranulation, respectively. Results: Modeling predicted masking of major IgE and T-cell epitopes of BLG by ligand binding. In line with this modeling, IgE binding in children allergic to milk was reduced toward holoBLG, which also impaired degranulation of mast cells. In mice, only treatments with holoBLG prevented allergic sensitization and anaphylaxis, while sustaining regulatory T cells. BLG facilitated quercetin-dependent AhR activation and, downstream of AhR, lung Cyp1A1 expression. HoloBLG shuttled iron into monocytic cells and impaired their antigen presentation. Conclusion: The cargo of holoBLG is decisive in preventing allergy in vivo. BLG without cargo acted as an allergen in vivo and further primed human mast cells for degranulation in an antigen-independent fashion. Our data provide a mechanistic explanation why the same proteins can act either as tolerogens or as allergens.	[Roth-Walter, Franziska; Afify, Sheriene Moussa; Regner, Andreas; Petje, Lisa-Marie; Hufnagl, Karin; Pali-Scholl, Isabella; Jensen-Jarolim, Erika] Med Univ Vienna, Interuniv Messerli Res Inst, Univ Vet Med Vienna, Vienna, Austria; [Roth-Walter, Franziska; Afify, Sheriene Moussa; Regner, Andreas; Petje, Lisa-Marie; Hufnagl, Karin; Pali-Scholl, Isabella; Jensen-Jarolim, Erika] Univ Vienna, Vet Pl 1, A-1210 Vienna, Austria; [Roth-Walter, Franziska; Untersmayr, Eva; Hufnagl, Karin; Pali-Scholl, Isabella; Jensen-Jarolim, Erika] Med Univ Vienna, Inst Pathophysiol & Allergy Res, Ctr Pathophysiol Infectiol & Immunol, Waehringer G 18-20, A-1090 Vienna, Austria; [Afify, Sheriene Moussa] Menoufia Univ, Lab Med & Immunol Dept, Fac Med, Menoufia, Egypt; [Pacios, Luis F.] Tech Univ Madrid, Dept Biotechnol, ETSIAAB, Ctr Plant Biotechnol & Genom,CBGP UPM INIA, Madrid, Spain; [Blokhuis, Bart R.; Redegeld, Frank] Univ Utrecht, Fac Sci, Div Pharmacol, Dept Pharmaceut Sci, Utrecht, Netherlands; [Fiocchi, Alessandro] Childrens Hosp Bambino Gesu, Rome, Italy; [Dvorak, Zdenek] Palacky Univ, Dept Cell Biol & Genet, Fac Sci, Olomouc, Czech Republic	Medical University of Vienna; University of Veterinary Medicine Vienna; University of Veterinary Medicine Vienna; University of Vienna; Medical University of Vienna; Egyptian Knowledge Bank (EKB); Menofia University; Universidad Politecnica de Madrid; Centro de Investigacion en Biotecnologia Genomica de Plantas (CBGP); Utrecht University; IRCCS Bambino Gesu; Palacky University Olomouc	Roth-Walter, F (corresponding author), Univ Vienna, Vet Pl 1, A-1210 Vienna, Austria.; Jensen-Jarolim, E (corresponding author), Med Univ Vienna, Inst Pathophysiol & Allergy Res, Ctr Pathophysiol Infectiol & Immunol, Waehringer G 18-20, A-1090 Vienna, Austria.; Roth-Walter, F (corresponding author), Med Univ Vienna, Comparat Med, Interuniv Messerli Res Inst, Univ Vet Med Vienna, Vet Pl 1, A-1210 Vienna, Austria.	franziska.roth-walter@meduniwien.ac.at; erika.jensen-jarolim@medunwien.ac.at	Pacios, Luis F./AAL-6124-2021; Roth-Walter, Franziska/V-4651-2017; Untersmayr, Eva/GRY-4470-2022	Pacios, Luis F./0000-0002-0585-4289; Roth-Walter, Franziska/0000-0001-5005-9228; Untersmayr, Eva/0000-0002-1963-499X	Austrian Science Fund FWF [SFB F4606-B28]; Biomedical International R1D GmbH, Vienna, Austria; Bencard Allergie GmbH, Munich, Germany; Egyptian Ministry of Higher Education	Austrian Science Fund FWF(Austrian Science Fund (FWF)); Biomedical International R1D GmbH, Vienna, Austria; Bencard Allergie GmbH, Munich, Germany; Egyptian Ministry of Higher Education(Science and Technology Development Fund (STDF))	Supported by the Austrian Science Fund FWF (grant SFB F4606-B28) and in part by Biomedical International R1D GmbH, Vienna, Austria, and by Bencard Allergie GmbH, Munich, Germany. S.M.A. was supported by a grant from the Egyptian Ministry of Higher Education.	Abbring S, 2019, CLIN EXP ALLERGY, V49, P1013, DOI 10.1111/cea.13399; Agoro R, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196921; Aguilera-Montilla N, 2013, BLOOD, V121, pE108, DOI 10.1182/blood-2012-07-445106; Bacher P, 2016, CELL, V167, P1067, DOI 10.1016/j.cell.2016.09.050; Bao GH, 2010, NAT CHEM BIOL, V6, P602, DOI [10.1038/NCHEMBIO.402, 10.1038/nchembio.402]; Bartfay WJ, 2003, CAN J CARDIOL, V19, P1163; Besle JM, 2010, J DAIRY SCI, V93, P2846, DOI 10.3168/jds.2009-2939; Bessede A, 2014, NATURE, V511, P184, DOI 10.1038/nature13323; Brick T, 2016, J ALLERGY CLIN IMMUN, V137, P1699, DOI 10.1016/j.jaci.2015.10.042; CarrascoMarin E, 1996, CELL IMMUNOL, V171, P173, DOI 10.1006/cimm.1996.9999; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Chaneton L, 2011, J DAIRY SCI, V94, P138, DOI 10.3168/jds.2010-3319; Chen J, 2017, ANN HEMATOL, V96, P1085, DOI 10.1007/s00277-017-2985-y; Chen WJ, 2019, FOOD CHEM, V274, P234, DOI 10.1016/j.foodchem.2018.08.106; Cook GM, 1998, MICROBIOL-UK, V144, P3297, DOI 10.1099/00221287-144-12-3297; Couroucli XI, 2002, MOL PHARMACOL, V61, P507, DOI 10.1124/mol.61.3.507; Cronin SJF, 2018, NATURE, V563, P564, DOI 10.1038/s41586-018-0701-2; Devireddy LR, 2010, CELL, V141, P1006, DOI 10.1016/j.cell.2010.04.040; Devireddy LR, 2005, CELL, V123, P1293, DOI 10.1016/j.cell.2005.10.027; Drury KE, 2016, JAMA PEDIATR, V170, P29, DOI 10.1001/jamapediatrics.2015.3065; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; El Hajji H, 2006, FREE RADICAL RES, V40, P303, DOI 10.1080/10715760500484351; Esser C, 2009, TRENDS IMMUNOL, V30, P447, DOI 10.1016/j.it.2009.06.005; Fine JM, 2012, EXP BRAIN RES, V219, P381, DOI 10.1007/s00221-012-3101-0; Flower DR, 2000, BBA-PROTEIN STRUCT M, V1482, P327, DOI 10.1016/S0167-4838(00)00169-2; Fluckinger M, 2004, ANTIMICROB AGENTS CH, V48, P3367, DOI 10.1128/AAC.48.9.3367-3372.2004; Fluckinger M, 2008, BBA-BIOMEMBRANES, V1778, P342, DOI 10.1016/j.bbamem.2007.10.010; Freier R, 2015, SCI REP-UK, V5, DOI 10.1038/srep12707; Gandhi R, 2010, NAT IMMUNOL, V11, P846, DOI 10.1038/ni.1915; Garrido-Arandia M, 2016, SCI REP-UK, V6, DOI 10.1038/srep33468; Goettel JA, 2016, CELL REP, V17, P1318, DOI 10.1016/j.celrep.2016.09.082; Grabenhenrich LB, 2018, PEDIAT ALLERG IMM-UK, V29, P58, DOI 10.1111/pai.12811; Hagag Adel A, 2016, Egypt J Immunol, V23, P97; Hesselink RW, 2013, MOL MEMBR BIOL, V30, P327, DOI 10.3109/09687688.2013.823018; Hufnagl K, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19883-0; Inoue R, 2001, CLIN EXP ALLERGY, V31, P1126, DOI 10.1046/j.1365-2222.2001.01135.x; Jacob T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-44999-2; Jarvinen KM, 2002, J ALLERGY CLIN IMMUN, V110, P293, DOI 10.1067/mai.2002.126080; Jason J, 2001, CLIN EXP IMMUNOL, V126, P466, DOI 10.1046/j.1365-2249.2001.01707.x; Jensen-Jarolim E, 2016, ALLERGY, V71, P286, DOI 10.1111/all.12797; Jin UH, 2018, TOXICOL SCI, V164, P205, DOI 10.1093/toxsci/kfy075; Jonsson K, 2016, PEDIATR RES, V79, P114, DOI 10.1038/pr.2015.187; Jordakieva G, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10914-6; Kaczmarski M, 2013, ADV MED SCI-POLAND, V58, P22, DOI 10.2478/v10039-012-0053-3; Kanakis CD, 2011, FOOD CHEM, V127, P1046, DOI 10.1016/j.foodchem.2011.01.079; Kehrer JP, 2010, CELL BIOL TOXICOL, V26, P83, DOI 10.1007/s10565-009-9119-9; Keppler JK, 2015, J MOL RECOGNIT, V28, P656, DOI 10.1002/jmr.2480; Khodr HH, 2002, J BIOL INORG CHEM, V7, P891, DOI 10.1007/s00775-002-0375-x; Kim YE, 2019, J FOOD SCI, V84, P3083, DOI 10.1111/1750-3841.14812; Koch S, 2017, ALLERGY, V72, P1686, DOI 10.1111/all.13170; Kontopidis G, 2002, J MOL BIOL, V318, P1043, DOI 10.1016/S0022-2836(02)00017-7; Kreitinger JM, 2016, J IMMUNOL, V196, P3217, DOI 10.4049/jimmunol.1502149; Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022; Lam HY, 2008, CLIN EXP ALLERGY, V38, P995, DOI 10.1111/j.1365-2222.2008.02968.x; Leung S, 2005, J BIOMOL SCREEN, V10, P157, DOI 10.1177/1087057104272394; Li XM, 2015, FOOD FUNCT, V6, P1841, DOI 10.1039/c5fo00117j; Liu HC, 2007, J DAIRY SCI, V90, P547, DOI 10.3168/jds.S0022-0302(07)71538-2; Loss G, 2011, J ALLERGY CLIN IMMUN, V128, P766, DOI 10.1016/j.jaci.2011.07.048; Machado Y, 2016, J ALLERGY CLIN IMMUN, V137, P1525, DOI 10.1016/j.jaci.2015.09.026; Mansouri A, 1998, BIOFACTORS, V7, P287, DOI 10.1002/biof.5520070401; Manzano-Szalai K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150819; MECHERI S, 1987, ANN INST PASTEUR IMM, V138, P213, DOI 10.1016/S0769-2625(87)80072-7; Mirpoor SF, 2017, FOOD CHEM, V233, P282, DOI 10.1016/j.foodchem.2017.04.126; Moreland JL, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-21; MORIKAWA K, 1995, LEUKEMIA LYMPHOMA, V18, P429, DOI 10.3109/10428199509059641; Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256; Nairz M, 2017, PFLUG ARCH EUR J PHY, V469, P397, DOI 10.1007/s00424-017-1944-8; Nairz M, 2015, EUR J IMMUNOL, V45, P3073, DOI 10.1002/eji.201545569; Negishi T, 2005, J IMMUNOL, V175, P7348, DOI 10.4049/jimmunol.175.11.7348; Novotna A, 2011, ENVIRON SCI TECHNOL, V45, P10133, DOI 10.1021/es2029334; Nwaru BI, 2014, BRIT J NUTR, V112, P2018, DOI 10.1017/S0007114514003122; Perron NR, 2008, INORG CHEM, V47, P6153, DOI 10.1021/ic7022727; Perron NR, 2009, CELL BIOCHEM BIOPHYS, V53, P75, DOI 10.1007/s12013-009-9043-x; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Plundrich NJ, 2017, FOOD FUNCT, V8, P1611, DOI [10.1039/C7FO00249A, 10.1039/c7fo00249a]; Qamar N, 2015, CLIN EXP ALLERGY, V45, P1663, DOI 10.1111/cea.12570; Quintana FJ, 2008, NATURE, V453, P65, DOI 10.1038/nature06880; Rawel HA, 2003, INT J BIOL MACROMOL, V32, P109, DOI 10.1016/S0141-8130(03)00044-8; Roth-Walter F, 2008, ALLERGY, V63, P882, DOI 10.1111/j.1398-9995.2008.01673.x; Roth-Walter F, 2014, Patent No. [EP 14150965.3, 14204570]; Roth-Walter F, 2014, Patent No. [EP 14150965.3, 141509653]; Roth-Walter F, 2018, WORLD ALLERGY ORGAN, V11, DOI 10.1186/s40413-018-0201-8; Roth-Walter F, 2017, SCI REP-UK, V7, DOI 10.1038/srep45067; Roth-Walter F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104803; Roth-Walter F, 2014, J BIOL CHEM, V289, P17416, DOI 10.1074/jbc.M114.567875; Sahihi M, 2012, J MACROMOL SCI B, V51, P2311, DOI 10.1080/00222348.2012.672854; Sakaguchi H, 2002, CLIN EXP ALLERGY, V32, P762, DOI 10.1046/j.1365-2222.2002.01370.x; Salvi A, 2001, BIOCHEM PHARMACOL, V61, P1237, DOI 10.1016/S0006-2952(01)00607-4; Shaheen SO, 2017, CLIN EXP ALLERGY, V47, P1615, DOI 10.1111/cea.13034; Shaheen SO, 2004, EUR RESPIR J, V24, P292, DOI 10.1183/09031936.04.00117803; Shields-Cutler RR, 2015, J BIOL CHEM, V290, P15949, DOI 10.1074/jbc.M115.645812; Skazik-Voogt C, 2016, ALTEX-ALTERN ANIM EX, V33, P37, DOI 10.14573/altex.1502041; Song CY, 2005, J BIOL CHEM, V280, P3574, DOI 10.1074/jbc.M407031200; Stein MM, 2016, NEW ENGL J MED, V375, P411, DOI 10.1056/NEJMoa1508749; Stojadinovic M, 2013, FOOD CHEM, V136, P1263, DOI 10.1016/j.foodchem.2012.09.040; Tao F, 2019, INT J BIOL MACROMOL, V126, P1186, DOI 10.1016/j.ijbiomac.2019.01.017; THEOBALD K, 1987, INT ARCH ALLER A IMM, V82, P295, DOI 10.1159/000234211; THEOBALD K, 1987, AGENTS ACTIONS, V20, P10, DOI 10.1007/BF01965620; THORSON JA, 1991, CELL IMMUNOL, V134, P126, DOI 10.1016/0008-8749(91)90336-A; Tong ZM, 2005, BIOCHEM J, V391, P441, DOI 10.1042/BJ20051020; Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334; Vaidyanathan B, 2017, J EXP MED, V214, P197, DOI 10.1084/jem.20160789; Villa M, 2017, EMBO J, V36, P116, DOI 10.15252/embj.201695027; Wang X, 2014, J DAIRY SCI, V97, P2559, DOI 10.3168/jds.2013-7461; Waser M, 2007, CLIN EXP ALLERGY, V37, P661, DOI 10.1111/j.1365-2222.2006.02640.x; Wojnar P, 2003, J BIOL CHEM, V278, P16209, DOI 10.1074/jbc.M210922200; Xu T, 2015, J IMMUNOL, V195, P5539, DOI 10.4049/jimmunol.1501198; Yang DG, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004335; Ye J, 2017, CELL REP, V21, P2277, DOI 10.1016/j.celrep.2017.10.114; Yu ES, 2008, BIOCHEM PHARMACOL, V76, P70, DOI 10.1016/j.bcp.2008.03.020; Yu Y, 2019, INT J MOL SCI, V20; Zhang LL, 2017, FOOD CHEM, V237, P39, DOI 10.1016/j.foodchem.2017.05.048; Zhang Q, 2018, J CELL MOL MED, V22, P4335, DOI 10.1111/jcmm.13723; Zommara M, 1998, BIOSCI BIOTECH BIOCH, V62, P710, DOI 10.1271/bbb.62.710	114	36	36	3	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2021	147	1					321	+		10.1016/j.jaci.2020.05.023	http://dx.doi.org/10.1016/j.jaci.2020.05.023		JAN 2021	18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PS2UA	32485264	Bronze, Green Published			2022-12-18	WOS:000607781700006
J	Milito, C; Pulvirenti, F; Cinetto, F; Lougaris, V; Soresina, A; Pecoraro, A; Vultaggio, A; Carrabba, M; Lassandro, G; Plebani, A; Spadaro, G; Matucci, A; Fabio, G; Dellepiane, RM; Martire, B; Agostini, C; Abeni, D; Tabolli, S; Quinti, I				Milito, Cinzia; Pulvirenti, Federica; Cinetto, Francesco; Lougaris, Vassilios; Soresina, Annarosa; Pecoraro, Antonio; Vultaggio, Alessandra; Carrabba, Maria; Lassandro, Giuseppe; Plebani, Alessandro; Spadaro, Giuseppe; Matucci, Andrea; Fabio, Giovanna; Dellepiane, Rosa Maria; Martire, Baldassarre; Agostini, Carlo; Abeni, Damiano; Tabolli, Stefano; Quinti, Isabella			Double-blind, placebo-controlled, randomized trial on low-dose azithromycin prophylaxis in patients with primary antibody deficiencies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Primary antibody defects; azithromycin; antibiotic prophylaxis; respiratory exacerbation; chronic obstructive pulmonary disease	TERM MACROLIDE TREATMENT; CYSTIC-FIBROSIS; PULMONARY-FUNCTION; LARGE COHORT; EXACERBATIONS; PREVENTION; INFECTIONS; THERAPY	Background: Lacking protective antibodies, patients with primary antibody deficiencies (PADs) experience frequent respiratory tract infections, leading to chronic pulmonary damage. Macrolide prophylaxis has proved effective in patients with chronic respiratory diseases. Objective: We aimed to test the efficacy and safety of orally administered low-dose azithromycin prophylaxis in patients with PADs. Methods: We designed a 3-year, double-blind, placebo-controlled, randomized clinical trial to test whether oral azithromycin (250 mg administered once daily 3 times a week for 2 years) would reduce respiratory exacerbations in patients with PADs and chronic infection-related pulmonary diseases. The primary end point was the number of annual respiratory exacerbations. Secondary end points included time to first exacerbation, additional antibiotic courses, number of hospitalizations, and safety. Results: Eighty-nine patients received azithromycin (n = 44) or placebo (n = 45). The number of exacerbations was 3.6 (95% CI, 2.5-4.7) per patient-year in the azithromycin arm and 5.2 (95% CI, 4.1-6.4) per patient-year in the placebo arm (P = .02). In the azithromycin group the hazard risk for having an acute exacerbation was 0.5 (95% CI, 0.3-0.9; P = .03), and the hazard risk for hospitalization was 0.5 (95% CI, 0.2-1.1; P = .04). The rate of additional antibiotic treatment per patient-year was 2.3 (95% CI, 2.1-3.4) in the intervention group and 3.6 (95% CI, 2.9-4.3) in the placebo group (P = .004). Haemophilus influenzae and Streptococcus pneumoniae were the prevalent isolates, and they were not susceptible to macrolides in 25% of patients of both arms. Azithromycin's safety profile was comparable with that of placebo. Conclusion: The study reached the main outcome centered on the reduction of exacerbation episodes per patient-year, with a consequent reduction in additional courses of antibiotics and risk of hospitalization.	[Milito, Cinzia; Pulvirenti, Federica; Quinti, Isabella] Sapienza Univ Rome, Dept Mol Med, Viale Univ 37, I-00185 Rome, Italy; [Cinetto, Francesco; Agostini, Carlo] Univ Padua, Dept Med DIMED, Padua, Italy; [Lougaris, Vassilios; Plebani, Alessandro] Univ Brescia, Dept Clin & Expt Sci, Brescia, Italy; [Lougaris, Vassilios; Plebani, Alessandro] ASST Spedali Civili Brescia, Brescia, Italy; [Soresina, Annarosa] Univ Brescia, ASST Spedali Civili Brescia, Dept Pediat, Brescia, Italy; [Pecoraro, Antonio; Spadaro, Giuseppe] Univ Naples Federico II, Dept Translat Med Sci, Naples, Italy; [Pecoraro, Antonio; Spadaro, Giuseppe] Univ Naples Federico II, Ctr Basic & Clin Immunol Res, Naples, Italy; [Vultaggio, Alessandra; Matucci, Andrea] AOU Careggi, Dept Med Geriatr, Immunoallergol Unit, Florence, Italy; [Carrabba, Maria; Fabio, Giovanna] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Internal Med, Milan, Italy; [Lassandro, Giuseppe; Martire, Baldassarre] Univ Bari, Dept Biomed & Evolut Age, Bari, Italy; [Dellepiane, Rosa Maria] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Pediat, Milan, Italy; [Abeni, Damiano; Tabolli, Stefano] IRCCS, Hlth Serv Res Unit IDI, Rome, Italy	Sapienza University Rome; University of Padua; University of Brescia; Hospital Spedali Civili Brescia; Hospital Spedali Civili Brescia; University of Brescia; University of Naples Federico II; University of Naples Federico II; University of Florence; Azienda Ospedaliero Universitaria Careggi; IRCCS Ca Granda Ospedale Maggiore Policlinico; Universita degli Studi di Bari Aldo Moro; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan	Quinti, I (corresponding author), Sapienza Univ Rome, Dept Mol Med, Viale Univ 37, I-00185 Rome, Italy.	isabella.quinti@uniroma1.it	Cinetto, Francesco/AAE-5328-2019; Alessandra, Vultaggio/K-3201-2014; Milito, Cinzia/AAP-7075-2020; Abeni, Damiano/AAA-1401-2019; Carrabba, Maria/AAM-5651-2020; Cinetto, Francesco/J-7386-2018	Cinetto, Francesco/0000-0001-8486-5850; Carrabba, Maria/0000-0002-0717-9096; Cinetto, Francesco/0000-0001-8486-5850; Ziyadullaev, Shukhrat/0000-0002-9309-3933	Agenzia Italiana del Farmaco (AIFA) [2011-004351-39]; Jeffrey Modell Foundation	Agenzia Italiana del Farmaco (AIFA); Jeffrey Modell Foundation	Clinical Trials no. EUDRACT 2011-004351-39 was funded by the Agenzia Italiana del Farmaco (AIFA). The Rome PID Clinical Research Center is supported by the Jeffrey Modell Foundation.	Agusti A, 2018, LANCET RESP MED, V18, P30296; Albert RK, 2011, NEW ENGL J MED, V365, P689, DOI 10.1056/NEJMoa1104623; Baron EJ, 2007, MANUAL OF CLINICAL MICROBIOLOGY, 9TH ED, P1; Beigelman A, 2015, J ALLERGY CLIN IMMUN, V135, P1171, DOI 10.1016/j.jaci.2014.10.001; Berger Melvin, 2017, Respir Med, V132, P181, DOI 10.1016/j.rmed.2017.10.016; Berkhof FF, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-125; Binder AM, 2013, AM J RESP CRIT CARE, V188, P807, DOI 10.1164/rccm.201307-1200OC; Bonilla FA, 2016, J ALLER CL IMM-PRACT, V4, P38, DOI 10.1016/j.jaip.2015.07.025; Brusselle GG, 2013, THORAX, V68, P322, DOI 10.1136/thoraxjnl-2012-202698; Cameron EJ, 2012, CLIN EXP ALLERGY, V42, P1302, DOI 10.1111/j.1365-2222.2012.03979.x; Clinical and Laboratory Standards Institute, 2012, M07A9 CLIN LAB STAND; Durandy A, 2013, NAT REV IMMUNOL, V13, P519, DOI 10.1038/nri3466; Equi A, 2002, LANCET, V360, P978, DOI 10.1016/S0140-6736(02)11081-6; Freeman AF, 2009, CURR OPIN ALLERGY CL, V9, P525, DOI 10.1097/ACI.0b013e328332be33; Hurst JR, 2014, J CLIN IMMUNOL, V34, P68, DOI 10.1007/s10875-013-9942-x; Lee RA, 2016, J HOSP MED, V11, P15, DOI 10.1002/jhm.2448; Lucas M, 2010, J ALLERGY CLIN IMMUN, V125, P1354, DOI 10.1016/j.jaci.2010.02.040; Malhotra-Kumar S, 2007, LANCET, V369, P482, DOI 10.1016/S0140-6736(07)60235-9; Picard C, 2018, J CLIN IMMUNOL, V38, P96, DOI 10.1007/s10875-017-0464-9; Plebani A, 2002, CLIN IMMUNOL, V104, P221, DOI 10.1006/clim.2002.5241; Pulvirenti F, 2018, J ALLERGY CLIN IMMUN, V142, P1999, DOI 10.1016/j.jaci.2018.08.014; Quinti I, 2007, J CLIN IMMUNOL, V27, P308, DOI 10.1007/s10875-007-9075-1; Quinti I, 2011, J CLIN IMMUNOL, V31, P315, DOI 10.1007/s10875-011-9511-0; Renna M, 2011, J CLIN INVEST, V121, P3554, DOI 10.1172/JCI46095; Rosell A, 2005, ARCH INTERN MED, V165, P891, DOI 10.1001/archinte.165.8.891; Saiman L, 2010, JAMA-J AM MED ASSOC, V303, P1707, DOI 10.1001/jama.2010.563; Spagnolo P, 2013, EUR RESPIR J, V42, P239, DOI 10.1183/09031936.00136712; Sperlich JM, 2018, J ALLER CL IMM-PRACT, V6, P159, DOI 10.1016/j.jaip.2017.05.024; Starner TD, 2008, ANTIMICROB AGENTS CH, V52, P137, DOI 10.1128/AAC.00607-07; Tabolli S, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00605; Thickett KM, 2002, QJM-INT J MED, V95, P655, DOI 10.1093/qjmed/95.10.655; Verma N, 2015, LANCET RESP MED, V3, P651, DOI 10.1016/S2213-2600(15)00202-7; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wong C, 2012, LANCET, V380, P660, DOI 10.1016/S0140-6736(12)60953-2; Zhou YJ, 2016, J ALLERGY CLIN IMMUN, V138, P1215, DOI 10.1016/j.jaci.2016.03.054	35	36	36	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2019	144	2					584	+		10.1016/j.jaci.2019.01.051	http://dx.doi.org/10.1016/j.jaci.2019.01.051			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IN6LC	30910492	Green Published, hybrid			2022-12-18	WOS:000478789300025
J	Garcia-Morato, MB; Apalategi, AC; Bravo-Gallego, LY; Moreno, AB; Simon-Fuentes, M; Garmendia, JV; Echevarria, AM; Rabes, TD; Dominguez-Soto, A; Lopez-Granados, E; Reyburn, HT; Pena, RR				Bravo Garcia-Morato, Maria; Calvo Apalategi, Ane; Yadira Bravo-Gallego, Luz; Blazquez Moreno, Alfonso; Simon-Fuentes, Miriam; Garmendia, Jenny V.; Mendez Echevarria, Ana; del Rosal Rabes, Teresa; Dominguez-Soto, Angeles; Lopez-Granados, Eduardo; Reyburn, Hugh T.; Rodriguez Pena, Rebeca			Impaired control of multiple viral infections in a family with complete IRF9 deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							STAT2 DEFICIENCY; DNA; DEGRADATION		[Bravo Garcia-Morato, Maria; Yadira Bravo-Gallego, Luz; Lopez-Granados, Eduardo; Rodriguez Pena, Rebeca] La Paz Univ Hosp, Dept Immunol, Madrid, Spain; [Bravo Garcia-Morato, Maria; Yadira Bravo-Gallego, Luz; Lopez-Granados, Eduardo; Rodriguez Pena, Rebeca] IdiPAZ, La Paz Inst Biomed Res, Lymphocyte Pathophysiol Grp, Madrid, Spain; [Calvo Apalategi, Ane; Blazquez Moreno, Alfonso; Reyburn, Hugh T.] CSIC, CNB, Dept Immunol & Oncol, Madrid, Spain; [Simon-Fuentes, Miriam; Dominguez-Soto, Angeles] CSIC, Ctr Invest Biol, Madrid, Spain; [Garmendia, Jenny V.] Univ Cent Venezuela, Inst Inmunol, Fac Med, Caracas, Venezuela; [Mendez Echevarria, Ana; del Rosal Rabes, Teresa] La Paz Univ Hosp, Paediat Infect Dis Dept, Madrid, Spain	Hospital Universitario La Paz; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); University of Central Venezuela; Hospital Universitario La Paz	Reyburn, HT (corresponding author), CSIC, CNB, Dept Immunol & Oncol, Madrid, Spain.	htreyburn@cnb.csic.es	DOMINGUEZ-SOTO, ANGELES/K-5937-2014	Simon-Fuentes, Miriam/0000-0002-8503-0174; Bravo Gallego, Luz Yadira/0000-0002-4919-5166; Garmendia, Jenny/0000-0002-4977-1899; Calvo Apalategi, Ane/0000-0003-3602-5210; Dominguez Soto, Angeles/0000-0003-1299-5992; ANA, MENDEZ ECHEVARRIA/0000-0002-7455-9080	MINECO/AEI/FEDER, UE [SAF2014-58752-R, SAF2017-83265-R, SAF2017-83785-R]; MINECO [SVP-2014-068263]; Spanish Association Against Cancer (AECC); Carlos III Health Institute [PI16/01605]	MINECO/AEI/FEDER, UE(Spanish Government); MINECO(Spanish Government); Spanish Association Against Cancer (AECC); Carlos III Health Institute(Instituto de Salud Carlos III)	Supported by grants SAF2014-58752-R and SAF2017-83265-R (to H.T.R.), SAF2017-83785-R (to A.D.-S.; MINECO/AEI/FEDER, UE), and a PhD studentship to A.B.M. (MINECO, SVP-2014-068263). E.L.-G. has grants from the Spanish Association Against Cancer (AECC) and Carlos III Health Institute PI16/01605).	Blazquez-Moreno A, 2017, P NATL ACAD SCI USA, V114, pE5645, DOI 10.1073/pnas.1706483114; Boisson-Dupuis S, 2012, CURR OPIN IMMUNOL, V24, P364, DOI 10.1016/j.coi.2012.04.011; Chen MX, 2016, MOL CELL, V64, P105, DOI 10.1016/j.molcel.2016.08.025; Cheon H, 2013, EMBO J, V32, P2751, DOI 10.1038/emboj.2013.203; Dominguez-Soto A, 2014, J IMMUNOL, V193, P5181, DOI 10.4049/jimmunol.1303375; Duncan CJA, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac4227; Esteso G, 2017, J BIOL CHEM, V292, P20472, DOI 10.1074/jbc.M117.818393; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; Garcia-Arriaza J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066894; Grbesa I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124670; Hallak LK, 2000, J VIROL, V74, P10508, DOI 10.1128/JVI.74.22.10508-10513.2000; Hambleton S, 2013, P NATL ACAD SCI USA, V110, P3053, DOI 10.1073/pnas.1220098110; Hayer A, 2016, NAT CELL BIOL, V18, P1311, DOI 10.1038/ncb3438; Hernandez N, 2018, J EXP MED, V215, P2567, DOI 10.1084/jem.20180628; Jenkins RW, 2011, J BIOL CHEM, V286, P13292, DOI 10.1074/jbc.M110.163378; Jiang LJ, 2011, P NATL ACAD SCI USA, V108, P1897, DOI 10.1073/pnas.1019059108; Kreins AY, 2015, J EXP MED, V212, P1641, DOI 10.1084/jem.20140280; Ma Z, 2015, P NATL ACAD SCI USA, V112, pE4306, DOI 10.1073/pnas.1503831112; Melzner I, 2005, BLOOD, V105, P2535, DOI 10.1182/blood-2004-09-3701; Misawa A, 2016, J BIOL CHEM, V291, P17861, DOI 10.1074/jbc.M116.718536; Moens L, 2017, J ALLERGY CLIN IMMUN, V139, P1995, DOI 10.1016/j.jaci.2016.10.033; Paul A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01831; Sainz B, 2014, CANCER RES, V74, P7309, DOI 10.1158/0008-5472.CAN-14-1354; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; VEALS SA, 1993, MOL CELL BIOL, V13, P196, DOI 10.1128/MCB.13.1.196; Wehr C, 2008, BLOOD, V111, P77, DOI 10.1182/blood-2007-06-091744	26	36	36	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2019	144	1					309	+		10.1016/j.jaci.2019.02.019	http://dx.doi.org/10.1016/j.jaci.2019.02.019			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IF9SM	30826365	Green Submitted			2022-12-18	WOS:000473432800033
J	Visvanathan, S; Baum, P; Vinisko, R; Schmid, R; Flack, M; Lalovic, B; Kleiner, O; Fuentes-Duculan, J; Garcet, S; Davis, JW; Grebe, KM; Fine, JS; Padula, SJ; Krueger, JG				Visvanathan, Sudha; Baum, Patrick; Vinisko, Richard; Schmid, Ramona; Flack, Mary; Lalovic, Bojan; Kleiner, Oliver; Fuentes-Duculan, Judilyn; Garcet, Sandra; Davis, Justin W.; Grebe, Kristie M.; Fine, Jay S.; Padula, Steven J.; Krueger, James G.			Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Risankizumab; ustekinumab; IL-23; IL-12; IL-17; psoriasis; biomarkers	PLAQUE PSORIASIS; DOUBLE-BLIND; BRODALUMAB; CYTOKINE; INTERLEUKIN-23; INFLAMMATION; SECUKINUMAB; MECHANISMS; EXPRESSION; ANTIBODY	Background: IL-23 contributes to the activation, maintenance, and proliferation of TH17 cells and plays a major role in psoriasis pathophysiology. IL-23p19 inhibition with risankizumab resulted in superior clinical responses in patients with psoriasis compared with ustekinumab (dual IL-12/IL-23 inhibitor), but comparative molecular effects have not been established. Objective: We investigated the similarities and differences in molecular and histopathologic profiles in skin lesions from patients with psoriasis receiving risankizumab versus ustekinumab at an early time point. Methods: Lesional skin biopsy samples from 81 patients with moderate-to-severe plaque psoriasis participating in 2 different studies (a phase I risankizumab study and a phase II study of risankizumab vs ustekinumab) were analyzed by using histopathology, immunohistochemistry, and RNA sequencing. Results: Risankizumab induced a rapid decrease in levels of proteins and transcriptomic biomarkers associated with the IL-23 pathway, which were maintained through 8 weeks. At week 4, risankizumab decreased histopathologic expression of biomarkers, including K16, Ki67, CD3, lipocalin-2, CD11c, dendritic cell lysosome-associated membrane glycoprotein, beta-defensin 2, and S100A7; global histopathologic scoring revealed that 54% and 69% of patients treated with 90 or 180 mg of risankizumab, respectively, were graded as experiencing "excellent improvement'' versus 29% of patients treated with ustekinumab. At week 4, there was a common decrease in expression of 2645 genes expressed in lesional skin between patients receiving risankizumab and ustekinumab and a significant decrease in 2682 genes unique to risankizumab treatment. Risankizumab more strongly downregulated expression of genes associated with keratinocytes, epidermal cells, and monocytes, versus ustekinumab. Conclusion: Risankizumab demonstrated more pronounced changes in the molecular and histopathologic profile of psoriatic skin lesions compared with ustekinumab at week 4.	[Visvanathan, Sudha; Vinisko, Richard; Flack, Mary; Lalovic, Bojan; Fine, Jay S.] Boehringer Ingelheim Pharmaceut, 900 Ridgebury Rd, Ridgefield, CT 06877 USA; [Baum, Patrick; Schmid, Ramona; Kleiner, Oliver] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany; [Fuentes-Duculan, Judilyn; Garcet, Sandra; Krueger, James G.] Rockefeller Univ, Lab Invest Dermatol, 1230 York Ave, New York, NY 10021 USA; [Davis, Justin W.] AbbVie, N Chicago, IL USA; [Grebe, Kristie M.] AbbVie, Worcester, MA USA; [Padula, Steven J.] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany	Boehringer Ingelheim; Boehringer Ingelheim; Rockefeller University; AbbVie; AbbVie; Boehringer Ingelheim	Visvanathan, S (corresponding author), Boehringer Ingelheim Pharmaceut, 900 Ridgebury Rd, Ridgefield, CT 06877 USA.	sudha.visvanathan@boehringer-ingelheim.com		Garcet, Sandra/0000-0002-4465-8547	Boehringer Ingelheim - Boehringer Ingelheim	Boehringer Ingelheim - Boehringer Ingelheim	Supported by Boehringer Ingelheim. The sponsor was involved in the study design, collection, analysis, and interpretation of the data.; Expertise in development of the beta-defensin 2 assay was provided by Ulrich Kunz, Boehringer Ingelheim (Ingelheim, Germany). Editorial assistance in the development of this manuscript was provided by Leigh Church, PhD, of Succinct Medical Communications (London, United Kingdom) and was funded by Boehringer Ingelheim.	Blauvelt A, 2017, J AM ACAD DERMATOL, V76, P60, DOI 10.1016/j.jaad.2016.08.008; Chyou S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032828; Cua DJ, 2003, NATURE, V421, P744, DOI 10.1038/nature01355; Flores RR, 2015, EUR J IMMUNOL, V45, P3114, DOI 10.1002/eji.201445403; Gaffen SL, 2014, NAT REV IMMUNOL, V14, P585, DOI 10.1038/nri3707; Hasegawa H, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00479; Hu D, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01571-8; Kolbinger F, 2017, J ALLERGY CLIN IMMUN, V139, P923, DOI 10.1016/j.jaci.2016.06.038; Krueger J, 2016, J ALLERGY CLIN IMMUN, V137, P1079, DOI 10.1016/j.jaci.2015.12.1318; Krueger JG, 2012, J ALLERGY CLIN IMMUN, V130, P145, DOI 10.1016/j.jaci.2012.04.024; Krueger JG, 2015, J ALLERGY CLIN IMMUN, V136; Kulig P, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13466; Langley RG, 2014, NEW ENGL J MED, V371, P326, DOI 10.1056/NEJMoa1314258; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Li BS, 2014, J INVEST DERMATOL, V134, P1828, DOI 10.1038/jid.2014.28; Lowes MA, 2014, ANNU REV IMMUNOL, V32, P227, DOI 10.1146/annurev-immunol-032713-120225; Nestle FO, 2009, NEW ENGL J MED, V361, P496, DOI 10.1056/NEJMra0804595; Neumann C, 2014, J EXP MED, V211, P1807, DOI 10.1084/jem.20131548; Papp KA, 2016, BRIT J DERMATOL, V175, P273, DOI 10.1111/bjd.14493; Papp KA, 2013, BRIT J DERMATOL, V168, P844, DOI 10.1111/bjd.12214; Papp KA, 2008, LANCET, V371, P1675, DOI 10.1016/S0140-6736(08)60726-6; Papp KA, 2017, NEW ENGL J MED, V376, P1551, DOI 10.1056/NEJMoa1607017; Papp KA, 2012, NEW ENGL J MED, V366, P1181, DOI 10.1056/NEJMoa1109017; Ramnath D, 2015, IMMUNOL CELL BIOL, V93, P771, DOI 10.1038/icb.2015.77; Russell CB, 2014, J IMMUNOL, V192, P3828, DOI 10.4049/jimmunol.1301737; Shibata S, 2013, J INVEST DERMATOL, V133, P479, DOI 10.1038/jid.2012.313; Sofen H, 2014, J ALLERGY CLIN IMMUN, V133, P1032, DOI 10.1016/j.jaci.2014.01.025; Swindell WR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079253; Swindell WR, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-527; Volpe E, 2008, NAT IMMUNOL, V9, P650, DOI 10.1038/ni.1613; Wang XQ, 2016, EUR J IMMUNOL, V46, P1343, DOI 10.1002/eji.201546095	31	36	38	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2019	143	6					2158	2169		10.1016/j.jaci.2018.11.042	http://dx.doi.org/10.1016/j.jaci.2018.11.042			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IB2QG	30578873	hybrid			2022-12-18	WOS:000470113200020
J	Rueter, K; Jones, AP; Siafarikas, A; Lim, EM; Bear, N; Noakes, PS; Prescott, SL; Palmer, DJ				Rueter, Kristina; Jones, Anderson P.; Siafarikas, Aris; Lim, Ee-Mun; Bear, Natasha; Noakes, Paul S.; Prescott, Susan L.; Palmer, Debra J.			Direct infant UV light exposure is associated with eczema and immune development	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy prevention; eczema; hereditary risk; infant; immune function; randomized controlled trial; UV light; vitamin D supplementation; wheeze	VITAMIN-D; FOOD ALLERGY; POTENTIAL ROLE; BONE-MARROW; SUPPLEMENTATION; SENSITIZATION; EOSINOPHILS; PREVALENCE; PREGNANCY; LATITUDE	Background: Suboptimal vitamin D levels during critical periods of immune development have emerged as an explanation for higher rates of allergic diseases associated with industrialization and residing at higher latitudes. Objective: We sought to determine the effects of early postnatal vitamin D supplementation on infant eczema and immune development. Methods: By using a double- blind randomized controlled trial, newborn infants were randomized to receive vitamin D supplementation (400 IU/d) or a placebo until 6 months of age. Some infants also wore personal UV dosimeters to measure direct UV light (290-380 nm) exposure. Infant vitamin D levels were measured at 3 and 6 months of age. Eczema, wheeze, and immune function outcomes were assessed at 6 months of age. Results: At 3 (P<.01) and 6 (P = .02) months of age, vitamin D levels were greater for the vitamin D-supplemented group than the placebo group, but there was no difference in eczema incidence between groups. Infants with eczema were found to have had less UV light exposure (median, 555 Joules per square meter [J/m(2); interquartile range, 322-1210 J/m(2)]) compared with those without eczema (median, 998 J/m(2) [interquartile range, 676-1577 J/m(2)]; P = .02). UV light exposure was also inversely correlated with IL-2, GM-CSF, and eotaxin production to Toll-like receptor ligands. Conclusion: This study is the first to demonstrate an association between greater direct UV light exposures in early infancy with lower incidence of eczema and proinflammatory immune markers by 6 months of age. Our findings indicate that UV light exposure appears more beneficial than vitamin D supplementation as an allergy prevention strategy in early life.	[Rueter, Kristina; Siafarikas, Aris; Noakes, Paul S.; Prescott, Susan L.; Palmer, Debra J.] Univ Western Australia, Sch Med, Crawley, Australia; [Rueter, Kristina; Siafarikas, Aris; Prescott, Susan L.] Princess Margaret Hosp, Subiaco, WA, Australia; [Rueter, Kristina; Prescott, Susan L.] WUN, InVIVO Planetary Hlth Grp, West New York, NJ USA; [Jones, Anderson P.; Siafarikas, Aris; Noakes, Paul S.; Prescott, Susan L.; Palmer, Debra J.] Univ Western Australia, Telethon Kids Inst, Subiaco, WA, Australia; [Lim, Ee-Mun] Sir Charles Gairdner Hosp, Dept Endocrinol & Diabet, Nedlands, WA, Australia; [Lim, Ee-Mun] Queen Elizabeth II Med Ctr, Dept Clin Biochem, PathWest Lab Med, Nedlands, WA, Australia; [Bear, Natasha] Child Adolescent Hlth Serv, Dept Clin Res & Educ, Perth, WA, Australia	University of Western Australia; Telethon Kids Institute; University of Western Australia; University of Western Australia; University of Western Australia	Palmer, DJ (corresponding author), Univ Western Australia, Sch Med, Crawley, Australia.; Palmer, DJ (corresponding author), Univ Western Australia, Telethon Kids Inst, Subiaco, WA, Australia.	debbie.palmer@telethonkids.org.au	Palmer, Debra/AAH-6160-2019; Palmer, Debra J/L-8554-2013	Palmer, Debra J/0000-0003-2498-8343	Medical Research Future Fund Next Generation Clinical Researchers Program; Telethon-New Children's Hospital Research Fund, Australia; Asthma Foundation of Western Australia, Australia; Princess Margaret Hospital Foundation, Australia	Medical Research Future Fund Next Generation Clinical Researchers Program(Medical Research Future Fund (MRFF)); Telethon-New Children's Hospital Research Fund, Australia; Asthma Foundation of Western Australia, Australia; Princess Margaret Hospital Foundation, Australia	D.J.P. is supported by a Career Development Fellowship funded from the Medical Research Future Fund Next Generation Clinical Researchers Program. This study was supported by grants from Telethon-New Children's Hospital Research Fund, Australia; Asthma Foundation of Western Australia, Australia; and the Princess Margaret Hospital Foundation, Australia. The trial intervention and placebo control products were donated by Ddrops, Woodbridge, Ontario, Canada.	Allen KJ, 2013, J ALLERGY CLIN IMMUN, V131, P1109, DOI 10.1016/j.jaci.2013.01.017; Baek JH, 2014, J PEDIATR-US, V165, P849, DOI 10.1016/j.jpeds.2014.06.058; Baiz N, 2014, J ALLERGY CLIN IMMUN, V133, P147, DOI 10.1016/j.jaci.2013.05.017; Camargo CA, 2007, J ALLERGY CLIN IMMUN, V120, P131, DOI 10.1016/j.jaci.2007.03.049; Chawes BL, 2016, JAMA-J AM MED ASSOC, V315, P353, DOI 10.1001/jama.2015.18318; Cote-Sierra J, 2004, P NATL ACAD SCI USA, V101, P3880, DOI 10.1073/pnas.0400339101; Goldring ST, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066627; Grant CC, 2016, ALLERGY, V71, P1325, DOI 10.1111/all.12909; Hanifin JM, 2004, J AM ACAD DERMATOL, V50, P391, DOI 10.1016/j.jaad.2003.08.003; Hart PH, 2011, NAT REV IMMUNOL, V11, P584, DOI 10.1038/nri3045; Hewison M, 2003, J IMMUNOL, V170, P5382, DOI 10.4049/jimmunol.170.11.5382; Hogan SP, 2001, NAT IMMUNOL, V2, P353, DOI 10.1038/86365; Holan V, 1998, J IMMUNOL, V161, P3237; Hong SP, 2008, J INVEST DERMATOL, V128, P2880, DOI 10.1038/jid.2008.169; Humbles AA, 2002, P NATL ACAD SCI USA, V99, P1479, DOI 10.1073/pnas.261462598; Jeffery LE, 2012, J IMMUNOL, V189, P5155, DOI 10.4049/jimmunol.1200786; Litonjua AA, 2016, JAMA-J AM MED ASSOC, V315, P362, DOI 10.1001/jama.2015.18589; Llop-Guevara A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088714; McGonigle TA, 2018, J IMMUNOL, V200, P260, DOI 10.4049/jimmunol.1700760; Moehrle M, 2000, INT ARCH OCC ENV HEA, V73, P575, DOI 10.1007/s004200000183; Mullins RJ, 2012, CURR ALLERGY ASTHM R, V12, P64, DOI 10.1007/s11882-011-0230-7; Ng RLX, 2013, J IMMUNOL, V190, P5471, DOI 10.4049/jimmunol.1202786; Osborne NJ, 2012, J ALLERGY CLIN IMMUN, V129, P865, DOI 10.1016/j.jaci.2012.01.037; Prescott S, 2011, PEDIAT ALLERG IMM-UK, V22, P155, DOI 10.1111/j.1399-3038.2011.01145.x; Quintern LE, 1997, J PHOTOCH PHOTOBIO B, V37, P158, DOI 10.1016/S1011-1344(96)04414-4; Siafarikas A, 2011, ARCH DIS CHILD, V96, P91, DOI 10.1136/adc.2009.178301; Silverberg JI, 2013, J INVEST DERMATOL, V133, P1752, DOI 10.1038/jid.2013.19; Sleijffers A, 2003, PHOTOCHEM PHOTOBIOL, V77, P271, DOI 10.1562/0031-8655(2003)077<0271:ECUALC>2.0.CO;2; Thyssen JP, 2015, J ALLERGY CLIN IMMUN, V136, P1163, DOI 10.1016/j.jaci.2015.06.042; Wagner CL, 2008, PEDIATRICS, V122, P1142, DOI 10.1542/peds.2008-1862; WEFERS H, 1991, J INVEST DERMATOL, V96, P959, DOI 10.1111/1523-1747.ep12476124; Weller R, 1997, BRIT J DERMATOL, V137, P665	32	36	36	2	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2019	143	3					1012	+		10.1016/j.jaci.2018.08.037	http://dx.doi.org/10.1016/j.jaci.2018.08.037			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HN6CQ	30366577	Bronze			2022-12-18	WOS:000460272900021
J	Suarez-Farinas, M; Suprun, M; Chang, HL; Gimenez, G; Grishina, G; Getts, R; Nadeau, K; Wood, RA; Sampson, HA				Suarez-Farinas, Mayte; Suprun, Maria; Chang, Helena L.; Gimenez, Gustavo; Grishina, Galina; Getts, Robert; Nadeau, Kari; Wood, Robert A.; Sampson, Hugh A.			Predicting development of sustained unresponsiveness to milk oral immunotherapy using epitope-specific antibody binding profiles	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cow's milk allergy; oral immunotherapy; omalizumab; desensitization; sustained unresponsiveness; allergenic epitopes; epitope-specific antibodies; machine learning; elastic net algorithm; bootstrap aggregating strategy	DOUBLE-BLIND; SEQUENTIAL EPITOPES; TOLERANCE INDUCTION; NATURAL-HISTORY; IGE-BINDING; FOLLOW-UP; CHILDREN; ALLERGY; PEANUT; OMALIZUMAB	Background: In a recent trial of milk oral immunotherapy (MOIT) with or without omalizumab in 55 patients with milk allergy treated for 28 months, 44 of 55 subjects passed a 10-g desensitization milk protein challenge; 23 of 55 subjects passed the 10-g sustained unresponsiveness (SU) challenge 8 weeks after discontinuing MOIT. Objective: We sought to determine whether IgE and IgG(4) antibody binding to allergenic milk protein epitopes changes with MOIT and whether this could predict the development of SU. Methods: By using a novel high-throughput Luminex-based assay to quantitate IgE and IgG(4) antibody binding to 66 sequential epitopes on 5 milk proteins, serum samples from 47 subjects were evaluated before and after MOIT. Machine learning strategies were used to predict whether a subject would have SU after 8 weeks of MOIT discontinuation. Results: MOIT profoundly altered IgE and IgG(4) binding to epitopes, regardless of treatment outcome. At the initiation of MOIT, subjects achieving SU exhibited significantly less antibody binding to 40 allergenic epitopes than subjects who were desensitized only (false discovery rate <= 0.05 and fold change > 1.5). Based on baseline epitope-specific antibody binding, we developed predictive models of SU. Using simulations, we show that, on average, IgE-binding epitopes alone perform significantly better than models using standard serum component proteins (average area under the curve, > 97% vs 80%). The optimum model using 6 IgE-binding epitopes achieved a 95% area under the curve and 87% accuracy. Conclusion: Despite the relatively small sample size, we have shown that by measuring the epitope repertoire, we can build reliable models to predict the probability of SU after MOIT. Baseline epitope profiles appear more predictive of MOIT response than those based on serum component proteins.	[Suarez-Farinas, Mayte; Suprun, Maria; Chang, Helena L.] Icahn Sch Med Mt Sinai, Populat Hlth Sci & Policy, New York, NY 10029 USA; [Suarez-Farinas, Mayte] Icahn Sch Med Mt Sinai, Genet & Genom, New York, NY 10029 USA; [Suprun, Maria; Gimenez, Gustavo; Grishina, Galina; Sampson, Hugh A.] Icahn Sch Med Mt Sinai, Pediat Allergy & Immunol, New York, NY 10029 USA; [Getts, Robert] Stanford Univ, Sch Med, AllerGenis, Stanford, CA 94305 USA; [Nadeau, Kari] Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA; [Wood, Robert A.] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Allergy Immunol, Baltimore, MD 21205 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Stanford University; Stanford University; Johns Hopkins University	Sampson, HA (corresponding author), Icahn Sch Med Mt Sinai, Jaffe Food Allergy Inst, Box 1089, New York, NY 10034 USA.	hugh.sampson@mssm.edu	Suprun, Maria/ABE-8323-2020; Suprun, Maria/AAE-5507-2022	Suprun, Maria/0000-0001-9161-4021; 	David H. and Julia Koch Research Program in Food Allergy Therapeutics; National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) [U19 AI44236]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM062754] Funding Source: NIH RePORTER	David H. and Julia Koch Research Program in Food Allergy Therapeutics; National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	M.S.-F. received research grants to Mount Sinai by AllerGenis. This research was funded in part by the David H. and JuliaKoch Research Program in Food Allergy Therapeutics and U19 AI44236, a grant from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID).	BARTKO JJ, 1966, PSYCHOL REP, V19, P3, DOI 10.2466/pr0.1966.19.1.3; Belliveau Paul P, 2005, MedGenMed, V7, P27; Beyer K, 2005, J ALLERGY CLIN IMMUN, V116, P704, DOI 10.1016/j.jaci.2005.05.007; Burks AW, 2012, NEW ENGL J MED, V367, P233, DOI 10.1056/NEJMoa1200435; Cerecedo I, 2008, J ALLERGY CLIN IMMUN, V122, P589, DOI 10.1016/j.jaci.2008.06.040; Cianferoni A, 2012, IMMUNOL ALLERGY CLIN, V32, P165, DOI 10.1016/j.iac.2011.10.002; Costello JC, 2014, NAT BIOTECHNOL, V32, P1202, DOI 10.1038/nbt.2877; da Rosa JC, 2017, J INVEST DERMATOL, V137, P305, DOI 10.1016/j.jid.2016.09.015; Dantzer JA, 2018, CLIN EXP ALLERGY, V48, P232, DOI 10.1111/cea.13084; Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01; Gamer M, CRAN2012; Gorelik M, 2015, J ALLERGY CLIN IMMUN, V135, P1283, DOI 10.1016/j.jaci.2014.11.010; Grabenhenrich LB, 2016, J ALLERGY CLIN IMMUN, V137, P1128, DOI 10.1016/j.jaci.2015.11.015; Han N, 2008, ALLERGY, V63, P198, DOI 10.1111/j.1398-9995.2007.01539.x; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Keet CA, 2012, J ALLERGY CLIN IMMUN, V129, pe1; Keet CA, 2013, J ALLERGY CLIN IMMUN, V132, P737, DOI 10.1016/j.jaci.2013.05.006; Keet CA, 2012, J ALLERGY CLIN IMMUN, V129, P448, DOI 10.1016/j.jaci.2011.10.023; Leek JT, 2012, BIOINFORMATICS, V28, P882, DOI 10.1093/bioinformatics/bts034; Li J., 2009, BATCH EFFECTS NOISE, P141, DOI DOI 10.1002/9780470685983.CH12; Lin J, 2009, J ALLERGY CLIN IMMUN, V124, P315, DOI 10.1016/j.jaci.2009.05.024; Longo G, 2008, J ALLERGY CLIN IMMUN, V121, P343, DOI 10.1016/j.jaci.2007.10.029; Meglio P, 2008, PEDIAT ALLERG IMM-UK, V19, P412, DOI 10.1111/j.1399-3038.2007.00670.x; Nadeau KC, 2011, J ALLERGY CLIN IMMUN, V127, P1622, DOI 10.1016/j.jaci.2011.04.009; Narisety SD, 2015, J ALLERGY CLIN IMMUN, V135, P1275, DOI 10.1016/j.jaci.2014.11.005; Narisety SD, 2015, J ALLERGY CLIN IMMUN, V135, pe1; Palesch YY, 2014, STROKE, V45, pE244, DOI 10.1161/STROKEAHA.114.006138; Pennington LF, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11610; Petersen TH, 2018, PEDIAT ALLERG IMM-UK, V29, P194, DOI 10.1111/pai.12854; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; */* S   5, 2010, J ALLERGY CLIN IMM S, V126, pS, DOI DOI 10.1016/J.JACI.2010.10.007; Savilahti EM, 2014, PEDIAT ALLERG IMM-UK, V25, P227, DOI 10.1111/pai.12186; Schneider LC, 2013, J ALLERGY CLIN IMMUN, V132, P1368, DOI 10.1016/j.jaci.2013.09.046; Sicherer SH, 2011, J ALLERGY CLIN IMMUN, V127, P594, DOI 10.1016/j.jaci.2010.11.044; Skripak JM, 2007, J ALLERGY CLIN IMMUN, V120, P1172, DOI 10.1016/j.jaci.2007.08.023; Skripak JM, 2008, J ALLERGY CLIN IMMUN, V122, P1154, DOI 10.1016/j.jaci.2008.09.030; Smyth G.K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Staden U, 2007, ALLERGY, V62, P1261, DOI 10.1111/j.1398-9995.2007.01501.x; Syed A, 2014, J ALLERGY CLIN IMMUN, V133, P500, DOI 10.1016/j.jaci.2013.12.1037; Wang J, 2010, J ALLERGY CLIN IMMUN, V125, pe1; Wang J, 2010, J ALLERGY CLIN IMMUN, V125, P695, DOI 10.1016/j.jaci.2009.12.017; Wood RA, 2016, J ALLERGY CLIN IMMUN, V137, P1103, DOI 10.1016/j.jaci.2015.10.005; Wood RA, 2013, J ALLERGY CLIN IMMUN, V131, P805, DOI 10.1016/j.jaci.2012.10.060	43	36	38	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2019	143	3					1038	1046		10.1016/j.jaci.2018.10.028	http://dx.doi.org/10.1016/j.jaci.2018.10.028			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HN6CQ	30528770	Green Accepted, Bronze			2022-12-18	WOS:000460272900024
J	Nowak-Wegrzyn, A; Wood, RA; Nadeau, KC; Pongracic, JA; Henning, AK; Lindblad, RW; Beyer, K; Sampson, HA				Nowak-Wegrzyn, Anna; Wood, Robert A.; Nadeau, Kari C.; Pongracic, Jacqueline A.; Henning, Alice K.; Lindblad, Robert W.; Beyer, Kirsten; Sampson, Hugh A.			Multicenter, randomized, double-blind, placebo-controlled clinical trial of vital wheat gluten oral immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Wheat allergy; food allergy; oral immunotherapy; sustained unresponsiveness; desensitization; oral tolerance; gluten	ALLERGY; CHILDREN; IGE; SAFE	Background: Wheat is a common food allergen that can cause anaphylaxis. Objective: We sought to determine the efficacy and safety of vital wheat gluten (VWG) oral immunotherapy (OIT). Methods: After baseline double-blind, placebo-controlled food challenge (DBPCFC), 46 patients with wheat allergy (median age, 8.7 years; range, 4.2-22.3 years) were randomized 1: 1 to low-dose VWG OIT or placebo, with biweekly escalation to 1445 mg of wheat protein (WP). After a year 1 DBPCFC, active subjects continued low-dose VWG OIT for another year and underwent a year 2 DBPCFC and, if passed, a subsequent off-therapy DBPCFC. Placebo-treated subjects crossed over to high-dose VWG OIT (maximum, 2748 mg of WP). Results: The median baseline successfully consumed dose (SCD) was 43 mg of WP in both groups. At year 1, 12 (52.2%) of 23 low-dose VWG OIT-treated and 0 (0%) of 23 placebo-treated subjects achieved the primary end point of an SCD of 4443 mg of WP or greater (P < .0001); median SCDs were 4443 and 143 mg, respectively. At year 2, 7 (30.4%) of 23 low-dose VWG OIT-treated subjects were desensitized to an SCD of 7443 mg of WP; 3 (13%) achieved sustained unresponsiveness 8 to 10 weeks off therapy. Among placebo-treated subjects who crossed over to high-dose VWG OIT, 12 (57.1%) of 21 were desensitized after 1 year (median SCD, 7443 mg of WP; nonsignificant vs low-dose VWG OIT). At year 1, skin prick test responses and wheat-and omega-5 gliadin-specific IgE levels did not differ between groups; the low-dose VWG OIT median specific IgG(4) level was greater than placebo (wheat, P = .0005; omega-5 gliadin, P = .0001). Year 1 SCDs correlated with wheat-specific (rho = 0.55, P = .0003) and omega-5 gliadin-specific (rho = 0.51, P = .001) IgG(4) levels in all subjects. Among 7822 low-dose VWG OIT doses in year 1, 15.4% were associated with adverse reactions: 0.04% were severe, and 0.08% subjects received epinephrine. Among 7921 placebo doses, 5.8% were associated with adverse reactions; none were severe. Conclusions: Low-and high-dose VWG OIT induced desensitization in about one half of the subjects after 1 year of treatment. Two years of low-dose VWG OIT resulted in 30% desensitization, and 13% had sustained unresponsiveness.	[Nowak-Wegrzyn, Anna; Sampson, Hugh A.] Icahn Sch Med Mt Sinai, Kravis Childrens Hosp, Jaffe Food Allergy Inst, Dept Pediat,Div Allergy & Immunol, New York, NY 10029 USA; [Wood, Robert A.] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Allergy & Immunol, Baltimore, MD 21205 USA; [Nadeau, Kari C.] Stanford Univ, Sch Med, Sean N Parker Ctr Allergy & Asthma Res, Div Allergy & Immunol, Palo Alto, CA 94304 USA; [Pongracic, Jacqueline A.] Northwestern Univ, Ann & Robert H Lurie Childrens Hosp Chicago, Feinberg Sch Med, Chicago, IL 60611 USA; [Henning, Alice K.; Lindblad, Robert W.] Emmes Corp, Rockville, MD USA; [Beyer, Kirsten] Charite Univ Med Berlin, Dept Pediat Pneumol & Immunol, Berlin, Germany	Icahn School of Medicine at Mount Sinai; Johns Hopkins University; Stanford University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Emmes Corporation; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Sampson, HA (corresponding author), Icahn Sch Med Mt Sinai, Jaffe Food Allergy Inst, Div Pediat Allergy & Immunol, New York, NY 10029 USA.	hugh.sampson@mssm.edu		Nowak-Wegrzyn, Anna/0000-0002-0960-9854	Harris Family Foundation; Food Allergy Research & Education, Inc (FARE); Thermo Fisher Scientific	Harris Family Foundation; Food Allergy Research & Education, Inc (FARE); Thermo Fisher Scientific	This project was supported by Linda and Bill Friend and the Harris Family Foundation, Food Allergy Research & Education, Inc (FARE), and Thermo Fisher Scientific.	Albin S, 2015, IMMUNOL ALLERGY CLIN, V35, P77, DOI 10.1016/j.iac.2014.09.011; Burks AW, 2012, NEW ENGL J MED, V367, P233, DOI 10.1056/NEJMoa1200435; Gernez Y, 2017, J ALLER CL IMM-PRACT, V5, P250, DOI 10.1016/j.jaip.2016.12.004; Jones SM, 2017, J ALLERGY CLIN IMMUN, V139, P1242, DOI 10.1016/j.jaci.2016.08.017; Jones SM, 2016, J ALLERGY CLIN IMMUN, V137, P1117, DOI 10.1016/j.jaci.2015.12.1316; Kasarda DD, 2013, J AGR FOOD CHEM, V61, P1155, DOI 10.1021/jf305122s; Keet CA, 2012, J ALLERGY CLIN IMMUN, V129, pe1; Keet CA, 2012, J ALLERGY CLIN IMMUN, V129, P448, DOI 10.1016/j.jaci.2011.10.023; Keet CA, 2009, ANN ALLERG ASTHMA IM, V102, P410, DOI 10.1016/S1081-1206(10)60513-3; Khayatzadeh A, 2016, IRAN J ALLERGY ASTHM, V15, P525; Lauener R, 2017, CLIN MED INSIGHTS-PE, V11, P1, DOI 10.1177/1179556517730018; Rekabi M, 2017, IMMUNOTHERAPY-UK, V9, P637, DOI 10.2217/imt-2017-0011; del Rio PR, 2014, J INVEST ALLERG CLIN, V24, P240; Sampson HA, 2014, J ALLERGY CLIN IMMUN, V134, P1016, DOI 10.1016/j.jaci.2014.05.013; Sampson HA, 2012, J ALLERGY CLIN IMMUN, V130, P1260, DOI 10.1016/j.jaci.2012.10.017; Sato S, 2015, J ALLERGY CLIN IMMUN, V136, P1131, DOI 10.1016/j.jaci.2015.07.019; Sicherer SH, 2016, J ALLER CL IMM-PRACT, V4, P239, DOI 10.1016/j.jaip.2015.11.015; Vickery BP, 2013, J ALLERGY CLIN IMMUN, V131; Vickery BP, 2017, J ALLERGY CLIN IMMUN, V139, P173, DOI 10.1016/j.jaci.2016.05.027; Wood RA, 2017, J INVEST ALLERG CLIN, V27, P151, DOI 10.18176/jiaci.0143; Wright BL, 2016, ALLERGY, V71, P1552, DOI 10.1111/all.12895	21	36	38	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2019	143	2					651	+		10.1016/j.jaci.2018.08.041	http://dx.doi.org/10.1016/j.jaci.2018.08.041			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HK2DJ	30389226	Bronze			2022-12-18	WOS:000457718700024
J	Alonso, SB; Ezquiaga, JG; Berzal, PT; Tardon, SD; San Jose, M; Lopez, PA; Bermejo, TB; Teruel, SQ; Zudaire, LAE				Bellon Alonso, Sara; Garcia Ezquiaga, Jorge; Torija Berzal, Patricia; Diaz Tardon, Sara; Munoz San Jose, Maria; Alonso Lopez, Patricia; Bracamonte Bermejo, Teresa; Quevedo Teruel, Sergio; Echeverria Zudaire, Luis Angel			Food protein-induced enterocolitis syndrome: Increased prevalence of this great unknown-results of the PREVALE study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									[Bellon Alonso, Sara; Garcia Ezquiaga, Jorge; Torija Berzal, Patricia; Diaz Tardon, Sara; Munoz San Jose, Maria; Alonso Lopez, Patricia; Bracamonte Bermejo, Teresa; Quevedo Teruel, Sergio; Echeverria Zudaire, Luis Angel] Severo Ochoa Univ Hosp, Madrid, Spain	Severo Ochoa University Hospital	Alonso, SB (corresponding author), Severo Ochoa Univ Hosp, Madrid, Spain.	sara.bellon.alonso@gmail.com						Goswami R, 2017, J ALLERGY CLIN IMMUN, V139, P1885, DOI 10.1016/j.jaci.2016.12.971; Katz Y, 2014, CURR OPIN ALLERGY CL, V14, P229, DOI 10.1097/ACI.0000000000000053; Mehr S, 2017, J ALLERGY CLIN IMMUN, V140, P1323, DOI 10.1016/j.jaci.2017.03.027; Nowak-Wegrzyn A, 2017, J ALLERGY CLIN IMMUN, V140, P1275, DOI 10.1016/j.jaci.2017.07.020; Nowak-Wegrzyn A, 2017, J ALLERGY CLIN IMMUN, V139, P1111, DOI 10.1016/j.jaci.2016.12.966; Vazquez-Ortiz M, 2017, J ALLER CL IMM-PRACT, V5, P512, DOI 10.1016/j.jaip.2016.12.029	6	36	37	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2019	143	1					430	433		10.1016/j.jaci.2018.08.045	http://dx.doi.org/10.1016/j.jaci.2018.08.045			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HG4BD	30244024				2022-12-18	WOS:000454918300054
J	Morten, M; Collison, A; Murphy, VE; Barker, D; Oldmeadow, C; Attia, J; Meredith, J; Powell, H; Robinson, PD; Sly, PD; Gibson, PG; Mattes, J				Morten, Matthew; Collison, Adam; Murphy, Vanessa E.; Barker, Daniel; Oldmeadow, Christopher; Attia, John; Meredith, Joseph; Powell, Heather; Robinson, Paul D.; Sly, Peter D.; Gibson, Peter G.; Mattes, Joerg			Managing Asthma in Pregnancy (MAP) trial: FENO levels and childhood asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Childhood asthma; pregnancy; asthma management; exhaled nitric oxide; asthma genetics	EXHALED NITRIC-OXIDE; QUESTIONNAIRE; MANAGEMENT; ORMDL3; LIFE; INFANTS; WHEEZE; RISK	Background: The single-center double-blind, randomized controlled Managing Asthma in Pregnancy (MAP) trial in Newcastle, Australia, compared a treatment algorithm using the fraction of exhaled nitric oxide (FENO) in combination with asthma symptoms (FENO group) against a treatment algorithm using clinical symptoms only (clinical group) in pregnant asthmatic women (Australian New Zealand Clinical Trials Registry, no. 12607000561482). The primary outcome was a 50% reduction in asthma exacerbations during pregnancy in the FENO group. However, the effect of FENO-guided management on the development of asthma in the offspring is unknown. Objective: We sought to investigate the effect of FENO-guided asthma management during pregnancy on asthma incidence in childhood. Methods: A total of 179 mothers consented to participate in the Growing into Asthma (GIA) double-blind follow-up study with the primary aim to determine the effect of FENO-guided asthma management on childhood asthma incidence. Results: A total of 140 children (78%) were followed up at 4 to 6 years of age. FENO-guided as compared to symptoms-only approach significantly reduced doctor-diagnosed asthma (25.9% vs 43.2%; odds ratio [OR], 0.46, 95% CI, 0.22-0.96; P 5.04). Furthermore, frequent wheeze (OR, 0.27; 95% CI, 0.09-0.87; P = .03), use of short-acting beta-agonists (OR, 0.49; 95% CI, 0.25-0.97; P 5.04), and emergency department visits for asthma (OR, 0.17; 95% CI, 0.04-0.76; P = .02) in the past 12 months were less common in children born to mothers from the FENO group. Doctor-diagnosed asthma was associated with common risk alleles for early onset asthma at gene locus 17q21 (P = .01 for rs8069176; P = .03 for rs8076131), and higher airways resistance (P = .02) and FENO levels (P 5.03). A causal mediation analysis suggested natural indirect effects of FENO-guided asthma management on childhood asthma through "any use'' and "time to first change in dose'' of inhaled corticosteroids during the MAP trial (OR: 0.83; 95% CI: 0.59-0.99, and OR: 0.90; 95% CI: 0.70-1.03, respectively). Conclusions: FENO-guided asthma management during pregnancy prevented doctor-diagnosed asthma in the offspring at preschool age, in part mediated through changes in use and dosing of inhaled corticosteroids during the MAP trial.	[Morten, Matthew; Collison, Adam; Murphy, Vanessa E.; Meredith, Joseph; Mattes, Joerg] Univ Newcastle, Prior Res Ctr GrowUpWell, Newcastle, NSW, Australia; [Powell, Heather; Gibson, Peter G.] Univ Newcastle, Prior Res Ctr Hlth Lungs, Newcastle, NSW, Australia; [Morten, Matthew; Collison, Adam; Murphy, Vanessa E.; Barker, Daniel; Oldmeadow, Christopher; Attia, John; Powell, Heather; Gibson, Peter G.; Mattes, Joerg] Univ Newcastle, Hunter Med Res Inst, Newcastle, NSW, Australia; [Morten, Matthew; Collison, Adam; Murphy, Vanessa E.; Barker, Daniel; Oldmeadow, Christopher; Attia, John; Powell, Heather; Gibson, Peter G.; Mattes, Joerg] Univ Newcastle, Sch Med & Publ Hlth, Newcastle, NSW, Australia; [Meredith, Joseph; Mattes, Joerg] John Hunter Childrens Hosp, Dept Paediat Resp & Sleep Med, Newcastle, NSW, Australia; [Robinson, Paul D.] Childrens Hosp Westmead, Dept Resp Med, Sydney, NSW, Australia; [Sly, Peter D.] Univ Queensland, Child Hlth Res Ctr, South Brisbane, Australia; [Gibson, Peter G.] John Hunter Hosp, Dept Resp & Sleep Med, Newcastle, NSW, Australia	University of Newcastle; University of Newcastle; Hunter Medical Research Institute; University of Newcastle; University of Newcastle; University of Sydney; University of Queensland; John Hunter Hospital	Mattes, J (corresponding author), Univ Newcastle, Discipline Paediat, Lot 1,HMRI Bldg Level 2 East, Newcastle, NSW 2305, Australia.	Joerg.mattes@newcastle.edu.au	Robinson, Paul D/AAT-8318-2020; Attia, John R/F-5376-2013; Sly, Peter D/F-1486-2010; gibson, peter/G-6194-2014; Collison, Adam/G-7718-2013	Attia, John R/0000-0001-9800-1308; Sly, Peter D/0000-0001-6305-2201; Meredith, Joseph/0000-0001-5206-6720; gibson, peter/0000-0001-5865-489X; Robinson, Paul/0000-0001-7397-105X; Oldmeadow, Christopher/0000-0001-6104-1322; Collison, Adam/0000-0002-3074-3046; Barker, Daniel/0000-0002-9707-4465	Asthma Australia scholarship; Hunter Medical Research Institute pilot project; National Health and Medical Research Council [G1400050]; University of Newcastle	Asthma Australia scholarship; Hunter Medical Research Institute pilot project; National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); University of Newcastle	This research project was supported by an Asthma Australia scholarship to M.M., Hunter Medical Research Institute pilot project funding, a National Health and Medical Research Council project grant (G1400050), and the University of Newcastle.	American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Bisgaard H, 2016, NEW ENGL J MED, V375, P2530, DOI 10.1056/NEJMoa1503734; Bouzigon E, 2008, NEW ENGL J MED, V359, P1985, DOI 10.1056/NEJMoa0806604; Caliskan M, 2013, NEW ENGL J MED, V368, P1398, DOI 10.1056/NEJMoa1211592; Gunawardhana LP, 2014, PEDIATR PULM, V49, P852, DOI 10.1002/ppul.22930; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Juniper EF, 2006, RESP MED, V100, P616, DOI 10.1016/j.rmed.2005.08.012; JUNIPER EF, 1992, THORAX, V47, P76, DOI 10.1136/thx.47.2.76; Lim RH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010134; Loser S, 2017, J ALLERGY CLIN IMMUN, V139, P1496, DOI 10.1016/j.jaci.2016.07.033; Loss GJ, 2016, AM J RESP CRIT CARE, V193, P889, DOI 10.1164/rccm.201507-1493OC; Martel MJ, 2009, EUR RESPIR J, V34, P579, DOI 10.1183/09031936.00074608; Mattes J, 2014, THORAX, V69, P383, DOI 10.1136/thoraxjnl-2013-203388; Miller M, 2014, J IMMUNOL, V192, P3475, DOI 10.4049/jimmunol.1303047; Miller M, 2012, P NATL ACAD SCI USA, V109, P16648, DOI 10.1073/pnas.1204151109; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Murphy VE, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0890-3; Powell CVE, 2002, ARCH DIS CHILD, V87, P376, DOI 10.1136/adc.87.5.376; Powell H, 2011, LANCET, V378, P983, DOI 10.1016/S0140-6736(11)60971-9; Robinson PD, 2013, EUR RESPIR J, V41, P507, DOI 10.1183/09031936.00069712; Strippoli MPF, 2007, ARCH DIS CHILD, V92, P861, DOI 10.1136/adc.2007.117978; VanderWeele TJ, 2009, EPIDEMIOLOGY, V20, P863, DOI 10.1097/EDE.0b013e3181ba333c; VanderWeele TJ, 2009, EPIDEMIOLOGY, V20, P18, DOI 10.1097/EDE.0b013e31818f69ce	24	36	38	2	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2018	142	6					1765	+		10.1016/j.jaci.2018.02.039	http://dx.doi.org/10.1016/j.jaci.2018.02.039			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HD2BJ	29524536				2022-12-18	WOS:000452315800012
J	Sogkas, G; Fedchenko, M; Dhingra, A; Jablonka, A; Schmidt, RE; Atschekzei, F				Sogkas, Georgios; Fedchenko, Mykola; Dhingra, Akshay; Jablonka, Alexandra; Schmidt, Reinhold E.; Atschekzei, Faranaz			Primary immunodeficiency disorder caused by phosphoinositide 3-kinase delta deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							CELL; IL-3; PI3K-DELTA; ADULT		[Sogkas, Georgios; Jablonka, Alexandra; Schmidt, Reinhold E.; Atschekzei, Faranaz] Hannover Med Sch, Div Immunol & Rheumatol, Hannover, Germany; [Fedchenko, Mykola] Hannover Med Sch, Inst Pathol, Hannover, Germany; [Dhingra, Akshay] Hannover Med Sch, Inst Virol, Hannover, Germany	Hannover Medical School; Hannover Medical School; Hannover Medical School	Sogkas, G (corresponding author), Hannover Med Sch, Div Immunol & Rheumatol, Hannover, Germany.	sogkas.georgios@mh-hannover.de			Young Academy Clinician/Scientist program of Hannover Medical School, Hannover, Germany; German Center for Infection Research, DZIF [TTU 07.801]	Young Academy Clinician/Scientist program of Hannover Medical School, Hannover, Germany; German Center for Infection Research, DZIF	G.S. and A.J. received funding from the Young Academy Clinician/Scientist program of Hannover Medical School, Hannover, Germany. This project was supported by the German Center for Infection Research, DZIF TTU 07.801.	Berndt A, 2010, NAT CHEM BIOL, V6, P117, DOI [10.1038/nchembio.293, 10.1038/NCHEMBIO.293]; Cheah CY, 2016, BLOOD, V128, P331, DOI 10.1182/blood-2016-02-702761; Didichenko SA, 2008, BLOOD, V112, P3949, DOI 10.1182/blood-2008-04-149419; Fabre S, 2005, J IMMUNOL, V174, P4161, DOI 10.4049/jimmunol.174.7.4161; Hagmann BR, 2017, CLIN EXP ALLERGY, V47, P71, DOI 10.1111/cea.12850; Kittner JM, 2007, ANN ALLERG ASTHMA IM, V98, P294, DOI 10.1016/S1081-1206(10)60722-3; Lucas CL, 2016, NAT REV IMMUNOL, V16, P702, DOI 10.1038/nri.2016.93; Okkenhaug K, 2002, SCIENCE, V297, P1031; Okkenhaug K, 2006, J IMMUNOL, V177, P5122, DOI 10.4049/jimmunol.177.8.5122; Rao VK, 2017, BLOOD, V130, P2307, DOI 10.1182/blood-2017-08-801191; Schroder C, 2017, CLIN IMMUNOL, V179, P1, DOI 10.1016/j.clim.2016.12.013; Soond DR, 2010, BLOOD, V115, P2203, DOI 10.1182/blood-2009-07-232330; Sun QY, 1996, BLOOD, V87, P83; Zhang KJ, 2013, J CLIN IMMUNOL, V33, P673	14	36	36	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2018	142	5					1650	+		10.1016/j.jaci.2018.06.039	http://dx.doi.org/10.1016/j.jaci.2018.06.039			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GZ5BL	30040974	Bronze			2022-12-18	WOS:000449429800032
J	Cheng, HW; Onder, L; Cupovic, J; Boesch, M; Novkovic, M; Pikor, N; Tarantino, I; Rodriguez, R; Schneider, T; Jochum, W; Brutsche, M; Ludewig, B				Cheng, Hung-Wei; Onder, Lucas; Cupovic, Jovana; Boesch, Maximilian; Novkovic, Mario; Pikor, Natalia; Tarantino, Ignazio; Rodriguez, Regulo; Schneider, Tino; Jochum, Wolfram; Brutsche, Martin; Ludewig, Burkhard			CCL19-producing fibroblastic stromal cells restrain lung carcinoma growth by promoting local antitumor T-cell responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Lung inflammation; lung adenocarcinoma; fibroblastic reticular cells; tumor microenvironment	TERTIARY LYMPHOID STRUCTURES; IMMUNE CONTEXTURE; RETICULAR CELLS; DENDRITIC CELLS; CANCER; TUMOR; ACTIVATION; LYMPHOCYTES; HOMEOSTASIS; PROGNOSIS	Background: A particular characteristic of non-small cell lung cancer is the composition of the tumor microenvironment with a very high proportion of fibroblastic stromal cells (FSCs). Objective: Lapses in our basic knowledge of fibroblast phenotype and function in the tumor microenvironment make it difficult to define whether FSC subsets exist that exhibit either tumor-promoting or tumor-suppressive properties. Methods: We used gene expression profiling of lung versus tumor FSCs from patients with non-small cell lung cancer. Moreover, CCL19-expressing FSCs were studied in transgenic mouse models by using a lung cancer metastasis model. Results: CCL19 mRNA expression in human tumor FSCs correlates with immune cell infiltration and intratumoral accumulation of CD8(+) T cells. Mechanistic dissection in murine lung carcinoma models revealed that CCL19-expressing FSCs form perivascular niches to promote accumulation of CD8(+) T cells in the tumor. Targeted ablation of CCL19-expressing tumor FSCs reduced immune cell recruitment and resulted in unleashed tumor growth. Conclusion: These data suggest that a distinct population of CCL19-producing FSCs fosters the development of an immune-stimulating intratumoral niche for immune cells to control cancer growth.	[Cheng, Hung-Wei; Onder, Lucas; Cupovic, Jovana; Boesch, Maximilian; Novkovic, Mario; Pikor, Natalia; Ludewig, Burkhard] Kantonsspital St Gallen, Inst Immunobiol, CH-9007 St Gallen, Switzerland; [Tarantino, Ignazio] Kantonsspital St Gallen, Clin Visceral Surg, St Gallen, Switzerland; [Rodriguez, Regulo; Jochum, Wolfram] Kantonsspital St Gallen, Inst Pathol, St Gallen, Switzerland; [Schneider, Tino; Brutsche, Martin] Kantonsspital St Gallen, Div Pneumol, St Gallen, Switzerland	Kantonsspital St. Gallen; Kantonsspital St. Gallen; Kantonsspital St. Gallen; Kantonsspital St. Gallen	Ludewig, B (corresponding author), Kantonsspital St Gallen, Inst Immunobiol, CH-9007 St Gallen, Switzerland.	Burkhard.Ludewig@kssg.ch	Tarantino, Ignazio/AAF-9710-2020	Brutsche, Martin/0000-0002-1612-3609; Bosch, Maximilian/0000-0002-0994-9883; Novkovic, Mario/0000-0001-7654-5777	Swiss National Science Foundation [146133]; Swiss Cancer League [KLS-2880-02-2012]; Cancer League of Eastern Switzerland; Wilhelm Sander Foundation [2011.080.1]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Swiss Cancer League; Cancer League of Eastern Switzerland; Wilhelm Sander Foundation	Supported by the Swiss National Science Foundation (146133 to B.L.), the Swiss Cancer League (KLS-2880-02-2012 to B.L. and M.B.), the Cancer League of Eastern Switzerland (to B.L. and M.B.), and the Wilhelm Sander Foundation (2011.080.1 to B.L.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Azzoli CG, 2009, J CLIN ONCOL, V27, P6251, DOI 10.1200/JCO.2009.23.5622; Bajenoff M, 2006, IMMUNITY, V25, P989, DOI 10.1016/j.immuni.2006.10.011; Bindea G, 2013, IMMUNITY, V39, P782, DOI 10.1016/j.immuni.2013.10.003; Blankenstein T, 2005, CURR OPIN IMMUNOL, V17, P180, DOI 10.1016/j.coi.2005.01.008; Boesch M, 2016, BBA-REV CANCER, V1866, P276, DOI 10.1016/j.bbcan.2016.10.003; Carvalho BS, 2010, BIOINFORMATICS, V26, P2363, DOI 10.1093/bioinformatics/btq431; Chai Q, 2013, IMMUNITY, V38, P1013, DOI 10.1016/j.immuni.2013.03.012; Chen YB, 2014, TUMOR BIOL, V35, P6707, DOI 10.1007/s13277-014-1908-y; Chevrier S, 2017, CELL, V169, P736, DOI 10.1016/j.cell.2017.04.016; Cremasco V, 2014, NAT IMMUNOL, V15, P973, DOI 10.1038/ni.2965; Cupovic J, 2016, IMMUNITY, V44, P622, DOI 10.1016/j.immuni.2015.12.022; Das A, 2017, IMMUNITY, V46, P106, DOI 10.1016/j.immuni.2016.12.014; de Chaisemartin L, 2011, CANCER RES, V71, P6391, DOI 10.1158/0008-5472.CAN-11-0952; Di Caro G, 2014, CLIN CANCER RES, V20, P2147, DOI 10.1158/1078-0432.CCR-13-2590; Donnem T, 2015, CLIN CANCER RES, V21, P2635, DOI 10.1158/1078-0432.CCR-14-1905; Drayton DL, 2006, NAT IMMUNOL, V7, P344, DOI 10.1038/ni1330; Egeblad M, 2005, COLD SH Q B, V70, P383, DOI 10.1101/sqb.2005.70.007; Ferlay J, 2013, EUR J CANCER, V49, P1374, DOI 10.1016/j.ejca.2012.12.027; Fridman WH, 2012, NAT REV CANCER, V12, P298, DOI 10.1038/nrc3245; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Germain C, 2014, AM J RESP CRIT CARE, V189, P832, DOI 10.1164/rccm.201309-1611OC; Gil-Cruz C, 2016, NAT IMMUNOL, V17, P1388, DOI 10.1038/ni.3566; Goc J, 2014, CANCER RES, V74, P705, DOI 10.1158/0008-5472.CAN-13-1342; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hermans IF, 1998, CANCER RES, V58, P3909; Hillinger S, 2006, BRIT J CANCER, V94, P1029, DOI 10.1038/sj.bjc.6603061; Hwang JY, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00258; Islami F, 2015, TRANSL LUNG CANCER R, V4, P327, DOI 10.3978/j.issn.2218-6751.2015.08.04; Itakura M, 2013, BRIT J CANCER, V109, P1100, DOI 10.1038/bjc.2013.440; Johnson BA, 2017, CLIN CANCER RES, V23, P1656, DOI 10.1158/1078-0432.CCR-16-2318; Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73; Kilvaer TK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134965; Kraman M, 2010, SCIENCE, V330, P827, DOI 10.1126/science.1195300; Lee JJ, 2014, P NATL ACAD SCI USA, V111, pE3091, DOI 10.1073/pnas.1411679111; Liao YD, 2013, J CANCER RES CLIN, V139, P1523, DOI 10.1007/s00432-013-1471-8; Link A, 2007, NAT IMMUNOL, V8, P1255, DOI 10.1038/ni1513; Mahmoud SMA, 2011, J CLIN ONCOL, V29, P1949, DOI 10.1200/JCO.2010.30.5037; Malhotra D, 2012, NAT IMMUNOL, V13, P499, DOI 10.1038/ni.2262; Martinet L, 2013, J IMMUNOL, V191, P2001, DOI 10.4049/jimmunol.1300872; Martinet L, 2012, ONCOIMMUNOLOGY, V1, P829, DOI 10.4161/onci.20492; Melosky B, 2016, J CLIN ONCOL, V34, P1676, DOI 10.1200/JCO.2015.63.8049; Messina JL, 2012, SCI REP-UK, V2, DOI 10.1038/srep00765; Naba A, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.014647; Novkovic M, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002515; Ohlund D, 2014, J EXP MED, V211, P1503, DOI 10.1084/jem.20140692; Ozdemir BC, 2014, CANCER CELL, V25, P719, DOI 10.1016/j.ccr.2014.04.005; Ohlund D, 2017, J EXP MED, V214, P579, DOI 10.1084/jem.20162024; Peske JD, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8114; Reck M, 2014, ANN ONCOL, V25, P27, DOI 10.1093/annonc/mdu199; Remark R, 2015, AM J RESP CRIT CARE, V191, P377, DOI 10.1164/rccm.201409-1671PP; Rhim AD, 2014, CANCER CELL, V25, P735, DOI 10.1016/j.ccr.2014.04.021; Sharma S, 2000, J IMMUNOL, V164, P4558, DOI 10.4049/jimmunol.164.9.4558; Solinas G, 2009, J LEUKOCYTE BIOL, V86, P1065, DOI 10.1189/jlb.0609385; Spitzer MH, 2017, CELL, V168, P487, DOI 10.1016/j.cell.2016.12.022; Stranford S, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00350; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thompson ED, 2010, J EXP MED, V207, P1791, DOI 10.1084/jem.20092454; Tirosh I, 2016, SCIENCE, V352, P189, DOI 10.1126/science.aad0501; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954	60	36	37	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2018	142	4					1257	+		10.1016/j.jaci.2017.12.998	http://dx.doi.org/10.1016/j.jaci.2017.12.998			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GV7RG	29391257	hybrid			2022-12-18	WOS:000446327300024
J	Neeland, MR; Koplin, JJ; Dang, TD; Dharmage, SC; Tang, ML; Prescott, SL; Saffery, R; Martino, DJ; Allen, KJ				Neeland, Melanie R.; Koplin, Jennifer J.; Dang, Thanh D.; Dharmage, Shyamali C.; Tang, Mimi L.; Prescott, Susan L.; Saffery, Richard; Martino, David J.; Allen, Katrina J.			Early life innate immune signatures of persistent food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; innate; monocytes; persistent; natural tolerance; endotoxin; cytokines; vitamin D; HealthNuts	VITAMIN-D; NATURAL-HISTORY; INFANTS; PREDICTORS; COHORT; PREVALENCE; HEALTHNUTS; RESPONSES; CRITERIA; CHILDREN	Background: Food allergy naturally resolves in a proportion of food-allergic children without intervention; however the underlying mechanisms governing the persistence or resolution of food allergy in childhood are not understood. Objectives: This study aimed to define the innate immune profiles associated with egg allergy at age 1 year, determine the phenotypic changes that occur with the development of natural tolerance in childhood, and explore the relationship between early life innate immune function and serum vitamin D. Methods: This study used longitudinally collected PBMC samples from a population-based cohort of challenge-confirmed egg-allergic infants with either persistent or transient egg allergy outcomes in childhood to phenotype and quantify the functional innate immune response associated with clinical phenotypes of egg allergy. Results: We show that infants with persistent egg allergy exhibit a unique innate immune signature, characterized by increased numbers of circulating monocytes and dendritic cells that produce more inflammatory cytokines both at baseline and following endotoxin exposure when compared with infants with transient egg allergy. Follow-up analysis revealed that this unique innate immune signature continues into childhood in those with persistent egg allergy and that increased serum vitamin D levels correlate with changes in innate immune profiles observed in children who developed natural tolerance to egg. Conclusions: Early life innate immune dysfunction may represent a key immunological driver and predictor of persistent food allergy in childhood. Serum vitamin D may play an immune-modulatory role in the development of natural tolerance.	[Neeland, Melanie R.; Koplin, Jennifer J.; Dang, Thanh D.; Dharmage, Shyamali C.; Tang, Mimi L.; Saffery, Richard; Martino, David J.; Allen, Katrina J.] Univ Melbourne, Murdoch Childrens Res Inst, Parkville, Vic, Australia; [Dang, Thanh D.; Tang, Mimi L.; Saffery, Richard; Martino, David J.; Allen, Katrina J.] Univ Melbourne, Dept Paediat, Parkville, Vic, Australia; [Dharmage, Shyamali C.] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Ctr Epidemiol & Biostat, Parkville, Vic, Australia; [Tang, Mimi L.; Allen, Katrina J.] Royal Childrens Hosp, Dept Allergy & Immunol, Parkville, Vic, Australia; [Prescott, Susan L.] Univ Western Australia, Telethon Kids Inst, Perth, WA, Australia	Murdoch Children's Research Institute; University of Melbourne; University of Melbourne; University of Melbourne; Royal Children's Hospital Melbourne; Telethon Kids Institute; University of Western Australia	Allen, KJ (corresponding author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Dept Allergy & Immunol, Flemington Rd, Parkville, Vic 3052, Australia.	katie.allen@rch.org.au	Martino, DJ/X-1753-2019; Neeland, Melanie/AAA-7402-2019; Saffery, Richard/GLS-1976-2022; Dang, Thanh/AAK-1608-2021; Allen, Katrina/I-4361-2018; Tang, Mimi/ABD-8350-2020	Martino, DJ/0000-0001-6823-4696; Saffery, Richard/0000-0002-9510-4181; Dang, Thanh/0000-0003-2010-5582; Allen, Katrina/0000-0002-1921-4493; Tang, Mimi/0000-0002-3839-5293; Koplin, Jennifer/0000-0002-7576-5142; Neeland, Melanie/0000-0001-7301-9982	National Health and Medical Research Council of Australia (NHMRC); Ilhan Food Allergy Foundation; AnaphylaxiStop; Charles and Sylvia Viertel Medical Research Foundation; Victorian Government's Operational Infrastructure Support Program; Murdoch Childrens Research Institute; NHMRC Centre for Food and Allergy Research	National Health and Medical Research Council of Australia (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Ilhan Food Allergy Foundation; AnaphylaxiStop; Charles and Sylvia Viertel Medical Research Foundation; Victorian Government's Operational Infrastructure Support Program; Murdoch Childrens Research Institute; NHMRC Centre for Food and Allergy Research(National Health and Medical Research Council (NHMRC) of Australia)	The HealthNuts study is supported by funding from the National Health and Medical Research Council of Australia (NHMRC), the Ilhan Food Allergy Foundation, AnaphylaxiStop, the Charles and Sylvia Viertel Medical Research Foundation, and the Victorian Government's Operational Infrastructure Support Program. The immunological work is supported by funding to M.R.N. from the Murdoch Childrens Research Institute and the NHMRC Centre for Food and Allergy Research.	Allen KJ, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009377; Allen KJ, 2013, J ALLERGY CLIN IMMUN, V131, P1109, DOI 10.1016/j.jaci.2013.01.017; Baiz N, 2014, J ALLERGY CLIN IMMUN, V133, P147, DOI 10.1016/j.jaci.2013.05.017; Dang TD, 2013, ALLERGY, V68, P1233, DOI 10.1111/all.12215; Dang TD, 2016, PEDIAT ALLERG IMM-UK, V27, P35, DOI 10.1111/pai.12498; Hartmann B, 2011, ALLERGY, V66, P540, DOI 10.1111/j.1398-9995.2010.02513.x; Hollams EM, 2017, J ALLERGY CLIN IMMUN, V139, P472, DOI 10.1016/j.jaci.2016.07.032; Jones AP, 2015, CLIN EXP ALLERGY, V45, P220, DOI 10.1111/cea.12449; Koplin JJ, 2016, J ALLERGY CLIN IMMUN, V137, P500, DOI 10.1016/j.jaci.2015.05.051; Koplin JJ, 2015, INT J EPIDEMIOL, V44, P1161, DOI 10.1093/ije/dyu261; Koplin JJ, 2012, J ALLERGY CLIN IMMUN, V129, P1145, DOI 10.1016/j.jaci.2011.09.044; Kosoy R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163831; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, P668, DOI 10.1016/j.jaci.2011.01.039; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Paxton GA, 2013, MED J AUSTRALIA, V198, P142, DOI 10.5694/mja11.11592; Peters RL, 2015, J ALLERGY CLIN IMMUN, V135, P1257, DOI 10.1016/j.jaci.2015.01.002; Peters RL, 2014, J ALLERGY CLIN IMMUN, V133, P485, DOI 10.1016/j.jaci.2013.11.032; Peters RL, 2015, J ALLERGY CLIN IMMUN, V135, pe1; Prescott S, 2011, PEDIAT ALLERG IMM-UK, V22, P155, DOI 10.1111/j.1399-3038.2011.01145.x; Pyle DM, 2013, J ALLERGY CLIN IMMUN, V131, P491, DOI 10.1016/j.jaci.2012.11.037; Stein MM, 2016, NEW ENGL J MED, V375, P411, DOI 10.1056/NEJMoa1508749; Suaini NHA, 2015, NUTRIENTS, V7, P6088, DOI 10.3390/nu7085271; Tang MLK, 2009, CURR OPIN ALLERGY CL, V9, P351, DOI 10.1097/ACI.0b013e32832db95a; Tulic MK, 2011, J ALLERGY CLIN IMMUN, V127, P470, DOI 10.1016/j.jaci.2010.09.020; Zhang YX, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad4322	25	36	36	3	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2018	142	3					857	+		10.1016/j.jaci.2017.10.024	http://dx.doi.org/10.1016/j.jaci.2017.10.024			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GS5RJ	29154959	Bronze			2022-12-18	WOS:000443726500018
J	Chen, J; Miller, M; Unno, H; Rosenthal, P; Sanderson, MJ; Broide, DH				Chen, Jun; Miller, Marina; Unno, Hirotoshi; Rosenthal, Peter; Sanderson, Michael J.; Broide, David H.			Orosomucoid-like 3 (ORMDL3) upregulates airway smooth muscle proliferation, contraction, and Ca2+ oscillations in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ORMDL3; asthma; airway smooth muscle; sarcoplasmic reticulum Ca2+ transport ATPase 2b; airway hyperresponsiveness	ALLERGIC-ASTHMA; CALCIUM OSCILLATIONS; BRONCHIAL-ASTHMA; CELLS; HYPERRESPONSIVENESS; RESPONSIVENESS; HYPERTROPHY; SENSITIVITY; EXPRESSION; SERCA	Background: Airway hyperresponsiveness is a major feature of asthma attributed predominantly to an extrinsic immune/ inflammatory response increasing airway smooth muscle (ASM) contractility. Objective: We investigated whether increased ASM expression of orosomucoid-like 3 (ORMDL3), a gene on chromosome 17q21 highly linked to asthma, induced increased ASM proliferation and contractility in vitro and influenced airway contractility and calcium flux in ASM in precision-cut lung slices (PCLSs) from wild-type and hORMDL3(Zp3-Cre) mice (which express increased levels of human ORMDL3 [hORMDL3]). Methods: Levels of ASMproliferation and contraction were assessed in ASM cells transfected with ORMDL3 in vitro. In addition, airway contractility and calcium oscillations were quantitated inASMcells inPCLSs derived fromnaivewild-type and naive hORMDL3(Zp3-Cre) mice, which do not have a blood supply. Results: Increased ASM expression of ORMDL3 in vitro resulted in increased ASM proliferation and contractility. PCLSs derived from naive hORMDL3(Zp3-Cre) mice, which do not have airway inflammation, exhibit increased airway contractility with increased calcium oscillations in ASM cells. Increased ASM ORMDL3 expression increases levels of ASM sarcoplasmic reticulum Ca2+ ATPase 2b (SERCA2b), which increases ASM proliferation and contractility. Conclusion: Overall, these studies provide evidence that an intrinsic increase in ORMDL3 expression in ASM can induce increased ASM proliferation and contractility, which might contribute to increased airway hyperresponsiveness in the absence of airway inflammation in asthmatic patients.	[Chen, Jun] Sichuan Univ, State Key Lab Biotherapy, Div Pulm Dis, Chengdu, Sichuan, Peoples R China; [Chen, Jun] Sichuan Univ, West China Hosp, Dept Resp & Crit Care Med, Chengdu, Sichuan, Peoples R China; [Chen, Jun; Sanderson, Michael J.] Univ Massachusetts, Sch Med, Dept Microbiol & Physiol Syst, Worcester, MA USA; [Miller, Marina; Unno, Hirotoshi; Rosenthal, Peter; Broide, David H.] Univ Calif San Diego, Dept Med, Biomed Sci Bldg,Rm 5090,9500 Gilman Dr, La Jolla, CA 92093 USA	Sichuan University; Sichuan University; University of Massachusetts System; University of Massachusetts Worcester; University of California System; University of California San Diego	Broide, DH (corresponding author), Univ Calif San Diego, Dept Med, Biomed Sci Bldg,Rm 5090,9500 Gilman Dr, La Jolla, CA 92093 USA.	dbroide@ucsd.edu		Broide, David/0000-0001-8405-9090	National Institutes of Health grants [AI 107779, AI 38425, AI 070535, AI 72115, AI 242236]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038425, R01AI107779, R37AI038425, U19AI070535, R01AI124236, R01AI072115] Funding Source: NIH RePORTER	National Institutes of Health grants(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants AI 107779, AI 38425, AI 070535, AI 72115, and AI 242236 (to D.H.B.).	Andiappan AK, 2016, J ALLERGY CLIN IMMUN, V137, P758, DOI 10.1016/j.jaci.2015.08.038; Bai Y, 2006, AM J PHYSIOL-LUNG C, V291, pL208, DOI 10.1152/ajplung.00494.2005; Bai Y, 2009, AM J PHYSIOL-LUNG C, V296, pL947, DOI 10.1152/ajplung.90288.2008; Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; Bentley J Kelley, 2008, Proc Am Thorac Soc, V5, P89, DOI 10.1513/pats.200705-063VS; Breslow DK, 2010, NATURE, V463, P1048, DOI 10.1038/nature08787; Brightling CE, 1999, AM J RESP CRIT CARE, V160, P406, DOI 10.1164/ajrccm.160.2.9810100; Busse WW, 2010, CHEST, V138, p4S, DOI 10.1378/chest.10-0100; Crimi E, 1998, AM J RESP CRIT CARE, V157, P4, DOI 10.1164/ajrccm.157.1.9703002; Croisier H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069598; EBINA M, 1993, AM REV RESPIR DIS, V148, P720, DOI 10.1164/ajrccm/148.3.720; EBINA M, 1990, AM REV RESPIR DIS, V141, P1327, DOI 10.1164/ajrccm/141.5_Pt_1.1327; Erle DJ, 2014, J CELL BIOL, V205, P621, DOI 10.1083/jcb.201401050; Greene AL, 2000, J BIOL CHEM, V275, P24722, DOI 10.1074/jbc.M001783200; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242, DOI 10.1164/ajrccm/139.1.242; Johnson PRA, 2001, AM J RESP CRIT CARE, V164, P474, DOI 10.1164/ajrccm.164.3.2010109; Kaur D, 2010, CLIN EXP ALLERGY, V40, P279, DOI 10.1111/j.1365-2222.2009.03423.x; LAMBERT RK, 1993, J APPL PHYSIOL, V74, P2771, DOI 10.1152/jappl.1993.74.6.2771; Lauzon AM, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00191; Leybaert L, 2012, PHYSIOL REV, V92, P1359, DOI 10.1152/physrev.00029.2011; Macklem PT, 1996, AM J RESP CRIT CARE, V153, P83, DOI 10.1164/ajrccm.153.1.8542167; Mahn K, 2010, THORAX, V65, P547, DOI 10.1136/thx.2009.129296; Mahn K, 2009, P NATL ACAD SCI USA, V106, P10775, DOI 10.1073/pnas.0902295106; Michelangeli F, 2011, BIOCHEM SOC T, V39, P789, DOI 10.1042/BST0390789; Miller M, 2017, J IMMUNOL, V198, P3017, DOI 10.4049/jimmunol.1601848; Miller M, 2015, J IMMUNOL, V195, P3546, DOI 10.4049/jimmunol.1501105; Miller M, 2014, J IMMUNOL, V192, P3475, DOI 10.4049/jimmunol.1303047; Miller M, 2012, P NATL ACAD SCI USA, V109, P16648, DOI 10.1073/pnas.1204151109; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; National Heart Lung and Blood Institute, 2007, EXP PAN REP 3 GUID D; Nivala M, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00114; Palmer LJ, 2000, AM J RESP CRIT CARE, V161, P1836, DOI 10.1164/ajrccm.161.6.9805104; Perez JF, 2005, J GEN PHYSIOL, V125, P535, DOI 10.1085/jgp.200409216; SAETTA M, 1991, AM REV RESPIR DIS, V143, P138, DOI 10.1164/ajrccm/143.1.138; Sanderson MJ, 2010, NAT MED, V16, P1190, DOI 10.1038/nm1110-1190; Sanderson MJ, 2010, ADV EXP MED BIOL, V661, P77, DOI 10.1007/978-1-60761-500-2_5; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; Sathish V, AM J PHYSIOL LUNG CE; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043, DOI 10.1164/ajrccm.159.4.9806052; Tan XH, 2014, BRIT J PHARMACOL, V171, P646, DOI 10.1111/bph.12460; Trian T, 2007, J EXP MED, V204, P3173, DOI 10.1084/jem.20070956; Vandecaetsbeek I, 2011, COLD SPRING HARB PER, V3, P1; Ver Heyen M, 2001, CIRC RES, V89, P838, DOI 10.1161/hh2101.098466; Woodruff PG, 2004, AM J RESP CRIT CARE, V169, P1001, DOI 10.1164/rccm.200311-1529OC; Wuytack F, 2002, CELL CALCIUM, V32, P279, DOI 10.1016/S0143416002001847; Yarova PL, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa0282	46	36	39	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2018	142	1					207	+		10.1016/j.jaci.2017.08.015	http://dx.doi.org/10.1016/j.jaci.2017.08.015			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GM1OC	28889952	Green Accepted, Bronze			2022-12-18	WOS:000437837500024
J	Vroman, H; Bergen, IM; van Hulst, JAC; van Nimwegen, M; van Uden, D; Schuijs, MJ; Pillai, SY; van Loo, G; Hammad, H; Lambrecht, BN; Hendriks, RW; Kool, M				Vroman, Heleen; Bergen, Ingrid M.; van Hulst, Jennifer A. C.; van Nimwegen, Menno; van Uden, Denise; Schuijs, Martijn J.; Pillai, Saravanan Y.; van Loo, Geert; Hammad, Hamida; Lambrecht, Bart N.; Hendriks, Rudi W.; Kool, Mirjam			TNF-alpha-induced protein 3 levels in lung dendritic cells instruct T(H)2 or T(H)17 cell differentiation in eosinophilic or neutrophilic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; T(H)2 cells; T(H)17 cells; dendritic cells; neutrophils	CD4(+) T-CELLS; NF-KAPPA-B; DUST MITE ALLERGEN; AIRWAY INFLAMMATION; IN-VIVO; INHALED ANTIGEN; TH2 RESPONSES; OX40 LIGAND; CROSS-TALK; EXPRESSION	Background: It is currently unknown why allergen exposure or environmental triggers in patients with mild-to-moderate asthma result in T(H)2-mediated eosinophilic inflammation, whereas patients with severe asthma often present with T(H)17-mediated neutrophilic inflammation. The activation state of dendritic cells (DCs) is crucial for both T(H)2 and T(H)17 cell differentiation and is mediated through nuclear factor kappa B activation. Ablation of TNF-alpha-induced protein 3 (TNFAIP3), one of the crucial negative regulators of nuclear factor kappa B activation in myeloid cells and DCs, was shown to control DC activation. Objective: In this study we investigated the precise role of TNFAIP3 in myeloid cells for the development of T(H)2- and T(H)17-cell mediated asthma. Methods: We exposed mice with conditional deletion of the Tnfaip3 gene in either myeloid cells (by using the lysozyme M [LysM] promotor) or specifically in DCs (by using the Cd11c promotor) to acute and chronic house dust mite (HDM)-driven asthma models. Results: We demonstrated that reduced Tnfaip3 gene expression in DCs in either Tnfaip3(CD11c) or Tnfaip3(LysM) mice dose-dependently controlled development of T(H)17-mediated neutrophilic severe asthma in both acute and chronic HDM-driven models, whereas wild-type mice had a purely T(H)2-mediated eosinophilic inflammation. TNFAIP3-deficient DCs induced HDM-specific T(H)17 cell differentiation through increased expression of the T(H)17-instructing cytokines IL-1 beta, IL-6, and IL-23, whereas HDM-specific T(H)2 cell differentiation was hampered by increased IL-12 and IL-6 production. Conclusions: These data show that the extent of TNFAIP3 expression in DCs controls T(H)2/T(H)17 cell differentiation. This implies that reducing DC activation could be a new pharmacologic intervention to treat patients with severe asthma who present with T(H)17-mediated neutrophilic inflammation.	[Vroman, Heleen; Bergen, Ingrid M.; van Hulst, Jennifer A. C.; van Nimwegen, Menno; van Uden, Denise; Pillai, Saravanan Y.; Lambrecht, Bart N.; Hendriks, Rudi W.; Kool, Mirjam] Erasmus MC, Dept Pulm Med, Rotterdam, Netherlands; [Schuijs, Martijn J.; van Loo, Geert; Hammad, Hamida; Lambrecht, Bart N.] VIB, Inflammat Res Ctr, Ghent, Belgium; [Schuijs, Martijn J.; Hammad, Hamida; Lambrecht, Bart N.] Univ Ghent, Dept Resp Med, Ghent, Belgium; [van Loo, Geert] Univ Ghent, Dept Biomed Mol Biol, Ghent, Belgium	Erasmus University Rotterdam; Erasmus MC; Flanders Institute for Biotechnology (VIB); Ghent University; Ghent University	Kool, M (corresponding author), Erasmus MC Univ Med Ctr, Wytemaweg 80, NL-3015 CN Rotterdam, Netherlands.	m.kool@erasmusmc.nl	van Loo, Geert/C-1505-2009; Hammad, Hamida/J-9391-2015; , van Loo Geert/AAD-1220-2019; Lambrecht, Bart N/K-2484-2014	Hammad, Hamida/0000-0003-3762-8603; , van Loo Geert/0000-0002-8427-4775; Lambrecht, Bart N/0000-0003-4376-6834; Schuijs, Martijn/0000-0001-6433-6417; Hendriks, Rudi/0000-0003-2291-0382	NWO-VENI [916.11.067]; European Framework Program 7 (FP7-MC-CIG) [304221]; Netherlands Lung Foundation [3.2.12.087, 4.2.13.054JO]	NWO-VENI(Netherlands Organization for Scientific Research (NWO)); European Framework Program 7 (FP7-MC-CIG); Netherlands Lung Foundation	Supported in part by NWO-VENI (916.11.067), the European Framework Program 7 (FP7-MC-CIG grant 304221.), and The Netherlands Lung Foundation (3.2.12.087 and 4.2.13.054JO).	Amsen D, 2004, CELL, V117, P515, DOI 10.1016/S0092-8674(04)00451-9; Barnes PJ, 1997, TRENDS PHARMACOL SCI, V18, P46, DOI 10.1016/S0165-6147(97)89796-9; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Chakir J, 2003, J ALLERGY CLIN IMMUN, V111, P1293, DOI 10.1067/mai.2003.1557; Choy DF, 2016, J ALLERGY CLIN IMMUN, V138, P1230, DOI 10.1016/j.jaci.2016.06.008; COGSWELL JP, 1994, J IMMUNOL, V153, P712; CONSTANT S, 1995, J EXP MED, V182, P1591, DOI 10.1084/jem.182.5.1591; Coquet JM, 2015, IMMUNITY, V43, P318, DOI 10.1016/j.immuni.2015.07.015; de Jong EC, 2002, J IMMUNOL, V168, P1704, DOI 10.4049/jimmunol.168.4.1704; Green RH, 2002, THORAX, V57, P875, DOI 10.1136/thorax.57.10.875; Guilliams M, 2016, IMMUNITY, V45, P669, DOI 10.1016/j.immuni.2016.08.015; Hadebe S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134219; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Hammer GE, 2011, NAT IMMUNOL, V12, P1184, DOI 10.1038/ni.2135; Hebel K, 2006, EUR J IMMUNOL, V36, P2912, DOI 10.1002/eji.200636356; Heger K, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001762; Helft J, 2015, IMMUNITY, V42, P1197, DOI 10.1016/j.immuni.2015.05.018; Hercor M, 2017, J LEUKOCYTE BIOL, V101, P5, DOI 10.1189/jlb.1HI1115-511R; HOSKEN NA, 1995, J EXP MED, V182, P1579, DOI 10.1084/jem.182.5.1579; Huang GH, 2012, CELL MOL IMMUNOL, V9, P287, DOI 10.1038/cmi.2012.10; Iezzi G, 2009, P NATL ACAD SCI USA, V106, P876, DOI 10.1073/pnas.0810769106; Jacquet A, 2013, ISRN ALLERGY, V2013, DOI [10.1155/2013/735031, DOI 10.1155/2013/735031]; Jakubzick C, 2008, J EXP MED, V205, P2839, DOI 10.1084/jem.20081430; Jenkins SJ, 2007, J IMMUNOL, V179, P3515, DOI 10.4049/jimmunol.179.6.3515; Kashiwakura J, 2004, J IMMUNOL, V173, P5247, DOI 10.4049/jimmunol.173.8.5247; KleinJan A, 2014, J IMMUNOL, V192, P1385, DOI 10.4049/jimmunol.1301888; Kool Mirjam, 2012, F1000 Biol Rep, V4, P6, DOI 10.3410/B4-6; Kool M, 2011, IMMUNITY, V35, P82, DOI 10.1016/j.immuni.2011.05.013; Kuipers H, 2004, J LEUKOCYTE BIOL, V76, P1028, DOI 10.1189/jlb.0604325; Kuipers H, 2003, J IMMUNOL, V171, P3645, DOI 10.4049/jimmunol.171.7.3645; Lambrecht BN, 2012, ANNU REV IMMUNOL, V30, P243, DOI 10.1146/annurev-immunol-020711-075021; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Li XN, 2012, J ALLERGY CLIN IMMUN, V130, P861, DOI 10.1016/j.jaci.2012.04.041; Ma A, 2012, NAT REV IMMUNOL, V12, P774, DOI 10.1038/nri3313; Matmati M, 2011, NAT GENET, V43, P908, DOI 10.1038/ng.874; McGeachy MJ, 2009, NAT IMMUNOL, V10, P314, DOI 10.1038/ni.1698; McKinley L, 2008, J IMMUNOL, V181, P4089, DOI 10.4049/jimmunol.181.6.4089; Nota B, 2014, HUM MUTAT, V35, P1128, DOI 10.1002/humu.22609; Plantinga M, 2013, IMMUNITY, V38, P322, DOI 10.1016/j.immuni.2012.10.016; Rainard P, 2008, MOL IMMUNOL, V45, P4020, DOI 10.1016/j.molimm.2008.06.010; Raymond M, 2011, J ALLERGY CLIN IMMUN, V128, P192, DOI 10.1016/j.jaci.2011.04.029; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Saeed AI, 2006, METHOD ENZYMOL, V411, P134, DOI 10.1016/S0076-6879(06)11009-5; Sanjabi S, 2000, P NATL ACAD SCI USA, V97, P12705, DOI 10.1073/pnas.230436397; Schuijs MJ, 2015, SCIENCE, V349, P1106, DOI 10.1126/science.aac6623; Sichien D, 2016, IMMUNITY, V45, P626, DOI 10.1016/j.immuni.2016.08.013; Soroosh P, 2013, J EXP MED, V210, P775, DOI 10.1084/jem.20121849; TEWARI M, 1995, J IMMUNOL, V154, P1699; Tindemans I, 2017, J ALLERGY CLIN IMMUN; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311; Vroman H, 2017, CLIN EXP ALLERGY, V47, P551, DOI 10.1111/cea.12834; Vroman H, 2015, IMMUNOBIOLOGY, V220, P254, DOI 10.1016/j.imbio.2014.09.016; Wang JY, 2013, ALLERGY ASTHMA IMMUN, V5, P68, DOI 10.4168/aair.2013.5.2.68; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Zhao DJ, 2016, BIOCHEM BIOPH RES CO, V472, P11, DOI 10.1016/j.bbrc.2015.11.009	55	36	39	1	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2018	141	5					1620	1633		10.1016/j.jaci.2017.08.012	http://dx.doi.org/10.1016/j.jaci.2017.08.012			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GF7KX	28888782	Bronze			2022-12-18	WOS:000432148200010
J	Xie, GG; Yang, HW; Peng, X; Lin, LH; Wang, J; Lin, K; Cui, ZL; Li, J; Xiao, H; Liang, YT; Li, L				Xie, Guogang; Yang, Haiwei; Peng, Xia; Lin, Lihui; Wang, Juan; Lin, Kun; Cui, Zelin; Li, Jia; Xiao, Hui; Liang, Yuting; Li, Li			Mast cell exosomes can suppress allergic reactions by binding to IgE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							MODEL		[Xie, Guogang; Xiao, Hui] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Dept Resp Med, Shanghai, Peoples R China; [Yang, Haiwei] Nanjing Med Univ, Affiliated Hosp 1, Dept Urol, Nanjing, Jiangsu, Peoples R China; [Peng, Xia; Lin, Lihui; Wang, Juan; Lin, Kun; Cui, Zelin; Li, Jia; Liang, Yuting; Li, Li] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Dept Lab Med, Shanghai, Peoples R China	Shanghai Jiao Tong University; Nanjing Medical University; Shanghai Jiao Tong University	Xie, GG (corresponding author), Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Dept Resp Med, Shanghai, Peoples R China.	annylish@126.com		GUOGANG, XIE/0000-0002-2167-1976				Almqvist N, 2008, IMMUNOLOGY, V125, P21, DOI 10.1111/j.1365-2567.2008.02812.x; Bufe A, 2009, J ALLERGY CLIN IMMUN, V123, P167, DOI 10.1016/j.jaci.2008.10.044; D'Inca F, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00073; Galli SJ, 2012, NAT MED, V18, P693, DOI 10.1038/nm.2755; GREIFF L, 1990, CLIN EXP ALLERGY, V20, P253, DOI 10.1111/j.1365-2222.1990.tb02680.x; Han SY, 2013, J NUTR, V143, P632, DOI 10.3945/jn.112.173302; Jensen B.M, 2006, CURR PROTOC IMMUNOL, V3, P3; Johansen N, 2016, ALLERGY, V71, P166; Kang JY, 2010, J ASTHMA, V47, P374, DOI 10.3109/02770901003801972; Lasser C, 2012, JOVE-J VIS EXP, DOI 10.3791/3037; Leaker BR, 2017, MUCOSAL IMMUNOL, V10, P408, DOI 10.1038/mi.2016.74; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Malm L, 2000, RHINOLOGY, V38, P1; Oldenbeuving NB, 2005, ALLERGY, V60, P751, DOI 10.1111/j.1398-9995.2005.00789.x; Pelaia G, 2012, NAT REV DRUG DISCOV, V11, P958, DOI 10.1038/nrd3792; Sibilano R, 2014, EUR J IMMUNOL, V44, P2558, DOI 10.1002/eji.201444546; Wurtzen PA, 2008, CLIN EXP ALLERGY, V38, P1290, DOI 10.1111/j.1365-2222.2008.03020.x	17	36	37	1	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2018	141	2					788	+		10.1016/j.jaci.2017.07.040	http://dx.doi.org/10.1016/j.jaci.2017.07.040			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FV2PQ	28916187	hybrid			2022-12-18	WOS:000424410800040
J	Rochman, M; Travers, J; Miracle, CE; Bedard, MC; Wen, T; Azouz, NP; Caldwell, JM; Kiran, KC; Sherrill, JD; Davis, BP; Rymer, JK; Kaufman, KM; Aronow, BJ; Rothenberg, ME				Rochman, Mark; Travers, Jared; Miracle, Cora E.; Bedard, Mary C.; Wen, Ting; Azouz, Nurit P.; Caldwell, Julie M.; Kiran, K. C.; Sherrill, Joseph D.; Davis, Benjamin P.; Rymer, Jeffrey K.; Kaufman, Kenneth M.; Aronow, Bruce J.; Rothenberg, Marc E.			Profound loss of esophageal tissue differentiation in patients with eosinophilic esophagitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophilic esophagitis; IL-1 cytokines; protease activity; IL-13; differentiation; whole-exome sequencing; mutations	INTERCELLULAR SPACES; EXPRESSION PROFILE; ATOPIC-DERMATITIS; ASTHMA; IL-13; PROLIFERATION; ASSOCIATION; MUTATIONS; FILAGGRIN	Background: A key question in the allergy field is to understand how tissue-specific disease is manifested. Eosinophilic esophagitis (EoE) is an emerging tissue-specific allergic disease with an unclear pathogenesis. Objective: Herein we tested the hypothesis that a defect in tissue-specific esophageal genes is an integral part of EoE pathogenesis. Methods: We interrogated the pattern of expression of esophagus-specific signature genes derived from the Human Protein Atlas in the EoE transcriptome and in EPC2 esophageal epithelial cells. Western blotting and immunofluorescence were used for evaluating expression of esophageal proteins in biopsy specimens from control subjects and patients with active EoE. Whole-exome sequencing was performed to identify mutations in esophagus-specific genes. Results: We found that approximately 39% of the esophagusspecific transcripts were altered in patients with EoE, with approximately 90% being downregulated. The majority of transcriptional changes observed in esophagus-specific genes were reproduced in vitro in esophageal epithelial cells differentiated in the presence of IL-13. Functional enrichment analysis revealed keratinization and differentiation as the most affected biological processes and identified IL-1 cytokines and serine peptidase inhibitors as the most dysregulated esophagus-specific protein families in patients with EoE. Accordingly, biopsy specimens from patients with EoE evidenced a profound loss of tissue differentiation, decreased expression of keratin 4 (KRT4) and cornulin (CRNN), and increased expression of KRT5 and KRT14. Whole-exome sequencing of 33 unrelated patients with EoE revealed 39 rare mutations in 18 esophagus-specific differentially expressed genes. Conclusions: A tissue-centered analysis has revealed a profound loss of esophageal tissue differentiation (identity) as an integral and specific part of the pathophysiology of EoE and implicated protease-and IL-1-related activities as putative central pathways in disease pathogenesis.	[Rochman, Mark; Travers, Jared; Miracle, Cora E.; Bedard, Mary C.; Wen, Ting; Azouz, Nurit P.; Caldwell, Julie M.; Kiran, K. C.; Sherrill, Joseph D.; Rymer, Jeffrey K.; Rothenberg, Marc E.] Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, 3333 Burnet Ave,MLC 7028, Cincinnati, OH 45229 USA; [Aronow, Bruce J.] Cincinnati Childrens Hosp Med Ctr, Div Biomed Informat, Cincinnati, OH 45229 USA; [Kaufman, Kenneth M.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Div Rheumatol, Ctr Autoimmune Genom & Etiol,Dept Pediat, Cincinnati, OH 45221 USA; [Kaufman, Kenneth M.] Cincinnati VA Med Ctr, Res Dept, Cincinnati, OH USA; [Davis, Benjamin P.] Univ Iowa Hosp & Clin, Dept Internal Med, Div Immunol, Iowa City, IA 52242 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center; University of Iowa	Rothenberg, ME (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, 3333 Burnet Ave,MLC 7028, Cincinnati, OH 45229 USA.	Marc.Rothenberg@cchmc.org		Miracle, Cora/0000-0002-8730-6779; Rochman, Mark/0000-0002-0818-927X; Azouz, Nurit/0000-0003-4969-1263; davis, benjamin/0000-0003-2108-8059; Travers, Jared/0000-0003-4786-604X; Bedard, Mary/0000-0003-3282-4189	National Institutes of Health [R37 AI045898, R01 AI124355, U19 AI070235, F30 DK109573, T32 GM063483, P30 DK078392]; Campaign Urging Research for Eosinophilic Disease (CURED); Buckeye Foundation; Sunshine Charitable Foundation; APFED HOPE award; Digestive Health Center Pilot/Feasibility award, Cincinnati Children's Hospital Medical Center (through an NIDDK) [P30 DK078392]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI066738, R01AI045898, T32AI060515, U19AI070235, R01AI124355, R37AI045898] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK078392, F30DK109573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM063483] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Campaign Urging Research for Eosinophilic Disease (CURED); Buckeye Foundation; Sunshine Charitable Foundation; APFED HOPE award; Digestive Health Center Pilot/Feasibility award, Cincinnati Children's Hospital Medical Center (through an NIDDK); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by National Institutes of Health grants R37 AI045898 (M.E.R.), R01 AI124355 (M.E.R.), U19 AI070235 (M.E.R.), F30 DK109573 and T32 GM063483 (J.T.), and P30 DK078392 (Gene and Protein Expression Core) (T.W., B.A.); the Campaign Urging Research for Eosinophilic Disease (CURED) (M.E.R.); the Buckeye Foundation (M.E.R.); the Sunshine Charitable Foundation and its supporters, Denise A. Bunning and David G. Bunning (M.E.R.); an APFED HOPE award (T.W.); and a Digestive Health Center Pilot/Feasibility award, Cincinnati Children's Hospital Medical Center (through an NIDDK P30 DK078392 mechanism) (T.W.).	Abdulnour-Nakhoul SM, 2013, CLIN IMMUNOL, V148, P265, DOI 10.1016/j.clim.2013.05.004; Afonina IS, 2011, MOL CELL, V44, P265, DOI 10.1016/j.molcel.2011.07.037; Andl CD, 2003, J BIOL CHEM, V278, P1824, DOI 10.1074/jbc.M209148200; Blanchard C, 2006, J CLIN INVEST, V116, P536, DOI 10.1172/JCI26679; Blanchard C, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Blanchard C, 2011, J ALLERGY CLIN IMMUN, V127, P208, DOI 10.1016/j.jaci.2010.10.039; Blanchard C, 2010, J IMMUNOL, V184, P4033, DOI 10.4049/jimmunol.0903069; Caldwell JM, 2014, J ALLERGY CLIN IMMUN, V134, P1114, DOI 10.1016/j.jaci.2014.07.026; Capocelli KE, 2015, J CLIN PATHOL, V68, P51, DOI 10.1136/jclinpath-2014-202586; Chen J, 2009, NUCLEIC ACIDS RES, V37, pW305, DOI 10.1093/nar/gkp427; D'Mello RJ, 2016, MUCOSAL IMMUNOL, V9, P744, DOI 10.1038/mi.2015.98; Davis BP, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.86355; FUCHS E, 1988, TRENDS GENET, V4, P277, DOI 10.1016/0168-9525(88)90169-2; Garlanda C, 2013, IMMUNITY, V39, P1003, DOI 10.1016/j.immuni.2013.11.010; Gresnigt MS, 2013, SEMIN IMMUNOL, V25, P458, DOI 10.1016/j.smim.2013.11.003; Herman ML, 2009, HUM MUTAT, V30, P537, DOI 10.1002/humu.20952; Jarzab J, 2010, INT ARCH ALLERGY IMM, V151, P28, DOI 10.1159/000232568; Katzka DA, 2015, CLIN GASTROENTEROL H, V13, P1242, DOI 10.1016/j.cgh.2014.12.032; Kiran KC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127755; Kottyan LC, 2014, NAT GENET, V46, P895, DOI 10.1038/ng.3033; Lambrecht BN, 2012, NAT MED, V18, P684, DOI 10.1038/nm.2737; Lieden A, 2009, ALLERGY, V64, P304, DOI 10.1111/j.1398-9995.2008.01856.x; Lu TX, 2009, J IMMUNOL, V182, P4994, DOI 10.4049/jimmunol.0803560; Ma Z, 2009, CLIN EXP ALLERGY, V39, P1136, DOI 10.1111/j.1365-2222.2009.03272.x; Muller S, 2009, PEDIAT ALLERG IMM-UK, V20, P358, DOI 10.1111/j.1399-3038.2008.00808.x; Ober C, 2011, IMMUNOL REV, V242, P10, DOI 10.1111/j.1600-065X.2011.01029.x; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Patel ZH, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00016; Rael EL, 2011, WORLD ALLERGY ORGAN, V4, P54, DOI 10.1097/WOX.0b013e31821188e0; Ravelli A, 2014, J PEDIATR GASTR NUTR, V59, P589, DOI 10.1097/MPG.0000000000000491; Rawson R, 2016, J ALLERGY CLIN IMMUN, V138, P791, DOI 10.1016/j.jaci.2016.02.028; Rochman M, 2015, MUCOSAL IMMUNOL, V8, P785, DOI 10.1038/mi.2014.109; Rothenberg ME, 2015, J ALLERGY CLIN IMMUN, V135, P500, DOI 10.1016/j.jaci.2014.07.049; Sherrill JD, 2014, GENES IMMUN, V15, P361, DOI 10.1038/gene.2014.27; Sherrill JD, 2014, MUCOSAL IMMUNOL, V7, P718, DOI 10.1038/mi.2013.90; Simon D, 2015, ALLERGY, V70, P443, DOI 10.1111/all.12570; Sleiman PMA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6593; Straumann A, 2001, J ALLERGY CLIN IMMUN, V108, P954, DOI 10.1067/mai.2001.119917; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; van Rhijn BD, 2014, CLIN GASTROENTEROL H, V12, P1815, DOI 10.1016/j.cgh.2014.02.037; Vigne S, 2012, BLOOD, V120, P3478, DOI 10.1182/blood-2012-06-439026; Wen T, 2013, GASTROENTEROLOGY, V145, P1289, DOI 10.1053/j.gastro.2013.08.046	42	36	38	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2017	140	3					738	+		10.1016/j.jaci.2016.11.042	http://dx.doi.org/10.1016/j.jaci.2016.11.042			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FF8CA	28104354	Bronze, Green Accepted			2022-12-18	WOS:000409241500013
J	Yagami, A; Aihara, M; Ikezawa, Z; Hide, M; Kishikawa, R; Morita, E; Chinuki, Y; Fukutomi, Y; Urisu, A; Fukushima, A; Itagaki, Y; Sugiura, S; Tanaka, H; Teshima, R; Kato, Z; Noguchi, E; Nakamura, M; Saito, H; Matsunaga, K				Yagami, Akiko; Aihara, Michiko; Ikezawa, Zenro; Hide, Michihiro; Kishikawa, Reiko; Morita, Eishin; Chinuki, Yuko; Fukutomi, Yuma; Urisu, Atsuo; Fukushima, Atsuki; Itagaki, Yasuharu; Sugiura, Shin-ichi; Tanaka, Hiroyuki; Teshima, Reiko; Kato, Zenichiro; Noguchi, Emiko; Nakamura, Masashi; Saito, Hirohisa; Matsunaga, Kayoko			Outbreak of immediate-type hydrolyzed wheat protein allergy due to a facial soap in Japan	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							EXERCISE-INDUCED ANAPHYLAXIS; COSMETIC CREAM; CONTACT-DERMATITIS; IGE		[Yagami, Akiko] Fujita Hlth Univ, Sch Med, Dept Allergol, Aichi, Japan; [Aihara, Michiko; Ikezawa, Zenro] Yokohama City Univ, Sch Med, Dept Dermatol, Kanagawa, Japan; [Hide, Michihiro] Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Dermatol, Hiroshima, Japan; [Kishikawa, Reiko] Natl Hosp Org Fukuoka Hosp, Dept Allergy, Fukuoka, Japan; [Morita, Eishin; Chinuki, Yuko] Shimane Univ, Fac Med, Dept Dermatol, Shimane, Japan; [Fukutomi, Yuma] Sagamihara Natl Hosp, Clin Res Ctr Allergy & Rheumatol, Kanagawa, Japan; [Urisu, Atsuo] Fujita Hlth Univ, Sch Med, Dept Pediat, Aichi, Japan; [Fukushima, Atsuki] Kochi Med Sch, Dept Ophthalmol, Kochi, Japan; [Itagaki, Yasuharu] Hokkaido Bunkyo Univ, Dept Hlth & Nutr, Hokkaido, Japan; [Sugiura, Shin-ichi] Doshisha Womens Coll Liberal Arts, Fac Pharmaceut Sci, Dept Clin Pharm, Kyoto, Japan; [Sugiura, Shin-ichi] Nagoya Univ, Ctr Res Lab Animals & Med Res Engn, Aichi, Japan; [Tanaka, Hiroyuki] Gifu Pharmaceut Univ, Dept Bioact Mol, Lab Pharmacol, Gifu, Japan; [Tanaka, Hiroyuki] Gifu Univ, United Grad Sch Drug Discovery & Med Informat Sci, Med Informat Sci Div, Field Biofunct Control, Gifu, Japan; [Teshima, Reiko] Natl Inst Hlth Sci, Div Environm Chem, Tokyo, Japan; [Kato, Zenichiro] Gifu Univ, United Grad Sch Drug Discovery & Med Informat Sci, Gifu, Japan; [Noguchi, Emiko] Univ Tsukuba, Fac Med, Dept Med Genet, Ibaraki, Japan; [Nakamura, Masashi; Matsunaga, Kayoko] Fujita Hlth Univ, Sch Med, Dept Integrat Med Sci Allerg Dis, Aichi, Japan; [Saito, Hirohisa] Natl Res Inst Child Hlth & Dev, Dept Allergy & Clin Immunol, Tokyo, Japan	Fujita Health University; Yokohama City University; Hiroshima University; Shimane University; Fujita Health University; Kochi University; Nagoya University; Gifu Pharmaceutical University; Gifu University; National Institute of Health Sciences - Japan; Gifu University; University of Tsukuba; Fujita Health University; National Center for Child Health & Development - Japan	Matsunaga, K (corresponding author), Fujita Hlth Univ, Sch Med, Dept Integrat Med Sci Allerg Dis, Aichi, Japan.	kamatsu@fujita-hu.ac.jp	Hide, Michihiro/H-2519-2019; Fukutomi, Yuma/AFQ-4306-2022	Hide, Michihiro/0000-0002-1569-6034; Saito, Hirohisa/0000-0002-6630-8337; Nakamura, Masashi/0000-0002-9746-0243	Ministry of Health, Labour, Welfare of Japan (Study on Quasi Drug/Cosmetic Additives Safety); Japanese Society of Allergology	Ministry of Health, Labour, Welfare of Japan (Study on Quasi Drug/Cosmetic Additives Safety); Japanese Society of Allergology	This study was partly supported by Grant-in-Aid of the Ministry of Health, Labour, Welfare of Japan (Study on Quasi Drug/Cosmetic Additives Safety, 2012-2014) and the Japanese Society of Allergology. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Airaksinen L, 2013, ANN ALLERG ASTHMA IM, V111, P577, DOI 10.1016/j.anai.2013.09.025; Barrientos N, 2012, ACTAS DERMO-SIFILOGR, V103, P750, DOI 10.1016/j.adengl.2012.09.013; Bouchez-Mahiout I, 2010, J AGR FOOD CHEM, V58, P4207, DOI 10.1021/jf903973x; Codreanu F, 2006, Eur Ann Allergy Clin Immunol, V38, P126; E1. European Union, OP SCI COMM CONS SAF; Fukutomi Y, 2009, JPN J ALLERGOL, V58, P1325; Hann S, 2007, CONTACT DERMATITIS, V56, P119, DOI 10.1111/j.1600-0536.2007.00977.x; Hiragun M, 2016, ALLERGOL INT, V65, P109, DOI 10.1016/j.alit.2015.07.004; Lauriere M, 2006, CONTACT DERMATITIS, V54, P283, DOI 10.1111/j.0105-1873.2006.00830.x; Livideanu C, 2007, CONTACT DERMATITIS, V57, p283A, DOI 10.1111/j.1600-0536.2007.01128.x; Ministry of Health, LAB WELF JAP PREL RE; Morita Eishin, 2009, Allergology International, V58, P493, DOI 10.2332/allergolint.09-RAI-0125; Nakamura M, 2014, ALLERGOL INT, V63, P243, DOI 10.2332/allergolint.13-OA-0618; Nakamura Rika, 2013, Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku, P50; Nakamura R, 2013, INT ARCH ALLERGY IMM, V160, P259, DOI 10.1159/000341671; Nakamura R, 2013, J ALLERGY CLIN IMMUN, V132, P1436, DOI 10.1016/j.jaci.2013.07.017; Olaiwan A, 2010, ANN DERMATOL VENER, V137, P281, DOI 10.1016/j.annder.2010.01.010; Pecquet C, 2002, CONTACT DERMATITIS, V46, P123, DOI 10.1034/j.1600-0536.2002.460220.x; Pecquet C, 2004, CONTACT DERMATITIS, V50, P182; Sanchez-Perez J, 2000, CONTACT DERMATITIS, V42, P360; Varjonen E, 2000, ALLERGY, V55, P294, DOI 10.1034/j.1398-9995.2000.00516.x; Yokooji T, 2013, ALLERGOL INT, V62, P435, DOI 10.2332/allergolint.13-OA-0561	22	36	37	2	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2017	140	3					879	+		10.1016/j.jaci.2017.03.019	http://dx.doi.org/10.1016/j.jaci.2017.03.019			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FF8CA	28633942	hybrid, Green Published			2022-12-18	WOS:000409241500033
J	Zeeuwen, PLJM; Ederveen, THA; van der Krieken, DA; Niehues, H; Boekhorst, J; Kezic, S; Hanssen, DAT; Otero, ME; van Vlijmen-Willems, IMJJ; Rodijk-Olthuis, D; Falcone, D; van den Bogaard, EHJ; Kamsteeg, M; de Koning, HD; Zeeuwen-Franssen, MEJ; van Steensel, MAM; Kleerebezem, M; Timmerman, HM; van Hijum, SAFT; Schalkwijk, J				Zeeuwen, Patrick L. J. M.; Ederveen, Thomas H. A.; van der Krieken, Danique A.; Niehues, Hanna; Boekhorst, Jos; Kezic, Sanja; Hanssen, Danielle A. T.; Otero, Marisol E.; van Vlijmen-Willems, Ivonne M. J. J.; Rodijk-Olthuis, Diana; Falcone, Denise; van den Bogaard, Ellen H. J.; Kamsteeg, Marijke; de Koning, Heleen D.; Zeeuwen-Franssen, Manon E. J.; van Steensel, Maurice A. M.; Kleerebezem, Michiel; Timmerman, Harro M.; van Hijum, Sacha A. F. T.; Schalkwijk, Joost			Gram-positive anaerobe cocci are underrepresented in the microbiome of filaggrin-deficient human skin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ATOPIC-DERMATITIS		[Zeeuwen, Patrick L. J. M.; van der Krieken, Danique A.; Niehues, Hanna; Hanssen, Danielle A. T.; Otero, Marisol E.; van Vlijmen-Willems, Ivonne M. J. J.; Rodijk-Olthuis, Diana; Falcone, Denise; van den Bogaard, Ellen H. J.; Kamsteeg, Marijke; de Koning, Heleen D.; Schalkwijk, Joost] Radboud Univ Nijmegen Med Ctr, Radboud Inst Mol Life Sci, Dept Dermatol, Nijmegen, Netherlands; [Ederveen, Thomas H. A.; Boekhorst, Jos; van Hijum, Sacha A. F. T.] Radboud Univ Nijmegen Med Ctr, Ctr Mol & Biomol Informat, Nijmegen, Netherlands; [Ederveen, Thomas H. A.; Boekhorst, Jos; Timmerman, Harro M.; van Hijum, Sacha A. F. T.] NIZO Food Res BV, Ede, Netherlands; [Kezic, Sanja] Acad Med Ctr, Coronel Inst Occupat Hlth, Amsterdam, Netherlands; [Zeeuwen-Franssen, Manon E. J.] Canisius Wilhelmina Hosp, Dept Dermatol, Nijmegen, Netherlands; [van Steensel, Maurice A. M.] Univ Dundee, Sch Med, Div Canc Sci, Dundee, Scotland; [van Steensel, Maurice A. M.] Univ Dundee, Div Biol Chem & Drug Dev, Sch Life Sci, Dundee, Scotland; [van Steensel, Maurice A. M.] ASTAR, Inst Med Biol, Singapore, Singapore; [Kleerebezem, Michiel] Wageningen Univ, Host Microbe Interact Grp, Wageningen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen; NIZO Food Research; University of Amsterdam; Academic Medical Center Amsterdam; Canisius-Wilhelmina Hospital; University of Dundee; University of Dundee; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Medical Biology (IMB); Wageningen University & Research	Zeeuwen, PLJM (corresponding author), Radboud Univ Nijmegen Med Ctr, Radboud Inst Mol Life Sci, Dept Dermatol, Nijmegen, Netherlands.	Patrick.Zeeuwen@Radboudumc.nl; Joost.Schalkwijk@Radboudumc.nl	Schalkwijk, Joost/R-7509-2019; van Steensel, Maurice A.M./V-3852-2019; Hanssen, Daniëlle/GRO-1300-2022; Falcone, Denise/P-5352-2015; Schalkwijk, Joost/N-1774-2013; Kamsteeg, M./L-4422-2015; Zeeuwen, Patrick/N-1779-2013; Ederveen, Thomas HA/G-6294-2016; van Vlijmen-Willems, Ivonne MJJ/P-5336-2015; Otero, M.E./L-4446-2015; van Hijum, Sacha/F-6445-2014; Kleerebezem, Michiel/AAT-2078-2021; van der Krieken, Danique/P-5416-2015; van den Bogaard, Ellen H./P-6212-2015; de Koning, Heleen/A-5374-2011; Niehues, Hanna/P-5071-2015	Schalkwijk, Joost/0000-0002-1308-1319; Falcone, Denise/0000-0003-1794-6516; Zeeuwen, Patrick/0000-0002-6878-2438; Ederveen, Thomas HA/0000-0003-0068-1275; van Vlijmen-Willems, Ivonne MJJ/0000-0002-3522-2573; van den Bogaard, Ellen H./0000-0003-4846-0287; Niehues, Hanna/0000-0002-6954-6955; van Steensel, Maurice/0000-0002-7507-2442; van Hijum, Sacha/0000-0003-0741-2991; Kleerebezem, Michiel/0000-0001-8552-2235; Boekhorst, Jos/0000-0002-4807-7838	TOP grant from the Netherlands Organization for Health Research and Development (ZonMw) [91211052]; Hotel Technology grant from ZonMw [435000002]	TOP grant from the Netherlands Organization for Health Research and Development (ZonMw); Hotel Technology grant from ZonMw	This study was funded by a TOP grant from the Netherlands Organization for Health Research and Development (ZonMw) (grant no. 91211052) and by a Hotel Technology grant from ZonMw (grant no. 435000002). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Blekhman R, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0759-1; Costello EK, 2009, SCIENCE, V326, P1694, DOI 10.1126/science.1177486; Grice EA, 2011, NAT REV MICROBIOL, V9, P244, DOI 10.1038/nrmicro2537; Kong HDH, 2012, GENOME RES, V22, P850, DOI 10.1101/gr.131029.111; Murphy EC, 2013, FEMS MICROBIOL REV, V37, P520, DOI 10.1111/1574-6976.12005; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Zeeuwen PLJM, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-11-r101; Zeeuwen PLJM, 2013, CURR OPIN ALLERGY CL, V13, P514, DOI 10.1097/ACI.0b013e328364ebeb	9	36	36	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2017	139	4					1368	1371		10.1016/j.jaci.2016.09.017	http://dx.doi.org/10.1016/j.jaci.2016.09.017			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ER4LR	27725187	Green Published, hybrid			2022-12-18	WOS:000398771800031
J	Anderson, HM; Lemanske, RF; Arron, JR; Holweg, CTJ; Rajamanickam, V; Gangnon, RE; Gern, JE; Jackson, DJ				Anderson, Halie M.; Lemanske, Robert F., Jr.; Arron, Joseph R.; Holweg, Cecile T. J.; Rajamanickam, Victoria; Gangnon, Ronald E.; Gern, James E.; Jackson, Daniel J.			Relationships among aeroallergen sensitization, peripheral blood eosinophils, and periostin in pediatric asthma development	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Biomarkers; children; asthma development; periostin; aeroallergen sensitization; peripheral blood eosinophils	PERSISTENT ASTHMA; AIRWAY INFLAMMATION; HIGH-RISK; CHILDREN; CHILDHOOD; LIFE; ATOPY; BIOMARKERS	Background: Biomarkers, preferably noninvasive, that predict asthma inception in children are lacking. Objective: Little is known about biomarkers of type 2 inflammation in early life in relation to asthma inception. We evaluated aeroallergen sensitization, peripheral blood eosinophils, and serum periostin as potential biomarkers of asthmain children. Methods: Children enrolled in the Childhood Origins of ASThma study were followed prospectively from birth. Blood samples were collected at ages 2, 4, 6, and 11 years, and serum specific IgE levels, blood eosionophil counts, and periostin levels were measured in 244 children. Relationships among these biomarkers, age, and asthma were assessed. Results: Serum periostin levels were approximately 2- to 3-fold higher in children than previously observed adult levels. Levels were highest at 2 years (145 ng/mL), and did not change significantly between 4 and 11 years (128 and 130 ng/mL). Age 2 year periostin level of 150 ng/mL or more predicted asthma at age 6 years (odds ratio [OR], 2.3; 95% CI, 1.3-4.4). Eosinophil count of 300 cells/mu L or more and aeroallergen sensitization at age 2 years were each associated with increased risk of asthma at age 6 years (OR, 3.1; 95% CI, 1.7-6.0 and OR, 3.3; 95% CI, 1.7-6.3). Children with any 2 of the biomarkers had a significantly increased risk of developing asthma by school age (<= 2 biomarkers vs none: OR, 6.6; 95% CI, 2.7-16.0). Conclusions: Serum periostin levels are significantly higher in children than in adults, likely due to bone turnover, which impairs clinical utility in children. Early life aeroallergen sensitization and elevated blood eosinophils are robust predictors of asthma development. Children with evidence of activation of multiple pathways of type 2 inflammation in early life are at greatest risk for asthma development.	[Anderson, Halie M.; Lemanske, Robert F., Jr.; Gern, James E.; Jackson, Daniel J.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat, Div Allergy Immunol & Rheumatol, Madison, WI 53706 USA; [Arron, Joseph R.; Holweg, Cecile T. J.] Genen Tech Inc, San Francisco, CA USA; [Rajamanickam, Victoria; Gangnon, Ronald E.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostatist & Med Informat, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Anderson, HM (corresponding author), 600 Highland Ave CSC K4 936, Madison, WI 53792 USA.	Handerson@pediatrics.wisc.edu		Gangnon, Ronald/0000-0003-2587-6714; Arron, Joseph/0000-0001-7677-9979	National Heart, Lung, and Blood Institute (NHLBI); AAAAI FIT Travel Scholarship; Pharmaxis; NHLBI; Michigan Public Health; Allegheny General Hospital; AAP; West Allegheny Health; California Chapter 4; Colorado Allergy Society; Pennsylvania Allergy Society; Howard Pilgrim Health; California Society of Allergy; NYC Allergy Society; World Allergy Organization; APAPARI; Western Society of Allergy, Asthma and Immunology; Kuwait Allergy Society; Lurie Childrens Hospital; Boston Children's Hospital; LA Children's Hospital; Northwestern University; Asthma and Allergy Foundation of America; Alaska Chapter; Egyptian Allergy Society; AAAAI; University of Wisconsin, Madison; National Institutes of Health; GlaxoSmithKline; Boehringer Ingelheim; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL070831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007635] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); AAAAI FIT Travel Scholarship; Pharmaxis; NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Michigan Public Health; Allegheny General Hospital(General Electric); AAP; West Allegheny Health; California Chapter 4; Colorado Allergy Society; Pennsylvania Allergy Society; Howard Pilgrim Health; California Society of Allergy; NYC Allergy Society; World Allergy Organization; APAPARI; Western Society of Allergy, Asthma and Immunology; Kuwait Allergy Society; Lurie Childrens Hospital; Boston Children's Hospital; LA Children's Hospital; Northwestern University; Asthma and Allergy Foundation of America; Alaska Chapter; Egyptian Allergy Society; AAAAI; University of Wisconsin, Madison; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); GlaxoSmithKline(GlaxoSmithKline); Boehringer Ingelheim(Boehringer Ingelheim); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	H. M. Anderson receives research support from the National Heart, Lung, and Blood Institute (NHLBI) and travel support from the AAAAI FIT Travel Scholarship. R. F. Lemanske, Jr is an employee of the University of Wisconsin, receives research support from NHLBI and Pharmaxis; serves as a consultant for Merck, Sepracor, SA Boney and Associates, GlaxoSmithKline, American Institute of Research, Genetech, Double Helix Development, Health Star Communications, and Boerhinger Ingelheim; receives speaker fees from Michigan Public Health, Allegheny General Hospital, AAP, West Allegheny Health, California Chapter 4, Colorado Allergy Society, Pennsylvania Allergy Society, Howard Pilgrim Health, California Society of Allergy, NYC Allergy Society, World Allergy Organization, APAPARI, Western Society of Allergy, Asthma and Immunology, Kuwait Allergy Society, Lurie Childrens Hospital, Boston Children's Hospital, LA Children's Hospital, Northwestern University, Asthma and Allergy Foundation of America, Alaska Chapter, and Egyptian Allergy Society; payment for manuscript preparation from the AAAAI; and Royalties from Elsevier and UpToDate. J. R. Arron is an empoyee of Genentech, Inc; has a patent with Genentech, Inc; and holds stock with the Roche Group. C. T. J. Holweg is an employee of Genetech Inc. V. Rajamanickam receives research funding from the University of Wisconsin, Madison. R. E. Gangnon receives research support from the NHLBI. J. E. Gern receives research support from the National Institutes of Health and GlaxoSmithKline; serves as a consultant for Genetech, Amgen, Novartis, PREP Biopharm, Inc, Janssen, Regeneron, and GlaxoSmithKline; receives payment for the development of educational presentations from Boehringer Ingelheim; and receives travel support from Boehringer Ingelheim. D. J. Jackson receives grant funding from the National Institutes of Health and serves as a consultant for Vectura.	Abbassi V, 1998, PEDIATRICS, V102, P507; Arbes SJ, 2013, CLIN EXP ALLERGY, V43, P544, DOI 10.1111/cea.12069; Arron Joseph R, 2013, Ann Am Thorac Soc, V10 Suppl, pS206, DOI 10.1513/AnnalsATS.201303-047AW; Backman K, 2015, PEDIAT ALLERG IMM-UK, V26, P668, DOI 10.1111/pai.12448; Brockow I, 2009, J INVEST ALLERG CLIN, V19, P180; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403, DOI 10.1164/ajrccm.162.4.9912111; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Gaffin JM, 2009, CURR OPIN ALLERGY CL, V9, P128, DOI 10.1097/ACI.0b013e32832678b0; Genuneit J, 2013, J ALLERGY CLIN IMMUN, V132, P1237, DOI 10.1016/j.jaci.2013.06.044; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Jia GQ, 2012, J ALLERGY CLIN IMMUN, V130, P647, DOI 10.1016/j.jaci.2012.06.025; Konradsen JR, 2015, PEDIAT ALLERG IMM-UK, V26, P772, DOI 10.1111/pai.12457; Kudo A, 2011, CELL MOL LIFE SCI, V68, P3201, DOI 10.1007/s00018-011-0784-5; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Lemanske RF, 2002, PEDIAT ALLERG IMM-UK, V13, P38, DOI 10.1034/j.1399-3038.13.s.15.8.x; Lopez-Guisa JM, 2012, J ALLERGY CLIN IMMUN, V129, P990, DOI 10.1016/j.jaci.2011.11.035; Luo G, 2015, BMC MED INFORM DECIS, V15, DOI 10.1186/s12911-015-0224-9; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Nichols J., UPTODATE; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Piippo-Savolainen E, 2007, ALLERGY ASTHMA PROC, V28, P163, DOI 10.2500/app.2007.28.2946; Sherman J, 2014, CLIN CHEM S, V60, pS25; Sly PD, 2008, LANCET, V372, P1100, DOI 10.1016/S0140-6736(08)61451-8; Song JS, 2015, ALLERGY, V70, P674, DOI 10.1111/all.12599; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Stoltz DJ, 2013, CLIN EXP ALLERGY, V43, P233, DOI 10.1111/cea.12050; Szefler SJ, 2012, J ALLERGY CLIN IMMUN, V129, pS9, DOI 10.1016/j.jaci.2011.12.979; Wenzel S, 2013, NEW ENGL J MED, V368, P2455, DOI 10.1056/NEJMoa1304048; Wolterink RGJK, 2013, CURR ALLERGY ASTHM R, V13, P271, DOI 10.1007/s11882-013-0346-z	31	36	39	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2017	139	3					790	796		10.1016/j.jaci.2016.05.033	http://dx.doi.org/10.1016/j.jaci.2016.05.033			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EP3QC	27484037	Green Accepted, Bronze			2022-12-18	WOS:000397295800010
J	Florea, AED; Braylan, RC; Schafernak, KT; Williams, KW; Daub, J; Goyal, RK; Puck, JM; Rao, VK; Pittaluga, S; Holland, SM; Uzel, G; Calvo, KR				Florea, Alina E. Dulau; Braylan, Raul C.; Schafernak, Kristian T.; Williams, Kelli W.; Daub, Janine; Goyal, Rakesh K.; Puck, Jennifer M.; Rao, V. Koneti; Pittaluga, Stefania; Holland, Steven M.; Uzel, Gulbu; Calvo, Katherine R.			Abnormal B-cell maturation in the bone marrow of patients with germline mutations in PIK3CD	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							DUST-MITE ALLERGENS; PHOSPHOINOSITIDE 3-KINASE; DERMATOPHAGOIDES-FARINAE; THERMODYNAMIC ANALYSIS; PI3K; TRANSCRIPTOME; HEMATOGONES; STABILITY; GENOME		[Florea, Alina E. Dulau; Braylan, Raul C.; Calvo, Katherine R.] NIH, Dept Lab Med, Ctr Clin, Bethesda, MD 20892 USA; [Schafernak, Kristian T.] Ann & Robert H Lurie Childrens Hosp Chicago, Dept Pathol & Lab Med, Chicago, IL 60611 USA; [Schafernak, Kristian T.] Phoenix Childrens Hosp, Div Pathol & Lab Med, Phoenix, AZ USA; [Williams, Kelli W.; Rao, V. Koneti; Holland, Steven M.; Uzel, Gulbu] NIAID, Lab Clin Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Goyal, Rakesh K.] UPMC, Childrens Hosp Pittsburgh, Pediat Hematol Oncol, Pittsburgh, PA USA; [Puck, Jennifer M.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; [Pittaluga, Stefania] NCI, Pathol Lab, NIH, Bldg 10, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); Ann & Robert H. Lurie Children's Hospital of Chicago; Phoenix Children's Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Calvo, KR (corresponding author), NIH, Dept Lab Med, Ctr Clin, Bethesda, MD 20892 USA.	calvok@mail.nih.gov	Rao, V. Koneti/AAR-2171-2020	Rao, V. Koneti/0000-0002-7881-6902; Schafernak, Kristian/0000-0003-3052-8925; Calvo, Katherine/0000-0002-0771-4191	Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Cancer Institute; National Institutes of Health Clinical Center; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000732] Funding Source: NIH RePORTER; CLINICAL CENTER [ZIACL090025, ZIACL080022] Funding Source: NIH RePORTER	Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Cancer Institute; National Institutes of Health Clinical Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); CLINICAL CENTER	This work was supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Cancer Institute, and National Institutes of Health Clinical Center. The content of this letter does not necessarily reflect the views or policies of the Department of Health and Human Services.	Angulo I, 2013, SCIENCE, V342, P866, DOI 10.1126/science.1243292; Arlian LG, 2011, INT ARCH ALLERGY IMM, V156, P171, DOI 10.1159/000323351; Avula-Poola S, 2012, INT ARCH ALLERGY IMM, V159, P226, DOI 10.1159/000336026; Browne CD, 2009, IMMUNITY, V31, P749, DOI 10.1016/j.immuni.2009.08.026; Carulli G, 2015, INT J HEMATOL, V102, P59, DOI 10.1007/s12185-015-1798-9; Chan TF, 2015, J ALLERGY CLIN IMMUN, V135, P539, DOI 10.1016/j.jaci.2014.09.031; Grabherr MG, 2011, NAT BIOTECHNOL, V29, P644, DOI 10.1038/nbt.1883; Kang S, 2006, P NATL ACAD SCI USA, V103, P1289, DOI 10.1073/pnas.0510772103; Lucas CL, 2014, NAT IMMUNOL, V15, P88, DOI 10.1038/ni.2771; McKenna RW, 2004, LEUKEMIA LYMPHOMA, V45, P277, DOI 10.1080/1042819031000151950; Morgan MAJ, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0071974, 10.1371/journal.pone.0056738, 10.1371/journal.pone.0069936]; Mueller GA, 2016, CLIN EXP ALLERGY, V46, P365, DOI 10.1111/cea.12680; Mueller GA, 2010, J BIOL CHEM, V285, P25394, DOI 10.1074/jbc.M110.128306; Okkenhaug K, 2003, NAT REV IMMUNOL, V3, P317, DOI 10.1038/nri1056; Vanhaesebroeck B, 2010, NAT REV MOL CELL BIO, V11, P329, DOI 10.1038/nrm2882; Werner M, 2010, IMMUNOL REV, V237, P55, DOI 10.1111/j.1600-065X.2010.00934.x; West GM, 2008, ANAL CHEM, V80, P4175, DOI 10.1021/ac702610a; Xu YR, 2014, ANAL CHEM, V86, P7041, DOI 10.1021/ac501278j	18	36	36	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2017	139	3					1032	1035		10.1016/j.jaci.2016.08.028	http://dx.doi.org/10.1016/j.jaci.2016.08.028			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EP3QC	27697496	Green Accepted, Bronze			2022-12-18	WOS:000397295800036
J	Burton, OT; Stranks, AJ; Tamayo, JM; Koleoglou, KJ; Schwartz, LB; Oettgen, HC				Burton, Oliver T.; Stranks, Amanda J.; Tamayo, Jaciel M.; Koleoglou, Kyle J.; Schwartz, Lawrence B.; Oettgen, Hans C.			A humanized mouse model of anaphylactic peanut allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE; mast cells; anaphylaxis; humanized mice; tryptase; peanut allergy	MUCOSAL MAST-CELLS; FC-GAMMA-RIIB; T-CELLS; FOOD ALLERGY; MURINE MODEL; POSITIVE SELECTION; ATOPIC-DERMATITIS; IN-VIVO; HUMAN B; IGE	Background: Food allergy is a growing health problem with very limited treatment options. Investigation of the immunologic pathways underlying allergic sensitization to foods in humans has been greatly constrained by the limited availability of intestinal tissue and gut-resident immune cells. Although mouse models have offered insights into pathways of food sensitization, differences between rodent and human immune physiology limit the extension of these findings to our understanding of human disease. Objective: We sought to develop a strategy for the generation of mice with humanized adaptive immune systems, complete with tissue engraftment by human mast cells that are competent to mount specific IgE-mediated responses and drive systemic anaphylaxis on ingestion challenge. Methods: Nonobese diabetic severe combined immunodeficient mice lacking the cytokine receptor common gamma chain (gamma(c) (-/-)) and carrying a human stem cell factor transgene were engrafted with human hematopoietic stem cells. The impact of peanut (PN) feeding and IgE neutralization on the development of immune responses, mast cell homeostasis, and anaphylactic food allergy was assessed in these animals. Results: Humanized nonobese diabetic severe combined immunodeficient common gamma chain-deficient stem cell factor (huNSG) mice exhibited robust engraftment with functional human T and B lymphocytes and human mast cells were found in significant numbers in their tissues, including the intestinal mucosa. Following gavage feeding with PN, they mounted specific antibody responses, including PN-specific IgE. When enterally challenged with PN, they exhibited mast-cell-mediated systemic anaphylaxis, as indicated by hypothermia and increases in plasma tryptase levels. Anti-IgE (omalizumab) treatment ablated this anaphylactic response. Conclusions: huNSG mice provide a novel tool for studying food allergy and IgE-mediated anaphylaxis.	[Burton, Oliver T.; Stranks, Amanda J.; Tamayo, Jaciel M.; Koleoglou, Kyle J.; Oettgen, Hans C.] Boston Childrens Hosp, Dept Med, Boston, MA USA; [Burton, Oliver T.; Stranks, Amanda J.; Tamayo, Jaciel M.; Oettgen, Hans C.] Harvard Med Sch, Dept Pediat, Boston, MA USA; [Schwartz, Lawrence B.] Virginia Commonwealth Univ, Div Rheumatol Allergy & Immunol, Richmond, VA USA; [Schwartz, Lawrence B.] Virginia Commonwealth Univ, Dept Internal Med, Richmond, VA USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Virginia Commonwealth University; Virginia Commonwealth University	Burton, OT (corresponding author), 10004A Karp Bldg,1 Blackfan Circle, Boston, MA 02115 USA.	oliver.burton@childrens.harvard.edu		Burton, Oliver/0000-0003-3884-7373; Oettgen, Hans/0000-0003-1199-1391	Bunning Food Allergy Foundation; National Institute of Allergy and Infectious Diseases [1R01AI119918-01, 5T32AI007512-28]; National Institute of Diabetes and Digestive and Kidney Diseases K01 career development grant [1K01DK106303-01]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI119918, P01AI031541, T32AI007512] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK106303] Funding Source: NIH RePORTER	Bunning Food Allergy Foundation; National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute of Diabetes and Digestive and Kidney Diseases K01 career development grant; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was funded by the Bunning Food Allergy Foundation and the National Institute of Allergy and Infectious Diseases (grant nos. 1R01AI119918-01 and 5T32AI007512-28). O.T.B. is currently funded by a National Institute of Diabetes and Digestive and Kidney Diseases K01 career development grant (grant no. 1K01DK106303-01).	Ackermann L, 1998, ARCH DERMATOL RES, V290, P353, DOI 10.1007/s004030050317; Adkins B, 2004, NAT REV IMMUNOL, V4, P553, DOI 10.1038/nri1394; Alvarez-Twose I, 2014, J ALLERGY CLIN IMMUN, V133, P520, DOI 10.1016/j.jaci.2013.06.020; BACCI S, 1995, DIGEST DIS SCI, V40, P357, DOI 10.1007/BF02065422; BAGNATO GF, 1995, ALLERGY, V50, P322, DOI 10.1111/j.1398-9995.1995.tb01155.x; Balzar S, 2005, AM J RESP CRIT CARE, V171, P431, DOI 10.1164/rccm.200407-949OC; Bartnikas LM, 2013, J ALLERGY CLIN IMMUN, V131, P451, DOI 10.1016/j.jaci.2012.11.032; Beck LA, 2004, J ALLERGY CLIN IMMUN, V114, P527, DOI 10.1016/j.jaci.2004.06.032; Bell WJ, 1997, HISTOCHEM J, V29, P759, DOI 10.1023/A:1026421303260; BIX M, 1992, NATURE, V359, P330, DOI 10.1038/359330a0; Brandt EB, 2003, J CLIN INVEST, V112, P1666, DOI 10.1172/JCI19785; Brehm MA, 2012, BLOOD, V119, P2778, DOI 10.1182/blood-2011-05-353243; Bruhns P, 2012, BLOOD, V119, P5640, DOI 10.1182/blood-2012-01-380121; Bryce PJ, 2004, IMMUNITY, V20, P381, DOI 10.1016/S1074-7613(04)00080-9; Burton OT, 2013, MUCOSAL IMMUNOL, V6, P740, DOI 10.1038/mi.2012.112; Burton OT, 2014, J ALLERGY CLIN IMMUN, V134, P1310, DOI 10.1016/j.jaci.2014.05.042; Burton OT, 2014, IMMUNITY, V41, P141, DOI 10.1016/j.immuni.2014.05.017; Burton OT, 2011, IMMUNOL REV, V242, P128, DOI 10.1111/j.1600-065X.2011.01024.x; Calzascia T, 2008, P NATL ACAD SCI USA, V105, P2999, DOI 10.1073/pnas.0712135105; Carroll NG, 2002, EUR RESPIR J, V19, P879, DOI 10.1183/09031936.02.00275802; Chicha L, 2005, ANN NY ACAD SCI, V1044, P236, DOI 10.1196/annals.1349.029; CONRAD DH, 1983, J IMMUNOL, V130, P327; EADY RAJ, 1979, BRIT J DERMATOL, V100, P623, DOI 10.1111/j.1365-2133.1979.tb08065.x; FDA, 2005, GUID IND EST MAX SAF; Fischer HJ, 2016, FASEB J, V30, P1724, DOI 10.1096/fj.15-277384; Flohr C, 2014, J INVEST DERMATOL, V134, P345, DOI 10.1038/jid.2013.298; FungLeung WP, 1996, J EXP MED, V183, P49, DOI 10.1084/jem.183.1.49; Ganeshan K, 2009, J ALLERGY CLIN IMMUN, V123, P231, DOI 10.1016/j.jaci.2008.10.011; GARRIGA MM, 1988, J ALLERGY CLIN IMMUN, V82, P425, DOI 10.1016/0091-6749(88)90015-2; Goettel JA, 2015, BLOOD, V125, P3886, DOI 10.1182/blood-2014-12-618363; Hamilton RG, 2005, J IMMUNOL METHODS, V303, P81, DOI 10.1016/j.jim.2005.06.008; HEARD BE, 1989, J PATHOL, V157, P59, DOI 10.1002/path.1711570108; Helm BA, 1996, J BIOL CHEM, V271, P7494, DOI 10.1074/jbc.271.13.7494; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Ishikawa F, 2005, BLOOD, V106, P1565, DOI 10.1182/blood-2005-02-0516; Ito R, 2013, J IMMUNOL, V191, P2890, DOI 10.4049/jimmunol.1203543; Kenney L, 2015, J IMMUNOL, V194; Kweon MN, 2000, J CLIN INVEST, V106, P199, DOI 10.1172/JCI8490; Lang JL, 2013, J IMMUNOL, V190, P2090, DOI 10.4049/jimmunol.1202810; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P150, DOI 10.1067/mai.2000.107395; MacGlashan D, 2004, J ALLERGY CLIN IMMUN, V114, P1472, DOI 10.1016/j.jaci.2004.07.064; Madan JC, 2012, CURR OPIN PEDIATR, V24, P753, DOI 10.1097/MOP.0b013e32835a1ac8; MARKOWITZ JS, 1993, P NATL ACAD SCI USA, V90, P2779, DOI 10.1073/pnas.90.7.2779; Mathias CB, 2011, J ALLERGY CLIN IMMUN, V127, P795, DOI 10.1016/j.jaci.2010.11.009; MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269; Milner JD, 2007, P NATL ACAD SCI USA, V104, P576, DOI 10.1073/pnas.0610289104; Molloy J, 2013, INT J ENV RES PUB HE, V10, P7235, DOI 10.3390/ijerph10127235; Nakae S, 2006, J IMMUNOL, V176, P2238, DOI 10.4049/jimmunol.176.4.2238; Nimmerjahn F, 2011, CURR TOP MICROBIOL, V350, P105, DOI 10.1007/82_2010_86; Oettgen HC, 2015, CURR OPIN IMMUNOL, V36, P109, DOI 10.1016/j.coi.2015.07.007; PESCI A, 1991, CHEST, V100, P1197, DOI 10.1378/chest.100.5.1197; Protonotariou E, 2004, MEDIAT INFLAMM, V13, P89, DOI 10.1080/09629350410001688468; Rajesh D, 2010, HUM IMMUNOL, V71, P551, DOI 10.1016/j.humimm.2010.02.019; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Reber LL, 2013, J ALLERGY CLIN IMMUN, V132, P881, DOI 10.1016/j.jaci.2013.06.008; Rivas MN, 2015, IMMUNITY, V42, P512, DOI 10.1016/j.immuni.2015.02.004; Rivas MN, 2013, J ALLERGY CLIN IMMUN, V131, P201, DOI 10.1016/j.jaci.2012.10.026; Schwartz LB, 2006, IMMUNOL ALLERGY CLIN, V26, P451, DOI 10.1016/j.iac.2006.05.010; Seung E, 2013, J INFECT DIS, V208, pS155, DOI 10.1093/infdis/jit448; Shultz LD, 2012, NAT REV IMMUNOL, V12, P786, DOI 10.1038/nri3311; Shultz LD, 2010, P NATL ACAD SCI USA, V107, P13022, DOI 10.1073/pnas.1000475107; Stefka AT, 2014, P NATL ACAD SCI USA, V111, P13145, DOI 10.1073/pnas.1412008111; STROBEL S, 1981, J CLIN PATHOL, V34, P851, DOI 10.1136/jcp.34.8.851; STROBEL S, 1983, GUT, V24, P222, DOI 10.1136/gut.24.3.222; Suzuki K, 2000, BLOOD, V96, P2172, DOI 10.1182/blood.V96.6.2172.h8002172_2172_2180; Takagi S, 2012, BLOOD, V119, P2768, DOI 10.1182/blood-2011-05-353201; Watanabe Y, 2009, INT IMMUNOL, V21, P843, DOI 10.1093/intimm/dxp050; Weigmann B, 2012, J ALLERGY CLIN IMMUN, V129, P1126, DOI 10.1016/j.jaci.2011.11.036; WENZEL S, 1986, J IMMUNOL METHODS, V86, P139, DOI 10.1016/0022-1759(86)90277-2; Zhao W, 2006, J IMMUNOL, V177, P694, DOI 10.4049/jimmunol.177.1.694	71	36	36	5	32	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2017	139	1					314	+		10.1016/j.jaci.2016.04.034	http://dx.doi.org/10.1016/j.jaci.2016.04.034			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EK5WM	27417025	Green Accepted, Bronze			2022-12-18	WOS:000393996800032
J	Hsu, AP; West, RR; Calvo, KR; Cuellar-Rodriguez, J; Parta, M; Kelly, SJ; Ganson, NJ; Hershfield, MS; Holland, SM; Hickstein, DD				Hsu, Amy P.; West, Robert R.; Calvo, Katherine R.; Cuellar-Rodriguez, Jennifer; Parta, Mark; Kelly, Susan J.; Ganson, Nancy J.; Hershfield, Michael S.; Holland, Steven M.; Hickstein, Dennis D.			Adenosine deaminase type 2 deficiency masquerading as GATA2 deficiency: Successful hematopoietic stem cell transplantation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							MUTATIONS; ADA2; IDENTIFICATION; VASCULOPATHY; CHILDREN; FOODS		[Hsu, Amy P.; Holland, Steven M.] NIAID, Lab Clin Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [West, Robert R.; Hickstein, Dennis D.] NCI, Expt Transplantat & Immunol Branch, NIH, Bethesda, MD 20892 USA; [Calvo, Katherine R.] NIH, Hematol Sect, Dept Lab Med, Ctr Clin, Bethesda, MD 20892 USA; [Cuellar-Rodriguez, Jennifer] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Infect Dis, Mexico City, DF, Mexico; [Parta, Mark] Leidos Biomed Res Inc, Frederick Natl Lab Canc Res, Clin Res Directorate, Clin Monitoring Res Program, Frederick, MD USA; [Kelly, Susan J.; Ganson, Nancy J.; Hershfield, Michael S.] Duke Univ, Sch Med, Dept Med, Durham, NC 27706 USA; [Hershfield, Michael S.] Duke Univ, Sch Med, Dept Biochem, Durham, NC USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Mexico; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Duke University; Duke University	Hickstein, DD (corresponding author), NCI, Expt Transplantat & Immunol Branch, NIH, Bethesda, MD 20892 USA.	hicksted@mail.nih.gov		Hsu, Amy/0000-0001-6841-2122; West, Robert/0000-0002-2079-0922	NATIONAL CANCER INSTITUTE [ZIABC010870] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000647] Funding Source: NIH RePORTER; CLINICAL CENTER [ZIACL090025] Funding Source: NIH RePORTER; CCR NIH HHS [HHSN261200800001C] Funding Source: Medline; Intramural NIH HHS [Z99 AI999999] Funding Source: Medline; NCI NIH HHS [HHSN261200800001E] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); CLINICAL CENTER; CCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Elkan PN, 2014, NEW ENGL J MED, V370, P921, DOI 10.1056/NEJMoa1307362; Ganapathi KA, 2015, BLOOD, V125, P56, DOI 10.1182/blood-2014-06-580340; Hsu AP, 2011, BLOOD, V118, P2653, DOI 10.1182/blood-2011-05-356352; Kagalwalla AF, 2011, J PEDIATR GASTR NUTR, V53, P145, DOI 10.1097/MPG.0b013e31821cf503; Molina-Infante J, 2016, GUT, V65, P524, DOI 10.1136/gutjnl-2015-310991; Pasquet M, 2013, BLOOD, V121, P822, DOI 10.1182/blood-2012-08-447367; Poursharifi P, 2009, CLIN BIOCHEM, V42, P1438, DOI 10.1016/j.clinbiochem.2008.10.019; Santiago TMG, 2015, JAMA DERMATOL, V151, P1230, DOI 10.1001/jamadermatol.2015.1635; Spergel JM, 2012, J ALLERGY CLIN IMMUN, V130, P461, DOI 10.1016/j.jaci.2012.05.021; Van Eyck L, 2015, J ALLERGY CLIN IMMUN, V135, P283, DOI 10.1016/j.jaci.2014.10.010; van Montfrans J, 2014, NEW ENGL J MED, V371, P478, DOI 10.1056/NEJMc1405506; Zhou Q, 2014, NEW ENGL J MED, V370, P911, DOI 10.1056/NEJMoa1307361	12	36	36	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2016	138	2					628	630		10.1016/j.jaci.2016.03.016	http://dx.doi.org/10.1016/j.jaci.2016.03.016			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DS5PY	27130863	Green Accepted, Bronze			2022-12-18	WOS:000380835800047
J	Keller, MD; Pandey, R; Li, D; Glessner, J; Tian, LF; Henrickson, SE; Chinn, IK; Monaco-Shawver, L; Heimall, J; Hou, CP; Otieno, FG; Jyonouchi, S; Calabrese, L; van Montfrans, J; Orange, JS; Hakonarson, H				Keller, Michael D.; Pandey, Rahul; Li, Dong; Glessner, Joseph; Tian, Lifeng; Henrickson, Sarah E.; Chinn, Ivan K.; Monaco-Shawver, Linda; Heimall, Jennifer; Hou, Cuiping; Otieno, Frederick G.; Jyonouchi, Soma; Calabrese, Leonard; van Montfrans, Joris; Orange, Jordan S.; Hakonarson, Hakon			Mutation in IRF2BP2 is responsible for a familial form of common variable immunodeficiency disorder	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Common variable immunodeficiency; machine learning; primary antibody deficiency; IRF2BP2; immunoglobulin	SUPPORT VECTOR MACHINE; IMMUNE-DEFICIENCY; DISEASE; GENE	Background: Genome-wide association studies have shown a pattern of rare copy number variations and single nucleotide polymorphisms in patients with common variable immunodeficiency disorder (CVID), which was recognizable by a support vector machine (SVM) algorithm. However, rare monogenic causes of CVID might lack such a genetic fingerprint. Objective: We sought to identify a unique monogenic cause of familial immunodeficiency and evaluate the use of SVM to identify patients with possible monogenic disorders. Methods: A family with multiple members with a diagnosis of CVID was screened by using whole-exome sequencing. The proband and other subjects with mutations associated with CVID-like phenotypes were screened through the SVM algorithm from our recent CVID genome-wide association study. RT-PCR, protein immunoblots, and in vitro plasmablast differentiation assays were performed on patient and control EBV lymphoblastoids cell lines. Results: Exome sequencing identified a novel heterozygous mutation in IRF2BP2 (c.1652G > A: p.[S551N]) in affected family members. Transduction of the mutant gene into control human B cells decreased production of plasmablasts in vitro, and IRF2BP2 transcripts and protein expression were increased in proband versus control EBV-immortalized lymphoblastoid cell lines. The SVM algorithm categorized the proband and subjects with other immunodeficiency-associated gene variants in TACI, BAFFR, ICOS, CD21, LRBA, and CD27 as genetically dissimilar from polygenic CVID. Conclusion: A novel IRFBP2 mutation was identified in a family with autosomal dominant CVID. Transduction experiments suggest that the mutant protein has an effect on B-cell differentiation and is likely amonogenic cause of the family's CVID phenotype. Successful grouping by the SVM algorithm suggests that our family and other subjects with rare immunodeficiency disorders cluster separately and lack the genetic pattern present in polygenic CVID cases.	[Keller, Michael D.] Childrens Natl Med Ctr, Div Allergy & Immunol, Washington, DC 20010 USA; [Pandey, Rahul; Li, Dong; Glessner, Joseph; Tian, Lifeng; Monaco-Shawver, Linda; Heimall, Jennifer; Hou, Cuiping; Otieno, Frederick G.; Hakonarson, Hakon] Childrens Hosp Philadelphia, Ctr Appl Genom, Philadelphia, PA 19104 USA; [Henrickson, Sarah E.; Monaco-Shawver, Linda; Heimall, Jennifer; Jyonouchi, Soma] Childrens Hosp Philadelphia, Div Allergy & Immunol, Philadelphia, PA 19104 USA; [Chinn, Ivan K.; Orange, Jordan S.] Texas Childrens Hosp, Div Rheumatol Allergy & Immunol, 1102 Bates St,Suite 330, Houston, TX 77030 USA; [Chinn, Ivan K.] Baylor Coll Med, Baylor Genom Inst, Houston, TX 77030 USA; [Calabrese, Leonard] Cleveland Clin, Dept Rheumatol & Immunol Dis, Cleveland, OH USA; [van Montfrans, Joris] Univ Med Ctr, Wilhelmina Childrens Hosp, Dept Pediat Immunol & Infect Dis, Utrecht, Netherlands	Children's National Health System; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Baylor College of Medicine; Baylor College of Medicine; Cleveland Clinic Foundation; Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis	Orange, JS (corresponding author), Texas Childrens Hosp, Div Rheumatol Allergy & Immunol, 1102 Bates St,Suite 330, Houston, TX 77030 USA.; Hakonarson, H (corresponding author), Childrens Hosp Philadelphia, Leonard & Madlyn Abramson Res Ctr, Room 1216E,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	orange@bcm.edu; hakonarson@email.chop.edu		orange, jordan/0000-0001-7117-7725; Glessner, Joseph/0000-0001-5131-2811; Henrickson, Sarah/0000-0001-5569-4132; Chinn, Ivan/0000-0001-5684-5457	Institute Development Fund from CHOP [U01HG006830]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD001399] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U01HG008684, U01HG006830] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI120989] Funding Source: NIH RePORTER	Institute Development Fund from CHOP; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by an Institute Development Fund from CHOP (U01HG006830), a donation to CAG from the Kubert Estate Foundation, and the Jeffrey Modell Foundation.	Bruno A, 2014, ONCOTARGET, V5, P5065, DOI 10.18632/oncotarget.2080; Carneiro FRG, 2011, MOL CELL BIOL, V31, P2889, DOI 10.1128/MCB.00974-10; Gathmann B, 2014, J ALLERGY CLIN IMMUN, V134, P116, DOI 10.1016/j.jaci.2013.12.1077; Grimbacher B, 2003, NAT IMMUNOL, V4, P261, DOI 10.1038/ni902; Jiang QH, 2013, INT J DATA MIN BIOIN, V8, P282, DOI 10.1504/IJDMB.2013.056078; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Kuijpers TW, 2010, J CLIN INVEST, V120, P214, DOI 10.1172/JCI40231; Lee CE, 2014, BLOOD, V124, P2964, DOI 10.1182/blood-2014-06-578542; Lee Y, 2010, METHODS MOL BIOL, V620, P347, DOI 10.1007/978-1-60761-580-4_11; Li J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7804; Li L, 2014, GENET MOL RES, V13, P4165, DOI 10.4238/2014.June.9.3; Lopez-Herrera G, 2012, AM J HUM GENET, V90, P986, DOI 10.1016/j.ajhg.2012.04.015; Losi CG, 2005, J CLIN IMMUNOL, V25, P496, DOI 10.1007/s10875-005-5637-2; Lucas M, 2010, J ALLERGY CLIN IMMUN, V125, P1354, DOI 10.1016/j.jaci.2010.02.040; Lupski JR, 2013, GENOME MED, V5, DOI 10.1186/gm461; Maggadottir SM, 2015, J ALLERGY CLIN IMMUN, V135, P1569, DOI 10.1016/j.jaci.2014.12.1939; Orange JS, 2011, J ALLERGY CLIN IMMUN, V127, P1360, DOI 10.1016/j.jaci.2011.02.039; Orru G, 2012, NEUROSCI BIOBEHAV R, V36, P1140, DOI 10.1016/j.neubiorev.2012.01.004; Panagopoulos I, 2014, ONCOL REP, V32, P40, DOI 10.3892/or.2014.3180; Recher M, 2011, BLOOD, V118, P6824, DOI 10.1182/blood-2011-06-362533; Resnick ES, 2012, BLOOD, V119, P1650, DOI 10.1182/blood-2011-09-377945; Romberg N, 2013, J CLIN INVEST, V123, P4283, DOI 10.1172/JCI69854; Sekine H, 2007, P NATL ACAD SCI USA, V104, P7193, DOI 10.1073/pnas.0700815104; Teng ACT, 2010, FASEB J, V24, P4825, DOI 10.1096/fj.10-167049; Tosato G, 2007, CURR PROTOC IMMUNOL, V7, P7, DOI DOI 10.1002/0471142735.IM0722S76; van Montfrans JM, 2012, J ALLERGY CLIN IMMUN, V129, P787, DOI 10.1016/j.jaci.2011.11.013; van Zelm MC, 2006, NEW ENGL J MED, V354, P1901, DOI 10.1056/NEJMoa051568; van Zelm MC, 2010, J CLIN INVEST, V120, P1265, DOI 10.1172/JCI39748; Yong PFK, 2011, ADV IMMUNOL, V111, P47, DOI 10.1016/B978-0-12-385991-4.00002-7	29	36	40	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2016	138	2					544	+		10.1016/j.jaci.2016.01.018	http://dx.doi.org/10.1016/j.jaci.2016.01.018			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DS5PY	27016798	Green Accepted, Bronze			2022-12-18	WOS:000380835800026
J	An, SS; Mitzner, W; Tang, WY; Ahn, K; Yoon, AR; Huang, J; Kilic, O; Yong, HM; Fahey, JW; Kumar, S; Biswal, S; Holgate, ST; Panettieri, RA; Solway, J; Liggett, SB				An, Steven S.; Mitzner, Wayne; Tang, Wan-Yee; Ahn, Kwangmi; Yoon, A-Rum; Huang, Jessie; Kilic, Onur; Yong, Hwan Mee; Fahey, Jed W.; Kumar, Sarvesh; Biswal, Shyam; Holgate, Stephen T.; Panettieri, Reynold A., Jr.; Solway, Julian; Liggett, Stephen B.			An inflammation-independent contraction mechanophenotype of airway smooth muscle in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							BRONCHI		[An, Steven S.; Mitzner, Wayne; Tang, Wan-Yee; Yoon, A-Rum; Huang, Jessie; Kilic, Onur; Yong, Hwan Mee; Kumar, Sarvesh; Biswal, Shyam] Johns Hopkins Univ, Dept Environm Hlth Sci, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA; [An, Steven S.] Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21218 USA; [Ahn, Kwangmi] NIH, Bldg 10, Bethesda, MD 20892 USA; [Fahey, Jed W.] Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Cullman Chemoprotect Ctr, Baltimore, MD 21205 USA; [Holgate, Stephen T.] Univ Southampton, Sch Med, Southampton, Hants, England; [Panettieri, Reynold A., Jr.] Univ Penn, Med Ctr, Airways Biol Initiat, Div Pulm Allergy & Crit Care, Philadelphia, PA 19104 USA; [Solway, Julian] Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA; [Liggett, Stephen B.] Univ S Florida, Morsani Coll Med, Dept Internal Med, Tampa, FL USA; [Liggett, Stephen B.] Univ S Florida, Morsani Coll Med, Mol Pharmacol & Physiol, Tampa, FL USA; [Liggett, Stephen B.] Univ S Florida, Morsani Coll Med, Ctr Personalized Med & Genom, Tampa, FL USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; National Institutes of Health (NIH) - USA; Johns Hopkins University; University of Southampton; University of Pennsylvania; University of Chicago; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	An, SS (corresponding author), Johns Hopkins Univ, Dept Environm Hlth Sci, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA.; An, SS (corresponding author), Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21218 USA.	san3@jhu.edu; sliggett@health.usf.edu	An, Steven/AAM-3848-2020; Ahn, Kwangmi/GLV-4077-2022; panettieri, reynold/AAG-9485-2019	An, Steven/0000-0003-4723-1888; Tang, Wan-Yee/0000-0002-0663-9820; Huang, Jessie/0000-0002-5297-3563; Liggett, Stephen B./0000-0002-0128-3669	Medical Research Council [G19/34, G0400473, G0800766] Funding Source: Medline; NHLBI NIH HHS [R37 HL045967, P01 HL114471, R56 HL045967, R01 HL107361, R01 HL045967, R01 HL097805] Funding Source: Medline; MRC [G19/34, G0400473] Funding Source: UKRI; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL045967, R01HL107361, R56HL045967, R01HL045967, P01HL114471, R01HL097805] Funding Source: NIH RePORTER	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		An SS, 2006, AM J RESP CELL MOL, V35, P55, DOI 10.1165/rcmb.2005-0453OC; BAI TR, 1990, AM REV RESPIR DIS, V141, P552, DOI 10.1164/ajrccm/141.3.552; BJORCK T, 1992, AM REV RESPIR DIS, V145, P1087; Chin LYM, 2012, EUR RESPIR J, V40, P45, DOI 10.1183/09031936.00065411; DEJONGSTE JC, 1987, EUR J RESPIR DIS, V71, P23; Deshpande DA, 2010, NAT MED, V16, P1299, DOI 10.1038/nm.2237; Ijpma G, 2015, AM J RESP CRIT CARE, V191, P884, DOI 10.1164/rccm.201407-1296OC; Krzywinski M, 2014, NAT METHODS, V11, P977, DOI 10.1038/nmeth.3137; Salter HH, 1868, ASTHMA ITS PATHOLOGY	9	36	37	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2016	138	1					294	297		10.1016/j.jaci.2015.12.1315	http://dx.doi.org/10.1016/j.jaci.2015.12.1315			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DR1IL	26936804	Green Accepted, hybrid			2022-12-18	WOS:000379659100036
J	Joseph, K; Tholanikunnel, BG; Wolf, B; Bork, K; Kaplan, AP				Joseph, Kusumam; Tholanikunnel, Baby G.; Wolf, Bethany; Bork, Konrad; Kaplan, Allen P.			Deficiency of plasminogen activator inhibitor 2 in plasma of patients with hereditary angioedema with normal C1 inhibitor levels	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hereditary angioedema; C1 inhibitor; bradykinin; plasminogen activator inhibitor	HAGEMAN-FACTOR; MISSENSE MUTATIONS; COAGULATION; GENE; BRADYKININ; FIBRINOLYSIS; ABNORMALITIES; PREKALLIKREIN; KALLIKREIN; CLEAVAGE	Background: Hereditary angioedema with normal C1 inhibitor levels (HAE-N) is associated with a Factor XII mutation in 30% of subjects; however, the role of this mutation in the pathogenesis of angioedema is unclear. Objective: We sought evidence of abnormalities in the pathways of bradykinin formation and bradykinin degradation in the plasma of patients with HAE-N both with and without the mutation. Methods: Bradykinin was added to plasma, and its rate of degradation was measured by using ELISA. Plasma autoactivation was assessed by using a chromogenic assay of kallikrein formation. Plasminogen activator inhibitors (PAIs) 1 and 2 were also measured by means of ELISA. Results: PAI-1 levels varied from 0.1 to 4.5 ng/mL (mean, 2.4 ng/mL) in 23 control subjects, from 0.0 to 2 ng/mL (mean, 0.54 ng/mL) in patients with HAE-N with a Factor XII mutation (12 samples), and from 0.0 to 3.7 ng/mL (mean, 1.03 ng/mL) in patients with HAE-N without a Factor XII mutation (11 samples). PAI-2 levels varied from 25 to 87 ng/mL (mean, 53.8 ng/mL) in control subjects and were 0 to 25 ng/mL (mean, 4.3 ng/mL) in patients with HAE-N with or without the Factor XII mutation. Autoactivation at a 1: 2 dilution was abnormally high in 8 of 17 patients with HAE-N (4 in each subcategory) and could be corrected by supplemental C1 inhibitor in 4 of them. Bradykinin degradation was markedly abnormal in 1 of 23 patients with HAE-N and normal in the remaining 22 patients. Conclusions: Bradykinin degradation was normal in all but 1 of 23 patients with HAE-N studied. By contrast, there was a marked abnormality in PAI-2 levels in patients with HAE-N that is not seen in patients with C1 inhibitor deficiency. PAI-1 levels varied considerably, but a statistically significant difference was not seen. A link between excessive fibrinolysis and bradykinin generation that is estrogen dependent is suggested.	[Joseph, Kusumam; Tholanikunnel, Baby G.] Med Univ S Carolina, Dept Biochem & Mol Biol, BSB 535B,173 Ashley Ave, Charleston, SC 29425 USA; [Wolf, Bethany] Med Univ S Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA; [Kaplan, Allen P.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; [Bork, Konrad] Johannes Gutenberg Univ Mainz, Dept Dermatol, D-55122 Mainz, Germany	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Johannes Gutenberg University of Mainz	Joseph, K (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, BSB 535B,173 Ashley Ave, Charleston, SC 29425 USA.	josephk@musc.edu	Bork, Konrad/AAE-4985-2022	Bork, Konrad/0000-0002-6084-4577; Wolf, Bethany/0000-0002-7124-5158	CSL Behring; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000062] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR029882] Funding Source: NIH RePORTER	CSL Behring; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	Supported by CSL Behring.	Binkley KE, 2000, J ALLERGY CLIN IMMUN, V106, P546; Bjorkqvist J, 2015, J CLIN INVEST, V125, P3132, DOI 10.1172/JCI77139; Bork K, 2000, LANCET, V356, P213, DOI 10.1016/S0140-6736(00)02483-1; Bork K, 2014, HAEMOPHILIA, V20, pe372, DOI 10.1111/hae.12519; BORK K, 1991, THROMB HAEMOSTASIS, V65, P1271; Bork K, 2007, AM J MED, V120, P987, DOI 10.1016/j.amjmed.2007.08.021; Bork K, 2011, CLIN IMMUNOL, V141, P31, DOI 10.1016/j.clim.2011.07.002; Bork K, 2009, J ALLERGY CLIN IMMUN, V124, P129, DOI 10.1016/j.jaci.2009.03.038; Bork K, 2009, BLOOD COAGUL FIBRIN, V20, P325, DOI 10.1097/MBC.0b013e32832811f8; Bouillet L, 2009, ANN ALLERG ASTHMA IM, V103, P448, DOI 10.1016/S1081-1206(10)60369-9; Brown NJ, 1997, THROMB HAEMOSTASIS, V77, P522; Cichon S, 2006, AM J HUM GENET, V79, P1098, DOI 10.1086/509899; COCHRANE CG, 1973, J EXP MED, V138, P1564, DOI 10.1084/jem.138.6.1564; COLLEN D, 1976, EUR J BIOCHEM, V69, P209, DOI 10.1111/j.1432-1033.1976.tb10875.x; Cronin JA, 2012, ANN ALLERG ASTHMA IM, V108, P61, DOI 10.1016/j.anai.2011.09.020; Dewald G, 2006, BIOCHEM BIOPH RES CO, V343, P1286, DOI 10.1016/j.bbrc.2006.03.092; DUNN JT, 1982, J BIOL CHEM, V257, P1779; ESPANA F, 1989, THROMB RES, V55, P369, DOI 10.1016/0049-3848(89)90069-8; HARPEL PC, 1985, J BIOL CHEM, V260, P4257; Joseph K, 2005, ADV IMMUNOL, V86, P159, DOI 10.1016/S0065-2776(04)86005-X; Joseph K, 2015, ALLERGY, V70, P115, DOI 10.1111/all.12520; Joseph K, 2002, P NATL ACAD SCI USA, V99, P896, DOI 10.1073/pnas.022626899; Joseph K, 2013, J ALLERGY CLIN IMMUN, V132, P470, DOI 10.1016/j.jaci.2013.03.026; Joseph K, 2010, ANN ALLERG ASTHMA IM, V104, P50, DOI 10.1016/j.anai.2009.11.014; KAPLAN AP, 1972, J EXP MED, V136, P1378, DOI 10.1084/jem.136.6.1378; Kiss N, 2013, CLIN IMMUNOL, V149, P142, DOI 10.1016/j.clim.2013.08.001; KRUITHOF EKO, 1987, BLOOD, V69, P460; KRUITHOF EKO, 1988, THROMB HAEMOSTASIS, V59, P7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN EG, 1982, J CELL BIOL, V94, P631, DOI 10.1083/jcb.94.3.631; Malde B, 2007, ANN ALLERG ASTHMA IM, V98, P57, DOI 10.1016/S1081-1206(10)60860-5; Mehta R, 2008, HAEMOPHILIA, V14, P1255, DOI 10.1111/j.1365-2516.2008.01834.x; MILES LA, 1983, THROMB RES, V29, P407, DOI 10.1016/0049-3848(83)90244-X; SCHOUSBOE I, 1985, BLOOD, V66, P1086; SILVERBERG M, 1980, J BIOL CHEM, V255, P7281; SMITH D, 1985, BLOOD, V66, P835; TANKERSLEY DL, 1984, BIOCHEMISTRY-US, V23, P273, DOI 10.1021/bi00297a016; van Geffen M, 2012, CLIN EXP IMMUNOL, V167, P472, DOI 10.1111/j.1365-2249.2011.04541.x; WEISS AS, 1974, J CLIN INVEST, V53, P622, DOI 10.1172/JCI107597; Zuraw BL, 2008, NEW ENGL J MED, V359, P1027, DOI 10.1056/NEJMcp0803977; Zuraw BL, 2012, ALLERGY ASTHMA PROC, V33, pS145, DOI 10.2500/aap.2012.33.3627	41	36	37	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2016	137	6					1822	+		10.1016/j.jaci.2015.07.041	http://dx.doi.org/10.1016/j.jaci.2015.07.041			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DO1GT	26395818	Green Accepted, Bronze			2022-12-18	WOS:000377527200024
J	Pralong, JA; Lemiere, C; Rochat, T; L'Archeveque, J; Labrecque, M; Cartier, A				Pralong, Jacques A.; Lemiere, Catherine; Rochat, Thierry; L'Archeveque, Jocelyne; Labrecque, Manon; Cartier, Andre			Predictive value of nonspecific bronchial responsiveness in occupational asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Bronchial responsiveness; methacholine challenge; occupational asthma	AIRWAY INFLAMMATION; PROVOCATION TESTS; DIAGNOSIS; HYPERRESPONSIVENESS; METHACHOLINE; CHALLENGE; ABSENCE; WORKER	Background: The diagnosis of occupational asthma (OA) can be challenging and needs a stepwise approach. However, the predictive value of the methacholine challenge has never been addressed specifically in this context. Objective: We sought to evaluate the sensitivity, specificity, and positive and negative predictive values of the methacholine challenge in OA. Methods: A Canadian database was used to review 1012 cases of workers referred for a suspicion of OA between 1983 and 2011 and having had a specific inhalation challenge. We calculated the sensitivity, specificity, and positive and negative predictive values of methacholine challenges at baseline of the specific inhalation challenge, at the workplace, and outside work. Results: At baseline, the methacholine challenge showed an overall sensitivity of 80.2% and a specificity of 47.1%, with positive and negative predictive values of 36.5% and 86.3%, respectively. Among the 430 subjects who were still working, the baseline measures displayed a sensitivity of 95.4%, a specificity of 40.1%, and positive and negative predictive values of 41.1% and 95.2%, respectively. Among the 582 subjects tested outside work, the baseline measures demonstrated a sensitivity and specificity of 66.7% and 52%, respectively, and positive and negative predictive values of 31.9% and 82.2%, respectively. When considering all subjects tested by a methacholine challenge at least once while at work (479), the sensitivity, specificity, and positive and negative predictive values were 98.1%, 39.1%, and 44.0% and 97.7%, respectively. Conclusion: A negative methacholine challenge in a patient still exposed to the causative agent at work makes the diagnosis of OA very unlikely.	[Pralong, Jacques A.; Lemiere, Catherine; L'Archeveque, Jocelyne; Labrecque, Manon; Cartier, Andre] Univ Montreal, Hop Sacre Coeur Montreal, Dept Chest Med, Montreal, PQ H3C 3J7, Canada; [Pralong, Jacques A.] Inst Work & Hlth, Epalinges, Switzerland; [Pralong, Jacques A.; Rochat, Thierry] Univ Hosp Geneva, Div Pulm Dis, Geneva, Switzerland	Universite de Montreal; University of Geneva	Pralong, JA (corresponding author), Hop Sacre Coeur, Dept Chest Med, 5400 Gouin West, Montreal, PQ H4J 1C5, Canada.	jacques.pralong@chuv.ch			GlaxoSmithKline; AstraZeneca; Teva; Merck; Merck Canada; AstraZeneca Pharma Canada	GlaxoSmithKline(GlaxoSmithKline); AstraZeneca(AstraZeneca); Teva(Teva Pharmaceutical Industries); Merck(Merck & Company); Merck Canada(Merck & Company); AstraZeneca Pharma Canada(AstraZeneca)	J. A. Pralong is employed by the Institute for Work and Health. C. Lemiere has received consultancy fees from GlaxoSmithKline, AstraZeneca, Teva, and Merck; has received research support from GlaxoSmithKline; has received lecture fees from AstraZeneca and Merck; and receives royalties from UpToDate. A. Cartier has received research support from Merck Canada and AstraZeneca Pharma Canada; has received lecture fees from Merck; and receives royalties from UpToDate. The rest of the authors declare that they have no relevant conflicts of interest.	BANKS DE, 1986, CHEST, V89, P389, DOI 10.1378/chest.89.3.389; Beach J, 2005, Evid Rep Technol Assess (Summ), P1; Celli BR, 2004, EUR RESPIR J, V23, P932, DOI 10.1183/09031936.04.00014304; CHANYEUNG M, 1995, NEW ENGL J MED, V333, P107, DOI 10.1056/NEJM199507133330207; Cockcroft DW, 2010, CHEST, V138, p18S, DOI 10.1378/chest.10-0088; COCKCROFT DW, 1979, CAN MED ASSOC J, V121, P602; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Lemiere C, 2000, CLIN EXP ALLERGY, V30, P415; Lemiere C, 2000, J ALLERGY CLIN IMMUN, V106, P1163; Lougheed MD, 2012, CAN RESPIR J, V19, P127, DOI 10.1155/2012/635624; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Nam YH, 2011, ALLERGY ASTHMA IMMUN, V3, P135, DOI 10.4168/aair.2011.3.2.135; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; PEPYS J, 1994, ALLERGY, V49, P397, DOI 10.1111/j.1398-9995.1994.tb00830.x; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; Pizzichini E, 1997, J ALLERGY CLIN IMMUN, V99, P539, DOI 10.1016/S0091-6749(97)70082-4; Rioux JP, 2008, EUR RESPIR J, V32, P997, DOI 10.1183/09031936.00100207; Tarlo SM, 2008, CHEST, V134, p1S, DOI 10.1378/chest.08-0201; Vandenplas O, 2014, EUR RESPIR J, V43, P1573, DOI 10.1183/09031936.00180313	19	36	36	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2016	137	2					412	416		10.1016/j.jaci.2015.06.026	http://dx.doi.org/10.1016/j.jaci.2015.06.026			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DC5BN	26220529	Green Accepted			2022-12-18	WOS:000369235500009
J	Machado-Carvalho, L; Martin, M; Torres, R; Gabasa, M; Alobid, I; Mullol, J; Pujols, L; Roca-Ferrer, J; Picado, C				Machado-Carvalho, Liliana; Martin, Margarita; Torres, Rosa; Gabasa, Marta; Alobid, Isam; Mullol, Joaquim; Pujols, Laura; Roca-Ferrer, Jordi; Picado, Cesar			Low E-prostanoid 2 receptor levels and deficient induction of the IL-1 beta/IL-1 type I receptor/COX-2 pathway: Vicious circle in patients with aspirin-exacerbated respiratory disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Aspirin-exacerbated respiratory disease; COX-2; E-prostanoid 2 receptor; fibroblasts; IL-1 beta; IL-1 receptor type I; microsomal prostaglandin E synthase 1; nasal mucosa; nasal polyps; prostaglandin E-2	CELL-LINE TIG-1; PROSTAGLANDIN E-2; NASAL POLYPS; CYCLOOXYGENASE-2 EXPRESSION; MESSENGER-RNA; OWN RECEPTOR; INTERLEUKIN-1; ASTHMA; RHINOSINUSITIS; FIBROBLASTS	Background: We hypothesized that the 2 reported alterations in aspirin-exacerbated respiratory disease (AERD), reduced expression/production of COX-2/prostaglandin (PG) E-2 and diminished expression of E-prostanoid (EP) 2 receptor, are closely linked. Objective: We sought to determine the mechanisms involved in the altered regulation of the COX pathway in patients with AERD. Methods: Fibroblasts were obtained from nasal mucosa; samples of control subjects (NM-C, n = 8) and from nasal polyps from patients with aspirin-exacerbated respiratory disease (NP-AERD, n = 8). Expression of the autocrine loop components regulating PGE(2) production and signaling, namely IL-1 type I receptor (IL-1RI), COX-2, microsomal prostaglandin E synthase 1 (mPGES-1), and EP receptors, was assessed at baseline and after stimulation with IL-1 beta, PGE(2), and specific EP receptor agonists. Results: Compared with NM-C fibroblasts, basal expression levels of IL-1RI and EP2 receptor were lower in NP-AERD fibroblasts. IL-1 beta-induced IL-1RI, COX-2, and mPGES-1 expression levels were also lower in these cells. Levels of IL-1RI positively correlated with COX-2 and mPGES-1 expression in both NM-C and NP-AERD fibroblasts. Incubation with either exogenous PGE(2) or selective EP2 agonist significantly increased expression of IL-1RI in NM-C fibroblasts and had hardly any effect on NP-AERD fibroblasts. Alterations in IL-1RI, COX-2, and mPGES-1 expression that were found in NP-AERD fibroblasts were corrected when EP2 receptor expression was normalized by transfection of NP-AERD fibroblasts. Conclusion: Altered expression of EP2 in patients with AERD contributes to deficient induction of IL-1RI, reducing the capacity of IL-1 beta to increase COX-2 and mPGES-1 expression, which results in low PGE(2) production. This impairment in the generation of PGE(2) subsequently reduces its ability to induce IL-1RI.	[Machado-Carvalho, Liliana; Martin, Margarita; Torres, Rosa; Gabasa, Marta; Alobid, Isam; Mullol, Joaquim; Pujols, Laura; Roca-Ferrer, Jordi; Picado, Cesar] IDIBAPS, Clin & Expt Resp Immunoallergy, Barcelona 08036, Spain; [Machado-Carvalho, Liliana; Torres, Rosa; Gabasa, Marta; Alobid, Isam; Mullol, Joaquim; Pujols, Laura; Roca-Ferrer, Jordi; Picado, Cesar] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Resp CIBERES, Madrid, Spain; [Martin, Margarita] Univ Barcelona, Sch Med, Biochem Unit, E-08007 Barcelona, Spain; [Picado, Cesar] Univ Barcelona, Hosp Clin, Pneumol & Resp Allergy Dept, E-08007 Barcelona, Spain; [Torres, Rosa] Univ Autonoma Barcelona, Dept Pharmacol, E-08193 Barcelona, Spain; [Alobid, Isam; Mullol, Joaquim] Hosp Clin Barcelona, Rhinol Unit, Barcelona, Spain; [Alobid, Isam; Mullol, Joaquim] Hosp Clin Barcelona, ENT Dept, Smell Clin, Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; Instituto de Salud Carlos III; University of Barcelona; University of Barcelona; Hospital Clinic de Barcelona; Autonomous University of Barcelona; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona	Machado-Carvalho, L (corresponding author), IDIBAPS, CELLEX, Clin & Expt Resp Immunoallergy, Casanova 143, Barcelona 08036, Spain.	lsmachad@clinic.ub.es	/AAL-7347-2021; Pujols, Laura/G-8920-2015; /AFX-9519-2022; Roca-Ferrer, Jordi/AFQ-4652-2022; Andorra, Margarita Martin/H-2025-2015	Pujols, Laura/0000-0003-3708-5098; Roca-Ferrer, Jordi/0000-0002-9527-2273; Andorra, Margarita Martin/0000-0002-9245-4899; Machado-Carvalho, Liliana/0000-0003-3230-4650	Centro de Investigaciones Biomedicas en Red de Enfermedades Respiratorias (CIBERES) from the Instituto de Salud Carlos III, Madrid, Spain; Spanish Ministry of Health [FIS PI12/254]; FEDER; Fundacion Respira (Spanish Respiratory Society)	Centro de Investigaciones Biomedicas en Red de Enfermedades Respiratorias (CIBERES) from the Instituto de Salud Carlos III, Madrid, Spain; Spanish Ministry of Health(Instituto de Salud Carlos IIISpanish Government); FEDER(European Commission); Fundacion Respira (Spanish Respiratory Society)	L.M.-C. was supported by a grant from the Centro de Investigaciones Biomedicas en Red de Enfermedades Respiratorias (CIBERES) from the Instituto de Salud Carlos III, Madrid, Spain. This study was supported by grants from the Spanish Ministry of Health (FIS PI12/254), FEDER, and Fundacion Respira (Spanish Respiratory Society).	AKAHOSHI T, 1988, J CLIN INVEST, V82, P1219, DOI 10.1172/JCI113719; BONIN PD, 1990, J BIOL CHEM, V265, P18643; Briones AM, 2005, MECH AGEING DEV, V126, P710, DOI 10.1016/j.mad.2005.01.006; Cahill KN, 2015, AM J RESP CELL MOL B; Casadevall J, 2000, THORAX, V55, P921, DOI 10.1136/thorax.55.11.921; Chung KF, 1999, THORAX, V54, P825, DOI 10.1136/thx.54.9.825; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Dinarello CA, 2011, BLOOD, V117, P3720, DOI 10.1182/blood-2010-07-273417; Fujino H, 2002, J BIOL CHEM, V277, P2614, DOI 10.1074/jbc.M109440200; Gosepath J, 2005, AM J RHINOL, V19, P111, DOI 10.1177/194589240501900201; Kim SH, 2007, PHARMACOGENET GENOM, V17, P295, DOI 10.1097/01.fpc.0000239977.61841.fe; Klein T, 2007, BBA-MOL CELL RES, V1773, P1605, DOI 10.1016/j.bbamcr.2007.09.001; Laidlaw TM, 2013, IMMUNOL ALLERGY CLIN, V33, P195, DOI 10.1016/j.iac.2012.11.006; Lee RU, 2011, ALLERGY ASTHMA IMMUN, V3, P3, DOI 10.4168/aair.2011.3.1.3; Machado-Carvalho L, 2014, RESP RES, V15, DOI 10.1186/s12931-014-0100-7; Martin MU, 2002, BBA-MOL CELL RES, V1592, P265, DOI 10.1016/S0167-4889(02)00320-8; Mascia K, 2005, J ALLERGY CLIN IMMUN, V116, P970, DOI 10.1016/j.jaci.2005.08.035; Mullol J, 2002, J ALLERGY CLIN IMMUN, V109, P824, DOI 10.1067/mai.2002.123534; Mullol J, 2013, IMMUNOL ALLERGY CLIN, V33, P163, DOI 10.1016/j.iac.2012.11.002; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Park JY, 2006, CLIN IMMUNOL, V119, P229, DOI 10.1016/j.clim.2006.01.016; Perez-Novo CA, 2005, J ALLERGY CLIN IMMUN, V115, P1189, DOI 10.1016/j.jaci.2005.02.029; Picado C, 1999, AM J RESP CRIT CARE, V160, P291, DOI 10.1164/ajrccm.160.1.9808048; Ricciotti E, 2011, ARTERIOSCL THROM VAS, V31, P986, DOI 10.1161/ATVBAHA.110.207449; Roca-Ferrer J, 2013, RESPIROLOGY, V18, P711, DOI 10.1111/resp.12076; Roca-Ferrer J, 2011, J ALLERGY CLIN IMMUN, V128, P66, DOI 10.1016/j.jaci.2011.01.065; Samad TA, 2001, NATURE, V410, P471, DOI 10.1038/35068566; SHIRAKAWA F, 1988, P NATL ACAD SCI USA, V85, P8201, DOI 10.1073/pnas.85.21.8201; SPRIGGS MK, 1990, J BIOL CHEM, V265, P22499; Steinke JW, 2015, AM J RHINOL ALLERGY, V29, P35, DOI 10.2500/ajra.2015.29.4123; Steinke JW, 2009, J ALLERGY CLIN IMMUN, V124, P724, DOI 10.1016/j.jaci.2009.07.031; Stevenson DD, 2006, J ALLERGY CLIN IMMUN, V118, P773, DOI 10.1016/j.jaci.2006.07.024; TAKII T, 1992, EUR J IMMUNOL, V22, P1221, DOI 10.1002/eji.1830220517; TAKII T, 1994, LYMPHOKINE CYTOK RES, V13, P213; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Weber A, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3105cm1	36	36	36	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2016	137	1					99	+		10.1016/j.jaci.2015.09.028	http://dx.doi.org/10.1016/j.jaci.2015.09.028			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DA3UK	26560040	Bronze			2022-12-18	WOS:000367724300048
J	Mader, J; Gallo, A; Schommartz, T; Handke, W; Nagel, CH; Gunther, P; Brune, W; Reich, K				Mader, Julia; Gallo, Antonio; Schommartz, Tim; Handke, Wiebke; Nagel, Claus-Henning; Guenther, Patrick; Brune, Wolfram; Reich, Kristian			Calcium spirulan derived from Spirulina platensis inhibits herpes simplex virus 1 attachment to human keratinocytes and protects against herpes labialis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Herpes simplex virus 1; Kaposi sarcoma-associated herpesvirus/human herpes virus 8; Spirulina microalgae; calcium spirulan; keratinocytes; herpes labialis; Kaposi sarcoma	SARCOMA-ASSOCIATED HERPESVIRUS; ANTIVIRAL ACTIVITY; CELLS	Background: Chronic infections with herpes simplex virus (HSV) type 1 are highly prevalent in populations worldwide and cause recurrent oral lesions in up to 40% of infected subjects. Objective: We investigated the antiviral activity of a defined Spirulina platensis microalga extract and of purified calcium spirulan (Ca-SP), a sulfated polysaccharide contained therein. Methods: The inhibitory effects of HSV-1 were assessed by using a plaque reduction assay and quantitative PCR in a susceptible mammalian epithelial cell line and confirmed in human keratinocytes. Time-of-addition and attachment experiments and fluorescence detection of the HSV-1 tegument protein VP16 were used to analyze the mechanism of HSV-1 inhibition. Effects of Ca-SP on Kaposi sarcoma-associated herpesvirus/human herpes virus 8 replication and uptake of the ORF45 tegument protein were tested in human retinal pigment epithelial cells. In an observational trial the prophylactic effects of topically applied Ca-SP were compared with those of systemic and topical nucleoside analogues in 198 volunteers with recurrent herpes labialis receiving permanent lip makeup. Results: Ca-SP inhibited HSV-1 infection in vitro with a potency at least comparable to that of acyclovir by blocking viral attachment and penetration into host cells. Ca-SP also inhibited entry of Kaposi sarcoma-associated herpesvirus/human herpes virus 8. In the clinical model of herpes exacerbation, the prophylactic effect of a Ca-SP and microalgae extract containing cream was superior to that of acyclovir cream. Conclusion: These data indicate a potential clinical use of Ca-SP containing Spirulina species extract for the prophylactic treatment of herpes labialis and suggest possible activity of Ca-SP against infections caused by other herpesviruses.	[Mader, Julia; Gallo, Antonio; Schommartz, Tim; Handke, Wiebke; Nagel, Claus-Henning; Brune, Wolfram] Leibniz Inst Expt Virol, Heinrich Pette Inst, Hamburg, Germany; [Mader, Julia; Reich, Kristian] Dermatologikum Hamburg, D-20354 Hamburg, Germany; [Guenther, Patrick] Ocean Pharma GmbH, Reinbek, Germany; [Brune, Wolfram] Partner Site Hamburg, German Ctr Infect Res DZIF, Hamburg, Germany	Heinrich Pette Institute; Dermatologikum Hamburg; German Center for Infection Research	Reich, K (corresponding author), Dermatologikum Hamburg, Stephans Pl 5, D-20354 Hamburg, Germany.	wolfram.brune@hpi.uni-hamburg.de; kreich@dermatologikum.de	Brune, Wolfram/H-5058-2019	Brune, Wolfram/0000-0002-6078-5255	German Center for Infection Research (DZIF) [TTU IICH 07.802]	German Center for Infection Research (DZIF)	Supported by a grant from the German Center for Infection Research (DZIF, TTU IICH 07.802).	Bidle KD, 2014, P NATL ACAD SCI USA, V111, P15606, DOI 10.1073/pnas.1417243111; Bin LH, 2014, J ALLERGY CLIN IMMUN, V134, P848, DOI 10.1016/j.jaci.2014.07.018; Bodsworth N J, 2001, Am J Clin Dermatol, V2, P77, DOI 10.2165/00128071-200102020-00004; Budt M, 2011, J VIROL, V85, P10415, DOI 10.1128/JVI.05071-11; Bussey KA, 2014, J VIROL, V88, P9245, DOI 10.1128/JVI.00841-14; Collins WJ, 2003, J VIROL, V77, P2686, DOI 10.1128/JVI.77.4.2686-2695.2003; HAYASHI K, 1993, PHYTOTHER RES, V7, P76, DOI 10.1002/ptr.2650070118; Hayashi K, 1996, AIDS RES HUM RETROV, V12, P1463, DOI 10.1089/aid.1996.12.1463; Hayashi T, 1996, J NAT PROD, V59, P83, DOI 10.1021/np960017o; Hernandez-Corona A, 2002, ANTIVIR RES, V56, P279, DOI 10.1016/S0166-3542(02)00132-8; HODNICHAK CM, 1984, J VIROL METHODS, V8, P191, DOI 10.1016/0166-0934(84)90013-2; Huber MT, 2001, J VIROL, V75, P10309, DOI 10.1128/JVI.75.21.10309-10318.2001; Hung SL, 2002, VIRUS RES, V86, P59, DOI 10.1016/S0168-1702(02)00055-2; Karkos PD, 2011, EVID-BASED COMPL ALT, V2011, DOI DOI 10.1093/ECAM/NEN058NEN058; Khan M, 2005, PHYTOTHER RES, V19, P1030, DOI 10.1002/ptr.1783; Khan M, 2006, J APPL TOXICOL, V26, P444, DOI 10.1002/jat.1159; Khan Z, 2005, CURR PHARM BIOTECHNO, V6, P373, DOI 10.2174/138920105774370607; Lee JB, 1998, J NAT PROD, V61, P1101, DOI 10.1021/np980143n; Lu J, 2010, BRIT J NUTR, V103, P1573, DOI 10.1017/S0007114509993758; Lukowski G, 2008, SKIN PHARMACOL PHYS, V21, P98, DOI 10.1159/000113066; Marles RJ, 2011, CRIT REV FOOD SCI, V51, P593, DOI 10.1080/10408391003721719; Meltzer SM, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2008.07.064; Pica F, 2012, J MED VIROL, V84, P132, DOI 10.1002/jmv.22233; Rechter S, 2006, ANTIVIR RES, V72, P197, DOI 10.1016/j.antiviral.2006.06.004; Rolinski J, 2014, J IMMUNOL RES, V2014, P5135; Schmidtke M, 2001, J VIROL METHODS, V95, P133, DOI 10.1016/S0166-0934(01)00305-6; Spear PG, 2000, VIROLOGY, V275, P1, DOI 10.1006/viro.2000.0529; Spruance SL, 2002, ANTIMICROB AGENTS CH, V46, P2238, DOI 10.1128/AAC.46.7.2238-2243.2002; Stranska R, 2002, ANTIMICROB AGENTS CH, V46, P2943, DOI 10.1128/AAC.46.9.2943-2947.2002; van Velzen M, 2013, J INFECT DIS, V208, P1359, DOI 10.1093/infdis/jit350; Wang W, 2012, MAR DRUGS, V10, P2795, DOI 10.3390/md10122795; WUDUNN D, 1989, J VIROL, V63, P52, DOI 10.1128/JVI.63.1.52-58.1989; Yogianti F, 2014, J INVEST DERMATOL, V134, P2610, DOI 10.1038/jid.2014.188; Zhu FX, 2005, J VIROL, V79, P800, DOI 10.1128/JVI.79.2.800-811.2005; Zhu FX, 2003, J VIROL, V77, P4221, DOI 10.1128/JVI.77.7.4221-4230.2003	35	36	38	1	28	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2016	137	1					197	+		10.1016/j.jaci.2015.07.027	http://dx.doi.org/10.1016/j.jaci.2015.07.027			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DA3UK	26341274	Bronze			2022-12-18	WOS:000367724300011
J	McGeachie, MJ; Wu, AC; Tse, SM; Clemmer, GL; Sordillo, J; Himes, BE; Lasky-Su, J; Chase, RP; Martinez, FD; Weeke, P; Shaffer, CM; Xu, H; Denny, JC; Roden, DM; Panettieri, RA; Raby, BA; Weiss, ST; Tantisira, KG				McGeachie, Michael J.; Wu, Ann C.; Tse, Sze Man; Clemmer, George L.; Sordillo, Joanne; Himes, Blanca E.; Lasky-Su, Jessica; Chase, Robert P.; Martinez, Fernando D.; Weeke, Peter; Shaffer, Christian M.; Xu, Hua; Denny, Josh C.; Roden, Dan M.; Panettieri, Reynold A., Jr.; Raby, Benjamin A.; Weiss, Scott T.; Tantisira, Kelan G.			CTNNA3 and SEMA3D: Promising loci for asthma exacerbation identified through multiple genome-wide association studies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; exacerbation; genome-wide association study; expression quantitative trait locus; CTNNA3; SEMA3D; biobank; childhood asthma	ALPHA-T-CATENIN; CHILDHOOD ASTHMA; LARGE-SCALE; C/EBP-BETA; EXPRESSION; CHILDREN; GENE; POLYMORPHISM; SEMAPHORINS; VARIANTS	Background: Asthma exacerbations are a major cause of morbidity and medical cost. Objective: The objective of this study was to identify genetic predictors of exacerbations in asthmatic subjects. Methods: We performed a genome-wide association study meta-analysis of acute asthma exacerbation in 2 pediatric clinical trials: the Childhood Asthma Management Program (n = 581) and the Childhood Asthma Research and Education (n = 205) network. Acute asthma exacerbations were defined as treatment with a 5-day course of oral steroids. We obtained a replication cohort from Biobank of Vanderbilt University Medical Center (BioVU; n = 786), the Vanderbilt University electronic medical record-linked DNA biobank. We used CD4(+) lymphocyte genome-wide mRNA expression profiling to identify associations of top single nucleotide polymorphisms with mRNA abundance of nearby genes. Results: A locus in catenin (cadherin-associated protein), alpha 3 (CTNNA3), reached genome-wide significance (rs7915695, P = 2.19 x 10(-8); mean exacerbations, 6.05 for minor alleles vs 3.71 for homozygous major alleles). Among the 4 top single nucleotide polymorphisms replicated in BioVU, rs993312 in Sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3D (SEMA3D) was significant (P = .0083) and displayed stronger association among African Americans (P = .0004 in BioVU [mean exacerbations, 3.91 vs 1.53]; P = .0089 in the Childhood Asthma Management Program [mean exacerbations, 6.0 vs 3.25]). CTNNA3 variants did not replicate in BioVU. A regulatory variant in the CTNNA3 locus was associated with CTNNA3 mRNA expression in CD4(+) cells from asthmatic patients (P = .00079). CTNNA3 appears to be active in the immune response, and SEMA3D has a plausible role in airway remodeling. We also provide a replication of a previous association of purinergic receptor P2X, ligand-gated ion channel, 7 (P2RX7), with asthma exacerbation. Conclusions: We identified 2 loci associated with exacerbations through a genome-wide association study. CTNNA3 met genome-wide significance thresholds, and SEMA3D replicated in a clinical biobank database.	[McGeachie, Michael J.; Tse, Sze Man; Clemmer, George L.; Sordillo, Joanne; Lasky-Su, Jessica; Chase, Robert P.; Raby, Benjamin A.; Weiss, Scott T.; Tantisira, Kelan G.] Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA; [Wu, Ann C.] Harvard Pilgrim Hlth Care Inst, Dept Populat Med, Ctr Child Hlth Care Studies, Boston, MA USA; [Wu, Ann C.] Harvard Univ, Sch Med, Boston, MA USA; [Wu, Ann C.] Childrens Hosp, Dept Pediat, Div Gen Pediat, Boston, MA 02115 USA; [Himes, Blanca E.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; [Martinez, Fernando D.] Univ Arizona, Arizona Resp Ctr, Tucson, AZ USA; [Weeke, Peter; Shaffer, Christian M.; Denny, Josh C.] Vanderbilt Univ, Sch Med, Dept Internal Med, Nashville, TN 37212 USA; [Roden, Dan M.] Vanderbilt Univ, Sch Med, Off Personalized Med, Nashville, TN 37212 USA; [Weeke, Peter] Copenhagen Univ Hosp, Dept Cardiol, Gentofte, Denmark; [Xu, Hua] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA; [Panettieri, Reynold A., Jr.] Univ Penn, Med Ctr, Airways Biol Initiat, Philadelphia, PA 19104 USA	Harvard University; Brigham & Women's Hospital; Harvard Pilgrim Health Care; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; University of Pennsylvania; University of Arizona; Vanderbilt University; Vanderbilt University; University of Copenhagen; University of Texas System; University of Texas Health Science Center Houston; University of Pennsylvania	McGeachie, MJ (corresponding author), Channing Div Network Med, 181 Longwood Ave, Boston, MA 02115 USA.	michael.mcgeachie@channing.harvard.edu	panettieri, reynold/AAG-9485-2019; Denny, Josh/AAL-3359-2021; Wu, Ann/AAY-4293-2020; Raby, Benjamin/AAK-3866-2021; Roden, Dan/ABD-5412-2021	Denny, Josh/0000-0002-3049-7332; Wu, Ann/0000-0003-0599-9063; 	Parker B. Francis Foundation; NIH [K08 HL088046, K99 HL105663, U01 HL065899, U19 HL065962, R01 NR013391, R01 HL086601]; Tryg Foundation (TrygFonden, Denmark) [7343-09]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U19HL065962, T15HL098122, R00HL109162, U01HL065899, R01HL056177, P01HL114471, R01HL086601, K99HL105663, R00HL105663, K08HL088046] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006694, P30ES013508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR013391] Funding Source: NIH RePORTER	Parker B. Francis Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Tryg Foundation (TrygFonden, Denmark); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))	M.J.M. is supported by a grant from the Parker B. Francis Foundation (principal investigator [PI]: McGeachie). A.C.W. is supported by NIH grant K08 HL088046 (PI: Wu). B.E.H. was funded by NIH grant K99 HL105663 (PI: Himes). PW was funded by an unrestricted research grant from the Tryg Foundation (J.nr. 7343-09, TrygFonden, Denmark). This work was further supported by NIH grants U01 HL065899 (PIs: Weiss and Tantisira), U19 HL065962 (PI: Roden), R01 NR013391 (PI: Tantisira), and R01 HL086601 (PI: Raby).	Akinbami Lara J, 2011, Natl Health Stat Report, P1; Anderson WH, 2013, ANN ALLERG ASTHMA IM, V110, P416, DOI 10.1016/j.anai.2013.04.002; Barbato A, 2006, AM J RESP CRIT CARE, V174, P975, DOI 10.1164/rccm.200602-189OC; Barnett SBL, 2011, J ALLERGY CLIN IMMUN, V127, P145, DOI 10.1016/j.jaci.2010.10.020; Berg T, 2002, BIOCHEM BIOPH RES CO, V293, P907, DOI 10.1016/S0006-291X(02)00319-4; Bernstein DI, 2013, TOXICOL SCI, V131, P242, DOI 10.1093/toxsci/kfs272; Bjornsdottir US, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021902; Bonnelykke K, 2014, NAT GENET, V46, P51, DOI 10.1038/ng.2830; Busse WW, 2010, LANCET, V376, P826, DOI 10.1016/S0140-6736(10)61380-3; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; CHILMONCZYK BA, 1993, NEW ENGL J MED, V328, P1665, DOI 10.1056/NEJM199306103282303; Cunningham J, 2011, ANN ALLERG ASTHMA IM, V106, P381, DOI 10.1016/j.anai.2011.01.030; Curtin JA, 2013, CLIN EXP ALLERGY, V43, P304, DOI 10.1111/cea.12046; Degenhardt K, 2013, NAT MED, V19, P760, DOI 10.1038/nm.3185; Denlinger LC, 2013, AM J RESP CRIT CARE, V187, P28, DOI 10.1164/rccm.201204-0750OC; Du R, 2012, J ALLERGY CLIN IMMUN, V129, P368, DOI 10.1016/j.jaci.2011.09.034; Dulek DE, 2011, BBA-GEN SUBJECTS, V1810, P1080, DOI 10.1016/j.bbagen.2011.01.012; Fuhlbrigge A, 2012, J ALLERGY CLIN IMMUN, V129, pS34, DOI 10.1016/j.jaci.2011.12.983; Fujii T, 2011, J PSYCHIATR RES, V45, P47, DOI 10.1016/j.jpsychires.2010.05.004; Gitler AD, 2004, DEV CELL, V7, P107, DOI 10.1016/j.devcel.2004.06.002; Greenberg S, 2013, CURR OPIN ALLERGY CL, V13, P225, DOI 10.1097/ACI.0b013e32836096de; Guilbert TW, 2004, CONTROL CLIN TRIALS, V25, P286, DOI 10.1016/j.cct.2004.03.002; Himes BE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099625; James AL, 2007, EUR RESPIR J, V30, P134, DOI 10.1183/09031936.00146905; Janssens B, 2001, J CELL SCI, V114, P3177; Kigel B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003287; Kim SH, 2009, CLIN EXP ALLERGY, V39, P203, DOI 10.1111/j.1365-2222.2008.03117.x; Kruger RR, 2005, NAT REV MOL CELL BIO, V6, P789, DOI 10.1038/nrm1740; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Li Y, 2010, GENET EPIDEMIOL, V34, P816, DOI 10.1002/gepi.20533; Mathias RA, 2010, J ALLERGY CLIN IMMUN, V125, P336, DOI 10.1016/j.jaci.2009.08.031; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Moorman Jeanne E, 2012, Vital Health Stat 3, P1; O'Hara RB, 2010, METHODS ECOL EVOL, V1, P118, DOI 10.1111/j.2041-210X.2010.00021.x; Park HW, 2014, J ALLERGY CLIN IMMUN, V133, P664, DOI 10.1016/j.jaci.2013.12.1042; Perin P, 2014, IMMUNOGENETICS, V66, P143, DOI 10.1007/s00251-013-0755-0; Petryszak R, 2014, NUCLEIC ACIDS RES, V42, pD926, DOI 10.1093/nar/gkt1270; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Raby B, AM THOR SOC 2011 M D, pA6189; Roden DM, 2008, CLIN PHARMACOL THER, V84, P362, DOI 10.1038/clpt.2008.89; Rumpel JA, 2012, J ALLERGY CLIN IMMUN, V130, P1302, DOI 10.1016/j.jaci.2012.09.001; Samoli E, 2011, ENVIRON RES, V111, P418, DOI 10.1016/j.envres.2011.01.014; Sorkness CA, 2007, J ALLERGY CLIN IMMUN, V119, P64, DOI 10.1016/j.jaci.2006.09.042; Strunk RC, 2003, J ALLERGY CLIN IMMUN, V112, P883, DOI 10.1016/j.jaci.2003.08.014; Strunk RC, 2008, J ALLERGY CLIN IMMUN, V122, P1138, DOI 10.1016/j.jaci.2008.09.028; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Takamatsu H, 2012, TRENDS IMMUNOL, V33, P127, DOI 10.1016/j.it.2012.01.008; Tantisira KG, 2007, J ALLERGY CLIN IMMUN, V120, P1285, DOI 10.1016/j.jaci.2007.09.005; Tavendale R, 2008, J ALLERGY CLIN IMMUN, V121, P860, DOI 10.1016/j.jaci.2008.01.015; Ward LD, 2012, NUCLEIC ACIDS RES, V40, pD930, DOI 10.1093/nar/gkr917; Williams LK, 2011, J ALLERGY CLIN IMMUN, V128, P1185, DOI 10.1016/j.jaci.2011.09.011; Xu MS, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-90; Yang HM, 2005, J CELL PHYSIOL, V204, P219, DOI 10.1002/jcp.20278	53	36	36	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2015	136	6					1503	1510		10.1016/j.jaci.2015.04.039	http://dx.doi.org/10.1016/j.jaci.2015.04.039			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CX9RZ	26073756	Green Accepted			2022-12-18	WOS:000366044300010
J	Seshadri, S; Lu, X; Purkey, MR; Homma, T; Choi, AW; Carter, R; Suh, L; Norton, J; Harris, KE; Conley, DB; Kato, A; Avila, PC; Czarnocka, B; Kopp, PA; Peters, AT; Grammer, LC; Chandra, RK; Tan, BK; Liu, Z; Kern, RC; Schleimer, RP				Seshadri, Sudarshan; Lu, Xiang; Purkey, Matthew R.; Homma, Tetsuya; Choi, Andrew Wonho; Carter, Roderick; Suh, Lydia; Norton, James; Harris, Kathleen E.; Conley, David B.; Kato, Atsushi; Avila, Pedro C.; Czarnocka, Barbara; Kopp, Peter A.; Peters, Anju T.; Grammer, Leslie C.; Chandra, Rakesh K.; Tan, Bruce K.; Liu, Zheng; Kern, Robert C.; Schleimer, Robert P.			Increased expression of the epithelial anion transporter pendrin/SLC26A4 in nasal polyps of patients with chronic rhinosinusitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Pendrin; SLC26A4; periostin; Muc5AC; chronic rhinosinusitis; nasal polyp; mucus; mucociliary clearance; nasal epithelial cells	MUC5B MUCIN GENES; CHRONIC SINUSITIS; ION-TRANSPORT; PENDRIN; ASTHMA; INTERLEUKIN-17A; PERSPECTIVES; PATHOGENESIS; PERIOSTIN; ETIOLOGY	Background: Chronic rhinosinusitis (CRS) is a multifactorial disease of unknown cause characterized by sinonasal inflammation, increased mucus production, and defective mucociliary clearance. Expression of Pendrin, an epithelial anion transporter, is increased in asthma and chronic obstructive pulmonary disease. Pendrin increases mucus production and regulates mucociliary clearance. Objectives: We sought to investigate the expression of pendrin and the mucus-related protein Muc5AC in sinonasal tissues of control subjects and patients with CRS and to evaluate the regulation of pendrin expression in nasal epithelial cells (NECs) in vitro. Methods: The expression and distribution of pendrin in sinonasal tissues was analyzed by using real-time PCR, immunoblot analysis, and immunohistochemistry. Differentiated NECs were used to study the regulation of pendrin expression. Results: Increased pendrin expression was observed in nasal polyp (NP) tissue of patients with CRS. Immunohistochemistry analysis revealed that pendrin was largely restricted to the epithelial layer. Pendrin expression significantly correlated with inflammatory cell markers, suggesting that the factors made by these cells might induce pendrin expression. Furthermore, both pendrin and periostin levels (a biomarker in asthma) correlated with IL-13 levels, suggesting that pendrin can be induced by this cytokine in sinonasal tissues. Expression of the mucus component protein Muc5AC correlated weakly with pendrin expression, indicating that pendrin might modulate mucus production in NPs. In cultured NECs pendrin expression was induced by T(H)2 cytokines and induced synergistically when TH2 cytokines were combined with IL-17A. Interestingly, human rhinovirus had a potentiating effect on IL-13-induced pendrin expression. Dexamethasone suppressed pendrin expression, suggesting that the therapeutic benefit of dexamethasone in asthmatic patients and those with CRS might involve regulation of pendrin expression. Conclusions: TH2-mediated pendrin expression is increased in NPs of patients with CRS and might lead to increased inflammation, mucus production, and decreased mucociliary clearance.	[Seshadri, Sudarshan; Lu, Xiang; Purkey, Matthew R.; Homma, Tetsuya; Choi, Andrew Wonho; Carter, Roderick; Suh, Lydia; Norton, James; Harris, Kathleen E.; Kato, Atsushi; Avila, Pedro C.; Peters, Anju T.; Grammer, Leslie C.; Schleimer, Robert P.] Northwestern Univ, Div Allergy & Immunol, Feinberg Sch Med, Chicago, IL 60611 USA; [Conley, David B.; Chandra, Rakesh K.; Tan, Bruce K.; Kern, Robert C.; Schleimer, Robert P.] Northwestern Univ, Dept Otolaryngol Head & Neck Surg, Feinberg Sch Med, Chicago, IL 60611 USA; [Kopp, Peter A.] Northwestern Univ, Div Endocrinol Metab & Mol Med, Feinberg Sch Med, Chicago, IL 60611 USA; [Lu, Xiang; Liu, Zheng] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Otolaryngol, Wuhan 430074, Peoples R China; [Czarnocka, Barbara] Ctr Postgrad Med Educ, Dept Biochem & Mol Biol, Warsaw, Poland	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Huazhong University of Science & Technology; Centre of Postgraduate Medical Education - Poland	Schleimer, RP (corresponding author), Northwestern Univ, Div Allergy & Immunol, Feinberg Sch Med, 240 E Huron St,McGaw Rm M-318, Chicago, IL 60611 USA.	sudarshan-seshadri@ouhsc.edu; rpschleimer@northwestern.edu	Czarnocka, Barbara/V-1048-2019; Seshadri, Sudarshan/J-5544-2016	Czarnocka, Barbara/0000-0001-7701-760X; Seshadri, Sudarshan/0000-0003-4910-8664; Kato, Atsushi/0000-0001-9144-3138; Chandra, Rakesh/0000-0002-3612-0026; Kopp, Peter A/0000-0001-5980-0529; Grammer, Leslie/0000-0001-6860-2014	National Institutes of Health [R37HL068546, R01HL078860, U19AI106683]; Ernest S. Bazley Foundation; National Natural Science Foundation of China (NSFC) [81020108018]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078860, R37HL068546, R21HL113913] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI106683, R01AI104733] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [K23DC012067] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ernest S. Bazley Foundation; National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	Supported in part by National Institutes of Health grants R37HL068546, R01HL078860, and U19AI106683 and by the Ernest S. Bazley Foundation (to R.P.S.). X.L. was supported by National Natural Science Foundation of China (NSFC) grant 81020108018 (to Z.L.).	Akdis CA, 2013, J ALLERGY CLIN IMMUN, V131, P1479, DOI 10.1016/j.jaci.2013.02.036; Antunes MB, 2009, IMMUNOL ALLERGY CLIN, V29, P631, DOI 10.1016/j.iac.2009.07.004; BERNSTEIN JM, 1994, ARCH OTOLARYNGOL, V120, P993; Bhattacharyya N, 2011, ANN OTO RHINOL LARYN, V120, P423, DOI 10.1177/000348941112000701; Brandt EB, 2013, J ALLERGY CLIN IMMUN, V132, P1194, DOI 10.1016/j.jaci.2013.06.048; Dejima K, 2006, ARCH OTOLARYNGOL, V132, P1352, DOI 10.1001/archotol.132.12.1352; Ding GQ, 2007, AM J RHINOL, V21, P359, DOI 10.2500/ajr.2007.21.3037; Everett LA, 1997, NAT GENET, V17, P411, DOI 10.1038/ng1297-411; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Fokkens WJ, 2012, CURR OPIN OTOLARYNGO, V20, P19, DOI 10.1097/MOO.0b013e32834e9084; Garnett JP, 2011, J BIOL CHEM, V286, P41069, DOI 10.1074/jbc.M111.266734; GLIKLICH RE, 1995, OTOLARYNG HEAD NECK, V113, P104, DOI 10.1016/S0194-5998(95)70152-4; Hamilos DL, 2014, J ALLERGY CLIN IMMUN, V133, P640, DOI 10.1016/j.jaci.2013.06.049; Hu XD, 2013, J INT MED RES, V41, P777, DOI 10.1177/0300060513478089; Ishida A, 2012, ALLERGOL INT, V61, P589, DOI 10.2332/allergolint.11-OA-0370; Jiang XD, 2011, AM J RHINOL ALLERGY, V25, pE171, DOI 10.2500/ajra.2011.25.3645; Kern RC, 2008, AM J RHINOL, V22, P549, DOI 10.2500/ajr.2008.22.3228; Kim DH, 2004, ARCH OTOLARYNGOL, V130, P747, DOI 10.1001/archotol.130.6.747; Lopez-Souza N, 2003, IN VITRO CELL DEV-AN, V39, P266; MAJIMA Y, 1983, BIORHEOLOGY, V20, P251; Makihara S, 2010, J ALLERGY CLIN IMMUN, V126, DOI 10.1016/j.jaci.2010.05.014; Meltzer EO, 2006, J ALLERGY CLIN IMMUN, V118, pS17, DOI 10.1016/j.jaci.2006.09.005; Meltzer Eli O, 2004, J Allergy Clin Immunol, V114, P155, DOI 10.1016/j.jaci.2004.09.029; Nakagami Y, 2008, J IMMUNOL, V181, P2203, DOI 10.4049/jimmunol.181.3.2203; Nakao I, 2008, J IMMUNOL, V180, P6262, DOI 10.4049/jimmunol.180.9.6262; Nakayama T, 2011, RHINOLOGY, V49, P392, DOI 10.4193/Rhino10.261; Nofziger C, 2011, CLIN PHARMACOL THER, V90, P399, DOI 10.1038/clpt.2011.128; Passali D, 1999, EUR ARCH OTO-RHINO-L, V256, P335, DOI 10.1007/s004050050158; Pearlman AN, 2008, CURR OPIN OTOLARYNGO, V16, P226, DOI 10.1097/MOO.0b013e3282fdcc9a; Pedemonte N, 2007, J IMMUNOL, V178, P5144, DOI 10.4049/jimmunol.178.8.5144; Peters AT, 2010, J ALLERGY CLIN IMMUN, V125, P397, DOI 10.1016/j.jaci.2009.10.072; Saitoh T, 2010, INT ARCH ALLERGY IMM, V151, P8, DOI 10.1159/000232566; Seshadri S, 2012, ALLERGY, V67, P920, DOI 10.1111/j.1398-9995.2012.02848.x; Skubis-Zegadlo J, 2005, BRIT J CANCER, V93, P144, DOI 10.1038/sj.bjc.6602628; Stankovic KM, 2008, LARYNGOSCOPE, V118, P881, DOI 10.1097/MLG.0b013e31816b4b6f; Tan BK, 2010, CURR OPIN OTOLARYNGO, V18, P21, DOI 10.1097/MOO.0b013e3283350053; Van Bruaene N, 2008, J ALLERGY CLIN IMMUN, V121, P1435, DOI 10.1016/j.jaci.2008.02.018; Wang YH, 2010, J EXP MED, V207, P2479, DOI 10.1084/jem.20101376; Zhang W, 2012, INT FORUM ALLERGY RH, V2, P471, DOI 10.1002/alr.21056	39	36	39	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2015	136	6					1548	U192		10.1016/j.jaci.2015.05.024	http://dx.doi.org/10.1016/j.jaci.2015.05.024			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CX9RZ	26143180	Green Accepted, Bronze			2022-12-18	WOS:000366044300016
J	Leung, DYM				Leung, Donald Y. M.			Atopic dermatitis: Age and race do matter!	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Atopic dermatitis; eczema; sleep disturbance; skin barrier dysfunction; genetic mutations; biologics; phenotype	SKIN BARRIER; FILAGGRIN; ECZEMA; ADULTS; EXPOSURE; CHILDREN; ANTIGEN; SHOWS		[Leung, Donald Y. M.] Natl Jewish Hlth, Dept Pediat, Denver, CO 80206 USA	National Jewish Health	Leung, DYM (corresponding author), Natl Jewish Hlth, 1400 Jackson St K926i, Denver, CO 80206 USA.	leungd@njhealth.org			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI117673] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041256] Funding Source: NIH RePORTER; NIAID NIH HHS [1 U19 AI117673-01] Funding Source: Medline; NIAMS NIH HHS [1 R01 AR41256] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Beck LA, 2014, NEW ENGL J MED, V371, P130, DOI 10.1056/NEJMoa1314768; Bin LH, 2014, J ALLERGY CLIN IMMUN, V134, P848, DOI 10.1016/j.jaci.2014.07.018; Brough HA, 2015, J ALLERGY CLIN IMMUN, V135, P164, DOI 10.1016/j.jaci.2014.10.007; Brough HA, 2014, J ALLERGY CLIN IMMUN, V134, P867, DOI 10.1016/j.jaci.2014.08.011; Cole C, 2014, J ALLERGY CLIN IMMUN, V134, P82, DOI 10.1016/j.jaci.2014.04.021; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P941, DOI 10.1016/j.jaci.2015.05.049; Elias PM, 2014, J ALLERGY CLIN IMMUN, V134, P781, DOI 10.1016/j.jaci.2014.05.048; Fishbein AB, 2015, J ALLERGY CLIN IMMUN, V136, P1170, DOI 10.1016/j.jaci.2015.08.028; Garg NK, 2015, J ALLERGY CLIN IMMUN, V135, P1085, DOI 10.1016/j.jaci.2014.10.043; Hamilton JD, 2014, J ALLERGY CLIN IMMUN, V134, P1293, DOI 10.1016/j.jaci.2014.10.013; Horimukai K, 2014, J ALLERGY CLIN IMMUN, V134, P824, DOI 10.1016/j.jaci.2014.07.060; Kelleher M, 2015, J ALLERGY CLIN IMMUN, V135, P930, DOI 10.1016/j.jaci.2014.12.013; Leung DYM, 2014, J ALLERGY CLIN IMMUN, V134, P769, DOI 10.1016/j.jaci.2014.08.008; Noda S, 2015, J ALLERGY CLIN IMMUN, V136, P1254, DOI 10.1016/j.jaci.2015.08.015; Noda S, 2015, J ALLERGY CLIN IMMUN, V135, P324, DOI 10.1016/j.jaci.2014.11.015; Samuelov L, 2014, J ALLERGY CLIN IMMUN, V134, P808, DOI 10.1016/j.jaci.2014.07.061; Schneider L, 2013, J ALLERGY CLIN IMMUN, V131, P295, DOI 10.1016/j.jaci.2012.12.672; Silverberg JI, 2014, J ALLERGY CLIN IMMUN, V133, P1041, DOI 10.1016/j.jaci.2013.08.012; Silverberg JI, 2013, J ALLERGY CLIN IMMUN, V132, P1132, DOI 10.1016/j.jaci.2013.08.031; Simpson EL, 2014, J ALLERGY CLIN IMMUN, V134, P818, DOI 10.1016/j.jaci.2014.08.005; Sofen H, 2014, J ALLERGY CLIN IMMUN, V133, P1032, DOI 10.1016/j.jaci.2014.01.025; Suarez-Farinas M, 2013, J ALLERGY CLIN IMMUN, V132, P361, DOI 10.1016/j.jaci.2013.04.046; Thawer-Esmail F, 2014, J ALLERGY CLIN IMMUN, V133, P280, DOI 10.1016/j.jaci.2013.09.053; Thyssen JP, 2014, J ALLERGY CLIN IMMUN, V134, P792, DOI 10.1016/j.jaci.2014.06.014	24	36	36	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2015	136	5					1265	1267		10.1016/j.jaci.2015.09.011	http://dx.doi.org/10.1016/j.jaci.2015.09.011			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CW1YE	26549637	Bronze			2022-12-18	WOS:000364787200015
J	Buchbinder, D; Stinson, JR; Nugent, DJ; Heurtier, L; Suarez, F; Sukumar, G; Dalgard, CL; Masson, C; Parisot, M; Zhang, Y; Matthews, HF; Su, HC; Durandy, A; Fischer, A; Kracker, S; Snow, AL				Buchbinder, David; Stinson, Jeffrey R.; Nugent, Diane J.; Heurtier, Lucie; Suarez, Felipe; Sukumar, Gauthaman; Dalgard, Clifton L.; Masson, Cecile; Parisot, Melanie; Zhang, Yu; Matthews, Helen F.; Su, Helen C.; Durandy, Anne; Fischer, Alain; Kracker, Sven; Snow, Andrew L.			Mild B-cell lymphocytosis in patients with a CARD11 C49Y mutation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							NF-KAPPA-B; LYMPHOMA		[Buchbinder, David; Nugent, Diane J.] Childrens Hosp Orange Cty, Dept Hematol, Orange, CA 92668 USA; [Buchbinder, David; Nugent, Diane J.] Univ Calif Irvine, Dept Pediat, Orange, CA 92668 USA; [Stinson, Jeffrey R.; Snow, Andrew L.] Uniformed Serv Univ Hlth Sci, Dept Pharmacol, Bethesda, MD 20814 USA; [Heurtier, Lucie; Suarez, Felipe; Durandy, Anne; Fischer, Alain; Kracker, Sven] Univ Paris 05, Sorbonne Paris Cite, Imagine Inst, Paris, France; [Heurtier, Lucie; Durandy, Anne; Fischer, Alain; Kracker, Sven] INSERM, UMR 1163, Human Lymphohematopoiesis Lab, Paris, France; [Suarez, Felipe] Hop Necker Enfants Malad, Serv Hematol Adultes, Paris, France; [Sukumar, Gauthaman; Dalgard, Clifton L.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Masson, Cecile] Univ Paris 05, Sorbonne Paris Cite, Imagine Inst, Bioinformat Platform, Paris, France; [Parisot, Melanie] Univ Paris 05, Sorbonne Paris Cite, Imagine Inst, Genom Core Facil, Paris, France; [Zhang, Yu; Matthews, Helen F.; Su, Helen C.] NIAID, Lab Host Defenses, NIH, Bethesda, MD 20892 USA; [Fischer, Alain] Hop Necker Enfants Malad, Dept Pediat Immunol Hematol & Rheumatol, Paris, France; [Fischer, Alain] Coll France, F-75231 Paris, France	Childrens Hospital of Orange County; University of California System; University of California Irvine; Uniformed Services University of the Health Sciences - USA; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Uniformed Services University of the Health Sciences - USA; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; College de France	Buchbinder, D (corresponding author), Childrens Hosp Orange Cty, Dept Hematol, Orange, CA 92668 USA.	sven.kracker@inserm.fr; andrew.snow@usuhs.edu	Heurtier, Lucie/H-2889-2017; Su, Helen C/H-9541-2015; Durandy, Anne/H-7475-2017; Sukumar, Gauthaman/A-1697-2018; Kracker, Sven/H-3681-2017	Heurtier, Lucie/0000-0002-2284-6774; Su, Helen C/0000-0002-5582-9110; Durandy, Anne/0000-0001-7706-8466; Kracker, Sven/0000-0003-4543-8236; Snow, Andrew/0000-0002-8728-6691; Parisot, Melanie/0000-0003-4312-2035; Dalgard, Clifton/0000-0003-2025-8239; Sukumar, Gauthaman/0000-0003-3129-4171	European Research Council [249816] Funding Source: Medline; Intramural NIH HHS [Z99 AI999999, ZIA AI001058-03, Z01 AI001059-01] Funding Source: Medline; NIAID NIH HHS [R21 AI109187] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001059, R21AI109187] Funding Source: NIH RePORTER	European Research Council(European Research Council (ERC)European Commission); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 2015, J CLIN IMMUNOL, V35, P32; Blonska M, 2011, CELL RES, V21, P55, DOI 10.1038/cr.2010.182; Chan WP, 2013, MOL CELL BIOL, V33, P429, DOI 10.1128/MCB.00850-12; Compagno M, 2009, NATURE, V459, P717, DOI 10.1038/nature07968; Lenz G, 2008, SCIENCE, V319, P1676, DOI 10.1126/science.1153629; Morbach H, 2010, CLIN EXP IMMUNOL, V162, P271, DOI 10.1111/j.1365-2249.2010.04206.x; Salisbury EM, 2014, IMMUNOLOGY, V141, P446, DOI 10.1111/imm.12207; Shinohara H, 2014, SCIENCE, V344, P760, DOI 10.1126/science.1250020; Snow AL, 2012, J EXP MED, V209, P2247, DOI 10.1084/jem.20120831; Turvey SE, 2014, J ALLERGY CLIN IMMUN, V134, P276, DOI 10.1016/j.jaci.2014.06.015	10	36	38	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2015	136	3					819	+		10.1016/j.jaci.2015.03.008	http://dx.doi.org/10.1016/j.jaci.2015.03.008			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CQ9EA	25930198	Green Accepted			2022-12-18	WOS:000360913300042
J	Ortega, H; Katz, L; Gunsoy, N; Keene, O; Yancey, S				Ortega, Hector; Katz, Lynn; Gunsoy, Necdet; Keene, Oliver; Yancey, Steven			Blood eosinophil counts predict treatment response in patients with severe eosinophilic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							MEPOLIZUMAB		[Ortega, Hector; Katz, Lynn; Yancey, Steven] GlaxoSmithKline, Resp Therapeut Area, Res Triangle Pk, NC 27709 USA; [Gunsoy, Necdet; Keene, Oliver] GlaxoSmithKline, Clin Stat, Stockley Pk, England	GlaxoSmithKline; GlaxoSmithKline	Ortega, H (corresponding author), GlaxoSmithKline, Resp Therapeut Area, Res Triangle Pk, NC 27709 USA.	hector.g.ortega@gsk.com		Ortega, Hector/0000-0002-2632-6370; Keene, Oliver/0000-0003-0016-9773				Fowler SJ, 2015, J ALLERGY CLIN IMMUN, V135, P822, DOI 10.1016/j.jaci.2014.09.034; Katz Lynn E, 2014, Ann Am Thorac Soc, V11, P531, DOI 10.1513/AnnalsATS.201310-354OC; Ortega HG, 2014, NEW ENGL J MED, V371, P1198, DOI 10.1056/NEJMoa1403290; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Schleich F, 2014, RESP MED, V108, P1723, DOI 10.1016/j.rmed.2014.10.007	5	36	38	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2015	136	3					825	+		10.1016/j.jaci.2015.05.039	http://dx.doi.org/10.1016/j.jaci.2015.05.039			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CQ9EA	26194540				2022-12-18	WOS:000360913300047
J	Garg, NK; Silverberg, JI				Garg, Nitin K.; Silverberg, Jonathan I.			Eczema is associated with osteoporosis and fractures in adults: A US population-based study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							BONE-MINERAL DENSITY; SEVERE ATOPIC-DERMATITIS; MODERATE		[Garg, Nitin K.; Silverberg, Jonathan I.] Northwestern Univ, Dept Dermatol, Chicago, IL 60611 USA; [Silverberg, Jonathan I.] Northwestern Univ, Dept Prevent Med, Chicago, IL 60611 USA; [Silverberg, Jonathan I.] Northwestern Univ, Dept Med Social Sci, Chicago, IL 60611 USA	Northwestern University; Northwestern University; Northwestern University	Garg, NK (corresponding author), Northwestern Univ, Dept Dermatol, Chicago, IL 60611 USA.	JonathanISilverberg@Gmail.com	silverberg, jonathan/ABH-2765-2021	silverberg, jonathan/0000-0003-3686-7805				AaltoKorte K, 1997, BRIT J DERMATOL, V136, P172; BUTLER JA, 1982, AM J CLIN NUTR, V36, P15, DOI 10.1093/ajcn/36.1.15; Carroll MD, 1990, SER LIP LIP HISP 198; Garg N, 2014, ANN ALLERG ASTHMA IM, V112, P525, DOI 10.1016/j.anai.2014.03.006; Haeck IM, 2009, BRIT J DERMATOL, V161, P1248, DOI 10.1111/j.1365-2133.2009.09327.x; Looker A. C., 2012, VITAL HLTH STAT, V11, P1; National Center for Health Statistics, 2006, NAT HLTH NUTR EX SUR; Silverberg J, 2014, J INVEST DERMATOL; van Velsen SGA, 2012, J AM ACAD DERMATOL, V66, P691, DOI 10.1016/j.jaad.2011.09.004; van Velsen SGA, 2010, J AM ACAD DERMATOL, V63, P824, DOI 10.1016/j.jaad.2009.12.015	10	36	37	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2015	135	4					1085	+		10.1016/j.jaci.2014.10.043	http://dx.doi.org/10.1016/j.jaci.2014.10.043			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CF0MQ	25512080				2022-12-18	WOS:000352238600039
J	Laidlaw, TM; Cutler, AJ; Kidder, MS; Liu, T; Cardet, JC; Chhay, H; Feng, CL; Boyce, JA				Laidlaw, Tanya M.; Cutler, Anya J.; Kidder, Molly S.; Liu, Tao; Cardet, Juan Carlos; Chhay, Heng; Feng, Chunli; Boyce, Joshua A.			Prostaglandin E-2 resistance in granulocytes from patients with aspirin-exacerbated respiratory disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Samter's triad; aspirin-exacerbated respiratory disease; AERD; aspirin triad; nonsteroidal anti-inflammatory drug; asthma; leukotriene; protein kinase A; prostaglandin E-2; cyclic AMP	PROTEIN-KINASE-A; FORMYL PEPTIDE RECEPTOR; INTOLERANT ASTHMA; LEUKOTRIENE C-4; SENSITIVE ASTHMA; POLYMORPHONUCLEAR LEUKOCYTES; ALLERGIC INFLAMMATION; REDUCED EXPRESSION; NASAL POLYPS; MAST-CELLS	Background: Aspirin-exacerbated respiratory disease (AERD) is an inflammatory condition of the respiratory tract and is characterized by overproduction of leukotrienes (LT) and large numbers of circulating granulocyte-platelet complexes. LT production can be suppressed by prostaglandin E-2 (PGE(2)) and the cyclic AMP-dependent protein kinase A (PKA). Objective: To determine if PGE(2)-dependent control of LT production by granulocytes is dysregulated in AERD. Methods: Granulocytes from well-characterized patients with and without AERD were activated ex vivo and subjected to a range of functional and biochemical analyses. Results: Granulocytes from subjects with AERD generated more LTB4 and cysteinyl LTs than did granulocytes from controls with aspirin-tolerant asthma and controls without asthma. When compared with controls, granulocytes from subjects with AERD had comparable levels of EP2 protein expression and PGE(2)-mediated cAMP accumulation, yet were resistant to PGE(2)-mediated suppression of LT generation. Percentages of platelet-adherent neutrophils correlated positively with LTB4 generation and inversely with responsiveness to PGE(2)-mediated suppression of LTB4. The PKA inhibitor H89 potentiated LTB4 generation by control granulocytes but was inactive in granulocytes from individuals with AERD and had no effect on platelet P-selectin induction. Both tonic PKA activity and levels of PKA catalytic gamma subunit protein were significantly lower in granulocytes from individuals with AERD relative to those from controls. Conclusions: Impaired granulocyte PKA function in AERD may lead to dysregulated control of 5-lipoxygenase activity by PGE(2), whereas adherent platelets lead to increased production of LTs, which contributes to the features of persistent respiratory tract inflammation and LT overproduction.	[Laidlaw, Tanya M.; Cardet, Juan Carlos; Boyce, Joshua A.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA; [Laidlaw, Tanya M.; Cutler, Anya J.; Kidder, Molly S.; Liu, Tao; Cardet, Juan Carlos; Chhay, Heng; Feng, Chunli; Boyce, Joshua A.] Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Jeff & Penny Vinik Ctr Allerg Dis Res, Boston, MA 02115 USA; [Boyce, Joshua A.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Boyce, JA (corresponding author), Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, 1 Jimmy Fund Way,Smith Bldg, Boston, MA 02115 USA.	jboyce@rics.bwh.harvard.edu		Cardet, Juan Carlos/0000-0002-9731-4828	National Institutes of Health [AI078908, AI095219, AT002782, AI082369, K23 HL111113, HL36110]; American Academy of Allergy, Asthma & Immunology Third and Fourth Year Fellow-In-Training Research Award; NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE [P50AT002782] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036110, R01HL117945] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007306, R21AI082369, R37AI052353, R01AI078908, U19AI095219] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Academy of Allergy, Asthma & Immunology Third and Fourth Year Fellow-In-Training Research Award; NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by National Institutes of Health grants AI078908, AI095219, AT002782, AI082369, K23 HL111113, and HL36110; by an American Academy of Allergy, Asthma & Immunology Third and Fourth Year Fellow-In-Training Research Award (to T.M.L.), and by generous contributions from the Vinik Family.	Adamjee J, 2006, J PATHOL, V209, P392, DOI 10.1002/path.1979; Berges-Gimeno MP, 2002, CLIN EXP ALLERGY, V32, P1491, DOI 10.1046/j.1365-2745.2002.01501.x; Boyce JA, 1996, BLOOD, V88, P4338; Cao YJ, 2009, J THROMB THROMBOLYS, V27, P233, DOI 10.1007/s11239-007-0190-x; Carter BZ, 1998, J BIOL CHEM, V273, P28277, DOI 10.1074/jbc.273.43.28277; Chilcoat CD, 2008, J LEUKOCYTE BIOL, V83, P964, DOI 10.1189/jlb.0405192; CHRISTIE PE, 1991, AM REV RESPIR DIS, V143, P1025, DOI 10.1164/ajrccm/143.5_Pt_1.1025; Corrigan CJ, 2012, J ALLERGY CLIN IMMUN, V129, P1636, DOI 10.1016/j.jaci.2012.02.007; Cowburn AS, 1998, J CLIN INVEST, V101, P834, DOI 10.1172/JCI620; Dahlen B, 1998, AM J RESP CRIT CARE, V157, P1187, DOI 10.1164/ajrccm.157.4.9707089; Dulin NO, 2001, J BIOL CHEM, V276, P20827, DOI 10.1074/jbc.C100195200; Feng CL, 2006, BLOOD, V107, P3243, DOI 10.1182/blood-2005-07-2772; Flamand N, 2002, MOL PHARMACOL, V62, P250, DOI 10.1124/mol.62.2.250; Huang SK, 2008, AM J RESP CRIT CARE, V177, P66, DOI 10.1164/rccm.200706-963OC; ISRAEL E, 1993, AM REV RESPIR DIS, V148, P1447, DOI 10.1164/ajrccm/148.6_Pt_1.1447; Jantti-Alanko S, 1989, Rhinol Suppl, V8, P59; Kanaoka Y, 2013, J BIOL CHEM, V288, P10967, DOI 10.1074/jbc.C113.453704; Kunikata T, 2005, NAT IMMUNOL, V6, P524, DOI 10.1038/ni1188; Laidlaw TM, 2012, BLOOD, V119, P3790, DOI 10.1182/blood-2011-10-384826; LEE CW, 1983, IMMUNOLOGY, V48, P27; Liu T, 2013, P NATL ACAD SCI USA, V110, P16987, DOI 10.1073/pnas.1313185110; Liu T, 2012, P NATL ACAD SCI USA, V109, P12692, DOI 10.1073/pnas.1207816109; Lundequist A, 2010, J IMMUNOL, V184, P433, DOI 10.4049/jimmunol.0902835; Luo M, 2005, J BIOL CHEM, V280, P40609, DOI 10.1074/jbc.M507045200; Luo M, 2004, J BIOL CHEM, V279, P41512, DOI 10.1074/jbc.M312568200; MACLOUF J, 1994, ANN NY ACAD SCI, V714, P143, DOI 10.1111/j.1749-6632.1994.tb12038.x; MACLOUF JA, 1988, J BIOL CHEM, V263, P174; Maekawa A, 2008, P NATL ACAD SCI USA, V105, P16695, DOI 10.1073/pnas.0808993105; Mascia K, 2005, J ALLERGY CLIN IMMUN, V116, P970, DOI 10.1016/j.jaci.2005.08.035; MAUGERI N, 1992, BLOOD, V80, P447; MAUGERI N, 1994, THROMB HAEMOSTASIS, V72, P450; Mita H, 2004, CLIN EXP ALLERGY, V34, P1262, DOI 10.1111/j.1365-2222.2004.02034.x; MURPHY RC, 1991, ADV EXP MED BIOL, V314, P91; Pitchford SC, 2003, J ALLERGY CLIN IMMUN, V112, P109, DOI 10.1067/mai.2003.1514; Roca-Ferrer J, 2011, J ALLERGY CLIN IMMUN, V128, P66, DOI 10.1016/j.jaci.2011.01.065; Sestini P, 1996, AM J RESP CRIT CARE, V153, P572, DOI 10.1164/ajrccm.153.2.8564100; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; Sousa AR, 1997, THORAX, V52, P940, DOI 10.1136/thx.52.11.940; Sugimoto Y, 2007, J BIOL CHEM, V282, P11613, DOI 10.1074/jbc.R600038200; Svensson L, 2002, J LEUKOCYTE BIOL, V72, P810; Szczeklik A, 2003, J ALLERGY CLIN IMMUN, V111, P913, DOI 10.1067/mai.2003.1487; Trudeau J, 2006, J ALLERGY CLIN IMMUN, V117, P1446, DOI 10.1016/j.jaci.2006.01.049; Wang XS, 2007, ALLERGY, V62, P620, DOI 10.1111/j.1398-9995.2007.01364.x; WELLER PF, 1983, P NATL ACAD SCI-BIOL, V80, P7626, DOI 10.1073/pnas.80.24.7626; White AA, 2005, ANN ALLERG ASTHMA IM, V95, P330, DOI 10.1016/S1081-1206(10)61150-7; Woloszynek JC, 2012, J BIOL CHEM, V287, P34101, DOI 10.1074/jbc.M112.394452; Ying S, 2006, J ALLERGY CLIN IMMUN, V117, P312, DOI 10.1016/j.jaci.2005.10.037; Ying S, 2004, J ALLERGY CLIN IMMUN, V114, P1309, DOI 10.1016/j.jaci.2004.08.034; Yoshimura Tsuyoshi, 2008, Allergol Int, V57, P429, DOI 10.2332 allergolint.O-08-545	49	36	36	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2014	133	6					1692	+		10.1016/j.jaci.2013.12.1034	http://dx.doi.org/10.1016/j.jaci.2013.12.1034			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AI2FI	24486071	Green Accepted			2022-12-18	WOS:000336672500023
J	Linehan, MF; Nurmatov, U; Frank, TL; Niven, RM; Baxter, DN; Sheikh, A				Linehan, Mary F.; Nurmatov, Ulugbek; Frank, Timothy L.; Niven, Robert M.; Baxter, David N.; Sheikh, Aziz			Does BCG vaccination protect against childhood asthma? Final results from the Manchester Community Asthma Study retrospective cohort study and updated systematic review and meta-analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Wheeze; asthma; atopy; allergy; BCG; children; systematic review; meta-analysis	CALMETTE-GUERIN VACCINATION; ATOPIC DISEASE; NEONATAL BCG; TUBERCULOSIS INFECTION; PRESCHOOL-CHILDREN; ALLERGIC DISEASE; PREVALENCE; RISK; SCHOOLCHILDREN; IMMUNIZATION	Background: The Manchester Community Asthma Study (MANCAS) found a protective effect against the risk of wheeze at age 6 to 11 years for children given neonatal BCG vaccination. Our subsequent systematic review and meta-analysis suggested that BCG vaccination did not protect against allergic sensitization but might have exerted a protective effect against nonatopic asthma. Objectives: We sought to assess whether the protective effect of BCG vaccination on wheeze observed in the MANCAS cohort was maintained at age 13 to 17 years and to incorporate the findings from this final MANCAS analysis into an updated systematic review and meta-analysis. Methods: BCG vaccination status was determined from health records and respiratory outcomes from questionnaire responses. We updated the systematic review and used fixed-effects and random-effects modeling to undertake meta-analyses. Results: There were 1608 participants in the final MANCAS analysis. The 12-month prevalence of wheeze was 15.1%. There was no difference in prevalence between those who were and were not BCG vaccinated (15.8% vs 14.3%; relative risk, 1.05; 95% CI, 0.94-1.19). The updated meta-analysis incorporated 4 new studies: this showed that the protective effect of BCG vaccination against the development of asthma identified in our previous meta-analysis was attenuated (odds ratio, 0.95; 95% CI, 0.89-1.00). No protective effect of BCG was seen for sensitization, eczema/atopic dermatitis, rhinoconjunctivitis, or allergy in general. Conclusions: Taken together, the final results of the MANCAS cohort and the updated systematic review and meta-analysis provide clearer evidence that any protective effect of BCG vaccination on childhood asthma is likely to be transient.	[Linehan, Mary F.; Frank, Timothy L.; Niven, Robert M.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Univ Hosp South Manchester NHS Fdn Trust, NIHR South Manchester Resp & Allergy Clin Res Fac, Manchester M13 9PL, Lancs, England; [Nurmatov, Ulugbek; Sheikh, Aziz] Univ Edinburgh, Allergy & Resp Res Grp, Ctr Populat Hlth Sci, Edinburgh EH8 9YL, Midlothian, Scotland; [Baxter, David N.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Clin Epidemiol & Publ Hlth Unit, Manchester, Lancs, England; [Sheikh, Aziz] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Gen Internal Med & Primary Care, Boston, MA 02115 USA	University of Manchester; Wythenshawe Hospital NHS Foundation Trust; University of Edinburgh; University of Manchester; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Linehan, MF (corresponding author), Wythenshawe Hosp, GP Res Unit, Educ & Res Ctr, 2nd Floor, Manchester M23 9LT, Lancs, England.	mary.linehan@manchester.ac.uk	frank, timothy/AAF-9833-2020; Sheikh, Aziz/D-2818-2009	Sheikh, Aziz/0000-0001-7022-3056; Frank, Timothy/0000-0002-1580-8980; Niven, Robert/0000-0003-2249-960X	National Institute for Health Research Clinical Research Facility at University Hospital of South Manchester NHS Foundation Trust; Moulton Charitable Foundation; North West Lung Centre Charity, Wythenshawe Hospital; School of Translational Medicine, University of Manchester; Centre for Population Health Sciences, University of Edinburgh; Harkness Fellowship in Health Care Policy and Practice from The Commonwealth Fund, a private independent foundation based in New York City	National Institute for Health Research Clinical Research Facility at University Hospital of South Manchester NHS Foundation Trust; Moulton Charitable Foundation; North West Lung Centre Charity, Wythenshawe Hospital; School of Translational Medicine, University of Manchester; Centre for Population Health Sciences, University of Edinburgh; Harkness Fellowship in Health Care Policy and Practice from The Commonwealth Fund, a private independent foundation based in New York City	This report is independent research supported by the National Institute for Health Research Clinical Research Facility at University Hospital of South Manchester NHS Foundation Trust. The views expressed in this publication are those of the author(s) and not necessarily those of the National Health Service, the National Institute of Health Research, or the Department of Health. The Manchester Community Asthma Study 2 was funded by the Moulton Charitable Foundation. Members of the research team were supported by the North West Lung Centre Charity, Wythenshawe Hospital; the School of Translational Medicine, University of Manchester; and the Centre for Population Health Sciences, University of Edinburgh. A. S. is supported by a Harkness Fellowship in Health Care Policy and Practice from The Commonwealth Fund, a private independent foundation based in New York City. The views presented here are those of the author and not necessarily those of The Commonwealth Fund, its directors, officers, or staff.	Aaby P, 2000, CLIN EXP ALLERGY, V30, P644, DOI 10.1046/j.1365-2222.2000.00803.x; Alm JS, 1997, LANCET, V350, P400, DOI 10.1016/S0140-6736(97)02207-1; Annus T, 2004, ALLERGY, V59, P1068, DOI 10.1111/j.1398-9995.2004.00557.x; Arnoldussen DL, 2011, J ALLERGY CLIN IMMUN, V127, P1081, DOI 10.1016/j.jaci.2010.12.1121; Arnoldussen DL, 2011, J ALLERGY CLIN IMMUN, V127, P246, DOI 10.1016/j.jaci.2010.07.039; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Braun-Fahrlander C, 1998, PEDIATR PULM, V25, P159, DOI 10.1002/(SICI)1099-0496(199803)25:3<159::AID-PPUL5>3.0.CO;2-H; Bremner SA, 2005, ARCH DIS CHILD, V90, P567, DOI 10.1136/adc.2004.051714; Cane RS, 2000, ARCH DIS CHILD, V82, P327, DOI 10.1136/adc.82.4.327; da Cunha SS, 2004, ALLERGY, V59, P857; de Andrade CR, 2013, RESP MED, V107, P317, DOI 10.1016/j.rmed.2012.10.009; Department of Health Joint Committee on Vaccination and Immunisation, 1992, IMMUNISATION INFECT; Flohr C, 2012, PEDIAT ALLERG IMM-UK, V23, P324, DOI 10.1111/j.1399-3038.2011.01248.x; Garcia-Marcosa L, 2005, INT ARCH ALLERGY IMM, V137, P303, DOI 10.1159/000086461; Gruber C, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.3.e36; Gruber C, 2002, PEDIAT ALLERG IMM-UK, V13, P177, DOI 10.1034/j.1399-3038.2002.01006.x; Gruber C, 2008, ALLERGY, V63, P1464, DOI 10.1111/j.1398-9995.2008.01696.x; Halonen M, 1999, AM J RESP CRIT CARE, V160, P564, DOI 10.1164/ajrccm.160.2.9809038; Hedman L, 2005, PEDIAT ALLERG IMM-UK, V16, P176, DOI 10.1111/j.1399-3038.2005.00231.x; Krause TG, 2003, JAMA-J AM MED ASSOC, V289, P1012, DOI 10.1001/jama.289.8.1012; Linehan MF, 2007, J ALLERGY CLIN IMMUN, V119, P1079, DOI 10.1016/j.jaci.2006.12.672; Linehan MF, 2006, INVESTIGATION PREVAL; Marks GB, 2003, J ALLERGY CLIN IMMUN, V111, P541, DOI 10.1067/mai.2003.171; Miyake Y, 2008, CLIN EXP ALLERGY, V38, P486, DOI 10.1111/j.1365-2222.2007.02869.x; Mohrenschlager M, 2007, PEDIAT ALLERG IMM-UK, V18, P5, DOI 10.1111/j.1399-3038.2006.00485.x; Mommers M, 2004, PEDIATR PULM, V38, P329, DOI 10.1002/ppul.20089; Netuveli G, 2007, J ROY SOC MED, V100, P19, DOI 10.1258/jrsm.100.1.19; Pahari A, 2002, Indian Pediatr, V39, P254; Puliyel JM, 1996, BRIT MED J, V313, P528, DOI 10.1136/bmj.313.7056.528; Rosa AM, 2009, J BRAS PNEUMOL, V35, P7, DOI 10.1590/S1806-37132009000100002; Savenije OE, 2011, J ALLERGY CLIN IMMUN, V127, P1505, DOI 10.1016/j.jaci.2011.02.002; Soysal A, 2008, PEDIAT ALLERG IMM-UK, V19, P709, DOI 10.1111/j.1399-3038.2007.00708.x; Steenhuis TJ, 2008, CLIN EXP ALLERGY, V38, P79, DOI 10.1111/j.1365-2222.2007.02859.x; Strannegard IL, 1998, ALLERGY, V53, P249, DOI 10.1111/j.1398-9995.1998.tb03884.x; Wickens K, 2001, AUST NZ J PUBL HEAL, V25, P44, DOI 10.1111/j.1467-842X.2001.tb00549.x	35	36	37	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2014	133	3					688	+		10.1016/j.jaci.2013.08.007	http://dx.doi.org/10.1016/j.jaci.2013.08.007			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EK	24084077				2022-12-18	WOS:000332397600009
J	Scholtens, S; Postma, DS; Moffatt, MF; Panasevich, S; Granell, R; Henderson, AJ; Melen, E; Nyberg, F; Pershagen, G; Jarvis, D; Ramasamy, A; Wjst, M; Svanes, C; Bouzigon, E; Demenais, F; Kauffmann, F; Siroux, V; von Mutius, E; Ege, MJ; Braun-Fahrlander, C; Genuneit, J; Brunekreef, B; Smit, HA; Wijga, AH; Kerkhof, M; Curjuric, I; Imboden, M; Thun, GA; Probst-Hensch, N; Freidin, MB; Bragina, EI; Deev, IA; Puzyrev, VP; Daley, D; Park, J; Becker, A; Chan-Yeung, M; Kozyrskyj, AL; Pare, P; Marenholz, I; Lau, S; Keil, T; Lee, YA; Kabesch, M; Wijmenga, C; Franke, L; Nolte, IM; Vonk, J; Kumar, A; Farrall, M; Cookson, WOCM; Strachan, DP; Koppelman, GH; Boezen, HM				Scholtens, Salome; Postma, Dirkje S.; Moffatt, Miriam F.; Panasevich, Sviatlana; Granell, Raquel; Henderson, A. John; Melen, Erik; Nyberg, Fredrik; Pershagen, Goeran; Jarvis, Deborah; Ramasamy, Adaikalavan; Wjst, Matthias; Svanes, Cecilie; Bouzigon, Emmanuelle; Demenais, Florence; Kauffmann, Francine; Siroux, Valerie; von Mutius, Erika; Ege, Markus Johannes; Braun-Fahrlaender, Charlotte; Genuneit, Jon; Brunekreef, Bert; Smit, Henriette A.; Wijga, Alet H.; Kerkhof, Marjan; Curjuric, Ivan; Imboden, Medea; Thun, Gian A.; Probst-Hensch, Nicole; Freidin, Maxim B.; Bragina, Elena Iu.; Deev, I. A.; Puzyrev, V. P.; Daley, Denise; Park, Julie; Becker, Allan; Chan-Yeung, Moira; Kozyrskyj, Anita L.; Pare, Peter; Marenholz, Ingo; Lau, Susanne; Keil, Thomas; Lee, Young-Ae; Kabesch, Michael; Wijmenga, Cisca; Franke, Lude; Nolte, Ilja M.; Vonk, Judith; Kumar, Ashish; Farrall, Martin; Cookson, William O. C. M.; Strachan, David P.; Koppelman, Gerard H.; Boezen, H. Marike		GABRIELA Study Grp	Novel childhood asthma genes interact with in utero and early-life tobacco smoke exposure	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							VARIANTS; PARKIN		[Scholtens, Salome; Kerkhof, Marjan; Nolte, Ilja M.; Vonk, Judith; Boezen, H. Marike] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands; [Scholtens, Salome; Postma, Dirkje S.; Kerkhof, Marjan; Koppelman, Gerard H.; Boezen, H. Marike] Univ Groningen, Univ Med Ctr Groningen, Groningen Res Inst Asthma, Groningen, Netherlands; [Scholtens, Salome; Postma, Dirkje S.; Kerkhof, Marjan; Koppelman, Gerard H.; Boezen, H. Marike] Univ Groningen, Univ Med Ctr Groningen, COPD GRIAC, Groningen, Netherlands; [Postma, Dirkje S.] Univ Groningen, Univ Med Ctr Groningen, Dept Pulmonol, Groningen, Netherlands; [Moffatt, Miriam F.; Cookson, William O. C. M.] Univ London Imperial Coll Sci Technol & Med, Div Resp Sci, London, England; [Jarvis, Deborah; Ramasamy, Adaikalavan] Univ London Imperial Coll Sci Technol & Med, London, England; [Panasevich, Sviatlana; Melen, Erik; Nyberg, Fredrik; Pershagen, Goeran] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; [Granell, Raquel; Henderson, A. John] Univ Bristol, Sch Social & Community Med, ALSPAC, Bristol, Avon, England; [Melen, Erik] Karolinska Inst, Sachs Childrens Hosp, Stockholm, Sweden; [Nyberg, Fredrik] AstraZeneca R&D, Global Epidemiol, Molndal, Sweden; Tech Univ Munich, Klinikum Rechts Isar, Inst Med Stat & Epidemiol IMSE, D-80290 Munich, Germany; [Wjst, Matthias] Helmholtz Ctr Munich, Comprehens Pneumol Ctr CPC, Inst Lung Biol & Dis ILBD, Neuherberg, Germany; [Svanes, Cecilie] Univ Bergen, Bergen Resp Res Grp, Inst Med, Bergen, Norway; [Svanes, Cecilie] Haukeland Hosp, Dept Occupat Med, N-5021 Bergen, Norway; [Bouzigon, Emmanuelle; Demenais, Florence] Inserm U946, Genet Variat & Human Dis Unit, Paris, France; [Bouzigon, Emmanuelle; Demenais, Florence] Univ Paris Diderot, Sorbonne Paris Cite, Inst Univ Hematol, Paris, France; [Bouzigon, Emmanuelle; Demenais, Florence] CEPH, Fdn Jean Dausset, Paris, France; [Kauffmann, Francine] CESP Ctr Res Epidemiol & Populat Hlth, Resp & Environm Epidemiol Team, Inserm U1018, Villejuif, France; [Kauffmann, Francine] Univ Paris 11, UMRS 1018, Villejuif, France; [Siroux, Valerie] Inserm U823, Ctr Rech Albert Bonniot, La Tronche, France; [Siroux, Valerie] Univ Grenoble 1, Grenoble, France; [von Mutius, Erika; Ege, Markus Johannes] Univ Childrens Hosp, LMU Munich, Munich, Germany; [Braun-Fahrlaender, Charlotte; Curjuric, Ivan; Imboden, Medea; Thun, Gian A.; Probst-Hensch, Nicole; Kumar, Ashish] Swiss Trop & Publ Hlth Inst, Dept Epidemiol & Publ Hlth, Basel, Switzerland; [Braun-Fahrlaender, Charlotte; Curjuric, Ivan; Imboden, Medea; Thun, Gian A.; Probst-Hensch, Nicole; Kumar, Ashish] Univ Basel, Basel, Switzerland; [Genuneit, Jon] Univ Ulm, Inst Epidemiol & Med Biometry, D-89069 Ulm, Germany; [Brunekreef, Bert] Univ Utrecht, Inst Risk Assessment Sci, Utrecht, Netherlands; [Brunekreef, Bert; Smit, Henriette A.] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Smit, Henriette A.; Wijga, Alet H.] Natl Inst Publ Hlth & Environm, Ctr Prevent & Hlth Serv Res, NL-3720 BA Bilthoven, Netherlands; [Freidin, Maxim B.; Bragina, Elena Iu.; Puzyrev, V. P.] Russian Acad Med Sci, Res Inst Med Genet, Siberian Branch, Tomsk, Russia; [Deev, I. A.; Puzyrev, V. P.] Siberian State Med Univ, Tomsk, Russia; [Daley, Denise; Park, Julie; Pare, Peter] Univ British Columbia, James Hogg ICAPTURE Ctr, Vancouver, BC V5Z 1M9, Canada; [Chan-Yeung, Moira] Univ British Columbia, Occupat & Environm Lung Dis Unit, Vancouver, BC V5Z 1M9, Canada; [Becker, Allan] Univ Manitoba, Winnipeg, MB, Canada; [Kozyrskyj, Anita L.] Univ Alberta, Dept Pediat, Fac Med & Dent, Edmonton, AB, Canada; [Kozyrskyj, Anita L.] Univ Alberta, Sch Publ Hlth, Edmonton, AB, Canada; [Marenholz, Ingo; Lee, Young-Ae] Charite, Pediat Pneumol,Expt & Clin Res Ctr, D-13353 Berlin, Germany; [Lau, Susanne] Charite, D-13353 Berlin, Germany; [Keil, Thomas] Charite, Inst Social Med Epidemiol & Hlth Econ, D-13353 Berlin, Germany; [Marenholz, Ingo; Lee, Young-Ae] Max Delbruck Ctr Mol Med, Berlin, Germany; [Kabesch, Michael] Univ Childrens Hosp Regensburg KUNO, Dept Paediat Pneumol & Allergy, Regensburg, Germany; [Wijmenga, Cisca; Franke, Lude] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, Groningen, Netherlands; [Kumar, Ashish; Farrall, Martin] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England; [Strachan, David P.] Univ London, Div Populat Hlth Sci & Educ, London, England; [Koppelman, Gerard H.] Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp, Dept Pediat Pulmonol & Pediat Allergol, Groningen, Netherlands	University of Groningen; University of Groningen; University of Groningen; University of Groningen; Imperial College London; Imperial College London; Karolinska Institutet; University of Bristol; Karolinska Institutet; AstraZeneca; Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Bergen; University of Bergen; Haukeland University Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Foundation Jean Dausset-CEPH; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; University of Basel; Swiss Tropical & Public Health Institute; University of Basel; Ulm University; Utrecht University; Utrecht University; Utrecht University Medical Center; Netherlands National Institute for Public Health & the Environment; Russian Academy of Medical Sciences; Russian Academy of Sciences; Tomsk National Research Medical Center; Research Institute of Medical Genetics - Tomsk; Siberian State Medical University; University of British Columbia; University of British Columbia; University of Manitoba; University of Alberta; University of Alberta; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Groningen; University of Oxford; Wellcome Centre for Human Genetics; University of London; University of Groningen	Scholtens, S (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands.	h.m.boezen@umcg.nl	Kabesch, Michael/AAB-5701-2020; Bragina, Elena/A-8049-2014; Kabesch, Michael/GZM-1583-2022; Wijmenga, Cisca/AAE-7719-2019; Cookson, William/HHC-1790-2022; Granell, Raquel/AAY-4846-2020; Pare, Peter D/C-7425-2011; Koppelman, Gerard/AAG-9187-2020; Demenais, Florence/G-3298-2013; Granell, Raquel/AAB-5256-2022; Genuneit, Jon/I-9323-2012; Franke, Lude/P-7036-2016; Freidin, Maxim B/A-8222-2014; Bragina, Elena/AAF-7983-2019; Puzyrev, Valery P/S-3144-2016; siroux, valerie/N-1865-2013; Puzyrev, Valery P/A-7925-2014; Vonk, Judith M/ABA-3009-2020; Vonk, Judith/K-8477-2019; Freydin, Maxim/A-5603-2011; Svanes, Cecilie/N-7556-2017; Ramasamy, Adaikalavan/G-2632-2010; Ege, Markus/C-1962-2012; Bouzigon, Emmanuelle/L-2766-2017; Deev, Ivan A/S-5929-2016; Wijmenga, Cisca/D-2173-2009	Bragina, Elena/0000-0002-1103-3073; Wijmenga, Cisca/0000-0002-5635-1614; Demenais, Florence/0000-0001-8361-0936; Granell, Raquel/0000-0002-4890-4012; Genuneit, Jon/0000-0001-5764-1528; Franke, Lude/0000-0002-5159-8802; Freidin, Maxim B/0000-0002-1439-6259; Puzyrev, Valery P/0000-0002-2113-4556; siroux, valerie/0000-0001-7329-7237; Vonk, Judith M/0000-0001-7531-4547; Vonk, Judith/0000-0001-7531-4547; Freydin, Maxim/0000-0002-1439-6259; Svanes, Cecilie/0000-0001-8512-5192; Ramasamy, Adaikalavan/0000-0002-7598-2892; Ege, Markus/0000-0001-6643-3923; Bouzigon, Emmanuelle/0000-0001-5756-4286; Deev, Ivan A/0000-0002-4449-4810; Koppelman, Gerard/0000-0001-8567-3252; Pershagen, Goran/0000-0002-9701-1130; von Mutius, Erika/0000-0002-8893-4515; Jarvis, Deborah/0000-0002-1753-3896; Nyberg, Fredrik/0000-0003-0892-5668; brunekreef, bert/0000-0001-9908-0060; Kumar, Ashish/0000-0002-7075-5930; Thun, Gian Andri/0000-0003-4436-3455; Scholtens, Salome/0000-0002-0651-5203	Medical Research Council [G1000758] Funding Source: Medline; Wellcome Trust [090532, 097117, WT084703MA] Funding Source: Medline; Wellcome Trust [096964/Z/11/Z] Funding Source: researchfish; Asthma UK [MRC-Asthma UK Centre] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); Wellcome Trust(Wellcome TrustEuropean Commission); Asthma UK		Apweiler R, 2012, NUCLEIC ACIDS RES, V40, pD71, DOI 10.1093/nar/gkr981; Bouzigon E, 2008, NEW ENGL J MED, V359, P1985, DOI 10.1056/NEJMoa0806604; Dafou D, 2010, NEOPLASIA, V12, P579, DOI 10.1593/neo.10340; Maritz GS, 2011, INT J ENV RES PUB HE, V8, P875, DOI 10.3390/ijerph8030875; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Panasevich S, 2010, CLIN EXP ALLERGY, V40, P458, DOI 10.1111/j.1365-2222.2010.03452.x; Reijmerink NE, 2009, ALLERGY, V64, P898, DOI 10.1111/j.1398-9995.2009.01939.x; West AB, 2003, J MOL BIOL, V326, P11, DOI 10.1016/S0022-2836(02)01376-1; Wilson GR, 2010, HUM MOL GENET, V19, P1593, DOI 10.1093/hmg/ddq031	9	36	37	0	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2014	133	3					885	888		10.1016/j.jaci.2013.08.049	http://dx.doi.org/10.1016/j.jaci.2013.08.049			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EK	24315450	Green Published, Green Accepted, hybrid, Green Submitted			2022-12-18	WOS:000332397600035
J	Broesby-Olsen, S; Kristensen, T; Vestergaard, H; Brixen, K; Moller, MB; Bindslev-Jensen, C				Broesby-Olsen, Sigurd; Kristensen, Thomas; Vestergaard, Hanne; Brixen, Kim; Moller, Michael Boe; Bindslev-Jensen, Carsten		Mastocytosis Ctr Odense Univ Hosp	KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Indolent systemic mastocytosis; KIT D816V; mutation burden; allele burden; mast cell; anaphylaxis; osteoporosis	BLOOD MONONUCLEAR-CELLS; PERIPHERAL-BLOOD; C-KIT; MAST-CELLS; STANDARDIZATION; PREVALENCE; CLONALITY; FRACTURES; FEATURES; DENSITY	Background: Clinical manifestations of indolent systemic mastocytosis (ISM) comprise mediator-related symptoms, anaphylaxis, and osteoporosis. A new sensitive method for KIT D816V mutation detection allows quantification of the level of mutation-positive cells. Objective: To investigate whether the fraction of KIT D816V positive cells in peripheral blood (PB) or bone marrow (BM) aspirate in adult patients with ISM correlates with clinical manifestations of the disease. Methods: We included 48 adult patients with ISM (28 females/20 males) from our center in whom the KIT D816V mutation level in both BM aspirate and PB was analyzed. For each patient, the severity of mediator-related symptoms (skin, gastrointestinal, musculoskeletal, and neuropsychiatric) and episodes of anaphylaxis were evaluated by interview and medical record files. Bone mineral density was determined by using dual-energy x-ray absorptiometry. Results: Median fraction (range) of KIT D816V positive cells was 0.6 (0.01%-90%) in BM and 0.3 (0.003%-49%) in PB. Mutation level did not differ between patients with none/mild symptoms and patients with moderate/severe symptoms, patients with and without anaphylaxis, or patients with osteoporosis/osteopenia and normal bone mineral density. No significant differences in clinical profile were detected in patients with different levels of mutation except for an indication of longer disease duration and age in patients with highest mutation levels. Conclusion: To our knowledge, this is the first report on the clinical impact of the fraction of KIT D816V mutation positive cells in ISM, which in the present study does not seem to correlate with clinical manifestations of the disease.	[Broesby-Olsen, Sigurd; Bindslev-Jensen, Carsten] Odense Univ Hosp, Dept Dermatol, DK-5000 Odense C, Denmark; [Broesby-Olsen, Sigurd; Bindslev-Jensen, Carsten] Odense Univ Hosp, Allergy Ctr, DK-5000 Odense C, Denmark; [Broesby-Olsen, Sigurd; Vestergaard, Hanne; Brixen, Kim; Moller, Michael Boe; Bindslev-Jensen, Carsten] Univ Southern Denmark, Inst Clin Res, Odense, Denmark; [Kristensen, Thomas; Moller, Michael Boe] Odense Univ Hosp, Dept Pathol, DK-5000 Odense C, Denmark; [Vestergaard, Hanne] Odense Univ Hosp, Dept Hematol, DK-5000 Odense C, Denmark; [Brixen, Kim] Odense Univ Hosp, Dept Endocrinol, DK-5000 Odense C, Denmark	University of Southern Denmark; Odense University Hospital; University of Southern Denmark; Odense University Hospital; University of Southern Denmark; University of Southern Denmark; Odense University Hospital; University of Southern Denmark; Odense University Hospital; University of Southern Denmark; Odense University Hospital	Broesby-Olsen, S (corresponding author), Odense Univ Hosp, Dept Dermatol, Sdr Blvd 29, DK-5000 Odense C, Denmark.	sigurd.broesby-olsen@ouh.regionsyddanmark.dk	Bindslev-Jensen, Carsten/H-1877-2011; Møller, Michael Boe/AAD-2113-2019; Møller, Michael B/G-8340-2016	Bindslev-Jensen, Carsten/0000-0002-8940-038X; Møller, Michael Boe/0000-0003-2041-3630; Møller, Michael B/0000-0003-2041-3630				Akin C, 2005, ACTA HAEMATOL-BASEL, V114, P61, DOI 10.1159/000085563; Akin C, 2010, J ALLERGY CLIN IMMUN, V126, P1099, DOI 10.1016/j.jaci.2010.08.035; Brockow K, 2008, ALLERGY, V63, P226, DOI 10.1111/j.1398-9995.2007.01569.x; Brown SGA, 2004, J ALLERGY CLIN IMMUN, V114, P371, DOI 10.1016/j.jaci.2004.04.029; de Olano DG, 2007, CLIN EXP ALLERGY, V37, P1547, DOI 10.1111/j.1365-2222.2007.02804.x; Escribano L, 2009, J ALLERGY CLIN IMMUN, V124, P514, DOI 10.1016/j.jaci.2009.05.003; Hanson J, 1997, J BONE MINER RES, V12, P1316, DOI 10.1359/jbmr.1997.12.8.1316; Horny HP, 2008, WHO CLASSIFICATION T, P54; Iwaki S, 2008, CELL SIGNAL, V20, P195, DOI 10.1016/j.cellsig.2007.10.013; Kristensen T, 2012, EUR J HAEMATOL, V89, P42, DOI 10.1111/j.1600-0609.2012.01789.x; Kristensen T, 2011, J MOL DIAGN, V13, P180, DOI 10.1016/j.jmoldx.2010.10.004; Kushnir-Sukhov NM, 2006, INT ARCH ALLERGY IMM, V139, P265, DOI 10.1159/000091172; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; Metcalfe DD, 2008, BLOOD, V112, P946, DOI 10.1182/blood-2007-11-078097; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; Pardanani A, 2010, CURR OPIN HEMATOL, V17, P125, DOI 10.1097/MOH.0b013e3283366c59; Rossini M, 2011, BONE, V49, P880, DOI 10.1016/j.bone.2011.07.004; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Siebenhaar F, 2007, J ALLERGY CLIN IMMUN, V120, P213, DOI 10.1016/j.jaci.2007.05.011; Valent P, 2007, EUR J CLIN INVEST, V37, P435, DOI 10.1111/j.1365-2362.2007.01807.x; van der Veer E, 2012, ALLERGY, V67, P431, DOI 10.1111/j.1398-9995.2011.02780.x; Worobec AS, 1998, CANCER, V83, P2120, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2120::AID-CNCR10>3.0.CO;2-C; Zhao W, 2007, LEUKEMIA, V21, P1574, DOI 10.1038/sj.leu.2404680	23	36	36	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2013	132	3					723	728		10.1016/j.jaci.2013.02.019	http://dx.doi.org/10.1016/j.jaci.2013.02.019			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207OS	23587333				2022-12-18	WOS:000323612000025
J	Wildbaum, G; Shahar, E; Katz, R; Karin, N; Etzioni, A; Pollack, S				Wildbaum, Gizi; Shahar, Eduardo; Katz, Rina; Karin, Nathan; Etzioni, Amos; Pollack, Shimon			RETRACTED: Continuous G-CSF therapy for isolated chronic mucocutaneous candidiasis: Complete clinical remission with restoration of IL-17 secretion (Retracted article. See vol. 141, pg. 1167, 2018)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter; Retracted Publication							IMMUNITY		[Wildbaum, Gizi; Shahar, Eduardo; Karin, Nathan; Etzioni, Amos; Pollack, Shimon] Technion Israel Inst Technol, Rappaport Fac Med, Dept Immunol, Haifa, Israel; [Shahar, Eduardo; Katz, Rina; Etzioni, Amos; Pollack, Shimon] Rambam Hlth Care Campus, Inst Allergy Immunol & AIDS, Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Rambam Health Care Campus	Wildbaum, G (corresponding author), Technion Israel Inst Technol, Rappaport Fac Med, Dept Immunol, Haifa, Israel.	pollack@rambam.health.gov.il						Cypowyj S, 2012, EUR J IMMUNOL, V42, P2246, DOI 10.1002/eji.201242605; Hanna S, 2011, J ALLERGY CLIN IMMUN, V127, P1433, DOI 10.1016/j.jaci.2011.03.026; Liu LY, 2011, J EXP MED, V208, P1635, DOI 10.1084/jem.20110958; McGeachy MJ, 2011, NAT IMMUNOL, V12, P521, DOI 10.1038/ni.2044; Milner JD, 2008, NATURE, V452, P773, DOI 10.1038/nature06764; Puel A, 2010, J EXP MED, V207, P291, DOI 10.1084/jem.20091983; SHAHAR E, 1995, LANCET, V346, P974, DOI 10.1016/S0140-6736(95)91599-0; Tamiya T, 2012, ARTERIOSCLER THROMB, P981; TIAN SS, 1994, BLOOD, V84, P1760; Zielinski CE, 2012, NATURE, V484, P514, DOI 10.1038/nature10957	10	36	40	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2013	132	3					761	764		10.1016/j.jaci.2013.04.018	http://dx.doi.org/10.1016/j.jaci.2013.04.018			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207OS	23791509				2022-12-18	WOS:000323612000037
J	Kamae, C; Nakagawa, N; Sato, H; Honma, K; Mitsuiki, N; Ohara, O; Kanegane, H; Pasic, S; Pan-Hammarstrom, Q; van Zelm, MC; Morio, T; Imai, K; Nonoyama, S				Kamae, Chikako; Nakagawa, Noriko; Sato, Hiroki; Honma, Kenichi; Mitsuiki, Noriko; Ohara, Osamu; Kanegane, Hirokazu; Pasic, Srdjan; Pan-Hammarstrom, Qiang; van Zelm, Menno C.; Morio, Tomohiro; Imai, Kohsuke; Nonoyama, Shigeaki			Common variable immunodeficiency classification by quantifying T-cell receptor and immunoglobulin kappa-deleting recombination excision circles	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							B-CELL; IMMUNE-DEFICIENCY		[Kamae, Chikako; Nakagawa, Noriko; Honma, Kenichi; Imai, Kohsuke; Nonoyama, Shigeaki] Natl Def Med Coll, Dept Pediat, Saitama, Japan; [Sato, Hiroki] Natl Def Med Coll, Dept Prevent Med & Publ Hlth, Saitama, Japan; [Mitsuiki, Noriko; Ohara, Osamu] Kazusa DNA Res Inst, Dept Human Genome Res, Chiba, Japan; [Mitsuiki, Noriko; Morio, Tomohiro] Tokyo Med & Dent Univ, Dept Pediat, Tokyo, Japan; [Kanegane, Hirokazu] Toyama Univ, Dept Pediat, Toyama 930, Japan; [Pasic, Srdjan] Univ Belgrade, Fac Med, Dept Immunol, Mother & Child Hlth Inst, Belgrade, Serbia; [Pan-Hammarstrom, Qiang] Karolinska Inst, Karolinska Univ Hosp, Dept Lab Med, Stockholm, Sweden; [van Zelm, Menno C.] Univ Med Ctr, Erasmus MC, Dept Immunol, Rotterdam, Netherlands	National Defense Medical College - Japan; National Defense Medical College - Japan; Kazusa DNA Research Institute; Tokyo Medical & Dental University (TMDU); University of Toyama; University of Belgrade; Karolinska Institutet; Karolinska University Hospital; Erasmus University Rotterdam; Erasmus MC	Kamae, C (corresponding author), Natl Def Med Coll, Dept Pediat, Saitama, Japan.	kimai.ped@tmd.ac.jp	van Zelm, Menno C/O-4404-2015; hammarstrom, qiang pan/ABA-4589-2021; Ohara, Osamu/G-5448-2015; Imai, Kohsuke/Q-2602-2015	van Zelm, Menno C/0000-0003-4161-1919; Ohara, Osamu/0000-0002-3328-9571; Imai, Kohsuke/0000-0003-2132-8403; pan-hammarstrom, qiang/0000-0003-1990-8804; Sato, Hiroki/0000-0002-6061-1511				Chapel H, 2008, BLOOD, V112, P277, DOI 10.1182/blood-2007-11-124545; Moratto D, 2006, CLIN IMMUNOL, V121, P203, DOI 10.1016/j.clim.2006.07.003; Morinishi Y, 2009, J PEDIATR-US, V155, P829, DOI 10.1016/j.jpeds.2009.05.026; Nakagawa N, 2011, J ALLERGY CLIN IMMUN, V128, P223, DOI 10.1016/j.jaci.2011.01.052; Resnick ES, 2012, BLOOD, V119, P1650, DOI 10.1182/blood-2011-09-377945; Rizzi M, 2011, J ALLERGY CLIN IMMUN, V128, P1371, DOI 10.1016/j.jaci.2011.07.055; van Zelm MC, 2007, J EXP MED, V204, P645, DOI 10.1084/jem.20060964; Verbsky JW, 2012, J CLIN IMMUNOL, V32, P82, DOI 10.1007/s10875-011-9609-4; Yong PFK, 2011, ADV IMMUNOL, V111, P47, DOI 10.1016/B978-0-12-385991-4.00002-7	9	36	36	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2013	131	5					1437	+		10.1016/j.jaci.2012.10.059	http://dx.doi.org/10.1016/j.jaci.2012.10.059			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	144AU	23273952				2022-12-18	WOS:000318912200030
J	Varga, EM; Kausar, F; Aberer, W; Zach, M; Eber, E; Durham, SR; Shamji, MH				Varga, Eva-Maria; Kausar, Fahima; Aberer, Werner; Zach, Maximilian; Eber, Ernst; Durham, Stephen R.; Shamji, Mohamed H.			Tolerant beekeepers display venom-specific functional IgG(4) antibodies in the absence of specific IgE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							IMMUNOTHERAPY; BINDING; CHILDREN; CELLS		[Varga, Eva-Maria; Zach, Maximilian; Eber, Ernst] Med Univ Graz, Dept Paediat, Resp & Allerg Dis Div, Graz, Austria; [Kausar, Fahima; Durham, Stephen R.; Shamji, Mohamed H.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW7 2AZ, England; [Aberer, Werner] Med Univ Graz, Dept Environm Dermatol & Allergy, Graz, Austria	Medical University of Graz; Imperial College London; Medical University of Graz	Varga, EM (corresponding author), Med Univ Graz, Dept Paediat, Resp & Allerg Dis Div, Graz, Austria.	s.durham@imperial.ac.uk	Shamji, Mohamed/AAD-1788-2019; Shamji, Mohamed/AAU-8811-2020	Shamji, Mohamed/0000-0003-3425-3463	Medical Research Council [G1000758B] Funding Source: researchfish; National Institute for Health Research [NF-SI-0508-10212] Funding Source: researchfish; MRC [G0601303] Funding Source: UKRI; Medical Research Council [G0601303, G1000758] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Golden DBK, 2004, NEW ENGL J MED, V351, P668, DOI 10.1056/NEJMoa022952; James LK, 2011, J ALLERGY CLIN IMMUN, V127, P509, DOI 10.1016/j.jaci.2010.12.1080; Meiler F, 2008, J EXP MED, V205, P2887, DOI 10.1084/jem.20080193; Shamji MH, 2006, J IMMUNOL METHODS, V317, P71, DOI 10.1016/j.jim.2006.09.004; Varga EM, 2009, CLIN EXP ALLERGY, V39, P1353, DOI 10.1111/j.1365-2222.2009.03303.x; Wachholz PA, 2003, J ALLERGY CLIN IMMUN, V112, P915, DOI 10.1016/S0091-6749(03)02022-0	6	36	37	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2013	131	5					1419	1421		10.1016/j.jaci.2012.08.037	http://dx.doi.org/10.1016/j.jaci.2012.08.037			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	144AU	23063581				2022-12-18	WOS:000318912200021
J	Maslova, E; Granstrom, C; Hansen, S; Petersen, SB; Strom, M; Willett, WC; Olsen, SF				Maslova, Ekaterina; Granstrom, Charlotta; Hansen, Susanne; Petersen, Sesilje B.; Strom, Marin; Willett, Walter C.; Olsen, Sjurdur F.			Peanut and tree nut consumption during pregnancy and allergic disease in children-should mothers decrease their intake? Longitudinal evidence from the Danish National Birth Cohort	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cohort; pregnancy; peanuts; tree nuts; asthma; wheeze; allergic rhinitis	T-HELPER-1 CYTOKINE PRODUCTION; ASTHMA PRIMARY PREVENTION; GOVERNMENT ADVICE; CHILDHOOD ASTHMA; ZINC-DEFICIENCY; ATOPIC ECZEMA; FATTY-ACIDS; RISK-FACTOR; AVOIDANCE; SENSITIZATION	Background: The relation between maternal peanut intake during pregnancy and allergic disease development in children has been controversial. Objective: We used data from the Danish National Birth Cohort to examine associations between maternal peanut and tree nut intake during pregnancy and allergic outcomes in children at 18 months and 7 years of age. Methods: We estimated maternal peanut and tree nut intake (n = 61,908) using a validated midpregnancy food frequency questionnaire. At 18 months, we used parental report of childhood asthma diagnosis, wheeze symptoms, and recurrent wheeze (>3 episodes). We defined current asthma at 7 years as doctor-diagnosed asthma plus wheeze in the past 12 months and allergic rhinitis as a self-reported doctor's diagnosis. We also used alternative classifications based on registry-based International Classification of Diseases, Tenth Revision, codes and drug dispensary data. We report here odds ratios (ORs) comparing intake of 1 or more times per week versus no intake. Results: We found that maternal intake of peanuts (OR, 0.79; 95% CI, 0.65-0.97) and tree nuts (OR, 0.75; 95% CI, 0.67-0.84) was inversely associated with asthma in children at 18 months of age. Compared with mothers consuming no peanuts, children whose mothers reported eating peanuts 1 or more times per week were 0.66 (95% CI, 0.44-0.98) and 0.83 (95% CI, 0.70-1.00) times as likely to have a registry-based and medication-related asthma diagnosis, respectively. Higher tree nut intake was inversely associated with a medication-related asthma diagnosis (OR, 0.81; 95% CI, 0.73-0.90) and self-reported allergic rhinitis (OR, 0.80; 95% CI, 0.64-1.01). Conclusions: Our results do not suggest that women should decrease peanut and tree nut intake during pregnancy; instead, consumption of peanuts and tree nuts during pregnancy might even decrease the risk of allergic disease development in children. (J Allergy Clin Immunol 2012;130:724-32.)	[Maslova, Ekaterina; Willett, Walter C.; Olsen, Sjurdur F.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; [Maslova, Ekaterina; Willett, Walter C.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; [Granstrom, Charlotta; Hansen, Susanne; Petersen, Sesilje B.; Strom, Marin; Olsen, Sjurdur F.] Statens Serum Inst, Dept Epidemiol Res, Ctr Fetal Programming, DK-2300 Copenhagen, Denmark	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Statens Serum Institut	Maslova, E (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave,Bldg 2, Boston, MA 02115 USA.	emaslova@post.harvard.edu	Hansen, Susanne/F-1657-2017; Hansen, Susanne/AAE-7275-2021	Olsen, Sjurdur/0000-0003-3017-7096; Strom, Marin/0000-0003-1926-6610	Danish Council for Strategic Research [09-067124]; Danish Council for Independent Research \ Medical Sciences; Danish Agency for Science, Technology and Innovation [09-063410]; Lundbeck foundation [R13-A907]; European Union ( EU) Integrated Research Project EARNEST [FOOD-CT-2005-007036]; Commission of the European Communities; March of Dimes Birth Defects Foundation; Danish Heart Association; Danish Medical Research Council; Sygekassernes Helsefond; Danish National Research Foundation; Danish Pharmaceutical Association; Ministry of Health; National Board of Health; Statens Serum Institut	Danish Council for Strategic Research(Danske Strategiske Forskningsrad (DSF)); Danish Council for Independent Research \ Medical Sciences(Det Frie Forskningsrad (DFF)); Danish Agency for Science, Technology and Innovation; Lundbeck foundation(Lundbeckfonden); European Union ( EU) Integrated Research Project EARNEST; Commission of the European Communities(European Commission); March of Dimes Birth Defects Foundation(March of Dimes); Danish Heart Association; Danish Medical Research Council(Danish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Sygekassernes Helsefond; Danish National Research Foundation(Danmarks Grundforskningsfond); Danish Pharmaceutical Association; Ministry of Health; National Board of Health; Statens Serum Institut	Supported by the Danish Council for Strategic Research (09-067124); the Danish Council for Independent Research vertical bar Medical Sciences, the Danish Agency for Science, Technology and Innovation (09-063410); the Lundbeck foundation (R13-A907); and the European Union ( EU) Integrated Research Project EARNEST (FOOD-CT-2005-007036). The EU project EARNEST (http://www.metabolic-programming.org) receives financial support from the Commission of the European Communities under the FP 6 priority 5: food quality and safety. The Danish National Birth Cohort has been financed by the March of Dimes Birth Defects Foundation, the Danish Heart Association, the Danish Medical Research Council, Sygekassernes Helsefond, the Danish National Research Foundation, the Danish Pharmaceutical Association, the Ministry of Health, the National Board of Health, and the Statens Serum Institut.	Almqvist C, 2010, PAEDIATR PERINAT EP, V24, P171, DOI 10.1111/j.1365-3016.2010.01095.x; [Anonymous], 2002, FORSKN DAT DANM STAT; ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Azzi A, 2004, ANN NY ACAD SCI, V1031, P86, DOI 10.1196/annals.1331.009; Becker A, 2004, J ALLERGY CLIN IMMUN, V113, P650, DOI 10.1016/j.jaci.2004.01.754; Calder PC, 2006, AM J CLIN NUTR, V83, p1505S, DOI 10.1093/ajcn/83.6.1505S; Chan-Yeung M, 2005, J ALLERGY CLIN IMMUN, V116, P49, DOI 10.1016/j.jaci.2005.03.029; CHANDRA RK, 1989, BMJ-BRIT MED J, V299, P228, DOI 10.1136/bmj.299.6693.228; Chatzi L, 2008, THORAX, V63, P507, DOI 10.1136/thx.2007.081745; Chen CM, 2010, INT J HYG ENVIR HEAL, V213, P1, DOI 10.1016/j.ijheh.2009.12.003; D Zalewski P, 2006, CURR OPIN PHARMACOL, V6, P237, DOI 10.1016/j.coph.2006.01.005; Dean T, 2007, J HUM NUTR DIET, V20, P95, DOI 10.1111/j.1365-277X.2007.00751.x; DesRoches A, 2010, J INVEST ALLERG CLIN, V20, P289; Devereux G, 2007, CLIN EXP ALLERGY, V37, P1000, DOI 10.1111/j.1365-2222.2007.02757.x; Devereux G, 2006, AM J RESP CRIT CARE, V174, P499, DOI 10.1164/rccm.200512-1946OC; Drever N, 2010, CURR ALLERGY ASTHM R, V10, P453, DOI 10.1007/s11882-010-0136-9; Du Toit G, 2008, J ALLERGY CLIN IMMUN, V122, P984, DOI 10.1016/j.jaci.2008.08.039; Fox AT, 2009, J ALLERGY CLIN IMMUN, V123, P417, DOI 10.1016/j.jaci.2008.12.014; Frank L, 1999, PEDIATR ALLERGY IMMU, V10, P27, DOI 10.1034/j.1399-3038.1999.101010.x; Gurka MJ, 2009, J PEDIATR-US, V155, P781, DOI 10.1016/j.jpeds.2009.06.035; Han SN, 2000, IMMUNOLOGY, V100, P487, DOI 10.1046/j.1365-2567.2000.00070.x; Hederos CA, 2007, PEDIAT ALLERG IMM-UK, V18, P135, DOI 10.1111/j.1399-3038.2006.00474.x; Islam S, 1999, J PEDIATR SURG, V34, P172, DOI 10.1016/S0022-3468(99)90251-8; Jensen Annette Ostergaard, 2010, Clin Epidemiol, V2, P67; King JG, 2008, J NUTR, V138, p1736S, DOI 10.1093/jn/138.9.1736S; Kramer MS, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000133.pub2; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Li-Weber M, 2002, EUR J IMMUNOL, V32, P2401, DOI 10.1002/1521-4141(200209)32:9&lt;2401::AID-IMMU2401&gt;3.0.CO;2-S; Litonjua AA, 2006, AM J CLIN NUTR, V84, P903, DOI 10.1093/ajcn/84.4.903; Malmberg KJ, 2002, CLIN CANCER RES, V8, P1772; McLean S, 2010, BMJ-BRIT MED J, V340, P593; Mikkelsen TB, 2006, PUBLIC HEALTH NUTR, V9, P771, DOI 10.1079/PHN2005883; Miles L, 2010, NUTR BULL, V35, P240, DOI 10.1111/j.1467-3010.2010.01839.x; Miyake Y, 2009, THORAX, V64, P815, DOI 10.1136/thx.2009.115931; Moth G, 2007, ACTA PAEDIATR, V96, P1470, DOI 10.1111/j.1651-2227.2007.00460.x; Moth G, 2007, EUR J CLIN PHARMACOL, V63, P605, DOI 10.1007/s00228-007-0286-4; Nwaru BI, 2010, PEDIAT ALLERG IMM-UK, V21, P29, DOI 10.1111/j.1399-3038.2009.00949.x; Osborn DA, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003664; Osterballe M, 2005, PEDIAT ALLERG IMM-UK, V16, P567, DOI 10.1111/j.1399-3038.2005.00251.x; Prasad AS, 2000, J INFECT DIS, V182, pS62, DOI 10.1086/315916; Richter M, 2003, CHEST, V123, p446S, DOI 10.1378/chest.123.3_suppl.446S; Ryan E, 2006, INT J FOOD SCI NUTR, V57, P219, DOI 10.1080/09637480600768077; Saxholt E, 2008, FOOD COMPOSITION DAT; Shaheen SO, 2008, AM J RESP CRIT CARE, V178, P113, DOI 10.1164/rccm.200804-546ED; Shaheen SO, 2004, EUR RESPIR J, V24, P292, DOI 10.1183/09031936.04.00117803; Sicherer SH, 2008, BR J NUTR, V103, P1278; Thijs C, 2011, ALLERGY, V66, P58, DOI 10.1111/j.1398-9995.2010.02445.x; VOJNIK C, 1977, J NUTR, V107, P862, DOI 10.1093/jn/107.5.862; Willers SM, 2008, AM J RESP CRIT CARE, V178, P124, DOI 10.1164/rccm.200710-1544OC; Willett W, 2012, NUTR EPIDEMIOLOGY; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9; ZEIGER RS, 1989, J ALLERGY CLIN IMMUN, V84, P72, DOI 10.1016/0091-6749(89)90181-4	53	36	38	0	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2012	130	3					724	732		10.1016/j.jaci.2012.05.014	http://dx.doi.org/10.1016/j.jaci.2012.05.014			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	001LZ	22743306				2022-12-18	WOS:000308463500022
J	Brown, SGA; Wiese, MD; van Eeden, P; Stone, SF; Chuter, CL; Gunner, J; Wanandy, T; Phillips, M; Heddle, RJ				Brown, Simon G. A.; Wiese, Michael D.; van Eeden, Pauline; Stone, Shelley F.; Chuter, Christine L.; Gunner, Jareth; Wanandy, Troy; Phillips, Michael; Heddle, Robert J.			Ultrarush versus semirush initiation of insect venom immunotherapy: A randomized controlled trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Insect sting allergy; anaphylaxis; immunotherapy; venom immunotherapy; randomized controlled trial	JUMPER ANT VENOM; ALLERGY; SAFETY; ANAPHYLAXIS; HYPERSENSITIVITY; MANAGEMENT; INDUCTION; PROTOCOLS; SEVERITY; WASP	Background: Venom immunotherapy can be initiated by different schedules, but randomized comparisons have not been performed. Objective: We aimed to compare the safety of 2 initiation schedules. Methods: Patients of any age with prior immediate generalized reactions to jack jumper ant (Myrmecia pilosula) stings were randomized to venom immunotherapy initiation by a semirush schedule over 10 visits (9 weeks) or an ultrarush schedule over 3 visits (2 weeks). In a concurrent treatment efficacy study, the target maintenance dose was randomized to either 50 mu g or 100 mu g. The primary outcome was the occurrence of 1 or more objective systemic reactions during venom immunotherapy initiation. Analyses were by intention to treat. We also assessed outcomes in patients who declined randomization. Results: Of 213 eligible patients, 93 were randomized to semirush (44 patients) or ultrarush (49 patients) initiation. Objective systemic reactions were more likely during ultrarush initiation (65% vs 29%; P <. 001), as were severe reactions (12% vs 0%; P = .029). Times to maximal increases in venom-specific IgG(4) were no different between treatments, whereas the maximal increase in venom-specific IgE occurred earlier with ultrarush treatment. Similar differences between methods were observed in patients who declined randomization. One hundred seventy-eight patients were randomized to maintenance doses of either 50 mu g (90 patients) or 100 mu g (88 patients). The target maintenance dose had no effect on the primary outcome, but multiple-failure-per-subject analysis found that the 50 mg dose reduced the likelihood of reactions. Conclusion: Ultrarush initiation increases the risk of systemic reactions. A lower maintenance dose reduces the risk of repeated reactions, but the effect on treatment efficacy is unknown. (J Allergy Clin Immunol 2012;130:162-8.)	[Brown, Simon G. A.] Royal Perth Hosp, Dept Emergency Med, Perth, WA 6001, Australia; [Brown, Simon G. A.; Wiese, Michael D.; Chuter, Christine L.; Gunner, Jareth; Wanandy, Troy] Royal Hobart Hosp, Jack Jumper Allergy Program, Hobart, Tas, Australia; [Wanandy, Troy] Royal Hobart Hosp, Dept Pharm, Hobart, Tas, Australia; [Brown, Simon G. A.; van Eeden, Pauline; Stone, Shelley F.] Univ Western Australia, Ctr Clin Res Emergency Med, Perth, WA 6009, Australia; [Phillips, Michael] Univ Western Australia, Western Australian Inst Med Res, Clin Trials WA, Perth, WA 6009, Australia; [Wiese, Michael D.] Univ S Australia, Sansom Inst Hlth Res, Adelaide, SA 5001, Australia; [Wanandy, Troy] Univ Tasmania, Menzies Res Inst Tasmania, Hobart, Tas, Australia; [Heddle, Robert J.] SA Pathol, Clin Immunol Units, Adelaide, SA, Australia; [Heddle, Robert J.] Royal Adelaide Hosp, Adelaide, SA 5000, Australia; [Heddle, Robert J.] Flinders Univ S Australia, Sch Med, Bedford Pk, SA 5042, Australia	Royal Perth Hospital; University of Western Australia; Royal Hobart Hospital; Royal Hobart Hospital; University of Western Australia; University of Western Australia; University of South Australia; University of Tasmania; SA Pathology; Royal Adelaide Hospital; Flinders University South Australia	Brown, SGA (corresponding author), Royal Perth Hosp, Dept Emergency Med, GPO Box X2213, Perth, WA 6001, Australia.	simon.brown@uwa.edu.au	van Eeden, Pauline/H-4952-2014; Wiese, Michael D/A-4743-2011; Stone, Shelley/C-3804-2013; van Eeden, Pauline/O-8713-2014	Wiese, Michael D/0000-0002-3255-9242; Phillips, Michael/0000-0002-0252-9085; Brown, Simon/0000-0002-9961-0890	Department of Health and Human Services, Tasmanian Government; Royal Perth Hospital Medical Research Foundation, Western Australia; Australian National Health and Medical Research Council (NHMRC) [513901]; National Health and Medical Research Council (NHMRC) Australia; Department of Health and Human Services (DHHS) Tasmania; DHHS; Royal Perth Hospital Medical Research Foundation; Australian NHMRC	Department of Health and Human Services, Tasmanian Government; Royal Perth Hospital Medical Research Foundation, Western Australia; Australian National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); National Health and Medical Research Council (NHMRC) Australia(National Health and Medical Research Council (NHMRC) of Australia); Department of Health and Human Services (DHHS) Tasmania; DHHS; Royal Perth Hospital Medical Research Foundation; Australian NHMRC(National Health and Medical Research Council (NHMRC) of Australia)	This research was sponsored and funded by the Department of Health and Human Services, Tasmanian Government. The Royal Perth Hospital Medical Research Foundation, Western Australia, provided funding for the laboratory studies. S. G. A. B. was supported by the Australian National Health and Medical Research Council (NHMRC), Career Development Award 513901. The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or the writing of the report.; Disclosure of potential conflict of interest: S. G. A. Brown and M. D. Wiese received research support from the National Health and Medical Research Council (NHMRC) Australia and the Department of Health and Human Services (DHHS) Tasmania. T. Wanandy is employed by the DHHS Tasmania. R. J. Heddle received research support from the DHHS, the Royal Perth Hospital Medical Research Foundation, and the Australian NHMRC. The rest of the authors declare that they have no relevant conflicts of interest.	BIRNBAUM J, 1993, CLIN EXP ALLERGY, V23, P226, DOI 10.1111/j.1365-2222.1993.tb00886.x; Birnbaum J, 2003, CLIN EXP ALLERGY, V33, P58, DOI 10.1046/j.1365-2222.2003.01564.x; Brehler R, 2000, J ALLERGY CLIN IMMUN, V105, P1231, DOI 10.1067/mai.2000.105708; Brown SGA, 2004, J ALLERGY CLIN IMMUN, V114, P371, DOI 10.1016/j.jaci.2004.04.029; Brown SGA, 2003, LANCET, V361, P1001, DOI 10.1016/S0140-6736(03)12827-9; Elberink JNGO, 2002, J ALLERGY CLIN IMMUN, V110, P174, DOI 10.1067/mai.2002.125827; Golden DBK, 2004, NEW ENGL J MED, V351, P668, DOI 10.1056/NEJMoa022952; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; Krishna MT, 2011, CLIN EXP ALLERGY, V41, P1201, DOI 10.1111/j.1365-2222.2011.03788.x; Ozdemir C, 2011, CLIN EXP ALLERGY, V41, P1226, DOI 10.1111/j.1365-2222.2011.03812.x; Pumphrey RSH, 2000, CLIN EXP ALLERGY, V30, P1144, DOI 10.1046/j.1365-2222.2000.00864.x; Roll A, 2006, J INVEST ALLERG CLIN, V16, P79; Rueff F, 2010, J ALLERGY CLIN IMMUN, V126, P105, DOI 10.1016/j.jaci.2010.04.025; Sturm G, 2002, J ALLERGY CLIN IMMUN, V110, P928, DOI 10.1067/mai.2002.129124; van Eeden PE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016741; VANDERLINDEN PWG, 1994, J ALLERGY CLIN IMMUN, V94, P151, DOI 10.1053/ai.1994.v94.a54889; Wachholz PA, 2003, CLIN EXP ALLERGY, V33, P1171, DOI 10.1046/j.1365-2222.2003.01765.x; Wiese MD, 2007, ALLERGY, V62, P437, DOI 10.1111/j.1398-9995.2007.01320.x; Wiese MD, 2008, J PHARMACEUT BIOMED, V46, P58, DOI 10.1016/j.jpba.2007.08.028; Wiese MD, 2011, J PHARMACEUT BIOMED, V54, P303, DOI 10.1016/j.jpba.2010.08.024	20	36	36	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2012	130	1					162	168		10.1016/j.jaci.2012.02.022	http://dx.doi.org/10.1016/j.jaci.2012.02.022			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	977GN	22460067				2022-12-18	WOS:000306644800024
J	Simpson, EL; Keck, LE; Chalmers, JR; Williams, HC				Simpson, Eric L.; Keck, Laura E.; Chalmers, Joanne R.; Williams, Hywel C.			How should an incident case of atopic dermatitis be defined? A systematic review of primary prevention studies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Outcomes; atopic dermatitis; eczema; systematic review; definition; incident case; disease criteria	PLACEBO-CONTROLLED TRIAL; RANDOMIZED CONTROLLED-TRIAL; HIGH-RISK INFANTS; FISH-OIL SUPPLEMENTATION; 1ST 6 MONTHS; LINOLENIC ACID SUPPLEMENTATION; PARTIAL WHEY HYDROLYSATE; BRIEF NEONATAL EXPOSURE; DOUBLE-BLIND TRIAL; 5-YEAR FOLLOW-UP	Background: Eczema prevention is now an active area of dermatologic and allergy research. Defining an incident case is therefore a prerequisite for such a study. Objective: We sought to examine how an incident case of atopic dermatitis was defined in previous atopic dermatitis prevention studies in order to make recommendations on a standard definition of new atopic dermatitis cases for use in future prevention trials. Methods: We conducted a systematic review of controlled interventional atopic dermatitis prevention studies by using searches of MEDLINE and Cochrane databases for studies published from 1980 to the end of January 2011. Studies that included atopic dermatitis as a secondary outcome, such as asthma prevention trials, were included. Results: One hundred two studies were included in the final analysis, of which 27 (26.5%) did not describe any criteria for defining an incident case of atopic dermatitis. Of the remaining 75 studies with reported disease criteria, the Hanifin-Rajka criteria were the most commonly used (28 studies). A disease definition unique to that particular study (21 studies) was the second most commonly used disease definition, although the sources for such novel definitions were not cited. Conclusions: The results from this systematic review highlight the need for improved reporting and standardization of the definition used for an incident case in atopic dermatitis prevention studies. Most prevention studies have used disease definitions such as the Hanifin-Rajka criteria that include disease chronicity. While acceptable for cumulative incidence outcomes, inclusion of disease chronicity precludes the precise measurement of disease onset. We propose a definition based on existing scientific studies that could be used in future prospective studies. (J Allergy Clin Immunol 2012;130:137-44.)	[Simpson, Eric L.; Keck, Laura E.] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97239 USA; [Chalmers, Joanne R.; Williams, Hywel C.] Univ Nottingham, Ctr Evidence Based Dermatol, Nottingham NG7 2RD, England	Oregon Health & Science University; University of Nottingham	Simpson, EL (corresponding author), Oregon Hlth & Sci Univ, Dept Dermatol, 3303 SW Bond Ave, Portland, OR 97239 USA.	simpsone@ohsu.edu		williams, hywel/0000-0002-5646-3093; Chalmers, Joanne/0000-0002-2281-7367	Oregon Clinical and Translational Research Institute; National Institute of Arthritis and Musculoskeletal and Skin Diseases [K23AR057486]; UK National Institute for Health Research (NIHR) [RP-PG-0407-10177]; National Institute for Health Research; National Institute for Health Research [RP-PG-0407-10177] Funding Source: researchfish; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K23AR057486] Funding Source: NIH RePORTER	Oregon Clinical and Translational Research Institute; National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); UK National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); National Institute for Health Research(National Institute for Health Research (NIHR)); National Institute for Health Research(National Institute for Health Research (NIHR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This project was supported by Oregon Clinical and Translational Research Institute and by award no. K23AR057486 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. H. C. W. and J.R.C. contributed to this article as part of a UK National Institute for Health Research (NIHR) Programme Grant for Applied Research funding scheme (grant no. RP-PG-0407-10177). The views expressed in this publication are those of the author(s) and not necessarily those of the National Health Service, the NIHR, or the Department of Health in England.; Disclosure of potential conflict of interest: H. C. Williams has received research support from the National Institute for Health Research. The rest of the authors declare that they have no relevant conflicts of interest.	Abrahamsson TR, 2007, J ALLERGY CLIN IMMUN, V119, P1174, DOI 10.1016/j.jaci.2007.01.007; Almqvist C, 2007, J ALLERGY CLIN IMMUN, V119, P1438, DOI 10.1016/j.jaci.2007.01.046; ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; Arslanoglu S, 2008, J NUTR, V138, P1091, DOI 10.1093/jn/138.6.1091; Bottcher MF, 2008, PEDIAT ALLERG IMM-UK, V19, P497, DOI 10.1111/j.1399-3038.2007.00687.x; Brenninkmeijer EEA, 2008, BRIT J DERMATOL, V158, P754, DOI 10.1111/j.1365-2133.2007.08412.x; BRUNO G, 1993, ALLERGY PROC, V14, P181, DOI 10.2500/108854193778878682; BURR ML, 1989, J EPIDEMIOL COMMUN H, V43, P125, DOI 10.1136/jech.43.2.125; BURR ML, 1993, ARCH DIS CHILD, V68, P724, DOI 10.1136/adc.68.6.724; BUSINCO L, 1987, ANN ALLERGY, V59, P183; BUSINCO L, 1983, ANN ALLERGY, V51, P296; Chamlin SL, 2009, PEDIATR DERMATOL, V26, P247, DOI 10.1111/j.1525-1470.2008.00807.x; Chan YH, 2002, J PAEDIATR CHILD H, V38, P84, DOI 10.1046/j.1440-1754.2002.00725.x; CHANDRA RK, 1989, BMJ-BRIT MED J, V299, P228, DOI 10.1136/bmj.299.6693.228; CHANDRA RK, 1989, ANN ALLERGY, V63, P102; Chandra RK, 1997, J PEDIATR GASTR NUTR, V24, P380, DOI 10.1097/00005176-199704000-00005; CHANDRA RK, 1986, CLIN ALLERGY, V16, P563, DOI 10.1111/j.1365-2222.1986.tb01995.x; CHANDRA RK, 1985, CLIN ALLERGY, V15, P517, DOI 10.1111/j.1365-2222.1985.tb02304.x; Chirico G, 1997, ALLERGY, V52, P82, DOI 10.1111/j.1398-9995.1997.tb02549.x; Custovic A, 2001, LANCET, V358, P188, DOI 10.1016/S0140-6736(01)05406-X; D'Agata A, 1996, Pediatr Med Chir, V18, P469; de Jong MH, 1998, ARCH DIS CHILD, V79, P126, DOI 10.1136/adc.79.2.126; de Jong MH, 2002, ARCH DIS CHILD, V86, P365, DOI 10.1136/adc.86.5.365; de Seta L, 1994, Pediatr Med Chir, V16, P251; Denburg JA, 2005, PEDIATR RES, V57, P276, DOI 10.1203/01.PDR.0000148279.72611.1D; Dotterud CK, 2010, BRIT J DERMATOL, V163, P616, DOI 10.1111/j.1365-2133.2010.09889.x; Dunder T, 2007, ARCH PEDIAT ADOL MED, V161, P972, DOI 10.1001/archpedi.161.10.972; Dunstan JA, 2003, J ALLERGY CLIN IMMUN, V112, P1178, DOI 10.1016/j.jaci.2003.09.009; Exl BM, 2000, EUR J NUTR, V39, P145, DOI 10.1007/s003940070018; FALTHMAGNUSSON K, 1992, J ALLERGY CLIN IMMUN, V89, P709, DOI 10.1016/0091-6749(92)90378-F; FALTHMAGNUSSON K, 1987, J ALLERGY CLIN IMMUN, V80, P868, DOI 10.1016/S0091-6749(87)80279-8; Filipiak B, 2007, J PEDIATR-US, V151, P352, DOI 10.1016/j.jpeds.2007.05.018; Foisy Michelle, 2011, Evid Based Child Health, V6, P1322; Furuhjelm C, 2009, ACTA PAEDIATR, V98, P1461, DOI 10.1111/j.1651-2227.2009.01355.x; Gruber C, 2010, J ALLERGY CLIN IMMUN, V126, P791, DOI 10.1016/j.jaci.2010.07.022; Halken S, 1993, Pediatr Allergy Immunol, V4, P173, DOI 10.1111/j.1399-3038.1993.tb00088.x; HALKEN S, 1992, ALLERGY, V47, P545, DOI 10.1111/j.1398-9995.1992.tb00680.x; Halken S, 2000, PEDIATR ALLERGY IMMU, V11, P149, DOI 10.1034/j.1399-3038.2000.00081.x; Halkjaer LB, 2006, ARCH DERMATOL, V142, P561, DOI 10.1001/archderm.142.5.561; HANIFIN JM, 1977, ARCH DERMATOL, V113, P663, DOI 10.1001/archderm.113.5.663; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Hattevig G, 1999, ACTA PAEDIATR, V88, P7, DOI 10.1080/080352599750029268; HATTEVIG G, 1989, CLIN EXP ALLERGY, V19, P27, DOI 10.1111/j.1365-2222.1989.tb02339.x; Herrmann ME, 1996, EUR J PEDIATR, V155, P770, DOI 10.1007/BF02002904; HIDE DW, 1994, J ALLERGY CLIN IMMUN, V93, P842, DOI 10.1016/0091-6749(94)90375-1; Hide DW, 1996, ALLERGY, V51, P89, DOI 10.1111/j.1398-9995.1996.tb04563.x; Hoppu U, 2005, EUR J CLIN NUTR, V59, P123, DOI 10.1038/sj.ejcn.1602048; Horak F, 2004, CLIN EXP ALLERGY, V34, P1220, DOI 10.1111/j.1365-2222.2004.02024.x; Huurre A, 2008, CLIN EXP ALLERGY, V38, P1342, DOI 10.1111/j.1365-2222.2008.03008.x; Kajosaari M, 1991, Adv Exp Med Biol, V310, P453; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kim JY, 2010, PEDIAT ALLERG IMM-UK, V21, pE386, DOI 10.1111/j.1399-3038.2009.00958.x; Kitz R, 2006, PEDIAT ALLERG IMM-UK, V17, P112, DOI 10.1111/j.1399-3038.2005.00369.x; KJELLMAN NIM, 1979, CLIN ALLERGY, V9, P347, DOI 10.1111/j.1365-2222.1979.tb02493.x; Koopman LP, 2002, AM J RESP CRIT CARE, V166, P307, DOI 10.1164/rccm.2106026; Kopp MV, 2008, PEDIATRICS, V121, pE850, DOI 10.1542/peds.2007-1492; Kramer MS, 2001, JAMA-J AM MED ASSOC, V285, P413, DOI 10.1001/jama.285.4.413; Kuitunen M, 2009, J ALLERGY CLIN IMMUN, V123, P335, DOI 10.1016/j.jaci.2008.11.019; Kukkonen K, 2007, J ALLERGY CLIN IMMUN, V119, P192, DOI 10.1016/j.jaci.2006.09.009; Laitinen K, 2005, BRIT J NUTR, V94, P565, DOI 10.1079/BJN20051503; Laubereau B, 2004, J PEDIATR-US, V144, P602, DOI 10.1016/j.jpeds.2003.12.029; Lauritzen L, 2005, LIPIDS, V40, P669, DOI 10.1007/s11745-005-1429-6; LILJA G, 1989, CLIN EXP ALLERGY, V19, P473, DOI 10.1111/j.1365-2222.1989.tb02416.x; LINDFORS ATB, 1992, ALLERGY, V47, P207, DOI 10.1111/j.1398-9995.1992.tb00652.x; LOVEGROVE JA, 1994, BRIT J NUTR, V71, P223, DOI 10.1079/BJN19940129; LUCAS A, 1990, BRIT MED J, V300, P837, DOI 10.1136/bmj.300.6728.837; MALLET E, 1992, J PEDIATR-US, V121, pS95, DOI 10.1016/S0022-3476(05)81415-5; Marini A, 1996, ACTA PAEDIATR, V85, P1, DOI 10.1111/j.1651-2227.1996.tb14267.x; Marks GB, 2006, J ALLERGY CLIN IMMUN, V118, P53, DOI 10.1016/j.jaci.2006.04.004; Matejek N, 1998, NUTR RES, V18, P1389, DOI 10.1016/S0271-5317(98)00117-1; MERRETT TG, 1988, ANN ALLERGY, V61, P13; MISKELLY FG, 1988, ARCH DIS CHILD, V63, P388, DOI 10.1136/adc.63.4.388; MOORE WJ, 1985, ARCH DIS CHILD, V60, P722, DOI 10.1136/adc.60.8.722; Moro G, 2006, ARCH DIS CHILD, V91, P814, DOI 10.1136/adc.2006.098251; Nentwich I, 2001, ALLERGY, V56, P1144, DOI 10.1111/j.1398-9995.2001x.00926.x; Niers L, 2009, ALLERGY, V64, P1349, DOI 10.1111/j.1398-9995.2009.02021.x; Nilsson L, 1998, ARCH PEDIAT ADOL MED, V152, P734; Odelram H, 1996, ALLERGY, V51, P192, DOI 10.1111/j.1398-9995.1996.tb00063.x; Odhiambo JA, 2009, J ALLERGY CLIN IMMUN, V124, P1251, DOI 10.1016/j.jaci.2009.10.009; Oldaeus G, 1997, ARCH DIS CHILD, V77, P4, DOI 10.1136/adc.77.1.4; Porch MC, 1998, NUTR RES, V18, P1413, DOI 10.1016/S0271-5317(98)00119-5; POYSA L, 1991, ALLERGY PROC, V12, P107, DOI 10.2500/108854191779011800; Rautava S, 2002, J ALLERGY CLIN IMMUN, V109, P119, DOI 10.1067/mai.2002.120273; RYSTEDT I, 1985, ACTA DERM-VENEREOL, V65, P206; Saarinen KM, 1999, J ALLERGY CLIN IMMUN, V104, P457, DOI 10.1016/S0091-6749(99)70393-3; Schmitt J, 2010, Br J Dermatol, V163, P1166, DOI 10.1111/j.1365-2133.2010.10054.x; Schmitt J, 2007, J ALLERGY CLIN IMMUN, V120, P1389, DOI 10.1016/j.jaci.2007.08.011; SCHMITZ J, 1992, J PEDIATR-US, V121, pS85, DOI 10.1016/S0022-3476(05)81413-1; Schoetzau A, 2002, PEDIAT ALLERG IMM-UK, V13, P234, DOI 10.1034/j.1399-3038.2002.01050.x; Shams K, 2011, CLIN EXP DERMATOL, V36, P573, DOI 10.1111/j.1365-2230.2011.04078.x; Shao Jie, 2006, Zhonghua Er Ke Za Zhi, V44, P684; SHOHET L, 1985, Acta Paediatrica Hungarica, V26, P35; SIGURS N, 1992, PEDIATRICS, V89, P735; Simpson EL, 2006, DERMATOL THER, V19, P108, DOI 10.1111/j.1529-8019.2006.00059.x; Simpson EL, 2010, J AM ACAD DERMATOL, V63, P587, DOI 10.1016/j.jaad.2009.11.011; Soh SE, 2009, CLIN EXP ALLERGY, V39, P571, DOI 10.1111/j.1365-2222.2008.03133.x; Steenhuis TJ, 2008, CLIN EXP ALLERGY, V38, P79, DOI 10.1111/j.1365-2222.2007.02859.x; Szajewska H, 2004, ACTA PAEDIATR, V93, P1159, DOI 10.1080/08035250410026554; Taylor AL, 2007, J ALLERGY CLIN IMMUN, V119, P184, DOI 10.1016/j.jaci.2006.08.036; Tsai Y T, 1991, Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi, V32, P137; Van den Berg A, 2007, ARCH PEDIAT ADOL MED, V161, P1095, DOI 10.1001/archpedi.161.11.1095; van den Berg Anemone, 2004, BMC Pediatr, V4, P17, DOI 10.1186/1471-2431-4-17; van Gool CJAW, 2003, AM J CLIN NUTR, V77, P943, DOI 10.1093/ajcn/77.4.943; VANDENPLAS Y, 1992, ANN ALLERGY, V68, P419; VANDENPLAS Y, 1995, EUR J PEDIATR, V154, P488, DOI 10.1007/BF02029362; VANDENPLAS Y, 1995, EUR J CLIN NUTR, V49, pS84; von Berg A, 2003, J ALLERGY CLIN IMMUN, V111, P533, DOI 10.1067/mai.2003.101; von Berg A, 2007, J ALLERGY CLIN IMMUN, V119, P718, DOI 10.1016/j.jaci.2006.11.017; West CE, 2009, PEDIATR ALLERGY IMMU, V20, P430, DOI 10.1111/j.1399-3038.2009.00745.x; Wickens K, 2008, J ALLERGY CLIN IMMUN, V122, P788, DOI 10.1016/j.jaci.2008.07.011; WILLEMS R, 1993, ANN ALLERGY, V71, P147; Williams HC, 2002, ARCH DERMATOL, V138, P391, DOI 10.1001/archderm.138.3.391; Williams HC, 1995, BRIT J DERMATOL, V133, P941, DOI 10.1111/j.1365-2133.1995.tb06930.x; Williams HC, 2006, ARCH DERMATOL, V142, P1201, DOI 10.1001/archderm.142.9.1201; ZEIGER RS, 1993, J ALLERGY CLIN IMMUN, V91, P723, DOI 10.1016/0091-6749(93)90191-H; ZEIGER RS, 1989, J ALLERGY CLIN IMMUN, V84, P72, DOI 10.1016/0091-6749(89)90181-4	116	36	37	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2012	130	1					137	144		10.1016/j.jaci.2012.01.075	http://dx.doi.org/10.1016/j.jaci.2012.01.075			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	977GN	22424882	Green Accepted			2022-12-18	WOS:000306644800020
J	Verbinnen, B; Covens, K; Moens, L; Meyts, I; Bossuyt, X				Verbinnen, Bert; Covens, Kris; Moens, Leen; Meyts, Isabelle; Bossuyt, Xavier			Human CD20(+)CD43(+)CD27(+)CD5(-) B cells generate antibodies to capsular polysaccharides of Streptococcus pneumoniae	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ANTIGENS		[Verbinnen, Bert; Moens, Leen; Bossuyt, Xavier] Univ Hosp Leuven, Fac Med, Expt Immunol Lab, Louvain, Belgium; [Verbinnen, Bert; Covens, Kris; Bossuyt, Xavier] Univ Hosp Leuven, KU Leuven Antibody Ctr, PharmAbs, Louvain, Belgium; [Covens, Kris] Univ Hosp Leuven, Fac Med, Ctr Mol & Vasc Biol, Louvain, Belgium	KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven	Verbinnen, B (corresponding author), Univ Hosp Leuven, Fac Med, Expt Immunol Lab, Louvain, Belgium.	Xavier.Bossuyt@uzleuven.be	Bossuyt, Xavier/B-2085-2019; Meyts, Isabelle/Z-3295-2019	Bossuyt, Xavier/0000-0001-6856-8485; 				BARRETT DJ, 1992, CELL IMMUNOL, V143, P66, DOI 10.1016/0008-8749(92)90006-B; Baumgarth N, 2011, NAT REV IMMUNOL, V11, P34, DOI 10.1038/nri2901; Descatoire M, 2011, J EXP MED, V208, P2563, DOI 10.1084/jem.20112232; Griffin DO, 2011, J EXP MED, V208, P67, DOI 10.1084/jem.20101499; Haas KM, 2011, J IMMUNOL, V187, P5183, DOI 10.4049/jimmunol.1101990; Haas KM, 2005, IMMUNITY, V23, P7, DOI 10.1016/j.immuni.2005.04.011; Jeurissen A, 2007, CLIN CHEM, V53, P505, DOI 10.1373/clinchem.2006.080051; Kruetzmann S, 2003, J EXP MED, V197, P939, DOI 10.1084/jem.20022020; Perez-Andres M, 2011, J EXP MED, V208, P2565, DOI 10.1084/jem.20112203	9	36	36	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2012	130	1					272	275		10.1016/j.jaci.2012.04.040	http://dx.doi.org/10.1016/j.jaci.2012.04.040			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	977GN	22664161				2022-12-18	WOS:000306644800042
J	Boyce, JA; Bochner, B; Finkelman, FD; Rothenberg, ME				Boyce, Joshua A.; Bochner, Bruce; Finkelman, Fred D.; Rothenberg, Marc E.			Advances in mechanisms of asthma, allergy, and immunology in 2011	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Galactose-alpha-1,3-galactose; cyclic AMP; calcitonin gene-related peptide; dendritic cell; genome-wide association study; facilitated antigen binding; facilitated antigen presentation; interferon; lipopolysaccharide; toluidine diisothiocyanate; Toll-like receptor; vascular endothelial growth factor	DENDRITIC CELLS; T(H)17 CELLS; IGE; IMMUNOTHERAPY; OMALIZUMAB	2011 was marked by rapid progress in the identification of basic mechanisms of allergic disease and the translation of these mechanisms into human cell systems. Studies published in the Journal of Allergy and Clinical Immunology this year provided new insights into the molecular determinants of allergenicity, as well as the environmental, cellular, and genetic factors involved in sensitization to allergens. Several articles focused on mechanisms of allergen immunotherapy and the development of novel strategies to achieve tolerance to allergens. Additional studies identified substantial contributions from T(H)17-type cells and cytokines to human disease pathogenesis. Finally, new therapeutic applications of anti-IgE were identified. The highlights of these studies and their potential clinical implications are summarized in this review. (J Allergy Clin Immunol 2012;129:335-41.)	[Boyce, Joshua A.] Harvard Univ, Div Rheumatol Immunol & Allergy, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; [Bochner, Bruce] Johns Hopkins Univ, Div Allergy & Clin Immunol, Dept Med, Baltimore, MD USA; [Finkelman, Fred D.; Rothenberg, Marc E.] Cincinnati Childrens Hosp, Div Allergy & Immunol, Dept Pediat, Med Ctr, Cincinnati, OH USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Johns Hopkins University; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Boyce, JA (corresponding author), Harvard Univ, Div Rheumatol Immunol & Allergy, Brigham & Womens Hosp, Sch Med, 1 Jimmy Fund Way,Smith Res Bldg,Rm 616C, Boston, MA 02115 USA.	jboyce@rics.bwh.harvard.edu			Sanofi-Aventis; United States Diagnostics Standards; NIAID; NHLBI; Dana Foundation; National Institutes of Health; FAAN; Department of Defense	Sanofi-Aventis(Sanofi-Aventis); United States Diagnostics Standards; NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Dana Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); FAAN; Department of Defense(United States Department of Defense)	B. Bochner has received consulting fees from Sanofi-Aventis and United States Diagnostics Standards; has received research support from the NIAID, NHLBI, and the Dana Foundation; and is Editor in Chief for the Up-to-Date Allergy & Immunology section. M. E. Rothenberg has equity interest in Cephalon; is a consultant and Chief Scientific Office for Immune Pharmaceuticals; has received research support from the National Institutes of Health, FAAN, and the Department of Defense; is on the APFED Medical Advisory Board; and is on the International Eosinophil Society Executive Council. The rest of the authors declare that they have no relevant conflicts of interest.	Albrecht M, 2011, J ALLERGY CLIN IMMUN, V128, P168, DOI 10.1016/j.jaci.2011.01.067; Arkestal K, 2011, J ALLERGY CLIN IMMUN, V127, P1024, DOI 10.1016/j.jaci.2011.01.033; Bisgaard H, 2011, J ALLERGY CLIN IMMUN, V128, P646, DOI 10.1016/j.jaci.2011.04.060; Commins SP, 2011, J ALLERGY CLIN IMMUN, V127, P1286, DOI 10.1016/j.jaci.2011.02.019; Commins SP, 2009, J ALLERGY CLIN IMMUN, V123, P426, DOI 10.1016/j.jaci.2008.10.052; Dai XJ, 2011, J ALLERGY CLIN IMMUN, V127, P806, DOI 10.1016/j.jaci.2010.12.006; Dreschler K, 2011, J ALLERGY CLIN IMMUN, V127, P487, DOI 10.1016/j.jaci.2010.12.003; Geri G, 2011, J ALLERGY CLIN IMMUN, V128, P655, DOI 10.1016/j.jaci.2011.05.029; Gerold G, 2008, NAT IMMUNOL, V9, P761, DOI 10.1038/ni.1618; Gilles S, 2011, J ALLERGY CLIN IMMUN, V127, P454, DOI 10.1016/j.jaci.2010.12.1082; Gronlund H, 2009, J ALLERGY CLIN IMMUN, V123, P1189, DOI 10.1016/j.jaci.2009.03.011; Hansel A, 2011, J ALLERGY CLIN IMMUN, V127, P787, DOI 10.1016/j.jaci.2010.12.009; Holm J, 2011, J ALLERGY CLIN IMMUN, V127, P1029, DOI 10.1016/j.jaci.2011.01.062; James LK, 2011, J ALLERGY CLIN IMMUN, V127, P509, DOI 10.1016/j.jaci.2010.12.1080; Kay AB, 2011, J ALLERGY CLIN IMMUN, V127, P232, DOI 10.1016/j.jaci.2010.10.028; Keles S, 2011, J ALLERGY CLIN IMMUN, V128, P808, DOI 10.1016/j.jaci.2011.04.033; Liu SY, 2011, J ALLERGY CLIN IMMUN, V127, P1014, DOI 10.1016/j.jaci.2010.12.008; Lluis A, 2011, J ALLERGY CLIN IMMUN, V127, P1587, DOI 10.1016/j.jaci.2011.03.015; Maddur MS, 2011, J ALLERGY CLIN IMMUN, V127, P823, DOI 10.1016/j.jaci.2010.12.1102; Mathias CB, 2011, J ALLERGY CLIN IMMUN, V127, P795, DOI 10.1016/j.jaci.2010.11.009; Maurer M, 2011, J ALLERGY CLIN IMMUN, V128, P202, DOI 10.1016/j.jaci.2011.04.038; MOSCATO G, 1991, J OCCUP ENVIRON MED, V33, P720, DOI 10.1097/00043764-199106000-00014; Nakamura Y, 2011, J ALLERGY CLIN IMMUN, V127, P1038, DOI 10.1016/j.jaci.2011.02.006; Newcomb DC, 2011, J ALLERGY CLIN IMMUN, V127, P1006, DOI 10.1016/j.jaci.2010.11.043; Niespodziana K, 2011, J ALLERGY CLIN IMMUN, V127, P1562, DOI 10.1016/j.jaci.2011.02.004; Peng RD, 2011, J ALLERGY CLIN IMMUN, V128, P390, DOI 10.1016/j.jaci.2011.04.050; Raymond M, 2011, J ALLERGY CLIN IMMUN, V128, P192, DOI 10.1016/j.jaci.2011.04.029; Reece P, 2011, J ALLERGY CLIN IMMUN, V127, P447, DOI 10.1016/j.jaci.2010.11.006; Rothers J, 2011, J ALLERGY CLIN IMMUN, V128, P397, DOI 10.1016/j.jaci.2011.04.044; Saini S, 2011, J ALLERGY CLIN IMMUN, V128, P567, DOI 10.1016/j.jaci.2011.06.010; Schneider E, 2011, J ALLERGY CLIN IMMUN, V128, P864, DOI 10.1016/j.jaci.2011.04.043; Schwarz A, 2011, J ALLERGY CLIN IMMUN, V128, P826, DOI 10.1016/j.jaci.2011.06.005; Smit LAM, 2011, J ALLERGY CLIN IMMUN, V128, P185, DOI 10.1016/j.jaci.2011.04.007; Wallner M, 2011, J ALLERGY CLIN IMMUN, V127, P1571, DOI 10.1016/j.jaci.2011.01.064; Wan YZI, 2011, J ALLERGY CLIN IMMUN, V127, P223, DOI 10.1016/j.jaci.2010.10.006	35	36	39	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2012	129	2					335	341		10.1016/j.jaci.2011.12.968	http://dx.doi.org/10.1016/j.jaci.2011.12.968			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	887TC	22284930				2022-12-18	WOS:000299951700006
J	Direskeneli, H; Fujita, H; Akdis, CA				Direskeneli, Haner; Fujita, Hiroyuki; Akdis, Cezmi A.			Regulation of T(H)17 and regulatory T cells in patients with Behcet disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Behcet disease; T(H)17; regulatory T cell	AUTOINFLAMMATION		[Fujita, Hiroyuki; Akdis, Cezmi A.] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, CH-7270 Davos, Switzerland; [Direskeneli, Haner] Marmara Univ, Sch Med, Dept Rheumatol, Istanbul, Turkey; [Fujita, Hiroyuki] Yokohama City Univ, Grad Sch Med, Dept Environm Immunodermatol, Yokohama, Kanagawa 232, Japan	Swiss Institute of Allergy & Asthma Research; University of Zurich; Marmara University; Yokohama City University	Akdis, CA (corresponding author), Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Obere Str 22, CH-7270 Davos, Switzerland.	akdisac@siaf.uzh.ch	Direskeneli, Haner/AAS-5508-2020; Akdis, Cezmi/AAV-4844-2020	Akdis, Cezmi/0000-0001-8020-019X				Akdis CA, 2011, J ALLERGY CLIN IMMUN, V127, P18, DOI 10.1016/j.jaci.2010.11.030; Akdis M, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Akdis M, 2011, J ALLERGY CLIN IMMUN, V127, P701, DOI 10.1016/j.jaci.2010.11.050; Ben Ahmed M, 2004, ARTHRITIS RHEUM-US, V50, P2291, DOI 10.1002/art.20334; Chi W, 2008, INVEST OPHTH VIS SCI, V49, P3058, DOI 10.1167/iovs.07-1390; Chi W, 2010, MOL VIS, V16, P880; Direskeneli H, 2006, RHEUMATOLOGY, V45, P1461, DOI 10.1093/rheumatology/kel329; Direskeneli H, 2010, CLIN EXP RHEUMATOL, V28, pS86; Geri G, 2011, J ALLERGY CLIN IMMUN, V128, P655, DOI 10.1016/j.jaci.2011.05.029; Goldbach-Mansky R, 2009, J ALLERGY CLIN IMMUN, V124, P1141, DOI 10.1016/j.jaci.2009.11.016; Hamzaoui K, 2011, J NEUROIMMUNOL, V233, P249, DOI 10.1016/j.jneuroim.2011.01.012; Kim J, 2010, CLIN EXP RHEUMATOL, V28, pS16; Sakane T, 1999, NEW ENGL J MED, V341, P1284, DOI 10.1056/NEJM199910213411707; Vugmeyster Y, 2010, MABS-AUSTIN, V2, P335, DOI 10.4161/mabs.2.3.11850; Yamaguchi Y, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3005	15	36	39	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2011	128	3					665	666		10.1016/j.jaci.2011.07.008	http://dx.doi.org/10.1016/j.jaci.2011.07.008			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	812HS	21878243				2022-12-18	WOS:000294283400028
J	Reginald, K; Westritschnig, K; Linhart, B; Focke-Tejkl, M; Jahn-Schmid, B; Eckl-Dorna, J; Heratizadeh, A; Stocklinger, A; Balic, N; Spitzauer, S; Niederberger, V; Werfel, T; Thalhamer, J; Weidinger, S; Novak, N; Ollert, M; Hirschl, AM; Valenta, R				Reginald, Kavita; Westritschnig, Kerstin; Linhart, Birgit; Focke-Tejkl, Margarete; Jahn-Schmid, Beatrice; Eckl-Dorna, Julia; Heratizadeh, Annice; Stoecklinger, Angelika; Balic, Nadja; Spitzauer, Susanne; Niederberger, Verena; Werfel, Thomas; Thalhamer, Josef; Weidinger, Stephan; Novak, Natalija; Ollert, Markus; Hirschl, Alexander M.; Valenta, Rudolf			Staphylococcus aureus fibronectin-binding protein specifically binds IgE from patients with atopic dermatitis and requires antigen presentation for cellular immune responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Staphylococcus aureus; atopic dermatitis; bacterial antigen; bacterial allergen; allergy; IgE; superinfection; superantigen	POLLEN ALLERGEN; SERUM IGE; GENOME; VIRULENCE; TH17; IDENTIFICATION; KERATINOCYTES; SUPERANTIGENS; DETERMINANTS; INFECTIONS	Background: Staphylococcus aureus superinfections occur in more than 90% of patients with atopic dermatitis (AD) and aggravate skin inflammation. S aureus toxins lead to tissue damage and augment T-cell-mediated skin inflammation by a superantigen effect. Objective: To characterize IgE-reactive proteins from S aureus. Methods: A genomic S aureus library was screened with IgE from patients with AD for DNA clones coding for IgE-reactive antigens. One was identified as fibronectin-binding protein (FBP). Recombinant FBP was expressed in Escherichia coli, purified, and tested for specific IgE reactivity in patients with AD. Its allergenic activity was studied in basophil activation experiments and T-cell cultures. The in vivo allergenic activity was investigated by sensitizing mice. Results: Using IgE from patients with AD for screening of a genomic S aureus library, an IgE-reactive DNA clone was isolated that coded for FBP. Recombinant FBP was expressed in E coli and purified. It reacted specifically with IgE from patients with AD and exhibited allergenic activity in basophil degranulation assays. FBP showed specific T-cell reactivity requiring antigen presentation and induced the secretion of proinflammatory cytokines from PBMCs. Mice sensitized with FBP mounted FBP-specific IgE responses, showed FBP-specific basophil degranulation as well as FBP-specific T-cell proliferation, and mixed T(H)2/T(H)1 cytokine secretion. Conclusion: Evidence is provided that specific humoral and cellular immune responses to S aureus antigens dependent on antigen presentation represent a novel mechanism for S aureus-induced skin inflammation in AD. Furthermore, FBP may be used for the development of novel diagnostic and therapeutic strategies for S aureus infections. (J Allergy Clin Immunol 2011; 128: 82-91.)	[Reginald, Kavita; Westritschnig, Kerstin; Linhart, Birgit; Jahn-Schmid, Beatrice; Valenta, Rudolf] Med Univ Vienna, Div Immunopathol, Dept Pathophysiol & Allergy Res, Ctr Pathophysiol Infectiol & Immunol, A-1090 Vienna, Austria; [Focke-Tejkl, Margarete; Valenta, Rudolf] Med Univ Vienna, Christian Doppler Lab Allergy Res, Dept Pathophysiol & Allergy Res, Ctr Pathophysiol Infectiol & Immunol, A-1090 Vienna, Austria; [Eckl-Dorna, Julia; Niederberger, Verena] Med Univ Vienna, Dept Otorhinolaryngol, A-1090 Vienna, Austria; [Balic, Nadja; Spitzauer, Susanne] Med Univ Vienna, Inst Med & Chem Lab Diagnost, A-1090 Vienna, Austria; [Hirschl, Alexander M.] Med Univ Vienna, Dept Clin Microbiol, A-1090 Vienna, Austria; [Stoecklinger, Angelika; Thalhamer, Josef] Salzburg Univ, Dept Mol Biol, A-5020 Salzburg, Austria; [Ollert, Markus] Tech Univ Munich, Clin Res Div Mol & Clin Allergotoxicol, Munich, Germany; [Weidinger, Stephan; Ollert, Markus] Tech Univ Munich, Dept Dermatol & Allergy, Munich, Germany; [Novak, Natalija] Univ Bonn, Dept Dermatol & Allergy, D-5300 Bonn, Germany; [Heratizadeh, Annice; Werfel, Thomas] Hannover Med Sch, Div Immunodermatol & Allergy Res, Dept Dermatol & Allergy, Hannover, Germany	Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Salzburg University; Technical University of Munich; Technical University of Munich; University of Bonn; Hannover Medical School	Valenta, R (corresponding author), Med Univ Vienna, Div Immunopathol, Dept Pathophysiol & Allergy Res, Ctr Pathophysiol Infectiol & Immunol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	rudolf.valenta@meduniwien.ac.at	Werfel, Thomas/B-6921-2012; Reginald, Kavita/ABB-7985-2021; Weidinger, Stephan/C-8461-2011; Thalhamer, Josef/E-5787-2011; Stoecklinger, Angelika/C-7616-2016; Eckl-Dorna, Julia/AAY-6371-2020	Reginald, Kavita/0000-0003-1530-5934; Weidinger, Stephan/0000-0003-3944-252X; Thalhamer, Josef/0000-0003-2285-6400; Stoecklinger, Angelika/0000-0002-0351-8142; Eckl-Dorna, Julia/0000-0001-5981-1607; Valenta, Rudolf/0000-0001-5944-3365; Linhart, Birgit/0000-0001-6857-3049; Ollert, Markus W./0000-0002-8055-0103	Austrian Science Fund [F1804, F1815, F1818, P20011-B13]; Christian Doppler Research Association, Vienna, Austria; Biomay, Vienna, Austria; Biomay AG; Christian Doppler Forschungsgesellschaft; Austrian Science Foundation; German Research Council; Bundesministerium fur Bildung und Forschung; Christian Doppler Research Association; Biomay; Phadia	Austrian Science Fund(Austrian Science Fund (FWF)); Christian Doppler Research Association, Vienna, Austria; Biomay, Vienna, Austria; Biomay AG; Christian Doppler Forschungsgesellschaft; Austrian Science Foundation(Austrian Science Fund (FWF)); German Research Council(German Research Foundation (DFG)); Bundesministerium fur Bildung und Forschung(Federal Ministry of Education & Research (BMBF)); Christian Doppler Research Association; Biomay; Phadia(Phadia)	Supported by grants F1804, F1815, and F1818 from the Austrian Science Fund; the Christian Doppler Research Association, Vienna, Austria; and a research grant from Biomay, Vienna, Austria. B.J.-S. is supported by grant P20011-B13 from the Austrian Science Fund.; Disclosure of potential conflict of interest: V. Niederberger receives research support from the Austrian Science Fund (FWF). J. Thalhamer has consultant arrangements with Biomay AG and receives research support from Biomay AG, Christian Doppler Forschungsgesellschaft, and the Austrian Science Foundation. S. Weidinger receives research support from the German Research Council and the Bundesministerium fur Bildung und Forschung. N. Novak receives research support from the German Research Council and is a lecturer for Phadia. R. Valenta receives research support from the Austrian Science Fund, the Christian Doppler Research Association, Biomay, and Phadia and has provided legal consultation or expert witness testimony in cases related to allergy therapy and allergy diagnosis. The rest of the authors have declared that they have no conflict of interest.	Baba T, 2002, LANCET, V359, P1819, DOI 10.1016/S0140-6736(02)08713-5; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Bunikowski R, 1999, J ALLERGY CLIN IMMUN, V103, P119, DOI 10.1016/S0091-6749(99)70535-X; CHOI YW, 1989, P NATL ACAD SCI USA, V86, P8941, DOI 10.1073/pnas.86.22.8941; Darsow U, 2004, ALLERGY, V59, P1318, DOI 10.1111/j.1398-9995.2004.00556.x; Deleo FR, 2009, J CLIN INVEST, V119, P2464, DOI 10.1172/JCI38226; Diep BA, 2006, LANCET, V367, P731, DOI 10.1016/S0140-6736(06)68231-7; Edlmayr J, 2009, J IMMUNOL, V182, P6298, DOI 10.4049/jimmunol.0713622; FLOCK JI, 1987, EMBO J, V6, P2351, DOI 10.1002/j.1460-2075.1987.tb02511.x; Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; Fraser JD, 2008, IMMUNOL REV, V225, P226, DOI 10.1111/j.1600-065X.2008.00681.x; Gill SR, 2005, J BACTERIOL, V187, P2426, DOI 10.1128/JB.187.7.2426-2438.2005; Hammad H, 2007, J EXP MED, V204, P357, DOI 10.1084/jem.20061196; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; HAUSER C, 1985, DERMATOLOGICA, V170, P114, DOI 10.1159/000249514; He R, 2007, P NATL ACAD SCI USA, V104, P15817, DOI 10.1073/pnas.0706942104; Hemmer W, 2010, CLIN EXP ALLERGY, V40, P679, DOI 10.1111/j.1365-2222.2010.03486.x; Herron-Olson L, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001120; Holden MTG, 2004, P NATL ACAD SCI USA, V101, P9786, DOI 10.1073/pnas.0402521101; Holgate ST, 2007, TRENDS IMMUNOL, V28, P248, DOI 10.1016/j.it.2007.04.007; Jahn-Schmid B, 2002, J IMMUNOL, V169, P6005, DOI 10.4049/jimmunol.169.10.6005; KONING F, 1992, J IMMUNOL, V149, P317; Kuroda M, 2001, LANCET, V357, P1225, DOI 10.1016/S0140-6736(00)04403-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; Linhart B, 2007, J IMMUNOL, V178, P3924, DOI 10.4049/jimmunol.178.6.3924; Littman DR, 2010, CELL, V140, P845, DOI 10.1016/j.cell.2010.02.021; Lubbe J, 2003, AM J CLIN DERMATOL, V4, P641; Mittermann I, 2008, J INVEST DERMATOL, V128, P1451, DOI 10.1038/sj.jid.5701195; Natter S, 1998, FASEB J, V12, P1559, DOI 10.1096/fasebj.12.14.1559; NISINI R, 1992, EUR J IMMUNOL, V22, P2033, DOI 10.1002/eji.1830220812; Novak N, 2003, J ALLERGY CLIN IMMUN, V112, P252, DOI 10.1067/mai.2003.1595; Ohta T, 2004, DNA RES, V11, P51, DOI 10.1093/dnares/11.1.51; Oyoshi MK, 2009, J ALLERGY CLIN IMMUN, V124, P485, DOI 10.1016/j.jaci.2009.05.042; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Peacock SJ, 1999, MICROBIOL-SGM, V145, P3477, DOI 10.1099/00221287-145-12-3477; Romagnani S, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2392; Sambrook J., 1982, MOL CLONING; Schulmeister U, 2009, J IMMUNOL, V182, P7019, DOI 10.4049/jimmunol.0712366; SIGNAS C, 1989, P NATL ACAD SCI USA, V86, P699, DOI 10.1073/pnas.86.2.699; Sinha B, 1999, CELL MICROBIOL, V1, P101, DOI 10.1046/j.1462-5822.1999.00011.x; Stern DA, 2007, J ALLERGY CLIN IMMUN, V119, P351, DOI 10.1016/j.jaci.2006.10.013; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; Valenta R, 1996, J INVEST DERMATOL, V107, P203, DOI 10.1111/1523-1747.ep12329617; Valenta R, 2009, TRENDS IMMUNOL, V30, P109, DOI 10.1016/j.it.2008.12.004; Werfel T, 2009, J INVEST DERMATOL, V129, P1878, DOI 10.1038/jid.2009.71	48	36	39	3	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2011	128	1					82	U141		10.1016/j.jaci.2011.02.034	http://dx.doi.org/10.1016/j.jaci.2011.02.034			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	785RE	21513970	Bronze			2022-12-18	WOS:000292245600010
J	Webb, L; Petersen, M; Boden, S; LaBelle, V; Bird, JA; Howell, D; Burks, AW; Laubach, S				Webb, Luke; Petersen, Maureen; Boden, Stephen; LaBelle, Virginia; Bird, J. Andrew; Howell, Druhan; Burks, A. Wesley; Laubach, Susan			Single-dose influenza vaccination of patients with egg allergy in a multicenter study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Webb, Luke; Petersen, Maureen; Laubach, Susan] Walter Reed Army Med Ctr, Dept Allergy Immunol, Washington, DC 20307 USA; [Boden, Stephen; LaBelle, Virginia; Burks, A. Wesley] Duke Univ, Med Ctr, Dept Pediat, Div Allergy Immunol, Durham, NC 27710 USA; [Bird, J. Andrew] Univ Texas SW Med Ctr Dallas, Dept Allergy Immunol, Dallas, TX 75390 USA; [Howell, Druhan] Univ S Alabama, Dept Allergy Immunol, Mobile, AL 36688 USA	United States Department of Defense; United States Army; Walter Reed National Military Medical Center; Duke University; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of South Alabama	Webb, L (corresponding author), Walter Reed Army Med Ctr, Dept Allergy Immunol, Washington, DC 20307 USA.	Susan.Laubach@us.army.mil		Bird, John/0000-0003-3772-6078	NIAID NIH HHS [5T32-AI007062-32, T32 AI007062] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007062] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Chung EY, 2010, PEDIATRICS, V125, pE1024, DOI 10.1542/peds.2009-2512; Gagnon R, 2010, J ALLERGY CLIN IMMUN, V126, P317, DOI 10.1016/j.jaci.2010.05.037; Greenhawt MJ, 2010, ANN ALLERG ASTHMA IM, V105, P387, DOI 10.1016/j.anai.2010.08.015; James JM, 1998, J PEDIATR-US, V133, P624, DOI 10.1016/S0022-3476(98)70101-5; Li JT, 2010, J ALLERGY CLIN IMMUN, V125, P1412, DOI 10.1016/j.jaci.2010.03.009; Owens G, 2011, J ALLERGY CLIN IMMUN, V127, P264, DOI 10.1016/j.jaci.2010.10.005; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Thompson M. G., 2010, Morbidity and Mortality Weekly Report, V59, P1057; Waibel KH, 2010, J ALLERGY CLIN IMMUN, V125, P749, DOI 10.1016/j.jaci.2009.12.015	10	36	37	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2011	128	1					218	219		10.1016/j.jaci.2011.02.013	http://dx.doi.org/10.1016/j.jaci.2011.02.013			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	785RE	21459425	Green Accepted			2022-12-18	WOS:000292245600031
J	Milovanovic, M; Heine, G; Hallatschek, W; Opitz, B; Radbruch, A; Worm, M				Milovanovic, Milena; Heine, Guido; Hallatschek, Werner; Opitz, Bastian; Radbruch, Andreas; Worm, Margitta			Vitamin D receptor binds to the epsilon germline gene promoter and exhibits transrepressive activity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Vitamin D receptor; calcitriol; epsilon germline transcript; class-switch recombination; IgE; histone acetylation	CLASS SWITCH RECOMBINATION; HISTONE DEACETYLASES; B-CELLS; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; 1,25-DIHYDROXYVITAMIN D-3; ASTHMA; COREPRESSORS; TRANSCRIPTION; ASSOCIATION; ACCESSIBILITY	Background: Recently, an increased incidence of allergic diseases has been associated with vitamin D deficiency. We demonstrated previously that calcitriol, the active form of vitamin D, inhibits epsilon germline transcription, a prerequisite for IgE production. However, the underlying mechanisms remain unexplored. Objective: We sought to investigate whether the epsilon germline gene promoter (I epsilon) represents a primary vitamin D receptor (VDR) target. Therefore we investigated VDR binding to I epsilon, analyzed VDR-complex composition in more detail, and delineated its functional consequences. Methods: The VDR binding to I epsilon in human B cells, the composition of the VDR-recruited complex, and the acetylation pattern were investigated by means of chromatin immunoprecipitation. The calcitriol-mediated action on I epsilon was analyzed by using a reporter gene assay. Results: We demonstrate that I epsilon is a possible VDR target. Calcitriol-activated VDR binds together with retinoid X receptor alpha to the I epsilon region. The heterodimer interacts with silencing mediator for retinoid and thyroid hormone receptors, which recruits histone deacetylase (HDAC) 1 and HDAC3. The inhibition of silencing mediator for retinoid and thyroid hormone receptors or HDACs reversed the site-specific deacetylation of histones 3 and 4 and the calcitriol-driven inhibition of the epsilon germline transcription. The VDR-complex transrepressive actions on I epsilon were confirmed in a reporter assay. Conclusion: We show here that inhibition of IgE production by calcitriol is mediated by its transrepressive activity through the VDR-corepressor complex affecting chromatin compacting around the I epsilon region. Our findings shed new light on mechanisms of VDR transrepression and understanding of IgE regulation. (J Allergy Clin Immunol 2010;126:1016-23.)	[Milovanovic, Milena; Heine, Guido; Worm, Margitta] Charite, Dept Dermatol & Allergy, CCM, Allergy Ctr Charite, D-10117 Berlin, Germany; [Hallatschek, Werner; Opitz, Bastian] Charite, Dept Internal Med Infect Dis & Pulm Med, D-10117 Berlin, Germany; [Radbruch, Andreas] Deutsch Rheuma Forschungszentrum Berlin, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Deutsches Rheuma-Forschungszentrum (DRFZ)	Worm, M (corresponding author), Charite, Dept Dermatol & Allergy, CCM, Allergy Ctr Charite, Charite Pl 1, D-10117 Berlin, Germany.	margitta.worm@charite.de	Heine, Guido/G-1656-2018	Heine, Guido/0000-0003-1467-9862; Opitz, Bastian/0000-0003-1276-836X; Worm, Margitta/0000-0002-3449-1245	Deutsche Forschungsgemeinschaft [DFG-SFB650 TP5]; NaFoG-Promotionsforderung des Landes Berlin	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); NaFoG-Promotionsforderung des Landes Berlin	Supported in part by the Deutsche Forschungsgemeinschaft (DFG-SFB650 TP5). Milena Milovanovic received a scholarship from the NaFoG-Promotionsforderung des Landes Berlin.	Bhavsar P, 2008, J ALLERGY CLIN IMMUN, V121, P580, DOI 10.1016/j.jaci.2007.12.1156; Carlberg C, 2009, ANTICANCER RES, V29, P3485; Chowdhury M, 2008, P NATL ACAD SCI USA, V105, P15872, DOI 10.1073/pnas.0808462105; Dudley DD, 2005, ADV IMMUNOL, V86, P43, DOI 10.1016/S0065-2776(04)86002-4; Grabiec AM, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2489; Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485; Heine G, 2002, EUR J IMMUNOL, V32, P3395, DOI 10.1002/1521-4141(2002012)32:12<3395::AID-IMMU3395>3.0.CO;2-I; Heine G, 2008, EUR J IMMUNOL, V38, P2210, DOI 10.1002/eji.200838216; Hibler EA, 2010, J STEROID BIOCHEM, V121, P438, DOI 10.1016/j.jsbmb.2010.03.052; Holick MF, 2008, MOL ASPECTS MED, V29, P361, DOI 10.1016/j.mam.2008.08.008; Hong SH, 2001, MOL CELL BIOL, V21, P7172, DOI 10.1128/MCB.21.21.7172-7182.2001; Khan N, 2008, BIOCHEM J, V409, P581, DOI 10.1042/BJ20070779; Lee JW, 2001, CELL MOL LIFE SCI, V58, P289, DOI 10.1007/PL00000856; Martino DJ, 2010, ALLERGY, V65, P7, DOI 10.1111/j.1398-9995.2009.02186.x; Meyer MB, 2006, MOL ENDOCRINOL, V20, P1447, DOI 10.1210/me.2006-0031; Miller J, 2010, DERMATOL THER, V23, P13, DOI 10.1111/j.1529-8019.2009.01287.x; Milovanovic M, 2009, CLIN EXP ALLERGY, V39, P671, DOI 10.1111/j.1365-2222.2009.03233.x; Mora JR, 2008, NAT REV IMMUNOL, V8, P685, DOI 10.1038/nri2378; Nakayama Y, 2006, J CELL BIOCHEM, V99, P1308, DOI 10.1002/jcb.20952; Nambu Y, 2003, SCIENCE, V302, P2137, DOI 10.1126/science.1092481; Poulsen LK, 2007, ANN MED, V39, P440, DOI 10.1080/07853890701449354; Raby BA, 2004, AM J RESP CRIT CARE, V170, P1057, DOI 10.1164/rccm.200404-447OC; Sanchez-Martinez R, 2008, MOL CELL BIOL, V28, P3817, DOI 10.1128/MCB.01909-07; Shahbazian MD, 2007, ANNU REV BIOCHEM, V76, P75, DOI 10.1146/annurev.biochem.76.052705.162114; Stanya KJ, 2009, CELL DIV, V4, DOI 10.1186/1747-1028-4-7; Toropainen S, 2010, J MOL BIOL, V400, P284, DOI 10.1016/j.jmb.2010.05.031; Turunen MM, 2007, NUCLEIC ACIDS RES, V35, P2734, DOI 10.1093/nar/gkm179; Vollmert C, 2004, CLIN EXP ALLERGY, V34, P1841, DOI 10.1111/j.1365-2222.2004.02047.x; Wang LL, 2009, J EXP MED, V206, P1817, DOI 10.1084/jem.20081678; Wang TJ, 2010, LANCET, V376, P180, DOI 10.1016/S0140-6736(10)60588-0; Wjst M, 2005, BMC GENET, V6, DOI 10.1186/1471-2156-6-2; Wjst M, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-60; Zhang K, 2003, J LEUKOCYTE BIOL, V73, P323, DOI 10.1189/jlb.0702339	33	36	36	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2010	126	5					1016	U184		10.1016/j.jaci.2010.08.020	http://dx.doi.org/10.1016/j.jaci.2010.08.020			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	674HB	20926124	Bronze			2022-12-18	WOS:000283727100019
J	Slager, RE; Hawkins, GA; Ampleford, EJ; Bowden, A; Stevens, LE; Morton, MT; Tomkinson, A; Wenzel, SE; Longphre, M; Bleecker, ER; Meyers, DA				Slager, Rebecca E.; Hawkins, Gregory A.; Ampleford, Elizabeth J.; Bowden, Alexandra; Stevens, Lauren E.; Morton, Matthew T.; Tomkinson, Adrian; Wenzel, Sally E.; Longphre, Malinda; Bleecker, Eugene R.; Meyers, Deborah A.			IL-4 receptor alpha polymorphisms are predictors of a pharmacogenetic response to a novel IL-4/IL-13 antagonist	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							DUTCH POPULATION; ASTHMA; ASSOCIATION; ATOPY; GENE		[Slager, Rebecca E.; Hawkins, Gregory A.; Ampleford, Elizabeth J.; Bleecker, Eugene R.; Meyers, Deborah A.] Wake Forest Univ, Bowman Gray Sch Med, Ctr Genom & Personalized Med Res, Winston Salem, NC 27106 USA; [Bowden, Alexandra; Stevens, Lauren E.; Morton, Matthew T.; Tomkinson, Adrian; Longphre, Malinda] Aerovance, Berkeley, CA USA; [Wenzel, Sally E.] Univ Pittsburgh, Med Ctr, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA USA	Wake Forest University; Wake Forest Baptist Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Slager, RE (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Ctr Genom & Personalized Med Res, Winston Salem, NC 27106 USA.	dmeyers@wfubmc.edu			NHLBI NIH HHS [K12 HL089992, HL089992, HL65899, U01 HL065899] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K12HL089992, U01HL065899] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; Howard TD, 2001, AM J RESP CELL MOL, V25, P377, DOI 10.1165/ajrcmb.25.3.4483; Howard TD, 2002, AM J HUM GENET, V70, P230, DOI 10.1086/338242; Kabesch M, 2006, J ALLERGY CLIN IMMUN, V117, P269, DOI 10.1016/j.jaci.2005.10.024; Tachdjian R, 2009, J EXP MED, V206, P2191, DOI 10.1084/jem.20091480; Tomkinson A, 2010, ALLERGY, V65, P69, DOI 10.1111/j.1398-9995.2009.02156.x; Vercelli D, 2002, CURR OPIN ALLERGY CL, V2, P389, DOI 10.1097/00130832-200210000-00004; Wenzel S, 2007, LANCET, V370, P1422, DOI 10.1016/S0140-6736(07)61600-6; Wenzel SE, 2007, AM J RESP CRIT CARE, V175, P570, DOI 10.1164/rccm.200607-909OC	9	36	36	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2010	126	4					875	878		10.1016/j.jaci.2010.08.001	http://dx.doi.org/10.1016/j.jaci.2010.08.001			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	658SP	20920778	Green Accepted, Bronze			2022-12-18	WOS:000282510000031
J	Bonnelykke, K; Pipper, CB; Bisgaard, H				Bonnelykke, Klaus; Pipper, Christian Bressen; Bisgaard, Hans			Transfer of maternal IgE can be a common cause of increased IgE levels in cord blood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE; cord blood; infant; intrauterine; atopy	IMMUNOGLOBULIN-E; ALLERGIC SENSITIZATION; ATOPIC DISEASE; IN-UTERO; PREGNANCY; ASTHMA; FETUS; ORDER; RISK; AGE	Background: IgE in cord blood is thought to be a product of the fetus. A high level of total IgE is therefore used as a measure of atopic propensity in the newborn. We recently found strong evidence that allergen-specific IgE in cord blood was the result of transfer of maternal IgE to fetal blood or cord blood (maternofetal transfer) rather than fetal production. This also suggests that total IgE in cord blood might primarily be a maternal product. Objective: We sought to determine to what extent increased levels of total IgE in cord blood is the result of maternofetal transfer of IgE. Methods: Total IgE in cord blood was analyzed in a prospective birth cohort study. Maternofetal transfer of IgE was detected by means of high-sensitivity analyses of cord blood IgA and allergen-specific IgE and comparison with parental IgE levels and levels at 6 months of age. Results: Forty-six percent of cord blood samples with increased IgE levels (>= 0.5 IU/mL) showed indication of maternofetal transfer of IgE. Maternal origin of IgE in these samples was validated by showing reduced levels of IgE at 6 months of age compared with samples with no indication of maternofetal transfer (geometric mean, 9.4 vs 5.4 IU/mL; P = .01). Maternofetal transfer was not appropriately accounted for by the conventional method of cord blood IgA measurement. Conclusions: Maternofetal transfer might be a common cause of increased cord blood IgE levels. Future studies should take potential maternofetal transfer into account or use other markers of atopy. (J Allergy Clin Immunol 2010;126:657-63.)	[Bonnelykke, Klaus; Pipper, Christian Bressen; Bisgaard, Hans] Univ Copenhagen, Copenhagen Univ Hosp, Danish Pediat Asthma Ctr, Copenhagen Prospect Studies Asthma Childhood, Gentofte 2820, Denmark	University of Copenhagen	Bonnelykke, K (corresponding author), Univ Copenhagen, Copenhagen Univ Hosp, Danish Pediat Asthma Ctr, Copenhagen Prospect Studies Asthma Childhood, Ledreborg 34, Gentofte 2820, Denmark.	kb@copsac.dk	Bisgaard, Hans/N-4761-2016; Kronow, Joern/B-1054-2011	Bisgaard, Hans/0000-0003-4131-7592; Pipper, Christian Bressen/0000-0003-0261-616X; Bonnelykke, Klaus/0000-0003-2003-1018	Lundbeck Foundation [R16-2007-1694] Funding Source: researchfish	Lundbeck Foundation(Lundbeckfonden)		AVRECH OM, 1994, INT ARCH ALLERGY IMM, V103, P160, DOI 10.1159/000236622; Bisgaard H, 2004, ANN ALLERG ASTHMA IM, V93, P381, DOI 10.1016/S1081-1206(10)61398-1; Bonnelykke K, 2008, J ALLERGY CLIN IMMUN, V121, P646, DOI 10.1016/j.jaci.2007.12.1149; CAIN TW, 2006, ALLERGY CLIN IMMUNOL, V18, P230; COOKSON WOCM, 1992, LANCET, V340, P381, DOI 10.1016/0140-6736(92)91468-N; Edenharter G, 1998, CLIN EXP ALLERGY, V28, P671; HALONEN M, 1991, CLIN EXP ALLERGY, V21, P235, DOI 10.1111/j.1365-2222.1991.tb00836.x; Heinrich J, 2002, EUR RESPIR J, V20, P617, DOI 10.1183/09031936.02.02322001; Jones CA, 1998, LANCET, V351, P1859, DOI 10.1016/S0140-6736(05)78805-X; Karmaus W, 2004, CLIN EXP ALLERGY, V34, P853, DOI 10.1111/j.1365-2222.2004.01959.x; Karmaus W, 2001, AM J EPIDEMIOL, V154, P909, DOI 10.1093/aje/154.10.909; LILJA G, 1990, ALLERGY, V45, P436, DOI 10.1111/j.1398-9995.1990.tb01094.x; LILJA G, 1992, ALLERGY, V47, P522, DOI 10.1111/j.1398-9995.1992.tb00676.x; LILJA G, 1988, CLIN ALLERGY, V18, P131, DOI 10.1111/j.1365-2222.1988.tb02852.x; Lima JO, 2000, J ALLERGY CLIN IMMUN, V106, P911, DOI 10.1067/mai.2000.110228; Liu CA, 2003, J ALLERGY CLIN IMMUN, V112, P899, DOI 10.1016/j.jaci.2003.08.030; Malek A, 1996, AM J REPROD IMMUNOL, V36, P248; MILLER D L, 1973, Federation Proceedings, V32, P1013; MILLER DL, 1973, J ALLERGY CLIN IMMUN, V52, P182, DOI 10.1016/0091-6749(73)90035-3; Ownby DR, 1996, PEDIATR ALLERGY IMMU, V7, P125, DOI 10.1111/j.1399-3038.1996.tb00119.x; Paganelli R, 1998, ALLERGY, V53, P763; Peters JL, 2009, J ALLERGY CLIN IMMUN, V123, P1041, DOI 10.1016/j.jaci.2009.02.027; Scirica CV, 2007, J ALLERGY CLIN IMMUN, V119, P81, DOI 10.1016/j.jaci.2006.09.002; Shirakawa T, 1997, EUR J EPIDEMIOL, V13, P395, DOI 10.1023/A:1007361013917; Warner JA, 2000, BRIT MED BULL, V56, P883, DOI 10.1258/0007142001903571	25	36	39	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2010	126	3					657	663		10.1016/j.jaci.2010.06.027	http://dx.doi.org/10.1016/j.jaci.2010.06.027			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	646CF	20816197				2022-12-18	WOS:000281512500037
J	Nelson, H; Bonuccelli, C; Radner, F; Ottosson, A; Carroll, KJ; Andersson, TLG; LaForce, C				Nelson, Harold; Bonuccelli, Catherine; Radner, Finn; Ottosson, Anders; Carroll, Kevin J.; Andersson, Tomas L. G.; LaForce, Craig			Safety of formoterol in patients with asthma: Combined analysis of data from double-blind, randomized controlled trials	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; formoterol; inhaled corticosteroid; long-acting beta(2)-adrenergic agonist; safety; serious adverse events	METERED-DOSE INHALER; ACTING BETA-AGONISTS; PERSISTENT ASTHMA; REPORTED OUTCOMES; SINGLE INHALER; BUDESONIDE; ADULTS; BUDESONIDE/FORMOTEROL; EFFICACY; MODERATE	Background: Concerns exist that regular long-acting beta(2)-adrenergic agonist (LABA) therapy may increase the risk of serious asthma-related events. Objective: To assess risks of formoterol-containing versus non-LABA treatment by using a large asthma database. Methods: This analysis included all blind, parallel-arm, randomized, active-controlled and/or placebo-controlled AstraZeneca-sponsored asthma studies with formoterol-containing and non-LABA comparator arms. Serious adverse events were assessed for inclusion in all-cause death, asthma-related death, asthma-related intubation, and asthma-related hospitalization categories by using blind adjudication. Data were combined across trials; relative risk (RR) was assessed by using Mantel-Haenszel methods. Results: Data were from 13,542 formoterol-randomized and 9968 non-LABA patients 4 years or older (42 trials), of whom 93% and 89%, respectively, received inhaled corticosteroid as part of randomized treatment or allowed medication. Incidence of all-cause death was low (n = 3 and n = 4, respectively), with numerically lower all-cause deaths/1000 patient-treatment years in the formoterol-treated group (0.53) versus the non-LABA group (0.82) (RR, 0.64; 95% confidence interval [CI], 0.14-2.92). No asthma-related deaths and 1 asthma-related intubation (formoterol-treated group) occurred. Asthma-related hospitalizations/1000 patient-treatment years were lower numerically in the formoterol-treated group (12.1) versus the non-LABA group (16.4) (RR, 0.73; 95% CI, 0.54-1.01), with fewer study discontinuations in the formoterol-treated group (12.7% vs 15.4%, respectively; RR, 0.79; 95% CI, 0.74-0.85). Relative to non-LABA, increasing daily formoterol dose (>= 4.5, 9, 18, 36 mu g) did not increase the rate or incidence of asthma-related hospitalization. Conclusion: No evidence of increased risk of asthma-related hospitalization, no asthma-related deaths, and a low incidence of all-cause death and asthma-related intubation were seen with formoterol-containing versus non-LABA treatment. (J Allergy Clin Immunol 2010;125:390-6.)	[Nelson, Harold] Natl Jewish Hlth, Dept Med, Denver, CO 80206 USA; [Bonuccelli, Catherine] AstraZeneca LP, Wilmington, DE USA; [Radner, Finn; Ottosson, Anders; Andersson, Tomas L. G.] AstraZeneca, Lund, Sweden; [Carroll, Kevin J.] AstraZeneca, Macclesfield, Cheshire, England; [LaForce, Craig] Univ N Carolina, Sch Med, Chapel Hill, NC USA	National Jewish Health; AstraZeneca; AstraZeneca; AstraZeneca; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Nelson, H (corresponding author), Natl Jewish Hlth, Dept Med, 1400 Jackson St,Room A02, Denver, CO 80206 USA.	nelsonh@njhealth.org			Genentech	Genentech(Roche HoldingGenentech)	Disclosure of potential conflict of interest: H. Nelson has consultant arrangements with Genentech/Novartis. Abbott Labs, MediciNova, GlaxoSmithKline, AstraZeneca, Amgen. Schering-Plough, Dyson, Sepracor. and NycoMed; receives research support from Genentech.	[Anonymous], 3 NAT HEART LUNG BLO; Barker L, 2008, STAT MED, V27, P4030, DOI 10.1002/sim.3234; Bensch G, 2002, ANN ALLERG ASTHMA IM, V89, P180, DOI 10.1016/S1081-1206(10)61935-7; Bisgaard H, 2006, CHEST, V130, P1733, DOI 10.1378/chest.130.6.1733; CASTLE W, 1993, BRIT MED J, V306, P1034, DOI 10.1136/bmj.306.6884.1034; Cates CJ, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006923.pub2; Chervinsky P, 2008, ANN ALLERG ASTHMA IM, V101, P463, DOI 10.1016/S1081-1206(10)60284-0; Corren J, 2007, CLIN THER, V29, P823, DOI 10.1016/j.clinthera.2007.05.011; *GLAXOSMITHKLINE, 2008, JOINT M PULM ALL DRU; Global Initiative for Asthma, GLOB STRAT ASTHM MAN; *INT C HARM TECHN, 1998, E9 INT C HARM TECHN; Kerwin EM, 2009, ANN ALLERG ASTHMA IM, V103, P62, DOI 10.1016/S1081-1206(10)60145-7; Kramer JM, 2009, NEW ENGL J MED, V360, P1592, DOI 10.1056/NEJMp0810561; Lalloo UG, 2003, CHEST, V123, P1480, DOI 10.1378/chest.123.5.1480; LEVENSON M, 2008, LONG ACT BET AG ADV; Mann M, 2003, CHEST, V124, P70, DOI 10.1378/chest.124.1.70; Murphy K, 2008, CURR MED RES OPIN, V24, P879, DOI 10.1185/030079908X273354; Nelson HS, 2009, ANN ALLERG ASTHMA IM, V102, P11, DOI 10.1016/S1081-1206(10)60101-9; Nelson HS, 2006, CHEST, V129, P15, DOI 10.1378/chest.129.1.15; Noonan M, 2006, DRUGS, V66, P2235, DOI 10.2165/00003495-200666170-00006; O'Byrne PM, 2001, AM J RESP CRIT CARE, V164, P1392, DOI 10.1164/ajrccm.164.8.2104102; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Peters SP, 2008, ALLERGY ASTHMA PROC, V29, P499, DOI 10.2500/aap.2008.29.3147; Sears MR, 2009, EUR RESPIR J, V33, P21, DOI 10.1183/09031936.00145006; *US FDA, 2005, PUBL HLTH ADV; Zetterstrom O, 2001, EUR RESPIR J, V18, P262, DOI 10.1183/09031936.01.00065801	26	36	36	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2					390	396		10.1016/j.jaci.2009.11.036	http://dx.doi.org/10.1016/j.jaci.2009.11.036			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	558RU	20159250				2022-12-18	WOS:000274764000017
J	Calvert, J; Burney, P				Calvert, James; Burney, Peter			Ascaris, atopy, and exercise-induced bronchoconstriction in rural and urban South African children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; atopy; Ascaris species; IgE; South Africa	BRONCHIAL HYPERRESPONSIVENESS; ANTHELMINTIC TREATMENT; BODY-MASS; ASTHMA; IGE; INFECTIONS; PARASITES; RISK; SENSITIZATION; COMMUNITIES	Background: Populations with endemic parasitosis have high levels of IgE but low levels of allergic disease. We investigated the association between infection with the parasite Ascaris allergic sensitization, and exercise-induced bronchospasm (EIB). Objective: We sought to investigate the effect of Ascaris infection on bronchial hyperreactivity, skin testing, and specific IgE levels. Methods: A cross-sectional prevalence survey was conducted in urban and rural South African children to measure levels of EIB. A sample of children was enrolled in a nested case-control study for further investigation based on response to exercise. Analyses used weighted logistic regression. Results: Geometric mean total IgE levels were higher in Ascaris-infected subjects (infected subjects: 451 IU (95% CI, 356-572) vs uninfected subjects: 344 IU (95% CI, 271-437), P = .04), and high levels of total IgE were positively associated with detection of specific IgE to the aeroallergens tested, but there was no significant association between Ascaris infection and titers of specific IgE. Ascaris infection was associated with a decreased risk of a positive skin test response (odds ratio, 0.63; 95% CI, 0.42-0.94; P = .03) but an increased risk of EIB (odds ratio, 1.62; 95% CI, 1.23-2.11; P = .001). Conclusion: In areas of high parasite endemicity, Ascaris might induce an inflammatory response in the lungs independent of its effect on IgE production. This could explain some of the contradictory findings seen in studies examining the association between geohelminth infection, atopy, and asthma. (J Allergy Clin Immunol 2010;125:100-5.)	[Calvert, James; Burney, Peter] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW7 2AZ, England	Imperial College London	Calvert, J (corresponding author), Southmead Hosp, N Bristol Lung Ctr, Bristol BS10 5NB, Avon, England.	james.calvert@nbt.nhs.uk		Burney, Peter/0000-0001-8635-5678	Wellcome Trust	Wellcome Trust(Wellcome TrustEuropean Commission)	Supported by a Wellcome Trust Training Fellowship in Tropical Clinical Epidemiology (J.M.C.).	ALSHISHTAWY MM, 1991, INT ARCH ALLER A IMM, V96, P348, DOI 10.1159/000235520; Arshad SH, 2005, CHEST, V127, P502, DOI 10.1378/chest.127.2.502; ASH RL, 1998, PARASITES GUIDE LAB; Bundy D. A. P., 1992, World Health Statistics Quarterly, V45, P168; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; Calvert J, 2005, J ALLERGY CLIN IMMUN, V116, P773, DOI 10.1016/j.jaci.2005.05.025; CARSWELL F, 1977, CLIN ALLERGY, V7, P445, DOI 10.1111/j.1365-2222.1977.tb01475.x; CHAN MS, 1994, PARASITOLOGY, V109, P373, DOI 10.1017/S0031182000078410; Chinn S, 1999, EUR RESPIR J, V14, P876, DOI 10.1034/j.1399-3003.1999.14d25.x; Chinn S, 1996, EUR J EPIDEMIOL, V12, P155, DOI 10.1007/BF00145501; COCKCROFT DW, 2008, MIDDLETONS ALLERGY P, P1295; COLE TJ, 1995, ARCH DIS CHILD, V73, P25, DOI 10.1136/adc.73.1.25; Cooper PJ, 2006, LANCET, V367, P1598, DOI 10.1016/S0140-6736(06)68697-2; CUSTOVIC A, 1994, CHEST, V105, P1127, DOI 10.1378/chest.105.4.1127; GODFREY R C, 1975, Clinical Allergy, V5, P201, DOI 10.1111/j.1365-2222.1975.tb01853.x; GODFREY RC, 1976, NATURE, V259, P484, DOI 10.1038/259484a0; HAGEL I, 1993, CLIN EXP IMMUNOL, V94, P80, DOI 10.1111/j.1365-2249.1993.tb05981.x; Klasen S, 1997, SOC INDIC RES, V41, P51, DOI 10.1023/A:1006892216864; Kurukulaaratchy RJ, 2004, THORAX, V59, P563, DOI 10.1136/thx.2003.010462; LYNCH NR, 1993, J ALLERGY CLIN IMMUN, V92, P404, DOI 10.1016/0091-6749(93)90119-Z; Lynch NR, 1999, THORAX, V54, P659, DOI 10.1136/thx.54.8.659; Lynch NR, 1998, J ALLERGY CLIN IMMUN, V101, P217, DOI 10.1016/S0091-6749(98)70386-0; Lynch NR, 1997, AM J RESP CRIT CARE, V156, P50, DOI 10.1164/ajrccm.156.1.9606081; LYNCH NR, 1992, J INVEST ALLERG CLIN, V2, P97; Mannino DM, 2002, CHEST, V122, P409, DOI 10.1378/chest.122.2.409; MERRETT TG, 1976, CLIN ALLERGY, V6, P131, DOI 10.1111/j.1365-2222.1976.tb01890.x; Palmer LJ, 2002, AM J RESP CRIT CARE, V165, P1489, DOI 10.1164/rccm.2107020; Pearce N, 2000, THORAX, V55, P424, DOI 10.1136/thorax.55.5.424; Pereira MU, 2007, EUR RESPIR J, V29, P1154, DOI 10.1183/09031936.00127606; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; Rasmussen F, 1999, THORAX, V54, P587, DOI 10.1136/thx.54.7.587; Selassie FG, 2000, CLIN EXP ALLERGY, V30, P356, DOI 10.1046/j.1365-2222.2000.00706.x; *STATACORP, 1999, STATA US GUID REL 7; Stoten A, 2005, PARASITE IMMUNOL, V27, P431, DOI 10.1111/j.1365-3024.2005.00786.x; TSUJI M, 1977, INT ARCH ALLER A IMM, V55, P78, DOI 10.1159/000231912; TURNER KJ, 1979, INT ARCH ALLER A IMM, V58, P232, DOI 10.1159/000232197; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; VANNIEKERK CH, 1979, CLIN ALLERGY, V9, P319; VANNIEKERK CH, 1979, S AFR MED J, V55, P756; 1996, OXFORD TXB MED	40	36	36	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2010	125	1					100	105		10.1016/j.jaci.2009.09.010	http://dx.doi.org/10.1016/j.jaci.2009.09.010			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	544MG	19962746	Green Accepted			2022-12-18	WOS:000273660500010
J	Gill, BV; Rice, TR; Cartier, A; Gautrin, D; Neis, B; Horth-Susin, L; Jong, M; Swanson, M; Lehrer, SB				Gill, Beth V.; Rice, Timothy R.; Cartier, Andre; Gautrin, Denise; Neis, Barbara; Horth-Susin, Lise; Jong, Michael; Swanson, Mark; Lehrer, Samuel B.			Identification of crab proteins that elicit IgE reactivity in snow crab-processing workers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Crab; occupational allergy; RAST; IgE reactivity; immunoblot	MAJOR ALLERGEN; MOLECULAR CHARACTERIZATION; OCCUPATIONAL ASTHMA; BINDING EPITOPES; TROPOMYOSIN; MITE	Background: The expanding snow crab-processing industry has resulted in increased numbers of workers at risk of occupational allergy. Objective: Our study is to identify relevant allergenic proteins in cooked snow crab meat (CM) and crab water (CW) used for cooking for improved remediation, diagnosis, and treatment. Methods: Extracts were prepared from CM extracts, CW extracts, and an air-filter collection near the crab cooker. Of the 207 workers, 24 with the highest IgE antibody reactivity to CM and CW extracts, as determined by using RASTs, were tested for reactivity to nitrocellulose membranes containing CM and CW proteins separated with SDS-PAGE. A 3-serum pool was similarly incubated against nitrocellulose-bound proteins from air samples collected near the crab cooker. Results: Of the 207 sera tested, 27 and 39 sera exhibited positive IgE antibody reactivity (>= 2%) to CM and CW extracts, respectively. Twenty-two of 24 sera with the highest RAST activity (>= 3.5% binding) demonstrated IgE binding to multiple proteins (13.6-50 kd). A majority of the sera reacted to 4 proteins: 79% and 71% to a 34.0-kd protein, 79% and 42% to a 25-kd protein, 67% and 71% to an 18.5-kd protein, and 75% to a 14.4-kd protein in both CM and CW extracts, respectively. The pool of IgE-positive sera blotted against the air-filter extract reacted to 14.4-, 18.5-, 34.0-, 43.2-, and 50-kd proteins present in both crab extracts. Conclusion: Four major IgE-reactive proteins were identified in CM extracts, CW extracts, and air-filter eluate. Analysis of any potential association of protein reactivity with disease suggested crab proteins at 34.0 and 14.4 kd might be more relevant. (J Allergy Clin Immunol 2009;124:1055-61.)	[Gill, Beth V.; Rice, Timothy R.; Lehrer, Samuel B.] Tulane Univ, Hlth Sci Ctr, Dept Med, Sect Clin Immunol Allergy & Rheumatol, New Orleans, LA 70118 USA; [Gill, Beth V.] Collom & Carney Clin, Texarkana, TX USA; [Rice, Timothy R.] Columbia Univ, Coll Phys & Surg, New York, NY USA; [Cartier, Andre; Gautrin, Denise] Hop Sacre Coeur, Montreal, PQ H4J 1C5, Canada; [Neis, Barbara] Mem Univ Newfoundland, Dept Sociol & SafetyNet, St John, NF, Canada; [Horth-Susin, Lise] RANA Resp Core Grp, Winnipeg, MB, Canada; [Jong, Michael] Mem Univ & Labrador Grenfell Hlth, Happy Valley, NF, Canada; [Swanson, Mark] Mayo Clin & Mayo Fdn, Rochester, MN USA	Tulane University; Columbia University; Universite de Montreal; Memorial University Newfoundland; Mayo Clinic	Lehrer, SB (corresponding author), Tulane Univ Med Ctr Hosp & Clin, 1700 Perdido St SL 57, New Orleans, LA 70112 USA.	sblehrer@tulane.edu			Canadian Institutes of Health Research [CAHR-43269]; Newfoundland Workplace Health, Safety, and Compensation Commission and Memorial University; Air Labrador; Health Labrador Corporation; Summit Technologies; AstraZeneca and GlaxoSmithKline; Quan-Tec-Air; USA, Inc; National Fisheries Institute; Center for Asthma at Work; Committee on Occupational Lung Diseases of Montreal, Workers' Compensation Board of Quebec (CSST); Bureau d'evaluation medicale of the Ministry of Labour, province of Quebec; Social Sciences and Humanity Research Council; Trudeau Foundation; National Fisheries Institute and Bumble Bee	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Newfoundland Workplace Health, Safety, and Compensation Commission and Memorial University; Air Labrador; Health Labrador Corporation; Summit Technologies; AstraZeneca and GlaxoSmithKline(AstraZeneca); Quan-Tec-Air; USA, Inc; National Fisheries Institute; Center for Asthma at Work; Committee on Occupational Lung Diseases of Montreal, Workers' Compensation Board of Quebec (CSST); Bureau d'evaluation medicale of the Ministry of Labour, province of Quebec; Social Sciences and Humanity Research Council; Trudeau Foundation; National Fisheries Institute and Bumble Bee	Supported by Canadian Institutes of Health Research grant CAHR-43269 through SafetyNet, a Community Research Alliance on Health and Safety in Marine and Coastal Work based at Memorial University in St John's, Newfoundland, Canada. Support was also provided by the Newfoundland Workplace Health, Safety, and Compensation Commission and Memorial University. In-kind Support was provided by the Newfoundland Department of Government Services; Air Labrador; Health Labrador Corporation; Summit Technologies; AstraZeneca and GlaxoSmithKline; Quan-Tec-Air; USA, Inc; and the National Fisheries Institute.; Disclosure of potential conflict of interest: A. Cartier has received research Support from the Center for Asthma at Work; is supported by the Canadian Institutes of Health Research; is President of the Committee on Occupational Lung Diseases of Montreal, Workers' Compensation Board of Quebec (CSST); and is an expert for the Bureau d'evaluation medicale of the Ministry of Labour, province of Quebec. B. Neis has received research support from the Social Sciences and Humanity Research Council, the Canadian Institutes for Health Research, Memorial University, and the Trudeau Foundation. S. B. Lehrer has received research support from the National Fisheries Institute and Bumble Bee. The rest of the authors have declared that they have no conflict of interest.	AKI T, 1995, J ALLERGY CLIN IMMUN, V96, P74, DOI 10.1016/S0091-6749(95)70035-8; Asturias JA, 1998, BBA-GENE STRUCT EXPR, V1397, P27, DOI 10.1016/S0167-4781(98)00006-2; Asturias JA, 1999, J IMMUNOL, V162, P4342; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTIER A, 1984, J ALLERGY CLIN IMMUN, V74, P261, DOI 10.1016/0091-6749(84)90256-2; CARTIER A, 1986, J ALLERGY CLIN IMMUN, V78, P344, DOI 10.1016/S0091-6749(86)80087-2; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; *FAO UN, 2005 COR CONS DAT; Griffin P., 1994, ANN OCCUP HYG, V<bold>38</bold>, P923; Howse D, 2006, ENVIRON RES, V101, P163, DOI 10.1016/j.envres.2005.06.008; Ishikawa M, 1998, J FOOD SCI, V63, P44, DOI 10.1111/j.1365-2621.1998.tb15672.x; Ishikawa M, 1998, BIOSCI BIOTECH BIOCH, V62, P1337, DOI 10.1271/bbb.62.1337; Jeebhay MF, 2001, OCCUP ENVIRON MED, V58, P553, DOI 10.1136/oem.58.9.553; Leung PSC, 1998, J ALLERGY CLIN IMMUN, V102, P847, DOI 10.1016/S0091-6749(98)70027-2; Leung PSC, 1998, MOL MAR BIOL BIOTECH, V7, P12; Malo JL, 1997, CLIN EXP ALLERGY, V27, P75, DOI 10.1046/j.1365-2222.1997.d01-421.x; Miyazawa H, 1996, J ALLERGY CLIN IMMUN, V98, P948, DOI 10.1016/S0091-6749(96)80011-X; Mykles DL, 1998, J MUSCLE RES CELL M, V19, P105, DOI 10.1023/A:1005352410725; ORFORD RR, 1985, AM J IND MED, V7, P155, DOI 10.1002/ajim.4700070207; Ortega HG, 2001, AM J IND MED, V39, P598, DOI 10.1002/ajim.1059; RAHMAN AMA, 2009, P 29 ICOH INT C OCC; Santos ABR, 1999, J ALLERGY CLIN IMMUN, V104, P329, DOI 10.1016/S0091-6749(99)70375-1; *SHELLF OCC HLTH S, 2004 2005 SHELLF PRO; Weytjens K, 1999, ALLERGY, V54, P892, DOI 10.1034/j.1398-9995.1999.00120.x; WHITEWAY G, 2003, THESIS MEMORIAL U NE	25	36	38	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2009	124	5					1055	1061		10.1016/j.jaci.2009.06.030	http://dx.doi.org/10.1016/j.jaci.2009.06.030			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	523XI	19665776				2022-12-18	WOS:000272108000028
J	Tassone, L; Notarangelo, LD; Bonomi, V; Savoldi, G; Savoldi, A; Soresina, A; Smith, CIE; Porta, F; Plebani, A; Notarangelo, LD; Badolato, R				Tassone, Laura; Notarangelo, Lucia D.; Bonomi, Vanessa; Savoldi, Gianfranco; Savoldi, Alberto; Soresina, Annarosa; Smith, C. I. Edvard; Porta, Fulvio; Plebani, Alessandro; Notarangelo, Luigi D.; Badolato, Raffaele			Clinical and genetic diagnosis of warts, hypogammaglobulinemia, infections, and myelokathexis syndrome in 10 patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							WHIM-SYNDROME; CXCR4; IMMUNODEFICIENCY; MUTATIONS; LYMPHOMA; DISEASE; CXCL12		[Tassone, Laura; Notarangelo, Lucia D.; Bonomi, Vanessa; Savoldi, Gianfranco; Soresina, Annarosa; Porta, Fulvio; Plebani, Alessandro; Notarangelo, Luigi D.; Badolato, Raffaele] Univ Brescia, Ist Med Mol Angelo Nocivelli & Clin Pediat, Brescia, Italy; [Savoldi, Alberto] Univ Ferrara, I-44100 Ferrara, Italy; [Smith, C. I. Edvard] Karolinska Inst, Novum, Dept Lab Med, Clin Res Ctr, Huddinge, Sweden	University of Brescia; University of Ferrara; Karolinska Institutet	Tassone, L (corresponding author), Univ Brescia, Ist Med Mol Angelo Nocivelli & Clin Pediat, Brescia, Italy.	badolato@med.unibs.it	Plebani, Alessandro/C-8593-2011; Badolato, Raffaele/A-8081-2010	Badolato, Raffaele/0000-0001-7375-5410; SMITH, C. I. Edvard/0000-0003-1907-3392	Telethon [GGP07134] Funding Source: Medline	Telethon(Fondazione Telethon)		Balabanian K, 2005, BLOOD, V105, P2449, DOI 10.1182/blood-2004-06-2289; Chae KM, 2001, J AM ACAD DERMATOL, V44, P124, DOI 10.1067/mjd.2001.111337; Diaz GA, 2005, IMMUNOL REV, V203, P235, DOI 10.1111/j.0105-2896.2005.00226.x; Gorlin RJ, 2000, AM J MED GENET, V91, P368, DOI 10.1002/(SICI)1096-8628(20000424)91:5<368::AID-AJMG10>3.0.CO;2-9; Gulino AV, 2004, BLOOD, V104, P444, DOI 10.1182/blood-2003-10-3532; Hernandez PA, 2003, NAT GENET, V34, P70, DOI 10.1038/ng1149; Imashuku S, 2002, ANN HEMATOL, V81, P470, DOI 10.1007/s00277-002-0489-9; Kawai T, 2007, BLOOD, V109, P78, DOI 10.1182/blood-2006-05-025296; Tarzi MD, 2005, J ALLERGY CLIN IMMUN, V116, P1101, DOI 10.1016/j.jaci.2005.08.040; Vinurel H, 2008, REV MAL RESPIR, V25, P614, DOI 10.1016/S0761-8425(08)71621-8	10	36	38	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2009	123	5					1170	1173		10.1016/j.jaci.2008.12.1133	http://dx.doi.org/10.1016/j.jaci.2008.12.1133			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	449CW	19321197				2022-12-18	WOS:000266309400028
J	Smith, HE; Hogger, C; Lallemant, C; Crook, D; Frew, AJ				Smith, Helen E.; Hogger, Claire; Lallemant, Camille; Crook, David; Frew, Anthony J.			Is structured allergy history sufficient when assessing patients with asthma and rhinitis in general practice?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy history; primary care; skin prick tests; validity		Background: Many United Kingdom patients with asthma and rhinitis are allergic, but in primary care few diagnostic and management decisions are made with formal allergy assessment. Arguably, knowing a patient's atopic status might be helpful in distinguishing the cause of disease and in selecting appropriate treatments. Objectives: Our objective was to estimate the extent to which a formal allergy assessment (a structured allergy history and skin prick tests to 5 common aeroallergens) would improve the precision of allergy diagnosis compared with a patient's self-report or the structured allergy history alone. Methods: One hundred twenty-seven patients with asthma, rhinitis, or both were recruited from 4 general practices in Wessex, United Kingdom. Allergy status based on the patient's opinion and on structured allergy history alone was compared with formal allergy assessment. Assessments were validated by an independent allergy specialist reviewing the files. Patients were given written advice specific to their allergies and followed up 3 months later to assess satisfaction, recall, and effect on health and behavior. Results: Self-reporting misclassified allergic status in many patients. A structured allergy history alone was little better and resulted in false-positive rates for cat allergy of 32%, grass pollen of 48%, house dust mite of 75%, tree pollen of 54%, and dog of 27% compared with formal allergy assessment. Skin prick testing combined with a structured history was essential to reach a correct causative diagnosis. Three months later, 41% patients had made changes to lifestyle, medications, or both, and 18% reported clinical improvement. Conclusions: Skin prick testing improves the accuracy of an assessment of allergic status based on patient opinion or a structured allergy history alone. (J Allergy Clin Immunol 2009;123:646-50.)	[Smith, Helen E.; Lallemant, Camille; Crook, David] Brighton & Sussex Med School, Div Primary Care & Publ Hlth, Brighton BN1 9PH, E Sussex, England; [Hogger, Claire] Univ Southampton, Sch Med, Southampton SO9 5NH, Hants, England; [Frew, Anthony J.] Brighton Gen Hosp, Dept Resp Med, Brighton, E Sussex, England	University of Brighton; University of Southampton; Brighton and Sussex University Hospitals NHS Trust; Brighton General Hospital	Smith, HE (corresponding author), Brighton & Sussex Med School, Div Primary Care & Publ Hlth, Mayfield House, Brighton BN1 9PH, E Sussex, England.	h.e.smith@bsms.ac.uk	Kelly, Frank J/C-6125-2009; Smith, Helen E/M-2449-2016	Kelly, Frank J/0000-0003-2558-8392; Smith, Helen E/0000-0003-1883-6124; Crook, David/0000-0002-9587-3730	Allergy Therapeutics	Allergy Therapeutics	Disclosure of potential conflict of interest: A. J. Frew has received honoraria from and served on advisory boards for ALK-Abello, has received speakers' honoraria and research support from Allergy Therapeutics, and has served as an officer for the European Academy of Allergy, Asthma & Immunology and the British Society for Allergy and Clinical Immunology. The rest of the authors have declared that they have no conflict of interest.	Ahlstedt Staffan, 2006, Prim Care Respir J, V15, P228, DOI 10.1016/j.pcrj.2006.05.004; BRYDON M, 1993, CLIN EXP ALLERGY, V23, P1037, DOI 10.1111/j.1365-2222.1993.tb00296.x; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; Gendo K, 2004, ANN INTERN MED, V140, P278, DOI 10.7326/0003-4819-140-4-200402170-00010; Gupta R, 2004, CLIN EXP ALLERGY, V34, P520, DOI 10.1111/j.1365-2222.2004.1935.x; Heinzerling L, 2005, ALLERGY, V60, P1287, DOI 10.1111/j.1398-9995.2005.00895.x; *ISAAC STEER COMM, 1998, LANCET, V351, P12225; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Mackinnon A, 2000, COMPUT BIOL MED, V30, P127, DOI 10.1016/S0010-4825(00)00006-8; REID MJ, 1993, J ALLERGY CLIN IMMUN, V92, P6, DOI 10.1016/0091-6749(93)90030-J; Sheikh A, 1999, BRIT J GEN PRACT, V49, P67; Sibbald B, 1997, J ADV NURS, V26, P537, DOI 10.1046/j.1365-2648.1997.t01-14-00999.x	13	36	38	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2009	123	3					646	650		10.1016/j.jaci.2008.11.005	http://dx.doi.org/10.1016/j.jaci.2008.11.005			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	426TQ	19135237	Bronze			2022-12-18	WOS:000264731200024
J	Faeste, CK; Namork, E; Lindvik, H				Faeste, Christiana Kruse; Namork, Ellen; Lindvik, Helene			Allergenicity and antigenicity of fenugreek (Trigonella foenum-graecum) proteins in foods	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen; allergenicity; antigenicity; cross-reactivity; fenugreek; food; IgE; immunoblotting; legumes; open food challenge; peanut; polyclonal antibody; skin prick tests	CROSS-ALLERGENICITY; ALLERGY; IGE; ANAPHYLAXIS; CORIANDER; SPICES; PEANUT; TESTS	Background: Fenugreek is an ingredient in Indian-style spiced foods. Reports of adverse reactions reflect a trend toward a more international cuisine. Fenugreek allergy has not been systematically investigated so far. Objective: Study the allergenicity and antigenicity of fenugreek proteins using patient sera and a newly developed polyclonal antifenugreek antibody. Methods: Allergenic fenugreek proteins were identified by immunoblotting, using sera from 29 patients with specific IgE to peanut and other legumes. In addition, 2 patients were evaluated by skin prick test and open food challenge with native fenugreek powder. Spiced and flavored food products were analyzed for fenugreek by semiquantitative IgE and IgG immunoblotting. Results: High levels of specific IgE to both peanut and fenugreek were seen in most sera. Fenugreek sensitization is believed to be a consequence of cross-reactivity in patients with peanut allergy. Primary fenugreek allergy was suspected in only I case. The fenugreek dose eliciting objective symptoms was about 2 mg in the open food challenge. Major fenugreek allergens were identified at 50, 52, and 74 kd and peanut proteins at 22, 36, and 40 kd. A specific polyclonal antifenugreek antibody was found suitable for food analysis. In a food survey, about 1/3 of the fenugreek-containing products were labeled correctly. Conclusion: Fenugreek seed powder, an ingredient in spiced foods, contains several potential allergens. There is evidence for a high rate of cross-reactivity to peanut. (J Allergy Clin Immunol 2009;1,23:187-94.)	[Faeste, Christiana Kruse] Natl Vet Inst, N-0106 Oslo, Norway; [Namork, Ellen] Norwegian Inst Publ Hlth, Oslo, Norway; [Lindvik, Helene] Rikshosp Univ Hosp, Voksentoppcn Childrens Ctr Asthma & Allergy, Oslo, Norway	Norwegian Veterinary Institute; Norwegian Institute of Public Health (NIPH); University of Oslo; National Hospital Norway	Faeste, CK (corresponding author), Natl Vet Inst, POB 750, N-0106 Oslo, Norway.	christiane.faste@vetinst.no			National Veterinary Institute; Berit Stensby at the Norwegian Institute for Public Health	National Veterinary Institute; Berit Stensby at the Norwegian Institute for Public Health	We thank Dr Eliann Egaas at the National Veterinary Institute, Dr Ragnhild Halvorson at Voksentoppen Children's Center for Asthma and Allergy, and Prof Martinus Lovik at the Norwegian Institute for Public Health for fruitful discussions. We also thank Dr Gaynour Sletten for editing the manuscript. Lena Haugland Moen and Kjersti Eriksen Lovberg at the National Veterinary Institute and Berit Stensby at the Norwegian Institute for Public Health are gratefully acknowledged for their technical assistance.	BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V84, P701, DOI 10.1016/0091-6749(89)90298-4; Bin-Hafeez B, 2003, INT IMMUNOPHARMACOL, V3, P257, DOI 10.1016/S1567-5769(02)00292-8; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Celik-Bilgili S, 2005, CLIN EXP ALLERGY, V35, P268, DOI 10.1111/j.1365-2222.2005.02150.x; DUGUE P, 1993, PRESSE MED, V22, P922; Ebo DG, 2006, ACTA CLIN BELG, V61, P152, DOI 10.1179/acb.2006.025; Egger M, 2006, ALLERGY, V61, P461, DOI 10.1111/j.1398-9995.2006.00994.x; Hourihane JO, 2002, CURR OPIN ALLERGY CL, V2, P227, DOI 10.1097/00130832-200206000-00012; Ibanez M D, 2003, Allergol Immunopathol (Madr), V31, P151; LOVIK M, 2004, J EPIDEMIOL, V14, P155; Madar Z, 2002, BRIT J NUTR, V88, pS287, DOI 10.1079/BJN2002719; Moneret-Vautrin D A, 2002, Allerg Immunol (Paris), V34, P135; Moneret-Vautrin DA, 1999, J ALLERGY CLIN IMMUN, V104, P883, DOI 10.1016/S0091-6749(99)70303-9; MUHLEMANN RJ, 1991, SCHWEIZ MED WSCHR, V121, P1696; NICOLIE B, 2007, 26 C EUR AC ALL CLIN; NIINIMAKI A, 1995, ANN ALLERG ASTHMA IM, V75, P280; Ohnuma N, 1998, ALLERGY, V53, P452, DOI 10.1111/j.1398-9995.1998.tb03924.x; OLIVEPEREZ A, 1992, J ALLERGOL IMMUNOPAT, V20, P85; Petropoulos G.A., 2002, FENUGREEKTHE GENUS T, DOI 10.4324/9780203217474; Rao PU, 1996, NUTR RES, V16, P1495, DOI 10.1016/0271-5317(96)00163-7; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; San Ireneo MM, 2000, J INVEST ALLERG CLIN, V10, P187; Sastre J, 1996, ALLERGY, V51, P117, DOI 10.1111/j.1398-9995.1996.tb04568.x; Scholl I, 2004, INT ARCH ALLERGY IMM, V135, P247, DOI 10.1159/000081950; Simon J. E., 1984, Herbs, an indexed bibliography, 1971-1980.; *USDA, 2001, NUTR DAT STAND REF; VANTOORENENBERGEN AW, 1985, J ALLERGY CLIN IMMUN, V76, P477, DOI 10.1016/0091-6749(85)90730-4; VANTOORENENBERGEN AW, 1987, J ALLERGY CLIN IMMUN, V79, P108, DOI 10.1016/S0091-6749(87)80024-6; Verstege A, 2005, CLIN EXP ALLERGY, V35, P1220, DOI 10.1111/j.1365-2222.2005.2324.x; Wang J, 2008, J ALLERGY CLIN IMMUN, V121, P1219, DOI 10.1016/j.jaci.2007.12.1150	31	36	37	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2009	123	1					187	194		10.1016/j.jaci.2008.09.012	http://dx.doi.org/10.1016/j.jaci.2008.09.012			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	399IP	18930518				2022-12-18	WOS:000262793900031
J	Koetzler, R; Zaheer, RS; Wiehler, S; Holden, NS; Giembycz, MA; Proud, D				Koetzler, Rommy; Zaheer, Raza S.; Wiehler, Shahina; Holden, Neil S.; Giembycz, Mark A.; Proud, David			Nitric oxide inhibits human rhinovirus-induced transcriptional activation of CXCL10 in airway epithelial cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Human rhinovirus; asthma; airway epithelial cell; CXCL10; IFN-gamma-inducible protein of 10 kd; nitric oxide; IFN response factors; nuclear factor kappa B	NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; CYTOKINE PRODUCTION; S-NITROSYLATION; DNA-BINDING; IFN-GAMMA; IN-VITRO; INFECTION; INDUCTION; ASTHMA	Background: Human rhinovirus (HRV) infections trigger exacerbations of asthma and chronic obstructive pulmonary disease. Nitric oxide (NO) inhibits HRV replication in human airway epithelial cells and suppresses HRV-induced epithelial production of several cytokines and chemokines. Objective: We sought to delineate the mechanisms by which NO inhibits HRV-induced epithelial production of CXCL10, a chemoattractant for type 1 T cells and natural killer cells. Methods: Primary human bronchial epithelial cells or cells of the BEAS-2B human bronchial epithelial cell line were exposed to HRV-16 in the presence or absence of the NO donor 3-(2-hydroxy-2-nitroso-1-propylhydrazino)-1-propanamine (PAPA NONOate). A cGMP analogue and an inhibitor of soluble guanylyl cyclase were used to examine the role of the cyclic guanosine monophosphate (cGMP) pathway in the actions of NO. BEAS-2B cells were transfected with CXCL10 promoter-luciferase constructs and the effects of PAPA NONOate were examined to study mechanisms of transcriptional regulation. Electrophoretic mobility shift assays were also used. Results: PAPA NONOate inhibited HRV-16-induced increases in CXCL10 mRNA and protein. Inhibition of CXCL10 production occurred through a cGMP-independent pathway. PAPA NONOate inhibited HRV-16-induced CXCL10 transcription by blocking nuclear translocation, binding, or both of both nuclear factor kappa B and IFN response factors (IRFs) to their respective recognition elements in the CXCL10 promoter. Conclusions: NO inhibits HRV-16-induced production of CXCL10 by inhibiting viral activation of nuclear factor kappa B and of IRFs, including IRF-1, through a cGMP-independent pathway. The broad-ranging inhibition of HRV-induced epithelial cytokine and chemokine production by NO suggests a potential therapeutic utility of NO donors in viral exacerbations of asthma and chronic obstructive pulmonary disease. (J Allergy Clin Immunol 2009;123:201-8.)	[Koetzler, Rommy; Zaheer, Raza S.; Wiehler, Shahina; Holden, Neil S.; Giembycz, Mark A.; Proud, David] Univ Calgary, Inst Infect Immun & Inflammat, Airway Inflammat Grp, Calgary, AB T2N 4N1, Canada	University of Calgary	Proud, D (corresponding author), Univ Calgary, Fac Med, Dept Physiol & Biophys, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	dproud@ucalgary.ca		Holden, Neil/0000-0001-5824-3417	Canadian Institutes of Health Research [43923]; American Academy of Allergy, Asthma Immunology	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); American Academy of Allergy, Asthma Immunology	Supported by grant no. 43923 from the Canadian Institutes of Health Research, Do Proud is the recipient of a Canada Research Chair in Inflammatory Airway Diseases. Rummy Koetzler was the recipient of a ST*AR award from the American Academy of Allergy, Asthma & Immunology. Rommy Koetzler and Raza Zaheer are recipients of studentship awards from the Lung Association of Alberta and Northwest Territories.	de Gouw HWFM, 1998, EUR RESPIR J, V11, P126, DOI 10.1183/09031936.98.11010126; Donninger H, 2003, J INFECT DIS, V187, P1809, DOI 10.1086/375246; Genin P, 2000, J IMMUNOL, V164, P5352, DOI 10.4049/jimmunol.164.10.5352; Hiscott J, 2006, ONCOGENE, V25, P6844, DOI 10.1038/sj.onc.1209941; Khetsuriani N, 2007, J ALLERGY CLIN IMMUN, V119, P314, DOI 10.1016/j.jaci.2006.08.041; Kim J, 2000, J IMMUNOL, V165, P3384, DOI 10.4049/jimmunol.165.6.3384; Kroncke KD, 2001, INT IMMUNOPHARMACOL, V1, P1407, DOI 10.1016/S1567-5769(01)00087-X; Lander HM, 1997, J BIOL CHEM, V272, P4323, DOI 10.1074/jbc.272.7.4323; Leigh R, 2008, J ALLERGY CLIN IMMUN, V121, P1238, DOI 10.1016/j.jaci.2008.01.067; Majumder S, 1998, J IMMUNOL, V161, P4736; Marshall HE, 2004, P NATL ACAD SCI USA, V101, P8841, DOI 10.1073/pnas.0403034101; Matthews JR, 1996, NUCLEIC ACIDS RES, V24, P2236, DOI 10.1093/nar/24.12.2236; Morita R, 2005, J IMMUNOL, V175, P806, DOI 10.4049/jimmunol.175.2.806; Mosser AG, 2005, AM J RESP CRIT CARE, V171, P645, DOI 10.1164/rccm.200407-970OC; Nakaya T, 2001, BIOCHEM BIOPH RES CO, V283, P1150, DOI 10.1006/bbrc.2001.4913; Nasuhara Y, 1999, J BIOL CHEM, V274, P19965, DOI 10.1074/jbc.274.28.19965; Nikitovic D, 1998, BIOCHEM BIOPH RES CO, V242, P109, DOI 10.1006/bbrc.1997.7930; Paludan SR, 2001, EUR CYTOKINE NETW, V12, P297; Proud D, 2005, CURR OPIN ALLERGY CL, V5, P37, DOI 10.1097/00130832-200502000-00008; Proud D, 2006, AM J RESP CELL MOL, V35, P513, DOI 10.1165/rcmb.2006-0199TR; Reynaert NL, 2004, P NATL ACAD SCI USA, V101, P8945, DOI 10.1073/pnas.0400588101; Sanders SP, 1998, J VIROL, V72, P934, DOI 10.1128/JVI.72.2.934-942.1998; Sanders SP, 2004, J ALLERGY CLIN IMMUN, V113, P697, DOI 10.1016/j.jaci.2004.01.755; Sanders SP, 2001, J ALLERGY CLIN IMMUN, V107, P235, DOI 10.1067/mai.2001.112028; Sanders SP, 2001, AM J RESP CELL MOL, V24, P317, DOI 10.1165/ajrcmb.24.3.4131; Spurrell JCL, 2005, AM J PHYSIOL-LUNG C, V289, pL85, DOI 10.1152/ajplung.00397.2004; SUBAUSTE MC, 1995, J CLIN INVEST, V96, P549, DOI 10.1172/JCI118067; Traves SL, 2007, CURR OPIN PHARMACOL, V7, P252, DOI 10.1016/j.coph.2006.11.010; Uetani K, 2000, J IMMUNOL, V165, P988, DOI 10.4049/jimmunol.165.2.988; Wark PAB, 2007, J ALLERGY CLIN IMMUN, V120, P586, DOI 10.1016/j.jaci.2007.04.046; WU CQ, 1994, J INTERFERON RES, V14, P357, DOI 10.1089/jir.1994.14.357	31	36	37	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2009	123	1					201	208		10.1016/j.jaci.2008.09.041	http://dx.doi.org/10.1016/j.jaci.2008.09.041			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	399IP	18986693				2022-12-18	WOS:000262793900033
J	Schroeder, NWJ; Crother, TR; Naiki, Y; Chen, S; Wong, MH; Yilmaz, A; Slepenkin, A; Schulte, D; Alsabeh, R; Doherty, TM; Peterson, E; Nel, AE; Arditi, M				Schroeder, Nicolas W. J.; Crother, Timothy R.; Naiki, Yoshikazu; Chen, Shuang; Wong, Michelle H.; Yilmaz, Atilla; Slepenkin, Anatoly; Schulte, Danica; Alsabeh, Randa; Doherty, Terence M.; Peterson, Ellena; Nel, Andre E.; Arditi, Moshe			Innate immune responses during respiratory tract infection with a bacterial pathogen induce allergic airway sensitization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; allergic sensitization; adjuvant; dendritic cell; Chlamydia pneumoniae; regulatory T cells; bacterial pneumonia; allergen	TOLL-LIKE RECEPTORS; DENDRITIC CELLS; HYGIENE HYPOTHESIS; ADAPTIVE IMMUNITY; T-CELLS; ASTHMA; ANTIGEN; PNEUMONIAE; ACTIVATION; EPIDEMIC	Background: The original hygiene hypothesis predicts that infections should protect against asthma but does not account for increasing evidence that certain infections might also promote asthma development. A mechanistic reconciliation of these findings has not yet emerged. In particular, the role of innate immunity in this context is unclear. Objective: We sought to test whether bacterial respiratory tract infection causes airway sensitization toward an antigen encountered in parallel and to elucidate the contribution of innate immune responses. Methods: Mice were infected with different doses of Chlamydia pneumoniae, followed by exposure to human serum albumin (HSA) and challenge with HSA 2 weeks later. Airway inflammation, immunoglobulins, and lymph node cytokines were assessed. Furthermore, adoptive transfer of dendritic cells (DCs) and depletion of regulatory T (Treg) cells was performed. Results: C pneumoniae-induced lung inflammation triggered sensitization toward HSA, resulting in eosinophilic airway inflammation after HSA challenge. Airway sensitization depended on the severity and timing of infection: low-dose infection and antigen exposure within 5 days of infection induced allergic sensitization, whereas high-dose infection or antigen exposure 10 days after infection did not. Temporal and dose-related effects reflected DC activation and could be reproduced by means of adoptive transfer of HSA-pulsed lung DCs from infected mice. MyD88 deficiency in DCs abolished antigen sensitization, and depletion of Treg cells prolonged the time window in which sensitization could occur. Conclusions: We conclude that moderate, but not severe, pulmonary bacterial infection can induce allergic sensitization to inert inhaled antigens through a mechanism that requires MyD88-dependent DC activation and is controlled by Treg cells.	[Alsabeh, Randa] Univ Calif Los Angeles, Dept Pathol, Los Angeles, CA 90048 USA; [Alsabeh, Randa] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Lab Med, Los Angeles, CA 90048 USA; [Yilmaz, Atilla] Univ Erlangen Nurnberg, Med Clin 2, Erlangen, Germany; [Slepenkin, Anatoly; Peterson, Ellena] Univ Calif Irvine, Dept Pathol, Irvine, CA 92717 USA; [Nel, Andre E.] Univ Calif Los Angeles, Dept Med, Div Clin Immunol & Allergy, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of Erlangen Nuremberg; University of California System; University of California Irvine; University of California System; University of California Los Angeles	Arditi, M (corresponding author), Cedars Sinai Med Ctr, Div Pediat Infect Dis & Immunol, 8700 Beverly Blvd,Rm 4221, Los Angeles, CA 90048 USA.	moshe.arditi@cshs.org	Nel, Andre E/J-2808-2012; Crother, Timothy R/E-2879-2010	Crother, Timothy R/0000-0001-8465-6127	National Institutes of Health [AI067995, AI058128, HL66436]; UCLA Asthma and Allergic Disease Clinical Research Center [AI50495]; Deutsche Forschungsgemeinschaft (DFG) [Schr 726/2]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066436] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI067995, R01AI058128, P01AI050495, R56AI067995] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UCLA Asthma and Allergic Disease Clinical Research Center; Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants AI067995. AI058128. and HL66436 to M.A.. by grant AI50495 (UCLA Asthma and Allergic Disease Clinical Research Center). and by a Deutsche Forschungsgemeinschaft (DFG) grant to N.W.J.S. (Schr 726/2).	Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Dahl ME, 2004, NAT IMMUNOL, V5, P337, DOI 10.1038/ni1041; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Eken C, 2008, J IMMUNOL, V180, P817, DOI 10.4049/jimmunol.180.2.817; Han XB, 2004, EUR J IMMUNOL, V34, P981, DOI 10.1002/eji.200324387; Hoebe K, 2004, NAT IMMUNOL, V5, P971, DOI 10.1038/ni1004-971; Holgate ST, 1999, NATURE, V402, pB2, DOI 10.1038/35037000; Inaba K, 1997, J EXP MED, V186, P665, DOI 10.1084/jem.186.5.665; Johnston SL, 2005, AM J RESP CRIT CARE, V172, P1078, DOI 10.1164/rccm.200412-1743PP; Kaiko GE, 2008, J IMMUNOL, V180, P2225, DOI 10.4049/jimmunol.180.4.2225; Kalina W V, 2004, Clin Dev Immunol, V11, P113, DOI 10.1080/10446670410001722131; Korsgren M, 1997, J EXP MED, V185, P885, DOI 10.1084/jem.185.5.885; Lambrecht BN, 2003, NAT REV IMMUNOL, V3, P994, DOI 10.1038/nri1249; Lewkowich IP, 2005, J EXP MED, V202, P1549, DOI 10.1084/jem.20051506; MacDowell AL, 2005, IMMUNOL ALLERGY CLIN, V25, P45, DOI 10.1016/j.iac.2004.09.011; Marsland BJ, 2004, NAT IMMUNOL, V5, P865, DOI 10.1038/ni0904-865a; Martin RJ, 2006, CLIN CHEST MED, V27, P87, DOI 10.1016/j.ccm.2005.10.004; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; Naiki Y, 2005, J BIOL CHEM, V280, P29242, DOI 10.1074/jbc.M503225200; Orihuela CJ, 2004, J INFECT DIS, V190, P1661, DOI 10.1086/424596; Pasare C, 2004, MICROBES INFECT, V6, P1382, DOI 10.1016/j.micinf.2004.08.018; Pasare C, 2003, CURR OPIN IMMUNOL, V15, P677, DOI 10.1016/j.coi.2003.09.002; Piggott DA, 2005, J CLIN INVEST, V115, P459, DOI 10.1172/JCI200522462; Redecke V, 2004, J IMMUNOL, V172, P2739, DOI 10.4049/jimmunol.172.5.2739; Schnare M, 2001, NAT IMMUNOL, V2, P947, DOI 10.1038/ni712; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Umetsu DT, 2006, IMMUNOL REV, V212, P238, DOI 10.1111/j.0105-2896.2006.00413.x; Umetsu DT, 2004, NAT MED, V10, P232, DOI 10.1038/nm0304-232; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490	30	36	38	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2008	122	3					595	602		10.1016/j.jaci.2008.06.038	http://dx.doi.org/10.1016/j.jaci.2008.06.038			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	348TW	18774395	Bronze, Green Accepted			2022-12-18	WOS:000259234000024
J	Foster, SB; McIntosh, K; Thompson, B; Lu, M; Yin, W; Rich, KC; Mendez, H; Serchuck, LK; Diaz, C; Paul, ME; Shearer, WT				Foster, Samuel B.; McIntosh, Kenneth; Thompson, Bruce; Lu, Ming; Yin, Wanrong; Rich, Kenneth C.; Mendez, Hermann; Serchuck, Leslie K.; Diaz, Clemente; Paul, Mary E.; Shearer, William T.			Increased incidence of asthma in HIV-infected children treated with highly active antiretroviral therapy in the National Institutes of Health Women and Infants Transmission Study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						pediatric HIV infection; CD4(+) T cell-mediated induction of asthma; highly active antiretroviral therapy--produced immunoreconstitution	AIRWAY INFLAMMATION; VIRAL-INFECTIONS; HYPERRESPONSIVENESS; HYPERREACTIVITY; INDIVIDUALS; PREVALENCE; PATHOLOGY; DISEASES; MODELS; AIDS	Background: Immunoreconstitution of HIV+ patients after treatment with highly active antiretroviral therapy (HAART) appears to provoke inflammatory diseases. Objective: We sought to determine whether HIV+ children receiving HAART(HIV+ HAART(+)) have a higher incidence of asthma than HIV+ children not receiving HAART (HIV+ HAART(-)). Methods: Two thousand six hundred sixty-four children (193 HIV+ and 2471 HIV- children) born to HIV+ women were evaluated for the incidence and prevalence of asthma (ie, asthma medication use) and change of CD4(+) T-cell percentage with time. Results: The HIV+ HAART(+) children had higher CD4(+) T-cell percentages, lower CD8(+) T-cell percentages, and lower viral burdens than the HIV+ HAART(-) children (P <= .05 to P <= .01). The cumulative incidence of asthma medication use in HIV+ HAART(+) children at 13.5 years increased to 33.5% versus 11.5% in HIV+ HAART(-) children (hazard ratio, 3.34; P = .01) and was equal to that in the HIV- children. In children born before the HAART era, the prevalence of asthma medication use for HIV+ HAART(+) children at 11 years of age was 10.4% versus 3.8% for HIV+ HAART(-) children (odds ratio, 3.38; P = .02) and was equal to that of the HIV- children. The rate of change of CD4(+) IF cells around the time of first asthma medication for HIV+ HAART(+) versus HIV+ HAART(--) children was 0.81 %/y versus -1.43 %/y (P = .01). Conclusion: The increased incidence of asthma in HIV+ HAART(+) children might be driven by immunoreconstitution of CD4(+) T cells.	[Foster, Samuel B.; Paul, Mary E.; Shearer, William T.] Texas Childrens Hosp, Houston, TX 77030 USA; [Foster, Samuel B.; Paul, Mary E.; Shearer, William T.] Baylor Coll Med, Dept Pediat, Allergy & Immunol Sect, Houston, TX 77030 USA; [McIntosh, Kenneth] Harvard Univ, Childrens Hosp, Sch Med, Div Infect Dis, Boston, MA 02115 USA; [Thompson, Bruce; Lu, Ming; Yin, Wanrong] Clin Trials & Surveys Corp, Baltimore, MD USA; [Rich, Kenneth C.] Univ Illinois, Dept Pediat, Chicago, IL USA; [Mendez, Hermann] SUNY, Dept Pediat, Brooklyn, NY USA; [Serchuck, Leslie K.] NICHHD, Pediat Adolescent & Maternal AIDS Branch, Bethesda, MD 20892 USA; [Diaz, Clemente] Puerto Rico Sch Med, Dept Pediat, San Juan, PR USA	Baylor College of Medicine; Baylor College of Medicine; Harvard University; Boston Children's Hospital; Harvard Medical School; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; State University of New York (SUNY) System; SUNY Maritime College; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Shearer, WT (corresponding author), Texas Childrens Hosp, 6621 Fannin St MC FC330-01, Houston, TX 77030 USA.	wtsheare@TexasChildrensHospital.org	Paul, Mary/AAA-2722-2021	Shearer, William/0000-0002-2483-2130	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD041983] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [K01RR000188, M01RR000188] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072705, R01HL079533] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027551, U01AI041089, U01AI034840, P30AI036211] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR000188, K01 RR000188, RR0188] Funding Source: Medline; NHLBI NIH HHS [R01 HL079533, HL96040, HL72705, HL079533, R01 HL072705] Funding Source: Medline; NIAID NIH HHS [U01 AI027551, P30 AI036211, AI36211, U01 AI041089, AI27551, AI41089, U01 AI034840-08] Funding Source: Medline; NICHD NIH HHS [HD41983, U01 HD041983] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Busse WW, 2007, J ALLERGY CLIN IMMUN, V119, P43, DOI 10.1016/j.jaci.2006.10.021; BUSSE WW, 2003, ALLERGY PRINCIPLES P, P1175; CALVELLI T, 1993, CYTOMETRY, V14, P702, DOI 10.1002/cyto.990140703; Chapoval SP, 2001, J ALLERGY CLIN IMMUN, V108, P764, DOI 10.1067/mai.2001.118794; Colin AA, 2001, AM J RESP CRIT CARE, V163, P865, DOI 10.1164/ajrccm.163.4.9901040; Corry DB, 2006, J ALLERGY CLIN IMMUN, V117, pS461, DOI 10.1016/j.jaci.2005.09.001; COX DR, 1972, J R STAT SOC B, V34, P187; Diggle P., 2002, ANAL LONGITUDINAL DA; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Foster SB, 2007, J ALLERGY CLIN IMMUN, V119, P750, DOI 10.1016/j.jaci.2007.01.002; Friedlander SL, 2005, J ALLERGY CLIN IMMUN, V116, P267, DOI 10.1016/j.jaci.2005.06.003; Galli L, 2003, PEDIAT ALLERG IMM-UK, V14, P42, DOI 10.1046/j.1439-0388.2003.02104.x; GAVETT SH, 1994, AM J RESP CELL MOL, V10, P587, DOI 10.1165/ajrcmb.10.6.8003337; Gutin F., 2004, Journal of Allergy and Clinical Immunology, V113, pS127, DOI 10.1016/j.jaci.2003.12.451; Heymann PW, 2004, J ALLERGY CLIN IMMUN, V114, P239, DOI 10.1016/j.jaci.2004.04.006; Kalbfleisch JD, 1980, STAT ANAL FAILURE TI, DOI [DOI 10.1002/9781118032985, 10.1002/9781118032985]; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; LIN RY, 1995, ANN ALLERG ASTHMA IM, V74, P510; MACAUBAS C, 2003, PEDIAT ALLERGY PRINC, P337; McCullagh P, 1989, CHAPMAN HALL CRC MON, V37; MOSCATO G, 1993, CHEST, V103, P796, DOI 10.1378/chest.103.3.796; O'Sullivan S, 2001, AM J RESP CRIT CARE, V164, P560, DOI 10.1164/ajrccm.164.4.2102018; ODONNELL CR, 1988, CHEST, V94, P945, DOI 10.1378/chest.94.5.945; PALUMBO PE, 1995, J PEDIATR-US, V126, P592, DOI 10.1016/S0022-3476(95)70357-8; Paul ME, 2005, J ALLERGY CLIN IMMUN, V115, P848, DOI 10.1016/j.jaci.2004.11.054; Poirier CD, 2001, AM J RESP CRIT CARE, V164, P542, DOI 10.1164/ajrccm.164.4.2010019; Reveille JD, 2006, BEST PRACT RES CL RH, V20, P1159, DOI 10.1016/j.berh.2006.08.015; Schaller M, 2006, J ALLERGY CLIN IMMUN, V118, P295, DOI 10.1016/j.jaci.2006.05.025; Shearer WT, 1997, NEW ENGL J MED, V336, P1337, DOI 10.1056/NEJM199705083361901; Shelburne SA, 2006, J ANTIMICROB CHEMOTH, V58, P1094, DOI 10.1093/jac/dkl390; SHEON AR, 1996, J WOMENS HEALTH, V5, P69, DOI DOI 10.1089/JWH.1996.5.69; STOVER DE, 1985, AM J MED, V78, P429, DOI 10.1016/0002-9343(85)90334-1; Swain SD, 2006, AM J PATHOL, V168, P466, DOI 10.2353/ajpath.2006.050724; Taussig LM, 2003, J ALLERGY CLIN IMMUN, V111, P661, DOI 10.1067/mai.2003.162; von Mutius E, 2007, NEW ENGL J MED, V357, P1545, DOI 10.1056/NEJMe078119; Wallace JM, 1997, CHEST, V111, P121, DOI 10.1378/chest.111.1.121; Werk LN, 2000, PEDIATRICS, V105, P585, DOI 10.1542/peds.105.3.585; [No title captured]	39	36	38	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2008	122	1					159	165		10.1016/j.jaci.2008.04.043	http://dx.doi.org/10.1016/j.jaci.2008.04.043			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	325RD	18547627	Green Accepted			2022-12-18	WOS:000257605100026
J	Sharma, HP; Wood, RA; Bravo, AR; Matsui, EC				Sharma, Hemant P.; Wood, Robert A.; Bravo, Andrea R.; Matsui, Elizabeth C.			A comparison of skin prick tests, intradermal skin tests, and specific IgE in the diagnosis of mouse allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mouse allergen; skin test; nasal challenge; diagnostic testing	LABORATORY-ANIMAL WORKERS; RESPIRATORY ALLERGY; NASAL; ASTHMA; TECHNICIANS; CHALLENGE; SYMPTOMS; RHINITIS; EXPOSURE; CHILDREN	Background: Mouse sensitization is assessed by using skin testing and serum levels of mouse allergen-specific IgE (m-IgE). However, it is unknown whether a positive skin test response or m-IgE result accurately identifies those with clinically relevant mouse sensitization. Objective: We sought to compare skin testing and m-IgE measurement in the diagnosis of mouse allergy. Methods: Sixty-nine mouse laboratory workers underwent skin prick tests (SPTs), intradermal tests (IDTs), and serum IgE measurements to mouse allergen, followed by nasal challenge to increasing concentrations of mouse allergen. Challenge response was assessed by nasal symptom score. Results: Thirty-eight women and 31 men with a mean age of 30 years were studied. Forty-nine workers reported mouse-related symptoms, of whom 10 had positive m-IgE results and 12 had positive SPT responses. Fifteen had negative SPT responses but positive IDT responses. Positive nasal challenges were observed in 70% of workers with positive m-IgE results, 83% of workers with positive SPT responses, 33% of workers with negative SPT responses/positive IDT responses, and 0% of workers with negative IDT responses. SPTs performed best, having the highest positive and negative predictive values. Among participants with a positive challenge result, those with a positive SPT response or m-IgE result had a significantly lower challenge threshold than those with a positive IDT response (P = .01). Workers with a positive challenge result were more likely to have an increase in nasal eosinophilia after the challenge compared with those with a negative challenge result (P = .03). Conclusions: SPTs perform best in discriminating patients with and without mouse allergy. Mouse-specific IgE and IDTs appear to be less useful than SPTs in the diagnosis of mouse allergy.	[Sharma, Hemant P.; Wood, Robert A.; Bravo, Andrea R.; Matsui, Elizabeth C.] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Pediat Allergy & Immunol, Baltimore, MD 21218 USA	Johns Hopkins University	Matsui, EC (corresponding author), MHS, 600 N Wolfe St,CMSC 1102, Baltimore, MD 21287 USA.	ematsui@jhmi.edu		Matsui, Elizabeth/0000-0001-8134-5593	NIAID NIH HHS [T32 AI07007, K23AI060955, R01AI070630] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007007, R01AI070630, K23AI060955] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGRUP G, 1986, BRIT J IND MED, V43, P192; AOYAMA K, 1992, BRIT J IND MED, V49, P41; BEESON MF, 1983, CLIN ALLERGY, V13, P433, DOI 10.1111/j.1365-2222.1983.tb02619.x; Belda J, 2001, CLIN EXP ALLERGY, V31, P1111, DOI 10.1046/j.1365-2222.2001.01133.x; BROWN WG, 1979, J ALLERGY CLIN IMMUN, V63, P328, DOI 10.1016/0091-6749(79)90127-1; COCKCROFT A, 1981, LANCET, V1, P827; DAVIES GE, 1983, BRIT J IND MED, V40, P442; DAVIES GE, 1981, INT ARCH ALLER A IMM, V64, P302, DOI 10.1159/000232707; Day JH, 2006, ANN ALLERG ASTHMA IM, V96, P263, DOI 10.1016/S1081-1206(10)61235-5; Eldridge MW, 2000, J ALLERGY CLIN IMMUN, V105, P475, DOI 10.1067/mai.2000.104552; Gautrin D, 2001, EUR RESPIR J, V17, P904, DOI 10.1183/09031936.01.17509040; Hollander A, 1997, AM J RESP CRIT CARE, V155, P562, DOI 10.1164/ajrccm.155.2.9032195; Hurst DS, 2002, OTOLARYNG HEAD NECK, V127, P177, DOI 10.1067/mhn.2002.127890; Matsui EC, 2005, J ALLERGY CLIN IMMUN, V115, P358, DOI 10.1016/j.jaci.2004.11.007; Matsui EC, 2006, ANN ALLERG ASTHMA IM, V97, P514, DOI 10.1016/S1081-1206(10)60943-X; Nelson HS, 1996, J ALLERGY CLIN IMMUN, V97, P1193, DOI 10.1016/S0091-6749(96)70184-7; OHMAN JL, 1994, J ALLERGY CLIN IMMUN, V94, P810, DOI 10.1016/0091-6749(94)90147-3; Pacheco KA, 2003, AM J RESP CRIT CARE, V167, P983, DOI 10.1164/rccm.2112062; PEPYS J, 1975, Clinical Allergy, V5, P431, DOI 10.1111/j.1365-2222.1975.tb01882.x; RASANEN L, 1994, ALLERGY, V49, P342, DOI 10.1111/j.1398-9995.1994.tb02279.x; REDDY PM, 1978, J ALLERGY CLIN IMMUN, V61, P36, DOI 10.1016/0091-6749(78)90471-2; Saengpanich S, 2002, LARYNGOSCOPE, V112, P47, DOI 10.1097/00005537-200201000-00009; SCHUMACHER MJ, 1981, J ALLERGY CLIN IMMUN, V68, P310, DOI 10.1016/0091-6749(81)90157-3; Schwindt CD, 2005, ANN ALLERG ASTHMA IM, V94, P627, DOI 10.1016/S1081-1206(10)61319-1; Sicherer SH, 1997, J ALLERGY CLIN IMMUN, V99, P798, DOI 10.1016/S0091-6749(97)80014-0; Wood RA, 1999, J ALLERGY CLIN IMMUN, V103, P773, DOI 10.1016/S0091-6749(99)70419-7	26	36	40	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2008	121	4					933	939		10.1016/j.jaci.2008.01.023	http://dx.doi.org/10.1016/j.jaci.2008.01.023			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286YY	18325579	Bronze			2022-12-18	WOS:000254884000018
J	Vanoirbeek, JAJ; De Vooght, V; Vanhooren, HM; Nawrot, TS; Nemery, B; Hoet, PHM				Vanoirbeek, Jeroen A. J.; De Vooght, Vanessa; Vanhooren, Hadewijch M.; Nawrot, Tim S.; Nemery, Benoit; Hoet, Peter H. M.			How long do the systemic and ventilatory responses to toluene diisocyanate persist in dermally sensitized mice?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						TDI; dermal sensitization; occupational asthma; murine model; lymphocyte subtypes; IL-4; IFN-gamma; MIP-2	TRIMELLITIC ANHYDRIDE POWDER; OCCUPATIONAL ASTHMA; IMMUNOLOGICAL DETERMINANTS; BRONCHIAL REACTIVITY; AIRWAY RESPONSES; MURINE MODEL; MOUSE MODEL; IFN-GAMMA; EXPOSURE; AGENTS	Background: Years after removal from exposure, workers with occupational asthma still show respiratory symptoms and airway hyperresponsiveness on re-exposure to the offending agent. Objective: We investigated the persistence of the respiratory responsiveness to toluene diisocyanate (TDI) in a mouse model. Methods: BALB/C mice received dermal applications of TDI on days 1 and 8, and a single intranasal instillation of TDI on day 10, 15, 20, 25, 30, 40, 50, 60, or 90. After instillation, early (1 hour) changes in ventilatory function and methacholine responsiveness (22 hours) were assessed. Cell counts and macrophage inflammatory protein 2 were measured in bronchoalveolar lavage. Total serum IgE, IgG(1), and IgG(2a) were quantified. Lymphocyte subpopulations were assessed in auricular and cervical lymph nodes, and release of IL-4 and IFN-gamma by these lymph node cells was measured. Results: Toluene diisocyanate-treated mice showed immediate ventilatory changes, increased methacholine reactivity, and an influx of neutrophils and macrophage inflammatory protein 2 in bronchoalveolar lavage as long as 50 days after initial treatment. These mice also showed a relative increase in CD19(+) cells and a decrease in CD4(+) and CD8(+) cells in auricular lymph nodes. Increased release of IL-4 and IFN-gamma in auricular lymph node cells was observed only until 20 days after sensitization. Total serum IgE, IgG(1), and IgG(2a) remained significantly elevated in TDI-sensitized mice until 90 days after dermal sensitization. Conclusion: Ventilatory and lung inflammatory responses decrease with increasing delay between sensitization and challenge, despite persistent Immoral signs of sensitization.	[Vanoirbeek, Jeroen A. J.; De Vooght, Vanessa; Vanhooren, Hadewijch M.; Nawrot, Tim S.; Nemery, Benoit; Hoet, Peter H. M.] Katholieke Univ Leuven, Lab Lung Toxicol, B-3000 Louvain, Belgium	KU Leuven	Hoet, PHM (corresponding author), Katholieke Univ Leuven, Lab Lung Toxicol, Herestraat 49 bus 706, B-3000 Louvain, Belgium.	peter.hoet@med.kuleuven.be	Vanoirbeek, Jeroen/D-5183-2016; Nawrot, Tim/AAA-4531-2019; Nemery, Benoit/N-3155-2019; Hoet, Peter/H-9987-2013; Nemery, Benoit/D-1224-2013	Vanoirbeek, Jeroen/0000-0001-5508-3518; Nemery, Benoit/0000-0003-0571-4689; Hoet, Peter/0000-0002-0292-6603; Nawrot, Tim/0000-0002-3583-3593				ARAKAWA H, 1993, J ALLERGY CLIN IMMUN, V92, P425, DOI 10.1016/0091-6749(93)90121-U; BUTCHER BT, 1982, J ALLERGY CLIN IMMUN, V70, P231, DOI 10.1016/0091-6749(82)90058-6; Dearman RJ, 2001, J APPL TOXICOL, V21, P153, DOI 10.1002/jat.743; Gautrin D, 2002, CURR OPIN ALLERGY CL, V2, P123, DOI 10.1097/00130832-200204000-00007; Herrick CA, 2002, J ALLERGY CLIN IMMUN, V109, P873, DOI 10.1067/mai.2002.123533; Jones MG, 2006, J ALLERGY CLIN IMMUN, V117, P663, DOI 10.1016/j.jaci.2005.09.053; Kimber I, 2002, CONTACT DERMATITIS, V47, P315, DOI 10.1034/j.1600-0536.2002.470601.x; Larsen ST, 2007, TOXICOL LETT, V170, P223, DOI 10.1016/j.toxlet.2007.03.009; Lemiere C, 2000, AM J RESP CRIT CARE, V162, P976, DOI 10.1164/ajrccm.162.3.9910031; Lemiere C, 1996, AM J RESP CRIT CARE, V154, P329, DOI 10.1164/ajrccm.154.2.8756802; Lemiere C, 2003, ANN ALLERG ASTHMA IM, V90, P52, DOI 10.1016/S1081-1206(10)61650-X; Maestrelli P, 1997, CLIN EXP ALLERGY, V27, P1292; Maghni K, 2004, AM J RESP CRIT CARE, V169, P367, DOI 10.1164/rccm.200309-1238OC; Malo JL, 2004, CURR OPIN PULM MED, V10, P57, DOI 10.1097/00063198-200401000-00010; Mapp CE, 2005, AM J RESP CRIT CARE, V172, P280, DOI 10.1164/rccm.200311-1575SO; Matheson JM, 2005, TOXICOL SCI, V84, P99, DOI 10.1093/toxsci/kfi051; Matheson JM, 2005, TOXICOL SCI, V84, P88, DOI 10.1093/toxsci/kfi050; Park HS, 1999, J ALLERGY CLIN IMMUN, V104, P847, DOI 10.1016/S0091-6749(99)70297-6; Park HS, 1997, CLIN EXP ALLERGY, V27, P1145; Park HS, 1999, CLIN EXP ALLERGY, V29, P1395; Pisati G, 2007, INT ARCH OCC ENV HEA, V80, P298, DOI 10.1007/s00420-006-0134-3; Pochanke V, 2006, EUR J IMMUNOL, V36, P2434, DOI 10.1002/eji.200635949; Rachiotis G, 2007, THORAX, V62, P147, DOI 10.1136/thx.2006.061952; Sehra S, 2003, J IMMUNOL, V171, P2080, DOI 10.4049/jimmunol.171.4.2080; Tarkowski M, 2007, AM J PHYSIOL-LUNG C, V292, pL207, DOI 10.1152/ajplung.00157.2005; Vandenplas O, 1997, EUR RESPIR J, V10, P2612, DOI 10.1183/09031936.97.10112612; Vanoirbeek JAJ, 2004, TOXICOL SCI, V80, P310, DOI 10.1093/toxsci/kfh155; Vanoirbeek JAJ, 2003, TOXICOL SCI, V76, P338, DOI 10.1093/toxsci/kfg235; Vanoirbeek JAJ, 2006, J ALLERGY CLIN IMMUN, V117, P1090, DOI 10.1016/j.jaci.2006.01.027; Wisnewski AV, 2003, J ALLERGY CLIN IMMUN, V112, P538, DOI 10.1067/mai.2003.1713; Zhang XD, 2004, J ALLERGY CLIN IMMUN, V113, P320, DOI 10.1016/j.jaci.2003.11.047; Zhang XD, 2002, ALLERGY, V57, P620, DOI 10.1034/j.1398-9995.2002.03548.x	32	36	36	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2					456	463		10.1016/j.jaci.2007.09.006	http://dx.doi.org/10.1016/j.jaci.2007.09.006			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	265CX	17980417	Green Published			2022-12-18	WOS:000253337800027
J	Grundinann, SA; Heinfort, PB; Luger, TA; Brehler, R				Grundinann, Sonja A.; Heinfort, Pia B.; Luger, Thornas A.; Brehler, Randolf			Anti-IgE (omalizumab): A new therapeutic approach for chronic rhinosinusitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Grundinann, Sonja A.; Heinfort, Pia B.; Luger, Thornas A.; Brehler, Randolf] Univ Hosp Munster, Dept Dermatol, Munster, Germany	University of Munster	Grundinann, SA (corresponding author), Univ Hosp Munster, Dept Dermatol, Munster, Germany.	sonja.grundmann@ukmuenster.de						Fokkens W, 2005, ALLERGY, V60, P583, DOI 10.1111/j.1398-9995.2005.00830.x; *GLOB IN ASTHM, 2006, NIH PUBLICATION; Holgate ST, 2006, LANCET, V368, P780, DOI 10.1016/S0140-6736(06)69288-X; Pleis John R, 2002, Vital Health Stat 10, P1; Strunk RC, 2006, NEW ENGL J MED, V354, P2689, DOI 10.1056/NEJMct055184; Vignola AM, 2004, ALLERGY, V59, P709, DOI 10.1111/j.1398-9995.2004.00550.x; Walker S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003559.pub3	7	36	36	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2008	121	1					257	258		10.1016/j.jaci.2007.09.036	http://dx.doi.org/10.1016/j.jaci.2007.09.036			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	251KM	18206513				2022-12-18	WOS:000252372000042
J	Woszczek, G; Chen, LY; Nagineni, S; Kern, S; Barb, J; Munson, PJ; Logun, C; Danner, RL; Shelhamer, JH				Woszczek, Grzegorz; Chen, Li-Yuan; Nagineni, Sahrudaya; Kern, Steven; Barb, Jennifer; Munson, Peter J.; Logun, Carolea; Danner, Robert L.; Shelhamer, James H.			Leukotriene D-4 induces gene expression in human monocytes through cysteinyl leukotriene type I receptor	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						human monocytes; cysteinyl leukotrienes; immediate-early genes; chemotaxis	HUMAN ENDOTHELIAL-CELLS; DENDRITIC CELLS; CYSLT(1) RECEPTOR; PROTEIN-KINASE; RESPONSES; ASTHMA; IMMUNE; DIFFERENTIATION; INFLAMMATION; ACTIVATION	Background: Cysteinyl leukotrienes (CysLTs) are important mediators of innate immune responsiveness and chronic inflammatory diseases. CysLTs acting through CysLT receptors can influence the migration and activity of cells, such as eosinophils, monocytes, and dendritic cells. Objective: We sought to determine the gene expression signature of human monocytes in response to CysLTs and to elucidate the signaling pathways involved in monocyte activation. Methods: Gene expression was analyzed by using oligonucleotide microarrays. Responsiveness to CysLTs was assessed by using real-time PCR, calcium flux, kinase activation, and chemotaxis assays. Results: CysLT type 1 receptor (CysLTR(1)) transcript 1 is predominantly expressed in human monocytes, and CysLTs signal through CysLTR(1) in these cells. Several immediate-early genes, including early growth response 2 and 3, FBJ murine osteosarcoma viral oncogene homolog B, activating transcription factor 3, and nuclear receptor subfamily 4 were significantly induced by leukotriene (LT) D-4. This effect was mediated by CysLTR(1) coupled to the G protein alpha inhibitory subunit, activation of phospholipase C, and inositol-1,4,5-triphosphate and store-operated calcium channels. LTD4 induced p38 mitogen-activated protein kinase phosphorylation, a pathway also involved in the regulation of immediate-early gene expression in monocytes. LTD4 stimulated monocyte chemotactic activity that was fully blocked by a selective CysLTR(1) inhibitor, MK571, and pertussis toxin, suggesting that CysLTR(1) coupled to the G protein alpha inhibitory subunit is a dominant functional pathway in human monocytes. Conclusion: Our data show that CysLTs acting through CysLTR(1) can significantly influence the activation and migration of human monocytes and that these effects can be fully inhibited by CysLTR(1) antagonists.	[Woszczek, Grzegorz; Chen, Li-Yuan; Nagineni, Sahrudaya; Kern, Steven; Logun, Carolea; Danner, Robert L.; Shelhamer, James H.] NIH, Dept Crit Care Med, Ctr Clin, Bethesda, MD 20892 USA; [Barb, Jennifer; Munson, Peter J.] NIH, Ctr Informat Technol, Math & Stat Comp Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH Center for Information Technology (CIT)	Shelhamer, JH (corresponding author), NIH, Dept Crit Care Med, Ctr Clin, Bldg 10 Rm 2C145,9000 ville Pike, Bethesda, MD 20892 USA.	jshelhamer@cc.nih.gov	Woszczek, Grzegorz/H-5792-2012; Chen, Liyuan/AAF-3864-2020	Barb, Jennifer/0000-0003-3022-0154	Medical Research Council [G0400503B] Funding Source: researchfish; Intramural NIH HHS [Z99 CT999999] Funding Source: Medline; CENTER FOR INFORMATION TECHNOLOGY [Z01CT000266] Funding Source: NIH RePORTER; CLINICAL CENTER [ZIACL001164, ZIACL008071] Funding Source: NIH RePORTER	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CENTER FOR INFORMATION TECHNOLOGY(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Center for Information Technology (CIT)); CLINICAL CENTER		Bautz F, 2001, BLOOD, V97, P3433, DOI 10.1182/blood.V97.11.3433; Capra V, 2004, BIOCHEM PHARMACOL, V67, P1569, DOI 10.1016/j.bcp.2003.12.027; Ciana P, 2006, EMBO J, V25, P4615, DOI 10.1038/sj.emboj.7601341; Fregonese L, 2002, CLIN EXP ALLERGY, V32, P745, DOI 10.1046/j.1365-2222.2002.01384.x; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Hamilton A, 1998, J ALLERGY CLIN IMMUN, V102, P177, DOI 10.1016/S0091-6749(98)70083-1; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; HOLGATE ST, 2003, J ALLERGY CLIN IMM S, V111, pS6; Holgate Stephen T., 2003, Journal of Allergy and Clinical Immunology, V111, pS18, DOI 10.1067/mai.2003.25; Hoshino M, 1998, J BIOL CHEM, V273, P4878, DOI 10.1074/jbc.273.9.4878; Jahnsen FL, 2001, THORAX, V56, P823, DOI 10.1136/thorax.56.11.823; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kanaoka Y, 2004, J IMMUNOL, V173, P1503, DOI 10.4049/jimmunol.173.3.1503; KHARBANDA S, 1991, J CLIN INVEST, V88, P571, DOI 10.1172/JCI115341; Kim DC, 2006, J IMMUNOL, V176, P4440, DOI 10.4049/jimmunol.176.7.4440; Leigh R, 2002, AM J RESP CRIT CARE, V166, P1212, DOI 10.1164/rccm.200206-509OC; Lynch KR, 1999, NATURE, V399, P789; Mellor EA, 2003, P NATL ACAD SCI USA, V100, P11589, DOI 10.1073/pnas.2034927100; Parameswaran K, 2004, J ALLERGY CLIN IMMUN, V114, P73, DOI 10.1016/j.jaci.2004.03.054; Peters-Golden M, 2005, J IMMUNOL, V174, P589, DOI 10.4049/jimmunol.174.2.589; Robbiani DF, 2000, CELL, V103, P757, DOI 10.1016/S0092-8674(00)00179-3; Romagnani P, 2005, CIRC RES, V97, P314, DOI 10.1161/01.RES.0000177670.72216.9b; Tacke F, 2006, J EXP MED, V203, P583, DOI 10.1084/jem.20052119; Thivierge M, 2001, J IMMUNOL, V167, P2855, DOI 10.4049/jimmunol.167.5.2855; Thivierge M, 2006, J ALLERGY CLIN IMMUN, V117, P1155, DOI 10.1016/j.jaci.2005.12.1342; Thompson C, 2006, AM J RESP CELL MOL, V35, P697, DOI 10.1165/rcmb.2005-0407OC; Uzonyi B, 2006, P NATL ACAD SCI USA, V103, P6326, DOI 10.1073/pnas.0601223103; van de Ven R, 2006, J IMMUNOL, V176, P5191, DOI 10.4049/jimmunol.176.9.5191; Wieland GD, 2005, J CELL SCI, V118, P3203, DOI 10.1242/jcs.02445; Woszczek G, 2005, J IMMUNOL, V175, P5152, DOI 10.4049/jimmunol.175.8.5152; Woszczek G, 2007, J IMMUNOL, V178, P5262, DOI 10.4049/jimmunol.178.8.5262	31	36	37	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2008	121	1					215	221		10.1016/j.jaci.2007.09.013	http://dx.doi.org/10.1016/j.jaci.2007.09.013			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	251KM	18028998	Green Accepted			2022-12-18	WOS:000252372000033
J	Lemiere, C; Forget, A; Dufour, MH; Boulet, LP; Blais, L				Lemiere, Catherine; Forget, Amelie; Dufour, Marie-Helene; Boulet, Louis-Philippe; Blais, Lucie			Characteristics and medical resource use of asthmatic subjects with and without work-related asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						occupational asthma; work-exacerbated asthma; work-related asthma; medical resource	OCCUPATIONAL ASTHMA; AIRWAY INFLAMMATION; SYMPTOMS; EXPOSURE	Background: Asthma is work related when there is an association between symptoms and work. Occupational asthma (OA) is induced by the workplace, whereas work-exacerbated asthma (WEA) is triggered by the workplace but not induced by it. Objective: We sought to compare the clinical characteristics and the use of medical resources between subjects with work-related asthma (WRA) and asthmatic control subjects without WRA, as well as between subjects with OA and subjects with WEA. Methods: We performed a retrospective cohort study of the charts of subjects with WRA who were investigated between 2001 and 2004 in our centers. These subjects were matched according to sex, age, and FEV1 to subjects with non-WRA investigated during the same period. All charts were linked to the information provided by the Regie de l'assurance maladie du Quebec, including outpatient clinic visits and visits to the emergency department and hospitalizations during the year before and after the initial assessment in our centers. Results: Three hundred fifty-one subjects had WRA (WEA, 145; OA, 206), whereas 384 subjects were asthmatic control subjects without WRA. Subjects with WRA had more asthma exacerbations than subjects with non-WRA. The risk factor of experiencing a severe asthma exacerbation was no greater for OA than for WEA (odds ratio, 1.15; 95% CI, 0.75-1.75). Conclusion: WRA is associated with a larger use of medical resources than non-WRA. Clinical implications: Improving the diagnosis and management of WRA is crucial for limiting the use of medical resources associated with this condition.	[Lemiere, Catherine; Forget, Amelie; Blais, Lucie] Hop Sacre Coeur, Dept Chest Med, Montreal, PQ H4J 1C5, Canada; [Dufour, Marie-Helene; Boulet, Louis-Philippe] Univ Laval, Hop Laval, Inst Cardiol & Pneumol, Unite Rech Pneumol, Laval, PQ, Canada	Universite de Montreal; Laval University	Lemiere, C (corresponding author), Hop Sacre Coeur, Dept Chest Med, 5400 Gouin W, Montreal, PQ H4J 1C5, Canada.	catherine.lemiere@umontreal.ca						[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; Breton CV, 2006, OCCUP ENVIRON MED, V63, P411, DOI 10.1136/oem.2005.025064; Girard F, 2004, AM J RESP CRIT CARE, V170, P845, DOI 10.1164/rccm.200403-380OC; Henneberger PK, 2003, J OCCUP ENVIRON MED, V45, P360, DOI 10.1097/01.jom.0000063620.37065.6f; Henneberger PK, 2002, INT J OCCUP ENV HEAL, V8, P291; HUDSON P, 1985, J ALLERGY CLIN IMMUN, V76, P682, DOI 10.1016/0091-6749(85)90671-2; Johnson AR, 2000, AM J RESP CRIT CARE, V162, P2058, DOI 10.1164/ajrccm.162.6.9805079; Juniper E, 1994, HISTAMINE METHACHOLI; Larbanois A, 2002, EUR RESPIR J, V19, P1107, DOI 10.1183/09031936.02.00272202a; Le Moual N, 2005, AM J RESP CRIT CARE, V172, P440, DOI 10.1164/rccm.200501-111OC; Lemiere C, 2006, J OCCUP ENVIRON MED, V48, P656, DOI 10.1097/01.jom.0000226917.47400.2a; Maghni K, 2004, AM J RESP CRIT CARE, V169, P367, DOI 10.1164/rccm.200309-1238OC; Nicholson PJ, 2005, OCCUP ENVIRON MED, V62, P290, DOI 10.1136/oem.2004.016287; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799; Saarinen K, 2003, EUR RESPIR J, V22, P305, DOI 10.1183/09031936.03.00100102; Vandenplas O, 2003, EUR RESPIR J, V21, P706, DOI 10.1183/09031936.03.00113303; Vandenplas O., 2006, ASTHMA WORKPLACE, P227, DOI 10.3109/9780849374531	18	36	36	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2007	120	6					1354	1359		10.1016/j.jaci.2007.07.043	http://dx.doi.org/10.1016/j.jaci.2007.07.043			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241JX	17889289				2022-12-18	WOS:000251653800016
J	Esnault, S; Rosenthal, LA; Shen, ZJ; Sedgwick, JB; Szakaly, RJ; Sorkness, RL; Malter, JS				Esnault, Stephane; Rosenthal, Louis A.; Shen, Zhong-Jian; Sedgwick, Julie B.; Szakaly, Renee J.; Sorkness, Ronald L.; Malter, James S.			A critical role for Pin1 in allergic pulmonary eosinophilia in rats	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophil; asthma; apoptosis; cytokines	COLONY-STIMULATING FACTOR; PROLYL ISOMERASE PIN1; FACTOR MESSENGER-RNA; PERIPHERAL-BLOOD EOSINOPHILS; GM-CSF; AIRWAY; INFLAMMATION; EXPRESSION; JUGLONE; IL-5	Background: Infiltration, accumulation, and degranulation of eosinophils in the lung are hallmarks of active allergic asthma. The pulmonary response to inhaled allergen triggers the secretion of eosinophil chemoattractants and antiapoptotic cytokines, including GM-CSF, IL-3, IL-4, IL-5, and eotaxin, among others. We recently showed that in vitro pint regulated eosinophil production of and response to GM-CSF. Objective: We sought to determine the effect of Pint inhibition on pulmonary eosinophilia after allergen challenge. Methods: The Pint inhibitorjuglone (5-bydroxy-1,4-naphthoquinone) was administered to allergen-sensitized and allergen-challenged Brown Norway rats. Bronchoalveolar lavage fluid and lungs were assessed for inflammation, cytokine expression, and Pin1 activity. Results: Juglone-treated rats showed a dramatic reduction (approximately 75%) in bronchoalveolar lavage fluid and pulmonary eosinophilia but no change in lymphocyte, monocyte/macrophage, or neutrophil numbers. GM-CSF and IL-5 expression were also significantly reduced, whereas Pin1-independent cytokines, such as eotaxin or IL-4, as well as housekeeping mRNAs and proteins, including actin, were unaffected by juglone. The eosinophils present in the lung in juglone-treated rats showed significantly greater apoptosis. Conclusion: These data suggest that in vivo Pint blockade attenuates GM-CSF and IL-5 production and can selectively reduce eosinophilic allergic inflammation. Clinical implications: Eosinophils can be selectively reduced by Pint blockade, despite allergen challenge.	Univ Wisconsin, Waisman Ctr Dev Disabil, Dept Pathol & Lab Med, Sch Med & Publ Hlth, Madison, WI 53705 USA; Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Ctr Clin Sci, Madison, WI USA; Univ Wisconsin, Sch Med & Publ Hlth, Morris Inst Resp Res, Ctr Clin Sci, Madison, WI USA; Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Malter, JS (corresponding author), Univ Wisconsin, Waisman Ctr Dev Disabil, Dept Pathol & Lab Med, Sch Med & Publ Hlth, R509T,1500 Highland Ave, Madison, WI 53705 USA.	jsmalter@wisc.edu	Esnault, Stephane/AAJ-4511-2020; Rosenthal, Louis/A-8868-2008; Esnault, Stephane/AAO-4712-2020	Esnault, Stephane/0000-0001-7238-8671				Becker EBE, 2006, NEURON, V49, P655, DOI 10.1016/j.neuron.2006.01.034; BOCHNER BS, 1995, J IMMUNOL, V154, P799; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Chao SH, 2001, NUCLEIC ACIDS RES, V29, P767, DOI 10.1093/nar/29.3.767; Chen LJ, 2005, XENOBIOTICA, V35, P1019, DOI 10.1080/00498250500356621; CLUTTERBUCK EJ, 1989, BLOOD, V73, P1504; Esnault S, 1999, J IMMUNOL, V163, P5228; Esnault S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000226; Esnault S, 2006, J IMMUNOL, V177, P6999, DOI 10.4049/jimmunol.177.10.6999; Flood-Page PT, 2003, AM J RESP CRIT CARE, V167, P199, DOI 10.1164/rccm.200208-789OC; Fulkerson PC, 2006, P NATL ACAD SCI USA, V103, P16418, DOI 10.1073/pnas.0607863103; HANSEL TT, 1991, J IMMUNOL METHODS, V145, P105, DOI 10.1016/0022-1759(91)90315-7; Hennig L, 1998, BIOCHEMISTRY-US, V37, P5953, DOI 10.1021/bi973162p; Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283; KITA H, 1991, J EXP MED, V174, P745, DOI 10.1084/jem.174.3.745; Lee JJ, 2004, SCIENCE, V305, P1773, DOI 10.1126/science.1099472; Lemanske Robert F. Jr., 2003, Journal of Allergy and Clinical Immunology, V111, pS502; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; Liou YC, 2003, NATURE, V424, P556, DOI 10.1038/nature01832; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Liu LY, 2002, J IMMUNOL, V169, P6452, DOI 10.4049/jimmunol.169.11.6452; Liu WF, 2001, FEBS LETT, V496, P105, DOI 10.1016/S0014-5793(01)02411-5; Lu KP, 1996, NATURE, V380, P544; Martinez-Moczygemba M, 2003, J ALLERGY CLIN IMMUN, V112, P653, DOI 10.1067/mai.2003.1796; Mikus LD, 2001, AM J RESP CELL MOL, V24, P74, DOI 10.1165/ajrcmb.24.1.4125; RAMESH KS, 1987, J CELL BIOCHEM, V34, P203, DOI 10.1002/jcb.240340306; Romagnani S, 2002, MOL IMMUNOL, V38, P881, DOI 10.1016/S0161-5890(02)00013-5; ROTHENBERG ME, 2005, ANNU REV IMMUNOL, V24, P1; Ryo A, 2005, CLIN CANCER RES, V11, P7523, DOI 10.1158/1078-0432.CCR-05-0457; Ryo A, 2003, MOL CELL, V12, P1413, DOI 10.1016/S1097-2765(03)00490-8; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; Shen ZJ, 2005, NAT IMMUNOL, V6, P1280, DOI 10.1038/ni1266; Sorkness RL, 2004, J ALLERGY CLIN IMMUN, V114, P1027, DOI 10.1016/j.jaci.2004.07.015; Sorkness RL, 2007, AM J PHYSIOL-LUNG C, V292, pL85, DOI 10.1152/ajplung.00234.2006; TAI PC, 1990, CLIN EXP IMMUNOL, V80, P426	35	36	36	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2007	120	5					1082	1088		10.1016/j.jaci.2007.06.024	http://dx.doi.org/10.1016/j.jaci.2007.06.024			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	231TZ	17720236				2022-12-18	WOS:000250973400015
J	Lim, A; Luderschmidt, S; Weidinger, A; Schnopp, C; Ring, J; Hein, R; Ollert, M; Mempel, M				Lim, Annick; Luderschmidt, Stephan; Weidinger, Anke; Schnopp, Christina; Ring, Johannes; Hein, Ruediger; Ollert, Markus; Mempel, Martin			The IgE repertoire in PBMCs of atopic patients is characterized by individual rearrangements without variable region of the heavy immunoglobulin chain bias	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						B cells; atopic eczema; IgE repertoire; omalizumab	CLASS SWITCH RECOMBINATION; 3 UNRELATED PATIENTS; B-CELLS; NASAL-MUCOSA; GENE USAGE; SOMATIC HYPERMUTATION; ALLERGIC RHINITIS; PERIPHERAL-BLOOD; DERMATITIS; EPSILON	Background: Patients with atopic diseases are characterized by high levels of specific IgE production. However, little is known about the composition of their B-cell repertoires. Objectives: We sought to analyze the complete PBMC-derived IgE repertoire and to compare clonal expansions between different patients. Methods: We have analyzed the IgE-bearing B-cell receptor repertoire in highly atopic patients (> 1000 IU/mL) using quantitative RT-PCR, complementarity determining region 3 spectratyping, and sequence analysis. Three representative patients were additionally followed during anti-IgE therapy. Results: Atopic patients exhibited 100 to 1000 times more IgE-specific transcripts than control individuals. These patients used a variable region of the heavy immunoglobulin chain (VH) E repertoire highly similar to their IgM and IgG repertoires, with preference of VH3b, VH4, VH3a, and VH1 segments. Each patient harbored individual clonal expansions, most probably as correlation of allergen-specific IgE production. Common expansions within the complementary determining region 3 shared by several individuals with similar sensitization patterns were found in spectratyping analysis. However, these antigen-driven expansions showed differences on the sequence level. In omalizumab-treated patients the clinical improvement was paralleled by a clear increase in the ratio of IgG/IgE transcripts. Conclusion: The IgE repertoire in atopic patients follows the VH use patterns seen for other immunoglobulins and seems to preferentially recruit individual rearrangements rather than public expansions. Clinical implications: The detailed analysis of the IgE B-cell repertoire is highly suitable to follow changes in IgE uses during different therapy modalities.	Unite Rech & Expertise Immunite Antivirale Biothe, Paris, France; Inst Pasteur, INSERM, U668, F-75724 Paris, France; Tech Univ Munich, Dept Dermatol & Allergy, D-8000 Munich, Germany; Tech Univ Munich, Clin Res Div Mol & Clin Allergotoxicol, D-8000 Munich, Germany; Tech Univ Munich, GSF, Natl Res Ctr Environm & Hlth, Div Environm Dermatol & Allergy, D-8000 Munich, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Technical University of Munich; Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; University of Munich	Mempel, M (corresponding author), Tech Univ Munich, Klin & Poliklin Dermatol & Allergol, Biedersteiner Str 29, D-80802 Munich, Germany.	m.mempel@irz.tum.de	Ring, Johannes/GLN-4341-2022	Ring, Johannes/0000-0001-8236-3152; Ollert, Markus W./0000-0002-8055-0103				Achatz G, 2006, CHEM IMMUNOL ALLERGY, V91, P204; Andreasson U, 2006, J MOL BIOL, V362, P212, DOI 10.1016/j.jmb.2006.06.062; Bando Y, 2004, IMMUNOL LETT, V94, P99, DOI 10.1016/j.imlet.2004.04.006; Baskin B, 1997, EUR J IMMUNOL, V27, P130, DOI 10.1002/eji.1830270120; BREZINSCHEK HP, 1995, J IMMUNOL, V155, P190; Cameron L, 2003, J IMMUNOL, V171, P3816, DOI 10.4049/jimmunol.171.7.3816; Coker HA, 2005, J ALLERGY CLIN IMMUN, V116, P445, DOI 10.1016/j.jaci.2005.04.032; Coker HA, 2003, J IMMUNOL, V171, P5602, DOI 10.4049/jimmunol.171.10.5602; COME J, 1997, J CLIN INVEST, V99, P879; Cutler C, 2006, BLOOD, V108, P756, DOI 10.1182/blood-2006-01-0233; Davies JM, 2004, CLIN EXP ALLERGY, V34, P429, DOI 10.1111/j.1365-2222.2004.01900.x; Durham SR, 1997, INT ARCH ALLERGY IMM, V113, P128, DOI 10.1159/000237525; Edwards MR, 2002, J IMMUNOL, V168, P6305, DOI 10.4049/jimmunol.168.12.6305; Fear DJ, 2004, J IMMUNOL, V173, P4529, DOI 10.4049/jimmunol.173.7.4529; GUIGOU V, 1990, MOL IMMUNOL, V27, P935, DOI 10.1016/0161-5890(90)90161-R; HABA S, 1994, J IMMUNOL, V152, P51; Horst A, 2002, CLIN EXP IMMUNOL, V130, P370, DOI 10.1046/j.1365-2249.2002.02025.x; Jeannin P, 1998, J IMMUNOL, V160, P3555; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; Kohsaka H, 1996, J CLIN INVEST, V98, P2794, DOI 10.1172/JCI119106; Kunz B, 1997, DERMATOLOGY, V195, P10, DOI 10.1159/000245677; Manz RA, 2005, ANNU REV IMMUNOL, V23, P367, DOI 10.1146/annurev.immunol.23.021704.115723; Moser K, 2006, CURR OPIN IMMUNOL, V18, P265, DOI 10.1016/j.coi.2006.03.004; Musette P, 1996, P NATL ACAD SCI USA, V93, P12461, DOI 10.1073/pnas.93.22.12461; Oettgen HC, 1999, J CLIN INVEST, V104, P829, DOI 10.1172/JCI8205; PANNETIER C, 1993, P NATL ACAD SCI USA, V90, P4319, DOI 10.1073/pnas.90.9.4319; Ring J, 2001, Curr Allergy Rep, V1, P39, DOI 10.1007/s11882-001-0095-2; SCHNEIDER T, 1994, J ALLERGY CLIN IMMUN, V94, P61, DOI 10.1016/0091-6749(94)90072-8; Snow RE, 1997, EUR J IMMUNOL, V27, P162, DOI 10.1002/eji.1830270124; Snow RE, 1999, IMMUNOLOGY, V98, P646, DOI 10.1046/j.1365-2567.1999.00910.x; THOMPSON KM, 1994, EUR J IMMUNOL, V24, P1771, DOI 10.1002/eji.1830240808; Tilgner J, 1997, CLIN EXP IMMUNOL, V107, P528, DOI 10.1046/j.1365-2249.1997.d01-960.x; van der Kolk LE, 2002, BLOOD, V100, P2257, DOI 10.1182/blood.V100.6.2257.h81802002257_2257_2259; VANDERSTOEP N, 1993, J EXP MED, V177, P99, DOI 10.1084/jem.177.1.99; Worm M, 1997, J MOL MED, V75, P440, DOI 10.1007/s001090050129	35	36	40	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2007	120	3					696	706		10.1016/j.jaci.2007.05.035	http://dx.doi.org/10.1016/j.jaci.2007.05.035			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	211DV	17631954				2022-12-18	WOS:000249505400032
J	Poole, JA; Wyatt, TA; Von Essen, SG; Hervert, J; Parks, C; Mathisen, T; Romberger, DJ				Poole, Jill A.; Wyatt, Todd A.; Von Essen, Susanna G.; Hervert, John; Parks, Conrad; Mathisen, Tracy; Romberger, Debra J.			Repeat organic dust exposure-induced monocyte inflammation is associated with protein kinase C activity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						monocyte; adaptation; organic dust; swine; cytokines; inflammation; protein kinase C	DOSE-RESPONSE RELATIONSHIPS; BRONCHIAL EPITHELIAL-CELLS; ENDOTOXIN-TOLERANCE; IN-VITRO; ENVIRONMENTAL EXPOSURES; ALVEOLAR MACROPHAGES; PULMONARY-FUNCTION; SWINE; FARMERS; WORKERS	Background: Organic dust exposure results in an inflammatory response that attenuates over time, but repetitive exposures can result in chronic respiratory diseases. Mechanisms underlying this modulated response are not clear. Objective: This study investigated the effects of repeat versus single organic dust exposure-induced inflammatory mediators and protein kinase C (PKC) activity in monocytes. Methods: Settled organic dust was obtained from swine confinement facilities. Promonocytic THP-1 cells and human peripheral blood monocytes were pretreated with or without dust extract and then restimulated. Culture supernatants were evaluated for TNF-alpha, IL-6, CXCL8, and IL-10. Responses were compared with endotoxin-depleted dust, LPS, and peptidoglycan. PKC isoform (alpha, delta, epsilon, zeta) activation was evaluated by direct kinase activity. PKC isoform inhibitors' effects on TNF-alpha secretion were studied. Results: Single exposure to organic dust stimulated monocyte secretion of TNF-alpha, IL-6, CXCL8, and IL-10 compared with unstimulated cells. TNF-a and IL-6 were diminished in pretreated cells restimulated with dust. Secretion of CXCL8 and IL-10 remained persistently elevated. TNF-alpha responses were retained after marked depletion of endotoxin. Dust exposure induced significant PKC alpha, delta, epsilon, and zeta activation, peaking at 30 to 60 minutes. PKC isoform activation was attenuated in repeat exposed cells. Inhibition of PKC alpha and PKC epsilon reduced dust-induced TNF-alpha secretion. Conclusion: Repeat organic dust exposure modulated inflammatory mediator production in monocytes independent of endotoxin. The inability of PKC to be reactivated may account for this observation. Clinical implications: Targeting PKC and specific mediators associated with repetitive organic dust exposure may result in novel therapeutic strategies.	Univ Nebraska, Med Ctr, Pulm Crit Care Sleep & Allergy Sect, Dept Internal Med, Omaha, NE 68198 USA; Omaha Vet Adm Med Ctr, Omaha, NE USA	University of Nebraska System; University of Nebraska Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Nebraska-Western Iowa Health Care System	Poole, JA (corresponding author), Univ Nebraska, Med Ctr, Pulm Crit Care Sleep & Allergy Sect, Dept Internal Med, 985300, Omaha, NE 68198 USA.	japoole@unmc.edu			NIEHS NIH HHS [K08 ES015522] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K08ES015522] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aksoy E, 2004, INT J BIOCHEM CELL B, V36, P183, DOI 10.1016/S1357-2725(03)00210-3; Barbarin V, 2004, AM J RESP CELL MOL, V31, P78, DOI 10.1165/rcmb.2003-0299OC; Borish Larry C., 2003, Journal of Allergy and Clinical Immunology, V111, pS460; Brown DM, 1996, OCCUP ENVIRON MED, V53, P387, DOI 10.1136/oem.53.6.387; DONHAM KJ, 1995, AM J IND MED, V27, P405, DOI 10.1002/ajim.4700270309; Dosman JA, 2006, AM J IND MED, V49, P761, DOI 10.1002/ajim.20339; Fan HK, 2004, J ENDOTOXIN RES, V10, P71, DOI 10.1179/096805104225003997; Garantziotis S, 2006, AM J RESP CELL MOL, V35, P662, DOI 10.1165/rcmb.2006-0055OC; Heagy W, 2003, SHOCK, V19, P321, DOI 10.1097/00024382-200304000-00005; Hoffmann HJ, 2005, INT ARCH ALLERGY IMM, V138, P121, DOI 10.1159/000088433; Kline JN, 2004, AM J IND MED, V46, P416, DOI 10.1002/ajim.20065; Lee CG, 2002, J BIOL CHEM, V277, P35466, DOI 10.1074/jbc.M206395200; Muller-Suur C, 2002, EUR RESPIR J, V20, P686, DOI 10.1183/09031936.02.02002002; Palmberg L, 1998, THORAX, V53, P260, DOI 10.1136/thx.53.4.260; Palmberg L, 2002, SCAND J WORK ENV HEA, V28, P256, DOI 10.5271/sjweh.673; Pennings HJ, 1998, EUR RESPIR J, V12, P45, DOI 10.1183/09031936.98.12010045; Quinn TJ, 2000, J APPL PHYSIOL, V88, P173, DOI 10.1152/jappl.2000.88.1.173; Reynolds SJ, 1996, AM J IND MED, V29, P33, DOI 10.1002/(SICI)1097-0274(199601)29:1<33::AID-AJIM5>3.0.CO;2-#; Romberger DJ, 2002, J APPL PHYSIOL, V93, P289, DOI 10.1152/japplphysiol.00815.2001; SCHWARTZ DA, 1992, ANN INTERN MED, V116, P630, DOI 10.7326/0003-4819-116-8-630; SCHWARTZ DA, 1995, AM J RESP CRIT CARE, V151, P47, DOI 10.1164/ajrccm.151.1.7812571; Schwende H, 1996, J LEUKOCYTE BIOL, V59, P555, DOI 10.1002/jlb.59.4.555; Sfeir T, 2001, CRIT CARE MED, V29, P129, DOI 10.1097/00003246-200101000-00026; Spurzem JR, 2002, CLIN CHEST MED, V23, P795, DOI 10.1016/S0272-5231(02)00024-2; VANESSEN S, 2003, J AGR SAF HLTH, V9, P185; VANESSEN S, 1999, OCCUP MED, V14, P337; Vogelzang PFJ, 1997, INT ARCH OCC ENV HEA, V70, P327, DOI 10.1007/s004200050226; Wang ZP, 1996, AM J RESP CRIT CARE, V154, P1261, DOI 10.1164/ajrccm.154.5.8912733; West MA, 2002, CRIT CARE MED, V30, pS64, DOI 10.1097/00003246-200201001-00009	29	36	36	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2007	120	2					366	373		10.1016/j.jaci.2007.04.033	http://dx.doi.org/10.1016/j.jaci.2007.04.033			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	198VF	17555806	Green Submitted			2022-12-18	WOS:000248654900023
J	Wallner, M; Stocklinger, A; Thalhamer, T; Bohle, B; Vogel, L; Briza, P; Breiteneder, H; Vieths, S; Hartl, A; Mari, A; Ebner, C; Lackner, P; Hammerl, P; Thalhamer, J; Ferreira, F				Wallner, Michael; Stoecklinger, Angelika; Thalhamer, Theresa; Bohle, Barbara; Vogel, Lothar; Briza, Peter; Breiteneder, Heimo; Vieths, Stefan; Hartl, Arnulf; Mari, Adriano; Ebner, Christof; Lackner, Peter; Hammerl, Peter; Thalhamer, Josef; Ferreira, Fatima			Allergy multivaccines created by DNA shuffling of tree pollen allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						gene shuffling; tree pollen allergens; Bet v 1 family; T-cell epitope; IgE epitope; IgE cross-reactivity; genetic immunization; hypoallergen; allergen chimera	BIRCH POLLEN; RECOMBINANT ALLERGENS; CLINICAL-EFFICACY; CROSS-REACTIVITY; POTENTIAL USE; T-CELLS; IMMUNOTHERAPY; VACCINATION; CHILDREN; PROTEIN	Background: The major allergens of trees belonging to the Fagales order are collectively known as the Bet v 1 family. Members of the Fagales order have distinct geographic distribution, and it is expected that depending on the exposure pattern of the individual, inclusion of other Bet v 1 family members might increase the efficacy of the treatment. Objective: We aimed to generate molecules that are suitable for specific immunotherapy not only against birch pollen allergy but also against allergies caused by other cross-reactive tree pollens. Methods: Fourteen genes of the Bet v 1 family were randomly recombined in vitro by means of DNA shuffling. This library of chimeric proteins was screened for molecules displaying low capacity to induce release of inflammatory mediators but with T-cell immunogenicity higher than that of the parental allergens. Results: Two chimeric proteins were selected from the library of shuffled clones displaying low allergenicity and high immunogenicity, as determined in in vitro assays using human and animal cells and antibodies, as well as in vivo in animal models of allergy. Conclusion: Our results show that it is possible to randomly recombine in vitro T- and B-cell epitopes of a family of related allergens and to select chimeric proteins that perfectly match the criteria presently thought to be relevant for improving allergen-specific immunotherapy. Clinical implications: The hypoallergenic chimeras described here recombine epitopes of the major Fagales pollen allergens and thus can efficiently substitute a mixture of extracts used for treating patients with tree pollen-induced spring pollinosis worldwide.	Salzburg Univ, Dept Mol Biol, A-5020 Salzburg, Austria; Salzburg Univ, Christian Doppler Lab Allergy Diag & Therapy, A-5020 Salzburg, Austria; Med Univ Vienna, Ctr Physiol & Pathophysiol, Dept Pathophysiol, Vienna, Austria; Paul Ehrlich Inst, Div Allergol, D-6070 Langen, Germany; Paracelsus Private Med Univ, Salzburg, Austria; IDI IRCCS, Ctr Clin & Exp Allergol, Rome, Italy; Allergieambulatorium, Vienna, Austria	Salzburg University; Salzburg University; Medical University of Vienna; Paul Ehrlich Institute; Paracelsus Private Medical University; IRCCS Istituto Dermopatico dell'Immacolata (IDI)	Ferreira, F (corresponding author), Salzburg Univ, Dept Mol Biol, Hellbrunnerstr 34, A-5020 Salzburg, Austria.	fatima.ferreira@sbg.ac.at	Stoecklinger, Angelika/C-7616-2016; Ferreira, Fatima/AAB-4321-2019; Lackner, Peter/L-2900-2015; Briza, Peter/D-7309-2012; Ferreira, Fatima/E-4889-2011; Thalhamer, Josef/E-5787-2011; Wallner, Michael/L-5437-2015	Stoecklinger, Angelika/0000-0002-0351-8142; Ferreira, Fatima/0000-0003-0989-2335; Lackner, Peter/0000-0003-4681-6307; Briza, Peter/0000-0002-4941-6782; Ferreira, Fatima/0000-0003-0989-2335; Thalhamer, Josef/0000-0003-2285-6400; Wallner, Michael/0000-0001-6568-7892; Bohle, Barbara/0000-0002-5105-7985; Hartl, Arnulf/0000-0001-9626-6425				Bohle B, 2004, J IMMUNOL, V172, P6642, DOI 10.4049/jimmunol.172.11.6642; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Ferreira F, 2004, ADV IMMUNOL, V84, P79, DOI 10.1016/S0065-2776(04)84003-3; Ferreira F, 1998, FASEB J, V12, P231, DOI 10.1096/fasebj.12.2.231; Ferreira F, 1996, J EXP MED, V183, P599, DOI 10.1084/jem.183.2.599; Gafvelin G, 2007, J BIOL CHEM, V282, P3778, DOI 10.1074/jbc.M607938200; Gajhede M, 1996, NAT STRUCT BIOL, V3, P1040, DOI 10.1038/nsb1296-1040; Hartl A, 1999, J ALLERGY CLIN IMMUN, V103, P107, DOI 10.1016/S0091-6749(99)70533-6; Jahn-Schmid B, 2005, J ALLERGY CLIN IMMUN, V116, P213, DOI 10.1016/j.jaci.2005.04.019; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; Koradi R, 1996, J MOL GRAPHICS, V14, P29; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Larche M, 2006, CURR OPIN IMMUNOL, V18, P745, DOI 10.1016/j.coi.2006.09.013; Mari A, 2003, CLIN EXP ALLERGY, V33, P1419, DOI 10.1046/j.1365-2222.2003.01773.x; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Niederberger V, 2004, P NATL ACAD SCI USA, V101, P14677, DOI 10.1073/pnas.0404735101; Niggemann B, 2006, ALLERGY, V61, P855, DOI 10.1111/j.1398-9995.2006.01068.x; Radauer C, 2006, J ALLERGY CLIN IMMUN, V117, P141, DOI 10.1016/j.jaci.2005.09.010; Shen MY, 2006, PROTEIN SCI, V15, P2507, DOI 10.1110/ps.062416606; Sinha N, 2002, BIOPHYS J, V83, P2946, DOI 10.1016/S0006-3495(02)75302-2; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; Tulic MK, 2004, J ALLERGY CLIN IMMUN, V113, P235, DOI 10.1016/j.jaci.2003.11.001; Valenta R, 2002, NAT REV IMMUNOL, V2, P446, DOI 10.1038/nri824; Valovirta E, 2006, ALLERGY, V61, P1177, DOI 10.1111/j.1398-9995.2006.01190.x; van Neerven RJJ, 1999, J IMMUNOL, V163, P2944; Vogel L, 2005, ALLERGY, V60, P1021, DOI 10.1111/j.1398-9995.2005.00803.x; Wallner M, 2004, METHODS, V32, P219, DOI 10.1016/j.ymeth.2003.08.004; Weber RW, 2003, J ALLERGY CLIN IMMUN, V112, P229, DOI 10.1067/mai.2003.1683; Weiss R, 2006, INT ARCH ALLERGY IMM, V139, P332, DOI 10.1159/000091946; Zhao HM, 1997, NUCLEIC ACIDS RES, V25, P1307, DOI 10.1093/nar/25.6.1307	31	36	50	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2007	120	2					374	380		10.1016/j.jaci.2007.05.021	http://dx.doi.org/10.1016/j.jaci.2007.05.021			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	198VF	17624416				2022-12-18	WOS:000248654900024
J	Arias-Irigoyen, J; Lombardero, M; Arteaga, C; Carpizo, JA; Barber, D				Arias-Irigoyen, Jose; Lombardero, Manuel; Arteaga, Carmen; Andres Carpizo, Jose; Barber, Domingo			Limited IgE cross-reactivity between Dermatophagoides pteronyssinus and Glycyphagus domesticus in patients naturally exposed to both mite species	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Glycyphagus domesticus; Dermatophagoides pteronyssinus; mite group 2 allergens; cross-reactivity; house dust; mite identification; storage mites	HOUSE-DUST MITES; LEPIDOGLYPHUS-DESTRUCTOR; TYROPHAGUS-PUTRESCENTIAE; ALLERGIC PATIENTS; STORAGE MITES; ACARUS-SIRO; MONOCLONAL-ANTIBODIES; SKIN-TEST; SENSITIZATION; IDENTIFICATION	Background: Contradictory results have been found when analyzing the IgE cross-reactivity among pyroglyphid mites and storage mites, as well as the role of these as true sensitizing agents. Objective: We sought to study the prevalence of sensitization to Glycyphagus domesticus in patients naturally exposed to this mite together with the more ubiquitous Dermatophagoides pteronyssinus and the IgE cross-reactivity between them. Methods: Mite species present in house (lust samples of consecutive patients with mite allergy from Huelva (southwest Spain) were determined by means of light microscopy. Clinical sensitization was assessed by using skin prick and conjunctival provocation tests. Cross-reactivity at the IgE level was studied by using serum IgE determination and inhibition of RAST, IgE immunoblotting, and mite group 2 immunoassays. Results: After D pteronyssinus, which is present in about 95% of house dust samples, G domesticus was the most important mite and present in about 50% of the samples. Tyrophagus putrescentiae and Lepidoglyphus destructor were detected in third and fourth place, respectively. About half of the patients with G domesticus at home were sensitized to this mite. A low IgE cross-reactivity was observed between D pteronyssinus and G domesticus, but an important IgE cross-reactivity was detected among glycyphagid mites at the level of group 2 allergens. C onclusion: Glycyphagid mites can act as primary sensitizing agents independently of pyroglyphid mites in a subset of patients naturally exposed to them. Clinical implications: The inclusion of glycyphagid mite extracts in the diagnostic battery in areas with adequate mite growing conditions is important to ensure proper diagnosis.	ALK Abello SA, Dept ID, Madrid, Spain	ALK-Abello AS	Lombardero, M (corresponding author), Miguel Fleta 19, E-28037 Madrid, Spain.	manuel.lombardero@es.alk-abello.com	Barber, Domingo/Y-9516-2019	Barber, Domingo/0000-0002-5488-5700				ARIAS J, 2002, ALERGOLOGIA INMUNOLO, V17, P61; BARBER D, 1998, REV ESP ALERGOL I S2, V13, P182; Boquete M, 2000, J INVEST ALLERG CLIN, V10, P229; CARREIRA J, 1994, ARB PEI GSH, V87, P155; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; COLLOFF MJ, 1992, CLIN EXP ALLERGY, V22, P823, DOI 10.1111/j.1365-2222.1992.tb02826.x; EBNER C, 1994, CLIN EXP ALLERGY, V24, P347, DOI 10.1111/j.1365-2222.1994.tb00245.x; Gafvelin G, 2001, J ALLERGY CLIN IMMUN, V107, P511, DOI 10.1067/mai.2001.112264; GONZALEZ J, 1997, POLEN AIRE HUELVA RE, P41; *IUIS ALL NOM SUBC, 2007, OFF LIST ALL; JOHANSSON E, 1994, CLIN EXP ALLERGY, V24, P743, DOI 10.1111/j.1365-2222.1994.tb00985.x; Kemp SF, 1997, CLIN EXP ALLERGY, V27, P893, DOI 10.1111/j.1365-2222.1997.tb01229.x; King TP, 2000, INT ARCH ALLERGY IMM, V123, P99, DOI 10.1159/000024440; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALLING HJ, 1993, ALLERGY S1, V48, P22; Munhbayarlah S, 1998, YONSEI MED J, V39, P109, DOI 10.3349/ymj.1998.39.2.109; Musken H, 2002, J INVEST ALLERG CLIN, V12, P177; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; SANCHEZMADRID F, 1984, J IMMUNOL METHODS, V73, P367, DOI 10.1016/0022-1759(84)90412-5; Simpson A, 2003, ALLERGY, V58, P53, DOI 10.1034/j.1398-9995.2003.23354.x; Thomas WR, 2002, INT ARCH ALLERGY IMM, V129, P1, DOI 10.1159/000065179; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; van der Heide S, 1998, ALLERGY, V53, P426, DOI 10.1111/j.1398-9995.1998.tb03917.x; van Hage-Hamsten M, 1998, ALLERGY, V53, P49, DOI 10.1111/j.1398-9995.1998.tb04997.x; VANHAGEHAMSTEN M, 1987, CLIN ALLERGY, V17, P23; VENTAS P, 1991, IMMUNOL LETT, V29, P229, DOI 10.1016/0165-2478(91)90175-A; Vidal C, 2004, ALLERGY, V59, P401, DOI 10.1111/j.1398-9995.2003.00430.x; Vidal C, 1997, J ALLERGY CLIN IMMUN, V100, P716, DOI 10.1016/S0091-6749(97)70181-7	28	36	38	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2007	120	1					98	104		10.1016/j.jaci.2007.02.028	http://dx.doi.org/10.1016/j.jaci.2007.02.028			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	190NS	17412407				2022-12-18	WOS:000248066400014
J	Prescott, SL; Irvine, J; Dunstan, JA; Hii, C; Ferrante, A				Prescott, Susan L.; Irvine, James; Dunstan, Janet A.; Hii, Charles; Ferrante, Antonio			Protein kinase C xi: A novel protective neonatal T-cell marker that can be upregulated by allergy prevention strategies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						protein kinase C; neonate; cytokines; fish oil; polyunsaturated fatty acids; atopic dermatitis; sensitization; allergy prevention; predictive markers; cord blood; allergy	INTERFERON-GAMMA PRODUCTION; FISH-OIL SUPPLEMENTATION; BLOOD MONONUCLEAR-CELLS; CORD-BLOOD; HIGH-RISK; IMMUNE-RESPONSES; PREGNANCY; ATOPY; INFANCY; IGE	Background: Variations in neonatal T-cell function have been associated with allergic disease. Objectives: To examine the relationship between neonatal T-cell protein kinase (PKC) expression and subsequent allergic disease. Methods: T cells were purified from cord blood samples (n = 74) obtained from a cohort of mothers who received either 4 g/d fish oil or a placebo from 20 weeks of gestation. PKC expression was examined in relationship to supplementation, fatty acid levels, cytokine production, and allergic outcomes at I year and 2.5 years of age. Results: Neonatal T-cell PKC zeta expression was lower in children who had evidence of allergic disease at 1 year (P = .001) and 2.5 years (P = .052) of age. It was also lower in children with sensitization (positive skin prick test) at each age (P = .02 and P = .072, respectively). PKC zeta expression was inversely correlated to PKC alpha (r = -0.28; P = .025), which was strongly related to IL-5 responses to allergens (ovalbumin, r = 0.59; P = .003; dust mite, r = 0.52; P = .011) at I year of age. Fish oil supplementation was associated with significantly higher PKC zeta expression (P = .014), whereas most other isozymes were reduced by fish oil supplementation. Conclusion: This is the first study to show that allergic disease is associated with altered expression of T-cell PKC isozymes in the neonatal period. It has also demonstrated that fish oil can modulate expression of PKC isozymes in a potentially favorable direction. Clinical implications: Protein kinase C zeta should be explored further as an early marker and potential target for disease prevention.	Univ Western Australia, Sch Pediat & Child Hlth, Perth, WA 6009, Australia; Womens & Childrens Hosp, Dept Immunopathol, Adelaide, SA, Australia; Univ Adelaide, Dept Pediat, Adelaide, SA, Australia	University of Western Australia; Womens & Childrens Hospital Australia; University of Adelaide	Prescott, SL (corresponding author), Univ Western Australia, Sch Pediat & Child Hlth, Princess Margaret Hosp, POB D184, Perth, WA 6001, Australia.	sprescott@meddent.uwa.edu.au	Prescott, Susan/H-5665-2014					Bergmann RL, 1997, CLIN EXP ALLERGY, V27, P752, DOI 10.1046/j.1365-2222.1997.310899.x; Borres MP, 2004, PEDIATR ALLERGY IMMU, V15, P216, DOI 10.1111/j.1399-3038.2004.00143.x; CRONER S, 1986, ALLERGY, V41, P68, DOI 10.1111/j.1398-9995.1986.tb00277.x; Devereux G, 2002, CLIN EXP ALLERGY, V32, P43, DOI 10.1046/j.0022-0477.2001.01267.x; Dunstan JA, 2004, EUR J CLIN NUTR, V58, P429, DOI 10.1038/sj.ejcn.1601825; Dunstan JA, 2003, CLIN EXP ALLERGY, V33, P442, DOI 10.1046/j.1365-2222.2003.01590.x; Dunstan JA, 2003, J ALLERGY CLIN IMMUN, V112, P1178, DOI 10.1016/j.jaci.2003.09.009; Egerton M, 1998, INT IMMUNOL, V10, P223, DOI 10.1093/intimm/10.2.223; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Hansen L G, 1993, Pediatr Allergy Immunol, V4, P34, DOI 10.1111/j.1399-3038.1993.tb00063.x; HIDE DW, 1991, CLIN EXP ALLERGY, V21, P739, DOI 10.1111/j.1365-2222.1991.tb03204.x; Hii CST, 2003, BIOCHEM J, V370, P497, DOI 10.1042/BJ20021122; Kondo N, 1998, CLIN EXP ALLERGY, V28, P1340; Li YQ, 1999, IMMUNOLOGY, V96, P524; Marks GB, 2006, J ALLERGY CLIN IMMUN, V118, P53, DOI 10.1016/j.jaci.2006.04.004; MARTINEZ FD, 1995, J ALLERGY CLIN IMMUN, V96, P652, DOI 10.1016/S0091-6749(95)70264-4; Matsuoka T, 2001, PEDIATR INT, V43, P453, DOI 10.1046/j.1442-200X.2001.01445.x; Mori TA, 2000, AM J CLIN NUTR, V71, P1085; Noakes PS, 2003, ALLERGY, V58, P1053, DOI 10.1034/j.1398-9995.2003.00290.x; ODELRAM H, 1995, ALLERGY, V50, P585, DOI 10.1111/j.1398-9995.1995.tb01204.x; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Prescott SL, 1998, CLIN EXP ALLERGY, V28, P39; Rincon M, 2000, FREE RADICAL BIO MED, V28, P1328, DOI 10.1016/S0891-5849(00)00219-7; Rowe J, 2001, J INFECT DIS, V184, P80, DOI 10.1086/320996; TANG MLK, 1994, LANCET, V344, P983, DOI 10.1016/S0140-6736(94)91641-1; Upham JW, 2004, J ALLERGY CLIN IMMUN, V114, P1202, DOI 10.1016/j.jaci.2004.06.051; van der Velden VHJ, 2001, CLIN EXP ALLERGY, V31, P997, DOI 10.1046/j.1365-2222.2001.01176.x; WARNER JA, 1994, CLIN EXP ALLERGY, V24, P423, DOI 10.1111/j.1365-2222.1994.tb00930.x	28	36	36	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2007	120	1					200	206		10.1016/j.jaci.2007.03.045	http://dx.doi.org/10.1016/j.jaci.2007.03.045			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	190NS	17544492				2022-12-18	WOS:000248066400029
J	Gober, LM; Eckman, JA; Sterba, PM; Vasagar, K; Schroeder, JT; Golden, DBK; Saini, SS				Gober, Laura M.; Eckman, John A.; Sterba, Patricia M.; Vasagar, Kavitha; Schroeder, John T.; Golden, David B. K.; Saini, Sarbjit S.			Expression of activation markers on basophils in a controlled model of anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; basophil; activation marker	HISTAMINE-RELEASE; HYMENOPTERA-VENOM; CD63 EXPRESSION; UP-REGULATION; ALLERGY; VITRO; DIAGNOSIS; SENSITIVITY; CD203C; TESTS	Background: Anaphylaxis has variable clinical presentations and lacks reliable biomarkers. Expression of activation markers on basophils has been useful in assessing sensitization in IgE-mediated diseases but has not been examined in vivo in anaphylaxis. Objective: The study's goals were to assess the baseline expression of activation markers on basophils in individuals with a sting reaction history, the degree of change in expression of these markers after intentional sting challenge, and the relationship between in vitro and in vivo activation marker expression. Methods: Patients allergic to insect venom were enrolled and grouped by clinical category defined by a history of a systemic or large local reaction and use of venom immunotherapy. Blood was collected before and after sting challenge. Enriched basophils were analyzed for activation marker expression. In select subjects, basophils were examined after in vitro stimulation with insect venom for activation marker expression and histamine release. Results: Of 35 sting-challenge participants, 21 provided adequate samples for analysis. Pre-sting basophil CD63 expression was significantly higher in systemic reactors on immunotherapy. Following sting challenge, the rise in basophil CD69 expression and CD203c was significantly higher in systemic reactors on immunotherapy. Levels of activation markers on basophils were greater after in vitro venom stimulation than after in vivo challenge. Conclusion: Broader shifts in expression of basophil activation markers after in vivo challenge occurred among subjects with a history of in vivo systemic anaphylaxis despite venom immunotherapy. Clinical implications: Basophil activation markers may be potential biomarkers for anaphylaxis.	Johns Hopkins Univ, Sch Med, Dept Med, Div Allergy & Clin Immunol, Baltimore, MD 21218 USA	Johns Hopkins University	Saini, SS (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	ssaini@jhmi.edu			PHS HHS [A10827] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Binder M, 2002, INT ARCH ALLERGY IMM, V129, P160, DOI 10.1159/000065875; Boumiza R, 2003, CLIN EXP ALLERGY, V33, P259, DOI 10.1046/j.1365-2222.2003.01594.x; Buhring HJ, 2004, INT ARCH ALLERGY IMM, V133, P317, DOI 10.1159/000077351; Buhring HJ, 2001, BLOOD, V97, P3303, DOI 10.1182/blood.V97.10.3303; Buhring HJ, 1999, BLOOD, V94, P2343; Crockard AD, 2001, CLIN EXP ALLERGY, V31, P345, DOI 10.1046/j.1365-2222.2001.01043.x; Eberlein-Konig B, 2006, J INVEST ALLERG CLIN, V16, P5; Ebo DG, 2004, CLIN EXP ALLERGY, V34, P332, DOI 10.1111/j.1365-2222.2004.01891.x; Erdmann SM, 2004, ALLERGY, V59, P1102, DOI 10.1111/j.1398-9995.2004.00624.x; Estelle F, 2006, J ALLERGY CLIN IMMUN, V117, P367, DOI 10.1016/j.jaci.2005.12.002; GILBERT HS, 1975, BLOOD, V46, P279; Golden DBK, 2006, J ALLERGY CLIN IMMUN, V117, P670, DOI 10.1016/j.jaci.2005.12.1313; Golden DBK, 2005, J ALLERGY CLIN IMMUN, V115, P439, DOI 10.1016/j.jaci.2005.01.005; Hauswirth AW, 2002, J ALLERGY CLIN IMMUN, V110, P102, DOI 10.1067/mai.2002.125257; HOFFMAN DR, 1984, ANN ALLERGY, V52, P276; Kleine-Tebbe J, 2006, INT ARCH ALLERGY IMM, V141, P79, DOI 10.1159/000094495; KNOL EF, 1991, J ALLERGY CLIN IMMUN, V88, P328, DOI 10.1016/0091-6749(91)90094-5; Kosnik M, 2005, ALLERGY, V60, P1401, DOI 10.1111/j.1398-9995.2005.00894.x; Lambert C, 2003, CYTOM PART B-CLIN CY, V52B, P13, DOI 10.1002/cyto.b.10012; LICHTENS.LM, 1968, AM J MED, V44, P514, DOI 10.1016/0002-9343(68)90052-1; Lie WJ, 1999, J ALLERGY CLIN IMMUN, V104, P1000, DOI 10.1016/S0091-6749(99)70081-3; Lin RY, 2000, J ALLERGY CLIN IMMUN, V106, P65, DOI 10.1067/mai.2000.107600; MACGLASHAN DW, 1993, J ALLERGY CLIN IMMUN, V91, P605, DOI 10.1016/0091-6749(93)90266-I; Moneret-Vautrin DA, 1999, ANN ALLERG ASTHMA IM, V82, P33, DOI 10.1016/S1081-1206(10)62657-9; Paris-Kohler A, 2000, J ALLERGY CLIN IMMUN, V105, P339, DOI 10.1016/S0091-6749(00)90085-X; Platz IJ, 2001, INT ARCH ALLERGY IMM, V126, P335, DOI 10.1159/000049531; Saini S, 2004, J ALLERGY CLIN IMMUN, V114, P768, DOI 10.1016/j.jaci.2004.06.015; Sainte-Laudy J, 2000, CLIN EXP ALLERGY, V30, P1166, DOI 10.1046/j.1365-2222.2000.00863.x; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Sanz ML, 2002, CLIN EXP ALLERGY, V32, P277, DOI 10.1046/j.1365-2222.2002.01305.x; Schroeder JT, 2001, CLIN EXP ALLERGY, V31, P1369, DOI 10.1046/j.1365-2222.2001.01130.x; SCHWARTZ LB, 1989, J CLIN INVEST, V83, P1551, DOI 10.1172/JCI114051; Vasagar K, 2006, CLIN EXP ALLERGY, V36, P770, DOI 10.1111/j.1365-2222.2006.02494.x; Yoshimura C, 2002, J ALLERGY CLIN IMMUN, V109, P817, DOI 10.1067/mai.2002.123532	35	36	36	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2007	119	5					1181	1188		10.1016/j.jaci.2007.01.008	http://dx.doi.org/10.1016/j.jaci.2007.01.008			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167CB	17335884				2022-12-18	WOS:000246427200019
J	Flinterman, AE; Hoekstra, MO; Meijer, Y; van Ree, R; Akkerdaas, JH; Bruijnzeel-Koomen, CA; Knulst, AC; Pasmans, SG				Flinterman, Annebeth E.; Hoekstra, Maarten O.; Meijer, Yolanda; van Ree, Ronald; Akkerdaas, Jaap H.; Bruijnzeel-Koomen, Carla A.; Knulst, Andre C.; Pasmans, Suzanne G.			Clinical reactivity to hazelnut in children: Association with sensitization to birch pollen or nuts?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							DOUBLE-BLIND; FOOD CHALLENGES; ALLERGY; PEANUT; IDENTIFICATION; AGES		Univ Utrecht, Med Ctr, Dept Dermatol Allergol, Utrecht, Netherlands; Univ Utrecht, Med Ctr, Dept Pediat, Utrecht, Netherlands; Acad Med Ctr, Dept Expt Immunol, Amsterdam, Netherlands	Utrecht University; Utrecht University; University of Amsterdam; Academic Medical Center Amsterdam	Flinterman, AE (corresponding author), Univ Utrecht, Med Ctr, Dept Dermatol Allergol, Utrecht, Netherlands.		Pasmans, Suzanne/AAI-6016-2021	Pasmans, Suzanne/0000-0003-1018-4475				Bindslev-Jensen C, 2004, ALLERGY, V59, P690, DOI 10.1111/j.1398-9995.2004.00466.x; Clark AT, 2005, PEDIATR ALLERGY IMMU, V16, P507, DOI 10.1111/j.1399-3038.2005.00310.x; Cudowska B, 2004, Rocz Akad Med Bialymst, V49, P111; Enrique E, 2005, J ALLERGY CLIN IMMUN, V116, P1073, DOI 10.1016/j.jaci.2005.08.027; Flinterman AE, 2006, J ALLERGY CLIN IMMUN, V117, P448, DOI 10.1016/j.jaci.2005.11.035; HIRSCHWEHR R, 1992, J ALLERGY CLIN IMMUN, V90, P927, DOI 10.1016/0091-6749(92)90465-E; Ortolani C, 2000, J ALLERGY CLIN IMMUN, V105, P577, DOI 10.1067/mai.2000.103052; Pastorello EA, 2002, J ALLERGY CLIN IMMUN, V109, P563, DOI 10.1067/mai.2002.121946; Pumphrey RSH, 1999, CLIN EXP ALLERGY, V29, P1256, DOI 10.1046/j.1365-2222.1999.00588.x; Sicherer SH, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.1.e6; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P128, DOI 10.1067/mai.2001.115755; vanderVeen MJ, 1997, J ALLERGY CLIN IMMUN, V100, P327, DOI 10.1016/S0091-6749(97)70245-8; Wensing M, 2002, CLIN EXP ALLERGY, V32, P1757, DOI 10.1046/j.1365-2222.2002.01555.x	13	36	37	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2006	118	5					1186	1189		10.1016/j.jaci.2006.08.017	http://dx.doi.org/10.1016/j.jaci.2006.08.017			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137GY	17088148				2022-12-18	WOS:000244282300028
J	Holgate, ST				Holgate, Stephen T.			Rhinoviruses in the pathogenesis of asthma: The bronchial epithelium as a major disease target	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						asthma; rhinovirus; airway epithelium; growth factors; interferons	BACTERIAL PATHOGENS; CHILDREN; INFECTION; CELLS; RNA; ASSOCIATION; PERSISTENCE; ILLNESSES; INFANCY		Univ Southampton, Infect Inflammat & Repair Div, Southampton Gen Hosp, Sch Med, Southampton SO16 6YD, Hants, England	University of Southampton	Holgate, ST (corresponding author), Univ Southampton, Infect Inflammat & Repair Div, Southampton Gen Hosp, Sch Med, MP 810,F Level,South Block, Southampton SO16 6YD, Hants, England.	sth@soton.ac.uk						Babu KS, 2003, EUR RESPIR J, V21, P1046, DOI 10.1183/09031936.03.00069202; BISGAARD H, 2006, NEW ENGL J MED, V354, P2058; Bossios A, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-114; BUCCHIERI F, 2006, P AM THORAC SOC, V3, pA842; CRISAFI GM, 2006, P AM THORAC SOC, V3, pA15; Davies DE, 2003, J ALLERGY CLIN IMMUN, V111, P215, DOI 10.1067/mai.2003.128; De Silva D, 2006, J MED VIROL, V78, P666, DOI 10.1002/jmv.20591; Edwards MR, 2006, AM J RESP CELL MOL, V34, P616, DOI 10.1165/rcmb.2005-0385OC; Finch PW, 2004, ADV CANCER RES, V91, P69, DOI 10.1016/S0065-230X(04)91003-2; Garbino J, 2004, AM J RESP CRIT CARE, V170, P1197, DOI 10.1164/rccm.200406-781OC; Gern JE, 1996, J IMMUNOL, V156, P621; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Heymann PW, 2004, J ALLERGY CLIN IMMUN, V114, P239, DOI 10.1016/j.jaci.2004.04.006; Hicks LA, 2006, J AM GERIATR SOC, V54, P284, DOI 10.1111/j.1532-5415.2005.00529.x; Holgate ST, 2000, J ALLERGY CLIN IMMUN, V105, P193, DOI 10.1016/S0091-6749(00)90066-6; INOUE D, 2005, RESPIR PHYSL NE 1222; Jacques J, 2006, J CLIN VIROL, V35, P463, DOI 10.1016/j.jcv.2005.11.009; Jartti T, 2004, J MED VIROL, V72, P695, DOI 10.1002/jmv.20027; Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654, DOI 10.1164/ajrccm.154.3.8810601; Kling S, 2005, CLIN EXP ALLERGY, V35, P672, DOI 10.1111/j.1365-2222.2005.02244.x; Knight DA, 2003, RESPIROLOGY, V8, P432, DOI 10.1046/j.1440-1843.2003.00493.x; Korppi M, 2004, PEDIATR INFECT DIS J, V23, P995, DOI 10.1097/01.inf.0000143642.72480.53; Lee BE, 2006, J MED VIROL, V78, P702, DOI 10.1002/jmv.20595; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Louie JK, 2005, CLIN INFECT DIS, V41, P262, DOI 10.1086/430915; Malmstrom K, 2006, J ALLERGY CLIN IMMUN, V118, P591, DOI 10.1016/j.jaci.2006.04.032; Mosser AG, 2005, AM J RESP CRIT CARE, V171, P645, DOI 10.1164/rccm.200407-970OC; MURRAY CS, 2006, IN PRESS LANCET; Nokso-Koivisto J, 2004, J MED VIROL, V72, P241, DOI 10.1002/jmv.10581; Oliver BGG, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-71; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Papadopoulos NG, 2000, J INFECT DIS, V181, P1875, DOI 10.1086/315513; Pitkaranta A, 2006, INT J PEDIATR OTORHI, V70, P647, DOI 10.1016/j.ijporl.2005.08.018; Puddicombe SM, 2006, P AM THORAC SOC, V3, pA424; Sinha A, 2003, NEW ENGL J MED, V349, P350, DOI 10.1056/NEJMoa013136; Suvilehto J, 2006, J CLIN VIROL, V35, P292, DOI 10.1016/j.jcv.2005.08.009; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Wilkinson TMA, 2006, CHEST, V129, P317, DOI 10.1378/chest.129.2.317; Winther B, 2006, J MED VIROL, V78, P644, DOI 10.1002/jmv.20588; Wright SM, 2000, J APPL PHYSIOL, V89, P1283, DOI 10.1152/jappl.2000.89.4.1283; Xatzipsaiti M, 2005, AM J RESP CRIT CARE, V172, P1037, DOI 10.1164/rccm.200502-315OC; Xepapadaki P, 2005, J ALLERGY CLIN IMMUN, V116, P299, DOI 10.1016/j.jaci.2005.04.007	42	36	41	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2006	118	3					587	590		10.1016/j.jaci.2006.06.023	http://dx.doi.org/10.1016/j.jaci.2006.06.023			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086BV	16950275				2022-12-18	WOS:000240649000009
J	Barnes, KC; Grant, A; Gao, PS; Baltadjieva, D; Berg, T; Chi, P; Zhang, S; Zambelli-Weiner, A; Ehrlich, E; Zardkoohi, O; Brummet, ME; Stockton, M; Watkins, T; Gao, L; Gittens, M; Wills-Karp, M; Cheadle, C; Beck, LA; Beaty, TH; Becker, KG; Garcia, JGN; Mathias, RA				Barnes, Kathleen C.; Grant, Audrey; Gao, Peisong; Baltadjieva, Daniela; Berg, Tiina; Chi, Peter; Zhang, Shu; Zambelli-Weiner, April; Ehrlich, Eva; Zardkoohi, Omeed; Brummet, Mary E.; Stockton, Maria; Watkins, Tonya; Gao, Li; Gittens, Marquita; Wills-Karp, Marsha; Cheadle, Christopher; Beck, Lisa A.; Beaty, Terri H.; Becker, Kevin G.; Garcia, Joe G. N.; Mathias, Rasika A.			Polymorphisms in the novel gene acyloxyacyl hydroxylase (AOAH) are associated with asthma and associated phenotypes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CD14; acylotyacyl hydroxylase; association; asthma; total IgE; soluble CD14; family-based association test	SOLUBLE CD14 LEVELS; ENDOTOXIN-NEUTRALIZING CAPACITY; GENOME-WIDE SCAN; PROMOTER POLYMORPHISM; BACTERIAL LIPOPOLYSACCHARIDE; SUSCEPTIBILITY LOCI; IGE CONCENTRATION; LEUKOCYTE ENZYME; SERUM; DEACYLATION	Background: The gene encoding acyloxyacyl hydroxylase (AOAH), an enzyme that hydrolyzes secondary fatty acyl chains of LPS, is localized on chromosome 7p14-p12, where evidence for linkage to total IgE (tIgE) concentrations and asthma has been previously reported. Objective: We hypothesized that variants in AOAH are associated with asthma and related phenotypes. Because both AOAH and soluble CD14 respond to LPS, we tested for gene-gene interaction. Methods: We investigated the association between 28 single nucleotide polymorphisms throughout the AOAH gene and asthma, concentrations of tIgE, the ratio of IL-13/IFN-gamma, and soluble CD14 levels among 125 African Caribbean, multiplex asthmatic pedigrees (n = 834). Real-time PCR was used to assess whether AOAH cDNA expression differed with AOAH genotype. Results: Significant effects were observed for all 4 phenotypes and AOAH markers in 3 distinct regions (promoter, introns 1-6, and the intron 12/exon 13 boundary/intron 13 region) by means of single-marker and haplotype analyses, with the strongest evidence for a 2-single-nucleotide-polymorphism haplotype and log[tIgE] (P = .006). There was no difference in AOAH expression levels by AOAH genotype for any of the markers. Comparing genotypic distributions at both the AOAH marker rs2727831 and CD14(-260)C > T raises the possibility of gene-gene interaction (P = .006-.036). Conclusion: Our results indicate that polymorphisms in markers within the AOAH gene are associated with risk of asthma and-associated quantitative traits (IgE and cytokine levels) among asthmatic subjects and their families in Barbados, and there is an interactive effect on tIgE and asthma concentrations between an AOAH marker and the functional CD14(-260)C > T polymorphism. Clinical implications: AOAH is a novel innate immunity candidate gene associated with asthma and related phenotypes in an African ancestry population.	Johns Hopkins Univ, Dept Med, Div Clin Immunol & Allergy, Baltimore, MD 21218 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21218 USA; Johns Hopkins Sch Med, Dept Med, Div Pulm & Crit Care Med, Baltimore, MD USA; Johns Hopkins Univ, Johns Hopkins Sch Med, Baltimore, MD 21218 USA; Childrens Hosp, Med Ctr, Div Immunobiol, Cincinnati, OH 45229 USA; Johns Hopkins Univ, Dept Dermatol, Baltimore, MD 21218 USA; NIA, DNA Array Unit, Baltimore, MD 21224 USA; NHGRI, Genometr Sect, Inherited Dis Res Branch, NIH, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); NIH National Institute on Aging (NIA)	Barnes, KC (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle,Rm 3A-62, Baltimore, MD 21224 USA.	kbarnes@jhmi.edu	Garcia, Joe GN/E-8862-2010	Gittens-St.Hilaire, Marquita/0000-0002-1891-8966; Becker, Kevin/0000-0002-6794-6656	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067736, U01HL066615] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045839] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NHLBI NIH HHS [U01 HL 66615, HL 67736] Funding Source: Medline; NIAID NIH HHS [AI 50024-03, R01 AI045839] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allen EM, 2003, J CLIN ENDOCR METAB, V88, P1292, DOI 10.1210/jc.2002-020634; Amar J, 2004, J HYPERTENS, V22, P1523, DOI 10.1097/01.hjh.0000133724.16947.a3; ANIELS SE, 1996, NATURE, V33, P247; ARDITI M, 1993, INFECT IMMUN, V61, P3149, DOI 10.1128/IAI.61.8.3149-3156.1993; Arias MA, 2000, J IMMUNOL, V164, P3480, DOI 10.4049/jimmunol.164.7.3480; Baldini M, 1999, AM J RESP CELL MOL, V20, P976, DOI 10.1165/ajrcmb.20.5.3494; Barnes KC, 1996, GENOMICS, V37, P41, DOI 10.1006/geno.1996.0518; Barnes KC, 2006, GENES IMMUN, V7, P27, DOI 10.1038/sj.gene.6364267; Barnes KC, 1999, J ALLERGY CLIN IMMUN, V104, P485, DOI 10.1016/S0091-6749(99)70398-2; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Buckova D, 2003, ALLERGY, V58, P1023, DOI 10.1034/j.1398-9995.2003.00271.x; Choudhry S, 2005, AM J RESP CRIT CARE, V172, P173, DOI 10.1164/rccm.200409-1232OC; Cody MJ, 1997, J ENDOTOXIN RES, V4, P371, DOI 10.1177/096805199700400509; Dizier MH, 2000, AM J RESP CRIT CARE, V162, P1812, DOI 10.1164/ajrccm.162.5.2002113; Eng HL, 2004, GENES IMMUN, V5, P426, DOI 10.1038/sj.gene.6364100; FLEULNER JA, 2004, INFECT IMMUN, V72, P3171; FREY EA, 1992, J EXP MED, V176, P1665, DOI 10.1084/jem.176.6.1665; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Gaffney PM, 2000, AM J HUM GENET, V66, P547, DOI 10.1086/302767; Gao PS, 1999, CLIN GENET, V56, P164; GRUNWALD U, 1993, CIRC SHOCK, V39, P220; Guerra S, 2004, AM J RESP CRIT CARE, V169, P70, DOI 10.1164/rccm.200304-499OC; HAGEN FS, 1991, BIOCHEMISTRY-US, V30, P8415, DOI 10.1021/bi00098a020; HALL CL, 1983, P NATL ACAD SCI-BIOL, V80, P6671, DOI 10.1073/pnas.80.21.6671; HAZIOT A, 1995, J IMMUNOL, V154, P6529; Heinzmann A, 2003, EUR J IMMUNOGENET, V30, P345, DOI 10.1046/j.1365-2370.2003.00414.x; Horvath S, 2001, GENET EPIDEMIOL, V21, pS403; Kabesch M, 2004, ALLERGY, V59, P520, DOI 10.1111/j.1398-9995.2004.00439.x; Katz SS, 1999, J BIOL CHEM, V274, P36579, DOI 10.1074/jbc.274.51.36579; KITCHENS RL, 1992, J EXP MED, V176, P485, DOI 10.1084/jem.176.2.485; Kitchens RL, 2001, J CLIN INVEST, V108, P485, DOI 10.1172/JCI200113139; Koppelman GH, 2001, AM J RESP CRIT CARE, V163, P965, DOI 10.1164/ajrccm.163.4.2004164; KRUGER C, 1991, CLIN EXP IMMUNOL, V85, P297; Laitinen T, 2001, NAT GENET, V28, P87, DOI 10.1038/88319; Landmann R, 1996, J INFECT DIS, V173, P661, DOI 10.1093/infdis/173.3.661; Leung TF, 2003, PEDIAT ALLERG IMM-UK, V14, P255, DOI 10.1034/j.1399-3038.2003.00048.x; LeVan TD, 2001, J IMMUNOL, V167, P5838, DOI 10.4049/jimmunol.167.10.5838; Liu AH, 2002, J ALLERGY CLIN IMMUN, V109, P379, DOI 10.1067/mai.2002.122157; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu MF, 2005, NAT IMMUNOL, V6, P989, DOI 10.1038/ni1246; Lu MF, 2003, J EXP MED, V197, P1745, DOI 10.1084/jem.20030420; LUCHI M, 1993, J IMMUNOL, V151, P959; Martin AC, 2006, AM J RESP CRIT CARE, V173, P617, DOI 10.1164/rccm.200509-1367OC; Medzhitov R, 2000, NEW ENGL J MED, V343, P338, DOI 10.1056/NEJM200008033430506; MUNFORD RS, 1986, SCIENCE, V234, P203, DOI 10.1126/science.3529396; MUNFORD RS, 1989, J BIOL CHEM, V264, P15613; NOCKHER WA, 1995, KIDNEY INT, V48, P1469, DOI 10.1038/ki.1995.436; Nores JER, 1999, EUR J IMMUNOL, V29, P265, DOI 10.1002/(SICI)1521-4141(199901)29:01<265::AID-IMMU265>3.3.CO;2-7; POHLMAN TH, 1987, J EXP MED, V165, P1393, DOI 10.1084/jem.165.5.1393; Rabinowitz D, 2000, HUM HERED, V50, P211, DOI 10.1159/000022918; Sackesen C, 2005, ALLERGY, V60, P1485, DOI 10.1111/j.1398-9995.2005.00874.x; Satsangi J, 1996, NAT GENET, V14, P199, DOI 10.1038/ng1096-199; Sawcer S, 1996, NAT GENET, V13, P464, DOI 10.1038/ng0896-464; SCHUTT C, 1992, RES IMMUNOL, V143, P71, DOI 10.1016/0923-2494(92)80082-V; Sengler C, 2003, CLIN EXP ALLERGY, V33, P166, DOI 10.1046/j.1365-2222.2003.01549.x; Sharma M, 2004, IMMUNOGENETICS, V56, P544, DOI 10.1007/s00251-004-0721-y; Shimada K, 2004, INT J CARDIOL, V94, P87, DOI 10.1016/j.ijcard.2003.05.007; Staab JF, 1999, J ENDOTOXIN RES, V5, P205; WHITMORE TE, 1994, GENOMICS, V21, P457, DOI 10.1006/geno.1994.1298; Williams RL, 2000, BIOMETRICS, V56, P645, DOI 10.1111/j.0006-341X.2000.00645.x; Woo JG, 2003, J ALLERGY CLIN IMMUN, V112, P438, DOI 10.1067/mai.2003.1634; WRIGHT SD, 1995, J IMMUNOL, V155, P6; WURFEL MM, 1995, J EXP MED, V181, P1743, DOI 10.1084/jem.181.5.1743; Zambelli-Weiner A, 2005, J ALLERGY CLIN IMMUN, V115, P1203, DOI 10.1016/j.jaci.2005.03.001; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	65	36	38	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2006	118	1					70	77		10.1016/j.jaci.2006.03.036	http://dx.doi.org/10.1016/j.jaci.2006.03.036			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	065UH	16815140				2022-12-18	WOS:000239184800008
J	Moore, ML; Peebles, RS				Moore, Martin L.; Peebles, R. Stokes, Jr.			Update on the role of prostaglandins in allergic lung inflammation: Separating friends from foes, harder than you might think	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						allergy; prostaglandins	AIRWAY INFLAMMATION; INHALED PGE(2); RECEPTOR; ASTHMA; RESPONSES; MICE; TH2; D-2; E-2; RELEASE	Prostaglandins (PGs), small lipid molecules derived from arachidonic acid by COX enzymes, are critical mediators-of allergic inflammation. Our understanding of the role of PGs in allergic lung inflammation has been hampered by the very short biologic half-life of these mediators, which has made mechanistic studies difficult in human subjects. However, advances in molecular biology and pharmacology have given investigators the opportunity to examine the role of specific prostanoids in the development of allergic inflammation in animal models. Studies investigating specific PG receptors are also elucidating the mechanisms by which PGs regulate the pulmonary allergic phenotype. This review summarizes the current literature on the role of PGs and PG receptors in allergic lung inflammation.	Vanderbilt Univ, Sch Med, Div Allergy Pulm & Crit Care Med, Ctr Lung Res, Nashville, TN 37232 USA	Vanderbilt University	Peebles, RS (corresponding author), Vanderbilt Univ, Sch Med, Div Allergy Pulm & Crit Care Med, Ctr Lung Res, T-1218 MCN, Nashville, TN 37232 USA.	stokes.peebles@vanderbilt.edu						Arakida Y, 2000, EUR J PHARMACOL, V403, P169, DOI 10.1016/S0014-2999(00)00583-5; Chevalier E, 2005, J IMMUNOL, V175, P2056, DOI 10.4049/jimmunol.175.4.2056; Fujitani Y, 2002, J IMMUNOL, V168, P443, DOI 10.4049/jimmunol.168.1.443; Gauvreau GM, 1999, AM J RESP CRIT CARE, V159, P31, DOI 10.1164/ajrccm.159.1.9804030; Gavett SH, 1999, J CLIN INVEST, V104, P721, DOI 10.1172/JCI6890; Hartert TV, 2000, AM J RESP CRIT CARE, V162, P637, DOI 10.1164/ajrccm.162.2.9904038; Hashimoto K, 2005, J IMMUNOL, V174, P525, DOI 10.4049/jimmunol.174.1.525; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; Honda K, 2003, J EXP MED, V198, P533, DOI 10.1084/jem.20022218; Jaffar Z, 2002, J IMMUNOL, V169, P5997, DOI 10.4049/jimmunol.169.10.5997; Kunikata T, 2005, NAT IMMUNOL, V6, P524, DOI 10.1038/ni1188; Mandal AK, 2004, J EXP MED, V199, P1317, DOI 10.1084/jem.20031666; Martin JG, 2002, J IMMUNOL, V169, P3963, DOI 10.4049/jimmunol.169.7.3963; Matsuoka T, 2000, SCIENCE, V287, P2013, DOI 10.1126/science.287.5460.2013; Oguma T, 2004, NEW ENGL J MED, V351, P1752, DOI 10.1056/NEJMoa031785; Peebles RS, 2002, AM J RESP CRIT CARE, V165, P1154, DOI 10.1164/rccm.2106025; Pierzchalska M, 2003, J ALLERGY CLIN IMMUN, V111, P1041, DOI 10.1067/mai.2003.1491; Sestini P, 1996, AM J RESP CRIT CARE, V153, P572, DOI 10.1164/ajrccm.153.2.8564100; Shi H, 1998, EUR RESPIR J, V11, P624; Shin HD, 2003, J ALLERGY CLIN IMMUN, V112, P454, DOI 10.1067/mai.2003.1641; Shiraishi Y, 2005, J PHARMACOL EXP THER, V312, P954, DOI 10.1124/jpet.104.078212; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Sousa AR, 2002, NEW ENGL J MED, V347, P1493, DOI 10.1056/NEJMoa013508; Spicuzza L, 1998, BRIT J PHARMACOL, V123, P1246, DOI 10.1038/sj.bjp.0701720; Spik I, 2005, J IMMUNOL, V174, P3703, DOI 10.4049/jimmunol.174.6.3703; Takano H, 2002, BMC NEUROSCI, V3, DOI 10.1186/1471-2202-3-15; Unoki M, 2000, HUM GENET, V106, P440, DOI 10.1007/s004390000267	27	36	38	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2006	117	5					1036	1039		10.1016/j.jaci.2005.12.1314	http://dx.doi.org/10.1016/j.jaci.2005.12.1314			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	041EM	16675329				2022-12-18	WOS:000237436300009
J	Pimiento, AJP; Lastra, LP; Cabreros, MIR; Sanchez, LAG; Mosquera, MR; Cubero, AG				Pimiento, AJP; Lastra, LP; Cabreros, MIR; Sanchez, LAG; Mosquera, MR; Cubero, AG			Hypersensitivity to lansoprazole and rabeprazole with tolerance to other proton pump inhibitors	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							PANTOPRAZOLE; ANAPHYLAXIS; OMEPRAZOLE		Hosp Univ Puerta Hierro, Dept Allergy, Madrid 28035, Spain	Hospital Puerta de Hierro-Majadahonda	Pimiento, AJP (corresponding author), Hosp Univ Puerta Hierro, Dept Allergy, C San Martin Porres 4, Madrid 28035, Spain.							Cockayne SE, 1999, BRIT J DERMATOL, V141, P173; Fardet L, 2002, AM J GASTROENTEROL, V97, P1578, DOI 10.1016/S0002-9270(02)04116-3; Galindo PA, 1999, ANN ALLERG ASTHMA IM, V82, P52, DOI 10.1016/S1081-1206(10)62660-9; Gonzalez P, 2002, Allergol Immunopathol (Madr), V30, P342; Heaton NR, 2004, CLIN EXP DERMATOL, V29, P612, DOI 10.1111/j.1365-2230.2004.01616.x; Kollmeier AP, 2004, J ALLERGY CLIN IMMUN, V114, P975, DOI 10.1016/j.jaci.2004.05.068; Natsch S, 2000, ANN PHARMACOTHER, V34, P474; Porcel S, 2005, ALLERGY, V60, P1087, DOI 10.1111/j.1398-9995.2005.00765.x; Roldan FP, 1999, AM J GASTROENTEROL, V94, P1995, DOI 10.1111/j.1572-0241.1999.01995.x; ZALLO MG, 2004, ALLERGOL IMMUNOPATH, V32, P92	10	36	37	1	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2006	117	3					707	708		10.1016/j.jaci.2005.11.001	http://dx.doi.org/10.1016/j.jaci.2005.11.001			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	025JY	16522476				2022-12-18	WOS:000236263100032
J	Wisnivesky, JP; Leventhal, H; Halm, EA				Wisnivesky, JP; Leventhal, H; Halm, EA			Predictors of asthma-related health care utilization and quality of life among inner-city patients with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; hospitalization; quality of life; predictors; allergic sensitization	EMERGENCY-DEPARTMENT VISITS; RISK-FACTORS; DEPRESSIVE SYMPTOMS; HOSPITAL ADMISSION; AFRICAN-AMERICANS; UNITED-STATES; ADULTS; QUESTIONNAIRE; MORBIDITY; CHILDREN	Background: Asthma morbidity and mortality are highest among minority inner-city populations. Objective: To identify factors associated with acute health care resource utilization and asthma-related quality of life among high-risk, minority patients with asthma. Methods: We interviewed a prospective cohort of 198 adults hospitalized for asthma in an inner city hospital over a period of 1 year. Detailed information about sociodemographics, asthma history, access to care, asthma medications, and self-reported allergy to aeroallergens was collected at baseline. Data on resource utilization (emergency department visits and hospital admissions for asthma) and asthma-related quality of life were obtained at 6 months after discharge. Multivariate analyses were used to identify predictors of resource utilization and quality of life. Results: The mean age of patients was 49.9 +/- 17.4 years, 78% were women, and 97% were nonwhite. At 6 months, 49% of patients had an emergency department visit or hospitalization. In multivariate analysis, adjusting for age, sex, medication regimen, and asthma severity, patients with a physician in charge of their asthma care had lower odds of resource utilization (odds ratio, 0.4; P = .03). Conversely, a self-reported history of cockroach allergy was associated with greater utilization (odds ratio, 2.3; P = .05). Asthma-related quality of life was worse among patients who spoke mostly Spanish or who reported allergy to cockroaches (P < .004). Conclusion: Lack of an established asthma care provider, language barriers, and self-reported allergy to cockroaches are associated with higher resource utilization and worse quality of life among minority, inner-city patients with asthma. Interventions targeting these factors may lead to better outcomes among these patients.	CUNY Mt Sinai Sch Med, Dept Med, Div Gen Internal Med, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Med, Div Pulm Crit Care & Sleep Med, New York, NY 10029 USA; Rutgers State Univ, Inst Hlth Hlth Care Policy & Aging Res, New Brunswick, NJ USA; Rutgers State Univ, Dept Psychol, New Brunswick, NJ USA; Mt Sinai Sch Med, Dept Hlth Policy, New York, NY USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Icahn School of Medicine at Mount Sinai	Wisnivesky, JP (corresponding author), CUNY Mt Sinai Sch Med, Dept Med, Div Gen Internal Med, Box 1087,1 Gustave L Levy Pl, New York, NY 10029 USA.	juan.wisnivesky@mssm.edu			AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K08HS013312, R01HS009973] Funding Source: NIH RePORTER; AHRQ HHS [R01 HS09973, K08 HS013312] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Adams RJ, 2000, THORAX, V55, P566, DOI 10.1136/thorax.55.7.566; Awadh N, 1996, RESP MED, V90, P485, DOI 10.1016/S0954-6111(96)90176-6; Blixen CE, 1999, J ASTHMA, V36, P195, DOI 10.3109/02770909909056317; BROWN EM, 1994, ANN EMERG MED, V24, P1083, DOI 10.1016/S0196-0644(94)70237-3; BUSSE PJ, 2005, IN PRESS J ALLERGY C; Cabana MD, 2004, J ALLERGY CLIN IMMUN, V114, P352, DOI 10.1016/j.jaci.2004.04.047; CARR W, 1992, AM J PUBLIC HEALTH, V82, P59, DOI 10.2105/AJPH.82.1.59; Cowie RL, 2001, J ASTHMA, V38, P179, DOI 10.1081/JAS-100000037; CRANE J, 1992, INT J EPIDEMIOL, V21, P737, DOI 10.1093/ije/21.4.737; DALES RE, 1995, THORAX, V50, P520, DOI 10.1136/thx.50.5.520; Diette GB, 2002, ARCH INTERN MED, V162, P1123, DOI 10.1001/archinte.162.10.1123; Eisner MD, 2001, RESP RES, V2, P53, DOI 10.1186/rr37; Ford JG, 2001, CHEST, V120, P1129, DOI 10.1378/chest.120.4.1129; Fuhlbrigge AL, 2002, AM J RESP CRIT CARE, V166, P1044, DOI 10.1164/rccm.2107057; GOTTLIEB DJ, 1995, CHEST, V108, P28, DOI 10.1378/chest.108.1.28; Grant E N, 1999, Curr Opin Pulm Med, V5, P27, DOI 10.1097/00063198-199901000-00005; HAAS JS, 1994, J GEN INTERN MED, V9, P121, DOI 10.1007/BF02600024; HALM EA, 2005, IN PRESS CHEST; Homa DM, 2000, AM J RESP CRIT CARE, V161, P504, DOI 10.1164/ajrccm.161.2.9906025; Juniper EF, 1999, EUR RESPIR J, V14, P32, DOI 10.1034/j.1399-3003.1999.14a08.x; JUNIPER EF, 1995, AM J RESP CRIT CARE, V151, P66, DOI 10.1164/ajrccm.151.1.7812574; JUNIPER EF, 1992, THORAX, V47, P76, DOI 10.1136/thx.47.2.76; Komaromy M, 1996, MED CARE, V34, P594, DOI 10.1097/00005650-199606000-00009; Lewis SA, 2002, AM J RESP CRIT CARE, V165, P961, DOI 10.1164/ajrccm.165.7.2103044; LI D, 1995, AM J RESP CRIT CARE, V151, P647; Magadle R, 2002, CHEST, V121, P329, DOI 10.1378/chest.121.2.329; Mancuso CA, 2000, J GEN INTERN MED, V15, P301, DOI 10.1046/j.1525-1497.2000.07006.x; Mancuso CA, 2001, MED CARE, V39, P1326, DOI 10.1097/00005650-200112000-00008; MANSON A, 1988, MED CARE, V26, P1119, DOI 10.1097/00005650-198812000-00003; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Murray MD, 1997, J CLIN EPIDEMIOL, V50, P167, DOI 10.1016/S0895-4356(96)00333-2; National Heart Lung Blood Institute, 1997, 2 NAT HEART LUNG BLO; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Osborne ML, 1998, AM J RESP CRIT CARE, V157, P123, DOI 10.1164/ajrccm.157.1.9612063; Pesola GR, 2004, ACAD EMERG MED, V11, P944, DOI 10.1197/j.aem.2004.03.020; Ray NF, 1998, CHEST, V113, P1277, DOI 10.1378/chest.113.5.1277; Rogers L, 2002, CHEST, V122, P1580, DOI 10.1378/chest.122.5.1580; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Salamzadeh J, 2003, J ASTHMA, V40, P645, DOI 10.1081/JAS-120019035; Sanjuas C, 2001, J CLIN EPIDEMIOL, V54, P182, DOI 10.1016/S0895-4356(00)00297-3; Schatz M, 2003, J ALLERGY CLIN IMMUN, V111, P503, DOI 10.1067/mai.2003.178; Schatz M, 2003, AM J MANAG CARE, V9, P538; Sicherer SH, 2004, J ALLERGY CLIN IMMUN, V114, P159, DOI 10.1016/j.jaci.2004.04.018; Singh AK, 1999, ARCH INTERN MED, V159, P1237, DOI 10.1001/archinte.159.11.1237; STEVENSON LKM, 1998, C P WORK TOG COMB UR, P1; TARGONSKI PV, 1995, J ASTHMA, V32, P365, DOI 10.3109/02770909509082761; Tough S C, 1999, Can Respir J, V6, P429; Ungar WJ, 1998, J CLIN EPIDEMIOL, V51, P1335, DOI 10.1016/S0895-4356(98)00117-6; Wakefield M, 1997, CHEST, V112, P1527, DOI 10.1378/chest.112.6.1527; Wakefield M, 1997, AUST NZ J MED, V27, P277, DOI 10.1111/j.1445-5994.1997.tb01979.x; Weber EJ, 2002, AM J MED, V113, P371, DOI 10.1016/S0002-9343(02)01242-1; Weiss KB, 2001, J ALLERGY CLIN IMMUN, V107, P3, DOI 10.1067/mai.2001.112262; Zoratti EM, 1998, AM J RESP CRIT CARE, V158, P371, DOI 10.1164/ajrccm.158.2.9608039	53	36	36	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2005	116	3					636	642		10.1016/j.jaci.2005.05.031	http://dx.doi.org/10.1016/j.jaci.2005.05.031			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IE	16159636	Bronze			2022-12-18	WOS:000235686500026
J	Gauvreau, GM; Boulet, LP; Postma, DS; Kawayama, T; Watson, RM; Duong, M; Deschesnes, F; De Monchy, JGR; O'Byrne, PM				Gauvreau, GM; Boulet, LP; Postma, DS; Kawayama, T; Watson, RM; Duong, M; Deschesnes, F; De Monchy, JGR; O'Byrne, PM			Effect of low-dose ciclesonide on allergen-induced responses in subjects with mild allergic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						inhaled corticosteroid; allergen inhalation; airway inflammation	INDUCED AIRWAY RESPONSES; INHALED BUDESONIDE; INFLAMMATION; PROGENITORS; CHALLENGE; BONE; BRONCHOCONSTRICTION; REPRODUCIBILITY; FLUTICASONE; ANTAGONIST	Background: Inhalation of allergens by sensitized patients with asthma induces reversible airway obstruction, airway hyperresponsiveness, and eosinophilic airway inflammation. Attenuation of allergen-induced bronchoconstriction and inflammation has been used to examine the efficacy of therapeutic agents such as inhaled corticosteroids in asthma. Ciclesonide, a nonhalogenated inhaled corticosteroid being developed for the treatment of persistent asthma, remains inactive until cleaved by esterases in the lung. Objective: This study examined the effect of low doses of inhaled ciclesonide, 40 Kg and 80 mu g, on allergen-induced bronchoconstriction, serum eosinophil cationic protein, and eosinophilic airway inflammation. Methods: Twenty-one nonsmokers with mild atopic asthma completed a multicenter, randomized, 3-way crossover study comparing the effects of 7-day treatment of ciclesomide or placebo. Allergen-induced responses, including the early and late fall in FEV1, peripheral blood eosinophils, serum eosinophil cationic protein levels, and eosinophils in induced sputum were measured. Results: Ciclesonide 80 jig attenuated the early and late asthmatic responses, including the change in FEV1, serum eosinophil cationic protein, and sputum eosinophils measured at 24 hours postchallenge (P < .025). Ciclesonide 40 Kg attenuated the late asthmatic responses and sputum eosinophils measured at 24 hours postchallenge (P < .025), with no effect on the early allergen-induced bronchoconstriction, 24-hour FEV1, or serum eosinophil cationic protein levels (P < .025). Conclusion: With the exception of 24-hour postchallenge peripheral blood eosinophils, a low dose of ciclesonide, 80 mu g, was effective in blocking all allergen-induced responses measured.	McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada; Univ Laval, Hop Laval, Inst Cardiol & Pneumol, Quebec City, PQ, Canada; Univ Groningen Hosp, Dept Pulmonol, Groningen, Netherlands	McMaster University; Laval University; University of Groningen	O'Byrne, PM (corresponding author), McMaster Univ, Dept Med, HSC 3W10,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	obyrnep@mcmaster.ca		O'Byrne, Paul/0000-0003-0979-281X				Boulet LP, 1998, EUR RESPIR J, V11, P1194, DOI 10.1183/09031936.98.11051194; Boulet LP, 2001, CLIN EXP ALLERGY, V31, P430, DOI 10.1046/j.1365-2222.2001.01014.x; COCKCROFT DW, 1987, AM REV RESPIR DIS, V135, P264; Cockcroft DW, 1985, AIRWAY RESPONSIVENES, P22; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828, DOI 10.1164/ajrccm.155.6.9196082; Gauvreau GM, 2003, J ALLERGY CLIN IMMUN, V112, P331, DOI 10.1067/mai.2003.1689; Gauvreau GM, 1997, AM J RESP CRIT CARE, V156, P1738, DOI 10.1164/ajrccm.156.6.96-08042; Gauvreau GM, 1999, J ALLERGY CLIN IMMUN, V104, P66, DOI 10.1016/S0091-6749(99)70115-6; Gauvreau GM, 1996, AM J RESP CRIT CARE, V154, P1267, DOI 10.1164/ajrccm.154.5.8912734; Gauvreau GM, 2001, AM J RESP CRIT CARE, V164, P1495, DOI 10.1164/ajrccm.164.8.2102033; Gauvreau GM, 2000, AM J RESP CRIT CARE, V162, P2139, DOI 10.1164/ajrccm.162.6.2001120; Hamilton A, 1998, J ALLERGY CLIN IMMUN, V102, P177, DOI 10.1016/S0091-6749(98)70083-1; Hamilton AL, 1997, THORAX, V52, P348, DOI 10.1136/thx.52.4.348; INMAN MD, 1995, J ALLERGY CLIN IMMUN, V95, P1191, DOI 10.1016/S0091-6749(95)70075-7; Inman MD, 2001, AM J RESP CRIT CARE, V164, P569, DOI 10.1164/ajrccm.164.4.2007063; Inman MD, 1996, AM J RESP CELL MOL, V15, P305, DOI 10.1165/ajrcmb.15.3.8924277; Kidney JC, 1997, J ALLERGY CLIN IMMUN, V100, P65, DOI 10.1016/S0091-6749(97)70196-9; Larsen BB, 2003, ALLERGY, V58, P207, DOI 10.1034/j.1398-9995.2003.00052.x; Lee DKC, 2005, CHEST, V127, P851, DOI 10.1378/chest.127.3.851; Leigh R, 2002, AM J RESP CRIT CARE, V166, P1212, DOI 10.1164/rccm.200206-509OC; MASUYAMA K, 1994, IMMUNOLOGY, V82, P192; *NAT I HLTH NAT HE, 2002, NIH PUBL NUMB; OBYME PM, 1987, AM REV RESPIR DIS, V136, P740; Parameswaran K, 2004, AM J RESP CRIT CARE, V169, P915, DOI 10.1164/rccm.200312-1645OC; Parameswaran K, 2000, Can Respir J, V7, P313; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799; Postma DS, 2001, EUR RESPIR J, V17, P1083, DOI 10.1183/09031936.01.00099701; Subbarao P, 2005, J ALLERGY CLIN IMMUN, V115, P745, DOI 10.1016/j.jaci.2004.11.023; Wood LJ, 1999, AM J RESP CRIT CARE, V159, P1457, DOI 10.1164/ajrccm.159.5.9808123	30	36	41	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2005	116	2					285	291		10.1016/j.jaci.2005.05.021	http://dx.doi.org/10.1016/j.jaci.2005.05.021			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017ID	16083781	Bronze			2022-12-18	WOS:000235686400007
J	Nakajima, T; Iikura, M; Okayama, Y; Matsumoto, K; Uchiyama, C; Shirakawa, T; Yang, X; Adra, CN; Hirai, K; Saito, H				Nakajima, T; Iikura, M; Okayama, Y; Matsumoto, K; Uchiyama, C; Shirakawa, T; Yang, X; Adra, CN; Hirai, K; Saito, H			Identification of granulocyte subtype-selective receptors and ion channels by using a high-density oligonucleotide probe array	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						basophils; eosinophils; granulocytes; G protein-coupled receptors; ion channels	AFFINITY IGE RECEPTOR; HUMAN MAST-CELLS; FC-EPSILON-RI; GENE-EXPRESSION; HUMAN BASOPHILS; HUMAN-LUNG; ACTIVATED RECEPTOR-2; HUMAN EOSINOPHILS; FATAL ASTHMA; PROTEIN	Background: During inflammation, neutrophils, basophils, and eosinophils release cell type-specific mediators and proteases through signaling molecules, such as G protein-coupled receptors and ion channels. As such, ion channels and receptors, including G protein-coupled receptors, are common drug targets. Objective: We sought to identify, for the first time, ion channels and receptors preferentially expressed by each granulocyte subtype. Methods: Using GeneChip, we compared approximately 20,000 transcripts present in 7 leukocyte types, platelets, mast cells, and fibroblasts to identify granulocyte subtype-selective transcripts for receptors and ion channels. Granulocyte subtype-selective transcripts were chosen on the basis of several conditions, such as the transcript having a 5-fold or greater expression level compared with the maximum level of other leukocytes. Results: Fifty-one transcripts were chosen to be preferentially expressed by each granulocyte subtype. Seventeen of the 51 transcripts have not been previously reported as granulocyte subtype selective. Among the 17 receptors and ion channels, 6 were basophil selective, eosinophil selective, or both and were not highly expressed by other organs, indicating that they might be potential targets for antiallergy drugs. Conclusion: Use of this database of potential cell type-selective drug targets should minimize the efforts required for pharmaceutical development.	Natl Res Inst Child Hlth & Dev, Dept Allergy & Immunol, Setagaya Ku, Tokyo 1548567, Japan; Harvard Univ, Sch Med, Childrens Hosp, Dept Med, Boston, MA USA; Beth Israel Deaconess Med Ctr, Dept Pathol & Med, Boston, MA 02215 USA; Kyoto Univ, Grad Sch Publ Hlth, Dept Hlth Promot & Human Behav, Kyoto, Japan; RIKEN, Res Ctr Allergy & Immunol, Lab Allergy & Immunol, Yokohama, Kanagawa, Japan; Univ Tokyo, Grad Sch Med, Dept Bioregulat Funct, Tokyo, Japan; Org Pharmaceut Safety & Res, Tokyo, Japan	National Center for Child Health & Development - Japan; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Kyoto University; RIKEN; University of Tokyo	Saito, H (corresponding author), Natl Res Inst Child Hlth & Dev, Dept Allergy & Immunol, Setagaya Ku, 3-35-31 Taishido, Tokyo 1548567, Japan.		Okayama, Yoshimichi/AAG-4352-2021	Saito, Hirohisa/0000-0002-6630-8337	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI043663] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 43663] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADRA CN, 1994, P NATL ACAD SCI USA, V91, P10178, DOI 10.1073/pnas.91.21.10178; Adra CN, 1999, CLIN GENET, V55, P431, DOI 10.1034/j.1399-0004.1999.550606.x; Arock M, 2002, J LEUKOCYTE BIOL, V71, P557; Bochner BS, 2000, J ALLERGY CLIN IMMUN, V106, P817, DOI 10.1067/mai.2000.110813; Bradding P, 2003, J LEUKOCYTE BIOL, V73, P614, DOI 10.1189/jlb.1202602; CHURCH MK, 1982, J IMMUNOL, V129, P2116; Donato JL, 2002, J CLIN INVEST, V109, P51, DOI 10.1172/JCI14025; Drews J, 2000, SCIENCE, V287, P1960, DOI 10.1126/science.287.5460.1960; Fukagawa K, 2002, INVEST OPHTH VIS SCI, V43, P58; Gounni AS, 2001, FASEB J, V15, P940, DOI 10.1096/fj.00-0378com; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; Hirai K, 1997, CRIT REV IMMUNOL, V17, P325, DOI 10.1615/CritRevImmunol.v17.i3-4.40; Hopkins AL, 2002, NAT REV DRUG DISCOV, V1, P727, DOI 10.1038/nrd892; Iida M, 2001, BLOOD, V97, P1016, DOI 10.1182/blood.V97.4.1016; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Kepley CL, 2001, AM J RESP CRIT CARE, V164, P1053, DOI 10.1164/ajrccm.164.6.2102025; KOSHINO T, 1993, CLIN EXP ALLERGY, V23, P919, DOI 10.1111/j.1365-2222.1993.tb00276.x; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LIN CS, 1993, J EXP MED, V177, P637, DOI 10.1084/jem.177.3.637; Loitto VM, 2002, J LEUKOCYTE BIOL, V71, P212; Luccioli S, 2002, J ALLERGY CLIN IMMUN, V110, P117, DOI 10.1067/mai.2002.125828; MATSUMOTO K, 1995, BLOOD, V86, P1437, DOI 10.1182/blood.V86.4.1437.bloodjournal8641437; Moffatt JD, 2002, AM J RESP CELL MOL, V26, P680, DOI 10.1165/ajrcmb.26.6.4693; Nakajima T, 2002, BLOOD, V100, P3861, DOI 10.1182/blood-2002-02-0602; Nakajima T, 2001, BLOOD, V98, P1127, DOI 10.1182/blood.V98.4.1127; Nutku E, 2003, BLOOD, V101, P5014, DOI 10.1182/blood-2002-10-3058; O'Reilly M, 2002, J RECEPT SIGNAL TR R, V22, P431, DOI 10.1081/RRS-120014612; Oehler R, 2000, BLOOD, V95, P1086, DOI 10.1182/blood.V95.3.1086.003k09_1086_1092; OKAYAMA Y, 1994, J IMMUNOL METHODS, V169, P153, DOI 10.1016/0022-1759(94)90259-3; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; SAITO H, 1987, J IMMUNOL, V138, P3927; Savage COS, 2002, CLIN MED, V2, P458, DOI 10.7861/clinmedicine.2-5-458; Schmidlin F, 2001, AM J RESP CRIT CARE, V164, P1276, DOI 10.1164/ajrccm.164.7.2101157; Schroeder JT, 2001, J ALLERGY CLIN IMMUN, V107, P265, DOI 10.1067/mai.2001.112846; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Yoshimura C, 2001, J ALLERGY CLIN IMMUN, V108, P215, DOI 10.1067/mai.2001.116575; Zambrowicz BP, 2003, NAT REV DRUG DISCOV, V2, P38, DOI 10.1038/nrd987	37	36	42	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2004	113	3					528	535		10.1016/j.jaci.2003.12.036	http://dx.doi.org/10.1016/j.jaci.2003.12.036			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	802DM	15007357				2022-12-18	WOS:000220144200027
J	Zhang, XD; Fedan, JS; Lewis, DM; Siegel, PD				Zhang, XD; Fedan, JS; Lewis, DM; Siegel, PD			Asthmalike biphasic airway responses in Brown Norway rats sensitized by dermal exposure to dry trimellitic anhydride powder	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						trimellitic anhydride; dermal exposure; enhanced pause; airway challenge; late-phase airway response	GUINEA-PIGS; HEXAHYDROPHTHALIC ANHYDRIDE; RESPIRATORY ALLERGY; ACID ANHYDRIDES; HYPERSENSITIVITY; RESPONSIVENESS; INHALATION; IRRITATION; CHALLENGE; INDUCTION	Background: Trimellitic anhydride (TMA) can induce specific IgE and occupational asthma. The significance of dermal exposure to TMA in immunologic sensitization and on subsequent airway responses is not clearly known. An animal model displaying both an early-phase airway response (EAR) and a late-phase airway response (LAR) after sensitization and subsequent inhalation challenge to a low-molecular-weight chemical has not been previously reported. Objective: The present study investigated EAR and LAR after TMA inhalation challenge in Brown Norway rats sensitized by skin exposure to TMA dry powder. Methods: Twenty milligrams of dry TMA powder was applied to the skin of each clipped rat's dorsum on days 0, 7, 14, and 21 and occluded overnight with surgical tape. Rats were challenged for 10 minutes with 0.2 to 40 mg/m(3) of TMA aerosol after day 35. Enhanced pause (an index of airway resistance) was recorded overnight in a whole-body plethysmography system. Specific IgE and pulmonary eosinophilia were also measured. Results: Concentration-dependent responses to TMA were observed: provocation with 0.2 mg/m(3) produced no response; 1 mg/m(3) induced only EAR; and 5 mg/m(3) and 40 mg/m(3) induced both EAR and LAR. Specific IgE was positive; airway eosinophilic inflammation was observed. Conclusion: TMA powder applied to the skin can lead to both immunologic sensitization and subsequent dose-dependent biphasic airway responses after TMA aerosol challenge.	NIOSH, Ctr Dis Control & Prevent, Hlth Effects Lab Div, Morgantown, WV 26505 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)	Siegel, PD (corresponding author), NIOSH, Ctr Dis Control & Prevent, Hlth Effects Lab Div, 1095 Willowdale Rd, Morgantown, WV 26505 USA.		Fedan, Jeffrey S/E-2968-2013	Fedan, Jeffrey S/0000-0002-3812-3220				ARAKAWA H, 1993, J ALLERGY CLIN IMMUN, V92, P425, DOI 10.1016/0091-6749(93)90121-U; Arts JHE, 2003, TOXICOL APPL PHARM, V187, P38, DOI 10.1016/S0041-008X(02)00023-6; Arts JHE, 2001, INHAL TOXICOL, V13, P719, DOI 10.1080/08958370152409937; Arts JHE, 1998, TOXICOL APPL PHARM, V152, P66, DOI 10.1006/taap.1998.8504; Barker RD, 1998, OCCUP ENVIRON MED, V55, P684, DOI 10.1136/oem.55.10.684; BOTHAM PA, 1989, TOXICOL LETT, V47, P25, DOI 10.1016/0378-4274(89)90083-0; Djuric VJ, 1998, BRAIN BEHAV IMMUN, V12, P272, DOI 10.1006/brbi.1998.0538; Dohi M, 1999, LAB INVEST, V79, P1559; DURHAM SR, 1987, J ALLERGY CLIN IMMUN, V79, P398, DOI 10.1016/0091-6749(87)90161-8; FAWCETT IW, 1977, CLIN ALLERGY, V7, P1, DOI 10.1111/j.1365-2222.1977.tb01418.x; GRAMMER LC, 1992, ALLERGY PROC, V13, P139, DOI 10.2500/108854192778878755; HALLOY D, 2001, AM J RESP CRIT CAR S, V163, pA927; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; HAYES JP, 1992, CLIN EXP ALLERGY, V22, P694, DOI 10.1111/j.1365-2222.1992.tb00193.x; Lin CC, 2001, RESPIRATION, V68, P178, DOI 10.1159/000050489; Palmqvist M, 2001, EUR RESPIR J, V17, P872, DOI 10.1183/09031936.01.17508720; PATTERSON R, 1982, J ALLERGY CLIN IMMUN, V70, P19, DOI 10.1016/0091-6749(82)90196-8; PAULUHN J, 1991, J APPL TOXICOL, V11, P423, DOI 10.1002/jat.2550110608; Pauluhn J, 2002, J APPL TOXICOL, V22, P89, DOI 10.1002/jat.831; SANTING RE, 1994, J ALLERGY CLIN IMMUN, V93, P1021, DOI 10.1016/S0091-6749(94)70051-6; SARLO K, 1994, J ALLERGY CLIN IMMUN, V94, P747, DOI 10.1016/0091-6749(94)90183-X; VANTONGEREN MJA, 1995, ANN OCCUP HYG, V39, P559, DOI 10.1093/annhyg/39.5.559; ZEISS CR, 1977, J ALLERGY CLIN IMMUN, V60, P96, DOI 10.1016/0091-6749(77)90033-1; Zhang XD, 2002, ALLERGY, V57, P620, DOI 10.1034/j.1398-9995.2002.03548.x; Zhang XD, 1998, ALLERGY, V53, P20, DOI 10.1111/j.1398-9995.1998.tb03769.x; Zhao H, 1997, ALLERGY, V52, P18, DOI 10.1111/j.1398-9995.1997.tb02541.x	26	36	39	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2004	113	2					320	326		10.1016/j.jaci.2003.11.047	http://dx.doi.org/10.1016/j.jaci.2003.11.047			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	773EX	14767449				2022-12-18	WOS:000188885700022
J	Kurukulaaratchy, RJ; Matthews, S; Waterhouse, L; Arshad, SH				Kurukulaaratchy, RJ; Matthews, S; Waterhouse, L; Arshad, SH			Factors influencing symptom expression in children with bronchial hyperresponsiveness at 10 years of age	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; atopy; bronchial hyperresponsiveness; child-hood wheezing; risk factors	ENVIRONMENTAL-FACTORS; ALLERGIC DISORDERS; RISK-FACTORS; RESPONSIVENESS; PREVALENCE; ASTHMA; HYPERREACTIVITY; REACTIVITY; CHILDHOOD; SMOKING	Objectives: We sought to identify factors associated with wheezing symptoms in children found to have bronchial hyperresponsiveness (BHR) at 10 years of age. Methods: Children were seen at birth, 1, 2, 4 and 10 years of age in an entire population birth cohort study (n = 1456). At each stage information was collected prospectively on genetic and environmental risk factors for BHR. Skin prick testing was performed at 4 and 10 years of age. Spirometry and methacholine bronchial challenge were conducted at 10 years of age when BHR was considered present If PC20 FEV1 was < 4.0 mg/mL. In children with BHR at 10 years of age, factors independently associated with current wheezing were determined by logistic regression. Results: BHR was identified in 169 10-year-olds at bronchial challenge, 55.6% of whom manifested current wheeze. In children with BHR, current wheezers had higher Log(10) total IgE and greater BHR than those who had never wheezed. Symptomatic BHR was independently associated with atopic sensitization (P < .001) and maternal asthma (P = .011) at 10 years of age. If only factors present in the first 4 years of life were considered, parental smoking at 4 years of age (P = .021), maternal asthma (P = .017), and atopic sensitization at 4 years of age (P = .004) were independently associated with symptomatic BHR at 10 years of age. Conclusions: Symptomatic BHR is associated with greater degrees of BHR and higher total IgE. Heredity, atopy, and environmental exposure might influence symptom expression in children with BHR.	St Mary Hosp, David Hide Asthma & Allergy Res Ctr, Newport PO30 5TG, Isle Wight, England		Arshad, SH (corresponding author), St Mary Hosp, David Hide Asthma & Allergy Res Ctr, Newport PO30 5TG, Isle Wight, England.			Kurukulaaratchy, Ramesh/0000-0002-1588-2400				Alexander HL, 1921, ARCH INTERN MED, V27, P184, DOI 10.1001/archinte.1921.00100080047004; AQUILINA AT, 1980, AM REV RESPIR DIS, V122, P3; ARSHAD SH, 1992, J ALLERGY CLIN IMMUN, V90, P235, DOI 10.1016/0091-6749(92)90077-F; Arshad SH, 2002, ACTA PAEDIATR, V91, P1334; ARSHAD SH, 1993, CLIN EXP ALLERGY, V23, P504, DOI 10.1111/j.1365-2222.1993.tb03238.x; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BRAMAN SS, 1987, CHEST, V91, P671, DOI 10.1378/chest.91.5.671; Chinn S, 1999, EUR RESPIR J, V14, P876, DOI 10.1034/j.1399-3003.1999.14d25.x; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Dharmage SC, 1998, J ASTHMA, V35, P391, DOI 10.3109/02770909809048947; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; FORASTIERE F, 1994, AM J RESP CRIT CARE, V149, P365, DOI 10.1164/ajrccm.149.2.8306031; Green RM, 2002, BMJ-BRIT MED J, V324, P763, DOI 10.1136/bmj.324.7340.763; Holgate ST, 2000, AM J RESP CRIT CARE, V162, pS113, DOI 10.1164/ajrccm.162.supplement_2.ras-12; KOLNAAR BG, 1995, EUR RESPIR J, V10, P44; Kurukulaaratchy RJ, 2002, RESP MED, V96, P163, DOI 10.1053/rmed.2001.1236; LEE DA, 1983, BRIT MED J, V286, P1256, DOI 10.1136/bmj.286.6373.1256; MARTINEZ FD, 1988, AM REV RESPIR DIS, V138, P518, DOI 10.1164/ajrccm/138.3.518; Niggemann B, 2001, EUR RESPIR J, V17, P246, DOI 10.1183/09031936.01.17202460; RAMSDALE EH, 1985, J ALLERGY CLIN IMMUN, V75, P573; Rasmussen F, 2002, PEDIATR PULM, V34, P164, DOI 10.1002/ppul.10155; SALOME CM, 1987, CLIN ALLERGY, V17, P271, DOI 10.1111/j.1365-2222.1987.tb02015.x; SEARS MR, 1986, THORAX, V41, P283, DOI 10.1136/thx.41.4.283; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; Tariq SM, 1998, J ALLERGY CLIN IMMUN, V101, P587, DOI 10.1016/S0091-6749(98)70164-2; Thaminy A, 2000, EUR RESPIR J, V16, P1091, DOI 10.1034/j.1399-3003.2000.16f12.x	26	36	37	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2003	112	2					311	316		10.1067/mai.2003.1623	http://dx.doi.org/10.1067/mai.2003.1623			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	709WY	12897736				2022-12-18	WOS:000184650600014
J	Mastruzzo, C; Greco, LR; Nakano, K; Nakano, A; Palermo, F; Pistorio, MP; Salinaro, ET; Jordana, M; Dolovich, J; Crimi, N; Vancheri, C				Mastruzzo, C; Greco, LR; Nakano, K; Nakano, A; Palermo, F; Pistorio, MP; Salinaro, ET; Jordana, M; Dolovich, J; Crimi, N; Vancheri, C			Impact of intranasal budesonide on immune inflammatory responses and epithelial remodeling in chronic upper airway inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						nasal polyps; budesonide; TGF-beta; CD4 T cells; CD8 T cells; IL-4; IL-5; epithelial remodeling	GROWTH-FACTOR-BETA; CD8(+) T-CELLS; HUMAN LYMPHOCYTES-T; TRANSFORMING GROWTH-FACTOR-BETA-1; TGF-BETA; CONTROLLED-TRIAL; GENE-EXPRESSION; NASAL POLYPS; DOUBLE-BLIND; ASTHMA	Background: Histologic and immunohistologic features of nasal polyps (NP) are similar to those observed in asthma, thus suggesting a similar immunopathology. Objective: The primary objective of this study was to further understand the anti-inflammatory and immunoregulatory effects of locally delivered corticosteroids. To this end, the effect of intranasal budesonide on the expression of specific cytokines, lymphocyte subsets, and epithelial remodeling in this model of airway tissue inflammation were studied. Methods: We used immunohistochemical techniques to examine nasal mucosae (NM) from healthy individuals and nasal polyp (NP) tissues from patients with nasal polyposis obtained before and after intranasal budesonide treatment. Results: First, the density of CD8(+) cells was markedly increased in NP tissues after intranasal budesonide treatment from 16.1 +/- 8.4 (M +/- SEM) per mm(2) to 39.9 +/- 24.1. Second, the density of cells immunoreactive for IL-4, IL-5, IFN-gamma, IL-12, and TGF-beta in NP was significantly greater than in control NM tissues. The density of IL-4(+) and IL-5(+) cells in NP tissues significantly decreased after budesonide treatment from 40 +/- 12 to 17.8 +/- 8 and from 19.3 +/- 11 to 10.4 +/- 7, respectively. In contrast, the density of IFN-gamma(+) and IL-12(+) cells remained unchanged. In addition, we found that the density of TGF-beta(+) cells significantly increased after intranasal budesonide from 18 +/- 5 to 41 +/- 9. Third, damage to the entire length of the NP epithelium was quantified using a grading system. The epithelium of untreated NP was substantially damaged; remarkable epithelial restitution with no apparent changes in stromal collagen deposition was observed after intranasal budesonide treatment. Conclusions: These findings demonstrate that intranasal budesonide induced an increase in CD8 population and a selective regulatory effect on tissue cytokine expression. Furthermore, intranasal budesonide promoted epithelial remodeling. We hypothesize that these immunoregulatory and remodeling effects elicited by steroids might be, at least in part, mediated by the induction of TGF-beta.	Univ Catania, Dept Internal & Specialist Med, Sect Resp Dis, I-95125 Catania, Italy; Univ Catania, Infect Dis Sect, I-95125 Catania, Italy; McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada; McMaster Univ, Dept Pediat, Hamilton, ON, Canada	University of Catania; University of Catania; McMaster University; McMaster University	Mastruzzo, C (corresponding author), Univ Catania, Dept Internal & Specialist Med, Sect Resp Dis, Via Passo Gravina 187, I-95125 Catania, Italy.		Crimi, Nunzio/AAL-2994-2020; VANCHERI, Carlo/K-9417-2016	Crimi, Nunzio/0000-0002-8591-4535; VANCHERI, Carlo/0000-0002-5120-9926				Almawi WY, 1998, NEPHROL DIAL TRANSPL, V13, P2450, DOI 10.1093/ndt/13.10.2450; AYANLARBATUMAN O, 1991, J CLIN INVEST, V88, P1574, DOI 10.1172/JCI115469; BROEKELMANN TJ, 1991, P NATL ACAD SCI USA, V88, P6642, DOI 10.1073/pnas.88.15.6642; Calabresi PA, 1998, NEUROLOGY, V51, P289, DOI 10.1212/WNL.51.1.289; FARGEAS C, 1992, EUR J IMMUNOL, V22, P2173, DOI 10.1002/eji.1830220833; Faul JL, 1998, THORAX, V53, P753, DOI 10.1136/thx.53.9.753; Filiaci F, 2000, RHINOLOGY, V38, P185; Gray JD, 1998, J IMMUNOL, V160, P2248; GRAY JD, 1994, J EXP MED, V180, P1937, DOI 10.1084/jem.180.5.1937; Haneda K, 1999, AM J RESP CELL MOL, V21, P268, DOI 10.1165/ajrcmb.21.2.3576; Holgate ST, 2000, CLIN EXP ALLERGY, V30, P1; JORDANA M, 2000, ASTHMA RHINITIS, P223; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; LEE HM, 1993, J IMMUNOL, V151, P668; Letterio JJ, 2000, CYTOKINE GROWTH F R, V11, P81, DOI 10.1016/S1359-6101(99)00031-3; LILDHOLDT T, 1995, CLIN OTOLARYNGOL, V20, P26, DOI 10.1111/j.1365-2273.1995.tb00007.x; NONAKA M, 1995, J IMMUNOL, V155, P3234; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Rinne J, 2002, J ALLERGY CLIN IMMUN, V109, P426, DOI 10.1067/mai.2002.121703; Sime PJ, 1997, J CLIN INVEST, V100, P768, DOI 10.1172/JCI119590; Song XY, 1998, J CLIN INVEST, V101, P2615, DOI 10.1172/JCI2480; Tomaki M, 2000, J IMMUNOL, V165, P4040, DOI 10.4049/jimmunol.165.7.4040; TRIGG CJ, 1994, AM J RESP CRIT CARE, V150, P17, DOI 10.1164/ajrccm.150.1.8025745; Vukmanovic-Stejic M, 2001, IMMUNOLOGY, V102, P115, DOI 10.1046/j.1365-2567.2001.01193.x; Wardlaw AJ, 1999, J ALLERGY CLIN IMMUN, V104, P917, DOI 10.1016/S0091-6749(99)70069-2; WLADISLAVOSKYWASERMAN P, 1984, CLIN ALLERGY, V14, P241, DOI 10.1111/j.1365-2222.1984.tb02203.x	26	36	39	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2003	112	1					37	44		10.1067/mai.2003.1586	http://dx.doi.org/10.1067/mai.2003.1586			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	698QQ	12847477				2022-12-18	WOS:000184010600007
J	Uchi, H; Arrighi, JF; Aubry, JP; Furue, M; Hauser, C				Uchi, H; Arrighi, JF; Aubry, JP; Furue, M; Hauser, C			The sesquiterpene lactone parthenolide inhibits LPS- but not TNF-alpha-induced maturation of human monocyte-derived dendritic cells by inhibition of the p38 mitogen-activated protein kinase pathway	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						dendritic cells; maturation; lipopolysaccharide; signal transduction	NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; SIGNAL-TRANSDUCTION PATHWAY; TOLL-LIKE RECEPTORS; COLONY-STIMULATING FACTOR; COSTIMULATORY MOLECULES; DIFFERENTIAL EXPRESSION; COORDINATE REGULATION; TANACETUM-PARTHENIUM; CYTOKINES	Background: Dendritic cells (DCs) are the most potent antigenpresenting cells, and the manipulation of DC maturation provides a strategy for the treatment of allergic and inflammatory diseases. Objective: In this study we examined the effect of the anti-inflammatory sesquiterpene lactone parthenolide (PTL) on DC maturation induced by LPS or TNF-alpha. Methods: Human monocyte-derived DCs generated by means of culture with GM-CSF and IL-4 were pretreated with PTL and subsequently stimulated with LPS or TNF-alpha. Results: PTL inhibited the upregulation of CD80, CD83, CD86, CD40, and MHC class II; the allostimulatory function; the production of TNF-alpha and IL-12; and the downregulation of FITC-labeled dextran uptake in human monocyte-derived DCs stimulated with LPS but not with TNF-alpha. The inhibitory effect of PTL on DC maturation was preceded by inhibition of the phosphorylation of p38 mitogen-activated protein kinase but not the nuclear translocation of NF-kappaB. Conclusion: These results might offer PTL not only as a promising compound for the treatment of LPS-induced disorders, including sepsis or septic shock, by inhibition of excessive DC maturation but also as a tool to further dissect the signaling pathways involved in DC maturation.	Kyushu Univ, Grad Sch Med Sci, Dept Dermatol, Higashi Ku, Fukuoka 8128582, Japan; CIPF, St Julien En Genevois, France; Univ Geneva, Dept Dermatol, Geneva, Switzerland; Univ Geneva, Div Immunol & Allergol, Geneva, Switzerland	Kyushu University; Centre d'Immunologie Pierre Fabre; University of Geneva; University of Geneva	Uchi, H (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Dermatol, Higashi Ku, 3-1-1,Maidashi, Fukuoka 8128582, Japan.							Aiba S, 1997, EUR J IMMUNOL, V27, P3031, DOI 10.1002/eji.1830271141; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Allard RW, 1999, ANNU REV GENET, V33, P1, DOI 10.1146/annurev.genet.33.1.1; Ardeshna KM, 2000, BLOOD, V96, P1039, DOI 10.1182/blood.V96.3.1039.015k04_1039_1046; Arrighi JF, 2001, J IMMUNOL, V166, P3837, DOI 10.4049/jimmunol.166.6.3837; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; BLAECKE A, IN PRESS CYTOMETRY; Carpentier I, 1998, FEBS LETT, V425, P195, DOI 10.1016/S0014-5793(98)00226-9; CAUX C, 1994, J EXP MED, V180, P1263, DOI 10.1084/jem.180.4.1263; CAUX C, 1992, NATURE, V360, P258, DOI 10.1038/360258a0; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; HAUSEN BM, 1983, ACTA DERM-VENEREOL, V63, P308; Hehner SP, 1999, J IMMUNOL, V163, P5617; Hehner SP, 1998, J BIOL CHEM, V273, P1288, DOI 10.1074/jbc.273.3.1288; HEPTINSTALL S, 1985, LANCET, V1, P1071; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Hwang D, 1996, BIOCHEM BIOPH RES CO, V226, P810, DOI 10.1006/bbrc.1996.1433; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Jakob T, 1998, J IMMUNOL, V161, P3042; JOHNSON ES, 1985, BRIT MED J, V291, P569, DOI 10.1136/bmj.291.6495.569; Kang BY, 2001, IMMUNOL LETT, V77, P159, DOI 10.1016/S0165-2478(01)00211-5; Kopp E, 1999, GENE DEV, V13, P2059, DOI 10.1101/gad.13.16.2059; Muzio M, 2000, J IMMUNOL, V164, P5998, DOI 10.4049/jimmunol.164.11.5998; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; Neumann M, 2000, BLOOD, V95, P277; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Oyama T, 1998, J IMMUNOL, V160, P1224; Puig-Kroger A, 2000, J IMMUNOL, V165, P4338, DOI 10.4049/jimmunol.165.8.4338; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; REID CDL, 1992, J IMMUNOL, V149, P2681; ROAKE JA, 1995, J EXP MED, V181, P2237, DOI 10.1084/jem.181.6.2237; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SCHMID I, 1994, J IMMUNOL METHODS, V170, P145, DOI 10.1016/0022-1759(94)90390-5; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Verhasselt V, 1997, J IMMUNOL, V158, P2919; Visintin A, 2001, J IMMUNOL, V166, P249, DOI 10.4049/jimmunol.166.1.249; Yoshimura S, 2001, INT IMMUNOL, V13, P675, DOI 10.1093/intimm/13.5.675; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681; Zhou LJ, 1996, P NATL ACAD SCI USA, V93, P2588, DOI 10.1073/pnas.93.6.2588	44	36	40	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2002	110	2					269	276	UNSP 1/84/126381	10.1067/mai.2002.126381	http://dx.doi.org/10.1067/mai.2002.126381			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	585DY	12170268	Bronze			2022-12-18	WOS:000177509800012
J	Helsper, JPFG; Gilissen, LJWJ; van Ree, R; America, AHP; Cordewener, JHG; Bosch, D				Helsper, JPFG; Gilissen, LJWJ; van Ree, R; America, AHP; Cordewener, JHG; Bosch, D			Quadrupole time-of-flight mass spectrometry: A method to study the actual expression of allergen isoforms identified by PCR cloning	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						amino acid sequencing; apple; Bet v 1; food allergy; isoforms; Mal d 1; mass; spectrometry; quadrupole-time-of-flight; quantification	BIRCH POLLEN ALLERGEN; BET-V-I; CROSS-REACTIVITY; LIQUID-CHROMATOGRAPHY; MAJOR ALLERGEN; APPLE ALLERGEN; FOOD ALLERGY; Q-TOF; BET-V-1; EPITOPES	Background: Over the past 2 decades, molecular biology has shown that most major allergens exist in multiple isoforms. Very little is known about the relevance of allergen isoforms at the level of expressed protein (ie, actual allergen exposure). Objective: The aim of this study was to evaluate the applicability of state-of-the-art quadrupole time-of-flight mass spectrometry (Q-TOF MSMS) to the identification and quantification of allergen isoforms at the protein level. Methods: Q-TOF MSMS is a mass spectrometric approach for sequencing peptides and proteins. In our study it was applied to recombinant (r)Mal d 1, rBet v 1a and rBet v 1d, and natural (n)Mal d 1 from fruits of Malus domestica, cultivar Granny Smith. Results: Q-TOF MSMS allowed sequencing of about 70% of all amino acids in Mal d 1 and about 60% of those in Bet v 1. Mixing experiments with rBet v 1 isoforms and with rMal d 1 and nMal d 1 revealed that the technique allows identification of isoforms in mixtures down to a level of at least 5%. Recombinant Mal d 1 was identified as a Mal d la representative, whereas Granny Smith apples were shown to contain Mal d 1b-like allergen isoforms. In this apple cultivar hitherto unreported modifications of Mal d 1b were identified. Q-TOF MSMS allowed semiquantitative measurement of allergen at the femtomole to picomole level. Conclusion: Q-TOF MSMS is a powerful tool to rind out whether an allergen isoform, detected at the cDNA level, is really expressed in quantities relevant for the allergic patient.	Plant Res Int, NL-6700 AA Wageningen, Netherlands; Cent Lab Netherlands, Red Cross Blood Transfus Serv, Amsterdam, Netherlands		Helsper, JPFG (corresponding author), Plant Res Int, POB 16, NL-6700 AA Wageningen, Netherlands.		gilisen, luud/F-5496-2017	America, Antoine/0000-0002-0167-1194				Aalberse RC, 1998, ALLERGY, V53, P54, DOI 10.1111/j.1398-9995.1998.tb04940.x; Aalberse RC, 1997, CLIN REV ALLERG IMMU, V15, P375, DOI 10.1007/BF02737733; AKKERDAAS JH, 1995, ALLERGY, V50, P215, DOI 10.1111/j.1398-9995.1995.tb01136.x; BJORKSTEN F, 1980, ALLERGY, V35, P671, DOI 10.1111/j.1398-9995.1980.tb02020.x; Borchers C, 1999, J CHROMATOGR A, V854, P119, DOI 10.1016/S0021-9673(99)00479-3; Breiteneder H, 1998, ALLERGY, V53, P31, DOI 10.1111/j.1398-9995.1998.tb04956.x; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; Clauwaert KM, 1999, RAPID COMMUN MASS SP, V13, P1540, DOI 10.1002/(SICI)1097-0231(19990730)13:14<1540::AID-RCM688>3.0.CO;2-1; FAHLBUSCH B, 1995, INT ARCH ALLERGY IMM, V108, P119, DOI 10.1159/000237128; Ferreira F, 1998, FASEB J, V12, P231, DOI 10.1096/fasebj.12.2.231; Friedl-Hajek R, 1999, MOL IMMUNOL, V36, P639, DOI 10.1016/S0161-5890(99)00078-4; Hartl A, 1999, INT ARCH ALLERGY IMM, V120, P17, DOI 10.1159/000024216; Jeanville PM, 2000, J PHARMACEUT BIOMED, V23, P897, DOI 10.1016/S0731-7085(00)00362-9; Jensen ON, 1999, METH MOL B, V112, P513; Kristensen DB, 2000, ELECTROPHORESIS, V21, P430, DOI 10.1002/(SICI)1522-2683(20000101)21:2<430::AID-ELPS430>3.3.CO;2-S; Morris HR, 1997, J PROTEIN CHEM, V16, P469, DOI 10.1023/A:1026309410737; Scheurer S, 1999, MOL IMMUNOL, V36, P155, DOI 10.1016/S0161-5890(99)00033-4; SCHONING B, 1995, J SCI FOOD AGR, V67, P431, DOI 10.1002/jsfa.2740670403; Son DY, 1999, EUR J NUTR, V38, P201, DOI 10.1007/s003940050063; Spangfort MD, 1999, ALLERGY, V54, P23, DOI 10.1111/j.1398-9995.1999.tb05021.x; SWOBODA I, 1995, J BIOL CHEM, V270, P2607, DOI 10.1074/jbc.270.6.2607; VIETHS S, 1994, INT ARCH ALLERGY IMM, V104, P399, DOI 10.1159/000236698; Vieths S, 1997, ENVIRON TOXICOL PHAR, V4, P61, DOI 10.1016/S1382-6689(97)10043-6; Vinh J, 1999, BIOCHEMISTRY-US, V38, P3133, DOI 10.1021/bi982304s	24	36	38	0	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2002	110	1					131	138		10.1067/mai.2002.125599	http://dx.doi.org/10.1067/mai.2002.125599			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	574CF	12110832	Bronze			2022-12-18	WOS:000176870300024
J	Aksoy, MO; Mardini, IA; Yang, Y; Bin, W; Zhou, SW; Kelsen, SG				Aksoy, MO; Mardini, IA; Yang, Y; Bin, W; Zhou, SW; Kelsen, SG			Glucocorticoid effects on the beta-adrenergic receptor-adenylyl cyclase system of human airway epithelium	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						beta-adrenergic receptor gene expression; airways; asthma; dexamethasone	SMOOTH-MUSCLE; MESSENGER-RNA; NITRIC-OXIDE; CELLS; PROTEIN; LUNG; DEXAMETHASONE; EXPRESSION; INCREASE; CULTURE	Background: Activation of the beta(2)-adrenergic receptor (beta(2)AR) system expressed by human airway epithelial cells elicits a variety of cyclic adenosine monophosphate (cAMP)-dependent processes that help determine airway caliber and the intensity of airway inflammation in asthma. Glucocorticoids, mainstays in the treatment of asthma, profoundly affect the expression and function of the beta(2)-adrenergic receptor-adenylyl cyclase (beta(2)AR-AC) system in a variety of cell types. However, the effects of glucocorticoids on the beta(2)AR-AC system expressed by human airway epithelial cells are unstudied. Objective: We examined the effects of dexamethasone (DEX) On beta(2)AR gene expression and the function of the beta(2)AR-AC system in cultured human airway epithelial cells. Methods: Studies were performed in normal airway epithelial cells and BEAS-2B cells. beta(2)AR gene expression was assessed from measurements of P-adrenergic receptor density, beta(2)AR mRNA, and the activity of a full-length beta(2)AR promoter-luciferase reporter construct. The function of the beta(2)AR-AC system was assessed from cAMP production in response to the beta(2)-agonist isoproterenol and the expression of the stimulatory G protein Galphas. Results: DEX had no effect on beta-adrenergic receptor density or on the beta(1)/beta(2) ratio over a wide range of concentrations and exposure times. However, DEX significantly but transiently enhanced beta(2)AR mRNA levels (similar to1.5-fold) and beta(2)AR promoter activity (similar to1.5-fold), indicating increased beta(2)AR gene transcription. DEX also dose-dependently enhanced cAMP responses to isoproterenol but not to forskolin, a direct activator of adenylyl cyclase. DEX-induced changes in cAMP production were associated with small (similar to15%) increases in Galphas expression. Conclusions: These data indicate that glucocorticoids only transiently enhance beta(2)AR gene transcription and fail to increase steady-state levels of beta(2)AR protein in human airway epithelial cells. Nonetheless, glucocorticoid-induced effects on the beta(2)AR-AC system of human airway epithelial cells contribute to the beneficial effects of corticosteroids in asthma by enhancing the functional response to beta(2)-agonists.	Temple Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Kelsen, SG (corresponding author), Temple Univ Hosp & Med Sch, Parkinson Pavil,Room 761,3401 N Broad St, Philadelphia, PA 19140 USA.				NHLBI NIH HHS [HL-40295] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040295] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adcock IM, 1996, EUR RESPIR J, V9, P160, DOI 10.1183/09031936.96.09010160; Aksoy MO, 2001, AM J PHYSIOL-LUNG C, V281, pL1271, DOI 10.1152/ajplung.2001.281.5.L1271; CHENG JB, 1980, ENDOCRINOLOGY, V107, P1646, DOI 10.1210/endo-107-5-1646; COLLINS S, 1988, J BIOL CHEM, V263, P9067; DAVIES AO, 1980, J CLIN ENDOCR METAB, V51, P599, DOI 10.1210/jcem-51-3-599; DAVIS DJ, 1990, PEDIATR RES, V28, P190, DOI 10.1203/00006450-199009000-00003; FRASER CM, 1980, BIOCHEM BIOPH RES CO, V94, P390, DOI 10.1016/S0006-291X(80)80233-6; HADCOCK JR, 1989, J BIOL CHEM, V264, P19928; Kalavantavanich K, 2000, AM J PHYSIOL-LUNG C, V278, pL1101, DOI 10.1152/ajplung.2000.278.5.L1101; KALINER M, 1985, J ALLERGY CLIN IMMUN, V76, P321, DOI 10.1016/0091-6749(85)90648-7; KELSEN SG, 1995, AM J RESP CRIT CARE, V152, P1774, DOI 10.1164/ajrccm.152.6.8520736; Kelsen SG, 1997, AM J PHYSIOL-LUNG C, V272, pL916, DOI 10.1152/ajplung.1997.272.5.L916; KELSEN SG, 1992, AM J RESP CELL MOL, V7, P66, DOI 10.1165/ajrcmb/7.1.66; KOBILKA BK, 1987, P NATL ACAD SCI USA, V84, P46, DOI 10.1073/pnas.84.1.46; KOYAMA S, 1991, AM J PHYSIOL, V261, pL126, DOI 10.1152/ajplung.1991.261.2.L126; LeVan TD, 1997, AM J PHYSIOL-LUNG C, V272, pL838, DOI 10.1152/ajplung.1997.272.5.L838; Li XH, 1997, BRAIN RES, V759, P213, DOI 10.1016/S0006-8993(97)00256-4; MAK JCW, 1995, AM J PHYSIOL-LUNG C, V268, pL41, DOI 10.1152/ajplung.1995.268.1.L41; MANO K, 1979, LIFE SCI, V25, P1925, DOI 10.1016/0024-3205(79)90614-3; Mitchell J, 1997, AM J PHYSIOL-ENDOC M, V273, pE528, DOI 10.1152/ajpendo.1997.273.3.E528; NAKANE T, 1990, J IMMUNOL, V145, P260; NIJAMP FP, 1992, PHYSIOL REV, V72, P323; PENN RB, 1994, AM J RESP CELL MOL, V11, P496, DOI 10.1165/ajrcmb.11.4.7917318; Polito AJ, 1998, J ALLERGY CLIN IMMUN, V102, P714, DOI 10.1016/S0091-6749(98)70008-9; ROS M, 1989, BIOCHEM J, V257, P737, DOI 10.1042/bj2570737; Sanders SP, 1998, J VIROL, V72, P934, DOI 10.1128/JVI.72.2.934-942.1998; Sanders SP, 2001, AM J RESP CELL MOL, V24, P317, DOI 10.1165/ajrcmb.24.3.4131; SANDERSON MJ, 1989, AM REV RESPIR DIS, V139, P432, DOI 10.1164/ajrccm/139.2.432; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SMITH PL, 1982, J MEMBRANE BIOL, V70, P215; TAMAOKI J, 1995, AM J RESP CRIT CARE, V152, P1325, DOI 10.1164/ajrccm.152.4.7551390; VERDI JM, 1990, J BIOL CHEM, V265, P20314	32	36	37	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2002	109	3					491	497		10.1067/mai.2002.122154	http://dx.doi.org/10.1067/mai.2002.122154			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	534KW	11897997				2022-12-18	WOS:000174586400017
J	Brutsche, MH; Joos, L; Brutsche, IEAC; Bissinger, R; Tamm, M; Custovic, A; Woodcock, A				Brutsche, MH; Joos, L; Brutsche, IEAC; Bissinger, R; Tamm, M; Custovic, A; Woodcock, A			Array-based diagnostic gene-expression score for atopy and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; respiratory hypersensitivity; health-status indicators; gene expression	SEVERITY	Whether gene expression is useful in discriminating different atopic phenotypes is unclear. The aim of the study was to evaluate a gene-expression score for the diagnosis of atopy and asthma and to assess disease activity as a guide for therapeutic, decisions. Purified mRNA from PBMCs of 18 atopic asthmatic subjects, 8 atopic nonasthmatic subjects, and 14 healthy control subjects was hybridized to cDNA membranes. A composite atopy gene expression (CAGE) score was determined by using 10 genes dysregulated in atopic individuals according to a specific algorithm. The CAGE score was better than total IgE in differentiating atopic from nonatopic subjects (sensitivity, 96%; specificity, 92%). Correlation between the CAGE score and total IgE (P < .001) was found, and there was a trend for correlation with asthma severity (P = .051). The CAGE score was able to quantify phenotype-specific alteration in gene expression of atopic individuals. The CAGE score might be used as a diagnostic tool or to monitor the effects and side effects of therapy.	Univ Basel Hosp, Dept Pneumol, CH-4031 Basel, Switzerland; Wythenshawe Hosp, N W Lung Res Ctr, Manchester M23 9LT, Lancs, England	University of Basel; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital	Brutsche, MH (corresponding author), Univ Basel Hosp, Dept Pneumol, Petersgraben 4, CH-4031 Basel, Switzerland.		Custovic, Adnan/A-2435-2012	Custovic, Adnan/0000-0001-5218-7071; Brutsche, Martin/0000-0002-1612-3609; Woodcock, Ashley/0000-0002-5428-8578				AAS K, 1981, ALLERGY, V36, P3, DOI 10.1111/j.1398-9995.1981.tb01818.x; Ahlbom A, 1993, BIOSTATISTICS EPIDEM; BAILEY WC, 1992, AM J MED, V93, P263, DOI 10.1016/0002-9343(92)90231-Y; Brutsche MH, 2001, CLIN EXP IMMUNOL, V123, P181, DOI 10.1046/j.1365-2249.2001.01441.x; Cockcroft DW, 1996, J ALLERGY CLIN IMMUN, V98, P1016, DOI 10.1016/S0091-6749(96)80185-0; Colice GL, 1999, AM J RESP CRIT CARE, V160, P1962, DOI 10.1164/ajrccm.160.6.9902112; Custovic A, 1998, THORAX, V53, P63, DOI 10.1136/thx.53.1.63; National Heart Lung Blood Institute, 1997, 2 NAT HEART LUNG BLO	8	36	39	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2002	109	2					271	273		10.1067/mai.2002.121530	http://dx.doi.org/10.1067/mai.2002.121530			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	528EZ	11842296				2022-12-18	WOS:000174232600011
J	Confino-Cohen, R; Aharoni, D; Goldberg, A; Gurevitch, I; Buchs, A; Weiss, M; Weissgarten, J; Rapoport, MJ				Confino-Cohen, R; Aharoni, D; Goldberg, A; Gurevitch, I; Buchs, A; Weiss, M; Weissgarten, J; Rapoport, MJ			Evidence for aberrant regulation of the p21Ras pathway in PBMCs of patients with chronic idiopathic urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						human; signal transduction; T lymphocytes; chronic idiopathic urticaria; autoinummity; p21Ras; human son ofseven-less; p120GTPase-activating protein	T-CELL-RECEPTOR; NONOBESE DIABETIC MICE; AFFINITY IGE RECEPTOR; FC-EPSILON-RI; ALPHA-SUBUNIT; AUTOLOGOUS SERUM; ACTIVATION; AUTOANTIBODIES; P21(RAS); PROTEIN	Background: Recent data suggest that a subpopulation of patients with chronic urticaria has an autoimmune disorder. Aberrant expression and regulation of the p21Ras pathway has been reported in lymphoid cells in a variety of systemic autoimmune diseases but not in chronic idiopathic urticaria (CIU). Objectives: The aim of this study was to examine the expression, regulation, and function of the p21Ras pathway in patients with CIU. Methods: Twenty-four patients with CIU and 14 control subjects were enrolled. All patients and 9 control subjects were intradermally injected with autologous serum. PBMCs were isolated, and the p21Ras and its regulatory proteins were studied. Results: We found increased expression of the p21ras protooncogene in patients with CIU. This was associated with a low expression of the p21Ras stimulatory element human son of sevenless (hSOS1) but normally expressed p21Ras inhibitory element p120GTPase-activating protein. The basal nonstimulated membrane/cytoplasmic ratio of hSOS1, which indicates the p21Ras pathway activity, was higher in patients compared with that seen in control subjects. Moreover, after stimulation, both patients and control subjects decreased their hSOS1 membrane/cytoplasmic ratio. The magnitude of this decrease was much higher in patients than in control subjects: 14- and approximately 2-fold, respectively. The basal and stimulated activities of the p21Ras downstream key regulatory enzyme mitogen-activated protein kinase were comparable in patients and control subjects, as was their in vitro mitogen-stimulated lymphocyte proliferation. Conclusion: Our data demonstrate for the first time an aberrant signaling through the p21Ras pathway in lymphocytes of patients with CIU. This finding further supports the autoimmune basis of this disease.	Sapir Med Ctr, Allergy & Clin Immunol Unit, Kefar Sava, Israel; Tel Aviv Univ, Sackler Sch Med, Assaf Harofeh Med Ctr, Diabet & Endocrinol Unit, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, Assaf Harofeh Med Ctr, Dept Internal Med C, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, Assaf Harofeh Med Ctr, Serv Nephrol, IL-69978 Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine; Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Sackler Faculty of Medicine; Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Sackler Faculty of Medicine; Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Sackler Faculty of Medicine	Rapoport, MJ (corresponding author), Assaf Harofeh Med Ctr, Dept Internal Med C, IL-70300 Zerifin, Israel.							BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOUME HR, 1990, NATURE, V348, P125; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Dong C, 2001, J CLIN IMMUNOL, V21, P253, DOI 10.1023/A:1010975124110; DOWNWARD J, 1992, IMMUNOL TODAY, V13, P89, DOI 10.1016/0167-5699(92)90148-Z; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ELIAS J, 1986, J ALLERGY CLIN IMMUN, V78, P914, DOI 10.1016/0091-6749(86)90240-X; Fagiolo U, 1999, J ALLERGY CLIN IMMUN, V103, P1143, DOI 10.1016/S0091-6749(99)70190-9; Ferrer M, 1998, J ALLERGY CLIN IMMUN, V101, P672, DOI 10.1016/S0091-6749(98)70176-9; Fiebiger E, 1995, J CLIN INVEST, V96, P2606, DOI 10.1172/JCI118325; FINKEL TH, 1989, J IMMUNOL, V142, P3006; GRATTAN CEH, 1986, BRIT J DERMATOL, V114, P583, DOI 10.1111/j.1365-2133.1986.tb04065.x; GRATTAN CEH, 1990, INT ARCH ALLER A IMM, V93, P198, DOI 10.1159/000235301; GRATTAN CEH, 1991, CLIN EXP ALLERGY, V21, P695, DOI 10.1111/j.1365-2222.1991.tb03198.x; Greaves M, 2000, J ALLERGY CLIN IMMUN, V105, P664, DOI 10.1067/mai.2000.105706; HAKIMI J, 1990, J BIOL CHEM, V265, P22079; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; HUANG DCS, 1993, MOL CELL BIOL, V13, P2420, DOI 10.1128/MCB.13.4.2420; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P305; IZQUIERDO PM, 1995, IMMUNOL TODAY, V16, P159; LAZARUS AH, 1993, J EXP MED, V178, P1765, DOI 10.1084/jem.178.5.1765; LEZNOFF A, 1983, ARCH DERMATOL, V119, P636, DOI 10.1001/archderm.119.8.636; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Marrack P, 2001, NAT MED, V7, P899, DOI 10.1038/90935; NATBONY SF, 1983, J ALLERGY CLIN IMMUN, V71, P177, DOI 10.1016/0091-6749(83)90096-9; Niimi N, 1996, J INVEST DERMATOL, V106, P1001, DOI 10.1111/1523-1747.ep12338544; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Rapoport MJ, 1999, AUTOIMMUNITY, V29, P147, DOI 10.3109/08916939908995385; RAPOPORT MJ, 1993, J EXP MED, V177, P1221, DOI 10.1084/jem.177.4.1221; Rapoport MJ, 1996, J IMMUNOL, V157, P4721; Rapoport MJ, 1999, LUPUS, V8, P24, DOI 10.1191/096120399678847362; RISKE F, 1991, J BIOL CHEM, V266, P11245; Rubinfeld H, 1999, J BIOL CHEM, V274, P30349, DOI 10.1074/jbc.274.43.30349; Salojin K, 1997, J EXP MED, V186, P887, DOI 10.1084/jem.186.6.887; Yung Y, 1997, FEBS LETT, V408, P292, DOI 10.1016/S0014-5793(97)00442-0	35	36	37	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2002	109	2					349	356		10.1067/mai.2002.121314	http://dx.doi.org/10.1067/mai.2002.121314			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	528EZ	11842308				2022-12-18	WOS:000174232600023
J	Zheng, T; Zhu, Z; Wang, JM; Homer, RJ; Elias, JA				Zheng, T; Zhu, Z; Wang, JM; Homer, RJ; Elias, JA			IL-11: Insights in asthma from overexpression transgenic modeling	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						interleukin 11; asthma; transgenic modeling; airway remodeling; fibrosis	LEUKEMIA INHIBITORY FACTOR; SIGNAL TRANSDUCER GP130; GROWTH-FACTOR-BETA; MOLECULAR-CLONING; INTERLEUKIN-11 PRODUCTION; HEMATOPOIETIC CYTOKINE; ONCOSTATIN-M; EXPRESSION; CELLS; LUNG	The evolution of our understanding of IL-11 mirrors, in many ways, the problems that are faced by investigators in the post-genome era and the types of techniques that might need to be used to deal with these issues. IL-11 was discovered as a soluble factor in fibroblast supernatants that stimulated the proliferation of "IL-6-dependent" plasmacytoma cells. It was subsequently demonstrated to be an important stimulator of platelet reconstitution and a pleiotropic regulator of nonrespiratory tissues. In the lung, IL-11 is produced by a variety of structural cells and eosinophils in response to a variety of stimuli, including TGF-beta, major basic proteins, and viruses. IL-11 is also detected in exaggerated quantities at sites of virus infection. Its potential effector functions at these sites were defined with constitutive and inducible overexpression transgenic modeling systems which demonstrated that IL-11 causes nodular mononuclear infiltrates, airway remodeling with subepithelial fibrosis, airways obstruction, and airways hyperresponsiveness and can block alveolar development when expressed during development. In accord with these murine findings, IL-11 is selectively expressed in eosinophils and epithelial cells in patients with moderate and severe asthma where expression correlates directly with disease severity and inversely with FEV1. Studies using transgenic mice also demonstrated that IL-11 inhibits antigen-induced tissue inflammation. Thus IL-11 might be an important regulator of inflammatory and remodeling responses in the asthmatic airway.	Yale Univ, Sch Med, Dept Internal Med, Pulm & Crit Care Med Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Med, Allergy & Clin Immunol Sect, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; VA Connecticut Healthcare Syst, Pathol & Lab Med Serv, W Haven, CT USA	Yale University; Yale University; Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System	Elias, JA (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Pulm & Crit Care Med Sect, 333 Cedar St,105 LCI, New Haven, CT 06520 USA.			Homer, Robert/0000-0002-2055-5885	NHLBI NIH HHS [HL-64242, HL-56389] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064242, P01HL056389, P50HL056389] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adunyah SE, 1995, ANN NY ACAD SCI, V766, P296, DOI 10.1111/j.1749-6632.1995.tb26681.x; Akira S, 1997, INT J BIOCHEM CELL B, V29, P1401, DOI 10.1016/S1357-2725(97)00063-0; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; Bozza M, 2001, J INTERF CYTOK RES, V21, P21, DOI 10.1089/107999001459123; CHEREL M, 1995, BLOOD, V86, P2534; Czupryn M, 1995, ANN NY ACAD SCI, V762, P152; Du XX, 1997, BLOOD, V89, P3897, DOI 10.1182/blood.V89.11.3897; Einarsson O, 1996, J CLIN INVEST, V97, P915, DOI 10.1172/JCI118514; Elias JA, 1997, AM J PHYSIOL-LUNG C, V273, pL648, DOI 10.1152/ajplung.1997.273.3.L648; ELIAS JA, 1994, J BIOL CHEM, V269, P22261; ELIAS JA, 1995, ENDOCRINOLOGY, V136, P489, DOI 10.1210/en.136.2.489; ELIAS JA, 1994, J IMMUNOL, V152, P2421; Gabay C, 1996, CLIN EXP IMMUNOL, V105, P260, DOI 10.1046/j.1365-2249.1996.d01-757.x; Grotzinger J, 1999, BIOL CHEM, V380, P803, DOI 10.1515/BC.1999.100; Hemmann U, 1996, J BIOL CHEM, V271, P12999, DOI 10.1074/jbc.271.22.12999; Hill GR, 1998, J CLIN INVEST, V102, P115, DOI 10.1172/JCI3132; Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; KEITH JC, 1994, STEM CELLS, V12, P79; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Mahboubi K, 2000, J IMMUNOL, V164, P3837, DOI 10.4049/jimmunol.164.7.3837; MAIER R, 1993, J BIOL CHEM, V268, P21527; Matsui S, 1999, RESP MED, V93, P637, DOI 10.1016/S0954-6111(99)90103-8; MCKINLEY D, 1992, GENOMICS, V13, P814, DOI 10.1016/0888-7543(92)90158-O; Minshall E, 2000, J ALLERGY CLIN IMMUN, V105, P232, DOI 10.1016/S0091-6749(00)90070-8; Morris JC, 1996, EXP HEMATOL, V24, P1369; Nakashima T, 2000, BIOCHEM BIOPH RES CO, V275, P768, DOI 10.1006/bbrc.2000.3379; Orazi A, 1996, LAB INVEST, V75, P33; PAUL SR, 1992, LEUKEMIA RES, V16, P247, DOI 10.1016/0145-2126(92)90062-C; PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512; Peterson RL, 1996, AM J PATHOL, V149, P895; Ray P, 1997, J CLIN INVEST, V100, P2501, DOI 10.1172/JCI119792; Redlich CA, 1996, J IMMUNOL, V157, P1705; Rochester CL, 1996, J IMMUNOL, V156, P4449; Taga T, 1996, J NEUROCHEM, V67, P1; Tang WL, 1996, J CLIN INVEST, V98, P2845, DOI 10.1172/JCI119113; Tang WL, 1998, J BIOL CHEM, V273, P5506, DOI 10.1074/jbc.273.10.5506; Trepicchio WL, 1996, J IMMUNOL, V157, P3627; Wang JM, 2000, J IMMUNOL, V165, P2222, DOI 10.4049/jimmunol.165.4.2222; WANG XY, 1995, J BIOL CHEM, V270, P27999; Waxman AB, 1998, J CLIN INVEST, V101, P1970, DOI 10.1172/JCI1337; Yang YC, 1995, ANN NY ACAD SCI, V762, P31; YIN TG, 1992, J EXP MED, V175, P211, DOI 10.1084/jem.175.1.211; YIN TG, 1994, J BIOL CHEM, V269, P3731; YIN TG, 1994, EXP HEMATOL, V22, P467; ZHANG XG, 1994, J EXP MED, V179, P1337, DOI 10.1084/jem.179.4.1337; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHENG T, 1994, J IMMUNOL, V153, P4742	49	36	49	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2001	108	4					489	496						8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	485NK	11590369				2022-12-18	WOS:000171760300002
J	Tumas, DB; Chan, B; Werther, W; Wrin, T; Vennari, J; Desjardin, N; Shields, RL; Jardieu, P				Tumas, DB; Chan, B; Werther, W; Wrin, T; Vennari, J; Desjardin, N; Shields, RL; Jardieu, P			Anti-IgE efficacy in murine asthma models is dependent on the method of allergen sensitization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						respiratory syncytial virus; asthma; IgE; animal disease models; dust mite allergen	INDUCED AIRWAY HYPERREACTIVITY; HOUSE-DUST MITE; ANIMAL-MODELS; MAST-CELL; LUNG-FUNCTION; SERUM IGE; T-CELLS; P-I; HYPERRESPONSIVENESS; ADHESION	Background: Murine models used to delineate mechanisms and key mediators of asthma have yielded conflicting results and suggest that the dominant mechanism and mediators required for disease induction differ depending on the model and method of allergen sensitization used. Objective: The goal of this study was to determine whether the mode of allergen sensitization influenced the role that IgE had in allergen-induced pulmonary eosinophilic inflammation. Methods: Mice were exposed to dust mite extract in 2 models of allergic inflammation that differed in the method of sensitization, We compared sensitization by aerosol exposure with and without concomitant human respiratory syncytial virus infection with sensitization by means of systemic (intraperitoneal) exposure with adjuvant, After sensitization, animals were similarly challenged with aerosolized allergen. Animals were treated with anti-IgE mAb to deplete IgE and to determine its role in the induction of allergic inflammation and mucosa pathology in these models. Results: Concomitant respiratory syncytial virus infection significantly enhanced allergen sensitization by aerosol exposure and exacerbated eosinophilic inflammation and airway mucosa pathology. Depletion of IgE in this model significantly reduced lung eosinophilic inflammation and airway mucose pathology, However, in the model in which animals were sensitized by means of systemic allergen exposure with adjuvant, depletion of IgE had no ameliorative effect on lung inflammation or pathology, Conclusion: We demonstrated that the method of antigen sensitization can delineate the role of IgE in allergen-induced lung inflammation. In a murine model that more closely resembles ambient allergen exposure in human subjects, IgE had a critical role in the pathogenesis of allergic asthma and mucosa pathology. The results parallel the results reported with anti-IgE efficacy in allergic asthmatic human subjects.	Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA; Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	Tumas, DB (corresponding author), Genentech Inc, Dept Pathol, Mail Stop 72B,1 DNA Way, San Francisco, CA 94080 USA.							ADELROTH E, 1990, AM REV RESPIR DIS, V142, P91; ARM JP, 1992, ADV IMMUNOL, V51, P323, DOI 10.1016/S0065-2776(08)60491-5; BEASLEY R, 1988, THORAX, V43, P679, DOI 10.1136/thx.43.9.679; Boulet LP, 1997, AM J RESP CRIT CARE, V155, P1835, DOI 10.1164/ajrccm.155.6.9196083; BOUSQUET J, 1994, AM J RESP CRIT CARE, V150, pS33, DOI 10.1164/ajrccm/150.5_Pt_2.S33; BROIDE DH, 1991, J ALLERGY CLIN IMMUN, V88, P637, DOI 10.1016/0091-6749(91)90158-K; BURKE C, 1992, EUR RESPIR J, V5, P73; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Chin JE, 1998, AM J RESP CELL MOL, V18, P158, DOI 10.1165/ajrcmb.18.2.2565m; Chin JE, 1997, AM J PHYSIOL-LUNG C, V272, pL219, DOI 10.1152/ajplung.1997.272.2.L219; Coyle AJ, 1996, J EXP MED, V183, P1303, DOI 10.1084/jem.183.4.1303; DeSanctis GT, 1997, NAT MED, V3, P460, DOI 10.1038/nm0497-460; DJUKANOVIC R, 1994, CLIN EXP ALLERGY, V24, P6, DOI 10.1111/j.1365-2222.1994.tb00909.x; DJUKANOVIC R, 1992, AM REV RESPIR DIS, V145, P669, DOI 10.1164/ajrccm/145.3.669; Doherty P C, 1994, Trends Microbiol, V2, P148, DOI 10.1016/0966-842X(94)90662-9; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828, DOI 10.1164/ajrccm.155.6.9196082; FRIGAS E, 1992, EUR RESPIR J, V13, pS123; GAFFNEY E, 1992, LAB METHODS HISTOTEC; Galli SJ, 1997, J EXP MED, V186, P343, DOI 10.1084/jem.186.3.343; GAVETT SH, 1994, AM J RESP CELL MOL, V10, P587, DOI 10.1165/ajrcmb.10.6.8003337; Gessner JE, 1998, ANN HEMATOL, V76, P231, DOI 10.1007/s002770050396; Gleich GJ, 1997, P NATL ACAD SCI USA, V94, P2101, DOI 10.1073/pnas.94.6.2101; Gonzalo JA, 1998, J EXP MED, V188, P157, DOI 10.1084/jem.188.1.157; Gonzalo JA, 1996, J CLIN INVEST, V98, P2332, DOI 10.1172/JCI119045; GRAHAM BS, 1991, J MED VIROL, V34, P7, DOI 10.1002/jmv.1890340103; GRAHAM BS, 1988, J MED VIROL, V26, P153, DOI 10.1002/jmv.1890260207; GRAHAM BS, 1993, J IMMUNOL, V151, P2032; HAAKFRENDSCHO M, 1994, IMMUNOLOGY, V82, P306; Hatfield CA, 1997, AM J PHYSIOL-LUNG C, V273, pL513, DOI 10.1152/ajplung.1997.273.3.L513; Henderson WR, 1997, J CLIN INVEST, V100, P3083, DOI 10.1172/JCI119863; Herz U, 1996, IMMUNOL CELL BIOL, V74, P209, DOI 10.1038/icb.1996.30; Heusser C, 1997, CURR OPIN IMMUNOL, V9, P805, DOI 10.1016/S0952-7915(97)80182-3; Heusser CH, 1997, INT ARCH ALLERGY IMM, V113, P231, DOI 10.1159/000237555; HEWITT CRA, 1995, J EXP MED, V182, P1537, DOI 10.1084/jem.182.5.1537; HOGG JC, 1984, CLIN CHEST MED, V5, P567; Jardieu P, 1995, CURR OPIN IMMUNOL, V7, P779, DOI 10.1016/0952-7915(95)80047-6; KUNG TT, 1994, INT ARCH ALLERGY IMM, V105, P83, DOI 10.1159/000236807; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; Mehlhop PD, 1997, P NATL ACAD SCI USA, V94, P1344, DOI 10.1073/pnas.94.4.1344; MINOR TE, 1974, JAMA-J AM MED ASSOC, V227, P292, DOI 10.1001/jama.227.3.292; Miyajima I, 1997, J CLIN INVEST, V99, P901, DOI 10.1172/JCI119255; NACLERIO RM, 1993, J ALLERGY CLIN IMMUN, V92, P717, DOI 10.1016/0091-6749(93)90015-8; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; Oshiba A, 1996, J CLIN INVEST, V97, P1398, DOI 10.1172/JCI118560; OWNBY DR, 1998, ALLERGY PRINCIPLES P, P1059; Padrid PA, 1998, AM J RESP CELL MOL, V18, P453, DOI 10.1165/ajrcmb.18.4.3055; Pauwels RA, 1997, AM J RESP CRIT CARE, V156, pS78, DOI 10.1164/ajrccm.156.4.12-tac-1; Persson CGA, 1997, TRENDS PHARMACOL SCI, V18, P465; Persson CGA, 1997, THORAX, V52, P569, DOI 10.1136/thx.52.6.569; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; RA C, 1989, J BIOL CHEM, V264, P15323; ROCHE WR, 1989, LANCET, V1, P520; Rothenberg ME, 1997, J EXP MED, V185, P785, DOI 10.1084/jem.185.4.785; SCHULZ O, 1995, EUR J IMMUNOL, V25, P3191, DOI 10.1002/eji.1830251131; Schulz O, 1998, J EXP MED, V187, P271, DOI 10.1084/jem.187.2.271; Schwarze J, 1997, J CLIN INVEST, V100, P226, DOI 10.1172/JCI119516; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; Shakib F, 1998, IMMUNOL TODAY, V19, P313, DOI 10.1016/S0167-5699(98)01284-5; SIGURS N, 1995, PEDIATRICS, V95, P500; Stark J, 1996, J IMMUNOL, V156, P4774; Stelts D, 1998, AM J RESP CELL MOL, V18, P463, DOI 10.1165/ajrcmb.18.4.2957; Strannegard O, 1997, PEDIAT ALLERG IMM-UK, V8, P1, DOI 10.1111/j.1399-3038.1997.tb00134.x; VanOosterhout AJM, 1997, AM J RESP CELL MOL, V17, P386, DOI 10.1165/ajrcmb.17.3.2679; Wolyniec WW, 1998, AM J RESP CELL MOL, V18, P777, DOI 10.1165/ajrcmb.18.6.3056; Zuany-Amorim C, 1998, SCIENCE, V280, P1265, DOI 10.1126/science.280.5367.1265	65	36	54	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2001	107	6					1025	1033		10.1067/mai.2001.115625	http://dx.doi.org/10.1067/mai.2001.115625			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	445JR	11398080				2022-12-18	WOS:000169454800014
J	Viquez, OM; Summer, CG; Dodo, HW				Viquez, OM; Summer, CG; Dodo, HW			Isolation and molecular characterization of the first genomic clone of a major peanut allergen, Ara h 2	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy peanut; allergens; genomic library; promoter; Ara h 2; genomic clone; major allergen	ATOPIC-DERMATITIS; IDENTIFICATION; ANAPHYLAXIS; SEQUENCES; PROTEIN	Background: Peanuts have been identified as potent food allergens responsible for life-threatening IgE reactions among hypersensitive individuals. With the current increase of peanut allergies, there is an urgent need to molecularly characterize the genes encoding the target proteins and to understand the nature of their regulation, Objectives: The objectives of this study were to isolate, sequence, and characterize at least one full-length genomic clone encoding the major peanut allergen Ara h 2. Methods: A peanut genomic library constructed in a Lambda Fix II vector, was screened with an 80-bp oligonucleotide probe constructed on the basis of the 5' end of a published Ara h 2 cDNA partial sequence. One putative positive lambda clone was isolated, digested with BamHI to release its 16-kb insert, and confirmed by means of dot blot and Southern hybridization. The positive clone was subcloned in pBluescript SK+ vector, sequenced, and characterized, Results: Sequence analysis revealed a full-length genomic clone with an open reading frame starting with an initiation codon (ATG) at position 1 and ending with a termination codon (TGA) at position 622, One putative polyadenylation signal (AATAAA) is identified at positions 951 in the 3' untranslated region, and 6 additional stop codons are located at positions 628, 769, 901, 946, 967, and 982 downstream from the start codon. In the 5' promoter region, a putative TATA box (TATTATTA) is located at position -72 upstream from the start codon, The deduced amino acid sequence has 207 residues and includes a putative signal peptide of 21 residues. Conclusions: The results reveal for the first time information on the structure of a major peanut allergen, Ara h 2, Comparison of the cDNA and genomic sequences revealed the absence of an intron but the presence of 2 isoforms of Ara h 2 or different members of the same gene family.	Alabama A&M Univ, Dept Food & Anim Sci, Normal, AL 35762 USA; Res Genet Inc, Huntsville, AL 35801 USA	Alabama A&M University	Viquez, OM (corresponding author), Alabama A&M Univ, Dept Food & Anim Sci, POB 1628, Normal, AL 35762 USA.							Alberts B, 1994, MOL BIOL CELL; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; BANNON GA, 1992, J ALLERGY CLIN IMMUN, V90, P962; BIRSE C, 1996, FUNCTIONAL POLYADENY; BURKS AW, 1994, J ALLERGY CLIN IMMUN, V93, P743, DOI 10.1016/0091-6749(94)90254-2; BURKS AW, 1992, J ALLERGY CLIN IMMUN, V90, P962, DOI 10.1016/0091-6749(92)90469-I; BURKS AW, 1991, J ALLERGY CLIN IMMUN, V88, P172, DOI 10.1016/0091-6749(91)90325-I; Burks W, 1998, ALLERGY, V53, P725, DOI 10.1111/j.1398-9995.1998.tb03967.x; DODO HW, 2000, INT FOOD NUTR C TUSK, P15; ELLISON K, 1983, BIOTECHNOLOGY, V12, P115; Greger IH, 1998, EMBO J, V17, P4771, DOI 10.1093/emboj/17.16.4771; GRIERSON D, 1988, PLANT MOL BIOL; *HOEF SCI INSTR, 1991, TKO 100DNA MIN FLUOR; Kleber-Janke T, 1999, INT ARCH ALLERGY IMM, V119, P265, DOI 10.1159/000024203; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; NORDLEE JA, 1981, J ALLERGY CLIN IMMUN, V68, P376, DOI 10.1016/0091-6749(81)90136-6; ONEIL CE, 1995, FOOD TECHNOL-CHICAGO, V49, P103; OPPENHEIMER JJ, 1992, J ALLERGY CLIN IMMUN, V90, P256, DOI 10.1016/0091-6749(92)90080-L; Rabjohn P, 1999, J CLIN INVEST, V103, P535, DOI 10.1172/JCI5349; SACHS MI, 1981, J ALLERGY CLIN IMMUN, V67, P27, DOI 10.1016/0091-6749(81)90041-5; SAMPSON HA, 1990, J ALLERGY CLIN IMMUN, V86, P1, DOI 10.1016/S0091-6749(05)80115-0; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V104, P186, DOI 10.1016/S0091-6749(99)70133-8; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; Stanley JS, 1997, ARCH BIOCHEM BIOPHYS, V342, P244, DOI 10.1006/abbi.1997.9998; Steinman HA, 1996, J ALLERGY CLIN IMMUN, V98, P241, DOI 10.1016/S0091-6749(96)70146-X; *STRAT INC, 1999, INSTR MAN PBLUESCR M; Tatusova TA, 1999, FEMS MICROBIOL LETT, V174, P247, DOI 10.1111/j.1574-6968.1999.tb13575.x; TAYLOR SL, 1992, FOOD TECHNOL, V46, P46; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450	32	36	41	0	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2001	107	4					713	717						5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	423RG	11295663	Bronze			2022-12-18	WOS:000168190100026
J	Yamashita, N; Sekine, K; Miyasaka, T; Kawashima, R; Nakajima, Y; Nakano, J; Yamamoto, T; Horiuchi, T; Hirai, K; Ohta, K				Yamashita, N; Sekine, K; Miyasaka, T; Kawashima, R; Nakajima, Y; Nakano, J; Yamamoto, T; Horiuchi, T; Hirai, K; Ohta, K			Platelet-derived growth factor is involved in the augmentation of airway responsiveness through remodeling of airways in diesel exhaust particulate-treated mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; airway hyperresponsiveness; platelet-derived growth factor; airway remodeling; diesel exhaust particulate; acetylcholine	SMOOTH-MUSCLE; SUBEPITHELIAL FIBROSIS; ASTHMATIC-PATIENTS; T-LYMPHOCYTES; MILD ASTHMA; INFLAMMATION; EOSINOPHILS; PARTICLES; CYTOKINES; SEVERITY	Background: Thickening of the region adjacent to the basement membrane is a key component of the remodeling of the asthmatic airway and is caused by collagen deposition in the region. Objective: We sought to clarify the role of platelet-derived growth factor (PDGF), a competence factor of fibroblast, in the enhanced airway responsiveness and remodeling in a murine model. Methods: Diesel exhaust particulates (DEPs) were administered intranasally every other day for 2 weeks with or without anti-PDGF-beta neutralizing antibody or goat IgG. Pulmonary function was then analyzed by using whole-body plethysmography before and after acetylcholine inhalation. Results: Anti-PDGF-beta neutralizing antibody significantly inhibited both the elevation of airway resistance elicited by 1.25 and 2.5 mg/mL acetylcholine and the increase in the airway wall thickening induced by DEPs. In addition, bronchoalveolar lavage fluid cell analysis revealed that anti-PDCF-beta neutralizing antibody did not affect cellular infiltration at the airways. Conclusion: PDGF plays an important role in the process of remodeling brought about by DEP exposure in mice.	Teikyo Univ, Sch Med, Dept Med, Itabashi Ku, Tokyo 173, Japan; Kanto Chyuo Hosp, Tokyo, Japan; Univ Tokyo, Grad Sch Med, Dept Bioregulatory Funct, Tokyo, Japan	Teikyo University; University of Tokyo	Ohta, K (corresponding author), Teikyo Univ, Sch Med, Dept Med, Itabashi Ku, 2-11-1 Kaga, Tokyo 173, Japan.		Yamashita, Naomi/F-5045-2011					Altraja A, 1996, AM J RESP CELL MOL, V15, P482, DOI 10.1165/ajrcmb.15.4.8879182; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; Bonner JC, 1998, AM J PHYSIOL-LUNG C, V274, pL72, DOI 10.1152/ajplung.1998.274.1.L72; Boulet LP, 1997, CHEST, V112, P45, DOI 10.1378/chest.112.1.45; BOUSQUET J, 1995, INT ARCH ALLERGY IMM, V107, P211, DOI 10.1159/000236980; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; BREWSTER CEP, 1990, AM J RESP CELL MOL B, V3, P697; Busse W, 1999, AM J RESP CRIT CARE, V160, P1035, DOI 10.1164/ajrccm.160.3.9902064; CHANEZ P, 1995, ALLERGY, V50, P878, DOI 10.1111/j.1398-9995.1995.tb02493.x; Chetta A, 1996, AM J RESP CRIT CARE, V153, P910, DOI 10.1164/ajrccm.153.3.8630572; Chetta A, 1997, CHEST, V111, P852, DOI 10.1378/chest.111.4.852; Crimi E, 1998, AM J RESP CRIT CARE, V157, P4, DOI 10.1164/ajrccm.157.1.9703002; DeSanctis GT, 1997, AM J RESP CRIT CARE, V156, pS82, DOI 10.1164/ajrccm.156.4.12-tac-2; Diaz-Sanchez D, 1999, J ALLERGY CLIN IMMUN, V104, P1183, DOI 10.1016/S0091-6749(99)70011-4; EBINA M, 1990, AM REV RESPIR DIS, V141, P1322, DOI 10.1164/ajrccm/141.5_Pt_1.1322; EBINA M, 1990, AM REV RESPIR DIS, V141, P1327, DOI 10.1164/ajrccm/141.5_Pt_1.1327; Elias JA, 1999, J CLIN INVEST, V104, P1001, DOI 10.1172/JCI8124; FUJIMAKI H, 1995, INT ARCH ALLERGY IMM, V108, P268, DOI 10.1159/000237163; Haley KJ, 1998, AM J RESP CRIT CARE, V157, P1; HOLGATE ST, 1992, AM REV RESPIR DIS, V145, pS2, DOI 10.1164/ajrccm/145.2_Pt_2.S2; HOUSTON JC, 1953, THORAX, V8, P207, DOI 10.1136/thx.8.3.207; Hoyle GW, 1999, AM J PATHOL, V154, P1763, DOI 10.1016/S0002-9440(10)65432-6; Huang J, 1999, AM J RESP CRIT CARE, V160, P725, DOI 10.1164/ajrccm.160.2.9809040; JAMES AL, 1988, AM REV RESPIR DIS, V138, P136, DOI 10.1164/ajrccm/138.1.136; JEFFERY PK, 1995, AM J RESP CRIT CARE, V151, P489; KELLEY J, 1990, AM REV RESPIR DIS, V141, P765, DOI 10.1164/ajrccm/141.3.765; Laitinen LA, 1996, J ALLERGY CLIN IMMUN, V98, pS3, DOI 10.1016/S0091-6749(96)80122-9; LAMBERT RK, 1993, J APPL PHYSIOL, V74, P2771, DOI 10.1152/jappl.1993.74.6.2771; LEVITT RC, 1990, AM J PHYSIOL, V258, pL157, DOI 10.1152/ajplung.1990.258.4.L157; Nel AE, 1998, J ALLERGY CLIN IMMUN, V102, P539, DOI 10.1016/S0091-6749(98)70269-6; Nightingale JA, 2000, AM J RESP CRIT CARE, V162, P161, DOI 10.1164/ajrccm.162.1.9908092; OHNO I, 1995, AM J RESP CELL MOL, V13, P639, DOI 10.1165/ajrcmb.13.6.7576701; Ohta K, 1999, J ALLERGY CLIN IMMUN, V104, P1024, DOI 10.1016/S0091-6749(99)70084-9; Ohta K, 1997, CHEST, V111, pS105, DOI 10.1378/chest.111.6_Supplement.105S; Olivieri D, 1997, AM J RESP CRIT CARE, V155, P1864, DOI 10.1164/ajrccm.155.6.9196087; PIERCE GF, 1989, J CELL BIOL, V109, P429, DOI 10.1083/jcb.109.1.429; RAINES EW, 1985, METHOD ENZYMOL, V109, P749; RAINES EW, 1982, J BIOL CHEM, V257, P5154; ROCHE WR, 1989, LANCET, V1, P520; ROSS R, 1974, P NATL ACAD SCI USA, V71, P1207, DOI 10.1073/pnas.71.4.1207; Suzuki NL, 1996, THORAX, V51, P1036, DOI 10.1136/thx.51.10.1036; Synek M, 1996, AM J RESP CRIT CARE, V154, P224, DOI 10.1164/ajrccm.154.1.8680684; TIDDENS HAWM, 1995, AM J RESP CRIT CARE, V152, P260, DOI 10.1164/ajrccm.152.1.7599833; Ushio H, 1999, TOXICOL LETT, V105, P17, DOI 10.1016/S0378-4274(98)00379-8; Vignola AM, 1998, J ALLERGY CLIN IMMUN, V101, P149, DOI 10.1016/S0091-6749(98)70378-1; WIGGS BR, 1992, AM REV RESPIR DIS, V145, P1251, DOI 10.1164/ajrccm/145.6.1251; Woessner JF, 1976, METHODOLOGY CONNECTI, P227	47	36	36	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2001	107	1					135	142		10.1067/mai.2001.111433	http://dx.doi.org/10.1067/mai.2001.111433			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	394PW	11150003				2022-12-18	WOS:000166533300023
J	Poonai, N; Antony, MM; Binkley, KE; Stenn, P; Swinson, RP; Corey, P; Silverman, FS; Tarlo, SM				Poonai, N; Antony, MM; Binkley, KE; Stenn, P; Swinson, RP; Corey, P; Silverman, FS; Tarlo, SM			Carbon dioxide inhalation challenges in idiopathic environmental intolerance	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Meeting of the International-Society-for-the-Advancement-of-Respiratory-Psychophysiology	1998	PERPIGNAN, FRANCE	Int Soc Advancement Respiratory Psychophysiol		multiple chemical sensitivity; panic disorder; carbon dioxide; idiopathic environmental intolerance	MULTIPLE CHEMICAL-SENSITIVITY; SODIUM LACTATE INFUSION; ANXIETY SENSITIVITY; PANIC DISORDER; HYPOCHONDRIACAL CONCERNS; ENRICHED AIR; HYPERVENTILATION; ATTACKS; ILLNESS; SENSITIZATION	Background: Idiopathic environmental intolerance (IEI) is associated with unexplained physical symptoms, which overlap considerably with those of panic disorder (PD), Objective: This study tested the hypothesis that patients with symptoms to suggest IEI exhibit features of PD in response to nonnoxious environmental stimuli. Methods: A single-blind, case-control 35% carbon dioxide inhalation challenge was conducted at a university-based occupational health unit with the use of standardized psychologic questionnaires involving 36 patients with IEI and 37 healthy control subjects. The main outcome measures included panic attack symptoms and scores on the Anxiety Sensitivity Index, a measure of panic-related anxiety. Results: Patients with IEI scored significantly higher on the Anxiety Sensitivity Index than control subjects did (P < .05). Significantly more patients with IEI (71%) than control subjects (26%) fulfilled panic attack criteria after carbon dioxide (P < .001). Physiologic responses to the challenge were not significantly different between groups. Conclusions: Results suggest that, similar to patients with PD, patients with DEI display high anxiety sensitivity and in response to carbon dioxide inhalation tend to experience heightened anxiety and panic attacks.	Univ Toronto, Gage Occupat & Environm Hlth Unit, Toronto, ON M5T 1R4, Canada; St Joseph Hosp, Anxiety Treatment & Res Ctr, Toronto, ON, Canada; McMaster Univ, Dept Psychiat & Behav Neurobiol, Toronto, ON, Canada; St Michaels Hosp, Dept Psychiat, Toronto, ON, Canada; Univ Toronto, Dept Psychiat, Toronto, ON M5T 1R4, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Saint Joseph's Health Centre, Toronto; McMaster University; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto	Tarlo, SM (corresponding author), Univ Toronto, Gage Occupat & Environm Hlth Unit, 223 Coll St, Toronto, ON M5T 1R4, Canada.		Telch, Michael J/E-7027-2010; Antony, Martin/K-1991-2012	Antony, Martin/0000-0002-3508-377X; Tarlo, Susan/0000-0002-4746-5310				AAAAI Board Directors, 1999, J ALLERGY CLIN IMMUN, V103, P36; American Psychiatric Association, 1994, DIAGNOSTIC STAT MANU, V4th ed.; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; ASMUNDSON GJG, 1994, BEHAV RES THER, V32, P237, DOI 10.1016/0005-7967(94)90117-1; Bell IR, 1997, ENVIRON HEALTH PERSP, V105, P457, DOI 10.2307/3433353; Binkley KE, 1997, J ALLERGY CLIN IMMUN, V99, P570, DOI 10.1016/S0091-6749(97)70086-1; BRODER I, 1994, H40782C64601SS ONT M; CLARK DM, 1986, BEHAV RES THER, V24, P461, DOI 10.1016/0005-7967(86)90011-2; CULLEN MR, 1987, WORKERS MULTIPLE CHE, P655; DONNELL CD, 1989, BEHAV RES THER, V27, P325, DOI 10.1016/0005-7967(89)90002-8; Fiedler N, 1997, ENVIRON HEALTH PERSP, V105, P409; Fiedler N, 1996, PSYCHOSOM MED, V58, P38, DOI 10.1097/00006842-199601000-00007; First M.B., 1996, STRUCTURED CLIN INTE; GAFFNEY FA, 1988, ARCH GEN PSYCHIAT, V45, P53; GORMAN JM, 1990, BIOL PSYCHIAT, V28, P743, DOI 10.1016/0006-3223(90)90510-9; GRIEZ E, 1990, AM J PSYCHIAT, V147, P796; GRIEZ EJL, 1987, PSYCHIAT RES, V20, P87, DOI 10.1016/0165-1781(87)90001-1; HOLLOWAY W, 1987, J ABNORM PSYCHOL, V96, P330, DOI 10.1037/0021-843X.96.4.330; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Kipen H, 1997, ENVIRON HEALTH PERSP, V105, P405, DOI 10.1289/ehp.97105s2405; LEVIN AS, 1987, OCCUP MED, V2, P669; Leznoff A, 1997, J ALLERGY CLIN IMMUN, V99, P438, DOI 10.1016/S0091-6749(97)70067-8; LIEBOWITZ MR, 1984, ARCH GEN PSYCHIAT, V41, P764; MARGRAF J, 1986, PSYCHOSOM MED, V48, P23, DOI 10.1097/00006842-198601000-00002; Meggs WJ, 1997, ENVIRON HEALTH PERSP, V105, P473, DOI 10.2307/3433355; Miller CS, 1997, ENVIRON HEALTH PERSP, V105, P445, DOI 10.2307/3433351; OTTO MW, 1992, J ANXIETY DISORD, V6, P93, DOI 10.1016/0887-6185(92)90008-U; Otto MW, 1998, J ANXIETY DISORD, V12, P225, DOI 10.1016/S0887-6185(98)00011-5; PERNA G, 1995, AM J PSYCHIAT, V152, P85; PERNA G, 1994, PSYCHIAT RES, V52, P159, DOI 10.1016/0165-1781(94)90085-X; Peterson R. A., 1993, ANXIETY SENSITIVITY; RAPEE RM, 1992, J ABNORM PSYCHOL, V101, P538, DOI 10.1037/0021-843X.101.3.538; REISS S, 1986, BEHAV RES THER, V24, P1, DOI 10.1016/0005-7967(86)90143-9; SANDERSON WC, 1988, BEHAV RES THER, V26, P333, DOI 10.1016/0005-7967(88)90086-1; SHEAR MK, 1994, ARCH GEN PSYCHIAT, V51, P346; SHUSTERMAN D, 1988, J OCCUP ENVIRON MED, V30, P565; SIMON GE, 1990, AM J PSYCHIAT, V147, P901; SIMON GE, 1993, ANN INTERN MED, V119, P97, DOI 10.7326/0003-4819-119-2-199307150-00001; Smoller JW, 1996, AM J RESP CRIT CARE, V154, P6, DOI 10.1164/ajrccm.154.1.8680700; Sturges LV, 1998, J ANXIETY DISORD, V12, P103, DOI 10.1016/S0887-6185(98)00004-8; TAYLOR S, 1991, J ANXIETY DISORD, V5, P293, DOI 10.1016/0887-6185(91)90030-W; TERR AI, 1986, ARCH INTERN MED, V146, P145, DOI 10.1001/archinte.146.1.145; VANDENHOUT MA, 1987, AM J PSYCHIAT, V144, P788; WOLPE J, 1982, PRACTICE BEHAV THERA, P141	44	36	36	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2000	105	2	1				358	363		10.1016/S0091-6749(00)90088-5	http://dx.doi.org/10.1016/S0091-6749(00)90088-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	285RQ	10669859				2022-12-18	WOS:000085402200023
J	Tkaczyk, C; Villa, I; Peronet, R; David, B; Chouaib, S; Mecheri, S				Tkaczyk, C; Villa, I; Peronet, R; David, B; Chouaib, S; Mecheri, S			In vitro and in vivo immunostimulatory potential of bone marrow-derived mast cells on B- and T-lymphocyte activation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mast cells; adhesion molecules; lymphocyte activation; T-H1 cytokines	FC-EPSILON-RI; CYTOKINE PRODUCTION; MESSENGER-RNA; TNF-ALPHA; ANTIGEN; MOUSE; EXPRESSION; LFA-1; DEGRANULATION; INTERLEUKIN-4	Background: Mast cells, which play a unique role in inflammatory and allergic responses, have also been shown to actively participate to the build-up of protective host defense mechanisms. Recently, they have been shown to stimulate resting B cells and to form heterotypic aggregates with activated T cells, resulting in mast cell degranulation. Objectives: Our aim is to investigate the cytokine requirements and the mechanisms by which murine mast cells activate resting B and T lymphocytes, Methods: Mouse bone marrow-derived mast cells (BMMCs) or peritoneal mast cells were cocultured with resting splenocytes, Activation of B and T lymphocytes was assessed by measuring cell proliferation, blast formation, and cytokine release. Results: We report that addition of IL-4-treated BMMCs to normal spleen cells resulted within 48 hours in a B- and T-cell activation with substantial amounts of the T-H1 cytokines IFN-gamma and IL-12 and no detectable IL-4, We also demonstrate that mature mast cells in the peritoneal cavity are able to induce spleen cell activation and cytokine release. Addition of antileukocyte function-associated antigen 1 and anti-intercellular adhesion molecule 1 to the cocultures completely abrogates mast cell-induced blast formation and cytokine release. Experiments performed in vivo indicate that spleen cells from mice injected with BMMCs sustain their capacity of proliferation and cytokine production in vitro without any further stimulation. Conclusion: These observations suggest that mast cells may exert a helper effect on B and T lymphocytes, initiate T-H1-type immune responses, and may participate, through this mechanism, in the downregulation of allergic responses.	Inst Pasteur, Unite Immunoallergie, F-75724 Paris 15, France; Inst Gustave Roussy, INSERM, F-94805 Villejuif, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy	Mecheri, S (corresponding author), Inst Pasteur, Unite Immunoallergie, 28 Rue Dr Roux, F-75724 Paris 15, France.		Chouaib, Salem/F-7939-2016; Mecheri, Salah/M-8315-2013					Bhattacharyya SP, 1998, J LEUKOCYTE BIOL, V63, P337, DOI 10.1002/jlb.63.3.337; BROWN MA, 1987, CELL, V50, P809, DOI 10.1016/0092-8674(87)90339-4; BUCKLEY MG, 1995, IMMUNOLOGY, V84, P410; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; FOX CC, 1994, CELL IMMUNOL, V158, P253, DOI 10.1006/cimm.1994.1272; FRANDJI P, 1993, J IMMUNOL, V151, P6318; FRANDJI P, 1995, CELL IMMUNOL, V163, P37, DOI 10.1006/cimm.1995.1096; Frandji P, 1998, EUR J IMMUNOL, V28, P844, DOI 10.1002/(SICI)1521-4141(199803)28:03<844::AID-IMMU844>3.3.CO;2-W; GEISSLER D, 1990, EUR J IMMUNOL, V20, P2591, DOI 10.1002/eji.1830201210; GORDON JR, 1990, NATURE, V346, P274, DOI 10.1038/346274a0; HAMAWY MM, 1994, IMMUNOL TODAY, V15, P62, DOI 10.1016/0167-5699(94)90135-X; Inamura N, 1998, J IMMUNOL, V160, P4026; Lukacs NW, 1996, BLOOD, V87, P2262, DOI 10.1182/blood.V87.6.2262.bloodjournal8762262; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; Marietta EV, 1996, EUR J IMMUNOL, V26, P49, DOI 10.1002/eji.1830260108; Mecheri S, 1997, IMMUNOL TODAY, V18, P212; MEKORI YA, 1990, ISRAEL J MED SCI, V26, P337; Nechushtan H, 1996, CRIT REV ONCOL HEMAT, V23, P131, DOI 10.1016/1040-8428(96)00200-4; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; PONT S, 1986, J IMMUNOL, V136, P3750; RODER JC, 1979, J IMMUNOL, V123, P2174; Ryan JJ, 1998, J IMMUNOL, V161, P6915; Salomon B, 1998, J IMMUNOL, V161, P5138; Smith TJ, 1996, IMMUNOL TODAY, V17, P60, DOI 10.1016/0167-5699(96)80580-9; THOMPSON HL, 1992, J ALLERGY CLIN IMMUN, V89, P239; Tkaczyk C, 1996, J IMMUNOL, V157, P1720; Tkaczyk C, 1999, IMMUNOLOGY, V97, P333; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.iy.13.040195.001343	29	36	36	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2000	105	1	1				134	142		10.1016/S0091-6749(00)90188-X	http://dx.doi.org/10.1016/S0091-6749(00)90188-X			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	278LW	10629463				2022-12-18	WOS:000084992100018
J	Kim, YK; Lee, MH; Jee, YK; Hong, SC; Bae, JM; Chang, YS; Jung, JW; Lee, BJ; Son, JW; Cho, SH; Min, KU; Kim, YY				Kim, YK; Lee, MH; Jee, YK; Hong, SC; Bae, JM; Chang, YS; Jung, JW; Lee, BJ; Son, JW; Cho, SH; Min, KU; Kim, YY			Spider mite allergy in apple-cultivating farmers: European red mite (Panonychus ulmi) and two-spotted spider mite (Tetranychus urticae) may be important allergens in the development of work-related asthma and rhinitis symptoms	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						spider mites; European red mite; 2-spotted spider mite; allergy; apple farmer; asthma; occupational asthma	HOUSE DUST MITE; STORAGE MITES; DERMATOPHAGOIDES-PTERONYSSINUS; OCCUPATIONAL ALLERGY; IGE; PREVALENCE; POPULATION; FARINAE; KOCH	Background: Recent investigations have suggested that the citrus red mite (Panonychus citri) is the most important allergen affecting citrus-cultivating farmers with asthma, allergic rhinitis, or both. Objective: We sought to evaluate type I hypersensitivity to spider mites, particularly the European red mite (Panonychus ulmi) and the two-spotted spider mite (Tetranychus urticae), and to determine the relationship between hypersensitivity to spider mites and respiratory dysfunction. Methods: We performed a cross-sectional survey. Questionnaires were given, and skin prick tests for 11 inhalant allergens common in Korea and 2 species of spider mites (European red mite and two spotted spider mite) were performed in 725 apple-cultivating farmers in Korea. Results: Results of skin prick tests in the apple farmers indicated that European red mite (23.2%) was the most common sensitizing allergen, followed by Tyrophagus putrescentiae (21.2%), two-spotted spider mite (16.6%), Dermatophagoides farinae (16.3%), D pteronyssinus (14.4%), cockroach (13.1%), and Hop Japanese (Humulus Japonicus) pollen (12.0%). Positive skin responses (mean wheal size greater than or equal to 3 mm) to one or more of 13 inhalant allergens were found in 48.2% of farmers tested, whereas 40 subjects (8.6%) had an isolated skin response to the spider mites. Among 119 farmers,vith work-related asthmatic symptoms, the positive skin response rates to European red mite and two-spotted spider mite were 40.4% and 27.0%, respectively. These figures a ere significantly higher than those found among farmers without work-related symptoms (19.1% and 14.1%, respectively; P < .01). The prevalence of work-related asthma symptoms was higher in farmers with positive skin responses to spider mites than in those with negative skin responses to spider mites and those with positive skin responses to any allergen tested (31.4% vs 15.0% vs 21.0%, respectively; P < .05). Conclusion: Spider mites, particularly European red mite and 2-spotted spider mite, are common sensitizing allergens in apple-cultivating farmers. These spider mites may be important causative allergens in the development of work-related respiratory symptoms in these workers.	Seoul Natl Univ, Coll Med, Dept Internal Med, Chongno Gu, Seoul 110744, South Korea; Seoul Natl Univ, Med Res Ctr, Inst Allergy & Clin Immunol, Seoul 110744, South Korea; Cheju Univ, Coll Med, Dept Pediat, Cheju, South Korea; Cheju Univ, Coll Med, Dept Prevent Med, Cheju, South Korea; Danguk Univ, Coll Med, Dept Internal Med, Chunan, South Korea	Seoul National University (SNU); Seoul National University (SNU); Jeju National University; Jeju National University; Dankook University	Kim, YY (corresponding author), Seoul Natl Univ, Coll Med, Dept Internal Med, Chongno Gu, 28 Yongon Dong, Seoul 110744, South Korea.		Cho, Sang Heon/J-2793-2012; Chang, Yoon-Seok/J-5628-2012; Min, Kyung-Up/J-5468-2012	Chang, Yoon-Seok/0000-0003-3157-0447; Jee, Young-Koo/0000-0001-5800-8038				ARLIAN LG, 1984, J ALLERGY CLIN IMMUN, V74, P172, DOI 10.1016/0091-6749(84)90282-3; BLAINEY AD, 1989, J ALLERGY CLIN IMMUN, V84, P296, DOI 10.1016/0091-6749(89)90411-9; Burches E, 1996, CLIN EXP ALLERGY, V26, P1262, DOI 10.1111/j.1365-2222.1996.tb00523.x; COCKCROFT A, 1981, LANCET, V1, P827; GRIFFIN P, 1989, J ALLERGY CLIN IMMUN, V84, P108, DOI 10.1016/0091-6749(89)90184-X; IVERSEN M, 1990, ALLERGY, V45, P81, DOI 10.1111/j.1398-9995.1990.tb00462.x; Kim YK, 1999, CLIN EXP ALLERGY, V29, P1102, DOI 10.1046/j.1365-2222.1999.00607.x; Kim YK, 1999, ANN ALLERG ASTHMA IM, V82, P223, DOI 10.1016/S1081-1206(10)62601-4; KROIDL R, 1992, CLIN EXP ALLERGY, V22, P958, DOI 10.1111/j.1365-2222.1992.tb02070.x; LEE SW, 1994, J AGR SCI, V36, P383; LEE SW, 1984, J AGR SCI, V27, P86; LUCZYNSKA CM, 1990, CLIN EXP ALLERGY, V20, P403, DOI 10.1111/j.1365-2222.1990.tb02801.x; MALO JL, 1992, J ALLERGY CLIN IMMUN, V90, P937, DOI 10.1016/0091-6749(92)90466-F; PEARCE N, 1993, EUR RESPIR J, V6, P1455; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; PLATTSMILLS TAE, 1986, J ALLERGY CLIN IMMUN, V78, P398, DOI 10.1016/0091-6749(86)90024-2; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P505, DOI 10.1016/0091-6749(87)90369-1; Ree Han-Il, 1997, Korean Journal of Parasitology, V35, P9, DOI 10.3347/kjp.1997.35.1.9; REUNALA T, 1983, CLIN ALLERGY, V13, P383, DOI 10.1111/j.1365-2222.1983.tb02612.x; SLOVAK AJM, 1981, BRIT J IND MED, V38, P38; SPIEKSMA FTM, 1991, CLIN EXP ALLERGY, V21, P655, DOI 10.1111/j.1365-2222.1991.tb03192.x; VANHAGEHAMSTEN M, 1991, ALLERGY, V46, P142, DOI 10.1111/j.1398-9995.1991.tb00558.x	22	36	37	1	8	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1999	104	6					1285	1292		10.1016/S0091-6749(99)70026-6	http://dx.doi.org/10.1016/S0091-6749(99)70026-6			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	266FD	10589014				2022-12-18	WOS:000084289200026
J	Kelso, JM; Cockrell, GE; Helm, RM; Burks, AW				Kelso, JM; Cockrell, GE; Helm, RM; Burks, AW			Common allergens in avian meats	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; chicken; turkey; game birds; cross-reactivity	PROTEIN SENSITIZATION; CHICKEN MEAT; FOOD; CHILDREN	Background: Reports of allergy to bird meats are uncommon, and most have been in patients with "bird-egg syndrome." Objective: We sought to evaluate 3 patients who reported allergic reactions to several avian meats, but who denied allergic reactions to eating eggs. The patients required yellow fever vaccine for entry into the military. Methods: Patients were skin tested with commercial extracts of chicken, turkey, and egg, as well as with crude extracts made from dove and quail meat, and with yellow fever vaccine. Immunoblots for IgE antibody were performed by using the same materials used for skin testing plus extracts of duck and goose meat. Results: Skin tests were positive in all 3 patients to chicken, turkey, dove, quail, and yellow fever vaccine and negative to egg. This included some positive skin test responses to bird meats the patients denied ever having eaten. The vaccine was administered in graded doses. Immunoblots revealed IgE binding to several proteins of similar molecular weights in all of the avian meats but not to egg or yellow fever vaccine. Again, this included IgE antibody to some bird meats the patients denied ever having eaten. Conclusion: Patients allergic to one bird meat may be allergic to others, including game birds, probably because of crossreacting allergens. Such patients may have to exercise caution even when eating bird meats they have not previously ingested, The relationship of this allergy to yellow fever vaccine, if any, remains to be determined.	USN, Dept Internal Med, Div Allergy, San Diego, CA 92134 USA; Univ Arkansas Med Sci, Arkansas Childrens Hosp, Div Pediat Allergy Immunol, Little Rock, AR 72205 USA	United States Department of Defense; United States Navy; Arkansas Children's Hospital; University of Arkansas System; University of Arkansas Medical Sciences	Kelso, JM (corresponding author), USN, Dept Clin Res, Med Ctr, San Diego, CA 92134 USA.							Bausela BA, 1997, ANN ALLERG ASTHMA IM, V78, P213, DOI 10.1016/S1081-1206(10)63389-3; BAUSELA BA, 1991, ALLERGY, V46, P614, DOI 10.1111/j.1398-9995.1991.tb00632.x; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; HOFFMAN BR, 1991, J ALLERGY CLIN IMMUN, V87, P192; Liccardi G, 1997, J ALLERGY CLIN IMMUN, V100, P577, DOI 10.1016/S0091-6749(97)70154-4; PETER G, 1997, 1997 RED BOOK REPORT, P32; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; SZEPFALUSI Z, 1994, J ALLERGY CLIN IMMUN, V93, P932, DOI 10.1016/0091-6749(94)90388-3; Vila L, 1998, ANN ALLERG ASTHMA IM, V80, P195, DOI 10.1016/S1081-1206(10)62955-9; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450	10	36	37	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1999	104	1					202	204		10.1016/S0091-6749(99)70136-3	http://dx.doi.org/10.1016/S0091-6749(99)70136-3			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	221QZ	10400862				2022-12-18	WOS:000081738900032
J	Shichijo, M; Inagaki, N; Kimata, M; Serizawa, I; Saito, H; Nagai, H				Shichijo, M; Inagaki, N; Kimata, M; Serizawa, I; Saito, H; Nagai, H			Role of cyclic 3 ',5 '-adenosine monophosphate in the regulation of chemical mediator release and cytokine production from cultured human mast cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Conference on New Trends in Immunopharmacology 1997	JUL   12, 1997	TOKYO, JAPAN	Novartis Pharma K K Tokyo		mast cell; histamine; leukotrienes	HUMAN-LUNG FRAGMENTS; HISTAMINE-RELEASE; IMMUNOLOGICAL RELEASE; SODIUM CROMOGLYCATE; HUMAN BASOPHILS; STEEL FACTOR; INHIBITION; RAT; PHOSPHODIESTERASE; SALBUTAMOL	Background: Cultured human mast cells are known to resemble human lung mast cells in terms of the profiles of intracellular protease, the characteristics of histamine release, and the pharmacologic properties. Objective: The role of cyclic 3',5'-adenosine monophosphate (cAMP) in chemical mediator release and cytokine production by human mast cells was determined. Methods: We investigated the effects of cAMP-elevating agents on IgE-mediated chemical mediator release and cytokine production by cultured human mast cells. We also examined the relationship between intracellular cAMP levels and the inhibition of chemical mediator release or cytokine production by various drugs. Results: beta-agonists significantly suppressed IgE-mediated release of histamine, leukotrienes, and PGD2 (chemical mediators) and the production of GM-CSF, IL-5 and macrophage inflammatory protein-1 alpha (cytokines). Phosphodiesterase inhibitors (theophylline, rolipram, and cilostazol) had no effect on chemical mediators but suppressed cytokine production. Dibutyryl cAMP significantly suppressed both chemical mediator release and cytokine production, suggesting that their induction was regulated by intracellular cAMP, Elevation of cAMP by beta-agonists at 10 minutes after treatment correlated well with the inhibition of histamine release, There was a significant relationship between cAMP elevation at 180 minutes and the inhibition of GM-CSF production at 360 minutes by beta-agonists, rolipram, or cilostazol. Although 100 mu mol/L theophylline significantly inhibited GM-CSF production, it had no effect on cAMP. Conclusion: Elevation of cAMP may be responsible for the inhibitory effect of beta-agonists, rolipram, and cilostazol on chemical mediator release and cytokine production by cultured human mast cells. In contrast, theophylline may inhibit GM-CSF production independently of cAMP.	Gifu Pharmaceut Univ, Dept Pharmacol, Gifu 502, Japan; Natl Childrens Med Res Ctr, Div Allergy, Tokyo, Japan; Kirin Brewery Co Ltd, Pharmaceut Res Lab, Gunma, Japan	Gifu Pharmaceutical University; National Center for Child Health & Development - Japan; Kirin Brewery Company Limited	Nagai, H (corresponding author), Gifu Pharmaceut Univ, Dept Pharmacol, 5-6-1 Mitahora Higashi, Gifu 502, Japan.			Saito, Hirohisa/0000-0002-6630-8337				BARNES PJ, 1994, EUR RESPIR J, V7, P579, DOI 10.1183/09031936.94.07030579; BUTCHERS PR, 1979, BRIT J PHARMACOL, V67, P23; CHURCH MK, 1983, BRIT J PHARMACOL, V78, P671, DOI 10.1111/j.1476-5381.1983.tb09419.x; CRAIG SS, 1986, AM J PATHOL, V124, P427; DEWECK AL, 1993, ALLERGY CLIN IMMUNOL, V5, P9; EBISAWA M, 1995, J ALLERGY CLIN IMMUN, V95, P219; ENNIS M, 1981, NATURE, V289, P186, DOI 10.1038/289186a0; FOREMAN JC, 1977, J PHYSIOL-LONDON, V271, P193, DOI 10.1113/jphysiol.1977.sp011996; FROSSARD N, 1981, BRIT J PHARMACOL, V73, P933, DOI 10.1111/j.1476-5381.1981.tb08748.x; HUGHES JM, 1983, EUR J PHARMACOL, V95, P239; Igarashi Y, 1996, CLIN EXP ALLERGY, V26, P597; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; ISHIZAKA T, 1981, P NATL ACAD SCI-BIOL, V78, P6812, DOI 10.1073/pnas.78.11.6812; KUROSAWA M, 1986, J IMMUNOL, V136, P616; LACOUR M, 1994, INT IMMUNOL, V6, P1333, DOI 10.1093/intimm/6.9.1333; LOUIS R, 1992, INT J IMMUNOPHARMACO, V14, P191, DOI 10.1016/0192-0561(92)90030-O; MUNOZ E, 1990, J EXP MED, V172, P95, DOI 10.1084/jem.172.1.95; OKAYAMA Y, 1992, INT ARCH ALLERGY IMM, V97, P216, DOI 10.1159/000236122; PEACHELL PT, 1988, J IMMUNOL, V140, P571; PEACHELL PT, 1992, J IMMUNOL, V148, P2503; PETERS SP, 1982, AM REV RESPIR DIS, V126, P1034; PRADELLES P, 1985, ANAL CHEM, V57, P1170, DOI 10.1021/ac00284a003; SAITO H, 1995, INT ARCH ALLERGY IMM, V107, P63, DOI 10.1159/000236932; SAITO H, 1989, J IMMUNOL, V143, P250; Saito H, 1996, J IMMUNOL, V157, P343; SELDON PM, 1995, MOL PHARMACOL, V48, P747; Shichijo M, 1998, CLIN EXP ALLERGY, V28, P1228; SYDBOM A, 1981, ACTA PHYSL SCAND, V73, P933; TWENTYMAN OP, 1993, AM REV RESPIR DIS, V147, P1425, DOI 10.1164/ajrccm/147.6_Pt_1.1425; TWENTYMAN OP, 1991, AM REV RESPIR DIS, V144, P782, DOI 10.1164/ajrccm/144.4.782; UNDEM BJ, 1988, J PHARMACOL EXP THER, V247, P209; UNDEM BJ, 1990, J BIOL CHEM, V265, P6750; Underwood DC, 1997, J PHARMACOL EXP THER, V280, P210; VERGHESE MW, 1995, J PHARMACOL EXP THER, V272, P1313; WHITE JR, 1984, P NATL ACAD SCI-BIOL, V81, P3978, DOI 10.1073/pnas.81.13.3978; YAMATODANI A, 1985, J CHROMATOGR, V344, P115, DOI 10.1016/S0378-4347(00)82012-5; YANAGIDA M, 1995, BLOOD, V86, P3705, DOI 10.1182/blood.V86.10.3705.bloodjournal86103705; YOSHII N, 1988, IMMUNOPHARMACOLOGY, V16, P107, DOI 10.1016/0162-3109(88)90019-7; YOUNG KD, 1983, INT ARCH ALLER A IMM, V70, P138, DOI 10.1159/000233311	39	36	36	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1999	103	5	2	S			S421	S428		10.1016/S0091-6749(99)70157-0	http://dx.doi.org/10.1016/S0091-6749(99)70157-0			8	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	199TV	10329844				2022-12-18	WOS:000080500200003
J	Quiralte, J; Sanchez-Garcia, F; Torres, MJ; Blanco, C; Castillo, R; Ortega, N; de Castro, FR; Perez-Aciego, P; Carrillo, T				Quiralte, J; Sanchez-Garcia, F; Torres, MJ; Blanco, C; Castillo, R; Ortega, N; de Castro, FR; Perez-Aciego, P; Carrillo, T			Association of HLA-DR11 with the anaphylactoid reaction caused by nonsteroidal anti-inflammatory drugs	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HLA; NSAID sensitivity; anaphylactoid reaction	ASPIRIN-INDUCED ASTHMA; ANTIINFLAMMATORY DRUGS; PCR-SSP	Background: Several HLA alleles have been associated with asthma induced by nonsteroidal anti-inflammatory drugs (NSAIDs). The existence of HLA markers linked to other NSAID-induced reactions, such as cutaneous and anaphylactoid reactions, has not been established. Objective: The purpose of our work was to study the HLA-DRB1 and HLA-DQB1 alleles in patients with cutaneous and anaphylactoid reactions caused by NSAIDs. Methods: We have analyzed 114 HLA DRB1 and 26 HLA-DQB1 alleles in 21 patients with anaphylactoid reactions caused by NSAIDs, 47 patients who had exclusively cutaneous reactions during single blind, placebo-controlled oral challenges with NSAIDs, and 167 tolerant control subjects (29 of whom had also had an IgE-mediated anaphylaxis to different agents). HLA-DRB1 and HLA-DQB1 alleles were typed by the polymerase chain reaction sequence-specific primers method with genomic DNA. Results: The frequency of HLA-DR11 alleles was 58.8% in the anaphylactoid reaction group, compared with 15.9% in the NSAID-tolerant healthy control subjects (OR, 7:3; 95% confidence interval, 2.8-19.0; P <.02) and 6.3% in the group of the patients with a tolerance for NSAIDs and with IgE-mediated anaphylaxis (OR, 18.75; 95% confidence interval, 4.3-81.1; P <.004). No differences were observed among HLA-DR11 alleles analyzed, There were no significant HLA-DQB1 associations with NSAID-induced anaphylactoid reactions. Patients with cutaneous reactions had HLA frequencies that did not differ significantly from the tolerant control subjects. Conclusion: The HLA-DRB1*11 alleles showed a positive association with NSAID-induced anaphylactoid reactions.	Hosp Ciudad Jaen, Unidad Algeria, Jaen, Spain; Hosp Univ Ntra Senora, Secc Algeria, Las Palmas Gran Canaria, Spain; Hosp Univ Ntra Senora, Unidad Invest, Las Palmas Gran Canaria, Spain; Hosp Univ Ntra Senora, Unidad Immunol, Las Palmas Gran Canaria, Spain		Quiralte, J (corresponding author), Hosp Ciudad Jaen, Unidad Algeria, Avda Ejercito Espanol 10, Jaen, Spain.		de Castro, Felipe Rodriguez/R-8416-2019; Torres, Maria/GVU-3391-2022; Torres, María José/T-3518-2017; IBIS, ALERGICAS/C-1733-2016; Blanco, Carlos/B-3895-2012	Torres, María José/0000-0001-5228-471X; Blanco, Carlos/0000-0002-2893-6594; Sanchez-Garcia, Florentino/0000-0003-0304-6023; Rodriguez de Castro, Felipe/0000-0002-6812-2739				BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; Dekker JW, 1997, CLIN EXP ALLERGY, V27, P574, DOI 10.1046/j.1365-2222.1997.540848.x; DUNN OJ, 1961, J AM STAT ASSOC, V56, P52, DOI 10.2307/2282330; HALDANE JBS, 1956, ANN HUM GENET, V20, P309; ISRAEL E, 1993, AM REV RESPIR DIS, V148, P1447, DOI 10.1164/ajrccm/148.6_Pt_1.1447; JUHLIN L, 1981, BRIT J DERMATOL, V104, P369, DOI 10.1111/j.1365-2133.1981.tb15306.x; KRISHNAMOORTHY R, 1993, GENETICS ASTHMA, P225; LEE TH, 1991, J ALLERGY CLIN IMMUN, V88, P827, DOI 10.1016/0091-6749(91)90237-I; LYMPANY PA, 1993, J ALLERGY CLIN IMMUN, V92, P114, DOI 10.1016/0091-6749(93)90045-H; MULLARKEY MF, 1986, AM REV RESPIR DIS, V133, P261; OLERUP O, 1993, TISSUE ANTIGENS, V41, P119, DOI 10.1111/j.1399-0039.1993.tb01991.x; OLERUP O, 1993, TISSUE ANTIGENS, V41, P55; OLERUP O, 1992, TISSUE ANTIGENS, V39, P187; Quiralte J, 1996, J ALLERGY CLIN IMMUN, V98, P678, DOI 10.1016/S0091-6749(96)70102-1; Quiralte J, 1997, ANN ALLERG ASTHMA IM, V78, P293, DOI 10.1016/S1081-1206(10)63184-5; STEVENSON DD, 1984, J ALLERGY CLIN IMMUN, V74, P617, DOI 10.1016/0091-6749(84)90115-5; STEVENSON DD, 1995, IMMUNOL ALLERGY CLIN, V15, P545; SZCZEKLIK A, 1977, J ALLERGY CLIN IMMUN, V60, P276, DOI 10.1016/0091-6749(77)90106-3; WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x	19	36	40	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1999	103	4					685	689		10.1016/S0091-6749(99)70243-5	http://dx.doi.org/10.1016/S0091-6749(99)70243-5			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	186HY	10200020				2022-12-18	WOS:000079723900024
J	Dioun, AF; Ewenstein, BM; Geha, RS; Schneider, LC				Dioun, AF; Ewenstein, BM; Geha, RS; Schneider, LC			IgE-mediated allergy and desensitization to factor IX in hemophilia B	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; anaphylaxis; desensitization; factor IX deficiency	FACTOR-VIII; HUMAN INSULIN; INHIBITORS	Background: We describe two patients with factor IX deficiency and high levels of inhibitors to factor IX who developed anaphylaxis to factor IX. Objective: The aim of this study was to develop a skin test, RAST, and desensitization protocol for factor IX allergy, Methods: The patients were evaluated by skin test and RAST to factor IX. They also underwent desensitization to factor IX. Results: Both patients had positive skin test and RAST reactions to factor IS. Control subjects had negative reactions. Both patients were successfully desensitized to factor IX by using two different desensitization protocols. The patients' skin test anti RAST reactions to factor IX converted to negative after desensitization. Conclusions: IgE-mediated reactions to factor IS do occur and may be diagnosed with the use of skin test and RAST. Patients with this type of reaction may be successfully desensitized to factor IX.	Harvard Univ, Childrens Hosp, Sch Med, Dept Pediat,Div Immunol,Allergy Program, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Pediat,Div Hematol Oncol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School	Dioun, AF (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Dept Pediat,Div Immunol,Allergy Program, 300 Longwood Ave, Boston, MA 02115 USA.			Ewenstein, Bruce/0000-0003-3871-8619	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007321] Funding Source: NIH RePORTER; NICHD NIH HHS [5 T 32 HD07321] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSON JA, 1992, JAMA-J AM MED ASSOC, V268, P2845, DOI 10.1001/jama.1992.03490200097011; BOUSQUET J, 1993, ALLERGY PRINCIPLES P, P573; BRIT E, 1991, BLOOD COAGUL FIBR S1, V2, P47; Chng HH, 1995, ALLERGY, V50, P984, DOI 10.1111/j.1398-9995.1995.tb02512.x; EDELL S, 1971, NEW ENGL J MED, V285, P580; EHRENFORTH S, 1992, LANCET, V339, P594, DOI 10.1016/0140-6736(92)90874-3; GRAMMER L, 1986, CLIN REV ALLERG, V4, P189; HAMILTON RG, 1992, MANUAL CLIN IMMUNOLO, P689; HOYER LW, 1991, BLOOD COAGUL FIBRIN, V2, P11; JAMIESON DM, 1987, ANN ALLERGY, V58, P215; ORSTAVIK KH, 1988, BRIT J HAEMATOL, V68, P451, DOI 10.1111/j.1365-2141.1988.tb04234.x; Sawamoto Y, 1996, THROMB RES, V83, P279, DOI 10.1016/0049-3848(96)00136-3; Shapiro S S, 1984, Prog Clin Biol Res, V150, P45; Sullivan TJ, 1993, ALLERGY PRINCIPLES P, P1726; THOMPSON DM, 1993, DIABETES CARE, V16, P957, DOI 10.2337/diacare.16.6.957; Warrier I, 1997, J PEDIAT HEMATOL ONC, V19, P23, DOI 10.1097/00043426-199701000-00003; WEINREB NJ, 1971, NEW ENGL J MED, V285, P1151	17	36	36	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1998	102	1					113	117		10.1016/S0091-6749(98)70061-2	http://dx.doi.org/10.1016/S0091-6749(98)70061-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	102DX	9679854	Bronze			2022-12-18	WOS:000074909500016
J	Mahajan, P; Pearlman, D; Okamoto, L				Mahajan, P; Pearlman, D; Okamoto, L			The effect of fluticasone propionate on functional status and sleep in children with asthma and on the quality of life of their parents	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						fluticasone propionate; quality of life; children; asthma	OF-LIFE; ILLNESS; HEALTH	Background: Although in the past drug interventions were measured primarily on the basis of their efficacy and safety, today we are increasingly interested in what impact treatments have on the patient's day-to-day activities and quality of life, Objectives: We sought to assess the effect of treatment with fluticasone propionate (FP) on functional status and sleep disturbances in children with asthma and to evaluate possible changes in the quality of life of the parents of these children after treatment. Methods: As part of a randomized, double-blind, parallel-group, placebo-controlled, multicenter study on the effects of FP powder (50 or 100 mu g twice daily) on growth in children aged 4 to 11 years with mild-to-moderate asthma (n = 325), parents/caregivers completed the following questionnaires at baseline and at weeks 24 and 52 of treatment: Functional Status IIR (FSII), Sleep Scale-Children (SLP-C), and Quality of Life of Parents of Asthmatic Children (QOL-PAC), Change from baseline to weeks 24 and 52 within each treatment group was analyzed by using paired t tests, and differences between treatment groups were analyzed by using analysis of covariance, Results: Mean FSII and SLP-C scores improved significantly over baseline values with either 50 or 100 mu g FP at weeks 23 and 52 (p < 0.05) and were significantly better than scores in the placebo group (p < 0,05), In contrast, FSII scores at week 52 and SLP-C scores at weeks 23 and 52 decreased significantly in the placebo group (p < 0.05), QOL-PAC results revealed that scores on the Burden scale were significantly improved in both FP groups at weeks 24 and 52, Subjective Norms and Social scales improved significantly only in the 100 mu g FP group at week 52, Conclusions: The results of this study show that FP (either 50 or 100 mu g twice a day) was associated with significant improvements in functional status and decreased sleep disturbances in children with asthma, In addition, treatment of children with FP was associated with a decreased burden on the parents of these children with asthma.	Glaxo Wellcome Inc, Global Hlth Outcomes, Res Triangle Pk, NC 27709 USA; Colorado Allergy & Asthma Clin, Aurora, CO USA	GlaxoSmithKline	Mahajan, P (corresponding author), Glaxo Wellcome Inc, Global Hlth Outcomes, POB 13398, Res Triangle Pk, NC 27709 USA.							Allen DB, 1998, J PEDIATR-US, V132, P472, DOI 10.1016/S0022-3476(98)70023-X; BOYER G, 1992, J ALLERGY CLIN IMMUN, V89, P186; CHERVINSKY P, 1994, J ALLERGY CLIN IMMUN, V94, P676, DOI 10.1016/0091-6749(94)90174-0; Guyatt GH, 1997, PEDIATRICS, V99, P165, DOI 10.1542/peds.99.2.165; *INT CONS REP DIAG, 1992, PUBL DEP HHS; Juniper EF, 1996, QUAL LIFE RES, V5, P27, DOI 10.1007/BF00435966; KONIG P, 1996, IN PRESS EUR RESP J; LEWIS CC, 1989, MED CARE, V27, pS54, DOI 10.1097/00005650-198903001-00005; Mahajan P, 1997, J ASTHMA, V34, P227, DOI 10.3109/02770909709068193; MRAZEK D, 1992, AM PSYCH ASS 145 ANN; NEWACHECK PW, 1986, AM J PUBLIC HEALTH, V76, P178, DOI 10.2105/AJPH.76.2.178; NOONAN M, 1995, AM J RESP CRIT CARE, V152, P1467, DOI 10.1164/ajrccm.152.5.7582278; Okamoto LJ, 1996, ANN ALLERG ASTHMA IM, V76, P455, DOI 10.1016/S1081-1206(10)63463-1; PERI G, 1991, J ASTHMA, V28, P91, DOI 10.3109/02770909109082733; SCHULZ RM, 1994, J ASTHMA, V31, P209, DOI 10.3109/02770909409044828; STEIN REK, 1990, MED CARE, V28, P1041, DOI 10.1097/00005650-199011000-00006; TAYLOR WR, 1992, PEDIATRICS, V90, P657; TOWNSEND M, 1991, ANN ALLERGY, V67, P403; 1987, AM REV RESPIR DIS, V136, P225, DOI 10.1164/ajrccm/136.1.225	19	36	35	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1998	102	1					19	23		10.1016/S0091-6749(98)70050-8	http://dx.doi.org/10.1016/S0091-6749(98)70050-8			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	102DX	9679843				2022-12-18	WOS:000074909500005
J	Woods, RK; Weiner, JM; Thien, F; Abramson, M; Walters, EH				Woods, RK; Weiner, JM; Thien, F; Abramson, M; Walters, EH			The effects of monosodium glutamate in adults with asthma who perceive themselves to be monosodium glutamate-intolerant	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						monosodium glutamate; asthma; randomized double-blind; placebo-controlled trial	DOUBLE-BLIND; FOOD CHALLENGES	Background: Many previous clinical studies of food-induced asthma suffer from inadequate baseline or control data. A statistically valid, randomized, double-blind, placebo-controlled, monosodium glutamate (MSG)-challenge protocol was developed for identifying early and late asthmatic reactions in an individual. Objective: We sought to determine whether MSG would induce bronchoconstriction in a group of adults with asthma who perceived that they were MSG sensitive. Methods: Twelve subjects (seven women, mean age 35.3 years) with clinically documented asthma and a perception of MSG-induced asthma were recruited. FEV1 and peak expiratory flow data were obtained for 3 whole control days, as well as time-matched data for 3 separate challenge days (1 gm MSG, 5 gm MSG, and 5 gm lactose [placebo]). Opaque capsule challenges were given as a single dose in the morning after an overnight fast. Subjects complied with atl elimination diet throughout the study. Nonspecific bronchial hyperresponsiveness was measured at baseline, after the control days, and at the conclusion of the challenges. Venous blood samples were taken at baseline and on each challenge day to determine soluble inflammatory marker (eosinophil cationic protein and tryptase) activity. Results: No immediate or definite late asthmatic reactions occurred. One subject's FEV1 declined more than 15% on MSG challenge, but 95% confidence limits for the control-day spirometry showed that this decline was within her daily variation, hence the challenge was deemed to be negative. No significant changes in bronchial hyperresponsiveness or soluble inflammatory markers were found. Conclusions: MSG induced asthma was not demonstrated in this study. This study highlighted the importance of adequate baseline and control data and indicated that such a rigorous protocol for individual assessment is feasible.	Alfred Hosp, Dept Resp Med, Melbourne, Vic, Australia; Alfred Hosp, Dept Med, Melbourne, Vic, Australia; Alfred Hosp, Dept Allergy & Clin Immunol, Melbourne, Vic, Australia; Alfred Hosp, Dept Epidemiol & Prevent Med, Melbourne, Vic, Australia; Monash Univ, Sch Med, Melbourne, Vic 3004, Australia	Florey Institute of Neuroscience & Mental Health; Florey Institute of Neuroscience & Mental Health; Florey Institute of Neuroscience & Mental Health; Florey Institute of Neuroscience & Mental Health; Monash University	Walters, EH (corresponding author), Alfred Hosp, Dept Resp Med, Commercial Rd, Prahran, Vic 3181, Australia.		WALTERS, Eugene/AAL-2264-2021; Abramson, Michael/AAQ-2671-2020	Abramson, Michael/0000-0002-9954-0538; Weiner, John/0000-0001-5895-8973; Thien, Francis/0000-0003-0925-6566				ABRAMSON MJ, 1995, MED J AUSTRALIA, V162, P78, DOI 10.5694/j.1326-5377.1995.tb138438.x; *ALFR HOSP NUTR DE, 1995, EXCL DIET, V1; ALLEN DH, 1987, J ALLERGY CLIN IMMUN, V80, P530, DOI 10.1016/0091-6749(87)90003-0; ALTMAN DR, 1994, J ALLERGY CLIN IMMUN, V93, P303; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; BOCK SA, 1990, J PEDIATR-US, V117, P561, DOI 10.1016/S0022-3476(05)80689-4; BOUSQUET J, 1991, FOOD ALLERGY ADVERSE; Connolly M J, 1988, Pulm Pharmacol, V1, P53, DOI 10.1016/0952-0600(88)90011-7; DAWSON KP, 1990, NEW ZEAL MED J, V103, P239; GERMANO P, 1991, Journal of Allergy and Clinical Immunology, V87, P177, DOI 10.1016/0091-6749(91)91438-Y; Hodge L, 1996, THORAX, V51, P805, DOI 10.1136/thx.51.8.805; *I FOOD TECHN EXP, 1980, MON GLUT MSG; James JM, 1996, AM J RESP CRIT CARE, V153, P597, DOI 10.1164/ajrccm.153.2.8564104; JOHNS DP, 1993, AM REV RESPIR DIS, V147, P1245, DOI 10.1164/ajrccm/147.5.1245; MAPP CE, 1994, CLIN EXP ALLERGY, V24, P730, DOI 10.1111/j.1365-2222.1994.tb00983.x; MONERET-VAUTRIN D A, 1987, Allergie et Immunologie (Paris), V19, P29; NICHOLAS PG, 1991, CHEM AUSTR, V58, P556; NORUSIS MJ, 1993, SPSS WIND BAS SYST U; OCONNOR G, 1987, AM REV RESPIR DIS, V136, P1412, DOI 10.1164/ajrccm/136.6.1412; ONORATO J, 1986, J ALLERGY CLIN IMMUN, V78, P1139, DOI 10.1016/0091-6749(86)90263-0; PULCE C, 1992, ADVERSE DRUG REACT T, V11, P19; PULLINGER LE, 1991, THESIS DEAKIN U VICT; QUANJER PH, 1983, B EUR PHYSIOPATH RES, V19, P1; RAITEN DJ, 1995, ANAL ADVERSE REACTIO, P73; RHODES J, 1991, FOOD ADDIT CONTAM, V8, P265, DOI 10.1080/02652039109373976; SCHWARTZSTEIN RM, 1987, J ASTHMA, V24, P167, DOI 10.3109/02770908709070933; STENTON SC, 1994, EUR RESPIR J, V7, P806, DOI 10.1183/09031936.94.07040806; Stevenson DD, 1997, J ALLERGY CLIN IMMUN, V99, P1670; SWAIN A, 1991, FRIENDLY FOOD; THIEN F, 1997, CLIN ASTHMA REV, V1, P77; VENGE P, 1994, ALLERGY, V49, P1, DOI 10.1111/j.1398-9995.1994.tb00765.x; Woods RK, 1996, AUST NZ J MED, V26, P504, DOI 10.1111/j.1445-5994.1996.tb00596.x	33	36	37	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1998	101	6	1				762	771		10.1016/S0091-6749(98)70305-7	http://dx.doi.org/10.1016/S0091-6749(98)70305-7			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZW470	9648703				2022-12-18	WOS:000074414200009
J	Naclerio, RM; Adkinson, NF; Moylan, B; Baroody, FM; Proud, D; KageySobotka, A; Lichtenstein, LM; Hamilton, R				Naclerio, RM; Adkinson, NF; Moylan, B; Baroody, FM; Proud, D; KageySobotka, A; Lichtenstein, LM; Hamilton, R			Nasal provocation with allergen induces a secondary serum IgE antibody response	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE; nasal challenge; beclomethasone; human; antigen; allergic rhinitis	IMMUNOGLOBULIN-E; IMMUNOTHERAPY; CHALLENGE; OXYMETAZOLINE; KALLIKREIN; SECRETIONS; HISTAMINE; RHINITIS; ANTIGEN; PLASMA	The study of the IgE response to seasonal antigen exposure is limited by its occurrence once a year and by the variability of patient exposure to pollens. To overcome these problems, me investigated whether nasal challenge with antigen causes an increase in serum anti-ragweed IgE levels. We challenged individuals with ragweed allergy intranasally with nanogram quantities of ragweed antigen extract and measured their serum anti-ragweed IgE levels before and at weekly intervals after challenge. In a series of studies we found that there was a reproducible rise in antigen-specific serum IgE levels beginning the first week after challenge that plateaued at about 180% of baseline levels during the fourth week and remained elevated for 8 weeks. Not all individuals showed this response. The magnitude of the allergen-specific IgE response to nasal challenge appeared to be greater than the response to seasonal exposure. Treatment with intranasal beclomethasone before challenge did not affect the response. The results demonstrate a human in vivo model for the study of the antigen-specific secondary IgE response to allergen.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21218	Johns Hopkins University					NIDCD NIH HHS [R01 DC 02714] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC002714] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BAUMGARTEN CR, 1986, J IMMUNOL, V137, P1323; BAUMGARTEN CR, 1986, J IMMUNOL, V137, P977; BRINKMANN V, 1995, J IMMUNOL, V155, P3322; Butler JE, 1991, IMMUNOCHEMISTRY SOLI, P173; GEORGITIS JW, 1985, J ALLERGY CLIN IMMUN, V75, P496, DOI 10.1016/S0091-6749(85)80023-3; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P261, DOI 10.1016/0091-6749(82)90062-8; HAMILTON RG, 1992, MANUAL CLIN IMMUNOLO, P689; ILIOPOULOS O, 1990, J ALLERGY CLIN IMMUN, V86, P851, DOI 10.1016/S0091-6749(05)80146-0; IMANARI T, 1986, RADIOCHEMICAL ASSAYS, P205; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; MAJCHEL AM, 1993, J ALLERGY CLIN IMMUN, V92, P767, DOI 10.1016/0091-6749(93)90021-7; MARSH DG, 1975, ANTIGENS, V3, P271; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1993, J ALLERGY CLIN IMMUN, V92, P717, DOI 10.1016/0091-6749(93)90015-8; NICKELSEN JA, 1981, J ALLERGY CLIN IMMUN, V68, P41, DOI 10.1016/0091-6749(81)90121-4; SCHLEIMER RP, 1988, ALLERGY PRINCIPLES P, P739; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; SMITH JM, 1988, ALLERGY PRINCIPLES P, P891; SVENSSON C, 1992, CLIN EXP ALLERGY, V22, P411, DOI 10.1111/j.1365-2222.1992.tb03103.x; WATASE T, 1986, Rhinology (Utrecht), V24, P181	20	36	36	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1997	100	4					505	510		10.1016/S0091-6749(97)70143-X	http://dx.doi.org/10.1016/S0091-6749(97)70143-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YA529	9338545	hybrid			2022-12-18	WOS:A1997YA52900013
J	Redington, AE; Springall, DR; Meng, QH; Tuck, AB; Holgate, ST; Polak, JM; Howarth, PH				Redington, AE; Springall, DR; Meng, QH; Tuck, AB; Holgate, ST; Polak, JM; Howarth, PH			Immunoreactive endothelin in bronchial biopsy specimens: Increased expression in asthma and modulation by corticosteroid therapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; endothelin; bronchial biopsy; corticosteroids; inflammation; remodeling; collagen	AIRWAY EPITHELIAL-CELLS; BRONCHOALVEOLAR LAVAGE FLUID; GUINEA-PIG; MUCOSAL BIOPSIES; VASOCONSTRICTOR PEPTIDE; VASOACTIVE PEPTIDE; SYMPTOMATIC ASTHMA; FLOW OBSTRUCTION; CYTOKINES; MITOGENESIS	Background: The human endothelin (ET) family comprises three 21-amino-acid peptides, which are potent bronchoconstrictors and have a number of other biologic properties relevant to the pathophysiology of asthma, Objective: We sought to compare the expression of immunoreactive ET in bronchial biopsy specimens from subjects with asthma treated only with inhaled beta(2)-agonists, subjects with asthma treated with beta(2)-agonists and corticosteroids, and control subjects without asthma, Methods: Biopsy specimens were obtained by fiberoptic bronchoscopy and stained immunohistochemically with a specific ET antiserum. Epithelial ET expression was quantitated by using a computer-assisted system of image analysis. Numbers of inflammatory cells and depth of subepithelial collagen deposition were also determined. Results: Immunoreactive EI was principally localized in the airway epithelium. The proportion of epithelium immunostained was significantly increased in the subjects with asthma not treated with steroids (35.4% +/- 3.8%) compared with that of both the control subjects (16.2% +/- 1.9%, p < 0.0001) and the subjects with asthma treated with steroids (14.3% +/- 2.0%, p < 0.0001), The last two groups did not differ significantly from one another. There were no significant correlations between ET expression and either physiologic parameters or indexes of airway inflammation and remodeling. Conclusion: Bronchial epithelial expression of immunoreactive ET is increased in subjects with asthma receiving treatment only with beta(2)-agonists but not in subjects with asthma also receiving corticosteroid therapy. These findings are consistent with the hypothesis that ET is implicated in the pathophysiology of asthma.	UNIV MED,SOUTHAMPTON GEN HOSP,SOUTHAMPTON,HANTS,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT HISTOCHEM,LONDON W12 0HS,ENGLAND	University of Southampton; Imperial College London				Howarth, Peter/0000-0003-0619-7927				Adner M, 1996, EUR RESPIR J, V9, P351, DOI 10.1183/09031936.96.09020351; ADVENIER C, 1990, BRIT J PHARMACOL, V100, P168, DOI 10.1111/j.1476-5381.1990.tb12071.x; ANDERSSON SE, 1992, BIOCHEM BIOPH RES CO, V188, P1116, DOI 10.1016/0006-291X(92)91347-S; ARINAMI T, 1991, AM J HUM GENET, V48, P990; BHAGAT RG, 1985, AM REV RESPIR DIS, V131, P902; BLACK PN, 1989, FEBS LETT, V255, P129, DOI 10.1016/0014-5793(89)81075-0; BRITTEN KM, 1993, BIOTECH HISTOCHEM, V68, P271, DOI 10.3109/10520299309105629; BROIDE DH, 1992, J ALLERGY CLIN IMMUN, V89, P958, DOI 10.1016/0091-6749(92)90218-Q; CALDERON E, 1994, BIOCHEM PHARMACOL, V48, P2065, DOI 10.1016/0006-2952(94)90506-1; Chanez P, 1996, J ALLERGY CLIN IMMUN, V98, P412, DOI 10.1016/S0091-6749(96)70166-5; DJUKANOVIC R, 1991, AM REV RESPIR DIS, V143, P772, DOI 10.1164/ajrccm/143.4_Pt_1.772; ENDO T, 1992, BIOCHEM BIOPH RES CO, V186, P1594, DOI 10.1016/S0006-291X(05)81590-6; GIAID A, 1991, AM J RESP CELL MOL, V4, P50, DOI 10.1165/ajrcmb/4.1.50; GLASSBERG MK, 1994, AM J RESP CELL MOL, V10, P316, DOI 10.1165/ajrcmb.10.3.7509612; HALLER H, 1991, AM J PHYSIOL, V261, pL478, DOI 10.1152/ajplung.1991.261.6.L478; HAY DWP, 1990, BRIT J PHARMACOL, V100, P383, DOI 10.1111/j.1476-5381.1990.tb15814.x; HAY DWP, 1993, BRIT J PHARMACOL, V110, P1175, DOI 10.1111/j.1476-5381.1993.tb13938.x; HSU S, 1988, NEUROSCI LETT, V85, P169; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; ISHIDA K, 1990, BIOCHEM BIOPH RES CO, V173, P496, DOI 10.1016/S0006-291X(05)80061-0; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; KAHALEH MB, 1991, ARTHRITIS RHEUM, V34, P978, DOI 10.1002/art.1780340807; LAGENTE V, 1989, BIOCHEM BIOPH RES CO, V158, P625, DOI 10.1016/0006-291X(89)92767-8; LOZEWICZ S, 1990, THORAX, V45, P12, DOI 10.1136/thx.45.1.12; LUNDGREN R, 1988, EUR RESPIR J, V1, P883; MAGGI CA, 1989, EUR J PHARMACOL, V160, P179; MATTOLI S, 1991, J ALLERGY CLIN IMMUN, V88, P376, DOI 10.1016/0091-6749(91)90100-3; NAKANO J, 1994, CLIN EXP ALLERGY, V24, P330, DOI 10.1111/j.1365-2222.1994.tb00243.x; *NAT HEART LUNG BL, 1992, J ALLERGY CLIN IMMUN, V88, P808; NOGUCHI K, 1995, J APPL PHYSIOL, V79, P700, DOI 10.1152/jappl.1995.79.3.700; PAYNE AN, 1988, EUR J PHARMACOL, V158, P303, DOI 10.1016/0014-2999(88)90085-4; REDINGTON AE, 1995, AM J RESP CRIT CARE, V151, P1034; Redington AE, 1997, THORAX, V52, P310, DOI 10.1136/thx.52.4.310; SAKURAI T, 1992, TRENDS PHARMACOL SCI, V13, P103; SHIMURA S, 1992, AM J PHYSIOL, V262, pL208, DOI 10.1152/ajplung.1992.262.2.L208; SODERBERG M, 1990, EUR RESPIR J, V3, P261; SPRINGALL DR, 1991, LANCET, V337, P697, DOI 10.1016/0140-6736(91)90279-X; TAKUWA N, 1989, J BIOL CHEM, V264, P7856; Turner AJ, 1996, BIOCHEM PHARMACOL, V51, P91, DOI 10.1016/0006-2952(95)02036-5; UCHIDA Y, 1988, EUR J PHARMACOL, V154, P227, DOI 10.1016/0014-2999(88)90106-9; VITTORI E, 1992, AM REV RESPIR DIS, V146, P1320, DOI 10.1164/ajrccm/146.5_Pt_1.1320; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	43	36	36	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1997	100	4					544	552		10.1016/S0091-6749(97)70148-9	http://dx.doi.org/10.1016/S0091-6749(97)70148-9			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YA529	9338550				2022-12-18	WOS:A1997YA52900019
J	Kotsimbos, ATC; Humbert, M; Minshall, E; Durham, S; Pfister, R; Menz, G; Tavernier, J; Kay, AB; Hamid, Q				Kotsimbos, ATC; Humbert, M; Minshall, E; Durham, S; Pfister, R; Menz, G; Tavernier, J; Kay, AB; Hamid, Q			Upregulation of alpha GM-CSF-receptor in nonatopic asthma but not in atopic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						intrinsic asthma; macrophages; GM-CSF receptor	COLONY-STIMULATING FACTOR; ACTIVATED T-CELLS; MESSENGER-RNA; BRONCHOALVEOLAR LAVAGE; BRONCHIAL BIOPSIES; MAST-CELLS; ALVEOLAR MACROPHAGES; HUMAN EOSINOPHILS; LYMPHOCYTES-T; MILD ASTHMA	Background: Intrinsic asthma is characterized by an increased number of activated eosinophils and macrophages and an increased expression of the hematopoietic growth factor granulocyte-macrophage colony-stimulating factor (GMCSF) in the bronchial mucosa. Objective: This study was carried out to investigate the expression of alpha GM-CSF receptor (alpha GM-CSBr) messenger RNA and protein in the bronchial mucosa of patients with intrinsic or atopic asthma and of control subjects and to correlate the expression of alpha GM-CSFr to the number of EG2(+) cells (eosinophils) and CD68(+) cells (macrophages) and pulmonary function. Methods: Nineteen patients with stable asthma (9 with atopic and 10 with intrinsic asthma) and 22 normal control subjects (12 atopic and 10 nonatopic subjects) were recruited, and FEV1 (percent predicted) and PC20 were measured before bronchoscopy. Endobronchial biopsy specimens were obtained and examined for membrane-bound alpha GM-CSFr by using in situ hybridization and immunocytochemistry. Results: alpha GM-CSFr mRNA- and protein-positive cells were identified in biopsy specimens from ail four groups studied. There was no significant difference in the number of cells expressing alpha GM-CSFr mRNA and protein in patients with atopic asthma compared with atopic and nonatopic control subjects. However, the numbers of alpha GM-CSFr mRNA- and protein-positive cells were significantly higher in nonatopic patients with asthma compared with atopic patients with asthma and atopic and nonatopic control subjects (p < 0.001). In the patients with intrinsic asthma, the number of alpha GM-CSFr mRNA-positive cells per millimeter of basement membrane correlated with numbers of CD68(+) cells (r(2) = 0.87, p < 0.001) but not with EG2(+) cells, and colocalization studies demonstrated that 80% of the cells expressing alpha GM-CSFr mRNA were CD68(+). The expression of GM-CSF was also significantly increased in patients with intrinsic asthma compared with those with atopic asthma and control subjects (p < 0.05), In addition, in intrinsic asthma, there was a correlation between alpha GM-CSFr mRNA and FEV1 (r(2) = 0.61, p < 0.05. Conclusion: These results demonstrate that elevated numbers of cells expressing alpha GM-CSFr can be detected in nonatopic asthma but not in atopic asthma and suggest that this increased expression is predominantly macrophage-associated and may play an important pathophysiologic role in intrinsic asthma.	MCGILL UNIV,MEAKINS CHRISTIE LABS,MONTREAL,PQ H2X 2P2,CANADA; ROYAL BROMPTON HOSP,NATL HEART & LUNG INST,LONDON SW3 6LY,ENGLAND; ROCHE LABS,BRUSSELS,BELGIUM; HOCHGEBIRGSKLIN DAVOS WOLFGANG,ASTHMA & ALLERGY CLIN,DAVOS,SWITZERLAND	McGill University; Imperial College London; Royal Brompton Hospital				Humbert, Marc/0000-0003-0703-2892				ALAM R, 1992, J EXP MED, V176, P781, DOI 10.1084/jem.176.3.781; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BENTLEY AM, 1992, AM REV RESPIR DIS, V146, P500, DOI 10.1164/ajrccm/146.2.500; BENTLEY AM, 1994, J INVEST ALLERG CLIN, V4, P222; BENTLEY AM, 1993, AM J RESP CELL MOL, V8, P35, DOI 10.1165/ajrcmb/8.1.35; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; BRATTON DL, 1995, J CLIN INVEST, V95, P211, DOI 10.1172/JCI117642; BUSSE WW, 1990, J ALLERGY CLIN IMMUN, V85, P671, DOI 10.1016/0091-6749(90)90181-3; CARROLL MP, 1985, J ALLERGY CLIN IMMUN, V75, P290, DOI 10.1016/0091-6749(85)90060-0; CLUZEL M, 1987, J ALLERGY CLIN IMMUN, V80, P195, DOI 10.1016/0091-6749(87)90129-1; CORRIGAN CJ, 1995, AM J RESP CELL MOL, V12, P567, DOI 10.1165/ajrcmb.12.5.7742019; DUNNILL MS, 1969, THORAX, V24, P176, DOI 10.1136/thx.24.2.176; DURHAM SR, 1992, J IMMUNOL, V148, P2390; HAMID Q, 1987, P NATL ACAD SCI USA, V84, P6760, DOI 10.1073/pnas.84.19.6760; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; HAMID Q, 1992, IMMUNOLOGY, V75, P659; HAMID Q, 1992, DIAGNOSTIC MOL PATHO, V1, P169; HOLGATE ST, 1989, ROLE INFLAMMATORY PR, P179; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; JOSEPH M, 1983, J CLIN INVEST, V71, P221, DOI 10.1172/JCI110762; KAY AB, 1992, IMMUNOLOGY, V77, P330; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697, DOI 10.1164/ajrccm/147.3.697; LANFRANCONE L, 1995, ONCOGENE, V10, P907; LOPEZ AF, 1991, J BIOL CHEM, V266, P24741; LOPEZ AF, 1986, J CLIN INVEST, V78, P1220, DOI 10.1172/JCI112705; MCFADDEN ER, 1992, NEW ENGL J MED, V327, P1928, DOI 10.1056/NEJM199212313272708; METCALF D, 1985, SCIENCE, V229, P16, DOI 10.1126/science.2990035; METCALF D, 1986, BLOOD, V67, P257; METZGER WJ, 1987, AM REV RESPIR DIS, V135, P433; MIYAJIMA A, 1993, BLOOD, V82, P1960; MOQBEL R, 1991, J EXP MED, V174, P749, DOI 10.1084/jem.174.3.749; NAKAGAWA Y, 1994, J BIOL CHEM, V269, P10905; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; POULTER LW, 1994, IMMUNOL TODAY, V15, P258, DOI 10.1016/0167-5699(94)90004-3; RANKIN JA, 1989, J ALLERGY CLIN IMMUN, V83, P722, DOI 10.1016/0091-6749(89)90005-5; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROBINSON DS, 1993, J ALLERGY CLIN IMMUN, V92, P397, DOI 10.1016/0091-6749(93)90118-Y; RONCO LV, 1995, J IMMUNOL, V154, P3444; SPITERI MA, 1991, CLIN EXP IMMUNOL, V83, P157; STERK PJ, 1989, EUR RESPIR J, V2, P267; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; VANCHERI C, 1991, AM J RESP CELL MOL, V4, P11, DOI 10.1165/ajrcmb/4.1.11; WALKER C, 1994, AM J RESP CRIT CARE, V150, P1038, DOI 10.1164/ajrccm.150.4.7921434; WALKER C, 1991, J ALLERGY CLIN IMMUN, V88, P935, DOI 10.1016/0091-6749(91)90251-I; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; WOGNUM AW, 1994, BLOOD, V84, P764; YING S, 1993, AM J RESP CELL MOL, V9, P356, DOI 10.1165/ajrcmb/9.4.356; YING S, 1991, Clinical and Experimental Allergy, V21, P745, DOI 10.1111/j.1365-2222.1991.tb03205.x	52	36	37	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1997	99	5					666	672		10.1016/S0091-6749(97)70029-0	http://dx.doi.org/10.1016/S0091-6749(97)70029-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WY600	9155834				2022-12-18	WOS:A1997WY60000015
J	Wickens, K; Martin, I; Pearce, N; Fitzharris, P; Kent, R; Holbrook, N; Siebers, R; Smith, S; Trethowen, H; Lewis, S; Town, I; Crane, J				Wickens, K; Martin, I; Pearce, N; Fitzharris, P; Kent, R; Holbrook, N; Siebers, R; Smith, S; Trethowen, H; Lewis, S; Town, I; Crane, J			House dust mite allergen levels in public places in New Zealand	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						dust mite; allergen; public places	SELF-REPORTED PREVALENCE; ASTHMA SYMPTOMS; P-I; EXPOSURE; CHILDREN; CHILDHOOD; ENGLAND	Background: House dust mite allergens are a risk factor for asthma in New Zealand, and levels in domestic dwellings have been found to be high compared with levels in most other countries, Studies in other countries have demonstrated lower levels of Dermatophagoides pteronyssimus allergens in public places compared with levels in domestic dwellings. Objectives: The purpose of this study was to measure reservoir Her p I levels in public places in New Zealand and to examine determinants of these levels. Methods: Reservoir dust was obtained in the two centers (Christchurch and Wellington) from hotels, hospitals, rest homes, churches, primary schools, childcare centers, cinemas, bank head offices, and airplanes; samples were also obtained from ski lodges, Single measurements of temperature and relative humidity were taken with thermohygrometers and an average humidity over 2 weeks was estimated with use of waxed wooden sticks. Information was collected on building construction, type of heating, and frequency of cleaning. Der p 1 levels (micrograms per gram of fine dust) for Boor (n = 202), bed (n = 65), and seat (n = 24) samples in public places were expressed as geometric means (95% confidence intervals). Results: Der p 1 levels in public places were significantly lower than domestic levels in both Wellington and Christchurch. Both Boor and bed levels were higher in hotels than in other public places, After controlling for potential confounders, floor Der p 1 levels were higher with carpeted floors (p < 0.0001) and lower with recent cleaning (p = 0.02) and bed Her p 1 levels were higher with timber wall construction (p = 0.03). Other building, heating, or cleaning characteristics did not show significant associations with allergen levels. Conclusion: Der p 1 levels were much lower in public places than in domestic dwellings with floor levels primarily affected by floor covering.	CHRISTCHURCH SCH MED, DEPT MED, CANTERBURY RESP RES GRP, CHRISTCHURCH, NEW ZEALAND; BLDG RES ASSOC NEW ZEALAND, PORIRUA, NEW ZEALAND	University of Otago	Wickens, K (corresponding author), WELLINGTON SCH MED, WELLINGTON ASTHMA RES GRP, POB 7343, WELLINGTON, NEW ZEALAND.		Siebers, Robert/A-4102-2009	Siebers, Robert/0000-0002-6359-3144; Pearce, Neil/0000-0002-9938-7852				CRANE J, 1994, NEW ZEAL MED J, V107, P417; CUSTOVIC A, 1994, CLIN EXP ALLERGY, V24, P1164, DOI 10.1111/j.1365-2222.1994.tb03323.x; Fitzharris P, 1996, J ALLERGY CLIN IMMUN, V97, P784; FRIEDMAN FM, 1992, ALLERGY PROC, V13, P259, DOI 10.2500/108854192778817095; GREEN WF, 1992, J ALLERGY CLIN IMMUN, V89, P1196, DOI 10.1016/0091-6749(92)90305-L; KORSGAARD J, 1983, ALLERGY, V38, P85, DOI 10.1111/j.1398-9995.1983.tb01591.x; KUEHR J, 1994, CLIN EXP ALLERGY, V24, P229, DOI 10.1111/j.1365-2222.1994.tb00224.x; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; MARKS GB, 1995, CLIN EXP ALLERGY, V25, P114, DOI 10.1111/j.1365-2222.1995.tb01015.x; MARTIN I, 1997, IN PRESS AUST NZ J M; MARTIN I, 1996, THESIS U OTAGO OTAGO, P97; MURRAY AB, 1983, PEDIATRICS, V71, P418; PEARCE N, 1993, EUR RESPIR J, V6, P1455; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141, DOI 10.1164/ajrccm.153.1.8542107; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; SPORIK R, 1992, CLIN EXP ALLERGY, V22, P897, DOI 10.1111/j.1365-2222.1992.tb02062.x; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; VANSTRIEN RT, 1994, CLIN EXP ALLERGY, V24, P843, DOI 10.1111/j.1365-2222.1994.tb01807.x; WICKENS K, 1997, IN PRESS CLIN EXP AL; WICKMAN M, 1991, J ALLERGY CLIN IMMUN, V88, P89, DOI 10.1016/0091-6749(91)90305-8	22	36	38	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1997	99	5					587	593		10.1016/S0091-6749(97)70017-4	http://dx.doi.org/10.1016/S0091-6749(97)70017-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WY600	9155822				2022-12-18	WOS:A1997WY60000003
J	Schroeder, JT; MacGlashan, DW				Schroeder, JT; MacGlashan, DW			New concepts: The basophil	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							MAST-CELLS; SECRETION; IL-4; TRANSCRIPTION; ACTIVATION; EXPRESSION; INDUCTION; CALCIUM; PROTEIN				Schroeder, JT (corresponding author), JOHNS HOPKINS UNIV,CTR ASTHMA & ALLERGY,DEPT MED,DIV CLIN IMMUNOL,5501 HOPKINS BAYVIEW CIRCLE,BALTIMORE,MD 21224, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027906] Funding Source: NIH RePORTER; NIAID NIH HHS [AI07290, AI27906] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CASOLARO V, 1995, P NATL ACAD SCI USA, V92, P11623, DOI 10.1073/pnas.92.25.11623; Gibbs BF, 1996, EUR J IMMUNOL, V26, P2493, DOI 10.1002/eji.1830261033; Kasaian MT, 1996, INT IMMUNOL, V8, P1287, DOI 10.1093/intimm/8.8.1287; Li HM, 1996, J IMMUNOL, V157, P1207; Li HM, 1996, J IMMUNOL, V156, P4833; MACGLASHAN D, 1994, J IMMUNOL, V152, P3006; MACGLASHAN D, 1991, J IMMUNOL, V147, P2259; Ochensberger B, 1996, BLOOD, V88, P3028, DOI 10.1182/blood.V88.8.3028.bloodjournal8883028; OCHENSBERGER B, 1995, BLOOD, V86, P4039, DOI 10.1182/blood.V86.11.4039.bloodjournal86114039; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; Schroeder J. T., 1996, Journal of Allergy and Clinical Immunology, V97, P358, DOI 10.1016/S0091-6749(96)80921-3; Schroeder JT, 1996, J EXP MED, V183, P1265, DOI 10.1084/jem.183.3.1265; SCHROEDER JT, 1994, J ALLERGY CLIN IMMUN, V94, P1189, DOI 10.1016/0091-6749(94)90331-X; SCHROEDER JT, 1995, ALLERGY, V50, P463, DOI 10.1111/j.1398-9995.1995.tb01180.x; SCHROEDER JT, 1994, J IMMUNOL, V153, P1808; SCHROEDER JT, 1995, J ALLERGY CLIN IMMUN, V95, P344; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0	18	36	37	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1997	99	4					429	433		10.1016/S0091-6749(97)70065-4	http://dx.doi.org/10.1016/S0091-6749(97)70065-4			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WU274	9111483	hybrid			2022-12-18	WOS:A1997WU27400001
J	Watanabe, S; Itoh, T; Arai, KI				Watanabe, S; Itoh, T; Arai, KI			Roles of JAK kinases in human GM-CSF receptor signal transduction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						JAK family kinases; GM-CSF receptor signal transduction	COLONY-STIMULATING FACTOR; PROTEIN-TYROSINE KINASE; PHOSPHOTYROSINE PHOSPHATASE; INTERFERON-ALPHA/BETA; INTERLEUKIN-3; ACTIVATION; TRANSCRIPTION; CELLS; PHOSPHORYLATION; PROMOTER	The receptors for human interleukin-3(IL-3) and human granulocyte-macrophage colony-stimulating factor (GM-CSF), hIL-3R, hGM-CSFR, respectively, consists of two subunits, alpha and beta, both of which are members of the cytokine receptor superfamily. Phosphorylation of tyrosine residues in the hGMR beta subunit and several cellular proteins is observed after hGM-CSF stimulation. We analyzed the role of tyrosine residues in the hGMR beta subunit and the nature of tyrosine kinase, JAK2, in hGMR signal transduction using several hGMR beta subunit mutants. In addition to the box1 region, a membrane distal region (a.a. 544-589) of the hGMR beta was required for c-fos activation. Only one tyrosine residue (Tyr577) existed within the region 544 to 589, and substitution of Tyr577 to phenylalanine in GMR beta 589 resulted in loss of c-fos activation. In contrast, the same substitution in a wild type receptor did not effect GM-CSF induced activities such as c-fos messenger RNA (mRNA) induction and proliferation, but the substitution abolished Shc phosphorylation. These results suggest that the activation of Shc is not essential for c-fos activation and several tyrosine residues cooperate for c-fos activation. It is well documented that IL-3 or GM-CSF activate JAK2 in BA/F3 cells. The role of JAK2 in IL-3/GM-CSF functions, however, is largely unknown. We examined the role of JAK2 in GM-CSF induced signaling pathways. Dominant negative JAK2 (Delta JAK2) lacking the C-terminus kinase domain suppressed IL-3/GM-CSF induced c-fos activation and c-myc activation and proliferation, suggesting that JAK2 was involved in both signaling pathways. Protein tyrosine phosphatase SHP-2 (also called PTP 1D) and Shc were phosphorylated by IL-3/GM-CSF in BA/F3 cells; however, these phosphorylation events were inhibited by the expression of Delta JAK. Taken together, these results indicate that JAK2 is a primary kinase regulating all the known activities of GM-CSF. JAK2 mediates GM-CSF induced c-fos activation through receptor phosphorylation and Shc/PTP-1D activation.			Watanabe, S (corresponding author), UNIV TOKYO,INST MED SCI,DEPT MOL & DEV BIOL,MINATO KU,4-6-1 SHIROKANEDAI,TOKYO 108,JAPAN.		Itoh, Tohru/GYQ-8698-2022	Itoh, Tohru/0000-0002-6579-1638				ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; BRIZZI MF, 1994, J BIOL CHEM, V269, P31680; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; Itoh T, 1996, J BIOL CHEM, V271, P7587, DOI 10.1074/jbc.271.13.7587; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LUO H, 1995, EMBO J, V14, P1412, DOI 10.1002/j.1460-2075.1995.tb07127.x; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MIYAJIMA A, 1993, BLOOD, V82, P1960; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; Muto A, 1996, J EXP MED, V183, P1911, DOI 10.1084/jem.183.4.1911; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TORIGOE T, 1992, BLOOD, V80, P617; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WATANABE S, 1995, MOL BIOL CELL, V6, P627, DOI 10.1091/mbc.6.6.627; WATANABE S, 1993, MOL CELL BIOL, V13, P1440, DOI 10.1128/MCB.13.3.1440; WATANABE S, 1993, MOL BIOL CELL, V4, P983, DOI 10.1091/mbc.4.10.983; WATANABE S, 1995, J BIOL CHEM, V270, P9615, DOI 10.1074/jbc.270.16.9615; Watanabe S, 1996, MOLECULAR BIOLOGY OF HEMATOPOIESIS 5, P453; WATANABE S, 1996, IN PRESS BLOOD; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764	28	36	36	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1996	98	6	2	S			S183	S191		10.1016/S0091-6749(96)70065-9	http://dx.doi.org/10.1016/S0091-6749(96)70065-9			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WC447	8977526				2022-12-18	WOS:A1996WC44700003
J	Howland, WC; Dockhorn, R; Gillman, S; Gross, GN; Hille, D; Simpson, B; Furst, JA; Feiss, G; Smith, JA				Howland, WC; Dockhorn, R; Gillman, S; Gross, GN; Hille, D; Simpson, B; Furst, JA; Feiss, G; Smith, JA			A comparison of effects of triamcinolone acetonide aqueous nasal spray, oral prednisone, and placebo on adrenocortical function in male patients with allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						triamcinolone acetonide; adrenocortical function; adrenal gland hypofunction; corticosteroids; allergic rhinitis; hay fever; aqueous nasal spray; prednisone; clinical trial	PERENNIAL RHINITIS; DOUBLE-BLIND; BECLOMETHASONE DIPROPIONATE; ADRENAL-FUNCTION; AEROSOL; CORTICOSTEROIDS; MULTICENTER; FLUNISOLIDE; EFFICACY; CHILDREN	Background: One of the risks associated with the use of oral corticosteroids is suppression of function. Triamcinolone acetonide (TAA) aqueous nasal spray administered once daily (110 mu g and 220 mu g) has been shown to reduce allergic rhinitis symptoms. Objective: This multicenter, placebo-controlled, double-blind study determined the effects of TAA aqueous nasal spray, placebo and oral prednisone on adrenocortical function in patients with allergic rhinitis. Methods: Sixty-four patients received TAA aqueous nasal spray (220 mu g or 440 mu g), oral prednisone (10 mg), or placebo once daily for 6 weeks. Adrenocortical function was assessed after cosyntropin stimulation for 6 hours before treatment and after 6 weeks of treatment. Results: There was no statistically significant effect on adrenocortical function in patients who received either dose of TAA aqueous nasal spray compared with placebo. In contrast, prednisone produced statistically significant (p < 0.001) reductions in adrenocortical function compared with placebo; reductions occurred in both the mean 6-hour plasma cortisol levels and mean change in 6-hour plasma cortisol levels from pretreatment. Results: There was no statistically significant effect on adrenocortical function in patients who received either dose of TAA aqueous nasal spray compared with placebo. In contrast, prednisone produced statistically significant (p < 0.001) reductions in adrenocortical function compared with placebo, reductions occurred in both the mean 6-hour plasma cortisol levels and mean change in 6-hour plasma cortisol levels from pretreatment. Conclusion: This study demonstrated that, unlike oral prednisone, TAA aqueous nasal spray, in therapeutic doses, did not alter alter adrenocortical function and was comparable to treatment with placebo in its absence of measurable effects on adrenocortical function.	HEALTHQUEST RES,LENEXA,KS; HEALTHQUEST RES,ORANGE,CA; HEALTHQUEST RES,DALLAS,TX; RHONE POULENC RORER,PARIS,FRANCE; RHONE POULENC RORER,COLLEGEVILLE,PA	Sanofi-Aventis	Howland, WC (corresponding author), HEALTHQUEST RES THERAPY & RES INST INC,3807 SPICEWOOD SPRINGS RD,SUITE 250,AUSTIN,TX 78759, USA.							CLAMAN HN, 1983, HOSP PRACT, V18, P143; CLAYTON DE, 1981, J ALLERGY CLIN IMMUN, V67, P2, DOI 10.1016/0091-6749(81)90037-3; FEISS G, 1992, J ALLERGY CLIN IMMUN, V89, P1151, DOI 10.1016/0091-6749(92)90299-H; FINDLAY S, 1992, ANN ALLERGY, V68, P228; GROSSMAN J, 1993, PEDIATRICS, V92, P594; HARDING S M, 1988, European Respiratory Journal, V1, p196S; HAYNES R C JR, 1990, P1431; HOROWITZ M, 1979, MED J AUSTRALIA, V2, P660, DOI 10.5694/j.1326-5377.1979.tb127274.x; KOBAYASHI RH, 1995, CLIN THER, V17, P503, DOI 10.1016/0149-2918(95)80115-4; MABRY RL, 1992, OTOLARYNG HEAD NECK, V107, P855, DOI 10.1177/019459989210700608.2; MAYNARD DE, 1966, ANN INTERN MED, V64, P552, DOI 10.7326/0003-4819-64-3-552; MCEVOY GE, 1995, AHFS DRUG INFORMATIO, P2094; MICHELS MI, 1967, ANN ALLERGY, V25, P569; ORGEL HA, 1986, J ALLERGY CLIN IMMUN, V77, P858, DOI 10.1016/0091-6749(86)90384-2; ORGEL HA, 1991, J ALLERGY CLIN IMMUN, V88, P257, DOI 10.1016/0091-6749(91)90336-M; PEDERSEN S, 1988, EUR RESPIR J, V1, P433; SETTIPANE G, 1995, CLIN THER, V17, P252, DOI 10.1016/0149-2918(95)80023-9; SHERMAN B, 1982, J ALLERGY CLIN IMMUN, V69, P208, DOI 10.1016/0091-6749(82)90101-4; SMITH JA, 1995, UNPUB J AM BOARD FAM; SPECKART PF, 1971, ARCH INTERN MED, V128, P761, DOI 10.1001/archinte.128.5.761; SPECTOR S, 1990, ANN ALLERGY, V64, P300; STORMS W, 1991, ANN ALLERGY, V66, P329; STREETEN DHP, 1984, ENDOCR REV, V5, P371, DOI 10.1210/edrv-5-3-371; TINKELMAN D, 1990, ANN ALLERGY, V64, P234; TRUHAN AP, 1989, ANN ALLERGY, V62, P375; TURKELTAUB PC, 1982, ALLERGY, V37, P303, DOI 10.1111/j.1398-9995.1982.tb01916.x; TURKELTAUB PC, 1976, J ALLERGY CLIN IMMUN, V58, P597, DOI 10.1016/0091-6749(76)90206-2; VANAS A, 1991, ANN ALLERGY, V67, P156; WELCH MJ, 1994, CLIN THER, V16, P253; WOOD JB, 1965, LANCET, V1, P243	30	36	36	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1996	98	1					32	38		10.1016/S0091-6749(96)70223-3	http://dx.doi.org/10.1016/S0091-6749(96)70223-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VA692	8765815				2022-12-18	WOS:A1996VA69200004
J	Leung, R; Thien, FCK; Baldo, B; Czarny, D				Leung, R; Thien, FCK; Baldo, B; Czarny, D			Royal jelly-induced asthma and anaphylaxis: Clinical characteristics and immunologic correlations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							NITROCELLULOSE; ALLERGENS		ALFRED HOSP,DEPT RESP MED,ASTHMA & ALLERGY UNIT,PRAHRAN,VIC 3181,AUSTRALIA; ROYAL N SHORE HOSP,KOLLING INST MED RES,ST LEONARDS,NSW 2065,AUSTRALIA	Florey Institute of Neuroscience & Mental Health; Royal North Shore Hospital; University of Sydney; Kolling Institute of Medical Research			Leung, Roland/ABB-5798-2021					PALMA MS, 1992, J APICULT RES, V31, P42, DOI 10.1080/00218839.1992.11101259; THIEN FCK, 1993, MED J AUSTRALIA, V159, P639, DOI 10.5694/j.1326-5377.1993.tb138070.x; TOVEY ER, 1989, ELECTROPHORESIS, V10, P243, DOI 10.1002/elps.1150100405; Townsend GF, 1940, BIOCHEM J, V34, P1155, DOI 10.1042/bj0341155; WALSH BJ, 1984, J IMMUNOL METHODS, V73, P139, DOI 10.1016/0022-1759(84)90039-5	5	36	38	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1995	96	6	1				1004	1007		10.1016/S0091-6749(95)70242-3	http://dx.doi.org/10.1016/S0091-6749(95)70242-3			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TN124	8543734				2022-12-18	WOS:A1995TN12400022
J	ACKERMAN, V; CARPI, S; BELLINI, A; VASSALLI, G; MARINI, M; MATTOLI, S				ACKERMAN, V; CARPI, S; BELLINI, A; VASSALLI, G; MARINI, M; MATTOLI, S			CONSTITUTIVE EXPRESSION OF ENDOTHELIN IN BRONCHIAL EPITHELIAL-CELLS OF PATIENTS WITH SYMPTOMATIC AND ASYMPTOMATIC ASTHMA AND MODULATION BY HISTAMINE AND INTERLEUKIN-1	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; AIRWAY EPITHELIUM; AIR-FLOW OBSTRUCTION; ENDOTHELIN	BRONCHOALVEOLAR LAVAGE FLUID; ALLERGIC ASTHMATICS; ACTIVATION; CORTICOSTEROIDS; OBSTRUCTION; LYMPHOCYTES; RESPONSES; RELEASE	Background: An upregulation of endothelin-1 expression occurs in bronchial epithelial cells of asthmatic patients. This peptide may mediate bronchoconstriction in asthma, but the mechanisms that modulate endothelin-1 synthesis and release are unknown. Objective: This study was done to compare rite pattern of endothelin-1 expression in patients with symptomatic and asymptomatic asthma and evaluate the ability of inflammatory factors to upregulate endothelin-1 synthesis and release in the epithelial cells of subjects who are free of symptoms. Methods: Two groups of 10 asthmatic patients were selected. One group had symptomatic asthma with airflow obstruction and moderately to severely increased airway responsiveness. The second group was free of symptoms: they did not show airflow obstruction, and airway responsiveness was borderline or slightly increased. Bronchial biopsy specimens were obtained by means of bronchoscopy and used for immunohistochemical evaluation, epithelial cell isolation, and stimulation experiments with interleukin-1 and histamine. Results: Endothelin-1 immunoreactivity was detected in vivo in the bronchial epithelial cells of all the patients with symptoms and in only two subjects without current symptoms. Incubation of bronchial epithelial cells from patients with asymptomatic asthma with interleukin-1 or histamine, for 8 to 24 hours, resulted in increased expression of endothelin-1 messenger RNA and release of appreciable amounts of the peptide of the culture medium. Those effects were dose- and time-dependent. Histamine and interleukin-1 were effective at concentrations similar, to those detected in the bronchoalveolar lavage of patients with symptomatic asthma. Conclusions: Endothelin-1 expression is upregulated in bronchial epithelial cells of asthmatic patients with symptoms and evidence of functional derangement as compared with patients without symptoms and airflow obstruction. Exposure of cells from patients with asymptomatic asthma to factors that are released during acute exacerbation of the disease induces endothelin synthesis and release.	INST EXPTL MED,DIAGNOST CTR RESP & ALLERG DIS,I-20144 MILAN,ITALY; UNIV MILAN,DEPT PATHOL & EXPTL BIOL,MILAN,ITALY	University of Milan			Mattoli, Sabrina/H-8211-2014	Mattoli, Sabrina/0000-0002-6866-604X				ACKERMAN V, 1994, CHEST, V105, P687, DOI 10.1378/chest.105.3.687; ADVENIER C, 1990, BRIT J PHARMACOL, V100, P168, DOI 10.1111/j.1476-5381.1990.tb12071.x; BELLINI A, 1993, J ALLERGY CLIN IMMUN, V92, P412, DOI 10.1016/0091-6749(93)90120-5; BELLINI A, 1993, CHEST, V103, P997, DOI 10.1378/chest.103.4.997; CARPI S, 1993, CHEST, V104, P1346, DOI 10.1378/chest.104.5.1346; CASALE TB, 1987, J CLIN INVEST, V79, P1197, DOI 10.1172/JCI112937; Conover WJ, 1980, PRACTICAL NONPARAMET; CORTIJO J, 1989, AGENTS ACTIONS, V28, P45, DOI 10.1007/BF02022979; DJUKANOVICH R, 1990, AM REV RESPIR DIS, V142, p43P4; HAY DWP, 1993, TRENDS PHARMACOL SCI, V14, P29, DOI 10.1016/0165-6147(93)90111-V; JARJOUR NN, 1991, AM REV RESPIR DIS, V144, P83, DOI 10.1164/ajrccm/144.1.83; MARINI M, 1991, AM J RESP CELL MOL, V4, P519, DOI 10.1165/ajrcmb/4.6.519; MARINI M, 1992, CHEST, V102, P661, DOI 10.1378/chest.102.3.661; MARINI M, 1992, J ALLERGY CLIN IMMUN, V90, P76; MARINI M, 1991, AM J RESPIR CELL MOL, V5, P424; MATTOLI S, 1985, J ALLERGY CLIN IMMUN, V76, P214, DOI 10.1016/0091-6749(85)90704-3; MATTOLI S, 1991, J ALLERGY CLIN IMMUN, V87, P794, DOI 10.1016/0091-6749(91)90125-8; MATTOLI S, 1991, J ALLERGY CLIN IMMUN, V88, P376, DOI 10.1016/0091-6749(91)90100-3; MATTOLI S, 1990, AM J RESP CELL MOL, V3, P145, DOI 10.1165/ajrcmb/3.2.145; NOAH TL, 1991, AM J RESP CELL MOL, V5, P484, DOI 10.1165/ajrcmb/5.5.484; NOMURA S, 1989, LANCET, V334, P520; Snedecor G.W., 1980, STAT METHODS, V7; SOLOPERTO M, 1991, AM J PHYSIOL, V260, pL530, DOI 10.1152/ajplung.1991.260.6.L530; SPRINGALL DR, 1991, LANCET, V337, P697, DOI 10.1016/0140-6736(91)90279-X; VITTORI E, 1992, AM REV RESPIR DIS, V146, P1320, DOI 10.1164/ajrccm/146.5_Pt_1.1320; WOOLCOCK A, 1975, AIRWAY RESPONSIVENES, P80	26	36	37	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1995	96	5	1				618	627		10.1016/S0091-6749(95)70260-1	http://dx.doi.org/10.1016/S0091-6749(95)70260-1			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TG528	7499678	Bronze			2022-12-18	WOS:A1995TG52800007
J	HADJILIADIS, D; KHAN, K; TARLO, SM				HADJILIADIS, D; KHAN, K; TARLO, SM			SKIN-TEST RESPONSES TO LATEX IN AN ALLERGY AND ASTHMA CLINIC	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									TORONTO HOSP,CTR ASTHMA,DIV WESTERN,TORONTO,ON M5T 2S8,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto				Tarlo, Susan/0000-0002-4746-5310				FUCHS T, 1994, J ALLERGY CLIN IMMUN, V93, P951, DOI 10.1016/0091-6749(94)90393-X; OWNBY DR, 1994, J ALLERGY CLIN IMMUN, V93, P282; RANDOLPH C, 1994, J ALLERGY CLIN IMMUN, V93, P298; REINHEIMER GA, 1994, J ALLERGY CLIN IMMUN, V93, P281; TURJANMAA K, 1994, J ALLERGY CLIN IMMUN, V93, P299	5	36	37	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1995	96	3					431	432		10.1016/S0091-6749(95)70067-6	http://dx.doi.org/10.1016/S0091-6749(95)70067-6			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RU660	7560650				2022-12-18	WOS:A1995RU66000020
J	AKASAWA, A; HSIEH, LS; LIN, Y				AKASAWA, A; HSIEH, LS; LIN, Y			SERUM REACTIVITIES TO LATEX PROTEINS (HEVEA-BRASILIENSIS)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						LATER ALLERGENS; IGE-REACTIVE PROTEINS; LATEX PARTICLES; LATEX C-SERUM	RUBBER ELONGATION-FACTOR; ANTIGENS; IDENTIFICATION; CHILDREN; CONTACT	Background: In recent years there has been an increasing incidence of allergy to latex among health care workers and children with spina bifida. The allergic response in these individuals can be severe and occasionally fatal Several allergens have been identified with the use of sera from different patient groups. In our effort to identify reagents for in vitro testing and clinical use, we investigated the reactivities of latex proteins to sera collected from a wide range of patients with latex allergy. Methods: Twenty-six serum samples were obtained from adult patients with latex allergy, both hospital workers and non-hospital workers. Serum pools were made either from sera of children with spina bifida or sera of adult patients with Eater allergy. proteins from C-serum and lattex particles of latex sap (nonammoniated) were separated by different gel electrophoresis techniques and evaluated for specific IgE binding by immunoblotting. Results: More than 50% of the sera tested reacted to an 18 kd protein, a 25.6 kd acidic protein with an isoelectric point of 3.5, or to both proteins; whereas only 23% of the individual serum samples tested reacted to the rubber elongation factor which has been reported to be a major Eater allergen. The immunoreactive patterns of children's and adults' serum pools were similar but not identical. Conclusions: With the use of gel electrophoresis and immunoblotting techniques, different immunoreactive proteins were identified in C-serum and particles of latex. Rubber elongation factor, which reacted to only 23% of sera tested, did not appear to cross-react immunologically with other latex allergens.	US FDA,CTR BIOL EVALUAT & RES,DIV ALLERGEN PROD & PARASITOL,IMMUNOBIOCHEM LAB,BETHESDA,MD	US Food & Drug Administration (FDA)								AKASAWA A, 1993, INT ARCH ALLERGY IMM, V101, P177, DOI 10.1159/000236516; ALENIUS H, 1993, INT ARCH ALLERGY IMM, V102, P61, DOI 10.1159/000236551; ALENIUS H, 1994, J ALLERGY CLIN IMMUN, V93, P300; BEEZHOLD D, 1994, J ALLERGY CLIN IMMUN, V93, P182; CZUPPON AB, 1993, J ALLERGY CLIN IMMUN, V92, P690, DOI 10.1016/0091-6749(93)90012-5; DENNIS MS, 1989, J BIOL CHEM, V264, P18618; DENNIS MS, 1989, J BIOL CHEM, V264, P18608; KURUP VP, 1993, J ALLERGY CLIN IMMUN, V91, P1128, DOI 10.1016/0091-6749(93)90314-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN MN, 1991, PLANT PHYSIOL, V95, P469, DOI 10.1104/pp.95.2.469; MORALES C, 1989, CLIN EXP ALLERGY, V19, P425, DOI 10.1111/j.1365-2222.1989.tb02409.x; NUTTER AF, 1979, BRIT J DERMATOL, V101, P597, DOI 10.1111/j.1365-2133.1979.tb15107.x; RICHMAN PG, 1988, J BIOL STAND, V16, P225, DOI 10.1016/0092-1157(88)90010-8; SLATER JE, 1992, J ALLERGY CLIN IMMUN, V89, P673, DOI 10.1016/0091-6749(92)90373-A; SLATER JE, 1994, J ALLERGY CLIN IMMUN, V93, P644, DOI 10.1016/S0091-6749(94)70076-1; TURJANMAA K, 1990, LANCET, V336, P1588, DOI 10.1016/0140-6736(90)93372-V	16	36	37	0	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1995	95	6					1196	1205		10.1016/S0091-6749(95)70076-5	http://dx.doi.org/10.1016/S0091-6749(95)70076-5			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RD309	7797788				2022-12-18	WOS:A1995RD30900007
J	HEFLE, SL; HELM, RM; BURKS, AW; BUSH, RK				HEFLE, SL; HELM, RM; BURKS, AW; BUSH, RK			COMPARISON OF COMMERCIAL PEANUT SKIN-TEST EXTRACTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						PEANUT ALLERGY; SKIN TESTING; ALLERGENIC EXTRACTS	ATOPIC-DERMATITIS; ALLERGEN; PROTEINS; IDENTIFICATION	Background: Skin prick testing is a major tool for diagnosing food allergy. Food allergen extracts have not been standardized; this may lead to great variability in the predictive accuracy of skin prick tests. Methods: Six commercial peanut skin test extracts were compared in vitro with RAST inhibition assays, ELISA, and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) followed by immunoblotting with sera from peanut-allergic adults and in vivo by skin prick testing. Results: ELISA showed that the content of peanut allergens Ara h I and Ara h II in the extracts ranged from 0.0015 to 0.0236 and 0.0001 to 0.0164 mg Eq/ml, respectively. RAST inhibition studies showed that the extracts produced curves of similar slope, suggesting conservation of allergenic epitopes. SDS-PAGE revealed differences in protein profiles because roasted extracts generally possessed the same number and proportion of major protein bands but raw extracts varied more in both respects. SDS-PAGE and immunoblotting showed that two of the extracts contained major IgE-binding protein bands that did not appear in the others. One roasted extract gave little protein banding and consequently little IgE binding. Conclusions: Skin testing results showed no differences in the ability of the extracts to provoke a positive skin test response in peanut-sensitive subjects.	WILLIAM S MIDDLETON MEM VET ADM MED CTR, MADISON, WI 53705 USA; UNIV WISCONSIN, DEPT MED, MADISON, WI USA; ARKANSAS CHILDRENS HOSP, DEPT PEDIAT IMMUNOL & ALLERGY, LITTLE ROCK, AR 72202 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital; University of Wisconsin System; University of Wisconsin Madison; Arkansas Children's Hospital								AAS K, 1972, ACTA ALLERGOL, V27, P439; BARNETT D, 1986, BIOCHIM BIOPHYS ACTA, V882, P97, DOI 10.1016/0304-4165(86)90060-7; BARNETT D, 1983, J ALLERGY CLIN IMMUN, V72, P61, DOI 10.1016/0091-6749(83)90053-2; BURKS AW, 1992, J ALLERGY CLIN IMMUN, V90, P962, DOI 10.1016/0091-6749(92)90469-I; BURKS AW, 1991, J ALLERGY CLIN IMMUN, V88, P172, DOI 10.1016/0091-6749(91)90325-I; BUSH R, 1983, J ALLERGY CLIN IMMUN, V71, P95, DOI 10.1016/0091-6749(83)90151-3; ESCH RE, 1989, ADV BIOSCI, V74, P3; GUERIN B, 1979, CLIN ALLERGY, V9, P283, DOI 10.1111/j.1365-2222.1979.tb01555.x; HANCOCK K, 1983, ANAL BIOCHEM, V133, P157, DOI 10.1016/0003-2697(83)90237-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMANSKE RF, 1987, CLIN REV ALLERG, V5, P23; MAHABOOBBASHA SM, 1976, J AGR FOOD CHEM, V24, P359, DOI 10.1021/jf60204a058; TAYLOR S L, 1982, Journal of Allergy and Clinical Immunology, V69, P128; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAYER HR, 1988, BIOCHEMISTRY-US, V27, P5718, DOI 10.1021/bi00415a049; TURKELTAUB PC, 1982, J ALLERGY CLIN IMMUN, V70, P343, DOI 10.1016/0091-6749(82)90023-9; YUNGINGER JW, 1987, ABEITEN P EHRICH I G, V80, P251; Yunginger JW, 1992, MANUAL CLIN LAB IMMU, V4th, P678	18	36	36	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1995	95	4					837	842		10.1016/S0091-6749(95)70127-3	http://dx.doi.org/10.1016/S0091-6749(95)70127-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QT468	7722164				2022-12-18	WOS:A1995QT46800009
J	SIMONS, FER; MURRAY, HE; SIMONS, KJ				SIMONS, FER; MURRAY, HE; SIMONS, KJ			QUANTITATION OF H-1-RECEPTOR ANTAGONISTS IN SKIN AND SERUM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HISTAMINE H-1-RECEPTOR ANTAGONISTS; CETIRIZINE; HYDROXYZINE; BIOPSY	EOSINOPHIL CHEMOTAXIS; ATOPIC-DERMATITIS; CETIRIZINE; HYDROXYZINE; URTICARIA; PHARMACOKINETICS; ANTIHISTAMINE; PLACEBO; INHIBITION; CHILDREN	Background: Cetirizine and hydroxyzine produce prompt, long-lasting peripheral H-1-blockade in skin. We hypothesized that after oral administration of these H-1-receptor antagonists, skin concentrations would be higher than serum concentrations and would correlate with peripheral H-1 blockade. Methods: In a randomized, double-blind, parallel-group study in 13 healthy subjects, skin biopsies, venipunctures, and epicutaneous tests with histamine were performed before ingestion of 10 mg cetirizine or 50 mg hydroxyzine and 1, 3, 6, 9, and 24 hours after administration. Subjects then took 10 mg cetirizine or 50 mg hydroxyzine at 21:00 hours for 6 consecutive days. all tests were repeated at 168 hours (steady state), 12 hours after the last dose. Results: Skin cetirizine concentrations were lower than serum cetirizine concentrations from 1 to 9 hours but were higher at 24 hours and equivalent at 168 hours (steady state). Skin hydroxyzine concentrations were higher than serum hydroxyzine concentrations at all test times. After hydroxyzine dosing, cetirizine, the active metabolite of hydroxyzine arising in vivo, was found in skin and serum. Single doses of cetirizine or hydroxyzine produced highly significant suppression of wheals and flares from 3 to 24 hours inclusive, and this suppression was maintained at steady state. Conclusion: Cetirizine and hydroxyzine enter the skin readily, and their sustained high concentrations in skin after single or multiple dosing may contribute to their well-known efficacy in symptomatic treatment of urticaria and other skin disorders in which histamine plays a role.	UNIV MANITOBA,FAC MED,WINNIPEG,MB R3T 2N2,CANADA; UNIV MANITOBA,FAC PHARM,WINNIPEG,MB R3T 2N2,CANADA; UNIV MANITOBA,FAC MED,WINNIPEG,MB R3T 2N2,CANADA; UNIV MANITOBA,FAC SCI,WINNIPEG,MB R3T 2N2,CANADA	University of Manitoba; University of Manitoba; University of Manitoba; University of Manitoba			Murray, Heather/GQY-8016-2022					ADVENIER C, 1989, DRUGS, V38, P634, DOI 10.2165/00003495-198938040-00009; CHEN XY, 1990, PHARMACEUT RES, V7, pS282; COULIE PJ, 1991, DRUG INVEST, V3, P324, DOI 10.1007/BF03259746; DEVOS C, 1989, INT ARCH ALLER A IMM, V88, P212, DOI 10.1159/000234789; GENGO FM, 1987, CLIN PHARMACOL THER, V42, P265, DOI 10.1038/clpt.1987.145; GOETZ DW, 1991, ANN ALLERGY, V67, P448; GREAVES MW, 1993, DERMATOLOGY GENERAL, P413; HANNUKSELA M, 1993, ANN ALLERGY, V70, P127; HOLFORD NHG, 1981, CLIN PHARMACOKINET, V6, P429, DOI 10.2165/00003088-198106060-00002; JUHLIN L, 1988, BRIT J DERMATOL, V119, P67, DOI 10.1111/j.1365-2133.1988.tb07103.x; JUHLIN L, 1987, J ALLERGY CLIN IMMUN, V80, P599, DOI 10.1016/0091-6749(87)90014-5; KALIVAS J, 1990, J ALLERGY CLIN IMMUN, V86, P1014, DOI 10.1016/S0091-6749(05)80246-5; KONTOUFILI K, 1991, J AM ACAD DERMATOL, V24, P1090, DOI 10.1016/0190-9622(91)70163-V; LEPREVOST C, 1988, INT ARCH ALLER A IMM, V87, P9, DOI 10.1159/000234641; LEVANDER S, 1991, EUR J CLIN PHARMACOL, V41, P435, DOI 10.1007/BF00626365; NETER J, 1993, APPL LINEAR STAT MOD, P517; SCHWINGHAMMER TL, 1988, J CLIN PHARMACOL, V28, P388, DOI 10.1002/j.1552-4604.1988.tb05745.x; SIMONS F E R, 1991, Journal of Allergy and Clinical Immunology, V87, P225, DOI 10.1016/0091-6749(91)91625-4; SIMONS FER, 1984, J ALLERGY CLIN IMMUN, V73, P69, DOI 10.1016/0091-6749(84)90486-X; SIMONS FER, 1990, J ALLERGY CLIN IMMUN, V86, P540; SIMONS FER, 1984, J PEDIATR-US, V104, P123; SIMONS FER, 1993, ALLERGY PRINCIPLES P, P856; SIMONS KJ, 1994, J ALLERGY CLIN IMMUN, V93, P235; SPENCER CM, 1993, DRUGS, V46, P1055, DOI 10.2165/00003495-199346060-00008; SUSSMAN G, 1991, ANN ALLERGY, V67, P433; WATSON WTA, 1989, J ALLERGY CLIN IMMUN, V84, P457, DOI 10.1016/0091-6749(89)90358-8; WOOD SG, 1987, ANN ALLERGY, V59, P31	27	36	37	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1995	95	3					759	764		10.1016/S0091-6749(95)70183-4	http://dx.doi.org/10.1016/S0091-6749(95)70183-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QM017	7897161	Bronze			2022-12-18	WOS:A1995QM01700018
J	CARDOT, E; TILLIELEBLOND, I; JEANNIN, P; FACON, A; BREUIL, K; PATTE, F; TONNEL, AB				CARDOT, E; TILLIELEBLOND, I; JEANNIN, P; FACON, A; BREUIL, K; PATTE, F; TONNEL, AB			ANAPHYLACTIC REACTION TO LOCAL-ADMINISTRATION OF RIFAMYCIN SV	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ANAPHYLAXIS; RIFAMYCIN; CUTANEOUS TESTS; HISTAMINE RELEASE	CONTACT-DERMATITIS; ALLERGY; INHIBITION; URTICARIA	Background and objective: Systemic reactions during anesthesia are commonly attributed to muscle relaxants, hypnotics, macromolecular solutions, latex, or parenteral antibiotics. After exclusion of these different components as causes, we were interested in the potential implication of rifamycin in the systemic reaction, which occurred during anesthesia, and in the immunologic mechanism by which it can trigger this reaction. Methods: We report four cases of systemic reactions occurring after local administration of rifamycin. Three patients needed orthopedic surgery, and the fourth needed a urethrotomy. Severe systemic reactions occurred in all four patients when the surgeon washed the incision ai ea with a rifamycin solution. All patients correctly responded to appropriate treatment and recovered. Skin tests were performed 2 months after the incident with the drugs used during anesthesia, latex, and rifamycin. To assess the relationship with a possible IgE-mediated mechanism two in vitro tests were concomitantly performed to evaluate the cell reactivity to rifamycin: (1) determination of histamine release from peripheral basophils and (2) platelet cytotoxicity test, which explored the presence on platelets of specific IgE antibodies bound to the low-affinity receptor for IgE. Results: Skin tests were performed with different drugs used during surgery, and results were only positive for rifamycin in the four cases, accompanied in two cases by a systemic reaction. Histamine release from basophils was positive in three of four patients. The platelet cytotoxicity test results were positive in all four cases. Conclusion: It appeals that rifamycin, used locally during surgery is apt to trigger severe systemic anaphylactic reactions, which ale linked to an IgE-related process. This situation is worth pointing out, especially in patients who undergo repeated orthopedic operations during which, at least in Europe, rifamycin is commonly used for the prevention of local sepsis.	CTR HOSP REG & UNIV LILLE,HOP A CALMETTE,SERV PNEUMOL & IMMUNOALLERGOL,F-59037 LILLE,FRANCE; INST PASTEUR,INSERM,U416,LILLE,FRANCE; CTR HOSP REG & UNIV LILLE,DEPT ANESTHESIE REANIMAT CHIRURG 2,LILLE,FRANCE; CTR HOSP REG & UNIV POITIERS,SERV PNEUMOL,POITIERS,FRANCE	Universite de Lille - ISITE; CHU Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; CHU Lille; CHU Poitiers; Universite de Poitiers			JEANNIN, Pascale/K-8656-2015	JEANNIN, Pascale/0000-0002-3666-3856				BALATO N, 1988, CONTACT DERMATITIS, V19, P310, DOI 10.1111/j.1600-0536.1988.tb02937.x; BERNSTEIN RL, 1987, ANESTHESIOLOGY, V67, P567, DOI 10.1097/00000542-198710000-00021; Bessot J C, 1977, Poumon Coeur, V33, P107; GINGOLD BS, 1982, SURGERY, V91, P394; GROB JJ, 1987, CONTACT DERMATITIS, V16, P284, DOI 10.1111/j.1600-0536.1987.tb01460.x; GUERRA L, 1991, CONTACT DERMATITIS, V25, P328, DOI 10.1111/j.1600-0536.1991.tb01886.x; ISELIN F, 1990, Annales de Chirurgie de la Main et du Membre Superieur, V9, P65, DOI 10.1016/S0753-9053(05)80441-7; JOSEPH M, 1986, EUR J IMMUNOL, V16, P306, DOI 10.1002/eji.1830160318; JOSEPH M, 1988, CLIN REV ALLERG, V6, P1; LAXENAIRE MC, 1993, ANN FR ANESTH, V12, P91, DOI 10.1016/S0750-7658(05)81015-9; LEVY JH, 1988, J CLIN ANESTH, V1, P3946; MANCUSO G, 1992, CONTACT DERMATITIS, V27, P124, DOI 10.1111/j.1600-0536.1992.tb05231.x; MELCHIOR E, 1979, REV PRATICIEN, V29, P3535; MILPIED B, 1986, CONTACT DERMATITIS, V14, P252, DOI 10.1111/j.1600-0536.1986.tb01240.x; PATTERSON R, 1988, J ALLERGY CLIN IMMUN, V81, P380, DOI 10.1016/0091-6749(88)90905-0; PIAZZA I, 1989, ALLERGOLOGIE S, V12, P96; RIBOLDI A, 1985, CONTACT DERMATITIS, V12, P180, DOI 10.1111/j.1600-0536.1985.tb01097.x; SLATER JE, 1989, NEW ENGL J MED, V320, P1126, DOI 10.1056/NEJM198904273201707; TSICOPOULOS A, 1990, EUR J IMMUNOL, V20, P1201, DOI 10.1002/eji.1830200602; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; VERVLOET D, 1985, CLIN ALLERGY, V15, P501, DOI 10.1111/j.1365-2222.1985.tb02302.x	21	36	36	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1995	95	1	1				1	7		10.1016/S0091-6749(95)70145-1	http://dx.doi.org/10.1016/S0091-6749(95)70145-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QC312	7529781	Bronze			2022-12-18	WOS:A1995QC31200001
J	AMIRAV, I; GOREN, A; PAWLOWSKI, NA				AMIRAV, I; GOREN, A; PAWLOWSKI, NA			WHAT DO PEDIATRICIANS IN-TRAINING KNOW ABOUT THE CORRECT USE OF INHALERS AND SPACER DEVICES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; INHALED THERAPY; SPACER DEVICES; TRAINING METERED-DOSE INHALER	METERED-DOSE INHALERS; CANISTER NEBULIZERS; CHILDHOOD ASTHMA; INHALATION; AEROSOL; CHILDREN; MASK	Most patients with asthma in the United Stares are cared for by nonspecialist physicians. Because inhaled medications are the mainstay of asthma therapy and their successful use requires both practical skills and theoretic knowledge, we wondered how much nonspecialist physicians know about the use of metered-dose inhalers and spacer devices. Fifty pediatricians in training were interviewed individually. Practical knowledge was assessed by asking each to demonstrate correct use of a placebo inhaler and a spacer device (Inspirease [Key Pharmaceuticals, Inc., Miami, Fla.] and Aerochamber with mask [Monaghan Medical Corp., Plattsburgh, N.Y.]). Of the seven recommended steps for use of metered-dose inhalers, the residents demonstrated an average of 3.8 steps correctly. The most common errors included not shaking the metered-dose inhaler before use (18% of residents correct) and insufficient breath holding (28% correct). In testing spacer use, the most common errors included not shaking the canister (16% correct) and incorrect number of activations and inhalations (12% correct). Many residents were not familiar with correct assembly of the spacer (48% correct). Theoretic knowledge of metered-dose inhaler and spacer use was evaluated by a written questionnaire. The most common deficiencies in theoretic knowledge related to the purpose of slow inspiration and breath holding. Most of the participants had been treating children with asthma and had prescribed metered-dose inhalers (45 of 50, 90%) and spacer devices (76%) in the past. The results suggest that despite substantial involvement in asthma management, pediatricians in training have significant inadequacies in knowledge of the practical and theoretic aspects of metered-dose inhaler and spacer use. Asthma specialists may need to fake a leading role in the development and implementation of educational programs about inhaled therapy.	UNIV PENN, CHILDRENS HOSP PHILADELPHIA,SCH MED,DIV PULM MED, ALLERGY SECT, PHILADELPHIA, PA 19104 USA; UNIV PENN, CHILDRENS HOSP PHILADELPHIA, SCH MED, DIV ALLERGY & IMMUNOL, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia			Amirav, Israel/I-9286-2019	Amirav, Israel/0000-0002-6917-5285				ALTMAN L, 1993, NY TIMES        0420, P3; APPEL D, 1982, J FAM PRACTICE, V14, P1135; BENATAR SR, 1986, NEW ENGL J MED, V314, P423, DOI 10.1056/NEJM198602133140706; BUIST AS, 1989, J ALLERGY CLIN IMMUN, V84, P275, DOI 10.1016/0091-6749(89)90408-9; BURTON AJ, 1984, BRIT MED J, V288, P1650, DOI 10.1136/bmj.288.6431.1650-a; CONNER WT, 1989, PEDIATR PULM, V6, P263, DOI 10.1002/ppul.1950060410; CROFT RD, 1989, ARCH DIS CHILD, V64, P742, DOI 10.1136/adc.64.5.742; DEBLAQUIERE P, 1989, AM REV RESPIR DIS, V140, P910, DOI 10.1164/ajrccm/140.4.910; DOLOVICH MB, 1981, CHEST S, V80, pS8344; EPSTEIN SW, 1979, CAN MED ASSOC J, V120, P813; EVANS R, 1987, CHEST, V91, pS65, DOI 10.1378/chest.91.6_Supplement.65S; GUIDRY GG, 1992, CHEST, V101, P31, DOI 10.1378/chest.101.1.31; HEMSTREET MP, 1991, AM J ASTHMA ALLERGY, V4, P145; INTERIANO B, 1993, ARCH INTERN MED, V153, P81, DOI 10.1001/archinte.153.1.81; KELLING JS, 1983, CHEST, V83, P612, DOI 10.1378/chest.83.4.612; LEE H, 1987, J PEDIATR-US, V110, P249, DOI 10.1016/S0022-3476(87)80163-4; LEE HS, 1983, CLIN PEDIATR, V22, P440; LEVISON H, 1985, J PEDIATR-US, V107, P662, DOI 10.1016/S0022-3476(85)80389-9; MICKLE TR, 1990, DICP ANN PHARMAC, V24, P927, DOI 10.1177/106002809002401003; MUNT PW, 1979, CAN MED ASSOC J, V120, P781; NEWHOUSE MT, 1986, NEW ENGL J MED, V315, P870, DOI 10.1056/NEJM198610023151406; NEWMAN SP, 1985, CHEST, V88, pS152, DOI 10.1378/chest.88.2.152S; NEWMAN SP, 1981, EUR J RESPIR DIS, V62, P3; OCALLAGHAN C, 1989, BRIT MED J, V298, P160, DOI 10.1136/bmj.298.6667.160; RUBIN DH, 1989, J DEV BEHAV PEDIATR, V10, P307; SAUNDERS KB, 1965, BRIT MED J, V1, P1037, DOI 10.1136/bmj.1.5441.1037; SHIM C, 1980, AM J MED, V69, P891, DOI 10.1016/S0002-9343(80)80016-7; SLY PD, 1991, J PAEDIATR CHILD H, V27, P7, DOI 10.1111/j.1440-1754.1991.tb00337.x; SMITH NA, 1984, AUST PAEDIATR J, V20, P47; SPEIGHT ANP, 1983, BRIT MED J, V286, P1253, DOI 10.1136/bmj.286.6373.1253; TAL A, 1987, ISRAEL J MED SCI, V23, P168; TOGWOOD J, 1981, AM REV RESPIR DIS S, V123, P113; 1991, J ALLERGY CLIN IMMUN, V88, P425; 1990, MMWR-MORBID MORTAL W, V39, P493; 1992, NIH923091 US DEP HLT	35	36	39	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1994	94	4					669	675		10.1016/0091-6749(94)90173-2	http://dx.doi.org/10.1016/0091-6749(94)90173-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PM273	7930299				2022-12-18	WOS:A1994PM27300004
J	WICKERN, GM; NISH, WA; BITNER, AS; FREEMAN, TM				WICKERN, GM; NISH, WA; BITNER, AS; FREEMAN, TM			ALLERGY TO BETA-LACTAMS - A SURVEY OF CURRENT PRACTICES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ADVERSE REACTIONS; ALLERGIST; CEPHALOSPORIN; PENICILLIN; SKIN TESTING SURVEY	PENICILLIN ALLERGY; SKIN	Many issues related to the diagnosis and management of beta-lactam drug allergy still await definitive recommendations. To determine how practicing allergists deal with some of these dilemmas, a questionnaire was mailed to 3500 physician members and fellows of the American Academy of Allergy and Immunology. It was also sent to each of the allergy training program directors in the United States to determine what is currently taught to fellows in training. Benzylpenicilloyl-polylysine (Pre-Pen) and fresh penicillin G are used for skin testing by more than 86% of both respondent groups, whereas minor determinant mixtures are used by only 40%. Epicutaneous followed by intradermal injection was the skin test technique used by 86% of these allergists. More than 90% said they would skin test in cases of reaction history of urticaria, whereas only 1.5% would test in cases of family history of penicillin allergy. Practicing allergists and program directors differed slightly when queried about cephalosporin cross-reactivity. Program directors were more cautious in their use of cephalosporins with patients allergic to penicillin. Program directors were also more likely to repeat skirt testing before future penicillin courses than were practicing allergists. Clearly, some individual approaches to the diagnosis and management of beta-lactam allergy are practiced. Development of practice guidelines by our professional organizations may be useful.	WILFORD HALL USAF MED CTR,DEPT ALLERGY IMMUNOL,SAN ANTONIO,TX	United States Department of Defense; United States Air Force								BEALL GN, 1987, ANN INTERN MED, V107, P205; BOCHNER BS, 1991, NEW ENGL J MED, V324, P1785, DOI 10.1056/NEJM199106203242506; BRANDT MA, 1993, J ALLERGY CLIN IMMUN, V91, P263; LIN RY, 1992, ARCH INTERN MED, V152, P930, DOI 10.1001/archinte.152.5.930; MOSS RB, 1991, REV INFECT DIS, V13, pS598; PARKER PJ, 1991, J ALLERGY CLIN IMMUN, V88, P213, DOI 10.1016/0091-6749(91)90331-H; SAXON A, 1984, J INFECT DIS, V149, P16, DOI 10.1093/infdis/149.1.16; SHEPHERD GM, 1991, IMMUNOL ALLERGY CLIN, V11, P611; SOGN DD, 1992, ARCH INTERN MED, V152, P1025, DOI 10.1001/archinte.152.5.1025; SULLIVAN TJ, 1981, J ALLERGY CLIN IMMUN, V68, P171, DOI 10.1016/0091-6749(81)90180-9	10	36	37	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1994	94	4					725	731		10.1016/0091-6749(94)90180-5	http://dx.doi.org/10.1016/0091-6749(94)90180-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PM273	7930306				2022-12-18	WOS:A1994PM27300011
J	STEWART, GE; DIAZ, JD; LOCKEY, RF; SELEZNICK, MJ; TRUDEAU, WL; LEDFORD, DK				STEWART, GE; DIAZ, JD; LOCKEY, RF; SELEZNICK, MJ; TRUDEAU, WL; LEDFORD, DK			COMPARISON OF ORAL PULSE METHOTREXATE WITH PLACEBO IN THE TREATMENT OF SEVERE GLUCOCORTICOSTEROID-DEPENDENT ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; METHOTREXATE; GLUCOCORTICOSTEROIDS	PNEUMOCYSTIS-CARINII PNEUMONIA; LOW-DOSE METHOTREXATE; RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; THERAPY	Background: This study compared the efficacy of weekly oral administration of methotrexate and placebo in treatment of 24 subjects with chronic glucocorticosteroid-dependent asthma. Methods: The 33-week randomized, double-blind, placebo-controlled crossover trial compared once weekly 15 mg doses of methotrexate with placebo. At the time of entry the subjects' mean dosage of prednisone was 23.8 mg/day (range, 12.5 to 85 mg) and glucocorticosteroid therapy had been used continuously for a mean duration of 78 months (range, 5 to 360 months). Results: Of the 21 subjects who completed the study, 13 tolerated lower daily prednisone doses during methotrexate treatment compared with placebo. When treated with methotrexate, subjects required 14.2% less prednisone than when treated with placebo (p = 0.0447), their subjective symptom scores improved 21.4% (p < 0.05), and mean forced expiratory volume in 1 second values tended to improve. Mean serum theophylline levels did not change significantly between the methotrexate and placebo arms of the study. Adverse effects were minimal, with nausea and headache occurring twice as often during methotrexate therapy compared with placebo. Conclusion: Short-term, low-dose, pulse therapy with orally administered methotrexate results in a decrease in the daily glucocorticosteroid requirement in a majority of subjects with severe asthma and is accompanied by improvement in subjective symptom scores without unacceptable side effects or deterioration of pulmonary function.	UNIV S FLORIDA, DIV CLIN IMMUNOL & ALLERGY, TAMPA, FL USA; JAMES A HALEY VET HOSP, TAMPA, FL 33612 USA	State University System of Florida; University of South Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital								ALTZSMITH M, 1987, AM J MED, V83, P179, DOI 10.1016/0002-9343(87)90517-1; BERGSTRESSER PR, 1976, ARCH DERMATOL, V112, P977, DOI 10.1001/archderm.112.7.977; BOND WS, 1977, AM J HOSP PHARM, V34, P479, DOI 10.1093/ajhp/34.5.0479; CALDERON E, 1991, J ALLERGY CLIN IMMUN, V88, P274, DOI 10.1016/0091-6749(91)90339-P; COFFEY MJ, 1994, CHEST, V105, P117, DOI 10.1378/chest.105.1.117; DALY H, 1986, LANCET, V1, P557; DYER PD, 1991, J ALLERGY CLIN IMMUN, V88, P208, DOI 10.1016/0091-6749(91)90330-Q; ERZURUM SC, 1991, ANN INTERN MED, V114, P353, DOI 10.7326/0003-4819-114-5-353; GEDDES DM, 1991, CLIN EXP ALLERGY, V21, P541, DOI 10.1111/j.1365-2222.1991.tb00844.x; GLYNNBARNHART AM, 1991, J ALLERGY CLIN IMMUN, V88, P180, DOI 10.1016/0091-6749(91)90326-J; GUSS S, 1992, PEDIATRICS, V89, P635; KEEGAN JM, 1988, J RHEUMATOL, V15, P1585; KEHRL JH, 1983, ANN ALLERGY, V50, P2; KUITERT LM, 1991, THORAX, V46, P936, DOI 10.1136/thx.46.12.936; LEDFORD DK, 1993, ALLERGY PROC, V14, P23, DOI 10.2500/108854193778816806; LEFF RL, 1990, ANN INTERN MED, V112, P716, DOI 10.7326/0003-4819-112-9-716_1; LIEGLER DG, 1969, CLIN PHARMACOL THER, V10, P849; MIYAMOTO T, 1972, ANN ALLERGY, V30, P587; MULLARKEY MF, 1990, ANN INTERN MED, V112, P577, DOI 10.7326/0003-4819-112-8-577; MULLARKEY MF, 1988, NEW ENGL J MED, V318, P603, DOI 10.1056/NEJM198803103181004; MULLARKEY MF, 1986, ANN ALLERGY, V56, P347; PERRUQUET JL, 1983, ARTHRITIS RHEUM, V26, P1291, DOI 10.1002/art.1780261021; REMINE SG, 1980, ANN SURG, V192, P581, DOI 10.1097/00000658-198010000-00016; SHINER RJ, 1990, LANCET, V336, P137, DOI 10.1016/0140-6736(90)91659-X; SORKNESS C A, 1991, Journal of Allergy and Clinical Immunology, V87, P298, DOI 10.1016/0091-6749(91)91915-G; STEMPEL DA, 1991, ANN ALLERGY, V67, P346; TAYLOR JR, 1977, ARCH DERMATOL, V113, P588, DOI 10.1001/archderm.113.5.588; THYSS A, 1986, LANCET, V1, P256; VALLERAND H, 1992, LANCET, V339, P1551, DOI 10.1016/0140-6736(92)91325-3; WALLIS PJW, 1989, ANN RHEUM DIS, V48, P247, DOI 10.1136/ard.48.3.247; WOLLNER A, 1991, THORAX, V46, P205, DOI 10.1136/thx.46.3.205	31	36	36	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1994	94	3	1				482	489		10.1016/0091-6749(94)90204-6	http://dx.doi.org/10.1016/0091-6749(94)90204-6			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PG907	8083453				2022-12-18	WOS:A1994PG90700007
J	DAY, JH; BUCKERIDGE, DL; WELSH, AC				DAY, JH; BUCKERIDGE, DL; WELSH, AC			RISK ASSESSMENT IN DETERMINING SYSTEMIC REACTIVITY TO HONEYBEE STINGS IN STING-THREATENED INDIVIDUALS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ANAPHYLAXIS; BEES; BITES AND STINGS; RISK; SKIN TESTS; IGE; IGG	BEE-VENOM IMMUNOTHERAPY; SKIN-TESTS; DIAGNOSTIC METHODS; INSECT ALLERGY; ANTIBODIES; IGE; HYPERSENSITIVITY; SENSITIVITY; PREVALENCE; KEEPERS	We evaluated the diagnostic parameters (sting rate, venom-specific RAST IgE, venom-specific RAST IgG, venom-specific IgG(4), venom-specific skin test) of 224 individuals at risk of honeybee sting, assigned them a level of risk on the basis of a hypothetical risk model, and then sting challenged each subject with a live honeybee. Of the 70 subjects at the lowest risk level, only three (4.3%) experienced equivocal or mild systemic reactions, whereas eight (72.7%) of the 11 at the highest risk level experienced systemic reactions, of which five (45.5% were severe. Increase in risk level was associated with an ina eased proportion of systemic reactions (p < 0.001). Of the individual diagnostic parameters s, venom-specific RAST IgE was the best single predictor of reactivity (likelihood ratio = 0.759, p < 0.01). Venom-specific skin testing at a concentration of 0.1 mu g/ml was a better discriminator than a concentration of 1.0 mu g/ml but did not predict one severe systemic reaction. Three methods of prediction of risk and severity of reaction were examined; the one that assessed risk in the most clinically, useful manner was similar to the hypothetical risk model. This model compared well with classical methods of risk assessment and may be used to assess high-risk individuals exposed to honeybees when management could include prophylactic immunotherapy.	QUEENS UNIV,KINGSTON,ON,CANADA	Queens University - Canada	DAY, JH (corresponding author), KINGSTON GEN HOSP,DIV ALLERGY & IMMUNOL,76 STUART ST,KINGSTON K7L 2V7,ON,CANADA.							AALBERSE RC, 1983, J IMMUNOL, V130, P722; BARNARD JH, 1973, J ALLERGY CLIN IMMUN, V52, P259, DOI 10.1016/0091-6749(73)90044-4; BARSELA S, 1983, J ALLERGY CLIN IMMUN, V72, P690, DOI 10.1016/0091-6749(83)90631-0; BLAAUW PJ, 1985, J ALLERGY CLIN IMMUN, V75, P556, DOI 10.1016/0091-6749(85)90029-6; BOUSQUET J, 1982, CLIN ALLERGY, V12, P331, DOI 10.1111/j.1365-2222.1982.tb02537.x; BOUSQUET J, 1984, J ALLERGY CLIN IMMUN, V73, P322; BOYD JC, 1975, ANN INTERN MED, V82, P489, DOI 10.7326/0003-4819-82-4-489; DAVID MF, 1987, CLIN INVEST MED, V10, pB48; DEVEY ME, 1989, J ALLERGY CLIN IMMUN, V84, P326, DOI 10.1016/0091-6749(89)90416-8; GEORGITIS JW, 1985, J ALLERGY CLIN IMMUN, V76, P803, DOI 10.1016/0091-6749(85)90752-3; GOLDEN DBK, 1987, CLIN REV ALLERG, V5, P119; GOLDEN DBK, 1982, J ALLERGY CLIN IMMUN, V69, P489, DOI 10.1016/0091-6749(82)90172-5; GOLDEN DBK, 1989, JAMA-J AM MED ASSOC, V262, P240, DOI 10.1001/jama.262.2.240; GOLDEN DBK, 1985, J ALLERGY CLIN IMMUN, V77, P727; HEINIG JH, 1988, CLIN ALLERGY, V18, P71, DOI 10.1111/j.1365-2222.1988.tb02845.x; HOFFMAN DR, 1979, ANN ALLERGY, V43, P211; HUNT KJ, 1976, ANN INTERN MED, V85, P56, DOI 10.7326/0003-4819-85-1-56; KAMPELMACHER MJ, 1987, CLIN ALLERGY, V17, P317, DOI 10.1111/j.1365-2222.1987.tb02021.x; LOCKEY RF, 1990, J ALLERGY CLIN IMMUN, V86, P775, DOI 10.1016/S0091-6749(05)80182-4; MIYACHI S, 1979, INT ARCH ALLER A IMM, V60, P148, DOI 10.1159/000232336; MOSBECH H, 1984, ALLERGY, V39, P543, DOI 10.1111/j.1398-9995.1984.tb00876.x; MULLER U, 1991, J ALLERGY CLIN IMMUN, V87, P702, DOI 10.1016/0091-6749(91)90392-2; NORDVALL SL, 1984, CLIN ALLERGY, V14, P341, DOI 10.1111/j.1365-2222.1984.tb02214.x; PARKER JL, 1982, J ALLERGY CLIN IMMUN, V69, P200, DOI 10.1016/0091-6749(82)90100-2; PATRIZZI R, 1979, ALLERGY, V34, P249, DOI 10.1111/j.1398-9995.1979.tb01705.x; SACKETT DL, 1991, CLIN EPIDEMIOLOGY BA, P120; SANTRACH PJ, 1980, ANN ALLERGY, V45, P130; SIMEL DL, 1987, MED DECIS MAKING, V7, P107, DOI 10.1177/0272989X8700700208; SULLIVAN TJ, 1981, J ALLERGY CLIN IMMUN, V68, P171, DOI 10.1016/0091-6749(81)90180-9; URBANEK R, 1983, CLIN ALLERGY, V13, P229, DOI 10.1111/j.1365-2222.1983.tb02592.x; URBANEK R, 1985, J PEDIATR-US, V107, P367, DOI 10.1016/S0022-3476(85)80508-4; VANDERZWAN JK, 1993, J ALLERGY CLIN IMMUN, V91, P282; ZORA JA, 1988, J ALLERGY CLIN IMMUN, V81, P77, DOI 10.1016/0091-6749(88)90223-0; 1991, HLTH REPORTS S11, V3, P166; 1990, PRODUCTION VALUE HON, P2	35	36	37	0	7	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1994	93	4					691	705		10.1016/0091-6749(94)90249-6	http://dx.doi.org/10.1016/0091-6749(94)90249-6			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NH497	8163779				2022-12-18	WOS:A1994NH49700002
J	DORION, BJ; BURKS, AW; HARBECK, R; WILLIAMS, LW; TRUMBLE, A; HELM, RM; LEUNG, DYM				DORION, BJ; BURKS, AW; HARBECK, R; WILLIAMS, LW; TRUMBLE, A; HELM, RM; LEUNG, DYM			THE PRODUCTION OF INTERFERON-GAMMA IN RESPONSE TO A MAJOR PEANUT ALLERGY, ARA H-II, CORRELATES WITH SERUM LEVELS OF IGE ANTI-ARA H-II	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						PEANUT ALLERGY; IGE; FOOD ALLERGY; INTEL INTERLEUKIN-4; INTERFERON ON GAMMA	T-CELL CLONES; ATOPIC-DERMATITIS; ANAPHYLACTIC REACTIONS; FOOD HYPERSENSITIVITY; IFN-GAMMA; INVITRO; IL-4	The current study was undertaken to examine the potential role of T cells in the pathogenesis of peanut allergy. Peripheral blood mononuclear cells (PBMCs) from patients with peanut allergy, patients with asthma, and nonatopic normal control subjects were assessed for proliferation after stimulation with a 17 kd major peanut allergen (Ara h II), ovalbumin, casein, soy, and Candida albicans. We found that Ara h II and C. albicans induced significantly higher levels of proliferation than ovalbumin, casein, and soy. Because interferon-gamma (IFN-gamma) and interleukin-4 (IL-4) play critical roles in IgE regulation, we assessed the production of these cytokines after stimulation with C. albicans and Ara h II. C. albicans stimulated similar levels of IFN-gamma in all three study groups. In contrast, after stimulation with Ara h II, culture supernatants from PBMCs of subjects with peanut allergy contained significantly lower levels of IFN-gamma than did the PBMCs of the two control groups (p = 0.02). More important, there was a significant (p = 0.05) inverse correlation between the serum IgE anti-Ara h II levels and IFN-gamma production by PBMCs from the respective peanut-allergic patients. IL-4 protein was not detected in culture supernatants of PBMCs stimulated with Ara h II. However, amplification of cytokine gene transcripts by polymerase chain reaction did demonstrate IL-4 expression in Ara h II-stimulated PBMCs from both patients with peanut allergy and control subjects. These data suggest that the level of IFN-gamma production in response to Ara h II may be an important factor in determining the development of peanut-specific IgE responses.	NATL JEWISH CTR IMMUNOL & RESP MED, DEPT PEDIAT, DENVER, CO 80206 USA; UNIV COLORADO, HLTH SCI CTR, DEPT PEDIAT, DENVER, CO 80262 USA; UNIV ARKANSAS MED SCI HOSP, LITTLE ROCK, AR USA; ARKANSAS CHILDRENS HOSP, DEPT PEDIAT, LITTLE ROCK, AR 72202 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Arkansas System; University of Arkansas Medical Sciences; Arkansas Children's Hospital					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI026629] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041256] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-26629] Funding Source: Medline; NIAMS NIH HHS [AR-41256] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; BURKS AW, 1986, NEW ENGL J MED, V314, P560, DOI 10.1056/NEJM198602273140907; BURKS AW, 1992, J ALLERGY CLIN IMMUN, V90, P962, DOI 10.1016/0091-6749(92)90469-I; BURKS AW, 1988, J PEDIATR-US, V113, P447, DOI 10.1016/S0022-3476(88)80626-7; COFFMAN RL, 1986, J IMMUNOL, V136, P949; DELPRETE G, 1988, J IMMUNOL, V140, P4193; FINKELMAN FD, 1988, J IMMUNOL, V141, P2335; FINKELMAN FD, 1988, J IMMUNOL, V140, P1022; GAUCHAT JF, 1990, J EXP MED, V172, P463, DOI 10.1084/jem.172.2.463; GEHA RS, 1992, J ALLERGY CLIN IMMUN, V90, P143, DOI 10.1016/0091-6749(92)90064-9; HAYGLASS KT, 1991, J EXP MED, V173, P279, DOI 10.1084/jem.173.2.279; KONDO N, 1990, J ALLERGY CLIN IMMUN, V86, P253, DOI 10.1016/S0091-6749(05)80073-9; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; PENE J, 1989, J CELL BIOCHEM, V39, P253, DOI 10.1002/jcb.240390305; SAMPSON HA, 1992, ACTA DERM-VENEREOL, P34; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; YUNINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450	20	36	38	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1994	93	1	1				93	99		10.1016/0091-6749(94)90237-2	http://dx.doi.org/10.1016/0091-6749(94)90237-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MT781	8308186				2022-12-18	WOS:A1994MT78100011
J	OWNBY, DR; OWNBY, HE; MCCULLOUGH, JA; SHAFER, AW				OWNBY, DR; OWNBY, HE; MCCULLOUGH, JA; SHAFER, AW			THE PREVALENCE OF ANTI-LATEX IGE ANTIBODIES IN 1000 VOLUNTEER BLOOD-DONORS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	36	36	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1994	93	1	2				282	282						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MV317					2022-12-18	WOS:A1994MV31700716
J	CLAVEAU, J; LAVOIE, A; BRUNET, C; BEDARD, PM; HEBERT, J				CLAVEAU, J; LAVOIE, A; BRUNET, C; BEDARD, PM; HEBERT, J			CHRONIC IDIOPATHIC URTICARIA - POSSIBLE CONTRIBUTION OF HISTAMINE-RELEASING FACTOR TO PATHOGENESIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CHRONIC IDIOPATHIC URTICARIA; HISTAMINE-RELEASING FACTOR; HISTAMINE CONTENT	MONONUCLEAR-CELLS; ACTIVATING FACTOR; HUMAN BASOPHILS; SKIN; MONOCYTE; IMMUNOTHERAPY; IGE	Background: Histamine-releasing factor was recently shown to be clinically relevant in allergic rhinitis and asthma. HRF could also be involved in the pathogenicity of chronic idiopathic urticaria (CU). The purpose of this study was to investigate the role of HRF in the pathophysiology of CU. Methods: Blisters were induced on lesional and nonlesional skin of 12 patients with CU and on normal skin of five control subjects. HRF activity and histamine content were measured in all samples recovered from each skin site. Results: Significantly more HRF was found in blister fluids from lesional skin of patients with CU as compared with nonlesional skin and skin of control subjects. In addition, histamine content in blister fluids from affected skin of patients with CU was significantly higher in comparison with both nonlesional skin of patients with CU and skin of control subjects. HRF activity was also higher in blister fluids from nonlesional skin of patients with CU than that of control subjects, in spite of equivalent histamine content. Conclusion: These data suggest that the inflammatory reaction found in CU disease is associated with the cutaneous release of HPF.	CHU LAVAL,CTR RECH INFLAMMAT & IMMUNOL RHUMATOL,9800,2705 BOUL LAURIER,QUEBEC CITY G1V 4G2,QUEBEC,CANADA	Laval University								ALAM R, 1992, J CLIN INVEST, V89, P723, DOI 10.1172/JCI115648; ALAM R, 1985, ALLERGY, V40, P124, DOI 10.1111/j.1398-9995.1985.tb02671.x; ALAM R, 1989, J IMMUNOL, V142, P3431; BEDARD PM, 1986, J ALLERGY CLIN IMMUN, V78, P1121, DOI 10.1016/0091-6749(86)90260-5; BRUNET C, 1988, J ALLERGY CLIN IMMUN, V82, P398, DOI 10.1016/0091-6749(88)90011-5; BRUNET C, 1992, J ALLERGY CLIN IMMUN, V89, P87, DOI 10.1016/S0091-6749(05)80044-2; ELIAS J, 1986, J ALLERGY CLIN IMMUN, V78, P914, DOI 10.1016/0091-6749(86)90240-X; GRANT JA, 1991, J ALLERGY CLIN IMMUN, V88, P683, DOI 10.1016/0091-6749(91)90170-S; GREAVES MW, 1974, CLIN ALLERGY, V4, P265, DOI 10.1111/j.1365-2222.1974.tb01384.x; JACQUES P, 1992, J ALLERGY CLIN IMMUN, V89, P1139, DOI 10.1016/0091-6749(92)90297-F; KAPLAN AP, 1978, J ALLERGY CLIN IMMUN, V61, P350, DOI 10.1016/0091-6749(78)90113-6; KERN F, 1976, J CLIN INVEST, V57, P1369, DOI 10.1172/JCI108405; KUNA P, 1992, J EXP MED, V175, P489, DOI 10.1084/jem.175.2.489; KUNA P, 1992, J IMMUNOL, V149, P636; KUNA P, 1989, J ALLERGY CLIN IMMUN, V83, P816, DOI 10.1016/0091-6749(89)90020-1; MEKORI YA, 1983, J ALLERGY CLIN IMMUN, V72, P681, DOI 10.1016/0091-6749(83)90629-2; SAMPSON HA, 1989, NEW ENGL J MED, V321, P228, DOI 10.1056/NEJM198907273210405; SHODI N, 1990, J ALLERGY CLIN IMMUN, V85, P204; THUESON DO, 1979, J IMMUNOL, V123, P626; WARNER JA, 1986, J IMMUNOL, V136, P2583	20	36	37	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1993	92	1	1				132	137		10.1016/0091-6749(93)90047-J	http://dx.doi.org/10.1016/0091-6749(93)90047-J			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LQ353	7687607	Bronze			2022-12-18	WOS:A1993LQ35300019
J	CALDERON, E; LOCKEY, RF; BUKANTZ, SC; COFFEY, RG; LEDFORD, DK				CALDERON, E; LOCKEY, RF; BUKANTZ, SC; COFFEY, RG; LEDFORD, DK			IS THERE A ROLE FOR CYCLOSPORINE IN ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							PLATELET-ACTIVATING FACTOR; INTERLEUKIN-2 IL-2 RESPONSIVENESS; CORTICOSTEROID-DEPENDENT ASTHMA; ALLERGEN-SPECIFIC INDUCTION; LOW-DOSE CYCLOSPORINE; CIS-TRANS ISOMERASE; LUNG MAST-CELLS; T-CELL; DOUBLE-BLIND; FISH OIL				CALDERON, E (corresponding author), UNIV S FLORIDA,JAMES A HALEY VET AFFAIRS HOSP,COLL MED,DIV ALLERGY & IMMUNOL,TAMPA,FL 33612, USA.							BARNES PJ, 1990, IMMUNOL ALLERGY CLIN, V10, P241; BARTHELSON R, 1990, J ALLERGY CLIN IMMUN, V86, P193, DOI 10.1016/S0091-6749(05)80066-1; BENDTZEN K, 1984, SCAND J IMMUNOL, V20, P43, DOI 10.1111/j.1365-3083.1984.tb00976.x; BENEZRA D, 1988, TRANSPLANT P, V20, P644; BENSON A, 1989, TRANSPLANTATION, V47, P696, DOI 10.1097/00007890-198904000-00024; BEVERIDGE T, 1981, CURR THER RES CLIN E, V30, P5; BONAVIDA B, 1989, INT ARCH ALLER A IMM, V88, P157, DOI 10.1159/000234772; BUNJES D, 1981, EUR J IMMUNOL, V11, P657, DOI 10.1002/eji.1830110812; BURKE MD, 1989, CYCLOSPORIN MODE ACT, P267; CHIARA MD, 1989, BIOCHEM J, V264, P21, DOI 10.1042/bj2640021; CIRILLO R, 1990, J IMMUNOL, V144, P3891; COLOMBANI PM, 1985, SCIENCE, V228, P337, DOI 10.1126/science.3885394; CORRIGAN CJ, 1990, IMMUNOL ALLERGY CLIN, V10, P319; CORRIGAN CJ, 1990, AM REV RESPIR DIS, V141, P970, DOI 10.1164/ajrccm/141.4_Pt_1.; de Prost Y, 1989, Acta Derm Venereol Suppl (Stockh), V144, P136; DROSOS AA, 1986, ANN RHEUM DIS, V45, P732, DOI 10.1136/ard.45.9.732; DURHAM SR, 1984, J ALLERGY CLIN IMMUN, V74, P49, DOI 10.1016/0091-6749(84)90086-1; EISEN D, 1990, NEW ENGL J MED, V323, P290, DOI 10.1056/NEJM199008023230502; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; ESA AH, 1988, TRANSPLANT P, V20, P80; ESCHENBACHER WL, 1987, CHEST, V92, P105, DOI 10.1378/chest.92.1.105; FEUTREN G, 1987, J PEDIATR-US, V111, P1063, DOI 10.1016/S0022-3476(87)80057-4; FINNERTY N A, 1990, Journal of Allergy and Clinical Immunology, V85, P266; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FUJISAWA T, 1990, AM REV RESPIR DIS, V141, P689, DOI 10.1164/ajrccm/141.3.689; GALLI SJ, 1990, LAB INVEST, V62, P5; GARIM EH, 1981, AM J DIS CHILD, V142, P985; GOULON M, 1989, PRESSE MED, V18, P341; GRANELLIPIPERNO A, 1984, J EXP MED, V160, P1792, DOI 10.1084/jem.160.6.1792; GRANELLIPIPERNO A, 1988, TRANSPLANTATION, V46, pS53; GUPTA AK, 1989, J AM ACAD DERMATOL, V21, P1245, DOI 10.1016/S0190-9622(89)70339-X; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1988, TRANSPLANTATION, V46, pS29; Harrison W B, 1988, Agents Actions Suppl, V24, P236; HECKMATT J, 1989, LANCET, V1, P1063, DOI 10.1016/S0140-6736(89)92456-2; HEROLD KC, 1986, J IMMUNOL, V136, P1315; HEULE F, 1988, TRANSPLANT P, V20, P32; HIESTAND PC, 1986, PROG ALLERGY, V38, P239; HIRAI K, 1990, J EXP MED, V172, P1525, DOI 10.1084/jem.172.5.1525; HULTSCH T, 1990, J IMMUNOL, V144, P2659; IOYOSHI E, 1989, JAPAN J DERMATOL, V99, P877; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; KASLOW J E, 1990, Journal of Allergy and Clinical Immunology, V85, P219; KAUFMANN Y, 1984, J IMMUNOL, V133, P3107; KELLEY VE, 1989, TRANSPLANT P, V21, P848; KIM JH, 1989, REV INFECT DIS, V11, P677; KLAUSTERMEYER WB, 1987, J ALLERGY CLIN IMMUN, V79, P720, DOI 10.1016/0091-6749(87)90202-8; LEGRUE SJ, 1983, J IMMUNOL, V131, P712; LICHTIGER S, 1990, LANCET, V336, P16, DOI 10.1016/0140-6736(90)91521-B; MARONE G, 1988, RES CLIN LAB, V18, P53, DOI 10.1007/BF02918819; MENCIAHUERTA JM, 1990, IMMUNOL ALLERGY CLIN, V10, P337; MENCIAHUERTA JM, 1989, INT ARCH ALLER A IMM, V88, P154, DOI 10.1159/000234771; MIYAJIMA A, 1988, FASEB J, V2, P2462, DOI 10.1096/fasebj.2.9.2836253; MOZZANICA N, 1988, TRANSPLANT P, V20, P78; MULLARKEY MF, 1988, NEW ENGL J MED, V318, P603, DOI 10.1056/NEJM198803103181004; NOMA T, 1989, J ALLERGY CLIN IMMUN, V84, P255, DOI 10.1016/0091-6749(89)90333-3; PALAY DA, 1986, J IMMUNOL, V136, P4348; PAUL WE, 1987, FASEB J, V1, P456, DOI 10.1096/fasebj.1.6.3315808; PELEMAN R, 1990, Journal of Allergy and Clinical Immunology, V85, P232; PEREIRA GMB, 1990, J IMMUNOL, V144, P2109; PIGATTO PD, 1988, TRANSPLANT P, V20, P91; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; REEM GH, 1983, SCIENCE, V221, P63, DOI 10.1126/science.6407112; RENZ H, 1990, J IMMUNOL, V145, P3641; ROMAGNANI S, 1989, INT ARCH ALLER A IMM, V88, P111, DOI 10.1159/000234758; SAWCHUK RJ, 1981, CLIN CHEM, V27, P1368; SHAW LM, 1989, CLIN CHEM, V35, P5; SHAW LM, 1989, CLIN CHEM, V35, P1299; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; SHINER RJ, 1990, LANCET, V336, P137, DOI 10.1016/0140-6736(90)91659-X; SIBILLE Y, 1990, AM REV RESPIR DIS, V141, P471, DOI 10.1164/ajrccm/141.2.471; SIDERAS P, 1988, P NATL ACAD SCI USA, V85, P218, DOI 10.1073/pnas.85.1.218; STOOF TJ, 1989, J INTERN MED, V226, P437, DOI 10.1111/j.1365-2796.1989.tb01421.x; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; THOMSON AW, 1986, SCAND J IMMUNOL, V24, P163, DOI 10.1111/j.1365-3083.1986.tb02082.x; TOUVAY C, 1989, BIOCHEM BIOPH RES CO, V163, P118, DOI 10.1016/0006-291X(89)92107-4; TOWLER HMA, 1989, EYE, V3, P282, DOI 10.1038/eye.1989.39; TRIGGIANI M, 1989, INT ARCH ALLER A IMM, V88, P253, DOI 10.1159/000234801; TUGWELL P, 1990, LANCET, V335, P1051, DOI 10.1016/0140-6736(90)92630-Z; VANDERHEIDE JJH, 1990, TRANSPLANTATION, V49, P523, DOI 10.1097/00007890-199003000-00010; VANOOSTERHOUT AJM, 1988, EUR J PHARMACOL, V149, P191, DOI 10.1016/0014-2999(88)90063-5; VIRANT FS, 1990, IMMUNOL ALLERGY CLIN, V10, P283; WASIK MA, 1989, CLIN IMMUNOL IMMUNOP, V52, P331, DOI 10.1016/0090-1229(89)90184-0; WIESNER RH, 1990, NEW ENGL J MED, V322, P1419, DOI 10.1056/NEJM199005173222003; WOOD AJ, 1983, TRANSPLANT P, V15, P2409; WOODS A, 1987, J IMMUNOL, V138, P4293; YOSHIZAWA I, 1989, J ALLERGY CLIN IMMUN, V84, P246, DOI 10.1016/0091-6749(89)90332-1; 1990, CHEST, V97, P1299	88	36	36	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1992	89	2					629	636		10.1016/0091-6749(92)90331-U	http://dx.doi.org/10.1016/0091-6749(92)90331-U			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HD753	1740590				2022-12-18	WOS:A1992HD75300016
J	PARIS, S; DEBEAUPUIS, JP; PREVOST, MC; CASOTTO, M; LATGE, JP				PARIS, S; DEBEAUPUIS, JP; PREVOST, MC; CASOTTO, M; LATGE, JP			THE 31-KD MAJOR ALLERGEN, ALT A I1563, OF ALTERNARIA-ALTERNATA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALTERNARIA; ALLERGENS; GLYCOPROTEINS; PURIFICATION	CROSSED RADIOIMMUNOELECTROPHORESIS; GLYCOPROTEIN ALLERGEN; POLLEN; PROTEINS; IMMUNOASSAYS; PURIFICATION	A component of Alternaria extract, previously identified as the major allergen, Alt a I1563, was purified to homogeneity from Alternaria mycelium by means of acetone precipitation and ion-exchange chromatography. The homogeneity of Alt a I1563 was assessed by one single band after sodium dodecyl sulfate-polyacrylamide gel electrophoresis, by one single radiolabeled band after transfer to nitrocellulose, and by one single peak after size-exclusion chromatography by high-performance liquid chromatography. Alt a I1563 was isolated as a heat-stable acidic glycoprotein (carbohydrate content, 20%; pI, 4.0 to 4.5; 31 kd). The role of the carbohydrate moiety in the allergenicity is suggested. This major allergen is located in the cytoplasm of mycelium and spore.	INST PASTEUR,CENT MICROSCOPIE ELECTRON STN,F-75724 PARIS 15,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	PARIS, S (corresponding author), INST PASTEUR,UNITE MYCOL,25 RUE DR ROUX,F-75724 PARIS 15,FRANCE.		Latge, Jean Paul/C-9846-2014; latge, jean paul/F-3581-2011; Debeaupuis, Jean-Paul/A-2035-2012					Al-Doory Y, 1984, MOULD ALLERGY; AUKRUST L, 1982, Allergy (Copenhagen), V37, P36; AUKRUST L, 1985, Allergy (Copenhagen), V40, P43, DOI 10.1111/j.1398-9995.1985.tb02641.x; BARNES C, 1990, Journal of Allergy and Clinical Immunology, V85, P169; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSH RK, 1982, CLIN ALLERGY, V12, P29, DOI 10.1111/j.1365-2222.1982.tb03123.x; BUSH RK, 1983, J ALLERGY CLIN IMMUN, V71, P239, DOI 10.1016/0091-6749(83)90105-7; BUSH RK, 1987, CLIN REV ALLERG, V5, P3; CARLEMALM E, 1982, J MICROSC-OXFORD, V126, P123, DOI 10.1111/j.1365-2818.1982.tb00362.x; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FOLGERT J, 1990, Journal of Allergy and Clinical Immunology, V85, P150; GROTE M, 1988, ALLERGY, V43, P603, DOI 10.1111/j.1398-9995.1988.tb00934.x; HAAVIK S, 1985, J CHROMATOGR, V321, P199, DOI 10.1016/S0021-9673(01)90436-4; JAGGI KS, 1987, MOL CELL BIOCHEM, V78, P177, DOI 10.1007/BF00229692; JONES OT, 1987, BIOL MEMBRANES PRACT, P139; KROUTIL LA, 1987, J ALLERGY CLIN IMMUN, V80, P170, DOI 10.1016/0091-6749(87)90126-6; LABROUSSE H, 1982, J IMMUNOL METHODS, V48, P133, DOI 10.1016/0022-1759(82)90188-0; LABROUSSE H, 1987, J IMMUNOL METHODS, V103, P9, DOI 10.1016/0022-1759(87)90235-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSH DG, 1988, INT ARCH ALLER A IMM, V85, P194; NILSEN BM, 1986, INT ARCH ALLER A IMM, V80, P113, DOI 10.1159/000234037; NYHOLM L, 1983, J ALLERGY CLIN IMMUN, V71, P461, DOI 10.1016/0091-6749(83)90462-1; PARIS S, 1990, J ALLERGY CLIN IMMUN, V85, P941, DOI 10.1016/0091-6749(90)90081-E; PARIS S, 1990, INT ARCH ALLER A IMM, V92, P1, DOI 10.1159/000235216; PELTRE G, 1984, 3RD INT P EHRLICH SE, P121; Smestad Paulsen B, 1985, Int Arch Allergy Appl Immunol, V78, P206; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIJAY HM, 1981, INT ARCH ALLER A IMM, V65, P410, DOI 10.1159/000232782; YUNGINGER JW, 1980, J ALLERGY CLIN IMMUN, V66, P138, DOI 10.1016/0091-6749(80)90061-5	29	36	36	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1991	88	6					902	908		10.1016/0091-6749(91)90247-L	http://dx.doi.org/10.1016/0091-6749(91)90247-L			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GW262	1744361				2022-12-18	WOS:A1991GW26200011
J	GARRIGA, MM; BERKEBILE, C; METCALFE, DD				GARRIGA, MM; BERKEBILE, C; METCALFE, DD			A COMBINED SINGLE-BLIND, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DETERMINE THE REPRODUCIBILITY OF HYPERSENSITIVITY REACTIONS TO ASPARTAME	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							IMMEDIATE ADVERSE REACTIONS; ORAL FOOD CHALLENGE; ADULT PATIENTS; HEADACHE; SAFETY	Aspartame is an O-methyl ester composed of phenylalanine and aspartic acid. After its final approval as a sweetner in 1981, a number of reports of adverse reactions to aspartame appeared in the literature. To explore the pathogenesis of such reactions, we initiated a study in July 1986 to identify subjects with hypersensitivity reactions to aspartame with blinded challenge procedures. The study was closed after 32 months. During that time, we advertised in local newspapers and worked closely with the local community of allergists and dermatologists in an attempt to recruit subjects with hypersensitivity reactions to aspartame. A total of 61 self-referrals and physician referrals were screened, with 20 referrals evaluated in clinic. After this evaluation, 12 patients underwent single- and double-blind challenge with up to 2000 mg of aspartame. No subject with a clearly reproducible adverse reaction to aspartame was identified. In summary, we found that it is difficult to recruit study subjects with a history of hypersensitivity reactions to aspartame and that subjects who believed themselves allergic to aspartame did not have reproducible reactions.	NIAID,CLIN INVEST LAB,MAST CELL PHYSIOL SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								ATKINS FM, 1985, J ALLERGY CLIN IMMUN, V75, P348, DOI 10.1016/0091-6749(85)90071-5; ATKINS FM, 1985, J ALLERGY CLIN IMMUN, V75, P356, DOI 10.1016/0091-6749(85)90072-7; DEWS PB, 1987, FOOD CHEM TOXICOL, V25, P549, DOI 10.1016/0278-6915(87)90208-0; DYER J, 1982, J ALLERGY CLIN IMMUN, V70, P82, DOI 10.1016/0091-6749(82)90233-0; GARRIGA MM, 1988, ANN ALLERGY, V61, P63; KOEHLER SM, 1988, HEADACHE, V28, P10, DOI 10.1111/j.1365-2524.1988.hed2801010.x; KULCZYCKI A, 1986, ANN INTERN MED, V104, P207, DOI 10.7326/0003-4819-104-2-207; LEON AS, 1989, ARCH INTERN MED, V149, P2318, DOI 10.1001/archinte.149.10.2318; LIPTON RB, 1989, HEADACHE, V39, P90; MAZUR RH, 1984, ASPARTAME PHYSL BIOC, P3; NORVICK NL, 1985, ANN INTERN MED, V102, P206; SCHIFFMAN SS, 1987, NEW ENGL J MED, V317, P1181, DOI 10.1056/NEJM198711053171903; STEGINK LD, 1987, FOOD TECHNOL     JAN, P119; SZUCS EF, 1986, FOOD CHEM TOXICOL, V24, P171, DOI 10.1016/0278-6915(86)90353-4; YOST DA, 1989, AM FAM PHYSICIAN, V39, P201; 1984, EVALUATION CONSUMER; 1987, FOOD DRUG ADM APPROV	17	36	36	0	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1991	87	4					821	827		10.1016/0091-6749(91)90128-B	http://dx.doi.org/10.1016/0091-6749(91)90128-B			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FG059	2013676				2022-12-18	WOS:A1991FG05900011
J	GRAMMER, LC; HARRIS, KE; SHAUGHNESSY, MA; SPARKS, P; AYARS, GH; ALTMAN, LC; PATTERSON, R				GRAMMER, LC; HARRIS, KE; SHAUGHNESSY, MA; SPARKS, P; AYARS, GH; ALTMAN, LC; PATTERSON, R			CLINICAL AND IMMUNOLOGICAL EVALUATION OF 37 WORKERS EXPOSED TO GASEOUS FORMALDEHYDE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV, SCH MED, DEPT MED, ALLERGY IMMUNOL SECT, CHICAGO, IL 60611 USA; PROVIDENCE MED CTR, OCCUPAT HLTH SERV, SEATTLE, WA 98124 USA; UNIV WASHINGTON, DEPT MED, DIV ALLERGY & INFECT DIS, SEATTLE, WA 98195 USA	Northwestern University; University of Washington; University of Washington Seattle	GRAMMER, LC (corresponding author), NORTHWESTERN UNIV, SCH MED, DEPT MED, OCCUPAT MED SECT, 303 E CHICAGO AVE, CHICAGO, IL 60611 USA.			Grammer, Leslie/0000-0001-6860-2014	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 11403] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANKS DE, 1986, ANN ALLERGY, V57, P389; BERNSTEIN IL, 1982, J ALLERGY CLIN IMMUN, V70, P24, DOI 10.1016/0091-6749(82)90197-X; FASSBINDER W, 1978, VOX SANG, V35, P41, DOI 10.1111/j.1423-0410.1978.tb02899.x; GIBSON JE, 1983, FORMALDEHYDE TOXICIT, P312; HART RW, 1984, DHHS NIH84218 US DEP, P323; HENDRICK DJ, 1977, BRIT J IND MED, V34, P11; KWONG F, 1983, ANN ALLERGY, V50, P326; LEE HK, 1984, TOXICOL APPL PHARM, V75, P147, DOI 10.1016/0041-008X(84)90085-1; NORDMAN H, 1985, J ALLERGY CLIN IMMUN, V75, P91, DOI 10.1016/0091-6749(85)90018-1; PATTERSON R, 1987, J ALLERGY CLIN IMMUN, V79, P705, DOI 10.1016/0091-6749(87)90199-0; PATTERSON R, 1985, J LAB CLIN MED, V106, P93; PATTERSON R, 1985, NEW ENGL REG ALLERGY, V6, P238; PATTERSON R, 1986, INT ARCH ALLER A IMM, V79, P53, DOI 10.1159/000233942; SANDLER SG, 1978, ISRAEL J MED SCI, V14, P1177; SEPULVEDA R, 1979, CLIN ALLERGY, V9, P359, DOI 10.1111/j.1365-2222.1979.tb02494.x; SNYDER SL, 1975, ANAL BIOCHEM, V64, P284, DOI 10.1016/0003-2697(75)90431-5; VOLLER A, 1976, B WORLD HEALTH ORGAN, V53, P55; ZEISS CR, 1985, CLIN REV ALLERG, V3, P217, DOI 10.1007/BF02992984; ZEISS CR, 1987, J ALLERGY CLIN IMMUN, V79, P59, DOI 10.1016/S0091-6749(87)80017-9; ZEISS CR, 1982, J ALLERGY CLIN IMMUN, V70, P15, DOI 10.1016/0091-6749(82)90195-6; 1984, 84100 NAT I OCC SAF	21	36	37	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1990	86	2					177	181		10.1016/S0091-6749(05)80063-6	http://dx.doi.org/10.1016/S0091-6749(05)80063-6			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DV316	2384647				2022-12-18	WOS:A1990DV31600006
J	MACY, E; BULPITT, K; CHAMPLIN, RE; SAXON, A				MACY, E; BULPITT, K; CHAMPLIN, RE; SAXON, A			ANAPHYLAXIS TO INFUSION OF AUTOLOGOUS BONE-MARROW - AN APPARENT REACTION TO SELF, MEDIATED BY IGE ANTIBODY TO BOVINE SERUM-ALBUMIN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,DIV HEMATOL ONCOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	MACY, E (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DIV CLIN IMMUNOL & ALLERGY,CHS 52-175,LOS ANGELES,CA 90024, USA.			Macy, Eric/0000-0002-5857-9444	PHS HHS [A1-15332, A1-07126, A1-15251] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMLOT PL, 1985, INT ARCH ALLER A IMM, V77, P171, DOI 10.1159/000233776; BIELORY L, 1988, MEDICINE, V67, P40, DOI 10.1097/00005792-198801000-00003; BOXER M, 1987, ARCH INTERN MED, V147, P269, DOI 10.1001/archinte.147.2.269; DICKE KA, 1979, EXP HEMATOL, V7, P170; ERSKINE JG, 1981, BRIT MED J, V282, P2011, DOI 10.1136/bmj.282.6281.2011-a; HASSNER A, 1984, J IMMUNOL, V132, P2844; Kojis FG, 1942, AM J DIS CHILD, V64, P93, DOI 10.1001/archpedi.1942.02010070094011; LICHTENSTEIN LM, 1974, NEW ENGL J MED, V290, P1223, DOI 10.1056/NEJM197405302902204; MACY E, 1988, FASEB J, V2, P3003, DOI 10.1096/fasebj.2.14.3263291; NAGUWA SM, 1985, CLIN REV ALLERG, V3, P117, DOI 10.1007/BF02993045; ROMAGNANI S, 1985, SEMIN HEMATOL, V22, P41; SAXON A, 1988, MANUAL ALLERGY IMMUN, P15; STEINER D, 1988, J ALLERGY CLIN IMMUN, V81, P238, DOI 10.1016/0091-6749(88)90513-1; von Pirquet CE, 1911, ARCH INTERN MED, V7, P259; WALKER SA, 1986, CLIN EXP IMMUNOL, V66, P633; WELLS JR, 1979, CRYOBIOLOGY, V16, P201, DOI 10.1016/0011-2240(79)90032-4	16	36	37	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1989	83	5					871	875		10.1016/0091-6749(89)90099-7	http://dx.doi.org/10.1016/0091-6749(89)90099-7			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U7161	2654255				2022-12-18	WOS:A1989U716100005
J	TAUDORF, E; LAURSEN, L; LANNER, A; BJORKSTEN, B; DREBORG, S; WEEKE, B				TAUDORF, E; LAURSEN, L; LANNER, A; BJORKSTEN, B; DREBORG, S; WEEKE, B			SPECIFIC IGE, IGG, AND IGA ANTIBODY-RESPONSE TO ORAL IMMUNOTHERAPY IN BIRCH POLLINOSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									STATE UNIV COPENHAGEN HOSP,DEPT MED TTA,ALLERGY UNIT,COPENHAGEN,DENMARK; LINKOPING UNIV HOSP,DEPT PEDIAT,S-58185 LINKOPING,SWEDEN; PHARMACIA AB,DIV ALLERGY & DIAGNOST,UPPSALA,SWEDEN	University of Copenhagen; Linkoping University; Pfizer; Pharmacia Corporation	TAUDORF, E (corresponding author), BISPEBJERG HOSP,DEPT MED,BISPEBJERG BAKKE 23,DK-2200 COPENHAGEN N,DENMARK.							ANDRE C, 1975, J EXP MED, V142, P1509, DOI 10.1084/jem.142.6.1509; BLOCH KJ, 1984, J ALLERGY CLIN IMMUN, V74, P482, DOI 10.1016/0091-6749(84)90382-8; CHALLACOMBE SJ, 1980, J EXP MED, V152, P1459, DOI 10.1084/jem.152.6.1459; DJURUP R, 1985, J ALLERGY CLIN IMMUN, V76, P46, DOI 10.1016/0091-6749(85)90803-6; DJURUP R, 1985, ALLERGY, V40, P469, DOI 10.1111/j.1398-9995.1985.tb00253.x; DREBORG S, 1986, CLIN ALLERGY, V16, P271; HANSON DG, 1979, J IMMUNOL, V123, P2337; LAFONT S, 1982, J EXP MED, V155, P1573, DOI 10.1084/jem.155.5.1573; MOLLER C, 1987, CLIN ALLERGY, V17, P551, DOI 10.1111/j.1365-2222.1987.tb02051.x; MOLLER C, 1986, ALLERGY, V41, P271, DOI 10.1111/j.1398-9995.1986.tb02028.x; TAUDORF E, 1987, J ALLERGY CLIN IMMUN, V80, P153, DOI 10.1016/0091-6749(87)90124-2; TOMASI TB, 1980, TRANSPLANTATION, V29, P353, DOI 10.1097/00007890-198005000-00001	12	36	37	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1989	83	3					589	594		10.1016/0091-6749(89)90070-5	http://dx.doi.org/10.1016/0091-6749(89)90070-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T8596	2647818				2022-12-18	WOS:A1989T859600004
J	MARSHALL, T; SHULT, P; BUSSE, WW				MARSHALL, T; SHULT, P; BUSSE, WW			RELEASE OF LYSOSOMAL-ENZYME BETA-GLUCURONIDASE FROM ISOLATED HUMAN EOSINOPHILS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WISCONSIN,SCH MED,DEPT MED,DIV ALLERGY,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI010404, R01AI023181, R01AI015685] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 10404, AI 23181, AI 15685] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BASS DA, 1980, J CLIN INVEST, V66, P1265, DOI 10.1172/JCI109978; BEESON PB, 1977, EOSINOPHIL, P1; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BUSSE WW, 1977, J CLIN INVEST, V59, P1080, DOI 10.1172/JCI108731; Cohen SG, 1983, ALLERGY PRINCIPLES P, P701; CONNELL JT, 1968, J ALLERGY, V41, P1, DOI 10.1016/0021-8707(68)90002-6; FISHMAN WH, 1967, CLIN CHIM ACTA, V15, P435, DOI 10.1016/0009-8981(67)90008-3; GLEICH GJ, 1984, ANNU REV IMMUNOL, V2, P429, DOI 10.1146/annurev.immunol.2.1.429; GOLDSTEIN IM, 1975, J CELL BIOL, V66, P647, DOI 10.1083/jcb.66.3.647; LOWRY OH, 1951, J BIOL CHEM, V193, P265; OLSSON I, 1981, MONOGR ALLERGY, V17, P130; PILOT ML, 1950, AM J CLIN PATHOL, V20, P870, DOI 10.1093/ajcp/20.9_ts.870; PINCUS SH, 1981, BLOOD, V58, P1175; SHULT PA, 1985, J LAB CLIN MED, V106, P638; SPRY CJF, 1976, CLIN EXP IMMUNOL, V24, P423; TAI PC, 1976, CLIN EXP IMMUNOL, V24, P415; WEISSMANN G, 1980, NEW ENGL J MED, V303, P27; WEST BC, 1975, AM J PATHOL, V81, P575; WHITE JG, 1974, AM J PATHOL, V75, P45; WINQVIST I, 1982, IMMUNOLOGY, V47, P531; WRIGHT DG, 1977, AM J PATHOL, V87, P273; ZEIGER RS, 1976, J EXP MED, V144, P1049, DOI 10.1084/jem.144.4.1049; ZEIGER RS, 1977, J IMMUNOL, V118, P540; ZURIER RB, 1974, J CLIN INVEST, V53, P297, DOI 10.1172/JCI107550; ZURIER RB, 1973, P NATL ACAD SCI USA, V70, P844, DOI 10.1073/pnas.70.3.844	25	36	37	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1988	82	4					550	555		10.1016/0091-6749(88)90964-5	http://dx.doi.org/10.1016/0091-6749(88)90964-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q6399	3170999				2022-12-18	WOS:A1988Q639900004
J	ATKINS, FM; WILSON, M; BOCK, SA				ATKINS, FM; WILSON, M; BOCK, SA			COTTONSEED HYPERSENSITIVITY - NEW CONCERNS OVER AN OLD PROBLEM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV COLORADO,SCH MED,DENVER,CO 80202	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	ATKINS, FM (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,1400 JACKSON ST,DENVER,CO 80206, USA.							AAS K, 1966, INT ARCH ALLER A IMM, V29, P453, DOI 10.1159/000229729; ATKINS FM, 1985, J ALLERGY CLIN IMMUN, V75, P356, DOI 10.1016/0091-6749(85)90072-7; BAER H, 1983, ALLERGY PRINCIPLES P, P255; BAHN SL, 1980, ALLERGIES MILK, P202; BERNTON HARRY S., 1940, JOUR ALLERGY, V11, P138, DOI 10.1016/S0021-8707(40)90828-0; BERNTON HS, 1949, JAMA-J AM MED ASSOC, V140, P869, DOI 10.1001/jama.1949.02900450019005; BOCK SA, 1977, CLIN ALLERGY, V7, P375, DOI 10.1111/j.1365-2222.1977.tb01466.x; BROWN GRAFTON TYLER, 1929, JOUR AMER MED ASSOC, V93, P370; CHOI YR, 1982, J AM OIL CHEM SOC, V59, P564, DOI 10.1007/BF02636325; CLARK SP, 1978, J AM OIL CHEM SOC, V55, P691; FIGLEY KD, 1949, J ALLERGY, V20, P198, DOI 10.1016/0021-8707(49)90095-7; GOLBERT TM, 1969, J ALLERGY, V44, P96, DOI 10.1016/0021-8707(69)90005-7; HARRIS MC, 1950, J ALLERGY, V21, P2086; ITKIN IH, 1973, 19 YEAR OLD WHITE FE, P81; MALISH D, 1981, J ALLERGY CLIN IMMUN, V67, P35, DOI 10.1016/0091-6749(81)90042-7; NORMAN PS, 1983, ALLERGY PRINCIPLES P, P295; SPADARO JJ, 1979, J AM OIL CHEM SOC, V56, P422, DOI 10.1007/BF02671529; SPIES JOSEPH R., 1939, JOUR ALLERGY, V10, P113, DOI 10.1016/S0021-8707(39)90044-4; STARE FJ, 1986, NEW ENGL J MED, V315, P971, DOI 10.1056/NEJM198610093151518; 1985, FED REG, V50, P3211	20	36	36	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1988	82	2					242	250		10.1016/0091-6749(88)91006-8	http://dx.doi.org/10.1016/0091-6749(88)91006-8			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P8741	3403864	Bronze			2022-12-18	WOS:A1988P874100016
J	BRESTEL, EP; THRUSH, LB				BRESTEL, EP; THRUSH, LB			THE TREATMENT OF GLUCOCORTICOSTEROID-DEPENDENT CHRONIC URTICARIA WITH STANOZOLOL	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									W VIRGINIA UNIV,MED CTR,SCH MED,DEPT MED,MORGANTOWN,WV 26506; W VIRGINIA UNIV,MED CTR,SCH MED,DEPT MICROBIOL,MORGANTOWN,WV 26506	West Virginia University; West Virginia University								AGOSTONI A, 1980, J ALLERGY CLIN IMMUN, V65, P75, DOI 10.1016/0091-6749(80)90181-5; AHN YS, 1983, NEW ENGL J MED, V308, P1396, DOI 10.1056/NEJM198306093082306; AHN YS, 1985, ANN INTERN MED, V102, P298, DOI 10.7326/0003-4819-102-3-298; BARBIERI RL, 1981, OBSTET GYNECOL, V57, P722; CARRELL RW, 1982, NATURE, V298, P329, DOI 10.1038/298329a0; CHAMPION RH, 1969, BRIT J DERMATOL, V81, P588, DOI 10.1111/j.1365-2133.1969.tb16041.x; DAVID J, 1985, BRIT MED J, V291, P1170, DOI 10.1136/bmj.291.6503.1170; DAVIS AE, 1986, P NATL ACAD SCI USA, V83, P3161, DOI 10.1073/pnas.83.10.3161; DMOWSKI WP, 1979, FERTIL STERIL, V31, P237; EISENBERG B C, 1959, J Am Med Assoc, V169, P14; FARAH FS, 1971, J ALLERGY CLIN IMMUN, V48, P257, DOI 10.1016/0091-6749(71)90025-X; FINK AI, 1934, J ALLERGY, V5, P615; FRETWELL MD, 1982, J ALLERGY CLIN IMMUN, V69, P306, DOI 10.1016/S0091-6749(82)80008-0; GADEK JE, 1980, J CLIN INVEST, V66, P82, DOI 10.1172/JCI109838; GELFAND JA, 1976, NEW ENGL J MED, V295, P1444, DOI 10.1056/NEJM197612232952602; GORRELL GJ, 1985, CAN MED ASSOC J, V132, P100; GUY WH, 1951, AMA ARCH DERM SYPH, V63, P377, DOI 10.1001/archderm.1951.01570030091012; HARRIS A, 1983, ANN ALLERGY, V51, P161; HUNT LT, 1980, BIOCHEM BIOPH RES CO, V95, P864, DOI 10.1016/0006-291X(80)90867-0; JACOBSON KW, 1980, JAMA-J AM MED ASSOC, V243, P1644, DOI 10.1001/jama.243.16.1644; JONES RR, 1983, BRIT J DERMATOL, V108, P695, DOI 10.1111/j.1365-2133.1983.tb01082.x; LAHITA RG, 1979, ARTHRITIS RHEUM, V22, P1195, DOI 10.1002/art.1780221106; LEECH SH, 1981, ANN ALLERGY, V46, P201; LUCIANO AA, 1981, AM J OBSTET GYNECOL, V141, P723, DOI 10.1016/S0002-9378(15)33318-4; MEGGS WJ, 1984, NEW ENGL J MED, V311, P1236, DOI 10.1056/NEJM198411083111907; MORLEY KD, 1982, BRIT MED J, V284, P1431, DOI 10.1136/bmj.284.6327.1431; PRIDE SM, 1984, CAN MED ASSOC J, V131, P763; SCHREIBER AD, 1987, NEW ENGL J MED, V316, P503, DOI 10.1056/NEJM198702263160903; SPAULDING WB, 1960, ANN INTERN MED, V53, P739, DOI 10.7326/0003-4819-53-4-739; TROMOVITCH TA, 1967, CALIF MED, V106, P211	30	36	36	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1988	82	2					265	269		10.1016/0091-6749(88)91010-X	http://dx.doi.org/10.1016/0091-6749(88)91010-X			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P8741	3403867				2022-12-18	WOS:A1988P874100020
J	STYRT, B; ROCKLIN, RE; KLEMPNER, MS				STYRT, B; ROCKLIN, RE; KLEMPNER, MS			CHARACTERIZATION OF THE NEUTROPHIL RESPIRATORY BURST IN ATOPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TUFTS UNIV,SCH MED,DEPT MED,DIV EXPTL MED,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT MED,DIV ALLERGY,BOSTON,MA 02111; NEW ENGLAND MED CTR,BOSTON,MA 02111	Tufts University; Tufts University; Tufts Medical Center	STYRT, B (corresponding author), MICHIGAN STATE UNIV,DEPT MED,B-220 LIFE SCI BLDG,E LANSING,MI 48824, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016732] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 18028, AI 16732] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEER DJ, 1982, NEW ENGL J MED, V306, P454, DOI 10.1056/NEJM198202253060804; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BUSSE WW, 1976, J ALLERGY CLIN IMMUN, V58, P586, DOI 10.1016/0091-6749(76)90205-0; BUSSE WW, 1977, J CLIN INVEST, V59, P1080, DOI 10.1172/JCI108731; BUSSE WW, 1985, AM REV RESPIR DIS, V132, P1194; BUSSE WW, 1979, AM REV RESPIR DIS, V120, P377; Colton T., 1974, STAT MED, V1; GALANT SP, 1978, NEW ENGL J MED, V299, P933, DOI 10.1056/NEJM197810262991707; HINSON JM, 1984, J APPL PHYSIOL, V56, P411, DOI 10.1152/jappl.1984.56.2.411; HSIEH KH, 1981, ANN ALLERGY, V47, P38; HSIEH KH, 1980, ANN ALLERGY, V44, P313; Katagiri M, 1983, Arerugi, V32, P80; LEE TH, 1984, AM REV RESPIR DIS, V129, P409; LEMMI CAE, 1985, AGENTS ACTIONS, V16, P323, DOI 10.1007/BF01982867; Matusiewicz R, 1983, Pneumonol Pol, V51, P377; METZGER WJ, 1986, J ALLERGY CLIN IMMUN, V78, P282; MITA H, 1985, LIFE SCI, V37, P907, DOI 10.1016/0024-3205(85)90526-0; MURPHY KR, 1986, AM REV RESPIR DIS, V134, P62; NEIJENS HJ, 1984, AM REV RESPIR DIS, V130, P744; OZAKI Y, 1984, AGENTS ACTIONS, V15, P182, DOI 10.1007/BF01972347; POLYAK NR, 1984, ZH MIKROBIOL EPIDEMI, V1, P80; RADERMECKER M, 1981, INT ARCH ALLER A IMM, V65, P144, DOI 10.1159/000232750; RING J, 1983, J AM ACAD DERMATOL, V8, P378, DOI 10.1016/S0190-9622(83)70043-5; ROCKLIN RE, 1982, IMMUNOPHARMACOLOGY, P49; SELIGMANN BE, 1983, J IMMUNOL, V130, P1902; STYRT B, 1986, BLOOD, V67, P334; SWINSCOW TDW, 1976, BR MED J; VANGELDER BF, 1962, BIOCHIM BIOPHYS ACTA, V58, P593, DOI 10.1016/0006-3002(62)90073-2; VICKERS MR, 1982, AGENTS ACTIONS, V12, P630, DOI 10.1007/BF01965071; WOLFSON M, 1985, J IMMUNOL, V135, P2057; YAMASHITA T, 1985, ARCH BIOCHEM BIOPHYS, V241, P447, DOI 10.1016/0003-9861(85)90569-7	31	36	37	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1988	81	1					20	26		10.1016/0091-6749(88)90215-1	http://dx.doi.org/10.1016/0091-6749(88)90215-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M0274	2828450	Bronze			2022-12-18	WOS:A1988M027400004
J	GUILL, MF; BUCKLEY, RH; ROCHA, W; KEMP, JP; SEGAL, AT; SHIRLEY, LR; TINKELMAN, DG; SHAATHSCHWEN, Z; DIETRICH, KK; WILLE, LJ; TSAI, TH				GUILL, MF; BUCKLEY, RH; ROCHA, W; KEMP, JP; SEGAL, AT; SHIRLEY, LR; TINKELMAN, DG; SHAATHSCHWEN, Z; DIETRICH, KK; WILLE, LJ; TSAI, TH			MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF TERFENADINE SUSPENSION IN THE TREATMENT OF FALL-ALLERGIC RHINITIS IN CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MERRELL DOW PHARMACEUT INC,RES INST,DEPT CLIN RES,2110 E GALBRAITH RD,CINCINNATI,OH 45215; MED COLL GEORGIA,DEPT PEDIAT,AUGUSTA,GA 30912; DUKE UNIV,MED CTR,DEPT PEDIAT,DIV ALLERGY & IMMUNOL & PULM DIS,DURHAM,NC 27710; PEDIAT ALLERGY MED GRP,SAN DIEGO,CA; ALLERGY ASSOCIATES,DALLAS,TX; MED UNIV S CAROLINA,DEPT PEDIAT,CHARLESTON,SC 29425; ATLANTA ALLERGY & IMMUNOL RES FDN INC,ATLANTA,GA	Dow Chemical Company; University System of Georgia; Augusta University; Duke University; Medical University of South Carolina			Buckley, Rebecca/AAB-1578-2019					BROSTOFF J, 1982, POSTGRAD MED J, V58, P422, DOI 10.1136/pgmj.58.681.422; CHENG HC, 1982, ARZNEIMITTELFORSCH, V32-2, P1160; CHENG HC, 1982, DRUG DEVELOP RES, V2, P181, DOI 10.1002/ddr.430020208; GARTEIZ DA, 1982, ARZNEIMITTEL-FORSCH, V32-2, P1185; GASTPAR H, 1982, ARZNEIMITTEL-FORSCH, V32-2, P1211; HUTHER KJ, 1977, EUR J CLIN PHARMACOL, V12, P195, DOI 10.1007/BF00609860; KEMP JP, 1985, ANN ALLERGY, V54, P502; LOCKHART JDF, 1983, PRACTITIONER, V227, P1313; MCLOUGHLIN J, 1983, ANN ALLERGY, V51, P506; MELILLO G, 1982, ARZNEIMITTEL-FORSCH, V32-2, P1202; MOSER L, 1978, EUR J CLIN PHARMACOL, V14, P417, DOI 10.1007/BF00716383; NICHOLSON AN, 1982, BRIT J CLIN PHARMACO, V13, P199, DOI 10.1111/j.1365-2125.1982.tb01356.x; VANLANDEGHEM VH, 1980, CLIN PHARMACOL THER, V27, P290; WIECH NL, 1982, ARZNEIMITTELFORSCH, V32-2, P1167	14	36	36	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1986	78	1	1				4	9		10.1016/0091-6749(86)90107-7	http://dx.doi.org/10.1016/0091-6749(86)90107-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	D2996	2873161				2022-12-18	WOS:A1986D299600002
J	CLARK, TJH				CLARK, TJH			INHALED CORTICOSTEROID-THERAPY - A SUBSTITUTE FOR THEOPHYLLINE AS WELL AS PREDNISOLONE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BROMPTON HOSP,LONDON SW3 6HP,ENGLAND	Royal Brompton Hospital	CLARK, TJH (corresponding author), GUYS HOSP,SCH MED,LONDON SE1 9RT,ENGLAND.							BRATTSAND R, 1982, EUR J RESPIR DIS, V63, P62; CHANG KC, 1982, CLIN ALLERGY, V12, P369, DOI 10.1111/j.1365-2222.1982.tb02541.x; CLARK TJH, 1982, EUR J RESPIR DIS, V63, P235; COOPER EJ, 1977, Q J MED, V46, P295; COSTELLO JF, 1974, THORAX, V29, P571, DOI 10.1136/thx.29.5.571; CROMPTON GK, 1983, STEROIDS ASTHMA, P166; GADDIE J, 1973, LANCET, V2, P280; GODFREY S, 1978, J ALLERGY CLIN IMMUN, V62, P335, DOI 10.1016/0091-6749(78)90133-1; HOLGATE ST, 1977, LANCET, V2, P375; MOUNTAIN RD, 1984, ARCH INTERN MED, V144, P724, DOI 10.1001/archinte.144.4.724; MUNCH EP, 1982, EUR J RESPIR DIS, V63, P143; MYGIND N, 1980, TOPICAL STEROID TREA, P171; PRIOR JG, 1976, BR MED J, V1, P76; Smith J M, 1978, Clin Allergy, V8, P479, DOI 10.1111/j.1365-2222.1978.tb01499.x; SMITH MJ, 1983, THORAX, V38, P676, DOI 10.1136/thx.38.9.676; SMITH MJ, 1983, LANCET, V1, P265, DOI 10.1016/S0140-6736(83)91686-0; SPEIZER FE, 1968, BRIT MED J, V1, P339, DOI 10.1136/bmj.1.5588.339; STEENHOEK A, 1984, RESPIRATION, V45, P1; TOOGOOD JH, 1984, AM REV RESPIR DIS, V129, P723, DOI 10.1164/arrd.1984.129.5.723; TOOGOOD JH, 1977, J ALLERGY CLIN IMMUN, V59, P298, DOI 10.1016/0091-6749(77)90051-3; WILSON JD, 1981, LANCET, V1, P1235; WOODCOCK AA, 1983, LANCET, V1, P610; WYATT R, 1978, NEW ENGL J MED, V299, P1387, DOI 10.1056/NEJM197812212992504; 1982, BR MED J, V285, P1251; 1975, LANCET, V2, P469; 1984, LANCET, V1, P375	26	36	36	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	2					330	334		10.1016/0091-6749(85)90649-9	http://dx.doi.org/10.1016/0091-6749(85)90649-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	APE89	4019960				2022-12-18	WOS:A1985APE8900013
J	VERVLOET, D; ARNAUD, A; SENFT, M; DIDIER, A; BONGRAND, P; CHARPIN, J				VERVLOET, D; ARNAUD, A; SENFT, M; DIDIER, A; BONGRAND, P; CHARPIN, J			ANAPHYLACTIC REACTIONS TO SUXAMETHONIUM PREVENTION OF MEDIATOR RELEASE BY CHOLINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOP ST MARGUERITE,DEPT IMMUNOL,F-13277 MARSEILLE,FRANCE; HOP ST MARGUERITE,INSERM,U174,F-13277 MARSEILLE 9,FRANCE	UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	VERVLOET, D (corresponding author), HOP ST MARGUERITE,DEPT CHEST DIS & ALLERGOL,BP 29,F-13277 MARSEILLE 9,FRANCE.		Bongrand, Pierre/C-4456-2013	Bongrand, Pierre/0000-0001-6185-6572				ASSEM ESK, 1981, ANAESTHESIA, V36, P405, DOI 10.1111/j.1365-2044.1981.tb10248.x; BALDO BA, 1983, NATURE, V306, P262, DOI 10.1038/306262a0; FISHER MM, 1980, ANAESTH INTENS CARE, V8, P211, DOI 10.1177/0310057X8000800222; FISHER MM, 1979, ANAESTH INTENS CARE, V7, P58, DOI 10.1177/0310057X7900700110; FISHER MMC, 1980, ANESTHESIOLOGY, V52, P15; HARLE DG, 1984, LANCET, V1, P930; HEDIN H, 1982, INT ARCH ALLER A IMM, V68, P122, DOI 10.1159/000233080; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; MONERETVAUTRIN DA, 1981, CLIN ALLERGY, V11, P175, DOI 10.1111/j.1365-2222.1981.tb01582.x; SHORE PA, 1959, J PHARMACOL EXP THER, V127, P182; VERVLOET D, 1983, J ALLERGY CLIN IMMUN, V71, P552, DOI 10.1016/0091-6749(83)90436-0; VERVLOET D, 1985, J ALLERGY CLIN IMMUN, V75, P338, DOI 10.1016/0091-6749(85)90069-7; VERVLOET D, 1979, J ALLERGY CLIN IMMUN, V63, P448; VERVLOET D, 1983, LANCET, V2, P8360; YOUNGMAN PR, 1983, LANCET, V2, P597	15	36	36	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	2					222	225		10.1016/0091-6749(85)90705-5	http://dx.doi.org/10.1016/0091-6749(85)90705-5			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	APE88	2410473				2022-12-18	WOS:A1985APE8800017
J	FORDHUTCHINSON, AW				FORDHUTCHINSON, AW			LEUKOTRIENE INVOLVEMENT IN PATHOLOGIC PROCESSES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											FORDHUTCHINSON, AW (corresponding author), MERCK FROSST CANADA INC,POB 1005,POINTE CLAIRE DOR H9R 4P8,QUEBEC,CANADA.							BISGAARD H, 1982, PROSTAGLANDINS, V23, P797, DOI 10.1016/0090-6980(82)90124-1; BISGAARD H, 1984, PROSTAGLANDINS, V27, P369, DOI 10.1016/0090-6980(84)90196-5; BRAIN SD, 1982, J INVEST DERMATOL, V78, P328; BRAIN SD, 1982, LANCET, V2, P762; BRAIN SD, UNPUB RELEASE LEUKOT; BRAY MA, 1981, BRIT J PHARMACOL, V72, P483, DOI 10.1111/j.1476-5381.1981.tb11000.x; CAMP R, J INVEST DERMATOL; CAMP RDR, 1982, BRIT J PHARMACOL, V75, P168; CHOWANIEC O, 1979, ACTA DERM-VENEREOL, V59, P39; CROMWELL O, 1981, LANCET, V2, P164; DAHLEN SE, 1983, P NATL ACAD SCI-BIOL, V80, P1712, DOI 10.1073/pnas.80.6.1712; DAVIDSON EM, 1982, J PHARM PHARM, V34, P225; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; FORDHUTCHINSON AW, 1978, J PHARMACOL METHOD, V1, P3, DOI 10.1016/0160-5402(78)90003-7; FORDHUTCHINSON AW, PROSTAGLANDINS; GOETZL EJ, 1980, J IMMUNOL, V125, P1789; HAMMARSTROM S, 1975, P NATL ACAD SCI USA, V72, P5130, DOI 10.1073/pnas.72.12.5130; HAYES EC, 1983, J IMMUNOL, V131, P429; KLICKSTEIN LB, 1980, J CLIN INVEST, V66, P1166, DOI 10.1172/JCI109947; MACGLASHAN DW, 1982, J CLIN INVEST, V70, P747, DOI 10.1172/JCI110670; RACKHAM A, 1983, PROSTAGLANDINS, V25, P193, DOI 10.1016/0090-6980(83)90104-1; RAE SA, 1982, LANCET, V2, P1122; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SHARON P, 1983, GASTROENTEROLOGY, V84, P1306; SIMMONS PM, 1983, BIOCHEM PHARMACOL, V32, P1353, DOI 10.1016/0006-2952(83)90446-X; SMITH MJH, 1980, J PHARM PHARMACOL, V32, P517, DOI 10.1111/j.2042-7158.1980.tb12985.x; STENMARK KR, 1983, NEW ENGL J MED, V309, P77, DOI 10.1056/NEJM198307143090204; WEDMORE CV, 1980, NATURE, V284, P646; YOUNG RN, 1983, PROSTAGLANDINS, V26, P605, DOI 10.1016/0090-6980(83)90197-1	29	36	36	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	3					437	440		10.1016/0091-6749(84)90144-1	http://dx.doi.org/10.1016/0091-6749(84)90144-1			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TQ633	6088617				2022-12-18	WOS:A1984TQ63300024
J	KAUFFMAN, HF; VANDERHEIDE, S; BEAUMONT, F; DEMONCHY, JGR; DEVRIES, K				KAUFFMAN, HF; VANDERHEIDE, S; BEAUMONT, F; DEMONCHY, JGR; DEVRIES, K			THE ALLERGENIC AND ANTIGENIC PROPERTIES OF SPORE EXTRACTS OF ASPERGILLUS-FUMIGATUS - A COMPARATIVE-STUDY OF SPORE EXTRACTS WITH MYCELIUM AND CULTURE FILTRATE EXTRACTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									STATE UNIV GRONINGEN HOSP,DEPT PULMONOL,INTERNAL MED CLIN,9713 EZ GRONINGEN,NETHERLANDS	University of Groningen	KAUFFMAN, HF (corresponding author), STATE UNIV GRONINGEN HOSP,DEPT ALLERGOL,INTERNAL MED CLIN,9713 EZ GRONINGEN,NETHERLANDS.							BARDANA EJ, 1981, CRC CR REV CL LAB SC, V13, P21; BARRETOBERGTER E, 1981, CARBOHYD RES, V95, P205, DOI 10.1016/S0008-6215(00)85577-9; DEBRACCO MMDE, 1976, CLIN IMMUNOL IMMUNOP, V5, P333; KARR RM, 1981, J ALLERGY CLIN IMMUN, V67, P194, DOI 10.1016/0091-6749(81)90061-0; KAUFFMAN HF, 1983, J ALLERGY CLIN IMMUN, V72, P255, DOI 10.1016/0091-6749(83)90029-5; KAUFFMAN HF, 1980, INT ARCH ALLER A IMM, V62, P252, DOI 10.1159/000232521; KIM SJ, 1978, AM REV RESPIR DIS, V118, P547; MARSH DG, 1981, J ALLERGY CLIN IMMUN, V67, P206, DOI 10.1016/0091-6749(81)90063-4; MARX JJ, 1976, J ALLERGY CLIN IMMUN, V57, P328, DOI 10.1016/0091-6749(76)90089-0; Mayer M.M., 1961, EXPT IMMUNOCHEMISTRY, P133; SCHAFFNER A, 1982, J CLIN INVEST, V69, P617, DOI 10.1172/JCI110489; SCHOLER HJ, 1974, ASPERGILLOSIS FARMER, P45; STEVENS EAM, 1970, THORAX, V25, P11, DOI 10.1136/thx.25.1.11; TOVEY ER, 1981, NATURE, V289, P592, DOI 10.1038/289592a0	14	36	36	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	5					567	573		10.1016/0091-6749(84)90512-8	http://dx.doi.org/10.1016/0091-6749(84)90512-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SS045	6425387	Bronze			2022-12-18	WOS:A1984SS04500005
J	KAY, AB; MACLEAN, CMU; WILKINSON, AH; ELRAB, MOG				KAY, AB; MACLEAN, CMU; WILKINSON, AH; ELRAB, MOG			THE PREVALENCE OF ASTHMA AND RHINITIS IN A SUDANESE COMMUNITY SEASONALLY EXPOSED TO A POTENT AIRBORNE ALLERGEN (THE GREEN NIMITTI MIDGE, CLADOTANYTARSUS-LEWISI)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV EDINBURGH,USHER INST,DEPT COMMUNITY MED,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND; UNIV KHARTOUM,DEPT MED MIKROBIOL & PARASITOL,CLIN IMMUNOL UNIT,KHARTOUM,SUDAN	University of Edinburgh; University of Khartoum	KAY, AB (corresponding author), BROMPTON HOSP,INST CARDIOTHORAC,DEPT ALLERGY & CLIN IMMUNOL,LONDON SW3 6HP,ENGLAND.							BARKER DJP, 1973, MED TROPICS PRACTICA; CRANSTON PS, ANN TROP MED; ELRAB MOG, 1980, J ALLERGY CLIN IMMUN, V66, P190; FREEMAN PAUL, 1950, PROC ROY ENT SOC LONDON SER B, V19, P58; GREGG I, 1977, ASTHMA, P215; KAY AB, 1978, CLIN EXP IMMUNOL, V34, P106; LEWIS D. J., 1956, ACTA TROPICA, V13, P142; Lewis D. J., 1954, Proceedings of the Royal Entomological Society of London (A), V29, P124; MANTLE J, 1974, CLIN ALLERGY, V4, P161, DOI 10.1111/j.1365-2222.1974.tb01373.x; SATTI MH, 1974, SUDAN MED J, V12, P77	10	36	36	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	3					345	352		10.1016/0091-6749(83)90090-8	http://dx.doi.org/10.1016/0091-6749(83)90090-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QH188	6826993	Bronze			2022-12-18	WOS:A1983QH18800012
J	LASSER, EC; LANG, JH; CURD, JG; COCHRANE, CG; LYON, SG; HOWARD, MM; HAMBLIN, AE; REVAK, SD				LASSER, EC; LANG, JH; CURD, JG; COCHRANE, CG; LYON, SG; HOWARD, MM; HAMBLIN, AE; REVAK, SD			THE PLASMA CONTACT SYSTEM IN ATOPIC ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF SAN DIEGO,SCH MED,DEPT RADIOL,LA JOLLA,CA 92093; SCRIPPS CLIN & RES FDN,DEPT MOLEC IMMUNOL & CLIN RES,LA JOLLA,CA 92037; SCRIPPS CLIN & RES FDN,DEPT IMMUNOPATHOL,LA JOLLA,CA 92037	University of California System; University of California San Diego; Scripps Research Institute; Scripps Research Institute					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI010386] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM 00543] Funding Source: Medline; NIAID NIH HHS [AI 10386] Funding Source: Medline; NIGMS NIH HHS [GM 22794] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE K, 1967, EXPERIENTIA, V23, P626, DOI 10.1007/BF02144161; ANSELL G, 1980, INVEST RADIOL, V15, pS32, DOI 10.1097/00004424-198011001-00010; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; DAHL R, 1981, ALLERGY, V36, P129, DOI 10.1111/j.1398-9995.1981.tb04107.x; DESHAZO RD, 1979, J IMMUNOL, V122, P692; DUNN JT, 1982, J BIOL CHEM, V257, P1779; ENGELBERG H, 1977, FED PROC, V36, P70; GRIFFIN JH, 1979, SEMIN THROMB HEMOST, V5, P254; HERXHEIMER H, 1961, J PHYSIOL-LONDON, V158, pP38; JAQUES LB, 1979, SCIENCE, V206, P528, DOI 10.1126/science.386509; KALINER MA, 1979, NEW ENGL J MED, V301, P498, DOI 10.1056/NEJM197908303010910; KLUFT C, 1978, J LAB CLIN MED, V91, P83; KUEHL FA, 1980, SCIENCE, V210, P978, DOI 10.1126/science.6254151; LARSEN ML, 1978, THROMB RES, V13, P288; LASSER EC, 1971, RADIOLOGY, V100, P683, DOI 10.1148/100.3.683; LASSER EC, 1981, RADIOLOGY, V140, P11, DOI 10.1148/radiology.140.1.6166025; LASSER EC, 1979, J ALLERGY CLIN IMMUN, V64, P102; LICHTENSTEIN LM, 1972, CLIN IMMUNOBIOL, V1, P243; Lukjan H, 1972, Allerg Immunol (Leipz), V18, P25; Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2; MCCONAHEY PJ, 1966, INT ARCH ALLER A IMM, V29, P185, DOI 10.1159/000229699; MEIER HL, 1977, J CLIN INVEST, V60, P18, DOI 10.1172/JCI108754; NEWBALL HH, 1979, J CLIN INVEST, V64, P457, DOI 10.1172/JCI109483; OUCHTERLONY O, 1973, HDB EXPT IMMUNOLOGY, pCH19; PINCKARD RN, 1975, J IMMUNOL, V115, P525; SAITO H, 1971, ADV INTERN MED, V25, P217; Silbert J E, 1975, Adv Exp Med Biol, V52, P51; TEIEN AN, 1977, THROMB RES, V10, P399, DOI 10.1016/0049-3848(77)90150-5; UVAS B, 1970, ACTA PHYSL SCAN S336, V78, P3; VARONIER HS, 1968, INT ARCH ALLER A IMM, V34, P293, DOI 10.1159/000230120; WASSERMAN SI, 1977, J CLIN INVEST, V60, P189, DOI 10.1172/JCI108756; YURT RW, 1977, J IMMUNOL, V118, P1201	32	36	36	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	1					83	88		10.1016/0091-6749(83)90056-8	http://dx.doi.org/10.1016/0091-6749(83)90056-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QZ198	6189880				2022-12-18	WOS:A1983QZ19800011
J	NATH, P; JOSHI, AP; AGRAWAL, KP				NATH, P; JOSHI, AP; AGRAWAL, KP			BIOCHEMICAL CORRELATES OF AIRWAY HYPERREACTIVITY IN GUINEA-PIGS - ROLE OF LYSOPHOSPHATIDYL CHOLINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									INST NUCL MED & ALLIED SCI,ASTHMA RES CELL,DELHI,INDIA	Defence Research & Development Organisation (DRDO); Institute of Nuclear Medicine & Allied Sciences (INMAS)	AGRAWAL, KP (corresponding author), VALLABHBHAI PATEL CHEST INST,CSIR,CTR BIOCHEM,DELHI,INDIA.							ABRAHAM WM, 1982, PHYSIOLOGIST, V25, P225; ABRAMSON D, 1964, J LIPID RES, V5, P628; ADLER M, 1981, P NATL ACAD SCI US, V78, P1237; AGRAWAL KP, 1978, INDIAN J CHEST DIS, V20, P5; AGRAWAL KP, 1981, RESP PHYSIOL, V43, P23, DOI 10.1016/0034-5687(81)90085-2; AGRAWAL KP, 1979, ASPECTS ALLERGY, V12, P14; ALOIA RC, 1974, LIPIDS, V9, P993, DOI 10.1007/BF02533824; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BIERBAUM TJ, 1979, BIOCHIM BIOPHYS ACTA, V555, P102, DOI 10.1016/0005-2736(79)90075-0; BRUNETTE DM, 1971, J MEMBRANE BIOL, V5, P215, DOI 10.1007/BF01870550; COFFEY RG, 1975, INT ARCH ALLER A IMM, V48, P171, DOI 10.1159/000231303; COFFEY RG, 1974, J CLIN INVEST, V54, P138, DOI 10.1172/JCI107735; CORR PB, 1981, AM HEART J, V102, P605, DOI 10.1016/0002-8703(81)90751-1; CURRY JJ, 1946, J CLIN INVEST, V25, P785, DOI 10.1172/JCI101764; DAUTREBANDE L, 1941, PRESSE MED, V49, P942; DOUGLAS JS, 1973, J PHARMACOL EXP THER, V184, P169; DOUGLAS JS, 1977, J PHARMACOL EXP THER, V202, P116; FAIRHURST AS, 1980, BIOCHEM PHARMACOL, V29, P155, DOI 10.1016/0006-2952(80)90323-8; Fiske CH, 1925, J BIOL CHEM, V66, P375; FOLCH J, 1957, J BIOL CHEM, V226, P497; GLOSSMANN H, 1980, MOL CELL ENDOCRINOL, V19, P243, DOI 10.1016/0303-7207(80)90054-4; KLEINBAUM DG, 1978, APPLIED REGRESSION A, P231; KUNOS G, 1968, NATURE, V217, P1077, DOI 10.1038/2171077a0; KUNOS G, 1973, NATURE-NEW BIOL, V241, P119, DOI 10.1038/newbio241119a0; LEE Y, 1977, BIOCHEMISTRY-US, V16, P1303, DOI 10.1021/bi00626a010; LIMBIRD LE, 1976, MOL PHARMACOL, V12, P559; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAKINO S, 1970, J ALLERGY, V46, P178, DOI 10.1016/0021-8707(70)90096-1; MIDDLETON E, 1980, J PHARM SCI-US, V69, P243, DOI 10.1002/jps.2600690244; OLSSON OAT, 1971, ACTA ALLERGOL, V26, P438; PICHARD AL, 1977, J BIOL CHEM, V252, P4872; REUTER H, 1973, PHILOS T R SOC B, V265, P87, DOI 10.1098/rstb.1973.0011; SHIER WT, 1976, P NATL ACAD SCI USA, V73, P1586, DOI 10.1073/pnas.73.5.1586; SOBEL BE, 1978, J CLIN INVEST, V62, P546, DOI 10.1172/JCI109159; STRITTMATTER WJ, 1979, BIOCHEM BIOPH RES CO, V88, P147, DOI 10.1016/0006-291X(79)91709-1; STRITTMATTER WJ, 1979, SCIENCE, V204, P1205, DOI 10.1126/science.221977; Szentivanyi A, 1979, Ann N Y Acad Sci, V332, P295, DOI 10.1111/j.1749-6632.1979.tb47123.x; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; TAKINO Y, 1971, J ALLERGY, V47, P247, DOI 10.1016/S0091-6749(71)80003-9; WELTZIEN HU, 1979, BIOCHIM BIOPHYS ACTA, V559, P259, DOI 10.1016/0304-4157(79)90004-2; WILLIAMS LT, 1976, J CLIN INVEST, V57, P149, DOI 10.1172/JCI108254; ZWILLER J, 1976, FEBS LETT, V69, P286, DOI 10.1016/0014-5793(76)80705-3	42	36	36	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	4					351	358		10.1016/0091-6749(83)90499-2	http://dx.doi.org/10.1016/0091-6749(83)90499-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RN330	6311885				2022-12-18	WOS:A1983RN33000004
J	SIMONS, FER; FRITH, EM; SIMONS, KJ				SIMONS, FER; FRITH, EM; SIMONS, KJ			THE PHARMACOKINETICS AND ANTIHISTAMINIC EFFECTS OF BROMPHENIRAMINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MANITOBA,FAC MED,DEPT PEDIAT,WINNIPEG R3T 2N2,MANITOBA,CANADA; UNIV MANITOBA,FAC PHARM,WINNIPEG R3T 2N2,MANITOBA,CANADA	University of Manitoba; University of Manitoba								BIERMAN CW, 1980, PEDIATRIC PHARM THER, P213; BILLUPS NF, 1981, AM DRUG INDEX 1981; BLAMOUTIER J, 1978, CURR MED RES OPIN, V5, P366, DOI 10.1185/03007997809111899; BRUCE RB, 1968, J MED CHEM, V11, P1031, DOI 10.1021/jm00311a026; BURNS JJ, 1963, ANN NY ACAD SCI, V104, P881, DOI 10.1111/j.1749-6632.1963.tb57090.x; CHAO MK, 1979, J PHARM SCI, V68, P1463, DOI 10.1002/jps.2600681137; COOK TJ, 1973, J ALLERGY CLIN IMMUN, V51, P71, DOI 10.1016/S0091-6749(73)80002-8; COX DC, 1979, J ASSOC OFF ANA CHEM, V62, P552; Douglas W. W., 1980, PHARMACOL BASIS THER, P609; DUNDAS E, 1961, J ALLERGY, V32, P1, DOI 10.1016/0021-8707(61)90032-6; GHANEKAR AG, 1978, J PHARM SCI, V67, P873, DOI 10.1002/jps.2600670643; GIBALDI M, 1975, PHARMACOKINETICS, P1; GOTH A, 1978, ALLERGY PRINCIPLES P, P454; HUDANICK J, 1964, J PHARM SCI, V53, P332, DOI 10.1002/jps.2600530320; KABASAKALIAN P, 1968, J PHARM SCI-US, V57, P621, DOI 10.1002/jps.2600570416; KJELLMAN NIM, 1978, J OTOLARYNGOL, V7, P257; KJELLMAN NIM, 1975, ACTA ALLERGOL, V30, P48; KOZIOL TR, 1979, J PHARM SCI, V9, P1135; MENDEHALL W, 1979, INTRO PROBABILITY ST, P288; PEARLMAN DS, 1976, DRUGS, V12, P258, DOI 10.2165/00003495-197612040-00002; PEETS EA, 1972, J PHARMACOL EXP THER, V180, P464; RANDALL JE, 1979, PEDIATRICS, V63, P483; RHOADES RB, 1975, J ALLERGY CLIN IMMUN, V55, P180, DOI 10.1016/0091-6749(75)90014-7; SCHILLER IW, 1959, NEW ENGL J MED, V261, P478, DOI 10.1056/NEJM195909032611002; SEPPALA T, 1981, BRIT J CLIN PHARMACO, V12, P179; SIMONS FER, 1982, J ALLERGY CLIN IMMUN, V69, P376, DOI 10.1016/0091-6749(82)90149-X; WEINBERGER M, 1980, ALLERGIC DISEASES IN, P311; 1981, COMPENDIUM PHARM SPE	28	36	37	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	6					458	464		10.1016/0091-6749(82)90009-4	http://dx.doi.org/10.1016/0091-6749(82)90009-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PT744	6128358	Bronze			2022-12-18	WOS:A1982PT74400009
J	HIRSCH, SR; KALBFLEISCH, JH; GOLBERT, TM; JOSEPHSON, BM; MCCONNELL, LH; SCANLON, R; KNIKER, WT; FINK, JN; MURPHREE, JJ; COHEN, SH				HIRSCH, SR; KALBFLEISCH, JH; GOLBERT, TM; JOSEPHSON, BM; MCCONNELL, LH; SCANLON, R; KNIKER, WT; FINK, JN; MURPHREE, JJ; COHEN, SH			RINKEL INJECTION THERAPY - A MULTI-CENTER CONTROLLED-STUDY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MED COLL WISCONSIN,DEPT MED,MILWAUKEE,WI 53233	Medical College of Wisconsin	HIRSCH, SR (corresponding author), VET ADM CTR,RES SERV,WOOD,WI 53193, USA.							ANDERSON JM, 1932, J ALLERGY, V3, P306; BOOTH BN, 1972, ALLERGIC DISEASES, P569; FADAL RG, 1975, T AM SOC OPHTHALMOL, V15, P158; GLEICH GJ, 1977, J ALLERGY CLIN IMMUN, V60, P188, DOI 10.1016/0091-6749(77)90123-3; HANSEL FRENCH K., 1941, JOUR ALLERGY, V12, P457, DOI 10.1016/S0021-8707(41)90222-8; IRONS JS, 1977, J ALLERGY CLIN IMMUN, V59, P190, DOI 10.1016/0091-6749(77)90149-X; JOHNSTONE D, 1961, PEDIATRICS, V27, P39; JOHNSTONE DE, 1957, AMA J DIS CHILD, V94, P1; LEVY DA, 1971, J CLIN INVEST, V50, P360, DOI 10.1172/JCI106503; LICHTENSTEIN LM, 1971, ANN INTERN MED, V75, P663, DOI 10.7326/0003-4819-75-5-663; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LOWELL FC, 1963, J ALLERGY, V34, P165, DOI 10.1016/0021-8707(63)90069-8; LOWELL FC, 1965, NEW ENGL J MED, V273, P675, DOI 10.1056/NEJM196509232731302; LOWELL FC, 1965, J ALLERGY, V36, P214; Noon L, 1911, LANCET, V1, P1572; NORMAN PS, 1968, J ALLERGY, V42, P93, DOI 10.1016/0021-8707(68)90139-1; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; Phillips EW, 1926, J AMER MED ASSOC, V86, P182, DOI 10.1001/jama.1926.02670290022008; RINKEL H J, 1949, Ann Allergy, V7, P625; RINKEL H J, 1949, Ann Allergy, V7, P631; RINKEL H J, 1949, Ann Allergy, V7, P639; RINKEL HJ, 1962, ARCHIV OTOLARYNGOL, V76, P491; RINKEL HJ, 1963, ARCHIV OTOLARYNGOL, V77, P205; RINKEL HJ, 1963, ARCHIV OTOLARYNGOL, V77, P42; SADAN N, 1969, NEW ENGL J MED, V280, P623, DOI 10.1056/NEJM196903202801201; SPRECACE GA, 1966, J ALLERGY, V38, P9, DOI 10.1016/0021-8707(66)90068-2; VANMETRE TE, 1980, J ALLERGY CLIN IMMUN, V65, P288, DOI 10.1016/0091-6749(80)90158-X; Vaughan WT, 1923, J AMER MED ASSOC, V80, P0245, DOI 10.1001/jama.1923.02640310025009; Williams R I, 1971, Otolaryngol Clin North Am, V4, P507; WILLOUGHBY JW, 1974, OTOLARYNG CLIN N AM, V7, P579	30	36	38	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	2					133	155		10.1016/0091-6749(81)90172-X	http://dx.doi.org/10.1016/0091-6749(81)90172-X			23	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MD162	7019293	Bronze			2022-12-18	WOS:A1981MD16200010
J	COCKCROFT, DW; CARTIER, A; JONES, G; TARLO, SM; DOLOVICH, J; HARGREAVE, FE				COCKCROFT, DW; CARTIER, A; JONES, G; TARLO, SM; DOLOVICH, J; HARGREAVE, FE			ASTHMA CAUSED BY OCCUPATIONAL EXPOSURE TO A FURAN-BASED BINDER SYSTEM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ST JOSEPHS HOSP,DEPT MED,REG CHEST & ALLERGY UNIT,HAMILTON L8N 1Y4,ONTARIO,CANADA; MCMASTER UNIV,HAMILTON L8S 4L8,ONTARIO,CANADA	McGill University; McMaster University; McMaster University				Tarlo, Susan/0000-0002-4746-5310				ANDERTON RC, 1979, J ALLERGY CLIN IMMUN, V63, P315, DOI 10.1016/0091-6749(79)90125-8; BURGE PS, 1979, THORAX, V34, P308, DOI 10.1136/thx.34.3.308; BUTCHER BT, 1976, J ALLERGY CLIN IMMUN, V58, P89, DOI 10.1016/0091-6749(76)90110-X; CARTIER A, 1980, J ALLERGY CLIN IMMUN, V65, P207; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; COCKCROFT DW, 1979, AM REV RESPIR DIS, V119, P505; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1979, AM REV RESPIR DIS, V120, P1053; COCKCROFT DW, 1979, CAN MED ASSOC J, V121, P602; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; DOLOVICH J, 1972, J ALLERGY CLIN IMMUN, V49, P43, DOI 10.1016/0091-6749(72)90122-4; FAWCETT IW, 1977, CLIN ALLERGY, V7, P1, DOI 10.1111/j.1365-2222.1977.tb01418.x; GELFAND HH, 1963, J ALLERGY, V34, P374, DOI 10.1016/0021-8707(63)90056-X; LAM S, 1979, J ALLERGY CLIN IMMUN, V63, P28, DOI 10.1016/0091-6749(79)90158-1; MACCIA CA, 1976, AM REV RESPIR DIS, V113, P701; PEPYS J, 1972, Clinical Allergy, V2, P197, DOI 10.1111/j.1365-2222.1972.tb01283.x; PEPYS J, 1972, Clinical Allergy, V2, P225, DOI 10.1111/j.1365-2222.1972.tb01287.x; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; POPA V, 1969, DIS CHEST, V56, P395, DOI 10.1378/chest.56.5.395; VALLIERES M, 1977, AM REV RESPIR DIS, V115, P867; ZEISS CR, 1977, J ALLERGY CLIN IMMUN, V60, P96, DOI 10.1016/0091-6749(77)90033-1	21	36	36	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	6					458	463		10.1016/0091-6749(80)90006-8	http://dx.doi.org/10.1016/0091-6749(80)90006-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KV363	6159383				2022-12-18	WOS:A1980KV36300005
J	GREEN, AW; REISMAN, RE; ARBESMAN, CE				GREEN, AW; REISMAN, RE; ARBESMAN, CE			CLINICAL AND IMMUNOLOGICAL STUDIES OF PATIENTS WITH LARGE LOCAL REACTIONS FOLLOWING INSECT STINGS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BUFFALO GEN HOSP,ALLERGY RES LAB,BUFFALO,NY 14203; SUNY BUFFALO,SCH MED,DEPT MED,DIV ALLERGY,BUFFALO,NY 14214	Buffalo General Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NIAID NIH HHS [R01-AI 14501] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014501] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENTON AW, 1963, SCIENCE, V142, P228, DOI 10.1126/science.142.3589.228; BROWN H, 1970, ARCH INTERN MED, V125, P665, DOI 10.1001/archinte.125.4.665; HABERMAN.E, 1972, SCIENCE, V177, P314, DOI 10.1126/science.177.4046.314; HOFFMAN DR, 1978, ANN ALLERGY, V41, P278; LIGHT WC, 1976, CLIN ALLERGY, V6, P293, DOI 10.1111/j.1365-2222.1976.tb01909.x; NORMAN PS, 1978, ALLERGY PRINCIPLES P; REISMAN RE, 1975, J ALLERGY CLIN IMMUN, V56, P443, DOI 10.1016/0091-6749(75)90062-7; REISMAN RE, 1979, CLIN ALLERGY, V9, P303, DOI 10.1111/j.1365-2222.1979.tb01557.x; SHIMIZU M, 1978, J IMMUNOL METHODS, V19, P317, DOI 10.1016/0022-1759(78)90016-9; SOBOTKA AK, 1978, J IMMUNOL, V121, P2477	10	36	36	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	3					186	189		10.1016/0091-6749(80)90037-8	http://dx.doi.org/10.1016/0091-6749(80)90037-8			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KH358	7410742				2022-12-18	WOS:A1980KH35800003
J	MORRIS, HG				MORRIS, HG			DRUG-INDUCED DESENSITIZATION OF BETA-ADRENERGIC RECEPTORS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material											MORRIS, HG (corresponding author), NATL JEWISH HOSP & RES CTR,3800 E COLFAX AVE,DENVER,CO 80206, USA.							AVNER B P, 1977, American Review of Respiratory Disease, V115, P45; AVNER BP, 1978, J PHARMACOL EXP THER, V207, P23; BENOY CJ, 1975, BRIT J PHARMACOL, V55, P547, DOI 10.1111/j.1476-5381.1975.tb07431.x; BROOKS SM, 1979, J ALLERGY CLIN IMMUN, V63, P401, DOI 10.1016/0091-6749(79)90213-6; BUSSE W, 1979, 35TH P AM AC ALL ANN; CONOLLY ME, 1976, J CLIN INVEST, V58, P1307, DOI 10.1172/JCI108586; Conolly ME, 1973, CHEST              S, V63, p16S; ELLULMICALLEF R, 1975, LANCET, V2, P1269; FIREMAN P, 1973, INT ARCH ALLER A IMM, V45, P123, DOI 10.1159/000231014; GALANT SP, 1978, NEW ENGL J MED, V299, P933, DOI 10.1056/NEJM197810262991707; IZARD SR, 1971, J ALLERGY, V47, P309, DOI 10.1016/S0091-6749(71)80134-3; JENNE JW, 1977, J ALLERGY CLIN IMMUN, V59, P383, DOI 10.1016/0091-6749(77)90023-9; Lefkowitz R J, 1978, Adv Cyclic Nucleotide Res, V9, P1; MANO K, 1979, 35TH P AM AC ALL ANN; MORRIS HG, 1977, CLIN PHARMACOL THER, V22, P352; MORRIS HG, 1977, J CYCLIC NUCL PROT, V3, P439; MORRIS HG, ADV CYCLIC NUCLEOTID; NELSON HS, 1975, J ALLERGY CLIN IMMUN, V55, P299, DOI 10.1016/0091-6749(75)90002-0; NELSON HS, 1977, AM REV RESPIR DIS, V116, P871; PLUMMER AL, 1978, CHEST, V73, P949, DOI 10.1378/chest.73.6.949; STEPHAN WC, 1980, J ALLERGY CLIN IMMUN, V65, P105, DOI 10.1016/0091-6749(80)90193-1; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; TATTERSFIELD AE, 1976, LANCET, V1, P422; TIPTON WR, 1979, AM REV RESPIR DIS, V119, P84; WESSELS MR, 1979, MOL PHARMACOL, V16, P10	25	36	36	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	65	2					83	86		10.1016/0091-6749(80)90190-6	http://dx.doi.org/10.1016/0091-6749(80)90190-6			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JF199	6101338				2022-12-18	WOS:A1980JF19900001
J	NELSON, HS				NELSON, HS			EFFECT OF PRESERVATIVES AND DILUTION ON THE DETERIORATION OF RUSSIAN THISTLE (SALSOLA-PESTIFER), A POLLEN EXTRACT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											NELSON, HS (corresponding author), FITZSIMONS ARMY MED CTR,ALLERGY IMMUNOL SERV,DENVER,CO 80240, USA.							ALLES GORDON A., 1933, JOUR ALLERGY, V5, P5, DOI 10.1016/S0021-8707(33)90164-1; ARBESMAN CARL E., 1939, JOUR ALLERGY, V10, P521, DOI 10.1016/S0021-8707(39)90247-9; ARBESMAN CE, 1940, J ALLERGY, V11, P18; AUGUSTIN R, 1962, IMMUNOLOGY, V5, P424; BAER H, 1974, J ALLERGY CLIN IMMUN, V54, P157, DOI 10.1016/0091-6749(74)90052-9; BAER H, 1974, DEV BIOL STAND, V24, P115; CENTER JG, 1974, J ALLERGY CLIN IMMUN, V54, P305, DOI 10.1016/0091-6749(74)90016-5; CLOCK RO, 1917, J INFECT DIS, V21, P387; DERRICK E, 1964, ACTA ALLERGOL, V19, P121, DOI 10.1111/j.1398-9995.1964.tb03234.x; DOCKHORN R, 1978, ANN ALLERGY, V40, P203; DOCKHORN RJ, 1977, ANN ALLERGY, V38, P129; FOUCARD T, 1973, Clinical Allergy, V3, P91, DOI 10.1111/j.1365-2222.1973.tb01313.x; FRANKLIN RM, 1976, J ALLERGY CLIN IMMUN, V58, P51, DOI 10.1016/0091-6749(76)90106-8; HAMPTON SF, 1949, J ALLERGY, V20, P19, DOI 10.1016/0021-8707(49)90080-5; HJORTH NIELS, 1957, ACTA ALLERGOL, V11, P249, DOI 10.1111/j.1398-9995.1957.tb03036.x; HJORTH NIELS, 1958, ACTA ALLERGOL, V12, P316, DOI 10.1111/j.1398-9995.1958.tb03088.x; JOHNSON MC, 1955, J ALLERGY, V26, P429, DOI 10.1016/0021-8707(55)90034-4; MAGNUS K, 1956, AM REV TUBERC PULM, V74, P297; MALLEY A, 1962, J ALLERGY, V33, P84, DOI 10.1016/0021-8707(62)90067-9; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; OSMUNDSE.PE, 1967, ACTA ALLERGOL, V22, P61, DOI 10.1111/j.1398-9995.1967.tb03191.x; PEDDECORD KM, 1976, J ALLERGY CLIN IMMUN, V57, P56, DOI 10.1016/0091-6749(76)90079-8; RANCOUR JM, 1973, J ALLERGY CLIN IMMUN, V51, P114, DOI 10.1016/S0091-6749(73)80078-8; SULLIVAN CLEMENT J., 1939, JOUR ALLERGY, V10, P551, DOI 10.1016/S0021-8707(39)90249-2	24	36	36	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	63	6					417	425		10.1016/0091-6749(79)90216-1	http://dx.doi.org/10.1016/0091-6749(79)90216-1			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GY514	447944	Bronze			2022-12-18	WOS:A1979GY51400009
J	APOLD, J; AKSNES, L				APOLD, J; AKSNES, L			CORRELATION BETWEEN INCREASED BRONCHIAL RESPONSIVENESS TO HISTAMINE AND DIMINISHED PLASMA CYCLIC ADENOSINE-MONOPHOSPHATE RESPONSE AFTER EPINEPHRINE IN ASTHMATIC-CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV BERGEN,DEPT PEDIAT,N-5014 BERGEN,NORWAY	University of Bergen								AKSNES L, 1976, SCAND J CLIN LAB INV, V36, P289, DOI 10.3109/00365517609055263; BERNSTEIN RA, 1972, J LAB CLIN MED, V80, P772; CADE JF, 1971, LANCET, V2, P186; GILMAN AG, 1970, P NATL ACAD SCI USA, V67, P305, DOI 10.1073/pnas.67.1.305; MADSEN SN, 1975, ACTA ENDOCRINOL-COP, V81, P208; MAKINO S, 1970, J ALLERGY, V46, P178, DOI 10.1016/0021-8707(70)90096-1; MAKINO S, 1966, J ALLERGY, V38, P127, DOI 10.1016/0021-8707(66)90036-0; MURAD F, 1971, P NATL ACAD SCI USA, V68, P736, DOI 10.1073/pnas.68.4.736; PARKER CW, 1973, ASTHMA PHYSIOLOGY IM; ROBISON GA, 1967, ANN NY ACAD SCI, V139, P703, DOI 10.1111/j.1749-6632.1967.tb41239.x; SCHWARTZ HJ, 1973, J ALLERGY CLIN IMMUN, V51, P88, DOI 10.1016/S0091-6749(73)80024-7; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; TSANG CPW, 1972, J CLIN ENDOCR METAB, V35, P809, DOI 10.1210/jcem-35-6-809	13	36	36	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	5					343	347		10.1016/0091-6749(77)90015-X	http://dx.doi.org/10.1016/0091-6749(77)90015-X			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DF215	192769				2022-12-18	WOS:A1977DF21500001
J	GLEICH, GJ; DUNNETTE, SL				GLEICH, GJ; DUNNETTE, SL			COMPARISON OF PROCEDURES FOR MEASUREMENT OF IGE PROTEIN IN SERUM AND SECRETIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN,ALLERG DIS RES LAB,ROCHESTER,MN 55901; MAYO GRAD SCH MED,ROCHESTER,MN 55901	Mayo Clinic; Mayo Clinic								ARBESMAN CE, 1972, J ALLERGY CLIN IMMUN, V49, P72, DOI 10.1016/0091-6749(72)90058-9; BAZARAL M, 1972, J ALLERGY CLIN IMMUN, V49, P189, DOI 10.1016/0091-6749(72)90113-3; CARSON D, 1975, J IMMUNOL, V115, P561; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; HANSEN RL, 1972, INT ARCH ALLER A IMM, V42, P607, DOI 10.1159/000230641; HOFFMAN DR, 1973, J ALLERGY CLIN IMMUN, V51, P303, DOI 10.1016/0091-6749(73)90132-2; JOHANSSO.SG, 1967, LANCET, V2, P951; JOHANSSON SGO, 1976, CLIN ALLERGY, V6, P91, DOI 10.1111/j.1365-2222.1976.tb01417.x; MACY NE, 1968, P SOC EXP BIOL MED, V128, P1098; Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2; NAKAJIMA S, 1975, CLIN EXP IMMUNOL, V21, P306; NERENBERG ST, 1975, J LAB CLIN MED, V86, P887; Nye L, 1975, Clin Allergy, V5, P13; POLMAR SH, 1973, J IMMUNOL, V110, P1253; ROWE DS, 1969, B WORLD HEALTH ORGAN, V40, P613; SIEBER A, 1974, CLIN CHIM ACTA, V50, P153, DOI 10.1016/0009-8981(74)90089-8; SMITH HJ, 1972, J ALLERGY CLIN IMMUN, V50, P193, DOI 10.1016/0091-6749(72)90013-9; UNDERDOWN BJ, 1976, J IMMUNOL, V116, P1435; WELTMAN JK, 1976, J ALLERGY CLIN IMMUN, V58, P426, DOI 10.1016/0091-6749(76)90123-8; WIDE L, 1966, BIOCHIM BIOPHYS ACTA, V130, P257, DOI 10.1016/0304-4165(66)90032-8; WIEDERMANN G, 1974, Z IMMUNITATSFORSCH, V147, P366; YUNGINGER JW, 1973, J ALLERGY CLIN IMMUN, V51, P174, DOI 10.1016/0091-6749(73)90022-5; YUNGINGER JW, 1972, J ALLERGY CLIN IMMUN, V50, P326, DOI 10.1016/0091-6749(72)90036-X	24	36	36	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	5					377	382		10.1016/0091-6749(77)90022-7	http://dx.doi.org/10.1016/0091-6749(77)90022-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DF215	404346				2022-12-18	WOS:A1977DF21500008
J	GREENBAUM, J; COCKCROFT, D; HARGREAVE, FE; DOLOVICH, J				GREENBAUM, J; COCKCROFT, D; HARGREAVE, FE; DOLOVICH, J			SODIUM CROMOGLYCATE IN RAGWEED-ALLERGIC CONJUNCTIVITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ST JOSEPHS HOSP,DEPT MED,HAMILTON,ONTARIO,CANADA; MCMASTER UNIV,HAMILTON 16,ONTARIO,CANADA; ST JOSEPHS HOSP,DEPT PEDIAT,HAMILTON,ONTARIO,CANADA	McGill University; McMaster University; McMaster University; McGill University; McMaster University								CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; CHATTERJEE J, 1974, CAN MED ASSOC J, V110, P659; CHU J, 1976, LANCET, V1, P964; DOLOVICH J, 1974, CAN MED ASSOC J, V111, P684; EASTY D L, 1972, Clinical Allergy, V2, P99, DOI 10.1111/j.1365-2222.1972.tb01274.x; FOREMAN JC, 1976, BRIT MED J, V1, P820, DOI 10.1136/bmj.1.6013.820; FREIER S, 1973, LANCET, V1, P913; FROST M, 1973, LANCET, V2, P389; HEATLEY RV, 1975, GUT, V16, P559, DOI 10.1136/gut.16.7.559; HOLOPAIN.E, 1971, LANCET, V1, P55; Hopper I, 1972, J Laryngol Otol, V86, P725; KAZDAN JJ, 1976, CAN J OPHTHALMOL, V11, P300; MANI V, 1976, LANCET, V1, P439; RICE NSC, 1973, CLIN ALLERGY, V3, P629, DOI 10.1111/j.1365-2222.1973.tb03066.x; SHEFFER AL, 1975, NEW ENGL J MED, V293, P1220, DOI 10.1056/NEJM197512112932402; 1976, BRIT MED J, V1, P361	16	36	36	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	6					437	439		10.1016/0091-6749(77)90006-9	http://dx.doi.org/10.1016/0091-6749(77)90006-9			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DJ990	405408				2022-12-18	WOS:A1977DJ99000005
J	IMBER, WE				IMBER, WE			ALLERGIC SKIN TESTING - CLINICAL INVESTIGATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ST LOUIS UNIV,SCH MED,DEPT MED,ALLERGY & IMMUNOL SECT,ST LOUIS,MO 63156	Saint Louis University								ARBESMAN CE, 1946, J ALLERGY, V17, P203, DOI 10.1016/0021-8707(46)90145-1; BAER H, 1970, J ALLERGY, V45, P347, DOI 10.1016/0021-8707(70)90043-2; COOK TJ, 1973, J ALLERGY CLIN IMMUN, V51, P71, DOI 10.1016/S0091-6749(73)80002-8; FEINBERG SAMUEL M., 1933, JOUR ALLERGY, V5, P19, DOI 10.1016/S0021-8707(33)90166-5; INDRAJANA T, 1971, ANN ALLERGY, V29, P639; LEWIS WH, 1975, ANN ALLERGY, V35, P42; NIE NH, 1975, STATISTICAL PACKAGE; PATTERSON R, 1972, ALLERGIC DIS DIAGNOS, P77; SHELDON JM, 1967, MANUAL CLINICAL ALLE, P56; SLAVIN RG, 1974, MED CLIN N AM, V58, P65, DOI 10.1016/S0025-7125(16)32177-0	10	36	36	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	60	1					47	55		10.1016/0091-6749(77)90082-3	http://dx.doi.org/10.1016/0091-6749(77)90082-3			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DN224	874209				2022-12-18	WOS:A1977DN22400007
J	IRONS, JS; PRUZANSKY, JJ; PATTERSON, R				IRONS, JS; PRUZANSKY, JJ; PATTERSON, R			IMMUNOTHERAPY - MECHANISMS OF ACTION SUGGESTED BY MEASUREMENTS OF IMMUNOLOGICAL AND CELLULAR PARAMETERS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,MED CTR,DEPT MED,SECT ALLERGY IMMUNOL,CHICAGO,IL	Northwestern University								ARBESMAN CE, 1960, J ALLERGY, V31, P342, DOI 10.1016/0021-8707(60)90070-8; ARBESMAN CE, 1967, J ALLERGY, V39, P124; ARBESMAN CE, 1960, J ALLERGY, V31, P333, DOI 10.1016/0021-8707(60)90069-1; Brown A, 1927, J IMMUNOL, V13, P273; CONNELL JT, 1964, J ALLERGY, V35, P169, DOI 10.1016/0021-8707(64)90031-0; CONNELL JT, 1963, J IMMUNOL, V91, P197; CONNELL JT, 1964, J ALLERGY, V35, P18, DOI 10.1016/0021-8707(64)90045-0; Cooke RA, 1935, J EXP MED, V62, P733, DOI 10.1084/jem.62.6.733; COOKE RA, 1944, J ALLERGY, V15, P212; EVANS R, 1972, J ALLERGY CLIN IMMUN, V49, P285, DOI 10.1016/0091-6749(72)90096-6; FRANKLIN W, 1967, J AMER MED ASSOC, V201, P915, DOI 10.1001/jama.201.12.915; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; GORDON J, 1958, J EXP MED, V108, P37, DOI 10.1084/jem.108.1.37; Harley D, 1933, LANCET, V2, P1469; IRONS JL, TO BE PUBLISHED; IRONS JS, 1974, J ALLERGY CLIN IMMUN, V53, P113; ISHIZAKA K, 1967, J IMMUNOL, V99, P1187; ISHIZAKA T, 1969, J IMMUNOL, V102, P884; JOHNSTONE DE, 1968, PEDIATRICS, V42, P793; JOHNSTONE DE, 1957, AM J DIS CHILD, V44, P1; Katz G, 1941, J AMER MED ASSOC, V117, P1782, DOI 10.1001/jama.1941.02820470030008; KING TP, 1967, BIOCHEMISTRY-US, V6, P1992, DOI 10.1021/bi00859a017; LEVY DA, 1967, J IMMUNOL, V99, P1068; LEVY DA, 1966, J IMMUNOL, V97, P203; LEVY DA, 1971, J CLIN INVEST, V50, P360, DOI 10.1172/JCI106503; LEVY DA, 1967, J ALLERGY, V39, P124; LICHTENS.LM, 1968, AM J MED, V44, P514, DOI 10.1016/0002-9343(68)90052-1; LICHTENSTEIN, 1971, ANN INTERN MED, V75, P663; LICHTENSTEIN LM, 1970, IMMUNOLOGY, V19, P831; LICHTENSTEIN LM, 1968, J ALLERGY, V41, P49, DOI 10.1016/0021-8707(68)90007-5; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LICHTENSTEIN LM, 1969, J ALLERGY, V43, P180; LICHTENSTEIN LM, 1967, J ALLERGY, V40, P160, DOI 10.1016/0021-8707(67)90005-6; LICHTENSTEIN LM, 1966, J IMMUNOL, V96, P169; LIDD D, 1962, J ALLERGY, V33, P45, DOI 10.1016/0021-8707(62)90062-X; Loveless MH, 1943, J IMMUNOL, V47, P165; LOWELL FC, 1963, J ALLERGY, V34, P165, DOI 10.1016/0021-8707(63)90069-8; MEACOCK SCR, 1965, J ALLERGY, V36, P1, DOI 10.1016/0021-8707(65)90027-4; MELAM H, 1971, J ALLERGY, V47, P262, DOI 10.1016/S0091-6749(71)80004-0; MELAM HL, 1970, J ALLERGY, V46, P292, DOI 10.1016/0021-8707(70)90069-9; Noon L, 1911, LANCET, V1, P1572; NORMAN PS, 1972, J ALLERGY CLIN IMMUN, V50, P31, DOI 10.1016/0091-6749(72)90077-2; NORMAN PS, 1971, J ALLERGY, V47, P273, DOI 10.1016/S0091-6749(71)80005-2; PRAUSNITZ C, 1921, ZBL BAKT           1, V86, P160; PRUZANSK.JJ, 1965, J ALLERGY, V36, P196; PRUZANSKY JJ, 1964, J ALLERGY, V35, P1, DOI 10.1016/0021-8707(64)90042-5; PRUZANSKY JJ, 1967, J ALLERGY, V39, P44, DOI 10.1016/0021-8707(67)90126-8; PRUZANSKY JJ, 1968, J AMER MED ASSOC, V203, P805, DOI 10.1001/jama.203.9.805; PRUZANSKY JJ, 1972, ALLERGIC DISEASES DI, P48; SADAN N, 1969, NEW ENGL J MED, V280, P623, DOI 10.1056/NEJM196903202801201; SEHON AH, 1971, IMMUNOLOGICAL DISEAS, V2, P785; Sherman WB, 1941, J IMMUNOL, V40, P289; SHERMAN WILLIAM B., 1940, JOUR ALLERGY, V11, P225, DOI 10.1016/S0021-8707(40)90568-8; STARR MS, 1970, INT ARCH ALLER A IMM, V38, P514, DOI 10.1159/000230304; VANARSDE.PP, 1965, FED PROC, V24, P632; VANARSDEL P, 1961, J ALLERGY, V32, P348, DOI 10.1016/0021-8707(61)90103-4; VANMETRE TE, 1969, J ALLERGY, V43, P180; Vaughan WT, 1931, J AMER MED ASSOC, V97, P0090, DOI 10.1001/jama.1931.02730020018005; WEINSTOCK M, 1970, INT ARCH ALLER A IMM, V37, P385, DOI 10.1159/000230801; WIDE L, 1967, LANCET, V2, P1105; ZEISS CR, 1973, J IMMUNOL, V110, P414	62	36	36	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	56	1					64	77		10.1016/0091-6749(75)90035-4	http://dx.doi.org/10.1016/0091-6749(75)90035-4			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AH615	48527				2022-12-18	WOS:A1975AH61500007
